ID   S26A4_HUMAN             Reviewed;         780 AA.
AC   O43511; B7Z266; O43170;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   23-FEB-2022, entry version 203.
DE   RecName: Full=Pendrin;
DE   AltName: Full=Sodium-independent chloride/iodide transporter;
DE   AltName: Full=Solute carrier family 26 member 4;
GN   Name=SLC26A4; Synonyms=PDS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT PDS CYS-667.
RC   TISSUE=Thyroid;
RX   PubMed=9398842; DOI=10.1038/ng1297-411;
RA   Everett L.A., Glaser B., Beck J.C., Idol J.R., Buchs A., Heyman M.,
RA   Adawi F., Hazani E., Nassir E., Baxevanis A.D., Sheffield V.C., Green E.D.;
RT   "Pendred syndrome is caused by mutations in a putative sulphate transporter
RT   gene (PDS).";
RL   Nat. Genet. 17:411-422(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   FUNCTION.
RX   PubMed=10192399; DOI=10.1038/7783;
RA   Scott D.A., Wang R., Kreman T.M., Sheffield V.C., Karnishki L.P.;
RT   "The Pendred syndrome gene encodes a chloride-iodide transport protein.";
RL   Nat. Genet. 21:440-443(1999).
RN   [5]
RP   VARIANTS PDS PHE-138; ALA-139; VAL-209; PRO-236; HIS-271; HIS-409; PRO-416;
RP   TRP-445; TYR-565 AND ARG-723.
RX   PubMed=9618166; DOI=10.1093/hmg/7.7.1099;
RA   van Hauwe P., Everett L.A., Coucke P., Scott D.A., Kraft M.L.,
RA   Ris-Stalpers C., Bolder C., Otten B., de Vijlder J.J.M., Dietrich N.L.,
RA   Ramesh A., Srisailapathy S.C.R., Parving A., Cremers C.W.R.J.,
RA   Willems P.J., Smith R.J.H., Green E.D., van Camp G.;
RT   "Two frequent missense mutations in Pendred syndrome.";
RL   Hum. Mol. Genet. 7:1099-1104(1998).
RN   [6]
RP   VARIANTS PDS PHE-138; PRO-236; GLY-384; HIS-409; MET-410; PRO-416; HIS-530;
RP   CYS-556 AND GLU-672.
RX   PubMed=9618167; DOI=10.1093/hmg/7.7.1105;
RA   Coyle B., Reardon W., Herbrick J.-A., Tsui L.-C., Gausden E., Lee J.,
RA   Coffey R., Grueters A., Grossman A., Phelps P.D., Luxon L.,
RA   Kendall-Taylor P., Scherer S.W., Trembath R.C.;
RT   "Molecular analysis of the PDS gene in Pendred syndrome (sensorineural
RT   hearing loss and goitre).";
RL   Hum. Mol. Genet. 7:1105-1112(1998).
RN   [7]
RP   VARIANTS DFNB4 LEU-490 AND SER-497.
RX   PubMed=9500541; DOI=10.1038/ng0398-215;
RA   Li X.C., Everett L.A., Lalwani A.K., Desmukh D., Friedman T.B., Green E.D.,
RA   Wilcox E.R.;
RT   "A mutation in PDS causes non-syndromic recessive deafness.";
RL   Nat. Genet. 18:215-217(1998).
RN   [8]
RP   VARIANTS DFNB4 VAL-209; GLU-369; VAL-372; MET-721 AND ARG-723.
RX   PubMed=10190331; DOI=10.1007/s004390050933;
RA   Usami S., Abe S., Weston M.D., Shinkawa H., Van Camp G., Kimberling W.J.;
RT   "Non-syndromic hearing loss associated with enlarged vestibular aqueduct is
RT   caused by PDS mutations.";
RL   Hum. Genet. 104:188-192(1999).
RN   [9]
RP   VARIANT PDS TRP-445.
RX   PubMed=10602116;
RX   DOI=10.1002/(sici)1096-8628(20000103)90:1<38::aid-ajmg8>3.0.co;2-r;
RA   Masmoudi S., Charfedine I., Hmani M., Grati M., Ghorbel A.M.,
RA   Elgaied-Boulila A., Drira M., Hardelin J.-P., Ayadi M.;
RT   "Pendred syndrome: phenotypic variability in two families carrying the same
RT   PDS missense mutation.";
RL   Am. J. Med. Genet. 90:38-44(2000).
RN   [10]
RP   VARIANT PDS ASN-508.
RX   PubMed=10718825; DOI=10.1046/j.1365-2265.2000.00930.x;
RA   Bogazzi F., Raggi F., Ultimieri F., Campomori A., Cosci C., Berrettini S.,
RA   Neri E., La Rocca R., Ronca G., Martino E., Bartalena L.;
RT   "A novel mutation in the pendrin gene associated with Pendred's syndrome.";
RL   Clin. Endocrinol. (Oxf.) 52:279-285(2000).
RN   [11]
RP   VARIANT PDS ILE-193.
RX   PubMed=10878664; DOI=10.1038/sj.ejhg.5200489;
RA   Adato A., Raskin L., Petit C., Bonne-Tamir B.;
RT   "Deafness heterogeneity in a Druze isolate from the Middle East: novel OTOF
RT   and PDS mutations, low prevalence of GJB2 35delG mutation and indication
RT   for a new DFNB locus.";
RL   Eur. J. Hum. Genet. 8:437-442(2000).
RN   [12]
RP   VARIANTS DFNB4 PHE-117; VAL-209; PRO-236; MET-410; PRO-416; TRP-445 AND
RP   ARG-446.
RX   PubMed=10700480; DOI=10.1093/qjmed/93.2.99;
RA   Reardon W., O'Mahoney C.F., Trembath R., Jan H., Phelps P.D.;
RT   "Enlarged vestibular aqueduct: a radiological marker of Pendred syndrome,
RT   and mutation of the PDS gene.";
RL   QJM 93:99-104(2000).
RN   [13]
RP   VARIANTS PDS PHE-138 AND PRO-411.
RX   PubMed=11375792; DOI=10.1530/eje.0.1440585;
RA   Gonzalez Trevino O., Karamanoglu Arseven O., Ceballos C.J., Vives V.I.,
RA   Ramirez R.C., Gomez V.V., Medeiros-Neto G., Kopp P.;
RT   "Clinical and molecular analysis of three Mexican families with Pendred's
RT   syndrome.";
RL   Eur. J. Endocrinol. 144:585-593(2001).
RN   [14]
RP   VARIANTS PDS GLN-29; CYS-105; ASP-106; PHE-138; VAL-209; PRO-236; LEU-335;
RP   PRO-416; ASP-480; HIS-530; ALA-653 AND GLU-672, AND VARIANT SER-597.
RX   PubMed=11317356; DOI=10.1002/humu.1116;
RA   Campbell C., Cucci R.A., Prasad S., Green G.E., Edeal J.B., Galer C.E.,
RA   Karniski L.P., Sheffield V.C., Smith R.J.H.;
RT   "Pendred syndrome, DFNB4, and PDS/SLC26A4 identification of eight novel
RT   mutations and possible genotype-phenotype correlations.";
RL   Hum. Mutat. 17:403-411(2001).
RN   [15]
RP   VARIANTS PDS TRP-445; HIS-556 AND MET-721, AND VARIANTS DFNB4 ILE-132 AND
RP   MET-410.
RX   PubMed=11748854; DOI=10.1002/humu.1238;
RA   Lopez-Bigas N., Melchionda S., de Cid R., Grifa A., Zelante L., Govea N.,
RA   Arbones M.L., Gasparini P., Estivill X.;
RT   "Identification of five new mutations of PDS/SLC26A4 in Mediterranean
RT   families with hearing impairment.";
RL   Hum. Mutat. 18:548-548(2001).
RN   [16]
RP   ERRATUM OF PUBMED:11748854.
RX   PubMed=12112665; DOI=10.1002/humu.9043;
RA   Lopez-Bigas N., Melchionda S., de Cid R., Grifa A., Zelante L., Govea N.,
RA   Arbones M.L., Gasparini P., Estivill X.;
RL   Hum. Mutat. 20:77-78(2002).
RN   [17]
RP   CHARACTERIZATION OF VARIANTS PDS ARG-102; PHE-117; PHE-138; VAL-209;
RP   PRO-236; MET-410; ARG-446; CYS-556 AND GLU-672.
RX   PubMed=11932316; DOI=10.1210/jcem.87.4.8435;
RA   Taylor J.P., Metcalfe R.A., Watson P.F., Weetman A.P., Trembath R.C.;
RT   "Mutations of the PDS gene, encoding pendrin, are associated with protein
RT   mislocalization and loss of iodide efflux: implications for thyroid
RT   dysfunction in Pendred syndrome.";
RL   J. Clin. Endocrinol. Metab. 87:1778-1784(2002).
RN   [18]
RP   VARIANTS PDS ARG-28; THR-133; HIS-409 AND MET-410, AND VARIANT SER-597.
RX   PubMed=11919333; DOI=10.1203/00006450-200204000-00013;
RA   Fugazzola L., Cerutti N., Mannavola D., Crino A., Cassio A., Gasparoni P.,
RA   Vannucchi G., Beck-Peccoz P.;
RT   "Differential diagnosis between Pendred and pseudo-Pendred syndromes:
RT   clinical, radiologic, and molecular studies.";
RL   Pediatr. Res. 51:479-484(2002).
RN   [19]
RP   VARIANTS PDS ASP-239 AND ARG-723.
RX   PubMed=12974744; DOI=10.1034/j.1399-0004.2003.00144.x;
RA   Tekin M., Akcayoez D., Comak E., Bogoclu G., Duman T., Fitoz S., Ilhan I.,
RA   Akar N.;
RT   "Screening the SLC26A4 gene in probands with deafness and goiter (Pendred
RT   syndrome) ascertained from a large group of students of the schools for the
RT   deaf in Turkey.";
RL   Clin. Genet. 64:371-374(2003).
RN   [20]
RP   VARIANTS DFNB4 SER-123; VAL-147 AND PHE-666.
RX   PubMed=14508505; DOI=10.1038/sj.ejhg.5201073;
RA   Tsukamoto K., Suzuki H., Harada D., Namba A., Abe S., Usami S.;
RT   "Distribution and frequencies of PDS (SLC26A4) mutations in Pendred
RT   syndrome and nonsyndromic hearing loss associated with enlarged vestibular
RT   aqueduct: a unique spectrum of mutations in Japanese.";
RL   Eur. J. Hum. Genet. 11:916-922(2003).
RN   [21]
RP   VARIANTS PDS THR-133; PHE-138; GLY-384 AND HIS-530.
RX   PubMed=12788906; DOI=10.1210/jc.2002-021334;
RA   Borck G., Roth C., Martine U., Wildhardt G., Pohlenz J.;
RT   "Mutations in the PDS gene in German families with Pendred's syndrome:
RT   V138F is a founder mutation.";
RL   J. Clin. Endocrinol. Metab. 88:2916-2921(2003).
RN   [22]
RP   VARIANTS DFNB4 ARG-28; LEU-90; ASP-239; PRO-252; TYR-392; PRO-409; MET-410;
RP   LYS-457; GLN-676; MET-721 AND ARG-723, AND VARIANT PHE-455.
RX   PubMed=12676893; DOI=10.1136/jmg.40.4.242;
RA   Park H.-J., Shaukat S., Liu X.-Z., Hahn S.H., Naz S., Ghosh M., Kim H.-N.,
RA   Moon S.-K., Abe S., Tukamoto K., Riazuddin S., Kabra M., Erdenetungalag R.,
RA   Radnaabazar J., Khan S., Pandya A., Usami S., Nance W.E., Wilcox E.R.,
RA   Riazuddin S., Griffith A.J.;
RT   "Origins and frequencies of SLC26A4 (PDS) mutations in east and south
RT   Asians: global implications for the epidemiology of deafness.";
RL   J. Med. Genet. 40:242-248(2003).
RN   [23]
RP   VARIANTS PDS/DFNB4 GLY-24; GLN-29; CYS-78; VAL-104; CYS-105; ASP-106;
RP   PHE-138; ALA-139; VAL-209; PRO-236; HIS-271; LEU-335; GLY-384; HIS-409;
RP   MET-410; PRO-416; ARG-421; ALA-429 DEL; TRP-445; ASP-480; HIS-530; CYS-556;
RP   TYR-565; ALA-653; GLU-672; SER-683 AND ARG-723, AND VARIANTS TYR-324 AND
RP   SER-597.
RX   PubMed=14679580; DOI=10.1002/ajmg.a.20272;
RA   Prasad S., Koelln K.A., Cucci R.A., Trembath R.C., Van Camp G.,
RA   Smith R.J.H.;
RT   "Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing
RT   high-performance liquid chromatography and the identification of eleven
RT   novel mutations.";
RL   Am. J. Med. Genet. A 124:1-9(2004).
RN   [24]
RP   VARIANTS PDS GLN-29; CYS-78; PRO-137; PHE-138; ILE-193; VAL-209; PRO-236;
RP   ASN-391; HIS-409; MET-410; PRO-416; TRP-445; HIS-530; ILE-552; PRO-694;
RP   MET-721 AND ASN-724, AND VARIANT SER-597.
RX   PubMed=15355436; DOI=10.1111/j.1399-0004.2004.00296.x;
RA   Blons H., Feldmann D., Duval V., Messaz O., Denoyelle F., Loundon N.,
RA   Sergout-Allaoui A., Houang M., Duriez F., Lacombe D., Delobel B., Leman J.,
RA   Catros H., Journel H., Drouin-Garraud V., Obstoy M.-F., Toutain A.,
RA   Oden S., Toublanc J.E., Couderc R., Petit C., Garabedian E.-N., Marlin S.;
RT   "Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of
RT   mutations in France and phenotypic heterogeneity.";
RL   Clin. Genet. 66:333-340(2004).
RN   [25]
RP   VARIANT PDS PRO-416.
RX   PubMed=15531480; DOI=10.1210/jc.2004-1013;
RA   Napiontek U., Borck G., Mueller-Forell W., Pfarr N., Bohnert A.,
RA   Keilmann A., Pohlenz J.;
RT   "Intrafamilial variability of the deafness and goiter phenotype in Pendred
RT   syndrome caused by a T416P mutation in the SLC26A4 gene.";
RL   J. Clin. Endocrinol. Metab. 89:5347-5351(2004).
RN   [26]
RP   VARIANTS PDS ARG-514 AND SER-530, AND VARIANTS GLY-609 AND CYS-776.
RX   PubMed=15689455; DOI=10.1136/jmg.2004.024208;
RA   Pryor S.P., Madeo A.C., Reynolds J.C., Sarlis N.J., Arnos K.S., Nance W.E.,
RA   Yang Y., Zalewski C.K., Brewer C.C., Butman J.A., Griffith A.J.;
RT   "SLC26A4/PDS genotype-phenotype correlation in hearing loss with
RT   enlargement of the vestibular aqueduct (EVA): evidence that Pendred
RT   syndrome and non-syndromic EVA are distinct clinical and genetic
RT   entities.";
RL   J. Med. Genet. 42:159-165(2005).
RN   [27]
RP   VARIANT CYS-776, AND CHARACTERIZATION OF VARIANT CYS-776.
RX   PubMed=16684826; DOI=10.1210/jc.2006-0142;
RA   Pfarr N., Borck G., Turk A., Napiontek U., Keilmann A., Mueller-Forell W.,
RA   Kopp P., Pohlenz J.;
RT   "Goitrous congenital hypothyroidism and hearing impairment associated with
RT   mutations in the TPO and SLC26A4/PDS genes.";
RL   J. Clin. Endocrinol. Metab. 91:2678-2681(2006).
RN   [28]
RP   VARIANT MET-99.
RX   PubMed=17146393; DOI=10.1097/01.mlg.0000244389.68568.a7;
RA   Propst E.J., Blaser S., Stockley T.L., Harrison R.V., Gordon K.A.,
RA   Papsin B.C.;
RT   "Temporal bone imaging in GJB2 deafness.";
RL   Laryngoscope 116:2178-2186(2006).
RN   [29]
RP   VARIANTS PDS PHE-138; VAL-209; PRO-236; GLY-384; MET-402; PRO-416; TRP-445;
RP   ARG-514; HIS-530; TYR-565 AND THR-775, VARIANTS DFNB4 LEU-335; MET-402;
RP   SER-530 AND THR-775, AND VARIANTS SER-597; GLY-609 AND CYS-776.
RX   PubMed=19204907; DOI=10.1002/humu.20884;
RA   Choi B.Y., Stewart A.K., Madeo A.C., Pryor S.P., Lenhard S., Kittles R.,
RA   Eisenman D., Kim H.J., Niparko J., Thomsen J., Arnos K.S., Nance W.E.,
RA   King K.A., Zalewski C.K., Brewer C.C., Shawker T., Reynolds J.C.,
RA   Butman J.A., Karniski L.P., Alper S.L., Griffith A.J.;
RT   "Hypo-functional SLC26A4 variants associated with nonsyndromic hearing loss
RT   and enlargement of the vestibular aqueduct: genotype-phenotype correlation
RT   or coincidental polymorphisms?";
RL   Hum. Mutat. 30:599-608(2009).
RN   [30]
RP   VARIANT DFNB4 ILE-281, AND VARIANTS VAL-6; ALA-144; THR-185 AND SER-597.
RX   PubMed=20597900; DOI=10.1111/j.1469-1809.2010.00581.x;
RA   Pourova R., Janousek P., Jurovcik M., Dvorakova M., Malikova M.,
RA   Raskova D., Bendova O., Leonardi E., Murgia A., Kabelka Z., Astl J.,
RA   Seeman P.;
RT   "Spectrum and frequency of SLC26A4 mutations among Czech patients with
RT   early hearing loss with and without enlarged vestibular aqueduct (EVA).";
RL   Ann. Hum. Genet. 74:299-307(2010).
RN   [31]
RP   VARIANT DFNB4 LYS-558.
RX   PubMed=20108392;
RA   Alasti F., Peeters N., Wuyts W., Sanati M.H., Van Camp G.;
RT   "Novel human pathological mutations. Gene symbol: SLC26A4. Disease:
RT   Deafness, non-syndromic, autosomal recessive.";
RL   Hum. Genet. 127:116-116(2010).
RN   [32]
RP   VARIANTS DFNB4 THR-185 AND LEU-335, VARIANTS LEU-335; GLY-384; TRP-445;
RP   SER-597; CYS-775 AND CYS-776, AND CHARACTERIZATION OF VARIANT DFNB4
RP   THR-185.
RX   PubMed=24051746; DOI=10.1001/jamaoto.2013.4185;
RA   Chattaraj P., Reimold F.R., Muskett J.A., Shmukler B.E., Chien W.W.,
RA   Madeo A.C., Pryor S.P., Zalewski C.K., Butman J.A., Brewer C.C.,
RA   Kenna M.A., Alper S.L., Griffith A.J.;
RT   "Use of SLC26A4 mutation testing for unilateral enlargement of the
RT   vestibular aqueduct.";
RL   JAMA Otolaryngol. Head Neck Surg. 139:907-913(2013).
RN   [33]
RP   VARIANT PHE-455.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T.,
RA   O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T.,
RA   Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J.,
RA   Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M.,
RA   Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N.,
RA   Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P.,
RA   Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A.,
RA   Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G.,
RA   Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M.,
RA   Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M.,
RA   McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M.,
RA   Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P.,
RA   Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G.,
RA   Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
RN   [34]
RP   VARIANTS DFNB4 PRO-227 AND CYS-556.
RX   PubMed=28281779; DOI=10.1089/gtmb.2016.0328;
RA   Wang R., Han S., Khan A., Zhang X.;
RT   "Molecular Analysis of Twelve Pakistani Families with Nonsyndromic or
RT   Syndromic Hearing Loss.";
RL   Genet. Test. Mol. Biomarkers 21:316-321(2017).
CC   -!- FUNCTION: Sodium-independent transporter of chloride and iodide.
CC       {ECO:0000269|PubMed:10192399}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Cell membrane; Multi-pass membrane protein.
CC       Note=Localizes to the apical brush border of cells in the cortical
CC       collecting ducts of the kidney. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43511-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43511-2; Sequence=VSP_056688;
CC   -!- TISSUE SPECIFICITY: High expression in adult thyroid, lower expression
CC       in adult and fetal kidney and fetal brain. Not expressed in other
CC       tissues.
CC   -!- DISEASE: Pendred syndrome (PDS) [MIM:274600]: An autosomal recessive
CC       disorder characterized by congenital sensorineural hearing loss in
CC       association with thyroid goiter. The disorder may account for up to 10%
CC       of the cases of hereditary deafness. The deafness is most often
CC       associated with a Mondini cochlear defect. Deafness occurs early,
CC       starting at birth or during the first years of life. It is bilateral,
CC       sometimes asymmetrical, fluctuant and often progressive. Thyroid
CC       perturbations, such as thyroid goiter and/or hypothyroidism appear most
CC       commonly during adolescence, but they can be congenital or appear
CC       later. {ECO:0000269|PubMed:10602116, ECO:0000269|PubMed:10718825,
CC       ECO:0000269|PubMed:10878664, ECO:0000269|PubMed:11317356,
CC       ECO:0000269|PubMed:11375792, ECO:0000269|PubMed:11748854,
CC       ECO:0000269|PubMed:11919333, ECO:0000269|PubMed:11932316,
CC       ECO:0000269|PubMed:12788906, ECO:0000269|PubMed:12974744,
CC       ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436,
CC       ECO:0000269|PubMed:15531480, ECO:0000269|PubMed:15689455,
CC       ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:9398842,
CC       ECO:0000269|PubMed:9618166, ECO:0000269|PubMed:9618167}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Deafness, autosomal recessive, 4 (DFNB4) [MIM:600791]: A form
CC       of non-syndromic sensorineural hearing loss. Sensorineural deafness
CC       results from damage to the neural receptors of the inner ear, the nerve
CC       pathways to the brain, or the area of the brain that receives sound
CC       information. DFNB4 is associated with an enlarged vestibular aqueduct.
CC       {ECO:0000269|PubMed:10190331, ECO:0000269|PubMed:10700480,
CC       ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:12676893,
CC       ECO:0000269|PubMed:14508505, ECO:0000269|PubMed:14679580,
CC       ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:20108392,
CC       ECO:0000269|PubMed:20597900, ECO:0000269|PubMed:24051746,
CC       ECO:0000269|PubMed:28281779, ECO:0000269|PubMed:9500541}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the SLC26A/SulP transporter (TC 2.A.53) family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Hereditary hearing loss homepage; Note=Gene page;
CC       URL="https://hereditaryhearingloss.org/recessive-genes";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=S&genename=SLC26A4+%40+PDS";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Pendrin entry;
CC       URL="https://en.wikipedia.org/wiki/Pendrin";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=A missing sense - Issue 133
CC       of November 2011;
CC       URL="https://web.expasy.org/spotlight/back_issues/133";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF030880; AAC51873.1; -; mRNA.
DR   EMBL; AK294388; BAH11752.1; -; mRNA.
DR   EMBL; AC002467; AAB88773.2; -; Genomic_DNA.
DR   EMBL; AC078937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS5746.1; -. [O43511-1]
DR   RefSeq; NP_000432.1; NM_000441.1. [O43511-1]
DR   RefSeq; XP_005250482.1; XM_005250425.2. [O43511-1]
DR   SMR; O43511; -.
DR   BioGRID; 111198; 12.
DR   STRING; 9606.ENSP00000265715; -.
DR   BindingDB; O43511; -.
DR   ChEMBL; CHEMBL4523138; -.
DR   DrugBank; DB05382; Iodine.
DR   TCDB; 2.A.53.2.17; the sulfate permease (sulp) family.
DR   iPTMnet; O43511; -.
DR   PhosphoSitePlus; O43511; -.
DR   BioMuta; SLC26A4; -.
DR   jPOST; O43511; -.
DR   MassIVE; O43511; -.
DR   PaxDb; O43511; -.
DR   PeptideAtlas; O43511; -.
DR   PRIDE; O43511; -.
DR   ProteomicsDB; 49001; -. [O43511-1]
DR   ProteomicsDB; 6414; -.
DR   Antibodypedia; 31372; 167 antibodies from 25 providers.
DR   DNASU; 5172; -.
DR   Ensembl; ENST00000644269; ENSP00000494017; ENSG00000091137.
DR   GeneID; 5172; -.
DR   KEGG; hsa:5172; -.
DR   MANE-Select; ENST00000644269.2; ENSP00000494017.1; NM_000441.2; NP_000432.1.
DR   UCSC; uc003vep.4; human. [O43511-1]
DR   CTD; 5172; -.
DR   DisGeNET; 5172; -.
DR   GeneCards; SLC26A4; -.
DR   GeneReviews; SLC26A4; -.
DR   HGNC; HGNC:8818; SLC26A4.
DR   HPA; ENSG00000091137; Tissue enriched (thyroid).
DR   MalaCards; SLC26A4; -.
DR   MIM; 274600; phenotype.
DR   MIM; 600791; phenotype.
DR   MIM; 605646; gene.
DR   neXtProt; NX_O43511; -.
DR   OpenTargets; ENSG00000091137; -.
DR   Orphanet; 95713; Athyreosis.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   Orphanet; 705; Pendred syndrome.
DR   Orphanet; 95720; Thyroid hypoplasia.
DR   PharmGKB; PA35506; -.
DR   VEuPathDB; HostDB:ENSG00000091137; -.
DR   eggNOG; KOG0236; Eukaryota.
DR   GeneTree; ENSGT01040000240463; -.
DR   HOGENOM; CLU_003182_9_4_1; -.
DR   InParanoid; O43511; -.
DR   OMA; KMEQCGF; -.
DR   OrthoDB; 690428at2759; -.
DR   PhylomeDB; O43511; -.
DR   TreeFam; TF313784; -.
DR   PathwayCommons; O43511; -.
DR   Reactome; R-HSA-427601; Multifunctional anion exchangers.
DR   Reactome; R-HSA-5619046; Defective SLC26A4 causes Pendred syndrome (PDS).
DR   SignaLink; O43511; -.
DR   SIGNOR; O43511; -.
DR   BioGRID-ORCS; 5172; 8 hits in 1038 CRISPR screens.
DR   GeneWiki; Pendrin; -.
DR   GenomeRNAi; 5172; -.
DR   Pharos; O43511; Tbio.
DR   PRO; PR:O43511; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O43511; protein.
DR   Bgee; ENSG00000091137; Expressed in thyroid gland and 147 other tissues.
DR   ExpressionAtlas; O43511; baseline and differential.
DR   Genevisible; O43511; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031526; C:brush border membrane; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015301; F:anion:anion antiporter activity; IBA:GO_Central.
DR   GO; GO:0015106; F:bicarbonate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015108; F:chloride transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015111; F:iodide transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0019531; F:oxalate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0008271; F:secondary active sulfate transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0015116; F:sulfate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015698; P:inorganic anion transport; TAS:ProtInc.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0006885; P:regulation of pH; ISS:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; ISS:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc.
DR   GO; GO:0008272; P:sulfate transport; TAS:ProtInc.
DR   Gene3D; 3.30.750.24; -; 1.
DR   InterPro; IPR030285; Pendrin.
DR   InterPro; IPR018045; S04_transporter_CS.
DR   InterPro; IPR011547; SLC26A/SulP_dom.
DR   InterPro; IPR001902; SLC26A/SulP_fam.
DR   InterPro; IPR002645; STAS_dom.
DR   InterPro; IPR036513; STAS_dom_sf.
DR   PANTHER; PTHR11814; PTHR11814; 1.
DR   PANTHER; PTHR11814:SF33; PTHR11814:SF33; 1.
DR   Pfam; PF01740; STAS; 1.
DR   Pfam; PF00916; Sulfate_transp; 1.
DR   SUPFAM; SSF52091; SSF52091; 1.
DR   TIGRFAMs; TIGR00815; sulP; 1.
DR   PROSITE; PS01130; SLC26A; 1.
DR   PROSITE; PS50801; STAS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Chloride; Deafness; Disease variant;
KW   Membrane; Non-syndromic deafness; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..780
FT                   /note="Pendrin"
FT                   /id="PRO_0000080164"
FT   TOPO_DOM        1..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..108
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        109
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        110..130
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        131..135
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        136..156
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        157..191
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        192..212
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        213..218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        219..239
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        240..263
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        264..284
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        285..295
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        296..316
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        317..344
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        345..365
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        366..384
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        385..405
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        406..421
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        422..442
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        443..448
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        449..469
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        470..486
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        487..507
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        508..780
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          535..729
FT                   /note="STAS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00198"
FT   VAR_SEQ         1..431
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056688"
FT   VARIANT         6
FT                   /note="G -> V (in dbSNP:rs111033423)"
FT                   /evidence="ECO:0000269|PubMed:20597900"
FT                   /id="VAR_064988"
FT   VARIANT         24
FT                   /note="R -> G (in Pendred syndrome/deafness individuals;
FT                   dbSNP:rs1268256689)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021638"
FT   VARIANT         28
FT                   /note="S -> R (in PDS and DFNB4; dbSNP:rs539699299)"
FT                   /evidence="ECO:0000269|PubMed:11919333,
FT                   ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021639"
FT   VARIANT         29
FT                   /note="E -> Q (in PDS; dbSNP:rs111033205)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021640"
FT   VARIANT         78
FT                   /note="Y -> C (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021641"
FT   VARIANT         90
FT                   /note="S -> L (in DFNB4; dbSNP:rs370588279)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021642"
FT   VARIANT         99
FT                   /note="T -> M (in dbSNP:rs141142414)"
FT                   /evidence="ECO:0000269|PubMed:17146393"
FT                   /id="VAR_064989"
FT   VARIANT         102
FT                   /note="G -> R (in PDS; fails to localize to cell membrane;
FT                   abolishes iodide transport; dbSNP:rs1219724284)"
FT                   /evidence="ECO:0000269|PubMed:11932316"
FT                   /id="VAR_021643"
FT   VARIANT         104
FT                   /note="A -> V (in Pendred syndrome/deafness individuals;
FT                   dbSNP:rs1203167658)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021644"
FT   VARIANT         105
FT                   /note="Y -> C (in PDS; dbSNP:rs1442599990)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021645"
FT   VARIANT         106
FT                   /note="A -> D (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021646"
FT   VARIANT         117
FT                   /note="L -> F (in DFNB4 and PDS; does not affect protein
FT                   localization to cell membrane; does not affect iodide
FT                   transport; dbSNP:rs145254330)"
FT                   /evidence="ECO:0000269|PubMed:10700480,
FT                   ECO:0000269|PubMed:11932316"
FT                   /id="VAR_021647"
FT   VARIANT         123
FT                   /note="P -> S (in DFNB4; dbSNP:rs984967571)"
FT                   /evidence="ECO:0000269|PubMed:14508505"
FT                   /id="VAR_027238"
FT   VARIANT         132
FT                   /note="T -> I (in DFNB4; dbSNP:rs1554354370)"
FT                   /evidence="ECO:0000269|PubMed:11748854"
FT                   /id="VAR_021648"
FT   VARIANT         133
FT                   /note="S -> T (in PDS; dbSNP:rs121908365)"
FT                   /evidence="ECO:0000269|PubMed:11919333,
FT                   ECO:0000269|PubMed:12788906"
FT                   /id="VAR_021649"
FT   VARIANT         137
FT                   /note="S -> P (in PDS; dbSNP:rs1554354382)"
FT                   /evidence="ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021650"
FT   VARIANT         138
FT                   /note="V -> F (in PDS; fails to localize to cell membrane;
FT                   abolishes iodide transport; dbSNP:rs111033199)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:11375792, ECO:0000269|PubMed:11932316,
FT                   ECO:0000269|PubMed:12788906, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:9618166, ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021651"
FT   VARIANT         139
FT                   /note="G -> A (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:9618166"
FT                   /id="VAR_021652"
FT   VARIANT         144
FT                   /note="V -> A (found at heterozygosity in a patient with
FT                   non-syndromic deafness; uncertain pathological
FT                   significance; dbSNP:rs772023020)"
FT                   /evidence="ECO:0000269|PubMed:20597900"
FT                   /id="VAR_064990"
FT   VARIANT         147
FT                   /note="M -> V (in DFNB4; dbSNP:rs760413427)"
FT                   /evidence="ECO:0000269|PubMed:14508505"
FT                   /id="VAR_027239"
FT   VARIANT         185
FT                   /note="R -> T (in DFNB4; also found at heterozygosity in a
FT                   patient with non-syndromic deafness; uncertain pathological
FT                   significance; may affect subcellular location at the plasma
FT                   membrane; dbSNP:rs542620119)"
FT                   /evidence="ECO:0000269|PubMed:20597900"
FT                   /id="VAR_064991"
FT   VARIANT         193
FT                   /note="T -> I (in PDS; dbSNP:rs111033348)"
FT                   /evidence="ECO:0000269|PubMed:10878664,
FT                   ECO:0000269|PubMed:15355436"
FT                   /id="VAR_011623"
FT   VARIANT         209
FT                   /note="G -> V (in DFNB4 and PDS; severely reduces iodide
FT                   transport without affecting protein localization to cell
FT                   membrane; dbSNP:rs111033303)"
FT                   /evidence="ECO:0000269|PubMed:10190331,
FT                   ECO:0000269|PubMed:10700480, ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:11932316, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:9618166"
FT                   /id="VAR_007440"
FT   VARIANT         227
FT                   /note="A -> P (in DFNB4)"
FT                   /evidence="ECO:0000269|PubMed:28281779"
FT                   /id="VAR_079503"
FT   VARIANT         236
FT                   /note="L -> P (in PDS and DFNB4; common mutation; fails to
FT                   localize to cell membrane; abolishes iodide transport;
FT                   dbSNP:rs80338848)"
FT                   /evidence="ECO:0000269|PubMed:10700480,
FT                   ECO:0000269|PubMed:11317356, ECO:0000269|PubMed:11932316,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436,
FT                   ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:9618166,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_007441"
FT   VARIANT         239
FT                   /note="V -> D (in PDS and DFNB4; dbSNP:rs111033256)"
FT                   /evidence="ECO:0000269|PubMed:12676893,
FT                   ECO:0000269|PubMed:12974744"
FT                   /id="VAR_021653"
FT   VARIANT         252
FT                   /note="S -> P (in DFNB4; dbSNP:rs1315422549)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021654"
FT   VARIANT         271
FT                   /note="D -> H (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:9618166"
FT                   /id="VAR_021655"
FT   VARIANT         281
FT                   /note="V -> I (in DFNB4; dbSNP:rs727505080)"
FT                   /evidence="ECO:0000269|PubMed:20597900"
FT                   /id="VAR_064992"
FT   VARIANT         301
FT                   /note="P -> L (in dbSNP:rs34373141)"
FT                   /id="VAR_053663"
FT   VARIANT         324
FT                   /note="N -> Y (in dbSNP:rs36039758)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_053664"
FT   VARIANT         335
FT                   /note="F -> L (in PDS and DFNB4; dbSNP:rs111033212)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:24051746"
FT                   /id="VAR_021656"
FT   VARIANT         369
FT                   /note="K -> E (in DFNB4; dbSNP:rs121908361)"
FT                   /evidence="ECO:0000269|PubMed:10190331"
FT                   /id="VAR_007442"
FT   VARIANT         372
FT                   /note="A -> V (in DFNB4; dbSNP:rs121908364)"
FT                   /evidence="ECO:0000269|PubMed:10190331"
FT                   /id="VAR_007443"
FT   VARIANT         384
FT                   /note="E -> G (in PDS; also found at heterozygosity in a
FT                   patient with hearing loss and unilateral enlargement of the
FT                   vestibular aqueduct; uncertain pathological significance;
FT                   dbSNP:rs111033244)"
FT                   /evidence="ECO:0000269|PubMed:12788906,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:24051746, ECO:0000269|PubMed:9618167"
FT                   /id="VAR_007444"
FT   VARIANT         391
FT                   /note="S -> N (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021657"
FT   VARIANT         392
FT                   /note="N -> Y (in DFNB4; dbSNP:rs201562855)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021658"
FT   VARIANT         402
FT                   /note="V -> M (in PDS and DFNB4; dbSNP:rs397516414)"
FT                   /evidence="ECO:0000269|PubMed:19204907"
FT                   /id="VAR_058580"
FT   VARIANT         409
FT                   /note="R -> H (in PDS; dbSNP:rs111033305)"
FT                   /evidence="ECO:0000269|PubMed:11919333,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436,
FT                   ECO:0000269|PubMed:9618166, ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021659"
FT   VARIANT         409
FT                   /note="R -> P (in DFNB4; dbSNP:rs111033305)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021660"
FT   VARIANT         410
FT                   /note="T -> M (in DFNB4 and PDS; fails to localize to cell
FT                   membrane; abolishes iodide transport; dbSNP:rs111033220)"
FT                   /evidence="ECO:0000269|PubMed:10700480,
FT                   ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:11919333,
FT                   ECO:0000269|PubMed:11932316, ECO:0000269|PubMed:12676893,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021661"
FT   VARIANT         411
FT                   /note="A -> P (in PDS; dbSNP:rs1293971731)"
FT                   /evidence="ECO:0000269|PubMed:11375792"
FT                   /id="VAR_021662"
FT   VARIANT         416
FT                   /note="T -> P (in PDS and DFNB4; common mutation;
FT                   dbSNP:rs28939086)"
FT                   /evidence="ECO:0000269|PubMed:10700480,
FT                   ECO:0000269|PubMed:11317356, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436, ECO:0000269|PubMed:15531480,
FT                   ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:9618166,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_007445"
FT   VARIANT         421
FT                   /note="Q -> R (in Pendred syndrome/deafness individuals;
FT                   dbSNP:rs201660407)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021663"
FT   VARIANT         429
FT                   /note="Missing (in Pendred syndrome/deafness individuals)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021664"
FT   VARIANT         445
FT                   /note="L -> W (in PDS and DFNB4; also found at
FT                   heterozygosity in a patient with hearing loss and
FT                   unilateral enlargement of the vestibular aqueduct;
FT                   uncertain pathological significance; dbSNP:rs111033307)"
FT                   /evidence="ECO:0000269|PubMed:10602116,
FT                   ECO:0000269|PubMed:10700480, ECO:0000269|PubMed:11748854,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:15355436,
FT                   ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:24051746,
FT                   ECO:0000269|PubMed:9618166"
FT                   /id="VAR_011624"
FT   VARIANT         446
FT                   /note="Q -> R (in DFNB4 and PDS; fails to localize to cell
FT                   membrane; abolishes iodide transport; dbSNP:rs768471577)"
FT                   /evidence="ECO:0000269|PubMed:10700480,
FT                   ECO:0000269|PubMed:11932316"
FT                   /id="VAR_021665"
FT   VARIANT         455
FT                   /note="I -> F (in dbSNP:rs375576481)"
FT                   /evidence="ECO:0000269|PubMed:12676893,
FT                   ECO:0000269|PubMed:27535533"
FT                   /id="VAR_021666"
FT   VARIANT         457
FT                   /note="N -> K (in DFNB4; dbSNP:rs1554359670)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021667"
FT   VARIANT         480
FT                   /note="V -> D (in PDS; retains residual transport
FT                   function)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021668"
FT   VARIANT         490
FT                   /note="I -> L (in DFNB4; dbSNP:rs200511789)"
FT                   /evidence="ECO:0000269|PubMed:9500541"
FT                   /id="VAR_021669"
FT   VARIANT         497
FT                   /note="G -> S (in DFNB4; dbSNP:rs111033308)"
FT                   /evidence="ECO:0000269|PubMed:9500541"
FT                   /id="VAR_007446"
FT   VARIANT         508
FT                   /note="T -> N (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:10718825"
FT                   /id="VAR_027240"
FT   VARIANT         514
FT                   /note="Q -> R (in PDS; dbSNP:rs111033316)"
FT                   /evidence="ECO:0000269|PubMed:15689455,
FT                   ECO:0000269|PubMed:19204907"
FT                   /id="VAR_027241"
FT   VARIANT         530
FT                   /note="Y -> H (in PDS; dbSNP:rs111033254)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:12788906, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021670"
FT   VARIANT         530
FT                   /note="Y -> S (in PDS and DFNB4; dbSNP:rs747636919)"
FT                   /evidence="ECO:0000269|PubMed:15689455,
FT                   ECO:0000269|PubMed:19204907"
FT                   /id="VAR_027242"
FT   VARIANT         552
FT                   /note="S -> I (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021671"
FT   VARIANT         556
FT                   /note="Y -> C (in PDS and DFNB4; partially affects protein
FT                   localization to cell membrane; abolishes iodide transport;
FT                   dbSNP:rs763006761)"
FT                   /evidence="ECO:0000269|PubMed:11932316,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:28281779,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021672"
FT   VARIANT         556
FT                   /note="Y -> H (in PDS)"
FT                   /evidence="ECO:0000269|PubMed:11748854"
FT                   /id="VAR_021673"
FT   VARIANT         558
FT                   /note="N -> K (in DFNB4)"
FT                   /evidence="ECO:0000269|PubMed:20108392"
FT                   /id="VAR_064993"
FT   VARIANT         565
FT                   /note="C -> Y (in PDS; dbSNP:rs111033257)"
FT                   /evidence="ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:19204907, ECO:0000269|PubMed:9618166"
FT                   /id="VAR_021674"
FT   VARIANT         597
FT                   /note="L -> S (found at heterozygosity in a patient with
FT                   hearing loss and unilateral enlargement of the vestibular
FT                   aqueduct; uncertain pathological significance;
FT                   dbSNP:rs55638457)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:11919333, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:15355436, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:20597900, ECO:0000269|PubMed:24051746"
FT                   /id="VAR_021675"
FT   VARIANT         609
FT                   /note="V -> G (in dbSNP:rs17154335)"
FT                   /evidence="ECO:0000269|PubMed:15689455,
FT                   ECO:0000269|PubMed:19204907"
FT                   /id="VAR_027243"
FT   VARIANT         653
FT                   /note="V -> A (in PDS; retains residual transport function;
FT                   dbSNP:rs1554361015)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021676"
FT   VARIANT         666
FT                   /note="S -> F (in DFNB4; dbSNP:rs1584337274)"
FT                   /evidence="ECO:0000269|PubMed:14508505"
FT                   /id="VAR_027244"
FT   VARIANT         667
FT                   /note="F -> C (in PDS; dbSNP:rs121908360)"
FT                   /evidence="ECO:0000269|PubMed:9398842"
FT                   /id="VAR_007447"
FT   VARIANT         672
FT                   /note="G -> E (in PDS; partially affects protein
FT                   localization to cell membrane; abolishes iodide transport;
FT                   dbSNP:rs111033309)"
FT                   /evidence="ECO:0000269|PubMed:11317356,
FT                   ECO:0000269|PubMed:11932316, ECO:0000269|PubMed:14679580,
FT                   ECO:0000269|PubMed:9618167"
FT                   /id="VAR_021677"
FT   VARIANT         676
FT                   /note="L -> Q (in DFNB4; dbSNP:rs111033318)"
FT                   /evidence="ECO:0000269|PubMed:12676893"
FT                   /id="VAR_021678"
FT   VARIANT         683
FT                   /note="F -> S (in Pendred syndrome/deafness individuals;
FT                   dbSNP:rs1060499808)"
FT                   /evidence="ECO:0000269|PubMed:14679580"
FT                   /id="VAR_021679"
FT   VARIANT         687
FT                   /note="D -> Y (in dbSNP:rs35548413)"
FT                   /id="VAR_053665"
FT   VARIANT         694
FT                   /note="S -> P (in PDS; dbSNP:rs981410021)"
FT                   /evidence="ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021680"
FT   VARIANT         721
FT                   /note="T -> M (in DFNB4 and PDS; dbSNP:rs121908363)"
FT                   /evidence="ECO:0000269|PubMed:10190331,
FT                   ECO:0000269|PubMed:11748854, ECO:0000269|PubMed:12676893,
FT                   ECO:0000269|PubMed:15355436"
FT                   /id="VAR_007448"
FT   VARIANT         723
FT                   /note="H -> R (in DFNB4 and PDS; common mutation in Korea
FT                   and Japan; dbSNP:rs121908362)"
FT                   /evidence="ECO:0000269|PubMed:10190331,
FT                   ECO:0000269|PubMed:12676893, ECO:0000269|PubMed:12974744,
FT                   ECO:0000269|PubMed:14679580, ECO:0000269|PubMed:9618166"
FT                   /id="VAR_007449"
FT   VARIANT         724
FT                   /note="D -> N (in PDS; dbSNP:rs994170964)"
FT                   /evidence="ECO:0000269|PubMed:15355436"
FT                   /id="VAR_021681"
FT   VARIANT         740
FT                   /note="G -> S (in dbSNP:rs17154353)"
FT                   /id="VAR_027245"
FT   VARIANT         775
FT                   /note="M -> C (found at heterozygosity in a patient with
FT                   hearing loss and unilateral enlargement of the vestibular
FT                   aqueduct; requires 2 nucleotide substitutions; uncertain
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:24051746"
FT                   /id="VAR_080402"
FT   VARIANT         775
FT                   /note="M -> T (in PDS and DFNB4; dbSNP:rs1562845849)"
FT                   /evidence="ECO:0000269|PubMed:19204907"
FT                   /id="VAR_058581"
FT   VARIANT         776
FT                   /note="R -> C (found at heterozygosity in a patient with
FT                   hearing loss and unilateral enlargement of the vestibular
FT                   aqueduct; unknown pathological significance; retains its
FT                   ability to transport iodide in vitro; dbSNP:rs111033255)"
FT                   /evidence="ECO:0000269|PubMed:15689455,
FT                   ECO:0000269|PubMed:16684826, ECO:0000269|PubMed:19204907,
FT                   ECO:0000269|PubMed:24051746"
FT                   /id="VAR_027246"
SQ   SEQUENCE   780 AA;  85723 MW;  3AEF5D720B155CE0 CRC64;
     MAAPGGRSEP PQLPEYSCSY MVSRPVYSEL AFQQQHERRL QERKTLRESL AKCCSCSRKR
     AFGVLKTLVP ILEWLPKYRV KEWLLSDVIS GVSTGLVATL QGMAYALLAA VPVGYGLYSA
     FFPILTYFIF GTSRHISVGP FPVVSLMVGS VVLSMAPDEH FLVSSSNGTV LNTTMIDTAA
     RDTARVLIAS ALTLLVGIIQ LIFGGLQIGF IVRYLADPLV GGFTTAAAFQ VLVSQLKIVL
     NVSTKNYNGV LSIIYTLVEI FQNIGDTNLA DFTAGLLTIV VCMAVKELND RFRHKIPVPI
     PIEVIVTIIA TAISYGANLE KNYNAGIVKS IPRGFLPPEL PPVSLFSEML AASFSIAVVA
     YAIAVSVGKV YATKYDYTID GNQEFIAFGI SNIFSGFFSC FVATTALSRT AVQESTGGKT
     QVAGIISAAI VMIAILALGK LLEPLQKSVL AAVVIANLKG MFMQLCDIPR LWRQNKIDAV
     IWVFTCIVSI ILGLDLGLLA GLIFGLLTVV LRVQFPSWNG LGSIPSTDIY KSTKNYKNIE
     EPQGVKILRF SSPIFYGNVD GFKKCIKSTV GFDAIRVYNK RLKALRKIQK LIKSGQLRAT
     KNGIISDAVS TNNAFEPDED IEDLEELDIP TKEIEIQVDW NSELPVKVNV PKVPIHSLVL
     DCGAISFLDV VGVRSLRVIV KEFQRIDVNV YFASLQDYVI EKLEQCGFFD DNIRKDTFFL
     TVHDAILYLQ NQVKSQEGQG SILETITLIQ DCKDTLELIE TELTEEELDV QDEAMRTLAS
//
ID   OR8D4_HUMAN             Reviewed;         314 AA.
AC   Q8NGM9; Q6IFE9;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   23-FEB-2022, entry version 150.
DE   RecName: Full=Olfactory receptor 8D4;
DE   AltName: Full=Olfactory receptor OR11-275;
GN   Name=OR8D4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION.
RX   PubMed=14983052; DOI=10.1073/pnas.0307882100;
RA   Malnic B., Godfrey P.A., Buck L.B.;
RT   "The human olfactory receptor gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2584-2589(2004).
RN   [4]
RP   ERRATUM OF PUBMED:14983052.
RA   Malnic B., Godfrey P.A., Buck L.B.;
RL   Proc. Natl. Acad. Sci. U.S.A. 101:7205-7205(2004).
CC   -!- FUNCTION: Odorant receptor. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Human Olfactory Receptor Data Exploratorium (HORDE);
CC       URL="http://genome.weizmann.ac.il/horde/card/index/symbol:OR8D4";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB065761; BAC05981.1; -; Genomic_DNA.
DR   EMBL; BC137180; AAI37181.1; -; mRNA.
DR   EMBL; BC137206; AAI37207.1; -; mRNA.
DR   EMBL; BK004313; DAA04711.1; -; Genomic_DNA.
DR   CCDS; CCDS31698.1; -.
DR   RefSeq; NP_001005197.1; NM_001005197.1.
DR   SMR; Q8NGM9; -.
DR   BioGRID; 130777; 1.
DR   STRING; 9606.ENSP00000325381; -.
DR   GlyGen; Q8NGM9; 1 site.
DR   iPTMnet; Q8NGM9; -.
DR   PhosphoSitePlus; Q8NGM9; -.
DR   BioMuta; OR8D4; -.
DR   DMDM; 38372729; -.
DR   MassIVE; Q8NGM9; -.
DR   PaxDb; Q8NGM9; -.
DR   PRIDE; Q8NGM9; -.
DR   Antibodypedia; 56775; 74 antibodies from 19 providers.
DR   DNASU; 338662; -.
DR   Ensembl; ENST00000321355; ENSP00000325381; ENSG00000181518.
DR   Ensembl; ENST00000641687; ENSP00000493391; ENSG00000181518.
DR   GeneID; 338662; -.
DR   KEGG; hsa:338662; -.
DR   MANE-Select; ENST00000641687.1; ENSP00000493391.1; NM_001005197.2; NP_001005197.1.
DR   UCSC; uc010saa.3; human.
DR   CTD; 338662; -.
DR   GeneCards; OR8D4; -.
DR   HGNC; HGNC:14840; OR8D4.
DR   HPA; ENSG00000181518; Not detected.
DR   neXtProt; NX_Q8NGM9; -.
DR   PharmGKB; PA32762; -.
DR   VEuPathDB; HostDB:ENSG00000181518; -.
DR   eggNOG; ENOG502SJS1; Eukaryota.
DR   GeneTree; ENSGT01040000240383; -.
DR   HOGENOM; CLU_012526_1_0_1; -.
DR   InParanoid; Q8NGM9; -.
DR   OMA; RDKSISY; -.
DR   OrthoDB; 936700at2759; -.
DR   PhylomeDB; Q8NGM9; -.
DR   TreeFam; TF352753; -.
DR   PathwayCommons; Q8NGM9; -.
DR   BioGRID-ORCS; 338662; 4 hits in 637 CRISPR screens.
DR   GeneWiki; OR8D4; -.
DR   GenomeRNAi; 338662; -.
DR   Pharos; Q8NGM9; Tdark.
DR   PRO; PR:Q8NGM9; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q8NGM9; protein.
DR   Bgee; ENSG00000181518; Expressed in dorsolateral prefrontal cortex and 2 other tissues.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0005549; F:odorant binding; IBA:GO_Central.
DR   GO; GO:0004984; F:olfactory receptor activity; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007608; P:sensory perception of smell; IBA:GO_Central.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000725; Olfact_rcpt.
DR   Pfam; PF13853; 7tm_4; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00245; OLFACTORYR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   2: Evidence at transcript level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Olfaction; Receptor; Reference proteome; Sensory transduction;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..314
FT                   /note="Olfactory receptor 8D4"
FT                   /id="PRO_0000150661"
FT   TOPO_DOM        1..25
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        26..46
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        47..54
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        55..75
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        76..99
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        100..120
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        121..139
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        140..160
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        161..197
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        198..217
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        218..237
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        238..258
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        259..271
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        272..292
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        293..314
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        97..189
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         55
FT                   /note="L -> R (in dbSNP:rs17127947)"
FT                   /id="VAR_034257"
FT   VARIANT         92
FT                   /note="I -> V (in dbSNP:rs17127950)"
FT                   /id="VAR_034258"
FT   VARIANT         120
FT                   /note="C -> Y (in dbSNP:rs10750250)"
FT                   /id="VAR_053245"
FT   VARIANT         133
FT                   /note="R -> K (in dbSNP:rs7926767)"
FT                   /id="VAR_024118"
FT   VARIANT         200
FT                   /note="F -> L (in dbSNP:rs10790610)"
FT                   /id="VAR_024119"
FT   VARIANT         205
FT                   /note="F -> S (in dbSNP:rs12270203)"
FT                   /id="VAR_034259"
FT   VARIANT         283
FT                   /note="L -> P (in dbSNP:rs7942047)"
FT                   /id="VAR_024120"
FT   VARIANT         298
FT                   /note="R -> K (in dbSNP:rs7927385)"
FT                   /id="VAR_024121"
SQ   SEQUENCE   314 AA;  35019 MW;  7D9AB003A8D3B0DA CRC64;
     MGVKNHSTVT EFLLSGLTEQ AELQLPLFCL FLGIYTVTVV GNLSMISIIR LNRQLHTPMY
     YFLSSLSFLD FCYSSVITPK MLSGFLCRDR SISYSGCMIQ LFFFCVCVIS ECYMLAAMAC
     DRYVAICSPL LYRVIMSPRV CSLLVAAVFS VGFTDAVIHG GCILRLSFCG SNIIKHYFCD
     IVPLIKLSCS STYIDELLIF VIGGFNMVAT SLTIIISYAF ILTSILRIHS KKGRCKAFST
     CSSHLTAVLM FYGSLMSMYL KPASSSSLTQ EKVSSVFYTT VILMLNPLIY SLRNNEVRNA
     LMKLLRRKIS LSPG
//
ID   OR8J1_HUMAN             Reviewed;         316 AA.
AC   Q8NGP2; B2RNQ6; B9EH63; Q6IFC2; Q96RC3;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   23-FEB-2022, entry version 144.
DE   RecName: Full=Olfactory receptor 8J1;
DE   AltName: Full=Olfactory receptor OR11-183;
GN   Name=OR8J1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT CYS-120.
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT CYS-120.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 68-284, AND VARIANT CYS-120.
RX   PubMed=12213199; DOI=10.1006/geno.2002.6830;
RA   Fuchs T., Malecova B., Linhart C., Sharan R., Khen M., Herwig R.,
RA   Shmulevich D., Elkon R., Steinfath M., O'Brien J.K., Radelof U.,
RA   Lehrach H., Lancet D., Shamir R.;
RT   "DEFOG: a practical scheme for deciphering families of genes.";
RL   Genomics 80:295-302(2002).
RN   [5]
RP   IDENTIFICATION, AND VARIANT CYS-120.
RX   PubMed=14983052; DOI=10.1073/pnas.0307882100;
RA   Malnic B., Godfrey P.A., Buck L.B.;
RT   "The human olfactory receptor gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2584-2589(2004).
RN   [6]
RP   ERRATUM OF PUBMED:14983052.
RA   Malnic B., Godfrey P.A., Buck L.B.;
RL   Proc. Natl. Acad. Sci. U.S.A. 101:7205-7205(2004).
CC   -!- FUNCTION: Odorant receptor. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Human Olfactory Receptor Data Exploratorium (HORDE);
CC       URL="http://genome.weizmann.ac.il/horde/card/index/symbol:OR8J1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB065748; BAC05968.1; -; Genomic_DNA.
DR   EMBL; AF399515; AAK95000.1; -; Genomic_DNA.
DR   EMBL; AP002512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC137066; AAI37067.1; -; mRNA.
DR   EMBL; BC137067; AAI37068.1; -; mRNA.
DR   EMBL; BK004340; DAA04738.1; -; Genomic_DNA.
DR   CCDS; CCDS31529.1; -.
DR   RefSeq; NP_001005205.2; NM_001005205.2.
DR   SMR; Q8NGP2; -.
DR   STRING; 9606.ENSP00000304060; -.
DR   GlyGen; Q8NGP2; 1 site.
DR   iPTMnet; Q8NGP2; -.
DR   PhosphoSitePlus; Q8NGP2; -.
DR   BioMuta; OR8J1; -.
DR   DMDM; 296439255; -.
DR   PaxDb; Q8NGP2; -.
DR   PeptideAtlas; Q8NGP2; -.
DR   PRIDE; Q8NGP2; -.
DR   Antibodypedia; 58978; 50 antibodies from 13 providers.
DR   DNASU; 219477; -.
DR   Ensembl; ENST00000303039; ENSP00000304060; ENSG00000172487.
DR   Ensembl; ENST00000533152; ENSP00000477259; ENSG00000172487.
DR   Ensembl; ENST00000574644; ENSP00000460206; ENSG00000262796.
DR   GeneID; 219477; -.
DR   KEGG; hsa:219477; -.
DR   MANE-Select; ENST00000533152.3; ENSP00000477259.3; NM_001005205.3; NP_001005205.2.
DR   UCSC; uc010rjh.2; human.
DR   CTD; 219477; -.
DR   DisGeNET; 219477; -.
DR   GeneCards; OR8J1; -.
DR   HGNC; HGNC:14855; OR8J1.
DR   HPA; ENSG00000172487; Not detected.
DR   neXtProt; NX_Q8NGP2; -.
DR   PharmGKB; PA32772; -.
DR   VEuPathDB; HostDB:ENSG00000172487; -.
DR   eggNOG; ENOG502SMQ4; Eukaryota.
DR   GeneTree; ENSGT00950000182718; -.
DR   HOGENOM; CLU_012526_5_5_1; -.
DR   InParanoid; Q8NGP2; -.
DR   OMA; CASHMMS; -.
DR   OrthoDB; 980876at2759; -.
DR   PhylomeDB; Q8NGP2; -.
DR   TreeFam; TF352753; -.
DR   PathwayCommons; Q8NGP2; -.
DR   BioGRID-ORCS; 219477; 2 hits in 557 CRISPR screens.
DR   GeneWiki; OR8J1; -.
DR   GenomeRNAi; 219477; -.
DR   Pharos; Q8NGP2; Tdark.
DR   PRO; PR:Q8NGP2; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q8NGP2; protein.
DR   Bgee; ENSG00000172487; Expressed in muscle tissue and 1 other tissue.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0005549; F:odorant binding; IBA:GO_Central.
DR   GO; GO:0004984; F:olfactory receptor activity; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007608; P:sensory perception of smell; IBA:GO_Central.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000725; Olfact_rcpt.
DR   Pfam; PF13853; 7tm_4; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00245; OLFACTORYR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   2: Evidence at transcript level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Olfaction; Receptor; Reference proteome; Sensory transduction;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..316
FT                   /note="Olfactory receptor 8J1"
FT                   /id="PRO_0000150669"
FT   TOPO_DOM        1..25
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        26..46
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        47..54
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        55..75
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        76..99
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        100..120
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        121..139
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        140..160
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        161..197
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        198..217
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        218..237
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        238..258
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        259..272
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        273..293
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        294..316
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        97..189
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         36
FT                   /note="G -> V (in dbSNP:rs7927015)"
FT                   /id="VAR_034268"
FT   VARIANT         114
FT                   /note="M -> L (in dbSNP:rs7942730)"
FT                   /id="VAR_034269"
FT   VARIANT         120
FT                   /note="Y -> C (in dbSNP:rs10896290)"
FT                   /evidence="ECO:0000269|PubMed:12213199,
FT                   ECO:0000269|PubMed:14983052, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.1"
FT                   /id="VAR_060013"
SQ   SEQUENCE   316 AA;  35415 MW;  8EDA4AFC2D918868 CRC64;
     MAPENFTRVT EFILTGVSSC PELQIPLFLV FLVLYGLTMA GNLGIITLTS VDSRLQTPMY
     FFLQHLALIN LGNSTVIAPK MLINFLVKKK TTSFYECATQ LGGFLFFIVS EVIMLALMAY
     DRYVAICNPL LYMVVVSRRL CLLLVSLTYL YGFSTAIVVS SYVFSVSYCS SNIINHFYCD
     NVPLLALSCS DTYLPETVVF ISAATNVVGS LIIVLVSYFN IVLSILKICS SEGRKKAFST
     CASHMMAVTI FYGTLLFMYV QPRSNHSLDT DDKMASVFYT LVIPMLNPLI YSLRNKDVKT
     ALQRFMTNLC YSFKTM
//
ID   MXI1_HUMAN              Reviewed;         228 AA.
AC   P50539; B1ANN7; D3DR25; D3DRA9; Q15887; Q6FHW2; Q96E53;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   23-FEB-2022, entry version 195.
DE   RecName: Full=Max-interacting protein 1;
DE            Short=Max interactor 1;
DE   AltName: Full=Class C basic helix-loop-helix protein 11;
DE            Short=bHLHc11;
GN   Name=MXI1; Synonyms=BHLHC11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8425219; DOI=10.1016/0092-8674(93)90662-a;
RA   Zervos A.S., Gyuris J., Brent R.;
RT   "Mxi1, a protein that specifically interacts with Max to bind Myc-Max
RT   recognition sites.";
RL   Cell 72:223-232(1993).
RN   [2]
RP   ERRATUM OF PUBMED:8425219.
RA   Zervos A.S., Gyuris J., Brent R.;
RL   Cell 79:388-388(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8838813; DOI=10.1006/geno.1996.0144;
RA   Wechsler D.S., Shelly C.A., Dang C.V.;
RT   "Genomic organization of human MXI1, a putative tumor suppressor gene.";
RL   Genomics 32:466-470(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8918230; DOI=10.1016/0378-1119(96)00206-5;
RA   Shimizu E., Shirasawa H., Kodama K., Sato T., Shimizu B.;
RT   "Expression, regulation and polymorphism of the mxi1 genes.";
RL   Gene 176:45-48(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Hippocampus, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 216-228.
RX   PubMed=7789959; DOI=10.1007/bf00209493;
RA   Albarosa R., Didonato S., Finocchiaro G.;
RT   "Redefinition of the coding sequence of the MXI1 gene and identification of
RT   a polymorphic repeat in the 3' non-coding region that allows the detection
RT   of loss of heterozygosity of chromosome 10q25 in glioblastomas.";
RL   Hum. Genet. 95:709-711(1995).
RN   [11]
RP   VARIANT PROSTATE CANCER ALA-152.
RX   PubMed=7773287; DOI=10.1038/ng0395-249;
RA   Eagle L.R., Yin X., Brothman A.R., Williams B.J., Atkin N.B.,
RA   Prochownik E.V.;
RT   "Mutation of the MXI1 gene in prostate cancer.";
RL   Nat. Genet. 9:249-255(1995).
CC   -!- FUNCTION: Transcriptional repressor. MXI1 binds with MAX to form a
CC       sequence-specific DNA-binding protein complex which recognizes the core
CC       sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional
CC       activity by competing for MAX.
CC   -!- SUBUNIT: Interacts with SMC3 (By similarity). Efficient DNA binding
CC       requires dimerization with another bHLH protein. Binds DNA as a
CC       heterodimer with MAX. Interacts with RNF17 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P50539; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-752241, EBI-739580;
CC       P50539; Q53RC5: DKFZp547I014; NbExp=3; IntAct=EBI-752241, EBI-10212065;
CC       P50539; O75356: ENTPD5; NbExp=3; IntAct=EBI-752241, EBI-7416931;
CC       P50539; P61244: MAX; NbExp=6; IntAct=EBI-752241, EBI-751711;
CC       P50539; P61244-2: MAX; NbExp=3; IntAct=EBI-752241, EBI-10218525;
CC       P50539-3; Q13137: CALCOCO2; NbExp=6; IntAct=EBI-10211940, EBI-739580;
CC       P50539-3; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-10211940, EBI-3867333;
CC       P50539-3; O95967: EFEMP2; NbExp=3; IntAct=EBI-10211940, EBI-743414;
CC       P50539-3; Q15323: KRT31; NbExp=3; IntAct=EBI-10211940, EBI-948001;
CC       P50539-3; Q6A162: KRT40; NbExp=3; IntAct=EBI-10211940, EBI-10171697;
CC       P50539-3; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-10211940, EBI-11959885;
CC       P50539-3; P60370: KRTAP10-5; NbExp=3; IntAct=EBI-10211940, EBI-10172150;
CC       P50539-3; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-10211940, EBI-10172290;
CC       P50539-3; P60410: KRTAP10-8; NbExp=6; IntAct=EBI-10211940, EBI-10171774;
CC       P50539-3; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-10211940, EBI-10172052;
CC       P50539-3; Q6L8G8: KRTAP5-7; NbExp=3; IntAct=EBI-10211940, EBI-11987425;
CC       P50539-3; Q99750: MDFI; NbExp=3; IntAct=EBI-10211940, EBI-724076;
CC       P50539-3; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10211940, EBI-945833;
CC       P50539-3; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-10211940, EBI-22310682;
CC       P50539-3; Q5VY43: PEAR1; NbExp=3; IntAct=EBI-10211940, EBI-1249608;
CC       P50539-3; Q8N720: ZNF655; NbExp=3; IntAct=EBI-10211940, EBI-625509;
CC       P50539-4; Q6A162: KRT40; NbExp=3; IntAct=EBI-16436111, EBI-10171697;
CC       P50539-4; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-16436111, EBI-739895;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P50539-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P50539-2; Sequence=VSP_012825;
CC       Name=3;
CC         IsoId=P50539-3; Sequence=VSP_037943;
CC       Name=4;
CC         IsoId=P50539-4; Sequence=VSP_012825, VSP_043170;
CC   -!- TISSUE SPECIFICITY: High levels found in the brain, heart and lung
CC       while lower levels are seen in the liver, kidney and skeletal muscle.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in
CC       tissues of the prostate. Most prostate cancers are adenocarcinomas that
CC       develop in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of patients
CC       include small cell carcinoma, mucinous carcinoma, prostatic ductal
CC       carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal
CC       cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC       carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:7773287}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MXI1ID209.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L07648; AAA75508.1; -; mRNA.
DR   EMBL; U32515; AAC50446.1; -; Genomic_DNA.
DR   EMBL; U32512; AAC50446.1; JOINED; Genomic_DNA.
DR   EMBL; U32513; AAC50446.1; JOINED; Genomic_DNA.
DR   EMBL; U32514; AAC50446.1; JOINED; Genomic_DNA.
DR   EMBL; D63940; BAA09972.1; -; mRNA.
DR   EMBL; BT007069; AAP35732.1; -; mRNA.
DR   EMBL; CR536576; CAG38813.1; -; mRNA.
DR   EMBL; AL360182; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49565.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49567.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49568.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49569.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49570.1; -; Genomic_DNA.
DR   EMBL; BC012907; AAH12907.1; -; mRNA.
DR   EMBL; BC035128; AAH35128.2; -; mRNA.
DR   EMBL; S78470; AAD14282.1; -; Genomic_DNA.
DR   CCDS; CCDS31284.1; -. [P50539-4]
DR   CCDS; CCDS7563.1; -. [P50539-3]
DR   CCDS; CCDS7564.2; -. [P50539-1]
DR   PIR; A45182; A45182.
DR   RefSeq; NP_001008541.1; NM_001008541.1. [P50539-4]
DR   RefSeq; NP_005953.4; NM_005962.4. [P50539-1]
DR   RefSeq; NP_569157.2; NM_130439.3. [P50539-3]
DR   SMR; P50539; -.
DR   BioGRID; 110686; 47.
DR   CORUM; P50539; -.
DR   DIP; DIP-205N; -.
DR   ELM; P50539; -.
DR   IntAct; P50539; 24.
DR   MINT; P50539; -.
DR   STRING; 9606.ENSP00000331152; -.
DR   iPTMnet; P50539; -.
DR   PhosphoSitePlus; P50539; -.
DR   BioMuta; MXI1; -.
DR   DMDM; 116242666; -.
DR   EPD; P50539; -.
DR   jPOST; P50539; -.
DR   MassIVE; P50539; -.
DR   MaxQB; P50539; -.
DR   PaxDb; P50539; -.
DR   PeptideAtlas; P50539; -.
DR   PRIDE; P50539; -.
DR   ProteomicsDB; 56235; -. [P50539-1]
DR   ProteomicsDB; 56236; -. [P50539-2]
DR   ProteomicsDB; 56237; -. [P50539-3]
DR   ProteomicsDB; 56238; -. [P50539-4]
DR   Antibodypedia; 18346; 249 antibodies from 30 providers.
DR   DNASU; 4601; -.
DR   Ensembl; ENST00000239007; ENSP00000239007; ENSG00000119950.
DR   Ensembl; ENST00000332674; ENSP00000331152; ENSG00000119950. [P50539-3]
DR   Ensembl; ENST00000361248; ENSP00000354606; ENSG00000119950. [P50539-4]
DR   Ensembl; ENST00000369612; ENSP00000358625; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650644; ENSP00000498900; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650696; ENSP00000499158; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650810; ENSP00000498390; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650843; ENSP00000498547; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650900; ENSP00000499209; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000650952; ENSP00000499161; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651004; ENSP00000498396; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651167; ENSP00000498764; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651467; ENSP00000499128; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651495; ENSP00000498536; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651516; ENSP00000498873; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651613; ENSP00000498554; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651811; ENSP00000498472; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651848; ENSP00000498238; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000651866; ENSP00000498306; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000652028; ENSP00000498928; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000652463; ENSP00000499087; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000652506; ENSP00000498573; ENSG00000119950. [P50539-2]
DR   Ensembl; ENST00000652604; ENSP00000498971; ENSG00000119950. [P50539-4]
DR   GeneID; 4601; -.
DR   KEGG; hsa:4601; -.
DR   MANE-Select; ENST00000332674.9; ENSP00000331152.5; NM_130439.3; NP_569157.2. [P50539-3]
DR   UCSC; uc001kyy.3; human. [P50539-1]
DR   CTD; 4601; -.
DR   DisGeNET; 4601; -.
DR   GeneCards; MXI1; -.
DR   HGNC; HGNC:7534; MXI1.
DR   HPA; ENSG00000119950; Low tissue specificity.
DR   MalaCards; MXI1; -.
DR   MIM; 176807; phenotype.
DR   MIM; 600020; gene.
DR   neXtProt; NX_P50539; -.
DR   OpenTargets; ENSG00000119950; -.
DR   PharmGKB; PA31335; -.
DR   VEuPathDB; HostDB:ENSG00000119950; -.
DR   eggNOG; KOG2483; Eukaryota.
DR   GeneTree; ENSGT00940000155809; -.
DR   HOGENOM; CLU_082604_0_0_1; -.
DR   InParanoid; P50539; -.
DR   OMA; AQKHSNG; -.
DR   OrthoDB; 1311585at2759; -.
DR   PhylomeDB; P50539; -.
DR   TreeFam; TF315654; -.
DR   PathwayCommons; P50539; -.
DR   SignaLink; P50539; -.
DR   SIGNOR; P50539; -.
DR   BioGRID-ORCS; 4601; 7 hits in 1068 CRISPR screens.
DR   ChiTaRS; MXI1; human.
DR   GeneWiki; MXI1; -.
DR   GenomeRNAi; 4601; -.
DR   Pharos; P50539; Tbio.
DR   PRO; PR:P50539; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P50539; protein.
DR   Bgee; ENSG00000119950; Expressed in calcaneal tendon and 254 other tissues.
DR   ExpressionAtlas; P50539; baseline and differential.
DR   Genevisible; P50539; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:NTNU_SB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disease variant; DNA-binding; Nucleus;
KW   Proto-oncogene; Reference proteome; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..228
FT                   /note="Max-interacting protein 1"
FT                   /id="PRO_0000127285"
FT   DOMAIN          67..119
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          29..76
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          161..228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        54..71
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        168..187
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        188..228
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..36
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8918230, ECO:0000303|Ref.5"
FT                   /id="VSP_012825"
FT   VAR_SEQ         1..25
FT                   /note="MERVKMINVQRLLEAAEFLERRERE -> MGKRGRPRKEARCEGAGLAPAAP
FT                   PAVPPAVAAPQPPALPEDPAGAKPRCPFSDIFNTSENSMEKHINTFLQNVQILLEAASY
FT                   LEQIEKENKK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037943"
FT   VAR_SEQ         68..77
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5"
FT                   /id="VSP_043170"
FT   VARIANT         152
FT                   /note="E -> A (in prostate cancer; dbSNP:rs137852603)"
FT                   /evidence="ECO:0000269|PubMed:7773287"
FT                   /id="VAR_004499"
FT   CONFLICT        61
FT                   /note="S -> T (in Ref. 1; AAA75508)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   228 AA;  26062 MW;  82F83F499B907DD3 CRC64;
     MERVKMINVQ RLLEAAEFLE RRERECEHGY ASSFPSMPSP RLQHSKPPRR LSRAQKHSSG
     SSNTSTANRS THNELEKNRR AHLRLCLERL KVLIPLGPDC TRHTTLGLLN KAKAHIKKLE
     EAERKSQHQL ENLEREQRFL KWRLEQLQGP QEMERIRMDS IGSTISSDRS DSEREEIEVD
     VESTEFSHGE VDNISTTSIS DIDDHSSLPS IGSDEGYSSA SVKLSFTS
//
ID   GLPK5_HUMAN             Reviewed;         529 AA.
AC   Q6ZS86; B2R9I2; D3DNG2; Q8N2A7; Q8N5E6;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2011, sequence version 2.
DT   23-FEB-2022, entry version 143.
DE   RecName: Full=Putative glycerol kinase 5;
DE            Short=GK 5;
DE            Short=Glycerokinase 5;
DE            EC=2.7.1.30;
DE   AltName: Full=ATP:glycerol 3-phosphotransferase 5;
GN   Name=GK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Amygdala, Kidney, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + glycerol = ADP + H(+) + sn-glycerol 3-phosphate;
CC         Xref=Rhea:RHEA:21644, ChEBI:CHEBI:15378, ChEBI:CHEBI:17754,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:57597, ChEBI:CHEBI:456216;
CC         EC=2.7.1.30;
CC   -!- PATHWAY: Polyol metabolism; glycerol degradation via glycerol kinase
CC       pathway; sn-glycerol 3-phosphate from glycerol: step 1/1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q6ZS86-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6ZS86-2; Sequence=VSP_032122, VSP_032123;
CC       Name=3;
CC         IsoId=Q6ZS86-3; Sequence=VSP_032121;
CC   -!- SIMILARITY: Belongs to the FGGY kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK090901; BAC03542.1; -; mRNA.
DR   EMBL; AK127641; BAC87068.1; -; mRNA.
DR   EMBL; AK313792; BAG36529.1; -; mRNA.
DR   EMBL; AC108679; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78974.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78975.1; -; Genomic_DNA.
DR   EMBL; BC032470; AAH32470.1; -; mRNA.
DR   CCDS; CCDS33871.1; -. [Q6ZS86-1]
DR   RefSeq; NP_001034636.1; NM_001039547.2. [Q6ZS86-1]
DR   SMR; Q6ZS86; -.
DR   BioGRID; 129160; 3.
DR   STRING; 9606.ENSP00000418001; -.
DR   iPTMnet; Q6ZS86; -.
DR   PhosphoSitePlus; Q6ZS86; -.
DR   BioMuta; GK5; -.
DR   DMDM; 338817880; -.
DR   EPD; Q6ZS86; -.
DR   jPOST; Q6ZS86; -.
DR   MassIVE; Q6ZS86; -.
DR   MaxQB; Q6ZS86; -.
DR   PaxDb; Q6ZS86; -.
DR   PeptideAtlas; Q6ZS86; -.
DR   PRIDE; Q6ZS86; -.
DR   ProteomicsDB; 68203; -. [Q6ZS86-1]
DR   ProteomicsDB; 68204; -. [Q6ZS86-2]
DR   ProteomicsDB; 68205; -. [Q6ZS86-3]
DR   Antibodypedia; 35071; 198 antibodies from 26 providers.
DR   DNASU; 256356; -.
DR   Ensembl; ENST00000392993; ENSP00000418001; ENSG00000175066.
DR   Ensembl; ENST00000480757; ENSP00000419031; ENSG00000175066. [Q6ZS86-2]
DR   Ensembl; ENST00000492097; ENSP00000420312; ENSG00000175066. [Q6ZS86-2]
DR   GeneID; 256356; -.
DR   KEGG; hsa:256356; -.
DR   MANE-Select; ENST00000392993.7; ENSP00000418001.1; NM_001039547.3; NP_001034636.1.
DR   UCSC; uc003euq.2; human. [Q6ZS86-1]
DR   CTD; 256356; -.
DR   DisGeNET; 256356; -.
DR   GeneCards; GK5; -.
DR   HGNC; HGNC:28635; GK5.
DR   HPA; ENSG00000175066; Low tissue specificity.
DR   neXtProt; NX_Q6ZS86; -.
DR   OpenTargets; ENSG00000175066; -.
DR   PharmGKB; PA162389723; -.
DR   VEuPathDB; HostDB:ENSG00000175066; -.
DR   eggNOG; KOG2517; Eukaryota.
DR   GeneTree; ENSGT01000000214434; -.
DR   HOGENOM; CLU_009281_2_3_1; -.
DR   InParanoid; Q6ZS86; -.
DR   OMA; CTFLTWN; -.
DR   OrthoDB; 519426at2759; -.
DR   PhylomeDB; Q6ZS86; -.
DR   TreeFam; TF321504; -.
DR   PathwayCommons; Q6ZS86; -.
DR   UniPathway; UPA00618; UER00672.
DR   BioGRID-ORCS; 256356; 5 hits in 1046 CRISPR screens.
DR   ChiTaRS; GK5; human.
DR   GenomeRNAi; 256356; -.
DR   Pharos; Q6ZS86; Tbio.
DR   PRO; PR:Q6ZS86; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q6ZS86; protein.
DR   Bgee; ENSG00000175066; Expressed in C1 segment of cervical spinal cord and 194 other tissues.
DR   ExpressionAtlas; Q6ZS86; baseline and differential.
DR   Genevisible; Q6ZS86; HS.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004370; F:glycerol kinase activity; IBA:GO_Central.
DR   GO; GO:0016773; F:phosphotransferase activity, alcohol group as acceptor; IBA:GO_Central.
DR   GO; GO:0019563; P:glycerol catabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006071; P:glycerol metabolic process; IBA:GO_Central.
DR   GO; GO:0046167; P:glycerol-3-phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IBA:GO_Central.
DR   GO; GO:0006641; P:triglyceride metabolic process; IBA:GO_Central.
DR   CDD; cd07793; FGGY_GK5_metazoa; 1.
DR   InterPro; IPR043129; ATPase_NBD.
DR   InterPro; IPR000577; Carb_kinase_FGGY.
DR   InterPro; IPR018485; Carb_kinase_FGGY_C.
DR   InterPro; IPR018483; Carb_kinase_FGGY_CS.
DR   InterPro; IPR018484; Carb_kinase_FGGY_N.
DR   InterPro; IPR037444; GK5_FGGY.
DR   Pfam; PF02782; FGGY_C; 1.
DR   Pfam; PF00370; FGGY_N; 1.
DR   PIRSF; PIRSF000538; GlpK; 1.
DR   SUPFAM; SSF53067; SSF53067; 2.
DR   PROSITE; PS00445; FGGY_KINASES_2; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; ATP-binding; Glycerol metabolism; Kinase;
KW   Nucleotide-binding; Reference proteome; Transferase.
FT   CHAIN           1..529
FT                   /note="Putative glycerol kinase 5"
FT                   /id="PRO_0000323754"
FT   NP_BIND         439..444
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         28
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         98
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         275
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         297
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..279
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_032121"
FT   VAR_SEQ         273..301
FT                   /note="VADQQSAMFGECCFQTGDVKLTMGTGTFL -> LKVPGYDQNICYIFGKGTI
FT                   EPVFYHGSTL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_032122"
FT   VAR_SEQ         302..529
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_032123"
FT   CONFLICT        339
FT                   /note="T -> I (in Ref. 1; BAC87068)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   529 AA;  59156 MW;  9ED7CB1DA4D9417D CRC64;
     MSGLLTDPEQ RAQEPRYPGF VLGLDVGSSV IRCHVYDRAA RVCGSSVQKV ENLYPQIGWV
     EIDPDVLWIQ FVAVIKEAVK AAGIQMNQIV GLGISTQRAT FITWNKKTGN HFHNFISWQD
     LRAVELVKSW NNSLLMKIFH SSCRVLHFFT RSKRLFTASL FTFTTQQTSL RLVWILQNLT
     EVQKAVEEEN CCFGTIDTWL LYKLTKGSVY ATDFSNASTT GLFDPYKMCW SGMITSLISI
     PLSLLPPVRD TSHNFGSVDE EIFGVPIPIV ALVADQQSAM FGECCFQTGD VKLTMGTGTF
     LDINTGNSLQ QTTGGFYPLI GWKIGQEVVC LAESNAGDTG TAIKWAQQLD LFTDAAETEK
     MAKSLEDSEG VCFVPSFSGL QAPLNDPWAC ASFMGLKPST SKYHLVRAIL ESIAFRNKQL
     YEMMKKEIHI PVRKIRADGG VCKNGFVMQM TSDLINENID RPADIDMSCL GAASLAGLAV
     GFWTDKEELK KLRQSEVVFK PQKKCQEYEM SLENWAKAVK RSMNWYNKT
//
ID   AP1S3_HUMAN             Reviewed;         154 AA.
AC   Q96PC3; B4DQZ1; Q8WTY1; Q96DD1;
DT   20-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   23-FEB-2022, entry version 157.
DE   RecName: Full=AP-1 complex subunit sigma-3;
DE   AltName: Full=Adaptor protein complex AP-1 subunit sigma-1C;
DE   AltName: Full=Adaptor-related protein complex 1 subunit sigma-1C;
DE   AltName: Full=Clathrin assembly protein complex 1 sigma-1C small chain;
DE   AltName: Full=Golgi adaptor HA1/AP1 adaptin sigma-1C subunit;
DE   AltName: Full=Sigma 1C subunit of AP-1 clathrin;
DE   AltName: Full=Sigma-adaptin 1C;
DE   AltName: Full=Sigma1C-adaptin;
GN   Name=AP1S3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11598180; DOI=10.1091/mbc.12.10.2907;
RA   Boehm M., Bonifacino J.S.;
RT   "Adaptins: the final recount.";
RL   Mol. Biol. Cell 12:2907-2920(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, INVOLVEMENT IN PSORS15, VARIANTS PSORS15 CYS-4 AND TRP-33,
RP   CHARACTERIZATION OF VARIANTS PSORS15 CYS-4 AND TRP-33, AND VARIANTS LYS-17;
RP   ALA-22; ILE-32; VAL-79; THR-83 AND GLU-124.
RX   PubMed=24791904; DOI=10.1016/j.ajhg.2014.04.005;
RA   Setta-Kaffetzi N., Simpson M.A., Navarini A.A., Patel V.M., Lu H.C.,
RA   Allen M.H., Duckworth M., Bachelez H., Burden A.D., Choon S.E.,
RA   Griffiths C.E., Kirby B., Kolios A., Seyger M.M., Prins C., Smahi A.,
RA   Trembath R.C., Fraternali F., Smith C.H., Barker J.N., Capon F.;
RT   "AP1S3 mutations are associated with pustular psoriasis and impaired Toll-
RT   like receptor 3 trafficking.";
RL   Am. J. Hum. Genet. 94:790-797(2014).
CC   -!- FUNCTION: Subunit of clathrin-associated adaptor protein complex 1 that
CC       plays a role in protein sorting in the late-Golgi/trans-Golgi network
CC       (TGN) and/or endosomes. The AP complexes mediate both the recruitment
CC       of clathrin to membranes and the recognition of sorting signals within
CC       the cytosolic tails of transmembrane cargo molecules. Involved in TLR3
CC       trafficking (PubMed:24791904). {ECO:0000269|PubMed:24791904}.
CC   -!- SUBUNIT: Adaptor protein complex 1 (AP-1) is a heterotetramer composed
CC       of two large adaptins (gamma-type subunit AP1G1 and beta-type subunit
CC       AP1B1), a medium adaptin (mu-type subunit AP1M1 or AP1M2) and a small
CC       adaptin (sigma-type subunit AP1S1 or AP1S2 or AP1S3).
CC   -!- INTERACTION:
CC       Q96PC3; Q6PD74: AAGAB; NbExp=3; IntAct=EBI-3923129, EBI-719906;
CC       Q96PC3-2; Q6PD74: AAGAB; NbExp=3; IntAct=EBI-12780485, EBI-719906;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus. Cytoplasmic vesicle membrane;
CC       Peripheral membrane protein; Cytoplasmic side. Membrane, clathrin-
CC       coated pit. Note=Component of the coat surrounding the cytoplasmic face
CC       of coated vesicles located at the Golgi complex.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q96PC3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96PC3-2; Sequence=VSP_015944;
CC       Name=4;
CC         IsoId=Q96PC3-4; Sequence=VSP_040384;
CC       Name=3;
CC         IsoId=Q96PC3-3; Sequence=VSP_015942, VSP_015943;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DISEASE: Psoriasis 15, pustular (PSORS15) [MIM:616106]: A form of
CC       pustular psoriasis, a life-threatening disease defined by repeated
CC       flares of sudden onset consisting of diffuse erythematous skin eruption
CC       characterized by rapid coverage with pustules, high-grade fever,
CC       asthenia, marked leukocytosis, and elevated serum levels of C-reactive
CC       protein. {ECO:0000269|PubMed:24791904}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the adaptor complexes small subunit family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF393369; AAL09586.1; -; mRNA.
DR   EMBL; AK299026; BAG61103.1; -; mRNA.
DR   EMBL; AC012512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093884; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009606; AAH09606.1; -; mRNA.
DR   EMBL; BC021898; AAH21898.1; -; mRNA.
DR   CCDS; CCDS42827.1; -. [Q96PC3-4]
DR   RefSeq; NP_001034658.1; NM_001039569.1. [Q96PC3-4]
DR   PDB; 4HMY; X-ray; 7.00 A; S=1-154.
DR   PDB; 6CM9; EM; 3.73 A; S=1-154.
DR   PDB; 6CRI; EM; 6.80 A; S/a/b=1-142.
DR   PDB; 6D83; EM; 4.27 A; S=1-154.
DR   PDB; 6D84; EM; 6.72 A; Q/S=1-154.
DR   PDB; 6DFF; EM; 3.90 A; S=1-154.
DR   PDBsum; 4HMY; -.
DR   PDBsum; 6CM9; -.
DR   PDBsum; 6CRI; -.
DR   PDBsum; 6D83; -.
DR   PDBsum; 6D84; -.
DR   PDBsum; 6DFF; -.
DR   SMR; Q96PC3; -.
DR   BioGRID; 126229; 17.
DR   ComplexPortal; CPX-5049; Ubiquitous AP-1 Adaptor complex, sigma1c variant.
DR   CORUM; Q96PC3; -.
DR   IntAct; Q96PC3; 7.
DR   STRING; 9606.ENSP00000379891; -.
DR   iPTMnet; Q96PC3; -.
DR   PhosphoSitePlus; Q96PC3; -.
DR   BioMuta; AP1S3; -.
DR   DMDM; 21541959; -.
DR   jPOST; Q96PC3; -.
DR   MassIVE; Q96PC3; -.
DR   MaxQB; Q96PC3; -.
DR   PaxDb; Q96PC3; -.
DR   PeptideAtlas; Q96PC3; -.
DR   PRIDE; Q96PC3; -.
DR   ProteomicsDB; 77660; -. [Q96PC3-1]
DR   ProteomicsDB; 77661; -. [Q96PC3-2]
DR   ProteomicsDB; 77662; -. [Q96PC3-3]
DR   ProteomicsDB; 77663; -. [Q96PC3-4]
DR   Antibodypedia; 54195; 103 antibodies from 13 providers.
DR   DNASU; 130340; -.
DR   Ensembl; ENST00000396654; ENSP00000379891; ENSG00000152056. [Q96PC3-4]
DR   Ensembl; ENST00000415298; ENSP00000401705; ENSG00000152056. [Q96PC3-3]
DR   Ensembl; ENST00000443700; ENSP00000397155; ENSG00000152056. [Q96PC3-2]
DR   Ensembl; ENST00000446015; ENSP00000388738; ENSG00000152056.
DR   GeneID; 130340; -.
DR   KEGG; hsa:130340; -.
DR   MANE-Select; ENST00000396654.7; ENSP00000379891.2; NM_001039569.2; NP_001034658.1. [Q96PC3-4]
DR   UCSC; uc002vnn.4; human. [Q96PC3-1]
DR   CTD; 130340; -.
DR   DisGeNET; 130340; -.
DR   GeneCards; AP1S3; -.
DR   HGNC; HGNC:18971; AP1S3.
DR   HPA; ENSG00000152056; Tissue enhanced (epididymis).
DR   MalaCards; AP1S3; -.
DR   MIM; 615781; gene.
DR   MIM; 616106; phenotype.
DR   neXtProt; NX_Q96PC3; -.
DR   OpenTargets; ENSG00000152056; -.
DR   Orphanet; 163931; Acrodermatitis continua of Hallopeau.
DR   Orphanet; 247353; Generalized pustular psoriasis.
DR   Orphanet; 163927; Pustulosis palmaris et plantaris.
DR   VEuPathDB; HostDB:ENSG00000152056; -.
DR   eggNOG; KOG0934; Eukaryota.
DR   GeneTree; ENSGT00970000193372; -.
DR   HOGENOM; CLU_061221_4_1_1; -.
DR   InParanoid; Q96PC3; -.
DR   OMA; YTAISER; -.
DR   OrthoDB; 1307450at2759; -.
DR   PhylomeDB; Q96PC3; -.
DR   TreeFam; TF312921; -.
DR   PathwayCommons; Q96PC3; -.
DR   Reactome; R-HSA-164940; Nef mediated downregulation of MHC class I complex cell surface expression.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   SignaLink; Q96PC3; -.
DR   BioGRID-ORCS; 130340; 9 hits in 1047 CRISPR screens.
DR   ChiTaRS; AP1S3; human.
DR   GenomeRNAi; 130340; -.
DR   Pharos; Q96PC3; Tbio.
DR   PRO; PR:Q96PC3; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q96PC3; protein.
DR   Bgee; ENSG00000152056; Expressed in corpus epididymis and 150 other tissues.
DR   ExpressionAtlas; Q96PC3; baseline and differential.
DR   Genevisible; Q96PC3; HS.
DR   GO; GO:0030121; C:AP-1 adaptor complex; IEA:InterPro.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0035615; F:clathrin adaptor activity; IEA:InterPro.
DR   GO; GO:0006605; P:protein targeting; IMP:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; IBA:GO_Central.
DR   CDD; cd14831; AP1_sigma; 1.
DR   InterPro; IPR044733; AP1_sigma.
DR   InterPro; IPR016635; AP_complex_ssu.
DR   InterPro; IPR022775; AP_mu_sigma_su.
DR   InterPro; IPR000804; Clathrin_sm-chain_CS.
DR   InterPro; IPR011012; Longin-like_dom_sf.
DR   PANTHER; PTHR11753; PTHR11753; 1.
DR   Pfam; PF01217; Clat_adaptor_s; 1.
DR   PIRSF; PIRSF015588; AP_complex_sigma; 1.
DR   SUPFAM; SSF64356; SSF64356; 1.
DR   PROSITE; PS00989; CLAT_ADAPTOR_S; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Coated pit; Cytoplasmic vesicle;
KW   Disease variant; Golgi apparatus; Membrane; Protein transport;
KW   Reference proteome; Transport.
FT   CHAIN           1..154
FT                   /note="AP-1 complex subunit sigma-3"
FT                   /id="PRO_0000193801"
FT   VAR_SEQ         98..104
FT                   /note="VCELDII -> TWPFARA (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015942"
FT   VAR_SEQ         105..154
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015943"
FT   VAR_SEQ         144..154
FT                   /note="VSTVSQTMGER -> NRLSPRGRDCSEPRSCHCTLA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015944"
FT   VAR_SEQ         144..154
FT                   /note="VSTVSQTMGER -> TMEEYMNKPTF (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_040384"
FT   VARIANT         4
FT                   /note="F -> C (in PSORS15; results in decreased protein
FT                   levels; dbSNP:rs116107386)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072545"
FT   VARIANT         17
FT                   /note="Q -> K (in dbSNP:rs750870128)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072546"
FT   VARIANT         22
FT                   /note="T -> A (in dbSNP:rs149183052)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072547"
FT   VARIANT         32
FT                   /note="T -> I (in dbSNP:rs78536455)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072548"
FT   VARIANT         33
FT                   /note="R -> W (in PSORS15; results in decreased TLR3
FT                   targeting to the endosomes indicating impaired function;
FT                   dbSNP:rs138292988)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072549"
FT   VARIANT         79
FT                   /note="L -> V (in dbSNP:rs34353588)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072550"
FT   VARIANT         83
FT                   /note="I -> T (in dbSNP:rs202157374)"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072551"
FT   VARIANT         124
FT                   /note="Q -> E"
FT                   /evidence="ECO:0000269|PubMed:24791904"
FT                   /id="VAR_072552"
SQ   SEQUENCE   154 AA;  18280 MW;  178755E8EA4E9ABE CRC64;
     MIHFILLFSR QGKLRLQKWY ITLPDKERKK ITREIVQIIL SRGHRTSSFV DWKELKLVYK
     RYASLYFCCA IENQDNELLT LEIVHRYVEL LDKYFGNVCE LDIIFNFEKA YFILDEFIIG
     GEIQETSKKI AVKAIEDSDM LQEVSTVSQT MGER
//
ID   TYW5_HUMAN              Reviewed;         315 AA.
AC   A2RUC4; B2RNE3; Q8N1R2;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 1.
DT   23-FEB-2022, entry version 110.
DE   RecName: Full=tRNA wybutosine-synthesizing protein 5 {ECO:0000305|PubMed:20739293};
DE            Short=hTYW5;
DE            EC=1.14.11.42 {ECO:0000269|PubMed:20739293, ECO:0000269|PubMed:20972222};
DE   AltName: Full=tRNA(Phe) (7-(3-amino-3-carboxypropyl)wyosine(37)-C(2))-hydroxylase;
GN   Name=TYW5; Synonyms=C2orf60;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Retinoblastoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=20739293; DOI=10.1074/jbc.m110.156398;
RA   Noma A., Ishitani R., Kato M., Nagao A., Nureki O., Suzuki T.;
RT   "Expanding role of the jumonji C domain as an RNA hydroxylase.";
RL   J. Biol. Chem. 285:34503-34507(2010).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 4-311 IN COMPLEX WITH
RP   2-OXOGLUTARATE AND NICKEL ION, FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   COFACTOR, SUBUNIT, AND MUTAGENESIS OF ARG-108 AND ARG-149.
RX   PubMed=20972222; DOI=10.1093/nar/gkq919;
RA   Kato M., Araiso Y., Noma A., Nagao A., Suzuki T., Ishitani R., Nureki O.;
RT   "Crystal structure of a novel JmjC-domain-containing protein, TYW5,
RT   involved in tRNA modification.";
RL   Nucleic Acids Res. 39:1576-1585(2011).
CC   -!- FUNCTION: tRNA hydroxylase that acts as a component of the wybutosine
CC       biosynthesis pathway. Wybutosine is a hyper modified guanosine with a
CC       tricyclic base found at the 3'-position adjacent to the anticodon of
CC       eukaryotic phenylalanine tRNA. Catalyzes the hydroxylation of 7-(a-
CC       amino-a-carboxypropyl)wyosine (yW-72) into undermodified
CC       hydroxywybutosine (OHyW*). OHyW* being further transformed into
CC       hydroxywybutosine (OHyW) by LCMT2/TYW4. OHyW is a derivative of
CC       wybutosine found in higher eukaryotes. {ECO:0000269|PubMed:20739293,
CC       ECO:0000269|PubMed:20972222}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate + 7-[(3S)-3-amino-3-carboxypropyl]wyosine(37)
CC         in tRNA(Phe) + O2 = 7-(2-hydroxy-3-amino-3-carboxypropyl)wyosine(37)
CC         in tRNA(Phe) + CO2 + succinate; Xref=Rhea:RHEA:37899, Rhea:RHEA-
CC         COMP:10379, Rhea:RHEA-COMP:11848, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16526, ChEBI:CHEBI:16810, ChEBI:CHEBI:30031,
CC         ChEBI:CHEBI:73543, ChEBI:CHEBI:73603; EC=1.14.11.42;
CC         Evidence={ECO:0000269|PubMed:20739293, ECO:0000269|PubMed:20972222};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37900;
CC         Evidence={ECO:0000269|PubMed:20739293};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:20972222};
CC       Note=Binds 1 Fe(2+) ion per subunit. {ECO:0000269|PubMed:20972222};
CC   -!- PATHWAY: tRNA modification; wybutosine-tRNA(Phe) biosynthesis.
CC       {ECO:0000269|PubMed:20739293, ECO:0000269|PubMed:20972222}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:20972222}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=A2RUC4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=A2RUC4-2; Sequence=VSP_029106;
CC   -!- SIMILARITY: Belongs to the TYW5 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH63502.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK095272; BAC04517.1; -; mRNA.
DR   EMBL; AK298977; BAG61071.1; -; mRNA.
DR   EMBL; AC097717; AAY24162.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70191.1; -; Genomic_DNA.
DR   EMBL; BC063502; AAH63502.1; ALT_INIT; mRNA.
DR   EMBL; BC132835; AAI32836.1; -; mRNA.
DR   EMBL; BC136837; AAI36838.1; -; mRNA.
DR   CCDS; CCDS42795.1; -. [A2RUC4-1]
DR   RefSeq; NP_001034782.1; NM_001039693.2. [A2RUC4-1]
DR   PDB; 3AL5; X-ray; 2.50 A; A/B/C/D=1-315.
DR   PDB; 3AL6; X-ray; 2.80 A; A/B/C/D=1-315.
DR   PDBsum; 3AL5; -.
DR   PDBsum; 3AL6; -.
DR   SMR; A2RUC4; -.
DR   BioGRID; 126193; 13.
DR   IntAct; A2RUC4; 8.
DR   STRING; 9606.ENSP00000346627; -.
DR   iPTMnet; A2RUC4; -.
DR   PhosphoSitePlus; A2RUC4; -.
DR   BioMuta; TYW5; -.
DR   EPD; A2RUC4; -.
DR   jPOST; A2RUC4; -.
DR   MassIVE; A2RUC4; -.
DR   MaxQB; A2RUC4; -.
DR   PaxDb; A2RUC4; -.
DR   PeptideAtlas; A2RUC4; -.
DR   PRIDE; A2RUC4; -.
DR   ProteomicsDB; 511; -. [A2RUC4-1]
DR   ProteomicsDB; 512; -. [A2RUC4-2]
DR   Antibodypedia; 34079; 90 antibodies from 19 providers.
DR   DNASU; 129450; -.
DR   Ensembl; ENST00000354611; ENSP00000346627; ENSG00000162971.
DR   GeneID; 129450; -.
DR   KEGG; hsa:129450; -.
DR   MANE-Select; ENST00000354611.9; ENSP00000346627.4; NM_001039693.3; NP_001034782.1.
DR   UCSC; uc002uvi.5; human. [A2RUC4-1]
DR   CTD; 129450; -.
DR   GeneCards; TYW5; -.
DR   HGNC; HGNC:26754; TYW5.
DR   HPA; ENSG00000162971; Low tissue specificity.
DR   neXtProt; NX_A2RUC4; -.
DR   OpenTargets; ENSG00000162971; -.
DR   PharmGKB; PA162379298; -.
DR   VEuPathDB; HostDB:ENSG00000162971; -.
DR   eggNOG; KOG2132; Eukaryota.
DR   GeneTree; ENSGT00940000158493; -.
DR   HOGENOM; CLU_016785_4_0_1; -.
DR   InParanoid; A2RUC4; -.
DR   OMA; PLYDDRP; -.
DR   OrthoDB; 1385616at2759; -.
DR   PhylomeDB; A2RUC4; -.
DR   TreeFam; TF332364; -.
DR   BRENDA; 1.14.11.42; 2681.
DR   PathwayCommons; A2RUC4; -.
DR   Reactome; R-HSA-6782861; Synthesis of wybutosine at G37 of tRNA(Phe).
DR   SignaLink; A2RUC4; -.
DR   UniPathway; UPA00375; -.
DR   BioGRID-ORCS; 129450; 6 hits in 1046 CRISPR screens.
DR   GenomeRNAi; 129450; -.
DR   Pharos; A2RUC4; Tbio.
DR   PRO; PR:A2RUC4; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; A2RUC4; protein.
DR   Bgee; ENSG00000162971; Expressed in epithelial cell of pancreas and 177 other tissues.
DR   ExpressionAtlas; A2RUC4; baseline and differential.
DR   Genevisible; A2RUC4; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:Reactome.
DR   GO; GO:0016706; F:2-oxoglutarate-dependent dioxygenase activity; IBA:GO_Central.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000049; F:tRNA binding; IDA:UniProtKB.
DR   GO; GO:0102524; F:tRNAPhe (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0031591; P:wybutosine biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR041667; Cupin_8.
DR   InterPro; IPR003347; JmjC_dom.
DR   InterPro; IPR029612; TYW5.
DR   PANTHER; PTHR12461:SF50; PTHR12461:SF50; 1.
DR   Pfam; PF13621; Cupin_8; 1.
DR   SMART; SM00558; JmjC; 1.
DR   PROSITE; PS51184; JMJC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Dioxygenase; Iron; Metal-binding;
KW   Oxidoreductase; Reference proteome; tRNA processing.
FT   CHAIN           1..315
FT                   /note="tRNA wybutosine-synthesizing protein 5"
FT                   /id="PRO_0000309274"
FT   DOMAIN          102..267
FT                   /note="JmjC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00538"
FT   METAL           160
FT                   /note="Iron; catalytic"
FT   METAL           162
FT                   /note="Iron; catalytic"
FT   METAL           235
FT                   /note="Iron; catalytic"
FT   BINDING         106
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000269|PubMed:20972222"
FT   BINDING         166
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000269|PubMed:20972222"
FT   BINDING         175
FT                   /note="2-oxoglutarate"
FT                   /evidence="ECO:0000269|PubMed:20972222"
FT   VAR_SEQ         1..163
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_029106"
FT   VARIANT         50
FT                   /note="S -> G (in dbSNP:rs10497844)"
FT                   /id="VAR_036926"
FT   MUTAGEN         108
FT                   /note="R->A: Abolishes enzyme activity and ability to bind
FT                   tRNA."
FT                   /evidence="ECO:0000269|PubMed:20972222"
FT   MUTAGEN         149
FT                   /note="R->A: Abolishes enzyme activity and ability to bind
FT                   tRNA."
FT                   /evidence="ECO:0000269|PubMed:20972222"
FT   STRAND          10..13
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           16..22
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           24..26
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          30..34
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           40..43
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           46..53
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          57..66
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   TURN            70..72
FT                   /evidence="ECO:0007829|PDB:3AL6"
FT   STRAND          76..81
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           82..90
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   TURN            114..116
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           121..124
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           126..129
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           140..142
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          143..151
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          156..160
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          163..170
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          175..180
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           182..188
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          194..196
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   TURN            205..207
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           211..213
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          216..221
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          226..229
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          234..241
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          243..250
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           255..257
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   STRAND          263..265
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           270..286
FT                   /evidence="ECO:0007829|PDB:3AL5"
FT   HELIX           291..308
FT                   /evidence="ECO:0007829|PDB:3AL5"
SQ   SEQUENCE   315 AA;  36548 MW;  F291C48E8CA729FE CRC64;
     MAGQHLPVPR LEGVSREQFM QHLYPQRKPL VLEGIDLGPC TSKWTVDYLS QVGGKKEVKI
     HVAAVAQMDF ISKNFVYRTL PFDQLVQRAA EEKHKEFFVS EDEKYYLRSL GEDPRKDVAD
     IRKQFPLLKG DIKFPEFFKE EQFFSSVFRI SSPGLQLWTH YDVMDNLLIQ VTGKKRVVLF
     SPRDAQYLYL KGTKSEVLNI DNPDLAKYPL FSKARRYECS LEAGDVLFIP ALWFHNVISE
     EFGVGVNIFW KHLPSECYDK TDTYGNKDPT AASRAAQILD RALKTLAELP EEYRDFYARR
     MVLHIQDKAY SKNSE
//
ID   MINY2_HUMAN             Reviewed;         621 AA.
AC   Q8NBR6; B2RTT8; Q9ULQ6;
DT   22-JUL-2008, integrated into UniProtKB/Swiss-Prot.
DT   22-JUL-2008, sequence version 2.
DT   23-FEB-2022, entry version 131.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase MINDY-2 {ECO:0000303|PubMed:27292798};
DE            EC=3.4.19.12 {ECO:0000269|PubMed:27292798};
DE   AltName: Full=Deubiquitinating enzyme MINDY-2 {ECO:0000303|PubMed:27292798};
DE   AltName: Full=Protein FAM63B;
GN   Name=MINDY2 {ECO:0000312|HGNC:HGNC:26954}; Synonyms=FAM63B, KIAA1164;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-605 (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 231-621 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis from
RT   size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND GENE FAMILY.
RX   PubMed=27292798; DOI=10.1016/j.molcel.2016.05.009;
RA   Abdul Rehman S.A., Kristariyanto Y.A., Choi S.Y., Nkosi P.J., Weidlich S.,
RA   Labib K., Hofmann K., Kulathu Y.;
RT   "MINDY-1 is a member of an evolutionarily conserved and structurally
RT   distinct new family of deubiquitinating enzymes.";
RL   Mol. Cell 63:146-155(2016).
RN   [8]
RP   BINDING TO POLYUBIQUITIN CHAINS, AND MUTAGENESIS OF ALA-519 AND ALA-546.
RX   PubMed=28082312; DOI=10.15252/embr.201643205;
RA   Kristariyanto Y.A., Abdul Rehman S.A., Weidlich S., Knebel A., Kulathu Y.;
RT   "A single MIU motif of MINDY-1 recognizes K48-linked polyubiquitin
RT   chains.";
RL   EMBO Rep. 18:392-402(2017).
CC   -!- FUNCTION: Hydrolase that can remove 'Lys-48'-linked conjugated
CC       ubiquitin from proteins (PubMed:27292798). Binds to polyubiquitin
CC       chains of different linkage types, including 'Lys-6', 'Lys-11', 'Lys-
CC       29', 'Lys-33', 'Lys-48' and 'Lys-63' (PubMed:28082312). May play a
CC       regulatory role at the level of protein turnover (PubMed:27292798).
CC       {ECO:0000269|PubMed:27292798, ECO:0000269|PubMed:28082312}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:27292798};
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NBR6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NBR6-2; Sequence=VSP_034719;
CC   -!- SIMILARITY: Belongs to the MINDY deubiquitinase family. FAM63
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=EAW77545.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471082; EAW77545.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471082; EAW77546.1; -; Genomic_DNA.
DR   EMBL; BC140811; AAI40812.1; -; mRNA.
DR   EMBL; BC144616; AAI44617.1; -; mRNA.
DR   EMBL; AK075319; BAC11545.1; -; mRNA.
DR   EMBL; AB032990; BAA86478.1; -; mRNA.
DR   CCDS; CCDS42046.1; -. [Q8NBR6-1]
DR   CCDS; CCDS45268.1; -. [Q8NBR6-2]
DR   RefSeq; NP_001035540.1; NM_001040450.2. [Q8NBR6-1]
DR   RefSeq; NP_001035543.1; NM_001040453.2. [Q8NBR6-2]
DR   PDB; 6Z49; X-ray; 2.00 A; A/B/C/D=241-504.
DR   PDB; 6Z7V; X-ray; 2.65 A; A/B=241-504.
DR   PDB; 7NPI; X-ray; 2.81 A; A/G/M/S/Y/e/k=241-504.
DR   PDBsum; 6Z49; -.
DR   PDBsum; 6Z7V; -.
DR   PDBsum; 7NPI; -.
DR   SASBDB; Q8NBR6; -.
DR   SMR; Q8NBR6; -.
DR   BioGRID; 120085; 30.
DR   IntAct; Q8NBR6; 17.
DR   MINT; Q8NBR6; -.
DR   STRING; 9606.ENSP00000452885; -.
DR   iPTMnet; Q8NBR6; -.
DR   PhosphoSitePlus; Q8NBR6; -.
DR   BioMuta; MINDY2; -.
DR   DMDM; 205831477; -.
DR   EPD; Q8NBR6; -.
DR   jPOST; Q8NBR6; -.
DR   MassIVE; Q8NBR6; -.
DR   MaxQB; Q8NBR6; -.
DR   PaxDb; Q8NBR6; -.
DR   PeptideAtlas; Q8NBR6; -.
DR   PRIDE; Q8NBR6; -.
DR   ProteomicsDB; 72812; -. [Q8NBR6-1]
DR   ProteomicsDB; 72813; -. [Q8NBR6-2]
DR   Antibodypedia; 63975; 60 antibodies from 12 providers.
DR   DNASU; 54629; -.
DR   Ensembl; ENST00000450403; ENSP00000393231; ENSG00000128923. [Q8NBR6-2]
DR   Ensembl; ENST00000559228; ENSP00000452885; ENSG00000128923.
DR   GeneID; 54629; -.
DR   KEGG; hsa:54629; -.
DR   MANE-Select; ENST00000559228.6; ENSP00000452885.1; NM_001040450.3; NP_001035540.1.
DR   UCSC; uc002afi.4; human. [Q8NBR6-1]
DR   CTD; 54629; -.
DR   DisGeNET; 54629; -.
DR   GeneCards; MINDY2; -.
DR   HGNC; HGNC:26954; MINDY2.
DR   HPA; ENSG00000128923; Low tissue specificity.
DR   MIM; 618408; gene.
DR   neXtProt; NX_Q8NBR6; -.
DR   OpenTargets; ENSG00000128923; -.
DR   PharmGKB; PA142671873; -.
DR   VEuPathDB; HostDB:ENSG00000128923; -.
DR   eggNOG; KOG2427; Eukaryota.
DR   GeneTree; ENSGT00390000016607; -.
DR   HOGENOM; CLU_022566_3_1_1; -.
DR   InParanoid; Q8NBR6; -.
DR   OMA; EYTPECV; -.
DR   OrthoDB; 1601180at2759; -.
DR   PhylomeDB; Q8NBR6; -.
DR   TreeFam; TF314589; -.
DR   PathwayCommons; Q8NBR6; -.
DR   SignaLink; Q8NBR6; -.
DR   BioGRID-ORCS; 54629; 101 hits in 1083 CRISPR screens.
DR   ChiTaRS; MINDY2; human.
DR   GenomeRNAi; 54629; -.
DR   Pharos; Q8NBR6; Tbio.
DR   PRO; PR:Q8NBR6; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q8NBR6; protein.
DR   Bgee; ENSG00000128923; Expressed in cerebellum and 243 other tissues.
DR   ExpressionAtlas; Q8NBR6; baseline and differential.
DR   Genevisible; Q8NBR6; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0016807; F:cysteine-type carboxypeptidase activity; IDA:UniProtKB.
DR   GO; GO:0071795; F:K11-linked polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0036435; F:K48-linked polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0071796; F:K6-linked polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:1990380; F:Lys48-specific deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent deubiquitinase; IEA:UniProtKB-EC.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IBA:GO_Central.
DR   InterPro; IPR007518; MINDY.
DR   InterPro; IPR033979; MINDY_domain.
DR   PANTHER; PTHR18063; PTHR18063; 1.
DR   Pfam; PF04424; MINDY_DUB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Hydrolase; Phosphoprotein; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..621
FT                   /note="Ubiquitin carboxyl-terminal hydrolase MINDY-2"
FT                   /id="PRO_0000344042"
FT   REGION          1..106
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          119..179
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          507..559
FT                   /note="Ubiquitin-binding domain (UBD)"
FT                   /evidence="ECO:0000305|PubMed:27292798"
FT   REGION          556..621
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        145..179
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        561..594
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        595..621
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        266
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:Q8N5J2"
FT   ACT_SITE        448
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q8N5J2"
FT   SITE            542
FT                   /note="Ubiquitin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q8N5J2"
FT   SITE            545..546
FT                   /note="Ubiquitin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q8N5J2"
FT   SITE            549
FT                   /note="Ubiquitin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q8N5J2"
FT   MOD_RES         94
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         580
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10574461,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_034719"
FT   MUTAGEN         519
FT                   /note="A->G: Strongly decreased binding to 'Lys-48' or
FT                   'Lys-63'-tetraubiquitin chains."
FT                   /evidence="ECO:0000269|PubMed:28082312"
FT   MUTAGEN         546
FT                   /note="A->G: No effect on binding to 'Lys-48'- or 'Lys-63'-
FT                   tetraubiquitin chains."
FT                   /evidence="ECO:0000269|PubMed:28082312"
SQ   SEQUENCE   621 AA;  67106 MW;  ED97D0BBCA6DC421 CRC64;
     MESSPESLQP LEHGVAAGPA SGTGSSQEGL QETRLAAGDG PGVWAAETSG GNGLGAAAAR
     RSLPDSASPA GSPEVPGPCS SSAGLDLKDS GLESPAAAEA PLRGQYKVTA SPETAVAGVG
     HELGTAGDAG ARPDLAGTCQ AELTAAGSEE PSSAGGLSSS CSDPSPPGES PSLDSLESFS
     NLHSFPSSCE FNSEEGAENR VPEEEEGAAV LPGAVPLCKE EEGEETAQVL AASKERFPGQ
     SVYHIKWIQW KEENTPIITQ NENGPCPLLA ILNVLLLAWK VKLPPMMEII TAEQLMEYLG
     DYMLDAKPKE ISEIQRLNYE QNMSDAMAIL HKLQTGLDVN VRFTGVRVFE YTPECIVFDL
     LDIPLYHGWL VDPQIDDIVK AVGNCSYNQL VEKIISCKQS DNSELVSEGF VAEQFLNNTA
     TQLTYHGLCE LTSTVQEGEL CVFFRNNHFS TMTKYKGQLY LLVTDQGFLT EEKVVWESLH
     NVDGDGNFCD SEFHLRPPSD PETVYKGQQD QIDQDYLMAL SLQQEQQSQE INWEQIPEGI
     SDLELAKKLQ EEEDRRASQY YQEQEQAAAA AAAASTQAQQ GQPAQASPSS GRQSGNSERK
     RKEPREKDKE KEKEKNSCVI L
//
ID   UDB11_HUMAN             Reviewed;         529 AA.
AC   O75310; Q3KNV9;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   23-FEB-2022, entry version 165.
DE   RecName: Full=UDP-glucuronosyltransferase 2B11;
DE            Short=UDPGT 2B11;
DE            EC=2.4.1.17;
DE   Flags: Precursor;
GN   Name=UGT2B11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9675083; DOI=10.1006/bbrc.1998.8908;
RA   Beaulieu M., Levesque E., Hum D.W., Belanger A.;
RT   "Isolation and characterization of a human orphan UDP-
RT   glucuronosyltransferase, UGT2B11.";
RL   Biochem. Biophys. Res. Commun. 248:44-50(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: UDPGT is of major importance in the conjugation and
CC       subsequent elimination of potentially toxic xenobiotics and endogenous
CC       compounds.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glucuronate acceptor + UDP-alpha-D-glucuronate = acceptor
CC         beta-D-glucuronoside + H(+) + UDP; Xref=Rhea:RHEA:21032,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:58052, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:132367, ChEBI:CHEBI:132368; EC=2.4.1.17;
CC   -!- INTERACTION:
CC       O75310; Q12797-6: ASPH; NbExp=3; IntAct=EBI-12891746, EBI-12092171;
CC       O75310; P55061: TMBIM6; NbExp=3; IntAct=EBI-12891746, EBI-1045825;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane {ECO:0000305}; Single-pass
CC       membrane protein {ECO:0000305}. Endoplasmic reticulum membrane
CC       {ECO:0000305}; Single-pass membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- SIMILARITY: Belongs to the UDP-glycosyltransferase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF016492; AAC27891.1; -; mRNA.
DR   EMBL; BC069441; AAH69441.1; -; mRNA.
DR   EMBL; BC107059; AAI07060.1; -; mRNA.
DR   EMBL; BC107060; AAI07061.1; -; mRNA.
DR   CCDS; CCDS3527.1; -.
DR   PIR; JE0200; JE0200.
DR   RefSeq; NP_001064.1; NM_001073.2.
DR   SMR; O75310; -.
DR   BioGRID; 115945; 6.
DR   IntAct; O75310; 2.
DR   STRING; 9606.ENSP00000387683; -.
DR   ChEMBL; CHEMBL4523985; -.
DR   CAZy; GT1; Glycosyltransferase Family 1.
DR   GlyGen; O75310; 1 site.
DR   iPTMnet; O75310; -.
DR   PhosphoSitePlus; O75310; -.
DR   BioMuta; UGT2B11; -.
DR   jPOST; O75310; -.
DR   MassIVE; O75310; -.
DR   PaxDb; O75310; -.
DR   PeptideAtlas; O75310; -.
DR   PRIDE; O75310; -.
DR   ProteomicsDB; 49886; -.
DR   Antibodypedia; 57751; 56 antibodies from 13 providers.
DR   DNASU; 10720; -.
DR   Ensembl; ENST00000446444; ENSP00000387683; ENSG00000213759.
DR   GeneID; 10720; -.
DR   KEGG; hsa:10720; -.
DR   MANE-Select; ENST00000446444.2; ENSP00000387683.1; NM_001073.3; NP_001064.1.
DR   UCSC; uc003heh.5; human.
DR   CTD; 10720; -.
DR   DisGeNET; 10720; -.
DR   GeneCards; UGT2B11; -.
DR   HGNC; HGNC:12545; UGT2B11.
DR   HPA; ENSG00000213759; Tissue enriched (breast).
DR   MIM; 603064; gene.
DR   neXtProt; NX_O75310; -.
DR   OpenTargets; ENSG00000213759; -.
DR   PharmGKB; PA37187; -.
DR   VEuPathDB; HostDB:ENSG00000213759; -.
DR   eggNOG; KOG1192; Eukaryota.
DR   GeneTree; ENSGT00940000165281; -.
DR   HOGENOM; CLU_012949_0_2_1; -.
DR   InParanoid; O75310; -.
DR   OMA; DAIICET; -.
DR   OrthoDB; 508327at2759; -.
DR   PhylomeDB; O75310; -.
DR   TreeFam; TF315472; -.
DR   BRENDA; 2.4.1.17; 2681.
DR   PathwayCommons; O75310; -.
DR   Reactome; R-HSA-156588; Glucuronidation.
DR   SignaLink; O75310; -.
DR   BioGRID-ORCS; 10720; 22 hits in 959 CRISPR screens.
DR   ChiTaRS; UGT2B11; human.
DR   GenomeRNAi; 10720; -.
DR   Pharos; O75310; Tbio.
DR   PRO; PR:O75310; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; O75310; protein.
DR   Bgee; ENSG00000213759; Expressed in intestine and 50 other tissues.
DR   Genevisible; O75310; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008210; P:estrogen metabolic process; IDA:UniProtKB.
DR   GO; GO:0052697; P:xenobiotic glucuronidation; IDA:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:ProtInc.
DR   CDD; cd03784; GT1_Gtf-like; 1.
DR   InterPro; IPR002213; UDP_glucos_trans.
DR   InterPro; IPR035595; UDP_glycos_trans_CS.
DR   Pfam; PF00201; UDPGT; 1.
DR   PROSITE; PS00375; UDPGT; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Glycoprotein; Glycosyltransferase; Membrane;
KW   Microsome; Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..529
FT                   /note="UDP-glucuronosyltransferase 2B11"
FT                   /id="PRO_0000036035"
FT   TRANSMEM        493..513
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         135
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BWQ1"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   529 AA;  61038 MW;  CE4AC3C71CFC2AB4 CRC64;
     MTLKWTSVLL LIHLSCYFSS GSCGKVLVWA AEYSHWMNMK TILKELVQRG HEVTVLASSA
     SILFDPNDAS TLKFEVYPTS LTKTEFENII MQQVKRWSDI RKDSFWLYFS QEQEILWELY
     DIFRNFCKDV VSNKKVMKKL QESRFDIVFA DAVFPCGELL AALLNIRFVY SLRFTPGYTI
     ERHSGGLIFP PSYIPIVMSK LSDQMTFMER VKNMIYVLYF DFWFQMSDMK KWDQFYSEVL
     GRPTTLFETM GKADIWLMRN SWSFQFPHPF LPNVDFVGGF HCKPAKPLPK EMEEFVQSSG
     ENGVVVFSLG SVISNMTAER ANVIATALAK IPQKVLWRFD GNKPDALGLN TRLYKWIPQN
     DLLGHPKTRA FITHGGANGI YEAIYHGIPM VGIPLFFDQP DNIAHMKAKG AAVRLDFNTM
     SSTDLLNALK TVINDPLYKE NIMKLSRIQH DQPVKPLDRA VFWIEFVMPH KGAKHLRVAA
     HDLTWFQYHS LDVIGFLLAC VATVIFIITK FCLFCFWKFA RKGKKGKRD
//
ID   PDE11_HUMAN             Reviewed;         933 AA.
AC   Q9HCR9; Q14CD1; Q53T16; Q96S76; Q9GZY7; Q9HB46; Q9NY45;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   23-FEB-2022, entry version 152.
DE   RecName: Full=Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;
DE            EC=3.1.4.35;
DE            EC=3.1.4.53;
DE   AltName: Full=cAMP and cGMP phosphodiesterase 11A;
GN   Name=PDE11A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, SUBCELLULAR
RP   LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Prostate;
RX   PubMed=10906126; DOI=10.1074/jbc.m003041200;
RA   Yuasa K., Kotera J., Fujishige K., Michibata H., Sasaki T., Omori K.;
RT   "Isolation and characterization of two novel phosphodiesterase PDE11A
RT   variants showing unique structure and tissue-specific expression.";
RL   J. Biol. Chem. 275:31469-31479(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10725373; DOI=10.1073/pnas.97.7.3702;
RA   Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I.,
RA   Soderling S., Hetman J., Beavo J.A., Phillips S.C.;
RT   "Molecular cloning and characterization of a distinct human
RT   phosphodiesterase gene family: PDE11A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3702-3707(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND ACTIVITY REGULATION.
RX   PubMed=11050148; DOI=10.1073/pnas.200355397;
RA   Hetman J.M., Robas N.M., Baxendale R., Fidock M., Phillips S.C.,
RA   Soderling S.H., Beavo J.A.;
RT   "Cloning and characterisation of two splice variants of human
RT   phosphodiesterase 11A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12891-12895(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND
RP   4), AND TISSUE SPECIFICITY.
RX   PubMed=11121118; DOI=10.1046/j.1432-1327.2001.01866.x;
RA   Yuasa K., Kanoh Y., Okumura K., Omori K.;
RT   "Genomic organization of the human phosphodiesterase PDE11A gene:
RT   evolutionary relatedness with other PDEs containing GAF domains.";
RL   Eur. J. Biochem. 268:168-178(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=15800651; DOI=10.1038/sj.ijir.3901317;
RA   Loughney K., Taylor J., Florio V.A.;
RT   "3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human
RT   tissues.";
RL   Int. J. Impot. Res. 17:320-325(2005).
RN   [8]
RP   ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=16079899; DOI=10.1038/sj.ijir.3901377;
RA   Francis S.H.;
RT   "Phosphodiesterase 11 (PDE11): is it a player in human testicular
RT   function?";
RL   Int. J. Impot. Res. 17:467-468(2005).
RN   [9]
RP   DOMAIN, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-355.
RX   PubMed=16330539; DOI=10.1074/jbc.m511468200;
RA   Gross-Langenhoff M., Hofbauer K., Weber J., Schultz A., Schultz J.E.;
RT   "cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10
RT   and cGMP for the tandem GAF domain of phosphodiesterase 11.";
RL   J. Biol. Chem. 281:2841-2846(2006).
RN   [10]
RP   INVOLVEMENT IN PPNAD2, TISSUE SPECIFICITY, AND VARIANTS HIS-804 AND
RP   GLY-867.
RX   PubMed=16767104; DOI=10.1038/ng1809;
RA   Horvath A., Boikos S., Giatzakis C., Robinson-White A., Groussin L.,
RA   Griffin K.J., Stein E., Levine E., Delimpasi G., Hsiao H.P., Keil M.,
RA   Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S.,
RA   Cramer K., Gaillard R.C., Bertagna X., Carney J.A., Bertherat J.,
RA   Bossis I., Stratakis C.A.;
RT   "A genome-wide scan identifies mutations in the gene encoding
RT   phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical
RT   hyperplasia.";
RL   Nat. Genet. 38:794-800(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-239, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
CC   -!- FUNCTION: Plays a role in signal transduction by regulating the
CC       intracellular concentration of cyclic nucleotides cAMP and cGMP.
CC       Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP,
CC       respectively. {ECO:0000269|PubMed:10725373,
CC       ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3',5'-cyclic GMP + H2O = GMP + H(+); Xref=Rhea:RHEA:16957,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:57746,
CC         ChEBI:CHEBI:58115; EC=3.1.4.35;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3',5'-cyclic AMP + H2O = AMP + H(+); Xref=Rhea:RHEA:25277,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:58165,
CC         ChEBI:CHEBI:456215; EC=3.1.4.53;
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000250};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by 3-isobutyl-1-methylxanthine (IBMX),
CC       zaprinast and dipyridamole. cGMP acts as an allosteric activator.
CC       Weakly inhibited by Sildenafil (Viagra) and Tadalafil (Cialis);
CC       however, the fact that the protein is probably absent from testis,
CC       suggests that it is not biologically relevant and is not related with
CC       erectile dysfunction. {ECO:0000269|PubMed:10725373,
CC       ECO:0000269|PubMed:11050148, ECO:0000269|PubMed:16079899,
CC       ECO:0000269|PubMed:16330539}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.0 uM for cAMP (isoform 1) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.4 uM for cGMP (isoform 1) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.0 uM for cAMP (isoform 2) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.5 uM for cGMP (isoform 2) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.3 uM for cAMP (isoform 3) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.7 uM for cGMP (isoform 3) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.04 uM for cAMP (isoform 4) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=0.52 uM for cGMP (isoform 4) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         Vmax=3.6 pmol/min/ug enzyme with cAMP as substrate (isoform 4)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=3.9 pmol/min/ug enzyme with cGMP as substrate (isoform 4)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=270 pmol/min/ug enzyme with cAMP as substrate (isoform 1)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=120 pmol/min/ug enzyme with cGMP as substrate (isoform 1)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10906126}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=PDE11A4;
CC         IsoId=Q9HCR9-1; Sequence=Displayed;
CC       Name=2; Synonyms=PDE11A3;
CC         IsoId=Q9HCR9-2; Sequence=VSP_019900, VSP_019901;
CC       Name=3; Synonyms=PDE11A2;
CC         IsoId=Q9HCR9-3; Sequence=VSP_019899;
CC       Name=4; Synonyms=PDE11A1;
CC         IsoId=Q9HCR9-4; Sequence=VSP_019898;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is present in prostate, pituitary, heart
CC       and liver. It is however not present in testis nor in penis, suggesting
CC       that weak inhibition by Tadalafil (Cialis) is not relevant (at protein
CC       level). Isoform 2 may be expressed in testis. Isoform 4 is expressed in
CC       adrenal cortex. {ECO:0000269|PubMed:10725373,
CC       ECO:0000269|PubMed:11121118, ECO:0000269|PubMed:15800651,
CC       ECO:0000269|PubMed:16079899, ECO:0000269|PubMed:16767104}.
CC   -!- DOMAIN: The tandem GAF domains bind cGMP, and regulate enzyme activity.
CC       The binding of cGMP stimulates enzyme activity.
CC       {ECO:0000269|PubMed:16330539}.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 2 (PPNAD2)
CC       [MIM:610475]: A rare bilateral adrenal defect causing ACTH-independent
CC       Cushing syndrome. Macroscopic appearance of the adrenals is
CC       characteristic with small pigmented micronodules observed in the
CC       cortex. Adrenal glands show overall normal size and weight, and
CC       multiple small yellow-to-dark brown nodules surrounded by a cortex with
CC       a uniform appearance. Microscopically, there are moderate diffuse
CC       cortical hyperplasia with mostly nonpigmented nodules, multiple
CC       capsular deficits and massive circumscribed and infiltrating extra-
CC       adrenal cortical excrescences with micronodules. Clinical
CC       manifestations of Cushing syndrome include facial and truncal obesity,
CC       abdominal striae, muscular weakness, osteoporosis, arterial
CC       hypertension, diabetes. {ECO:0000269|PubMed:16767104}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDE11AID44448ch2q31.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB036704; BAB16371.1; -; mRNA.
DR   EMBL; AB038041; BAB16372.1; -; mRNA.
DR   EMBL; AJ251509; CAB82573.1; -; mRNA.
DR   EMBL; AF281865; AAG32023.1; -; mRNA.
DR   EMBL; AJ278682; CAC15567.1; -; mRNA.
DR   EMBL; AB048423; BAB62712.1; -; Genomic_DNA.
DR   EMBL; AB048423; BAB62713.2; -; Genomic_DNA.
DR   EMBL; AB048423; BAB62714.1; -; Genomic_DNA.
DR   EMBL; AC073834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073892; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083824; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011998; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC012499; AAY14803.1; -; Genomic_DNA.
DR   EMBL; BC112393; AAI12394.1; -; mRNA.
DR   EMBL; BC114431; AAI14432.1; -; mRNA.
DR   CCDS; CCDS33334.1; -. [Q9HCR9-1]
DR   CCDS; CCDS42785.1; -. [Q9HCR9-2]
DR   CCDS; CCDS42786.1; -. [Q9HCR9-4]
DR   CCDS; CCDS46459.1; -. [Q9HCR9-3]
DR   RefSeq; NP_001070664.1; NM_001077196.1. [Q9HCR9-4]
DR   RefSeq; NP_001070665.1; NM_001077197.1. [Q9HCR9-2]
DR   RefSeq; NP_001070826.1; NM_001077358.1. [Q9HCR9-3]
DR   RefSeq; NP_058649.3; NM_016953.3. [Q9HCR9-1]
DR   SMR; Q9HCR9; -.
DR   STRING; 9606.ENSP00000286063; -.
DR   BindingDB; Q9HCR9; -.
DR   ChEMBL; CHEMBL2717; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00820; Tadalafil.
DR   DrugBank; DB09283; Trapidil.
DR   DrugCentral; Q9HCR9; -.
DR   GuidetoPHARMACOLOGY; 1311; -.
DR   iPTMnet; Q9HCR9; -.
DR   PhosphoSitePlus; Q9HCR9; -.
DR   BioMuta; PDE11A; -.
DR   DMDM; 296439264; -.
DR   jPOST; Q9HCR9; -.
DR   MassIVE; Q9HCR9; -.
DR   PaxDb; Q9HCR9; -.
DR   PeptideAtlas; Q9HCR9; -.
DR   PRIDE; Q9HCR9; -.
DR   ProteomicsDB; 81789; -. [Q9HCR9-1]
DR   ProteomicsDB; 81790; -. [Q9HCR9-2]
DR   ProteomicsDB; 81791; -. [Q9HCR9-3]
DR   ProteomicsDB; 81792; -. [Q9HCR9-4]
DR   Antibodypedia; 19565; 270 antibodies from 31 providers.
DR   DNASU; 50940; -.
DR   Ensembl; ENST00000286063; ENSP00000286063; ENSG00000128655.
DR   Ensembl; ENST00000389683; ENSP00000374333; ENSG00000128655. [Q9HCR9-4]
DR   Ensembl; ENST00000409504; ENSP00000386539; ENSG00000128655. [Q9HCR9-3]
DR   GeneID; 50940; -.
DR   KEGG; hsa:50940; -.
DR   MANE-Select; ENST00000286063.11; ENSP00000286063.5; NM_016953.4; NP_058649.3.
DR   UCSC; uc002ulp.4; human. [Q9HCR9-1]
DR   CTD; 50940; -.
DR   DisGeNET; 50940; -.
DR   GeneCards; PDE11A; -.
DR   HGNC; HGNC:8773; PDE11A.
DR   HPA; ENSG00000128655; Tissue enhanced (liver, parathyroid gland).
DR   MalaCards; PDE11A; -.
DR   MIM; 604961; gene.
DR   MIM; 610475; phenotype.
DR   neXtProt; NX_Q9HCR9; -.
DR   OpenTargets; ENSG00000128655; -.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33121; -.
DR   VEuPathDB; HostDB:ENSG00000128655; -.
DR   eggNOG; KOG3689; Eukaryota.
DR   GeneTree; ENSGT00940000162151; -.
DR   HOGENOM; CLU_006980_0_1_1; -.
DR   OMA; ENRNMFF; -.
DR   OrthoDB; 904682at2759; -.
DR   PhylomeDB; Q9HCR9; -.
DR   TreeFam; TF316499; -.
DR   BRENDA; 3.1.4.17; 2681.
DR   PathwayCommons; Q9HCR9; -.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   SABIO-RK; Q9HCR9; -.
DR   SignaLink; Q9HCR9; -.
DR   SIGNOR; Q9HCR9; -.
DR   BioGRID-ORCS; 50940; 9 hits in 1045 CRISPR screens.
DR   ChiTaRS; PDE11A; human.
DR   GeneWiki; PDE11A; -.
DR   GenomeRNAi; 50940; -.
DR   Pharos; Q9HCR9; Tchem.
DR   PRO; PR:Q9HCR9; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9HCR9; protein.
DR   Bgee; ENSG00000128655; Expressed in liver and 145 other tissues.
DR   ExpressionAtlas; Q9HCR9; baseline and differential.
DR   Genevisible; Q9HCR9; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; IBA:GO_Central.
DR   GO; GO:0030553; F:cGMP binding; IDA:UniProtKB.
DR   GO; GO:0004118; F:cGMP-stimulated cyclic-nucleotide phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0004112; F:cyclic-nucleotide phosphodiesterase activity; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008152; P:metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IBA:GO_Central.
DR   GO; GO:0010754; P:negative regulation of cGMP-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd00077; HDc; 1.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   Gene3D; 3.30.450.40; -; 2.
DR   InterPro; IPR003018; GAF.
DR   InterPro; IPR029016; GAF-like_dom_sf.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR036971; PDEase_catalytic_dom_sf.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF01590; GAF; 2.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00065; GAF; 2.
DR   SMART; SM00471; HDc; 1.
DR   PROSITE; PS00126; PDEASE_I_1; 1.
DR   PROSITE; PS51845; PDEASE_I_2; 1.
PE   1: Evidence at protein level;
KW   Allosteric enzyme; Alternative splicing; cAMP; cGMP; Cushing syndrome;
KW   Cytoplasm; Hydrolase; Metal-binding; Phosphoprotein; Reference proteome;
KW   Repeat.
FT   CHAIN           1..933
FT                   /note="Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase
FT                   11A"
FT                   /id="PRO_0000247040"
FT   DOMAIN          217..370
FT                   /note="GAF 1"
FT   DOMAIN          402..558
FT                   /note="GAF 2"
FT   DOMAIN          588..912
FT                   /note="PDEase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   REGION          42..125
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        57..83
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        664
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250"
FT   METAL           668
FT                   /note="Divalent metal cation 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   METAL           704
FT                   /note="Divalent metal cation 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   METAL           705
FT                   /note="Divalent metal cation 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   METAL           705
FT                   /note="Divalent metal cation 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   METAL           816
FT                   /note="Divalent metal cation 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01192"
FT   BINDING         424
FT                   /note="3',5'-cGMP"
FT                   /evidence="ECO:0000250|UniProtKB:Q922S4"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P0C1Q2"
FT   MOD_RES         163
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P0C1Q2"
FT   MOD_RES         239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VAR_SEQ         1..444
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10725373"
FT                   /id="VSP_019898"
FT   VAR_SEQ         1..358
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11050148"
FT                   /id="VSP_019899"
FT   VAR_SEQ         1..250
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10906126,
FT                   ECO:0000303|PubMed:11050148"
FT                   /id="VSP_019900"
FT   VAR_SEQ         251..304
FT                   /note="KTLVSKFFDVHAGTPLLPCSSTENSNEVQVPWGKGIIGYVGEHGETVNIPDA
FT                   YQ -> MLKQARRPLFRNVLSATQWKKVKITRLVQISGASLAEKQEKHQDFLIQRQTKT
FT                   K (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10906126,
FT                   ECO:0000303|PubMed:11050148"
FT                   /id="VSP_019901"
FT   VARIANT         804
FT                   /note="R -> H (in dbSNP:rs75127279)"
FT                   /evidence="ECO:0000269|PubMed:16767104"
FT                   /id="VAR_027056"
FT   VARIANT         867
FT                   /note="R -> G (in dbSNP:rs61306957)"
FT                   /evidence="ECO:0000269|PubMed:16767104"
FT                   /id="VAR_027057"
FT   MUTAGEN         355
FT                   /note="D->A: Induces a decrease in enzyme activity due to
FT                   the inability of cGMP to bind and stimulate enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:16330539"
FT   CONFLICT        184
FT                   /note="R -> Q (in Ref. 1; BAB16371, 4; BAB62712 and 6;
FT                   AAI12394/AAI14432)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        921
FT                   /note="S -> SS (in Ref. 1; BAB16371/BAB16372, 2; CAB82573,
FT                   3; AAG32023/CAC15567, 4; BAB62712/BAB62713/BAB62714 and 6;
FT                   AAI12394/AAI14432)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   933 AA;  104752 MW;  B725AE6963D6E799 CRC64;
     MAASRLDFGE VETFLDRHPE LFEDYLMRKG KQEMVEKWLQ RHSQGQGALG PRPSLAGTSS
     LAHSTCRGGS SVGGGTGPNG SAHSQPLPGG GDCGGVPLSP SWAGGSRGDG NLQRRASQKE
     LRKSFARSKA IHVNRTYDEQ VTSRAQEPLS SVRRRALLRK ASSLPPTTAH ILSALLESRV
     NLPRYPPTAI DYKCHLKKHN ERQFFLELVK DISNDLDLTS LSYKILIFVC LMVDADRCSL
     FLVEGAAAGK KTLVSKFFDV HAGTPLLPCS STENSNEVQV PWGKGIIGYV GEHGETVNIP
     DAYQDRRFND EIDKLTGYKT KSLLCMPIRS SDGEIIGVAQ AINKIPEGAP FTEDDEKVMQ
     MYLPFCGIAI SNAQLFAASR KEYERSRALL EVVNDLFEEQ TDLEKIVKKI MHRAQTLLKC
     ERCSVLLLED IESPVVKFTK SFELMSPKCS ADAENSFKES MEKSSYSDWL INNSIAELVA
     STGLPVNISD AYQDPRFDAE ADQISGFHIR SVLCVPIWNS NHQIIGVAQV LNRLDGKPFD
     DADQRLFEAF VIFCGLGINN TIMYDQVKKS WAKQSVALDV LSYHATCSKA EVDKFKAANI
     PLVSELAIDD IHFDDFSLDV DAMITAALRM FMELGMVQKF KIDYETLCRW LLTVRKNYRM
     VLYHNWRHAF NVCQLMFAML TTAGFQDILT EVEILAVIVG CLCHDLDHRG TNNAFQAKSG
     SALAQLYGTS ATLEHHHFNH AVMILQSEGH NIFANLSSKE YSDLMQLLKQ SILATDLTLY
     FERRTEFFEL VSKGEYDWNI KNHRDIFRSM LMTACDLGAV TKPWEISRQV AELVTSEFFE
     QGDRERLELK LTPSAIFDRN RKDELPRLQL EWIDSICMPL YQALVKVNVK LKPMLDSVAT
     NRSKWEELHQ KRLLASTASS SPASVMVAKE DRN
//
ID   TM236_HUMAN             Reviewed;         351 AA.
AC   Q5W0B7; B2RXH7;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 1.
DT   23-FEB-2022, entry version 124.
DE   RecName: Full=Transmembrane protein 236;
GN   Name=TMEM236; Synonyms=FAM23A, FAM23B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- INTERACTION:
CC       Q5W0B7; P41181: AQP2; NbExp=3; IntAct=EBI-13378608, EBI-12701138;
CC       Q5W0B7; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-13378608, EBI-18304435;
CC       Q5W0B7; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-13378608, EBI-13345167;
CC       Q5W0B7; P35372-10: OPRM1; NbExp=3; IntAct=EBI-13378608, EBI-12807478;
CC       Q5W0B7; Q7Z7N9: TMEM179B; NbExp=3; IntAct=EBI-13378608, EBI-11724423;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the TMEM236 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL139238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC157856; AAI57857.1; -; mRNA.
DR   CCDS; CCDS41492.1; -.
DR   RefSeq; NP_001092314.1; NM_001098844.2.
DR   BioGRID; 575888; 6.
DR   IntAct; Q5W0B7; 6.
DR   STRING; 9606.ENSP00000366715; -.
DR   GlyGen; Q5W0B7; 1 site.
DR   iPTMnet; Q5W0B7; -.
DR   PhosphoSitePlus; Q5W0B7; -.
DR   BioMuta; TMEM236; -.
DR   DMDM; 73620896; -.
DR   MassIVE; Q5W0B7; -.
DR   PaxDb; Q5W0B7; -.
DR   PeptideAtlas; Q5W0B7; -.
DR   PRIDE; Q5W0B7; -.
DR   ProteomicsDB; 65759; -.
DR   Antibodypedia; 68395; 32 antibodies from 8 providers.
DR   DNASU; 653567; -.
DR   Ensembl; ENST00000377495; ENSP00000366715; ENSG00000148483.
DR   GeneID; 653567; -.
DR   KEGG; hsa:653567; -.
DR   MANE-Select; ENST00000377495.2; ENSP00000366715.1; NM_001098844.3; NP_001092314.1.
DR   UCSC; uc009xjx.5; human.
DR   CTD; 653567; -.
DR   GeneCards; TMEM236; -.
DR   HGNC; HGNC:23473; TMEM236.
DR   HPA; ENSG00000148483; Tissue enriched (intestine).
DR   neXtProt; NX_Q5W0B7; -.
DR   OpenTargets; ENSG00000148483; -.
DR   PharmGKB; PA134931867; -.
DR   VEuPathDB; HostDB:ENSG00000148483; -.
DR   eggNOG; ENOG502QVFM; Eukaryota.
DR   GeneTree; ENSGT00390000015525; -.
DR   HOGENOM; CLU_072609_0_0_1; -.
DR   InParanoid; Q5W0B7; -.
DR   OMA; RTHYWLI; -.
DR   OrthoDB; 667499at2759; -.
DR   PhylomeDB; Q5W0B7; -.
DR   TreeFam; TF328759; -.
DR   PathwayCommons; Q5W0B7; -.
DR   SignaLink; Q5W0B7; -.
DR   BioGRID-ORCS; 653567; 10 hits in 986 CRISPR screens.
DR   ChiTaRS; TMEM236; human.
DR   GenomeRNAi; 653567; -.
DR   Pharos; Q5W0B7; Tdark.
DR   PRO; PR:Q5W0B7; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q5W0B7; protein.
DR   Bgee; ENSG00000148483; Expressed in small intestine and 78 other tissues.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR020394; Uncharacterised_FAM23-like_TM.
DR   PANTHER; PTHR31453; PTHR31453; 1.
PE   1: Evidence at protein level;
KW   Glycoprotein; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..351
FT                   /note="Transmembrane protein 236"
FT                   /id="PRO_0000186716"
FT   TRANSMEM        7..27
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        49..69
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..108
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        121..141
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        264..284
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        301..321
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          177..216
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        177..215
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        193
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   351 AA;  39663 MW;  9DE0E117BE24D76C CRC64;
     MASGRLIKFV VFELLEFAAF SIPTLVITEQ FATAYQGTRA RSDNTHYWLI ISCSIAYVAL
     VTLLIWVPVK VILHKKRYIY RKIKGWRPVL MMCVVLTTLP CLTFSIAVTE VQKSINGSAD
     VLPDMLPDLP VSLVLLSLIM VDIIEKLRIY PLRGSQKSSE NGHIHSTSLQ HIKTVTEQVR
     QSPENAASPQ ATNSTQVSQP SGAMTRSQES VFMGPQEPSC DSGILRMMSR RDVRAELFLW
     SFLLWSDTIE MVRVAGHPNV YKSSWLYPVY IFSFISLLRI TFTPQNPLLN SLSVLLQDLP
     FVFVRLGLII ALGTITPVLG LCKNILVTLS YIYFNYLTRI RIFSAFEMSP F
//
ID   SSPN_HUMAN              Reviewed;         243 AA.
AC   Q14714; B3KS67;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 3.
DT   23-FEB-2022, entry version 163.
DE   RecName: Full=Sarcospan;
DE   AltName: Full=K-ras oncogene-associated protein;
DE   AltName: Full=Kirsten-ras-associated protein;
GN   Name=SSPN; Synonyms=KRAG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Skeletal muscle;
RX   PubMed=9395445; DOI=10.1074/jbc.272.50.31221;
RA   Crosbie R.H., Heighway J., Venzke D.P., Lee J.C., Campbell K.P.;
RT   "Sarcospan, the 25-kDa transmembrane component of the dystrophin-
RT   glycoprotein complex.";
RL   J. Biol. Chem. 272:31221-31224(1997).
RN   [2]
RP   SEQUENCE REVISION.
RA   Crosbie R.H., Heighway J., Venzke D.P., Campbell K.P.;
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 27-243 (ISOFORM 1).
RC   TISSUE=Brain, and Lung;
RX   PubMed=8661122; DOI=10.1006/geno.1996.0340;
RA   Heighway J., Betticher D.C., Hoban P.R., Altermatt H.J., Cowen R.;
RT   "Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate
RT   receptor gene, and a novel human gene, KRAG.";
RL   Genomics 35:207-214(1996).
CC   -!- FUNCTION: Component of the dystrophin-glycoprotein complex (DGC), a
CC       complex that spans the muscle plasma membrane and forms a link between
CC       the F-actin cytoskeleton and the extracellular matrix. Preferentially
CC       associates with the sarcoglycan subcomplex of the DGC.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass membrane
CC       protein {ECO:0000250}. Cell membrane, sarcolemma {ECO:0000250}. Cell
CC       junction, synapse, postsynaptic cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}. Note=Also found in myotendinous
CC       junctions and in the postsynaptic membrane of neuromuscular junctions.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=SPN1;
CC         IsoId=Q14714-1; Sequence=Displayed;
CC       Name=2; Synonyms=SPN2;
CC         IsoId=Q14714-2; Sequence=VSP_004431;
CC       Name=3;
CC         IsoId=Q14714-3; Sequence=VSP_046351;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed exclusively in heart and
CC       skeletal muscle. Isoform 2 is expressed in heart, skeletal muscle,
CC       thymus, prostate, testis, ovary, small intestine, colon and spleen.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF016028; AAC61660.2; -; mRNA.
DR   EMBL; AL136756; CAB66690.1; -; mRNA.
DR   EMBL; AK092925; BAG52629.1; -; mRNA.
DR   EMBL; AC022509; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC055720; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062299; AAH62299.1; -; mRNA.
DR   EMBL; X89105; CAA61479.1; -; mRNA.
DR   CCDS; CCDS44850.1; -. [Q14714-3]
DR   CCDS; CCDS8707.1; -. [Q14714-1]
DR   PIR; S57712; S57712.
DR   RefSeq; NP_001129295.1; NM_001135823.1. [Q14714-3]
DR   RefSeq; NP_005077.2; NM_005086.4. [Q14714-1]
DR   RefSeq; XP_011519155.1; XM_011520853.2. [Q14714-3]
DR   RefSeq; XP_011519156.1; XM_011520854.2. [Q14714-3]
DR   RefSeq; XP_011519157.1; XM_011520855.2. [Q14714-3]
DR   BioGRID; 113755; 3.
DR   CORUM; Q14714; -.
DR   IntAct; Q14714; 2.
DR   MINT; Q14714; -.
DR   STRING; 9606.ENSP00000242729; -.
DR   iPTMnet; Q14714; -.
DR   PhosphoSitePlus; Q14714; -.
DR   SwissPalm; Q14714; -.
DR   BioMuta; SSPN; -.
DR   DMDM; 13431900; -.
DR   jPOST; Q14714; -.
DR   MassIVE; Q14714; -.
DR   PaxDb; Q14714; -.
DR   PeptideAtlas; Q14714; -.
DR   PRIDE; Q14714; -.
DR   ProteomicsDB; 3623; -.
DR   ProteomicsDB; 60142; -. [Q14714-1]
DR   ProteomicsDB; 60143; -. [Q14714-2]
DR   Antibodypedia; 24301; 66 antibodies from 20 providers.
DR   DNASU; 8082; -.
DR   Ensembl; ENST00000242729; ENSP00000242729; ENSG00000123096.
DR   Ensembl; ENST00000422622; ENSP00000396087; ENSG00000123096. [Q14714-3]
DR   Ensembl; ENST00000540266; ENSP00000442893; ENSG00000123096. [Q14714-3]
DR   GeneID; 8082; -.
DR   KEGG; hsa:8082; -.
DR   MANE-Select; ENST00000242729.7; ENSP00000242729.2; NM_005086.5; NP_005077.2.
DR   UCSC; uc001rhd.4; human. [Q14714-1]
DR   CTD; 8082; -.
DR   DisGeNET; 8082; -.
DR   GeneCards; SSPN; -.
DR   HGNC; HGNC:11322; SSPN.
DR   HPA; ENSG00000123096; Tissue enhanced (tongue).
DR   MIM; 601599; gene.
DR   neXtProt; NX_Q14714; -.
DR   OpenTargets; ENSG00000123096; -.
DR   PharmGKB; PA36146; -.
DR   VEuPathDB; HostDB:ENSG00000123096; -.
DR   eggNOG; ENOG502RYPH; Eukaryota.
DR   GeneTree; ENSGT00390000007747; -.
DR   HOGENOM; CLU_1271931_0_0_1; -.
DR   InParanoid; Q14714; -.
DR   OMA; ALDSCQC; -.
DR   OrthoDB; 1462432at2759; -.
DR   PhylomeDB; Q14714; -.
DR   TreeFam; TF332100; -.
DR   PathwayCommons; Q14714; -.
DR   SignaLink; Q14714; -.
DR   SIGNOR; Q14714; -.
DR   BioGRID-ORCS; 8082; 9 hits in 1040 CRISPR screens.
DR   ChiTaRS; SSPN; human.
DR   GenomeRNAi; 8082; -.
DR   Pharos; Q14714; Tbio.
DR   PRO; PR:Q14714; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q14714; protein.
DR   Bgee; ENSG00000123096; Expressed in myometrium and 247 other tissues.
DR   ExpressionAtlas; Q14714; baseline and differential.
DR   Genevisible; Q14714; HS.
DR   GO; GO:0016010; C:dystrophin-associated glycoprotein complex; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0030133; C:transport vesicle; IDA:LIFEdb.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   InterPro; IPR007237; CD20-like.
DR   InterPro; IPR030429; Sarcospan.
DR   PANTHER; PTHR15260; PTHR15260; 1.
DR   Pfam; PF04103; CD20; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Cell junction; Cell membrane; Membrane;
KW   Postsynaptic cell membrane; Reference proteome; Synapse; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..243
FT                   /note="Sarcospan"
FT                   /id="PRO_0000072226"
FT   TOPO_DOM        1..53
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        54..74
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        75..86
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        87..107
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        108..122
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        123..143
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        144..193
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        194..214
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        215..243
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..43
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        24..43
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..103
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046351"
FT   VAR_SEQ         108..218
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11230166,
FT                   ECO:0000303|PubMed:9395445"
FT                   /id="VSP_004431"
FT   VARIANT         186
FT                   /note="S -> N (in dbSNP:rs12313670)"
FT                   /id="VAR_051384"
FT   VARIANT         228
FT                   /note="V -> I (in dbSNP:rs12313736)"
FT                   /id="VAR_051385"
FT   CONFLICT        13
FT                   /note="Missing (in Ref. 1)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   243 AA;  26618 MW;  0D6B24B9848253F9 CRC64;
     MGKNKQPRGQ QRQGGPPAAD AAGPDDMEPK KGTGAPKECG EEEPRTCCGC RFPLLLALLQ
     LALGIAVTVV GFLMASISSS LLVRDTPFWA GIIVCLVAYL GLFMLCVSYQ VDERTCIQFS
     MKLLYFLLSA LGLTVCVLAV AFAAHHYSQL TQFTCETTLD SCQCKLPSSE PLSRTFVYRD
     VTDCTSVTGT FKLFLLIQMI LNLVCGLVCL LACFVMWKHR YQVFYVGVRI CSLTASEGPQ
     QKI
//
ID   A7L3B_HUMAN             Reviewed;          97 AA.
AC   Q96GX2;
DT   23-MAR-2010, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 2.
DT   23-FEB-2022, entry version 105.
DE   RecName: Full=Ataxin-7-like protein 3B;
GN   Name=ATXN7L3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION.
RX   PubMed=16680195; DOI=10.1371/journal.pcbi.0020046;
RA   Svensson O., Arvestad L., Lagergren J.;
RT   "Genome-wide survey for biologically functional pseudogenes.";
RL   PLoS Comput. Biol. 2:E46-E46(2006).
RN   [4]
RP   CHROMOSOMAL REARRANGEMENT.
RX   PubMed=23475819; DOI=10.1136/jnnp-2012-304555;
RA   Rajakulendran S., Roberts J., Koltzenburg M., Hanna M.G., Stewart H.;
RT   "Deletion of chromosome 12q21 affecting KCNC2 and ATXN7L3B in a family with
RT   neurodevelopmental delay and ataxia.";
RL   J. Neurol. Neurosurg. Psych. 84:1255-1257(2013).
RN   [5]
RP   FUNCTION, INTERACTION WITH ENY2 AND USP22, AND SUBCELLULAR LOCATION.
RX   PubMed=27601583; DOI=10.1128/mcb.00193-16;
RA   Li W., Atanassov B.S., Lan X., Mohan R.D., Swanson S.K., Farria A.T.,
RA   Florens L., Washburn M.P., Workman J.L., Dent S.Y.;
RT   "Cytoplasmic ATXN7L3B interferes with nuclear functions of the SAGA
RT   deubiquitinase module.";
RL   Mol. Cell. Biol. 36:2855-2866(2016).
CC   -!- FUNCTION: By binding to ENY2, interferes with the nuclear functions of
CC       the deubiquitinase (DUB) module of the SAGA complex which consists of
CC       ENY2, ATXN7, ATXN7L3 and the histone deubiquitinating component USP22.
CC       Affects USP22 DUB activity toward histones indirectly by changing the
CC       subcellular distribution of ENY2 and altering ENY2 availability for
CC       ATXN7L3 interaction. Regulates H2B monoubiquitination (H2Bub1) levels
CC       through cytoplasmic sequestration of ENY2 resulting in loss of nuclear
CC       ENY2-ATXN7L3 association which destabilizes ATXN7L3. Affects protein
CC       expression levels of ENY2 and ATXN7L3. {ECO:0000269|PubMed:27601583}.
CC   -!- SUBUNIT: Interacts strongly with ENY2. Interacts weakly with USP22.
CC       {ECO:0000269|PubMed:27601583}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:27601583}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ATXN7L3B has been
CC       found in a mother and her two children with varying degrees of
CC       neurodevelopmental delay and cerebellar ataxia. One child also exhibits
CC       episodes of unresponsiveness suggestive of absence seizures and facial
CC       dysmorphism. Deletion at 12q21.1 deletes the entire single exon of
CC       ATXN7L3B. {ECO:0000269|PubMed:23475819}.
CC   -!- MISCELLANEOUS: Encoded by an expressed retrotransposed copy of the
CC       ATXN7L3 locus that emerged prior to the speciation event separating
CC       primates and rodents.
CC   -!- SIMILARITY: Belongs to the SGF11 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH09111.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC025257; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009111; AAH09111.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS53815.1; -.
DR   RefSeq; NP_001129734.1; NM_001136262.1.
DR   BioGRID; 139266; 11.
DR   IntAct; Q96GX2; 2.
DR   STRING; 9606.ENSP00000430000; -.
DR   GlyGen; Q96GX2; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96GX2; -.
DR   PhosphoSitePlus; Q96GX2; -.
DR   BioMuta; ATXN7L3B; -.
DR   EPD; Q96GX2; -.
DR   jPOST; Q96GX2; -.
DR   MassIVE; Q96GX2; -.
DR   MaxQB; Q96GX2; -.
DR   PaxDb; Q96GX2; -.
DR   PeptideAtlas; Q96GX2; -.
DR   PRIDE; Q96GX2; -.
DR   ProteomicsDB; 76676; -.
DR   Antibodypedia; 52794; 54 antibodies from 12 providers.
DR   DNASU; 552889; -.
DR   Ensembl; ENST00000519948; ENSP00000430000; ENSG00000253719.
DR   GeneID; 552889; -.
DR   KEGG; hsa:552889; -.
DR   MANE-Select; ENST00000519948.4; ENSP00000430000.2; NM_001136262.2; NP_001129734.1.
DR   UCSC; uc001sxd.5; human.
DR   CTD; 552889; -.
DR   DisGeNET; 552889; -.
DR   GeneCards; ATXN7L3B; -.
DR   HGNC; HGNC:37931; ATXN7L3B.
DR   HPA; ENSG00000253719; Low tissue specificity.
DR   MIM; 615579; gene.
DR   neXtProt; NX_Q96GX2; -.
DR   OpenTargets; ENSG00000253719; -.
DR   PharmGKB; PA165512339; -.
DR   VEuPathDB; HostDB:ENSG00000253719; -.
DR   eggNOG; ENOG502TFV2; Eukaryota.
DR   GeneTree; ENSGT00940000162576; -.
DR   HOGENOM; CLU_2359075_0_0_1; -.
DR   InParanoid; Q96GX2; -.
DR   OMA; QRAPPDF; -.
DR   OrthoDB; 1244885at2759; -.
DR   PhylomeDB; Q96GX2; -.
DR   TreeFam; TF353123; -.
DR   PathwayCommons; Q96GX2; -.
DR   SignaLink; Q96GX2; -.
DR   BioGRID-ORCS; 552889; 5 hits in 1041 CRISPR screens.
DR   ChiTaRS; ATXN7L3B; human.
DR   GenomeRNAi; 552889; -.
DR   Pharos; Q96GX2; Tdark.
DR   PRO; PR:Q96GX2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q96GX2; protein.
DR   Bgee; ENSG00000253719; Expressed in forebrain and 260 other tissues.
DR   Genevisible; Q96GX2; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IEP:UniProtKB.
DR   InterPro; IPR042933; ATXN7L3B.
DR   PANTHER; PTHR47733; PTHR47733; 1.
PE   1: Evidence at protein level;
KW   Chromosomal rearrangement; Cytoplasm; Phosphoprotein; Reference proteome.
FT   CHAIN           1..97
FT                   /note="Ataxin-7-like protein 3B"
FT                   /id="PRO_0000392529"
FT   REGION          77..97
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        83..97
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         92
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UD01"
SQ   SEQUENCE   97 AA;  10771 MW;  722ADB410FCEFC9A CRC64;
     MEEISLANLD TNKLEAIAQE IYVDLIEDSC LGFCFEVHRA VKCGYFYLEF AETGSVKDFG
     IQPVEDKGAC RLPLCSLPGE PGNGPDQQLQ RSPPEFQ
//
ID   RPEL1_HUMAN             Reviewed;         228 AA.
AC   Q2QD12;
DT   19-FEB-2014, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 1.
DT   23-FEB-2022, entry version 118.
DE   RecName: Full=Ribulose-phosphate 3-epimerase-like protein 1;
DE            EC=5.1.3.1 {ECO:0000250|UniProtKB:Q96AT9};
DE   AltName: Full=Ribulose-5-phosphate-3-epimerase-like protein 1;
GN   Name=RPEL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=16201836; DOI=10.1371/journal.pbio.0030357;
RA   Marques A.C., Dupanloup I., Vinckenbosch N., Reymond A., Kaessmann H.;
RT   "Emergence of young human genes after a burst of retroposition in
RT   primates.";
RL   PLoS Biol. 3:E357-E357(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Catalyzes the reversible epimerization of D-ribulose 5-
CC       phosphate to D-xylulose 5-phosphate. {ECO:0000250|UniProtKB:Q96AT9}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-ribulose 5-phosphate = D-xylulose 5-phosphate;
CC         Xref=Rhea:RHEA:13677, ChEBI:CHEBI:57737, ChEBI:CHEBI:58121;
CC         EC=5.1.3.1; Evidence={ECO:0000250|UniProtKB:Q96AT9};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000250|UniProtKB:Q96AT9};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:Q96AT9};
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q96AT9};
CC       Name=Co(2+); Xref=ChEBI:CHEBI:48828;
CC         Evidence={ECO:0000250|UniProtKB:Q96AT9};
CC       Note=Binds 1 divalent metal cation per subunit. Active with Fe(2+), and
CC       probably also with Mn(2+), Zn(2+) and Co(2+).
CC       {ECO:0000250|UniProtKB:Q96AT9};
CC   -!- PATHWAY: Carbohydrate degradation. {ECO:0000250|UniProtKB:Q96AT9}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:Q96AT9}.
CC   -!- MISCELLANEOUS: According to some authors, RPEL1 is a RPE retrogene on
CC       chromosome 2 which is likely to be functional.
CC       {ECO:0000305|PubMed:16201836}.
CC   -!- SIMILARITY: Belongs to the ribulose-phosphate 3-epimerase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ120706; ABC40667.1; -; Genomic_DNA.
DR   EMBL; AL360001; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49655.1; -; Genomic_DNA.
DR   EMBL; BC137242; AAI37243.1; -; mRNA.
DR   EMBL; BC137243; AAI37244.1; -; mRNA.
DR   EMBL; BC157829; AAI57830.1; -; mRNA.
DR   EMBL; BC157875; AAI57876.1; -; mRNA.
DR   EMBL; BC171806; AAI71806.1; -; mRNA.
DR   EMBL; BC171885; AAI71885.1; -; mRNA.
DR   CCDS; CCDS65929.1; -.
DR   RefSeq; NP_001137381.1; NM_001143909.1.
DR   SMR; Q2QD12; -.
DR   BioGRID; 609427; 3.
DR   IntAct; Q2QD12; 1.
DR   STRING; 9606.ENSP00000476672; -.
DR   iPTMnet; Q2QD12; -.
DR   PhosphoSitePlus; Q2QD12; -.
DR   BioMuta; RPEL1; -.
DR   jPOST; Q2QD12; -.
DR   MassIVE; Q2QD12; -.
DR   MaxQB; Q2QD12; -.
DR   PeptideAtlas; Q2QD12; -.
DR   PRIDE; Q2QD12; -.
DR   Antibodypedia; 71379; 28 antibodies from 14 providers.
DR   DNASU; 729020; -.
DR   Ensembl; ENST00000441178; ENSP00000476672; ENSG00000235376.
DR   GeneID; 729020; -.
DR   KEGG; hsa:729020; -.
DR   MANE-Select; ENST00000441178.2; ENSP00000476672.1; NM_001143909.1; NP_001137381.1.
DR   UCSC; uc009xxi.2; human.
DR   CTD; 729020; -.
DR   DisGeNET; 729020; -.
DR   GeneCards; RPEL1; -.
DR   HGNC; HGNC:45241; RPEL1.
DR   HPA; ENSG00000235376; Not detected.
DR   neXtProt; NX_Q2QD12; -.
DR   OpenTargets; ENSG00000235376; -.
DR   VEuPathDB; HostDB:ENSG00000235376; -.
DR   eggNOG; KOG3111; Eukaryota.
DR   GeneTree; ENSGT00390000001447; -.
DR   HOGENOM; CLU_054856_0_1_1; -.
DR   OMA; AYIPTML; -.
DR   OrthoDB; 1554029at2759; -.
DR   PathwayCommons; Q2QD12; -.
DR   Reactome; R-HSA-71336; Pentose phosphate pathway.
DR   SignaLink; Q2QD12; -.
DR   BioGRID-ORCS; 729020; 22 hits in 926 CRISPR screens.
DR   GenomeRNAi; 729020; -.
DR   Pharos; Q2QD12; Tbio.
DR   PRO; PR:Q2QD12; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q2QD12; protein.
DR   Bgee; ENSG00000235376; Expressed in frontal cortex and 4 other tissues.
DR   Genevisible; Q2QD12; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IBA:GO_Central.
DR   GO; GO:0004750; F:ribulose-phosphate 3-epimerase activity; IBA:GO_Central.
DR   GO; GO:0044262; P:cellular carbohydrate metabolic process; IBA:GO_Central.
DR   GO; GO:0019323; P:pentose catabolic process; IBA:GO_Central.
DR   GO; GO:0009052; P:pentose-phosphate shunt, non-oxidative branch; IBA:GO_Central.
DR   CDD; cd00429; RPE; 1.
DR   Gene3D; 3.20.20.70; -; 1.
DR   HAMAP; MF_02227; RPE; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR026019; Ribul_P_3_epim.
DR   InterPro; IPR000056; Ribul_P_3_epim-like.
DR   InterPro; IPR011060; RibuloseP-bd_barrel.
DR   PANTHER; PTHR11749; PTHR11749; 1.
DR   Pfam; PF00834; Ribul_P_3_epim; 1.
DR   PIRSF; PIRSF001461; RPE; 1.
DR   SUPFAM; SSF51366; SSF51366; 1.
DR   PROSITE; PS01085; RIBUL_P_3_EPIMER_1; 1.
PE   2: Evidence at transcript level;
KW   Carbohydrate metabolism; Cobalt; Iron; Isomerase; Manganese; Metal-binding;
KW   Reference proteome; Zinc.
FT   CHAIN           1..228
FT                   /note="Ribulose-phosphate 3-epimerase-like protein 1"
FT                   /id="PRO_0000425564"
FT   REGION          146..149
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   REGION          175..177
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   REGION          197..198
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   ACT_SITE        37
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   ACT_SITE        175
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   METAL           35
FT                   /note="Divalent metal cation; via tele nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   METAL           37
FT                   /note="Divalent metal cation"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   METAL           70
FT                   /note="Divalent metal cation; via pros nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   METAL           175
FT                   /note="Divalent metal cation"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   BINDING         10
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
FT   BINDING         70
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P32719"
SQ   SEQUENCE   228 AA;  25023 MW;  231D8799E36AD588 CRC64;
     MASGCKIGPS ILNSDLANLG AKCLQMLDSG ADYLHLDVMD GHFVPNITFG HPVVESLRKQ
     LGQDPFFDMH MMVSKPEQWV KPMAVAEANQ YTFHLEATEN PGTLIKDIRE NGMKVGLAIK
     PGTSVEYLAP WANQIDMALV MTVEPGFGEQ KFMEDMMPKV HWLRTQFPSL DIEGDGGVGS
     DTVHKCAEAG ANMTVSGSAI MRSEDPRSVI NLLRNICSEA AQKRSLDR
//
ID   5HT2A_HUMAN             Reviewed;         471 AA.
AC   P28223; B2RAC5; B4DZ79; F5GWE8; Q5T8C0;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   23-FEB-2022, entry version 214.
DE   RecName: Full=5-hydroxytryptamine receptor 2A;
DE            Short=5-HT-2;
DE            Short=5-HT-2A;
DE   AltName: Full=Serotonin receptor 2A;
GN   Name=HTR2A; Synonyms=HTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain stem;
RX   PubMed=1722404; DOI=10.1016/0006-291x(91)92105-s;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M., Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1323014; DOI=10.1016/0169-328x(92)90005-v;
RA   Chen K., Yang W., Grimsby J., Shih J.C.;
RT   "The human 5-HT2 receptor is encoded by a multiple intron-exon gene.";
RL   Brain Res. Mol. Brain Res. 14:20-26(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=8035173; DOI=10.1046/j.1471-4159.1994.63020465.x;
RA   Cook E.H. Jr., Fletcher K.E., Wainwright M., Marks N., Yan S.Y.,
RA   Leventhal B.L.;
RT   "Primary structure of the human platelet serotonin 5-HT2A receptor:
RT   identify with frontal cortex serotonin 5-HT2A receptor.";
RL   J. Neurochem. 63:465-469(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-464 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Tritch R.J., Robinson D.L., Sahagan B.G., Horlick R.A.;
RT   "Cloning and nucleotide sequence of the human(5HT) type 2 receptor.";
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 105-218, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1330647; DOI=10.1016/0922-4106(92)90123-d;
RA   Stam N.J., van Huizen F., van Alebeek C., Brands J., Dijkema R.,
RA   Tonnaer J.A., Olijve W.;
RT   "Genomic organization, coding sequence and functional expression of human
RT   5-HT2 and 5-HT1A receptor genes.";
RL   Eur. J. Pharmacol. 227:153-162(1992).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   PubMed=11150294; DOI=10.1074/jbc.m008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10
RT   of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   INTERACTION WITH PATJ; MPP3; PRDX6; DLG4; DLG1; CASK; APBA1 AND MAGI2, AND
RP   MUTAGENESIS OF GLY-463; ASN-465; CYS-470 AND VAL-471.
RX   PubMed=14988405; DOI=10.1074/jbc.m312106200;
RA   Becamel C., Gavarini S., Chanrion B., Alonso G., Galeotti N., Dumuis A.,
RA   Bockaert J., Marin P.;
RT   "The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of
RT   PDZ proteins.";
RL   J. Biol. Chem. 279:20257-20266(2004).
RN   [13]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and
RT   5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in
RT   CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [15]
RP   INTERACTION WITH GRM2, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18297054; DOI=10.1038/nature06612;
RA   Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V.,
RA   Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G.,
RA   Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C.;
RT   "Identification of a serotonin/glutamate receptor complex implicated in
RT   psychosis.";
RL   Nature 452:93-97(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=19057895; DOI=10.1007/s00210-008-0378-4;
RA   Knauer C.S., Campbell J.E., Chio C.L., Fitzgerald L.W.;
RT   "Pharmacological characterization of mitogen-activated protein kinase
RT   activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors.";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 379:461-471(2009).
RN   [17]
RP   INTERACTION WITH DRD2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21645528; DOI=10.1016/j.neuropharm.2011.05.023;
RA   Albizu L., Holloway T., Gonzalez-Maeso J., Sealfon S.C.;
RT   "Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine
RT   D2 receptors.";
RL   Neuropharmacology 61:770-777(2011).
RN   [18]
RP   REVIEW.
RX   PubMed=20945968; DOI=10.33549/physiolres.931903;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [19]
RP   INTERACTION WITH GRM2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22300836; DOI=10.1016/j.neuropharm.2012.01.010;
RA   Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C.,
RA   Schmidt M., Meyer A.H., Unger L., Marek G.J., Mezler M.;
RT   "Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular
RT   signaling cascades.";
RL   Neuropharmacology 62:2184-2191(2012).
RN   [20]
RP   PHOSPHORYLATION AT SER-280, AND MUTAGENESIS OF SER-280.
RX   PubMed=24637012; DOI=10.1074/mcp.m113.036558;
RA   Karaki S., Becamel C., Murat S., Mannoury la Cour C., Millan M.J.,
RA   Prezeau L., Bockaert J., Marin P., Vandermoere F.;
RT   "Quantitative phosphoproteomics unravels biased phosphorylation of
RT   serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic
RT   agonists.";
RL   Mol. Cell. Proteomics 13:1273-1285(2014).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=24089568; DOI=10.1128/jvi.02252-13;
RA   Assetta B., Maginnis M.S., Gracia Ahufinger I., Haley S.A., Gee G.V.,
RA   Nelson C.D., O'Hara B.A., Allen Ramdial S.A., Atwood W.J.;
RT   "5-HT2 receptors facilitate JC polyomavirus entry.";
RL   J. Virol. 87:13490-13498(2013).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF LEU-229.
RX   PubMed=28129538; DOI=10.1016/j.cell.2016.12.033;
RA   Wacker D., Wang S., McCorvy J.D., Betz R.M., Venkatakrishnan A.J.,
RA   Levit A., Lansu K., Schools Z.L., Che T., Nichols D.E., Shoichet B.K.,
RA   Dror R.O., Roth B.L.;
RT   "Crystal structure of an LSD-bound human serotonin receptor.";
RL   Cell 168:377-389(2017).
RN   [23]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=8655141; DOI=10.1007/bf02281871;
RA   Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W.,
RA   Koerner J., Bondy B., Chen K., Shih J.C., Knapp M., Propping P.,
RA   Noethen M.M.;
RT   "Systematic screening for mutations in the human serotonin-2A (5-HT2A)
RT   receptor gene: identification of two naturally occurring receptor variants
RT   and association analysis in schizophrenia.";
RL   Hum. Genet. 97:614-619(1996).
RN   [24]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=10581480;
RX   DOI=10.1002/(sici)1096-8628(19991215)88:6<621::aid-ajmg9>3.0.co;2-h;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [25]
RP   VARIANTS VAL-197; VAL-447 AND TYR-452.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [26]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin) (PubMed:1330647, PubMed:18703043, PubMed:19057895). Also
CC       functions as a receptor for various drugs and psychoactive substances,
CC       including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-
CC       aminopropane (DOI) and lysergic acid diethylamide (LSD)
CC       (PubMed:28129538). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors (PubMed:28129538).
CC       Beta-arrestin family members inhibit signaling via G proteins and
CC       mediate activation of alternative signaling pathways (PubMed:28129538).
CC       Signaling activates phospholipase C and a phosphatidylinositol-calcium
CC       second messenger system that modulates the activity of
CC       phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions
CC       from intracellular stores (PubMed:18703043, PubMed:28129538). Affects
CC       neural activity, perception, cognition and mood (PubMed:18297054).
CC       Plays a role in the regulation of behavior, including responses to
CC       anxiogenic situations and psychoactive substances. Plays a role in
CC       intestinal smooth muscle contraction, and may play a role in arterial
CC       vasoconstriction. {ECO:0000269|PubMed:1330647,
CC       ECO:0000269|PubMed:18297054, ECO:0000269|PubMed:18703043,
CC       ECO:0000269|PubMed:19057895, ECO:0000269|PubMed:21645528,
CC       ECO:0000269|PubMed:22300836, ECO:0000269|PubMed:28129538}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for human JC
CC       polyomavirus/JCPyV. {ECO:0000269|PubMed:24089568}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with MPDZ and PATJ
CC       (PubMed:11150294, PubMed:14988405). May interact (via C-terminus) with
CC       MPP3, PRDX6, DLG4, DLG1, CASK, APBA1 and MAGI2 (PubMed:14988405).
CC       Interacts with GRM2 and DRD2; this may affect signaling
CC       (PubMed:18297054, PubMed:21645528, PubMed:22300836).
CC       {ECO:0000269|PubMed:11150294, ECO:0000269|PubMed:14988405,
CC       ECO:0000269|PubMed:18297054, ECO:0000269|PubMed:21645528,
CC       ECO:0000269|PubMed:22300836}.
CC   -!- INTERACTION:
CC       P28223; P28223: HTR2A; NbExp=3; IntAct=EBI-6656333, EBI-6656333;
CC       P28223; P41595: HTR2B; NbExp=3; IntAct=EBI-6656333, EBI-7474947;
CC       P28223; P28335: HTR2C; NbExp=5; IntAct=EBI-6656333, EBI-994141;
CC       P28223-1; Q14416: GRM2; NbExp=4; IntAct=EBI-15573967, EBI-10232876;
CC       P28223-1; P28335-1: HTR2C; NbExp=3; IntAct=EBI-15573967, EBI-21299643;
CC       P28223-1; P18654: Rps6ka3; Xeno; NbExp=2; IntAct=EBI-15573967, EBI-397744;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28129538};
CC       Multi-pass membrane protein {ECO:0000305}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P35363}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P14842}. Cytoplasmic vesicle
CC       {ECO:0000250|UniProtKB:P14842}. Membrane, caveola
CC       {ECO:0000250|UniProtKB:P14842}. Cell junction, synapse, presynapse
CC       {ECO:0000250|UniProtKB:P14842}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28223-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28223-2; Sequence=VSP_046663;
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex (at protein level).
CC       Detected in blood platelets. {ECO:0000269|PubMed:18297054}.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the interaction
CC       with PATJ, CASK, APBA1, DLG1 and DLG4. {ECO:0000269|PubMed:11150294,
CC       ECO:0000269|PubMed:14988405}.
CC   -!- MISCELLANEOUS: Binds lysergic acid diethylamine (LSD) in the
CC       orthosteric pocket (Probable). Bound LSD dissociates extremely slowly,
CC       with a residence time of about 221 minutes at 37 degrees Celsius.
CC       {ECO:0000269|PubMed:28129538}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HTR2A";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57830; CAA40963.1; -; mRNA.
DR   EMBL; S42168; AAB22791.2; -; Genomic_DNA.
DR   EMBL; S42165; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S42167; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S71229; AAB31320.1; -; mRNA.
DR   EMBL; AF498982; AAM21129.1; -; mRNA.
DR   EMBL; AK302787; BAG63991.1; -; mRNA.
DR   EMBL; AK314132; BAG36822.1; -; mRNA.
DR   EMBL; AL160397; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136958; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08770.1; -; Genomic_DNA.
DR   EMBL; BC069356; AAH69356.1; -; mRNA.
DR   EMBL; BC069576; AAH69576.1; -; mRNA.
DR   EMBL; BC074848; AAH74848.1; -; mRNA.
DR   EMBL; BC074849; AAH74849.1; -; mRNA.
DR   EMBL; BC096839; AAH96839.1; -; mRNA.
DR   EMBL; M86841; AAA58354.1; -; mRNA.
DR   EMBL; S50130; AAB24166.2; -; Genomic_DNA.
DR   EMBL; S49737; AAB24166.2; JOINED; Genomic_DNA.
DR   EMBL; S50113; AAB24166.2; JOINED; Genomic_DNA.
DR   CCDS; CCDS9405.1; -. [P28223-1]
DR   PIR; A43956; A43956.
DR   RefSeq; NP_000612.1; NM_000621.4. [P28223-1]
DR   RefSeq; NP_001159419.1; NM_001165947.2.
DR   PDB; 6A93; X-ray; 3.00 A; A/B=70-265, A/B=313-403.
DR   PDB; 6A94; X-ray; 2.90 A; A/B=70-265, A/B=313-403.
DR   PDB; 6WGT; X-ray; 3.40 A; A/B/C=66-265, A/B/C=311-405.
DR   PDB; 6WH4; X-ray; 3.40 A; A/B/C=66-265, A/B/C=311-405.
DR   PDB; 6WHA; EM; 3.36 A; A=66-404.
DR   PDBsum; 6A93; -.
DR   PDBsum; 6A94; -.
DR   PDBsum; 6WGT; -.
DR   PDBsum; 6WH4; -.
DR   PDBsum; 6WHA; -.
DR   SMR; P28223; -.
DR   BioGRID; 109588; 8.
DR   DIP; DIP-41844N; -.
DR   IntAct; P28223; 21.
DR   MINT; P28223; -.
DR   STRING; 9606.ENSP00000437737; -.
DR   BindingDB; P28223; -.
DR   ChEMBL; CHEMBL224; -.
DR   DrugBank; DB13940; 2,5-Dimethoxy-4-ethylthioamphetamine.
DR   DrugBank; DB01537; 4-Bromo-2,5-dimethoxyphenethylamine.
DR   DrugBank; DB14010; 5-methoxy-N,N-dimethyltryptamine.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB06288; Amisulpride.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB08927; Amperozide.
DR   DrugBank; DB04599; Aniracetam.
DR   DrugBank; DB05227; APD791.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB05687; BL-1020.
DR   DrugBank; DB09223; Blonanserin.
DR   DrugBank; DB09128; Brexpiprazole.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB09016; Butriptyline.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB08810; Cinitapride.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB06512; Deramciclane.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB01488; Dimethyltryptamine.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB06446; Dotarizine.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB12177; Eplivanserin.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB04908; Flibanserin.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB04842; Fluspirilene.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB05079; HY10275.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB12465; Ketanserin.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB08815; Lurasidone.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB14009; Medical Cannabis.
DR   DrugBank; DB00933; Mesoridazine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB01454; Midomafetamine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB01442; MMDA.
DR   DrugBank; DB01618; Molindone.
DR   DrugBank; DB13948; N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DR   DrugBank; DB14011; Nabiximols.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB12555; Nelotanserin.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB05316; Pimavanserin.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB12693; Ritanserin.
DR   DrugBank; DB12163; Sarpogrelate.
DR   DrugBank; DB08839; Serotonin.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB06109; YKP-1358.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB00315; Zolmitriptan.
DR   DrugBank; DB09225; Zotepine.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P28223; -.
DR   GuidetoPHARMACOLOGY; 6; -.
DR   TCDB; 9.A.14.3.17; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P28223; 5 sites.
DR   iPTMnet; P28223; -.
DR   PhosphoSitePlus; P28223; -.
DR   BioMuta; HTR2A; -.
DR   DMDM; 543727; -.
DR   MassIVE; P28223; -.
DR   PaxDb; P28223; -.
DR   PeptideAtlas; P28223; -.
DR   PRIDE; P28223; -.
DR   ProteomicsDB; 24094; -.
DR   ProteomicsDB; 54453; -. [P28223-1]
DR   Antibodypedia; 2927; 372 antibodies from 34 providers.
DR   DNASU; 3356; -.
DR   Ensembl; ENST00000542664; ENSP00000437737; ENSG00000102468.
DR   GeneID; 3356; -.
DR   KEGG; hsa:3356; -.
DR   MANE-Select; ENST00000542664.4; ENSP00000437737.1; NM_000621.5; NP_000612.1.
DR   UCSC; uc001vbr.5; human. [P28223-1]
DR   CTD; 3356; -.
DR   DisGeNET; 3356; -.
DR   GeneCards; HTR2A; -.
DR   HGNC; HGNC:5293; HTR2A.
DR   HPA; ENSG00000102468; Tissue enhanced (brain, choroid plexus).
DR   MalaCards; HTR2A; -.
DR   MIM; 182135; gene.
DR   neXtProt; NX_P28223; -.
DR   OpenTargets; ENSG00000102468; -.
DR   PharmGKB; PA193; -.
DR   VEuPathDB; HostDB:ENSG00000102468; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01030000234619; -.
DR   HOGENOM; CLU_009579_11_3_1; -.
DR   InParanoid; P28223; -.
DR   OMA; RLYNNDF; -.
DR   OrthoDB; 962038at2759; -.
DR   PhylomeDB; P28223; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P28223; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P28223; -.
DR   SIGNOR; P28223; -.
DR   BioGRID-ORCS; 3356; 4 hits in 1036 CRISPR screens.
DR   GeneWiki; 5-HT2A_receptor; -.
DR   GenomeRNAi; 3356; -.
DR   Pharos; P28223; Tclin.
DR   PRO; PR:P28223; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P28223; protein.
DR   Bgee; ENSG00000102468; Expressed in dorsolateral prefrontal cortex and 158 other tissues.
DR   ExpressionAtlas; P28223; baseline and differential.
DR   Genevisible; P28223; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005901; C:caveola; IEA:UniProtKB-SubCell.
DR   GO; GO:0070852; C:cell body fiber; IEA:Ensembl.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0098666; C:G protein-coupled serotonin receptor complex; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071886; F:1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding; IDA:UniProtKB.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001587; F:Gq/11-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0098664; P:G protein-coupled serotonin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0043267; P:negative regulation of potassium ion transport; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007208; P:phospholipase C-activating serotonin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0044380; P:protein localization to cytoskeleton; IEA:Ensembl.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IEA:Ensembl.
DR   InterPro; IPR000455; 5HT2A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF30; PTHR24247:SF30; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00516; 5HT2ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Behavior; Cell junction; Cell membrane;
KW   Cell projection; Cytoplasmic vesicle; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Membrane;
KW   Phosphoprotein; Receptor; Reference proteome; Synapse; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..471
FT                   /note="5-hydroxytryptamine receptor 2A"
FT                   /id="PRO_0000068946"
FT   TOPO_DOM        1..75
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        76..99
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        100..110
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        111..132
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        133..148
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        149..171
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        172..191
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        192..215
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        216..233
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        234..254
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        255..324
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        325..346
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        347..362
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        363..384
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        385..471
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          155..160
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   REGION          336..340
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   REGION          450..471
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           172..174
FT                   /note="DRY motif; important for ligand-induced conformation
FT                   changes"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   MOTIF           376..380
FT                   /note="NPxxY motif; important for ligand-induced
FT                   conformation changes and signaling"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   MOTIF           469..471
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000269|PubMed:11150294,
FT                   ECO:0000269|PubMed:14988405"
FT   SITE            229
FT                   /note="Hydrophobic barrier that decreases the speed of
FT                   ligand binding and dissociation"
FT                   /evidence="ECO:0000269|PubMed:28129538"
FT   MOD_RES         280
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   CARBOHYD        8
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        44
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        51
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        148..227
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        349..353
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         1..138
FT                   /note="MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENR
FT                   TNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNY
FT                   FLMSLAIADMLLGFLVMPVSMLTILYG -> MQFLKSAKQKPNYYHIMLVEDQEEGTLH
FT                   QFNYCERCSESQNNKCISCVDPEDKW (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046663"
FT   VARIANT         25
FT                   /note="T -> N (in dbSNP:rs1805055)"
FT                   /evidence="ECO:0000269|PubMed:10581480,
FT                   ECO:0000269|PubMed:8655141"
FT                   /id="VAR_003448"
FT   VARIANT         197
FT                   /note="I -> V (in dbSNP:rs6304)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_013901"
FT   VARIANT         447
FT                   /note="A -> V (in dbSNP:rs6308)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_013902"
FT   VARIANT         452
FT                   /note="H -> Y (in dbSNP:rs6314)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10581480, ECO:0000269|PubMed:8655141"
FT                   /id="VAR_003449"
FT   MUTAGEN         229
FT                   /note="L->A: Strongly increases dissociation of bound
FT                   lysergic acid diethylamine, without affecting binding
FT                   affinity. Reduces signaling via arrestins, but has no
FT                   effect on signaling via the phosphatidylinositol-calcium
FT                   second messenger system."
FT                   /evidence="ECO:0000269|PubMed:28129538"
FT   MUTAGEN         280
FT                   /note="S->A: Increased ability of hallucinogens to
FT                   desensitize the receptor."
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   MUTAGEN         280
FT                   /note="S->D: Reduced receptor desensitization by
FT                   nonhallucinogenic agonists."
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   MUTAGEN         463
FT                   /note="G->V: Loss of interaction with PATJ."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         465
FT                   /note="N->S: No effect on interaction with PATJ. Acquires
FT                   the binding properties of HTR2C; when associated with S-
FT                   470."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         470
FT                   /note="C->S: No effect on interaction with PATJ. Acquires
FT                   the binding properties of HTR2C; when associated with S-
FT                   465."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         471
FT                   /note="V->A: Loss of interaction with PATJ, CASK, APBA1,
FT                   DLG1 and DLG4."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   HELIX           70..101
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           103..105
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           108..126
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           128..136
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   TURN            137..139
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           146..177
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   TURN            180..183
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           189..207
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           209..216
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   TURN            219..221
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           232..242
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           244..265
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           313..348
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   TURN            350..352
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           355..383
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   HELIX           385..395
FT                   /evidence="ECO:0007829|PDB:6A94"
FT   CONFLICT        P28223-2:49
FT                   /note="D -> N (in Ref. 5; BAG63991)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   471 AA;  52603 MW;  EF8AAC0BC5379DA2 CRC64;
     MDILCEENTS LSSTTNSLMQ LNDDTRLYSN DFNSGEANTS DAFNWTVDSE NRTNLSCEGC
     LSPSCLSLLH LQEKNWSALL TAVVIILTIA GNILVIMAVS LEKKLQNATN YFLMSLAIAD
     MLLGFLVMPV SMLTILYGYR WPLPSKLCAV WIYLDVLFST ASIMHLCAIS LDRYVAIQNP
     IHHSRFNSRT KAFLKIIAVW TISVGISMPI PVFGLQDDSK VFKEGSCLLA DDNFVLIGSF
     VSFFIPLTIM VITYFLTIKS LQKEATLCVS DLGTRAKLAS FSFLPQSSLS SEKLFQRSIH
     REPGSYTGRR TMQSISNEQK ACKVLGIVFF LFVVMWCPFF ITNIMAVICK ESCNEDVIGA
     LLNVFVWIGY LSSAVNPLVY TLFNKTYRSA FSRYIQCQYK ENKKPLQLIL VNTIPALAYK
     SSQLQMGQKK NSKQDAKTTD NDCSMVALGK QHSEEASKDN SDGVNEKVSC V
//
ID   DAAF6_HUMAN             Reviewed;         214 AA.
AC   Q9NQM4; D3DUX5; Q86WE1;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 131.
DE   RecName: Full=Dynein axonemal assembly factor 6 {ECO:0000312|HGNC:HGNC:28570};
DE   AltName: Full=PIH1 domain-containing protein 3 {ECO:0000312|HGNC:HGNC:28570};
DE   AltName: Full=Sarcoma antigen NY-SAR-97;
GN   Name=DNAAF6 {ECO:0000312|HGNC:HGNC:28570};
GN   Synonyms=CXorf41 {ECO:0000312|HGNC:HGNC:28570},
GN   PIH1D3 {ECO:0000312|HGNC:HGNC:28570};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-195, AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=12601173; DOI=10.1073/pnas.0437972100;
RA   Lee S.-Y., Obata Y., Yoshida M., Stockert E., Williamson B.,
RA   Jungbluth A.A., Chen Y.-T., Old L.J., Scanlan M.J.;
RT   "Immunomic analysis of human sarcoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:2651-2656(2003).
RN   [5]
RP   INVOLVEMENT IN CILD36, VARIANT CILD36 119-GLN--PHE-214 DEL,
RP   CHARACTERIZATION OF VARIANT CILD36 119-GLN--PHE-214 DEL, FUNCTION, AND
RP   INTERACTION WITH DNAAF2 AND DNAAF4.
RX   PubMed=28041644; DOI=10.1016/j.ajhg.2016.11.019;
RA   Paff T., Loges N.T., Aprea I., Wu K., Bakey Z., Haarman E.G., Daniels J.M.,
RA   Sistermans E.A., Bogunovic N., Dougherty G.W., Hoeben I.M.,
RA   Grosse-Onnebrink J., Matter A., Olbrich H., Werner C., Pals G.,
RA   Schmidts M., Omran H., Micha D.;
RT   "Mutations in PIH1D3 Cause X-Linked Primary Ciliary Dyskinesia with Outer
RT   and Inner Dynein Arm Defects.";
RL   Am. J. Hum. Genet. 100:160-168(2017).
RN   [6]
RP   INVOLVEMENT IN CILD36, VARIANTS CILD36 43-GLU--PHE-214 DEL; 89-TRP--PHE-214
RP   DEL; TYR-133 AND 171-GLN--PHE-214 DEL, CHARACTERIZATION OF VARIANTS CILD36
RP   43-GLU--PHE-214 DEL; 89-TRP--PHE-214 DEL; TYR-133 AND 171-GLN--PHE-214,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH DNAI2, AND
RP   FUNCTION.
RX   PubMed=28176794; DOI=10.1038/ncomms14279;
RG   UK10K Rare Group;
RA   Olcese C., Patel M.P., Shoemark A., Kiviluoto S., Legendre M.,
RA   Williams H.J., Vaughan C.K., Hayward J., Goldenberg A., Emes R.D.,
RA   Munye M.M., Dyer L., Cahill T., Bevillard J., Gehrig C., Guipponi M.,
RA   Chantot S., Duquesnoy P., Thomas L., Jeanson L., Copin B., Tamalet A.,
RA   Thauvin-Robinet C., Papon J.F., Garin A., Pin I., Vera G., Aurora P.,
RA   Fassad M.R., Jenkins L., Boustred C., Cullup T., Dixon M., Onoufriadis A.,
RA   Bush A., Chung E.M., Antonarakis S.E., Loebinger M.R., Wilson R.,
RA   Armengot M., Escudier E., Hogg C., Amselem S., Sun Z., Bartoloni L.,
RA   Blouin J.L., Mitchison H.M.;
RT   "X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic
RT   axonemal dynein assembly factor PIH1D3.";
RL   Nat. Commun. 8:14279-14279(2017).
CC   -!- FUNCTION: Plays a role in cytoplasmic pre-assembly of axonemal dynein.
CC       {ECO:0000269|PubMed:28041644, ECO:0000269|PubMed:28176794}.
CC   -!- SUBUNIT: Interacts with HSPA1A/B and HSP90AA1 (By similarity).
CC       Interacts with DNAAF2 and DNAAF4 (PubMed:28041644). Interacts wuth
CC       DNAI2 (PubMed:28176794). {ECO:0000250|UniProtKB:Q3KNI6,
CC       ECO:0000269|PubMed:28041644, ECO:0000269|PubMed:28176794}.
CC   -!- INTERACTION:
CC       Q9NQM4; Q4LE39-3: ARID4B; NbExp=3; IntAct=EBI-10239299, EBI-11957452;
CC       Q9NQM4; Q2M1V9: BTAF1; NbExp=3; IntAct=EBI-10239299, EBI-10239305;
CC       Q9NQM4; Q8IX12: CCAR1; NbExp=3; IntAct=EBI-10239299, EBI-356265;
CC       Q9NQM4; Q8IVW4: CDKL3; NbExp=3; IntAct=EBI-10239299, EBI-3919850;
CC       Q9NQM4; Q8NHY3: GAS2L2; NbExp=4; IntAct=EBI-10239299, EBI-7960826;
CC       Q9NQM4; Q92993: KAT5; NbExp=6; IntAct=EBI-10239299, EBI-399080;
CC       Q9NQM4; Q9H1H9: KIF13A; NbExp=3; IntAct=EBI-10239299, EBI-1759129;
CC       Q9NQM4; Q99571: P2RX4; NbExp=3; IntAct=EBI-10239299, EBI-2828248;
CC       Q9NQM4; Q7Z2X4-3: PID1; NbExp=3; IntAct=EBI-10239299, EBI-11953174;
CC       Q9NQM4; Q9Y2S7: POLDIP2; NbExp=3; IntAct=EBI-10239299, EBI-713000;
CC       Q9NQM4; P54646: PRKAA2; NbExp=3; IntAct=EBI-10239299, EBI-1383852;
CC       Q9NQM4; Q2TAL8: QRICH1; NbExp=3; IntAct=EBI-10239299, EBI-2798044;
CC       Q9NQM4; Q9H2S5: RNF39; NbExp=3; IntAct=EBI-10239299, EBI-12235180;
CC       Q9NQM4; Q8WW01: TSEN15; NbExp=3; IntAct=EBI-10239299, EBI-372432;
CC       Q9NQM4; Q8IY57-5: YAF2; NbExp=3; IntAct=EBI-10239299, EBI-12111538;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:28176794}. Golgi
CC       apparatus, trans-Golgi network {ECO:0000269|PubMed:28176794}.
CC       Note=Localized to the cytoplasm of spermatogenic cells.
CC       {ECO:0000250|UniProtKB:Q3KNI6}.
CC   -!- TISSUE SPECIFICITY: Expressed in testis, small intestine, prostate,
CC       adrenal gland, spleen, lung, bladder, breast and ovary. Expressed in
CC       ciliated epithelial cells (PubMed:28176794).
CC       {ECO:0000269|PubMed:12601173, ECO:0000269|PubMed:28176794}.
CC   -!- DISEASE: Ciliary dyskinesia, primary, 36, X-linked (CILD36)
CC       [MIM:300991]: A form of primary ciliary dyskinesia, a disorder
CC       characterized by abnormalities of motile cilia. Respiratory infections
CC       leading to chronic inflammation and bronchiectasis are recurrent, due
CC       to defects in the respiratory cilia. Some patients exhibit
CC       randomization of left-right body asymmetry and situs inversus. Primary
CC       ciliary dyskinesia associated with situs inversus is referred to as
CC       Kartagener syndrome. CILD36 inheritance is X-linked recessive. About
CC       half of CILD36 patients have laterality defects due to ciliary
CC       dysfunction at the embryonic node. {ECO:0000269|PubMed:28041644,
CC       ECO:0000269|PubMed:28176794}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PIH1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAO65181.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL136112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471120; EAX02716.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02717.1; -; Genomic_DNA.
DR   EMBL; BC033510; AAH33510.1; -; mRNA.
DR   EMBL; AY211928; AAO65181.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS14528.1; -.
DR   RefSeq; NP_001162625.1; NM_001169154.1.
DR   RefSeq; NP_775765.1; NM_173494.1.
DR   RefSeq; XP_011529157.1; XM_011530855.2.
DR   SMR; Q9NQM4; -.
DR   BioGRID; 126551; 16.
DR   IntAct; Q9NQM4; 15.
DR   STRING; 9606.ENSP00000441930; -.
DR   iPTMnet; Q9NQM4; -.
DR   PhosphoSitePlus; Q9NQM4; -.
DR   BioMuta; PIH1D3; -.
DR   DMDM; 71153251; -.
DR   MassIVE; Q9NQM4; -.
DR   PaxDb; Q9NQM4; -.
DR   PeptideAtlas; Q9NQM4; -.
DR   PRIDE; Q9NQM4; -.
DR   ProteomicsDB; 82164; -.
DR   Antibodypedia; 63940; 50 antibodies from 15 providers.
DR   DNASU; 139212; -.
DR   Ensembl; ENST00000336387; ENSP00000337757; ENSG00000080572.
DR   Ensembl; ENST00000372453; ENSP00000361531; ENSG00000080572.
DR   Ensembl; ENST00000535523; ENSP00000441930; ENSG00000080572.
DR   GeneID; 139212; -.
DR   KEGG; hsa:139212; -.
DR   MANE-Select; ENST00000372453.8; ENSP00000361531.3; NM_173494.2; NP_775765.1.
DR   UCSC; uc004enc.3; human.
DR   CTD; 139212; -.
DR   DisGeNET; 139212; -.
DR   GeneCards; DNAAF6; -.
DR   HGNC; HGNC:28570; DNAAF6.
DR   HPA; ENSG00000080572; Group enriched (fallopian tube, testis).
DR   MalaCards; DNAAF6; -.
DR   MIM; 300933; gene.
DR   MIM; 300991; phenotype.
DR   neXtProt; NX_Q9NQM4; -.
DR   OpenTargets; ENSG00000080572; -.
DR   Orphanet; 244; Primary ciliary dyskinesia.
DR   PharmGKB; PA134882142; -.
DR   VEuPathDB; HostDB:ENSG00000080572; -.
DR   eggNOG; ENOG502RZWX; Eukaryota.
DR   GeneTree; ENSGT00390000015219; -.
DR   HOGENOM; CLU_106090_1_0_1; -.
DR   InParanoid; Q9NQM4; -.
DR   OMA; ESMVVHK; -.
DR   OrthoDB; 1561656at2759; -.
DR   PhylomeDB; Q9NQM4; -.
DR   TreeFam; TF325677; -.
DR   PathwayCommons; Q9NQM4; -.
DR   SignaLink; Q9NQM4; -.
DR   BioGRID-ORCS; 139212; 5 hits in 656 CRISPR screens.
DR   GenomeRNAi; 139212; -.
DR   Pharos; Q9NQM4; Tbio.
DR   PRO; PR:Q9NQM4; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9NQM4; protein.
DR   Bgee; ENSG00000080572; Expressed in bronchial epithelial cell and 51 other tissues.
DR   Genevisible; Q9NQM4; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; ISS:UniProtKB.
DR   GO; GO:0045505; F:dynein intermediate chain binding; IMP:UniProtKB.
DR   GO; GO:0070286; P:axonemal dynein complex assembly; IMP:UniProtKB.
DR   GO; GO:0003341; P:cilium movement; IMP:UniProtKB.
DR   GO; GO:0030317; P:flagellated sperm motility; IMP:UniProtKB.
DR   GO; GO:0036159; P:inner dynein arm assembly; IMP:UniProtKB.
DR   GO; GO:0036158; P:outer dynein arm assembly; IMP:UniProtKB.
DR   InterPro; IPR026697; DNAAF6.
DR   InterPro; IPR041442; PIH1D1/2/3_CS-like.
DR   PANTHER; PTHR21083; PTHR21083; 1.
DR   Pfam; PF18201; PIH1_CS; 1.
PE   1: Evidence at protein level;
KW   Ciliopathy; Cytoplasm; Disease variant; Golgi apparatus;
KW   Kartagener syndrome; Primary ciliary dyskinesia; Reference proteome.
FT   CHAIN           1..214
FT                   /note="Dynein axonemal assembly factor 6"
FT                   /id="PRO_0000079736"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          34..68
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VARIANT         43..214
FT                   /note="Missing (in CILD36; strongly decreased expression at
FT                   protein level; almost complete loss of outer dynein arms
FT                   and less loss of inner dynein arms in motor cilia;
FT                   decreased cilia movement; no effect on trans-Golgi network
FT                   location; abolishes interaction with DNAI2)"
FT                   /evidence="ECO:0000269|PubMed:28176794"
FT                   /id="VAR_083176"
FT   VARIANT         89..214
FT                   /note="Missing (in CILD36; almost complete loss of inner
FT                   dynein arms and less loss of outer dynein arms in motor
FT                   cilia; immotile cilia; abolishes interaction with DNAI2)"
FT                   /evidence="ECO:0000269|PubMed:28176794"
FT                   /id="VAR_083177"
FT   VARIANT         119..214
FT                   /note="Missing (in CILD36; defective preassembly of outer
FT                   and inner dynein arms)"
FT                   /evidence="ECO:0000269|PubMed:28041644"
FT                   /id="VAR_078066"
FT   VARIANT         133
FT                   /note="D -> Y (in CILD36; no effect on expression at
FT                   protein level; almost complete loss of outer dynein arms
FT                   and inner dynein arms in motor cilia; immotile cilia;
FT                   abolishes interaction with DNAI2)"
FT                   /evidence="ECO:0000269|PubMed:28176794"
FT                   /id="VAR_083178"
FT   VARIANT         171..214
FT                   /note="Missing (in CILD36; almost complete loss of outer
FT                   dynein arms and inner dynein arms in motor cilia; immotile
FT                   cilia)"
FT                   /evidence="ECO:0000269|PubMed:28176794"
FT                   /id="VAR_083179"
SQ   SEQUENCE   214 AA;  24069 MW;  F86B2E210BBC06F6 CRC64;
     MESENMDSEN MKTENMESQN VDFESVSSVT ALEALSKLLN PEEEDDSDYG QTNGLSTIGA
     MGPGNIGPPQ IEELKVIPET SEENNEDIWN SEEIPEGAEY DDMWDVREIP EYEIIFRQQV
     GTEDIFLGLS KKDSSTGCCS ELVAKIKLPN TNPSDIQIDI QETILDLRTP QKKLLITLPE
     LVECTSAKAF YIPETETLEI TMTMKRELDI ANFF
//
ID   F217B_HUMAN             Reviewed;         383 AA.
AC   Q9NTX9; B3KWH1; Q9NTA3;
DT   10-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 131.
DE   RecName: Full=Protein FAM217B;
GN   Name=FAM217B; Synonyms=C20orf177;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 68-383.
RC   TISSUE=Kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-95.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- INTERACTION:
CC       Q9NTX9; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-19153639, EBI-11954519;
CC       Q9NTX9; Q92688: ANP32B; NbExp=3; IntAct=EBI-19153639, EBI-762428;
CC       Q9NTX9; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-19153639, EBI-11524452;
CC       Q9NTX9; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-19153639, EBI-8643161;
CC       Q9NTX9; Q53TS8: C2CD6; NbExp=3; IntAct=EBI-19153639, EBI-739879;
CC       Q9NTX9; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-19153639, EBI-10171570;
CC       Q9NTX9; Q96GN5: CDCA7L; NbExp=3; IntAct=EBI-19153639, EBI-5278764;
CC       Q9NTX9; Q8IYI6: EXOC8; NbExp=3; IntAct=EBI-19153639, EBI-742102;
CC       Q9NTX9; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-19153639, EBI-2549423;
CC       Q9NTX9; Q969R5: L3MBTL2; NbExp=3; IntAct=EBI-19153639, EBI-739909;
CC       Q9NTX9; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-19153639, EBI-77889;
CC       Q9NTX9; Q8WY64: MYLIP; NbExp=3; IntAct=EBI-19153639, EBI-6952711;
CC       Q9NTX9; P62875: POLR2L; NbExp=3; IntAct=EBI-19153639, EBI-359527;
CC       Q9NTX9; Q969G3: SMARCE1; NbExp=3; IntAct=EBI-19153639, EBI-455078;
CC       Q9NTX9; Q5MJ09: SPANXN3; NbExp=3; IntAct=EBI-19153639, EBI-12037215;
CC       Q9NTX9; P51687: SUOX; NbExp=3; IntAct=EBI-19153639, EBI-3921347;
CC       Q9NTX9; Q8N8B7-2: TCEANC; NbExp=3; IntAct=EBI-19153639, EBI-11955057;
CC       Q9NTX9; Q08117-2: TLE5; NbExp=3; IntAct=EBI-19153639, EBI-11741437;
CC       Q9NTX9; Q6DKK2: TTC19; NbExp=3; IntAct=EBI-19153639, EBI-948354;
CC       Q9NTX9; Q05516: ZBTB16; NbExp=3; IntAct=EBI-19153639, EBI-711925;
CC   -!- SIMILARITY: Belongs to the FAM217 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK125073; BAG54133.1; -; mRNA.
DR   EMBL; AL109928; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75424.1; -; Genomic_DNA.
DR   EMBL; BC054002; AAH54002.1; -; mRNA.
DR   EMBL; AL137442; CAB70739.2; -; mRNA.
DR   CCDS; CCDS13484.1; -.
DR   PIR; T46282; T46282.
DR   RefSeq; NP_001177755.1; NM_001190826.1.
DR   RefSeq; NP_001177756.1; NM_001190827.1.
DR   RefSeq; NP_071389.1; NM_022106.2.
DR   BioGRID; 122004; 35.
DR   IntAct; Q9NTX9; 29.
DR   STRING; 9606.ENSP00000351040; -.
DR   iPTMnet; Q9NTX9; -.
DR   PhosphoSitePlus; Q9NTX9; -.
DR   BioMuta; FAM217B; -.
DR   DMDM; 27734258; -.
DR   MassIVE; Q9NTX9; -.
DR   PaxDb; Q9NTX9; -.
DR   PeptideAtlas; Q9NTX9; -.
DR   PRIDE; Q9NTX9; -.
DR   ProteomicsDB; 82644; -.
DR   Antibodypedia; 48191; 27 antibodies from 8 providers.
DR   DNASU; 63939; -.
DR   Ensembl; ENST00000358293; ENSP00000351040; ENSG00000196227.
DR   Ensembl; ENST00000360816; ENSP00000354056; ENSG00000196227.
DR   GeneID; 63939; -.
DR   KEGG; hsa:63939; -.
DR   MANE-Select; ENST00000360816.8; ENSP00000354056.3; NM_022106.3; NP_071389.1.
DR   UCSC; uc002yba.4; human.
DR   CTD; 63939; -.
DR   DisGeNET; 63939; -.
DR   GeneCards; FAM217B; -.
DR   HGNC; HGNC:16170; FAM217B.
DR   HPA; ENSG00000196227; Low tissue specificity.
DR   neXtProt; NX_Q9NTX9; -.
DR   OpenTargets; ENSG00000196227; -.
DR   PharmGKB; PA25720; -.
DR   VEuPathDB; HostDB:ENSG00000196227; -.
DR   eggNOG; ENOG502R40C; Eukaryota.
DR   GeneTree; ENSGT00940000154543; -.
DR   HOGENOM; CLU_043958_0_0_1; -.
DR   InParanoid; Q9NTX9; -.
DR   OMA; RPSYYAF; -.
DR   PhylomeDB; Q9NTX9; -.
DR   TreeFam; TF337855; -.
DR   PathwayCommons; Q9NTX9; -.
DR   SignaLink; Q9NTX9; -.
DR   BioGRID-ORCS; 63939; 3 hits in 1047 CRISPR screens.
DR   ChiTaRS; FAM217B; human.
DR   GenomeRNAi; 63939; -.
DR   Pharos; Q9NTX9; Tdark.
DR   PRO; PR:Q9NTX9; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9NTX9; protein.
DR   Bgee; ENSG00000196227; Expressed in frontal cortex and 212 other tissues.
DR   ExpressionAtlas; Q9NTX9; baseline and differential.
DR   Genevisible; Q9NTX9; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   InterPro; IPR029266; FAM217.
DR   PANTHER; PTHR22145; PTHR22145; 1.
DR   Pfam; PF15344; FAM217; 1.
PE   1: Evidence at protein level;
KW   Reference proteome.
FT   CHAIN           1..383
FT                   /note="Protein FAM217B"
FT                   /id="PRO_0000079485"
FT   REGION          1..70
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          89..115
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          200..222
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          232..251
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          284..325
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          338..383
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..47
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..62
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        285..302
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        303..321
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        365..383
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VARIANT         95
FT                   /note="S -> G (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs1180582304)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035691"
FT   VARIANT         380
FT                   /note="Y -> C (in dbSNP:rs6027210)"
FT                   /id="VAR_050922"
FT   CONFLICT        68
FT                   /note="Q -> G (in Ref. 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        120
FT                   /note="E -> G (in Ref. 5; CAB70739)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   383 AA;  42052 MW;  56E1DB8E27CD544F CRC64;
     MNAGPSWNKV QHSKNSSGKR QSKSQVPHAS SQPRSSLTAV TQPTEEKLKE SISPEARRKR
     NPLGSRCQGA SGNKLFLDFQ SMKIIKENAD EDSASDLSDS ERIPIPPSPL TPPDLNLRAE
     EIDPVYFDLH PGQGHTKPEY YYPNFLPSPF SSWDLRDMAL LLNAENKTEA VPRVGGLLGK
     YIDRLIQLEW LQVQTVQCEK AKGGKARPPT APGTSGALKS PGRSKLIASA LSKPLPHQEG
     ASKSGPSRKK AFHHEEIHPS HYAFETSPRP IDVLGGTRFC SQRQTLEMRT EEKKKKSSKS
     TKLQRWDLSG SGSSSKVETS GHIRVPKQAA VILDSADSCK ASKTQAHAHP RKKGKAESCG
     HATVSSEKKL KTNGVKQNTY KLK
//
ID   PLD5_HUMAN              Reviewed;         536 AA.
AC   Q8N7P1; A1KXV0; B7Z324; Q494U9; Q8NB22;
DT   29-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   29-MAY-2007, sequence version 2.
DT   23-FEB-2022, entry version 148.
DE   RecName: Full=Inactive phospholipase D5;
DE            Short=Inactive PLD 5;
DE   AltName: Full=Inactive choline phosphatase 5;
DE   AltName: Full=Inactive phosphatidylcholine-hydrolyzing phospholipase D5;
DE   AltName: Full=PLDc;
GN   Name=PLD5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RA   Li X., Xie Y., Mao Y.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Brain, Corpus callosum, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 46-536 (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass membrane
CC       protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8N7P1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N7P1-2; Sequence=VSP_025725;
CC       Name=3;
CC         IsoId=Q8N7P1-3; Sequence=VSP_025724;
CC       Name=4;
CC         IsoId=Q8N7P1-4; Sequence=VSP_025726, VSP_025727;
CC   -!- SIMILARITY: Belongs to the phospholipase D family. {ECO:0000305}.
CC   -!- CAUTION: In contrast to other members of the family, it lacks the
CC       conserved active sites, suggesting that it has no phospholipase
CC       activity. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI01374.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAI01375.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAI01376.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY461578; AAS91020.1; -; mRNA.
DR   EMBL; AK091691; BAC03722.1; -; mRNA.
DR   EMBL; AK098092; BAC05230.1; -; mRNA.
DR   EMBL; AK295421; BAH12060.1; -; mRNA.
DR   EMBL; AL360271; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL583845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591686; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445704; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC101373; AAI01374.1; ALT_INIT; mRNA.
DR   EMBL; BC101374; AAI01375.1; ALT_INIT; mRNA.
DR   EMBL; BC101375; AAI01376.1; ALT_INIT; mRNA.
DR   CCDS; CCDS1621.2; -. [Q8N7P1-1]
DR   CCDS; CCDS55692.1; -. [Q8N7P1-4]
DR   RefSeq; NP_001182740.1; NM_001195811.1. [Q8N7P1-4]
DR   RefSeq; NP_001182741.1; NM_001195812.1. [Q8N7P1-3]
DR   RefSeq; NP_001307201.1; NM_001320272.1. [Q8N7P1-2]
DR   RefSeq; NP_689879.2; NM_152666.2.
DR   RefSeq; XP_006711815.1; XM_006711752.2.
DR   RefSeq; XP_011542417.1; XM_011544115.2.
DR   RefSeq; XP_011542418.1; XM_011544116.2.
DR   RefSeq; XP_011542422.1; XM_011544120.2. [Q8N7P1-3]
DR   RefSeq; XP_011542423.1; XM_011544121.2. [Q8N7P1-3]
DR   RefSeq; XP_011542424.1; XM_011544122.2. [Q8N7P1-3]
DR   RefSeq; XP_016856056.1; XM_017000567.1. [Q8N7P1-2]
DR   RefSeq; XP_016856057.1; XM_017000568.1. [Q8N7P1-2]
DR   RefSeq; XP_016856058.1; XM_017000569.1. [Q8N7P1-3]
DR   RefSeq; XP_016856059.1; XM_017000570.1. [Q8N7P1-3]
DR   BioGRID; 128302; 37.
DR   STRING; 9606.ENSP00000440896; -.
DR   GlyGen; Q8N7P1; 2 sites.
DR   iPTMnet; Q8N7P1; -.
DR   PhosphoSitePlus; Q8N7P1; -.
DR   BioMuta; PLD5; -.
DR   DMDM; 152112223; -.
DR   EPD; Q8N7P1; -.
DR   jPOST; Q8N7P1; -.
DR   MassIVE; Q8N7P1; -.
DR   PaxDb; Q8N7P1; -.
DR   PeptideAtlas; Q8N7P1; -.
DR   PRIDE; Q8N7P1; -.
DR   ProteomicsDB; 72311; -. [Q8N7P1-1]
DR   ProteomicsDB; 72312; -. [Q8N7P1-2]
DR   ProteomicsDB; 72313; -. [Q8N7P1-3]
DR   ProteomicsDB; 72314; -. [Q8N7P1-4]
DR   Antibodypedia; 34707; 126 antibodies from 20 providers.
DR   DNASU; 200150; -.
DR   Ensembl; ENST00000427495; ENSP00000401285; ENSG00000180287. [Q8N7P1-4]
DR   Ensembl; ENST00000442594; ENSP00000414188; ENSG00000180287.
DR   Ensembl; ENST00000536534; ENSP00000440896; ENSG00000180287.
DR   GeneID; 200150; -.
DR   KEGG; hsa:200150; -.
DR   MANE-Select; ENST00000536534.7; ENSP00000440896.1; NM_001372062.1; NP_001358991.1.
DR   UCSC; uc001hzl.4; human. [Q8N7P1-1]
DR   CTD; 200150; -.
DR   DisGeNET; 200150; -.
DR   GeneCards; PLD5; -.
DR   HGNC; HGNC:26879; PLD5.
DR   HPA; ENSG00000180287; Group enriched (brain, choroid plexus).
DR   neXtProt; NX_Q8N7P1; -.
DR   OpenTargets; ENSG00000180287; -.
DR   PharmGKB; PA142671168; -.
DR   VEuPathDB; HostDB:ENSG00000180287; -.
DR   eggNOG; KOG3603; Eukaryota.
DR   GeneTree; ENSGT00950000183059; -.
DR   HOGENOM; CLU_027021_0_0_1; -.
DR   InParanoid; Q8N7P1; -.
DR   OMA; CATKEQR; -.
DR   OrthoDB; 1057467at2759; -.
DR   PhylomeDB; Q8N7P1; -.
DR   TreeFam; TF313378; -.
DR   PathwayCommons; Q8N7P1; -.
DR   BioGRID-ORCS; 200150; 8 hits in 1032 CRISPR screens.
DR   ChiTaRS; PLD5; human.
DR   GeneWiki; PLD5; -.
DR   GenomeRNAi; 200150; -.
DR   Pharos; Q8N7P1; Tbio.
DR   PRO; PR:Q8N7P1; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8N7P1; protein.
DR   Bgee; ENSG00000180287; Expressed in pigmented layer of retina and 129 other tissues.
DR   ExpressionAtlas; Q8N7P1; baseline and differential.
DR   Genevisible; Q8N7P1; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   InterPro; IPR032803; PLDc_3.
DR   InterPro; IPR001736; PLipase_D/transphosphatidylase.
DR   Pfam; PF13918; PLDc_3; 1.
DR   SMART; SM00155; PLDc; 2.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Glycoprotein; Membrane; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..536
FT                   /note="Inactive phospholipase D5"
FT                   /id="PRO_0000288606"
FT   TRANSMEM        69..89
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          215..242
FT                   /note="PLD phosphodiesterase 1"
FT   DOMAIN          434..460
FT                   /note="PLD phosphodiesterase 2"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        302
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..208
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_025724"
FT   VAR_SEQ         1..108
FT                   /note="MEIRQHEWLSASPHEGFEQMRLKSRPKEPSPSLTRVGANFYSSVKQQDYSAS
FT                   VWLRRKDKLEHSQQKCIVIFALVCCFAILVALIFSAVDIMGEDEDGLSEKNCQNKC ->
FT                   MRMDSQKKIAKINVGK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_025725"
FT   VAR_SEQ         1..62
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.1"
FT                   /id="VSP_025726"
FT   VAR_SEQ         63
FT                   /note="H -> M (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.1"
FT                   /id="VSP_025727"
SQ   SEQUENCE   536 AA;  61312 MW;  2FC94D6AB4A19934 CRC64;
     MEIRQHEWLS ASPHEGFEQM RLKSRPKEPS PSLTRVGANF YSSVKQQDYS ASVWLRRKDK
     LEHSQQKCIV IFALVCCFAI LVALIFSAVD IMGEDEDGLS EKNCQNKCRI ALVENIPEGL
     NYSENAPFHL SLFQGWMNLL NMAKKSVDIV SSHWDLNHTH PSACQGQRLF EKLLQLTSQN
     IEIKLVSDVT ADSKVLEALK LKGAEVTYMN MTAYNKGRLQ SSFWIVDKQH VYIGSAGLDW
     QSLGQMKELG VIFYNCSCLV LDLQRIFALY SSLKFKSRVP QTWSKRLYGV YDNEKKLQLQ
     LNETKSQAFV SNSPKLFCPK NRSFDIDAIY SVIDDAKQYV YIAVMDYLPI SSTSTKRTYW
     PDLDAKIREA LVLRSVRVRL LLSFWKETDP LTFNFISSLK AICTEIANCS LKVKFFDLER
     ENACATKEQK NHTFPRLNRN KYMVTDGAAY IGNFDWVGND FTQNAGTGLV INQADVRNNR
     SIIKQLKDVF ERDWYSPYAK TLQPTKQPNC SSLFKLKPLS NKTATDDTGG KDPRNV
//
ID   NOL4_HUMAN              Reviewed;         638 AA.
AC   O94818; B4DSQ0; B7Z3Z7; F5H1E3; Q6IBS2; Q9BWF1;
DT   26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 2.
DT   23-FEB-2022, entry version 151.
DE   RecName: Full=Nucleolar protein 4;
DE   AltName: Full=Nucleolar-localized protein;
GN   Name=NOL4; Synonyms=NOLP; ORFNames=HRIHFB2255;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9813152; DOI=10.1006/bbrc.1998.9606;
RA   Ueki N., Kondo M., Seki N., Yano K., Oda T., Masuho Y., Muramatsu M.-A.;
RT   "NOLP: identification of a novel human nucleolar protein and determination
RT   of sequence requirements for its nucleolar localization.";
RL   Biochem. Biophys. Res. Commun. 252:97-102(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-638 (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 115-638 (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 115-638 (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 336-638 (ISOFORM 1), AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Fetal brain;
RX   PubMed=9853615; DOI=10.1038/4315;
RA   Ueki N., Oda T., Kondo M., Yano K., Noguchi T., Muramatsu M.-A.;
RT   "Selection system for genes encoding nuclear-targeted proteins.";
RL   Nat. Biotechnol. 16:1338-1342(1998).
CC   -!- INTERACTION:
CC       O94818-2; Q9BXJ5: C1QTNF2; NbExp=3; IntAct=EBI-10190763, EBI-2817707;
CC       O94818-2; Q13363-2: CTBP1; NbExp=4; IntAct=EBI-10190763, EBI-10171858;
CC       O94818-2; P56545: CTBP2; NbExp=3; IntAct=EBI-10190763, EBI-741533;
CC       O94818-2; P56545-3: CTBP2; NbExp=3; IntAct=EBI-10190763, EBI-10171902;
CC       O94818-2; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-10190763, EBI-10175124;
CC       O94818-2; P43364: MAGEA11; NbExp=3; IntAct=EBI-10190763, EBI-739552;
CC       O94818-2; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-10190763, EBI-16439278;
CC       O94818-2; P07237: P4HB; NbExp=3; IntAct=EBI-10190763, EBI-395883;
CC       O94818-2; Q8IX90: SKA3; NbExp=3; IntAct=EBI-10190763, EBI-1773976;
CC       O94818-2; O75971: SNAPC5; NbExp=3; IntAct=EBI-10190763, EBI-749483;
CC       O94818-2; O75971-2: SNAPC5; NbExp=3; IntAct=EBI-10190763, EBI-12004298;
CC       O94818-2; Q8N6V9: TEX9; NbExp=6; IntAct=EBI-10190763, EBI-746341;
CC       O94818-2; Q8NA42: ZNF383; NbExp=3; IntAct=EBI-10190763, EBI-20110775;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:9813152,
CC       ECO:0000269|PubMed:9853615}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O94818-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O94818-2; Sequence=VSP_010080;
CC       Name=3;
CC         IsoId=O94818-3; Sequence=VSP_043344;
CC       Name=4;
CC         IsoId=O94818-4; Sequence=VSP_045836;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in fetal brain, adult brain
CC       and testis. {ECO:0000269|PubMed:9813152}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH00313.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=BAA34576.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA34576.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB017800; BAA34576.1; ALT_SEQ; mRNA.
DR   EMBL; AK296539; BAH12383.1; -; mRNA.
DR   EMBL; AK299850; BAG61712.1; -; mRNA.
DR   EMBL; AC010798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC018972; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087397; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104985; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000313; AAH00313.1; ALT_SEQ; mRNA.
DR   EMBL; BT006763; AAP35409.1; -; mRNA.
DR   EMBL; CR456730; CAG33011.1; -; mRNA.
DR   EMBL; AB015339; BAA34797.1; -; mRNA.
DR   CCDS; CCDS11907.2; -. [O94818-1]
DR   CCDS; CCDS56058.1; -. [O94818-4]
DR   CCDS; CCDS56059.1; -. [O94818-3]
DR   CCDS; CCDS59308.1; -. [O94818-2]
DR   PIR; JE0335; JE0335.
DR   RefSeq; NP_001185475.1; NM_001198546.1.
DR   RefSeq; NP_001185476.1; NM_001198547.1. [O94818-3]
DR   RefSeq; NP_001185477.1; NM_001198548.1. [O94818-2]
DR   RefSeq; NP_001185478.1; NM_001198549.1. [O94818-4]
DR   RefSeq; NP_001269456.1; NM_001282527.1.
DR   RefSeq; NP_003778.2; NM_003787.4. [O94818-1]
DR   RefSeq; XP_006722626.1; XM_006722563.2. [O94818-1]
DR   RefSeq; XP_011524539.1; XM_011526237.1. [O94818-1]
DR   RefSeq; XP_011524540.1; XM_011526238.1.
DR   RefSeq; XP_016881548.1; XM_017026059.1. [O94818-4]
DR   BioGRID; 114256; 47.
DR   IntAct; O94818; 15.
DR   MINT; O94818; -.
DR   STRING; 9606.ENSP00000261592; -.
DR   iPTMnet; O94818; -.
DR   PhosphoSitePlus; O94818; -.
DR   BioMuta; NOL4; -.
DR   EPD; O94818; -.
DR   jPOST; O94818; -.
DR   MassIVE; O94818; -.
DR   MaxQB; O94818; -.
DR   PaxDb; O94818; -.
DR   PeptideAtlas; O94818; -.
DR   PRIDE; O94818; -.
DR   ProteomicsDB; 25628; -.
DR   ProteomicsDB; 50459; -. [O94818-1]
DR   ProteomicsDB; 50460; -. [O94818-2]
DR   ProteomicsDB; 50461; -. [O94818-3]
DR   Antibodypedia; 8389; 120 antibodies from 25 providers.
DR   DNASU; 8715; -.
DR   Ensembl; ENST00000261592; ENSP00000261592; ENSG00000101746.
DR   Ensembl; ENST00000535384; ENSP00000445733; ENSG00000101746. [O94818-4]
DR   Ensembl; ENST00000538587; ENSP00000443472; ENSG00000101746. [O94818-3]
DR   Ensembl; ENST00000589544; ENSP00000465450; ENSG00000101746. [O94818-2]
DR   GeneID; 8715; -.
DR   KEGG; hsa:8715; -.
DR   MANE-Select; ENST00000261592.10; ENSP00000261592.4; NM_003787.5; NP_003778.2.
DR   UCSC; uc002kxt.5; human. [O94818-1]
DR   CTD; 8715; -.
DR   DisGeNET; 8715; -.
DR   GeneCards; NOL4; -.
DR   HGNC; HGNC:7870; NOL4.
DR   HPA; ENSG00000101746; Tissue enhanced (brain, pituitary gland, retina, testis).
DR   MIM; 603577; gene.
DR   neXtProt; NX_O94818; -.
DR   OpenTargets; ENSG00000101746; -.
DR   PharmGKB; PA31674; -.
DR   VEuPathDB; HostDB:ENSG00000101746; -.
DR   eggNOG; ENOG502QR3R; Eukaryota.
DR   GeneTree; ENSGT00940000159992; -.
DR   HOGENOM; CLU_020587_0_0_1; -.
DR   InParanoid; O94818; -.
DR   OMA; CREMGDT; -.
DR   OrthoDB; 1009964at2759; -.
DR   PhylomeDB; O94818; -.
DR   TreeFam; TF325594; -.
DR   PathwayCommons; O94818; -.
DR   SignaLink; O94818; -.
DR   BioGRID-ORCS; 8715; 3 hits in 1042 CRISPR screens.
DR   ChiTaRS; NOL4; human.
DR   GenomeRNAi; 8715; -.
DR   Pharos; O94818; Tbio.
DR   PRO; PR:O94818; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; O94818; protein.
DR   Bgee; ENSG00000101746; Expressed in cortical plate and 140 other tissues.
DR   ExpressionAtlas; O94818; baseline and differential.
DR   Genevisible; O94818; HS.
DR   GO; GO:0005730; C:nucleolus; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; TAS:ProtInc.
DR   InterPro; IPR026747; NOL4.
DR   InterPro; IPR039788; NOL4/NOL4L.
DR   PANTHER; PTHR12449; PTHR12449; 1.
DR   PANTHER; PTHR12449:SF17; PTHR12449:SF17; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Nucleus; Reference proteome.
FT   CHAIN           1..638
FT                   /note="Nucleolar protein 4"
FT                   /id="PRO_0000096935"
FT   REGION          210..312
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          343..403
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          503..535
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          573..603
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        227..286
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        296..312
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..366
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        503..522
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..285
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045836"
FT   VAR_SEQ         1..87
FT                   /note="MESERDMYRQFQDWCLRTYGDSGKTKTVTRKKYERIVQLLNGSESSSTDNAK
FT                   FKFWVKSKGFQLGQPDEVRGGGGGAKQVLYVPVKT -> MADLMQETFLHHA (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043344"
FT   VAR_SEQ         413..514
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5,
FT                   ECO:0000303|Ref.6"
FT                   /id="VSP_010080"
FT   CONFLICT        637
FT                   /note="Q -> H (in Ref. 2; BAH12383)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   638 AA;  71357 MW;  02DF0130F10E0B3F CRC64;
     MESERDMYRQ FQDWCLRTYG DSGKTKTVTR KKYERIVQLL NGSESSSTDN AKFKFWVKSK
     GFQLGQPDEV RGGGGGAKQV LYVPVKTTDG VGVDEKLSLR RVAVVEDFFD IIYSMHVETG
     PNGEQIRKHA GQKRTYKAIS ESYAFLPREA VTRFLMSCSE CQKRMHLNPD GTDHKDNGKP
     PTLVTSMIDY NMPITMAYMK HMKLQLLNSQ QDEDESSIES DEFDMSDSTR MSAVNSDLSS
     NLEERMQSPQ NLHGQQDDDS AAESFNGNET LGHSSIASGG THSREMGDSN SDGKTGLEQD
     EQPLNLSDSP LSAQLTSEYR IDDHNSNGKN KYKNLLISDL KMEREARENG SKSPAHSYSS
     YDSGKNESVD RGAEDLSLNR GDEDEDDHED HDDSEKVNET DGVEAERLKA FNMFVRLFVD
     ENLDRMVPIS KQPKEKIQAI IDSCRRQFPE YQERARKRIR TYLKSCRRMK RSGFEMSRPI
     PSHLTSAVAE SILASACESE SRNAAKRMRL ERQQDESAPA DKQCKPEATQ ATYSTSAVPG
     SQDVLYINGN GTYSYHSYRG LGGGLLNLND ASSSGPTDLS MKRQLATSSG SSSSSNSRPQ
     LSPTEINAVR QLVAGYRESA AFLLRSADEL ENLILQQN
//
ID   GALT4_HUMAN             Reviewed;         578 AA.
AC   Q8N4A0; B2R775; B4DMX6; O00208;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2011, sequence version 2.
DT   23-FEB-2022, entry version 152.
DE   RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 4;
DE            EC=2.4.1.41 {ECO:0000269|PubMed:10984485, ECO:0000269|PubMed:29208955, ECO:0000269|PubMed:9804815};
DE   AltName: Full=Polypeptide GalNAc transferase 4;
DE            Short=GalNAc-T4 {ECO:0000303|PubMed:9804815};
DE            Short=pp-GaNTase 4;
DE   AltName: Full=Protein-UDP acetylgalactosaminyltransferase 4;
DE   AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 4;
GN   Name=GALNT4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND VARIANT ILE-506.
RX   PubMed=9804815; DOI=10.1074/jbc.273.46.30472;
RA   Bennett E.P., Hassan H., Mandel U., Mirgorodskaya E., Roepstorff P.,
RA   Burchell J., Taylor-Papadimitriou J., Hollingsworth M.A., Merkx G.,
RA   van Kessel A.G., Eiberg H., Steffensen R., Clausen H.;
RT   "Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-
RT   acetylgalactosaminyltransferase that complements other GalNAc-transferases
RT   in complete O-glycosylation of the MUC1 tandem repeat.";
RL   J. Biol. Chem. 273:30472-30481(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   THR-270 AND ILE-506.
RC   TISSUE=Kidney, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLY-51.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, DOMAIN, PATHWAY, AND MUTAGENESIS OF ASP-459.
RX   PubMed=10984485; DOI=10.1074/jbc.m005783200;
RA   Hassan H., Reis C.A., Bennett E.P., Mirgorodskaya E., Roepstorff P.,
RA   Hollingsworth M.A., Burchell J., Taylor-Papadimitriou J., Clausen H.;
RT   "The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-
RT   acetylgalactosaminyltransferase-T4 directs its glycopeptide
RT   specificities.";
RL   J. Biol. Chem. 275:38197-38205(2000).
RN   [6] {ECO:0007744|PDB:5NQA}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOG,
RP   DOMAIN, CATALYTIC ACTIVITY, FUNCTION, PATHWAY, COFACTOR, AND DISULFIDE
RP   BONDS.
RX   PubMed=29208955; DOI=10.1038/s41467-017-02006-0;
RA   de Las Rivas M., Lira-Navarrete E., Daniel E.J.P., Companon I., Coelho H.,
RA   Diniz A., Jimenez-Barbero J., Peregrina J.M., Clausen H., Corzana F.,
RA   Marcelo F., Jimenez-Oses G., Gerken T.A., Hurtado-Guerrero R.;
RT   "The interdomain flexible linker of the polypeptide GalNAc transferases
RT   dictates their long-range glycosylation preferences.";
RL   Nat. Commun. 8:1959-1959(2017).
CC   -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide
CC       biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a
CC       serine or threonine residue on the protein receptor. Has a highest
CC       activity toward Muc7, EA2 and Muc2, with a lowest activity than GALNT2.
CC       Glycosylates 'Thr-57' of SELPLG. {ECO:0000269|PubMed:10984485,
CC       ECO:0000269|PubMed:29208955, ECO:0000269|PubMed:9804815}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-O-
CC         [N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + H(+) + UDP;
CC         Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:10984485, ECO:0000269|PubMed:29208955,
CC         ECO:0000269|PubMed:9804815};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-
CC         O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + H(+) +
CC         UDP; Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:10984485, ECO:0000269|PubMed:29208955,
CC         ECO:0000269|PubMed:9804815};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:29208955};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:10984485, ECO:0000269|PubMed:29208955,
CC       ECO:0000269|PubMed:9804815}.
CC   -!- INTERACTION:
CC       Q8N4A0; P42858: HTT; NbExp=12; IntAct=EBI-21555925, EBI-466029;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000305|PubMed:9804815}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:9804815}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8N4A0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N4A0-2; Sequence=VSP_045009, VSP_045010;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in mucous cells.
CC       {ECO:0000269|PubMed:9804815}.
CC   -!- DOMAIN: There are two conserved domains in the glycosyltransferase
CC       region: the N-terminal domain (domain A, also called GT1 motif), which
CC       is probably involved in manganese coordination and substrate binding
CC       and the C-terminal domain (domain B, also called Gal/GalNAc-T motif),
CC       which is probably involved in catalytic reaction and UDP-Gal binding.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ricin B-type lectin domain directs the glycopeptide
CC       specificity. It is required in the glycopeptide specificity of enzyme
CC       activity but not for activity with naked peptide substrates, suggesting
CC       that it triggers the catalytic domain to act on GalNAc-glycopeptide
CC       substrates. {ECO:0000269|PubMed:10984485, ECO:0000269|PubMed:29208955}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Polypeptide N-acetylgalactosaminyltransferase 4;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_486";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y08564; CAA69875.1; -; Genomic_DNA.
DR   EMBL; AK297677; BAG60038.1; -; mRNA.
DR   EMBL; AK312870; BAG35722.1; -; mRNA.
DR   EMBL; AC010201; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025034; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC036390; AAH36390.1; -; mRNA.
DR   CCDS; CCDS53817.1; -. [Q8N4A0-1]
DR   RefSeq; NP_001186711.1; NM_001199782.1. [Q8N4A0-2]
DR   RefSeq; NP_003765.2; NM_003774.4. [Q8N4A0-1]
DR   PDB; 5NQA; X-ray; 1.90 A; A/B=1-578.
DR   PDB; 6H0B; X-ray; 1.80 A; A/B=1-578.
DR   PDBsum; 5NQA; -.
DR   PDBsum; 6H0B; -.
DR   SMR; Q8N4A0; -.
DR   BioGRID; 114240; 11.
DR   BioGRID; 1529357; 1.
DR   IntAct; Q8N4A0; 9.
DR   STRING; 9606.ENSP00000436604; -.
DR   CAZy; CBM13; Carbohydrate-Binding Module Family 13.
DR   CAZy; GT27; Glycosyltransferase Family 27.
DR   UniLectin; Q8N4A0; -.
DR   GlyGen; Q8N4A0; 2 sites, 2 O-linked glycans (1 site).
DR   iPTMnet; Q8N4A0; -.
DR   PhosphoSitePlus; Q8N4A0; -.
DR   SwissPalm; Q8N4A0; -.
DR   BioMuta; GALNT4; -.
DR   DMDM; 338817878; -.
DR   EPD; Q8N4A0; -.
DR   jPOST; Q8N4A0; -.
DR   MassIVE; Q8N4A0; -.
DR   MaxQB; Q8N4A0; -.
DR   PaxDb; Q8N4A0; -.
DR   PeptideAtlas; Q8N4A0; -.
DR   PRIDE; Q8N4A0; -.
DR   ProteomicsDB; 71900; -. [Q8N4A0-1]
DR   Antibodypedia; 53055; 154 antibodies from 25 providers.
DR   DNASU; 8693; -.
DR   Ensembl; ENST00000529983; ENSP00000436604; ENSG00000257594.
DR   GeneID; 100528030; -.
DR   GeneID; 8693; -.
DR   KEGG; hsa:100528030; -.
DR   KEGG; hsa:8693; -.
DR   MANE-Select; ENST00000529983.3; ENSP00000436604.2; NM_003774.5; NP_003765.2.
DR   UCSC; uc001tbd.4; human. [Q8N4A0-1]
DR   CTD; 100528030; -.
DR   CTD; 8693; -.
DR   DisGeNET; 100528030; -.
DR   DisGeNET; 8693; -.
DR   GeneCards; GALNT4; -.
DR   HGNC; HGNC:4126; GALNT4.
DR   HPA; ENSG00000257594; Tissue enhanced (stomach).
DR   MalaCards; GALNT4; -.
DR   MIM; 603565; gene.
DR   neXtProt; NX_Q8N4A0; -.
DR   OpenTargets; ENSG00000257594; -.
DR   PharmGKB; PA28539; -.
DR   VEuPathDB; HostDB:ENSG00000257594; -.
DR   eggNOG; KOG3736; Eukaryota.
DR   GeneTree; ENSGT00940000163607; -.
DR   HOGENOM; CLU_013477_0_1_1; -.
DR   InParanoid; Q8N4A0; -.
DR   OMA; DYRHLPT; -.
DR   OrthoDB; 606683at2759; -.
DR   PhylomeDB; Q8N4A0; -.
DR   TreeFam; TF352660; -.
DR   BRENDA; 2.4.1.41; 2681.
DR   PathwayCommons; Q8N4A0; -.
DR   Reactome; R-HSA-913709; O-linked glycosylation of mucins.
DR   SignaLink; Q8N4A0; -.
DR   UniPathway; UPA00378; -.
DR   BioGRID-ORCS; 100528030; 32 hits in 943 CRISPR screens.
DR   BioGRID-ORCS; 8693; 5 hits in 1034 CRISPR screens.
DR   Pharos; Q8N4A0; Tbio.
DR   PRO; PR:Q8N4A0; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q8N4A0; protein.
DR   Bgee; ENSG00000257594; Expressed in endometrium and 120 other tissues.
DR   Genevisible; Q8N4A0; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016266; P:O-glycan processing; TAS:Reactome.
DR   GO; GO:0018242; P:protein O-linked glycosylation via serine; IDA:UniProtKB.
DR   GO; GO:0018243; P:protein O-linked glycosylation via threonine; IDA:UniProtKB.
DR   CDD; cd02510; pp-GalNAc-T; 1.
DR   CDD; cd00161; RICIN; 1.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR045885; GalNAc-T.
DR   InterPro; IPR001173; Glyco_trans_2-like.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00535; Glycos_transf_2; 1.
DR   Pfam; PF00652; Ricin_B_lectin; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Disulfide bond; Glycoprotein;
KW   Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane;
KW   Metal-binding; Reference proteome; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..578
FT                   /note="Polypeptide N-acetylgalactosaminyltransferase 4"
FT                   /id="PRO_0000059108"
FT   TOPO_DOM        1..12
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        13..35
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        36..578
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          444..577
FT                   /note="Ricin B-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   REGION          134..243
FT                   /note="Catalytic subdomain A"
FT   REGION          303..365
FT                   /note="Catalytic subdomain B"
FT   METAL           227
FT                   /note="Manganese"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   METAL           229
FT                   /note="Manganese"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   METAL           362
FT                   /note="Manganese"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   BINDING         175
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   BINDING         204
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   BINDING         334
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   BINDING         370
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q10471"
FT   SITE            459
FT                   /note="Interaction with glycopeptide substrate"
FT                   /evidence="ECO:0000269|PubMed:29208955"
FT   SITE            478
FT                   /note="Interaction with glycopeptide substrate"
FT                   /evidence="ECO:0000269|PubMed:29208955"
FT   SITE            483
FT                   /note="Interaction with glycopeptide substrate"
FT                   /evidence="ECO:0000269|PubMed:29208955"
FT   CARBOHYD        471
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        124..357
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:29208955, ECO:0007744|PDB:5NQA"
FT   DISULFID        348..421
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:29208955, ECO:0007744|PDB:5NQA"
FT   DISULFID        457..477
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:29208955, ECO:0007744|PDB:5NQA"
FT   DISULFID        503..518
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:29208955, ECO:0007744|PDB:5NQA"
FT   DISULFID        547..565
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:29208955, ECO:0007744|PDB:5NQA"
FT   VAR_SEQ         1..120
FT                   /note="MAVRWTWAGKSCLLLAFLTVAYIFVELLVSTFHASAGAGRARELGSRRLSDL
FT                   QKNTEDLSRPLYKKPPADSRALGEWGKASKLQLNEDELKQQEELIERYAINIYLSDRIS
FT                   LHRHIEDKR -> MAWCVATADPAHTSRPLFTGLAVSRGSAGHAWSAGFDWAAVVVVTG
FT                   RRCRSGQTVPGAARSPLLPHPLPSPLRVPPPTGALGRPLPRWPQPRRTPFWSVISKATK
FT                   LRSPPWTSAPTASNL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045009"
FT   VAR_SEQ         121..292
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045010"
FT   VARIANT         51
FT                   /note="D -> G (in dbSNP:rs17853610)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_065257"
FT   VARIANT         270
FT                   /note="I -> T (in dbSNP:rs2230281)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_019576"
FT   VARIANT         506
FT                   /note="V -> I (in dbSNP:rs2230283)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:9804815"
FT                   /id="VAR_019577"
FT   MUTAGEN         459
FT                   /note="D->H: Affects the glycopeptide specificity and
FT                   abolishes ability to glycosylate Muc1, Muc2 and Muc5AC."
FT                   /evidence="ECO:0000269|PubMed:10984485"
FT   CONFLICT        11
FT                   /note="S -> T (in Ref. 1; CAA69875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="D -> Y (in Ref. 1; CAA69875)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="D -> Y (in Ref. 1; CAA69875)"
FT                   /evidence="ECO:0000305"
FT   STRAND          62..64
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           87..100
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           104..107
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           122..125
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   TURN            131..133
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          137..145
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           148..161
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   TURN            164..166
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          167..174
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           184..191
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          196..200
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           207..217
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          220..225
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          228..232
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           237..246
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          250..259
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   TURN            261..263
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          275..278
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          284..287
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           291..296
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          314..317
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           318..323
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           329..331
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          333..335
FT                   /evidence="ECO:0007829|PDB:5NQA"
FT   HELIX           338..347
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          351..363
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           376..386
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           388..390
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           391..397
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           399..403
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           410..418
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           424..430
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          444..451
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   TURN            452..455
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          456..459
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          464..466
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          473..476
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           482..484
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          486..488
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          494..496
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          498..500
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          502..505
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          514..517
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           527..529
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          539..541
FT                   /evidence="ECO:0007829|PDB:5NQA"
FT   TURN            542..544
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          547..552
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          558..564
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          567..569
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   HELIX           570..572
FT                   /evidence="ECO:0007829|PDB:6H0B"
FT   STRAND          574..577
FT                   /evidence="ECO:0007829|PDB:6H0B"
SQ   SEQUENCE   578 AA;  66666 MW;  6EEEF502A40CBD2E CRC64;
     MAVRWTWAGK SCLLLAFLTV AYIFVELLVS TFHASAGAGR ARELGSRRLS DLQKNTEDLS
     RPLYKKPPAD SRALGEWGKA SKLQLNEDEL KQQEELIERY AINIYLSDRI SLHRHIEDKR
     MYECKSQKFN YRTLPTTSVI IAFYNEAWST LLRTIHSVLE TSPAVLLKEI ILVDDLSDRV
     YLKTQLETYI SNLDRVRLIR TNKREGLVRA RLIGATFATG DVLTFLDCHC ECNSGWLEPL
     LERIGRDETA VVCPVIDTID WNTFEFYMQI GEPMIGGFDW RLTFQWHSVP KQERDRRISR
     IDPIRSPTMA GGLFAVSKKY FQYLGTYDTG MEVWGGENLE LSFRVWQCGG KLEIHPCSHV
     GHVFPKRAPY ARPNFLQNTA RAAEVWMDEY KEHFYNRNPP ARKEAYGDIS ERKLLRERLR
     CKSFDWYLKN VFPNLHVPED RPGWHGAIRS RGISSECLDY NSPDNNPTGA NLSLFGCHGQ
     GGNQFFEYTS NKEIRFNSVT ELCAEVPEQK NYVGMQNCPK DGFPVPANII WHFKEDGTIF
     HPHSGLCLSA YRTPEGRPDV QMRTCDALDK NQIWSFEK
//
ID   KAD3_HUMAN              Reviewed;         227 AA.
AC   Q9UIJ7; B4DP58; D3DRI1; E7ET30; Q5VYW6; Q9H576; Q9HC01; Q9NPB4;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   23-FEB-2022, entry version 196.
DE   RecName: Full=GTP:AMP phosphotransferase AK3, mitochondrial {ECO:0000255|HAMAP-Rule:MF_03169};
DE            EC=2.7.4.10 {ECO:0000255|HAMAP-Rule:MF_03169};
DE   AltName: Full=Adenylate kinase 3 {ECO:0000255|HAMAP-Rule:MF_03169};
DE            Short=AK 3 {ECO:0000255|HAMAP-Rule:MF_03169};
DE   AltName: Full=Adenylate kinase 3 alpha-like 1 {ECO:0000255|HAMAP-Rule:MF_03169};
GN   Name=AK3 {ECO:0000255|HAMAP-Rule:MF_03169}; Synonyms=AK3L1, AK6, AKL3L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=11485571; DOI=10.1042/0264-6021:3580225;
RA   Noma T., Fujisawa K., Yamashiro Y., Shinohara M., Nakazawa A., Gondo T.,
RA   Ishihara T., Yoshinobu K.;
RT   "Structure and expression of human mitochondrial adenylate kinase targeted
RT   to the mitochondrial matrix.";
RL   Biochem. J. 358:225-232(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Pheochromocytoma;
RA   Li Y., Peng Y., Jiang Z., Gu W., Han Z., Chen Z.;
RT   "A novel gene expressed in human pheochromocytoma.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS).
RG   Structural genomics consortium (SGC);
RT   "Structure of human adenylate kinase 3-like 1.";
RL   Submitted (MAY-2005) to the PDB data bank.
CC   -!- FUNCTION: Involved in maintaining the homeostasis of cellular
CC       nucleotides by catalyzing the interconversion of nucleoside phosphates.
CC       Has GTP:AMP phosphotransferase and ITP:AMP phosphotransferase
CC       activities. {ECO:0000255|HAMAP-Rule:MF_03169,
CC       ECO:0000269|PubMed:11485571}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 5'-triphosphate + AMP = a ribonucleoside 5'-
CC         diphosphate + ADP; Xref=Rhea:RHEA:13749, ChEBI:CHEBI:57930,
CC         ChEBI:CHEBI:61557, ChEBI:CHEBI:456215, ChEBI:CHEBI:456216;
CC         EC=2.7.4.10; Evidence={ECO:0000255|HAMAP-Rule:MF_03169,
CC         ECO:0000269|PubMed:11485571};
CC   -!- SUBUNIT: Monomer. {ECO:0000255|HAMAP-Rule:MF_03169}.
CC   -!- INTERACTION:
CC       Q9UIJ7; P02649: APOE; NbExp=3; IntAct=EBI-3916527, EBI-1222467;
CC       Q9UIJ7; Q92624: APPBP2; NbExp=6; IntAct=EBI-3916527, EBI-743771;
CC       Q9UIJ7; P23560-2: BDNF; NbExp=3; IntAct=EBI-3916527, EBI-12275524;
CC       Q9UIJ7; P23142-4: FBLN1; NbExp=3; IntAct=EBI-3916527, EBI-11956479;
CC       Q9UIJ7; P04406: GAPDH; NbExp=3; IntAct=EBI-3916527, EBI-354056;
CC       Q9UIJ7; P28799: GRN; NbExp=3; IntAct=EBI-3916527, EBI-747754;
CC       Q9UIJ7; P42858: HTT; NbExp=9; IntAct=EBI-3916527, EBI-466029;
CC       Q9UIJ7; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-3916527, EBI-1055254;
CC       Q9UIJ7; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-3916527, EBI-10171774;
CC       Q9UIJ7; O76024: WFS1; NbExp=3; IntAct=EBI-3916527, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix {ECO:0000255|HAMAP-
CC       Rule:MF_03169, ECO:0000269|PubMed:11485571}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UIJ7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UIJ7-2; Sequence=VSP_043090;
CC       Name=3;
CC         IsoId=Q9UIJ7-3; Sequence=VSP_044876;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle and
CC       liver, moderately expressed in pancreas and kidney, and weakly
CC       expressed in placenta, brain and lung. {ECO:0000269|PubMed:11485571}.
CC   -!- DOMAIN: Consists of three domains, a large central CORE domain and two
CC       small peripheral domains, NMPbind and LID, which undergo movements
CC       during catalysis. The LID domain closes over the site of phosphoryl
CC       transfer upon GTP binding. Assembling and dissambling the active center
CC       during each catalytic cycle provides an effective means to prevent GTP
CC       hydrolysis. {ECO:0000255|HAMAP-Rule:MF_03169, ECO:0000305|Ref.10}.
CC   -!- SIMILARITY: Belongs to the adenylate kinase family. AK3 subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03169}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB021870; BAA87913.1; -; mRNA.
DR   EMBL; AF183419; AAG09688.1; -; mRNA.
DR   EMBL; AK001553; BAA91753.1; -; mRNA.
DR   EMBL; AK001951; BAA91996.1; -; mRNA.
DR   EMBL; AK027534; BAB55183.1; -; mRNA.
DR   EMBL; AK098205; BAG53592.1; -; mRNA.
DR   EMBL; AK298200; BAG60470.1; -; mRNA.
DR   EMBL; AL136231; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353151; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58779.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58780.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58781.1; -; Genomic_DNA.
DR   EMBL; BC013771; AAH13771.1; -; mRNA.
DR   CCDS; CCDS56561.1; -. [Q9UIJ7-2]
DR   CCDS; CCDS56562.1; -. [Q9UIJ7-3]
DR   CCDS; CCDS6455.1; -. [Q9UIJ7-1]
DR   RefSeq; NP_001186781.1; NM_001199852.1. [Q9UIJ7-3]
DR   RefSeq; NP_001186782.1; NM_001199853.1. [Q9UIJ7-2]
DR   RefSeq; NP_001186784.1; NM_001199855.1. [Q9UIJ7-2]
DR   RefSeq; NP_001186785.1; NM_001199856.1. [Q9UIJ7-2]
DR   RefSeq; NP_057366.2; NM_016282.3. [Q9UIJ7-1]
DR   PDB; 1ZD8; X-ray; 1.48 A; A=1-227.
DR   PDB; 6ZJB; X-ray; 1.82 A; A/B/C/D/E/F=1-227.
DR   PDB; 6ZJD; X-ray; 1.75 A; A=1-227.
DR   PDB; 6ZJE; X-ray; 1.48 A; A=1-227.
DR   PDBsum; 1ZD8; -.
DR   PDBsum; 6ZJB; -.
DR   PDBsum; 6ZJD; -.
DR   PDBsum; 6ZJE; -.
DR   SMR; Q9UIJ7; -.
DR   BioGRID; 119127; 61.
DR   IntAct; Q9UIJ7; 20.
DR   MINT; Q9UIJ7; -.
DR   STRING; 9606.ENSP00000371230; -.
DR   CarbonylDB; Q9UIJ7; -.
DR   iPTMnet; Q9UIJ7; -.
DR   PhosphoSitePlus; Q9UIJ7; -.
DR   BioMuta; AK3; -.
DR   DMDM; 23831297; -.
DR   OGP; Q9UIJ7; -.
DR   REPRODUCTION-2DPAGE; IPI00465256; -.
DR   UCD-2DPAGE; Q9UIJ7; -.
DR   EPD; Q9UIJ7; -.
DR   jPOST; Q9UIJ7; -.
DR   MassIVE; Q9UIJ7; -.
DR   MaxQB; Q9UIJ7; -.
DR   PaxDb; Q9UIJ7; -.
DR   PeptideAtlas; Q9UIJ7; -.
DR   PRIDE; Q9UIJ7; -.
DR   ProteomicsDB; 18112; -.
DR   ProteomicsDB; 84535; -. [Q9UIJ7-1]
DR   ProteomicsDB; 84536; -. [Q9UIJ7-2]
DR   TopDownProteomics; Q9UIJ7-1; -. [Q9UIJ7-1]
DR   TopDownProteomics; Q9UIJ7-3; -. [Q9UIJ7-3]
DR   Antibodypedia; 24061; 386 antibodies from 28 providers.
DR   DNASU; 50808; -.
DR   Ensembl; ENST00000359883; ENSP00000352948; ENSG00000147853. [Q9UIJ7-2]
DR   Ensembl; ENST00000381809; ENSP00000371230; ENSG00000147853.
DR   Ensembl; ENST00000447596; ENSP00000413933; ENSG00000147853. [Q9UIJ7-3]
DR   Ensembl; ENST00000611749; ENSP00000482308; ENSG00000147853. [Q9UIJ7-2]
DR   GeneID; 50808; -.
DR   KEGG; hsa:50808; -.
DR   MANE-Select; ENST00000381809.8; ENSP00000371230.3; NM_016282.4; NP_057366.2.
DR   UCSC; uc003ziq.4; human. [Q9UIJ7-1]
DR   CTD; 50808; -.
DR   DisGeNET; 50808; -.
DR   GeneCards; AK3; -.
DR   HGNC; HGNC:17376; AK3.
DR   HPA; ENSG00000147853; Tissue enhanced (skeletal).
DR   MIM; 609290; gene.
DR   neXtProt; NX_Q9UIJ7; -.
DR   OpenTargets; ENSG00000147853; -.
DR   PharmGKB; PA164741184; -.
DR   VEuPathDB; HostDB:ENSG00000147853; -.
DR   eggNOG; KOG3078; Eukaryota.
DR   GeneTree; ENSGT00940000155120; -.
DR   HOGENOM; CLU_032354_1_1_1; -.
DR   InParanoid; Q9UIJ7; -.
DR   OMA; SRWVHLP; -.
DR   PhylomeDB; Q9UIJ7; -.
DR   TreeFam; TF312916; -.
DR   PathwayCommons; Q9UIJ7; -.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q9UIJ7; -.
DR   BioGRID-ORCS; 50808; 30 hits in 1068 CRISPR screens.
DR   ChiTaRS; AK3; human.
DR   EvolutionaryTrace; Q9UIJ7; -.
DR   GenomeRNAi; 50808; -.
DR   Pharos; Q9UIJ7; Tbio.
DR   PRO; PR:Q9UIJ7; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q9UIJ7; protein.
DR   Bgee; ENSG00000147853; Expressed in quadriceps femoris and 220 other tissues.
DR   Genevisible; Q9UIJ7; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005759; C:mitochondrial matrix; ISS:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046899; F:nucleoside triphosphate adenylate kinase activity; IDA:BHF-UCL.
DR   GO; GO:0006172; P:ADP biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0046033; P:AMP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0046039; P:GTP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0046041; P:ITP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0009142; P:nucleoside triphosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0046051; P:UTP metabolic process; IDA:BHF-UCL.
DR   CDD; cd01428; ADK; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   HAMAP; MF_00235; Adenylate_kinase_Adk; 1.
DR   HAMAP; MF_03169; Adenylate_kinase_AK3; 1.
DR   InterPro; IPR006259; Adenyl_kin_sub.
DR   InterPro; IPR000850; Adenylat/UMP-CMP_kin.
DR   InterPro; IPR033690; Adenylat_kinase_CS.
DR   InterPro; IPR007862; Adenylate_kinase_lid-dom.
DR   InterPro; IPR036193; ADK_active_lid_dom_sf.
DR   InterPro; IPR028586; AK3/Ak4_mitochondrial.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR23359; PTHR23359; 1.
DR   Pfam; PF05191; ADK_lid; 1.
DR   PRINTS; PR00094; ADENYLTKNASE.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF57774; SSF57774; 1.
DR   TIGRFAMs; TIGR01351; adk; 1.
DR   PROSITE; PS00113; ADENYLATE_KINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; GTP-binding; Kinase;
KW   Mitochondrion; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Transferase.
FT   CHAIN           1..227
FT                   /note="GTP:AMP phosphotransferase AK3, mitochondrial"
FT                   /id="PRO_0000158922"
FT   NP_BIND         17..22
FT                   /note="GTP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   NP_BIND         64..66
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   NP_BIND         91..94
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   NP_BIND         137..138
FT                   /note="GTP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   REGION          37..66
FT                   /note="NMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169,
FT                   ECO:0000269|Ref.10"
FT   REGION          127..164
FT                   /note="LID"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169,
FT                   ECO:0000269|Ref.10"
FT   BINDING         38
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         43
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         98
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         128
FT                   /note="GTP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         161
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         172
FT                   /note="AMP"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   BINDING         201
FT                   /note="GTP; via carbonyl oxygen"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03169"
FT   MOD_RES         20
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         34
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         57
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         64
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         64
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         80
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         80
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         174
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         174
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         189
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         189
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   MOD_RES         203
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTP7"
FT   VAR_SEQ         1..70
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2"
FT                   /id="VSP_043090"
FT   VAR_SEQ         51..90
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044876"
FT   CONFLICT        5
FT                   /note="A -> G (in Ref. 1; BAA87913)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        38
FT                   /note="S -> R (in Ref. 1; BAA87913)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        57
FT                   /note="K -> Q (in Ref. 1; BAA87913)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69..71
FT                   /note="DVM -> YVT (in Ref. 1; BAA87913)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        181
FT                   /note="K -> E (in Ref. 3; BAG60470)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..14
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           20..30
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          31..37
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           38..48
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           51..60
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   TURN            61..63
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           68..80
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          87..91
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           96..103
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          110..115
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           118..125
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          128..131
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   TURN            132..135
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          136..139
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   TURN            140..142
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   TURN            152..154
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           162..164
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           166..189
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   STRAND          193..197
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   HELIX           201..212
FT                   /evidence="ECO:0007829|PDB:1ZD8"
FT   TURN            213..215
FT                   /evidence="ECO:0007829|PDB:1ZD8"
SQ   SEQUENCE   227 AA;  25565 MW;  98A0EDF4FD9C9CEF CRC64;
     MGASARLLRA VIMGAPGSGK GTVSSRITTH FELKHLSSGD LLRDNMLRGT EIGVLAKAFI
     DQGKLIPDDV MTRLALHELK NLTQYSWLLD GFPRTLPQAE ALDRAYQIDT VINLNVPFEV
     IKQRLTARWI HPASGRVYNI EFNPPKTVGI DDLTGEPLIQ REDDKPETVI KRLKAYEDQT
     KPVLEYYQKK GVLETFSGTE TNKIWPYVYA FLQTKVPQRS QKASVTP
//
ID   NUBPL_HUMAN             Reviewed;         319 AA.
AC   Q8TB37; B4DHZ1; Q86TZ4; Q9H9M2;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   23-FEB-2022, entry version 160.
DE   RecName: Full=Iron-sulfur protein NUBPL;
DE   AltName: Full=IND1 homolog;
DE   AltName: Full=Nucleotide-binding protein-like;
DE   AltName: Full=huInd1;
DE   Flags: Precursor;
GN   Name=NUBPL; Synonyms=C14orf127;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Neuroblastoma;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Teratocarcinoma, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-319 (ISOFORM 1), AND VARIANT
RP   THR-198.
RC   TISSUE=Prostatic adenocarcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, IRON-SULFUR CLUSTER-BINDING, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF CYS-244 AND CYS-247.
RX   PubMed=19752196; DOI=10.1128/mcb.00817-09;
RA   Sheftel A.D., Stehling O., Pierik A.J., Netz D.J., Kerscher S.,
RA   Elsasser H.P., Wittig I., Balk J., Brandt U., Lill R.;
RT   "Human ind1, an iron-sulfur cluster assembly factor for respiratory complex
RT   I.";
RL   Mol. Cell. Biol. 29:6059-6073(2009).
RN   [6]
RP   INVOLVEMENT IN MC1DN21, AND VARIANT ARG-56.
RX   PubMed=20818383; DOI=10.1038/ng.659;
RA   Calvo S.E., Tucker E.J., Compton A.G., Kirby D.M., Crawford G., Burtt N.P.,
RA   Rivas M., Guiducci C., Bruno D.L., Goldberger O.A., Redman M.C.,
RA   Wiltshire E., Wilson C.J., Altshuler D., Gabriel S.B., Daly M.J.,
RA   Thorburn D.R., Mootha V.K.;
RT   "High-throughput, pooled sequencing identifies mutations in NUBPL and
RT   FOXRED1 in human complex I deficiency.";
RL   Nat. Genet. 42:851-858(2010).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   CHARACTERIZATION OF VARIANT ARG-56.
RX   PubMed=22072591; DOI=10.1002/humu.21654;
RA   Tucker E.J., Mimaki M., Compton A.G., McKenzie M., Ryan M.T.,
RA   Thorburn D.R.;
RT   "Next generation sequencing in molecular diagnosis: NUBPL mutations
RT   highlight the challenges of variant detection and interpretation.";
RL   Hum. Mutat. 33:411-418(2012).
RN   [9]
RP   VARIANTS MC1DN21 TYR-105 AND PHE-193, AND VARIANT ARG-56.
RX   PubMed=23553477; DOI=10.1212/wnl.0b013e31828f1914;
RA   Kevelam S.H., Rodenburg R.J., Wolf N.I., Ferreira P., Lunsing R.J.,
RA   Nijtmans L.G., Mitchell A., Arroyo H.A., Rating D., Vanderver A.,
RA   van Berkel C.G., Abbink T.E., Heutink P., van der Knaap M.S.;
RT   "NUBPL mutations in patients with complex I deficiency and a distinct MRI
RT   pattern.";
RL   Neurology 80:1577-1583(2013).
CC   -!- FUNCTION: Required for the assembly of the mitochondrial membrane
CC       respiratory chain NADH dehydrogenase (Complex I). May deliver of one or
CC       more Fe-S clusters to complex I subunits.
CC       {ECO:0000269|PubMed:19752196}.
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883;
CC       Note=Binds 1 [4Fe-4S] cluster.;
CC   -!- INTERACTION:
CC       Q8TB37; Q8N371-3: KDM8; NbExp=3; IntAct=EBI-12852610, EBI-12161375;
CC       Q8TB37; Q9Y5Y2: NUBP2; NbExp=6; IntAct=EBI-12852610, EBI-1048886;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:19752196}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8TB37-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TB37-2; Sequence=VSP_020985, VSP_008797;
CC   -!- TISSUE SPECIFICITY: Highest expression in liver and kidney. expressed
CC       at significant levels in small intestine and brain (at protein level).
CC       {ECO:0000269|PubMed:19752196}.
CC   -!- DISEASE: Mitochondrial complex I deficiency, nuclear type 21 (MC1DN21)
CC       [MIM:618242]: A form of mitochondrial complex I deficiency, the most
CC       common biochemical signature of mitochondrial disorders, a group of
CC       highly heterogeneous conditions characterized by defective oxidative
CC       phosphorylation, which collectively affects 1 in 5-10000 live births.
CC       Clinical disorders have variable severity, ranging from lethal neonatal
CC       disease to adult-onset neurodegenerative disorders. Phenotypes include
CC       macrocephaly with progressive leukodystrophy, non-specific
CC       encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh
CC       syndrome, Leber hereditary optic neuropathy, and some forms of
CC       Parkinson disease. MC1DN21 transmission pattern is consistent with
CC       autosomal recessive inheritance. {ECO:0000269|PubMed:20818383,
CC       ECO:0000269|PubMed:23553477}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to exon skipping. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the Mrp/NBP35 ATP-binding proteins family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH24919.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14203.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD62349.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BX248028; CAD62349.1; ALT_INIT; mRNA.
DR   EMBL; AK022722; BAB14203.1; ALT_INIT; mRNA.
DR   EMBL; AK295326; BAG58303.1; -; mRNA.
DR   EMBL; AK316445; BAH14816.1; -; mRNA.
DR   EMBL; CH471078; EAW65942.1; -; Genomic_DNA.
DR   EMBL; BC024919; AAH24919.1; ALT_INIT; mRNA.
DR   CCDS; CCDS41940.1; -. [Q8TB37-1]
DR   RefSeq; NP_001188502.1; NM_001201573.1.
DR   RefSeq; NP_079428.2; NM_025152.2. [Q8TB37-1]
DR   SMR; Q8TB37; -.
DR   BioGRID; 123190; 57.
DR   IntAct; Q8TB37; 11.
DR   STRING; 9606.ENSP00000281081; -.
DR   iPTMnet; Q8TB37; -.
DR   PhosphoSitePlus; Q8TB37; -.
DR   BioMuta; NUBPL; -.
DR   DMDM; 116242683; -.
DR   EPD; Q8TB37; -.
DR   jPOST; Q8TB37; -.
DR   MassIVE; Q8TB37; -.
DR   MaxQB; Q8TB37; -.
DR   PaxDb; Q8TB37; -.
DR   PeptideAtlas; Q8TB37; -.
DR   PRIDE; Q8TB37; -.
DR   ProteomicsDB; 73958; -. [Q8TB37-1]
DR   ProteomicsDB; 73959; -. [Q8TB37-2]
DR   Antibodypedia; 23093; 247 antibodies from 23 providers.
DR   DNASU; 80224; -.
DR   Ensembl; ENST00000281081; ENSP00000281081; ENSG00000151413.
DR   Ensembl; ENST00000547839; ENSP00000449918; ENSG00000151413. [Q8TB37-2]
DR   GeneID; 80224; -.
DR   KEGG; hsa:80224; -.
DR   MANE-Select; ENST00000281081.12; ENSP00000281081.7; NM_025152.3; NP_079428.2.
DR   UCSC; uc059apb.1; human. [Q8TB37-1]
DR   CTD; 80224; -.
DR   DisGeNET; 80224; -.
DR   GeneCards; NUBPL; -.
DR   HGNC; HGNC:20278; NUBPL.
DR   HPA; ENSG00000151413; Low tissue specificity.
DR   MalaCards; NUBPL; -.
DR   MIM; 613621; gene.
DR   MIM; 618242; phenotype.
DR   neXtProt; NX_Q8TB37; -.
DR   OpenTargets; ENSG00000151413; -.
DR   Orphanet; 2609; Isolated complex I deficiency.
DR   PharmGKB; PA134907818; -.
DR   VEuPathDB; HostDB:ENSG00000151413; -.
DR   eggNOG; KOG3022; Eukaryota.
DR   GeneTree; ENSGT00950000183193; -.
DR   HOGENOM; CLU_024839_0_2_1; -.
DR   InParanoid; Q8TB37; -.
DR   OMA; NMAYFTP; -.
DR   PhylomeDB; Q8TB37; -.
DR   TreeFam; TF323196; -.
DR   PathwayCommons; Q8TB37; -.
DR   Reactome; R-HSA-6799198; Complex I biogenesis.
DR   SignaLink; Q8TB37; -.
DR   BioGRID-ORCS; 80224; 104 hits in 1048 CRISPR screens.
DR   ChiTaRS; NUBPL; human.
DR   GenomeRNAi; 80224; -.
DR   Pharos; Q8TB37; Tbio.
DR   PRO; PR:Q8TB37; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q8TB37; protein.
DR   Bgee; ENSG00000151413; Expressed in calcaneal tendon and 226 other tissues.
DR   ExpressionAtlas; Q8TB37; baseline and differential.
DR   Genevisible; Q8TB37; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016226; P:iron-sulfur cluster assembly; IBA:GO_Central.
DR   GO; GO:0032981; P:mitochondrial respiratory chain complex I assembly; IMP:UniProtKB.
DR   GO; GO:0070584; P:mitochondrion morphogenesis; IMP:UniProtKB.
DR   Gene3D; 3.40.50.300; -; 1.
DR   HAMAP; MF_02040; Mrp_NBP35; 1.
DR   InterPro; IPR019591; Mrp/NBP35_ATP-bd.
DR   InterPro; IPR000808; Mrp_CS.
DR   InterPro; IPR044304; NUBPL-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR033756; YlxH/NBP35.
DR   PANTHER; PTHR42961; PTHR42961; 1.
DR   Pfam; PF10609; ParA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS01215; MRP; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Disease variant; Iron; Iron-sulfur;
KW   Metal-binding; Mitochondrion; Nucleotide-binding;
KW   Primary mitochondrial disease; Reference proteome; Transit peptide.
FT   TRANSIT         1..38
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000255"
FT   CHAIN           39..319
FT                   /note="Iron-sulfur protein NUBPL"
FT                   /id="PRO_0000184950"
FT   NP_BIND         75..82
FT                   /note="ATP"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         173
FT                   /note="D -> L (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_020985"
FT   VAR_SEQ         174..319
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_008797"
FT   VARIANT         56
FT                   /note="G -> R (rare variant found in a patient with
FT                   mitochondrial complex I deficiency; unknown pathological
FT                   significance; found in association with a nucleotide
FT                   transition causing exon skipping; does not affect protein
FT                   stability, processing and import in the mitochondrion; can
FT                   restore complex I activity when overexpressed in patient
FT                   fibroblasts; dbSNP:rs200401432)"
FT                   /evidence="ECO:0000269|PubMed:20818383,
FT                   ECO:0000269|PubMed:22072591, ECO:0000269|PubMed:23553477"
FT                   /id="VAR_064570"
FT   VARIANT         105
FT                   /note="D -> Y (in MC1DN21; dbSNP:rs397515440)"
FT                   /evidence="ECO:0000269|PubMed:23553477"
FT                   /id="VAR_069767"
FT   VARIANT         193
FT                   /note="L -> F (in MC1DN21; dbSNP:rs552722349)"
FT                   /evidence="ECO:0000269|PubMed:23553477"
FT                   /id="VAR_069768"
FT   VARIANT         198
FT                   /note="N -> T (in dbSNP:rs11558436)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_027895"
FT   MUTAGEN         244
FT                   /note="C->A: Defect in complex I assembly; when associated
FT                   with A-247."
FT                   /evidence="ECO:0000269|PubMed:19752196"
FT   MUTAGEN         247
FT                   /note="C->A: Defect in complex I assembly; when associated
FT                   with A-244."
FT                   /evidence="ECO:0000269|PubMed:19752196"
SQ   SEQUENCE   319 AA;  34083 MW;  7A497482A4D449A4 CRC64;
     MGIWQRLLLF GGVSLRAGGG ATAPLGGSRA MVCGRQLSGA GSETLKQRRT QIMSRGLPKQ
     KPIEGVKQVI VVASGKGGVG KSTTAVNLAL ALAANDSSKA IGLLDVDVYG PSVPKMMNLK
     GNPELSQSNL MRPLLNYGIA CMSMGFLVEE SEPVVWRGLM VMSAIEKLLR QVDWGQLDYL
     VVDMPPGTGD VQLSVSQNIP ITGAVIVSTP QDIALMDAHK GAEMFRRVHV PVLGLVQNMS
     VFQCPKCKHK THIFGADGAR KLAQTLGLEV LGDIPLHLNI REASDTGQPI VFSQPESDEA
     KAYLRIAVEV VRRLPSPSE
//
ID   GCR_HUMAN               Reviewed;         777 AA.
AC   P04150; A0ZXF9; B0LPG8; D3DQF4; F5ATB7; P04151; Q53EP5; Q6N0A4;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   23-FEB-2022, entry version 274.
DE   RecName: Full=Glucocorticoid receptor;
DE            Short=GR;
DE   AltName: Full=Nuclear receptor subfamily 3 group C member 1;
GN   Name=NR3C1; Synonyms=GRL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA).
RC   TISSUE=Fibroblast;
RX   PubMed=2867473; DOI=10.1038/318635a0;
RA   Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R.,
RA   Thompson E.B., Rosenfeld M.G., Evans R.M.;
RT   "Primary structure and expression of a functional human glucocorticoid
RT   receptor cDNA.";
RL   Nature 318:635-641(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS ALPHA AND BETA).
RX   PubMed=1707881;
RA   Encio I.J., Detera-Wadleigh S.D.;
RT   "The genomic structure of the human glucocorticoid receptor.";
RL   J. Biol. Chem. 266:7182-7188(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=20843780; DOI=10.1093/nar/gkq750;
RA   Wang W., Shen P., Thiyagarajan S., Lin S., Palm C., Horvath R.,
RA   Klopstock T., Cutler D., Pique L., Schrijver I., Davis R.W., Mindrinos M.,
RA   Speed T.P., Scharfe C.;
RT   "Identification of rare DNA variants in mitochondrial disorders with
RT   improved array-based sequencing.";
RL   Nucleic Acids Res. 39:44-58(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10).
RX   PubMed=17404046; DOI=10.1196/annals.1397.037;
RA   Turner J.D., Schote A.B., Keipes M., Muller C.P.;
RT   "A new transcript splice variant of the human glucocorticoid receptor:
RT   identification and tissue distribution of hGR Delta 313-338, an alternative
RT   exon 2 transactivation domain isoform.";
RL   Ann. N. Y. Acad. Sci. 1095:334-341(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), VARIANTS ASP-72; ALA-321 AND
RP   SER-766, AND CHARACTERIZATION OF VARIANTS ASP-72; ALA-321 AND SER-766.
RX   PubMed=21701417; DOI=10.1097/shk.0b013e318228eca7;
RA   Tung K., Baker A.C., Amini A., Green T.L., Chew V.W., Lim D., Nguyen S.T.,
RA   Yee K.S., Cho K., Greenhalgh D.G.;
RT   "Novel hyperactive glucocorticoid receptor isoform identified within a
RT   human population.";
RL   Shock 36:339-344(2011).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-2).
RC   TISSUE=Osteosarcoma;
RA   Munroe D.G., Pang J., Taylor G.R., Lau C., Plante R.K., Zhou L.;
RT   "Alternative splicing within the DNA binding domain creates a novel isoform
RT   of the human glucocorticoid receptor.";
RL   Submitted (SEP-1993) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-23 AND VAL-65.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394.
RX   PubMed=2026589;
RA   Leclerc S., Xie B.X., Roy R., Govindan M.V.;
RT   "Purification of a human glucocorticoid receptor gene promoter-binding
RT   protein. Production of polyclonal antibodies against the purified factor.";
RL   J. Biol. Chem. 266:8711-8719(1991).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394.
RX   PubMed=1958537; DOI=10.1016/0960-0760(91)90197-d;
RA   Govindan M.V., Pothier F., Leclerc S., Palaniswami R., Xie B.;
RT   "Human glucocorticoid receptor gene promotor-homologous down regulation.";
RL   J. Steroid Biochem. Mol. Biol. 40:317-323(1991).
RN   [16]
RP   DOMAINS.
RX   PubMed=3841189; DOI=10.1038/318670a0;
RA   Weinberger C., Hollenberg S.M., Rosenfeld M.G., Evans R.M.;
RT   "Domain structure of human glucocorticoid receptor and its relationship to
RT   the v-erb-A oncogene product.";
RL   Nature 318:670-672(1985).
RN   [17]
RP   ALTERNATIVE SPLICING (ISOFORMS GR-P; GR-A ALPHA AND GR-A BETA).
RX   PubMed=8358712;
RA   Moalli P.A., Pillay S., Krett N.L., Rosen S.T.;
RT   "Alternatively spliced glucocorticoid receptor messenger RNAs in
RT   glucocorticoid-resistant human multiple myeloma cells.";
RL   Cancer Res. 53:3877-3879(1993).
RN   [18]
RP   FUNCTION (ISOFORM BETA), AND TISSUE SPECIFICITY (ISOFORM BETA).
RX   PubMed=7769088; DOI=10.1172/jci117943;
RA   Bamberger C.M., Bamberger A.M., de Castro M., Chrousos G.P.;
RT   "Glucocorticoid receptor beta, a potential endogenous inhibitor of
RT   glucocorticoid action in humans.";
RL   J. Clin. Invest. 95:2435-2441(1995).
RN   [19]
RP   FUNCTION (ISOFORM BETA), SUBCELLULAR LOCATION (ISOFORMS ALPHA AND BETA),
RP   AND TISSUE SPECIFICITY (ISOFORM BETA).
RX   PubMed=8621628; DOI=10.1074/jbc.271.16.9550;
RA   Oakley R.H., Sar M., Cidlowski J.A.;
RT   "The human glucocorticoid receptor beta isoform. Expression, biochemical
RT   properties, and putative function.";
RL   J. Biol. Chem. 271:9550-9559(1996).
RN   [20]
RP   INTERACTION WITH HNRNPU.
RX   PubMed=9353307; DOI=10.1074/jbc.272.45.28471;
RA   Eggert M., Michel J., Schneider S., Bornfleth H., Baniahmad A.,
RA   Fackelmayer F.O., Schmidt S., Renkawitz R.;
RT   "The glucocorticoid receptor is associated with the RNA-binding nuclear
RT   matrix protein hnRNP U.";
RL   J. Biol. Chem. 272:28471-28478(1997).
RN   [21]
RP   INTERACTION WITH TADA2L AND THE ADA COMPLEX, AND MUTAGENESIS OF PHE-191;
RP   ILE-193; LEU-194; LEU-197; TRP-213; LEU-224; LEU-225; PHE-235 AND LEU-236.
RX   PubMed=9154805; DOI=10.1128/mcb.17.6.3065;
RA   Henriksson A., Almloef T., Ford J., McEwan I.J., Gustafsson J.-A.,
RA   Wright A.P.H.;
RT   "Role of the Ada adaptor complex in gene activation by the glucocorticoid
RT   receptor.";
RL   Mol. Cell. Biol. 17:3065-3073(1997).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH THE SMARCA4 COMPLEX; NCOA1; NCOA2 AND THE
RP   CREBBP/EP300 COMPLEX.
RX   PubMed=9590696; DOI=10.1038/30032;
RA   Fryer C.J., Archer T.K.;
RT   "Chromatin remodelling by the glucocorticoid receptor requires the BRG1
RT   complex.";
RL   Nature 393:88-91(1998).
RN   [23]
RP   INTERACTION WITH BAG1.
RX   PubMed=10477749; DOI=10.1083/jcb.146.5.929;
RA   Schneikert J., Huebner S., Martin E., Cato A.B.C.;
RT   "A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of
RT   glucocorticoid receptor activity.";
RL   J. Cell Biol. 146:929-940(1999).
RN   [24]
RP   ALTERNATIVE SPLICING (ISOFORMS ALPHA-2 AND BETA-2), AND TISSUE SPECIFICITY
RP   (ISOFORM ALPHA-2).
RX   PubMed=10566686; DOI=10.1210/jcem.84.11.6235;
RA   Rivers C., Levy A., Hancock J., Lightman S., Norman M.;
RT   "Insertion of an amino acid in the DNA-binding domain of the glucocorticoid
RT   receptor as a result of alternative splicing.";
RL   J. Clin. Endocrinol. Metab. 84:4283-4286(1999).
RN   [25]
RP   TISSUE SPECIFICITY.
RX   PubMed=10902803; DOI=10.1210/jcem.85.7.6663;
RA   Kayes-Wandover K.M., White P.C.;
RT   "Steroidogenic enzyme gene expression in the human heart.";
RL   J. Clin. Endocrinol. Metab. 85:2519-2525(2000).
RN   [26]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10866662; DOI=10.1128/mcb.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [27]
RP   EFFECT ON EXPANDED POLYGLUTAMINE PROTEIN.
RX   PubMed=10639135; DOI=10.1073/pnas.97.2.657;
RA   Diamond M.I., Robinson M.R., Yamamoto K.R.;
RT   "Regulation of expanded polyglutamine protein aggregation and nuclear
RT   localization by the glucocorticoid receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:657-661(2000).
RN   [28]
RP   FUNCTION (ISOFORM GR-P).
RX   PubMed=11358809;
RA   de Lange P., Segeren C.M., Koper J.W., Wiemer E., Sonneveld P.,
RA   Brinkmann A.O., White A., Brogan I.J., de Jong F.H., Lamberts S.W.;
RT   "Expression in hematological malignancies of a glucocorticoid receptor
RT   splice variant that augments glucocorticoid receptor-mediated effects in
RT   transfected cells.";
RL   Cancer Res. 61:3937-3941(2001).
RN   [29]
RP   GLUCOCORTICOID-MEDIATED DOWN-REGULATION.
RX   PubMed=11555652; DOI=10.1074/jbc.m106033200;
RA   Wallace A.D., Cidlowski J.A.;
RT   "Proteasome-mediated glucocorticoid receptor degradation restricts
RT   transcriptional signaling by glucocorticoids.";
RL   J. Biol. Chem. 276:42714-42721(2001).
RN   [30]
RP   REDUCTION OF CELL DEATH IN RESPONSE TO CORTICOSTEROIDS.
RX   PubMed=11238589; DOI=10.1084/jem.193.5.585;
RA   Strickland I., Kisich K., Hauk P.J., Vottero A., Chrousos G.P., Klemm D.J.,
RA   Leung D.Y.M.;
RT   "High constitutive glucocorticoid receptor beta in human neutrophils
RT   enables them to reduce their spontaneous rate of cell death in response to
RT   corticosteroids.";
RL   J. Exp. Med. 193:585-593(2001).
RN   [31]
RP   FUNCTION (ISOFORMS ALPHA AND ALPHA-B), ALTERNATIVE INITIATION, AND
RP   MUTAGENESIS OF MET-1 AND MET-27.
RX   PubMed=11435610; DOI=10.1210/mend.15.7.0667;
RA   Yudt M.R., Cidlowski J.A.;
RT   "Molecular identification and characterization of A and B forms of the
RT   glucocorticoid receptor.";
RL   Mol. Endocrinol. 15:1093-1103(2001).
RN   [32]
RP   INDUCTION (ISOFORMS ALPHA AND BETA).
RX   PubMed=11381138; DOI=10.1073/pnas.121455098;
RA   Webster J.C., Oakley R.H., Jewell C.M., Cidlowski J.A.;
RT   "Proinflammatory cytokines regulate human glucocorticoid receptor gene
RT   expression and lead to the accumulation of the dominant negative beta
RT   isoform: a mechanism for the generation of glucocorticoid resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6865-6870(2001).
RN   [33]
RP   SUMOYLATION, AND MUTAGENESIS OF LYS-277; LYS-293 AND LYS-703.
RX   PubMed=12144530; DOI=10.1042/bj20021085;
RA   Tian S., Poukka H., Palvimo J.J., Jaenne O.A.;
RT   "Small ubiquitin-related modifier-1 (SUMO-1) modification of the
RT   glucocorticoid receptor.";
RL   Biochem. J. 367:907-911(2002).
RN   [34]
RP   PHOSPHORYLATION AT SER-203 AND SER-211.
RX   PubMed=12000743; DOI=10.1074/jbc.m110530200;
RA   Wang Z., Frederick J., Garabedian M.J.;
RT   "Deciphering the phosphorylation 'code' of the glucocorticoid receptor in
RT   vivo.";
RL   J. Biol. Chem. 277:26573-26580(2002).
RN   [35]
RP   RETRACTED PAPER.
RX   PubMed=12415108; DOI=10.1073/pnas.192569699;
RA   Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RT   "Estrogen receptor-interacting protein that modulates its nongenomic
RT   activity-crosstalk with Src/Erk phosphorylation cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002).
RN   [36]
RP   RETRACTION NOTICE OF PUBMED:12415108.
RX   PubMed=19666546; DOI=10.1073/pnas.0907913106;
RA   Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RL   Proc. Natl. Acad. Sci. U.S.A. 106:14180-14180(2009).
RN   [37]
RP   REVIEW ON ALTERNATIVE SPLICING, AND ALTERNATIVE INITIATION.
RX   PubMed=15265776; DOI=10.1196/annals.1321.008;
RA   Lu N.Z., Cidlowski J.A.;
RT   "The origin and functions of multiple human glucocorticoid receptor
RT   isoforms.";
RL   Ann. N. Y. Acad. Sci. 1024:102-123(2004).
RN   [38]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=15211577; DOI=10.1002/jcb.20109;
RA   Guerrero-Santoro J., Yang L., Stallcup M.R., DeFranco D.B.;
RT   "Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix
RT   targeting and glucocorticoid receptor binding and coactivation.";
RL   J. Cell. Biochem. 92:810-819(2004).
RN   [39]
RP   FUNCTION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3; ALPHA-D1;
RP   ALPHA-D2 AND ALPHA-D3), SUBCELLULAR LOCATION (ISOFORM ALPHA-B), ALTERNATIVE
RP   INITIATION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3;
RP   ALPHA-D1; ALPHA-D2 AND ALPHA-D3), AND MUTAGENESIS OF MET-1; MET-27; MET-86;
RP   MET-90; MET-98; MET-316; MET-331 AND MET-336.
RX   PubMed=15866175; DOI=10.1016/j.molcel.2005.03.025;
RA   Lu N.Z., Cidlowski J.A.;
RT   "Translational regulatory mechanisms generate N-terminal glucocorticoid
RT   receptor isoforms with unique transcriptional target genes.";
RL   Mol. Cell 18:331-342(2005).
RN   [40]
RP   INTERACTION WITH NR4A3.
RX   PubMed=15591535; DOI=10.1210/me.2004-0333;
RA   Martens C., Bilodeau S., Maira M., Gauthier Y., Drouin J.;
RT   "Protein-protein interactions and transcriptional antagonism between the
RT   subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid
RT   receptor.";
RL   Mol. Endocrinol. 19:885-897(2005).
RN   [41]
RP   INTERACTION WITH HEXIM1.
RX   PubMed=15941832; DOI=10.1073/pnas.0409863102;
RA   Shimizu N., Ouchida R., Yoshikawa N., Hisada T., Watanabe H., Okamoto K.,
RA   Kusuhara M., Handa H., Morimoto C., Tanaka H.;
RT   "HEXIM1 forms a transcriptionally abortive complex with glucocorticoid
RT   receptor without involving 7SK RNA and positive transcription elongation
RT   factor b.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8555-8560(2005).
RN   [42]
RP   INTERACTION WITH MCM3AP.
RX   PubMed=16914116; DOI=10.1016/j.bbrc.2006.07.182;
RA   Osman W., Laine S., Zilliacus J.;
RT   "Functional interaction between the glucocorticoid receptor and
RT   GANP/MCM3AP.";
RL   Biochem. Biophys. Res. Commun. 348:1239-1244(2006).
RN   [43]
RP   INTERACTION WITH UNC45A.
RX   PubMed=16478993; DOI=10.1128/mcb.26.5.1722-1730.2006;
RA   Chadli A., Graham J.D., Abel M.G., Jackson T.A., Gordon D.F., Wood W.M.,
RA   Felts S.J., Horwitz K.B., Toft D.;
RT   "GCUNC-45 is a novel regulator for the progesterone receptor/hsp90
RT   chaperoning pathway.";
RL   Mol. Cell. Biol. 26:1722-1730(2006).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   INTERACTION WITH GSK3B, SUBCELLULAR LOCATION (ISOFORM ALPHA),
RP   PHOSPHORYLATION AT SER-404, MUTAGENESIS OF SER-404, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=18838540; DOI=10.1128/mcb.00808-08;
RA   Galliher-Beckley A.J., Williams J.G., Collins J.B., Cidlowski J.A.;
RT   "Glycogen synthase kinase 3beta-mediated serine phosphorylation of the
RT   human glucocorticoid receptor redirects gene expression profiles.";
RL   Mol. Cell. Biol. 28:7309-7322(2008).
RN   [47]
RP   PHOSPHORYLATION AT SER-203; SER-211 AND SER-226, AND MUTAGENESIS OF SER-211
RP   AND SER-226.
RX   PubMed=18483179; DOI=10.1210/me.2007-0219;
RA   Chen W., Dang T., Blind R.D., Wang Z., Cavasotto C.N., Hittelman A.B.,
RA   Rogatsky I., Logan S.K., Garabedian M.J.;
RT   "Glucocorticoid receptor phosphorylation differentially affects target gene
RT   expression.";
RL   Mol. Endocrinol. 22:1754-1766(2008).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134; SER-226 AND SER-267, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [49]
RP   FUNCTION (ISOFORMS ALPHA AND BETA), AND SUBCELLULAR LOCATION (ISOFORM
RP   BETA).
RX   PubMed=19248771; DOI=10.1016/j.bbrc.2009.02.110;
RA   Kino T., Manoli I., Kelkar S., Wang Y., Su Y.A., Chrousos G.P.;
RT   "Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent
RT   transcriptional activity.";
RL   Biochem. Biophys. Res. Commun. 381:671-675(2009).
RN   [50]
RP   FUNCTION (ISOFORM ALPHA), ACETYLATION AT LYS-480; LYS-492; LYS-494 AND
RP   LYS-495, MUTAGENESIS OF LYS-480; LYS-492; LYS-494 AND LYS-495, AND
RP   INTERACTION WITH CLOCK.
RX   PubMed=19141540; DOI=10.1096/fj.08-117697;
RA   Nader N., Chrousos G.P., Kino T.;
RT   "Circadian rhythm transcription factor CLOCK regulates the transcriptional
RT   activity of the glucocorticoid receptor by acetylating its hinge region
RT   lysine cluster: potential physiological implications.";
RL   FASEB J. 23:1572-1583(2009).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [52]
RP   INTERACTION WITH TACC1.
RX   PubMed=20078863; DOI=10.1186/1471-2199-11-3;
RA   Guyot R., Vincent S., Bertin J., Samarut J., Ravel-Chapuis P.;
RT   "The transforming acidic coiled coil (TACC1) protein modulates the
RT   transcriptional activity of the nuclear receptors TR and RAR.";
RL   BMC Mol. Biol. 11:3-3(2010).
RN   [53]
RP   FUNCTION (ISOFORMS ALPHA; BETA; ALPHA-2 AND 10).
RX   PubMed=20484466; DOI=10.1210/en.2009-1254;
RA   Taniguchi Y., Iwasaki Y., Tsugita M., Nishiyama M., Taguchi T., Okazaki M.,
RA   Nakayama S., Kambayashi M., Hashimoto K., Terada Y.;
RT   "Glucocorticoid receptor-beta and receptor-gamma exert dominant negative
RT   effect on gene repression but not on gene induction.";
RL   Endocrinology 151:3204-3213(2010).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [56]
RP   FUNCTION (ISOFORM ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA).
RX   PubMed=21664385; DOI=10.1016/j.bbamcr.2011.05.014;
RA   Psarra A.M., Sekeris C.E.;
RT   "Glucocorticoids induce mitochondrial gene transcription in HepG2 cells:
RT   role of the mitochondrial glucocorticoid receptor.";
RL   Biochim. Biophys. Acta 1813:1814-1821(2011).
RN   [57]
RP   SUBUNIT.
RX   PubMed=21730050; DOI=10.1074/jbc.m111.256610;
RA   Gallo L.I., Lagadari M., Piwien-Pilipuk G., Galigniana M.D.;
RT   "The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a
RT   mitochondrial protein that translocates to the nucleus to protect cells
RT   against oxidative stress.";
RL   J. Biol. Chem. 286:30152-30160(2011).
RN   [58]
RP   INTERACTION WITH CRY1 AND CRY2.
RX   PubMed=22170608; DOI=10.1038/nature10700;
RA   Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W.,
RA   Downes M., Evans R.M.;
RT   "Cryptochromes mediate rhythmic repression of the glucocorticoid
RT   receptor.";
RL   Nature 480:552-556(2011).
RN   [59]
RP   ACETYLATION, AND INTERACTION WITH CLOCK.
RX   PubMed=21980503; DOI=10.1371/journal.pone.0025612;
RA   Charmandari E., Chrousos G.P., Lambrou G.I., Pavlaki A., Koide H., Ng S.S.,
RA   Kino T.;
RT   "Peripheral CLOCK regulates target-tissue glucocorticoid receptor
RT   transcriptional activity in a circadian fashion in man.";
RL   PLoS ONE 6:E25612-E25612(2011).
RN   [60]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORMS ALPHA-B AND BETA-B),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [61]
RP   FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3).
RX   PubMed=23303127; DOI=10.1038/cddis.2012.193;
RA   Wu I., Shin S.C., Cao Y., Bender I.K., Jafari N., Feng G., Lin S.,
RA   Cidlowski J.A., Schleimer R.P., Lu N.Z.;
RT   "Selective glucocorticoid receptor translational isoforms reveal
RT   glucocorticoid-induced apoptotic transcriptomes.";
RL   Cell Death Dis. 4:E453-E453(2013).
RN   [62]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-8; SER-45 AND SER-267, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [63]
RP   MUTAGENESIS OF LYS-703.
RX   PubMed=23508108; DOI=10.1128/mcb.01470-12;
RA   Druker J., Liberman A.C., Antunica-Noguerol M., Gerez J., Paez-Pereda M.,
RA   Rein T., Iniguez-Lluhi J.A., Holsboer F., Arzt E.;
RT   "RSUME enhances glucocorticoid receptor SUMOylation and transcriptional
RT   activity.";
RL   Mol. Cell. Biol. 33:2116-2127(2013).
RN   [64]
RP   FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3), AND MUTAGENESIS OF
RP   ASP-101; 106-GLN-GLN-107 AND 113-SER-SER-114.
RX   PubMed=23820903; DOI=10.1210/me.2013-1009;
RA   Bender I.K., Cao Y., Lu N.Z.;
RT   "Determinants of the heightened activity of glucocorticoid receptor
RT   translational isoforms.";
RL   Mol. Endocrinol. 27:1577-1587(2013).
RN   [65]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [66]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-293, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [67]
RP   FUNCTION (ISOFORM BETA), AND SUBCELLULAR LOCATION (ISOFORM BETA).
RX   PubMed=26711253; DOI=10.1128/mcb.00908-15;
RA   He B., Cruz-Topete D., Oakley R.H., Xiao X., Cidlowski J.A.;
RT   "Human Glucocorticoid Receptor beta (hGRbeta) Regulates Gluconeogenesis and
RT   Inflammation in Mouse Liver.";
RL   Mol. Cell. Biol. 36:714-730(2015).
RN   [68]
RP   FUNCTION, AND INTERACTION WITH PNRC2.
RX   PubMed=25775514; DOI=10.1073/pnas.1409612112;
RA   Cho H., Park O.H., Park J., Ryu I., Kim J., Ko J., Kim Y.K.;
RT   "Glucocorticoid receptor interacts with PNRC2 in a ligand-dependent manner
RT   to recruit UPF1 for rapid mRNA degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E1540-E1549(2015).
RN   [69]
RP   FUNCTION (ISOFORM ALPHA), SUBCELLULAR LOCATION (ISOFORM ALPHA), TISSUE
RP   SPECIFICITY, DOMAIN, AND PHOSPHORYLATION AT SER-203 AND SER-211.
RX   PubMed=25847991; DOI=10.1073/pnas.1411356112;
RA   Matthews L.C., Berry A.A., Morgan D.J., Poolman T.M., Bauer K., Kramer F.,
RA   Spiller D.G., Richardson R.V., Chapman K.E., Farrow S.N., Norman M.R.,
RA   Williamson A.J., Whetton A.D., Taylor S.S., Tuckermann J.P., White M.R.,
RA   Ray D.W.;
RT   "Glucocorticoid receptor regulates accurate chromosome segregation and is
RT   associated with malignancy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:5479-5484(2015).
RN   [70]
RP   INTERACTION WITH FNIP1 AND FNIP2.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W.,
RA   Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance
RT   drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [71]
RP   IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2;
RP   AKT; CDK4 AND RAF1.
RX   PubMed=29127155; DOI=10.15252/embj.201796700;
RA   Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L.,
RA   Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H.,
RA   Bourboulia D., Bratslavsky G., Wong M., Mollapour M.;
RT   "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding
RT   of kinase and non-kinase clients.";
RL   EMBO J. 36:3650-3665(2017).
RN   [72]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258 AND LYS-277, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 521-777 OF MUTANT SER-602 IN
RP   COMPLEX WITH NCOA2; DEXAMETHASONE AND RU-486, AND MUTAGENESIS OF ARG-585;
RP   ASP-590; PHE-602; PRO-625 AND ILE-628.
RX   PubMed=12151000; DOI=10.1016/s0092-8674(02)00817-6;
RA   Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J.,
RA   McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M.,
RA   Lambert M.H., Moore J.T., Pearce K.H., Xu H.E.;
RT   "Crystal structure of the glucocorticoid receptor ligand binding domain
RT   reveals a novel mode of receptor dimerization and coactivator
RT   recognition.";
RL   Cell 110:93-105(2002).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 500-777 OF MUTANT SER-602 IN
RP   COMPLEX WITH COACTIVATOR PEPTIDE; DEXAMETHASONE AND WITH RU-486.
RX   PubMed=12686538; DOI=10.1074/jbc.m212711200;
RA   Kauppi B., Jakob C., Faernegaardh M., Yang J., Ahola H., Alarcon M.,
RA   Calles K., Engstrom O., Harlan J., Muchmore S., Ramqvist A.-K., Thorell S.,
RA   Oehman L., Greer J., Gustafsson J.-A., Carlstedt-Duke J., Carlquist M.;
RT   "The three-dimensional structures of antagonistic and agonistic forms of
RT   the glucocorticoid receptor ligand-binding domain: RU-486 induces a
RT   transconformation that leads to active antagonism.";
RL   J. Biol. Chem. 278:22748-22754(2003).
RN   [75]
RP   CHARACTERIZATION OF VARIANT GCCR VAL-641.
RX   PubMed=1704018; DOI=10.1172/jci115046;
RA   Hurley D.M., Accili D., Stratakis C.A., Karl M., Vamvakopoulos N.,
RA   Rorer E., Constantine K., Taylor S.I., Chrousos G.P.;
RT   "Point mutation causing a single amino acid substitution in the hormone
RT   binding domain of the glucocorticoid receptor in familial glucocorticoid
RT   resistance.";
RL   J. Clin. Invest. 87:680-686(1991).
RN   [76]
RP   VARIANTS TYR-421 AND PHE-753.
RX   PubMed=8358735;
RA   Powers J.H., Hillmann A.G., Tang D.C., Harmon J.M.;
RT   "Cloning and expression of mutant glucocorticoid receptors from
RT   glucocorticoid-sensitive and -resistant human leukemic cells.";
RL   Cancer Res. 53:4059-4065(1993).
RN   [77]
RP   VARIANT SER-363.
RX   PubMed=8445027; DOI=10.1210/jcem.76.3.8445027;
RA   Karl M., Lamberts S.W.J., Detera-Wadleigh S.D., Encio I.J., Stratakis C.A.,
RA   Hurley D.M., Accili D., Chrousos G.P.;
RT   "Familial glucocorticoid resistance caused by a splice site deletion in the
RT   human glucocorticoid receptor gene.";
RL   J. Clin. Endocrinol. Metab. 76:683-689(1993).
RN   [78]
RP   VARIANT GCCR ILE-729.
RX   PubMed=7683692; DOI=10.1172/jci116410;
RA   Malchoff D.M., Brufsky A., Reardon G., McDermott P., Javier E.C.,
RA   Bergh C.H., Rowe D., Malchoff C.D.;
RT   "A mutation of the glucocorticoid receptor in primary cortisol
RT   resistance.";
RL   J. Clin. Invest. 91:1918-1925(1993).
RN   [79]
RP   VARIANT PHE-753.
RX   PubMed=8316249; DOI=10.1210/mend.7.5.8316249;
RA   Ashraf J., Thompson E.B.;
RT   "Identification of the activation-labile gene: a single point mutation in
RT   the human glucocorticoid receptor presents as two distinct receptor
RT   phenotypes.";
RL   Mol. Endocrinol. 7:631-642(1993).
RN   [80]
RP   VARIANTS LYS-23 AND SER-363.
RX   PubMed=9150737; DOI=10.1007/s004390050425;
RA   Koper J.W., Stolk R.P., de Lange P., Huizenga N.A.T.M., Molijn G.-J.,
RA   Pols H.A.P., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O.,
RA   Lamberts S.W.J.;
RT   "Lack of association between five polymorphisms in the human glucocorticoid
RT   receptor gene and glucocorticoid resistance.";
RL   Hum. Genet. 99:663-668(1997).
RN   [81]
RP   VARIANTS LYS-23; VAL-65 AND SER-363.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [82]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [83]
RP   VARIANTS LYS-23; LEU-29; PHE-112; ASN-233 AND SER-363.
RX   PubMed=10898924;
RX   DOI=10.1002/1096-8628(20000612)96:3<412::aid-ajmg33>3.0.co;2-c;
RA   Feng J., Zheng J., Bennett W.P., Heston L.L., Jones I.R., Craddock N.,
RA   Sommer S.S.;
RT   "Five missense variants in the amino-terminal domain of the glucocorticoid
RT   receptor: no association with puerperal psychosis or schizophrenia.";
RL   Am. J. Med. Genet. 96:412-417(2000).
RN   [84]
RP   VARIANTS GCCR HIS-477 AND SER-679.
RX   PubMed=11589680; DOI=10.1046/j.1365-2265.2001.01323.x;
RA   Ruiz M., Lind U., Gaafvels M., Eggertsen G., Carlstedt-Duke J., Nilsson L.,
RA   Holtmann M., Stierna P., Wikstroem A.-C., Werner S.;
RT   "Characterization of two novel mutations in the glucocorticoid receptor
RT   gene in patients with primary cortisol resistance.";
RL   Clin. Endocrinol. (Oxf.) 55:363-371(2001).
RN   [85]
RP   VARIANT SER-363.
RX   PubMed=11344238; DOI=10.1210/jcem.86.5.7465;
RA   Dobson M.G., Redfern C.P.F., Unwin N., Weaver J.U.;
RT   "The N363S polymorphism of the glucocorticoid receptor: potential
RT   contribution to central obesity in men and lack of association with other
RT   risk factors for coronary heart disease and diabetes mellitus.";
RL   J. Clin. Endocrinol. Metab. 86:2270-2274(2001).
RN   [86]
RP   CHARACTERIZATION OF VARIANT GCCR ASN-559.
RX   PubMed=11701741; DOI=10.1210/jcem.86.11.8017;
RA   Kino T., Stauber R.H., Resau J.H., Pavlakis G.N., Chrousos G.P.;
RT   "Pathologic human GR mutant has a transdominant negative effect on the
RT   wild-type GR by inhibiting its translocation into the nucleus: importance
RT   of the ligand-binding domain for intracellular GR trafficking.";
RL   J. Clin. Endocrinol. Metab. 86:5600-5608(2001).
RN   [87]
RP   VARIANT LYS-23.
RX   PubMed=12351458; DOI=10.2337/diabetes.51.10.3128;
RA   van Rossum E.F.C., Koper J.W., Huizenga N.A.T.M., Uitterlinden A.G.,
RA   Janssen J.A.M.J.L., Brinkmann A.O., Grobbee D.E., de Jong F.H.,
RA   van Duyn C.M., Pols H.A.P., Lamberts S.W.J.;
RT   "A polymorphism in the glucocorticoid receptor gene, which decreases
RT   sensitivity to glucocorticoids in vivo, is associated with low insulin and
RT   cholesterol levels.";
RL   Diabetes 51:3128-3134(2002).
RN   [88]
RP   VARIANT PSEUDOHERMAPHRODITISM ALA-571.
RX   PubMed=11932321; DOI=10.1210/jcem.87.4.8379;
RA   Mendonca B.B., Leite M.V., de Castro M., Kino T., Elias L.L.K.,
RA   Bachega T.A.S., Arnhold I.J.P., Chrousos G.P., Latronico A.C.;
RT   "Female pseudohermaphroditism caused by a novel homozygous missense
RT   mutation of the GR gene.";
RL   J. Clin. Endocrinol. Metab. 87:1805-1809(2002).
RN   [89]
RP   VARIANT GCCR MET-747, AND ALTERED INTERACTION WITH THE COACTIVATOR NCOA2.
RX   PubMed=12050230; DOI=10.1210/jcem.87.6.8520;
RA   Vottero A., Kino T., Combe H., Lecomte P., Chrousos G.P.;
RT   "A novel, C-terminal dominant negative mutation of the GR causes familial
RT   glucocorticoid resistance through abnormal interactions with p160 steroid
RT   receptor coactivators.";
RL   J. Clin. Endocrinol. Metab. 87:2658-2667(2002).
RN   [90]
RP   VARIANT LYS-23.
RX   PubMed=15276593; DOI=10.1016/j.amjmed.2004.01.027;
RA   van Rossum E.F.C., Feelders R.A., van den Beld A.W., Uitterlinden A.G.,
RA   Janssen J.A.M.J.L., Ester W., Brinkmann A.O., Grobbee D.E., de Jong F.H.,
RA   Pols H.A.P., Koper J.W., Lamberts S.W.J.;
RT   "Association of the ER22/23EK polymorphism in the glucocorticoid receptor
RT   gene with survival and C-reactive protein levels in elderly men.";
RL   Am. J. Med. 117:158-162(2004).
RN   [91]
RP   VARIANT LYS-23.
RX   PubMed=15292341; DOI=10.1210/jc.2003-031422;
RA   van Rossum E.F.C., Voorhoeve P.G., te Velde S.J., Koper J.W.,
RA   Delemarre-van de Waal H.A., Kemper H.C.G., Lamberts S.W.J.;
RT   "The ER22/23EK polymorphism in the glucocorticoid receptor gene is
RT   associated with a beneficial body composition and muscle strength in young
RT   adults.";
RL   J. Clin. Endocrinol. Metab. 89:4004-4009(2004).
RN   [92]
RP   VARIANT GCCR PRO-773, CHARACTERIZATION OF VARIANT GCCR PRO-773, INVOLVEMENT
RP   IN GCCR, FUNCTION (ISOFORM ALPHA), INTERACTION WITH GRIP1, AND SUBCELLULAR
RP   LOCATION (ISOFORM ALPHA).
RX   PubMed=15769988; DOI=10.1210/jc.2004-1920;
RA   Charmandari E., Raji A., Kino T., Ichijo T., Tiulpakov A., Zachman K.,
RA   Chrousos G.P.;
RT   "A novel point mutation in the ligand-binding domain (LBD) of the human
RT   glucocorticoid receptor (hGR) causing generalized glucocorticoid
RT   resistance: the importance of the C terminus of hGR LBD in conferring
RT   transactivational activity.";
RL   J. Clin. Endocrinol. Metab. 90:3696-3705(2005).
RN   [93]
RP   VARIANTS LYS-23 AND SER-363, AND CHARACTERIZATION OF VARIANTS LYS-23 AND
RP   SER-363.
RX   PubMed=16030164; DOI=10.1210/jc.2005-0646;
RA   Russcher H., Smit P., van den Akker E.L., van Rossum E.F., Brinkmann A.O.,
RA   de Jong F.H., Lamberts S.W., Koper J.W.;
RT   "Two polymorphisms in the glucocorticoid receptor gene directly affect
RT   glucocorticoid-regulated gene expression.";
RL   J. Clin. Endocrinol. Metab. 90:5804-5810(2005).
RN   [94]
RP   VARIANT GCCR LEU-737, CHARACTERIZATION OF VARIANT GCCR LEU-737, FUNCTION
RP   (ISOFORM ALPHA), INTERACTION WITH GRIP1, AND SUBCELLULAR LOCATION (ISOFORM
RP   ALPHA).
RX   PubMed=17635946; DOI=10.1210/jc.2006-2830;
RA   Charmandari E., Kino T., Ichijo T., Jubiz W., Mejia L., Zachman K.,
RA   Chrousos G.P.;
RT   "A novel point mutation in helix 11 of the ligand-binding domain of the
RT   human glucocorticoid receptor gene causing generalized glucocorticoid
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 92:3986-3990(2007).
RN   [95]
RP   VARIANT GCCR GLN-714, AND CHARACTERIZATION OF VARIANT GCCR GLN-714.
RX   PubMed=20335448; DOI=10.1210/jc.2009-2463;
RA   Nader N., Bachrach B.E., Hurt D.E., Gajula S., Pittman A., Lescher R.,
RA   Kino T.;
RT   "A novel point mutation in helix 10 of the human glucocorticoid receptor
RT   causes generalized glucocorticoid resistance by disrupting the structure of
RT   the ligand-binding domain.";
RL   J. Clin. Endocrinol. Metab. 95:2281-2285(2010).
RN   [96]
RP   VARIANT GCCR ILE-556.
RX   PubMed=21362280;
RA   Zhu H.J., Dai Y.F., Wang O., Li M., Lu L., Zhao W.G., Xing X.P., Pan H.,
RA   Li N.S., Gong F.Y.;
RT   "Generalized glucocorticoid resistance accompanied with an adrenocortical
RT   adenoma and caused by a novel point mutation of human glucocorticoid
RT   receptor gene.";
RL   Chin. Med. J. 124:551-555(2011).
RN   [97]
RP   CHARACTERIZATION OF VARIANT GCCR ALA-423.
RX   PubMed=23426617; DOI=10.1210/jc.2012-3549;
RA   Roberts M.L., Kino T., Nicolaides N.C., Hurt D.E., Katsantoni E.,
RA   Sertedaki A., Komianou F., Kassiou K., Chrousos G.P., Charmandari E.;
RT   "A novel point mutation in the DNA-binding domain (DBD) of the human
RT   glucocorticoid receptor causes primary generalized glucocorticoid
RT   resistance by disrupting the hydrophobic structure of its DBD.";
RL   J. Clin. Endocrinol. Metab. 98:E790-E795(2013).
RN   [98]
RP   VARIANT GCCR GLY-575, AND CHARACTERIZATION OF VARIANT GCCR GLY-575.
RX   PubMed=24483153; DOI=10.1210/jc.2013-3005;
RA   Nicolaides N.C., Roberts M.L., Kino T., Braatvedt G., Hurt D.E.,
RA   Katsantoni E., Sertedaki A., Chrousos G.P., Charmandari E.;
RT   "A novel point mutation of the human glucocorticoid receptor gene causes
RT   primary generalized glucocorticoid resistance through impaired interaction
RT   with the LXXLL motif of the p160 coactivators: dissociation of the
RT   transactivating and transreppressive activities.";
RL   J. Clin. Endocrinol. Metab. 99:E902-E907(2014).
RN   [99]
RP   VARIANT GCCR ARG-726, AND CHARACTERIZATION OF VARIANT GCCR ARG-726.
RX   PubMed=26031419; DOI=10.1111/eci.12470;
RA   Nicolaides N.C., Geer E.B., Vlachakis D., Roberts M.L., Psarra A.M.,
RA   Moutsatsou P., Sertedaki A., Kossida S., Charmandari E.;
RT   "A novel mutation of the hGR gene causing Chrousos syndrome.";
RL   Eur. J. Clin. Invest. 45:782-791(2015).
RN   [100]
RP   CHARACTERIZATION OF VARIANT GCCR ILE-556.
RX   PubMed=26541474; DOI=10.1111/eci.12563;
RA   Nicolaides N.C., Skyrla E., Vlachakis D., Psarra A.M., Moutsatsou P.,
RA   Sertedaki A., Kossida S., Charmandari E.;
RT   "Functional characterization of the hGRalphaT556I causing Chrousos
RT   syndrome.";
RL   Eur. J. Clin. Invest. 46:42-49(2016).
RN   [101]
RP   VARIANTS GCCR SER-477; CYS-478 AND PRO-672, CHARACTERIZATION OF VARIANTS
RP   GCCR SER-477; CYS-478 AND CYS-478, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=27120390; DOI=10.1002/humu.23008;
RA   Vitellius G., Fagart J., Delemer B., Amazit L., Ramos N., Bouligand J.,
RA   Le Billan F., Castinetti F., Guiochon-Mantel A., Trabado S., Lombes M.;
RT   "Three novel heterozygous point mutations of NR3C1 causing glucocorticoid
RT   resistance.";
RL   Hum. Mutat. 37:794-803(2016).
CC   -!- FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Has a
CC       dual mode of action: as a transcription factor that binds to
CC       glucocorticoid response elements (GRE), both for nuclear and
CC       mitochondrial DNA, and as a modulator of other transcription factors.
CC       Affects inflammatory responses, cellular proliferation and
CC       differentiation in target tissues. Involved in chromatin remodeling
CC       (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to
CC       the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-
CC       dependent manner which recruits the RNA helicase UPF1 and the mRNA-
CC       decapping enzyme DCP1A, leading to RNA decay (PubMed:25775514). Could
CC       act as a coactivator for STAT5-dependent transcription upon growth
CC       hormone (GH) stimulation and could reveal an essential role of hepatic
CC       GR in the control of body growth (By similarity).
CC       {ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:25775514,
CC       ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:9590696}.
CC   -!- FUNCTION: [Isoform Alpha]: Has transcriptional activation and
CC       repression activity (PubMed:15866175, PubMed:19248771, PubMed:20484466,
CC       PubMed:23820903, PubMed:11435610, PubMed:15769988, PubMed:17635946,
CC       PubMed:19141540, PubMed:21664385). Mediates glucocorticoid-induced
CC       apoptosis (PubMed:23303127). Promotes accurate chromosome segregation
CC       during mitosis (PubMed:25847991). May act as a tumor suppressor
CC       (PubMed:25847991). May play a negative role in adipogenesis through the
CC       regulation of lipolytic and antilipogenic gene expression (By
CC       similarity). {ECO:0000250|UniProtKB:P06537,
CC       ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,
CC       ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,
CC       ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,
CC       ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,
CC       ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,
CC       ECO:0000269|PubMed:25847991}.
CC   -!- FUNCTION: [Isoform Beta]: Acts as a dominant negative inhibitor of
CC       isoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466). Has
CC       intrinsic transcriptional activity independent of isoform Alpha when
CC       both isoforms are coexpressed (PubMed:19248771, PubMed:26711253). Loses
CC       this transcription modulator function on its own (PubMed:20484466). Has
CC       no hormone-binding activity (PubMed:8621628). May play a role in
CC       controlling glucose metabolism by maintaining insulin sensitivity (By
CC       similarity). Reduces hepatic gluconeogenesis through down-regulation of
CC       PEPCK in an isoform Alpha-dependent manner (PubMed:26711253). Directly
CC       regulates STAT1 expression in isoform Alpha-independent manner
CC       (PubMed:26711253). {ECO:0000250|UniProtKB:P06537,
CC       ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,
CC       ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,
CC       ECO:0000269|PubMed:8621628}.
CC   -!- FUNCTION: [Isoform Alpha-2]: Has lower transcriptional activation
CC       activity than isoform Alpha. Exerts a dominant negative effect on
CC       isoform Alpha trans-repression mechanism (PubMed:20484466).
CC   -!- FUNCTION: [Isoform GR-P]: Increases activity of isoform Alpha.
CC       {ECO:0000269|PubMed:11358809}.
CC   -!- FUNCTION: [Isoform Alpha-B]: More effective than isoform Alpha in
CC       transcriptional activation, but not repression activity.
CC       {ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.
CC   -!- FUNCTION: [Isoform 10]: Has transcriptional activation activity.
CC       {ECO:0000269|PubMed:20484466}.
CC   -!- FUNCTION: [Isoform Alpha-C1]: Has transcriptional activation activity.
CC       {ECO:0000269|PubMed:15866175}.
CC   -!- FUNCTION: [Isoform Alpha-C2]: Has transcriptional activation activity.
CC       {ECO:0000269|PubMed:15866175}.
CC   -!- FUNCTION: [Isoform Alpha-C3]: Has highest transcriptional activation
CC       activity of all isoforms created by alternative initiation
CC       (PubMed:15866175, PubMed:23820903). Has transcriptional repression
CC       activity (PubMed:23303127). Mediates glucocorticoid-induced apoptosis
CC       (PubMed:23303127, PubMed:23820903). {ECO:0000269|PubMed:15866175,
CC       ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.
CC   -!- FUNCTION: [Isoform Alpha-D1]: Has transcriptional activation activity.
CC       {ECO:0000269|PubMed:15866175}.
CC   -!- FUNCTION: [Isoform Alpha-D2]: Has transcriptional activation activity.
CC       {ECO:0000269|PubMed:15866175}.
CC   -!- FUNCTION: [Isoform Alpha-D3]: Has lowest transcriptional activation
CC       activity of all isoforms created by alternative initiation
CC       (PubMed:15866175, PubMed:23820903). Has transcriptional repression
CC       activity (PubMed:23303127). {ECO:0000269|PubMed:15866175,
CC       ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.
CC   -!- SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,
CC       HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID, STIP1,
CC       or the immunophilin homolog PPP5C (PubMed:21730050). Upon ligand
CC       binding FKBP5 dissociates from the complex and FKBP4 takes its place,
CC       thereby linking the complex to dynein and mediating transport to the
CC       nucleus, where the complex dissociates (By similarity). Probably forms
CC       a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37,
CC       PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this
CC       complex does not contain co-chaperones STIP1/HOP and PTGES3/p23
CC       (PubMed:29127155). Directly interacts with UNC45A (PubMed:16478993).
CC       Binds to DNA as a homodimer, and as heterodimer with NR3C2 or the
CC       retinoid X receptor. Binds STAT5A and STAT5B homodimers and
CC       heterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2 and
CC       TRIM28 (By similarity). Interacts with several coactivator complexes,
CC       including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and
CC       p160 coactivators such as NCOA2 and NCOA6 (PubMed:10866662,
CC       PubMed:12151000, PubMed:12686538, PubMed:9154805, PubMed:9590696).
CC       Interaction with BAG1 inhibits transactivation (PubMed:10477749).
CC       Interacts with HEXIM1 and TGFB1I1 (PubMed:12415108, PubMed:15211577,
CC       PubMed:15941832). Interacts with NCOA1 (PubMed:9590696). Interacts with
CC       NCOA3, SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity).
CC       Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion
CC       (PubMed:19141540, PubMed:21980503, PubMed:22170608). Interacts with
CC       CIART (By similarity). Interacts with RWDD3 (By similarity). Interacts
CC       with UBE2I/UBC9 and this interaction is enhanced in the presence of
CC       RWDD3 (By similarity). Interacts with GRIP1 (PubMed:15769988,
CC       PubMed:17635946). Interacts with NR4A3 (via nuclear receptor DNA-
CC       binding domain), represses transcription activity of NR4A3 on the POMC
CC       promoter Nur response element (NurRE) (PubMed:15591535). Directly
CC       interacts with PNRC2 to attract and form a complex with UPF1 and DCP1A;
CC       the interaction leads to rapid mRNA degradation (PubMed:25775514).
CC       Interacts with GSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2
CC       (PubMed:27353360). Interacts (via C-terminus) with HNRNPU (via C-
CC       terminus) (PubMed:9353307). Interacts with MCM3AP (PubMed:16914116).
CC       Interacts (via domain NR LBD) with HSP90AA1 and HSP90AB1 (By
CC       similarity). In the absence of hormonal ligand, interacts with TACC1
CC       (PubMed:20078863). {ECO:0000250|UniProtKB:P06536,
CC       ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,
CC       ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,
CC       ECO:0000269|PubMed:12686538, ECO:0000269|PubMed:15211577,
CC       ECO:0000269|PubMed:15591535, ECO:0000269|PubMed:15769988,
CC       ECO:0000269|PubMed:15941832, ECO:0000269|PubMed:16478993,
CC       ECO:0000269|PubMed:16914116, ECO:0000269|PubMed:17635946,
CC       ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,
CC       ECO:0000269|PubMed:20078863, ECO:0000269|PubMed:21730050,
CC       ECO:0000269|PubMed:21980503, ECO:0000269|PubMed:22170608,
CC       ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27353360,
CC       ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:9154805,
CC       ECO:0000269|PubMed:9353307, ECO:0000269|PubMed:9590696}.
CC   -!- INTERACTION:
CC       P04150; P31749: AKT1; NbExp=5; IntAct=EBI-493507, EBI-296087;
CC       P04150; P01730: CD4; NbExp=2; IntAct=EBI-493507, EBI-353826;
CC       P04150; P00533: EGFR; NbExp=3; IntAct=EBI-493507, EBI-297353;
CC       P04150; P41235: HNF4A; NbExp=2; IntAct=EBI-493507, EBI-1049011;
CC       P04150; P07900: HSP90AA1; NbExp=8; IntAct=EBI-493507, EBI-296047;
CC       P04150; Q6ZU52: KIAA0408; NbExp=2; IntAct=EBI-493507, EBI-739493;
CC       P04150; P06239: LCK; NbExp=3; IntAct=EBI-493507, EBI-1348;
CC       P04150; P28702: RXRB; NbExp=4; IntAct=EBI-493507, EBI-748576;
CC       P04150; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-493507, EBI-745901;
CC       P04150; O95416: SOX14; NbExp=3; IntAct=EBI-493507, EBI-9087806;
CC       P04150; P82094: TMF1; NbExp=3; IntAct=EBI-493507, EBI-949763;
CC       P04150; P59598: Asxl1; Xeno; NbExp=2; IntAct=EBI-493507, EBI-5743705;
CC       P04150; Q62667: Mvp; Xeno; NbExp=2; IntAct=EBI-493507, EBI-918333;
CC       P04150-1; Q61026: Ncoa2; Xeno; NbExp=3; IntAct=EBI-15750116, EBI-688662;
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha]: Cytoplasm
CC       {ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,
CC       ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,
CC       ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,
CC       ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,
CC       ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}. Mitochondrion
CC       {ECO:0000269|PubMed:21664385}. Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:25847991}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:25847991}. Note=After
CC       ligand activation, translocates from the cytoplasm to the nucleus. In
CC       the presence of NR1D1 shows a time-dependent subcellular localization,
CC       localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By
CC       similarity). Lacks this diurnal pattern of localization in the absence
CC       of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20
CC       (By similarity). {ECO:0000250|UniProtKB:P06537,
CC       ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,
CC       ECO:0000269|PubMed:8621628}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Beta]: Nucleus
CC       {ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,
CC       ECO:0000269|PubMed:8621628}. Cytoplasm {ECO:0000269|PubMed:19248771,
CC       ECO:0000269|PubMed:26711253}. Note=Expressed predominantly in the
CC       nucleus with some expression also detected in the cytoplasm.
CC       {ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha-B]: Nucleus
CC       {ECO:0000269|PubMed:15866175}. Cytoplasm {ECO:0000269|PubMed:15866175}.
CC       Note=After ligand activation, translocates from the cytoplasm to the
CC       nucleus. {ECO:0000269|PubMed:15866175}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=16;
CC       Name=Alpha; Synonyms=Alpha-A, GR-alphaA;
CC         IsoId=P04150-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=Beta-A;
CC         IsoId=P04150-2; Sequence=VSP_003703;
CC       Name=Alpha-2; Synonyms=Gamma;
CC         IsoId=P04150-3; Sequence=VSP_007363;
CC       Name=Beta-2;
CC         IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;
CC       Name=GR-A alpha;
CC         IsoId=P04150-5; Sequence=VSP_013340;
CC       Name=GR-A beta;
CC         IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;
CC       Name=GR-P;
CC         IsoId=P04150-4; Sequence=Not described;
CC       Name=Alpha-B; Synonyms=GR-alphaB;
CC         IsoId=P04150-8; Sequence=VSP_018773;
CC       Name=Beta-B;
CC         IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;
CC       Name=10; Synonyms=hGRDelta313-338;
CC         IsoId=P04150-10; Sequence=VSP_043908;
CC       Name=Alpha-C1; Synonyms=GR-alphaC1;
CC         IsoId=P04150-11; Sequence=VSP_058317;
CC       Name=Alpha-C2; Synonyms=GR-alphaC2;
CC         IsoId=P04150-12; Sequence=VSP_058316;
CC       Name=Alpha-C3; Synonyms=GR-alphaC3;
CC         IsoId=P04150-13; Sequence=VSP_058315;
CC       Name=Alpha-D1; Synonyms=GR-alphaD1;
CC         IsoId=P04150-14; Sequence=VSP_058314;
CC       Name=Alpha-D2; Synonyms=GR-alphaD2;
CC         IsoId=P04150-15; Sequence=VSP_058313;
CC       Name=Alpha-D3; Synonyms=GR-alphaD3;
CC         IsoId=P04150-16; Sequence=VSP_058312;
CC   -!- TISSUE SPECIFICITY: Widely expressed including bone, stomach, lung,
CC       liver, colon, breast, ovary, pancreas and kidney (PubMed:25847991). In
CC       the heart, detected in left and right atria, left and right ventricles,
CC       aorta, apex, intraventricular septum, and atrioventricular node as well
CC       as whole adult and fetal heart (PubMed:10902803).
CC       {ECO:0000269|PubMed:10902803, ECO:0000269|PubMed:25847991}.
CC   -!- TISSUE SPECIFICITY: [Isoform Beta]: Widely expressed including brain,
CC       bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,
CC       skeletal muscle, heart, placenta and blood leukocytes.
CC       {ECO:0000269|PubMed:7769088, ECO:0000269|PubMed:8621628}.
CC   -!- TISSUE SPECIFICITY: [Isoform Alpha-2]: Widely expressed.
CC       {ECO:0000269|PubMed:10566686}.
CC   -!- INDUCTION: [Isoform Alpha]: Induced by TNF (at protein level).
CC       {ECO:0000269|PubMed:11381138}.
CC   -!- INDUCTION: [Isoform Beta]: Induced by TNF and becomes the predominant
CC       isoform which may lead to glucocorticoid resistance (at protein level).
CC       {ECO:0000269|PubMed:11381138}.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC       DNA-binding domain and a C-terminal ligand-binding domain
CC       (PubMed:3841189). The ligand-binding domain is required for correct
CC       chromosome segregation during mitosis although ligand binding is not
CC       required (PubMed:25847991). {ECO:0000269|PubMed:25847991,
CC       ECO:0000269|PubMed:3841189}.
CC   -!- PTM: Acetylation by CLOCK reduces its binding to glucocorticoid
CC       response elements and its transcriptional activity.
CC       {ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.
CC   -!- PTM: Increased proteasome-mediated degradation in response to
CC       glucocorticoids (PubMed:11555652). Isoform Alpha-B appears to be more
CC       susceptible to proteolytic degradation than isoform Alpha
CC       (PubMed:11435610). {ECO:0000269|PubMed:11435610,
CC       ECO:0000269|PubMed:11555652}.
CC   -!- PTM: Phosphorylated in the absence of hormone; becomes
CC       hyperphosphorylated in the presence of glucocorticoid. The Ser-203,
CC       Ser-226 and Ser-404-phosphorylated forms are mainly cytoplasmic, and
CC       the Ser-211-phosphorylated form is nuclear (PubMed:12000743,
CC       PubMed:18838540). Phosphorylation at Ser-211 increases transcriptional
CC       activity (PubMed:12000743, PubMed:18483179). Phosphorylation at Ser-
CC       203, Ser-226 and Ser-404 decreases signaling capacity (PubMed:12000743,
CC       PubMed:18483179, PubMed:18838540). Phosphorylation at Ser-404 may
CC       protect from glucocorticoid-induced apoptosis (PubMed:18838540).
CC       Phosphorylation at Ser-203 and Ser-211 is not required in regulation of
CC       chromosome segregation (PubMed:25847991). May be dephosphorylated by
CC       PPP5C, attenuates NR3C1 action (By similarity).
CC       {ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:12000743,
CC       ECO:0000269|PubMed:18483179, ECO:0000269|PubMed:18838540,
CC       ECO:0000269|PubMed:25847991}.
CC   -!- PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates its
CC       transcriptional activity (PubMed:12144530). Sumoylation at Lys-703
CC       positively regulates its transcriptional activity in the presence of
CC       RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 is
CC       dispensable whereas sumoylation at Lys-703 is critical for the
CC       stimulatory effect of RWDD3 on its transcriptional activity (By
CC       similarity). Heat shock increases sumoylation in a RWDD3-dependent
CC       manner (By similarity). {ECO:0000250|UniProtKB:P06536,
CC       ECO:0000269|PubMed:12144530}.
CC   -!- PTM: Ubiquitinated; restricts glucocorticoid-mediated transcriptional
CC       signaling. {ECO:0000250|UniProtKB:P06537}.
CC   -!- POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relatively more
CC       resistant to the effects of GCs with respect to the sensitivity of the
CC       adrenal feedback mechanism than non-carriers, resulting in a better
CC       metabolic health profile. Carriers have a better survival than non-
CC       carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23
CC       polymorphism is associated with a sex-specific, beneficial body
CC       composition at young-adult age, as well as greater muscle strength in
CC       males.
CC   -!- DISEASE: Glucocorticoid resistance, generalized (GCCR) [MIM:615962]: An
CC       autosomal dominant disease characterized by increased plasma cortisol
CC       concentration and high urinary free cortisol, resistance to adrenal
CC       suppression by dexamethasone, and the absence of Cushing syndrome
CC       typical signs. Clinical features include hypoglycemia, hypertension,
CC       metabolic alkalosis, chronic fatigue and profound anxiety.
CC       {ECO:0000269|PubMed:11589680, ECO:0000269|PubMed:11701741,
CC       ECO:0000269|PubMed:12050230, ECO:0000269|PubMed:15769988,
CC       ECO:0000269|PubMed:1704018, ECO:0000269|PubMed:17635946,
CC       ECO:0000269|PubMed:20335448, ECO:0000269|PubMed:21362280,
CC       ECO:0000269|PubMed:23426617, ECO:0000269|PubMed:24483153,
CC       ECO:0000269|PubMed:26031419, ECO:0000269|PubMed:26541474,
CC       ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:7683692}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform Beta]: High constitutive expression by
CC       neutrophils may provide a mechanism by which these cells escape
CC       glucocorticoid-induced cell death and up-regulation by proinflammatory
CC       cytokines such as IL8 further enhances their survival in the presence
CC       of glucocorticoids during inflammation. {ECO:0000269|PubMed:11238589}.
CC   -!- MISCELLANEOUS: Can up- or down-modulate aggregation and nuclear
CC       localization of expanded polyglutamine polypeptides derived from AR and
CC       HD through specific regulation of gene expression. Aggregation and
CC       nuclear localization of expanded polyglutamine proteins are regulated
CC       cellular processes that can be modulated by this receptor, a well-
CC       characterized transcriptional regulator. {ECO:0000269|PubMed:10639135}.
CC   -!- MISCELLANEOUS: [Isoform Alpha]: Predominant physiological form.
CC       {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-2]: Due to a partial intron retention.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform Beta-2]: Due to a partial intron retention.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform GR-A alpha]: Lacks exons 5, 6 and 7. Found in
CC       glucocorticoid-resistant myeloma patients.
CC       {ECO:0000269|PubMed:8358712}.
CC   -!- MISCELLANEOUS: [Isoform GR-A beta]: Lacks exons 5, 6 and 7.
CC       {ECO:0000269|PubMed:8358712}.
CC   -!- MISCELLANEOUS: [Isoform GR-P]: Encoded by exons 2-7 plus several
CC       basepairs from the subsequent intron region. Lacks the ligand binding
CC       domain. Accounts for up to 10-20% of mRNAs.
CC       {ECO:0000269|PubMed:8358712}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-B]: Produced by alternative initiation at
CC       Met-27 of isoform Alpha. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform Beta-B]: Produced by alternative initiation at
CC       Met-27 of isoform Beta. {ECO:0000269|PubMed:15866175, ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-C1]: Produced by alternative initiation
CC       at Met-86 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-C2]: Produced by alternative initiation
CC       at Met-90 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-C3]: Produced by alternative initiation
CC       at Met-98 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-D1]: Produced by alternative initiation
CC       at Met-316 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-D2]: Produced by alternative initiation
CC       at Met-331 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- MISCELLANEOUS: [Isoform Alpha-D3]: Produced by alternative initiation
CC       at Met-336 of isoform Alpha. {ECO:0000269|PubMed:15866175}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: Had previously been shown to interact with PELP1. However this
CC       paper was retracted as cell-based data was viewed as unreliable.
CC       {ECO:0000305|PubMed:12415108, ECO:0000305|PubMed:19666546}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nr3c1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Glucocorticoid_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X03225; CAA26976.1; -; mRNA.
DR   EMBL; X03348; CAA27054.1; -; mRNA.
DR   EMBL; AH005496; AAB64353.1; -; Genomic_DNA.
DR   EMBL; AH005496; AAB64354.1; -; Genomic_DNA.
DR   EMBL; HQ205546; ADP91135.1; -; Genomic_DNA.
DR   EMBL; HQ205547; ADP91138.1; -; Genomic_DNA.
DR   EMBL; HQ205548; ADP91141.1; -; Genomic_DNA.
DR   EMBL; HQ205549; ADP91144.1; -; Genomic_DNA.
DR   EMBL; HQ205550; ADP91147.1; -; Genomic_DNA.
DR   EMBL; HQ205551; ADP91150.1; -; Genomic_DNA.
DR   EMBL; HQ205552; ADP91153.1; -; Genomic_DNA.
DR   EMBL; HQ205553; ADP91156.1; -; Genomic_DNA.
DR   EMBL; HQ205554; ADP91159.1; -; Genomic_DNA.
DR   EMBL; HQ205555; ADP91162.1; -; Genomic_DNA.
DR   EMBL; HQ205556; ADP91165.1; -; Genomic_DNA.
DR   EMBL; HQ205557; ADP91168.1; -; Genomic_DNA.
DR   EMBL; HQ205558; ADP91171.1; -; Genomic_DNA.
DR   EMBL; HQ205559; ADP91174.1; -; Genomic_DNA.
DR   EMBL; HQ205560; ADP91177.1; -; Genomic_DNA.
DR   EMBL; HQ205561; ADP91180.1; -; Genomic_DNA.
DR   EMBL; HQ205562; ADP91183.1; -; Genomic_DNA.
DR   EMBL; HQ205563; ADP91186.1; -; Genomic_DNA.
DR   EMBL; HQ205564; ADP91189.1; -; Genomic_DNA.
DR   EMBL; HQ205565; ADP91192.1; -; Genomic_DNA.
DR   EMBL; HQ205566; ADP91195.1; -; Genomic_DNA.
DR   EMBL; HQ205567; ADP91198.1; -; Genomic_DNA.
DR   EMBL; HQ205568; ADP91201.1; -; Genomic_DNA.
DR   EMBL; HQ205569; ADP91204.1; -; Genomic_DNA.
DR   EMBL; HQ205570; ADP91207.1; -; Genomic_DNA.
DR   EMBL; HQ205571; ADP91210.1; -; Genomic_DNA.
DR   EMBL; HQ205572; ADP91213.1; -; Genomic_DNA.
DR   EMBL; HQ205573; ADP91216.1; -; Genomic_DNA.
DR   EMBL; HQ205574; ADP91219.1; -; Genomic_DNA.
DR   EMBL; HQ205575; ADP91222.1; -; Genomic_DNA.
DR   EMBL; HQ205576; ADP91225.1; -; Genomic_DNA.
DR   EMBL; HQ205577; ADP91228.1; -; Genomic_DNA.
DR   EMBL; HQ205578; ADP91231.1; -; Genomic_DNA.
DR   EMBL; HQ205579; ADP91234.1; -; Genomic_DNA.
DR   EMBL; HQ205580; ADP91237.1; -; Genomic_DNA.
DR   EMBL; HQ205581; ADP91240.1; -; Genomic_DNA.
DR   EMBL; HQ205582; ADP91243.1; -; Genomic_DNA.
DR   EMBL; HQ205583; ADP91246.1; -; Genomic_DNA.
DR   EMBL; HQ205584; ADP91249.1; -; Genomic_DNA.
DR   EMBL; HQ205585; ADP91252.1; -; Genomic_DNA.
DR   EMBL; AM183262; CAJ65924.1; -; mRNA.
DR   EMBL; HQ450643; AED99114.1; -; mRNA.
DR   EMBL; U01351; AAA16603.1; -; mRNA.
DR   EMBL; AK223594; BAD97314.1; -; mRNA.
DR   EMBL; BX640610; CAE45716.1; -; mRNA.
DR   EMBL; AY436590; AAQ97180.1; -; Genomic_DNA.
DR   EMBL; EU332858; ABY87547.1; -; Genomic_DNA.
DR   EMBL; AC005601; AAC34207.1; -; Genomic_DNA.
DR   EMBL; AC004782; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61872.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61873.1; -; Genomic_DNA.
DR   EMBL; BC015610; AAH15610.1; -; mRNA.
DR   EMBL; M69104; AAA88049.1; -; Genomic_DNA.
DR   EMBL; AH002750; AAA53151.1; -; Genomic_DNA.
DR   EMBL; S68378; AAB20466.1; -; Genomic_DNA.
DR   CCDS; CCDS34258.1; -. [P04150-3]
DR   CCDS; CCDS4278.1; -. [P04150-1]
DR   CCDS; CCDS47298.1; -. [P04150-2]
DR   PIR; A93370; QRHUGA.
DR   PIR; B93370; QRHUGB.
DR   RefSeq; NP_000167.1; NM_000176.2. [P04150-1]
DR   RefSeq; NP_001018084.1; NM_001018074.1. [P04150-1]
DR   RefSeq; NP_001018085.1; NM_001018075.1. [P04150-1]
DR   RefSeq; NP_001018086.1; NM_001018076.1. [P04150-1]
DR   RefSeq; NP_001018087.1; NM_001018077.1. [P04150-1]
DR   RefSeq; NP_001018661.1; NM_001020825.1. [P04150-2]
DR   RefSeq; NP_001019265.1; NM_001024094.1. [P04150-3]
DR   RefSeq; NP_001191187.1; NM_001204258.1. [P04150-8]
DR   RefSeq; NP_001191188.1; NM_001204259.1. [P04150-11]
DR   RefSeq; NP_001191189.1; NM_001204260.1. [P04150-12]
DR   RefSeq; NP_001191190.1; NM_001204261.1. [P04150-13]
DR   RefSeq; NP_001191191.1; NM_001204262.1. [P04150-14]
DR   RefSeq; NP_001191192.1; NM_001204263.1. [P04150-15]
DR   RefSeq; NP_001191193.1; NM_001204264.1. [P04150-16]
DR   RefSeq; XP_005268476.1; XM_005268419.3.
DR   RefSeq; XP_005268477.1; XM_005268420.4.
DR   RefSeq; XP_005268479.1; XM_005268422.3. [P04150-3]
DR   RefSeq; XP_005268480.1; XM_005268423.3. [P04150-3]
DR   RefSeq; XP_016864886.1; XM_017009397.1.
DR   RefSeq; XP_016864887.1; XM_017009398.1.
DR   PDB; 1M2Z; X-ray; 2.50 A; A/D=521-777.
DR   PDB; 1NHZ; X-ray; 2.30 A; A=500-777.
DR   PDB; 1P93; X-ray; 2.70 A; A/B/C/D=500-777.
DR   PDB; 3BQD; X-ray; 2.50 A; A=525-777.
DR   PDB; 3CLD; X-ray; 2.84 A; A/B=521-777.
DR   PDB; 3E7C; X-ray; 2.15 A; A/B=521-777.
DR   PDB; 3H52; X-ray; 2.80 A; A/B/C/D=528-777.
DR   PDB; 3K22; X-ray; 2.10 A; A/B=521-777.
DR   PDB; 3K23; X-ray; 3.00 A; A/B/C=521-777.
DR   PDB; 4CSJ; X-ray; 2.30 A; A=500-777.
DR   PDB; 4HN5; X-ray; 1.90 A; A/B=417-506.
DR   PDB; 4HN6; X-ray; 2.55 A; A/B=417-506.
DR   PDB; 4LSJ; X-ray; 2.35 A; A=522-777.
DR   PDB; 4MDD; X-ray; 2.40 A; A/B=522-777.
DR   PDB; 4P6W; X-ray; 1.95 A; A=526-777.
DR   PDB; 4P6X; X-ray; 2.50 A; A/C/E/G/I/K=523-777.
DR   PDB; 4UDC; X-ray; 2.50 A; A=500-777.
DR   PDB; 4UDD; X-ray; 1.80 A; A=500-777.
DR   PDB; 5CBX; X-ray; 2.00 A; A/B/E/F=415-495.
DR   PDB; 5CBY; X-ray; 2.00 A; A/B=415-495.
DR   PDB; 5CBZ; X-ray; 2.20 A; A/B/E/F=419-495.
DR   PDB; 5CC1; X-ray; 2.30 A; A/B/W/X=417-506.
DR   PDB; 5E69; X-ray; 1.85 A; A/B=417-506.
DR   PDB; 5E6A; X-ray; 2.20 A; A/B=417-506.
DR   PDB; 5E6B; X-ray; 2.25 A; A/B=417-506.
DR   PDB; 5E6C; X-ray; 2.20 A; A/B=417-506.
DR   PDB; 5E6D; X-ray; 2.40 A; A/B=417-506.
DR   PDB; 5EMC; X-ray; 2.30 A; A/B=411-500.
DR   PDB; 5EMP; X-ray; 2.30 A; A/B=411-500.
DR   PDB; 5EMQ; X-ray; 2.30 A; A/B=411-500.
DR   PDB; 5G3J; X-ray; 2.40 A; A=500-777.
DR   PDB; 5G5W; X-ray; 2.20 A; A=500-777.
DR   PDB; 5NFP; X-ray; 2.10 A; A=500-777.
DR   PDB; 5NFT; X-ray; 2.30 A; A=500-777.
DR   PDB; 5UC3; X-ray; 2.01 A; A/B=522-777.
DR   PDB; 5VA0; X-ray; 2.29 A; A/B=419-490.
DR   PDB; 5VA7; X-ray; 2.15 A; A/B=419-488.
DR   PDB; 6BQU; X-ray; 2.50 A; A/B=421-490.
DR   PDB; 6CFN; X-ray; 2.50 A; A/B/C/D/E/F/G/H=418-506.
DR   PDB; 6DXK; X-ray; 3.05 A; A/B=522-777.
DR   PDB; 6EL6; X-ray; 2.40 A; A=500-777.
DR   PDB; 6EL7; X-ray; 2.18 A; A=500-777.
DR   PDB; 6EL9; X-ray; 2.19 A; A=500-777.
DR   PDB; 6X6D; X-ray; 2.48 A; A/B=417-490.
DR   PDB; 6X6E; X-ray; 2.00 A; A/B=417-491.
DR   PDB; 6YMO; X-ray; 2.02 A; C/D=611-623.
DR   PDB; 6YO8; X-ray; 2.09 A; E/F/G/H=518-530.
DR   PDB; 6YOS; X-ray; 2.75 A; C=518-530, C=611-623.
DR   PDBsum; 1M2Z; -.
DR   PDBsum; 1NHZ; -.
DR   PDBsum; 1P93; -.
DR   PDBsum; 3BQD; -.
DR   PDBsum; 3CLD; -.
DR   PDBsum; 3E7C; -.
DR   PDBsum; 3H52; -.
DR   PDBsum; 3K22; -.
DR   PDBsum; 3K23; -.
DR   PDBsum; 4CSJ; -.
DR   PDBsum; 4HN5; -.
DR   PDBsum; 4HN6; -.
DR   PDBsum; 4LSJ; -.
DR   PDBsum; 4MDD; -.
DR   PDBsum; 4P6W; -.
DR   PDBsum; 4P6X; -.
DR   PDBsum; 4UDC; -.
DR   PDBsum; 4UDD; -.
DR   PDBsum; 5CBX; -.
DR   PDBsum; 5CBY; -.
DR   PDBsum; 5CBZ; -.
DR   PDBsum; 5CC1; -.
DR   PDBsum; 5E69; -.
DR   PDBsum; 5E6A; -.
DR   PDBsum; 5E6B; -.
DR   PDBsum; 5E6C; -.
DR   PDBsum; 5E6D; -.
DR   PDBsum; 5EMC; -.
DR   PDBsum; 5EMP; -.
DR   PDBsum; 5EMQ; -.
DR   PDBsum; 5G3J; -.
DR   PDBsum; 5G5W; -.
DR   PDBsum; 5NFP; -.
DR   PDBsum; 5NFT; -.
DR   PDBsum; 5UC3; -.
DR   PDBsum; 5VA0; -.
DR   PDBsum; 5VA7; -.
DR   PDBsum; 6BQU; -.
DR   PDBsum; 6CFN; -.
DR   PDBsum; 6DXK; -.
DR   PDBsum; 6EL6; -.
DR   PDBsum; 6EL7; -.
DR   PDBsum; 6EL9; -.
DR   PDBsum; 6X6D; -.
DR   PDBsum; 6X6E; -.
DR   PDBsum; 6YMO; -.
DR   PDBsum; 6YO8; -.
DR   PDBsum; 6YOS; -.
DR   SMR; P04150; -.
DR   BioGRID; 109165; 1416.
DR   CORUM; P04150; -.
DR   DIP; DIP-576N; -.
DR   ELM; P04150; -.
DR   IntAct; P04150; 92.
DR   MINT; P04150; -.
DR   STRING; 9606.ENSP00000231509; -.
DR   BindingDB; P04150; -.
DR   ChEMBL; CHEMBL2034; -.
DR   DrugBank; DB00240; Alclometasone.
DR   DrugBank; DB04630; Aldosterone.
DR   DrugBank; DB00288; Amcinonide.
DR   DrugBank; DB00394; Beclomethasone dipropionate.
DR   DrugBank; DB00443; Betamethasone.
DR   DrugBank; DB14669; Betamethasone phosphate.
DR   DrugBank; DB01222; Budesonide.
DR   DrugBank; DB01410; Ciclesonide.
DR   DrugBank; DB01013; Clobetasol propionate.
DR   DrugBank; DB13158; Clobetasone.
DR   DrugBank; DB00838; Clocortolone.
DR   DrugBank; DB01380; Cortisone acetate.
DR   DrugBank; DB13003; Cortivazol.
DR   DrugBank; DB11921; Deflazacort.
DR   DrugBank; DB01260; Desonide.
DR   DrugBank; DB00547; Desoximetasone.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB14649; Dexamethasone acetate.
DR   DrugBank; DB00223; Diflorasone.
DR   DrugBank; DB09095; Difluocortolone.
DR   DrugBank; DB06781; Difluprednate.
DR   DrugBank; DB01395; Drospirenone.
DR   DrugBank; DB00687; Fludrocortisone.
DR   DrugBank; DB00663; Flumethasone.
DR   DrugBank; DB00180; Flunisolide.
DR   DrugBank; DB00591; Fluocinolone acetonide.
DR   DrugBank; DB01047; Fluocinonide.
DR   DrugBank; DB00324; Fluorometholone.
DR   DrugBank; DB01185; Fluoxymesterone.
DR   DrugBank; DB00846; Flurandrenolide.
DR   DrugBank; DB13867; Fluticasone.
DR   DrugBank; DB08906; Fluticasone furoate.
DR   DrugBank; DB00588; Fluticasone propionate.
DR   DrugBank; DB11619; Gestrinone.
DR   DrugBank; DB02210; Hexane-1,6-Diol.
DR   DrugBank; DB00769; Hydrocortamate.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB14538; Hydrocortisone aceponate.
DR   DrugBank; DB14539; Hydrocortisone acetate.
DR   DrugBank; DB14540; Hydrocortisone butyrate.
DR   DrugBank; DB14541; Hydrocortisone cypionate.
DR   DrugBank; DB14542; Hydrocortisone phosphate.
DR   DrugBank; DB14543; Hydrocortisone probutate.
DR   DrugBank; DB14544; Hydrocortisone valerate.
DR   DrugBank; DB00367; Levonorgestrel.
DR   DrugBank; DB14596; Loteprednol etabonate.
DR   DrugBank; DB00253; Medrysone.
DR   DrugBank; DB00351; Megestrol acetate.
DR   DrugBank; DB00959; Methylprednisolone.
DR   DrugBank; DB00834; Mifepristone.
DR   DrugBank; DB00764; Mometasone.
DR   DrugBank; DB14512; Mometasone furoate.
DR   DrugBank; DB00717; Norethisterone.
DR   DrugBank; DB12637; Onapristone.
DR   DrugBank; DB05423; ORG-34517.
DR   DrugBank; DB01384; Paramethasone.
DR   DrugBank; DB01130; Prednicarbate.
DR   DrugBank; DB00860; Prednisolone.
DR   DrugBank; DB15566; Prednisolone acetate.
DR   DrugBank; DB14631; Prednisolone phosphate.
DR   DrugBank; DB00635; Prednisone.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00896; Rimexolone.
DR   DrugBank; DB14583; Segesterone acetate.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB09091; Tixocortol.
DR   DrugBank; DB00620; Triamcinolone.
DR   DrugBank; DB08867; Ulipristal.
DR   DrugBank; DB00596; Ulobetasol.
DR   DrugCentral; P04150; -.
DR   GuidetoPHARMACOLOGY; 625; -.
DR   GlyGen; P04150; 6 sites, 2 O-linked glycans (6 sites).
DR   iPTMnet; P04150; -.
DR   PhosphoSitePlus; P04150; -.
DR   BioMuta; NR3C1; -.
DR   DMDM; 121069; -.
DR   EPD; P04150; -.
DR   jPOST; P04150; -.
DR   MassIVE; P04150; -.
DR   MaxQB; P04150; -.
DR   PaxDb; P04150; -.
DR   PeptideAtlas; P04150; -.
DR   PRIDE; P04150; -.
DR   ProteomicsDB; 51657; -. [P04150-1]
DR   ProteomicsDB; 51658; -. [P04150-10]
DR   ProteomicsDB; 51659; -. [P04150-2]
DR   ProteomicsDB; 51660; -. [P04150-3]
DR   ProteomicsDB; 51661; -. [P04150-5]
DR   ProteomicsDB; 51662; -. [P04150-6]
DR   ProteomicsDB; 51663; -. [P04150-7]
DR   ProteomicsDB; 51664; -. [P04150-8]
DR   ProteomicsDB; 51665; -. [P04150-9]
DR   Antibodypedia; 1329; 1310 antibodies from 43 providers.
DR   DNASU; 2908; -.
DR   Ensembl; ENST00000231509; ENSP00000231509; ENSG00000113580. [P04150-3]
DR   Ensembl; ENST00000343796; ENSP00000343205; ENSG00000113580.
DR   Ensembl; ENST00000394464; ENSP00000377977; ENSG00000113580.
DR   Ensembl; ENST00000394466; ENSP00000377979; ENSG00000113580. [P04150-3]
DR   Ensembl; ENST00000415690; ENSP00000387672; ENSG00000113580. [P04150-2]
DR   Ensembl; ENST00000424646; ENSP00000405282; ENSG00000113580. [P04150-10]
DR   Ensembl; ENST00000503201; ENSP00000427672; ENSG00000113580.
DR   Ensembl; ENST00000504572; ENSP00000422518; ENSG00000113580. [P04150-3]
DR   GeneID; 2908; -.
DR   KEGG; hsa:2908; -.
DR   MANE-Select; ENST00000394464.7; ENSP00000377977.2; NM_000176.3; NP_000167.1.
DR   UCSC; uc003lmy.4; human. [P04150-1]
DR   CTD; 2908; -.
DR   DisGeNET; 2908; -.
DR   GeneCards; NR3C1; -.
DR   HGNC; HGNC:7978; NR3C1.
DR   HPA; ENSG00000113580; Low tissue specificity.
DR   MalaCards; NR3C1; -.
DR   MIM; 138040; gene.
DR   MIM; 615962; phenotype.
DR   neXtProt; NX_P04150; -.
DR   OpenTargets; ENSG00000113580; -.
DR   Orphanet; 786; Generalized glucocorticoid resistance syndrome.
DR   PharmGKB; PA181; -.
DR   VEuPathDB; HostDB:ENSG00000113580; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   GeneTree; ENSGT00940000156385; -.
DR   HOGENOM; CLU_020317_0_0_1; -.
DR   InParanoid; P04150; -.
DR   OMA; PKCMPQL; -.
DR   PhylomeDB; P04150; -.
DR   TreeFam; TF106510; -.
DR   PathwayCommons; P04150; -.
DR   Reactome; R-HSA-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-8849473; PTK6 Expression.
DR   Reactome; R-HSA-8939902; Regulation of RUNX2 expression and activity.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; P04150; -.
DR   SIGNOR; P04150; -.
DR   BioGRID-ORCS; 2908; 9 hits in 1071 CRISPR screens.
DR   ChiTaRS; NR3C1; human.
DR   EvolutionaryTrace; P04150; -.
DR   GeneWiki; Glucocorticoid_receptor; -.
DR   GenomeRNAi; 2908; -.
DR   Pharos; P04150; Tclin.
DR   PRO; PR:P04150; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P04150; protein.
DR   Bgee; ENSG00000113580; Expressed in endothelial cell and 261 other tissues.
DR   ExpressionAtlas; P04150; baseline and differential.
DR   Genevisible; P04150; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:ProtInc.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IEA:UniProtKB-SubCell.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0004883; F:glucocorticoid receptor activity; TAS:ProtInc.
DR   GO; GO:0051879; F:Hsp90 protein binding; IPI:UniProtKB.
DR   GO; GO:0004879; F:nuclear receptor activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0005496; F:steroid binding; IDA:UniProtKB.
DR   GO; GO:1990239; F:steroid hormone binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IMP:CAFA.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IDA:UniProtKB.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:CAFA.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0007059; P:chromosome segregation; IEA:UniProtKB-KW.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   DisProt; DP00030; -.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   IDEAL; IID00014; -.
DR   InterPro; IPR001409; Glcrtcd_rcpt.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF02155; GCR; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00528; GLCORTICOIDR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Alternative splicing;
KW   Apoptosis; Cell cycle; Cell division; Chromatin regulator;
KW   Chromosome partition; Cytoplasm; Cytoskeleton; Disease variant;
KW   DNA-binding; Isopeptide bond; Lipid-binding; Metal-binding; Methylation;
KW   Mitochondrion; Mitosis; Nucleus; Phosphoprotein; Pseudohermaphroditism;
KW   Receptor; Reference proteome; RNA-binding; Steroid-binding; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..777
FT                   /note="Glucocorticoid receptor"
FT                   /id="PRO_0000019937"
FT   DOMAIN          524..758
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        418..493
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         421..441
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         457..476
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..420
FT                   /note="Modulating"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          98..115
FT                   /note="Required for high transcriptional activity of
FT                   isoform Alpha-C3"
FT                   /evidence="ECO:0000269|PubMed:23820903"
FT   REGION          130..183
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          394..415
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          485..777
FT                   /note="Interaction with CLOCK"
FT   REGION          487..523
FT                   /note="Hinge"
FT   REGION          532..697
FT                   /note="Interaction with CRY1"
FT                   /evidence="ECO:0000269|PubMed:22170608"
FT   COMPBIAS        130..149
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        166..183
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         8
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         23
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         45
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         113
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         141
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   MOD_RES         203
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12000743,
FT                   ECO:0000269|PubMed:18483179, ECO:0000269|PubMed:25847991,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         211
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12000743,
FT                   ECO:0000269|PubMed:18483179, ECO:0000269|PubMed:25847991"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18483179,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         267
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         404
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000269|PubMed:18838540"
FT   MOD_RES         480
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MOD_RES         492
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MOD_RES         494
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MOD_RES         495
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   CROSSLNK        258
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        277
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:12144530"
FT   CROSSLNK        277
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        293
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:12144530"
FT   CROSSLNK        293
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        419
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P06537"
FT   CROSSLNK        703
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:12144530"
FT   VAR_SEQ         1..335
FT                   /note="Missing (in isoform Alpha-D3)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058312"
FT   VAR_SEQ         1..330
FT                   /note="Missing (in isoform Alpha-D2)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058313"
FT   VAR_SEQ         1..315
FT                   /note="Missing (in isoform Alpha-D1)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058314"
FT   VAR_SEQ         1..97
FT                   /note="Missing (in isoform Alpha-C3)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058315"
FT   VAR_SEQ         1..89
FT                   /note="Missing (in isoform Alpha-C2)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058316"
FT   VAR_SEQ         1..85
FT                   /note="Missing (in isoform Alpha-C1)"
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT                   /id="VSP_058317"
FT   VAR_SEQ         1..26
FT                   /note="Missing (in isoform Alpha-B and isoform Beta-B)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_018773"
FT   VAR_SEQ         313..338
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:17404046"
FT                   /id="VSP_043908"
FT   VAR_SEQ         451
FT                   /note="G -> GR (in isoform Alpha-2 and isoform Beta-2)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_007363"
FT   VAR_SEQ         491..674
FT                   /note="Missing (in isoform GR-A alpha and isoform GR-A
FT                   beta)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_013340"
FT   VAR_SEQ         728..777
FT                   /note="VVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK
FT                   -> NVMWLKPESTSHTLI (in isoform Beta, isoform Beta-B,
FT                   isoform Beta-2 and isoform GR-A beta)"
FT                   /evidence="ECO:0000303|PubMed:2867473"
FT                   /id="VSP_003703"
FT   VARIANT         23
FT                   /note="R -> K (reduces transactivation activity; does not
FT                   affect transrepression activity; dbSNP:rs6190)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10898924, ECO:0000269|PubMed:12351458,
FT                   ECO:0000269|PubMed:15276593, ECO:0000269|PubMed:15292341,
FT                   ECO:0000269|PubMed:16030164, ECO:0000269|PubMed:9150737,
FT                   ECO:0000269|Ref.9"
FT                   /id="VAR_014140"
FT   VARIANT         29
FT                   /note="F -> L (in dbSNP:rs148102613)"
FT                   /evidence="ECO:0000269|PubMed:10898924"
FT                   /id="VAR_015628"
FT   VARIANT         65
FT                   /note="F -> V (in dbSNP:rs6192)"
FT                   /evidence="ECO:0000269|PubMed:10391209, ECO:0000269|Ref.9"
FT                   /id="VAR_014622"
FT   VARIANT         72
FT                   /note="N -> D (variant of uncertain significance;
FT                   associated in cis with A-321 and S-766 in one individual;
FT                   doubles transactivation potential)"
FT                   /evidence="ECO:0000269|PubMed:21701417"
FT                   /id="VAR_075797"
FT   VARIANT         112
FT                   /note="L -> F (in dbSNP:rs542110718)"
FT                   /evidence="ECO:0000269|PubMed:10898924"
FT                   /id="VAR_015629"
FT   VARIANT         233
FT                   /note="D -> N (in dbSNP:rs1241576112)"
FT                   /evidence="ECO:0000269|PubMed:10898924"
FT                   /id="VAR_015630"
FT   VARIANT         321
FT                   /note="V -> A (variant of uncertain significance;
FT                   associated in cis with D-72 and S-766 in one individual;
FT                   doubles transactivation potential)"
FT                   /evidence="ECO:0000269|PubMed:21701417"
FT                   /id="VAR_075798"
FT   VARIANT         363
FT                   /note="N -> S (enhances transactivation activity; does not
FT                   affect transrepression activity; may increase sensitivity
FT                   to exogenously administered glucocorticoids; may contribute
FT                   to central obesity in men and show lack of association with
FT                   other risk factors for coronary heart disease and diabetes
FT                   mellitus; dbSNP:rs56149945)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10898924, ECO:0000269|PubMed:11344238,
FT                   ECO:0000269|PubMed:16030164, ECO:0000269|PubMed:8445027,
FT                   ECO:0000269|PubMed:9150737"
FT                   /id="VAR_004675"
FT   VARIANT         421
FT                   /note="C -> Y"
FT                   /evidence="ECO:0000269|PubMed:8358735"
FT                   /id="VAR_015631"
FT   VARIANT         423
FT                   /note="V -> A (in GCCR; unknown pathological significance;
FT                   reduces transactivation activity; delays nuclear
FT                   translocation; does not exert a dominant negative effect;
FT                   impairs DNA binding)"
FT                   /evidence="ECO:0000269|PubMed:23426617"
FT                   /id="VAR_075799"
FT   VARIANT         477
FT                   /note="R -> H (in GCCR; dbSNP:rs104893913)"
FT                   /evidence="ECO:0000269|PubMed:11589680"
FT                   /id="VAR_013472"
FT   VARIANT         477
FT                   /note="R -> S (in GCCR; loss of DNA-binding and of
FT                   transactivation activity; incomplete dexamethasone-induced
FT                   translocation to the nucleus; no effect on dexamethasone-
FT                   binding affinity compared with wild-type)"
FT                   /evidence="ECO:0000269|PubMed:27120390"
FT                   /id="VAR_077143"
FT   VARIANT         478
FT                   /note="Y -> C (in GCCR; decreased DNA-binding and
FT                   transactivation activity; incomplete dexamethasone-induced
FT                   translocation to the nucleus; no effect on dexamethasone-
FT                   binding affinity compared with wild-type)"
FT                   /evidence="ECO:0000269|PubMed:27120390"
FT                   /id="VAR_077144"
FT   VARIANT         556
FT                   /note="T -> I (in GCCR; reduces transactivation activity;
FT                   enhances transrepression activity; reduces affinity for
FT                   ligand; delays nuclear translocation; does not exert a
FT                   dominant negative effect; does not impair DNA binding)"
FT                   /evidence="ECO:0000269|PubMed:21362280,
FT                   ECO:0000269|PubMed:26541474"
FT                   /id="VAR_075800"
FT   VARIANT         559
FT                   /note="I -> N (in GCCR; interferes with translocation to
FT                   the nucleus and thereby strongly reduces transcription
FT                   activation; is equally impaired in nuclear export; acts as
FT                   dominant negative mutant; dbSNP:rs104893909)"
FT                   /evidence="ECO:0000269|PubMed:11701741"
FT                   /id="VAR_015632"
FT   VARIANT         571
FT                   /note="V -> A (in pseudohermaphroditism; female with
FT                   hypokalemia due to glucocorticoid resistance; 6-fold
FT                   reduction in binding affinity compared with the wild-type
FT                   receptor; dbSNP:rs104893911)"
FT                   /evidence="ECO:0000269|PubMed:11932321"
FT                   /id="VAR_025014"
FT   VARIANT         575
FT                   /note="V -> G (in GCCR; unknown pathological significance;
FT                   reduces transactivation activity; enhances transrepression
FT                   activity; reduces affinity for ligand; delays nuclear
FT                   translocation; does not exert a dominant negative effect;
FT                   does not impair DNA binding)"
FT                   /evidence="ECO:0000269|PubMed:24483153"
FT                   /id="VAR_075801"
FT   VARIANT         641
FT                   /note="D -> V (in GCCR; dbSNP:rs104893908)"
FT                   /evidence="ECO:0000269|PubMed:1704018"
FT                   /id="VAR_004676"
FT   VARIANT         672
FT                   /note="L -> P (in GCCR; loss of dexamethasone-binding,
FT                   dexamethasone-induced translocation to the nucleus and of
FT                   transactivation activity)"
FT                   /evidence="ECO:0000269|PubMed:27120390"
FT                   /id="VAR_077145"
FT   VARIANT         679
FT                   /note="G -> S (in GCCR; has 50% binding affinity;
FT                   dbSNP:rs104893914)"
FT                   /evidence="ECO:0000269|PubMed:11589680"
FT                   /id="VAR_013473"
FT   VARIANT         714
FT                   /note="R -> Q (in GCCR; unknown pathological significance;
FT                   reduces transactivation; reduces affinity for ligand;
FT                   exerts a dominant negative effect; does not impair DNA
FT                   binding)"
FT                   /evidence="ECO:0000269|PubMed:20335448"
FT                   /id="VAR_075802"
FT   VARIANT         726
FT                   /note="H -> R (in GCCR; unknown pathological significance;
FT                   reduces transactivation and transrepression activity;
FT                   reduces affinity for ligand; delays nuclear translocation;
FT                   does not impair DNA binding)"
FT                   /evidence="ECO:0000269|PubMed:26031419"
FT                   /id="VAR_075803"
FT   VARIANT         729
FT                   /note="V -> I (in GCCR; dbSNP:rs1027058734)"
FT                   /evidence="ECO:0000269|PubMed:7683692"
FT                   /id="VAR_004677"
FT   VARIANT         737
FT                   /note="F -> L (in GCCR; reduces transactivation of the
FT                   glucocorticoid-inducible tumor virus promoter; reduces
FT                   affinity for ligand; delays its nuclear translocation; acts
FT                   as dominant negative mutant; dbSNP:rs121909727)"
FT                   /evidence="ECO:0000269|PubMed:17635946"
FT                   /id="VAR_071935"
FT   VARIANT         747
FT                   /note="I -> M (in GCCR; alters interaction with NCOA2 and
FT                   strongly reduces transcription activation; acts as dominant
FT                   negative mutant; dbSNP:rs104893910)"
FT                   /evidence="ECO:0000269|PubMed:12050230"
FT                   /id="VAR_015633"
FT   VARIANT         753
FT                   /note="L -> F (in dbSNP:rs121909726)"
FT                   /evidence="ECO:0000269|PubMed:8316249,
FT                   ECO:0000269|PubMed:8358735"
FT                   /id="VAR_004678"
FT   VARIANT         766
FT                   /note="N -> S (variant of uncertain significance;
FT                   associated in cis with D-72 and A-321 in one individual;
FT                   doubles transactivation potential)"
FT                   /evidence="ECO:0000269|PubMed:21701417"
FT                   /id="VAR_075804"
FT   VARIANT         773
FT                   /note="L -> P (in GCCR; reduces transactivation of the
FT                   glucocorticoid-inducible tumor virus promoter; reduces
FT                   affinity for ligand; delays its nuclear translocation; acts
FT                   as dominant negative mutant; dbSNP:rs104893912)"
FT                   /evidence="ECO:0000269|PubMed:15769988"
FT                   /id="VAR_071936"
FT   MUTAGEN         1
FT                   /note="M->T: Abolishes expression of A-type isoforms."
FT                   /evidence="ECO:0000269|PubMed:11435610,
FT                   ECO:0000269|PubMed:15866175"
FT   MUTAGEN         27
FT                   /note="M->T: Abolishes expression of B-type isoforms."
FT                   /evidence="ECO:0000269|PubMed:11435610,
FT                   ECO:0000269|PubMed:15866175"
FT   MUTAGEN         86
FT                   /note="M->I: Abolishes expression of C-type isoforms; when
FT                   associated with I-90 and I-98."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         90
FT                   /note="M->I: Abolishes expression of C-type isoforms; when
FT                   associated with I-86 and I-98."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         98
FT                   /note="M->I: Abolishes expression of C-type isoforms; when
FT                   associated with I-86 and I-90."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         101
FT                   /note="D->A: Reduces transcription activation activity of
FT                   isoform Alpha-C3 by half."
FT                   /evidence="ECO:0000269|PubMed:23820903"
FT   MUTAGEN         101
FT                   /note="D->K: Reduces transcription activation activity of
FT                   isoform Alpha-C3 by half. Suppresses apoptosis-inducing
FT                   activity of isoform Alpha-C3. Impairs recruitment of
FT                   selected coregulators onto DNA binding sites."
FT                   /evidence="ECO:0000269|PubMed:23820903"
FT   MUTAGEN         106..107
FT                   /note="QQ->LL: Reduces activity of isoform Alpha-C3 by
FT                   half."
FT                   /evidence="ECO:0000269|PubMed:23820903"
FT   MUTAGEN         113..114
FT                   /note="SS->AA: Does not affect the activity of isoform
FT                   Alpha-C3."
FT                   /evidence="ECO:0000269|PubMed:23820903"
FT   MUTAGEN         191
FT                   /note="F->D: Reduces transactivation by the ADA complex."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         193
FT                   /note="I->D: Reduces transactivation by the ADA complex."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         194
FT                   /note="L->A: Strongly reduces transactivation by the ADA
FT                   complex; when associated with V-224 and F-225."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         197
FT                   /note="L->E: Reduces transactivation by the ADA complex."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         211
FT                   /note="S->A: Reduces expression of target genes IGFBP1 and
FT                   IRF8."
FT                   /evidence="ECO:0000269|PubMed:18483179"
FT   MUTAGEN         213
FT                   /note="W->A: Strongly reduces transactivation by the ADA
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         224
FT                   /note="L->V: Strongly reduces transactivation by the ADA
FT                   complex; when associated with A-194 and F-225."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         225
FT                   /note="L->F: Strongly reduces transactivation by the ADA
FT                   complex; when associated with A-194 and V-224."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         226
FT                   /note="S->A: Abolishes phosphorylation and enhances
FT                   transcriptional activation."
FT                   /evidence="ECO:0000269|PubMed:18483179"
FT   MUTAGEN         235
FT                   /note="F->L: Strongly reduces transactivation by the ADA
FT                   complex; when associated with V-236."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         236
FT                   /note="L->V: Strongly reduces transactivation by the ADA
FT                   complex; when associated with L-235."
FT                   /evidence="ECO:0000269|PubMed:9154805"
FT   MUTAGEN         277
FT                   /note="K->R: Strongly reduces sumoylation. Almost complete
FT                   loss of sumoylation; when associated with R-293."
FT                   /evidence="ECO:0000269|PubMed:12144530"
FT   MUTAGEN         293
FT                   /note="K->R: Strongly reduces sumoylation. Almost complete
FT                   loss of sumoylation; when associated with R-277."
FT                   /evidence="ECO:0000269|PubMed:12144530"
FT   MUTAGEN         316
FT                   /note="M->I: Abolishes expression of D-type isoforms; when
FT                   associated with I-331 and I-336."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         331
FT                   /note="M->I: Abolishes expression of D-type isoforms; when
FT                   associated with I-316 and I-336."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         336
FT                   /note="M->I: Abolishes expression of D-type isoforms; when
FT                   associated with I-316 and I-331."
FT                   /evidence="ECO:0000269|PubMed:15866175"
FT   MUTAGEN         404
FT                   /note="S->A: Abolishes phosphorylation. Does not affect
FT                   translocation to the nucleus following ligand stimulation.
FT                   Increases protein half-life and transcriptional repressor
FT                   activity. Alters repertoire of regulated genes. Increases
FT                   cell death."
FT                   /evidence="ECO:0000269|PubMed:18838540"
FT   MUTAGEN         404
FT                   /note="S->D: Does not affect translocation to the nucleus
FT                   following ligand stimulation."
FT                   /evidence="ECO:0000269|PubMed:18838540"
FT   MUTAGEN         480
FT                   /note="K->A: Decrease in acetylation and in repression of
FT                   its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer. Complete loss in acetylation and in repression
FT                   of its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer; when associated with A-492; A-494 and A-495."
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MUTAGEN         492
FT                   /note="K->A: Decrease in acetylation and in repression of
FT                   its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer. Complete loss in acetylation and in repression
FT                   of its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer; when associated with A-480; A-494 and A-495."
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MUTAGEN         494
FT                   /note="K->A: Decrease in acetylation and in repression of
FT                   its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer; when associated with A-495. Complete loss in
FT                   acetylation and in repression of its transcriptional
FT                   activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated
FT                   with A-480; A-492 and A-495."
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MUTAGEN         495
FT                   /note="K->A: Decrease in acetylation and in repression of
FT                   its transcriptional activity by CLOCK-ARNTL/BMAL1
FT                   heterodimer; when associated with A-494. Complete loss in
FT                   acetylation and in repression of its transcriptional
FT                   activity by CLOCK-ARNTL/BMAL1 heterodimer; when associated
FT                   with A-480; A-492 and A-494."
FT                   /evidence="ECO:0000269|PubMed:19141540"
FT   MUTAGEN         585
FT                   /note="R->A: Reduces activation mediated by ligand binding
FT                   domain; when associated with A-590."
FT                   /evidence="ECO:0000269|PubMed:12151000"
FT   MUTAGEN         590
FT                   /note="D->A: Reduces activation mediated by ligand binding
FT                   domain; when associated with A-585."
FT                   /evidence="ECO:0000269|PubMed:12151000"
FT   MUTAGEN         602
FT                   /note="F->S: Increases solubility. No effect on
FT                   transactivation by dexamethasone."
FT                   /evidence="ECO:0000269|PubMed:12151000"
FT   MUTAGEN         625
FT                   /note="P->A: Decreases transactivation by dexamethasone by
FT                   95%."
FT                   /evidence="ECO:0000269|PubMed:12151000"
FT   MUTAGEN         628
FT                   /note="I->A: Decreases dimerization and transactivation by
FT                   dexamethasone; when associated with S-602."
FT                   /evidence="ECO:0000269|PubMed:12151000"
FT   MUTAGEN         703
FT                   /note="K->R: Slightly reduces sumoylation. Inhibits the
FT                   stimulatory effect of RWDD3 on its transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12144530,
FT                   ECO:0000269|PubMed:23508108"
FT   CONFLICT        399
FT                   /note="R -> G (in Ref. 7; BAD97314)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        754
FT                   /note="A -> T (in Ref. 7; BAD97314)"
FT                   /evidence="ECO:0000305"
FT   TURN            422..424
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   STRAND          430..432
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   STRAND          435..437
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   HELIX           439..450
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   STRAND          458..461
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   TURN            467..472
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   HELIX           474..484
FT                   /evidence="ECO:0007829|PDB:5E69"
FT   HELIX           488..497
FT                   /evidence="ECO:0007829|PDB:6CFN"
FT   TURN            525..527
FT                   /evidence="ECO:0007829|PDB:1M2Z"
FT   HELIX           532..538
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   STRAND          550..552
FT                   /evidence="ECO:0007829|PDB:3K22"
FT   HELIX           556..579
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           589..615
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   STRAND          617..619
FT                   /evidence="ECO:0007829|PDB:4P6W"
FT   STRAND          621..624
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   STRAND          627..629
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           631..634
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           639..655
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           660..671
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   STRAND          673..675
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           683..702
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   STRAND          704..706
FT                   /evidence="ECO:0007829|PDB:4P6W"
FT   HELIX           708..741
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           743..745
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           751..765
FT                   /evidence="ECO:0007829|PDB:4UDD"
FT   HELIX           766..768
FT                   /evidence="ECO:0007829|PDB:6DXK"
FT   STRAND          769..771
FT                   /evidence="ECO:0007829|PDB:5UC3"
FT   MOD_RES         P04150-8:1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         P04150-9:1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
SQ   SEQUENCE   777 AA;  85659 MW;  C5C90C9A5DD16AAB CRC64;
     MDSKESLTPG REENPSSVLA QERGDVMDFY KTLRGGATVK VSASSPSLAV ASQSDSKQRR
     LLVDFPKGSV SNAQQPDLSK AVSLSMGLYM GETETKVMGN DLGFPQQGQI SLSSGETDLK
     LLEESIANLN RSTSVPENPK SSASTAVSAA PTEKEFPKTH SDVSSEQQHL KGQTGTNGGN
     VKLYTTDQST FDILQDLEFS SGSPGKETNE SPWRSDLLID ENCLLSPLAG EDDSFLLEGN
     SNEDCKPLIL PDTKPKIKDN GDLVLSSPSN VTLPQVKTEK EDFIELCTPG VIKQEKLGTV
     YCQASFPGAN IIGNKMSAIS VHGVSTSGGQ MYHYDMNTAS LSQQQDQKPI FNVIPPIPVG
     SENWNRCQGS GDDNLTSLGT LNFPGRTVFS NGYSSPSMRP DVSSPPSSSS TATTGPPPKL
     CLVCSDEASG CHYGVLTCGS CKVFFKRAVE GQHNYLCAGR NDCIIDKIRR KNCPACRYRK
     CLQAGMNLEA RKTKKKIKGI QQATTGVSQE TSENPGNKTI VPATLPQLTP TLVSLLEVIE
     PEVLYAGYDS SVPDSTWRIM TTLNMLGGRQ VIAAVKWAKA IPGFRNLHLD DQMTLLQYSW
     MFLMAFALGW RSYRQSSANL LCFAPDLIIN EQRMTLPCMY DQCKHMLYVS SELHRLQVSY
     EEYLCMKTLL LLSSVPKDGL KSQELFDEIR MTYIKELGKA IVKREGNSSQ NWQRFYQLTK
     LLDSMHEVVE NLLNYCFQTF LDKTMSIEFP EMLAEIITNQ IPKYSNGNIK KLLFHQK
//
ID   XIAP_HUMAN              Reviewed;         497 AA.
AC   P98170; D3DTF2; Q9NQ14;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   23-FEB-2022, entry version 228.
DE   RecName: Full=E3 ubiquitin-protein ligase XIAP;
DE            EC=2.3.2.27;
DE   AltName: Full=Baculoviral IAP repeat-containing protein 4;
DE   AltName: Full=IAP-like protein;
DE            Short=ILP;
DE            Short=hILP;
DE   AltName: Full=Inhibitor of apoptosis protein 3;
DE            Short=IAP-3;
DE            Short=hIAP-3;
DE            Short=hIAP3;
DE   AltName: Full=RING-type E3 ubiquitin transferase XIAP;
DE   AltName: Full=X-linked inhibitor of apoptosis protein;
DE            Short=X-linked IAP;
GN   Name=XIAP; Synonyms=API3, BIRC4, IAP3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT PRO-423.
RC   TISSUE=Fetal heart;
RX   PubMed=8654366; DOI=10.1002/j.1460-2075.1996.tb00629.x;
RA   Duckett C.S., Nava V.E., Gedrich R.W., Clem R.J., van Dongen J.L.,
RA   Gilfillan M.C., Shiels H., Hardwick J.M., Thompson C.B.;
RT   "A conserved family of cellular genes related to the baculovirus iap gene
RT   and encoding apoptosis inhibitors.";
RL   EMBO J. 15:2685-2694(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=8552191; DOI=10.1038/379349a0;
RA   Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G.,
RA   Farahani R., McLean M., Ikeda J., Mackenzie A., Korneluk R.G.;
RT   "Suppression of apoptosis in mammalian cells by NAIP and a related family
RT   of IAP genes.";
RL   Nature 379:349-353(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-107; PHE-133; GLU-242
RP   AND PRO-423.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=9230442; DOI=10.1038/40901;
RA   Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C.;
RT   "X-linked IAP is a direct inhibitor of cell-death proteases.";
RL   Nature 388:300-304(1997).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF CYS-450.
RX   PubMed=11447297; DOI=10.1073/pnas.161506698;
RA   Suzuki Y., Nakabayashi Y., Takahashi R.;
RT   "Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis
RT   protein promotes proteasomal degradation of caspase-3 and enhances its
RT   anti-apoptotic effect in Fas-induced cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8662-8667(2001).
RN   [9]
RP   MUTAGENESIS OF ASP-148; ASP-214; ASN-259; TRP-310 AND GLU-314.
RX   PubMed=11604410; DOI=10.1074/jbc.m109891200;
RA   Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H.,
RA   Connolly L.M., Day C.L., Tikoo A., Burke R., Wrobel C., Moritz R.L.,
RA   Simpson R.J., Vaux D.L.;
RT   "HtrA2 promotes cell death through its serine protease activity and its
RT   ability to antagonize inhibitor of apoptosis proteins.";
RL   J. Biol. Chem. 277:445-454(2002).
RN   [10]
RP   FUNCTION.
RX   PubMed=12121969; DOI=10.1074/jbc.m200317200;
RA   MacFarlane M., Merrison W., Bratton S.B., Cohen G.M.;
RT   "Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes
RT   Smac ubiquitination in vitro.";
RL   J. Biol. Chem. 277:36611-36616(2002).
RN   [11]
RP   AUTOUBIQUITINATION AT LYS-322 AND LYS-328.
RX   PubMed=12747801; DOI=10.1042/bj20030583;
RA   Shin H., Okada K., Wilkinson J.C., Solomon K.M., Duckett C.S., Reed J.C.,
RA   Salvesen G.S.;
RT   "Identification of ubiquitination sites on the X-linked inhibitor of
RT   apoptosis protein.";
RL   Biochem. J. 373:965-971(2003).
RN   [12]
RP   INTERACTION WITH COMMD1, AND FUNCTION.
RX   PubMed=14685266; DOI=10.1038/sj.emboj.7600031;
RA   Burstein E., Ganesh L., Dick R.D., van De Sluis B., Wilkinson J.C.,
RA   Klomp L.W., Wijmenga C., Brewer G.J., Nabel G.J., Duckett C.S.;
RT   "A novel role for XIAP in copper homeostasis through regulation of MURR1.";
RL   EMBO J. 23:244-254(2004).
RN   [13]
RP   INTERACTION WITH SEPTIN4.
RX   PubMed=15029247; DOI=10.1038/sj.emboj.7600155;
RA   Gottfried Y., Rotem A., Lotan R., Steller H., Larisch S.;
RT   "The mitochondrial ARTS protein promotes apoptosis through targeting
RT   XIAP.";
RL   EMBO J. 23:1627-1635(2004).
RN   [14]
RP   RETRACTED PAPER.
RX   PubMed=14645242; DOI=10.1074/jbc.m312044200;
RA   Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.-G.,
RA   Tsang B.K., Cheng J.Q.;
RT   "Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis
RT   protein (XIAP).";
RL   J. Biol. Chem. 279:5405-5412(2004).
RN   [15]
RP   RETRACTION NOTICE OF PUBMED:14645242.
RX   PubMed=27825084; DOI=10.1074/jbc.a116.312044;
RA   Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G.,
RA   Tsang B.K., Cheng J.Q.;
RL   J. Biol. Chem. 291:22846-22846(2016).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15665297;
RA   Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.;
RT   "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle.";
RL   Cancer Res. 65:210-218(2005).
RN   [17]
RP   INVOLVEMENT IN XLP2.
RX   PubMed=17080092; DOI=10.1038/nature05257;
RA   Rigaud S., Fondaneche M.-C., Lambert N., Pasquier B., Mateo V., Soulas P.,
RA   Galicier L., Le Deist F., Rieux-Laucat F., Revy P., Fischer A.,
RA   de Saint Basile G., Latour S.;
RT   "XIAP deficiency in humans causes an X-linked lymphoproliferative
RT   syndrome.";
RL   Nature 444:110-114(2006).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=17382285; DOI=10.1016/j.abb.2007.01.033;
RA   Mufti A.R., Burstein E., Duckett C.S.;
RT   "XIAP: cell death regulation meets copper homeostasis.";
RL   Arch. Biochem. Biophys. 463:168-174(2007).
RN   [19]
RP   INTERACTION WITH TCF25.
RX   PubMed=18068114; DOI=10.1016/j.bbrc.2007.11.146;
RA   Steen H., Lindholm D.;
RT   "Nuclear localized protein-1 (Nulp1) increases cell death of human
RT   osteosarcoma cells and binds the X-linked inhibitor of apoptosis protein.";
RL   Biochem. Biophys. Res. Commun. 366:432-437(2008).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=18414036; DOI=10.4161/cc.7.8.5783;
RA   Dubrez-Daloz L., Dupoux A., Cartier J.;
RT   "IAPs: more than just inhibitors of apoptosis proteins.";
RL   Cell Cycle 7:1036-1046(2008).
RN   [21]
RP   INTERACTION WITH PDCL3.
RX   PubMed=19012568; DOI=10.1111/j.1747-0285.2008.00719.x;
RA   Bisson W.H., Zhang Z., Welsh K., Huang J.W., Ryan J., Reed J.C.,
RA   Pellecchia M.;
RT   "Binding properties of the C-terminal domain of VIAF.";
RL   Chem. Biol. Drug Des. 72:331-336(2008).
RN   [22]
RP   FUNCTION, MUTAGENESIS OF HIS-467, AND INTERACTION WITH AIFM1.
RX   PubMed=17967870; DOI=10.1128/mcb.01065-07;
RA   Wilkinson J.C., Wilkinson A.S., Galban S., Csomos R.A., Duckett C.S.;
RT   "Apoptosis-inducing factor is a target for ubiquitination through
RT   interaction with XIAP.";
RL   Mol. Cell. Biol. 28:237-247(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   FUNCTION IN THE UBIQUITINATION OF PTEN, AND INTERACTION WITH PTEN.
RX   PubMed=19473982; DOI=10.1074/jbc.c109.009522;
RA   Van Themsche C., Leblanc V., Parent S., Asselin E.;
RT   "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN
RT   ubiquitination, content, and compartmentalization.";
RL   J. Biol. Chem. 284:20462-20466(2009).
RN   [25]
RP   INTERACTION WITH HAX1.
RX   PubMed=20171186; DOI=10.1016/j.bbrc.2010.02.084;
RA   Kang Y.J., Jang M., Park Y.K., Kang S., Bae K.H., Cho S., Lee C.K.,
RA   Park B.C., Chi S.W., Park S.G.;
RT   "Molecular interaction between HAX-1 and XIAP inhibits apoptosis.";
RL   Biochem. Biophys. Res. Commun. 393:794-799(2010).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=20888210; DOI=10.1016/j.ceb.2010.08.025;
RA   Lopez J., Meier P.;
RT   "To fight or die - inhibitor of apoptosis proteins at the crossroad of
RT   innate immunity and death.";
RL   Curr. Opin. Cell Biol. 22:872-881(2010).
RN   [27]
RP   S-NITROSYLATION AT CYS-450.
RX   PubMed=20670888; DOI=10.1016/j.molcel.2010.07.002;
RA   Nakamura T., Wang L., Wong C.C., Scott F.L., Eckelman B.P., Han X.,
RA   Tzitzilonis C., Meng F., Gu Z., Holland E.A., Clemente A.T., Okamoto S.,
RA   Salvesen G.S., Riek R., Yates J.R. III, Lipton S.A.;
RT   "Transnitrosylation of XIAP regulates caspase-dependent neuronal cell
RT   death.";
RL   Mol. Cell 39:184-195(2010).
RN   [28]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE OF THE NEDD8 CONJUGATION
RP   PATHWAY.
RX   PubMed=21145488; DOI=10.1016/j.molcel.2010.11.011;
RA   Broemer M., Tenev T., Rigbolt K.T., Hempel S., Blagoev B., Silke J.,
RA   Ditzel M., Meier P.;
RT   "Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases.";
RL   Mol. Cell 40:810-822(2010).
RN   [29]
RP   FUNCTION IN THE UBIQUITINATION OF CCS, AND INTERACTION WITH CCS.
RX   PubMed=20154138; DOI=10.1128/mcb.00900-09;
RA   Brady G.F., Galban S., Liu X., Basrur V., Gitlin J.D.,
RA   Elenitoba-Johnson K.S., Wilson T.E., Duckett C.S.;
RT   "Regulation of the copper chaperone CCS by XIAP-mediated ubiquitination.";
RL   Mol. Cell. Biol. 30:1923-1936(2010).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=20651737; DOI=10.1038/nrc2889;
RA   Gyrd-Hansen M., Meier P.;
RT   "IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and
RT   cancer.";
RL   Nat. Rev. Cancer 10:561-574(2010).
RN   [31]
RP   INTERACTION WITH SEPTIN4 ISOFORM ARTS AND DIABLO, AND MUTAGENESIS OF
RP   TRP-310; GLU-314 AND HIS-343.
RX   PubMed=21695558; DOI=10.1007/s10495-011-0622-0;
RA   Bornstein B., Gottfried Y., Edison N., Shekhtman A., Lev T., Glaser F.,
RA   Larisch S.;
RT   "ARTS binds to a distinct domain in XIAP-BIR3 and promotes apoptosis by a
RT   mechanism that is different from other IAP-antagonists.";
RL   Apoptosis 16:869-881(2011).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   FUNCTION IN THE UBIQUITINATION OF AIFM1.
RX   PubMed=22103349; DOI=10.1021/bi201483g;
RA   Lewis E.M., Wilkinson A.S., Davis N.Y., Horita D.A., Wilkinson J.C.;
RT   "Nondegradative ubiquitination of apoptosis inducing factor (AIF) by X-
RT   linked inhibitor of apoptosis at a residue critical for AIF-mediated
RT   chromatin degradation.";
RL   Biochemistry 50:11084-11096(2011).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=21447281;
RA   Damgaard R.B., Gyrd-Hansen M.;
RT   "Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and
RT   innate immunity.";
RL   Discov. Med. 11:221-231(2011).
RN   [35]
RP   INTERACTION WITH BIRC5/SURVIVIN.
RX   PubMed=21536684; DOI=10.1074/jbc.m111.237586;
RA   Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V.,
RA   Kopantzev E.P., Shakhparonov M.I.;
RT   "Survivin monomer plays an essential role in apoptosis regulation.";
RL   J. Biol. Chem. 286:23296-23307(2011).
RN   [36]
RP   INTERACTION WITH USP19.
RX   PubMed=21849505; DOI=10.1074/jbc.m111.282020;
RA   Mei Y., Hahn A.A., Hu S., Yang X.;
RT   "The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2.";
RL   J. Biol. Chem. 286:35380-35387(2011).
RN   [37]
RP   INTERACTION WITH RIPK1; RIPK2; RIPK3 AND RIPK4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J.,
RA   Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [38]
RP   REVIEW ON FUNCTION.
RX   PubMed=22095281; DOI=10.1038/cdd.2011.163;
RA   Darding M., Meier P.;
RT   "IAPs: guardians of RIPK1.";
RL   Cell Death Differ. 19:58-66(2012).
RN   [39]
RP   TISSUE SPECIFICITY.
RX   PubMed=30389919; DOI=10.1038/s41467-018-06941-4;
RA   Koren E., Yosefzon Y., Ankawa R., Soteriou D., Jacob A., Nevelsky A.,
RA   Ben-Yosef R., Bar-Sela G., Fuchs Y.;
RT   "ARTS mediates apoptosis and regeneration of the intestinal stem cell
RT   niche.";
RL   Nat. Commun. 9:4582-4582(2018).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TLE3 AND TCF7L2/TCF4.
RX   PubMed=22304967; DOI=10.1016/j.molcel.2011.12.032;
RA   Hanson A.J., Wallace H.A., Freeman T.J., Beauchamp R.D., Lee L.A., Lee E.;
RT   "XIAP monoubiquitylates Groucho/TLE to promote canonical Wnt signaling.";
RL   Mol. Cell 45:619-628(2012).
RN   [41]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH BCL2 AND SEPTIN4 ISOFORM ARTS,
RP   AND INTERACTION WITH BCL2 AND SEPTIN4 ISOFORM ARTS.
RX   PubMed=29020630; DOI=10.1016/j.celrep.2017.09.052;
RA   Edison N., Curtz Y., Paland N., Mamriev D., Chorubczyk N.,
RA   Haviv-Reingewertz T., Kfir N., Morgenstern D., Kupervaser M., Kagan J.,
RA   Kim H.T., Larisch S.;
RT   "Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis.";
RL   Cell Rep. 21:442-454(2017).
RN   [42]
RP   STRUCTURE BY NMR OF 124-240, AND MUTAGENESIS OF LEU-141; VAL-147; ASP-148;
RP   ILE-149; ASP-151; LEU-167 AND ASP-196.
RX   PubMed=10548111; DOI=10.1038/44617;
RA   Sun C., Cai M., Gunasekera A.H., Meadows R.P., Wang H., Chen J., Zhang H.,
RA   Wu W., Xu N., Ng S.-C., Fesik S.W.;
RT   "NMR structure and mutagenesis of the inhibitor-of-apoptosis protein
RT   XIAP.";
RL   Nature 401:818-822(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 238-358 IN COMPLEX WITH DIABLO/SMAC.
RX   PubMed=11140637; DOI=10.1038/35050006;
RA   Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T.,
RA   Herrmann J., Wu J.C., Fesik S.W.;
RT   "Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain.";
RL   Nature 408:1004-1008(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 120-260 IN COMPLEX WITH CASP7.
RX   PubMed=11257231; DOI=10.1016/s0092-8674(02)02075-5;
RA   Huang Y., Park Y.C., Rich R.L., Segal D., Myszka D.G., Wu H.;
RT   "Structural basis of caspase inhibition by XIAP: differential roles of the
RT   linker versus the BIR domain.";
RL   Cell 104:781-790(2001).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 253-350 IN COMPLEX WITH CASP9.
RX   PubMed=12620238; DOI=10.1016/s1097-2765(03)00054-6;
RA   Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M.,
RA   Alnemri E.S., Fairman R., Shi Y.;
RT   "Mechanism of XIAP-mediated inhibition of caspase-9.";
RL   Mol. Cell 11:519-527(2003).
RN   [46]
RP   STRUCTURE BY NMR OF 241-356.
RX   PubMed=15317454; DOI=10.1021/jm040037k;
RA   Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.-S., Betz S.F.,
RA   Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T.,
RA   Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R.,
RA   Tomaselli K.J., Zou H., Fesik S.W.;
RT   "Discovery of potent antagonists of the antiapoptotic protein XIAP for the
RT   treatment of cancer.";
RL   J. Med. Chem. 47:4417-4426(2004).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 249-354.
RX   PubMed=17336535; DOI=10.1016/j.bmc.2007.02.010;
RA   Wist A.D., Gu L., Riedl S.J., Shi Y., McLendon G.L.;
RT   "Structure-activity based study of the Smac-binding pocket within the BIR3
RT   domain of XIAP.";
RL   Bioorg. Med. Chem. 15:2935-2943(2007).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 10-99, MUTAGENESIS OF SER-87, AND
RP   SUBUNIT.
RX   PubMed=17698078; DOI=10.1016/j.jmb.2007.07.019;
RA   Lin S.-C., Huang Y., Lo Y.-C., Lu M., Wu H.;
RT   "Crystal structure of the BIR1 domain of XIAP in two crystal forms.";
RL   J. Mol. Biol. 372:847-854(2007).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 10-99 IN COMPLEX WITH TAB1,
RP   FUNCTION, AND MUTAGENESIS OF TYR-75; VAL-80; VAL-86 AND LEU-98.
RX   PubMed=17560374; DOI=10.1016/j.molcel.2007.05.006;
RA   Lu M., Lin S.-C., Huang Y., Kang Y.J., Rich R., Lo Y.-C., Myszka D.,
RA   Han J., Wu H.;
RT   "XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1
RT   dimerization.";
RL   Mol. Cell 26:689-702(2007).
RN   [50]
RP   STRUCTURE BY NMR OF 427-497.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RING domain of the baculoviral IAP repeat-
RT   containing protein 4 from Homo sapiens.";
RL   Submitted (MAR-2008) to the PDB data bank.
CC   -!- FUNCTION: Multi-functional protein which regulates not only caspases
CC       and apoptosis, but also modulates inflammatory signaling and immunity,
CC       copper homeostasis, mitogenic kinase signaling, cell proliferation, as
CC       well as cell invasion and metastasis. Acts as a direct caspase
CC       inhibitor. Directly bind to the active site pocket of CASP3 and CASP7
CC       and obstructs substrate entry. Inactivates CASP9 by keeping it in a
CC       monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase
CC       regulating NF-kappa-B signaling and the target proteins for its E3
CC       ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8,
CC       CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin.
CC       Ubiquitinion of CCS leads to enhancement of its chaperone activity
CC       toward its physiologic target, SOD1, rather than proteasomal
CC       degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to
CC       proteasomal degradation. Plays a role in copper homeostasis by
CC       ubiquitinating COMMD1 and promoting its proteasomal degradation. Can
CC       also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation
CC       pathway, targeting effector caspases for neddylation and inactivation.
CC       Ubiquitinates and therefore mediates the proteosomal degradation of
CC       BCL2 in response to apoptosis (PubMed:29020630). Regulates the BMP
CC       signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways
CC       leading to NF-kappa-B and JNK activation. Acts as an important
CC       regulator of innate immune signaling via regulation of Nodlike
CC       receptors (NLRs). Protects cells from spontaneous formation of the
CC       ripoptosome, a large multi-protein complex that has the capability to
CC       kill cancer cells in a caspase-dependent and caspase-independent
CC       manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and
CC       CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates
CC       TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in
CC       inhibition of its interaction with TCF7L2/TCF4 thereby allowing
CC       efficient recruitment and binding of the transcriptional coactivator
CC       beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific
CC       transcriptional program. {ECO:0000269|PubMed:11447297,
CC       ECO:0000269|PubMed:12121969, ECO:0000269|PubMed:14685266,
CC       ECO:0000269|PubMed:17560374, ECO:0000269|PubMed:17967870,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:20154138,
CC       ECO:0000269|PubMed:21145488, ECO:0000269|PubMed:22103349,
CC       ECO:0000269|PubMed:22304967, ECO:0000269|PubMed:29020630,
CC       ECO:0000269|PubMed:9230442}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- SUBUNIT: Monomer, and homodimer. Part of a complex composed of SEPTIN4
CC       isoform ARTS, XIAP and BCL2, within the complex interacts with SEPTIN4
CC       isoform ARTS and BCL2, SEPTIN4 isoform ARTS acts as a scaffold protein
CC       and stabilizes the complex (PubMed:29020630). Interacts (via BIR3
CC       domain) with DIABLO/SMAC; the interaction inhibits apoptotic suppressor
CC       activity (PubMed:21695558, PubMed:11140637). Interacts with
CC       HTRA2/PRSS25; the interaction inhibits apoptotic suppressor activity
CC       (PubMed:11604410). Interacts with TAB1/MAP3K7IP1 and AIFM1. Interaction
CC       with DIABLO/SMAC hinders binding of TAB1/MAP3K7IP1 and AIFM1. Interacts
CC       with TCF25 and COMMD1. Interacts (via BIR3 domain) with SEPTIN4 isoform
CC       ARTS (PubMed:21695558, PubMed:15029247). Interacts (via BIR3 domain)
CC       with SEPTIN4 (By similarity). Interacts with RIP1, RIP2, RIP3, RIP4,
CC       CCS and USP19. Interacts (via BIR 2 domain and BIR 3 domain) with HAX1
CC       (via C-terminus) and this interaction blocks ubiquitination of
CC       XIAP/BIRC4. Interacts with the monomeric form of BIRC5/survivin.
CC       Interacts with TLE3 and TCF7L2/TCF4. Interacts (via BIR 3 and RING
CC       domains) with PDCL3 (PubMed:19012568). {ECO:0000250|UniProtKB:Q60989,
CC       ECO:0000269|PubMed:11140637, ECO:0000269|PubMed:11257231,
CC       ECO:0000269|PubMed:11604410, ECO:0000269|PubMed:12620238,
CC       ECO:0000269|PubMed:14685266, ECO:0000269|PubMed:15029247,
CC       ECO:0000269|PubMed:17560374, ECO:0000269|PubMed:17698078,
CC       ECO:0000269|PubMed:17967870, ECO:0000269|PubMed:18068114,
CC       ECO:0000269|PubMed:19012568, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:20154138, ECO:0000269|PubMed:20171186,
CC       ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:21695558,
CC       ECO:0000269|PubMed:21849505, ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:22304967, ECO:0000269|PubMed:29020630}.
CC   -!- INTERACTION:
CC       P98170; Q9Y3E2: BOLA1; NbExp=3; IntAct=EBI-517127, EBI-1049556;
CC       P98170; A0A087WZT3: BOLA2B; NbExp=3; IntAct=EBI-517127, EBI-12006120;
CC       P98170; Q92851: CASP10; NbExp=3; IntAct=EBI-517127, EBI-495095;
CC       P98170; Q92851-4: CASP10; NbExp=3; IntAct=EBI-517127, EBI-6621134;
CC       P98170; P42574: CASP3; NbExp=4; IntAct=EBI-517127, EBI-524064;
CC       P98170; P55210: CASP7; NbExp=3; IntAct=EBI-517127, EBI-523958;
CC       P98170; P55211: CASP9; NbExp=23; IntAct=EBI-517127, EBI-516799;
CC       P98170; O14618: CCS; NbExp=2; IntAct=EBI-517127, EBI-11668690;
CC       P98170; P61024: CKS1B; NbExp=7; IntAct=EBI-517127, EBI-456371;
CC       P98170; Q9NR28: DIABLO; NbExp=9; IntAct=EBI-517127, EBI-517508;
CC       P98170; Q9NR28-1: DIABLO; NbExp=4; IntAct=EBI-517127, EBI-15490322;
CC       P98170; Q96FJ2: DYNLL2; NbExp=3; IntAct=EBI-517127, EBI-742371;
CC       P98170; P19447: ERCC3; NbExp=4; IntAct=EBI-517127, EBI-1183307;
CC       P98170; Q96CN9: GCC1; NbExp=3; IntAct=EBI-517127, EBI-746252;
CC       P98170; P07686: HEXB; NbExp=3; IntAct=EBI-517127, EBI-7133736;
CC       P98170; O43464: HTRA2; NbExp=21; IntAct=EBI-517127, EBI-517086;
CC       P98170; P83110: HTRA3; NbExp=8; IntAct=EBI-517127, EBI-2867394;
CC       P98170; P83110-1: HTRA3; NbExp=7; IntAct=EBI-517127, EBI-25469082;
CC       P98170; P83110-2: HTRA3; NbExp=6; IntAct=EBI-517127, EBI-22017714;
CC       P98170; P83105: HTRA4; NbExp=11; IntAct=EBI-517127, EBI-21776319;
CC       P98170; Q17RB8: LONRF1; NbExp=7; IntAct=EBI-517127, EBI-2341787;
CC       P98170; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-517127, EBI-348259;
CC       P98170; Q9HC98: NEK6; NbExp=4; IntAct=EBI-517127, EBI-740364;
CC       P98170; P46531: NOTCH1; NbExp=4; IntAct=EBI-517127, EBI-636374;
CC       P98170; Q96HA8: NTAQ1; NbExp=4; IntAct=EBI-517127, EBI-741158;
CC       P98170; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-517127, EBI-14066006;
CC       P98170; O43447: PPIH; NbExp=5; IntAct=EBI-517127, EBI-1055615;
CC       P98170; Q8N3J5: PPM1K; NbExp=3; IntAct=EBI-517127, EBI-3923368;
CC       P98170; P47897: QARS1; NbExp=3; IntAct=EBI-517127, EBI-347462;
CC       P98170; P63000: RAC1; NbExp=3; IntAct=EBI-517127, EBI-413628;
CC       P98170; P40937: RFC5; NbExp=9; IntAct=EBI-517127, EBI-712376;
CC       P98170; O43353: RIPK2; NbExp=20; IntAct=EBI-517127, EBI-358522;
CC       P98170; P57078: RIPK4; NbExp=2; IntAct=EBI-517127, EBI-4422308;
CC       P98170; Q06455-2: RUNX1T1; NbExp=3; IntAct=EBI-517127, EBI-11984663;
CC       P98170; O43236-6: SEPTIN4; NbExp=4; IntAct=EBI-517127, EBI-4372019;
CC       P98170; Q8IUQ4: SIAH1; NbExp=3; IntAct=EBI-517127, EBI-747107;
CC       P98170; Q9Y2D8: SSX2IP; NbExp=4; IntAct=EBI-517127, EBI-2212028;
CC       P98170; Q15750: TAB1; NbExp=4; IntAct=EBI-517127, EBI-358643;
CC       P98170; Q5W5X9-3: TTC23; NbExp=3; IntAct=EBI-517127, EBI-9090990;
CC       P98170; P0CG48: UBC; NbExp=3; IntAct=EBI-517127, EBI-3390054;
CC       P98170; P51668: UBE2D1; NbExp=6; IntAct=EBI-517127, EBI-743540;
CC       P98170; P62837: UBE2D2; NbExp=2; IntAct=EBI-517127, EBI-347677;
CC       P98170; P61077: UBE2D3; NbExp=2; IntAct=EBI-517127, EBI-348268;
CC       P98170; P61088: UBE2N; NbExp=2; IntAct=EBI-517127, EBI-1052908;
CC       P98170; Q13404: UBE2V1; NbExp=3; IntAct=EBI-517127, EBI-1050671;
CC       P98170; A5D8V6: VPS37C; NbExp=7; IntAct=EBI-517127, EBI-2559305;
CC       P98170; P98170: XIAP; NbExp=5; IntAct=EBI-517127, EBI-517127;
CC       P98170; PRO_0000021073 [Q9JIQ3]: Diablo; Xeno; NbExp=3; IntAct=EBI-517127, EBI-25438230;
CC       P98170; Q9JIY5: Htra2; Xeno; NbExp=4; IntAct=EBI-517127, EBI-2365838;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=TLE3 promotes its
CC       nuclear localization.
CC   -!- TISSUE SPECIFICITY: Expressed in colonic crypts (at protein level)
CC       (PubMed:30389919). Ubiquitous, except peripheral blood leukocytes
CC       (PubMed:8654366). {ECO:0000269|PubMed:30389919,
CC       ECO:0000269|PubMed:8654366}.
CC   -!- DOMAIN: The first BIR domain is involved in interaction with
CC       TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain
CC       is sufficient to inhibit CASP3 and CASP7, while the third BIR is
CC       involved in CASP9 inhibition. The interactions with DIABLO/SMAC and
CC       HTRA2/PRSS25 are mediated by the second and third BIR domains.
CC   -!- PTM: S-Nitrosylation down-regulates its E3 ubiquitin-protein ligase
CC       activity. {ECO:0000269|PubMed:20670888}.
CC   -!- PTM: Autoubiquitinated. {ECO:0000269|PubMed:12747801}.
CC   -!- DISEASE: Lymphoproliferative syndrome, X-linked, 2 (XLP2) [MIM:300635]:
CC       A rare immunodeficiency characterized by extreme susceptibility to
CC       infection with Epstein-Barr virus (EBV). Symptoms include severe or
CC       fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and
CC       malignant lymphoma. {ECO:0000269|PubMed:17080092}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}.
CC   -!- CAUTION: Was originally shown to be phosphorylated at Ser-87 by PKB,
CC       protecting the protein from ubiquitination and proteasomal degradation
CC       (PubMed:14645242). However, this work was later retracted
CC       (PubMed:27825084). {ECO:0000305|PubMed:14645242,
CC       ECO:0000305|PubMed:27825084}.
CC   -!- WEB RESOURCE: Name=BIRC4base; Note=XIAP mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/BIRC4base/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/birc4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U32974; AAC50518.1; -; mRNA.
DR   EMBL; U45880; AAC50373.1; -; mRNA.
DR   EMBL; AY886519; AAW62257.1; -; Genomic_DNA.
DR   EMBL; AL121601; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11858.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11859.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11860.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11861.1; -; Genomic_DNA.
DR   EMBL; BC032729; AAH32729.1; -; mRNA.
DR   CCDS; CCDS14606.1; -.
DR   PIR; S69544; S69544.
DR   RefSeq; NP_001158.2; NM_001167.3.
DR   RefSeq; NP_001191330.1; NM_001204401.1.
DR   RefSeq; XP_006724817.1; XM_006724754.2.
DR   RefSeq; XP_011529631.1; XM_011531329.2.
DR   PDB; 1C9Q; NMR; -; A=124-240.
DR   PDB; 1F9X; NMR; -; A=241-356.
DR   PDB; 1G3F; NMR; -; A=241-356.
DR   PDB; 1G73; X-ray; 2.00 A; C/D=238-358.
DR   PDB; 1I3O; X-ray; 2.70 A; E/F=124-240.
DR   PDB; 1I4O; X-ray; 2.40 A; C/D=120-260.
DR   PDB; 1I51; X-ray; 2.45 A; E/F=124-240.
DR   PDB; 1KMC; X-ray; 2.90 A; C/D=124-242.
DR   PDB; 1NW9; X-ray; 2.40 A; A=253-350.
DR   PDB; 1TFQ; NMR; -; A=241-356.
DR   PDB; 1TFT; NMR; -; A=241-356.
DR   PDB; 2ECG; NMR; -; A=430-497.
DR   PDB; 2JK7; X-ray; 2.82 A; A=241-356.
DR   PDB; 2KNA; NMR; -; A=357-449.
DR   PDB; 2OPY; X-ray; 2.80 A; A=249-354.
DR   PDB; 2OPZ; X-ray; 3.00 A; A/B/C/D=249-357.
DR   PDB; 2POI; X-ray; 1.80 A; A=10-99.
DR   PDB; 2POP; X-ray; 3.10 A; B/D=10-100.
DR   PDB; 2QRA; X-ray; 2.50 A; A/B/C/D=10-99.
DR   PDB; 2VSL; X-ray; 2.10 A; A=250-345.
DR   PDB; 3CLX; X-ray; 2.70 A; A/B/C/D=241-356.
DR   PDB; 3CM2; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J=241-356.
DR   PDB; 3CM7; X-ray; 3.10 A; A/B/C/D=241-356.
DR   PDB; 3EYL; X-ray; 3.00 A; A/B=241-356.
DR   PDB; 3G76; X-ray; 3.00 A; A/B/C/D/E/F/G/H=241-356.
DR   PDB; 3HL5; X-ray; 1.80 A; A/B=256-346.
DR   PDB; 3UW4; X-ray; 1.79 A; A=338-348.
DR   PDB; 3UW5; X-ray; 1.71 A; A/B=336-348.
DR   PDB; 4EC4; X-ray; 3.30 A; A/B/C/D/E/F/G/J/K/L=241-356.
DR   PDB; 4HY0; X-ray; 2.84 A; A/B/C/D/E/F/G/H=238-357.
DR   PDB; 4IC2; X-ray; 2.20 A; A/B=429-497.
DR   PDB; 4IC3; X-ray; 1.78 A; A/B=429-497.
DR   PDB; 4J3Y; X-ray; 1.45 A; A/C=152-236.
DR   PDB; 4J44; X-ray; 1.30 A; A/C=152-236.
DR   PDB; 4J45; X-ray; 1.48 A; A/C=152-236.
DR   PDB; 4J46; X-ray; 1.42 A; A/C=152-236.
DR   PDB; 4J47; X-ray; 1.35 A; A/C=152-236.
DR   PDB; 4J48; X-ray; 2.10 A; A/C=152-236.
DR   PDB; 4KJU; X-ray; 1.60 A; A/C=152-236.
DR   PDB; 4KJV; X-ray; 1.70 A; A/C=152-236.
DR   PDB; 4KMP; X-ray; 1.95 A; A/B=256-348.
DR   PDB; 4MTZ; X-ray; 2.10 A; A/B/C/D=10-99.
DR   PDB; 4OXC; X-ray; 2.90 A; A/B/C/D=10-99.
DR   PDB; 4WVS; X-ray; 2.09 A; A=156-231.
DR   PDB; 4WVT; X-ray; 1.96 A; A/B=156-231.
DR   PDB; 4WVU; X-ray; 2.02 A; A=156-231.
DR   PDB; 5C0K; X-ray; 2.20 A; A=249-354.
DR   PDB; 5C0L; X-ray; 2.60 A; A=246-354.
DR   PDB; 5C3H; X-ray; 2.65 A; A=249-354.
DR   PDB; 5C3K; X-ray; 2.02 A; A=249-354.
DR   PDB; 5C7A; X-ray; 2.36 A; A=249-354.
DR   PDB; 5C7B; X-ray; 2.68 A; A=249-354.
DR   PDB; 5C7C; X-ray; 2.32 A; A=249-354.
DR   PDB; 5C7D; X-ray; 2.25 A; A=249-354.
DR   PDB; 5C83; X-ray; 2.33 A; A=249-354.
DR   PDB; 5C84; X-ray; 2.36 A; A=249-354.
DR   PDB; 5M6E; X-ray; 2.32 A; A=249-354.
DR   PDB; 5M6F; X-ray; 2.39 A; A=249-354.
DR   PDB; 5M6H; X-ray; 2.50 A; A=249-354.
DR   PDB; 5M6L; X-ray; 2.61 A; A=249-354.
DR   PDB; 5M6M; X-ray; 2.37 A; A=249-354.
DR   PDB; 5O6T; X-ray; 1.57 A; A/B=434-497.
DR   PDB; 5OQW; X-ray; 2.31 A; A/B=249-354.
DR   PDB; 6EY2; X-ray; 2.70 A; A/B/C/D/E/F/G/H=241-356.
DR   PDB; 6GJW; X-ray; 1.90 A; A/B/C/D=10-99.
DR   PDB; 6QCI; X-ray; 2.30 A; A/B/C/D=10-99.
DR   PDBsum; 1C9Q; -.
DR   PDBsum; 1F9X; -.
DR   PDBsum; 1G3F; -.
DR   PDBsum; 1G73; -.
DR   PDBsum; 1I3O; -.
DR   PDBsum; 1I4O; -.
DR   PDBsum; 1I51; -.
DR   PDBsum; 1KMC; -.
DR   PDBsum; 1NW9; -.
DR   PDBsum; 1TFQ; -.
DR   PDBsum; 1TFT; -.
DR   PDBsum; 2ECG; -.
DR   PDBsum; 2JK7; -.
DR   PDBsum; 2KNA; -.
DR   PDBsum; 2OPY; -.
DR   PDBsum; 2OPZ; -.
DR   PDBsum; 2POI; -.
DR   PDBsum; 2POP; -.
DR   PDBsum; 2QRA; -.
DR   PDBsum; 2VSL; -.
DR   PDBsum; 3CLX; -.
DR   PDBsum; 3CM2; -.
DR   PDBsum; 3CM7; -.
DR   PDBsum; 3EYL; -.
DR   PDBsum; 3G76; -.
DR   PDBsum; 3HL5; -.
DR   PDBsum; 3UW4; -.
DR   PDBsum; 3UW5; -.
DR   PDBsum; 4EC4; -.
DR   PDBsum; 4HY0; -.
DR   PDBsum; 4IC2; -.
DR   PDBsum; 4IC3; -.
DR   PDBsum; 4J3Y; -.
DR   PDBsum; 4J44; -.
DR   PDBsum; 4J45; -.
DR   PDBsum; 4J46; -.
DR   PDBsum; 4J47; -.
DR   PDBsum; 4J48; -.
DR   PDBsum; 4KJU; -.
DR   PDBsum; 4KJV; -.
DR   PDBsum; 4KMP; -.
DR   PDBsum; 4MTZ; -.
DR   PDBsum; 4OXC; -.
DR   PDBsum; 4WVS; -.
DR   PDBsum; 4WVT; -.
DR   PDBsum; 4WVU; -.
DR   PDBsum; 5C0K; -.
DR   PDBsum; 5C0L; -.
DR   PDBsum; 5C3H; -.
DR   PDBsum; 5C3K; -.
DR   PDBsum; 5C7A; -.
DR   PDBsum; 5C7B; -.
DR   PDBsum; 5C7C; -.
DR   PDBsum; 5C7D; -.
DR   PDBsum; 5C83; -.
DR   PDBsum; 5C84; -.
DR   PDBsum; 5M6E; -.
DR   PDBsum; 5M6F; -.
DR   PDBsum; 5M6H; -.
DR   PDBsum; 5M6L; -.
DR   PDBsum; 5M6M; -.
DR   PDBsum; 5O6T; -.
DR   PDBsum; 5OQW; -.
DR   PDBsum; 6EY2; -.
DR   PDBsum; 6GJW; -.
DR   PDBsum; 6QCI; -.
DR   BMRB; P98170; -.
DR   SASBDB; P98170; -.
DR   SMR; P98170; -.
DR   BioGRID; 106828; 226.
DR   CORUM; P98170; -.
DR   DIP; DIP-27626N; -.
DR   IntAct; P98170; 102.
DR   MINT; P98170; -.
DR   STRING; 9606.ENSP00000360242; -.
DR   BindingDB; P98170; -.
DR   ChEMBL; CHEMBL4198; -.
DR   DrugBank; DB02628; 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide.
DR   DrugBank; DB06184; AEG35156.
DR   DrugBank; DB04209; Dequalinium.
DR   DrugBank; DB04612; N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE.
DR   GuidetoPHARMACOLOGY; 2790; -.
DR   MEROPS; I32.004; -.
DR   MoonDB; P98170; Predicted.
DR   GlyGen; P98170; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P98170; -.
DR   MetOSite; P98170; -.
DR   PhosphoSitePlus; P98170; -.
DR   BioMuta; XIAP; -.
DR   DMDM; 12643387; -.
DR   EPD; P98170; -.
DR   jPOST; P98170; -.
DR   MassIVE; P98170; -.
DR   MaxQB; P98170; -.
DR   PaxDb; P98170; -.
DR   PeptideAtlas; P98170; -.
DR   PRIDE; P98170; -.
DR   ProteomicsDB; 57803; -.
DR   Antibodypedia; 3975; 728 antibodies from 44 providers.
DR   DNASU; 331; -.
DR   Ensembl; ENST00000355640; ENSP00000347858; ENSG00000101966.
DR   Ensembl; ENST00000371199; ENSP00000360242; ENSG00000101966.
DR   Ensembl; ENST00000434753; ENSP00000395230; ENSG00000101966.
DR   GeneID; 331; -.
DR   KEGG; hsa:331; -.
DR   MANE-Select; ENST00000371199.8; ENSP00000360242.3; NM_001167.4; NP_001158.2.
DR   UCSC; uc004etx.4; human.
DR   CTD; 331; -.
DR   DisGeNET; 331; -.
DR   GeneCards; XIAP; -.
DR   GeneReviews; XIAP; -.
DR   HGNC; HGNC:592; XIAP.
DR   HPA; ENSG00000101966; Low tissue specificity.
DR   MalaCards; XIAP; -.
DR   MIM; 300079; gene.
DR   MIM; 300635; phenotype.
DR   neXtProt; NX_P98170; -.
DR   OpenTargets; ENSG00000101966; -.
DR   Orphanet; 538934; X-linked lymphoproliferative disease due to XIAP deficiency.
DR   PharmGKB; PA25361; -.
DR   VEuPathDB; HostDB:ENSG00000101966; -.
DR   eggNOG; KOG1101; Eukaryota.
DR   GeneTree; ENSGT00940000158743; -.
DR   HOGENOM; CLU_016347_1_1_1; -.
DR   InParanoid; P98170; -.
DR   OMA; CYTIITF; -.
DR   OrthoDB; 1340284at2759; -.
DR   PhylomeDB; P98170; -.
DR   TreeFam; TF105356; -.
DR   PathwayCommons; P98170; -.
DR   Reactome; R-HSA-111459; Activation of caspases through apoptosome-mediated cleavage.
DR   Reactome; R-HSA-111463; SMAC (DIABLO) binds to IAPs.
DR   Reactome; R-HSA-111464; SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes.
DR   Reactome; R-HSA-111469; SMAC, XIAP-regulated apoptotic response.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-8948747; Regulation of PTEN localization.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-9627069; Regulation of the apoptosome activity.
DR   SABIO-RK; P98170; -.
DR   SignaLink; P98170; -.
DR   SIGNOR; P98170; -.
DR   BioGRID-ORCS; 331; 12 hits in 718 CRISPR screens.
DR   ChiTaRS; XIAP; human.
DR   EvolutionaryTrace; P98170; -.
DR   GeneWiki; XIAP; -.
DR   GenomeRNAi; 331; -.
DR   Pharos; P98170; Tchem.
DR   PRO; PR:P98170; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P98170; protein.
DR   Bgee; ENSG00000101966; Expressed in quadriceps femoris and 227 other tissues.
DR   ExpressionAtlas; P98170; baseline and differential.
DR   Genevisible; P98170; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IBA:GO_Central.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; EXP:Reactome.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEP:UniProtKB.
DR   GO; GO:0055070; P:copper ion homeostasis; TAS:UniProtKB.
DR   GO; GO:0097340; P:inhibition of cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:1990001; P:inhibition of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1902530; P:positive regulation of protein linear polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030510; P:regulation of BMP signaling pathway; TAS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045088; P:regulation of innate immune response; TAS:UniProtKB.
DR   GO; GO:0070424; P:regulation of nucleotide-binding oligomerization domain containing signaling pathway; TAS:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd00022; BIR; 3.
DR   CDD; cd14395; UBA_BIRC4_8; 1.
DR   DisProt; DP01773; -.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR001370; BIR_rpt.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR042579; XIAP/BIRC8_UBA.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF00653; BIR; 3.
DR   SMART; SM00238; BIR; 3.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS01282; BIR_REPEAT_1; 3.
DR   PROSITE; PS50143; BIR_REPEAT_2; 3.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Cytoplasm; Isopeptide bond; Metal-binding;
KW   Nucleus; Phosphoprotein; Protease inhibitor; Reference proteome; Repeat;
KW   S-nitrosylation; Thiol protease inhibitor; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Wnt signaling pathway; Zinc; Zinc-finger.
FT   CHAIN           1..497
FT                   /note="E3 ubiquitin-protein ligase XIAP"
FT                   /id="PRO_0000122352"
FT   REPEAT          26..93
FT                   /note="BIR 1"
FT   REPEAT          163..230
FT                   /note="BIR 2"
FT   REPEAT          265..330
FT                   /note="BIR 3"
FT   ZN_FING         450..485
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          141..149
FT                   /note="Interaction with caspase-7"
FT   REGION          262..277
FT                   /note="Required for interaction with SEPTIN4 isoform ARTS"
FT                   /evidence="ECO:0000269|PubMed:21695558"
FT   REGION          329..350
FT                   /note="Required for interaction with DIABLO"
FT                   /evidence="ECO:0000269|PubMed:21695558"
FT   REGION          450..497
FT                   /note="Required for ubiquitination and subsequent
FT                   degradation of BCL2 during apoptosis"
FT                   /evidence="ECO:0000269|PubMed:29020630"
FT   METAL           300
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           303
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           320
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   METAL           327
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00029"
FT   MOD_RES         450
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:20670888"
FT   CROSSLNK        322
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:12747801"
FT   CROSSLNK        328
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:12747801"
FT   VARIANT         107
FT                   /note="N -> S (in dbSNP:rs28382721)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_022282"
FT   VARIANT         133
FT                   /note="S -> F (in dbSNP:rs28382722)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_022283"
FT   VARIANT         242
FT                   /note="D -> E (in dbSNP:rs28382723)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_022284"
FT   VARIANT         423
FT                   /note="Q -> P (in dbSNP:rs5956583)"
FT                   /evidence="ECO:0000269|PubMed:8654366, ECO:0000269|Ref.3"
FT                   /id="VAR_022285"
FT   MUTAGEN         75
FT                   /note="Y->G: Loss of interaction with TAB1/MAP3K7IP1; when
FT                   associated with G-75."
FT                   /evidence="ECO:0000269|PubMed:17560374"
FT   MUTAGEN         80
FT                   /note="V->A: Strongly reduced interaction with
FT                   TAB1/MAP3K7IP1. Reduced activation of MAP3K7/TAK1. Reduced
FT                   activation of NF-kappa-B."
FT                   /evidence="ECO:0000269|PubMed:17560374"
FT   MUTAGEN         80
FT                   /note="V->D: Loss of interaction with TAB1/MAP3K7IP1.
FT                   Reduced activation of MAP3K7/TAK1. Strongly reduced
FT                   activation of NF-kappa-B."
FT                   /evidence="ECO:0000269|PubMed:17560374"
FT   MUTAGEN         86
FT                   /note="V->E: Loss of dimerization. Reduces activation of
FT                   NF-kappa-B."
FT                   /evidence="ECO:0000269|PubMed:17560374"
FT   MUTAGEN         87
FT                   /note="S->A: No effect on dimerization."
FT                   /evidence="ECO:0000269|PubMed:17698078"
FT   MUTAGEN         87
FT                   /note="S->D,E: Abolishes dimerization. Interferes with
FT                   ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:17698078"
FT   MUTAGEN         98
FT                   /note="L->G: Loss of interaction with TAB1/MAP3K7IP1; when
FT                   associated with G-75."
FT                   /evidence="ECO:0000269|PubMed:17560374"
FT   MUTAGEN         141
FT                   /note="L->A: Reduced inhibition of caspase-3."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         147
FT                   /note="V->A: Reduced inhibition of caspase-3."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         148
FT                   /note="D->A: Abolishes inhibition of caspase-3. Reduced
FT                   interaction with HTRA2; when associated with S-214."
FT                   /evidence="ECO:0000269|PubMed:10548111,
FT                   ECO:0000269|PubMed:11604410"
FT   MUTAGEN         149
FT                   /note="I->A: Reduced inhibition of caspase-3."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         151
FT                   /note="D->A: Reduced inhibition of caspase-3."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         167
FT                   /note="L->A: Reduced inhibition of caspase-3."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         196
FT                   /note="D->A: Reduced inhibition of caspase-3. May affect
FT                   protein folding and stability."
FT                   /evidence="ECO:0000269|PubMed:10548111"
FT   MUTAGEN         214
FT                   /note="D->S: Reduced interaction with HTRA2. Reduced
FT                   interaction with HTRA2; when associated with A-148."
FT                   /evidence="ECO:0000269|PubMed:11604410"
FT   MUTAGEN         259
FT                   /note="N->D: Reduced interaction with HTRA2; when
FT                   associated with S-314."
FT                   /evidence="ECO:0000269|PubMed:11604410"
FT   MUTAGEN         310
FT                   /note="W->A: No effect on interaction with SEPTIN4 isoform
FT                   ARTS."
FT                   /evidence="ECO:0000269|PubMed:21695558"
FT   MUTAGEN         310
FT                   /note="W->R: Reduced interaction with HTRA2; when
FT                   associated with S-314."
FT                   /evidence="ECO:0000269|PubMed:11604410"
FT   MUTAGEN         314
FT                   /note="E->S: Decreased interaction with DIABLO/SMAC and
FT                   with HTRA2. Decreases interaction with HTRA2; when
FT                   associated with D-259 or A-310. No effect on interaction
FT                   with SEPTIN4 isoform ARTS."
FT                   /evidence="ECO:0000269|PubMed:11604410,
FT                   ECO:0000269|PubMed:21695558"
FT   MUTAGEN         343
FT                   /note="H->A: No effect on interaction with SEPTIN4 isoform
FT                   ARTS."
FT                   /evidence="ECO:0000269|PubMed:21695558"
FT   MUTAGEN         450
FT                   /note="C->A,S: Inhibits degradation of active caspase-3."
FT                   /evidence="ECO:0000269|PubMed:11447297"
FT   MUTAGEN         467
FT                   /note="H->A: Loss of E3 ubiquitin-protein ligase activity."
FT                   /evidence="ECO:0000269|PubMed:17967870"
FT   CONFLICT        162
FT                   /note="S -> C (in Ref. 2; AAC50373)"
FT                   /evidence="ECO:0000305"
FT   HELIX           22..24
FT                   /evidence="ECO:0007829|PDB:6GJW"
FT   HELIX           26..30
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   HELIX           31..33
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   HELIX           44..49
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   STRAND          52..54
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   STRAND          61..63
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   TURN            64..66
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   HELIX           79..86
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   TURN            91..97
FT                   /evidence="ECO:0007829|PDB:2POI"
FT   TURN            128..130
FT                   /evidence="ECO:0007829|PDB:1I3O"
FT   HELIX           136..142
FT                   /evidence="ECO:0007829|PDB:1I4O"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:1I3O"
FT   HELIX           158..161
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   HELIX           163..168
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   TURN            169..172
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   HELIX           175..177
FT                   /evidence="ECO:0007829|PDB:4WVT"
FT   HELIX           181..186
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   STRAND          189..191
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   STRAND          198..200
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   TURN            201..203
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   STRAND          206..208
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   HELIX           216..223
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   HELIX           228..232
FT                   /evidence="ECO:0007829|PDB:4J44"
FT   HELIX           244..246
FT                   /evidence="ECO:0007829|PDB:1F9X"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:1F9X"
FT   STRAND          254..256
FT                   /evidence="ECO:0007829|PDB:5C3K"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   HELIX           265..270
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   TURN            271..274
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   STRAND          277..279
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   HELIX           281..286
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   STRAND          289..291
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   STRAND          293..296
FT                   /evidence="ECO:0007829|PDB:2OPZ"
FT   STRAND          298..300
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   TURN            301..303
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   STRAND          306..309
FT                   /evidence="ECO:0007829|PDB:1G73"
FT   STRAND          311..313
FT                   /evidence="ECO:0007829|PDB:1F9X"
FT   HELIX           316..323
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   HELIX           328..333
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   HELIX           336..342
FT                   /evidence="ECO:0007829|PDB:3UW5"
FT   TURN            343..345
FT                   /evidence="ECO:0007829|PDB:3HL5"
FT   HELIX           346..353
FT                   /evidence="ECO:0007829|PDB:1G73"
FT   HELIX           354..356
FT                   /evidence="ECO:0007829|PDB:1G73"
FT   HELIX           368..372
FT                   /evidence="ECO:0007829|PDB:2KNA"
FT   HELIX           375..381
FT                   /evidence="ECO:0007829|PDB:2KNA"
FT   HELIX           386..400
FT                   /evidence="ECO:0007829|PDB:2KNA"
FT   HELIX           407..419
FT                   /evidence="ECO:0007829|PDB:2KNA"
FT   HELIX           437..447
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   TURN            451..453
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   STRAND          454..457
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   STRAND          460..463
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   HELIX           472..475
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   TURN            482..484
FT                   /evidence="ECO:0007829|PDB:5O6T"
FT   STRAND          489..493
FT                   /evidence="ECO:0007829|PDB:5O6T"
SQ   SEQUENCE   497 AA;  56685 MW;  9D394C16D45EB635 CRC64;
     MTFNSFEGSK TCVPADINKE EEFVEEFNRL KTFANFPSGS PVSASTLARA GFLYTGEGDT
     VRCFSCHAAV DRWQYGDSAV GRHRKVSPNC RFINGFYLEN SATQSTNSGI QNGQYKVENY
     LGSRDHFALD RPSETHADYL LRTGQVVDIS DTIYPRNPAM YSEEARLKSF QNWPDYAHLT
     PRELASAGLY YTGIGDQVQC FCCGGKLKNW EPCDRAWSEH RRHFPNCFFV LGRNLNIRSE
     SDAVSSDRNF PNSTNLPRNP SMADYEARIF TFGTWIYSVN KEQLARAGFY ALGEGDKVKC
     FHCGGGLTDW KPSEDPWEQH AKWYPGCKYL LEQKGQEYIN NIHLTHSLEE CLVRTTEKTP
     SLTRRIDDTI FQNPMVQEAI RMGFSFKDIK KIMEEKIQIS GSNYKSLEVL VADLVNAQKD
     SMQDESSQTS LQKEISTEEQ LRRLQEEKLC KICMDRNIAI VFVPCGHLVT CKQCAEAVDK
     CPMCYTVITF KQKIFMS
//
ID   PTBP3_HUMAN             Reviewed;         552 AA.
AC   O95758; B1ALY2; B1ALY3; B1ALY5; B1ALY6; B3KME7; Q68DB9; Q86YB3; Q86YH9;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   23-FEB-2022, entry version 176.
DE   RecName: Full=Polypyrimidine tract-binding protein 3;
DE   AltName: Full=Regulator of differentiation 1;
DE            Short=Rod1;
GN   Name=PTBP3; Synonyms=ROD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 7).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-167 (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-552 (ISOFORM 3), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10207106; DOI=10.1128/mcb.19.5.3829;
RA   Yamamoto H., Tsukahara K., Kanaoka Y., Jinno S., Okayama H.;
RT   "Isolation of a mammalian homologue of a fission yeast differentiation
RT   regulator.";
RL   Mol. Cell. Biol. 19:3829-3841(1999).
RN   [7]
RP   FUNCTION IN SPLICING REGULATION.
RX   PubMed=18335065; DOI=10.1371/journal.pone.0001801;
RA   Robinson F., Jackson R.J., Smith C.W.;
RT   "Expression of human nPTB is limited by extreme suboptimal codon content.";
RL   PLoS ONE 3:E1801-E1801(2008).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 1), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION IN ERYTHROPOIESIS, INTERACTION WITH THBS4, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=19441079; DOI=10.1002/jcp.21817;
RA   Sadvakassova G., Dobocan M.C., Difalco M.R., Congote L.F.;
RT   "Regulator of differentiation 1 (ROD1) binds to the amphipathic C-terminal
RT   peptide of thrombospondin-4 and is involved in its mitogenic activity.";
RL   J. Cell. Physiol. 220:672-679(2009).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-423, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=20937273; DOI=10.1016/j.febslet.2010.10.008;
RA   Tano K., Mizuno R., Okada T., Rakwal R., Shibato J., Masuo Y., Ijiri K.,
RA   Akimitsu N.;
RT   "MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing
RT   the expression of motility-related genes.";
RL   FEBS Lett. 584:4575-4580(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-454, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: RNA-binding protein that mediates pre-mRNA alternative
CC       splicing regulation. Plays a role in the regulation of cell
CC       proliferation, differentiation and migration. Positive regulator of
CC       EPO-dependent erythropoiesis. Participates in cell differentiation
CC       regulation by repressing tissue-specific exons. Promotes FAS exon 6
CC       skipping. Binds RNA, preferentially to both poly(G) and poly(U).
CC       {ECO:0000269|PubMed:10207106, ECO:0000269|PubMed:18335065,
CC       ECO:0000269|PubMed:19441079, ECO:0000269|PubMed:20937273}.
CC   -!- SUBUNIT: Interacts with THBS4 (via the acidic amphipathic C-terminus).
CC       {ECO:0000269|PubMed:19441079}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=3;
CC         IsoId=O95758-3; Sequence=Displayed;
CC       Name=1;
CC         IsoId=O95758-1; Sequence=VSP_035985;
CC       Name=2;
CC         IsoId=O95758-2; Sequence=VSP_035985, VSP_010867, VSP_010868;
CC       Name=4;
CC         IsoId=O95758-4; Sequence=VSP_035986;
CC       Name=5;
CC         IsoId=O95758-5; Sequence=VSP_010867;
CC       Name=6;
CC         IsoId=O95758-6; Sequence=VSP_035985, VSP_010867;
CC       Name=7;
CC         IsoId=O95758-7; Sequence=VSP_045608;
CC   -!- TISSUE SPECIFICITY: Expressed in several hematopoietic cell lines
CC       examined. {ECO:0000269|PubMed:10207106}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH39896.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA75466.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BI463123; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001685; BAG50959.1; -; mRNA.
DR   EMBL; AK302558; BAG63824.1; -; mRNA.
DR   EMBL; CR749471; CAH18301.1; -; mRNA.
DR   EMBL; AL158824; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL359073; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471105; EAW59100.1; -; Genomic_DNA.
DR   EMBL; BC039896; AAH39896.1; ALT_INIT; mRNA.
DR   EMBL; BC044585; AAH44585.1; -; mRNA.
DR   EMBL; BI463123; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB023967; BAA75466.1; ALT_INIT; mRNA.
DR   CCDS; CCDS55332.1; -. [O95758-6]
DR   CCDS; CCDS55333.1; -. [O95758-5]
DR   CCDS; CCDS59140.1; -. [O95758-7]
DR   CCDS; CCDS59141.1; -. [O95758-4]
DR   CCDS; CCDS6784.1; -. [O95758-3]
DR   RefSeq; NP_001157260.1; NM_001163788.2. [O95758-6]
DR   RefSeq; NP_001157262.1; NM_001163790.2. [O95758-5]
DR   RefSeq; NP_001231825.1; NM_001244896.1. [O95758-7]
DR   RefSeq; NP_001231826.1; NM_001244897.1. [O95758-2]
DR   RefSeq; NP_001231827.1; NM_001244898.1. [O95758-4]
DR   RefSeq; NP_005147.3; NM_005156.6. [O95758-3]
DR   RefSeq; XP_006717409.1; XM_006717346.1.
DR   SMR; O95758; -.
DR   BioGRID; 115312; 159.
DR   IntAct; O95758; 285.
DR   MINT; O95758; -.
DR   STRING; 9606.ENSP00000414921; -.
DR   iPTMnet; O95758; -.
DR   PhosphoSitePlus; O95758; -.
DR   SwissPalm; O95758; -.
DR   BioMuta; PTBP3; -.
DR   EPD; O95758; -.
DR   jPOST; O95758; -.
DR   MassIVE; O95758; -.
DR   MaxQB; O95758; -.
DR   PaxDb; O95758; -.
DR   PeptideAtlas; O95758; -.
DR   PRIDE; O95758; -.
DR   ProteomicsDB; 3178; -.
DR   ProteomicsDB; 51028; -. [O95758-3]
DR   ProteomicsDB; 51029; -. [O95758-1]
DR   ProteomicsDB; 51030; -. [O95758-2]
DR   ProteomicsDB; 51031; -. [O95758-4]
DR   ProteomicsDB; 51032; -. [O95758-5]
DR   ProteomicsDB; 51033; -. [O95758-6]
DR   Antibodypedia; 29656; 160 antibodies from 22 providers.
DR   DNASU; 9991; -.
DR   Ensembl; ENST00000334318; ENSP00000334499; ENSG00000119314. [O95758-5]
DR   Ensembl; ENST00000343327; ENSP00000340705; ENSG00000119314. [O95758-7]
DR   Ensembl; ENST00000374255; ENSP00000363373; ENSG00000119314.
DR   Ensembl; ENST00000374257; ENSP00000363375; ENSG00000119314. [O95758-6]
DR   Ensembl; ENST00000458258; ENSP00000414921; ENSG00000119314. [O95758-4]
DR   GeneID; 9991; -.
DR   KEGG; hsa:9991; -.
DR   MANE-Select; ENST00000374257.6; ENSP00000363375.1; NM_001163788.4; NP_001157260.1. [O95758-6]
DR   UCSC; uc004bfv.4; human. [O95758-3]
DR   CTD; 9991; -.
DR   DisGeNET; 9991; -.
DR   GeneCards; PTBP3; -.
DR   HGNC; HGNC:10253; PTBP3.
DR   HPA; ENSG00000119314; Low tissue specificity.
DR   MIM; 607527; gene.
DR   neXtProt; NX_O95758; -.
DR   OpenTargets; ENSG00000119314; -.
DR   PharmGKB; PA34625; -.
DR   VEuPathDB; HostDB:ENSG00000119314; -.
DR   eggNOG; KOG1190; Eukaryota.
DR   GeneTree; ENSGT01030000234743; -.
DR   HOGENOM; CLU_015171_7_1_1; -.
DR   InParanoid; O95758; -.
DR   OMA; NAHYARM; -.
DR   OrthoDB; 1545178at2759; -.
DR   PhylomeDB; O95758; -.
DR   TreeFam; TF319824; -.
DR   PathwayCommons; O95758; -.
DR   SignaLink; O95758; -.
DR   BioGRID-ORCS; 9991; 7 hits in 1052 CRISPR screens.
DR   ChiTaRS; PTBP3; human.
DR   GenomeRNAi; 9991; -.
DR   Pharos; O95758; Tbio.
DR   PRO; PR:O95758; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O95758; protein.
DR   Bgee; ENSG00000119314; Expressed in metanephros and 235 other tissues.
DR   ExpressionAtlas; O95758; baseline and differential.
DR   Genevisible; O95758; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003729; F:mRNA binding; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0043249; P:erythrocyte maturation; IEA:UniProtKB-KW.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0033119; P:negative regulation of RNA splicing; IDA:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IEA:InterPro.
DR   GO; GO:0043484; P:regulation of RNA splicing; IBA:GO_Central.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   CDD; cd12779; RRM1_ROD1; 1.
DR   CDD; cd12693; RRM2_PTBP1_like; 1.
DR   CDD; cd12703; RRM4_ROD1; 1.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR006536; HnRNP-L/PTB.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR034798; PTBP1/2/3_RRM2.
DR   InterPro; IPR021790; PTBP1_RRM.
DR   InterPro; IPR033110; PTBP3_RRM4.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR034326; ROD1_RRM1.
DR   InterPro; IPR000504; RRM_dom.
DR   Pfam; PF11835; RRM_8; 1.
DR   SMART; SM00360; RRM; 4.
DR   SUPFAM; SSF54928; SSF54928; 3.
DR   TIGRFAMs; TIGR01649; hnRNP-L_PTB; 1.
DR   PROSITE; PS50102; RRM; 4.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Differentiation; Erythrocyte maturation;
KW   Isopeptide bond; mRNA processing; mRNA splicing; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; RNA-binding; Ubl conjugation.
FT   CHAIN           1..552
FT                   /note="Polypyrimidine tract-binding protein 3"
FT                   /id="PRO_0000081873"
FT   DOMAIN          59..143
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          182..258
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          358..432
FT                   /note="RRM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          475..550
FT                   /note="RRM 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          32..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..455
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   MOD_RES         127
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   MOD_RES         138
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   MOD_RES         423
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        65
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   CROSSLNK        216
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P26599"
FT   VAR_SEQ         1..96
FT                   /note="MDGVVTDLITVGLKRGSDELLSSGIINGPFTMNSSTPSTANGNDSKKFKRDR
FT                   PPCSPSRVLHLRKIPCDVTEAEIISLGLPFGKVTNLLMLKGKSQ -> M (in
FT                   isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045608"
FT   VAR_SEQ         1..31
FT                   /note="Missing (in isoform 1, isoform 2 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035985"
FT   VAR_SEQ         1..14
FT                   /note="MDGVVTDLITVGLK -> MDASPSPFSLPKKLNELSAR (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035986"
FT   VAR_SEQ         39
FT                   /note="T -> TGVY (in isoform 2, isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005"
FT                   /id="VSP_010867"
FT   VAR_SEQ         510..552
FT                   /note="KDRKMALIQLGSVEEAIQALIELHNHDLGENHHLRVSFSKSTI -> GLANS
FT                   WAQVILLLPPPHSAGITGMSHHAWLSVLFSVSVPSVSSAYMFSILSCSFSSVPTRYFWT
FT                   KN (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010868"
FT   CONFLICT        259
FT                   /note="T -> I (in Ref. 1; BAG50959)"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         O95758-1:1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
SQ   SEQUENCE   552 AA;  59690 MW;  6254928B781A436A CRC64;
     MDGVVTDLIT VGLKRGSDEL LSSGIINGPF TMNSSTPSTA NGNDSKKFKR DRPPCSPSRV
     LHLRKIPCDV TEAEIISLGL PFGKVTNLLM LKGKSQAFLE MASEEAAVTM VNYYTPITPH
     LRSQPVYIQY SNHRELKTDN LPNQARAQAA LQAVSAVQSG SLALSGGPSN EGTVLPGQSP
     VLRIIIENLF YPVTLEVLHQ IFSKFGTVLK IITFTKNNQF QALLQYADPV NAHYAKMALD
     GQNIYNACCT LRIDFSKLTS LNVKYNNDKS RDFTRLDLPT GDGQPSLEPP MAAAFGAPGI
     ISSPYAGAAG FAPAIGFPQA TGLSVPAVPG ALGPLTITSS AVTGRMAIPG ASGIPGNSVL
     LVTNLNPDLI TPHGLFILFG VYGDVHRVKI MFNKKENALV QMADANQAQL AMNHLSGQRL
     YGKVLRATLS KHQAVQLPRE GQEDQGLTKD FSNSPLHRFK KPGSKNFQNI FPPSATLHLS
     NIPPSVTVDD LKNLFIEAGC SVKAFKFFQK DRKMALIQLG SVEEAIQALI ELHNHDLGEN
     HHLRVSFSKS TI
//
ID   CDS1_HUMAN              Reviewed;         461 AA.
AC   Q92903; B2RAL5; O00163;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   23-FEB-2022, entry version 165.
DE   RecName: Full=Phosphatidate cytidylyltransferase 1 {ECO:0000305};
DE            EC=2.7.7.41 {ECO:0000269|PubMed:9407135};
DE   AltName: Full=CDP-DAG synthase 1;
DE   AltName: Full=CDP-DG synthase 1;
DE   AltName: Full=CDP-diacylglycerol synthase 1;
DE            Short=CDS 1;
DE   AltName: Full=CDP-diglyceride pyrophosphorylase 1;
DE   AltName: Full=CDP-diglyceride synthase 1;
DE   AltName: Full=CTP:phosphatidate cytidylyltransferase 1;
GN   Name=CDS1 {ECO:0000312|HGNC:HGNC:1800}; Synonyms=CDS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Neuron;
RX   PubMed=8863531; DOI=10.1046/j.1471-4159.1996.67052200.x;
RA   Heacock A.M., Uhler M.D., Agranoff B.W.;
RT   "Cloning of CDP-diacylglycerol synthase from a human neuronal cell line.";
RL   J. Neurochem. 67:2200-2203(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte, and Placenta;
RX   PubMed=9115637; DOI=10.1089/dna.1997.16.281;
RA   Weeks R., Dowhan W., Shen H., Balantac N., Meengs B., Nudelman E.,
RA   Leung D.W.;
RT   "Isolation and expression of an isoform of human CDP-diacylglycerol
RT   synthase cDNA.";
RL   DNA Cell Biol. 16:281-289(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=9407135; DOI=10.1074/jbc.272.52.33402;
RA   Lykidis A., Jackson P.D., Rock C.O., Jackowski S.;
RT   "The role of CDP-diacylglycerol synthetase and phosphatidylinositol
RT   synthase activity levels in the regulation of cellular phosphatidylinositol
RT   content.";
RL   J. Biol. Chem. 272:33402-33409(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   PubMed=9806839; DOI=10.1006/geno.1998.5547;
RA   Halford S., Dulai K.S., Daw S.C.M., Fitzgibbon J., Hunt D.M.;
RT   "Isolation and chromosomal localization of two human CDP-diacylglycerol
RT   synthase (CDS) genes.";
RL   Genomics 54:140-144(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND ACTIVITY REGULATION.
RX   PubMed=25375833; DOI=10.1021/bi501250m;
RA   D'Souza K., Kim Y.J., Balla T., Epand R.M.;
RT   "Distinct properties of the two isoforms of CDP-diacylglycerol synthase.";
RL   Biochemistry 53:7358-7367(2014).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=26946540; DOI=10.1194/jlr.m060574;
RA   Qi Y., Kapterian T.S., Du X., Ma Q., Fei W., Zhang Y., Huang X.,
RA   Dawes I.W., Yang H.;
RT   "CDP-diacylglycerol synthases regulate the growth of lipid droplets and
RT   adipocyte development.";
RL   J. Lipid Res. 57:767-780(2016).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=31548309; DOI=10.1074/jbc.ra119.009992;
RA   Xu Y., Mak H.Y., Lukmantara I., Li Y.E., Hoehn K.L., Huang X., Du X.,
RA   Yang H.;
RT   "CDP-DAG synthase 1 and 2 regulate lipid droplet growth through distinct
RT   mechanisms.";
RL   J. Biol. Chem. 294:16740-16755(2019).
RN   [11]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-204.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalyzes the conversion of phosphatidic acid (PA) to CDP-
CC       diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of
CC       phosphatidylglycerol, cardiolipin and phosphatidylinositol
CC       (PubMed:9407135, PubMed:25375833). Exhibits almost no acyl chain
CC       preference for PA, showing no discrimination for the sn-1/sn-2 acyl
CC       chain composition of PAs (PubMed:25375833). Plays an important role in
CC       regulating the growth of lipid droplets which are storage organelles at
CC       the center of lipid and energy homeostasis (PubMed:26946540,
CC       PubMed:31548309). Positively regulates the differentiation and
CC       development of adipocytes (By similarity).
CC       {ECO:0000250|UniProtKB:P98191, ECO:0000269|PubMed:25375833,
CC       ECO:0000269|PubMed:26946540, ECO:0000269|PubMed:31548309,
CC       ECO:0000269|PubMed:9407135}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphate + CTP + H(+) = a CDP-1,2-
CC         diacyl-sn-glycerol + diphosphate; Xref=Rhea:RHEA:16229,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37563,
CC         ChEBI:CHEBI:58332, ChEBI:CHEBI:58608; EC=2.7.7.41;
CC         Evidence={ECO:0000269|PubMed:9407135};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16230;
CC         Evidence={ECO:0000305|PubMed:9407135};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + CTP + H(+) = 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-
CC         eicosatetraenoyl)-sn-glycero-3-cytidine-5'-diphosphate + diphosphate;
CC         Xref=Rhea:RHEA:45648, ChEBI:CHEBI:15378, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:37563, ChEBI:CHEBI:77091, ChEBI:CHEBI:85349;
CC         Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45649;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphate + CTP + H(+) = 1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-
CC         sn-glycero-3-cytidine-5'-diphosphate + diphosphate;
CC         Xref=Rhea:RHEA:45660, ChEBI:CHEBI:15378, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:37563, ChEBI:CHEBI:77098, ChEBI:CHEBI:85352;
CC         Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45661;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + CTP + H(+) = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-
CC         eicosatetraenoyl)-sn-glycero-3-cytidine-5'-diphosphate + diphosphate;
CC         Xref=Rhea:RHEA:45652, ChEBI:CHEBI:15378, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:37563, ChEBI:CHEBI:72864, ChEBI:CHEBI:85350;
CC         Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45653;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate
CC         + CTP + H(+) = 1,2-di-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-
CC         cytidine-5'-diphosphate + diphosphate; Xref=Rhea:RHEA:45656,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37563,
CC         ChEBI:CHEBI:77126, ChEBI:CHEBI:85351;
CC         Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45657;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate +
CC         CTP + H(+) = 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
CC         cytidine-5'-diphosphate + diphosphate; Xref=Rhea:RHEA:45664,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37563,
CC         ChEBI:CHEBI:74560, ChEBI:CHEBI:85353;
CC         Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45665;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-
CC         glycero-3-phosphate + CTP + H(+) = 1-octadecanoyl-2-
CC         (4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-cytidine-5'-
CC         diphosphate + diphosphate; Xref=Rhea:RHEA:45668, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:37563, ChEBI:CHEBI:77130,
CC         ChEBI:CHEBI:85354; Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45669;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate + CTP +
CC         H(+) = 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-cytidine-5'-
CC         diphosphate + diphosphate; Xref=Rhea:RHEA:45672, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:37563, ChEBI:CHEBI:77128,
CC         ChEBI:CHEBI:85355; Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45673;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CTP + H(+) =
CC         1,2-di-(9Z-octadecenoyl)-sn-glycero-3-cytidine-5'-diphosphate +
CC         diphosphate; Xref=Rhea:RHEA:45676, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:37563, ChEBI:CHEBI:74546,
CC         ChEBI:CHEBI:85356; Evidence={ECO:0000269|PubMed:25375833};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45677;
CC         Evidence={ECO:0000305|PubMed:25375833};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:O35052};
CC   -!- ACTIVITY REGULATION: Inhibited by its anionic phospholipid end
CC       products, with phosphatidylinositol-(4,5)- bisphosphate showing the
CC       strongest inhibition. {ECO:0000269|PubMed:25375833}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.8 uM for 1-stearoyl-2-arachidonoyl-sn-phosphatidic acid
CC         {ECO:0000269|PubMed:25375833};
CC         KM=0.6 uM for 1-stearoyl-2-linoleoyl-sn-phosphatidic acid
CC         {ECO:0000269|PubMed:25375833};
CC         Vmax=3.3 umol/min/mg enzyme for 1-stearoyl-2-arachidonoyl-sn-
CC         phosphatidic acid {ECO:0000269|PubMed:25375833};
CC         Vmax=3.6 umol/min/mg enzyme for 1-stearoyl-2-linoleoyl-sn-
CC         phosphatidic acid {ECO:0000269|PubMed:25375833};
CC   -!- PATHWAY: Phospholipid metabolism; CDP-diacylglycerol biosynthesis; CDP-
CC       diacylglycerol from sn-glycerol 3-phosphate: step 3/3.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with FOS; this
CC       interaction may enhance catalytic activity (By similarity).
CC       {ECO:0000250|UniProtKB:O35052, ECO:0000250|UniProtKB:P98191}.
CC   -!- INTERACTION:
CC       Q92903; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-13295305, EBI-18304435;
CC       Q92903; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-13295305, EBI-10192441;
CC       Q92903; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-13295305, EBI-18159983;
CC       Q92903; Q9UKG4: SLC13A4; NbExp=3; IntAct=EBI-13295305, EBI-12808018;
CC       Q92903; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-13295305, EBI-10982110;
CC       Q92903; Q9Y385: UBE2J1; NbExp=3; IntAct=EBI-13295305, EBI-988826;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:25375833, ECO:0000269|PubMed:26946540,
CC       ECO:0000269|PubMed:31548309}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Expressed in adult tissues such as placenta, brain,
CC       small intestine, ovary, testis and prostate. Highly expressed in fetal
CC       kidney, lung and brain. Lower level in fetal liver.
CC       {ECO:0000269|PubMed:9407135}.
CC   -!- SIMILARITY: Belongs to the CDS family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U65887; AAC50735.1; -; mRNA.
DR   EMBL; U60808; AAC51184.1; -; mRNA.
DR   EMBL; AK314245; BAG36912.1; -; mRNA.
DR   EMBL; CH471057; EAX05950.1; -; Genomic_DNA.
DR   EMBL; BC074833; AAH74833.1; -; mRNA.
DR   EMBL; BC074881; AAH74881.1; -; mRNA.
DR   CCDS; CCDS3608.1; -.
DR   RefSeq; NP_001254.2; NM_001263.3.
DR   BioGRID; 107471; 49.
DR   CORUM; Q92903; -.
DR   IntAct; Q92903; 18.
DR   STRING; 9606.ENSP00000295887; -.
DR   SwissLipids; SLP:000000532; -.
DR   iPTMnet; Q92903; -.
DR   PhosphoSitePlus; Q92903; -.
DR   BioMuta; CDS1; -.
DR   DMDM; 3123204; -.
DR   EPD; Q92903; -.
DR   jPOST; Q92903; -.
DR   MassIVE; Q92903; -.
DR   MaxQB; Q92903; -.
DR   PaxDb; Q92903; -.
DR   PeptideAtlas; Q92903; -.
DR   PRIDE; Q92903; -.
DR   ProteomicsDB; 75588; -.
DR   Antibodypedia; 25245; 95 antibodies from 20 providers.
DR   DNASU; 1040; -.
DR   Ensembl; ENST00000295887; ENSP00000295887; ENSG00000163624.
DR   GeneID; 1040; -.
DR   KEGG; hsa:1040; -.
DR   MANE-Select; ENST00000295887.6; ENSP00000295887.5; NM_001263.4; NP_001254.2.
DR   UCSC; uc011ccv.3; human.
DR   CTD; 1040; -.
DR   DisGeNET; 1040; -.
DR   GeneCards; CDS1; -.
DR   HGNC; HGNC:1800; CDS1.
DR   HPA; ENSG00000163624; Low tissue specificity.
DR   MIM; 603548; gene.
DR   neXtProt; NX_Q92903; -.
DR   OpenTargets; ENSG00000163624; -.
DR   PharmGKB; PA26346; -.
DR   VEuPathDB; HostDB:ENSG00000163624; -.
DR   eggNOG; KOG1440; Eukaryota.
DR   GeneTree; ENSGT00940000158223; -.
DR   HOGENOM; CLU_023471_0_1_1; -.
DR   InParanoid; Q92903; -.
DR   OMA; NFAWTHM; -.
DR   OrthoDB; 1072976at2759; -.
DR   PhylomeDB; Q92903; -.
DR   TreeFam; TF313464; -.
DR   BRENDA; 2.7.7.41; 2681.
DR   PathwayCommons; Q92903; -.
DR   Reactome; R-HSA-1483226; Synthesis of PI.
DR   SignaLink; Q92903; -.
DR   SIGNOR; Q92903; -.
DR   UniPathway; UPA00557; UER00614.
DR   BioGRID-ORCS; 1040; 7 hits in 1041 CRISPR screens.
DR   ChiTaRS; CDS1; human.
DR   GeneWiki; CDS1_(gene); -.
DR   GenomeRNAi; 1040; -.
DR   Pharos; Q92903; Tbio.
DR   PRO; PR:Q92903; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q92903; protein.
DR   Bgee; ENSG00000163624; Expressed in bronchial epithelial cell and 215 other tissues.
DR   ExpressionAtlas; Q92903; baseline and differential.
DR   Genevisible; Q92903; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0004142; F:diacylglycerol cholinephosphotransferase activity; NAS:UniProtKB.
DR   GO; GO:0004605; F:phosphatidate cytidylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016024; P:CDP-diacylglycerol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0140042; P:lipid droplet formation; IMP:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0007602; P:phototransduction; NAS:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   InterPro; IPR000374; PC_trans.
DR   InterPro; IPR016720; PC_Trfase_euk.
DR   PANTHER; PTHR13773; PTHR13773; 1.
DR   PIRSF; PIRSF018269; PC_trans_euk; 1.
DR   PROSITE; PS01315; CDS; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Lipid biosynthesis; Lipid metabolism; Magnesium;
KW   Membrane; Methylation; Nucleotidyltransferase; Phospholipid biosynthesis;
KW   Phospholipid metabolism; Phosphoprotein; Reference proteome; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..461
FT                   /note="Phosphatidate cytidylyltransferase 1"
FT                   /id="PRO_0000090713"
FT   TRANSMEM        96..116
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        149..169
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        183..203
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        230..250
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        279..299
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        357..377
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          1..67
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        18..56
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         7
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P98191"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35052"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P98191"
FT   VARIANT         99
FT                   /note="L -> F (in dbSNP:rs36068434)"
FT                   /id="VAR_048736"
FT   VARIANT         204
FT                   /note="K -> T (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036129"
FT   CONFLICT        444..461
FT                   /note="TLKTHLIEKGILQPTLKV -> P (in Ref. 1; AAC50735)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   461 AA;  53304 MW;  E9D761BA285A5AB1 CRC64;
     MLELRHRGSC PGPREAVSPP HREGEAAGGD HETESTSDKE TDIDDRYGDL DSRTDSDIPE
     IPPSSDRTPE ILKKALSGLS SRWKNWWIRG ILTLTMISLF FLIIYMGSFM LMLLVLGIQV
     KCFHEIITIG YRVYHSYDLP WFRTLSWYFL LCVNYFFYGE TVADYFATFV QREEQLQFLI
     RYHRFISFAL YLAGFCMFVL SLVKKHYRLQ FYMFAWTHVT LLITVTQSHL VIQNLFEGMI
     WFLVPISSVI CNDITAYLFG FFFGRTPLIK LSPKKTWEGF IGGFFSTVVF GFIAAYVLSK
     YQYFVCPVEY RSDVNSFVTE CEPSELFQLQ TYSLPPFLKA VLRQERVSLY PFQIHSIALS
     TFASLIGPFG GFFASGFKRA FKIKDFANTI PGHGGIMDRF DCQYLMATFV HVYITSFIRG
     PNPSKVLQQL LVLQPEQQLN IYKTLKTHLI EKGILQPTLK V
//
ID   CLOCK_HUMAN             Reviewed;         846 AA.
AC   O15516; A0AV01; A2I2N9; O14516; Q9UIT8;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   23-FEB-2022, entry version 211.
DE   RecName: Full=Circadian locomoter output cycles protein kaput;
DE            Short=hCLOCK;
DE            EC=2.3.1.48;
DE   AltName: Full=Class E basic helix-loop-helix protein 8;
DE            Short=bHLHe8;
GN   Name=CLOCK; Synonyms=BHLHE8, KIAA0334;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=10198158; DOI=10.1006/geno.1998.5675;
RA   Steeves T.D.L., King D.P., Zhao Y., Sangoram A.M., Du F., Bowcock A.M.,
RA   Moore R.Y., Takahashi J.S.;
RT   "Molecular cloning and characterization of the human CLOCK gene: expression
RT   in the suprachiasmatic nuclei.";
RL   Genomics 57:189-200(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-349.
RC   TISSUE=Brain;
RA   Ikeda M., Takehara N., Ebisawa T., Yamauchi T., Nomura M.;
RT   "Molecular cloning of human Clock cDNA 5'-end.";
RL   Submitted (AUG-1997) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   DNA-BINDING, AND ACTIVITY REGULATION.
RX   PubMed=11441146; DOI=10.1126/science.1060698;
RA   Rutter J., Reick M., Wu L.C., McKnight S.L.;
RT   "Regulation of clock and NPAS2 DNA binding by the redox state of NAD
RT   cofactors.";
RL   Science 293:510-514(2001).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KAT2B; CREBBP AND
RP   EP300.
RX   PubMed=14645221; DOI=10.1074/jbc.m311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the vascular
RT   clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [9]
RP   MUTAGENESIS OF GLU-116; GLY-332; HIS-360; GLU-367; VAL-601 AND PRO-840.
RX   PubMed=16474406; DOI=10.1038/ng1745;
RA   Sato T.K., Yamada R.G., Ukai H., Baggs J.E., Miraglia L.J., Kobayashi T.J.,
RA   Welsh D.K., Kay S.A., Ueda H.R., Hogenesch J.B.;
RT   "Feedback repression is required for mammalian circadian clock function.";
RL   Nat. Genet. 38:312-319(2006).
RN   [10]
RP   FUNCTION.
RX   PubMed=18587630; DOI=10.1007/s11010-008-9846-x;
RA   Li R., Yue J., Zhang Y., Zhou L., Hao W., Yuan J., Qiang B., Ding J.M.,
RA   Peng X., Cao J.M.;
RT   "CLOCK/BMAL1 regulates human nocturnin transcription through binding to the
RT   E-box of nocturnin promoter.";
RL   Mol. Cell. Biochem. 317:169-177(2008).
RN   [11]
RP   INTERACTION WITH ID2.
RX   PubMed=20861012; DOI=10.1074/jbc.m110.175182;
RA   Ward S.M., Fernando S.J., Hou T.Y., Duffield G.E.;
RT   "The transcriptional repressor ID2 can interact with the canonical clock
RT   components CLOCK and BMAL1 and mediate inhibitory effects on mPer1
RT   expression.";
RL   J. Biol. Chem. 285:38987-39000(2010).
RN   [12]
RP   INTERACTION WITH ARNTL; CRY1 AND PER2.
RX   PubMed=21613214; DOI=10.1074/jbc.m111.254680;
RA   Ye R., Selby C.P., Ozturk N., Annayev Y., Sancar A.;
RT   "Biochemical analysis of the canonical model for the mammalian circadian
RT   clock.";
RL   J. Biol. Chem. 286:25891-25902(2011).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH NR3C1.
RX   PubMed=21980503; DOI=10.1371/journal.pone.0025612;
RA   Charmandari E., Chrousos G.P., Lambrou G.I., Pavlaki A., Koide H., Ng S.S.,
RA   Kino T.;
RT   "Peripheral CLOCK regulates target-tissue glucocorticoid receptor
RT   transcriptional activity in a circadian fashion in man.";
RL   PLoS ONE 6:E25612-E25612(2011).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21659603; DOI=10.1126/science.1203430;
RA   Cotta-Ramusino C., McDonald E.R. III, Hurov K., Sowa M.E., Harper J.W.,
RA   Elledge S.J.;
RT   "A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1
RT   interacting protein required for ATR signaling.";
RL   Science 332:1313-1317(2011).
RN   [15]
RP   INTERACTION WITH KDM5A.
RX   PubMed=21960634; DOI=10.1126/science.1206022;
RA   DiTacchio L., Le H.D., Vollmers C., Hatori M., Witcher M., Secombe J.,
RA   Panda S.;
RT   "Histone lysine demethylase JARID1a activates CLOCK-BMAL1 and influences
RT   the circadian clock.";
RL   Science 333:1881-1885(2011).
RN   [16]
RP   FUNCTION.
RX   PubMed=22284746; DOI=10.1111/j.1538-7836.2012.04643.x;
RA   Tracey C.J., Pan X., Catterson J.H., Harmar A.J., Hussain M.M.,
RA   Hartley P.S.;
RT   "Diurnal expression of the thrombopoietin gene is regulated by CLOCK.";
RL   J. Thromb. Haemost. 10:662-669(2012).
RN   [17]
RP   REVIEW.
RX   PubMed=23576606; DOI=10.1152/ajpregu.00066.2013;
RA   Richards J., Gumz M.L.;
RT   "Mechanism of the circadian clock in physiology.";
RL   Am. J. Physiol. 304:R1053-R1064(2013).
RN   [18]
RP   PHOSPHORYLATION AT THR-451 AND THR-461, MUTAGENESIS OF THR-451 AND THR-461,
RP   AND INTERACTION WITH THE COMPLEX P35/CDK5.
RX   PubMed=24235147; DOI=10.1074/jbc.m113.494856;
RA   Kwak Y., Jeong J., Lee S., Park Y.U., Lee S.A., Han D.H., Kim J.H.,
RA   Ohshima T., Mikoshiba K., Suh Y.H., Cho S., Park S.K.;
RT   "Cyclin-dependent kinase 5 (Cdk5) regulates the function of CLOCK protein
RT   by direct phosphorylation.";
RL   J. Biol. Chem. 288:36878-36889(2013).
RN   [19]
RP   FUNCTION.
RX   PubMed=23785138; DOI=10.1523/jneurosci.2757-12.2013;
RA   Baeza-Raja B., Eckel-Mahan K., Zhang L., Vagena E., Tsigelny I.F.,
RA   Sassone-Corsi P., Ptacek L.J., Akassoglou K.;
RT   "p75 neurotrophin receptor is a clock gene that regulates oscillatory
RT   components of circadian and metabolic networks.";
RL   J. Neurosci. 33:10221-10234(2013).
RN   [20]
RP   SUMOYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ESR1.
RX   PubMed=23160374; DOI=10.1038/onc.2012.518;
RA   Li S., Wang M., Ao X., Chang A.K., Yang C., Zhao F., Bi H., Liu Y.,
RA   Xiao L., Wu H.;
RT   "CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the
RT   transcriptional activity of estrogen receptor-alpha.";
RL   Oncogene 32:4883-4891(2013).
RN   [21]
RP   REVIEW.
RX   PubMed=23303907; DOI=10.1152/physrev.00016.2012;
RA   Eckel-Mahan K., Sassone-Corsi P.;
RT   "Metabolism and the circadian clock converge.";
RL   Physiol. Rev. 93:107-135(2013).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24005054; DOI=10.1038/jid.2013.366;
RA   Al-Nuaimi Y., Hardman J.A., Biro T., Haslam I.S., Philpott M.P., Toth B.I.,
RA   Farjo N., Farjo B., Baier G., Watson R.E., Grimaldi B., Kloepper J.E.,
RA   Paus R.;
RT   "A meeting of two chronobiological systems: circadian proteins Period1 and
RT   BMAL1 modulate the human hair cycle clock.";
RL   J. Invest. Dermatol. 134:610-619(2014).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   REVIEW.
RX   PubMed=23916625; DOI=10.1016/j.tcb.2013.07.002;
RA   Partch C.L., Green C.B., Takahashi J.S.;
RT   "Molecular architecture of the mammalian circadian clock.";
RL   Trends Cell Biol. 24:90-99(2014).
RN   [25]
RP   ASSOCIATION WITH PASD1.
RX   PubMed=25936801; DOI=10.1016/j.molcel.2015.03.031;
RA   Michael A.K., Harvey S.L., Sammons P.J., Anderson A.P., Kopalle H.M.,
RA   Banham A.H., Partch C.L.;
RT   "Cancer/testis antigen PASD1 silences the circadian clock.";
RL   Mol. Cell 58:743-754(2015).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ARNTL; ASS1; NDUFA9
RP   AND IMPDH2.
RX   PubMed=28985504; DOI=10.1016/j.molcel.2017.09.008;
RA   Lin R., Mo Y., Zha H., Qu Z., Xie P., Zhu Z.J., Xu Y., Xiong Y., Guan K.L.;
RT   "CLOCK acetylates ASS1 to drive circadian rhythm of ureagenesis.";
RL   Mol. Cell 68:198-209(2017).
RN   [27]
RP   INTERACTION WITH PIWIL2.
RX   PubMed=28903391; DOI=10.18632/oncotarget.18973;
RA   Lu Y., Zheng X., Hu W., Bian S., Zhang Z., Tao D., Liu Y., Ma Y.;
RT   "Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating
RT   the stability and activity of BMAL1 and CLOCK.";
RL   Oncotarget 8:54913-54924(2017).
RN   [28]
RP   INTERACTION WITH HNF4A.
RX   PubMed=30530698; DOI=10.1073/pnas.1816411115;
RA   Qu M., Duffy T., Hirota T., Kay S.A.;
RT   "Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-
RT   specific circadian networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E12305-E12312(2018).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 29-89 IN COMPLEX WITH ARNTL AND
RP   DNA, FUNCTION, ACTIVITY REGULATION, SUBUNIT, AND MUTAGENESIS OF SER-38;
RP   SER-42; PHE-50 AND HIS-84.
RX   PubMed=23229515; DOI=10.1038/cr.2012.170;
RA   Wang Z., Wu Y., Li L., Su X.D.;
RT   "Intermolecular recognition revealed by the complex structure of human
RT   CLOCK-BMAL1 basic helix-loop-helix domains with E-box DNA.";
RL   Cell Res. 23:213-224(2013).
CC   -!- FUNCTION: Transcriptional activator which forms a core component of the
CC       circadian clock. The circadian clock, an internal time-keeping system,
CC       regulates various physiological processes through the generation of
CC       approximately 24 hour circadian rhythms in gene expression, which are
CC       translated into rhythms in metabolism and behavior. It is derived from
CC       the Latin roots 'circa' (about) and 'diem' (day) and acts as an
CC       important regulator of a wide array of physiological functions
CC       including metabolism, sleep, body temperature, blood pressure,
CC       endocrine, immune, cardiovascular, and renal function. Consists of two
CC       major components: the central clock, residing in the suprachiasmatic
CC       nucleus (SCN) of the brain, and the peripheral clocks that are present
CC       in nearly every tissue and organ system. Both the central and
CC       peripheral clocks can be reset by environmental cues, also known as
CC       Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the
CC       central clock is light, which is sensed by retina and signals directly
CC       to the SCN. The central clock entrains the peripheral clocks through
CC       neuronal and hormonal signals, body temperature and feeding-related
CC       cues, aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression to
CC       create a peak of protein expression once every 24 hours to control when
CC       a particular physiological process is most active with respect to the
CC       solar day. Transcription and translation of core clock components
CC       (CLOCK, NPAS2, ARNTL/BMAL1, ARNTL2/BMAL2, PER1, PER2, PER3, CRY1 and
CC       CRY2) plays a critical role in rhythm generation, whereas delays
CC       imposed by post-translational modifications (PTMs) are important for
CC       determining the period (tau) of the rhythms (tau refers to the period
CC       of a rhythm and is the length, in time, of one complete cycle). A
CC       diurnal rhythm is synchronized with the day/night cycle, while the
CC       ultradian and infradian rhythms have a period shorter and longer than
CC       24 hours, respectively. Disruptions in the circadian rhythms contribute
CC       to the pathology of cardiovascular diseases, cancer, metabolic
CC       syndromes and aging. A transcription/translation feedback loop (TTFL)
CC       forms the core of the molecular circadian clock mechanism.
CC       Transcription factors, CLOCK or NPAS2 and ARNTL/BMAL1 or ARNTL2/BMAL2,
CC       form the positive limb of the feedback loop, act in the form of a
CC       heterodimer and activate the transcription of core clock genes and
CC       clock-controlled genes (involved in key metabolic processes), harboring
CC       E-box elements (5'-CACGTG-3') within their promoters. The core clock
CC       genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form
CC       the negative limb of the feedback loop and interact with the
CC       CLOCK|NPAS2-ARNTL/BMAL1|ARNTL2/BMAL2 heterodimer inhibiting its
CC       activity and thereby negatively regulating their own expression. This
CC       heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G,
CC       which form a second feedback loop and which activate and repress
CC       ARNTL/BMAL1 transcription, respectively. Regulates the circadian
CC       expression of ICAM1, VCAM1, CCL2, THPO and MPL and also acts as an
CC       enhancer of the transactivation potential of NF-kappaB. Plays an
CC       important role in the homeostatic regulation of sleep. The CLOCK-
CC       ARNTL/BMAL1 heterodimer regulates the circadian expression of
CC       SERPINE1/PAI1, VWF, B3, CCRN4L/NOC, NAMPT, DBP, MYOD1, PPARGC1A,
CC       PPARGC1B, SIRT1, GYS2, F7, NGFR, GNRHR, BHLHE40/DEC1, ATF4, MTA1, KLF10
CC       and also genes implicated in glucose and lipid metabolism. Promotes
CC       rhythmic chromatin opening, regulating the DNA accessibility of other
CC       transcription factors. The CLOCK-ARNTL2/BMAL2 heterodimer activates the
CC       transcription of SERPINE1/PAI1 and BHLHE40/DEC1. The preferred binding
CC       motif for the CLOCK-ARNTL/BMAL1 heterodimer is 5'-CACGTGA-3', which
CC       contains a flanking Ala residue in addition to the canonical 6-
CC       nucleotide E-box sequence (PubMed:23229515). CLOCK specifically binds
CC       to the half-site 5'-CAC-3', while ARNTL binds to the half-site 5'-GTGA-
CC       3' (PubMed:23229515). The CLOCK-ARNTL/BMAL1 heterodimer also recognizes
CC       the non-canonical E-box motifs 5'-AACGTGA-3' and 5'-CATGTGA-3'
CC       (PubMed:23229515). CLOCK has an intrinsic acetyltransferase activity,
CC       which enables circadian chromatin remodeling by acetylating histones
CC       and nonhistone proteins, including its own partner ARNTL/BMAL1.
CC       Represses glucocorticoid receptor NR3C1/GR-induced transcriptional
CC       activity by reducing the association of NR3C1/GR to glucocorticoid
CC       response elements (GREs) via the acetylation of multiple lysine
CC       residues located in its hinge region (PubMed:21980503). The
CC       acetyltransferase activity of CLOCK is as important as its
CC       transcription activity in circadian control. Acetylates metabolic
CC       enzymes IMPDH2 and NDUFA9 in a circadian manner. Facilitated by BMAL1,
CC       rhythmically interacts and acetylates argininosuccinate synthase 1
CC       (ASS1) leading to enzymatic inhibition of ASS1 as well as the circadian
CC       oscillation of arginine biosynthesis and subsequent ureagenesis
CC       (PubMed:28985504). Drives the circadian rhythm of blood pressure
CC       through transcriptional activation of ATP1B1 (By similarity).
CC       {ECO:0000250|UniProtKB:O08785, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:18587630, ECO:0000269|PubMed:21659603,
CC       ECO:0000269|PubMed:21980503, ECO:0000269|PubMed:22284746,
CC       ECO:0000269|PubMed:23229515, ECO:0000269|PubMed:23785138,
CC       ECO:0000269|PubMed:24005054, ECO:0000269|PubMed:28985504}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetyl-CoA + L-lysyl-[protein] = CoA + H(+) + N(6)-acetyl-L-
CC         lysyl-[protein]; Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752,
CC         Rhea:RHEA-COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC   -!- ACTIVITY REGULATION: There is conflicting data about the effect of NAD
CC       cofactors on activity. PubMed:11441146 suggests that the redox state of
CC       the cell can modulate the transcriptional activity of the CLOCK-
CC       ARNTL/BMAL1 heterodimer; NADH and NADPH enhance the DNA-binding
CC       activity of the heterodimer. PubMed:23229515 reports that NADH and
CC       NADPH have no significant effect on DNA-binding activity of the CLOCK-
CC       ARNTL/BMAL1 heterodimer. {ECO:0000269|PubMed:11441146,
CC       ECO:0000269|PubMed:23229515}.
CC   -!- SUBUNIT: Component of the circadian clock oscillator which includes the
CC       CRY proteins, CLOCK or NPAS2, ARNTL/BMAL1 or ARNTL2/BMAL2, CSNK1D
CC       and/or CSNK1E, TIMELESS and the PER proteins (By similarity). Interacts
CC       with KMT2A; in a circadian manner (By similarity). Forms a heterodimer
CC       with ARNTL/BMAL1 (PubMed:21613214, PubMed:23229515). The CLOCK-
CC       ARNTL/BMAL1 heterodimer is required for E-box-dependent
CC       transactivation, for CLOCK nuclear translocation and degradation, and
CC       for phosphorylation of both CLOCK and ARNTL/BMAL1 (By similarity).
CC       Interacts with NR3C1 in a ligand-dependent fashion (PubMed:21980503).
CC       Interacts with ESR1 and estrogen stimulates this interaction
CC       (PubMed:23160374). Interacts with the complex p35/CDK5
CC       (PubMed:24235147). Interacts with RELA/p65 (By similarity). Interacts
CC       with KAT2B, CREBBP, EP300 (PubMed:14645221). Interacts with ID1 and ID3
CC       (By similarity). Interacts with ID2 (PubMed:20861012). Interacts with
CC       MTA1 (By similarity). Interacts with OGA (By similarity). Interacts
CC       with SIRT1 (By similarity). Interacts with CIPC (By similarity).
CC       Interacts with EZH2 (By similarity). Interacts with EIF4E, PIWIL1 and
CC       DDX4 (By similarity). Interacts with PER2 and CRY1 and the interaction
CC       with PER and CRY proteins requires translocation to the nucleus.
CC       Interacts with PER1 and CRY2 (By similarity). Interaction of the CLOCK-
CC       ARNTL/BMAL1 heterodimer with PER or CRY inhibits transcription
CC       activation (PubMed:21613214). Interaction of the CLOCK-ARNTL/BMAL1 with
CC       CRY1 is independent of DNA but with PER2 is off DNA (PubMed:21613214).
CC       The CLOCK-ARNTL/BMAL1 heterodimer interacts with GSK3B. Interacts with
CC       KDM5A (PubMed:21960634). Interacts with MYBBP1A (By similarity).
CC       Interacts with THRAP3 (By similarity). Interacts with MED1; this
CC       interaction requires the presence of THRAP3 (By similarity). Interacts
CC       with NCOA2 (By similarity). The CLOCK-ARNTL/BMAL1 heterodimer interacts
CC       with PASD1 (PubMed:25936801). Interacts with ASS1 and IMPDH2; in a
CC       circadian manner (PubMed:28985504). Interacts with NDUFA9
CC       (PubMed:28985504). Interacts with PIWIL2 (via PIWI domain)
CC       (PubMed:28903391). Interacts with HNF4A (PubMed:30530698).
CC       {ECO:0000250|UniProtKB:O08785, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:20861012, ECO:0000269|PubMed:21613214,
CC       ECO:0000269|PubMed:21960634, ECO:0000269|PubMed:21980503,
CC       ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23229515,
CC       ECO:0000269|PubMed:24235147, ECO:0000269|PubMed:25936801,
CC       ECO:0000269|PubMed:28903391, ECO:0000269|PubMed:28985504,
CC       ECO:0000269|PubMed:30530698}.
CC   -!- INTERACTION:
CC       O15516; O00327: ARNTL; NbExp=4; IntAct=EBI-1794265, EBI-1794206;
CC       O15516; O00327-8: ARNTL; NbExp=6; IntAct=EBI-1794265, EBI-11991546;
CC       O15516; Q8WYA1-3: ARNTL2; NbExp=4; IntAct=EBI-1794265, EBI-12268276;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:28985504}. Cytoplasm
CC       {ECO:0000250|UniProtKB:O08785}. Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:28985504}. Note=Shuttling between the cytoplasm and
CC       the nucleus is under circadian regulation and is ARNTL/BMAL1-dependent.
CC       Phosphorylated form located in the nucleus while the nonphosphorylated
CC       form found only in the cytoplasm. Sequestered to the cytoplasm in the
CC       presence of ID2 (By similarity). Localizes to sites of DNA damage in a
CC       H2AX-independent manner. {ECO:0000250|UniProtKB:O08785,
CC       ECO:0000269|PubMed:21659603}.
CC   -!- TISSUE SPECIFICITY: Hair follicles (at protein level). Expressed in all
CC       tissues examined including spleen, thymus, prostate, testis, ovary,
CC       small intestine, colon, leukocytes, heart, brain, placenta, lung,
CC       liver, skeletal muscle, kidney and pancreas. Highest levels in testis
CC       and skeletal muscle. Low levels in thymus, lung and liver. Expressed in
CC       all brain regions with highest levels in cerebellum. Highly expressed
CC       in the suprachiasmatic nucleus (SCN). {ECO:0000269|PubMed:10198158,
CC       ECO:0000269|PubMed:24005054}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000250|UniProtKB:O08785}.
CC   -!- PTM: O-glycosylated; contains O-GlcNAc. O-glycosylation by OGT prevents
CC       protein degradation by inhibiting ubiquitination. It also stabilizes
CC       the CLOCK-ARNTL/BMAL1 heterodimer thereby increasing CLOCK-ARNTL/BMAL1-
CC       mediated transcriptional activation of PER1/2/3 and CRY1/2.
CC       {ECO:0000250|UniProtKB:O08785}.
CC   -!- PTM: Phosphorylation is dependent on the CLOCK-ARNTL/BMAL1 heterodimer
CC       formation. Phosphorylation enhances the transcriptional activity,
CC       alters the subcellular localization and decreases the stability of the
CC       heterodimer by promoting its degradation. Phosphorylation shows
CC       circadian variations in the liver. May be phosphorylated by CSNK1D and
CC       CKSN1E. {ECO:0000269|PubMed:24235147}.
CC   -!- PTM: Sumoylation enhances its transcriptional activity and interaction
CC       with ESR1, resulting in up-regulation of ESR1 activity. Estrogen
CC       stimulates sumoylation. Desumoylation by SENP1 negatively regulates its
CC       transcriptional activity. Sumoylation stimulates cell proliferation and
CC       increases the proportion of S phase cells in breast cancer cell lines.
CC       {ECO:0000269|PubMed:23160374}.
CC   -!- PTM: Undergoes lysosome-mediated degradation in a time-dependent manner
CC       in the liver. {ECO:0000250|UniProtKB:O08785}.
CC   -!- MISCELLANEOUS: CLOCK-ARNTL/BMAL1 double mutations within the PAS
CC       domains result in synergistic desensitization to high levels of CRY on
CC       repression of CLOCK-ARNTL/BMAl1 transcriptional activity of PER1 and
CC       disrupt circadian rhythmicity.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20792.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF011568; AAB83969.1; -; mRNA.
DR   EMBL; AH008440; AAF13733.1; -; Genomic_DNA.
DR   EMBL; EF015897; ABM64208.1; -; Genomic_DNA.
DR   EMBL; AB002332; BAA20792.2; ALT_INIT; mRNA.
DR   EMBL; AK291708; BAF84397.1; -; mRNA.
DR   EMBL; BC126157; AAI26158.1; -; mRNA.
DR   EMBL; BC126159; AAI26160.1; -; mRNA.
DR   EMBL; AB005535; BAA21774.1; -; mRNA.
DR   CCDS; CCDS3500.1; -.
DR   RefSeq; NP_001254772.1; NM_001267843.1.
DR   RefSeq; NP_004889.1; NM_004898.3.
DR   RefSeq; XP_005265844.1; XM_005265787.2.
DR   RefSeq; XP_011532711.1; XM_011534409.2.
DR   RefSeq; XP_011532712.1; XM_011534410.2.
DR   RefSeq; XP_011532713.1; XM_011534411.2.
DR   RefSeq; XP_016864343.1; XM_017008854.1.
DR   PDB; 4H10; X-ray; 2.40 A; B=29-89.
DR   PDB; 6QPJ; X-ray; 2.31 A; A=105-265.
DR   PDBsum; 4H10; -.
DR   PDBsum; 6QPJ; -.
DR   SMR; O15516; -.
DR   BioGRID; 114944; 80.
DR   ComplexPortal; CPX-3229; CLOCK-BMAL1 transcription complex.
DR   ComplexPortal; CPX-3230; CLOCK-BMAL2 transcription complex.
DR   CORUM; O15516; -.
DR   DIP; DIP-46009N; -.
DR   IntAct; O15516; 17.
DR   MINT; O15516; -.
DR   STRING; 9606.ENSP00000308741; -.
DR   GlyGen; O15516; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O15516; -.
DR   PhosphoSitePlus; O15516; -.
DR   BioMuta; CLOCK; -.
DR   EPD; O15516; -.
DR   jPOST; O15516; -.
DR   MassIVE; O15516; -.
DR   MaxQB; O15516; -.
DR   PaxDb; O15516; -.
DR   PeptideAtlas; O15516; -.
DR   PRIDE; O15516; -.
DR   ProteomicsDB; 48706; -.
DR   Antibodypedia; 909; 515 antibodies from 41 providers.
DR   DNASU; 9575; -.
DR   Ensembl; ENST00000309964; ENSP00000308741; ENSG00000134852.
DR   Ensembl; ENST00000381322; ENSP00000370723; ENSG00000134852.
DR   Ensembl; ENST00000513440; ENSP00000426983; ENSG00000134852.
DR   GeneID; 9575; -.
DR   KEGG; hsa:9575; -.
DR   MANE-Select; ENST00000513440.6; ENSP00000426983.1; NM_004898.4; NP_004889.1.
DR   UCSC; uc003haz.3; human.
DR   CTD; 9575; -.
DR   DisGeNET; 9575; -.
DR   GeneCards; CLOCK; -.
DR   HGNC; HGNC:2082; CLOCK.
DR   HPA; ENSG00000134852; Low tissue specificity.
DR   MIM; 601851; gene.
DR   neXtProt; NX_O15516; -.
DR   OpenTargets; ENSG00000134852; -.
DR   PharmGKB; PA26609; -.
DR   VEuPathDB; HostDB:ENSG00000134852; -.
DR   eggNOG; KOG3561; Eukaryota.
DR   GeneTree; ENSGT00940000157580; -.
DR   HOGENOM; CLU_010044_2_2_1; -.
DR   InParanoid; O15516; -.
DR   OMA; RHRTDKM; -.
DR   OrthoDB; 205871at2759; -.
DR   PhylomeDB; O15516; -.
DR   TreeFam; TF324568; -.
DR   BRENDA; 2.3.1.48; 2681.
DR   PathwayCommons; O15516; -.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-9707616; Heme signaling.
DR   SignaLink; O15516; -.
DR   SIGNOR; O15516; -.
DR   BioGRID-ORCS; 9575; 6 hits in 1066 CRISPR screens.
DR   ChiTaRS; CLOCK; human.
DR   GeneWiki; CLOCK; -.
DR   GenomeRNAi; 9575; -.
DR   Pharos; O15516; Tbio.
DR   PRO; PR:O15516; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; O15516; protein.
DR   Bgee; ENSG00000134852; Expressed in secondary oocyte and 249 other tissues.
DR   ExpressionAtlas; O15516; baseline and differential.
DR   Genevisible; O15516; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0033391; C:chromatoid body; ISS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:1990513; C:CLOCK-BMAL transcription complex; IPI:ComplexPortal.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; IPI:MGI.
DR   GO; GO:0031490; F:chromatin DNA binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IMP:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; TAS:ProtInc.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0009648; P:photoperiodism; TAS:ProtInc.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; IDA:ComplexPortal.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IGI:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0042634; P:regulation of hair cycle; IMP:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:2000074; P:regulation of type B pancreatic cell development; ISS:UniProtKB.
DR   GO; GO:0051775; P:response to redox state; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   IDEAL; IID00430; -.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Acyltransferase; Biological rhythms; Cytoplasm;
KW   DNA damage; DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..846
FT                   /note="Circadian locomoter output cycles protein kaput"
FT                   /id="PRO_0000127163"
FT   DOMAIN          34..84
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          107..177
FT                   /note="PAS 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          262..332
FT                   /note="PAS 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   DOMAIN          336..379
FT                   /note="PAC"
FT   REGION          371..845
FT                   /note="Interaction with NR3C1"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   REGION          392..411
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          420..495
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          450..570
FT                   /note="Interaction with SIRT1"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   REGION          514..564
FT                   /note="Implicated in the circadian rhythmicity"
FT                   /evidence="ECO:0000250"
FT   REGION          624..654
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          764..783
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          811..846
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           32..47
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   COMPBIAS        427..464
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        475..495
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            39
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            43
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            47
FT                   /note="Interaction with E-box DNA"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   SITE            84
FT                   /note="Important for interaction with ARNTL/BMAL1"
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MOD_RES         38
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   MOD_RES         427
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   MOD_RES         451
FT                   /note="Phosphothreonine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:24235147"
FT   MOD_RES         461
FT                   /note="Phosphothreonine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:24235147"
FT   CROSSLNK        67
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   CROSSLNK        842
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:O08785"
FT   VARIANT         208
FT                   /note="S -> C (in dbSNP:rs34897046)"
FT                   /id="VAR_040061"
FT   VARIANT         380
FT                   /note="E -> K (in dbSNP:rs1056478)"
FT                   /id="VAR_040062"
FT   VARIANT         395
FT                   /note="L -> I (in dbSNP:rs6855837)"
FT                   /id="VAR_029076"
FT   VARIANT         542
FT                   /note="H -> R (in dbSNP:rs3762836)"
FT                   /id="VAR_029077"
FT   MUTAGEN         38
FT                   /note="S->E: Phosphomimetic mutant with no effect on DNA
FT                   binding or CLOCK-ARNTL/BMAL1 transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         42
FT                   /note="S->E: Phosphomimetic mutant with no effect on DNA
FT                   binding or CLOCK-ARNTL/BMAL1 transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         50
FT                   /note="F->M: No effect on ARNTL/BMAL1 binding."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         84
FT                   /note="H->L: Impaired ARNTL/BMAL1 binding."
FT                   /evidence="ECO:0000269|PubMed:23229515"
FT   MUTAGEN         116
FT                   /note="E->K: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity; when associated
FT                   with K-367 and L-601."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         332
FT                   /note="G->E: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity; when associated
FT                   with L-840."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         360
FT                   /note="H->Y: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         367
FT                   /note="E->K: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity; when associated
FT                   with E-116 and L-601."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         451
FT                   /note="T->F: Significant loss in phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:24235147"
FT   MUTAGEN         461
FT                   /note="T->F: Significant loss in phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:24235147"
FT   MUTAGEN         601
FT                   /note="V->L: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity; when associated
FT                   with K-116 and K-367."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   MUTAGEN         840
FT                   /note="P->L: 3-fold increase in PER1 reporter activity by
FT                   CLOCK-ARNTL/BMAL1. Some reduction of CRY1 inhibition of
FT                   CLOCK-ARNTL/BMAL1 transcriptional activity; when associated
FT                   with E-332."
FT                   /evidence="ECO:0000269|PubMed:16474406"
FT   CONFLICT        440
FT                   /note="S -> P (in Ref. 1; AAF13733)"
FT                   /evidence="ECO:0000305"
FT   HELIX           33..58
FT                   /evidence="ECO:0007829|PDB:4H10"
FT   STRAND          61..63
FT                   /evidence="ECO:0007829|PDB:4H10"
FT   HELIX           70..89
FT                   /evidence="ECO:0007829|PDB:4H10"
FT   HELIX           107..118
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   STRAND          130..134
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           138..142
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           146..149
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           160..162
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           163..174
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   STRAND          191..198
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   STRAND          210..221
FT                   /evidence="ECO:0007829|PDB:6QPJ"
FT   STRAND          249..257
FT                   /evidence="ECO:0007829|PDB:6QPJ"
SQ   SEQUENCE   846 AA;  95304 MW;  C292B451A33E4CBF CRC64;
     MLFTVSCSKM SSIVDRDDSS IFDGLVEEDD KDKAKRVSRN KSEKKRRDQF NVLIKELGSM
     LPGNARKMDK STVLQKSIDF LRKHKEITAQ SDASEIRQDW KPTFLSNEEF TQLMLEALDG
     FFLAIMTDGS IIYVSESVTS LLEHLPSDLV DQSIFNFIPE GEHSEVYKIL STHLLESDSL
     TPEYLKSKNQ LEFCCHMLRG TIDPKEPSTY EYVKFIGNFK SLNSVSSSAH NGFEGTIQRT
     HRPSYEDRVC FVATVRLATP QFIKEMCTVE EPNEEFTSRH SLEWKFLFLD HRAPPIIGYL
     PFEVLGTSGY DYYHVDDLEN LAKCHEHLMQ YGKGKSCYYR FLTKGQQWIW LQTHYYITYH
     QWNSRPEFIV CTHTVVSYAE VRAERRRELG IEESLPETAA DKSQDSGSDN RINTVSLKEA
     LERFDHSPTP SASSRSSRKS SHTAVSDPSS TPTKIPTDTS TPPRQHLPAH EKMVQRRSSF
     SSQSINSQSV GSSLTQPVMS QATNLPIPQG MSQFQFSAQL GAMQHLKDQL EQRTRMIEAN
     IHRQQEELRK IQEQLQMVHG QGLQMFLQQS NPGLNFGSVQ LSSGNSSNIQ QLAPINMQGQ
     VVPTNQIQSG MNTGHIGTTQ HMIQQQTLQS TSTQSQQNVL SGHSQQTSLP SQTQSTLTAP
     LYNTMVISQP AAGSMVQIPS SMPQNSTQSA AVTTFTQDRQ IRFSQGQQLV TKLVTAPVAC
     GAVMVPSTML MGQVVTAYPT FATQQQQSQT LSVTQQQQQQ SSQEQQLTSV QQPSQAQLTQ
     PPQQFLQTSR LLHGNPSTQL ILSAAFPLQQ STFPQSHHQQ HQSQQQQQLS RHRTDSLPDP
     SKVQPQ
//
ID   CHK1_HUMAN              Reviewed;         476 AA.
AC   O14757; A8K934; B4DDD0; B4DSK3; B5BTY6; F5H7S4; H2BI51;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   23-FEB-2022, entry version 236.
DE   RecName: Full=Serine/threonine-protein kinase Chk1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10673501, ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:14559997, ECO:0000269|PubMed:15659650, ECO:0000269|PubMed:9278511};
DE   AltName: Full=CHK1 checkpoint homolog;
DE   AltName: Full=Cell cycle checkpoint kinase;
DE   AltName: Full=Checkpoint kinase-1;
GN   Name=CHEK1; Synonyms=CHK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF
RP   CDC25A; CDC25B AND CDC25C, CATALYTIC ACTIVITY, INTERACTION WITH CDC25A;
RP   CDC25B AND CDC25C, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MUTAGENESIS OF
RP   ASP-130, AND VARIANT VAL-471.
RX   PubMed=9278511; DOI=10.1126/science.277.5331.1497;
RA   Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H.,
RA   Elledge S.J.;
RT   "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA
RT   damage to Cdk regulation through Cdc25.";
RL   Science 277:1497-1501(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND VARIANT VAL-471.
RX   PubMed=9382850; DOI=10.1016/s0960-9822(06)00417-9;
RA   Flaggs G., Plug A.W., Dunks K.M., Mundt K.E., Ford J.C., Quiggle M.R.E.,
RA   Taylor E.M., Westphal C.H., Ashley T., Hoekstra M.F., Carr A.M.;
RT   "Atm-dependent interactions of a mammalian chk1 homolog with meiotic
RT   chromosomes.";
RL   Curr. Biol. 7:977-986(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-471.
RX   PubMed=10717241; DOI=10.3892/ijo.16.4.731;
RA   Semba S., Ouyang H., Han S.-Y., Kato Y., Horii A.;
RT   "Analysis of the candidate target genes for mutation in microsatellite
RT   instability-positive cancers of the colorectum, stomach, and endometrium.";
RL   Int. J. Oncol. 16:731-737(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Fetal thymus;
RX   PubMed=22184239; DOI=10.1073/pnas.1104767109;
RA   Pabla N., Bhatt K., Dong Z.;
RT   "Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous
RT   inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:197-202(2012).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP   VAL-471.
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-156 AND VAL-471.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-471.
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-471.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-471.
RC   TISSUE=Bone marrow, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   ASP-130.
RX   PubMed=10673501;
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RT   "The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2)
RT   phosphorylate p53 at multiple DNA damage-inducible sites.";
RL   Genes Dev. 14:289-300(2000).
RN   [12]
RP   ERRATUM OF PUBMED:10673501.
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RL   Genes Dev. 14:750-750(2000).
RN   [13]
RP   PHOSPHORYLATION AT SER-345 BY ATR.
RX   PubMed=10859164;
RA   Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G.,
RA   Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J.;
RT   "Chk1 is an essential kinase that is regulated by Atr and required for the
RT   G(2)/M DNA damage checkpoint.";
RL   Genes Dev. 14:1448-1459(2000).
RN   [14]
RP   FUNCTION IN DNA REPLICATION, PHOSPHORYLATION BY ATR, AND MUTAGENESIS OF
RP   ASP-130.
RX   PubMed=11535615; DOI=10.1083/jcb.200104099;
RA   Feijoo C., Hall-Jackson C., Wu R., Jenkins D., Leitch J., Gilbert D.M.,
RA   Smythe C.;
RT   "Activation of mammalian Chk1 during DNA replication arrest: a role for
RT   Chk1 in the intra-S phase checkpoint monitoring replication origin
RT   firing.";
RL   J. Cell Biol. 154:913-923(2001).
RN   [15]
RP   PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF ASP-130;
RP   SER-317; SER-345; SER-357; SER-366 AND SER-468.
RX   PubMed=11390642; DOI=10.1128/mcb.21.13.4129-4139.2001;
RA   Zhao H., Piwnica-Worms H.;
RT   "ATR-mediated checkpoint pathways regulate phosphorylation and activation
RT   of human Chk1.";
RL   Mol. Cell. Biol. 21:4129-4139(2001).
RN   [16]
RP   SUBSTRATE SPECIFICITY, AND MUTAGENESIS OF ASP-130.
RX   PubMed=11821419; DOI=10.1074/jbc.m111705200;
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RT   "Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the
RT   oriented peptide library approach.";
RL   J. Biol. Chem. 277:16102-16115(2002).
RN   [17]
RP   ERRATUM OF PUBMED:11821419.
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RL   J. Biol. Chem. 277:35776-35777(2002).
RN   [18]
RP   FUNCTION IN DNA DAMAGE RESPONSE, PHOSPHORYLATION AT SER-317 AND SER-345,
RP   AND MUTAGENESIS OF LYS-38.
RX   PubMed=12446774; DOI=10.1128/mcb.22.24.8552-8561.2002;
RA   Heffernan T.P., Simpson D.A., Frank A.R., Heinloth A.N., Paules R.S.,
RA   Cordeiro-Stone M., Kaufmann W.K.;
RT   "An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation
RT   following UVC-induced DNA damage.";
RL   Mol. Cell. Biol. 22:8552-8561(2002).
RN   [19]
RP   SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND INTERACTION WITH BRCA1.
RX   PubMed=11836499; DOI=10.1038/ng837;
RA   Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., Brody L.C.;
RT   "BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA
RT   damage.";
RL   Nat. Genet. 30:285-289(2002).
RN   [20]
RP   FUNCTION IN DNA DAMAGE RESPONSE.
RX   PubMed=12399544; DOI=10.1073/pnas.182557299;
RA   Zhao H., Watkins J.L., Piwnica-Worms H.;
RT   "Disruption of the checkpoint kinase 1/cell division cycle 25A pathway
RT   abrogates ionizing radiation-induced S and G2 checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14795-14800(2002).
RN   [21]
RP   FUNCTION IN CDC25A TURNOVER, PHOSPHORYLATION AT SER-317 AND SER-345, AND
RP   MUTAGENESIS OF SER-317 AND SER-345.
RX   PubMed=12676583; DOI=10.1016/s1535-6108(03)00048-5;
RA   Soerensen C.S., Syljuaesen R.G., Falck J., Schroeder T., Roennstrand L.,
RA   Khanna K.K., Zhou B.-B., Bartek J., Lukas J.;
RT   "Chk1 regulates the S phase checkpoint by coupling the physiological
RT   turnover and ionizing radiation-induced accelerated proteolysis of
RT   Cdc25A.";
RL   Cancer Cell 3:247-258(2003).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF TLK1, CATALYTIC ACTIVITY, INTERACTION WITH
RP   TLK1, AND PHOSPHORYLATION AT SER-317.
RX   PubMed=12660173; DOI=10.1093/emboj/cdg151;
RA   Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J.,
RA   Hansen K.;
RT   "Human tousled like kinases are targeted by an ATM- and Chk1-dependent DNA
RT   damage checkpoint.";
RL   EMBO J. 22:1676-1687(2003).
RN   [23]
RP   FUNCTION IN CDC25A TURNOVER, AND MUTAGENESIS OF ASP-130.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J., Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein
RT   phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [24]
RP   PHOSPHORYLATION AT SER-317, AND MUTAGENESIS OF ASP-130; SER-317 AND
RP   SER-345.
RX   PubMed=12588868; DOI=10.1074/jbc.m210862200;
RA   Gatei M., Sloper K., Soerensen C., Syljuaesen R., Falck J., Hobson K.,
RA   Savage K., Lukas J., Zhou B.-B., Bartek J., Khanna K.K.;
RT   "Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of
RT   Chk1 on ser-317 in response to ionizing radiation.";
RL   J. Biol. Chem. 278:14806-14811(2003).
RN   [25]
RP   FUNCTION IN CDC25A TURNOVER, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=12676925; DOI=10.1074/jbc.m300229200;
RA   Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S.,
RA   Zhang H.;
RT   "Chk1 mediates S and G2 arrests through Cdc25A degradation in response to
RT   DNA-damaging agents.";
RL   J. Biol. Chem. 278:21767-21773(2003).
RN   [26]
RP   INTERACTION WITH YWHAZ AND XPO1, SUBCELLULAR LOCATION, ASSOCIATION WITH
RP   CHROMATIN, PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF
RP   SER-317; PHE-344; SER-345 AND MET-353.
RX   PubMed=12676962; DOI=10.1074/jbc.m300070200;
RA   Jiang K., Pereira E., Maxfield M., Russell B., Goudelock D.M., Sanchez Y.;
RT   "Regulation of Chk1 includes chromatin association and 14-3-3 binding
RT   following phosphorylation on ser-345.";
RL   J. Biol. Chem. 278:25207-25217(2003).
RN   [27]
RP   FUNCTION IN CDC25A TURNOVER.
RX   PubMed=12759351; DOI=10.1074/jbc.m302704200;
RA   Hassepass I., Voit R., Hoffmann I.;
RT   "Phosphorylation at serine 75 is required for UV-mediated degradation of
RT   human Cdc25A phosphatase at the S-phase checkpoint.";
RL   J. Biol. Chem. 278:29824-29829(2003).
RN   [28]
RP   INTERACTION WITH CLSPN, AND ACTIVITY REGULATION.
RX   PubMed=12766152; DOI=10.1074/jbc.m301136200;
RA   Chini C.C.S., Chen J.;
RT   "Human claspin is required for replication checkpoint control.";
RL   J. Biol. Chem. 278:30057-30062(2003).
RN   [29]
RP   FUNCTION IN MITOSIS, CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF
RP   CDC25A.
RX   PubMed=14559997; DOI=10.1128/mcb.23.21.7488-7497.2003;
RA   Chen M.-S., Ryan C.E., Piwnica-Worms H.;
RT   "Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase
RT   through 14-3-3 binding.";
RL   Mol. Cell. Biol. 23:7488-7497(2003).
RN   [30]
RP   REGULATION OF TLK1.
RX   PubMed=12955071; DOI=10.1038/sj.onc.1206691;
RA   Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B.,
RA   Nigg E.A., Khanna K.;
RT   "Suppression of tousled-like kinase activity after DNA damage or
RT   replication block requires ATM, NBS1 and Chk1.";
RL   Oncogene 22:5927-5937(2003).
RN   [31]
RP   PHOSPHORYLATION AT SER-317.
RX   PubMed=14657349; DOI=10.1073/pnas.2536810100;
RA   Wang Y., Qin J.;
RT   "MSH2 and ATR form a signaling module and regulate two branches of the
RT   damage response to DNA methylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003).
RN   [32]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=14988723; DOI=10.1038/sj.emboj.7600113;
RA   Pichierri P., Rosselli F.;
RT   "The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-
RT   NBS1-FANCD2 pathways.";
RL   EMBO J. 23:1178-1187(2004).
RN   [33]
RP   DOMAIN, MITOTIC PHOSPHORYLATION, PHOSPHORYLATION AT SER-345, AND
RP   MUTAGENESIS OF LYS-38.
RX   PubMed=14681223; DOI=10.1074/jbc.m312215200;
RA   Ng C.-P., Lee H.C., Ho C.W., Arooz T., Siu W.Y., Lau A., Poon R.Y.C.;
RT   "Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by
RT   their regulatory domains.";
RL   J. Biol. Chem. 279:8808-8819(2004).
RN   [34]
RP   FUNCTION IN MITOSIS, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-130.
RX   PubMed=15311285; DOI=10.1038/ncb1165;
RA   Kraemer A., Mailand N., Lukas C., Syljuaesen R.G., Wilkinson C.J.,
RA   Nigg E.A., Bartek J., Lukas J.;
RT   "Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1
RT   kinase.";
RL   Nat. Cell Biol. 6:884-891(2004).
RN   [35]
RP   INTERACTION WITH CLSPN, AND PHOSPHORYLATION AT SER-296; SER-317 AND
RP   SER-345.
RX   PubMed=15707391; DOI=10.1042/bj20041966;
RA   Clarke C.A.L., Clarke P.R.;
RT   "DNA-dependent phosphorylation of Chk1 and claspin in a human cell-free
RT   system.";
RL   Biochem. J. 388:705-712(2005).
RN   [36]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15710331; DOI=10.1016/j.ccr.2005.01.009;
RA   Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L.,
RA   Mansukhani M., Murty V.V.V.S., Gaciong Z., Meek S.E.M., Piwnica-Worms H.,
RA   Hibshoosh H., Parsons R.;
RT   "Lack of PTEN sequesters CHK1 and initiates genetic instability.";
RL   Cancer Cell 7:193-204(2005).
RN   [37]
RP   INTERACTION WITH PPM1D, PHOSPHORYLATION AT SER-317 AND SER-345, AND
RP   DEPHOSPHORYLATION BY PPM1D.
RX   PubMed=15870257; DOI=10.1101/gad.1291305;
RA   Lu X., Nannenga B., Donehower L.A.;
RT   "PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle
RT   checkpoints.";
RL   Genes Dev. 19:1162-1174(2005).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, FUNCTION IN TP53-DEPENDENT
RP   TRANSCRIPTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15659650; DOI=10.1091/mbc.e04-08-0689;
RA   Ou Y.-H., Chung P.-H., Sun T.-P., Shieh S.-Y.;
RT   "p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the
RT   regulation of DNA-damage-induced C-terminal acetylation.";
RL   Mol. Biol. Cell 16:1684-1695(2005).
RN   [39]
RP   INTERACTION WITH TIMELESS.
RX   PubMed=15798197; DOI=10.1128/mcb.25.8.3109-3116.2005;
RA   Uensal-Kacmaz K., Mullen T.E., Kaufmann W.K., Sancar A.;
RT   "Coupling of human circadian and cell cycles by the timeless protein.";
RL   Mol. Cell. Biol. 25:3109-3116(2005).
RN   [40]
RP   FUNCTION IN HOMOLOGOUS RECOMBINATION REPAIR, FUNCTION IN PHOSPHORYLATION OF
RP   RAD51, CATALYTIC ACTIVITY, INTERACTION WITH RAD51, AND MUTAGENESIS OF
RP   SER-317 AND SER-345.
RX   PubMed=15665856; DOI=10.1038/ncb1212;
RA   Soerensen C.S., Hansen L.T., Dziegielewski J., Syljuaesen R.G., Lundin C.,
RA   Bartek J., Helleday T.;
RT   "The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous
RT   recombination repair.";
RL   Nat. Cell Biol. 7:195-201(2005).
RN   [41]
RP   FUNCTION IN MITOTIC EXIT, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=15650047; DOI=10.1073/pnas.0409130102;
RA   Huang X., Tran T., Zhang L., Hatcher R., Zhang P.;
RT   "DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent
RT   mitotic exit DNA damage checkpoint.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1065-1070(2005).
RN   [42]
RP   FUNCTION IN TP53 ACTIVATION, FUNCTION IN PHOSPHORYLATION OF MDM4, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=16511572; DOI=10.1038/sj.emboj.7601010;
RA   Jin Y., Dai M.S., Lu S.Z., Xu Y., Luo Z., Zhao Y., Lu H.;
RT   "14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1,
RT   resulting in p53 activation.";
RL   EMBO J. 25:1207-1218(2006).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF CLSPN, INTERACTION WITH CLSPN, ACTIVITY
RP   REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=16963448; DOI=10.1074/jbc.m604373200;
RA   Chini C.C., Chen J.;
RT   "Repeated phosphopeptide motifs in human Claspin are phosphorylated by Chk1
RT   and mediate Claspin function.";
RL   J. Biol. Chem. 281:33276-33282(2006).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF RB1, AND CATALYTIC ACTIVITY.
RX   PubMed=17380128; DOI=10.1038/sj.emboj.7601652;
RA   Inoue Y., Kitagawa M., Taya Y.;
RT   "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB
RT   and E2F-1 after DNA damage.";
RL   EMBO J. 26:2083-2093(2007).
RN   [45]
RP   FUNCTION IN DNA CROSS-LINKS REPAIR, FUNCTION IN PHOSPHORYLATION OF FANCE,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=17296736; DOI=10.1128/mcb.02357-06;
RA   Wang X., Kennedy R.D., Ray K., Stuckert P., Ellenberger T., D'Andrea A.D.;
RT   "Chk1-mediated phosphorylation of FANCE is required for the Fanconi
RT   anemia/BRCA pathway.";
RL   Mol. Cell. Biol. 27:3098-3108(2007).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [47]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=18510930; DOI=10.1016/j.cell.2008.03.037;
RA   Sidi S., Sanda T., Kennedy R.D., Hagen A.T., Jette C.A., Hoffmans R.,
RA   Pascual J., Imamura S., Kishi S., Amatruda J.F., Kanki J.P., Green D.R.,
RA   D'Andrea A.A., Look A.T.;
RT   "Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses
RT   p53, Bcl-2, and caspase-3.";
RL   Cell 133:864-877(2008).
RN   [48]
RP   FUNCTION IN PHOSPHORYLATION OF NEK6, AND CATALYTIC ACTIVITY.
RX   PubMed=18728393; DOI=10.4161/cc.7.17.6551;
RA   Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I.,
RA   Chung J.H., Yun J.;
RT   "Nek6 is involved in G2/M phase cell cycle arrest through DNA damage-
RT   induced phosphorylation.";
RL   Cell Cycle 7:2705-2709(2008).
RN   [49]
RP   FUNCTION IN REPLICATION FORK MAINTENANCE, AND FUNCTION IN PCNA
RP   UBIQUITINATION.
RX   PubMed=18451105; DOI=10.1101/gad.1632808;
RA   Yang X.H., Shiotani B., Classon M., Zou L.;
RT   "Chk1 and Claspin potentiate PCNA ubiquitination.";
RL   Genes Dev. 22:1147-1152(2008).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [51]
RP   FUNCTION IN RAD51-MEDIATED DNA REPAIR, FUNCTION IN PHOSPHORYLATION OF BRCA2
RP   AND RAD51, AND CATALYTIC ACTIVITY.
RX   PubMed=18317453; DOI=10.1038/onc.2008.17;
RA   Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E.,
RA   Stambrook P.J.;
RT   "The checkpoint kinases Chk1 and Chk2 regulate the functional associations
RT   between hBRCA2 and Rad51 in response to DNA damage.";
RL   Oncogene 27:3977-3985(2008).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-296 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [54]
RP   INTERACTION WITH CDK5RAP3.
RX   PubMed=19223857; DOI=10.1038/cr.2009.14;
RA   Jiang H., Wu J., He C., Yang W., Li H.;
RT   "Tumor suppressor protein C53 antagonizes checkpoint kinases to promote
RT   cyclin-dependent kinase 1 activation.";
RL   Cell Res. 19:458-468(2009).
RN   [55]
RP   PHOSPHORYLATION AT SER-345, UBIQUITINATION AT LYS-436, INTERACTION WITH
RP   FBXO6, AND MUTAGENESIS OF SER-345; ARG-372; ARG-376; ARG-379 AND LYS-436.
RX   PubMed=19716789; DOI=10.1016/j.molcel.2009.06.030;
RA   Zhang Y.-W., Brognard J., Coughlin C., You Z., Dolled-Filhart M.,
RA   Aslanian A., Manning G., Abraham R.T., Hunter T.;
RT   "The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity
RT   to replication stress.";
RL   Mol. Cell 35:442-453(2009).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [57]
RP   FUNCTION IN NEK11 PHOSPHORYLATION.
RX   PubMed=19734889; DOI=10.1038/ncb1969;
RA   Melixetian M., Klein D.K., Soerensen C.S., Helin K.;
RT   "NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint.";
RL   Nat. Cell Biol. 11:1247-1253(2009).
RN   [58]
RP   INTERACTION WITH FEM1B, AND ACTIVITY REGULATION.
RX   PubMed=19330022; DOI=10.1038/onc.2009.58;
RA   Sun T.P., Shieh S.Y.;
RT   "Human FEM1B is required for Rad9 recruitment and CHK1 activation in
RT   response to replication stress.";
RL   Oncogene 28:1971-1981(2009).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [60]
RP   FUNCTION IN CDC25A DEGRADATION.
RX   PubMed=20090422; DOI=10.4161/cc.9.3.10513;
RA   Soerensen C.S., Melixetian M., Klein D.K., Helin K.;
RT   "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling.";
RL   Cell Cycle 9:450-455(2010).
RN   [61]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-296 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [63]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [64]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280; SER-296; SER-301;
RP   SER-331; SER-467 AND SER-468, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [65]
RP   FUNCTION IN PHOSPHORYLATION OF SPRTN, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, PROTEOLYTIC CLEAVAGE, ACTIVITY REGULATION, AND PHOSPHORYLATION AT
RP   SER-345.
RX   PubMed=31316063; DOI=10.1038/s41467-019-11095-y;
RA   Halder S., Torrecilla I., Burkhalter M.D., Popovic M., Fielden J., Vaz B.,
RA   Oehler J., Pilger D., Lessel D., Wiseman K., Singh A.N., Vendrell I.,
RA   Fischer R., Philipp M., Ramadan K.;
RT   "SPRTN protease and checkpoint kinase 1 cross-activation loop safeguards
RT   DNA replication.";
RL   Nat. Commun. 10:3142-3142(2019).
RN   [66]
RP   FUNCTION.
RX   PubMed=33108758; DOI=10.1016/j.molcel.2020.10.008;
RA   Li F., Kozono D., Deraska P., Branigan T., Dunn C., Zheng X.F., Parmar K.,
RA   Nguyen H., DeCaprio J., Shapiro G.I., Chowdhury D., D'Andrea A.D.;
RT   "CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication
RT   Stress.";
RL   Mol. Cell 0:0-0(2020).
RN   [67]
RP   FUNCTION, UBIQUITINATION BY TRAF4, AND MUTAGENESIS OF LYS-132.
RX   PubMed=32357935; DOI=10.1186/s13045-020-00869-3;
RA   Yu X., Li W., Liu H., Deng Q., Wang X., Hu H., Xu-Monette Z.Y., Xiong W.,
RA   Lu Z., Young K.H., Wang W., Li Y.;
RT   "Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is
RT   required for CHK1 activation.";
RL   J. Hematol. Oncol. 13:40-40(2020).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-289.
RX   PubMed=10761933; DOI=10.1016/s0092-8674(00)80704-7;
RA   Chen P., Luo C., Deng Y., Ryan K., Register J., Margosiak S.,
RA   Tempczyk-Russell A., Nguyen B., Myers P., Lundgren K., Kan C.-C.,
RA   O'Connor P.M.;
RT   "The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1:
RT   implications for Chk1 regulation.";
RL   Cell 100:681-692(2000).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-289.
RX   PubMed=12244092; DOI=10.1074/jbc.m201233200;
RA   Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O.,
RA   Green S.M., Concha N.O., Zhou B.-B.S.;
RT   "Structural basis for Chk1 inhibition by UCN-01.";
RL   J. Biol. Chem. 277:46609-46615(2002).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-289.
RX   PubMed=15974586; DOI=10.1021/jm049022c;
RA   Foloppe N., Fisher L.M., Howes R., Kierstan P., Potter A.,
RA   Robertson A.G.S., Surgenor A.E.;
RT   "Structure-based design of novel Chk1 inhibitors: insights into hydrogen
RT   bonding and protein-ligand affinity.";
RL   J. Med. Chem. 48:4332-4345(2005).
RN   [71]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-223 AND MET-312.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is required for
CC       checkpoint-mediated cell cycle arrest and activation of DNA repair in
CC       response to the presence of DNA damage or unreplicated DNA
CC       (PubMed:11535615, PubMed:12446774, PubMed:12399544, PubMed:14559997,
CC       PubMed:14988723, PubMed:15311285, PubMed:15665856, PubMed:15650047,
CC       PubMed:32357935). May also negatively regulate cell cycle progression
CC       during unperturbed cell cycles (PubMed:11535615, PubMed:12446774,
CC       PubMed:12399544, PubMed:14559997, PubMed:14988723, PubMed:15311285,
CC       PubMed:15665856, PubMed:15650047). This regulation is achieved by a
CC       number of mechanisms that together help to preserve the integrity of
CC       the genome (PubMed:11535615, PubMed:12446774, PubMed:12399544,
CC       PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15665856,
CC       PubMed:15650047). Recognizes the substrate consensus sequence [R-X-X-
CC       S/T] (PubMed:11535615, PubMed:12446774, PubMed:12399544,
CC       PubMed:14559997, PubMed:14988723, PubMed:15311285, PubMed:15665856,
CC       PubMed:15650047). Binds to and phosphorylates CDC25A, CDC25B and CDC25C
CC       (PubMed:9278511, PubMed:12676583, PubMed:14681206, PubMed:12676925,
CC       PubMed:12759351, PubMed:19734889, PubMed:14559997). Phosphorylation of
CC       CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at
CC       'Ser-216' creates binding sites for 14-3-3 proteins which inhibit
CC       CDC25A and CDC25C (PubMed:9278511). Phosphorylation of CDC25A at 'Ser-
CC       76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis
CC       of CDC25A (PubMed:9278511, PubMed:12676583, PubMed:14681206,
CC       PubMed:12676925, PubMed:12759351, PubMed:19734889). Phosphorylation of
CC       CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at
CC       'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for
CC       polyubiquitination and degradation of CDCD25A (PubMed:9278511,
CC       PubMed:19734889, PubMed:20090422). Inhibition of CDC25 leads to
CC       increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes
CC       and blocks cell cycle progression (PubMed:9278511). Also phosphorylates
CC       NEK6 (PubMed:18728393). Binds to and phosphorylates RAD51 at 'Thr-309',
CC       which promotes the release of RAD51 from BRCA2 and enhances the
CC       association of RAD51 with chromatin, thereby promoting DNA repair by
CC       homologous recombination (PubMed:15665856). Phosphorylates multiple
CC       sites within the C-terminus of TP53, which promotes activation of TP53
CC       by acetylation and promotes cell cycle arrest and suppression of
CC       cellular proliferation (PubMed:10673501, PubMed:15659650,
CC       PubMed:16511572). Also promotes repair of DNA cross-links through
CC       phosphorylation of FANCE (PubMed:17296736). Binds to and phosphorylates
CC       TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of
CC       the chromatin assembly factor ASF1A (PubMed:12660173, PubMed:12955071).
CC       This may enhance chromatin assembly both in the presence or absence of
CC       DNA damage (PubMed:12660173, PubMed:12955071). May also play a role in
CC       replication fork maintenance through regulation of PCNA
CC       (PubMed:18451105). May regulate the transcription of genes that
CC       regulate cell-cycle progression through the phosphorylation of histones
CC       (By similarity). Phosphorylates histone H3.1 (to form H3T11ph), which
CC       leads to epigenetic inhibition of a subset of genes (By similarity).
CC       May also phosphorylate RB1 to promote its interaction with the E2F
CC       family of transcription factors and subsequent cell cycle arrest
CC       (PubMed:17380128). Phosphorylates SPRTN, promoting SPRTN recruitment to
CC       chromatin (PubMed:31316063). Reduces replication stress and activates
CC       the G2/M checkpoint, by phosphorylating and inactivating PABIR1/FAM122A
CC       and promoting the serine/threonine-protein phosphatase 2A-mediated
CC       dephosphorylation and stabilization of WEE1 levels and activity
CC       (PubMed:33108758). {ECO:0000250|UniProtKB:O35280,
CC       ECO:0000269|PubMed:10673501, ECO:0000269|PubMed:11535615,
CC       ECO:0000269|PubMed:12399544, ECO:0000269|PubMed:12446774,
CC       ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12676583,
CC       ECO:0000269|PubMed:12676925, ECO:0000269|PubMed:12759351,
CC       ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:14559997,
CC       ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:14988723,
CC       ECO:0000269|PubMed:15311285, ECO:0000269|PubMed:15650047,
CC       ECO:0000269|PubMed:15659650, ECO:0000269|PubMed:15665856,
CC       ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:17296736,
CC       ECO:0000269|PubMed:17380128, ECO:0000269|PubMed:18451105,
CC       ECO:0000269|PubMed:18728393, ECO:0000269|PubMed:19734889,
CC       ECO:0000269|PubMed:20090422, ECO:0000269|PubMed:31316063,
CC       ECO:0000269|PubMed:32357935, ECO:0000269|PubMed:33108758,
CC       ECO:0000269|PubMed:9278511}.
CC   -!- FUNCTION: [Isoform 2]: Endogenous repressor of isoform 1, interacts
CC       with, and antagonizes CHK1 to promote the S to G2/M phase transition.
CC       {ECO:0000269|PubMed:22184239}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10673501, ECO:0000269|PubMed:12660173,
CC         ECO:0000269|PubMed:14559997, ECO:0000269|PubMed:15659650,
CC         ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:16511572,
CC         ECO:0000269|PubMed:16963448, ECO:0000269|PubMed:17296736,
CC         ECO:0000269|PubMed:17380128, ECO:0000269|PubMed:18317453,
CC         ECO:0000269|PubMed:18728393, ECO:0000269|PubMed:31316063,
CC         ECO:0000269|PubMed:9278511};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10673501,
CC         ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:14559997,
CC         ECO:0000269|PubMed:15659650, ECO:0000269|PubMed:15665856,
CC         ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:16963448,
CC         ECO:0000269|PubMed:17296736, ECO:0000269|PubMed:17380128,
CC         ECO:0000269|PubMed:18317453, ECO:0000269|PubMed:18728393,
CC         ECO:0000269|PubMed:31316063, ECO:0000269|PubMed:9278511};
CC   -!- ACTIVITY REGULATION: Activated through phosphorylation predominantly by
CC       ATR but also by ATM in response to DNA damage or inhibition of DNA
CC       replication (PubMed:11390642, PubMed:12588868, PubMed:12676583,
CC       PubMed:12676962, PubMed:15665856, PubMed:19716789). Activation is
CC       modulated by several mediators including CLSPN, BRCA1 and FEM1B
CC       (PubMed:11836499, PubMed:12766152, PubMed:16963448, PubMed:19330022).
CC       Proteolytic cleavage at the C-terminus by SPRTN during normal DNA
CC       replication activates the protein kinase activity (PubMed:31316063).
CC       {ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:11836499,
CC       ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583,
CC       ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:12766152,
CC       ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:16963448,
CC       ECO:0000269|PubMed:19330022, ECO:0000269|PubMed:19716789,
CC       ECO:0000269|PubMed:31316063}.
CC   -!- SUBUNIT: Interacts (phosphorylated by ATR) with RAD51
CC       (PubMed:15665856). Interacts with and phosphorylates CLSPN, an adapter
CC       protein that regulates the ATR-dependent phosphorylation of CHEK1
CC       (PubMed:16963448). Interacts with BRCA1 (PubMed:11836499). Interacts
CC       with and phosphorylates CDC25A, CDC25B and CDC25C (PubMed:9278511).
CC       Interacts with FBXO6, which regulates CHEK1 (PubMed:19716789).
CC       Interacts with PPM1D, which regulates CHEK1 through dephosphorylation
CC       (PubMed:15870257). Interacts with TIMELESS; DNA damage-dependent
CC       (PubMed:15798197). Interacts with FEM1B; activates CHEK1 in response to
CC       stress (PubMed:19330022). Interacts with TLK1 (PubMed:12660173).
CC       Interacts with XPO1 and YWHAZ (PubMed:12676962). Interacts with
CC       CDK5RAP3; antagonizes CHEK1 (PubMed:19223857).
CC       {ECO:0000269|PubMed:11836499, ECO:0000269|PubMed:12660173,
CC       ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:12766152,
CC       ECO:0000269|PubMed:15665856, ECO:0000269|PubMed:15707391,
CC       ECO:0000269|PubMed:15798197, ECO:0000269|PubMed:15870257,
CC       ECO:0000269|PubMed:16963448, ECO:0000269|PubMed:19223857,
CC       ECO:0000269|PubMed:19330022, ECO:0000269|PubMed:19716789,
CC       ECO:0000269|PubMed:9278511}.
CC   -!- SUBUNIT: [Isoform 1]: Isoform 1 associates with isoform 2, the
CC       interaction is disrupted upon phosphorylation by ATR.
CC       {ECO:0000269|PubMed:22184239}.
CC   -!- INTERACTION:
CC       O14757; P38398: BRCA1; NbExp=3; IntAct=EBI-974488, EBI-349905;
CC       O14757; P30307: CDC25C; NbExp=2; IntAct=EBI-974488, EBI-974439;
CC       O14757; Q9HAW4: CLSPN; NbExp=5; IntAct=EBI-974488, EBI-1369377;
CC       O14757; Q9UJM3: ERRFI1; NbExp=2; IntAct=EBI-974488, EBI-2941912;
CC       O14757; P08238: HSP90AB1; NbExp=3; IntAct=EBI-974488, EBI-352572;
CC       O14757; O00255: MEN1; NbExp=2; IntAct=EBI-974488, EBI-592789;
CC       O14757; Q06609: RAD51; NbExp=3; IntAct=EBI-974488, EBI-297202;
CC       O14757; P06400: RB1; NbExp=3; IntAct=EBI-974488, EBI-491274;
CC       O14757; Q9HCE7-2: SMURF1; NbExp=4; IntAct=EBI-974488, EBI-9845742;
CC       O14757; Q9UNS1: TIMELESS; NbExp=2; IntAct=EBI-974488, EBI-2212315;
CC       O14757; P61981: YWHAG; NbExp=7; IntAct=EBI-974488, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11836499,
CC       ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15311285,
CC       ECO:0000269|PubMed:15710331, ECO:0000269|PubMed:9278511}. Chromosome
CC       {ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:31316063,
CC       ECO:0000269|PubMed:9382850}. Cytoplasm {ECO:0000269|PubMed:12676962}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:15311285}. Note=Nuclear export is mediated at least
CC       in part by XPO1/CRM1 (PubMed:12676962). Also localizes to the
CC       centrosome specifically during interphase, where it may protect
CC       centrosomal CDC2 kinase from inappropriate activation by cytoplasmic
CC       CDC25B (PubMed:15311285). Proteolytic cleavage at the C-terminus by
CC       SPRTN promotes removal from chromatin (PubMed:31316063).
CC       {ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15311285,
CC       ECO:0000269|PubMed:31316063}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O14757-1; Sequence=Displayed;
CC       Name=2; Synonyms=Chk1-short {ECO:0000303|PubMed:22184239}, Chk1-S
CC       {ECO:0000303|PubMed:22184239};
CC         IsoId=O14757-2; Sequence=VSP_044008, VSP_044009;
CC       Name=3;
CC         IsoId=O14757-3; Sequence=VSP_045075;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously with the most abundant
CC       expression in thymus, testis, small intestine and colon.
CC       {ECO:0000269|PubMed:9278511, ECO:0000269|PubMed:9382850}.
CC   -!- DOMAIN: The autoinhibitory region (AIR) inhibits the activity of the
CC       kinase domain. {ECO:0000269|PubMed:14681223}.
CC   -!- PTM: Phosphorylated by ATR in a RAD17-dependent manner in response to
CC       ultraviolet irradiation and inhibition of DNA replication.
CC       Phosphorylated by ATM in response to ionizing irradiation. ATM and ATR
CC       can both phosphorylate Ser-317 and Ser-345 and this results in enhanced
CC       kinase activity. Phosphorylation at Ser-345 induces a change in the
CC       conformation of the protein, activates the kinase activity and is a
CC       prerequisite for interaction with FBXO6 and subsequent ubiquitination
CC       at Lys-436. Phosphorylation at Ser-345 also increases binding to 14-3-3
CC       proteins and promotes nuclear retention. Conversely, dephosphorylation
CC       at Ser-345 by PPM1D may contribute to exit from checkpoint mediated
CC       cell cycle arrest. Phosphorylation at Ser-280 by AKT1/PKB, may promote
CC       mono and/or diubiquitination. Also phosphorylated at undefined residues
CC       during mitotic arrest, resulting in decreased activity.
CC       {ECO:0000269|PubMed:10859164, ECO:0000269|PubMed:11390642,
CC       ECO:0000269|PubMed:12446774, ECO:0000269|PubMed:12588868,
CC       ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12676583,
CC       ECO:0000269|PubMed:12676925, ECO:0000269|PubMed:12676962,
CC       ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14681223,
CC       ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15650047,
CC       ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257,
CC       ECO:0000269|PubMed:19716789}.
CC   -!- PTM: Ubiquitinated. Mono or diubiquitination promotes nuclear exclusion
CC       (By similarity). The activated form (phosphorylated on Ser-345) is
CC       polyubiquitinated at Lys-436 by some SCF-type E3 ubiquitin ligase
CC       complex containing FBXO6 promoting its degradation. Ubiquitination and
CC       degradation are required to terminate the checkpoint and ensure that
CC       activated CHEK1 does not accumulate as cells progress through S phase,
CC       when replication forks encounter transient impediments during normal
CC       DNA replication. 'Lys-63'-mediated ubiquitination by TRAF4 at Lys-132
CC       activates cell cycle arrest and activation of DNA repair
CC       (PubMed:32357935). {ECO:0000250, ECO:0000269|PubMed:10859164,
CC       ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12446774,
CC       ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925,
CC       ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:14681223,
CC       ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15650047,
CC       ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257,
CC       ECO:0000269|PubMed:19716789}.
CC   -!- PTM: Proteolytically cleaved at the C-terminus by SPRTN during normal
CC       DNA replication, thereby promoting CHEK1 removal from chromatin and
CC       activating the protein kinase activity. {ECO:0000269|PubMed:31316063}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. NIM1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/chek1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF016582; AAC51736.1; -; mRNA.
DR   EMBL; AF032874; AAB88852.1; -; mRNA.
DR   EMBL; AB032387; BAA84577.1; -; Genomic_DNA.
DR   EMBL; JF289264; AEB71796.1; -; mRNA.
DR   EMBL; AK292549; BAF85238.1; -; mRNA.
DR   EMBL; AK293143; BAG56691.1; -; mRNA.
DR   EMBL; AK299783; BAG61665.1; -; mRNA.
DR   EMBL; AF527555; AAM78553.1; -; Genomic_DNA.
DR   EMBL; AB451222; BAG70036.1; -; mRNA.
DR   EMBL; AB451345; BAG70159.1; -; mRNA.
DR   EMBL; AP001132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67644.1; -; Genomic_DNA.
DR   EMBL; BC004202; AAH04202.1; -; mRNA.
DR   EMBL; BC017575; AAH17575.1; -; mRNA.
DR   CCDS; CCDS58191.1; -. [O14757-3]
DR   CCDS; CCDS81645.1; -. [O14757-2]
DR   CCDS; CCDS8459.1; -. [O14757-1]
DR   RefSeq; NP_001107593.1; NM_001114121.2. [O14757-1]
DR   RefSeq; NP_001107594.1; NM_001114122.2. [O14757-1]
DR   RefSeq; NP_001231775.1; NM_001244846.1. [O14757-3]
DR   RefSeq; NP_001265.2; NM_001274.5. [O14757-1]
DR   RefSeq; NP_001317357.1; NM_001330428.1. [O14757-2]
DR   RefSeq; XP_016872635.1; XM_017017146.1. [O14757-1]
DR   PDB; 1IA8; X-ray; 1.70 A; A=1-289.
DR   PDB; 1NVQ; X-ray; 2.00 A; A=1-289.
DR   PDB; 1NVR; X-ray; 1.80 A; A=1-289.
DR   PDB; 1NVS; X-ray; 1.80 A; A=1-289.
DR   PDB; 1ZLT; X-ray; 1.74 A; A=1-289.
DR   PDB; 1ZYS; X-ray; 1.70 A; A=1-273.
DR   PDB; 2AYP; X-ray; 2.90 A; A=1-269.
DR   PDB; 2BR1; X-ray; 2.00 A; A=1-289.
DR   PDB; 2BRB; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRG; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRH; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRM; X-ray; 2.20 A; A=1-289.
DR   PDB; 2BRN; X-ray; 2.80 A; A=1-289.
DR   PDB; 2BRO; X-ray; 2.20 A; A=1-289.
DR   PDB; 2C3J; X-ray; 2.10 A; A=1-289.
DR   PDB; 2C3K; X-ray; 2.60 A; A=1-289.
DR   PDB; 2C3L; X-ray; 2.35 A; A=1-289.
DR   PDB; 2CGU; X-ray; 2.50 A; A=1-289.
DR   PDB; 2CGV; X-ray; 2.60 A; A=1-289.
DR   PDB; 2CGW; X-ray; 2.20 A; A=1-289.
DR   PDB; 2CGX; X-ray; 2.20 A; A=1-289.
DR   PDB; 2E9N; X-ray; 2.50 A; A=2-270.
DR   PDB; 2E9O; X-ray; 2.10 A; A=2-270.
DR   PDB; 2E9P; X-ray; 2.60 A; A=2-270.
DR   PDB; 2E9U; X-ray; 2.00 A; A=2-270.
DR   PDB; 2E9V; X-ray; 2.00 A; A/B=2-269.
DR   PDB; 2GDO; X-ray; 3.00 A; A=1-289.
DR   PDB; 2GHG; X-ray; 3.50 A; A=2-270.
DR   PDB; 2HOG; X-ray; 1.90 A; A=2-307.
DR   PDB; 2HXL; X-ray; 1.80 A; A=2-307.
DR   PDB; 2HXQ; X-ray; 2.00 A; A=2-307.
DR   PDB; 2HY0; X-ray; 1.70 A; A=2-307.
DR   PDB; 2QHM; X-ray; 2.00 A; A=1-307.
DR   PDB; 2QHN; X-ray; 1.70 A; A=1-307.
DR   PDB; 2R0U; X-ray; 1.90 A; A=1-307.
DR   PDB; 2WMQ; X-ray; 2.48 A; A=1-289.
DR   PDB; 2WMR; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMS; X-ray; 2.70 A; A=1-289.
DR   PDB; 2WMT; X-ray; 2.55 A; A=1-289.
DR   PDB; 2WMU; X-ray; 2.60 A; A=1-289.
DR   PDB; 2WMV; X-ray; 2.01 A; A=1-289.
DR   PDB; 2WMW; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMX; X-ray; 2.45 A; A=1-289.
DR   PDB; 2X8D; X-ray; 1.90 A; A=1-289.
DR   PDB; 2X8E; X-ray; 2.50 A; A=1-276.
DR   PDB; 2X8I; X-ray; 1.92 A; A=1-289.
DR   PDB; 2XEY; X-ray; 2.70 A; A=1-289.
DR   PDB; 2XEZ; X-ray; 2.25 A; A=1-289.
DR   PDB; 2XF0; X-ray; 2.40 A; A=1-289.
DR   PDB; 2YDI; X-ray; 1.60 A; A=1-289.
DR   PDB; 2YDJ; X-ray; 1.85 A; A/B=1-276.
DR   PDB; 2YDK; X-ray; 1.90 A; A=1-276.
DR   PDB; 2YER; X-ray; 1.83 A; A=1-276.
DR   PDB; 2YEX; X-ray; 1.30 A; A=1-276.
DR   PDB; 2YM3; X-ray; 2.01 A; A=1-289.
DR   PDB; 2YM4; X-ray; 2.35 A; A=1-289.
DR   PDB; 2YM5; X-ray; 2.03 A; A=1-289.
DR   PDB; 2YM6; X-ray; 2.01 A; A=1-289.
DR   PDB; 2YM7; X-ray; 1.81 A; A=1-289.
DR   PDB; 2YM8; X-ray; 2.07 A; A=1-289.
DR   PDB; 2YWP; X-ray; 2.90 A; A=2-270.
DR   PDB; 3F9N; X-ray; 1.90 A; A=2-307.
DR   PDB; 3JVR; X-ray; 1.76 A; A=2-272.
DR   PDB; 3JVS; X-ray; 1.90 A; A=2-272.
DR   PDB; 3NLB; X-ray; 1.90 A; A=1-289.
DR   PDB; 3OT3; X-ray; 1.44 A; A=2-274.
DR   PDB; 3OT8; X-ray; 1.65 A; A=2-274.
DR   PDB; 3PA3; X-ray; 1.40 A; A=2-274.
DR   PDB; 3PA4; X-ray; 1.59 A; A=2-274.
DR   PDB; 3PA5; X-ray; 1.70 A; A=2-274.
DR   PDB; 3TKH; X-ray; 1.79 A; A=1-307.
DR   PDB; 3TKI; X-ray; 1.60 A; A=1-307.
DR   PDB; 3U9N; X-ray; 1.85 A; A=2-274.
DR   PDB; 4FSM; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSN; X-ray; 2.10 A; A=4-280.
DR   PDB; 4FSQ; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FSR; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FST; X-ray; 1.90 A; A=2-270.
DR   PDB; 4FSU; X-ray; 2.10 A; A=2-280.
DR   PDB; 4FSW; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSY; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSZ; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FT0; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FT3; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FT5; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FT7; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FT9; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTA; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FTC; X-ray; 2.00 A; A=2-280.
DR   PDB; 4FTI; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTJ; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTK; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FTL; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FTM; X-ray; 1.90 A; A=2-280.
DR   PDB; 4FTN; X-ray; 2.02 A; A=2-280.
DR   PDB; 4FTO; X-ray; 2.10 A; A=2-280.
DR   PDB; 4FTQ; X-ray; 2.00 A; A=2-280.
DR   PDB; 4FTR; X-ray; 2.25 A; A=2-280.
DR   PDB; 4FTT; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FTU; X-ray; 2.10 A; A=2-280.
DR   PDB; 4GH2; X-ray; 2.03 A; A=2-280.
DR   PDB; 4HYH; X-ray; 1.70 A; A=1-289.
DR   PDB; 4HYI; X-ray; 1.40 A; A=1-289.
DR   PDB; 4JIK; X-ray; 1.90 A; A=2-274.
DR   PDB; 4QYE; X-ray; 2.05 A; A=1-289.
DR   PDB; 4QYF; X-ray; 2.15 A; A=1-289.
DR   PDB; 4QYG; X-ray; 1.75 A; A/B=1-289.
DR   PDB; 4QYH; X-ray; 1.90 A; A/B=1-289.
DR   PDB; 4RVK; X-ray; 1.85 A; A=1-289.
DR   PDB; 4RVL; X-ray; 1.85 A; A=1-289.
DR   PDB; 4RVM; X-ray; 1.86 A; A=1-289.
DR   PDB; 5DLS; X-ray; 2.15 A; A=1-289.
DR   PDB; 5F4N; X-ray; 1.91 A; A=1-273.
DR   PDB; 5OOP; X-ray; 1.70 A; A=1-289.
DR   PDB; 5OOR; X-ray; 1.90 A; A=1-289.
DR   PDB; 5OOT; X-ray; 2.10 A; A=1-289.
DR   PDB; 5OP2; X-ray; 1.90 A; A=1-289.
DR   PDB; 5OP4; X-ray; 2.00 A; A=1-289.
DR   PDB; 5OP5; X-ray; 1.90 A; A=1-289.
DR   PDB; 5OP7; X-ray; 1.80 A; A=1-289.
DR   PDB; 5OPB; X-ray; 1.55 A; A=1-289.
DR   PDB; 5OPR; X-ray; 1.95 A; A=1-289.
DR   PDB; 5OPS; X-ray; 2.00 A; A=1-289.
DR   PDB; 5OPU; X-ray; 1.55 A; A=1-289.
DR   PDB; 5OPV; X-ray; 1.90 A; A=1-289.
DR   PDB; 5OQ5; X-ray; 1.40 A; A=1-289.
DR   PDB; 5OQ6; X-ray; 1.95 A; A=1-289.
DR   PDB; 5OQ7; X-ray; 2.10 A; A/B=1-289.
DR   PDB; 5OQ8; X-ray; 2.00 A; A=1-289.
DR   PDB; 5WI2; X-ray; 2.50 A; A/B=377-476.
DR   PDB; 6FC8; X-ray; 1.61 A; A=1-276.
DR   PDB; 6FCF; X-ray; 1.85 A; A=1-276.
DR   PDB; 6FCK; X-ray; 1.90 A; A=1-276.
DR   PDB; 7AKM; X-ray; 1.93 A; A/B=2-287.
DR   PDB; 7AKO; X-ray; 1.80 A; A/B=2-289.
DR   PDB; 7BJD; X-ray; 2.00 A; A=1-289.
DR   PDB; 7BJE; X-ray; 1.80 A; A=1-289.
DR   PDB; 7BJH; X-ray; 1.80 A; A=1-289.
DR   PDB; 7BJJ; X-ray; 1.80 A; A=1-289.
DR   PDB; 7BJM; X-ray; 2.30 A; A=1-289.
DR   PDB; 7BJO; X-ray; 2.30 A; A=1-289.
DR   PDB; 7BJR; X-ray; 1.90 A; A=1-289.
DR   PDB; 7BJX; X-ray; 2.40 A; A/B=1-289.
DR   PDB; 7BK1; X-ray; 2.00 A; A=1-289.
DR   PDB; 7BK2; X-ray; 2.00 A; A=1-289.
DR   PDB; 7BK3; X-ray; 2.00 A; A=1-289.
DR   PDB; 7BKN; X-ray; 2.74 A; A=1-289.
DR   PDB; 7BKO; X-ray; 2.30 A; A=1-289.
DR   PDB; 7MCK; X-ray; 1.65 A; A=1-289.
DR   PDBsum; 1IA8; -.
DR   PDBsum; 1NVQ; -.
DR   PDBsum; 1NVR; -.
DR   PDBsum; 1NVS; -.
DR   PDBsum; 1ZLT; -.
DR   PDBsum; 1ZYS; -.
DR   PDBsum; 2AYP; -.
DR   PDBsum; 2BR1; -.
DR   PDBsum; 2BRB; -.
DR   PDBsum; 2BRG; -.
DR   PDBsum; 2BRH; -.
DR   PDBsum; 2BRM; -.
DR   PDBsum; 2BRN; -.
DR   PDBsum; 2BRO; -.
DR   PDBsum; 2C3J; -.
DR   PDBsum; 2C3K; -.
DR   PDBsum; 2C3L; -.
DR   PDBsum; 2CGU; -.
DR   PDBsum; 2CGV; -.
DR   PDBsum; 2CGW; -.
DR   PDBsum; 2CGX; -.
DR   PDBsum; 2E9N; -.
DR   PDBsum; 2E9O; -.
DR   PDBsum; 2E9P; -.
DR   PDBsum; 2E9U; -.
DR   PDBsum; 2E9V; -.
DR   PDBsum; 2GDO; -.
DR   PDBsum; 2GHG; -.
DR   PDBsum; 2HOG; -.
DR   PDBsum; 2HXL; -.
DR   PDBsum; 2HXQ; -.
DR   PDBsum; 2HY0; -.
DR   PDBsum; 2QHM; -.
DR   PDBsum; 2QHN; -.
DR   PDBsum; 2R0U; -.
DR   PDBsum; 2WMQ; -.
DR   PDBsum; 2WMR; -.
DR   PDBsum; 2WMS; -.
DR   PDBsum; 2WMT; -.
DR   PDBsum; 2WMU; -.
DR   PDBsum; 2WMV; -.
DR   PDBsum; 2WMW; -.
DR   PDBsum; 2WMX; -.
DR   PDBsum; 2X8D; -.
DR   PDBsum; 2X8E; -.
DR   PDBsum; 2X8I; -.
DR   PDBsum; 2XEY; -.
DR   PDBsum; 2XEZ; -.
DR   PDBsum; 2XF0; -.
DR   PDBsum; 2YDI; -.
DR   PDBsum; 2YDJ; -.
DR   PDBsum; 2YDK; -.
DR   PDBsum; 2YER; -.
DR   PDBsum; 2YEX; -.
DR   PDBsum; 2YM3; -.
DR   PDBsum; 2YM4; -.
DR   PDBsum; 2YM5; -.
DR   PDBsum; 2YM6; -.
DR   PDBsum; 2YM7; -.
DR   PDBsum; 2YM8; -.
DR   PDBsum; 2YWP; -.
DR   PDBsum; 3F9N; -.
DR   PDBsum; 3JVR; -.
DR   PDBsum; 3JVS; -.
DR   PDBsum; 3NLB; -.
DR   PDBsum; 3OT3; -.
DR   PDBsum; 3OT8; -.
DR   PDBsum; 3PA3; -.
DR   PDBsum; 3PA4; -.
DR   PDBsum; 3PA5; -.
DR   PDBsum; 3TKH; -.
DR   PDBsum; 3TKI; -.
DR   PDBsum; 3U9N; -.
DR   PDBsum; 4FSM; -.
DR   PDBsum; 4FSN; -.
DR   PDBsum; 4FSQ; -.
DR   PDBsum; 4FSR; -.
DR   PDBsum; 4FST; -.
DR   PDBsum; 4FSU; -.
DR   PDBsum; 4FSW; -.
DR   PDBsum; 4FSY; -.
DR   PDBsum; 4FSZ; -.
DR   PDBsum; 4FT0; -.
DR   PDBsum; 4FT3; -.
DR   PDBsum; 4FT5; -.
DR   PDBsum; 4FT7; -.
DR   PDBsum; 4FT9; -.
DR   PDBsum; 4FTA; -.
DR   PDBsum; 4FTC; -.
DR   PDBsum; 4FTI; -.
DR   PDBsum; 4FTJ; -.
DR   PDBsum; 4FTK; -.
DR   PDBsum; 4FTL; -.
DR   PDBsum; 4FTM; -.
DR   PDBsum; 4FTN; -.
DR   PDBsum; 4FTO; -.
DR   PDBsum; 4FTQ; -.
DR   PDBsum; 4FTR; -.
DR   PDBsum; 4FTT; -.
DR   PDBsum; 4FTU; -.
DR   PDBsum; 4GH2; -.
DR   PDBsum; 4HYH; -.
DR   PDBsum; 4HYI; -.
DR   PDBsum; 4JIK; -.
DR   PDBsum; 4QYE; -.
DR   PDBsum; 4QYF; -.
DR   PDBsum; 4QYG; -.
DR   PDBsum; 4QYH; -.
DR   PDBsum; 4RVK; -.
DR   PDBsum; 4RVL; -.
DR   PDBsum; 4RVM; -.
DR   PDBsum; 5DLS; -.
DR   PDBsum; 5F4N; -.
DR   PDBsum; 5OOP; -.
DR   PDBsum; 5OOR; -.
DR   PDBsum; 5OOT; -.
DR   PDBsum; 5OP2; -.
DR   PDBsum; 5OP4; -.
DR   PDBsum; 5OP5; -.
DR   PDBsum; 5OP7; -.
DR   PDBsum; 5OPB; -.
DR   PDBsum; 5OPR; -.
DR   PDBsum; 5OPS; -.
DR   PDBsum; 5OPU; -.
DR   PDBsum; 5OPV; -.
DR   PDBsum; 5OQ5; -.
DR   PDBsum; 5OQ6; -.
DR   PDBsum; 5OQ7; -.
DR   PDBsum; 5OQ8; -.
DR   PDBsum; 5WI2; -.
DR   PDBsum; 6FC8; -.
DR   PDBsum; 6FCF; -.
DR   PDBsum; 6FCK; -.
DR   PDBsum; 7AKM; -.
DR   PDBsum; 7AKO; -.
DR   PDBsum; 7BJD; -.
DR   PDBsum; 7BJE; -.
DR   PDBsum; 7BJH; -.
DR   PDBsum; 7BJJ; -.
DR   PDBsum; 7BJM; -.
DR   PDBsum; 7BJO; -.
DR   PDBsum; 7BJR; -.
DR   PDBsum; 7BJX; -.
DR   PDBsum; 7BK1; -.
DR   PDBsum; 7BK2; -.
DR   PDBsum; 7BK3; -.
DR   PDBsum; 7BKN; -.
DR   PDBsum; 7BKO; -.
DR   PDBsum; 7MCK; -.
DR   SMR; O14757; -.
DR   BioGRID; 107536; 196.
DR   CORUM; O14757; -.
DR   DIP; DIP-24182N; -.
DR   ELM; O14757; -.
DR   IntAct; O14757; 55.
DR   MINT; O14757; -.
DR   STRING; 9606.ENSP00000388648; -.
DR   BindingDB; O14757; -.
DR   ChEMBL; CHEMBL4630; -.
DR   DrugBank; DB07647; (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL.
DR   DrugBank; DB07648; (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL.
DR   DrugBank; DB07037; (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL.
DR   DrugBank; DB07243; (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE.
DR   DrugBank; DB07078; (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE.
DR   DrugBank; DB07654; (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC.
DR   DrugBank; DB07213; (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL.
DR   DrugBank; DB07314; 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA.
DR   DrugBank; DB07228; 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA.
DR   DrugBank; DB08781; 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE.
DR   DrugBank; DB08774; 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine.
DR   DrugBank; DB07311; 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE.
DR   DrugBank; DB07034; 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID.
DR   DrugBank; DB07038; 2-(cyclohexylamino)benzoic acid.
DR   DrugBank; DB08779; 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol.
DR   DrugBank; DB08393; 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL.
DR   DrugBank; DB08392; 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL.
DR   DrugBank; DB07959; 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE.
DR   DrugBank; DB07075; 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE.
DR   DrugBank; DB07025; 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE.
DR   DrugBank; DB07655; 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE.
DR   DrugBank; DB07320; 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID.
DR   DrugBank; DB07336; 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL.
DR   DrugBank; DB08777; 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE.
DR   DrugBank; DB07158; 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE.
DR   DrugBank; DB08780; 6-MORPHOLIN-4-YL-9H-PURINE.
DR   DrugBank; DB08778; [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone.
DR   DrugBank; DB06852; CHIR-124.
DR   DrugBank; DB06486; Enzastaurin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08776; N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE.
DR   DrugBank; DB07653; N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE.
DR   DrugBank; DB06876; N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE.
DR   DrugBank; DB08683; REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE.
DR   DrugBank; DB05149; XL844.
DR   DrugCentral; O14757; -.
DR   GuidetoPHARMACOLOGY; 1987; -.
DR   iPTMnet; O14757; -.
DR   MetOSite; O14757; -.
DR   PhosphoSitePlus; O14757; -.
DR   BioMuta; CHEK1; -.
DR   CPTAC; CPTAC-3223; -.
DR   CPTAC; CPTAC-3282; -.
DR   CPTAC; CPTAC-922; -.
DR   EPD; O14757; -.
DR   jPOST; O14757; -.
DR   MassIVE; O14757; -.
DR   MaxQB; O14757; -.
DR   PaxDb; O14757; -.
DR   PeptideAtlas; O14757; -.
DR   PRIDE; O14757; -.
DR   ProteomicsDB; 27577; -.
DR   ProteomicsDB; 48208; -. [O14757-1]
DR   ProteomicsDB; 48209; -. [O14757-2]
DR   Antibodypedia; 3671; 1848 antibodies from 48 providers.
DR   CPTC; O14757; 6 antibodies.
DR   DNASU; 1111; -.
DR   Ensembl; ENST00000278916; ENSP00000278916; ENSG00000149554. [O14757-3]
DR   Ensembl; ENST00000428830; ENSP00000412504; ENSG00000149554.
DR   Ensembl; ENST00000438015; ENSP00000388648; ENSG00000149554.
DR   Ensembl; ENST00000524737; ENSP00000432890; ENSG00000149554.
DR   Ensembl; ENST00000532449; ENSP00000481616; ENSG00000149554.
DR   Ensembl; ENST00000534070; ENSP00000435371; ENSG00000149554.
DR   Ensembl; ENST00000544373; ENSP00000442317; ENSG00000149554. [O14757-2]
DR   GeneID; 1111; -.
DR   KEGG; hsa:1111; -.
DR   MANE-Select; ENST00000438015.7; ENSP00000388648.1; NM_001114122.3; NP_001107594.1.
DR   UCSC; uc001qcf.5; human. [O14757-1]
DR   CTD; 1111; -.
DR   DisGeNET; 1111; -.
DR   GeneCards; CHEK1; -.
DR   HGNC; HGNC:1925; CHEK1.
DR   HPA; ENSG00000149554; Tissue enhanced (bone marrow, lymphoid tissue, seminal vesicle).
DR   MIM; 603078; gene.
DR   neXtProt; NX_O14757; -.
DR   OpenTargets; ENSG00000149554; -.
DR   PharmGKB; PA110; -.
DR   VEuPathDB; HostDB:ENSG00000149554; -.
DR   eggNOG; KOG0590; Eukaryota.
DR   GeneTree; ENSGT00940000159682; -.
DR   InParanoid; O14757; -.
DR   OMA; HVEYIFL; -.
DR   PhylomeDB; O14757; -.
DR   TreeFam; TF351441; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O14757; -.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   SignaLink; O14757; -.
DR   SIGNOR; O14757; -.
DR   BioGRID-ORCS; 1111; 826 hits in 1082 CRISPR screens.
DR   ChiTaRS; CHEK1; human.
DR   EvolutionaryTrace; O14757; -.
DR   GeneWiki; CHEK1; -.
DR   GenomeRNAi; 1111; -.
DR   Pharos; O14757; Tchem.
DR   PRO; PR:O14757; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O14757; protein.
DR   Bgee; ENSG00000149554; Expressed in secondary oocyte and 169 other tissues.
DR   ExpressionAtlas; O14757; baseline and differential.
DR   Genevisible; O14757; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035402; F:histone kinase activity (H3-T11 specific); IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IMP:CACAO.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:RHEA.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:1902742; P:apoptotic process involved in development; IEA:Ensembl.
DR   GO; GO:0071313; P:cellular response to caffeine; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IMP:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0045815; P:epigenetic maintenance of chromatin in transcription-competent conformation; ISS:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0001833; P:inner cell mass cell proliferation; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0044818; P:mitotic G2/M transition checkpoint; IMP:UniProtKB.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; TAS:Reactome.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0006997; P:nucleus organization; IEA:Ensembl.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:CAFA.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0010569; P:regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:2000615; P:regulation of histone H3-K9 acetylation; ISS:UniProtKB.
DR   GO; GO:0046602; P:regulation of mitotic centrosome separation; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0010767; P:regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage; ISS:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; NAS:BHF-UCL.
DR   CDD; cd14069; STKc_Chk1; 1.
DR   InterPro; IPR034670; Chk1_catalytic_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Chromosome;
KW   Cytoplasm; Cytoskeleton; DNA damage; DNA repair; Isopeptide bond; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..476
FT                   /note="Serine/threonine-protein kinase Chk1"
FT                   /id="PRO_0000085848"
FT   DOMAIN          9..265
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         15..23
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..265
FT                   /note="Interaction with CLSPN"
FT                   /evidence="ECO:0000250"
FT   REGION          270..327
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          391..476
FT                   /note="Autoinhibitory region"
FT   COMPBIAS        281..327
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        130
FT                   /note="Proton acceptor"
FT   BINDING         38
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         280
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         286
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15707391,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         317
FT                   /note="Phosphoserine; by ATM and ATR"
FT                   /evidence="ECO:0000269|PubMed:11390642,
FT                   ECO:0000269|PubMed:12446774, ECO:0000269|PubMed:12588868,
FT                   ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:14657349,
FT                   ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         345
FT                   /note="Phosphoserine; by ATM and ATR"
FT                   /evidence="ECO:0000269|PubMed:10859164,
FT                   ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12446774,
FT                   ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:14681223,
FT                   ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15650047,
FT                   ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257,
FT                   ECO:0000269|PubMed:19716789, ECO:0000269|PubMed:31316063"
FT   MOD_RES         467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         468
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        132
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:32357935"
FT   CROSSLNK        436
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19716789"
FT   VAR_SEQ         1..94
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:22184239"
FT                   /id="VSP_044008"
FT   VAR_SEQ         95..97
FT                   /note="RIE -> MEK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:22184239"
FT                   /id="VSP_044009"
FT   VAR_SEQ         412..445
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045075"
FT   VARIANT         156
FT                   /note="R -> Q (in dbSNP:rs3731410)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_021123"
FT   VARIANT         223
FT                   /note="E -> V (in dbSNP:rs35817404)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040407"
FT   VARIANT         312
FT                   /note="V -> M (in dbSNP:rs34097480)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040408"
FT   VARIANT         471
FT                   /note="I -> V (in dbSNP:rs506504)"
FT                   /evidence="ECO:0000269|PubMed:10717241,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:9278511,
FT                   ECO:0000269|PubMed:9382850, ECO:0000269|Ref.6,
FT                   ECO:0000269|Ref.9"
FT                   /id="VAR_024571"
FT   MUTAGEN         38
FT                   /note="K->R: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12446774,
FT                   ECO:0000269|PubMed:14681223"
FT   MUTAGEN         130
FT                   /note="D->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10673501,
FT                   ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:11535615,
FT                   ECO:0000269|PubMed:11821419, ECO:0000269|PubMed:12588868,
FT                   ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:15311285,
FT                   ECO:0000269|PubMed:9278511"
FT   MUTAGEN         132
FT                   /note="K->R: Strong reduction of chromatin-associated CHK1
FT                   ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:32357935"
FT   MUTAGEN         317
FT                   /note="S->A: Abrogates interaction with RAD51; when
FT                   associated with A-345. Reduces phosphorylation and impairs
FT                   activation by hydroxyurea and ionizing radiation. Abrogates
FT                   nuclear retention upon checkpoint activation. Impairs
FT                   interaction with FBXO6."
FT                   /evidence="ECO:0000269|PubMed:11390642,
FT                   ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856"
FT   MUTAGEN         317
FT                   /note="S->E: Enhances interaction with RAD51; when
FT                   associated with E-345."
FT                   /evidence="ECO:0000269|PubMed:11390642,
FT                   ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856"
FT   MUTAGEN         344
FT                   /note="F->A: Impairs nuclear export."
FT                   /evidence="ECO:0000269|PubMed:12676962"
FT   MUTAGEN         345
FT                   /note="S->A: Abrogates interaction with RAD51; when
FT                   associated with A-317. Reduces phosphorylation and impairs
FT                   activation by hydroxyurea and ionizing radiation. Impairs
FT                   interaction with YWHAZ which is required for nuclear
FT                   retention after checkpoint activation."
FT                   /evidence="ECO:0000269|PubMed:11390642,
FT                   ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856,
FT                   ECO:0000269|PubMed:19716789"
FT   MUTAGEN         345
FT                   /note="S->E: Enhances interaction with RAD51; when
FT                   associated with E-317."
FT                   /evidence="ECO:0000269|PubMed:11390642,
FT                   ECO:0000269|PubMed:12588868, ECO:0000269|PubMed:12676583,
FT                   ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:15665856,
FT                   ECO:0000269|PubMed:19716789"
FT   MUTAGEN         353
FT                   /note="M->A: Impairs nuclear export."
FT                   /evidence="ECO:0000269|PubMed:12676962"
FT   MUTAGEN         357
FT                   /note="S->A: No effect on phosphorylation induced by
FT                   hydroxyurea."
FT                   /evidence="ECO:0000269|PubMed:11390642"
FT   MUTAGEN         366
FT                   /note="S->A: No effect on phosphorylation induced by
FT                   hydroxyurea."
FT                   /evidence="ECO:0000269|PubMed:11390642"
FT   MUTAGEN         372
FT                   /note="R->E: In 3RE mutant. Disrupts the folding and/or
FT                   conformation, allowing increased accessibility to FBXO6
FT                   component of SCF-type E3 ubiquitin ligase complex; when
FT                   associated with E-376 and E-379."
FT                   /evidence="ECO:0000269|PubMed:19716789"
FT   MUTAGEN         376
FT                   /note="R->E: In 3RE mutant. Disrupts the folding and/or
FT                   conformation, allowing increased accessibility to FBXO6
FT                   component of SCF-type E3 ubiquitin ligase complex; when
FT                   associated with E-372 and E-379."
FT                   /evidence="ECO:0000269|PubMed:19716789"
FT   MUTAGEN         379
FT                   /note="R->E: In 3RE mutant. Disrupts the folding and/or
FT                   conformation, allowing increased accessibility to FBXO6
FT                   component of SCF-type E3 ubiquitin ligase complex; when
FT                   associated with E-372 and E-376."
FT                   /evidence="ECO:0000269|PubMed:19716789"
FT   MUTAGEN         436
FT                   /note="K->R: Enhances stability of the protein, probably by
FT                   preventing ubiquitination at this site."
FT                   /evidence="ECO:0000269|PubMed:19716789"
FT   MUTAGEN         468
FT                   /note="S->A: No effect on phosphorylation induced by
FT                   hydroxyurea."
FT                   /evidence="ECO:0000269|PubMed:11390642"
FT   CONFLICT        163
FT                   /note="L -> S (in Ref. 5; BAG56691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        220
FT                   /note="D -> G (in Ref. 4; BAG61665)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        381
FT                   /note="F -> L (in Ref. 4; BAG61665)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..8
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          9..17
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   TURN            29..31
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          34..41
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           42..44
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           48..60
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          70..76
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          79..85
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          88..91
FT                   /evidence="ECO:0007829|PDB:2GDO"
FT   HELIX           92..95
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   TURN            98..100
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           104..123
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          125..127
FT                   /evidence="ECO:0007829|PDB:2GHG"
FT   HELIX           133..135
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          136..138
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          144..146
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:2C3J"
FT   STRAND          153..157
FT                   /evidence="ECO:0007829|PDB:3JVR"
FT   HELIX           171..173
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           176..179
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           186..203
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:4HYI"
FT   STRAND          213..215
FT                   /evidence="ECO:0007829|PDB:2XEY"
FT   HELIX           216..222
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:2E9U"
FT   HELIX           231..233
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           236..245
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   TURN            250..252
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   HELIX           256..259
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   TURN            263..266
FT                   /evidence="ECO:0007829|PDB:2YEX"
FT   STRAND          379..384
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   HELIX           386..399
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   STRAND          403..417
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   STRAND          423..432
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   STRAND          434..446
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   HELIX           448..461
FT                   /evidence="ECO:0007829|PDB:5WI2"
FT   HELIX           463..465
FT                   /evidence="ECO:0007829|PDB:5WI2"
SQ   SEQUENCE   476 AA;  54434 MW;  0ABD0FAB67E60F67 CRC64;
     MAVPFVEDWD LVQTLGEGAY GEVQLAVNRV TEEAVAVKIV DMKRAVDCPE NIKKEICINK
     MLNHENVVKF YGHRREGNIQ YLFLEYCSGG ELFDRIEPDI GMPEPDAQRF FHQLMAGVVY
     LHGIGITHRD IKPENLLLDE RDNLKISDFG LATVFRYNNR ERLLNKMCGT LPYVAPELLK
     RREFHAEPVD VWSCGIVLTA MLAGELPWDQ PSDSCQEYSD WKEKKTYLNP WKKIDSAPLA
     LLHKILVENP SARITIPDIK KDRWYNKPLK KGAKRPRVTS GGVSESPSGF SKHIQSNLDF
     SPVNSASSEE NVKYSSSQPE PRTGLSLWDT SPSYIDKLVQ GISFSQPTCP DHMLLNSQLL
     GTPGSSQNPW QRLVKRMTRF FTKLDADKSY QCLKETCEKL GYQWKKSCMN QVTISTTDRR
     NNKLIFKVNL LEMDDKILVD FRLSKGDGLE FKRHFLKIKG KLIDIVSSQK IWLPAT
//
ID   BBX_HUMAN               Reviewed;         941 AA.
AC   Q8WY36; A2RRM7; Q2TAJ1; Q7L3J8; Q7LBY8; Q8NDB0; Q8WY35; Q9H0J6;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   23-FEB-2022, entry version 155.
DE   RecName: Full=HMG box transcription factor BBX;
DE   AltName: Full=Bobby sox homolog;
DE   AltName: Full=HMG box-containing protein 2;
GN   Name=BBX; Synonyms=HBP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Bone marrow;
RX   PubMed=11680820; DOI=10.1007/s002940100241;
RA   Sanchez-Diaz A., Blanco M.A., Jones N., Moreno S.;
RT   "HBP2: a new mammalian protein that complements the fission yeast MBF
RT   transcription complex.";
RL   Curr. Genet. 40:110-118(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Lee C.-J., Chan W.-I., Appleby V.J., Orme A.T., Scotting P.J.;
RT   "BBX is expressed in developing CNS and in neuronal tumours.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Ovary, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-485 AND SER-822, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-844, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-243; SER-704 AND SER-822, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-844, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-844, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-385; LYS-573 AND LYS-696, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Transcription factor that is necessary for cell cycle
CC       progression from G1 to S phase. {ECO:0000269|PubMed:11680820}.
CC   -!- INTERACTION:
CC       Q8WY36-3; P42858: HTT; NbExp=6; IntAct=EBI-22013474, EBI-466029;
CC       Q8WY36-3; O76024: WFS1; NbExp=3; IntAct=EBI-22013474, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8WY36-1; Sequence=Displayed;
CC       Name=2; Synonyms=BBXa;
CC         IsoId=Q8WY36-2; Sequence=VSP_018006;
CC       Name=3;
CC         IsoId=Q8WY36-3; Sequence=VSP_054880, VSP_054881;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI10904.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF276948; AAL68984.1; -; mRNA.
DR   EMBL; AF276949; AAL68985.1; -; mRNA.
DR   EMBL; AF454941; AAL58870.1; -; mRNA.
DR   EMBL; AF454942; AAL58871.1; -; mRNA.
DR   EMBL; AL136769; CAB66703.1; -; mRNA.
DR   EMBL; AL834307; CAD38977.1; -; mRNA.
DR   EMBL; AC068765; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC072044; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC117477; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012837; AAH12837.2; -; mRNA.
DR   EMBL; BC110903; AAI10904.1; ALT_SEQ; mRNA.
DR   EMBL; BC131718; AAI31719.1; -; mRNA.
DR   CCDS; CCDS2950.1; -. [Q8WY36-2]
DR   CCDS; CCDS46881.1; -. [Q8WY36-1]
DR   CCDS; CCDS63712.1; -. [Q8WY36-3]
DR   RefSeq; NP_001136040.1; NM_001142568.2. [Q8WY36-1]
DR   RefSeq; NP_001263215.1; NM_001276286.1. [Q8WY36-3]
DR   RefSeq; NP_064620.2; NM_020235.6. [Q8WY36-2]
DR   RefSeq; XP_005247699.1; XM_005247642.3. [Q8WY36-1]
DR   RefSeq; XP_005247700.1; XM_005247643.3. [Q8WY36-1]
DR   RefSeq; XP_005247701.1; XM_005247644.3. [Q8WY36-1]
DR   RefSeq; XP_011511302.1; XM_011513000.1. [Q8WY36-1]
DR   RefSeq; XP_011511303.1; XM_011513001.1. [Q8WY36-1]
DR   RefSeq; XP_011511306.1; XM_011513004.2. [Q8WY36-2]
DR   RefSeq; XP_016862370.1; XM_017006881.1. [Q8WY36-1]
DR   RefSeq; XP_016862371.1; XM_017006882.1. [Q8WY36-2]
DR   SMR; Q8WY36; -.
DR   BioGRID; 121304; 96.
DR   IntAct; Q8WY36; 28.
DR   MINT; Q8WY36; -.
DR   STRING; 9606.ENSP00000319974; -.
DR   GlyGen; Q8WY36; 4 sites, 2 O-linked glycans (4 sites).
DR   iPTMnet; Q8WY36; -.
DR   PhosphoSitePlus; Q8WY36; -.
DR   BioMuta; BBX; -.
DR   DMDM; 74724044; -.
DR   EPD; Q8WY36; -.
DR   jPOST; Q8WY36; -.
DR   MassIVE; Q8WY36; -.
DR   MaxQB; Q8WY36; -.
DR   PaxDb; Q8WY36; -.
DR   PeptideAtlas; Q8WY36; -.
DR   PRIDE; Q8WY36; -.
DR   ProteomicsDB; 476; -.
DR   ProteomicsDB; 75124; -. [Q8WY36-1]
DR   ProteomicsDB; 75125; -. [Q8WY36-2]
DR   Antibodypedia; 32337; 113 antibodies from 24 providers.
DR   DNASU; 56987; -.
DR   Ensembl; ENST00000325805; ENSP00000319974; ENSG00000114439.
DR   Ensembl; ENST00000406780; ENSP00000385530; ENSG00000114439. [Q8WY36-2]
DR   Ensembl; ENST00000415149; ENSP00000408358; ENSG00000114439. [Q8WY36-2]
DR   Ensembl; ENST00000416476; ENSP00000403860; ENSG00000114439. [Q8WY36-3]
DR   GeneID; 56987; -.
DR   KEGG; hsa:56987; -.
DR   MANE-Select; ENST00000325805.13; ENSP00000319974.8; NM_001142568.3; NP_001136040.1.
DR   UCSC; uc003dwk.6; human. [Q8WY36-1]
DR   CTD; 56987; -.
DR   DisGeNET; 56987; -.
DR   GeneCards; BBX; -.
DR   HGNC; HGNC:14422; BBX.
DR   HPA; ENSG00000114439; Low tissue specificity.
DR   neXtProt; NX_Q8WY36; -.
DR   OpenTargets; ENSG00000114439; -.
DR   PharmGKB; PA25280; -.
DR   VEuPathDB; HostDB:ENSG00000114439; -.
DR   eggNOG; KOG2746; Eukaryota.
DR   GeneTree; ENSGT00940000158592; -.
DR   HOGENOM; CLU_435423_0_0_1; -.
DR   InParanoid; Q8WY36; -.
DR   OMA; LAEAKMC; -.
DR   OrthoDB; 1641977at2759; -.
DR   PhylomeDB; Q8WY36; -.
DR   TreeFam; TF106402; -.
DR   PathwayCommons; Q8WY36; -.
DR   SignaLink; Q8WY36; -.
DR   BioGRID-ORCS; 56987; 18 hits in 1085 CRISPR screens.
DR   ChiTaRS; BBX; human.
DR   GeneWiki; BBX_(gene); -.
DR   GenomeRNAi; 56987; -.
DR   Pharos; Q8WY36; Tbio.
DR   PRO; PR:Q8WY36; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q8WY36; protein.
DR   Bgee; ENSG00000114439; Expressed in corpus epididymis and 255 other tissues.
DR   ExpressionAtlas; Q8WY36; baseline and differential.
DR   Genevisible; Q8WY36; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR019102; TF_HMG_box_BBX_DUF2028.
DR   Pfam; PF09667; DUF2028; 2.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..941
FT                   /note="HMG box transcription factor BBX"
FT                   /id="PRO_0000232885"
FT   DNA_BIND        80..148
FT                   /note="HMG box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          39..80
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          157..200
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          221..242
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          438..482
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          499..600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          635..677
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          714..771
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          803..888
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          912..941
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          326..370
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        40..54
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        461..481
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        550..566
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        648..671
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        726..745
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        806..821
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        853..879
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VBW5"
FT   MOD_RES         485
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         704
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         822
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         844
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   CROSSLNK        385
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        573
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        696
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         303..628
FT                   /note="MCLASEGMKMEESKLIKAKESDGGRIKELEKGKEEKEIKMEKTDETRLQKEA
FT                   EFEKSAKENLRDSKELRNFEALQIDDIMAIKMEDPKEIRKEELEEDHKCSHFPDFSYSA
FT                   SSKIIISDVPSRKDHMCHPHGIMIIEDPAALNKPEKLKKKKKKSKMDRHGNDKSTPKKT
FT                   CKKRQSSESDIESVIYTIEAVAKGDWGIEKLGDTPRKKVRTSSSGKGSILDAKPPKKKV
FT                   KSREKKMSKEKSSDTTKESRPPDFISISASKNISGETPEGIKAEPLTPMEDALPPSLSG
FT                   QAKPEDSDCHRKIETCGSRKSERSCKGALYKTLVSEGM -> ENEAQEKETPLIMKGVG
FT                   MKKAGHLVRVGPVGARSSRRQSQKKTVSLAPQSWMKNLKKNSTASLNIVLLHLTGNVYL
FT                   SQEKRRRLEMCPQNRLKPAKVLSSLRKRTYSTKLSANISTKRRSPMFRKKEVGINGQTS
FT                   NSSWMPFTLQKPYFQKTETPWSLFIRLKISHPFSTLQSQQQRKNLWWAAKREKQGKPRL
FT                   HTLSGQQMAGYHQQEVLWMTNQRNNCRGVSLKQLRQTAMTNAHTTPRSGRRGAVLQKCL
FT                   PCLRSLASLRWLKWQPWKMCTEVRGQLRSPMMDSQKKCRRLLYLFPALTSEAPFHCKTL
FT                   CFTYYPSLVFTEGC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054880"
FT   VAR_SEQ         629..941
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054881"
FT   VAR_SEQ         735..764
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11230166, ECO:0000303|Ref.2"
FT                   /id="VSP_018006"
FT   VARIANT         576
FT                   /note="P -> S (in dbSNP:rs59781647)"
FT                   /id="VAR_061264"
SQ   SEQUENCE   941 AA;  105130 MW;  E45B359A602B5D8D CRC64;
     MKGSNRNKDH SAEGEGVGKR PKRKCLQWHP LLAKKLLDFS EEEEEEDEEE DIDKVQLLGA
     DGLEQDVGET EDDESPEQRA RRPMNAFLLF CKRHRSLVRQ EHPRLDNRGA TKILADWWAV
     LDPKEKQKYT DMAKEYKDAF MKANPGYKWC PTTNKPVKSP TPTVNPRKKL WAFPSDSSRD
     LPSPKKAKTE EMPQLNFGMA DPTQMGGLSM LLLAGEHALG TPEVSSGTCR PDVSESPELR
     QKSPLFQFAE ISSSTSHSDA STKQCQTSAL FQFAEISSNT SQLGGAEPVK RCGKSALFQL
     AEMCLASEGM KMEESKLIKA KESDGGRIKE LEKGKEEKEI KMEKTDETRL QKEAEFEKSA
     KENLRDSKEL RNFEALQIDD IMAIKMEDPK EIRKEELEED HKCSHFPDFS YSASSKIIIS
     DVPSRKDHMC HPHGIMIIED PAALNKPEKL KKKKKKSKMD RHGNDKSTPK KTCKKRQSSE
     SDIESVIYTI EAVAKGDWGI EKLGDTPRKK VRTSSSGKGS ILDAKPPKKK VKSREKKMSK
     EKSSDTTKES RPPDFISISA SKNISGETPE GIKAEPLTPM EDALPPSLSG QAKPEDSDCH
     RKIETCGSRK SERSCKGALY KTLVSEGMLT SLRANVDRGK RSSGKGNSSD HEGCWNEESW
     TFSQSGTSGS KKFKKTKPKE DCLLGSAKLD EEFEKKFNSL PQYSPVTFDR KCVPVPRKKK
     KTGNVSSEPT KTSKGPFQSQ KKNLFHKIVS KYKHKKEKPN VPEKGSGDKW SNKQLFLDAI
     HPTEAIFSED RNTMEPVHKV KNIPSIFNTP EPTTTQEPLV GSQKRKARKT KITHLVRTAD
     GRVSPAGGTL DDKPKEQLQR SLPKATETDC NDKCSHNTEV GETRSSTPEM PAVSAFFSLA
     ALAEVAAMEN VHRGQRSTPL THDGQPKEMP QAPVLISCAD Q
//
ID   CLTR1_HUMAN             Reviewed;         337 AA.
AC   Q9Y271; B2R954; D3DTE4; Q5JS94; Q8IV19;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   23-FEB-2022, entry version 170.
DE   RecName: Full=Cysteinyl leukotriene receptor 1;
DE            Short=CysLTR1;
DE   AltName: Full=Cysteinyl leukotriene D4 receptor;
DE            Short=LTD4 receptor;
DE   AltName: Full=G-protein coupled receptor HG55;
DE   AltName: Full=HMTMF81;
GN   Name=CYSLTR1; Synonyms=CYSLT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Tonsil;
RX   PubMed=10391245; DOI=10.1038/21658;
RA   Lynch K.R., O'Neill G.P., Liu Q., Im D.-S., Sawyer N., Metters K.M.,
RA   Coulombe N., Abramovitz M., Figueroa D.J., Zeng Z., Connolly B.M., Bai C.,
RA   Austin C.P., Chateauneuf A., Stocco R., Greig G.M., Kargman S., Hooks S.B.,
RA   Hosfield E., Williams D.L. Jr., Ford-Hutchinson A.W., Caskey C.T.,
RA   Evans J.F.;
RT   "Characterization of the human cysteinyl leukotriene CysLT1 receptor.";
RL   Nature 399:789-793(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte, Peripheral blood monocyte, and Spleen;
RX   PubMed=10462554; DOI=10.1124/mol.56.3.657;
RA   Sarau H.M., Ames R.S., Chambers J., Ellis C., Elshourbagy N., Foley J.J.,
RA   Schmidt D.B., Muccitelli R.M., Jenkins O., Murdock P.R., Herrity N.C.,
RA   Halsey W., Sathe G., Muir A.I., Nuthulaganti P., Dytko G.M., Buckley P.T.,
RA   Wilson S., Bergsma D.J., Hay D.W.P.;
RT   "Identification, molecular cloning, expression, and characterization of a
RT   cysteinyl leukotriene receptor.";
RL   Mol. Pharmacol. 56:657-663(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for cysteinyl leukotriene receptor 1
RT   (CYSLTR1).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for cysteinyl leukotrienes mediating
CC       bronchoconstriction of individuals with and without asthma. Stimulation
CC       by LTD4 results in the contraction and proliferation of smooth muscle,
CC       edema, eosinophil migration and damage to the mucus layer in the lung.
CC       This response is mediated via a G-protein that activates a
CC       phosphatidylinositol-calcium second messenger system. The rank order of
CC       affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in spleen and
CC       peripheral blood leukocytes. Lower expression in several tissues, such
CC       as lung (mostly in smooth muscle bundles and alveolar macrophages),
CC       placenta, small intestine, pancreas, colon and heart.
CC   -!- MISCELLANEOUS: Selective antagonists, such as montelukast (Singulair),
CC       zafirlukast (Accolate) and pranlukast (Onon), are used in the treatment
CC       of the asthma crisis.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF119711; AAD42285.1; -; mRNA.
DR   EMBL; AF133266; AAD42778.1; -; mRNA.
DR   EMBL; AY242130; AAO92297.1; -; Genomic_DNA.
DR   EMBL; AK313643; BAG36401.1; -; mRNA.
DR   EMBL; AL445202; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471104; EAW98598.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98599.1; -; Genomic_DNA.
DR   EMBL; BC035750; AAH35750.1; -; mRNA.
DR   CCDS; CCDS14439.1; -.
DR   RefSeq; NP_001269115.1; NM_001282186.1.
DR   RefSeq; NP_001269116.1; NM_001282187.1.
DR   RefSeq; NP_001269117.1; NM_001282188.1.
DR   RefSeq; NP_006630.1; NM_006639.3.
DR   PDB; 6RZ4; X-ray; 2.70 A; A=1-311.
DR   PDB; 6RZ5; X-ray; 2.53 A; A/B=1-311.
DR   PDBsum; 6RZ4; -.
DR   PDBsum; 6RZ5; -.
DR   SMR; Q9Y271; -.
DR   BioGRID; 116014; 1.
DR   IntAct; Q9Y271; 1.
DR   STRING; 9606.ENSP00000478492; -.
DR   BindingDB; Q9Y271; -.
DR   ChEMBL; CHEMBL1798; -.
DR   DrugBank; DB00587; Cinalukast.
DR   DrugBank; DB08855; Leukotriene C4.
DR   DrugBank; DB11858; Leukotriene D4.
DR   DrugBank; DB00471; Montelukast.
DR   DrugBank; DB00716; Nedocromil.
DR   DrugBank; DB01411; Pranlukast.
DR   DrugBank; DB00549; Zafirlukast.
DR   DrugCentral; Q9Y271; -.
DR   GuidetoPHARMACOLOGY; 269; -.
DR   SwissLipids; SLP:000001582; -.
DR   TCDB; 9.A.14.13.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q9Y271; 4 sites.
DR   iPTMnet; Q9Y271; -.
DR   PhosphoSitePlus; Q9Y271; -.
DR   BioMuta; CYSLTR1; -.
DR   DMDM; 20138087; -.
DR   jPOST; Q9Y271; -.
DR   MassIVE; Q9Y271; -.
DR   PaxDb; Q9Y271; -.
DR   PeptideAtlas; Q9Y271; -.
DR   PRIDE; Q9Y271; -.
DR   ProteomicsDB; 85673; -.
DR   Antibodypedia; 548; 320 antibodies from 31 providers.
DR   DNASU; 10800; -.
DR   Ensembl; ENST00000373304; ENSP00000362401; ENSG00000173198.
DR   Ensembl; ENST00000614798; ENSP00000478492; ENSG00000173198.
DR   GeneID; 10800; -.
DR   KEGG; hsa:10800; -.
DR   MANE-Select; ENST00000373304.4; ENSP00000362401.3; NM_006639.4; NP_006630.1.
DR   UCSC; uc004edb.5; human.
DR   CTD; 10800; -.
DR   DisGeNET; 10800; -.
DR   GeneCards; CYSLTR1; -.
DR   HGNC; HGNC:17451; CYSLTR1.
DR   HPA; ENSG00000173198; Tissue enhanced (lymphoid).
DR   MIM; 300201; gene.
DR   neXtProt; NX_Q9Y271; -.
DR   OpenTargets; ENSG00000173198; -.
DR   PharmGKB; PA38453; -.
DR   VEuPathDB; HostDB:ENSG00000173198; -.
DR   eggNOG; ENOG502QUJU; Eukaryota.
DR   GeneTree; ENSGT01040000240426; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; Q9Y271; -.
DR   OMA; CVMTLPL; -.
DR   OrthoDB; 390511at2759; -.
DR   PhylomeDB; Q9Y271; -.
DR   TreeFam; TF350009; -.
DR   PathwayCommons; Q9Y271; -.
DR   Reactome; R-HSA-391906; Leukotriene receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-9664535; LTC4-CYSLTR mediated IL4 production.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; Q9Y271; -.
DR   SIGNOR; Q9Y271; -.
DR   BioGRID-ORCS; 10800; 6 hits in 661 CRISPR screens.
DR   ChiTaRS; CYSLTR1; human.
DR   GeneWiki; Cysteinyl_leukotriene_receptor_1; -.
DR   GenomeRNAi; 10800; -.
DR   Pharos; Q9Y271; Tclin.
DR   PRO; PR:Q9Y271; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9Y271; protein.
DR   Bgee; ENSG00000173198; Expressed in bone marrow and 165 other tissues.
DR   Genevisible; Q9Y271; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001631; F:cysteinyl leukotriene receptor activity; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004974; F:leukotriene receptor activity; TAS:ProtInc.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IEA:Ensembl.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0007585; P:respiratory gaseous exchange by respiratory system; TAS:ProtInc.
DR   InterPro; IPR013310; CLT1_recept.
DR   InterPro; IPR004071; Cyst_leuk_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01902; CYSLT1RECPTR.
DR   PRINTS; PR01533; CYSLTRECPTR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..337
FT                   /note="Cysteinyl leukotriene receptor 1"
FT                   /id="PRO_0000069299"
FT   TOPO_DOM        1..28
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        29..49
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        50..57
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..78
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        79..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        107..127
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        128..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..162
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..193
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        194..214
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        215..230
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        231..251
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        252..276
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        277..297
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        298..337
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        169
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        96..173
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        272
FT                   /note="R -> T (in Ref. 7; AAH35750)"
FT                   /evidence="ECO:0000305"
FT   HELIX           18..49
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           57..73
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           76..84
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   TURN            85..87
FT                   /evidence="ECO:0007829|PDB:6RZ4"
FT   HELIX           92..126
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   TURN            128..130
FT                   /evidence="ECO:0007829|PDB:6RZ4"
FT   HELIX           131..134
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           137..154
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           156..158
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           184..197
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           199..222
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           227..244
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           246..259
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           267..285
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           286..289
FT                   /evidence="ECO:0007829|PDB:6RZ5"
FT   HELIX           290..298
FT                   /evidence="ECO:0007829|PDB:6RZ5"
SQ   SEQUENCE   337 AA;  38541 MW;  B9B53940F895F245 CRC64;
     MDETGNLTVS SATCHDTIDD FRNQVYSTLY SMISVVGFFG NGFVLYVLIK TYHKKSAFQV
     YMINLAVADL LCVCTLPLRV VYYVHKGIWL FGDFLCRLST YALYVNLYCS IFFMTAMSFF
     RCIAIVFPVQ NINLVTQKKA RFVCVGIWIF VILTSSPFLM AKPQKDEKNN TKCFEPPQDN
     QTKNHVLVLH YVSLFVGFII PFVIIIVCYT MIILTLLKKS MKKNLSSHKK AIGMIMVVTA
     AFLVSFMPYH IQRTIHLHFL HNETKPCDSV LRMQKSVVIT LSLAASNCCF DPLLYFFSGG
     NFRKRLSTFR KHSLSSVTYV PRKKASLPEK GEEICKV
//
ID   PAPOA_HUMAN             Reviewed;         745 AA.
AC   P51003; Q86SX4; Q86TV0; Q8IYF5; Q9BVU2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   23-FEB-2022, entry version 200.
DE   RecName: Full=Poly(A) polymerase alpha;
DE            Short=PAP-alpha;
DE            EC=2.7.7.19;
DE   AltName: Full=Polynucleotide adenylyltransferase alpha;
GN   Name=PAPOLA; Synonyms=PAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-725 (ISOFORMS 1 AND 2).
RC   TISSUE=B-cell, and Fetal brain;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-660 (ISOFORM 1).
RX   PubMed=8302877; DOI=10.1073/pnas.91.3.979;
RA   Thuresson A.-C., Aastroem J., Aastroem A., Groenvik K.-O., Virtanen A.;
RT   "Multiple forms of poly(A) polymerases in human cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:979-983(1994).
RN   [4]
RP   INTERACTION WITH NUDT21/CPSF5.
RX   PubMed=15169763; DOI=10.1074/jbc.m403927200;
RA   Dettwiler S., Aringhieri C., Cardinale S., Keller W., Barabino S.M.;
RT   "Distinct sequence motifs within the 68-kDa subunit of cleavage factor Im
RT   mediate RNA binding, protein-protein interactions, and subcellular
RT   localization.";
RL   J. Biol. Chem. 279:35788-35797(2004).
RN   [5]
RP   IDENTIFICATION IN A COMPLEX WITH CPSF1 AND FIP1L1, AND INTERACTION WITH
RP   FIP1L1.
RX   PubMed=14749727; DOI=10.1038/sj.emboj.7600070;
RA   Kaufmann I., Martin G., Friedlein A., Langen H., Keller W.;
RT   "Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and
RT   stimulates poly(A) polymerase.";
RL   EMBO J. 23:616-626(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   INTERACTION WITH AHCYL1 AND FIP1L1, AND FUNCTION.
RX   PubMed=19224921; DOI=10.1074/jbc.m807136200;
RA   Kiefer H., Mizutani A., Iemura S., Natsume T., Ando H., Kuroda Y.,
RA   Mikoshiba K.;
RT   "Inositol 1,4,5-triphosphate receptor-binding protein released with
RT   inositol 1,4,5-triphosphate (IRBIT) associates with components of the mRNA
RT   3' processing machinery in a phosphorylation-dependent manner and inhibits
RT   polyadenylation.";
RL   J. Biol. Chem. 284:10694-10705(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-24, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-24 AND SER-738, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-558, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Polymerase that creates the 3'-poly(A) tail of mRNA's. Also
CC       required for the endoribonucleolytic cleavage reaction at some
CC       polyadenylation sites. May acquire specificity through interaction with
CC       a cleavage and polyadenylation specificity factor (CPSF) at its C-
CC       terminus. {ECO:0000269|PubMed:19224921}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + RNA(n) = diphosphate + RNA(n)-3'-adenine ribonucleotide;
CC         Xref=Rhea:RHEA:11332, Rhea:RHEA-COMP:14527, Rhea:RHEA-COMP:17347,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:140395,
CC         ChEBI:CHEBI:173115; EC=2.7.7.19;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions. Also active with manganese. {ECO:0000250};
CC   -!- SUBUNIT: Monomer. Found in a complex with CPSF1, FIP1L1 and PAPOLA.
CC       Interacts with AHCYL1 and FIP1L1; the interaction with AHCYL1 seems to
CC       increase interaction with FIP1L1 (PubMed:19224921). Interacts with
CC       NUDT21; the interaction is diminished by acetylation. Interacts with
CC       KPNB1; the interaction promotes PAP nuclear import and is inhibited by
CC       acetylation of PAP (By similarity). {ECO:0000250|UniProtKB:P25500,
CC       ECO:0000250|UniProtKB:Q61183, ECO:0000269|PubMed:19224921}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=The 90 kDa form is
CC       nuclear while the 100 kDa and the 106 kDa forms are both nuclear and
CC       cytoplasmic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P51003-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P51003-2; Sequence=VSP_012895, VSP_012896;
CC   -!- PTM: Polysumoylated. Varying sumolyation depending on tissue- and cell-
CC       type. Highly sumoylated in bladder and NIH 3T3 cells. Sumoylation is
CC       required for nuclear localization and enhances PAP stability.
CC       Desumoylated by SENP1. Inhibits polymerase activity (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Hyperphosphorylation on multiple CDK2 consensus and non-consensus
CC       sites in the C-terminal Ser/Thr-rich region represses PAP activity in
CC       late M-phase. Phosphorylation/dephosphorylation may regulate the
CC       interaction between PAP and CPSF (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated in the C-terminus. Acetylation decreases interaction
CC       with NUDT21 and KPNB1, and inhibits nuclear localization through
CC       inhibiting binding to the importin alpha/beta complex (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the poly(A) polymerase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC000927; AAH00927.1; -; mRNA.
DR   EMBL; BC036014; AAH36014.1; -; mRNA.
DR   EMBL; BX248301; CAD62628.1; -; mRNA.
DR   EMBL; BX248753; CAD66560.1; -; mRNA.
DR   EMBL; BX161482; CAD61935.1; -; mRNA.
DR   EMBL; X76770; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS58334.1; -. [P51003-2]
DR   CCDS; CCDS9946.1; -. [P51003-1]
DR   RefSeq; NP_001238935.1; NM_001252006.1. [P51003-2]
DR   RefSeq; NP_001238936.1; NM_001252007.1.
DR   RefSeq; NP_001280556.1; NM_001293627.1.
DR   RefSeq; NP_001280557.1; NM_001293628.1.
DR   RefSeq; NP_001280561.1; NM_001293632.1.
DR   RefSeq; NP_116021.2; NM_032632.4. [P51003-1]
DR   SMR; P51003; -.
DR   BioGRID; 116119; 69.
DR   CORUM; P51003; -.
DR   DIP; DIP-27610N; -.
DR   DIP; DIP-40865N; -.
DR   IntAct; P51003; 17.
DR   MINT; P51003; -.
DR   STRING; 9606.ENSP00000216277; -.
DR   DrugBank; DB02153; 3-sulfino-L-alanine.
DR   DrugBank; DB01860; Cordycepin Triphosphate.
DR   DrugBank; DB03896; Triphosphoric acid.
DR   GlyGen; P51003; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P51003; -.
DR   MetOSite; P51003; -.
DR   PhosphoSitePlus; P51003; -.
DR   BioMuta; PAPOLA; -.
DR   DMDM; 59803092; -.
DR   EPD; P51003; -.
DR   jPOST; P51003; -.
DR   MassIVE; P51003; -.
DR   MaxQB; P51003; -.
DR   PaxDb; P51003; -.
DR   PeptideAtlas; P51003; -.
DR   PRIDE; P51003; -.
DR   ProteomicsDB; 56276; -. [P51003-1]
DR   ProteomicsDB; 56277; -. [P51003-2]
DR   Antibodypedia; 86; 140 antibodies from 22 providers.
DR   DNASU; 10914; -.
DR   Ensembl; ENST00000216277; ENSP00000216277; ENSG00000090060.
DR   Ensembl; ENST00000557320; ENSP00000450437; ENSG00000090060. [P51003-2]
DR   GeneID; 10914; -.
DR   KEGG; hsa:10914; -.
DR   MANE-Select; ENST00000216277.13; ENSP00000216277.8; NM_032632.5; NP_116021.2.
DR   UCSC; uc001yfo.5; human. [P51003-1]
DR   CTD; 10914; -.
DR   DisGeNET; 10914; -.
DR   GeneCards; PAPOLA; -.
DR   HGNC; HGNC:14981; PAPOLA.
DR   HPA; ENSG00000090060; Low tissue specificity.
DR   MIM; 605553; gene.
DR   neXtProt; NX_P51003; -.
DR   OpenTargets; ENSG00000090060; -.
DR   PharmGKB; PA32932; -.
DR   VEuPathDB; HostDB:ENSG00000090060; -.
DR   eggNOG; KOG2245; Eukaryota.
DR   GeneTree; ENSGT00940000154598; -.
DR   HOGENOM; CLU_011511_0_0_1; -.
DR   InParanoid; P51003; -.
DR   OMA; WRWPQPV; -.
DR   PhylomeDB; P51003; -.
DR   TreeFam; TF300842; -.
DR   BRENDA; 2.7.7.19; 2681.
DR   PathwayCommons; P51003; -.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   Reactome; R-HSA-72187; mRNA 3'-end processing.
DR   Reactome; R-HSA-73856; RNA Polymerase II Transcription Termination.
DR   Reactome; R-HSA-77595; Processing of Intronless Pre-mRNAs.
DR   SABIO-RK; P51003; -.
DR   SignaLink; P51003; -.
DR   SIGNOR; P51003; -.
DR   BioGRID-ORCS; 10914; 138 hits in 1050 CRISPR screens.
DR   ChiTaRS; PAPOLA; human.
DR   GeneWiki; PAPOLA; -.
DR   GenomeRNAi; 10914; -.
DR   Pharos; P51003; Tbio.
DR   PRO; PR:P51003; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P51003; protein.
DR   Bgee; ENSG00000090060; Expressed in testis and 242 other tissues.
DR   ExpressionAtlas; P51003; baseline and differential.
DR   Genevisible; P51003; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; ISS:UniProtKB.
DR   GO; GO:0004652; F:polynucleotide adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0031124; P:mRNA 3'-end processing; TAS:Reactome.
DR   GO; GO:0006378; P:mRNA polyadenylation; IDA:UniProtKB.
DR   GO; GO:0031440; P:regulation of mRNA 3'-end processing; IDA:UniProtKB.
DR   GO; GO:0043631; P:RNA polyadenylation; ISS:UniProtKB.
DR   Gene3D; 3.30.460.10; -; 1.
DR   InterPro; IPR043519; NT_sf.
DR   InterPro; IPR011068; NuclTrfase_I-like_C.
DR   InterPro; IPR007012; PolA_pol_cen_dom.
DR   InterPro; IPR007010; PolA_pol_RNA-bd_dom.
DR   InterPro; IPR014492; PolyA_polymerase.
DR   InterPro; IPR002934; Polymerase_NTP_transf_dom.
DR   Pfam; PF01909; NTP_transf_2; 1.
DR   Pfam; PF04928; PAP_central; 1.
DR   Pfam; PF04926; PAP_RNA-bind; 1.
DR   PIRSF; PIRSF018425; PolyA_polymerase; 1.
DR   SUPFAM; SSF55003; SSF55003; 1.
DR   SUPFAM; SSF81301; SSF81301; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Cytoplasm; Isopeptide bond;
KW   Magnesium; Manganese; Metal-binding; mRNA processing; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; RNA-binding; Transferase;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   CHAIN           2..745
FT                   /note="Poly(A) polymerase alpha"
FT                   /id="PRO_0000051612"
FT   NP_BIND         100..102
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         113..115
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         246..247
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          508..643
FT                   /note="Ser/Thr-rich"
FT   REGION          523..565
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          577..704
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          677..745
FT                   /note="Required for interaction with NUDT21"
FT   MOTIF           490..507
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           650..665
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1..21
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        577..600
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        611..641
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        652..672
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   METAL           113
FT                   /note="Magnesium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           113
FT                   /note="Magnesium 2; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           115
FT                   /note="Magnesium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           115
FT                   /note="Magnesium 2; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           167
FT                   /note="Magnesium 2; catalytic"
FT                   /evidence="ECO:0000250"
FT   BINDING         109
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         167
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         228
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   BINDING         237
FT                   /note="ATP"
FT                   /evidence="ECO:0000250"
FT   SITE            153
FT                   /note="Interaction with RNA"
FT                   /evidence="ECO:0000250"
FT   SITE            158
FT                   /note="Interaction with RNA"
FT                   /evidence="ECO:0000250"
FT   SITE            328
FT                   /note="Interaction with RNA"
FT                   /evidence="ECO:0000250"
FT   SITE            399
FT                   /note="Interaction with RNA"
FT                   /evidence="ECO:0000250"
FT   SITE            524
FT                   /note="Interaction with RNA"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         537
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61183"
FT   MOD_RES         558
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         641
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P25500"
FT   MOD_RES         650
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P25500"
FT   MOD_RES         736
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P25500"
FT   MOD_RES         738
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         740
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P25500"
FT   CROSSLNK        444
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000305"
FT   CROSSLNK        445
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000305"
FT   CROSSLNK        506
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000305"
FT   CROSSLNK        507
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000305"
FT   CROSSLNK        736
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        740
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         280..285
FT                   /note="EWPNPV -> YVFRLY (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_012895"
FT   VAR_SEQ         286..745
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_012896"
FT   CONFLICT        2..3
FT                   /note="PF -> GTSNSPGHSSFSAPSTKKIKTTRKQNIAWC (in Ref. 2;
FT                   CAD62628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        204..238
FT                   /note="CRVTDEILHLVPNIDNFRLTLRAIKLWAKRHNIYS -> MRKPTSFCVLQFL
FT                   SDISCFYTSFVLKLFIAILLTQ (in Ref. 2; CAD61935)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   745 AA;  82843 MW;  14A00CCCDAD9B374 CRC64;
     MPFPVTTQGS QQTQPPQKHY GITSPISLAA PKETDCVLTQ KLIETLKPFG VFEEEEELQR
     RILILGKLNN LVKEWIREIS ESKNLPQSVI ENVGGKIFTF GSYRLGVHTK GADIDALCVA
     PRHVDRSDFF TSFYDKLKLQ EEVKDLRAVE EAFVPVIKLC FDGIEIDILF ARLALQTIPE
     DLDLRDDSLL KNLDIRCIRS LNGCRVTDEI LHLVPNIDNF RLTLRAIKLW AKRHNIYSNI
     LGFLGGVSWA MLVARTCQLY PNAIASTLVH KFFLVFSKWE WPNPVLLKQP EECNLNLPVW
     DPRVNPSDRY HLMPIITPAY PQQNSTYNVS VSTRMVMVEE FKQGLAITDE ILLSKAEWSK
     LFEAPNFFQK YKHYIVLLAS APTEKQRLEW VGLVESKIRI LVGSLEKNEF ITLAHVNPQS
     FPAPKENPDK EEFRTMWVIG LVFKKTENSE NLSVDLTYDI QSFTDTVYRQ AINSKMFEVD
     MKIAAMHVKR KQLHQLLPNH VLQKKKKHST EGVKLTALND SSLDLSMDSD NSMSVPSPTS
     ATKTSPLNSS GSSQGRNSPA PAVTAASVTN IQATEVSVPQ VNSSESSGGT SSESIPQTAT
     QPAISPPPKP TVSRVVSSTR LVNPPPRSSG NAATSGNAAT KIPTPIVGVK RTSSPHKEES
     PKKTKTEEDE TSEDANCLAL SGHDKTEAKE QLDTETSTTQ SETIQTAASL LASQKTSSTD
     LSDIPALPAN PIPVIKNSIK LRLNR
//
ID   DEN10_HUMAN             Reviewed;         357 AA.
AC   Q8TCE6; B1AMV6; B4DDC3; D3DRC8; Q9NXW4;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   23-FEB-2022, entry version 130.
DE   RecName: Full=DENN domain-containing protein 10 {ECO:0000305};
DE   AltName: Full=Protein FAM45A;
GN   Name=DENND10 {ECO:0000312|HGNC:HGNC:31793};
GN   Synonyms=FAM45A {ECO:0000312|HGNC:HGNC:31793};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Adipose tissue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RAB27A AND RAB27B.
RX   PubMed=30771381; DOI=10.1016/j.bbamcr.2019.02.006;
RA   Zhang J., Zhang K., Qi L., Hu Q., Shen Z., Liu B., Deng J., Zhang C.,
RA   Zhang Y.;
RT   "DENN domain-containing protein FAM45A regulates the homeostasis of
RT   late/multivesicular endosomes.";
RL   Biochim. Biophys. Acta 1866:916-929(2019).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) regulating
CC       homeostasis of late endocytic pathway, including endosomal positioning,
CC       maturation and secretion, possibly through activating Rab proteins such
CC       as RAB27A and RAB27B. Seems to promote the exchange of GDP to GTP,
CC       converting inactive GDP-bound RAB27A and RAB27B into their active GTP-
CC       bound form. {ECO:0000269|PubMed:30771381}.
CC   -!- SUBUNIT: Interacts with RAB27A and RAB27B (GDP-bound forms
CC       preferentially). {ECO:0000269|PubMed:30771381}.
CC   -!- SUBCELLULAR LOCATION: Late endosome {ECO:0000269|PubMed:30771381}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8TCE6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TCE6-2; Sequence=VSP_038301;
CC   -!- SIMILARITY: Belongs to the DENND10 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK000031; BAA90894.1; -; mRNA.
DR   EMBL; AK293136; BAG56684.1; -; mRNA.
DR   EMBL; AL355598; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49406.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49407.1; -; Genomic_DNA.
DR   EMBL; BC022271; AAH22271.1; -; mRNA.
DR   CCDS; CCDS7609.1; -. [Q8TCE6-1]
DR   RefSeq; NP_001290040.1; NM_001303111.1. [Q8TCE6-2]
DR   RefSeq; NP_001290041.1; NM_001303112.1.
DR   RefSeq; NP_001290042.1; NM_001303113.1.
DR   RefSeq; NP_996892.1; NM_207009.3. [Q8TCE6-1]
DR   RefSeq; XP_016871750.1; XM_017016261.1. [Q8TCE6-2]
DR   RefSeq; XP_016871751.1; XM_017016262.1. [Q8TCE6-2]
DR   RefSeq; XP_016871752.1; XM_017016263.1. [Q8TCE6-2]
DR   BioGRID; 135667; 32.
DR   IntAct; Q8TCE6; 26.
DR   MINT; Q8TCE6; -.
DR   STRING; 9606.ENSP00000354688; -.
DR   iPTMnet; Q8TCE6; -.
DR   PhosphoSitePlus; Q8TCE6; -.
DR   BioMuta; FAM45A; -.
DR   DMDM; 51316043; -.
DR   EPD; Q8TCE6; -.
DR   jPOST; Q8TCE6; -.
DR   MassIVE; Q8TCE6; -.
DR   MaxQB; Q8TCE6; -.
DR   PaxDb; Q8TCE6; -.
DR   PeptideAtlas; Q8TCE6; -.
DR   PRIDE; Q8TCE6; -.
DR   ProteomicsDB; 74125; -. [Q8TCE6-1]
DR   ProteomicsDB; 74126; -. [Q8TCE6-2]
DR   Antibodypedia; 49417; 49 antibodies from 14 providers.
DR   DNASU; 404636; -.
DR   Ensembl; ENST00000361432; ENSP00000354688; ENSG00000119979.
DR   GeneID; 404636; -.
DR   KEGG; hsa:404636; -.
DR   MANE-Select; ENST00000361432.3; ENSP00000354688.2; NM_207009.4; NP_996892.1.
DR   UCSC; uc001ldw.5; human. [Q8TCE6-1]
DR   CTD; 404636; -.
DR   GeneCards; DENND10; -.
DR   HGNC; HGNC:31793; DENND10.
DR   HPA; ENSG00000119979; Low tissue specificity.
DR   neXtProt; NX_Q8TCE6; -.
DR   PharmGKB; PA134935316; -.
DR   VEuPathDB; HostDB:ENSG00000119979; -.
DR   eggNOG; ENOG502QVHR; Eukaryota.
DR   GeneTree; ENSGT00390000014431; -.
DR   HOGENOM; CLU_050301_0_0_1; -.
DR   InParanoid; Q8TCE6; -.
DR   OMA; VKMMEAY; -.
DR   OrthoDB; 1065142at2759; -.
DR   PhylomeDB; Q8TCE6; -.
DR   TreeFam; TF332501; -.
DR   PathwayCommons; Q8TCE6; -.
DR   SignaLink; Q8TCE6; -.
DR   BioGRID-ORCS; 404636; 29 hits in 1048 CRISPR screens.
DR   ChiTaRS; FAM45A; human.
DR   GenomeRNAi; 404636; -.
DR   Pharos; Q8TCE6; Tdark.
DR   PRO; PR:Q8TCE6; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q8TCE6; protein.
DR   Bgee; ENSG00000119979; Expressed in monocyte and 121 other tissues.
DR   ExpressionAtlas; Q8TCE6; baseline and differential.
DR   Genevisible; Q8TCE6; HS.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB.
DR   GO; GO:0032509; P:endosome transport via multivesicular body sorting pathway; IMP:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IMP:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; IMP:UniProtKB.
DR   InterPro; IPR042431; FAM45.
DR   InterPro; IPR037516; Tripartite_DENN.
DR   PANTHER; PTHR28544; PTHR28544; 1.
DR   PROSITE; PS50211; DENN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Endosome; Guanine-nucleotide releasing factor;
KW   Reference proteome.
FT   CHAIN           1..357
FT                   /note="DENN domain-containing protein 10"
FT                   /id="PRO_0000187034"
FT   DOMAIN          1..140
FT                   /note="uDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   DOMAIN          165..299
FT                   /note="cDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   DOMAIN          301..357
FT                   /note="dDENN"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00304"
FT   VAR_SEQ         1..18
FT                   /note="MAAAEVADTQLMLGVGLI -> MLSSDHLSTV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038301"
FT   CONFLICT        267
FT                   /note="K -> R (in Ref. 1; BAA90894)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   357 AA;  40513 MW;  B4AE072A5D9DB379 CRC64;
     MAAAEVADTQ LMLGVGLIEK DTNGEVLWVW CYPSTTATLR NLLLRKCCLT DENKLLHPFV
     FGQYRRTWFY ITTIEVPDSS ILKKVTHFSI VLTAKDFNPE KYAAFTRILC RMYLKHGSPV
     KMMESYIAVL TKGICQSEEN GSFLSKDFDA RKAYLAGSIK DIVSQFGMET VILHTALMLK
     KRIVVYHPKI EAVQEFTRTL PALVWHRQDW TILHSYVHLN ADELEALQMC TGYVAGFVDL
     EVSNRPDLYD VFVNLAESEI TIAPLAKEAM AMGKLHKEMG QLIVQSAEDP EKSESHVIQD
     IALKTREIFT NLAPFSEVSA DGEKRVLNLE ALKQKRFPPA TENFLYHLAA AEQMLKI
//
ID   ANO3_HUMAN              Reviewed;         981 AA.
AC   Q9BYT9; B7Z3F5;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   23-FEB-2022, entry version 145.
DE   RecName: Full=Anoctamin-3;
DE   AltName: Full=Transmembrane protein 16C;
GN   Name=ANO3; Synonyms=C11orf25, TMEM16C; ORFNames=GENX-3947;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Rosier M.F., Toselli E., Segurens-Soury B., Auffray C., Devignes M.D.;
RT   "Predominant brain expression and full-length characterization of a novel
RT   human 6.6-Kb transcript mapping at 11p14 in the telomeric part of WAGR
RT   locus.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   REVIEW.
RX   PubMed=21642943; DOI=10.1038/aps.2011.48;
RA   Duran C., Hartzell H.C.;
RT   "Physiological roles and diseases of Tmem16/Anoctamin proteins: are they
RT   all chloride channels?";
RL   Acta Pharmacol. Sin. 32:685-692(2011).
RN   [5]
RP   REVIEW.
RX   PubMed=21607626; DOI=10.1007/s00424-011-0975-9;
RA   Kunzelmann K., Tian Y., Martins J.R., Faria D., Kongsuphol P.,
RA   Ousingsawat J., Thevenod F., Roussa E., Rock J., Schreiber R.;
RT   "Anoctamins.";
RL   Pflugers Arch. 462:195-208(2011).
RN   [6]
RP   TISSUE SPECIFICITY, AND VARIANTS DYT24 CYS-490; TRP-494; GLY-685 AND
RP   ASN-862.
RX   PubMed=23200863; DOI=10.1016/j.ajhg.2012.10.024;
RA   Charlesworth G., Plagnol V., Holmstroem K.M., Bras J., Sheerin U.M.,
RA   Preza E., Rubio-Agusti I., Ryten M., Schneider S.A., Stamelou M.,
RA   Trabzuni D., Abramov A.Y., Bhatia K.P., Wood N.W.;
RT   "Mutations in ANO3 cause dominant craniocervical dystonia: ion channel
RT   implicated in pathogenesis.";
RL   Am. J. Hum. Genet. 91:1041-1050(2012).
RN   [7]
RP   REVIEW.
RX   PubMed=22302790; DOI=10.1113/expphysiol.2011.058214;
RA   Winpenny J.P., Gray M.A.;
RT   "The anoctamin (TMEM16) gene family: calcium-activated chloride channels
RT   come of age.";
RL   Exp. Physiol. 97:175-176(2012).
RN   [8]
RP   REVIEW, AND ABSENCE OF CALCIUM-ACTIVATED CHLORIDE CHANNEL ACTIVITY.
RX   PubMed=21984732; DOI=10.1113/expphysiol.2011.058198;
RA   Scudieri P., Sondo E., Ferrera L., Galietta L.J.;
RT   "The anoctamin family: TMEM16A and TMEM16B as calcium-activated chloride
RT   channels.";
RL   Exp. Physiol. 97:177-183(2012).
CC   -!- FUNCTION: Has calcium-dependent phospholipid scramblase activity;
CC       scrambles phosphatidylcholine and galactosylceramide (By similarity).
CC       Seems to act as potassium channel regulator and may inhibit pain
CC       signaling; can facilitate KCNT1/Slack channel activity by promoting its
CC       full single-channel conductance at very low sodium concentrations and
CC       by increasing its sodium sensitivity (By similarity). Does not exhibit
CC       calcium-activated chloride channel (CaCC) activity (PubMed:21984732).
CC       {ECO:0000250|UniProtKB:A2AHL1, ECO:0000303|PubMed:21984732}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-
CC         sn-glycero-3-phosphocholine(out); Xref=Rhea:RHEA:38571,
CC         ChEBI:CHEBI:57643; Evidence={ECO:0000250|UniProtKB:A2AHL1};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:38573;
CC         Evidence={ECO:0000250|UniProtKB:A2AHL1};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(out) = a
CC         beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(in);
CC         Xref=Rhea:RHEA:38899, ChEBI:CHEBI:18390;
CC         Evidence={ECO:0000250|UniProtKB:A2AHL1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38900;
CC         Evidence={ECO:0000250|UniProtKB:A2AHL1};
CC   -!- SUBUNIT: Interacts with KCNT1/Slack. {ECO:0000250|UniProtKB:A2AHL1}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Note=Shows an intracellular localization.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BYT9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYT9-2; Sequence=VSP_056893;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the forebrain striatum.
CC       {ECO:0000269|PubMed:23200863}.
CC   -!- DISEASE: Dystonia 24 (DYT24) [MIM:615034]: A form of dystonia, a
CC       disorder defined by the presence of sustained involuntary muscle
CC       contraction, often leading to abnormal postures. DYT24 is an autosomal
CC       dominant focal dystonia affecting the neck, laryngeal muscles, and
CC       muscles of the upper limbs. {ECO:0000269|PubMed:23200863}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: The term 'anoctamin' was coined because these channels
CC       are anion selective and have eight (OCT) transmembrane segments. There
CC       is some dissatisfaction in the field with the Ano nomenclature because
CC       it is not certain that all the members of this family are anion
CC       channels or have the 8-transmembrane topology.
CC   -!- SIMILARITY: Belongs to the anoctamin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ300461; CAC32454.1; -; mRNA.
DR   EMBL; AK295816; BAH12191.1; -; mRNA.
DR   EMBL; AC021698; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC036114; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079064; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083755; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC099687; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS31447.1; -. [Q9BYT9-1]
DR   CCDS; CCDS81557.1; -. [Q9BYT9-2]
DR   RefSeq; NP_001300655.1; NM_001313726.1.
DR   RefSeq; NP_001300656.1; NM_001313727.1. [Q9BYT9-2]
DR   RefSeq; NP_113606.2; NM_031418.3. [Q9BYT9-1]
DR   RefSeq; XP_016873607.1; XM_017018118.1. [Q9BYT9-2]
DR   SMR; Q9BYT9; -.
DR   BioGRID; 122027; 8.
DR   IntAct; Q9BYT9; 8.
DR   STRING; 9606.ENSP00000256737; -.
DR   TCDB; 1.A.17.1.20; the calcium-dependent chloride channel (ca-clc) family.
DR   GlyGen; Q9BYT9; 4 sites.
DR   iPTMnet; Q9BYT9; -.
DR   PhosphoSitePlus; Q9BYT9; -.
DR   BioMuta; ANO3; -.
DR   DMDM; 296434396; -.
DR   MassIVE; Q9BYT9; -.
DR   PaxDb; Q9BYT9; -.
DR   PeptideAtlas; Q9BYT9; -.
DR   PRIDE; Q9BYT9; -.
DR   ProteomicsDB; 6516; -.
DR   ProteomicsDB; 79708; -. [Q9BYT9-1]
DR   Antibodypedia; 25359; 114 antibodies from 25 providers.
DR   DNASU; 63982; -.
DR   Ensembl; ENST00000256737; ENSP00000256737; ENSG00000134343.
DR   Ensembl; ENST00000531568; ENSP00000432394; ENSG00000134343. [Q9BYT9-2]
DR   GeneID; 63982; -.
DR   KEGG; hsa:63982; -.
DR   MANE-Select; ENST00000256737.8; ENSP00000256737.3; NM_031418.4; NP_113606.2.
DR   UCSC; uc001mqt.5; human. [Q9BYT9-1]
DR   CTD; 63982; -.
DR   DisGeNET; 63982; -.
DR   GeneCards; ANO3; -.
DR   HGNC; HGNC:14004; ANO3.
DR   HPA; ENSG00000134343; Group enriched (brain, epididymis).
DR   MalaCards; ANO3; -.
DR   MIM; 610110; gene.
DR   MIM; 615034; phenotype.
DR   neXtProt; NX_Q9BYT9; -.
DR   OpenTargets; ENSG00000134343; -.
DR   Orphanet; 420485; Cranio-cervical dystonia with laryngeal and upper-limb involvement.
DR   PharmGKB; PA25489; -.
DR   VEuPathDB; HostDB:ENSG00000134343; -.
DR   eggNOG; KOG2514; Eukaryota.
DR   GeneTree; ENSGT00940000156257; -.
DR   HOGENOM; CLU_006685_1_3_1; -.
DR   InParanoid; Q9BYT9; -.
DR   OMA; WHFVKKN; -.
DR   OrthoDB; 1263362at2759; -.
DR   PhylomeDB; Q9BYT9; -.
DR   TreeFam; TF314265; -.
DR   PathwayCommons; Q9BYT9; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   SignaLink; Q9BYT9; -.
DR   BioGRID-ORCS; 63982; 18 hits in 1038 CRISPR screens.
DR   ChiTaRS; ANO3; human.
DR   GenomeRNAi; 63982; -.
DR   Pharos; Q9BYT9; Tbio.
DR   PRO; PR:Q9BYT9; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9BYT9; protein.
DR   Bgee; ENSG00000134343; Expressed in caudate nucleus and 138 other tissues.
DR   ExpressionAtlas; Q9BYT9; baseline and differential.
DR   Genevisible; Q9BYT9; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005254; F:chloride channel activity; IBA:GO_Central.
DR   GO; GO:0005229; F:intracellular calcium activated chloride channel activity; TAS:Reactome.
DR   GO; GO:0017128; F:phospholipid scramblase activity; IEA:Ensembl.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0061591; P:calcium activated galactosylceramide scrambling; IEA:Ensembl.
DR   GO; GO:0061590; P:calcium activated phosphatidylcholine scrambling; IEA:Ensembl.
DR   GO; GO:1902476; P:chloride transmembrane transport; IBA:GO_Central.
DR   GO; GO:0050982; P:detection of mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0016048; P:detection of temperature stimulus; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; IBA:GO_Central.
DR   InterPro; IPR032394; Anoct_dimer.
DR   InterPro; IPR007632; Anoctamin.
DR   InterPro; IPR031292; Anoctamin-3.
DR   PANTHER; PTHR12308; PTHR12308; 1.
DR   PANTHER; PTHR12308:SF16; PTHR12308:SF16; 1.
DR   Pfam; PF16178; Anoct_dimer; 1.
DR   Pfam; PF04547; Anoctamin; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disease variant; Dystonia;
KW   Glycoprotein; Lipid transport; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..981
FT                   /note="Anoctamin-3"
FT                   /id="PRO_0000072565"
FT   TOPO_DOM        1..403
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        404..424
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        425..469
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        470..490
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        491..550
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        551..571
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        572..592
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        593..613
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        614..640
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        641..661
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        662..761
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        762..782
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        783..810
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        811..831
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        832..914
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        915..935
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        936..981
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..33
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        425
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        448
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        455
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        866
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..146
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056893"
FT   VARIANT         490
FT                   /note="W -> C (in DYT24; dbSNP:rs1565132917)"
FT                   /evidence="ECO:0000269|PubMed:23200863"
FT                   /id="VAR_069732"
FT   VARIANT         494
FT                   /note="R -> W (in DYT24; dbSNP:rs587776922)"
FT                   /evidence="ECO:0000269|PubMed:23200863"
FT                   /id="VAR_069733"
FT   VARIANT         685
FT                   /note="S -> G (in DYT24; dbSNP:rs587776923)"
FT                   /evidence="ECO:0000269|PubMed:23200863"
FT                   /id="VAR_069734"
FT   VARIANT         781
FT                   /note="L -> V (in dbSNP:rs11825056)"
FT                   /id="VAR_057287"
FT   VARIANT         862
FT                   /note="K -> N (in DYT24; dbSNP:rs1277790116)"
FT                   /evidence="ECO:0000269|PubMed:23200863"
FT                   /id="VAR_069735"
FT   CONFLICT        162
FT                   /note="K -> R (in Ref. 1; CAC32454)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        176
FT                   /note="Q -> P (in Ref. 1; CAC32454)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        256
FT                   /note="N -> D (in Ref. 1; CAC32454)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   981 AA;  114657 MW;  FC7449D2D4810290 CRC64;
     MVHHSGSIQS FKQQKGMNIS KSEITKETSL KPSRRSLPCL AQSYAYSKSL SQSTSLFQST
     ESESQAPTSI TLISTDKAEQ VNTEENKNDS VLRCSFADLS DFCLALGKDK DYTDESEHAT
     YDRSRLINDF VIKDKSEFKT KLSKNDMNYI ASSGPLFKDG KKRIDYILVY RKTNIQYDKR
     NTFEKNLRAE GLMLEKEPAI ASPDIMFIKI HIPWDTLCKY AERLNIRMPF RKKCYYTDGR
     SKSMGRMQTY FRRIKNWMAQ NPMVLDKSAF PDLEESDCYT GPFSRARIHH FIINNKDTFF
     SNATRSRIVY HMLERTKYEN GISKVGIRKL INNGSYIAAF PPHEGAYKSS QPIKTHGPQN
     NRHLLYERWA RWGMWYKHQP LDLIRLYFGE KIGLYFAWLG WYTGMLIPAA IVGLCVFFYG
     LFTMNNSQVS QEICKATEVF MCPLCDKNCS LQRLNDSCIY AKVTYLFDNG GTVFFAIFMA
     IWATVFLEFW KRRRSILTYT WDLIEWEEEE ETLRPQFEAK YYKMEIVNPI TGKPEPHQPS
     SDKVTRLLVS VSGIFFMISL VITAVFGVVV YRLVVMEQFA SFKWNFIKQY WQFATSAAAV
     CINFIIIMLL NLAYEKIAYL LTNLEYPRTE SEWENSFALK MFLFQFVNLN SSIFYIAFFL
     GRFVGHPGKY NKLFDRWRLE ECHPSGCLID LCLQMGVIMF LKQIWNNFME LGYPLIQNWW
     SRHKIKRGIH DASIPQWEND WNLQPMNLHG LMDEYLEMVL QFGFTTIFVA AFPLAPLLAL
     LNNIIEIRLD AYKFVTQWRR PLPARATDIG IWLGILEGIG ILAVITNAFV IAITSDYIPR
     FVYEYKYGPC ANHVEPSENC LKGYVNNSLS FFDLSELGMG KSGYCRYRDY RGPPWSSKPY
     EFTLQYWHIL AARLAFIIVF EHLVFGIKSF IAYLIPDVPK GLHDRIRREK YLVQEMMYEA
     ELEHLQQQRR KSGQPVHHEW P
//
ID   LZIC_HUMAN              Reviewed;         190 AA.
AC   Q8WZA0; B2R6F0; B4E2N0; Q96IU1;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   23-FEB-2022, entry version 150.
DE   RecName: Full=Protein LZIC;
DE   AltName: Full=Leucine zipper and CTNNBIP1 domain-containing protein;
DE   AltName: Full=Leucine zipper and ICAT homologous domain-containing protein;
GN   Name=LZIC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Stomach;
RX   PubMed=11712074; DOI=10.3892/ijmm.8.6.611;
RA   Katoh M.;
RT   "Molecular cloning and characterization of LZIC, a novel gene encoding ICAT
RT   homologous protein with leucine zipper domain.";
RL   Int. J. Mol. Med. 8:611-615(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- SUBUNIT: Does not interact with CTNNB1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q8WZA0; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-5774346, EBI-1055254;
CC       Q8WZA0; P55072: VCP; NbExp=3; IntAct=EBI-5774346, EBI-355164;
CC       Q8WZA0; Q96NG5: ZNF558; NbExp=3; IntAct=EBI-5774346, EBI-373363;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8WZA0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WZA0-2; Sequence=VSP_056083;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       kidney. Up-regulated in several cases of gastric cancers.
CC       {ECO:0000269|PubMed:11712074}.
CC   -!- SIMILARITY: Belongs to the CTNNBIP1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB060688; BAB72100.1; -; mRNA.
DR   EMBL; AK304348; BAG65192.1; -; mRNA.
DR   EMBL; AK312550; BAG35447.1; -; mRNA.
DR   EMBL; AL357140; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471130; EAW71633.1; -; Genomic_DNA.
DR   EMBL; BC007240; AAH07240.2; -; mRNA.
DR   EMBL; BC063443; AAH63443.1; -; mRNA.
DR   CCDS; CCDS107.1; -. [Q8WZA0-1]
DR   RefSeq; NP_001303902.1; NM_001316973.1. [Q8WZA0-1]
DR   RefSeq; NP_001303903.1; NM_001316974.1. [Q8WZA0-2]
DR   RefSeq; NP_115744.2; NM_032368.4. [Q8WZA0-1]
DR   SMR; Q8WZA0; -.
DR   BioGRID; 124052; 19.
DR   IntAct; Q8WZA0; 16.
DR   STRING; 9606.ENSP00000366430; -.
DR   ChEMBL; CHEMBL4296296; -.
DR   GlyGen; Q8WZA0; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8WZA0; -.
DR   PhosphoSitePlus; Q8WZA0; -.
DR   BioMuta; LZIC; -.
DR   DMDM; 74751644; -.
DR   EPD; Q8WZA0; -.
DR   jPOST; Q8WZA0; -.
DR   MassIVE; Q8WZA0; -.
DR   MaxQB; Q8WZA0; -.
DR   PaxDb; Q8WZA0; -.
DR   PeptideAtlas; Q8WZA0; -.
DR   PRIDE; Q8WZA0; -.
DR   ProteomicsDB; 5835; -.
DR   ProteomicsDB; 75241; -. [Q8WZA0-1]
DR   TopDownProteomics; Q8WZA0-1; -. [Q8WZA0-1]
DR   Antibodypedia; 27776; 322 antibodies from 22 providers.
DR   DNASU; 84328; -.
DR   Ensembl; ENST00000377213; ENSP00000366418; ENSG00000162441.
DR   Ensembl; ENST00000377223; ENSP00000366430; ENSG00000162441.
DR   Ensembl; ENST00000400903; ENSP00000383695; ENSG00000162441.
DR   GeneID; 84328; -.
DR   KEGG; hsa:84328; -.
DR   MANE-Select; ENST00000377223.6; ENSP00000366430.1; NM_032368.5; NP_115744.2.
DR   UCSC; uc001aqm.4; human. [Q8WZA0-1]
DR   CTD; 84328; -.
DR   DisGeNET; 84328; -.
DR   GeneCards; LZIC; -.
DR   HGNC; HGNC:17497; LZIC.
DR   HPA; ENSG00000162441; Low tissue specificity.
DR   MIM; 610458; gene.
DR   neXtProt; NX_Q8WZA0; -.
DR   OpenTargets; ENSG00000162441; -.
DR   PharmGKB; PA30504; -.
DR   VEuPathDB; HostDB:ENSG00000162441; -.
DR   eggNOG; ENOG502QPUB; Eukaryota.
DR   GeneTree; ENSGT00940000159001; -.
DR   HOGENOM; CLU_091171_0_0_1; -.
DR   InParanoid; Q8WZA0; -.
DR   OMA; VIRMFAR; -.
DR   OrthoDB; 1483957at2759; -.
DR   PhylomeDB; Q8WZA0; -.
DR   TreeFam; TF314533; -.
DR   PathwayCommons; Q8WZA0; -.
DR   SignaLink; Q8WZA0; -.
DR   BioGRID-ORCS; 84328; 12 hits in 1047 CRISPR screens.
DR   ChiTaRS; LZIC; human.
DR   GenomeRNAi; 84328; -.
DR   Pharos; Q8WZA0; Tdark.
DR   PRO; PR:Q8WZA0; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8WZA0; protein.
DR   Bgee; ENSG00000162441; Expressed in testis and 209 other tissues.
DR   ExpressionAtlas; Q8WZA0; baseline and differential.
DR   Genevisible; Q8WZA0; HS.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:InterPro.
DR   Gene3D; 1.10.10.490; -; 1.
DR   InterPro; IPR009428; ICAT_dom.
DR   InterPro; IPR036911; ICAT_sf.
DR   InterPro; IPR040065; LZIC.
DR   PANTHER; PTHR16505; PTHR16505; 1.
DR   Pfam; PF06384; ICAT; 1.
DR   SUPFAM; SSF81730; SSF81730; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Reference proteome.
FT   CHAIN           1..190
FT                   /note="Protein LZIC"
FT                   /id="PRO_0000263691"
FT   COILED          2..63
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1
FT                   /note="M -> MNNFIFLKFMTLGTSRTGEIKM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056083"
FT   VARIANT         104
FT                   /note="G -> D (in dbSNP:rs2304778)"
FT                   /id="VAR_053371"
SQ   SEQUENCE   190 AA;  21495 MW;  2DDDD7B788F42DD8 CRC64;
     MASRGKTETS KLKQNLEEQL DRLMQQLQDL EECREELDTD EYEETKKETL EQLSEFNDSL
     KKIMSGNMTL VDELSGMQLA IQAAISQAFK TPEVIRLFAK KQPGQLRTRL AEMDRDLMVG
     KLERDLYTQQ KVEILTALRK LGEKLTADDE AFLSANAGAI LSQFEKVSTD LGSGDKILAL
     ASFEVEKTKK
//
ID   CENPI_HUMAN             Reviewed;         756 AA.
AC   Q92674; Q5JWZ9; Q96ED0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   23-FEB-2022, entry version 169.
DE   RecName: Full=Centromere protein I;
DE            Short=CENP-I;
DE   AltName: Full=FSH primary response protein 1;
DE   AltName: Full=Follicle-stimulating hormone primary response protein;
DE   AltName: Full=Interphase centromere complex protein 19;
DE   AltName: Full=Leucine-rich primary response protein 1;
GN   Name=CENPI; Synonyms=FSHPRH1, ICEN19, LRPR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8921378; DOI=10.1006/geno.1996.0528;
RA   Roberts R.G., Kendall E., Vetrie D., Bobrow M.;
RT   "Sequence and chromosomal location of a human homologue of LRPR1, an FSH
RT   primary response gene.";
RL   Genomics 37:122-124(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12640463; DOI=10.1038/ncb953;
RA   Liu S.-T., Hittle J.C., Jablonski S.A., Campbell M.S., Yoda K., Yen T.J.;
RT   "Human CENP-I specifies localization of CENP-F, MAD1 and MAD2 to
RT   kinetochores and is essential for mitosis.";
RL   Nat. Cell Biol. 5:341-345(2003).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16716197; DOI=10.1111/j.1365-2443.2006.00969.x;
RA   Izuta H., Ikeno M., Suzuki N., Tomonaga T., Nozaki N., Obuse C., Kisu Y.,
RA   Goshima N., Nomura F., Nomura N., Yoda K.;
RT   "Comprehensive analysis of the ICEN (Interphase Centromere Complex)
RT   components enriched in the CENP-A chromatin of human cells.";
RL   Genes Cells 11:673-684(2006).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH
RP   CENPH; CENPK; CENPN; CENPO; CENPP; CENPQ; CENPR AND CENPU, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16622420; DOI=10.1038/ncb1396;
RA   Okada M., Cheeseman I.M., Hori T., Okawa K., McLeod I.X., Yates J.R. III,
RA   Desai A., Fukagawa T.;
RT   "The CENP-H-I complex is required for the efficient incorporation of newly
RT   synthesized CENP-A into centromeres.";
RL   Nat. Cell Biol. 8:446-457(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE CENPA-CAD
RP   COMPLEX WITH CENPK; CENPL; CENPO; CENPP; CENPQ; CENPR AND CENPS.
RX   PubMed=16622419; DOI=10.1038/ncb1397;
RA   Foltz D.R., Jansen L.E.T., Black B.E., Bailey A.O., Yates J.R. III,
RA   Cleveland D.W.;
RT   "The human CENP-A centromeric nucleosome-associated complex.";
RL   Nat. Cell Biol. 8:458-469(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   SUMOYLATION, UBIQUITINATION BY RNF4, DESUMOYLATION BY SENP6, AND
RP   INTERACTION WITH SENP6.
RX   PubMed=20212317; DOI=10.1083/jcb.200909008;
RA   Mukhopadhyay D., Arnaoutov A., Dasso M.;
RT   "The SUMO protease SENP6 is essential for inner kinetochore assembly.";
RL   J. Cell Biol. 188:681-692(2010).
CC   -!- FUNCTION: Component of the CENPA-CAD (nucleosome distal) complex, a
CC       complex recruited to centromeres which is involved in assembly of
CC       kinetochore proteins, mitotic progression and chromosome segregation.
CC       May be involved in incorporation of newly synthesized CENPA into
CC       centromeres via its interaction with the CENPA-NAC complex. Required
CC       for the localization of CENPF, MAD1L1 and MAD2 (MAD2L1 or MAD2L2) to
CC       kinetochores. Involved in the response of gonadal tissues to follicle-
CC       stimulating hormone. {ECO:0000269|PubMed:12640463,
CC       ECO:0000269|PubMed:16622420}.
CC   -!- SUBUNIT: Component of the CENPA-CAD complex, composed of CENPI, CENPK,
CC       CENPL, CENPO, CENPP, CENPQ, CENPR and CENPS. The CENPA-CAD complex
CC       interacts with the CENPA-NAC complex, at least composed of CENPA,
CC       CENPC, CENPH, CENPM, CENPN, CENPT and CENPU. Interacts with SENP6.
CC       {ECO:0000269|PubMed:16622419, ECO:0000269|PubMed:16622420,
CC       ECO:0000269|PubMed:20212317}.
CC   -!- INTERACTION:
CC       Q92674; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-11085153, EBI-742887;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere. Note=Localizes
CC       exclusively in the centromeres. The CENPA-CAD complex is probably
CC       recruited on centromeres by the CENPA-NAC complex.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92674-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92674-2; Sequence=VSP_015797;
CC   -!- INDUCTION: By follicle-stimulating hormone (FSH).
CC   -!- PTM: Sumoylated. Sumoylated form can be polyubiquitinated by RNF4,
CC       leading to its degradation. Desumoylation by SENP6 prevents its
CC       degradation. {ECO:0000269|PubMed:20212317}.
CC   -!- SIMILARITY: Belongs to the CENP-I/CTF3 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X97249; CAA65884.1; -; mRNA.
DR   EMBL; AL109963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012462; AAH12462.1; -; mRNA.
DR   CCDS; CCDS14479.1; -. [Q92674-1]
DR   CCDS; CCDS83482.1; -. [Q92674-2]
DR   RefSeq; NP_001305452.1; NM_001318523.1. [Q92674-2]
DR   RefSeq; NP_006724.2; NM_006733.3. [Q92674-1]
DR   RefSeq; XP_005262168.1; XM_005262111.2. [Q92674-1]
DR   RefSeq; XP_011529196.1; XM_011530894.2. [Q92674-1]
DR   RefSeq; XP_011529197.1; XM_011530895.2. [Q92674-1]
DR   RefSeq; XP_011529199.1; XM_011530897.2. [Q92674-1]
DR   RefSeq; XP_011529201.1; XM_011530899.2. [Q92674-1]
DR   BioGRID; 108769; 34.
DR   ComplexPortal; CPX-5646; Kinetochore CCAN complex.
DR   CORUM; Q92674; -.
DR   IntAct; Q92674; 15.
DR   MINT; Q92674; -.
DR   STRING; 9606.ENSP00000362018; -.
DR   iPTMnet; Q92674; -.
DR   PhosphoSitePlus; Q92674; -.
DR   BioMuta; CENPI; -.
DR   DMDM; 77416860; -.
DR   EPD; Q92674; -.
DR   jPOST; Q92674; -.
DR   MassIVE; Q92674; -.
DR   MaxQB; Q92674; -.
DR   PaxDb; Q92674; -.
DR   PeptideAtlas; Q92674; -.
DR   PRIDE; Q92674; -.
DR   ProteomicsDB; 75403; -. [Q92674-1]
DR   ProteomicsDB; 75404; -. [Q92674-2]
DR   Antibodypedia; 28595; 155 antibodies from 26 providers.
DR   DNASU; 2491; -.
DR   Ensembl; ENST00000372926; ENSP00000362017; ENSG00000102384. [Q92674-2]
DR   Ensembl; ENST00000372927; ENSP00000362018; ENSG00000102384.
DR   Ensembl; ENST00000682095; ENSP00000507927; ENSG00000102384.
DR   Ensembl; ENST00000684367; ENSP00000507595; ENSG00000102384.
DR   GeneID; 2491; -.
DR   KEGG; hsa:2491; -.
DR   MANE-Select; ENST00000682095.1; ENSP00000507927.1; NM_001386188.2; NP_001373117.1.
DR   UCSC; uc004egy.4; human. [Q92674-1]
DR   CTD; 2491; -.
DR   DisGeNET; 2491; -.
DR   GeneCards; CENPI; -.
DR   HGNC; HGNC:3968; CENPI.
DR   HPA; ENSG00000102384; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 300065; gene.
DR   neXtProt; NX_Q92674; -.
DR   OpenTargets; ENSG00000102384; -.
DR   PharmGKB; PA28385; -.
DR   VEuPathDB; HostDB:ENSG00000102384; -.
DR   eggNOG; ENOG502QU9H; Eukaryota.
DR   GeneTree; ENSGT00390000013235; -.
DR   HOGENOM; CLU_022189_0_0_1; -.
DR   InParanoid; Q92674; -.
DR   OMA; LMRSTMK; -.
DR   PhylomeDB; Q92674; -.
DR   TreeFam; TF101137; -.
DR   PathwayCommons; Q92674; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-606279; Deposition of new CENPA-containing nucleosomes at the centromere.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; Q92674; -.
DR   SIGNOR; Q92674; -.
DR   BioGRID-ORCS; 2491; 288 hits in 687 CRISPR screens.
DR   ChiTaRS; CENPI; human.
DR   GeneWiki; CENPI; -.
DR   GenomeRNAi; 2491; -.
DR   Pharos; Q92674; Tbio.
DR   PRO; PR:Q92674; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q92674; protein.
DR   Bgee; ENSG00000102384; Expressed in lung and 165 other tissues.
DR   ExpressionAtlas; Q92674; baseline and differential.
DR   Genevisible; Q92674; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0034508; P:centromere complex assembly; IEA:InterPro.
DR   GO; GO:0007548; P:sex differentiation; TAS:ProtInc.
DR   InterPro; IPR012485; CENP-I.
DR   Pfam; PF07778; CENP-I; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Centromere; Chromosome; Nucleus; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN           1..756
FT                   /note="Centromere protein I"
FT                   /id="PRO_0000087354"
FT   REGION          1..60
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..48
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         523..756
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015797"
FT   CONFLICT        262..263
FT                   /note="FK -> LQ (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        389
FT                   /note="Y -> H (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        432
FT                   /note="F -> Y (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        450
FT                   /note="C -> S (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        532
FT                   /note="S -> C (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        576
FT                   /note="N -> D (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        642
FT                   /note="H -> Y (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        658
FT                   /note="G -> A (in Ref. 1; CAA65884)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   756 AA;  86720 MW;  A3439CF1729D7A66 CRC64;
     MSPQKRVKNV QAQNRTSQGS SSFQTTLSAW KVKQDPSNSK NISKHGQNNP VGDYEHADDQ
     AEEDALQMAV GYFEKGPIKA SQNKDKTLEK HLKTVENVAW KNGLASEEID ILLNIALSGK
     FGNAVNTRIL KCMIPATVIS EDSVVKAVSW LCVGKCSGST KVLFYRWLVA MFDFIDRKEQ
     INLLYGFFFA SLQDDALCPY VCHLLYLLTK KENVKPFRVR KLLDLQAKMG MQPHLQALLS
     LYKFFAPALI SVSLPVRKKI YFKNSENLWK TALLAVKQRN RGPSPEPLKL MLGPANVRPL
     KRKWNSLSVI PVLNSSSYTK ECGKKEMSLS DCLNRSGSFP LEQLQSFPQL LQNIHCLELP
     SQMGSVLNNS LLLHYINCVR DEPVLLRFYY WLSQTLQEEC IWYKVNNYEH GKEFTNFLDT
     IIRAECFLQE GFYSCEAFLY KSLPLWDGLC CRSQFLQLVS WIPFSSFSEV KPLLFDHLAQ
     LFFTSTIYFK CSVLQSLKEL LQNWLLWLSM DIHMKPVTNS PLETTLGGSM NSVSKLIHYV
     GWLSTTAMRL ESNNTFLLHF ILDFYEKVCD IYINYNLPLV VLFPPGIFYS ALLSLDTSIL
     NQLCFIMHRY RKNLTAAKKN ELVQKTKSEF NFSSKTYQEF NHYLTSMVGC LWTSKPFGKG
     IYIDPEILEK TGVAEYKNSL NVVHHPSFLS YAVSFLLQES PEERTVNVSS IRGKKWSWYL
     DYLFSQGLQG LKLFIRSSVH HSSIPRAEGI NCNNQY
//
ID   PIAS1_HUMAN             Reviewed;         651 AA.
AC   O75925; B2RB67; B3KSY9; C5J4B4; Q147X4; Q99751; Q9UN02;
DT   05-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   05-MAR-2002, sequence version 2.
DT   23-FEB-2022, entry version 207.
DE   RecName: Full=E3 SUMO-protein ligase PIAS1;
DE            EC=2.3.2.-;
DE   AltName: Full=DEAD/H box-binding protein 1;
DE   AltName: Full=E3 SUMO-protein transferase PIAS1 {ECO:0000305};
DE   AltName: Full=Gu-binding protein;
DE            Short=GBP;
DE   AltName: Full=Protein inhibitor of activated STAT protein 1;
DE   AltName: Full=RNA helicase II-binding protein;
GN   Name=PIAS1; Synonyms=DDXBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH STAT1.
RC   TISSUE=B-cell;
RX   PubMed=9724754; DOI=10.1073/pnas.95.18.10626;
RA   Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., Shuai K.;
RT   "Inhibition of Stat1-mediated gene activation by PIAS1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10626-10631(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10628744; DOI=10.1210/mend.14.1.0408;
RA   Tan J., Hall S.H., Hamil K.G., Grossman G., Petrusz P., Liao J., Shuai K.,
RA   French F.S.;
RT   "Protein inhibitor of activated STAT-1 (signal transducer and activator of
RT   transcription-1) is a nuclear receptor coregulator expressed in human
RT   testis.";
RL   Mol. Endocrinol. 14:14-26(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=19906316; DOI=10.1186/1471-2164-10-518;
RA   Wang P., Yu P., Gao P., Shi T., Ma D.;
RT   "Discovery of novel human transcript variants by analysis of intronic
RT   single-block EST with polyadenylation site.";
RL   BMC Genomics 10:518-518(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-651 (ISOFORM 1), INTERACTION WITH DDX21,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=B-cell;
RX   PubMed=9177271; DOI=10.1006/bbrc.1997.6642;
RA   Valdez B.C., Henning D., Perlaky L., Busch R.K., Busch H.;
RT   "Cloning and characterization of Gu/RH-II binding protein.";
RL   Biochem. Biophys. Res. Commun. 234:335-340(1997).
RN   [8]
RP   INTERACTION WITH CSRP2.
RX   PubMed=11672422; DOI=10.1042/0264-6021:3590485;
RA   Weiskirchen R., Moser M., Weiskirchen S., Erdel M., Dahmen S., Buettner R.,
RA   Gressner A.M.;
RT   "LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel
RT   marker of hepatic stellate cells and binding partner of the protein
RT   inhibitor of activated STAT1.";
RL   Biochem. J. 359:485-496(2001).
RN   [9]
RP   INTERACTION WITH UBE2I; SUMO1 AND TP53, AND MUTAGENESIS OF CYS-351.
RX   PubMed=11583632; DOI=10.1016/s1097-2765(01)00349-5;
RA   Kahyo T., Nishida T., Yasuda H.;
RT   "Involvement of PIAS1 in the sumoylation of tumor suppressor p53.";
RL   Mol. Cell 8:713-718(2001).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=11439351; DOI=10.1038/sj.onc.1204489;
RA   Gross M., Liu B., Tan J.-A., French F.S., Carey M., Shuai K.;
RT   "Distinct effects of PIAS proteins on androgen-mediated gene activation in
RT   prostate cancer cells.";
RL   Oncogene 20:3880-3887(2001).
RN   [11]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.m208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK
RT   activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [12]
RP   SUMOYLATION OF MDM2, AND SUBCELLULAR LOCATION.
RX   PubMed=12393906; DOI=10.1074/jbc.m208319200;
RA   Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H.;
RT   "Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and
RT   RanBP2 enzymes.";
RL   J. Biol. Chem. 277:50131-50136(2002).
RN   [13]
RP   INTERACTION WITH SP3 AND UBE2I.
RX   PubMed=12356736; DOI=10.1093/emboj/cdf510;
RA   Sapetschnig A., Rischitor G., Braun H., Doll A., Schergaut M., Melchior F.,
RA   Suske G.;
RT   "Transcription factor Sp3 is silenced through SUMO modification by PIAS1.";
RL   EMBO J. 21:5206-5215(2002).
RN   [14]
RP   INTERACTION WITH JUN AND TP53, AND SUMOYLATION.
RX   PubMed=11867732; DOI=10.1073/pnas.052559499;
RA   Schmidt D., Mueller S.;
RT   "Members of the PIAS family act as SUMO ligases for c-Jun and p53 and
RT   repress p53 activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2872-2877(2002).
RN   [15]
RP   INTERACTION WITH SATB2.
RX   PubMed=14701874; DOI=10.1101/gad.1153003;
RA   Dobreva G., Dambacher J., Grosschedl R.;
RT   "SUMO modification of a novel MAR-binding protein, SATB2, modulates
RT   immunoglobulin mu gene expression.";
RL   Genes Dev. 17:3048-3061(2003).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH PTK2/FAK1.
RX   PubMed=14500712; DOI=10.1074/jbc.m308562200;
RA   Kadare G., Toutant M., Formstecher E., Corvol J.C., Carnaud M.,
RA   Boutterin M.C., Girault J.A.;
RT   "PIAS1-mediated sumoylation of focal adhesion kinase activates its
RT   autophosphorylation.";
RL   J. Biol. Chem. 278:47434-47440(2003).
RN   [17]
RP   INTERACTION WITH PLAG1.
RX   PubMed=15208321; DOI=10.1074/jbc.m401753200;
RA   Van Dyck F., Delvaux E.L.D., Van de Ven W.J.M., Chavez M.V.;
RT   "Repression of the transactivating capacity of the oncoprotein PLAG1 by
RT   SUMOylation.";
RL   J. Biol. Chem. 279:36121-36131(2004).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   INTERACTION WITH KLF8.
RX   PubMed=16617055; DOI=10.1074/jbc.m513135200;
RA   Wei H., Wang X., Gan B., Urvalek A.M., Melkoumian Z.K., Guan J.-L.,
RA   Zhao J.;
RT   "Sumoylation delimits KLF8 transcriptional activity associated with the
RT   cell cycle regulation.";
RL   J. Biol. Chem. 281:16664-16671(2006).
RN   [20]
RP   INTERACTION WITH CHUK.
RX   PubMed=17540171; DOI=10.1016/j.cell.2007.03.056;
RA   Liu B., Yang Y., Chernishof V., Loo R.R., Jang H., Tahk S., Yang R.,
RA   Mink S., Shultz D., Bellone C.J., Loo J.A., Shuai K.;
RT   "Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1
RT   to restrict inflammation and immunity.";
RL   Cell 129:903-914(2007).
RN   [21]
RP   INTERACTION WITH DDX5.
RX   PubMed=17369852; DOI=10.1038/sj.onc.1210387;
RA   Jacobs A.M., Nicol S.M., Hislop R.G., Jaffray E.G., Hay R.T.,
RA   Fuller-Pace F.V.;
RT   "SUMO modification of the DEAD box protein p68 modulates its
RT   transcriptional activity and promotes its interaction with HDAC1.";
RL   Oncogene 26:5866-5876(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503 AND SER-522, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   RETRACTED PAPER.
RX   PubMed=19136629; DOI=10.1101/gad.489409;
RA   Weber S., Maass F., Schuemann M., Krause E., Suske G., Bauer U.M.;
RT   "PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling.";
RL   Genes Dev. 23:118-132(2009).
RN   [24]
RP   RETRACTION NOTICE OF PUBMED:19136629.
RX   PubMed=21724836;
RA   Weber S., Maass F., Schuemann M., Krause E., Suske G., Bauer U.M.;
RT   "Retraction. PRMT1-mediated arginine methylation of PIAS1 regulates STAT1
RT   signaling.";
RL   Genes Dev. 25:1451-1451(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503 AND SER-510, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   INTERACTION WITH EBOLAVIRUS VP35 (MICROBIAL INFECTION).
RX   PubMed=19557165; DOI=10.1371/journal.ppat.1000493;
RA   Chang T.H., Kubota T., Matsuoka M., Jones S., Bradfute S.B., Bray M.,
RA   Ozato K.;
RT   "Ebola Zaire virus blocks type I interferon production by exploiting the
RT   host SUMO modification machinery.";
RL   PLoS Pathog. 5:e1000493-e1000493(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-503, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH MTA1.
RX   PubMed=21965678; DOI=10.1074/jbc.m111.267237;
RA   Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R.;
RT   "SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1
RT   (MTA1) synergistically regulate its transcriptional repressor function.";
RL   J. Biol. Chem. 286:43793-43808(2011).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-485; SER-488 AND SER-503, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467; SER-468 AND SER-503, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-46 AND LYS-238, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [33]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-46; LYS-137 AND LYS-238, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [34]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-46 AND LYS-137, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [35]
RP   INTERACTION WITH SUMO1P1/SUMO5.
RX   PubMed=27211601; DOI=10.1038/srep26509;
RA   Liang Y.C., Lee C.C., Yao Y.L., Lai C.C., Schmitz M.L., Yang W.M.;
RT   "SUMO5, a novel poly-sumo isoform, regulates pml nuclear bodies.";
RL   Sci. Rep. 6:26509-26509(2016).
RN   [36]
RP   INTERACTION WITH PRDM1.
RX   PubMed=28842558; DOI=10.1038/s41467-017-00476-w;
RA   Wang W.F., Yan L., Liu Z., Liu L.X., Lin J., Liu Z.Y., Chen X.P., Zhang W.,
RA   Xu Z.Z., Shi T., Li J.M., Zhao Y.L., Meng G., Xia Y., Li J.Y., Zhu J.;
RT   "HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal
RT   misfolded Blimp-1s in lymphoma cells.";
RL   Nat. Commun. 8:363-363(2017).
RN   [37]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-40; LYS-46; LYS-137; LYS-238;
RP   LYS-453 AND LYS-493, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [38]
RP   STRUCTURE BY NMR OF 1-65, AND INTERACTION WITH TP53 AND DNA-BINDING.
RX   PubMed=15133049; DOI=10.1074/jbc.m403561200;
RA   Okubo S., Hara F., Tsuchida Y., Shimotakahara S., Suzuki S., Hatanaka H.,
RA   Yokoyama S., Tanaka H., Yasuda H., Shindo H.;
RT   "NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its
RT   interaction with tumor suppressor p53 and A/T-rich DNA oligomers.";
RL   J. Biol. Chem. 279:31455-31461(2004).
CC   -!- FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO)
CC       ligase, stabilizing the interaction between UBE2I and the substrate,
CC       and as a SUMO-tethering factor. Plays a crucial role as a
CC       transcriptional coregulation in various cellular pathways, including
CC       the STAT pathway, the p53 pathway and the steroid hormone signaling
CC       pathway. In vitro, binds A/T-rich DNA. The effects of this
CC       transcriptional coregulation, transactivation or silencing, may vary
CC       depending upon the biological context. Sumoylates PML (at'Lys-65' and
CC       'Lys-160') and PML-RAR and promotes their ubiquitin-mediated
CC       degradation. PIAS1-mediated sumoylation of PML promotes its interaction
CC       with CSNK2A1/CK2 which in turn promotes PML phosphorylation and
CC       degradation (By similarity). Enhances the sumoylation of MTA1 and may
CC       participate in its paralog-selective sumoylation. Plays a dynamic role
CC       in adipogenesis by promoting the SUMOylation and degradation of CEBPB
CC       (By similarity). {ECO:0000250|UniProtKB:O88907,
CC       ECO:0000269|PubMed:14500712, ECO:0000269|PubMed:21965678}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with NCOA2 and AR. Interacts with NR2C1; the
CC       interaction promotes its sumoylation (By similarity). Interacts with
CC       DDX21, CSRP2, AXIN1, JUN, UBE2I, SUMO1, SATB2, PLAG1, TP53 and STAT1
CC       (dimer), following IFNA1-stimulation. Interacts with SP3
CC       (preferentially when SUMO-modified). Interacts with KLF8; the
CC       interaction results in SUMO ligation and repression of KLF8
CC       transcriptional activity and of its cell cycle progression into G(1)
CC       phase. Interacts with CHUK/IKKA; this interaction induces PIAS1
CC       phosphorylation. Interacts with PTK2/FAK1; the interaction promotes its
CC       sumoylation. Interacts with DDX5. Interacts with PML (By similarity).
CC       Interacts with MTA1. Interacts with SUMO1P1/SUMO5 (PubMed:27211601).
CC       Interacts with PRDM1/Blimp-1 (PubMed:28842558). {ECO:0000250,
CC       ECO:0000269|PubMed:11583632, ECO:0000269|PubMed:11672422,
CC       ECO:0000269|PubMed:11867732, ECO:0000269|PubMed:12223491,
CC       ECO:0000269|PubMed:12356736, ECO:0000269|PubMed:14500712,
CC       ECO:0000269|PubMed:14701874, ECO:0000269|PubMed:15133049,
CC       ECO:0000269|PubMed:15208321, ECO:0000269|PubMed:16617055,
CC       ECO:0000269|PubMed:17369852, ECO:0000269|PubMed:17540171,
CC       ECO:0000269|PubMed:21965678, ECO:0000269|PubMed:27211601,
CC       ECO:0000269|PubMed:28842558, ECO:0000269|PubMed:9177271,
CC       ECO:0000269|PubMed:9724754}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus VP35; this
CC       interaction mediates the sumoylation of IRF7 and contributes to the
CC       viral inhibition of IFN-type I production.
CC       {ECO:0000269|PubMed:19557165}.
CC   -!- INTERACTION:
CC       O75925; P01023: A2M; NbExp=3; IntAct=EBI-629434, EBI-640741;
CC       O75925; A0A0S2Z5Q7: ALS2; NbExp=3; IntAct=EBI-629434, EBI-25928834;
CC       O75925; Q92870-2: APBB2; NbExp=3; IntAct=EBI-629434, EBI-21535880;
CC       O75925; P45381: ASPA; NbExp=3; IntAct=EBI-629434, EBI-750475;
CC       O75925; P54253: ATXN1; NbExp=7; IntAct=EBI-629434, EBI-930964;
CC       O75925; Q9UBB4: ATXN10; NbExp=3; IntAct=EBI-629434, EBI-702390;
CC       O75925; P54252: ATXN3; NbExp=9; IntAct=EBI-629434, EBI-946046;
CC       O75925; Q9UKL3: CASP8AP2; NbExp=4; IntAct=EBI-629434, EBI-2339650;
CC       O75925; P48643: CCT5; NbExp=3; IntAct=EBI-629434, EBI-355710;
CC       O75925; G5E9A7: DMWD; NbExp=3; IntAct=EBI-629434, EBI-10976677;
CC       O75925; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-629434, EBI-21603100;
CC       O75925; Q13216-2: ERCC8; NbExp=3; IntAct=EBI-629434, EBI-16466949;
CC       O75925; Q16595: FXN; NbExp=3; IntAct=EBI-629434, EBI-949340;
CC       O75925; Q53GS7: GLE1; NbExp=3; IntAct=EBI-629434, EBI-1955541;
CC       O75925; P28799: GRN; NbExp=3; IntAct=EBI-629434, EBI-747754;
CC       O75925; P07686: HEXB; NbExp=3; IntAct=EBI-629434, EBI-7133736;
CC       O75925; P28358: HOXD10; NbExp=3; IntAct=EBI-629434, EBI-12690664;
CC       O75925; P04792: HSPB1; NbExp=3; IntAct=EBI-629434, EBI-352682;
CC       O75925; O43464: HTRA2; NbExp=3; IntAct=EBI-629434, EBI-517086;
CC       O75925; P42858: HTT; NbExp=19; IntAct=EBI-629434, EBI-466029;
CC       O75925; O60333-2: KIF1B; NbExp=3; IntAct=EBI-629434, EBI-10975473;
CC       O75925; P02545: LMNA; NbExp=3; IntAct=EBI-629434, EBI-351935;
CC       O75925; P02545-2: LMNA; NbExp=3; IntAct=EBI-629434, EBI-351953;
CC       O75925; Q9UIS9: MBD1; NbExp=3; IntAct=EBI-629434, EBI-867196;
CC       O75925; P51608: MECP2; NbExp=3; IntAct=EBI-629434, EBI-1189067;
CC       O75925; P19404: NDUFV2; NbExp=3; IntAct=EBI-629434, EBI-713665;
CC       O75925; P35240: NF2; NbExp=3; IntAct=EBI-629434, EBI-1014472;
CC       O75925; P35240-4: NF2; NbExp=3; IntAct=EBI-629434, EBI-1014514;
CC       O75925; P29474: NOS3; NbExp=3; IntAct=EBI-629434, EBI-1391623;
CC       O75925; O43933: PEX1; NbExp=3; IntAct=EBI-629434, EBI-988601;
CC       O75925; O00628: PEX7; NbExp=3; IntAct=EBI-629434, EBI-5238811;
CC       O75925; O14832: PHYH; NbExp=3; IntAct=EBI-629434, EBI-721853;
CC       O75925; P50897: PPT1; NbExp=3; IntAct=EBI-629434, EBI-1237011;
CC       O75925; O75626: PRDM1; NbExp=2; IntAct=EBI-629434, EBI-948789;
CC       O75925; P05129: PRKCG; NbExp=3; IntAct=EBI-629434, EBI-949799;
CC       O75925; P41219: PRPH; NbExp=3; IntAct=EBI-629434, EBI-752074;
CC       O75925; Q16637: SMN2; NbExp=3; IntAct=EBI-629434, EBI-395421;
CC       O75925; P37840: SNCA; NbExp=3; IntAct=EBI-629434, EBI-985879;
CC       O75925; Q16143: SNCB; NbExp=3; IntAct=EBI-629434, EBI-727106;
CC       O75925; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-629434, EBI-5235340;
CC       O75925; Q6NUL7: SPTLC1; NbExp=3; IntAct=EBI-629434, EBI-25912847;
CC       O75925; Q9NUW8: TDP1; NbExp=3; IntAct=EBI-629434, EBI-2902553;
CC       O75925; P04637: TP53; NbExp=4; IntAct=EBI-629434, EBI-366083;
CC       O75925; O76024: WFS1; NbExp=3; IntAct=EBI-629434, EBI-720609;
CC       O75925; P54577: YARS1; NbExp=3; IntAct=EBI-629434, EBI-1048893;
CC       O75925; Q9P1N4; NbExp=3; IntAct=EBI-629434, EBI-25878161;
CC       O75925; PRO_0000037946 [P29991]; Xeno; NbExp=3; IntAct=EBI-629434, EBI-8826488;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000269|PubMed:12393906,
CC       ECO:0000269|PubMed:9177271}. Nucleus, PML body {ECO:0000250}.
CC       Note=Interaction with CSRP2 may induce a partial redistribution along
CC       the cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75925-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75925-2; Sequence=VSP_056219;
CC       Name=3;
CC         IsoId=O75925-3; Sequence=VSP_057195, VSP_057196;
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues with highest level in
CC       testis. {ECO:0000269|PubMed:11439351, ECO:0000269|PubMed:9177271}.
CC   -!- DOMAIN: The LXXLL motif is a transcriptional coregulator signature.
CC   -!- DOMAIN: The SP-RING-type domain is required for promoting EKLF
CC       sumoylation. {ECO:0000250}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:11867732,
CC       ECO:0000269|PubMed:12393906}.
CC   -!- SIMILARITY: Belongs to the PIAS family. {ECO:0000305}.
CC   -!- CAUTION: A paper showing that PRMT1-mediated arginine methylation of
CC       PIAS1 regulates STAT1 signaling has been retracted, because some of the
CC       data was found to be deliberately falsified.
CC       {ECO:0000305|PubMed:19136629, ECO:0000305|PubMed:21724836}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF077951; AAC36702.1; -; mRNA.
DR   EMBL; AF167160; AAD49722.1; -; mRNA.
DR   EMBL; FJ997900; ACR77525.1; -; mRNA.
DR   EMBL; AK094641; BAG52901.1; -; mRNA.
DR   EMBL; AK314515; BAG37114.1; -; mRNA.
DR   EMBL; AC107871; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC135628; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC118587; AAI18588.1; -; mRNA.
DR   EMBL; BC121797; AAI21798.1; -; mRNA.
DR   EMBL; U78524; AAB58488.1; -; mRNA.
DR   CCDS; CCDS45290.1; -. [O75925-1]
DR   CCDS; CCDS81902.1; -. [O75925-2]
DR   RefSeq; NP_001307616.1; NM_001320687.1. [O75925-2]
DR   RefSeq; NP_057250.1; NM_016166.2. [O75925-1]
DR   RefSeq; XP_016878177.1; XM_017022688.1. [O75925-2]
DR   PDB; 1V66; NMR; -; A=1-65.
DR   PDBsum; 1V66; -.
DR   BMRB; O75925; -.
DR   SMR; O75925; -.
DR   BioGRID; 114124; 143.
DR   CORUM; O75925; -.
DR   DIP; DIP-5970N; -.
DR   ELM; O75925; -.
DR   IntAct; O75925; 99.
DR   MINT; O75925; -.
DR   STRING; 9606.ENSP00000249636; -.
DR   iPTMnet; O75925; -.
DR   PhosphoSitePlus; O75925; -.
DR   BioMuta; PIAS1; -.
DR   EPD; O75925; -.
DR   jPOST; O75925; -.
DR   MassIVE; O75925; -.
DR   MaxQB; O75925; -.
DR   PaxDb; O75925; -.
DR   PeptideAtlas; O75925; -.
DR   PRIDE; O75925; -.
DR   ProteomicsDB; 3657; -.
DR   ProteomicsDB; 50293; -. [O75925-1]
DR   Antibodypedia; 26284; 368 antibodies from 35 providers.
DR   DNASU; 8554; -.
DR   Ensembl; ENST00000249636; ENSP00000249636; ENSG00000033800.
DR   Ensembl; ENST00000545237; ENSP00000438574; ENSG00000033800. [O75925-2]
DR   GeneID; 8554; -.
DR   KEGG; hsa:8554; -.
DR   MANE-Select; ENST00000249636.11; ENSP00000249636.6; NM_016166.3; NP_057250.1.
DR   UCSC; uc002aqz.4; human. [O75925-1]
DR   CTD; 8554; -.
DR   DisGeNET; 8554; -.
DR   GeneCards; PIAS1; -.
DR   HGNC; HGNC:2752; PIAS1.
DR   HPA; ENSG00000033800; Low tissue specificity.
DR   MIM; 603566; gene.
DR   neXtProt; NX_O75925; -.
DR   OpenTargets; ENSG00000033800; -.
DR   PharmGKB; PA33285; -.
DR   VEuPathDB; HostDB:ENSG00000033800; -.
DR   eggNOG; KOG2169; Eukaryota.
DR   GeneTree; ENSGT01030000234539; -.
DR   HOGENOM; CLU_020768_3_0_1; -.
DR   InParanoid; O75925; -.
DR   OMA; CADRRKM; -.
DR   OrthoDB; 1205949at2759; -.
DR   PhylomeDB; O75925; -.
DR   TreeFam; TF323787; -.
DR   PathwayCommons; O75925; -.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-3232142; SUMOylation of ubiquitinylation proteins.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   SignaLink; O75925; -.
DR   SIGNOR; O75925; -.
DR   UniPathway; UPA00886; -.
DR   BioGRID-ORCS; 8554; 76 hits in 1033 CRISPR screens.
DR   ChiTaRS; PIAS1; human.
DR   EvolutionaryTrace; O75925; -.
DR   GeneWiki; PIAS1; -.
DR   GenomeRNAi; 8554; -.
DR   Pharos; O75925; Tbio.
DR   PRO; PR:O75925; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; O75925; protein.
DR   Bgee; ENSG00000033800; Expressed in bone marrow and 246 other tissues.
DR   ExpressionAtlas; O75925; baseline and differential.
DR   Genevisible; O75925; HS.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0061665; F:SUMO ligase activity; IDA:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central.
DR   GO; GO:0003714; F:transcription corepressor activity; TAS:ProtInc.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; IDA:BHF-UCL.
DR   GO; GO:0007259; P:receptor signaling pathway via JAK-STAT; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 1.10.720.30; -; 1.
DR   Gene3D; 2.60.120.780; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR027226; PIAS1/PIAS3.
DR   InterPro; IPR023321; PINIT.
DR   InterPro; IPR038654; PINIT_sf.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   InterPro; IPR004181; Znf_MIZ.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10782:SF11; PTHR10782:SF11; 1.
DR   Pfam; PF14324; PINIT; 1.
DR   Pfam; PF02891; zf-MIZ; 1.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51466; PINIT; 1.
DR   PROSITE; PS50800; SAP; 1.
DR   PROSITE; PS51044; ZF_SP_RING; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..651
FT                   /note="E3 SUMO-protein ligase PIAS1"
FT                   /id="PRO_0000218974"
FT   DOMAIN          11..45
FT                   /note="SAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00186"
FT   DOMAIN          124..288
FT                   /note="PINIT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00799"
FT   REPEAT          520..523
FT                   /note="1"
FT   REPEAT          557..560
FT                   /note="2"
FT   REPEAT          598..601
FT                   /note="3; approximate"
FT   REPEAT          612..615
FT                   /note="4; approximate"
FT   ZN_FING         320..405
FT                   /note="SP-RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   REGION          462..473
FT                   /note="SUMO1-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          465..511
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          520..615
FT                   /note="4 X 4 AA repeats of N-T-S-L"
FT   REGION          599..632
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           19..23
FT                   /note="LXXLL motif"
FT   MOTIF           56..64
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           368..380
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        480..511
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   METAL           351
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           353
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           374
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           377
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         468
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88907"
FT   MOD_RES         485
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         487
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O88907"
FT   MOD_RES         488
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         510
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CROSSLNK        40
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        46
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        137
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        238
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        453
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        493
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..7
FT                   /note="MADSAEL -> MFTLQDSYV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056219"
FT   VAR_SEQ         312..325
FT                   /note="IKEKLTADPDSEIA -> STYDKLISLIQLFC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:19906316"
FT                   /id="VSP_057195"
FT   VAR_SEQ         326..651
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:19906316"
FT                   /id="VSP_057196"
FT   MUTAGEN         351
FT                   /note="C->A,S: Loss of UBE2I-binding; almost complete loss
FT                   of promotion of TP53 sumoylation; no loss of SUMO1- and
FT                   TP53-binding."
FT                   /evidence="ECO:0000269|PubMed:11583632"
FT   CONFLICT        119
FT                   /note="E -> K (in Ref. 1; AAC36702)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        266..268
FT                   /note="IVV -> MC (in Ref. 1; AAC36702)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        613
FT                   /note="S -> T (in Ref. 6; AAB58488)"
FT                   /evidence="ECO:0000305"
FT   HELIX           6..11
FT                   /evidence="ECO:0007829|PDB:1V66"
FT   HELIX           16..24
FT                   /evidence="ECO:0007829|PDB:1V66"
FT   HELIX           34..46
FT                   /evidence="ECO:0007829|PDB:1V66"
FT   HELIX           51..63
FT                   /evidence="ECO:0007829|PDB:1V66"
SQ   SEQUENCE   651 AA;  71836 MW;  AA69338221124119 CRC64;
     MADSAELKQM VMSLRVSELQ VLLGYAGRNK HGRKHELLTK ALHLLKAGCS PAVQMKIKEL
     YRRRFPQKIM TPADLSIPNV HSSPMPATLS PSTIPQLTYD GHPASSPLLP VSLLGPKHEL
     ELPHLTSALH PVHPDIKLQK LPFYDLLDEL IKPTSLASDN SQRFRETCFA FALTPQQVQQ
     ISSSMDISGT KCDFTVQVQL RFCLSETSCP QEDHFPPNLC VKVNTKPCSL PGYLPPTKNG
     VEPKRPSRPI NITSLVRLST TVPNTIVVSW TAEIGRNYSM AVYLVKQLSS TVLLQRLRAK
     GIRNPDHSRA LIKEKLTADP DSEIATTSLR VSLLCPLGKM RLTIPCRALT CSHLQCFDAT
     LYIQMNEKKP TWVCPVCDKK APYEHLIIDG LFMEILKYCT DCDEIQFKED GTWAPMRSKK
     EVQEVSASYN GVDGCLSSTL EHQVASHHQS SNKNKKVEVI DLTIDSSSDE EEEEPSAKRT
     CPSLSPTSPL NNKGILSLPH QASPVSRTPS LPAVDTSYIN TSLIQDYRHP FHMTPMPYDL
     QGLDFFPFLS GDNQHYNTSL LAAAAAAVSD DQDLLHSSRF FPYTSSQMFL DQLSAGGSTS
     LPTTNGSSSG SNSSLVSSNS LRESHSHTVT NRSSTDTASI FGIIPDIISL D
//
ID   IREB2_HUMAN             Reviewed;         963 AA.
AC   P48200; A0A0A6YY96; A8KAC7; E1CJT9; H0YKU0; Q13095; Q1HE21; Q59FQ7; Q8WVK6;
AC   Q9UF17;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 4.
DT   23-FEB-2022, entry version 186.
DE   RecName: Full=Iron-responsive element-binding protein 2;
DE            Short=IRE-BP 2;
DE   AltName: Full=Iron regulatory protein 2;
DE            Short=IRP2;
GN   Name=IREB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, RNA-BINDING, AND VARIANT
RP   THR-580.
RX   PubMed=7983023;
RA   Samaniego F., Chin J., Iwai K., Rouault T.A., Klausner R.D.;
RT   "Molecular characterization of a second iron-responsive element binding
RT   protein, iron regulatory protein 2. Structure, function, and post-
RT   translational regulation.";
RL   J. Biol. Chem. 269:30904-30910(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Ishiwata T., Sakurada M., Nishimura A., Nakagawa S., Nishi T., Kuga T.,
RA   Sawada S., Takei M.;
RT   "IgA nephropathy-related gene.";
RL   Submitted (SEP-2010) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-580.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-580.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-580.
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-580.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-580.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-580.
RX   PubMed=2172968; DOI=10.1073/pnas.87.20.7958;
RA   Rouault T.A., Tang C.K., Kaptain S., Burgess W.H., Haile D.J.,
RA   Samaniego F., McBride O.W., Harford J.B., Klausner R.D.;
RT   "Cloning of the cDNA encoding an RNA regulatory protein -- the human iron-
RT   responsive element-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7958-7962(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-963 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7622457; DOI=10.1074/jbc.270.28.16529;
RA   Guo B., Brown F.M., Phillips J.D., Yu Y., Leibold E.A.;
RT   "Characterization and expression of iron regulatory protein 2 (IRP2).
RT   Presence of multiple IRP2 transcripts regulated by intracellular iron
RT   levels.";
RL   J. Biol. Chem. 270:16529-16535(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 847-963 (ISOFORM 1).
RG   The European IMAGE consortium;
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   UBIQUITINATION, AND INTERACTION WITH RBCK1.
RX   PubMed=12629548; DOI=10.1038/ncb952;
RA   Yamanaka K., Ishikawa H., Megumi Y., Tokunaga F., Kanie M., Rouault T.A.,
RA   Morishima I., Minato N., Ishimori K., Iwai K.;
RT   "Identification of the ubiquitin-protein ligase that recognizes oxidized
RT   IRP2.";
RL   Nat. Cell Biol. 5:336-340(2003).
RN   [13]
RP   UBIQUITINATION, AND INTERACTION WITH FBXL5.
RX   PubMed=19762596; DOI=10.1126/science.1176333;
RA   Vashisht A.A., Zumbrennen K.B., Huang X., Powers D.N., Durazo A., Sun D.,
RA   Bhaskaran N., Persson A., Uhlen M., Sangfelt O., Spruck C., Leibold E.A.,
RA   Wohlschlegel J.A.;
RT   "Control of iron homeostasis by an iron-regulated ubiquitin ligase.";
RL   Science 326:718-721(2009).
RN   [14]
RP   UBIQUITINATION, AND INTERACTION WITH FBXL5.
RX   PubMed=19762597; DOI=10.1126/science.1176326;
RA   Salahudeen A.A., Thompson J.W., Ruiz J.C., Ma H.-W., Kinch L.N., Li Q.,
RA   Grishin N.V., Bruick R.K.;
RT   "An E3 ligase possessing an iron responsive hemerythrin domain is a
RT   regulator of iron homeostasis.";
RL   Science 326:722-726(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   INTERACTION WITH CIAO1 AND CIAO2A.
RX   PubMed=23891004; DOI=10.1016/j.cmet.2013.06.015;
RA   Stehling O., Mascarenhas J., Vashisht A.A., Sheftel A.D., Niggemeyer B.,
RA   Roesser R., Pierik A.J., Wohlschlegel J.A., Lill R.;
RT   "Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and
RT   maturation of different subsets of cytosolic-nuclear iron-sulfur
RT   proteins.";
RL   Cell Metab. 18:187-198(2013).
RN   [18]
RP   INVOLVEMENT IN NDCAMA, VARIANTS NDCAMA 357-GLY--SER-963 DEL AND
RP   419-ARG--SER-963 DEL, AND CHARACTERIZATION OF VARIANTS NDCAMA
RP   357-GLY--SER-963 DEL AND 419-ARG--SER-963 DEL.
RX   PubMed=30915432; DOI=10.1093/brain/awz072;
RA   Costain G., Ghosh M.C., Maio N., Carnevale A., Si Y.C., Rouault T.A.,
RA   Yoon G.;
RT   "Absence of iron-responsive element-binding protein 2 causes a novel
RT   neurodegenerative syndrome.";
RL   Brain 142:1195-1202(2019).
CC   -!- FUNCTION: RNA-binding protein that binds to iron-responsive elements
CC       (IRES), which are stem-loop structures found in the 5'-UTR of ferritin,
CC       and delta aminolevulinic acid synthase mRNAs, and in the 3'-UTR of
CC       transferrin receptor mRNA. Binding to the IRE element in ferritin
CC       results in the repression of its mRNA translation. Binding of the
CC       protein to the transferrin receptor mRNA inhibits the degradation of
CC       this otherwise rapidly degraded mRNA. {ECO:0000269|PubMed:7983023}.
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883; Evidence={ECO:0000250};
CC       Note=Binds 1 [4Fe-4S] cluster per subunit. [4Fe-4S]-binding affects
CC       RNA-binding activity, thereby inhibiting activity of the protein.
CC       {ECO:0000250};
CC   -!- SUBUNIT: Interacts with RBCK1 isoform 1 and isoform 2 only in iron-rich
CC       conditions (PubMed:12629548). Interacts (when associated with the 4Fe-
CC       4S) with FBXL5 (PubMed:19762596, PubMed:19762597). Interacts with CIAO1
CC       and CIAO2A (PubMed:23891004). {ECO:0000269|PubMed:12629548,
CC       ECO:0000269|PubMed:19762596, ECO:0000269|PubMed:19762597,
CC       ECO:0000269|PubMed:23891004}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48200-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48200-2; Sequence=VSP_056823, VSP_056824;
CC   -!- PTM: Ubiquitinated and degraded by the proteasome in presence of high
CC       level of iron and oxygen. Ubiquitinated by a SCF complex containing
CC       FBXL5. Upon iron and oxygen depletion FBXL5 is degraded, preventing
CC       ubiquitination and allowing its RNA-binding activity.
CC       {ECO:0000269|PubMed:12629548, ECO:0000269|PubMed:19762596,
CC       ECO:0000269|PubMed:19762597}.
CC   -!- DISEASE: Neurodegeneration, early-onset, with choreoathetoid movements
CC       and microcytic anemia (NDCAMA) [MIM:618451]: An autosomal recessive
CC       disorder characterized by severe neurological and extra-neurological
CC       manifestations. Clinical features include early-onset global
CC       developmental delay, absent speech, dystonia, spasticity,
CC       choreoathetoid movement disorder, seizures, and microcytic hypochromic
CC       anaemia unresponsive to iron supplementation.
CC       {ECO:0000269|PubMed:30915432}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the aconitase/IPM isomerase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA79926.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAD92640.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M58511; AAA69901.1; -; mRNA.
DR   EMBL; AB586699; BAJ19024.1; -; mRNA.
DR   EMBL; AK292992; BAF85681.1; -; mRNA.
DR   EMBL; AB209403; BAD92640.1; ALT_FRAME; mRNA.
DR   EMBL; DQ496102; ABF47091.1; -; Genomic_DNA.
DR   EMBL; AC011270; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC027228; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF459563; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471136; EAW99169.1; -; Genomic_DNA.
DR   EMBL; BC017880; AAH17880.1; -; mRNA.
DR   EMBL; BC117481; AAI17482.1; -; mRNA.
DR   EMBL; BC117483; AAI17484.1; -; mRNA.
DR   EMBL; U20180; AAA79926.1; ALT_FRAME; mRNA.
DR   EMBL; AL133439; CAB62825.1; -; mRNA.
DR   CCDS; CCDS10302.1; -. [P48200-1]
DR   CCDS; CCDS81912.1; -. [P48200-2]
DR   PIR; B57238; B57238.
DR   RefSeq; NP_001307870.1; NM_001320941.1.
DR   RefSeq; NP_001307872.1; NM_001320943.1. [P48200-2]
DR   RefSeq; NP_004127.1; NM_004136.3. [P48200-1]
DR   PDB; 6VCD; EM; 3.00 A; A=1-963.
DR   PDBsum; 6VCD; -.
DR   SMR; P48200; -.
DR   BioGRID; 109866; 49.
DR   IntAct; P48200; 13.
DR   STRING; 9606.ENSP00000258886; -.
DR   iPTMnet; P48200; -.
DR   PhosphoSitePlus; P48200; -.
DR   BioMuta; IREB2; -.
DR   DMDM; 308153591; -.
DR   EPD; P48200; -.
DR   jPOST; P48200; -.
DR   MassIVE; P48200; -.
DR   PaxDb; P48200; -.
DR   PeptideAtlas; P48200; -.
DR   PRIDE; P48200; -.
DR   ProteomicsDB; 39753; -.
DR   ProteomicsDB; 55871; -. [P48200-1]
DR   Antibodypedia; 27620; 344 antibodies from 35 providers.
DR   DNASU; 3658; -.
DR   Ensembl; ENST00000258886; ENSP00000258886; ENSG00000136381.
DR   Ensembl; ENST00000560440; ENSP00000452938; ENSG00000136381. [P48200-2]
DR   GeneID; 3658; -.
DR   KEGG; hsa:3658; -.
DR   MANE-Select; ENST00000258886.13; ENSP00000258886.8; NM_004136.4; NP_004127.2.
DR   UCSC; uc002bdq.4; human. [P48200-1]
DR   CTD; 3658; -.
DR   DisGeNET; 3658; -.
DR   GeneCards; IREB2; -.
DR   HGNC; HGNC:6115; IREB2.
DR   HPA; ENSG00000136381; Low tissue specificity.
DR   MalaCards; IREB2; -.
DR   MIM; 147582; gene.
DR   MIM; 618451; phenotype.
DR   neXtProt; NX_P48200; -.
DR   OpenTargets; ENSG00000136381; -.
DR   PharmGKB; PA29914; -.
DR   VEuPathDB; HostDB:ENSG00000136381; -.
DR   eggNOG; KOG0452; Eukaryota.
DR   GeneTree; ENSGT00940000157796; -.
DR   HOGENOM; CLU_069045_0_0_1; -.
DR   InParanoid; P48200; -.
DR   OMA; ECPDSVV; -.
DR   OrthoDB; 190960at2759; -.
DR   PhylomeDB; P48200; -.
DR   TreeFam; TF313476; -.
DR   PathwayCommons; P48200; -.
DR   Reactome; R-HSA-917937; Iron uptake and transport.
DR   SignaLink; P48200; -.
DR   SIGNOR; P48200; -.
DR   BioGRID-ORCS; 3658; 91 hits in 1054 CRISPR screens.
DR   ChiTaRS; IREB2; human.
DR   GenomeRNAi; 3658; -.
DR   Pharos; P48200; Tbio.
DR   PRO; PR:P48200; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P48200; protein.
DR   Bgee; ENSG00000136381; Expressed in neocortex and 227 other tissues.
DR   ExpressionAtlas; P48200; baseline and differential.
DR   Genevisible; P48200; HS.
DR   GO; GO:0005737; C:cytoplasm; NAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IBA:GO_Central.
DR   GO; GO:0003994; F:aconitate hydratase activity; IBA:GO_Central.
DR   GO; GO:0030350; F:iron-responsive element binding; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0030371; F:translation repressor activity; IEA:InterPro.
DR   GO; GO:0006879; P:cellular iron ion homeostasis; IEA:Ensembl.
DR   GO; GO:0006101; P:citrate metabolic process; IBA:GO_Central.
DR   GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0050892; P:intestinal absorption; IEA:Ensembl.
DR   GO; GO:0055072; P:iron ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0006826; P:iron ion transport; TAS:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IBA:GO_Central.
DR   CDD; cd01580; AcnA_IRP_Swivel; 1.
DR   Gene3D; 3.20.19.10; -; 1.
DR   Gene3D; 3.30.499.10; -; 3.
DR   InterPro; IPR044137; AcnA_IRP_Swivel.
DR   InterPro; IPR015931; Acnase/IPM_dHydase_lsu_aba_1/3.
DR   InterPro; IPR001030; Acoase/IPM_deHydtase_lsu_aba.
DR   InterPro; IPR015928; Aconitase/3IPM_dehydase_swvl.
DR   InterPro; IPR006249; Aconitase/IRP2.
DR   InterPro; IPR018136; Aconitase_4Fe-4S_BS.
DR   InterPro; IPR036008; Aconitase_4Fe-4S_dom.
DR   InterPro; IPR000573; AconitaseA/IPMdHydase_ssu_swvl.
DR   InterPro; IPR029755; IRE-BP2.
DR   PANTHER; PTHR11670; PTHR11670; 1.
DR   PANTHER; PTHR11670:SF31; PTHR11670:SF31; 1.
DR   Pfam; PF00330; Aconitase; 2.
DR   Pfam; PF00694; Aconitase_C; 1.
DR   PRINTS; PR00415; ACONITASE.
DR   SUPFAM; SSF53732; SSF53732; 1.
DR   TIGRFAMs; TIGR01341; aconitase_1; 1.
DR   PROSITE; PS00450; ACONITASE_1; 1.
DR   PROSITE; PS01244; ACONITASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; 4Fe-4S; Alternative splicing; Cytoplasm; Disease variant;
KW   Iron; Iron-sulfur; Metal-binding; Neurodegeneration; Reference proteome;
KW   RNA-binding; Ubl conjugation.
FT   CHAIN           1..963
FT                   /note="Iron-responsive element-binding protein 2"
FT                   /id="PRO_0000076684"
FT   METAL           512
FT                   /note="Iron-sulfur (4Fe-4S)"
FT                   /evidence="ECO:0000250"
FT   METAL           578
FT                   /note="Iron-sulfur (4Fe-4S)"
FT                   /evidence="ECO:0000250"
FT   METAL           581
FT                   /note="Iron-sulfur (4Fe-4S)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         342
FT                   /note="H -> V (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_056823"
FT   VAR_SEQ         343..962
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_056824"
FT   VARIANT         357..963
FT                   /note="Missing (in NDCAMA; may drastically decrease protein
FT                   expression level)"
FT                   /evidence="ECO:0000269|PubMed:30915432"
FT                   /id="VAR_082271"
FT   VARIANT         419..963
FT                   /note="Missing (in NDCAMA; may drastically decrease protein
FT                   expression level)"
FT                   /evidence="ECO:0000269|PubMed:30915432"
FT                   /id="VAR_082272"
FT   VARIANT         580
FT                   /note="I -> T (in dbSNP:rs2230940)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2172968,
FT                   ECO:0000269|PubMed:7983023, ECO:0000269|Ref.4,
FT                   ECO:0000269|Ref.5, ECO:0000269|Ref.7"
FT                   /id="VAR_058410"
FT   CONFLICT        195
FT                   /note="E -> G (in Ref. 3; BAF85681)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        239
FT                   /note="F -> L (in Ref. 1; AAA69901, 3; BAF85681 and 10;
FT                   AAA79926)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        452
FT                   /note="Q -> R (in Ref. 10; AAA79926)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        458
FT                   /note="T -> P (in Ref. 3; BAF85681)"
FT                   /evidence="ECO:0000305"
FT   STRAND          14..16
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          19..22
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          24..26
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           28..31
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            33..37
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           42..51
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          55..58
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           63..66
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            69..71
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          77..80
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           93..107
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          122..125
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           216..224
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           226..238
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          243..245
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          250..254
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           255..259
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          263..269
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           283..289
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           298..304
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            305..307
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          310..313
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          320..324
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           332..346
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          350..352
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          355..359
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           365..372
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            373..379
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           389..398
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           402..414
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          434..437
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           438..440
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           669..672
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           674..677
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           679..688
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          706..708
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          722..724
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          739..745
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           752..755
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           766..773
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            778..780
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          783..785
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           791..795
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            807..809
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          814..817
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            819..821
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          824..826
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           827..836
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          841..844
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          847..849
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          851..853
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           860..865
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          869..873
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           877..884
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   TURN            885..887
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          889..893
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           899..901
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          908..911
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          922..927
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   STRAND          934..938
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           943..950
FT                   /evidence="ECO:0007829|PDB:6VCD"
FT   HELIX           954..961
FT                   /evidence="ECO:0007829|PDB:6VCD"
SQ   SEQUENCE   963 AA;  105059 MW;  051228C6CE5362FD CRC64;
     MDAPKAGYAF EYLIETLNDS SHKKFFDVSK LGTKYDVLPY SIRVLLEAAV RNCDGFLMKK
     EDVMNILDWK TKQSNVEVPF FPARVLLQDF TGIPAMVDFA AMREAVKTLG GDPEKVHPAC
     PTDLTVDHSL QIDFSKCAIQ NAPNPGGGDL QKAGKLSPLK VQPKKLPCRG QTTCRGSCDS
     GELGRNSGTF SSQIENTPIL CPFHLQPVPE PETVLKNQEV EFGRNRERLQ FFKWSSRVFK
     NVAVIPPGTG MAHQINLEYL SRVVFEEKDL LFPDSVVGTD SHITMVNGLG ILGWGVGGIE
     TEAVMLGLPV SLTLPEVVGC ELTGSSNPFV TSIDVVLGIT KHLRQVGVAG KFVEFFGSGV
     SQLSIVDRTT IANMCPEYGA ILSFFPVDNV TLKHLEHTGF SKAKLESMET YLKAVKLFRN
     DQNSSGEPEY SQVIQINLNS IVPSVSGPKR PQDRVAVTDM KSDFQACLNE KVGFKGFQIA
     AEKQKDIVSI HYEGSEYKLS HGSVVIAAVI SCTNNCNPSV MLAAGLLAKK AVEAGLRVKP
     YIRTSLSPGS GMVTHYLSSS GVLPYLSKLG FEIVGYGCSI CVGNTAPLSD AVLNAVKQGD
     LVTCGILSGN KNFEGRLCDC VRANYLASPP LVVAYAIAGT VNIDFQTEPL GTDPTGKNIY
     LHDIWPSREE VHRVEEEHVI LSMFKALKDK IEMGNKRWNS LEAPDSVLFP WDLKSTYIRC
     PSFFDKLTKE PIALQAIENA HVLLYLGDSV TTDHISPAGS IARNSAAAKY LTNRGLTPRE
     FNSYGARRGN DAVMTRGTFA NIKLFNKFIG KPAPKTIHFP SGQTLDVFEA AELYQKEGIP
     LIILAGKKYG SGNSRDWAAK GPYLLGVKAV LAESYEKIHK DHLIGIGIAP LQFLPGENAD
     SLGLSGRETF SLTFPEELSP GITLNIQTST GKVFSVIASF EDDVEITLYK HGGLLNFVAR
     KFS
//
ID   ELAV4_HUMAN             Reviewed;         385 AA.
AC   P26378; B1APY6; B1APY7; B1APY8; B7Z4G7; Q8IYD4; Q96J74; Q96J75; Q9UD24;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   18-SEP-2019, sequence version 3.
DT   23-FEB-2022, entry version 190.
DE   RecName: Full=ELAV-like protein 4;
DE   AltName: Full=Hu-antigen D;
DE            Short=HuD;
DE   AltName: Full=Paraneoplastic encephalomyelitis antigen HuD;
GN   Name=ELAVL4; Synonyms=HUD, PNEM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND
RP   VARIANT SER-275.
RC   TISSUE=Brain;
RX   PubMed=1655278; DOI=10.1016/0092-8674(91)90184-z;
RA   Szabo A., Dalmau J., Manley G., Rosenfeld M., Wong E., Henson J.,
RA   Posner J.B., Furneaux H.M.;
RT   "HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding
RT   domains and is homologous to Elav and Sex-lethal.";
RL   Cell 67:325-333(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), AND VARIANT SER-275.
RC   TISSUE=Neuroblastoma;
RX   PubMed=12209604; DOI=10.1002/ijc.10550;
RA   Behrends U., Jandl T., Golbeck A., Lechner B., Mueller-Weihrich S.,
RA   Schmid I., Till H., Berthold F., Voltz R., Mautner J.M.;
RT   "Novel products of the HuD, HuC, NNP-1 and alpha-internexin genes
RT   identified by autologous antibody screening of a pediatric neuroblastoma
RT   library.";
RL   Int. J. Cancer 100:669-677(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS GLY-171
RP   AND THR-361.
RC   TISSUE=Hypothalamus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 245-284 (ISOFORM 1), FUNCTION, ALTERNATIVE
RP   SPLICING, AND VARIANT SER-275.
RX   PubMed=7898713; DOI=10.1212/wnl.45.3.544;
RA   Liu J., Dalmau J., Szabo A., Rosenfeld M., Huber J., Furneaux H.;
RT   "Paraneoplastic encephalomyelitis antigens bind to the AU-rich elements of
RT   mRNA.";
RL   Neurology 45:544-550(1995).
RN   [8]
RP   FUNCTION, AND RNA-BINDING.
RX   PubMed=10710437; DOI=10.1093/nar/28.7.e20;
RA   King P.H.;
RT   "RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-
RT   untranslated regions using a novel ELISA-based assay.";
RL   Nucleic Acids Res. 28:E20-E20(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=12034726; DOI=10.1074/jbc.m201982200;
RA   Beckel-Mitchener A.C., Miera A., Keller R., Perrone-Bizzozero N.I.;
RT   "Poly(A) tail length-dependent stabilization of GAP-43 mRNA by the RNA-
RT   binding protein HuD.";
RL   J. Biol. Chem. 277:27996-28002(2002).
RN   [10]
RP   FUNCTION.
RX   PubMed=12468554; DOI=10.1074/jbc.m209383200;
RA   Deschenes-Furry J., Belanger G., Perrone-Bizzozero N., Jasmin B.J.;
RT   "Post-transcriptional regulation of acetylcholinesterase mRNAs in nerve
RT   growth factor-treated PC12 cells by the RNA-binding protein HuD.";
RL   J. Biol. Chem. 278:5710-5717(2003).
RN   [11]
RP   FUNCTION.
RX   PubMed=17035636; DOI=10.1091/mbc.e06-02-0099;
RA   Zhu H., Hasman R.A., Barron V.A., Luo G., Lou H.;
RT   "A nuclear function of Hu proteins as neuron-specific alternative RNA
RT   processing regulators.";
RL   Mol. Biol. Cell 17:5105-5114(2006).
RN   [12]
RP   METHYLATION AT ARG-248.
RX   PubMed=16508003; DOI=10.1128/mcb.26.6.2273-2285.2006;
RA   Fujiwara T., Mori Y., Chu D.L., Koyama Y., Miyata S., Tanaka H., Yachi K.,
RA   Kubo T., Yoshikawa H., Tohyama M.;
RT   "CARM1 regulates proliferation of PC12 cells by methylating HuD.";
RL   Mol. Cell. Biol. 26:2273-2285(2006).
RN   [13]
RP   FUNCTION.
RX   PubMed=17234598; DOI=10.1523/jneurosci.4626-06.2007;
RA   Deschenes-Furry J., Mousavi K., Bolognani F., Neve R.L., Parks R.J.,
RA   Perrone-Bizzozero N.I., Jasmin B.J.;
RT   "The RNA-binding protein HuD binds acetylcholinesterase mRNA in neurons and
RT   regulates its expression after axotomy.";
RL   J. Neurosci. 27:665-675(2007).
RN   [14]
RP   FUNCTION.
RX   PubMed=18218628; DOI=10.1074/jbc.m706082200;
RA   Ratti A., Fallini C., Colombrita C., Pascale A., Laforenza U.,
RA   Quattrone A., Silani V.;
RT   "Post-transcriptional regulation of neuro-oncological ventral antigen 1 by
RT   the neuronal RNA-binding proteins ELAV.";
RL   J. Biol. Chem. 283:7531-7541(2008).
RN   [15]
RP   INTERACTION WITH SMN, SUBCELLULAR LOCATION, AND METHYLATION.
RX   PubMed=21088113; DOI=10.1093/hmg/ddq500;
RA   Hubers L., Valderrama-Carvajal H., Laframboise J., Timbers J., Sanchez G.,
RA   Cote J.;
RT   "HuD interacts with survival motor neuron protein and can rescue spinal
RT   muscular atrophy-like neuronal defects.";
RL   Hum. Mol. Genet. 20:553-579(2011).
RN   [16]
RP   INTERACTION WITH SMN.
RX   PubMed=21389246; DOI=10.1523/jneurosci.3631-10.2011;
RA   Fallini C., Zhang H., Su Y., Silani V., Singer R.H., Rossoll W.,
RA   Bassell G.J.;
RT   "The survival of motor neuron (SMN) protein interacts with the mRNA-binding
RT   protein HuD and regulates localization of poly(A) mRNA in primary motor
RT   neuron axons.";
RL   J. Neurosci. 31:3914-3925(2011).
RN   [17]
RP   TISSUE SPECIFICITY.
RX   PubMed=22387028; DOI=10.1016/j.molcel.2012.01.016;
RA   Lee E.K., Kim W., Tominaga K., Martindale J.L., Yang X., Subaran S.S.,
RA   Carlson O.D., Mercken E.M., Kulkarni R.N., Akamatsu W., Okano H.,
RA   Perrone-Bizzozero N.I., de Cabo R., Egan J.M., Gorospe M.;
RT   "RNA-binding protein HuD controls insulin translation.";
RL   Mol. Cell 45:826-835(2012).
RN   [18]
RP   FUNCTION.
RX   PubMed=24857657; DOI=10.1016/j.celrep.2014.04.050;
RA   Kang M.J., Abdelmohsen K., Hutchison E.R., Mitchell S.J., Grammatikakis I.,
RA   Guo R., Noh J.H., Martindale J.L., Yang X., Lee E.K., Faghihi M.A.,
RA   Wahlestedt C., Troncoso J.C., Pletnikova O., Perrone-Bizzozero N.,
RA   Resnick S.M., de Cabo R., Mattson M.P., Gorospe M.;
RT   "HuD regulates coding and noncoding RNA to induce APP[?]Abeta processing.";
RL   Cell Rep. 7:1401-1409(2014).
RN   [19]
RP   INTERACTION WITH SMN.
RX   PubMed=29061699; DOI=10.1523/jneurosci.1528-17.2017;
RA   Hao le T., Duy P.Q., An M., Talbot J., Iyer C.C., Wolman M., Beattie C.E.;
RT   "HuD and the Survival Motor Neuron Protein Interact in Motoneurons and Are
RT   Essential for Motoneuron Development, Function, and mRNA Regulation.";
RL   J. Neurosci. 37:11559-11571(2017).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 49-215 IN COMPLEX WITH RNA.
RX   PubMed=11175903; DOI=10.1038/84131;
RA   Wang X., Tanaka Hall T.M.;
RT   "Structural basis for recognition of AU-rich element RNA by the HuD
RT   protein.";
RL   Nat. Struct. Biol. 8:141-145(2001).
CC   -!- FUNCTION: RNA-binding protein that is involved in the post-
CC       transcriptional regulation of mRNAs (PubMed:7898713, PubMed:10710437,
CC       PubMed:12034726, PubMed:12468554, PubMed:17035636, PubMed:17234598).
CC       Plays a role in the regulation of mRNA stability, alternative splicing
CC       and translation (PubMed:7898713, PubMed:10710437, PubMed:12034726,
CC       PubMed:12468554, PubMed:17035636, PubMed:17234598). Binds to AU-rich
CC       element (ARE) sequences in the 3' untranslated region (UTR) of target
CC       mRNAs, including GAP43, VEGF, FOS, CDKN1A and ACHE mRNA
CC       (PubMed:7898713, PubMed:10710437, PubMed:12034726, PubMed:12468554).
CC       Many of the target mRNAs are coding for RNA-binding proteins,
CC       transcription factors and proteins involved in RNA processing and/or
CC       neuronal development and function (By similarity). By binding to the
CC       mRNA 3'UTR, decreases mRNA deadenylation and thereby contributes to the
CC       stabilization of mRNA molecules and their protection from decay
CC       (PubMed:12034726). Also binds to the polyadenylated (poly(A)) tail in
CC       the 3'UTR of mRNA, thereby increasing its affinity for mRNA binding
CC       (PubMed:12034726). Mainly plays a role in neuron-specific RNA
CC       processing by stabilization of mRNAs such as GAP43, ACHE and mRNAs of
CC       other neuronal proteins, thereby contributing to the differentiation of
CC       neural progenitor cells, nervous system development, learning and
CC       memory mechanisms (PubMed:12034726, PubMed:12468554, PubMed:17234598,
CC       PubMed:18218628). Involved in the negative regulation of the
CC       proliferative activity of neuronal stem cells and in the positive
CC       regulation of neuronal differentiation of neural progenitor cells (By
CC       similarity). Promotes neuronal differentiation of neural
CC       stem/progenitor cells in the adult subventricular zone of the
CC       hippocampus by binding to and stabilizing SATB1 mRNA (By similarity).
CC       Binds and stabilizes MSI1 mRNA in neural stem cells (By similarity).
CC       Exhibits increased binding to ACHE mRNA during neuronal
CC       differentiation, thereby stabilizing ACHE mRNA and enhancing its
CC       expression (PubMed:12468554, PubMed:17234598). Protects CDKN1A mRNA
CC       from decay by binding to its 3'-UTR (By similarity). May bind to APP
CC       and BACE1 mRNAS and the BACE1AS lncRNA and enhance their stabilization
CC       (PubMed:24857657). Plays a role in neurite outgrowth and in the
CC       establishment and maturation of dendritic arbors, thereby contributing
CC       to neocortical and hippocampal circuitry function (By similarity).
CC       Stabilizes GAP43 mRNA and protects it from decay during postembryonic
CC       development in the brain (PubMed:12034726). By promoting the
CC       stabilization of GAP43 mRNA, plays a role in NGF-mediated neurite
CC       outgrowth (By similarity). Binds to BDNF long 3'UTR mRNA, thereby
CC       leading to its stabilization and increased dendritic translation after
CC       activation of PKC (By similarity). By increasing translation of BDNF
CC       after nerve injury, may contribute to nerve regeneration (By
CC       similarity). Acts as a stabilizing factor by binding to the 3'UTR of
CC       NOVA1 mRNA, thereby increasing its translation and enhancing its
CC       functional activity in neuron-specific splicing (PubMed:18218628).
CC       Stimulates translation of mRNA in a poly(A)- and cap-dependent manner,
CC       possibly by associating with the EIF4F cap-binding complex (By
CC       similarity). May also negatively regulate translation by binding to the
CC       5'UTR of Ins2 mRNA, thereby repressing its translation (By similarity).
CC       Upon glucose stimulation, Ins2 mRNA is released from ELAVL4 and
CC       translational inhibition is abolished (By similarity). Also plays a
CC       role in the regulation of alternative splicing (PubMed:17035636). May
CC       regulate alternative splicing of CALCA pre-mRNA into Calcitonin and
CC       Calcitonin gene-related peptide 1 (CGRP) by competing with splicing
CC       regulator TIAR for binding to U-rich intronic sequences of CALCA pre-
CC       mRNA (PubMed:17035636). {ECO:0000250|UniProtKB:O09032,
CC       ECO:0000250|UniProtKB:Q61701, ECO:0000269|PubMed:10710437,
CC       ECO:0000269|PubMed:12034726, ECO:0000269|PubMed:12468554,
CC       ECO:0000269|PubMed:17035636, ECO:0000269|PubMed:17234598,
CC       ECO:0000269|PubMed:18218628, ECO:0000269|PubMed:24857657,
CC       ECO:0000269|PubMed:7898713}.
CC   -!- SUBUNIT: Component of a TAU mRNP complex, at least composed of IGF2BP1,
CC       ELAVL4 and G3BP (By similarity). Associates with the EIF4F cap-binding
CC       complex, composed of EIF4G, EIF4A, EIF4E and PABP (By similarity).
CC       Within the EIF4F cap-binding complex, interacts with EIF4A (By
CC       similarity). Interacts with SMN (via Tudor domain) in an RNA-
CC       independent manner; the interaction is required for localization of
CC       ELAVL4 to RNA granules (PubMed:21088113, PubMed:21389246,
CC       PubMed:29061699). Interacts with MAP1 light chain LC1 (via C-terminus);
CC       the interaction contributes to the association of ELAVL4 with
CC       microtubules (By similarity). Interacts with MAP1 light chain LC2 (By
CC       similarity). {ECO:0000250|UniProtKB:Q61701,
CC       ECO:0000269|PubMed:21088113, ECO:0000269|PubMed:21389246,
CC       ECO:0000269|PubMed:29061699}.
CC   -!- INTERACTION:
CC       P26378-2; Q00994: BEX3; NbExp=3; IntAct=EBI-21603100, EBI-741753;
CC       P26378-2; Q5H9J7: BEX5; NbExp=3; IntAct=EBI-21603100, EBI-10243741;
CC       P26378-2; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-21603100, EBI-350590;
CC       P26378-2; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-21603100, EBI-3508943;
CC       P26378-2; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-21603100, EBI-11748557;
CC       P26378-2; Q99504: EYA3; NbExp=3; IntAct=EBI-21603100, EBI-9089567;
CC       P26378-2; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-21603100, EBI-6425864;
CC       P26378-2; O60341: KDM1A; NbExp=3; IntAct=EBI-21603100, EBI-710124;
CC       P26378-2; Q9HAF1: MEAF6; NbExp=3; IntAct=EBI-21603100, EBI-399266;
CC       P26378-2; Q9H204: MED28; NbExp=3; IntAct=EBI-21603100, EBI-514199;
CC       P26378-2; Q9H8H3: METTL7A; NbExp=3; IntAct=EBI-21603100, EBI-1390168;
CC       P26378-2; A4FUJ8: MKL1; NbExp=3; IntAct=EBI-21603100, EBI-21250407;
CC       P26378-2; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-21603100, EBI-9092052;
CC       P26378-2; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-21603100, EBI-25852289;
CC       P26378-2; Q96MF7: NSMCE2; NbExp=3; IntAct=EBI-21603100, EBI-2557388;
CC       P26378-2; Q9NP74: PALMD; NbExp=3; IntAct=EBI-21603100, EBI-2811699;
CC       P26378-2; O75925: PIAS1; NbExp=3; IntAct=EBI-21603100, EBI-629434;
CC       P26378-2; P17612: PRKACA; NbExp=3; IntAct=EBI-21603100, EBI-476586;
CC       P26378-2; P54725: RAD23A; NbExp=3; IntAct=EBI-21603100, EBI-746453;
CC       P26378-2; Q5TAB7: RIPPLY2; NbExp=3; IntAct=EBI-21603100, EBI-10246897;
CC       P26378-2; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-21603100, EBI-21535400;
CC       P26378-2; Q9ULX5: RNF112; NbExp=3; IntAct=EBI-21603100, EBI-25829984;
CC       P26378-2; Q8N488: RYBP; NbExp=3; IntAct=EBI-21603100, EBI-752324;
CC       P26378-2; O75446: SAP30; NbExp=3; IntAct=EBI-21603100, EBI-632609;
CC       P26378-2; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-21603100, EBI-2510414;
CC       P26378-2; Q15554-4: TERF2; NbExp=3; IntAct=EBI-21603100, EBI-25840535;
CC       P26378-2; P37173: TGFBR2; NbExp=3; IntAct=EBI-21603100, EBI-296151;
CC       P26378-2; Q9BZW5-2: TM6SF1; NbExp=3; IntAct=EBI-21603100, EBI-25852210;
CC       P26378-2; Q6PID6: TTC33; NbExp=3; IntAct=EBI-21603100, EBI-2555404;
CC       P26378-2; P55072: VCP; NbExp=3; IntAct=EBI-21603100, EBI-355164;
CC       P26378-2; P58304: VSX2; NbExp=3; IntAct=EBI-21603100, EBI-6427899;
CC       P26378-2; Q9GZS3: WDR61; NbExp=3; IntAct=EBI-21603100, EBI-358545;
CC       P26378-2; Q15776: ZKSCAN8; NbExp=3; IntAct=EBI-21603100, EBI-2602314;
CC       P26378-2; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-21603100, EBI-749023;
CC       P26378-2; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-21603100, EBI-8489702;
CC       P26378-2; Q9UID6: ZNF639; NbExp=3; IntAct=EBI-21603100, EBI-947476;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21088113}.
CC       Perikaryon {ECO:0000250|UniProtKB:O09032}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:O09032}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q61701}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:Q61701}. Note=Co-localizes with ribosomal RNA in
CC       polysomes. {ECO:0000250|UniProtKB:O09032}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=6; Synonyms=Long {ECO:0000305};
CC         IsoId=P26378-6; Sequence=Displayed;
CC       Name=1; Synonyms=HUD1PRO;
CC         IsoId=P26378-1; Sequence=VSP_060281;
CC       Name=2; Synonyms=HUD1;
CC         IsoId=P26378-2; Sequence=VSP_060281, VSP_060283;
CC       Name=3; Synonyms=HUD4;
CC         IsoId=P26378-3; Sequence=VSP_060282, VSP_060283;
CC       Name=4; Synonyms=HUD3;
CC         IsoId=P26378-4; Sequence=VSP_060279, VSP_060283;
CC       Name=5;
CC         IsoId=P26378-5; Sequence=VSP_060280, VSP_060283;
CC   -!- TISSUE SPECIFICITY: Expressed in pancreatic beta cells (at protein
CC       level) (PubMed:22387028). Expressed in the brain (PubMed:1655278,
CC       PubMed:14702039). {ECO:0000269|PubMed:14702039,
CC       ECO:0000269|PubMed:1655278, ECO:0000269|PubMed:22387028}.
CC   -!- DOMAIN: The RRM 3 domain is required for binding to poly(A) RNA, for
CC       the association with polysomes and with the EIF4F cap-binding complex
CC       and for the stimulation of translation (By similarity). The RRM 1 and
CC       RRM 2 domains may contribute to polysome association and stimulation of
CC       translation (By similarity). {ECO:0000250|UniProtKB:Q61701}.
CC   -!- PTM: Methylated by CARM1, which leads to reduced RNA-binding activity
CC       and enhanced interaction with SMN (PubMed:21088113). Methylation at
CC       Arg-248 by CARM1 weakens protective binding to the 3'UTR of CDKN1A mRNA
CC       and down-regulates CDKN1A protein expression, thereby maintaining cells
CC       in a proliferative state (By similarity). Methylation is inhibited by
CC       NGF, which facilitates neurite outgrowth (By similarity).
CC       {ECO:0000250|UniProtKB:O09032, ECO:0000269|PubMed:21088113}.
CC   -!- SIMILARITY: Belongs to the RRM elav family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M62843; AAA58396.1; -; mRNA.
DR   EMBL; AY033995; AAK57538.1; -; mRNA.
DR   EMBL; AY033996; AAK57539.1; -; mRNA.
DR   EMBL; AY033997; AAK57540.1; -; mRNA.
DR   EMBL; AY033998; AAK57541.1; -; mRNA.
DR   EMBL; AK297338; BAH12553.1; -; mRNA.
DR   EMBL; AL583843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL592182; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL645730; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL731870; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06845.1; -; Genomic_DNA.
DR   EMBL; BC036071; AAH36071.1; -; mRNA.
DR   CCDS; CCDS44138.1; -. [P26378-4]
DR   CCDS; CCDS44140.1; -. [P26378-2]
DR   CCDS; CCDS53315.1; -. [P26378-5]
DR   CCDS; CCDS553.1; -. [P26378-1]
DR   CCDS; CCDS81321.1; -. [P26378-6]
DR   PIR; A40348; A40348.
DR   RefSeq; NP_001138246.1; NM_001144774.2. [P26378-2]
DR   RefSeq; NP_001138247.2; NM_001144775.2.
DR   RefSeq; NP_001138248.1; NM_001144776.2. [P26378-4]
DR   RefSeq; NP_001138249.1; NM_001144777.2. [P26378-5]
DR   RefSeq; NP_001281277.1; NM_001294348.1.
DR   RefSeq; NP_001311142.1; NM_001324213.1. [P26378-6]
DR   RefSeq; NP_068771.2; NM_021952.4. [P26378-1]
DR   PDB; 1FXL; X-ray; 1.80 A; A=49-215.
DR   PDB; 1G2E; X-ray; 2.30 A; A=49-215.
DR   PDBsum; 1FXL; -.
DR   PDBsum; 1G2E; -.
DR   SMR; P26378; -.
DR   BioGRID; 108311; 33.
DR   IntAct; P26378; 43.
DR   STRING; 9606.ENSP00000349594; -.
DR   iPTMnet; P26378; -.
DR   PhosphoSitePlus; P26378; -.
DR   BioMuta; ELAVL4; -.
DR   DMDM; 223590202; -.
DR   jPOST; P26378; -.
DR   MassIVE; P26378; -.
DR   MaxQB; P26378; -.
DR   PaxDb; P26378; -.
DR   PeptideAtlas; P26378; -.
DR   PRIDE; P26378; -.
DR   ProteomicsDB; 3315; -.
DR   ProteomicsDB; 54330; -. [P26378-1]
DR   ProteomicsDB; 54331; -. [P26378-2]
DR   ProteomicsDB; 54332; -. [P26378-3]
DR   ProteomicsDB; 54333; -. [P26378-4]
DR   ProteomicsDB; 54334; -. [P26378-5]
DR   Antibodypedia; 3839; 248 antibodies from 29 providers.
DR   DNASU; 1996; -.
DR   Ensembl; ENST00000371821; ENSP00000360886; ENSG00000162374.
DR   Ensembl; ENST00000371823; ENSP00000360888; ENSG00000162374. [P26378-1]
DR   Ensembl; ENST00000371824; ENSP00000360889; ENSG00000162374. [P26378-2]
DR   Ensembl; ENST00000371827; ENSP00000360892; ENSG00000162374. [P26378-4]
DR   Ensembl; ENST00000448907; ENSP00000399939; ENSG00000162374. [P26378-5]
DR   GeneID; 1996; -.
DR   KEGG; hsa:1996; -.
DR   MANE-Select; ENST00000371824.7; ENSP00000360889.2; NM_001144774.3; NP_001138246.1. [P26378-2]
DR   UCSC; uc001cry.3; human. [P26378-6]
DR   CTD; 1996; -.
DR   DisGeNET; 1996; -.
DR   GeneCards; ELAVL4; -.
DR   HGNC; HGNC:3315; ELAVL4.
DR   HPA; ENSG00000162374; Tissue enriched (brain).
DR   MIM; 168360; gene.
DR   neXtProt; NX_P26378; -.
DR   OpenTargets; ENSG00000162374; -.
DR   PharmGKB; PA27743; -.
DR   VEuPathDB; HostDB:ENSG00000162374; -.
DR   eggNOG; KOG0145; Eukaryota.
DR   GeneTree; ENSGT00940000157399; -.
DR   HOGENOM; CLU_026186_2_2_1; -.
DR   InParanoid; P26378; -.
DR   OMA; TMGQYED; -.
DR   OrthoDB; 614259at2759; -.
DR   PhylomeDB; P26378; -.
DR   TreeFam; TF313377; -.
DR   PathwayCommons; P26378; -.
DR   SignaLink; P26378; -.
DR   BioGRID-ORCS; 1996; 6 hits in 1039 CRISPR screens.
DR   ChiTaRS; ELAVL4; human.
DR   EvolutionaryTrace; P26378; -.
DR   GeneWiki; HuD_(protein); -.
DR   GenomeRNAi; 1996; -.
DR   Pharos; P26378; Tbio.
DR   PRO; PR:P26378; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P26378; protein.
DR   Bgee; ENSG00000162374; Expressed in endothelial cell and 167 other tissues.
DR   ExpressionAtlas; P26378; baseline and differential.
DR   Genevisible; P26378; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; IEA:Ensembl.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0042788; C:polysomal ribosome; IEA:Ensembl.
DR   GO; GO:0035925; F:mRNA 3'-UTR AU-rich region binding; IDA:UniProtKB.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:UniProtKB.
DR   GO; GO:0008143; F:poly(A) binding; IDA:UniProtKB.
DR   GO; GO:0097158; F:pre-mRNA intronic pyrimidine-rich binding; IDA:UniProtKB.
DR   GO; GO:0045182; F:translation regulator activity; IEA:Ensembl.
DR   GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0008306; P:associative learning; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0021895; P:cerebral cortex neuron differentiation; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; TAS:ProtInc.
DR   GO; GO:1905870; P:positive regulation of 3'-UTR-mediated mRNA stabilization; IDA:UniProtKB.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0031099; P:regeneration; IEA:Ensembl.
DR   GO; GO:0099547; P:regulation of translation at synapse, modulating synaptic transmission; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0006396; P:RNA processing; IDA:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   CDD; cd12650; RRM1_Hu; 1.
DR   CDD; cd12656; RRM3_HuD; 1.
DR   Gene3D; 3.30.70.330; -; 3.
DR   InterPro; IPR006548; ELAD_HU_SF.
DR   InterPro; IPR034775; ELAV/Hu_RRM1.
DR   InterPro; IPR034918; HuD_RRM3.
DR   InterPro; IPR002343; Hud_Sxl_RNA.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   Pfam; PF00076; RRM_1; 3.
DR   PRINTS; PR00961; HUDSXLRNA.
DR   SMART; SM00360; RRM; 3.
DR   SUPFAM; SSF54928; SSF54928; 2.
DR   TIGRFAMs; TIGR01661; ELAV_HUD_SF; 1.
DR   PROSITE; PS50102; RRM; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection; Cytoplasm;
KW   Methylation; mRNA processing; mRNA splicing; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding.
FT   CHAIN           1..385
FT                   /note="ELAV-like protein 4"
FT                   /id="PRO_0000081583"
FT   DOMAIN          51..129
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          137..217
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          302..380
FT                   /note="RRM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          12..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         38
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61701"
FT   MOD_RES         233
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61701"
FT   MOD_RES         248
FT                   /note="Asymmetric dimethylarginine; by CARM1; alternate"
FT                   /evidence="ECO:0000269|PubMed:16508003"
FT   MOD_RES         248
FT                   /note="Omega-N-methylarginine; by CARM1; alternate"
FT                   /evidence="ECO:0000269|PubMed:16508003"
FT   VAR_SEQ         1..8
FT                   /note="MEWNGLKM -> MEQ (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12209604"
FT                   /id="VSP_060279"
FT   VAR_SEQ         1..8
FT                   /note="MEWNGLKM -> MRLKNQ (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_060280"
FT   VAR_SEQ         1..7
FT                   /note="MEWNGLK -> MV (in isoform 1 and isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_060281"
FT   VAR_SEQ         1..7
FT                   /note="MEWNGLK -> MRLLLLREIVINESRNCSF (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12209604"
FT                   /id="VSP_060282"
FT   VAR_SEQ         264..277
FT                   /note="Missing (in isoform 2, isoform 3, isoform 4 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:12209604,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1655278"
FT                   /id="VSP_060283"
FT   VARIANT         171
FT                   /note="D -> G (in dbSNP:rs17853533)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058091"
FT   VARIANT         275
FT                   /note="P -> S (in dbSNP:rs2494876)"
FT                   /evidence="ECO:0000269|PubMed:12209604,
FT                   ECO:0000269|PubMed:1655278, ECO:0000269|PubMed:7898713"
FT                   /id="VAR_052204"
FT   VARIANT         361
FT                   /note="A -> T (in dbSNP:rs17853531)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058092"
FT   STRAND          51..57
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           64..72
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          77..84
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   TURN            86..88
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          91..101
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           102..112
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          123..126
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           132..134
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          138..143
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           150..157
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           158..160
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          163..170
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   TURN            172..174
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          177..187
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   HELIX           188..198
FT                   /evidence="ECO:0007829|PDB:1FXL"
FT   STRAND          211..214
FT                   /evidence="ECO:0007829|PDB:1FXL"
SQ   SEQUENCE   385 AA;  42398 MW;  A253E05DE653F4EE CRC64;
     MEWNGLKMII STMEPQVSNG PTSNTSNGPS SNNRNCPSPM QTGATTDDSK TNLIVNYLPQ
     NMTQEEFRSL FGSIGEIESC KLVRDKITGQ SLGYGFVNYI DPKDAEKAIN TLNGLRLQTK
     TIKVSYARPS SASIRDANLY VSGLPKTMTQ KELEQLFSQY GRIITSRILV DQVTGVSRGV
     GFIRFDKRIE AEEAIKGLNG QKPSGATEPI TVKFANNPSQ KSSQALLSQL YQSPNRRYPG
     PLHHQAQRFR LDNLLNMAYG VKRLMSGPVP PSACPPRFSP ITIDGMTSLV GMNIPGHTGT
     GWCIFVYNLS PDSDESVLWQ LFGPFGAVNN VKVIRDFNTN KCKGFGFVTM TNYDEAAMAI
     ASLNGYRLGD RVLQVSFKTN KAHKS
//
ID   S13A1_HUMAN             Reviewed;         595 AA.
AC   Q9BZW2; Q9H5Z0;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   23-FEB-2022, entry version 155.
DE   RecName: Full=Solute carrier family 13 member 1;
DE   AltName: Full=Renal sodium/sulfate cotransporter;
DE            Short=Na(+)/sulfate cotransporter;
DE            Short=hNaSi-1;
GN   Name=SLC13A1; Synonyms=NAS1, NASI1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RC   TISSUE=Kidney;
RX   PubMed=11161786; DOI=10.1006/geno.2000.6404;
RA   Lee A., Beck L., Markovich D.;
RT   "The human renal sodium sulfate cotransporter (SLC13A1; hNaSi-1) cDNA and
RT   gene: organization, chromosomal localization, and functional
RT   characterization.";
RL   Genomics 70:354-363(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
CC   -!- FUNCTION: Sodium/sulfate cotransporter that mediates sulfate
CC       reabsorption in the kidney.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Highly expressed in kidney; not detectable in the
CC       other tissues tested.
CC   -!- INDUCTION: Inhibited by thiosulfate, selenate, molybdate, tungstate,
CC       citrate and succinate.
CC   -!- SIMILARITY: Belongs to the SLC13A/DASS transporter (TC 2.A.47) family.
CC       NADC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF260824; AAG60583.1; -; mRNA.
DR   EMBL; AK026413; BAB15477.1; -; mRNA.
DR   CCDS; CCDS5786.1; -.
DR   RefSeq; NP_001311329.1; NM_001324400.1.
DR   RefSeq; NP_071889.2; NM_022444.3.
DR   SMR; Q9BZW2; -.
DR   BioGRID; 112450; 35.
DR   STRING; 9606.ENSP00000194130; -.
DR   DrugBank; DB00139; Succinic acid.
DR   TCDB; 2.A.47.1.16; the divalent anion:na(+) symporter (dass) family.
DR   GlyGen; Q9BZW2; 3 sites.
DR   PhosphoSitePlus; Q9BZW2; -.
DR   BioMuta; SLC13A1; -.
DR   DMDM; 23396850; -.
DR   EPD; Q9BZW2; -.
DR   MassIVE; Q9BZW2; -.
DR   PaxDb; Q9BZW2; -.
DR   PeptideAtlas; Q9BZW2; -.
DR   PRIDE; Q9BZW2; -.
DR   Antibodypedia; 62232; 31 antibodies from 12 providers.
DR   DNASU; 6561; -.
DR   Ensembl; ENST00000194130; ENSP00000194130; ENSG00000081800.
DR   GeneID; 6561; -.
DR   KEGG; hsa:6561; -.
DR   MANE-Select; ENST00000194130.7; ENSP00000194130.2; NM_022444.4; NP_071889.2.
DR   UCSC; uc003vkm.4; human.
DR   CTD; 6561; -.
DR   DisGeNET; 6561; -.
DR   GeneCards; SLC13A1; -.
DR   HGNC; HGNC:10916; SLC13A1.
DR   HPA; ENSG00000081800; Tissue enriched (kidney).
DR   MIM; 606193; gene.
DR   neXtProt; NX_Q9BZW2; -.
DR   OpenTargets; ENSG00000081800; -.
DR   PharmGKB; PA322; -.
DR   VEuPathDB; HostDB:ENSG00000081800; -.
DR   eggNOG; KOG1281; Eukaryota.
DR   GeneTree; ENSGT01030000234550; -.
DR   HOGENOM; CLU_005170_9_1_1; -.
DR   InParanoid; Q9BZW2; -.
DR   OMA; CMPWEIA; -.
DR   OrthoDB; 389981at2759; -.
DR   PhylomeDB; Q9BZW2; -.
DR   TreeFam; TF312913; -.
DR   PathwayCommons; Q9BZW2; -.
DR   Reactome; R-HSA-433137; Sodium-coupled sulphate, di- and tri-carboxylate transporters.
DR   BioGRID-ORCS; 6561; 4 hits in 1033 CRISPR screens.
DR   ChiTaRS; SLC13A1; human.
DR   GenomeRNAi; 6561; -.
DR   Pharos; Q9BZW2; Tbio.
DR   PRO; PR:Q9BZW2; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9BZW2; protein.
DR   Bgee; ENSG00000081800; Expressed in kidney epithelium and 34 other tissues.
DR   ExpressionAtlas; Q9BZW2; baseline and differential.
DR   Genevisible; Q9BZW2; HS.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015382; F:sodium:sulfate symporter activity; IBA:GO_Central.
DR   GO; GO:0098656; P:anion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0008272; P:sulfate transport; IBA:GO_Central.
DR   InterPro; IPR031312; Na/sul_symport_CS.
DR   InterPro; IPR001898; SLC13A/DASS.
DR   Pfam; PF00939; Na_sulph_symp; 1.
DR   PROSITE; PS01271; NA_SULFATE; 1.
PE   1: Evidence at protein level;
KW   Glycoprotein; Ion transport; Membrane; Reference proteome; Sodium;
KW   Sodium transport; Sulfate transport; Symport; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..595
FT                   /note="Solute carrier family 13 member 1"
FT                   /id="PRO_0000172485"
FT   TRANSMEM        13..33
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        41..61
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        77..97
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        108..128
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        131..151
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        239..259
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        290..310
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        348..368
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        381..401
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        464..484
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        491..511
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        512..532
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        554..574
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        174
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        207
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        591
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         42
FT                   /note="F -> L (in dbSNP:rs28364181)"
FT                   /id="VAR_029247"
FT   VARIANT         44
FT                   /note="V -> I (in dbSNP:rs28364177)"
FT                   /id="VAR_029248"
FT   VARIANT         157
FT                   /note="Q -> E (in dbSNP:rs28364196)"
FT                   /id="VAR_029249"
FT   VARIANT         174
FT                   /note="N -> S (in dbSNP:rs2140516)"
FT                   /id="VAR_022018"
FT   VARIANT         205
FT                   /note="Y -> C (in dbSNP:rs28364231)"
FT                   /id="VAR_029250"
FT   VARIANT         240
FT                   /note="T -> M (in dbSNP:rs10231144)"
FT                   /id="VAR_059804"
FT   VARIANT         277
FT                   /note="R -> H (in dbSNP:rs28364200)"
FT                   /id="VAR_029251"
FT   VARIANT         332
FT                   /note="V -> A (in dbSNP:rs28364201)"
FT                   /id="VAR_029252"
FT   VARIANT         392
FT                   /note="I -> T (in dbSNP:rs28364210)"
FT                   /id="VAR_029253"
FT   CONFLICT        481
FT                   /note="V -> A (in Ref. 2; BAB15477)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   595 AA;  66134 MW;  A4C48EC180F6DA14 CRC64;
     MKFFSYILVY RRFLFVVFTV LVLLPLPIVL HTKEAECAYT LFVVATFWLT EALPLSVTAL
     LPSLMLPMFG IMPSKKVASA YFKDFHLLLI GVICLATSIE KWNLHKRIAL KMVMMVGVNP
     AWLTLGFMSS TAFLSMWLSN TSTAAMVMPI AEAVVQQIIN AEAEVEATQM TYFNGSTNHG
     LEIDESVNGH EINERKEKTK PVPGYNNDTG KISSKVELEK NSGMRTKYRT KKGHVTRKLT
     CLCIAYSSTI GGLTTITGTS TNLIFAEYFN TRYPDCRCLN FGSWFTFSFP AALIILLLSW
     IWLQWLFLGF NFKEMFKCGK TKTVQQKACA EVIKQEYQKL GPIRYQEIVT LVLFIIMALL
     WFSRDPGFVP GWSALFSEYP GFATDSTVAL LIGLLFFLIP AKTLTKTTPT GEIVAFDYSP
     LITWKEFQSF MPWDIAILVG GGFALADGCE ESGLSKWIGN KLSPLGSLPA WLIILISSLM
     VTSLTEVASN PATITLFLPI LSPLAEAIHV NPLYILIPST LCTSFAFLLP VANPPNAIVF
     SYGHLKVIDM VKAGLGVNIV GVAVVMLGIC TWIVPMFDLY TYPSWAPAMS NETMP
//
ID   CACB2_HUMAN             Reviewed;         660 AA.
AC   Q08289; A6PVM5; A6PVM7; A6PVM8; O00304; Q5QJ99; Q5QJA0; Q5VVG9; Q5VVH0;
AC   Q5VWV6; Q6TME1; Q6TME2; Q6TME3; Q8WX81; Q96NZ3; Q96NZ4; Q96NZ5; Q9BWU2;
AC   Q9HD32; Q9Y340; Q9Y341;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 3.
DT   23-FEB-2022, entry version 207.
DE   RecName: Full=Voltage-dependent L-type calcium channel subunit beta-2;
DE            Short=CAB2;
DE   AltName: Full=Calcium channel voltage-dependent subunit beta 2;
DE   AltName: Full=Lambert-Eaton myasthenic syndrome antigen B;
DE            Short=MYSB;
GN   Name=CACNB2; Synonyms=CACNLB2, MYSB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2A; 2G AND 2H).
RC   TISSUE=Fetal brain;
RX   PubMed=8494331; DOI=10.1002/ana.410330126;
RA   Rosenfeld M.R., Wong E., Dalmau J., Manley G., Posner J.B., Sher E.,
RA   Furneaux H.M.;
RT   "Cloning and characterization of a Lambert-Eaton myasthenic syndrome
RT   antigen.";
RL   Ann. Neurol. 33:113-120(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2A).
RC   TISSUE=Brain;
RX   PubMed=9254841; DOI=10.1007/pl00008704;
RA   Taviaux S., Williams M.E., Harpold M.M., Nargeot J., Lory P.;
RT   "Assignment of human genes for beta 2 and beta 4 subunits of voltage-
RT   dependent Ca2+ channels to chromosomes 10p12 and 2q22-q23.";
RL   Hum. Genet. 100:151-154(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2A; 2B; 2C; 2D AND 2E).
RX   PubMed=12042350; DOI=10.1113/jphysiol.2002.018515;
RA   Colecraft H.M., Alseikhan B., Takahashi S.X., Chaudhuri D., Mittman S.,
RA   Yegnasubramanian V., Alvania R.S., Johns D.C., Marban E., Yue D.T.;
RT   "Novel functional properties of Ca(2+) channel beta subunits revealed by
RT   their expression in adult rat heart cells.";
RL   J. Physiol. (Lond.) 541:435-452(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2B; 2C; 2H; 2CN2 AND 2CN4),
RP   ALTERNATIVE SPLICING, AND SUBCELLULAR LOCATION.
RC   TISSUE=Heart;
RX   PubMed=14762176; DOI=10.1152/physiolgenomics.00207.2003;
RA   Foell J.D., Balijepalli R.C., Delisle B.P., Yunker A.M.R., Robia S.L.,
RA   Walker J.W., McEnery M.W., January C.T., Kamp T.J.;
RT   "Molecular heterogeneity of calcium channel beta-subunits in canine and
RT   human heart: evidence for differential subcellular localization.";
RL   Physiol. Genomics 17:183-200(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2A AND 2D).
RA   Mikala G., Yamaguchi H., Schwartz A.;
RT   "Cooperative effects of alpha2delta and beta2a subunits on surface
RT   expression of calcium channel alpha1c subunits.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2A).
RA   Li D., Roberts R.;
RT   "The beta 2 subunit of the voltage-dependent calcium channel (CACNB2):
RT   genomic structure and mutational analysis as a candidate gene for ARVD6.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2F).
RC   TISSUE=Jejunum;
RA   Lyford G.L., Strege P., Shepard A., Miller S., Rae J., Gibbons S.,
RA   Szurszewski J., Farrugia G.;
RT   "Human jejunum voltage-gated calcium channel subunits.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   INTERACTION WITH RRAD.
RX   PubMed=17525370; DOI=10.1161/circresaha.106.146399;
RA   Yada H., Murata M., Shimoda K., Yuasa S., Kawaguchi H., Ieda M., Adachi T.,
RA   Murata M., Ogawa S., Fukuda K.;
RT   "Dominant negative suppression of Rad leads to QT prolongation and causes
RT   ventricular arrhythmias via modulation of L-type Ca2+ channels in the
RT   heart.";
RL   Circ. Res. 101:69-77(2007).
RN   [12]
RP   INTERACTION WITH TMIGD2.
RX   PubMed=22419821; DOI=10.1091/mbc.e11-11-0934;
RA   Rahimi N., Rezazadeh K., Mahoney J.E., Hartsough E., Meyer R.D.;
RT   "Identification of IGPR-1 as a novel adhesion molecule involved in
RT   angiogenesis.";
RL   Mol. Biol. Cell 23:1646-1656(2012).
RN   [13]
RP   INTERACTION WITH CAMK2A.
RX   PubMed=28130356; DOI=10.1523/jneurosci.2068-16.2017;
RA   Stephenson J.R., Wang X., Perfitt T.L., Parrish W.P., Shonesy B.C.,
RA   Marks C.R., Mortlock D.P., Nakagawa T., Sutcliffe J.S., Colbran R.J.;
RT   "Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and
RT   Causes ASD-Related Behaviors.";
RL   J. Neurosci. 37:2216-2233(2017).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] GLY-99.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT BRGDA4 LEU-535, AND CHARACTERIZATION OF VARIANT BRGDA4 LEU-535.
RX   PubMed=17224476; DOI=10.1161/circulationaha.106.668392;
RA   Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C.,
RA   Aizawa Y., Guerchicoff A., Pfeiffer R., Oliva A., Wollnik B., Gelber P.,
RA   Bonaros E.P. Jr., Burashnikov E., Wu Y., Sargent J.D., Schickel S.,
RA   Oberheiden R., Bhatia A., Hsu L.F., Haissaguerre M., Schimpf R.,
RA   Borggrefe M., Wolpert C.;
RT   "Loss-of-function mutations in the cardiac calcium channel underlie a new
RT   clinical entity characterized by ST-segment elevation, short QT intervals,
RT   and sudden cardiac death.";
RL   Circulation 115:442-449(2007).
CC   -!- FUNCTION: The beta subunit of voltage-dependent calcium channels
CC       contributes to the function of the calcium channel by increasing peak
CC       calcium current, shifting the voltage dependencies of activation and
CC       inactivation, modulating G protein inhibition and controlling the
CC       alpha-1 subunit membrane targeting.
CC   -!- SUBUNIT: Component of a calcium channel complex consisting of a pore-
CC       forming alpha subunit (CACNA1S) and the ancillary subunits CACNB1 or
CC       CACNB2, CACNG1 and CACNA2D1. The channel complex contains alpha, beta,
CC       gamma and delta subunits in a 1:1:1:1 ratio, i.e. it contains either
CC       CACNB1 or CACNB2. Interacts with CACNA1C (By similarity). Interacts
CC       with RRAD. Interaction with RRAD regulates the trafficking of CACNA1C
CC       to the cell membrane (PubMed:17525370). Interacts with TMIGD2
CC       (PubMed:22419821). Interacts with CAMK2D. Interacts with CBARP (By
CC       similarity). Interacts with CAMK2A (PubMed:28130356).
CC       {ECO:0000250|UniProtKB:Q8VGC3, ECO:0000269|PubMed:17525370,
CC       ECO:0000269|PubMed:22419821, ECO:0000269|PubMed:28130356}.
CC   -!- INTERACTION:
CC       Q08289; P56545-3: CTBP2; NbExp=5; IntAct=EBI-2874501, EBI-10171902;
CC       Q08289; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-2874501, EBI-5460660;
CC       Q08289; O14744: PRMT5; NbExp=3; IntAct=EBI-2874501, EBI-351098;
CC       Q08289; Q8WUU8: TMEM174; NbExp=3; IntAct=EBI-2874501, EBI-10276729;
CC       Q08289-1; Q13936: CACNA1C; NbExp=4; IntAct=EBI-15707999, EBI-1038838;
CC   -!- SUBCELLULAR LOCATION: Cell membrane, sarcolemma {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}; Cytoplasmic side
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=10;
CC       Name=2d; Synonyms=CACNB2d;
CC         IsoId=Q08289-1; Sequence=Displayed;
CC       Name=2a; Synonyms=CACNB2a;
CC         IsoId=Q08289-2; Sequence=VSP_000627;
CC       Name=2b; Synonyms=CACNB2b, 2aN4;
CC         IsoId=Q08289-3; Sequence=VSP_000628;
CC       Name=2c; Synonyms=CACNB2c, 2aN2;
CC         IsoId=Q08289-4; Sequence=VSP_000626;
CC       Name=2e; Synonyms=CACNB2e;
CC         IsoId=Q08289-5; Sequence=VSP_000629;
CC       Name=2f;
CC         IsoId=Q08289-6; Sequence=VSP_000627, VSP_000630;
CC       Name=2g;
CC         IsoId=Q08289-7; Sequence=VSP_000630;
CC       Name=2h; Synonyms=2cN1;
CC         IsoId=Q08289-8; Sequence=VSP_000631;
CC       Name=2cN2;
CC         IsoId=Q08289-9; Sequence=VSP_000626, VSP_000631;
CC       Name=2cN4;
CC         IsoId=Q08289-10; Sequence=VSP_000628, VSP_000631;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues.
CC   -!- PTM: Regulated through phosphorylation at Thr-554 by CaMK2D.
CC       {ECO:0000250}.
CC   -!- DISEASE: Brugada syndrome 4 (BRGDA4) [MIM:611876]: A heart disease
CC       characterized by the association of Brugada syndrome with shortened QT
CC       intervals. Brugada syndrome is a tachyarrhythmia characterized by right
CC       bundle branch block and ST segment elevation on an electrocardiogram
CC       (ECG). It can cause the ventricles to beat so fast that the blood is
CC       prevented from circulating efficiently in the body. When this situation
CC       occurs, the individual will faint and may die in a few minutes if the
CC       heart is not reset. {ECO:0000269|PubMed:17224476}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the calcium channel beta subunit family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB51370.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S60415; AAB51370.1; ALT_FRAME; mRNA.
DR   EMBL; U95019; AAB53332.1; -; mRNA.
DR   EMBL; AF423189; AAL16948.1; -; mRNA.
DR   EMBL; AF423190; AAL16949.1; -; mRNA.
DR   EMBL; AF423191; AAL16950.1; -; mRNA.
DR   EMBL; AF423192; AAL16951.1; -; mRNA.
DR   EMBL; AF285239; AAG01473.2; -; mRNA.
DR   EMBL; AY393858; AAQ97606.1; -; mRNA.
DR   EMBL; AY393859; AAQ97607.1; -; mRNA.
DR   EMBL; AY393860; AAQ97608.1; -; mRNA.
DR   EMBL; AY393861; AAQ97609.1; -; mRNA.
DR   EMBL; AY393862; AAQ97610.1; -; mRNA.
DR   EMBL; AF137376; AAD33729.1; -; mRNA.
DR   EMBL; AF137377; AAD33730.1; -; mRNA.
DR   EMBL; AY027898; AAK16994.1; -; Genomic_DNA.
DR   EMBL; AY027893; AAK16994.1; JOINED; Genomic_DNA.
DR   EMBL; AY027894; AAK16994.1; JOINED; Genomic_DNA.
DR   EMBL; AY027895; AAK16994.1; JOINED; Genomic_DNA.
DR   EMBL; AY027896; AAK16994.1; JOINED; Genomic_DNA.
DR   EMBL; AY027897; AAK16994.1; JOINED; Genomic_DNA.
DR   EMBL; AF465485; AAL73495.1; -; mRNA.
DR   EMBL; AL139814; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL360231; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL390783; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450364; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450384; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353603; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86196.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86197.1; -; Genomic_DNA.
DR   EMBL; BC136409; AAI36410.1; -; mRNA.
DR   CCDS; CCDS41493.1; -. [Q08289-9]
DR   CCDS; CCDS41494.1; -. [Q08289-3]
DR   CCDS; CCDS7125.1; -. [Q08289-1]
DR   CCDS; CCDS7126.1; -. [Q08289-8]
DR   CCDS; CCDS7127.1; -. [Q08289-4]
DR   CCDS; CCDS7128.1; -. [Q08289-2]
DR   CCDS; CCDS7129.1; -. [Q08289-5]
DR   CCDS; CCDS81442.1; -. [Q08289-6]
DR   PIR; A48895; A48895.
DR   RefSeq; NP_000715.2; NM_000724.3. [Q08289-2]
DR   RefSeq; NP_001316989.1; NM_001330060.1. [Q08289-6]
DR   RefSeq; NP_963864.1; NM_201570.2. [Q08289-5]
DR   RefSeq; NP_963865.2; NM_201571.3. [Q08289-4]
DR   RefSeq; NP_963866.2; NM_201572.3. [Q08289-9]
DR   RefSeq; NP_963884.2; NM_201590.2. [Q08289-3]
DR   RefSeq; NP_963887.2; NM_201593.2. [Q08289-7]
DR   RefSeq; NP_963890.2; NM_201596.2. [Q08289-1]
DR   RefSeq; NP_963891.1; NM_201597.2. [Q08289-8]
DR   RefSeq; XP_011517961.1; XM_011519659.2. [Q08289-10]
DR   SMR; Q08289; -.
DR   BioGRID; 107237; 9.
DR   ComplexPortal; CPX-3195; Cardiac muscle voltage-gated calcium channel complex.
DR   IntAct; Q08289; 9.
DR   MINT; Q08289; -.
DR   STRING; 9606.ENSP00000320025; -.
DR   BindingDB; Q08289; -.
DR   ChEMBL; CHEMBL3317336; -.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB09231; Benidipine.
DR   DrugBank; DB13746; Bioallethrin.
DR   DrugBank; DB11148; Butamben.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugBank; DB09232; Cilnidipine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB00153; Ergocalciferol.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB13961; Fish oil.
DR   DrugBank; DB00270; Isradipine.
DR   DrugBank; DB09236; Lacidipine.
DR   DrugBank; DB00825; Levomenthol.
DR   DrugBank; DB00653; Magnesium sulfate.
DR   DrugBank; DB09238; Manidipine.
DR   DrugBank; DB01388; Mibefradil.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB06712; Nilvadipine.
DR   DrugBank; DB00393; Nimodipine.
DR   DrugBank; DB00401; Nisoldipine.
DR   DrugBank; DB01054; Nitrendipine.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB00421; Spironolactone.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB09089; Trimebutine.
DR   TCDB; 8.A.22.1.2; the ca(2+) channel auxiliary subunit Beta types 1-4 (cca-Beta) family.
DR   iPTMnet; Q08289; -.
DR   PhosphoSitePlus; Q08289; -.
DR   BioMuta; CACNB2; -.
DR   DMDM; 145559447; -.
DR   jPOST; Q08289; -.
DR   MassIVE; Q08289; -.
DR   MaxQB; Q08289; -.
DR   PaxDb; Q08289; -.
DR   PeptideAtlas; Q08289; -.
DR   PRIDE; Q08289; -.
DR   ProteomicsDB; 1694; -.
DR   ProteomicsDB; 58586; -. [Q08289-1]
DR   ProteomicsDB; 58587; -. [Q08289-2]
DR   ProteomicsDB; 58588; -. [Q08289-3]
DR   ProteomicsDB; 58589; -. [Q08289-4]
DR   ProteomicsDB; 58590; -. [Q08289-5]
DR   ProteomicsDB; 58591; -. [Q08289-6]
DR   ProteomicsDB; 58592; -. [Q08289-7]
DR   ProteomicsDB; 58593; -. [Q08289-8]
DR   ABCD; Q08289; 1 sequenced antibody.
DR   Antibodypedia; 12067; 570 antibodies from 35 providers.
DR   DNASU; 783; -.
DR   Ensembl; ENST00000282343; ENSP00000282343; ENSG00000165995. [Q08289-4]
DR   Ensembl; ENST00000324631; ENSP00000320025; ENSG00000165995.
DR   Ensembl; ENST00000352115; ENSP00000344474; ENSG00000165995. [Q08289-8]
DR   Ensembl; ENST00000377315; ENSP00000366532; ENSG00000165995. [Q08289-5]
DR   Ensembl; ENST00000377319; ENSP00000366536; ENSG00000165995. [Q08289-6]
DR   Ensembl; ENST00000377329; ENSP00000366546; ENSG00000165995. [Q08289-3]
DR   Ensembl; ENST00000396576; ENSP00000379821; ENSG00000165995. [Q08289-2]
DR   Ensembl; ENST00000645287; ENSP00000496203; ENSG00000165995. [Q08289-9]
DR   GeneID; 783; -.
DR   KEGG; hsa:783; -.
DR   MANE-Select; ENST00000324631.13; ENSP00000320025.8; NM_201596.3; NP_963890.2.
DR   UCSC; uc001ipr.3; human. [Q08289-1]
DR   CTD; 783; -.
DR   DisGeNET; 783; -.
DR   GeneCards; CACNB2; -.
DR   GeneReviews; CACNB2; -.
DR   HGNC; HGNC:1402; CACNB2.
DR   HPA; ENSG00000165995; Tissue enhanced (retina).
DR   MalaCards; CACNB2; -.
DR   MIM; 600003; gene.
DR   MIM; 611876; phenotype.
DR   neXtProt; NX_Q08289; -.
DR   OpenTargets; ENSG00000165995; -.
DR   Orphanet; 130; Brugada syndrome.
DR   PharmGKB; PA88; -.
DR   VEuPathDB; HostDB:ENSG00000165995; -.
DR   eggNOG; KOG3812; Eukaryota.
DR   GeneTree; ENSGT00950000182837; -.
DR   HOGENOM; CLU_021995_3_0_1; -.
DR   InParanoid; Q08289; -.
DR   OMA; TDREQDH; -.
DR   OrthoDB; 926074at2759; -.
DR   PhylomeDB; Q08289; -.
DR   TreeFam; TF316195; -.
DR   PathwayCommons; Q08289; -.
DR   Reactome; R-HSA-112308; Presynaptic depolarization and calcium channel opening.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5576893; Phase 2 - plateau phase.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   SignaLink; Q08289; -.
DR   SIGNOR; Q08289; -.
DR   BioGRID-ORCS; 783; 4 hits in 1036 CRISPR screens.
DR   ChiTaRS; CACNB2; human.
DR   GeneWiki; CACNB2; -.
DR   GenomeRNAi; 783; -.
DR   Pharos; Q08289; Tbio.
DR   PRO; PR:Q08289; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q08289; protein.
DR   Bgee; ENSG00000165995; Expressed in heart and 192 other tissues.
DR   ExpressionAtlas; Q08289; baseline and differential.
DR   Genevisible; Q08289; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:1990454; C:L-type voltage-gated calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0098684; C:photoreceptor ribbon synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IDA:BHF-UCL.
DR   GO; GO:0051015; F:actin filament binding; ISS:BHF-UCL.
DR   GO; GO:0005262; F:calcium channel activity; NAS:UniProtKB.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0099635; F:voltage-gated calcium channel activity involved in positive regulation of presynaptic cytosolic calcium levels; IEA:Ensembl.
DR   GO; GO:0070509; P:calcium ion import; IDA:BHF-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0098912; P:membrane depolarization during atrial cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086045; P:membrane depolarization during AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0007528; P:neuromuscular junction development; IBA:GO_Central.
DR   GO; GO:1904879; P:positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel; ISS:BHF-UCL.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:BHF-UCL.
DR   GO; GO:1901843; P:positive regulation of high voltage-gated calcium channel activity; ISS:BHF-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:1901385; P:regulation of voltage-gated calcium channel activity; IBA:GO_Central.
DR   GO; GO:0007601; P:visual perception; IEA:Ensembl.
DR   CDD; cd12040; SH3_CACNB2; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR035605; CACNB2_SH3.
DR   InterPro; IPR008145; GK/Ca_channel_bsu.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR005444; VDCC_L_b2su.
DR   InterPro; IPR000584; VDCC_L_bsu.
DR   Pfam; PF00625; Guanylate_kin; 1.
DR   Pfam; PF12052; VGCC_beta4Aa_N; 1.
DR   PRINTS; PR01626; LCACHANNELB.
DR   PRINTS; PR01628; LCACHANNELB2.
DR   SMART; SM00072; GuKc; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Brugada syndrome; Calcium; Calcium channel;
KW   Calcium transport; Cell membrane; Disease variant; Ion channel;
KW   Ion transport; Membrane; Phosphoprotein; Reference proteome; SH3 domain;
KW   Transport; Voltage-gated channel.
FT   CHAIN           1..660
FT                   /note="Voltage-dependent L-type calcium channel subunit
FT                   beta-2"
FT                   /id="PRO_0000144051"
FT   DOMAIN          114..183
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REGION          39..101
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          190..261
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          486..641
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        56..83
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        84..101
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        194..225
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        244..258
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        486..511
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        538..553
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        554..641
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            549
FT                   /note="Required for CaMK2D-binding"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         204
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VGC3"
FT   MOD_RES         207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CC27"
FT   MOD_RES         218
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CC27"
FT   MOD_RES         550
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CC27"
FT   MOD_RES         554
FT                   /note="Phosphothreonine; by CaMK2D"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VGC3"
FT   VAR_SEQ         1..71
FT                   /note="MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRF
FT                   KGSDGSTSSDTTSNSFVRQ -> MQCCGLVHRRRVRVSY (in isoform 2a and
FT                   isoform 2f)"
FT                   /evidence="ECO:0000303|PubMed:12042350,
FT                   ECO:0000303|PubMed:8494331, ECO:0000303|PubMed:9254841,
FT                   ECO:0000303|Ref.5, ECO:0000303|Ref.7"
FT                   /id="VSP_000627"
FT   VAR_SEQ         1..71
FT                   /note="MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRF
FT                   KGSDGSTSSDTTSNSFVRQ -> MLDRRLIAPQTKYIIPG (in isoform 2b and
FT                   isoform 2cN4)"
FT                   /evidence="ECO:0000303|PubMed:12042350,
FT                   ECO:0000303|PubMed:14762176"
FT                   /id="VSP_000628"
FT   VAR_SEQ         1..71
FT                   /note="MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRF
FT                   KGSDGSTSSDTTSNSFVRQ -> MKATWIRLLKRAKGGRLKNSDIC (in isoform
FT                   2e)"
FT                   /evidence="ECO:0000303|PubMed:12042350"
FT                   /id="VSP_000629"
FT   VAR_SEQ         1..40
FT                   /note="MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQ -> MNQGSGLD
FT                   LLKI (in isoform 2c and isoform 2cN2)"
FT                   /evidence="ECO:0000303|PubMed:12042350,
FT                   ECO:0000303|PubMed:14762176"
FT                   /id="VSP_000626"
FT   VAR_SEQ         224..268
FT                   /note="AIDIDATGLDAEENDIPANHRSPKPSANSVTSPHSKEKRMPFFKK -> AKQ
FT                   KQKS (in isoform 2f and isoform 2g)"
FT                   /evidence="ECO:0000303|PubMed:8494331, ECO:0000303|Ref.7"
FT                   /id="VSP_000630"
FT   VAR_SEQ         224..268
FT                   /note="AIDIDATGLDAEENDIPANHRSPKPSANSVTSPHSKEKRMPFFKK -> GAK
FT                   SADEQDQWKTAGLFWRFT (in isoform 2h, isoform 2cN2 and isoform
FT                   2cN4)"
FT                   /evidence="ECO:0000303|PubMed:14762176,
FT                   ECO:0000303|PubMed:8494331"
FT                   /id="VSP_000631"
FT   VARIANT         99
FT                   /note="A -> G (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs745502425)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036350"
FT   VARIANT         535
FT                   /note="S -> L (in BRGDA4; unknown pathological
FT                   significance; affects channel activity; dbSNP:rs121917812)"
FT                   /evidence="ECO:0000269|PubMed:17224476"
FT                   /id="VAR_044041"
FT   CONFLICT        56
FT                   /note="D -> N (in Ref. 4; AAQ97608)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="V -> L (in Ref. 5; AAD33729)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        100..101
FT                   /note="ER -> Q (in Ref. 5; AAD33729)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        122
FT                   /note="N -> D (in Ref. 5; AAD33729)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="L -> V (in Ref. 5; AAD33729/AAD33730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        406
FT                   /note="R -> T (in Ref. 5; AAD33729/AAD33730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        501
FT                   /note="D -> H (in Ref. 5; AAD33729/AAD33730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        524
FT                   /note="P -> G (in Ref. 5; AAD33729/AAD33730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        624
FT                   /note="Q -> QQ (in Ref. 5; AAD33729/AAD33730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        659
FT                   /note="R -> P (in Ref. 2; AAB53332, 3; AAG01473/AAL16948/
FT                   AAL16951/AAL16950, 4; AAQ97606/AAQ97607/AAQ97608/AAQ97609/
FT                   AAQ97610 and 6; AAL73495)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   660 AA;  73581 MW;  4A08B141EE66404E CRC64;
     MVQRDMSKSP PTAAAAVAQE IQMELLENVA PAGALGAAAQ SYGKGARRKN RFKGSDGSTS
     SDTTSNSFVR QGSADSYTSR PSDSDVSLEE DREAVRREAE RQAQAQLEKA KTKPVAFAVR
     TNVSYSAAHE DDVPVPGMAI SFEAKDFLHV KEKFNNDWWI GRLVKEGCEI GFIPSPVKLE
     NMRLQHEQRA KQGKFYSSKS GGNSSSSLGD IVPSSRKSTP PSSAIDIDAT GLDAEENDIP
     ANHRSPKPSA NSVTSPHSKE KRMPFFKKTE HTPPYDVVPS MRPVVLVGPS LKGYEVTDMM
     QKALFDFLKH RFEGRISITR VTADISLAKR SVLNNPSKHA IIERSNTRSS LAEVQSEIER
     IFELARTLQL VVLDADTINH PAQLSKTSLA PIIVYVKISS PKVLQRLIKS RGKSQAKHLN
     VQMVAADKLA QCPPELFDVI LDENQLEDAC EHLADYLEAY WKATHPPSSS LPNPLLSRTL
     ATSSLPLSPT LASNSQGSQG DQRTDRSAPI RSASQAEEEP SVEPVKKSQH RSSSSAPHHN
     HRSGTSRGLS RQETFDSETQ ESRDSAYVEP KEDYSHDHVD HYASHRDHNH RDETHGSSDH
     RHRESRHRSR DVDREQDHNE CNKQRSRHKS KDRYCEKDGE VISKKRNEAG EWNRDVYIRQ
//
ID   PCX4_HUMAN              Reviewed;        1172 AA.
AC   Q63HM2; A8MXM2; Q9BQG8; Q9H9F2;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 4.
DT   23-FEB-2022, entry version 129.
DE   RecName: Full=Pecanex-like protein 4;
DE   AltName: Full=Hepatitis C virus F protein-binding protein 2;
DE            Short=HCV F protein-binding protein 2;
DE   AltName: Full=Pecanex homolog protein 4 {ECO:0000312|HGNC:HGNC:20349};
GN   Name=PCNX4 {ECO:0000312|HGNC:HGNC:20349}; Synonyms=C14orf135, FBP2, PCNXL4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 487-1172, AND VARIANT SER-1000.
RC   TISSUE=Salivary gland;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 737-1172.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 889-1172.
RC   TISSUE=Amygdala;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 894-1172.
RA   Huang Y.-P., Wang L., Cheng J.;
RT   "Screening and identification of HCV F protein-binding protein 2.";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 909-1172.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
CC   -!- INTERACTION:
CC       Q63HM2; P0C045; Xeno; NbExp=3; IntAct=EBI-1104540, EBI-9351969;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the pecanex family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH33843.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14277.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAB66516.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAH56141.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL157911; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL163853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX648440; CAH56141.1; ALT_INIT; mRNA.
DR   EMBL; BC033843; AAH33843.2; ALT_INIT; mRNA.
DR   EMBL; AL136581; CAB66516.1; ALT_INIT; mRNA.
DR   EMBL; AY553876; AAS64574.1; -; mRNA.
DR   EMBL; AK022861; BAB14277.1; ALT_INIT; mRNA.
DR   CCDS; CCDS81809.1; -.
DR   RefSeq; NP_001317106.1; NM_001330177.1.
DR   RefSeq; NP_071940.4; NM_022495.5.
DR   BioGRID; 122178; 6.
DR   IntAct; Q63HM2; 6.
DR   STRING; 9606.ENSP00000317396; -.
DR   GlyGen; Q63HM2; 2 sites.
DR   iPTMnet; Q63HM2; -.
DR   PhosphoSitePlus; Q63HM2; -.
DR   BioMuta; PCNX4; -.
DR   DMDM; 206729932; -.
DR   jPOST; Q63HM2; -.
DR   MassIVE; Q63HM2; -.
DR   PaxDb; Q63HM2; -.
DR   PeptideAtlas; Q63HM2; -.
DR   PRIDE; Q63HM2; -.
DR   ProteomicsDB; 65881; -.
DR   Antibodypedia; 41; 67 antibodies from 15 providers.
DR   DNASU; 64430; -.
DR   Ensembl; ENST00000406854; ENSP00000384801; ENSG00000126773.
DR   GeneID; 64430; -.
DR   KEGG; hsa:64430; -.
DR   MANE-Select; ENST00000406854.6; ENSP00000384801.1; NM_001330177.2; NP_001317106.1.
DR   UCSC; uc059ccm.1; human.
DR   CTD; 64430; -.
DR   GeneCards; PCNX4; -.
DR   HGNC; HGNC:20349; PCNX4.
DR   HPA; ENSG00000126773; Low tissue specificity.
DR   neXtProt; NX_Q63HM2; -.
DR   OpenTargets; ENSG00000126773; -.
DR   PharmGKB; PA134919147; -.
DR   VEuPathDB; HostDB:ENSG00000126773; -.
DR   eggNOG; KOG3604; Eukaryota.
DR   GeneTree; ENSGT00940000156899; -.
DR   HOGENOM; CLU_008258_0_0_1; -.
DR   InParanoid; Q63HM2; -.
DR   OMA; AVCNYFI; -.
DR   OrthoDB; 1243516at2759; -.
DR   PhylomeDB; Q63HM2; -.
DR   PathwayCommons; Q63HM2; -.
DR   SignaLink; Q63HM2; -.
DR   BioGRID-ORCS; 64430; 1 hit in 235 CRISPR screens.
DR   ChiTaRS; PCNX4; human.
DR   GenomeRNAi; 64430; -.
DR   Pharos; Q63HM2; Tdark.
DR   PRO; PR:Q63HM2; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q63HM2; protein.
DR   Bgee; ENSG00000126773; Expressed in ventricular zone and 224 other tissues.
DR   ExpressionAtlas; Q63HM2; baseline and differential.
DR   Genevisible; Q63HM2; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR039797; Pecanex.
DR   InterPro; IPR007735; Pecanex_C.
DR   PANTHER; PTHR12372; PTHR12372; 1.
DR   Pfam; PF05041; Pecanex_C; 1.
PE   1: Evidence at protein level;
KW   Glycoprotein; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..1172
FT                   /note="Pecanex-like protein 4"
FT                   /id="PRO_0000253892"
FT   TRANSMEM        45..65
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        73..93
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        140..160
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        173..193
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        208..228
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        244..264
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        307..327
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        357..377
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        388..405
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        448..468
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        494..514
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        534..552
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        565..585
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        607..629
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        634..654
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1120
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1147
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         770
FT                   /note="Q -> H (in dbSNP:rs3742642)"
FT                   /id="VAR_028745"
FT   VARIANT         811
FT                   /note="D -> Y (in dbSNP:rs12895606)"
FT                   /id="VAR_028746"
FT   VARIANT         1000
FT                   /note="G -> S (in dbSNP:rs167437)"
FT                   /evidence="ECO:0000269|PubMed:17974005"
FT                   /id="VAR_028747"
FT   CONFLICT        535
FT                   /note="I -> F (in Ref. 2; CAH56141)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        554..555
FT                   /note="EK -> QE (in Ref. 2; CAH56141)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1172 AA;  132702 MW;  4F55E9D8A776D618 CRC64;
     MSPDVPLLND YKQDFFLKRF PQTVLGGPRF KLGYCAPPYI YVNQIILFLM PWVWGGVGTL
     LYQLGILKDY YTAALSGGLM LFTAFVIQFT SLYAKNKSTT VERILTTDIL AEEDEHEFTS
     CTGAETVKFL IPGKKYVANT VFHSILAGLA CGLGTWYLLP NRITLLYGST GGTALLFFFG
     WMTLCIAEYS LIVNTATETA TFQTQDTYEI IPLMRPLYIF FFVSVDLAHR FVVNMPALEH
     MNQILHILFV FLPFLWALGT LPPPDALLLW AMEQVLEFGL GGSSMSTHLR LLVMFIMSAG
     TAIASYFIPS TVGVVLFMTG FGFLLSLNLS DMGHKIGTKS KDLPSGPEKH FSWKECLFYI
     IILVLALLET SLLHHFAGFS QISKSNSQAI VGYGLMILLI ILWILREIQS VYIIGIFRNP
     FYPKDVQTVT VFFEKQTRLM KIGIVRRILL TLVSPFAMIA FLSLDSSLQG LHSVSVCIGF
     TRAFRMVWQN TENALLETVI VSTVHLISST DIWWNRSLDT GLRLLLVGII RDRLIQFISK
     LQFAVTVLLT SWTEKKQRRK TTATLCILNI VFSPFVLVII VFSTLLSSPL LPLFTLPVFL
     VGFPRPIQSW PGAAGTTACV CADTVYYYQM VPRLTAVLQT AMAAGSLGLL LPGSHYLGRF
     QDRLMWIMIL ECGYTYCSIN IKGLELQETS CHTAEARRVD EVFEDAFEQE YTRVCSLNEH
     FGNVLTPCTV LPVKLYSDAR NVLSGIIDSH ENLKEFKGDL IKVLVWILVQ YCSKRPGMKE
     NVHNTENKGK APLMLPALNT LPPPKSPEDI DSLNSETFND WSDDNIFDDE PTIKKVIEEK
     HQLKDLPGTN LFIPGSVESQ RVGDHSTGTV PENDLYKAVL LGYPAVDKGK QEDMPYIPLM
     EFSCSHSHLV CLPAEWRTSC MPSSKMKEMS SLFPEDWYQF VLRQLECYHS EEKASNVLEE
     IAKDKVLKDF YVHTVMTCYF SLFGIDNMAP SPGHILRVYG GVLPWSVALD WLTEKPELFQ
     LALKAFRYTL KLMIDKASLG PIEDFRELIK YLEEYERDWY IGLVSDEKWK EAILQEKPYL
     FSLGYDSNMG IYTGRVLSLQ ELLIQVGKLN PEAVRGQWAN LSWELLYATN DDEERYSIQA
     HPLLLRNLTV QAAEPPLGYP IYSSKPLHIH LY
//
ID   ZN148_HUMAN             Reviewed;         794 AA.
AC   Q9UQR1; D3DN27; O00389; O43591; Q58EY5; Q6PJ98;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   23-FEB-2022, entry version 194.
DE   RecName: Full=Zinc finger protein 148;
DE   AltName: Full=Transcription factor ZBP-89;
DE   AltName: Full=Zinc finger DNA-binding protein 89;
GN   Name=ZNF148; Synonyms=ZBP89;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9457682; DOI=10.1007/s003359900711;
RA   Law D.J., Tarle S.A., Merchant J.L.;
RT   "The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin
RT   gene expression.";
RL   Mamm. Genome 9:165-167(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10359087; DOI=10.1016/s0014-5793(99)00509-8;
RA   Ye S., Whatling C., Watkins H., Henney A.;
RT   "Human stromelysin gene promoter activity is modulated by transcription
RT   factor ZBP-89.";
RL   FEBS Lett. 450:268-272(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=B-cell, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-665.
RA   Law D.J., Chen X.N., Korenberg J.R., Mortensen E.R., Merchant J.L.;
RT   "The growth-regulating transcription factor ZBP-89 is located at human
RT   chromosome 3q21 and mouse chromosome 8B1.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   INTERACTION WITH HNRNPDL.
RX   PubMed=15190078; DOI=10.1074/jbc.m403160200;
RA   Boopathi E., Lenka N., Prabu S.K., Fang J.-K., Wilkinson F., Atchison M.,
RA   Giallongo A., Avadhani N.G.;
RT   "Regulation of murine cytochrome c oxidase Vb gene expression during
RT   myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein
RT   (JKTBP1) reciprocally regulate transcription activity by physical
RT   interaction with the BERF-1/ZBP-89 factor.";
RL   J. Biol. Chem. 279:35242-35254(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-194; SER-250; SER-306;
RP   SER-412 AND SER-784, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306 AND SER-784, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-607, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306; SER-665 AND SER-784, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306; SER-412 AND SER-665, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306 AND SER-412, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-356, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-356, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-356, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [20]
RP   INVOLVEMENT IN GDACCF.
RX   PubMed=27964749; DOI=10.1186/s13073-016-0386-9;
RA   Stevens S.J., van Essen A.J., van Ravenswaaij C.M., Elias A.F., Haven J.A.,
RA   Lelieveld S.H., Pfundt R., Nillesen W.M., Yntema H.G., van Roozendaal K.,
RA   Stegmann A.P., Gilissen C., Brunner H.G.;
RT   "Truncating de novo mutations in the Krueppel-type zinc-finger gene ZNF148
RT   in patients with corpus callosum defects, developmental delay, short
RT   stature, and dysmorphisms.";
RL   Genome Med. 8:131-131(2016).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-6; LYS-88; LYS-115; LYS-132;
RP   LYS-291; LYS-308; LYS-356; LYS-402; LYS-421 AND LYS-424, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Involved in transcriptional regulation. Represses the
CC       transcription of a number of genes including gastrin, stromelysin and
CC       enolase. Binds to the G-rich box in the enhancer region of these genes.
CC   -!- SUBUNIT: Interacts with HNRNPDL (PubMed:15190078). Interacts with the
CC       5FMC complex; the interaction requires association with CHTOP.
CC       Interacts with CAVIN1 (By similarity). {ECO:0000250|UniProtKB:Q61624,
CC       ECO:0000269|PubMed:15190078}.
CC   -!- INTERACTION:
CC       Q9UQR1; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-2688184, EBI-739624;
CC       Q9UQR1; Q05D60: DEUP1; NbExp=3; IntAct=EBI-2688184, EBI-748597;
CC       Q9UQR1; B7ZLH0: FAM22F; NbExp=3; IntAct=EBI-2688184, EBI-10220102;
CC       Q9UQR1; O76003: GLRX3; NbExp=3; IntAct=EBI-2688184, EBI-374781;
CC       Q9UQR1; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-2688184, EBI-739467;
CC       Q9UQR1; Q15323: KRT31; NbExp=3; IntAct=EBI-2688184, EBI-948001;
CC       Q9UQR1; Q8IUQ4: SIAH1; NbExp=3; IntAct=EBI-2688184, EBI-747107;
CC       Q9UQR1; Q9UDY6: TRIM10; NbExp=3; IntAct=EBI-2688184, EBI-6427325;
CC       Q9UQR1-2; Q96MT8-3: CEP63; NbExp=3; IntAct=EBI-11742222, EBI-11522539;
CC       Q9UQR1-2; B7ZLH0: FAM22F; NbExp=3; IntAct=EBI-11742222, EBI-10220102;
CC       Q9UQR1-2; Q9H8Y8: GORASP2; NbExp=5; IntAct=EBI-11742222, EBI-739467;
CC       Q9UQR1-2; Q6IE81-3: JADE1; NbExp=3; IntAct=EBI-11742222, EBI-12120084;
CC       Q9UQR1-2; O76011: KRT34; NbExp=3; IntAct=EBI-11742222, EBI-1047093;
CC       Q9UQR1-2; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-11742222, EBI-739832;
CC       Q9UQR1-2; Q99471: PFDN5; NbExp=3; IntAct=EBI-11742222, EBI-357275;
CC       Q9UQR1-2; Q58EX7: PLEKHG4; NbExp=3; IntAct=EBI-11742222, EBI-949255;
CC       Q9UQR1-2; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-11742222, EBI-302345;
CC       Q9UQR1-2; P78424: POU6F2; NbExp=3; IntAct=EBI-11742222, EBI-12029004;
CC       Q9UQR1-2; Q70EL1-9: USP54; NbExp=3; IntAct=EBI-11742222, EBI-11975223;
CC       Q9UQR1-2; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-11742222, EBI-12030590;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UQR1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UQR1-2; Sequence=VSP_055938, VSP_055939;
CC   -!- PTM: Sumoylated with SUMO2. Desumoylated by SENP3, resulting in the
CC       stimulation of transcription of its target genes (By similarity).
CC       {ECO:0000250}.
CC   -!- DISEASE: Global developmental delay, absent or hypoplastic corpus
CC       callosum, and dysmorphic facies (GDACCF) [MIM:617260]: An autosomal
CC       dominant syndrome characterized by underdevelopment of the corpus
CC       callosum, mild to moderate developmental delay and intellectual
CC       disability, variable microcephaly or mild macrocephaly, short stature,
CC       feeding problems, facial dysmorphisms, and cardiac and renal
CC       malformations. {ECO:0000269|PubMed:27964749}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF039019; AAC39926.1; -; mRNA.
DR   EMBL; AJ236885; CAA15422.1; -; mRNA.
DR   EMBL; AC108688; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79394.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79395.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79396.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79398.1; -; Genomic_DNA.
DR   EMBL; BC018971; AAH18971.1; -; mRNA.
DR   EMBL; BC050260; AAH50260.1; -; mRNA.
DR   EMBL; U96633; AAB57692.1; -; Genomic_DNA.
DR   CCDS; CCDS3031.1; -. [Q9UQR1-1]
DR   RefSeq; NP_001335353.1; NM_001348424.1. [Q9UQR1-1]
DR   RefSeq; NP_001335354.1; NM_001348425.1. [Q9UQR1-1]
DR   RefSeq; NP_001335355.1; NM_001348426.1. [Q9UQR1-1]
DR   RefSeq; NP_001335356.1; NM_001348427.1. [Q9UQR1-1]
DR   RefSeq; NP_001335357.1; NM_001348428.1. [Q9UQR1-1]
DR   RefSeq; NP_001335358.1; NM_001348429.1. [Q9UQR1-1]
DR   RefSeq; NP_001335359.1; NM_001348430.1. [Q9UQR1-1]
DR   RefSeq; NP_001335360.1; NM_001348431.1. [Q9UQR1-1]
DR   RefSeq; NP_001335361.1; NM_001348432.1. [Q9UQR1-1]
DR   RefSeq; NP_001335362.1; NM_001348433.1. [Q9UQR1-1]
DR   RefSeq; NP_068799.2; NM_021964.2. [Q9UQR1-1]
DR   SMR; Q9UQR1; -.
DR   BioGRID; 113501; 76.
DR   IntAct; Q9UQR1; 37.
DR   MINT; Q9UQR1; -.
DR   STRING; 9606.ENSP00000353863; -.
DR   GlyGen; Q9UQR1; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; Q9UQR1; -.
DR   PhosphoSitePlus; Q9UQR1; -.
DR   BioMuta; ZNF148; -.
DR   DMDM; 12643385; -.
DR   EPD; Q9UQR1; -.
DR   jPOST; Q9UQR1; -.
DR   MassIVE; Q9UQR1; -.
DR   MaxQB; Q9UQR1; -.
DR   PaxDb; Q9UQR1; -.
DR   PeptideAtlas; Q9UQR1; -.
DR   PRIDE; Q9UQR1; -.
DR   ProteomicsDB; 67196; -.
DR   ProteomicsDB; 85574; -. [Q9UQR1-1]
DR   Antibodypedia; 901; 250 antibodies from 29 providers.
DR   DNASU; 7707; -.
DR   Ensembl; ENST00000360647; ENSP00000353863; ENSG00000163848.
DR   Ensembl; ENST00000484491; ENSP00000420335; ENSG00000163848.
DR   Ensembl; ENST00000485866; ENSP00000420448; ENSG00000163848.
DR   Ensembl; ENST00000492394; ENSP00000419322; ENSG00000163848.
DR   GeneID; 7707; -.
DR   KEGG; hsa:7707; -.
DR   MANE-Select; ENST00000360647.9; ENSP00000353863.4; NM_021964.3; NP_068799.2.
DR   UCSC; uc003ehx.5; human. [Q9UQR1-1]
DR   CTD; 7707; -.
DR   DisGeNET; 7707; -.
DR   GeneCards; ZNF148; -.
DR   HGNC; HGNC:12933; ZNF148.
DR   HPA; ENSG00000163848; Low tissue specificity.
DR   MalaCards; ZNF148; -.
DR   MIM; 601897; gene.
DR   MIM; 617260; phenotype.
DR   neXtProt; NX_Q9UQR1; -.
DR   OpenTargets; ENSG00000163848; -.
DR   PharmGKB; PA37520; -.
DR   VEuPathDB; HostDB:ENSG00000163848; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000157406; -.
DR   HOGENOM; CLU_025987_1_0_1; -.
DR   InParanoid; Q9UQR1; -.
DR   OMA; FDQNFRS; -.
DR   OrthoDB; 1318335at2759; -.
DR   PhylomeDB; Q9UQR1; -.
DR   TreeFam; TF331779; -.
DR   PathwayCommons; Q9UQR1; -.
DR   SignaLink; Q9UQR1; -.
DR   SIGNOR; Q9UQR1; -.
DR   BioGRID-ORCS; 7707; 47 hits in 1087 CRISPR screens.
DR   ChiTaRS; ZNF148; human.
DR   GeneWiki; ZNF148; -.
DR   GenomeRNAi; 7707; -.
DR   Pharos; Q9UQR1; Tbio.
DR   PRO; PR:Q9UQR1; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9UQR1; protein.
DR   Bgee; ENSG00000163848; Expressed in female reproductive system and 266 other tissues.
DR   ExpressionAtlas; Q9UQR1; baseline and differential.
DR   Genevisible; Q9UQR1; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0007276; P:gamete generation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0065003; P:protein-containing complex assembly; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0021762; P:substantia nigra development; HEP:UniProtKB.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; DNA-binding; Dwarfism; Isopeptide bond;
KW   Mental retardation; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..794
FT                   /note="Zinc finger protein 148"
FT                   /id="PRO_0000047427"
FT   ZN_FING         171..193
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         199..221
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         227..249
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         255..278
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          298..336
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          574..596
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        310..336
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         51
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61624"
FT   MOD_RES         194
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         250
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61624"
FT   MOD_RES         306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         412
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         607
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         665
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         784
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231"
FT   CROSSLNK        6
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        88
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        115
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        132
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        291
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        308
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        356
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        356
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        402
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        421
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        424
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..205
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055938"
FT   VAR_SEQ         233..690
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055939"
FT   CONFLICT        287
FT                   /note="R -> T (in Ref. 2; CAA15422)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        348
FT                   /note="L -> V (in Ref. 2; CAA15422)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        379
FT                   /note="E -> K (in Ref. 6; AAB57692)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        495
FT                   /note="A -> R (in Ref. 2; CAA15422)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        616
FT                   /note="T -> N (in Ref. 6; AAB57692)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   794 AA;  88976 MW;  50413723459EBD1F CRC64;
     MNIDDKLEGL FLKCGGIDEM QSSRTMVVMG GVSGQSTVSG ELQDSVLQDR SMPHQEILAA
     DEVLQESEMR QQDMISHDEL MVHEETVKND EEQMETHERL PQGLQYALNV PISVKQEITF
     TDVSEQLMRD KKQIREPVDL QKKKKRKQRS PAKILTINED GSLGLKTPKS HVCEHCNAAF
     RTNYHLQRHV FIHTGEKPFQ CSQCDMRFIQ KYLLQRHEKI HTGEKPFRCD ECGMRFIQKY
     HMERHKRTHS GEKPYQCEYC LQYFSRTDRV LKHKRMCHEN HDKKLNRCAI KGGLLTSEED
     SGFSTSPKDN SLPKKKRQKT EKKSSGMDKE SALDKSDLKK DKNDYLPLYS SSTKVKDEYM
     VAEYAVEMPH SSVGGSHLED ASGEIHPPKL VLKKINSKRS LKQPLEQNQT ISPLSTYEES
     KVSKYAFELV DKQALLDSEG NADIDQVDNL QEGPSKPVHS STNYDDAMQF LKKKRYLQAA
     SNNSREYALN VGTIASQPSV TQAAVASVID ESTTASILES QALNVEIKSN HDKNVIPDEV
     LQTLLDHYSH KANGQHEISF SVADTEVTSS ISINSSEVPE VTPSENVGSS SQASSSDKAN
     MLQEYSKFLQ QALDRTSQND AYLNSPSLNF VTDNQTLPNQ PAFSSIDKQV YATMPINSFR
     SGMNSPLRTT PDKSHFGLIV GDSQHSFPFS GDETNHASAT STQDFLDQVT SQKKAEAQPV
     HQAYQMSSFE QPFRAPYHGS RAGIATQFST ANGQVNLRGP GTSAEFSEFP LVNVNDNRAG
     MTSSPDATTG QTFG
//
ID   TF2H3_HUMAN             Reviewed;         308 AA.
AC   Q13889; B2R819; B4DNZ6; Q7L0G0; Q96AT7;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   23-FEB-2022, entry version 183.
DE   RecName: Full=General transcription factor IIH subunit 3;
DE   AltName: Full=Basic transcription factor 2 34 kDa subunit;
DE            Short=BTF2 p34 {ECO:0000303|PubMed:8194529};
DE   AltName: Full=General transcription factor IIH polypeptide 3;
DE   AltName: Full=TFIIH basal transcription factor complex p34 subunit {ECO:0000303|PubMed:8194529};
GN   Name=GTF2H3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 1).
RG   NIEHS SNPs program;
RL   Submitted (SEP-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Eye, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-305 (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   57-68; 78-97; 107-112; 127-132 AND 239-251 (ISOFORMS 1/2).
RX   PubMed=8194529; DOI=10.1002/j.1460-2075.1994.tb06523.x;
RA   Humbert S., van Vuuren H.A., Lutz Y., Hoeijmakers J.H.J., Egly J.-M.,
RA   Moncollin V.;
RT   "p44 and p34 subunits of the BTF2/TFIIH transcription factor have
RT   homologies with SSL1, a yeast protein involved in DNA repair.";
RL   EMBO J. 13:2393-2398(1994).
RN   [7]
RP   IDENTIFICATION IN THE TFIIH BASAL TRANSCRIPTION FACTOR, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9852112; DOI=10.1074/jbc.273.51.34444;
RA   Kershnar E., Wu S.-Y., Chiang C.-M.;
RT   "Immunoaffinity purification and functional characterization of human
RT   transcription factor IIH and RNA polymerase II from clonal cell lines that
RT   conditionally express epitope-tagged subunits of the multiprotein
RT   complexes.";
RL   J. Biol. Chem. 273:34444-34453(1998).
RN   [8] {ECO:0007744|PDB:5IVW, ECO:0007744|PDB:5IY6, ECO:0007744|PDB:5IY7, ECO:0007744|PDB:5IY8, ECO:0007744|PDB:5IY9}
RP   STRUCTURE BY ELECTRON MICROSCOPY (6.30 ANGSTROMS), SUBUNIT, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=27193682; DOI=10.1038/nature17970;
RA   He Y., Yan C., Fang J., Inouye C., Tjian R., Ivanov I., Nogales E.;
RT   "Near-atomic resolution visualization of human transcription promoter
RT   opening.";
RL   Nature 533:359-365(2016).
CC   -!- FUNCTION: Component of the general transcription and DNA repair factor
CC       IIH (TFIIH) core complex, which is involved in general and
CC       transcription-coupled nucleotide excision repair (NER) of damaged DNA
CC       and, when complexed to CAK, in RNA transcription by RNA polymerase II.
CC       In NER, TFIIH acts by opening DNA around the lesion to allow the
CC       excision of the damaged oligonucleotide and its replacement by a new
CC       DNA fragment. In transcription, TFIIH has an essential role in
CC       transcription initiation. When the pre-initiation complex (PIC) has
CC       been established, TFIIH is required for promoter opening and promoter
CC       escape. Phosphorylation of the C-terminal tail (CTD) of the largest
CC       subunit of RNA polymerase II by the kinase module CAK controls the
CC       initiation of transcription. {ECO:0000269|PubMed:9852112}.
CC   -!- SUBUNIT: Part of a TFIID-containing RNA polymerase II pre-initiation
CC       complex that is composed of TBP and at least GTF2A1, GTF2A2, GTF2E1,
CC       GTF2E2, GTF2F1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2,
CC       ERCC3, TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10,
CC       TAF11, TAF12 and TAF13 (PubMed:27193682). Component of the 7-subunit
CC       TFIIH core complex composed of XPB/ERCC3, XPD/ERCC2, GTF2H1, GTF2H2,
CC       GTF2H3, GTF2H4 and GTF2H5, which is active in NER. The core complex
CC       associates with the 3-subunit CDK-activating kinase (CAK) module
CC       composed of CCNH/cyclin H, CDK7 and MNAT1 to form the 10-subunit
CC       holoenzyme (holo-TFIIH) active in transcription (PubMed:9852112).
CC       Interacts with RARA; the interaction requires prior phosphorylation of
CC       RARA on 'Ser-369' which then enhances interaction of RARA with CDK7 (By
CC       similarity). {ECO:0000250|UniProtKB:Q8VD76,
CC       ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:9852112}.
CC   -!- INTERACTION:
CC       Q13889; Q6P1K8: GTF2H2C_2; NbExp=5; IntAct=EBI-6380459, EBI-8469755;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:27193682,
CC       ECO:0000269|PubMed:9852112}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13889-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13889-2; Sequence=VSP_055153;
CC   -!- SIMILARITY: Belongs to the TFB4 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA82909.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/gtf2h3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK298128; BAG60408.1; -; mRNA.
DR   EMBL; AK313200; BAG36016.1; -; mRNA.
DR   EMBL; AF548661; AAN40702.1; -; Genomic_DNA.
DR   EMBL; AC117503; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW98426.1; -; Genomic_DNA.
DR   EMBL; BC039726; AAH39726.1; -; mRNA.
DR   EMBL; BC047868; AAH47868.2; -; mRNA.
DR   EMBL; BC065250; AAH65250.1; -; mRNA.
DR   EMBL; Z30093; CAA82909.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS61275.1; -. [Q13889-2]
DR   CCDS; CCDS9252.1; -. [Q13889-1]
DR   PIR; S44455; S44455.
DR   RefSeq; NP_001258795.1; NM_001271866.1.
DR   RefSeq; NP_001258796.1; NM_001271867.1. [Q13889-2]
DR   RefSeq; NP_001258797.1; NM_001271868.1.
DR   RefSeq; NP_001507.2; NM_001516.4. [Q13889-1]
DR   PDB; 5IVW; EM; 10.00 A; 3=1-308.
DR   PDB; 5IY6; EM; 7.20 A; 3=1-308.
DR   PDB; 5IY7; EM; 8.60 A; 3=1-308.
DR   PDB; 5IY8; EM; 7.90 A; 3=1-308.
DR   PDB; 5IY9; EM; 6.30 A; 3=1-308.
DR   PDB; 5O85; X-ray; 3.40 A; A/C=1-308.
DR   PDB; 5OF4; EM; 4.40 A; F=1-308.
DR   PDB; 6NMI; EM; 3.70 A; F=1-308.
DR   PDB; 6O9L; EM; 7.20 A; 4=1-308.
DR   PDB; 6O9M; EM; 4.40 A; 4=1-308.
DR   PDB; 6RO4; EM; 3.50 A; E=1-308.
DR   PDB; 7AD8; EM; 3.50 A; E=1-308.
DR   PDB; 7EGB; EM; 3.30 A; 3=1-308.
DR   PDB; 7EGC; EM; 3.90 A; 3=1-308.
DR   PDB; 7ENA; EM; 4.07 A; 3=1-308.
DR   PDB; 7ENC; EM; 4.13 A; 3=1-308.
DR   PDB; 7LBM; EM; 4.80 A; b=1-308.
DR   PDB; 7NVR; EM; 4.50 A; 4=1-308.
DR   PDB; 7NVW; EM; 4.30 A; 4=1-308.
DR   PDB; 7NVX; EM; 3.90 A; 4=1-308.
DR   PDB; 7NVY; EM; 7.30 A; 4=1-308.
DR   PDB; 7NVZ; EM; 7.20 A; 4=1-308.
DR   PDB; 7NW0; EM; 6.60 A; 4=1-308.
DR   PDBsum; 5IVW; -.
DR   PDBsum; 5IY6; -.
DR   PDBsum; 5IY7; -.
DR   PDBsum; 5IY8; -.
DR   PDBsum; 5IY9; -.
DR   PDBsum; 5O85; -.
DR   PDBsum; 5OF4; -.
DR   PDBsum; 6NMI; -.
DR   PDBsum; 6O9L; -.
DR   PDBsum; 6O9M; -.
DR   PDBsum; 6RO4; -.
DR   PDBsum; 7AD8; -.
DR   PDBsum; 7EGB; -.
DR   PDBsum; 7EGC; -.
DR   PDBsum; 7ENA; -.
DR   PDBsum; 7ENC; -.
DR   PDBsum; 7LBM; -.
DR   PDBsum; 7NVR; -.
DR   PDBsum; 7NVW; -.
DR   PDBsum; 7NVX; -.
DR   PDBsum; 7NVY; -.
DR   PDBsum; 7NVZ; -.
DR   PDBsum; 7NW0; -.
DR   SMR; Q13889; -.
DR   BioGRID; 109222; 40.
DR   CORUM; Q13889; -.
DR   DIP; DIP-787N; -.
DR   IntAct; Q13889; 22.
DR   MINT; Q13889; -.
DR   STRING; 9606.ENSP00000445162; -.
DR   iPTMnet; Q13889; -.
DR   PhosphoSitePlus; Q13889; -.
DR   BioMuta; GTF2H3; -.
DR   DMDM; 50403772; -.
DR   EPD; Q13889; -.
DR   jPOST; Q13889; -.
DR   MassIVE; Q13889; -.
DR   MaxQB; Q13889; -.
DR   PaxDb; Q13889; -.
DR   PeptideAtlas; Q13889; -.
DR   PRIDE; Q13889; -.
DR   ProteomicsDB; 59717; -. [Q13889-1]
DR   Antibodypedia; 19294; 123 antibodies from 25 providers.
DR   DNASU; 2967; -.
DR   Ensembl; ENST00000228955; ENSP00000228955; ENSG00000111358. [Q13889-2]
DR   Ensembl; ENST00000543341; ENSP00000445162; ENSG00000111358.
DR   GeneID; 2967; -.
DR   KEGG; hsa:2967; -.
DR   MANE-Select; ENST00000543341.7; ENSP00000445162.1; NM_001516.5; NP_001507.2.
DR   UCSC; uc001ufo.3; human. [Q13889-1]
DR   CTD; 2967; -.
DR   DisGeNET; 2967; -.
DR   GeneCards; GTF2H3; -.
DR   HGNC; HGNC:4657; GTF2H3.
DR   HPA; ENSG00000111358; Low tissue specificity.
DR   MIM; 601750; gene.
DR   neXtProt; NX_Q13889; -.
DR   OpenTargets; ENSG00000111358; -.
DR   PharmGKB; PA29043; -.
DR   VEuPathDB; HostDB:ENSG00000111358; -.
DR   eggNOG; KOG2487; Eukaryota.
DR   GeneTree; ENSGT00390000013143; -.
DR   HOGENOM; CLU_040211_1_0_1; -.
DR   InParanoid; Q13889; -.
DR   OMA; ACFCHRK; -.
DR   OrthoDB; 1220881at2759; -.
DR   PhylomeDB; Q13889; -.
DR   TreeFam; TF314336; -.
DR   PathwayCommons; Q13889; -.
DR   Reactome; R-HSA-112382; Formation of RNA Pol II elongation complex.
DR   Reactome; R-HSA-113418; Formation of the Early Elongation Complex.
DR   Reactome; R-HSA-167152; Formation of HIV elongation complex in the absence of HIV Tat.
DR   Reactome; R-HSA-167158; Formation of the HIV-1 Early Elongation Complex.
DR   Reactome; R-HSA-167160; RNA Pol II CTD phosphorylation and interaction with CE during HIV infection.
DR   Reactome; R-HSA-167161; HIV Transcription Initiation.
DR   Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape.
DR   Reactome; R-HSA-167172; Transcription of the HIV genome.
DR   Reactome; R-HSA-167200; Formation of HIV-1 elongation complex containing HIV-1 Tat.
DR   Reactome; R-HSA-167246; Tat-mediated elongation of the HIV-1 transcript.
DR   Reactome; R-HSA-427413; NoRC negatively regulates rRNA expression.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6781823; Formation of TC-NER Pre-Incision Complex.
DR   Reactome; R-HSA-6781827; Transcription-Coupled Nucleotide Excision Repair (TC-NER).
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-72086; mRNA Capping.
DR   Reactome; R-HSA-73762; RNA Polymerase I Transcription Initiation.
DR   Reactome; R-HSA-73772; RNA Polymerase I Promoter Escape.
DR   Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape.
DR   Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening.
DR   Reactome; R-HSA-73863; RNA Polymerase I Transcription Termination.
DR   Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation.
DR   Reactome; R-HSA-75955; RNA Polymerase II Transcription Elongation.
DR   Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance.
DR   Reactome; R-HSA-77075; RNA Pol II CTD phosphorylation and interaction with CE.
DR   SignaLink; Q13889; -.
DR   BioGRID-ORCS; 2967; 420 hits in 1031 CRISPR screens.
DR   ChiTaRS; GTF2H3; human.
DR   GenomeRNAi; 2967; -.
DR   Pharos; Q13889; Tbio.
DR   PRO; PR:Q13889; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q13889; protein.
DR   Bgee; ENSG00000111358; Expressed in epithelium of mammary gland and 246 other tissues.
DR   ExpressionAtlas; Q13889; baseline and differential.
DR   Genevisible; Q13889; HS.
DR   GO; GO:0000438; C:core TFIIH complex portion of holo TFIIH complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB.
DR   GO; GO:0000439; C:transcription factor TFIIH core complex; IBA:GO_Central.
DR   GO; GO:0005675; C:transcription factor TFIIH holo complex; IDA:UniProtKB.
DR   GO; GO:0097550; C:transcription preinitiation complex; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:ARUK-UCL.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006289; P:nucleotide-excision repair; IBA:GO_Central.
DR   GO; GO:0070816; P:phosphorylation of RNA polymerase II C-terminal domain; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:UniProtKB.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR004600; TFIIH_Tfb4/GTF2H3.
DR   InterPro; IPR036465; vWFA_dom_sf.
DR   PANTHER; PTHR12831; PTHR12831; 1.
DR   Pfam; PF03850; Tfb4; 1.
DR   TIGRFAMs; TIGR00627; tfb4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing; DNA damage;
KW   DNA repair; Metal-binding; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..308
FT                   /note="General transcription factor IIH subunit 3"
FT                   /id="PRO_0000119251"
FT   ZN_FING         268..285
FT                   /note="C4-type"
FT   VAR_SEQ         1..41
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055153"
FT   STRAND          10..15
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           19..27
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           34..51
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   STRAND          56..62
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   STRAND          67..71
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           106..120
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           133..150
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   STRAND          160..165
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           171..173
FT                   /evidence="ECO:0007829|PDB:6RO4"
FT   HELIX           174..186
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   STRAND          190..195
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           201..210
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           220..222
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           223..230
FT                   /evidence="ECO:0007829|PDB:5O85"
FT   HELIX           235..240
FT                   /evidence="ECO:0007829|PDB:6RO4"
FT   STRAND          256..258
FT                   /evidence="ECO:0007829|PDB:6RO4"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:6RO4"
FT   STRAND          266..271
FT                   /evidence="ECO:0007829|PDB:6RO4"
SQ   SEQUENCE   308 AA;  34378 MW;  E739E2176CD6BAA5 CRC64;
     MVSDEDELNL LVIVVDANPI WWGKQALKES QFTLSKCIDA VMVLGNSHLF MNRSNKLAVI
     ASHIQESRFL YPGKNGRLGD FFGDPGNPPE FNPSGSKDGK YELLTSANEV IVEEIKDLMT
     KSDIKGQHTE TLLAGSLAKA LCYIHRMNKE VKDNQEMKSR ILVIKAAEDS ALQYMNFMNV
     IFAAQKQNIL IDACVLDSDS GLLQQACDIT GGLYLKVPQM PSLLQYLLWV FLPDQDQRSQ
     LILPPPVHVD YRAACFCHRN LIEIGYVCSV CLSIFCNFSP ICTTCETAFK ISLPPVLKAK
     KKKLKVSA
//
ID   AVR2A_HUMAN             Reviewed;         513 AA.
AC   P27037; B2RAB8; B4DWQ2; D3DP85; Q53TH4; Q6NWV2; Q92474;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   23-FEB-2022, entry version 217.
DE   RecName: Full=Activin receptor type-2A;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor type IIA;
DE            Short=ACTR-IIA;
DE            Short=ACTRIIA;
DE   Flags: Precursor;
GN   Name=ACVR2A; Synonyms=ACVR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=1311955; DOI=10.1016/0167-4781(92)90472-c;
RA   Matzuk M.M., Bradley A.;
RT   "Cloning of the human activin receptor cDNA reveals high evolutionary
RT   conservation.";
RL   Biochim. Biophys. Acta 1130:105-108(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Testis;
RX   PubMed=1314589; DOI=10.1016/0006-291x(92)91194-u;
RA   Donaldson C.J., Mathews L.S., Vale W.W.;
RT   "Molecular cloning and binding properties of the human type II activin
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 184:310-316(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RA   Geiser A.G.;
RL   Submitted (DEC-1991) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Iimura T., Oida S.;
RL   Submitted (NOV-1994) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH BMP7.
RX   PubMed=12667445; DOI=10.1016/s1097-2765(03)00094-7;
RA   Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W.,
RA   Choe S.;
RT   "The BMP7/ActRII extracellular domain complex provides new insights into
RT   the cooperative nature of receptor assembly.";
RL   Mol. Cell 11:605-617(2003).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH ACVR1.
RX   PubMed=17911401; DOI=10.1677/joe-07-0281;
RA   Renlund N., O'Neill F.H., Zhang L., Sidis Y., Teixeira J.;
RT   "Activin receptor-like kinase-2 inhibits activin signaling by blocking the
RT   binding of activin to its type II receptor.";
RL   J. Endocrinol. 195:95-103(2007).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 191-488 IN COMPLEX WITH
RP   DORSOMORPHIN.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of activin receptor type-IIa (ACVR2A) kinase domain in
RT   complex with dorsomorphin.";
RL   Submitted (FEB-2011) to the PDB data bank.
RN   [12]
RP   VARIANTS ARG-258 AND ASN-306.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [13]
RP   VARIANT THR-367.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H.,
RA   Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J.,
RA   Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M.,
RA   Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L.,
RA   Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J.,
RA   Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A.,
RA   Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K.,
RA   Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene
RT   PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two
CC       type II and two type I transmembrane serine/threonine kinases. Type II
CC       receptors phosphorylate and activate type I receptors which
CC       autophosphorylate, then bind and activate SMAD transcriptional
CC       regulators. Receptor for activin A, activin B and inhibin A
CC       (PubMed:17911401). Mediates induction of adipogenesis by GDF6 (By
CC       similarity). {ECO:0000250|UniProtKB:P27038, ECO:0000269|PubMed:1314589,
CC       ECO:0000269|PubMed:17911401}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with AIP1. Part of a complex consisting of AIP1,
CC       ACVR2A, ACVR1B and SMAD3 (By similarity). Interacts with type I
CC       receptor ACVR1 (PubMed:17911401). Interacts with BMP7
CC       (PubMed:12667445). {ECO:0000250|UniProtKB:P27038,
CC       ECO:0000269|PubMed:12667445, ECO:0000269|PubMed:17911401}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P27037-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P27037-2; Sequence=VSP_054689;
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ACVR2ID567ch2q22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X63128; CAA44839.1; -; mRNA.
DR   EMBL; M93415; AAA35504.1; -; mRNA.
DR   EMBL; X62381; CAA44245.1; -; mRNA.
DR   EMBL; D31770; BAA06548.1; -; mRNA.
DR   EMBL; AK301629; BAG63114.1; -; mRNA.
DR   EMBL; AK314124; BAG36815.1; -; mRNA.
DR   EMBL; AC009480; AAX93050.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11561.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11562.1; -; Genomic_DNA.
DR   EMBL; BC067418; AAH67418.1; -; mRNA.
DR   EMBL; BC067417; AAH67417.1; -; mRNA.
DR   EMBL; BC069707; AAH69707.1; -; mRNA.
DR   CCDS; CCDS33301.1; -. [P27037-1]
DR   CCDS; CCDS63030.1; -. [P27037-2]
DR   PIR; JQ1486; JQ1486.
DR   RefSeq; NP_001265508.1; NM_001278579.1. [P27037-1]
DR   RefSeq; NP_001265509.1; NM_001278580.1. [P27037-2]
DR   RefSeq; NP_001607.1; NM_001616.4. [P27037-1]
DR   PDB; 3Q4T; X-ray; 1.96 A; A/B=191-488.
DR   PDB; 3SOC; X-ray; 1.95 A; A/B=191-488.
DR   PDB; 4ASX; X-ray; 2.05 A; A/B=191-488.
DR   PDB; 5NH3; X-ray; 2.35 A; A/B=20-135.
DR   PDBsum; 3Q4T; -.
DR   PDBsum; 3SOC; -.
DR   PDBsum; 4ASX; -.
DR   PDBsum; 5NH3; -.
DR   SMR; P27037; -.
DR   BioGRID; 106607; 86.
DR   DIP; DIP-520N; -.
DR   IntAct; P27037; 17.
DR   MINT; P27037; -.
DR   STRING; 9606.ENSP00000241416; -.
DR   BindingDB; P27037; -.
DR   ChEMBL; CHEMBL5616; -.
DR   DrugBank; DB12118; Sotatercept.
DR   DrugCentral; P27037; -.
DR   GuidetoPHARMACOLOGY; 1791; -.
DR   GlyGen; P27037; 2 sites.
DR   iPTMnet; P27037; -.
DR   PhosphoSitePlus; P27037; -.
DR   BioMuta; ACVR2A; -.
DR   DMDM; 114722; -.
DR   EPD; P27037; -.
DR   jPOST; P27037; -.
DR   MassIVE; P27037; -.
DR   MaxQB; P27037; -.
DR   PaxDb; P27037; -.
DR   PeptideAtlas; P27037; -.
DR   PRIDE; P27037; -.
DR   ProteomicsDB; 5369; -.
DR   ProteomicsDB; 54373; -. [P27037-1]
DR   ABCD; P27037; 1 sequenced antibody.
DR   Antibodypedia; 18817; 490 antibodies from 37 providers.
DR   DNASU; 92; -.
DR   Ensembl; ENST00000241416; ENSP00000241416; ENSG00000121989.
DR   Ensembl; ENST00000404590; ENSP00000384338; ENSG00000121989.
DR   Ensembl; ENST00000535787; ENSP00000439988; ENSG00000121989. [P27037-2]
DR   GeneID; 92; -.
DR   KEGG; hsa:92; -.
DR   MANE-Select; ENST00000241416.12; ENSP00000241416.7; NM_001616.5; NP_001607.1.
DR   UCSC; uc002twg.5; human. [P27037-1]
DR   CTD; 92; -.
DR   DisGeNET; 92; -.
DR   GeneCards; ACVR2A; -.
DR   HGNC; HGNC:173; ACVR2A.
DR   HPA; ENSG00000121989; Low tissue specificity.
DR   MalaCards; ACVR2A; -.
DR   MIM; 102581; gene.
DR   neXtProt; NX_P27037; -.
DR   OpenTargets; ENSG00000121989; -.
DR   PharmGKB; PA24494; -.
DR   VEuPathDB; HostDB:ENSG00000121989; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   GeneTree; ENSGT00940000157233; -.
DR   HOGENOM; CLU_000288_8_4_1; -.
DR   InParanoid; P27037; -.
DR   OMA; SRCTVQD; -.
DR   OrthoDB; 390511at2759; -.
DR   PhylomeDB; P27037; -.
DR   TreeFam; TF352876; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P27037; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1433617; Regulation of signaling by NODAL.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; P27037; -.
DR   SIGNOR; P27037; -.
DR   BioGRID-ORCS; 92; 36 hits in 1065 CRISPR screens.
DR   ChiTaRS; ACVR2A; human.
DR   EvolutionaryTrace; P27037; -.
DR   GeneWiki; ACVR2A; -.
DR   GenomeRNAi; 92; -.
DR   Pharos; P27037; Tchem.
DR   PRO; PR:P27037; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P27037; protein.
DR   Bgee; ENSG00000121989; Expressed in amniotic fluid and 241 other tissues.
DR   Genevisible; P27037; HS.
DR   GO; GO:0048179; C:activin receptor complex; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL.
DR   GO; GO:0034673; C:inhibin-betaglycan-ActRII complex; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; IPI:BHF-UCL.
DR   GO; GO:0048185; F:activin binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0015026; F:coreceptor activity; IDA:BHF-UCL.
DR   GO; GO:0019838; F:growth factor binding; IEA:Ensembl.
DR   GO; GO:0034711; F:inhibin binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IEA:Ensembl.
DR   GO; GO:0043621; F:protein self-association; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl.
DR   GO; GO:0048706; P:embryonic skeletal system development; IEA:Ensembl.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl.
DR   GO; GO:0007498; P:mesoderm development; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0043084; P:penile erection; IEA:Ensembl.
DR   GO; GO:0032927; P:positive regulation of activin receptor signaling pathway; IDA:HGNC-UCL.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:HGNC-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl.
DR   GO; GO:0042713; P:sperm ejaculation; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; TAS:ProtInc.
DR   Gene3D; 2.10.60.10; -; 1.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Disulfide bond;
KW   Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..513
FT                   /note="Activin receptor type-2A"
FT                   /id="PRO_0000024398"
FT   TOPO_DOM        20..135
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        136..161
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        162..513
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          192..485
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         198..206
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        322
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         219
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        66
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        30..60
FT                   /evidence="ECO:0000250|UniProtKB:P27038"
FT   DISULFID        50..78
FT                   /evidence="ECO:0000250|UniProtKB:P27038"
FT   DISULFID        85..104
FT                   /evidence="ECO:0000250|UniProtKB:P27038"
FT   DISULFID        91..103
FT                   /evidence="ECO:0000250|UniProtKB:P27038"
FT   DISULFID        105..110
FT                   /evidence="ECO:0000250|UniProtKB:P27038"
FT   VAR_SEQ         1..108
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054689"
FT   VARIANT         258
FT                   /note="S -> R (in dbSNP:rs34917571)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032809"
FT   VARIANT         306
FT                   /note="D -> N (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs764255410)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032810"
FT   VARIANT         367
FT                   /note="A -> T (found in a clear cell renal carcinoma case;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:21248752"
FT                   /id="VAR_064692"
FT   CONFLICT        13
FT                   /note="L -> V (in Ref. 4; BAA06548)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        204..206
FT                   /note="GCV -> PSL (in Ref. 4; BAA06548)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        348
FT                   /note="E -> V (in Ref. 4; BAA06548)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        507
FT                   /note="P -> L (in Ref. 8; AAH67417)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..34
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   HELIX           37..40
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          44..49
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          58..67
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          70..80
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          95..97
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          99..105
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   HELIX           110..112
FT                   /evidence="ECO:0007829|PDB:5NH3"
FT   STRAND          191..199
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          205..211
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          214..221
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           226..236
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          249..256
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          258..268
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           275..281
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           286..303
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          307..310
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          313..315
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          317..319
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          327..330
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          336..338
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          345..347
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           363..365
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           368..371
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           379..398
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   STRAND          404..406
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           416..419
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           425..432
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           443..446
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           449..461
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           466..468
FT                   /evidence="ECO:0007829|PDB:3SOC"
FT   HELIX           472..485
FT                   /evidence="ECO:0007829|PDB:3SOC"
SQ   SEQUENCE   513 AA;  57848 MW;  A89822E880979618 CRC64;
     MGAAAKLAFA VFLISCSSGA ILGRSETQEC LFFNANWEKD RTNQTGVEPC YGDKDKRRHC
     FATWKNISGS IEIVKQGCWL DDINCYDRTD CVEKKDSPEV YFCCCEGNMC NEKFSYFPEM
     EVTQPTSNPV TPKPPYYNIL LYSLVPLMLI AGIVICAFWV YRHHKMAYPP VLVPTQDPGP
     PPPSPLLGLK PLQLLEVKAR GRFGCVWKAQ LLNEYVAVKI FPIQDKQSWQ NEYEVYSLPG
     MKHENILQFI GAEKRGTSVD VDLWLITAFH EKGSLSDFLK ANVVSWNELC HIAETMARGL
     AYLHEDIPGL KDGHKPAISH RDIKSKNVLL KNNLTACIAD FGLALKFEAG KSAGDTHGQV
     GTRRYMAPEV LEGAINFQRD AFLRIDMYAM GLVLWELASR CTAADGPVDE YMLPFEEEIG
     QHPSLEDMQE VVVHKKKRPV LRDYWQKHAG MAMLCETIEE CWDHDAEARL SAGCVGERIT
     QMQRLTNIIT TEDIVTVVTM VTNVDFPPKE SSL
//
ID   AT2B1_HUMAN             Reviewed;        1220 AA.
AC   P20020; Q12992; Q12993; Q13819; Q13820; Q13821; Q16504; Q93082;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 4.
DT   23-FEB-2022, entry version 229.
DE   RecName: Full=Plasma membrane calcium-transporting ATPase 1 {ECO:0000305};
DE            EC=7.2.2.10 {ECO:0000305|PubMed:30190470};
DE   AltName: Full=Plasma membrane calcium ATPase isoform 1 {ECO:0000303|PubMed:8396145};
DE            Short=PMCA1 {ECO:0000303|PubMed:8396145};
DE   AltName: Full=Plasma membrane calcium pump isoform 1;
GN   Name=ATP2B1 {ECO:0000312|HGNC:HGNC:814};
GN   Synonyms=PMCA1 {ECO:0000303|PubMed:8396145};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Erythrocyte;
RX   PubMed=2844759;
RA   Verma A.K., Filoteo A.G., Stanford D.R., Wieben E.D., Penniston J.T.,
RA   Strehler E.E., Fischer R., Heim R., Vogel G., Mathews S.,
RA   Strehler-Page M.-A., James P., Vorherr T.E., Krebs J., Carafoli E.;
RT   "Complete primary structure of a human plasma membrane Ca2+ pump.";
RL   J. Biol. Chem. 263:14152-14159(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Osteoblast;
RX   PubMed=8386431; DOI=10.1002/jbmr.5650080415;
RA   Kumar R., Haugen J.D., Penniston J.T.;
RT   "Molecular cloning of a plasma membrane calcium pump from human
RT   osteoblasts.";
RL   J. Bone Miner. Res. 8:505-513(1993).
RN   [3]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS A AND B).
RC   TISSUE=Leukocyte;
RX   PubMed=8396145;
RA   Hilfiker H., Strehler-Page M.-A., Stauffer T.P., Carafoli E.,
RA   Strehler E.E.;
RT   "Structure of the gene encoding the human plasma membrane calcium pump
RT   isoform 1.";
RL   J. Biol. Chem. 268:19717-19725(1993).
RN   [4]
RP   SEQUENCE REVISION.
RA   Strehler E.E., Strehler-Page M.-A.;
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS A; C AND D).
RC   TISSUE=Fetal skeletal muscle;
RX   PubMed=2528729; DOI=10.1073/pnas.86.18.6908;
RA   Strehler E.E., Strehler-Page M.-A., Vogel G., Carafoli E.;
RT   "mRNAs for plasma membrane calcium pump isoforms differing in their
RT   regulatory domain are generated by alternative splicing that involves two
RT   internal donor sites in a single exon.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:6908-6912(1989).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), REGION, ALTERNATIVE
RP   SPLICING, AND SUBUNIT.
RC   TISSUE=Fetal brain;
RX   PubMed=1332771; DOI=10.1021/bi00162a016;
RA   Kessler F., Falchetto R., Heim R., Meili R., Vorherr T.E., Strehler E.E.,
RA   Carafoli E.;
RT   "Study of calmodulin binding to the alternatively spliced C-terminal domain
RT   of the plasma membrane Ca2+ pump.";
RL   Biochemistry 31:11785-11792(1992).
RN   [7]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND E).
RC   TISSUE=Brain cortex;
RX   PubMed=8245032;
RA   Stauffer T.P., Hilfiker H., Carafoli E., Strehler E.E.;
RT   "Quantitative analysis of alternative splicing options of human plasma
RT   membrane calcium pump genes.";
RL   J. Biol. Chem. 268:25993-26003(1993).
RN   [8]
RP   ERRATUM OF PUBMED:8245032.
RX   PubMed=7989379;
RA   Stauffer T.P., Hilfiker H., Carafoli E., Strehler E.E.;
RL   J. Biol. Chem. 269:32022-32022(1994).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM K).
RC   TISSUE=Small intestine mucosa;
RX   PubMed=7694502; DOI=10.1152/ajpgi.1993.265.5.g917;
RA   Howard A., Legon S., Walters J.R.;
RT   "Human and rat intestinal plasma membrane calcium pump isoforms.";
RL   Am. J. Physiol. 265:G917-G925(1993).
RN   [10]
RP   PHOSPHORYLATION BY CAMP KINASE.
RX   PubMed=2548572; DOI=10.1021/bi00436a020;
RA   James P.H., Pruschy M., Vorherr T.E., Penniston J.T., Carafoli E.;
RT   "Primary structure of the cAMP-dependent phosphorylation site of the plasma
RT   membrane calcium pump.";
RL   Biochemistry 28:4253-4258(1989).
RN   [11]
RP   PHOSPHORYLATION AT THR-1116 BY PROTEIN KINASE C.
RX   PubMed=1827443;
RA   Wang K.K.W., Wright L.C., Machan C.L., Allen B.G., Conigrave A.D.,
RA   Roufogalis B.D.;
RT   "Protein kinase C phosphorylates the carboxyl terminus of the plasma
RT   membrane Ca(2+)-ATPase from human erythrocytes.";
RL   J. Biol. Chem. 266:9078-9085(1991).
RN   [12]
RP   INTERACTION WITH PDZD11.
RX   PubMed=12763866; DOI=10.1111/j.1749-6632.2003.tb07230.x;
RA   Goellner G.M., DeMarco S.J., Strehler E.E.;
RT   "Characterization of PISP, a novel single-PDZ protein that binds to all
RT   plasma membrane Ca2+-ATPase b-splice variants.";
RL   Ann. N. Y. Acad. Sci. 986:461-471(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1155 AND SER-1182, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   INTERACTION WITH YWHAE, AND SUBCELLULAR LOCATION.
RX   PubMed=18029012; DOI=10.1016/j.ceca.2007.09.003;
RA   Linde C.I., Di Leva F., Domi T., Tosatto S.C., Brini M., Carafoli E.;
RT   "Inhibitory interaction of the 14-3-3 proteins with ubiquitous (PMCA1) and
RT   tissue-specific (PMCA3) isoforms of the plasma membrane Ca2+ pump.";
RL   Cell Calcium 43:550-561(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17; SER-1155; THR-1165;
RP   SER-1178 AND SER-1182, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT GLY-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-1155 AND THR-1165, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=21400627; DOI=10.1002/mrd.21303;
RA   Yang H., Choi K.C., Hyun S.H., Jeung E.B.;
RT   "Coexpression and estrogen-mediated regulation of TRPV6 and PMCA1 in the
RT   human endometrium during the menstrual cycle.";
RL   Mol. Reprod. Dev. 78:274-282(2011).
RN   [19]
RP   INTERACTION WITH SLC35G1 AND STIM1.
RX   PubMed=22084111; DOI=10.1073/pnas.1117231108;
RA   Krapivinsky G., Krapivinsky L., Stotz S.C., Manasian Y., Clapham D.E.;
RT   "POST, partner of stromal interaction molecule 1 (STIM1), targets STIM1 to
RT   multiple transporters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:19234-19239(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1155; SER-1178 AND SER-1182,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8; SER-17; SER-1155 AND
RP   THR-1165, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1155, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   FUNCTION.
RX   PubMed=29104511; DOI=10.7150/ijbs.19666;
RA   Long Y., Xia J.Y., Chen S.W., Gao C.L., Liang G.N., He X.M., Wu J.,
RA   Jiang C.X., Liu X., Huang W., Wan Q., Xu Y.;
RT   "ATP2B1 gene Silencing Increases Insulin Sensitivity through Facilitating
RT   Akt Activation via the Ca2+/calmodulin Signaling Pathway and Ca2+-
RT   associated eNOS Activation in Endothelial Cells.";
RL   Int. J. Biol. Sci. 13:1203-1212(2017).
RN   [24] {ECO:0007744|PDB:6A69}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.11 ANGSTROMS) IN COMPLEX WITH NPTN,
RP   BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, AND TOPOLOGY.
RX   PubMed=30190470; DOI=10.1038/s41467-018-06075-7;
RA   Gong D., Chi X., Ren K., Huang G., Zhou G., Yan N., Lei J., Zhou Q.;
RT   "Structure of the human plasma membrane Ca2+-ATPase 1 in complex with its
RT   obligatory subunit neuroplastin.";
RL   Nat. Commun. 9:3623-3623(2018).
RN   [25]
RP   VARIANT ARG-267.
RX   PubMed=9020386; DOI=10.1007/s001090050088;
RA   Benkwitz C., Kubsisch C., Kraft K., Neyses L.;
RT   "Investigation of the Met-267 Arg exchange in isoform 1 of the human plasma
RT   membrane calcium pump in patients with essential hypertension by the
RT   amplification-created restriction site technique.";
RL   J. Mol. Med. 75:62-66(1997).
CC   -!- FUNCTION: Catalyzes the hydrolysis of ATP coupled with the transport of
CC       calcium from the cytoplasm to the extracellular space thereby
CC       maintaining intracellular calcium homeostasis. Plays a role in blood
CC       pressure regulation through regulation of intracellular calcium
CC       concentration and nitric oxide production leading to regulation of
CC       vascular smooth muscle cells vasoconstriction. Positively regulates
CC       bone mineralization through absorption of calcium from the intestine.
CC       Plays dual roles in osteoclast differentiation and survival by
CC       regulating RANKL-induced calcium oscillations in preosteoclasts and
CC       mediating calcium extrusion in mature osteoclasts (By similarity).
CC       Regulates insulin sensitivity through calcium/calmodulin signaling
CC       pathway by regulating AKT1 activation and NOS3 activation in
CC       endothelial cells (PubMed:29104511). May play a role in synaptic
CC       transmission by modulating calcium and proton dynamics at the synaptic
CC       vesicles. {ECO:0000250|UniProtKB:G5E829, ECO:0000269|PubMed:29104511}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + Ca(2+)(in) + H2O = ADP + Ca(2+)(out) + H(+) + phosphate;
CC         Xref=Rhea:RHEA:18105, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29108, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:456216; EC=7.2.2.10;
CC         Evidence={ECO:0000305|PubMed:30190470};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18106;
CC         Evidence={ECO:0000305|PubMed:30190470};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=519.5 uM for ATP (in complex with NPTN)
CC         {ECO:0000269|PubMed:30190470};
CC         Vmax=325.5 nmol/min/mg enzyme {ECO:0000269|PubMed:30190470};
CC   -!- SUBUNIT: Monomer (PubMed:1332771). Dimer (PubMed:1332771). Oligomer
CC       (PubMed:1332771). Calmodulin binding (PubMed:1332771). Interacts with
CC       PDZD11 (PubMed:12763866). Interacts with SLC35G1 and STIM1; inhibits
CC       calcium-transporting ATPase activity after store depletion
CC       (PubMed:22084111). Interacts with YWHAE; interacts with the monomeric
CC       and dimeric forms of the YWHAE but prefer the monomer form; this
CC       interaction inhibits calcium-transporting ATPase activity
CC       (PubMed:18029012). Interacts with NPTN; this interaction stabilizes
CC       ATP2B1 and increases ATPase activity; this interaction controls T cell
CC       calcium homeostasis following T cell activation (PubMed:30190470).
CC       Interacts with EPB41; regulates small intestinal calcium absorption
CC       through regulation of membrane expression of ATP2B1 (By similarity).
CC       {ECO:0000250|UniProtKB:G5E829, ECO:0000269|PubMed:12763866,
CC       ECO:0000269|PubMed:1332771, ECO:0000269|PubMed:18029012,
CC       ECO:0000269|PubMed:22084111, ECO:0000269|PubMed:30190470}.
CC   -!- INTERACTION:
CC       P20020; Q14160: SCRIB; NbExp=2; IntAct=EBI-5279998, EBI-357345;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18029012};
CC       Multi-pass membrane protein {ECO:0000255}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:G5E829}. Cell junction, synapse
CC       {ECO:0000250|UniProtKB:G5E829}. Cell junction, synapse, presynaptic
CC       cell membrane {ECO:0000250|UniProtKB:G5E829}; Multi-pass membrane
CC       protein {ECO:0000255}. Cytoplasmic vesicle, secretory vesicle, synaptic
CC       vesicle membrane {ECO:0000250|UniProtKB:G5E829}; Multi-pass membrane
CC       protein {ECO:0000255}. Note=Colocalizes with SV2A in photoreceptor
CC       synaptic terminals. Colocalizes with NPTN to the immunological synapse.
CC       Colocalizes with EPB41 to the basolateral membrane in enterocyte.
CC       Preferentially sorted to recycling synaptic vesicles.
CC       {ECO:0000250|UniProtKB:G5E829}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=B; Synonyms=CI, hPMCA1b {ECO:0000303|PubMed:1332771};
CC         IsoId=P20020-3; Sequence=Displayed;
CC       Name=D; Synonyms=CIV, hPMCA1d {ECO:0000303|PubMed:1332771};
CC         IsoId=P20020-1; Sequence=VSP_059773;
CC       Name=A; Synonyms=CII, hPMCA1a {ECO:0000303|PubMed:1332771};
CC         IsoId=P20020-2; Sequence=VSP_059774, VSP_059775;
CC       Name=C; Synonyms=CIII, hPMCA1c {ECO:0000303|PubMed:1332771};
CC         IsoId=P20020-4; Sequence=VSP_059772;
CC       Name=E; Synonyms=CV;
CC         IsoId=P20020-5; Sequence=VSP_059774, VSP_059776;
CC       Name=K;
CC         IsoId=P20020-6; Sequence=VSP_059771;
CC   -!- TISSUE SPECIFICITY: Isoform B: Ubiquitously expressed. Isoform C: Found
CC       in brain cortex, skeletal muscle and heart muscle. Isoform D: Has only
CC       been found in fetal skeletal muscle. Isoform K: Found in small
CC       intestine and liver. Abundantly expressed in the endometrial epithelial
CC       cells and glandular epithelial cells in early-proliferative phase and
CC       early-secretory phases (PubMed:21400627).
CC       {ECO:0000269|PubMed:21400627}.
CC   -!- INDUCTION: Up-regulated at the proliferative phase of the mentrual
CC       cycle. Up-regulated by estrogen. {ECO:0000269|PubMed:21400627}.
CC   -!- DOMAIN: Isoforms A, C, D and E contain an additional calmodulin-binding
CC       subdomain B which is different in the different splice variants and
CC       shows pH dependent calmodulin binding properties.
CC       {ECO:0000269|PubMed:1332771}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC 3.A.3)
CC       family. Type IIB subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04027; AAA74511.1; -; mRNA.
DR   EMBL; M95541; AAA35999.1; -; mRNA.
DR   EMBL; M95542; AAA36000.1; -; mRNA.
DR   EMBL; L14561; AAD09924.1; -; Genomic_DNA.
DR   EMBL; L14561; AAD09925.1; -; Genomic_DNA.
DR   EMBL; M25824; AAA58383.1; -; Genomic_DNA.
DR   EMBL; M25824; AAA58382.1; -; Genomic_DNA.
DR   EMBL; M25824; AAA58381.1; -; Genomic_DNA.
DR   EMBL; S49852; AAB24324.1; -; mRNA.
DR   EMBL; U15686; AAA60983.1; -; mRNA.
DR   EMBL; U15687; AAA60984.1; -; mRNA.
DR   CCDS; CCDS41817.1; -. [P20020-2]
DR   CCDS; CCDS9035.1; -. [P20020-3]
DR   PIR; A30802; A30802.
DR   PIR; E49570; E49570.
DR   PIR; I55491; I55491.
DR   PIR; I70165; I70165.
DR   RefSeq; NP_001001323.1; NM_001001323.1. [P20020-2]
DR   RefSeq; NP_001673.2; NM_001682.2. [P20020-3]
DR   RefSeq; XP_011536709.1; XM_011538407.2.
DR   RefSeq; XP_016874847.1; XM_017019358.1.
DR   PDB; 6A69; EM; 4.11 A; A=1-1220.
DR   PDBsum; 6A69; -.
DR   SMR; P20020; -.
DR   BioGRID; 106980; 190.
DR   IntAct; P20020; 59.
DR   MINT; P20020; -.
DR   STRING; 9606.ENSP00000392043; -.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB01159; Halothane.
DR   TCDB; 3.A.3.2.25; the p-type atpase (p-atpase) superfamily.
DR   iPTMnet; P20020; -.
DR   PhosphoSitePlus; P20020; -.
DR   SwissPalm; P20020; -.
DR   BioMuta; ATP2B1; -.
DR   DMDM; 14286104; -.
DR   EPD; P20020; -.
DR   jPOST; P20020; -.
DR   MassIVE; P20020; -.
DR   MaxQB; P20020; -.
DR   PaxDb; P20020; -.
DR   PeptideAtlas; P20020; -.
DR   PRIDE; P20020; -.
DR   ProteomicsDB; 53706; -. [P20020-1]
DR   ProteomicsDB; 53707; -. [P20020-2]
DR   ProteomicsDB; 53708; -. [P20020-3]
DR   ProteomicsDB; 53709; -. [P20020-4]
DR   ProteomicsDB; 53710; -. [P20020-5]
DR   ProteomicsDB; 53711; -. [P20020-6]
DR   Antibodypedia; 2168; 135 antibodies from 29 providers.
DR   DNASU; 490; -.
DR   Ensembl; ENST00000261173; ENSP00000261173; ENSG00000070961.
DR   Ensembl; ENST00000359142; ENSP00000352054; ENSG00000070961. [P20020-2]
DR   Ensembl; ENST00000428670; ENSP00000392043; ENSG00000070961.
DR   GeneID; 490; -.
DR   KEGG; hsa:490; -.
DR   MANE-Select; ENST00000428670.8; ENSP00000392043.3; NM_001366521.1; NP_001353450.1.
DR   UCSC; uc001tbg.4; human. [P20020-3]
DR   CTD; 490; -.
DR   DisGeNET; 490; -.
DR   GeneCards; ATP2B1; -.
DR   HGNC; HGNC:814; ATP2B1.
DR   HPA; ENSG00000070961; Tissue enhanced (bone).
DR   MIM; 108731; gene.
DR   neXtProt; NX_P20020; -.
DR   OpenTargets; ENSG00000070961; -.
DR   PharmGKB; PA25107; -.
DR   VEuPathDB; HostDB:ENSG00000070961; -.
DR   eggNOG; KOG0204; Eukaryota.
DR   GeneTree; ENSGT00940000158686; -.
DR   InParanoid; P20020; -.
DR   OMA; IIPRLHV; -.
DR   OrthoDB; 115892at2759; -.
DR   PhylomeDB; P20020; -.
DR   TreeFam; TF300330; -.
DR   BRENDA; 7.2.2.10; 2681.
DR   PathwayCommons; P20020; -.
DR   Reactome; R-HSA-418359; Reduction of cytosolic Ca++ levels.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   SignaLink; P20020; -.
DR   SIGNOR; P20020; -.
DR   BioGRID-ORCS; 490; 82 hits in 1050 CRISPR screens.
DR   ChiTaRS; ATP2B1; human.
DR   GeneWiki; ATP2B1; -.
DR   GenomeRNAi; 490; -.
DR   Pharos; P20020; Tbio.
DR   PRO; PR:P20020; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P20020; protein.
DR   Bgee; ENSG00000070961; Expressed in putamen and 246 other tissues.
DR   ExpressionAtlas; P20020; baseline and differential.
DR   Genevisible; P20020; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0032591; C:dendritic spine membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0098982; C:GABA-ergic synapse; IDA:SynGO.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0001772; C:immunological synapse; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099059; C:integral component of presynaptic active zone membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0030285; C:integral component of synaptic vesicle membrane; ISS:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0032809; C:neuronal cell body membrane; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:SynGO-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0019829; F:ATPase-coupled cation transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015085; F:calcium ion transmembrane transporter activity; IDA:SynGO-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:P-type calcium transporter activity; IBA:GO_Central.
DR   GO; GO:1905056; F:P-type calcium transporter activity involved in regulation of presynaptic cytosolic calcium ion concentration; IDA:SynGO.
DR   GO; GO:0030165; F:PDZ domain binding; IBA:GO_Central.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:1990034; P:calcium ion export across plasma membrane; IDA:SynGO-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IBA:GO_Central.
DR   GO; GO:0071386; P:cellular response to corticosterone stimulus; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0001818; P:negative regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0003407; P:neural retina development; IEA:Ensembl.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; ISS:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; ISS:UniProtKB.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:1900076; P:regulation of cellular response to insulin stimulus; IMP:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; IDA:SynGO-UCL.
DR   GO; GO:0003056; P:regulation of vascular associated smooth muscle contraction; ISS:UniProtKB.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   Gene3D; 3.40.1110.10; -; 1.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR030320; ATP2B1.
DR   InterPro; IPR022141; ATP_Ca_trans_C.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR006408; P-type_ATPase_IIB.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   InterPro; IPR044492; P_typ_ATPase_HD_dom.
DR   PANTHER; PTHR24093:SF245; PTHR24093:SF245; 1.
DR   Pfam; PF12424; ATP_Ca_trans_C; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   SFLD; SFLDF00027; p-type_atpase; 1.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   SUPFAM; SSF81653; SSF81653; 1.
DR   SUPFAM; SSF81660; SSF81660; 1.
DR   SUPFAM; SSF81665; SSF81665; 1.
DR   TIGRFAMs; TIGR01517; ATPase-IIB_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 3.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Calmodulin-binding; Cell junction; Cell membrane;
KW   Cell projection; Cytoplasmic vesicle; Ion transport; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Synapse; Translocase; Transmembrane; Transmembrane helix; Transport.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   CHAIN           2..1220
FT                   /note="Plasma membrane calcium-transporting ATPase 1"
FT                   /id="PRO_0000046209"
FT   TOPO_DOM        2..105
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        106..126
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        127..154
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        155..175
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        176..366
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        367..386
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        387..418
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        419..439
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        440..855
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        856..876
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        877..882
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        883..903
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        904..927
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        928..948
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        949..971
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        972..991
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        992..1005
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1006..1027
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        1028..1039
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1040..1060
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30190470"
FT   TOPO_DOM        1061..1220
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REGION          297..356
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1100..1117
FT                   /note="Calmodulin-binding subdomain A"
FT                   /evidence="ECO:0000305|PubMed:1332771"
FT   REGION          1118..1220
FT                   /note="Required for basolateral membrane targeting"
FT                   /evidence="ECO:0000250|UniProtKB:P11505"
FT   REGION          1160..1220
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        297..321
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        338..356
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1180..1220
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        475
FT                   /note="4-aspartylphosphate intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ZWR1"
FT   METAL           475
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ZWR1"
FT   METAL           477
FT                   /note="Magnesium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ZWR1"
FT   METAL           797
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ZWR1"
FT   MOD_RES         2
FT                   /note="N-acetylglycine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         8
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:G5E829"
FT   MOD_RES         1116
FT                   /note="Phosphothreonine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:1827443"
FT   MOD_RES         1140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11505"
FT   MOD_RES         1155
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1165
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1178
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1182
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692"
FT   VAR_SEQ         1021..1056
FT                   /note="Missing (in isoform K)"
FT                   /id="VSP_059771"
FT   VAR_SEQ         1117
FT                   /note="Q -> QMDVVNAFQSGSSIQGALRRQPSIASQHHD (in isoform C)"
FT                   /id="VSP_059772"
FT   VAR_SEQ         1117
FT                   /note="Q -> QMDVVNAFQSGSSIQGALRRQPSIASQHHDVTNISTPTH (in
FT                   isoform D)"
FT                   /id="VSP_059773"
FT   VAR_SEQ         1118..1119
FT                   /note="IR -> MD (in isoform A and isoform E)"
FT                   /id="VSP_059774"
FT   VAR_SEQ         1125..1220
FT                   /note="RSSLYEGLEKPESRSSIHNFMTHPEFRIEDSEPHIPLIDDTDAEDDAPTKRN
FT                   SSPPPSPNKNNNAVDSGIHLTIEMNKSATSSSPGSPLHSLETSL -> QSGSSIQGALR
FT                   RQPSIASQHHDVTNISTPTHVVFSSSTASTTVGYSSGECIS (in isoform A)"
FT                   /id="VSP_059775"
FT   VAR_SEQ         1125..1220
FT                   /note="RSSLYEGLEKPESRSSIHNFMTHPEFRIEDSEPHIPLIDDTDAEDDAPTKRN
FT                   SSPPPSPNKNNNAVDSGIHLTIEMNKSATSSSPGSPLHSLETSL -> QSGSSIQGALR
FT                   RQPSIASQHHDVTNISTPTHVVFSSSTASTTVGFEW (in isoform E)"
FT                   /id="VSP_059776"
FT   VARIANT         267
FT                   /note="M -> R"
FT                   /evidence="ECO:0000269|PubMed:9020386"
FT                   /id="VAR_000698"
FT   CONFLICT        259..262
FT                   /note="LLLS -> MSAT (in Ref. 2; AAA36000)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1220 AA;  134685 MW;  7E75C19B1A501423 CRC64;
     MGDMANNSVA YSGVKNSLKE ANHDGDFGIT LAELRALMEL RSTDALRKIQ ESYGDVYGIC
     TKLKTSPNEG LSGNPADLER REAVFGKNFI PPKKPKTFLQ LVWEALQDVT LIILEIAAIV
     SLGLSFYQPP EGDNALCGEV SVGEEEGEGE TGWIEGAAIL LSVVCVVLVT AFNDWSKEKQ
     FRGLQSRIEQ EQKFTVIRGG QVIQIPVADI TVGDIAQVKY GDLLPADGIL IQGNDLKIDE
     SSLTGESDHV KKSLDKDPLL LSGTHVMEGS GRMVVTAVGV NSQTGIIFTL LGAGGEEEEK
     KDEKKKEKKN KKQDGAIENR NKAKAQDGAA MEMQPLKSEE GGDGDEKDKK KANLPKKEKS
     VLQGKLTKLA VQIGKAGLLM SAITVIILVL YFVIDTFWVQ KRPWLAECTP IYIQYFVKFF
     IIGVTVLVVA VPEGLPLAVT ISLAYSVKKM MKDNNLVRHL DACETMGNAT AICSDKTGTL
     TMNRMTVVQA YINEKHYKKV PEPEAIPPNI LSYLVTGISV NCAYTSKILP PEKEGGLPRH
     VGNKTECALL GLLLDLKRDY QDVRNEIPEE ALYKVYTFNS VRKSMSTVLK NSDGSYRIFS
     KGASEIILKK CFKILSANGE AKVFRPRDRD DIVKTVIEPM ASEGLRTICL AFRDFPAGEP
     EPEWDNENDI VTGLTCIAVV GIEDPVRPEV PDAIKKCQRA GITVRMVTGD NINTARAIAT
     KCGILHPGED FLCLEGKDFN RRIRNEKGEI EQERIDKIWP KLRVLARSSP TDKHTLVKGI
     IDSTVSDQRQ VVAVTGDGTN DGPALKKADV GFAMGIAGTD VAKEASDIIL TDDNFTSIVK
     AVMWGRNVYD SISKFLQFQL TVNVVAVIVA FTGACITQDS PLKAVQMLWV NLIMDTLASL
     ALATEPPTES LLLRKPYGRN KPLISRTMMK NILGHAFYQL VVVFTLLFAG EKFFDIDSGR
     NAPLHAPPSE HYTIVFNTFV LMQLFNEINA RKIHGERNVF EGIFNNAIFC TIVLGTFVVQ
     IIIVQFGGKP FSCSELSIEQ WLWSIFLGMG TLLWGQLIST IPTSRLKFLK EAGHGTQKEE
     IPEEELAEDV EEIDHAEREL RRGQILWFRG LNRIQTQIRV VNAFRSSLYE GLEKPESRSS
     IHNFMTHPEF RIEDSEPHIP LIDDTDAEDD APTKRNSSPP PSPNKNNNAV DSGIHLTIEM
     NKSATSSSPG SPLHSLETSL
//
ID   ODB2_HUMAN              Reviewed;         482 AA.
AC   P11182; B2R811; Q5VVL8;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 3.
DT   23-FEB-2022, entry version 246.
DE   RecName: Full=Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial;
DE            EC=2.3.1.168;
DE   AltName: Full=52 kDa mitochondrial autoantigen of primary biliary cirrhosis {ECO:0000303|PubMed:2908870};
DE   AltName: Full=Branched chain 2-oxo-acid dehydrogenase complex component E2 {ECO:0000303|PubMed:7543435, ECO:0000303|PubMed:9141421};
DE            Short=BCOADC-E2 {ECO:0000303|PubMed:7543435, ECO:0000303|PubMed:9141421};
DE   AltName: Full=Branched-chain alpha-keto acid dehydrogenase complex component E2;
DE            Short=BCKAD-E2;
DE            Short=BCKADE2;
DE   AltName: Full=Dihydrolipoamide acetyltransferase component of branched-chain alpha-keto acid dehydrogenase complex;
DE   AltName: Full=Dihydrolipoamide branched chain transacylase;
DE   AltName: Full=Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase;
DE   Flags: Precursor;
GN   Name=DBT; Synonyms=BCATE2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=1420314; DOI=10.1016/0167-4781(92)90169-z;
RA   Lau K.S., Chuang J.L., Herring W.J., Danner D.J., Cox R.P., Chuang D.T.;
RT   "The complete cDNA sequence for dihydrolipoyl transacylase (E2) of human
RT   branched-chain alpha-keto acid dehydrogenase complex.";
RL   Biochim. Biophys. Acta 1132:319-321(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3245861;
RA   Hummel K.B., Litwer S., Bradford A.P., Aitken A., Danner D.J., Yeaman S.J.;
RT   "Nucleotide sequence of a cDNA for branched chain acyltransferase with
RT   analysis of the deduced protein structure.";
RL   J. Biol. Chem. 263:6165-6168(1988).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=2708389;
RA   Danner D.J., Litwer S., Herring W.J., Pruckler J.;
RT   "Construction and nucleotide sequence of a cDNA encoding the full-length
RT   preprotein for human branched chain acyltransferase.";
RL   J. Biol. Chem. 264:7742-7746(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2742576; DOI=10.1016/0006-291x(89)91347-8;
RA   Nobukuni Y., Mitsubuchi H., Endo F., Matsuda I.;
RT   "Complete primary structure of the transacylase (E2b) subunit of the human
RT   branched chain alpha-keto acid dehydrogenase complex.";
RL   Biochem. Biophys. Res. Commun. 161:1035-1041(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-384.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-313.
RX   PubMed=2837277; DOI=10.1021/bi00406a025;
RA   Lau K.S., Griffin T.A., Hu C.-W.C., Chuang D.T.;
RT   "Conservation of primary structure in the lipoyl-bearing and dihydrolipoyl
RT   dehydrogenase binding domains of mammalian branched-chain alpha-keto acid
RT   dehydrogenase complex: molecular cloning of human and bovine transacylase
RT   (E2) cDNAs.";
RL   Biochemistry 27:1972-1981(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RX   PubMed=1429740;
RA   Lau K.S., Herring W.J., Chuang J.L., McKean M., Danner D.J., Cox R.P.,
RA   Chuang D.T.;
RT   "Structure of the gene encoding dihydrolipoyl transacylase (E2) component
RT   of human branched chain alpha-keto acid dehydrogenase complex and
RT   characterization of an E2 pseudogene.";
RL   J. Biol. Chem. 267:24090-24096(1992).
RN   [12]
RP   PROTEIN SEQUENCE OF 47-81.
RX   PubMed=7918575; DOI=10.1016/0304-4165(94)90161-9;
RA   Wynn R.M., Kochi H., Cox R.P., Chuang D.T.;
RT   "Differential processing of human and rat E1 alpha precursors of the
RT   branched-chain alpha-keto acid dehydrogenase complex caused by an N-
RT   terminal proline in the rat sequence.";
RL   Biochim. Biophys. Acta 1201:125-128(1994).
RN   [13]
RP   INVOLVEMENT IN PBC.
RX   PubMed=2908870; DOI=10.1002/hep.1840090110;
RA   Surh C.D., Danner D.J., Ahmed A., Coppel R.L., Mackay I.R., Dickson E.R.,
RA   Gershwin M.E.;
RT   "Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA
RT   clone of branched-chain alpha-keto acid dehydrogenase dihydrolipoamide
RT   acyltransferase, the 52 kD mitochondrial autoantigen.";
RL   Hepatology 9:63-68(1989).
RN   [14]
RP   INVOLVEMENT IN PBC.
RX   PubMed=7543435; DOI=10.1002/hep.1840220220;
RA   Leung P.S., Chuang D.T., Wynn R.M., Cha S., Danner D.J., Ansari A.,
RA   Coppel R.L., Gershwin M.E.;
RT   "Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis
RT   recognize a conformational epitope.";
RL   Hepatology 22:505-513(1995).
RN   [15]
RP   INVOLVEMENT IN PBC.
RX   PubMed=9141421; DOI=10.1002/hep.510250506;
RA   Nishio A., Van de Water J., Leung P.S., Joplin R., Neuberger J.M., Lake J.,
RA   Bjoerkland A., Toetterman T.H., Peters M., Worman H.J., Ansari A.A.,
RA   Coppel R.L., Gershwin M.E.;
RT   "Comparative studies of antimitochondrial autoantibodies in sera and bile
RT   in primary biliary cirrhosis.";
RL   Hepatology 25:1085-1089(1997).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-295, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-220, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   STRUCTURE BY NMR OF 62-145.
RX   PubMed=11839747; DOI=10.1074/jbc.m110952200;
RA   Chang C.-F., Chou H.-T., Chuang J.L., Chuang D.T., Huang T.-H.;
RT   "Solution structure and dynamics of the lipoic acid-bearing domain of human
RT   mitochondrial branched-chain alpha-keto acid dehydrogenase complex.";
RL   J. Biol. Chem. 277:15865-15873(2002).
RN   [21]
RP   STRUCTURE BY NMR OF 163-220.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the E3-binding domain of dihydrolipoamide branched
RT   chain transacylase.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [22]
RP   VARIANT MSUD2 CYS-276.
RX   PubMed=1847055; DOI=10.1016/0006-291x(91)91489-y;
RA   Fisher C.W., Lau K.S., Fisher C.R., Wynn R.M., Cox R.P., Chuang D.T.;
RT   "A 17-bp insertion and a Phe215-->Cys missense mutation in the
RT   dihydrolipoyl transacylase (E2) mRNA from a thiamine-responsive maple syrup
RT   urine disease patient WG-34.";
RL   Biochem. Biophys. Res. Commun. 174:804-809(1991).
RN   [23]
RP   VARIANTS MSUD2 MET-98 AND SER-384.
RX   PubMed=9621512; DOI=10.1007/s100380050047;
RA   Tsuruta M., Mitsubuchi H., Mardy S., Miura Y., Hayashida Y., Kinugasa A.,
RA   Ishitsu T., Matsuda I., Indo Y.;
RT   "Molecular basis of intermittent maple syrup urine disease: novel mutations
RT   in the E2 gene of the branched-chain alpha-keto acid dehydrogenase
RT   complex.";
RL   J. Hum. Genet. 43:91-100(1998).
CC   -!- FUNCTION: The branched-chain alpha-keto dehydrogenase complex catalyzes
CC       the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It
CC       contains multiple copies of three enzymatic components: branched-chain
CC       alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and
CC       lipoamide dehydrogenase (E3). Within this complex, the catalytic
CC       function of this enzyme is to accept, and to transfer to coenzyme A,
CC       acyl groups that are generated by the branched-chain alpha-keto acid
CC       decarboxylase component.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-N(6)-dihydrolipoyl-L-lysyl-[protein] + 2-methylpropanoyl-
CC         CoA = (R)-N(6)-(S(8)-2-methylpropanoyldihydrolipoyl)-L-lysyl-
CC         [protein] + CoA; Xref=Rhea:RHEA:18865, Rhea:RHEA-COMP:10475,
CC         Rhea:RHEA-COMP:10497, ChEBI:CHEBI:57287, ChEBI:CHEBI:57338,
CC         ChEBI:CHEBI:83100, ChEBI:CHEBI:83142; EC=2.3.1.168;
CC   -!- COFACTOR:
CC       Name=(R)-lipoate; Xref=ChEBI:CHEBI:83088;
CC       Note=Binds 1 lipoyl cofactor covalently.;
CC   -!- SUBUNIT: Forms a 24-polypeptide structural core with octahedral
CC       symmetry.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- DISEASE: Note=Patients with primary biliary cirrhosis (PBC) show
CC       autoantibodies against the E2 component of branched-chain alpha-keto
CC       acid dehydrogenase complex. PBC is a chronic, progressive cholestatic
CC       liver disease characterized by the presence of antimitochondrial
CC       autoantibodies in patients serum. It manifests with inflammatory
CC       obliteration of intra-hepatic bile duct, leading to liver cell damage
CC       and cirrhosis. {ECO:0000269|PubMed:2908870, ECO:0000269|PubMed:7543435,
CC       ECO:0000269|PubMed:9141421}.
CC   -!- DISEASE: Maple syrup urine disease 2 (MSUD2) [MIM:248600]: A metabolic
CC       disorder due to an enzyme defect in the catabolic pathway of the
CC       branched-chain amino acids leucine, isoleucine, and valine.
CC       Accumulation of these 3 amino acids and their corresponding keto acids
CC       leads to encephalopathy and progressive neurodegeneration. Clinical
CC       features include mental and physical retardation, feeding problems, and
CC       a maple syrup odor to the urine. The keto acids of the branched-chain
CC       amino acids are present in the urine. If untreated, maple syrup urine
CC       disease can lead to seizures, coma, and death. The disease is often
CC       classified by its pattern of signs and symptoms. The most common and
CC       severe form of the disease is the classic type, which becomes apparent
CC       soon after birth. Variant forms of the disorder become apparent later
CC       in infancy or childhood and are typically milder, but they still
CC       involve developmental delay and other medical problems if not treated.
CC       {ECO:0000269|PubMed:1847055, ECO:0000269|PubMed:9621512}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the 2-oxoacid dehydrogenase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35589.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAA64512.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X66785; CAA47285.1; -; mRNA.
DR   EMBL; J03208; AAA35589.1; ALT_INIT; mRNA.
DR   EMBL; M27093; AAA64512.1; ALT_INIT; mRNA.
DR   EMBL; BT007372; AAP36036.1; -; mRNA.
DR   EMBL; AL445928; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK313191; BAG36008.1; -; mRNA.
DR   EMBL; CH471097; EAW72963.1; -; Genomic_DNA.
DR   EMBL; BC016675; AAH16675.1; -; mRNA.
DR   EMBL; M19301; AAA59200.1; ALT_SEQ; mRNA.
DR   EMBL; X68104; CAA48225.1; -; Genomic_DNA.
DR   CCDS; CCDS767.1; -.
DR   PIR; A32422; A32422.
DR   RefSeq; NP_001909.3; NM_001918.3.
DR   PDB; 1K8M; NMR; -; A=62-145.
DR   PDB; 1K8O; NMR; -; A=62-145.
DR   PDB; 1ZWV; NMR; -; A=165-213.
DR   PDB; 2COO; NMR; -; A=163-220.
DR   PDB; 3RNM; X-ray; 2.40 A; E/F=165-213.
DR   PDBsum; 1K8M; -.
DR   PDBsum; 1K8O; -.
DR   PDBsum; 1ZWV; -.
DR   PDBsum; 2COO; -.
DR   PDBsum; 3RNM; -.
DR   BMRB; P11182; -.
DR   SMR; P11182; -.
DR   BioGRID; 107997; 179.
DR   ComplexPortal; CPX-2216; Mitochondrial 2-oxoisovalerate dehydrogenase complex.
DR   IntAct; P11182; 60.
DR   MINT; P11182; -.
DR   STRING; 9606.ENSP00000359151; -.
DR   GlyGen; P11182; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P11182; -.
DR   MetOSite; P11182; -.
DR   PhosphoSitePlus; P11182; -.
DR   SwissPalm; P11182; -.
DR   BioMuta; DBT; -.
DR   DMDM; 400668; -.
DR   EPD; P11182; -.
DR   jPOST; P11182; -.
DR   MassIVE; P11182; -.
DR   MaxQB; P11182; -.
DR   PaxDb; P11182; -.
DR   PeptideAtlas; P11182; -.
DR   PRIDE; P11182; -.
DR   ProteomicsDB; 52718; -.
DR   ABCD; P11182; 1 sequenced antibody.
DR   Antibodypedia; 19986; 189 antibodies from 24 providers.
DR   DNASU; 1629; -.
DR   Ensembl; ENST00000370132; ENSP00000359151; ENSG00000137992.
DR   GeneID; 1629; -.
DR   KEGG; hsa:1629; -.
DR   MANE-Select; ENST00000370132.8; ENSP00000359151.3; NM_001918.5; NP_001909.4.
DR   UCSC; uc001dta.4; human.
DR   CTD; 1629; -.
DR   DisGeNET; 1629; -.
DR   GeneCards; DBT; -.
DR   GeneReviews; DBT; -.
DR   HGNC; HGNC:2698; DBT.
DR   HPA; ENSG00000137992; Low tissue specificity.
DR   MalaCards; DBT; -.
DR   MIM; 248600; phenotype.
DR   MIM; 248610; gene.
DR   neXtProt; NX_P11182; -.
DR   Orphanet; 268145; Classic maple syrup urine disease.
DR   Orphanet; 268162; Intermediate maple syrup urine disease.
DR   Orphanet; 268173; Intermittent maple syrup urine disease.
DR   Orphanet; 268184; Thiamine-responsive maple syrup urine disease.
DR   PharmGKB; PA27167; -.
DR   VEuPathDB; HostDB:ENSG00000137992; -.
DR   eggNOG; KOG0558; Eukaryota.
DR   HOGENOM; CLU_016733_10_0_1; -.
DR   InParanoid; P11182; -.
DR   OrthoDB; 854035at2759; -.
DR   PhylomeDB; P11182; -.
DR   TreeFam; TF314182; -.
DR   BRENDA; 2.3.1.168; 2681.
DR   PathwayCommons; P11182; -.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   Reactome; R-HSA-70895; Branched-chain amino acid catabolism.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   SABIO-RK; P11182; -.
DR   SignaLink; P11182; -.
DR   BioGRID-ORCS; 1629; 7 hits in 1045 CRISPR screens.
DR   ChiTaRS; DBT; human.
DR   EvolutionaryTrace; P11182; -.
DR   GeneWiki; DBT_(gene); -.
DR   GenomeRNAi; 1629; -.
DR   Pharos; P11182; Tbio.
DR   PRO; PR:P11182; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P11182; protein.
DR   Bgee; ENSG00000137992; Expressed in amniotic fluid and 255 other tissues.
DR   ExpressionAtlas; P11182; baseline and differential.
DR   Genevisible; P11182; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0005947; C:mitochondrial alpha-ketoglutarate dehydrogenase complex; IPI:ComplexPortal.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0016407; F:acetyltransferase activity; IBA:GO_Central.
DR   GO; GO:0043754; F:dihydrolipoyllysine-residue (2-methylpropanoyl)transferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0031405; F:lipoic acid binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0009083; P:branched-chain amino acid catabolic process; IDA:ComplexPortal.
DR   Gene3D; 3.30.559.10; -; 1.
DR   Gene3D; 4.10.320.10; -; 1.
DR   InterPro; IPR003016; 2-oxoA_DH_lipoyl-BS.
DR   InterPro; IPR001078; 2-oxoacid_DH_actylTfrase.
DR   InterPro; IPR000089; Biotin_lipoyl.
DR   InterPro; IPR023213; CAT-like_dom_sf.
DR   InterPro; IPR036625; E3-bd_dom_sf.
DR   InterPro; IPR004167; PSBD.
DR   InterPro; IPR011053; Single_hybrid_motif.
DR   Pfam; PF00198; 2-oxoacid_dh; 1.
DR   Pfam; PF00364; Biotin_lipoyl; 1.
DR   Pfam; PF02817; E3_binding; 1.
DR   SUPFAM; SSF47005; SSF47005; 1.
DR   SUPFAM; SSF51230; SSF51230; 1.
DR   PROSITE; PS50968; BIOTINYL_LIPOYL; 1.
DR   PROSITE; PS00189; LIPOYL; 1.
DR   PROSITE; PS51826; PSBD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Direct protein sequencing;
KW   Disease variant; Lipoyl; Maple syrup urine disease; Mitochondrion;
KW   Phosphoprotein; Reference proteome; Transferase; Transit peptide.
FT   TRANSIT         1..61
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000255"
FT   CHAIN           62..482
FT                   /note="Lipoamide acyltransferase component of branched-
FT                   chain alpha-keto acid dehydrogenase complex, mitochondrial"
FT                   /id="PRO_0000020489"
FT   DOMAIN          64..139
FT                   /note="Lipoyl-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066"
FT   DOMAIN          172..209
FT                   /note="Peripheral subunit-binding (PSBD)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01170"
FT   REGION          147..168
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        452
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        456
FT                   /evidence="ECO:0000255"
FT   MOD_RES         105
FT                   /note="N6-lipoyllysine"
FT                   /evidence="ECO:0000250, ECO:0000255|PROSITE-
FT                   ProRule:PRU01066"
FT   MOD_RES         133
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         196
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         196
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         202
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         220
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         243
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         250
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         261
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         289
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         289
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         295
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         304
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         435
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         440
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   MOD_RES         440
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P53395"
FT   VARIANT         98
FT                   /note="I -> M (in MSUD2; dbSNP:rs121965001)"
FT                   /evidence="ECO:0000269|PubMed:9621512"
FT                   /id="VAR_015099"
FT   VARIANT         276
FT                   /note="F -> C (in MSUD2; dbSNP:rs121964999)"
FT                   /evidence="ECO:0000269|PubMed:1847055"
FT                   /id="VAR_004978"
FT   VARIANT         384
FT                   /note="G -> S (in MSUD2; dbSNP:rs12021720)"
FT                   /evidence="ECO:0000269|PubMed:16710414,
FT                   ECO:0000269|PubMed:9621512"
FT                   /id="VAR_015100"
FT   CONFLICT        321
FT                   /note="Q -> P (in Ref. 4; AAA64512)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        354
FT                   /note="L -> V (in Ref. 4; AAA64512)"
FT                   /evidence="ECO:0000305"
FT   STRAND          65..68
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          79..84
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          99..102
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          116..121
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   STRAND          125..129
FT                   /evidence="ECO:0007829|PDB:1K8O"
FT   STRAND          133..139
FT                   /evidence="ECO:0007829|PDB:1K8M"
FT   HELIX           175..183
FT                   /evidence="ECO:0007829|PDB:3RNM"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:3RNM"
FT   HELIX           196..198
FT                   /evidence="ECO:0007829|PDB:3RNM"
FT   HELIX           202..213
FT                   /evidence="ECO:0007829|PDB:3RNM"
SQ   SEQUENCE   482 AA;  53487 MW;  A7CA728C8F33D126 CRC64;
     MAAVRMLRTW SRNAGKLICV RYFQTCGNVH VLKPNYVCFF GYPSFKYSHP HHFLKTTAAL
     RGQVVQFKLS DIGEGIREVT VKEWYVKEGD TVSQFDSICE VQSDKASVTI TSRYDGVIKK
     LYYNLDDIAY VGKPLVDIET EALKDSEEDV VETPAVSHDE HTHQEIKGRK TLATPAVRRL
     AMENNIKLSE VVGSGKDGRI LKEDILNYLE KQTGAILPPS PKVEIMPPPP KPKDMTVPIL
     VSKPPVFTGK DKTEPIKGFQ KAMVKTMSAA LKIPHFGYCD EIDLTELVKL REELKPIAFA
     RGIKLSFMPF FLKAASLGLL QFPILNASVD ENCQNITYKA SHNIGIAMDT EQGLIVPNVK
     NVQICSIFDI ATELNRLQKL GSVGQLSTTD LTGGTFTLSN IGSIGGTFAK PVIMPPEVAI
     GALGSIKAIP RFNQKGEVYK AQIMNVSWSA DHRVIDGATM SRFSNLWKSY LENPAFMLLD
     LK
//
ID   ODP2_HUMAN              Reviewed;         647 AA.
AC   P10515; Q16783; Q53EP3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 3.
DT   23-FEB-2022, entry version 240.
DE   RecName: Full=Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial;
DE            EC=2.3.1.12;
DE   AltName: Full=70 kDa mitochondrial autoantigen of primary biliary cirrhosis;
DE            Short=PBC;
DE   AltName: Full=Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex;
DE   AltName: Full=M2 antigen complex 70 kDa subunit;
DE   AltName: Full=Pyruvate dehydrogenase complex component E2;
DE            Short=PDC-E2;
DE            Short=PDCE2;
DE   Flags: Precursor;
GN   Name=DLAT; Synonyms=DLTA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-43; ALA-318 AND
RP   ASN-451.
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-647.
RC   TISSUE=Placenta;
RX   PubMed=3174635; DOI=10.1073/pnas.85.19.7317;
RA   Coppel R.L., McNeilage L.J., Surh C.D., van de Water J., Spithill T.W.,
RA   Whittingham S., Gershwin M.E.;
RT   "Primary structure of the human M2 mitochondrial autoantigen of primary
RT   biliary cirrhosis: dihydrolipoamide acetyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7317-7321(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 73-647, AND LIPOYLATION AT LYS-132 AND
RP   LYS-259.
RC   TISSUE=Liver;
RX   PubMed=3191998; DOI=10.1016/0014-5793(88)80337-5;
RA   Thekkumkara T.J., Ho L., Wexler I.D., Pon G., Liu T., Patel M.S.;
RT   "Nucleotide sequence of a cDNA for the dihydrolipoamide acetyltransferase
RT   component of human pyruvate dehydrogenase complex.";
RL   FEBS Lett. 240:45-48(1988).
RN   [5]
RP   SUBUNIT.
RX   PubMed=14638692; DOI=10.1074/jbc.m308172200;
RA   Hiromasa Y., Fujisawa T., Aso Y., Roche T.E.;
RT   "Organization of the cores of the mammalian pyruvate dehydrogenase complex
RT   formed by E2 and E2 plus the E3-binding protein and their capacities to
RT   bind the E1 and E3 components.";
RL   J. Biol. Chem. 279:6921-6933(2004).
RN   [6]
RP   INTERACTION WITH PDHB.
RX   PubMed=20160912; DOI=10.1016/j.molcatb.2009.05.001;
RA   Patel M.S., Korotchkina L.G., Sidhu S.;
RT   "Interaction of E1 and E3 components with the core proteins of the human
RT   pyruvate dehydrogenase complex.";
RL   J. Mol. Catal., B Enzym. 61:2-6(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-466, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   INTERACTION WITH SIRT4, LIPOYLATION AT LYS-132 AND LYS-259, AND
RP   DELIPOYLATION AT LYS-132 AND LYS-259.
RX   PubMed=25525879; DOI=10.1016/j.cell.2014.11.046;
RA   Mathias R.A., Greco T.M., Oberstein A., Budayeva H.G., Chakrabarti R.,
RA   Rowland E.A., Kang Y., Shenk T., Cristea I.M.;
RT   "Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex
RT   activity.";
RL   Cell 159:1615-1625(2014).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   STRUCTURE BY NMR OF 214-315.
RX   PubMed=9649469; DOI=10.1016/s0016-5085(98)70375-0;
RA   Howard M.J., Fuller C., Broadhurst R.W., Perham R.N., Tang J.G., Quinn J.,
RA   Diamond A.G., Yeaman S.J.;
RT   "Three-dimensional structure of the major autoantigen in primary biliary
RT   cirrhosis.";
RL   Gastroenterology 115:139-146(1998).
RN   [13]
RP   INVOLVEMENT IN PDHE2 DEFICIENCY.
RX   PubMed=16049940; DOI=10.1002/ana.20550;
RA   Head R.A., Brown R.M., Zolkipli Z., Shahdadpuri R., King M.D.,
RA   Clayton P.T., Brown G.K.;
RT   "Clinical and genetic spectrum of pyruvate dehydrogenase deficiency:
RT   dihydrolipoamide acetyltransferase (E2) deficiency.";
RL   Ann. Neurol. 58:234-241(2005).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=15861126; DOI=10.1038/sj.emboj.7600663;
RA   Kato M., Chuang J.L., Tso S.C., Wynn R.M., Chuang D.T.;
RT   "Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl
RT   domain 2 of human pyruvate dehydrogenase complex.";
RL   EMBO J. 24:1763-1774(2005).
RN   [15]
RP   STRUCTURE BY NMR OF 92-186.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-058, a lipoyl domain of human 2-oxoacid
RT   dehydrogenase.";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=17532006; DOI=10.1016/j.jmb.2007.04.083;
RA   Devedjiev Y., Steussy C.N., Vassylyev D.G.;
RT   "Crystal structure of an asymmetric complex of pyruvate dehydrogenase
RT   kinase 3 with lipoyl domain 2 and its biological implications.";
RL   J. Mol. Biol. 370:407-416(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=17683942; DOI=10.1016/j.str.2007.07.001;
RA   Kato M., Li J., Chuang J.L., Chuang D.T.;
RT   "Distinct structural mechanisms for inhibition of pyruvate dehydrogenase
RT   kinase isoforms by AZD7545, dichloroacetate, and radicicol.";
RL   Structure 15:992-1004(2007).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 214-300 IN COMPLEX WITH PDK2.
RX   PubMed=18387944; DOI=10.1074/jbc.m800311200;
RA   Green T., Grigorian A., Klyuyeva A., Tuganova A., Luo M., Popov K.M.;
RT   "Structural and functional insights into the molecular mechanisms
RT   responsible for the regulation of pyruvate dehydrogenase kinase 2.";
RL   J. Biol. Chem. 283:15789-15798(2008).
RN   [19]
RP   STRUCTURE BY ELECTRON MICROSCOPY (18.3 ANGSTROMS) OF INNER CORE OF THE
RP   COMPLEX, AND SUBUNIT.
RX   PubMed=20361979; DOI=10.1016/j.jmb.2010.03.043;
RA   Vijayakrishnan S., Kelly S.M., Gilbert R.J., Callow P., Bhella D.,
RA   Forsyth T., Lindsay J.G., Byron O.;
RT   "Solution structure and characterisation of the human pyruvate
RT   dehydrogenase complex core assembly.";
RL   J. Mol. Biol. 399:71-93(2010).
CC   -!- FUNCTION: The pyruvate dehydrogenase complex catalyzes the overall
CC       conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the
CC       glycolytic pathway to the tricarboxylic cycle.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-N(6)-dihydrolipoyl-L-lysyl-[protein] + acetyl-CoA = (R)-
CC         N(6)-(S(8)-acetyldihydrolipoyl)-L-lysyl-[protein] + CoA;
CC         Xref=Rhea:RHEA:17017, Rhea:RHEA-COMP:10475, Rhea:RHEA-COMP:10478,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:83100,
CC         ChEBI:CHEBI:83111; EC=2.3.1.12;
CC   -!- COFACTOR:
CC       Name=(R)-lipoate; Xref=ChEBI:CHEBI:83088;
CC       Note=Binds 2 lipoyl cofactors covalently.;
CC   -!- SUBUNIT: Part of the multimeric pyruvate dehydrogenase complex that
CC       contains multiple copies of pyruvate dehydrogenase (subunits PDH1A and
CC       PDHB, E1), dihydrolipoamide acetyltransferase (DLAT, E2) and lipoamide
CC       dehydrogenase (DLD, E3) (PubMed:14638692). These subunits are bound to
CC       an inner core composed of about 48 DLAT and 12 PDHX molecules
CC       (PubMed:14638692, PubMed:20361979). Interacts with PDK2 and PDK3
CC       (PubMed:15861126, PubMed:17532006, PubMed:17683942, PubMed:18387944).
CC       Interacts with SIRT4 (PubMed:25525879). Interacts with PDHB
CC       (PubMed:20160912). {ECO:0000269|PubMed:14638692,
CC       ECO:0000269|PubMed:15861126, ECO:0000269|PubMed:17532006,
CC       ECO:0000269|PubMed:17683942, ECO:0000269|PubMed:18387944,
CC       ECO:0000269|PubMed:20160912, ECO:0000269|PubMed:20361979,
CC       ECO:0000269|PubMed:25525879}.
CC   -!- INTERACTION:
CC       P10515; P10515: DLAT; NbExp=2; IntAct=EBI-2959723, EBI-2959723;
CC       P10515; P11177: PDHB; NbExp=7; IntAct=EBI-2959723, EBI-1035872;
CC       P10515; Q15120: PDK3; NbExp=2; IntAct=EBI-2959723, EBI-1383915;
CC       P10515; Q9Y6E7: SIRT4; NbExp=6; IntAct=EBI-2959723, EBI-2606540;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- PTM: Delipoylated at Lys-132 and Lys-259 by SIRT4, delipoylation
CC       decreases the PHD complex activity. {ECO:0000269|PubMed:25525879}.
CC   -!- DISEASE: Note=Primary biliary cirrhosis is a chronic, progressive
CC       cholestatic liver disease characterized by the presence of
CC       antimitochondrial autoantibodies in patients' serum. It manifests with
CC       inflammatory obliteration of intra-hepatic bile duct, leading to liver
CC       cell damage and cirrhosis. Patients with primary biliary cirrhosis show
CC       autoantibodies against the E2 component of pyruvate dehydrogenase
CC       complex.
CC   -!- DISEASE: Pyruvate dehydrogenase E2 deficiency (PDHE2 deficiency)
CC       [MIM:245348]: Pyruvate dehydrogenase (PDH) deficiency is a major cause
CC       of primary lactic acidosis and neurological dysfunction in infancy and
CC       early childhood. In this form of PDH deficiency episodic dystonia is
CC       the major neurological manifestation, with other more common features
CC       of pyruvate dehydrogenase deficiency, such as hypotonia and ataxia,
CC       being less prominent. {ECO:0000269|PubMed:16049940}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 2-oxoacid dehydrogenase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA62253.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA62253.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK223596; BAD97316.1; -; mRNA.
DR   EMBL; AP000907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; J03866; AAA62253.1; ALT_SEQ; mRNA.
DR   EMBL; Y00978; CAA68787.1; -; mRNA.
DR   CCDS; CCDS8354.1; -.
DR   PIR; A40497; A40497.
DR   RefSeq; NP_001922.2; NM_001931.4.
DR   PDB; 1FYC; NMR; -; A=212-315.
DR   PDB; 1Y8N; X-ray; 2.60 A; B=212-319.
DR   PDB; 1Y8O; X-ray; 2.48 A; B=212-319.
DR   PDB; 1Y8P; X-ray; 2.63 A; B=212-319.
DR   PDB; 2DNE; NMR; -; A=92-186.
DR   PDB; 2PNR; X-ray; 2.50 A; C/G=212-319.
DR   PDB; 2Q8I; X-ray; 2.60 A; B=212-319.
DR   PDB; 3B8K; EM; 8.80 A; A=409-647.
DR   PDB; 3CRK; X-ray; 2.30 A; C/D=214-300.
DR   PDB; 3CRL; X-ray; 2.61 A; C/D=214-300.
DR   PDB; 6CT0; EM; 3.10 A; 0=1-647.
DR   PDB; 6H55; EM; 6.00 A; A=1-647.
DR   PDBsum; 1FYC; -.
DR   PDBsum; 1Y8N; -.
DR   PDBsum; 1Y8O; -.
DR   PDBsum; 1Y8P; -.
DR   PDBsum; 2DNE; -.
DR   PDBsum; 2PNR; -.
DR   PDBsum; 2Q8I; -.
DR   PDBsum; 3B8K; -.
DR   PDBsum; 3CRK; -.
DR   PDBsum; 3CRL; -.
DR   PDBsum; 6CT0; -.
DR   PDBsum; 6H55; -.
DR   SMR; P10515; -.
DR   BioGRID; 108081; 171.
DR   ComplexPortal; CPX-6233; Mitochondrial pyruvate dehydrogenase complex, somatic variant.
DR   ComplexPortal; CPX-6242; Mitochondrial pyruvate dehydrogenase complex, testis-specific variant.
DR   DIP; DIP-29496N; -.
DR   IntAct; P10515; 44.
DR   MINT; P10515; -.
DR   STRING; 9606.ENSP00000280346; -.
DR   ChEMBL; CHEMBL4523180; -.
DR   DrugBank; DB03760; Dihydrolipoic Acid.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB03758; Radicicol.
DR   CarbonylDB; P10515; -.
DR   GlyGen; P10515; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P10515; -.
DR   PhosphoSitePlus; P10515; -.
DR   SwissPalm; P10515; -.
DR   BioMuta; DLAT; -.
DR   DMDM; 215274207; -.
DR   EPD; P10515; -.
DR   jPOST; P10515; -.
DR   MassIVE; P10515; -.
DR   PaxDb; P10515; -.
DR   PeptideAtlas; P10515; -.
DR   PRIDE; P10515; -.
DR   ProteomicsDB; 52610; -.
DR   ABCD; P10515; 1 sequenced antibody.
DR   Antibodypedia; 18282; 327 antibodies from 30 providers.
DR   DNASU; 1737; -.
DR   Ensembl; ENST00000280346; ENSP00000280346; ENSG00000150768.
DR   GeneID; 1737; -.
DR   KEGG; hsa:1737; -.
DR   MANE-Select; ENST00000280346.11; ENSP00000280346.7; NM_001931.5; NP_001922.2.
DR   CTD; 1737; -.
DR   DisGeNET; 1737; -.
DR   GeneCards; DLAT; -.
DR   GeneReviews; DLAT; -.
DR   HGNC; HGNC:2896; DLAT.
DR   HPA; ENSG00000150768; Tissue enhanced (tongue).
DR   MalaCards; DLAT; -.
DR   MIM; 245348; phenotype.
DR   MIM; 608770; gene.
DR   neXtProt; NX_P10515; -.
DR   OpenTargets; ENSG00000150768; -.
DR   Orphanet; 79244; Pyruvate dehydrogenase E2 deficiency.
DR   PharmGKB; PA27350; -.
DR   VEuPathDB; HostDB:ENSG00000150768; -.
DR   eggNOG; KOG0557; Eukaryota.
DR   GeneTree; ENSGT00940000154943; -.
DR   InParanoid; P10515; -.
DR   OMA; TMEFESF; -.
DR   OrthoDB; 747232at2759; -.
DR   PhylomeDB; P10515; -.
DR   TreeFam; TF106145; -.
DR   BRENDA; 2.3.1.12; 2681.
DR   PathwayCommons; P10515; -.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   SABIO-RK; P10515; -.
DR   SignaLink; P10515; -.
DR   SIGNOR; P10515; -.
DR   BioGRID-ORCS; 1737; 23 hits in 1045 CRISPR screens.
DR   ChiTaRS; DLAT; human.
DR   EvolutionaryTrace; P10515; -.
DR   GeneWiki; Dihydrolipoyl_transacetylase; -.
DR   GenomeRNAi; 1737; -.
DR   Pharos; P10515; Tbio.
DR   PRO; PR:P10515; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P10515; protein.
DR   Bgee; ENSG00000150768; Expressed in heart and 247 other tissues.
DR   ExpressionAtlas; P10515; baseline and differential.
DR   Genevisible; P10515; HS.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005967; C:mitochondrial pyruvate dehydrogenase complex; IPI:ComplexPortal.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0045254; C:pyruvate dehydrogenase complex; IDA:UniProtKB.
DR   GO; GO:0004742; F:dihydrolipoyllysine-residue acetyltransferase activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0006086; P:acetyl-CoA biosynthetic process from pyruvate; IDA:ComplexPortal.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.559.10; -; 1.
DR   Gene3D; 4.10.320.10; -; 1.
DR   InterPro; IPR003016; 2-oxoA_DH_lipoyl-BS.
DR   InterPro; IPR001078; 2-oxoacid_DH_actylTfrase.
DR   InterPro; IPR000089; Biotin_lipoyl.
DR   InterPro; IPR023213; CAT-like_dom_sf.
DR   InterPro; IPR045257; E2/Pdx1.
DR   InterPro; IPR036625; E3-bd_dom_sf.
DR   InterPro; IPR006257; LAT1.
DR   InterPro; IPR004167; PSBD.
DR   InterPro; IPR011053; Single_hybrid_motif.
DR   PANTHER; PTHR23151; PTHR23151; 2.
DR   Pfam; PF00198; 2-oxoacid_dh; 1.
DR   Pfam; PF00364; Biotin_lipoyl; 2.
DR   Pfam; PF02817; E3_binding; 1.
DR   SUPFAM; SSF47005; SSF47005; 1.
DR   SUPFAM; SSF51230; SSF51230; 2.
DR   TIGRFAMs; TIGR01349; PDHac_trf_mito; 1.
DR   PROSITE; PS50968; BIOTINYL_LIPOYL; 2.
DR   PROSITE; PS00189; LIPOYL; 2.
DR   PROSITE; PS51826; PSBD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Carbohydrate metabolism;
KW   Glucose metabolism; Lipoyl; Mitochondrion; Phosphoprotein;
KW   Reference proteome; Repeat; Transferase; Transit peptide;
KW   Tricarboxylic acid cycle.
FT   TRANSIT         1..86
FT                   /note="Mitochondrion"
FT   CHAIN           87..647
FT                   /note="Dihydrolipoyllysine-residue acetyltransferase
FT                   component of pyruvate dehydrogenase complex, mitochondrial"
FT                   /id="PRO_0000020479"
FT   DOMAIN          91..167
FT                   /note="Lipoyl-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066"
FT   DOMAIN          218..294
FT                   /note="Lipoyl-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066"
FT   DOMAIN          356..393
FT                   /note="Peripheral subunit-binding (PSBD)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01170"
FT   REGION          29..49
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          184..219
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          312..346
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          417..647
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        190..204
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        314..346
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        620
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        624
FT                   /evidence="ECO:0000255"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         132
FT                   /note="N6-lipoyllysine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066,
FT                   ECO:0000269|PubMed:25525879, ECO:0000269|PubMed:3191998"
FT   MOD_RES         259
FT                   /note="N6-lipoyllysine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066,
FT                   ECO:0000269|PubMed:25525879, ECO:0000269|PubMed:3191998"
FT   MOD_RES         466
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         473
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BMF4"
FT   MOD_RES         547
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BMF4"
FT   VARIANT         43
FT                   /note="A -> V (in dbSNP:rs2303436)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047410"
FT   VARIANT         98
FT                   /note="S -> F (in dbSNP:rs537057)"
FT                   /id="VAR_047411"
FT   VARIANT         99
FT                   /note="L -> F (in dbSNP:rs537060)"
FT                   /id="VAR_047412"
FT   VARIANT         209
FT                   /note="Q -> R (in dbSNP:rs11553595)"
FT                   /id="VAR_047413"
FT   VARIANT         313
FT                   /note="D -> V (in dbSNP:rs11553592)"
FT                   /id="VAR_047414"
FT   VARIANT         318
FT                   /note="V -> A (in dbSNP:rs627441)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047415"
FT   VARIANT         451
FT                   /note="D -> N (in dbSNP:rs10891314)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047416"
FT   CONFLICT        112
FT                   /note="E -> K (in Ref. 4; CAA68787)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        342
FT                   /note="A -> T (in Ref. 3; AAA62253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        358
FT                   /note="S -> D (in Ref. 3; AAA62253)"
FT                   /evidence="ECO:0000305"
FT   STRAND          92..95
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          100..102
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          105..110
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          123..129
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          134..138
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          140..147
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          162..168
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   HELIX           170..177
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:2DNE"
FT   STRAND          218..222
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   STRAND          229..231
FT                   /evidence="ECO:0007829|PDB:1FYC"
FT   STRAND          232..238
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   STRAND          251..256
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   STRAND          261..265
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   STRAND          270..277
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:1Y8O"
FT   STRAND          289..297
FT                   /evidence="ECO:0007829|PDB:3CRK"
FT   HELIX           301..303
FT                   /evidence="ECO:0007829|PDB:2Q8I"
FT   HELIX           427..440
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          446..453
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           455..467
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          470..472
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           476..490
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           492..495
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          496..498
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          500..505
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          511..513
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   TURN            527..531
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           534..549
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           555..558
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          564..567
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   TURN            569..572
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          584..599
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          601..618
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   STRAND          620..622
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           625..640
FT                   /evidence="ECO:0007829|PDB:6CT0"
FT   HELIX           642..646
FT                   /evidence="ECO:0007829|PDB:6CT0"
SQ   SEQUENCE   647 AA;  68997 MW;  DD93A8E666E377C2 CRC64;
     MWRVCARRAQ NVAPWAGLEA RWTALQEVPG TPRVTSRSGP APARRNSVTT GYGGVRALCG
     WTPSSGATPR NRLLLQLLGS PGRRYYSLPP HQKVPLPSLS PTMQAGTIAR WEKKEGDKIN
     EGDLIAEVET DKATVGFESL EECYMAKILV AEGTRDVPIG AIICITVGKP EDIEAFKNYT
     LDSSAAPTPQ AAPAPTPAAT ASPPTPSAQA PGSSYPPHMQ VLLPALSPTM TMGTVQRWEK
     KVGEKLSEGD LLAEIETDKA TIGFEVQEEG YLAKILVPEG TRDVPLGTPL CIIVEKEADI
     SAFADYRPTE VTDLKPQVPP PTPPPVAAVP PTPQPLAPTP SAPCPATPAG PKGRVFVSPL
     AKKLAVEKGI DLTQVKGTGP DGRITKKDID SFVPSKVAPA PAAVVPPTGP GMAPVPTGVF
     TDIPISNIRR VIAQRLMQSK QTIPHYYLSI DVNMGEVLLV RKELNKILEG RSKISVNDFI
     IKASALACLK VPEANSSWMD TVIRQNHVVD VSVAVSTPAG LITPIVFNAH IKGVETIAND
     VVSLATKARE GKLQPHEFQG GTFTISNLGM FGIKNFSAII NPPQACILAI GASEDKLVPA
     DNEKGFDVAS MMSVTLSCDH RVVDGAVGAQ WLAEFRKYLE KPITMLL
//
ID   KDSR_HUMAN              Reviewed;         332 AA.
AC   Q06136; B2R5Y1; B4DMX0;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   23-FEB-2022, entry version 191.
DE   RecName: Full=3-ketodihydrosphingosine reductase;
DE            Short=KDS reductase;
DE            EC=1.1.1.102;
DE   AltName: Full=3-dehydrosphinganine reductase;
DE   AltName: Full=Follicular variant translocation protein 1;
DE            Short=FVT-1;
DE   AltName: Full=Short chain dehydrogenase/reductase family 35C member 1;
DE   Flags: Precursor;
GN   Name=KDSR; Synonyms=FVT1, SDR35C1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL TRANSLOCATION WITH
RP   KDSR.
RX   PubMed=8417785;
RA   Rimokh R., Gadoux M., Bertheas M.-F., Berger F., Garoscio M., Deleage G.,
RA   Germain D., Magaud J.-P.;
RT   "FVT-1, a novel human transcription unit affected by variant translocation
RT   t(2;18)(p11;q21) of follicular lymphoma.";
RL   Blood 81:136-142(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, and Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MEMBRANE TOPOLOGY.
RX   PubMed=15328338; DOI=10.1074/jbc.m405915200;
RA   Kihara A., Igarashi Y.;
RT   "FVT-1 is a mammalian 3-ketodihydrosphingosine reductase with an active
RT   site that faces the cytosolic side of the endoplasmic reticulum membrane.";
RL   J. Biol. Chem. 279:49243-49250(2004).
RN   [8]
RP   VARIANTS EKVP4 55-GLN-GLY-56 DELINS ARG; 86-VAL--GLN-107 DEL; PHE-186 AND
RP   260-GLN--GLN-293 DEL, CHARACTERIZATION OF VARIANTS EKVP4 55-GLN-GLY-56
RP   DELINS ARG; 86-VAL--GLN-107 DEL AND 260-GLN--GLN-293 DEL, AND FUNCTION.
RX   PubMed=28575652; DOI=10.1016/j.ajhg.2017.05.003;
RA   Boyden L.M., Vincent N.G., Zhou J., Hu R., Craiglow B.G., Bayliss S.J.,
RA   Rosman I.S., Lucky A.W., Diaz L.A., Goldsmith L.A., Paller A.S.,
RA   Lifton R.P., Baserga S.J., Choate K.A.;
RT   "Mutations in KDSR cause recessive progressive symmetric
RT   erythrokeratoderma.";
RL   Am. J. Hum. Genet. 100:978-984(2017).
CC   -!- FUNCTION: Catalyzes the reduction of 3-ketodihydrosphingosine (KDS) to
CC       dihydrosphingosine (DHS). {ECO:0000269|PubMed:28575652}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NADP(+) + sphinganine = 3-oxosphinganine + H(+) + NADPH;
CC         Xref=Rhea:RHEA:22640, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:57817, ChEBI:CHEBI:58299, ChEBI:CHEBI:58349;
CC         EC=1.1.1.102; Evidence={ECO:0000269|PubMed:15328338};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC   -!- INTERACTION:
CC       Q06136; P04792: HSPB1; NbExp=3; IntAct=EBI-3909166, EBI-352682;
CC       Q06136; O60333-2: KIF1B; NbExp=3; IntAct=EBI-3909166, EBI-10975473;
CC       Q06136; P02766: TTR; NbExp=3; IntAct=EBI-3909166, EBI-711909;
CC       Q06136; O76024: WFS1; NbExp=3; IntAct=EBI-3909166, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:15328338}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:15328338}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q06136-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q06136-2; Sequence=VSP_056641;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined. Highest
CC       expression in placenta. High expression in lung, kidney, stomach and
CC       small intestine, low expression in heart, spleen and skeletal muscle.
CC       Weakly expressed in normal hematopoietic tissues. Higher expression in
CC       some T-cell malignancies and PHA-stimulated lymphocytes.
CC   -!- DISEASE: Note=A chromosomal aberration involving KDSR is a cause of
CC       follicular lymphoma; also known as type II chronic lymphatic leukemia.
CC       Translocation t(2;18)(p11;q21) with a Ig J kappa chain region
CC       (PubMed:8417785). {ECO:0000269|PubMed:8417785}.
CC   -!- DISEASE: Erythrokeratodermia variabilis et progressiva 4 (EKVP4)
CC       [MIM:617526]: A form of erythrokeratodermia variabilis et progressiva,
CC       a genodermatosis characterized by the coexistence of two independent
CC       skin lesions: transient erythema and hyperkeratosis that is usually
CC       localized but occasionally occurs in its generalized form. Clinical
CC       presentation varies significantly within a family and from one family
CC       to another. Palmoplantar keratoderma is present in around 50% of cases.
CC       {ECO:0000269|PubMed:28575652}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X63657; CAA45197.1; -; mRNA.
DR   EMBL; BT006782; AAP35428.1; -; mRNA.
DR   EMBL; AK297670; BAG60032.1; -; mRNA.
DR   EMBL; AK312360; BAG35278.1; -; mRNA.
DR   EMBL; AC021803; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC036176; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471096; EAW63140.1; -; Genomic_DNA.
DR   EMBL; BC008797; AAH08797.1; -; mRNA.
DR   CCDS; CCDS11982.1; -. [Q06136-1]
DR   PIR; S37652; S37652.
DR   RefSeq; NP_002026.1; NM_002035.2. [Q06136-1]
DR   SMR; Q06136; -.
DR   BioGRID; 108807; 103.
DR   IntAct; Q06136; 16.
DR   MINT; Q06136; -.
DR   STRING; 9606.ENSP00000385083; -.
DR   SwissLipids; SLP:000000155; -.
DR   iPTMnet; Q06136; -.
DR   PhosphoSitePlus; Q06136; -.
DR   SwissPalm; Q06136; -.
DR   BioMuta; KDSR; -.
DR   DMDM; 544358; -.
DR   EPD; Q06136; -.
DR   jPOST; Q06136; -.
DR   MassIVE; Q06136; -.
DR   MaxQB; Q06136; -.
DR   PaxDb; Q06136; -.
DR   PeptideAtlas; Q06136; -.
DR   PRIDE; Q06136; -.
DR   ProteomicsDB; 4650; -.
DR   ProteomicsDB; 58417; -. [Q06136-1]
DR   Antibodypedia; 23084; 141 antibodies from 24 providers.
DR   DNASU; 2531; -.
DR   Ensembl; ENST00000326575; ENSP00000312939; ENSG00000119537. [Q06136-2]
DR   Ensembl; ENST00000645214; ENSP00000494352; ENSG00000119537.
DR   GeneID; 2531; -.
DR   KEGG; hsa:2531; -.
DR   MANE-Select; ENST00000645214.2; ENSP00000494352.1; NM_002035.4; NP_002026.1.
DR   UCSC; uc010dpw.4; human. [Q06136-1]
DR   CTD; 2531; -.
DR   DisGeNET; 2531; -.
DR   GeneCards; KDSR; -.
DR   HGNC; HGNC:4021; KDSR.
DR   HPA; ENSG00000119537; Low tissue specificity.
DR   MalaCards; KDSR; -.
DR   MIM; 136440; gene.
DR   MIM; 617526; phenotype.
DR   neXtProt; NX_Q06136; -.
DR   OpenTargets; ENSG00000119537; -.
DR   Orphanet; 317; Erythrokeratodermia variabilis.
DR   Orphanet; 316; Progressive symmetric erythrokeratodermia.
DR   PharmGKB; PA162392777; -.
DR   VEuPathDB; HostDB:ENSG00000119537; -.
DR   eggNOG; KOG1210; Eukaryota.
DR   GeneTree; ENSGT00940000156961; -.
DR   InParanoid; Q06136; -.
DR   OMA; NCAGMAI; -.
DR   PhylomeDB; Q06136; -.
DR   TreeFam; TF105430; -.
DR   BRENDA; 1.1.1.102; 2681.
DR   PathwayCommons; Q06136; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; Q06136; -.
DR   UniPathway; UPA00222; -.
DR   BioGRID-ORCS; 2531; 228 hits in 1052 CRISPR screens.
DR   ChiTaRS; KDSR; human.
DR   GeneWiki; 3-dehydrosphinganine_reductase; -.
DR   GenomeRNAi; 2531; -.
DR   Pharos; Q06136; Tbio.
DR   PRO; PR:Q06136; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; Q06136; protein.
DR   Bgee; ENSG00000119537; Expressed in endothelial cell and 245 other tissues.
DR   ExpressionAtlas; Q06136; baseline and differential.
DR   Genevisible; Q06136; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0047560; F:3-dehydrosphinganine reductase activity; IDA:MGI.
DR   GO; GO:0006666; P:3-keto-sphinganine metabolic process; IDA:MGI.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IBA:GO_Central.
DR   CDD; cd08939; KDSR-like_SDR_c; 1.
DR   InterPro; IPR045022; KDSR-like.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   PRINTS; PR00080; SDRFAMILY.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chromosomal rearrangement; Disease variant;
KW   Endoplasmic reticulum; Lipid metabolism; Membrane; NADP; Oxidoreductase;
KW   Palmoplantar keratoderma; Proto-oncogene; Reference proteome; Signal;
KW   Sphingolipid metabolism; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..332
FT                   /note="3-ketodihydrosphingosine reductase"
FT                   /id="PRO_0000031982"
FT   TOPO_DOM        26..270
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        271..291
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        292..293
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        294..314
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        315..332
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   NP_BIND         36..60
FT                   /note="NADP"
FT                   /evidence="ECO:0000305"
FT   ACT_SITE        186
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10001"
FT   ACT_SITE        190
FT                   /evidence="ECO:0000305"
FT   BINDING         173
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         139..202
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056641"
FT   VARIANT         55..56
FT                   /note="QG -> R (in EKVP4; loss of 3-dehydrosphinganine
FT                   reductase activity)"
FT                   /evidence="ECO:0000269|PubMed:28575652"
FT                   /id="VAR_079185"
FT   VARIANT         86..107
FT                   /note="Missing (in EKVP4; loss of 3-dehydrosphinganine
FT                   reductase activity)"
FT                   /evidence="ECO:0000269|PubMed:28575652"
FT                   /id="VAR_079186"
FT   VARIANT         186
FT                   /note="Y -> F (in EKVP4; dbSNP:rs1114167452)"
FT                   /evidence="ECO:0000269|PubMed:28575652"
FT                   /id="VAR_079187"
FT   VARIANT         260..293
FT                   /note="Missing (in EKVP4; loss of 3-dehydrosphinganine
FT                   reductase activity)"
FT                   /evidence="ECO:0000269|PubMed:28575652"
FT                   /id="VAR_079188"
SQ   SEQUENCE   332 AA;  36187 MW;  CB4BA5D020858F0C CRC64;
     MLLLAAAFLV AFVLLLYMVS PLISPKPLAL PGAHVVVTGG SSGIGKCIAI ECYKQGAFIT
     LVARNEDKLL QAKKEIEMHS INDKQVVLCI SVDVSQDYNQ VENVIKQAQE KLGPVDMLVN
     CAGMAVSGKF EDLEVSTFER LMSINYLGSV YPSRAVITTM KERRVGRIVF VSSQAGQLGL
     FGFTAYSASK FAIRGLAEAL QMEVKPYNVY ITVAYPPDTD TPGFAEENRT KPLETRLISE
     TTSVCKPEQV AKQIVKDAIQ GNFNSSLGSD GYMLSALTCG MAPVTSITEG LQQVVTMGLF
     RTIALFYLGS FDSIVRRCMM QREKSENADK TA
//
ID   KCNJ3_HUMAN             Reviewed;         501 AA.
AC   P48549; B4DEW7; Q8TBI0;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   23-FEB-2022, entry version 187.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 1;
DE            Short=GIRK-1;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.1;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 3;
GN   Name=KCNJ3; Synonyms=GIRK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8868049; DOI=10.1085/jgp.107.3.381;
RA   Chan K.W., Langan M.N., Sui J., Kozak A., Pabon A., Ladias J.A.A.,
RA   Logothetis D.E.;
RT   "A recombinant inwardly rectifying potassium channel coupled to GTP-binding
RT   proteins.";
RL   J. Gen. Physiol. 107:381-397(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8804710; DOI=10.1016/0169-328x(95)00349-w;
RA   Schoots O., Yue K.T., Macdonald J.F., Hampson D.R., Nobrega J.N.,
RA   Dixon L.M., van Tol H.H.M.;
RT   "Cloning of a G protein-activated inwardly rectifying potassium channel
RT   from human cerebellum.";
RL   Brain Res. Mol. Brain Res. 39:23-30(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Wagner V., Gorischek A., Bauernhofer T., Schreibmayer W.;
RT   "Splice variant hGIRK1d from human breast cancer cells.";
RL   Submitted (OCT-2009) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   GLYCOSYLATION AT ASN-119.
RX   PubMed=10889209; DOI=10.1074/jbc.m005338200;
RA   Pabon A., Chan K.W., Sui J.L., Wu X., Logothetis D.E., Thornhill W.B.;
RT   "Glycosylation of GIRK1 at Asn119 and ROMK1 at Asn117 has different
RT   consequences in potassium channel function.";
RL   J. Biol. Chem. 275:30677-30682(2000).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins. Inward
CC       rectifier potassium channels are characterized by a greater tendency to
CC       allow potassium to flow into the cell rather than out of it. Their
CC       voltage dependence is regulated by the concentration of extracellular
CC       potassium; as external potassium is raised, the voltage range of the
CC       channel opening shifts to more positive voltages. The inward
CC       rectification is mainly due to the blockage of outward current by
CC       internal magnesium. This receptor plays a crucial role in regulating
CC       the heartbeat.
CC   -!- SUBUNIT: Associates with GIRK2, GIRK3 or GIRK4 to form a G-protein
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48549-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48549-2; Sequence=VSP_045432, VSP_045433;
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel (TC
CC       1.A.2.1) family. KCNJ3 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U39196; AAB53094.1; -; mRNA.
DR   EMBL; U50964; AAB42176.1; -; mRNA.
DR   EMBL; GU074515; ADB11081.1; -; mRNA.
DR   EMBL; AK293824; BAG57228.1; -; mRNA.
DR   EMBL; AC061961; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093633; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107060; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022495; AAH22495.1; -; mRNA.
DR   CCDS; CCDS2200.1; -. [P48549-1]
DR   CCDS; CCDS58733.1; -. [P48549-2]
DR   PIR; G02468; G02468.
DR   RefSeq; NP_001247437.1; NM_001260508.1. [P48549-2]
DR   RefSeq; NP_001247438.1; NM_001260509.1.
DR   RefSeq; NP_001247439.1; NM_001260510.1.
DR   RefSeq; NP_002230.1; NM_002239.3. [P48549-1]
DR   SMR; P48549; -.
DR   BioGRID; 109962; 9.
DR   ComplexPortal; CPX-3278; I(KACh) inward rectifier potassium channel complex.
DR   IntAct; P48549; 1.
DR   STRING; 9606.ENSP00000295101; -.
DR   BindingDB; P48549; -.
DR   ChEMBL; CHEMBL1914277; -.
DR   DrugBank; DB00289; Atomoxetine.
DR   DrugBank; DB02451; B-nonylglucoside.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB08954; Ifenprodil.
DR   DrugCentral; P48549; -.
DR   GuidetoPHARMACOLOGY; 434; -.
DR   TCDB; 1.A.2.1.12; the inward rectifier k(+) channel (irk-c) family.
DR   GlyGen; P48549; 1 site.
DR   iPTMnet; P48549; -.
DR   PhosphoSitePlus; P48549; -.
DR   BioMuta; KCNJ3; -.
DR   DMDM; 1352482; -.
DR   MassIVE; P48549; -.
DR   PaxDb; P48549; -.
DR   PeptideAtlas; P48549; -.
DR   PRIDE; P48549; -.
DR   ProteomicsDB; 3990; -.
DR   ProteomicsDB; 55904; -. [P48549-1]
DR   Antibodypedia; 18931; 461 antibodies from 33 providers.
DR   DNASU; 3760; -.
DR   Ensembl; ENST00000295101; ENSP00000295101; ENSG00000162989.
DR   Ensembl; ENST00000544049; ENSP00000438410; ENSG00000162989. [P48549-2]
DR   GeneID; 3760; -.
DR   KEGG; hsa:3760; -.
DR   MANE-Select; ENST00000295101.3; ENSP00000295101.2; NM_002239.4; NP_002230.1.
DR   UCSC; uc002tyv.3; human. [P48549-1]
DR   CTD; 3760; -.
DR   DisGeNET; 3760; -.
DR   GeneCards; KCNJ3; -.
DR   HGNC; HGNC:6264; KCNJ3.
DR   HPA; ENSG00000162989; Tissue enhanced (brain, heart muscle).
DR   MIM; 601534; gene.
DR   neXtProt; NX_P48549; -.
DR   OpenTargets; ENSG00000162989; -.
DR   PharmGKB; PA215; -.
DR   VEuPathDB; HostDB:ENSG00000162989; -.
DR   eggNOG; KOG3827; Eukaryota.
DR   GeneTree; ENSGT01040000240379; -.
DR   HOGENOM; CLU_022738_13_0_1; -.
DR   InParanoid; P48549; -.
DR   OMA; PARMEGN; -.
DR   OrthoDB; 956263at2759; -.
DR   PhylomeDB; P48549; -.
DR   TreeFam; TF313676; -.
DR   PathwayCommons; P48549; -.
DR   Reactome; R-HSA-1296041; Activation of G protein gated Potassium channels.
DR   Reactome; R-HSA-997272; Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits.
DR   SignaLink; P48549; -.
DR   SIGNOR; P48549; -.
DR   BioGRID-ORCS; 3760; 13 hits in 1036 CRISPR screens.
DR   ChiTaRS; KCNJ3; human.
DR   GeneWiki; KCNJ3; -.
DR   GenomeRNAi; 3760; -.
DR   Pharos; P48549; Tchem.
DR   PRO; PR:P48549; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P48549; protein.
DR   Bgee; ENSG00000162989; Expressed in cerebellar vermis and 165 other tissues.
DR   ExpressionAtlas; P48549; baseline and differential.
DR   Genevisible; P48549; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0098688; C:parallel fiber to Purkinje cell synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:BHF-UCL.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0086089; F:voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization; IC:BHF-UCL.
DR   GO; GO:1902282; F:voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization; IC:BHF-UCL.
DR   GO; GO:0098914; P:membrane repolarization during atrial cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:1990573; P:potassium ion import across plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IC:BHF-UCL.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0099625; P:ventricular cardiac muscle cell membrane repolarization; IC:BHF-UCL.
DR   Gene3D; 2.60.40.1400; -; 1.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR041647; IRK_C.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR003274; K_chnl_inward-rec_Kir3.1.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR040445; Kir_TM.
DR   PANTHER; PTHR11767; PTHR11767; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF17655; IRK_C; 1.
DR   PRINTS; PR01327; KIR31CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Phosphoprotein; Potassium; Potassium transport; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN           1..501
FT                   /note="G protein-activated inward rectifier potassium
FT                   channel 1"
FT                   /id="PRO_0000154938"
FT   TOPO_DOM        1..80
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        81..105
FT                   /note="Helical; Name=M1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        106..129
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        130..141
FT                   /note="Helical; Pore-forming; Name=H5"
FT                   /evidence="ECO:0000250"
FT   INTRAMEM        142..148
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        149..157
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        158..179
FT                   /note="Helical; Name=M2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        180..501
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          1..40
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           143..148
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        12..34
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            173
FT                   /note="Role in the control of polyamine-mediated channel
FT                   gating and in the blocking by intracellular magnesium"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63250"
FT   MOD_RES         424
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P63250"
FT   CARBOHYD        119
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10889209"
FT   VAR_SEQ         235
FT                   /note="S -> G (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_045432"
FT   VAR_SEQ         236..501
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_045433"
FT   VARIANT         40
FT                   /note="K -> R (in dbSNP:rs16838016)"
FT                   /id="VAR_049669"
FT   CONFLICT        271
FT                   /note="C -> R (in Ref. 6; AAH22495)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        291
FT                   /note="E -> K (in Ref. 6; AAH22495)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   501 AA;  56603 MW;  825A28ACE2873269 CRC64;
     MSALRRKFGD DYQVVTTSSS GSGLQPQGPG QDPQQQLVPK KKRQRFVDKN GRCNVQHGNL
     GSETSRYLSD LFTTLVDLKW RWNLFIFILT YTVAWLFMAS MWWVIAYTRG DLNKAHVGNY
     TPCVANVYNF PSAFLFFIET EATIGYGYRY ITDKCPEGII LFLFQSILGS IVDAFLIGCM
     FIKMSQPKKR AETLMFSEHA VISMRDGKLT LMFRVGNLRN SHMVSAQIRC KLLKSRQTPE
     GEFLPLDQLE LDVGFSTGAD QLFLVSPLTI CHVIDAKSPF YDLSQRSMQT EQFEIVVILE
     GIVETTGMTC QARTSYTEDE VLWGHRFFPV ISLEEGFFKV DYSQFHATFE VPTPPYSVKE
     QEEMLLMSSP LIAPAITNSK ERHNSVECLD GLDDITTKLP SKLQKITGRE DFPKKLLRMS
     STTSEKAYSL GDLPMKLQRI SSVPGNSEEK LVSKTTKMLS DPMSQSVADL PPKLQKMAGG
     AARMEGNLPA KLRKMNSDRF T
//
ID   SCN9A_HUMAN             Reviewed;        1988 AA.
AC   Q15858; A1BUH5; Q6B4R9; Q6B4S0; Q6B4S1; Q70HX1; Q70HX2; Q8WTU1; Q8WWN4;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 3.
DT   23-FEB-2022, entry version 198.
DE   RecName: Full=Sodium channel protein type 9 subunit alpha {ECO:0000305};
DE   AltName: Full=Neuroendocrine sodium channel {ECO:0000303|PubMed:7720699};
DE            Short=hNE-Na {ECO:0000303|PubMed:7720699};
DE   AltName: Full=Peripheral sodium channel 1;
DE            Short=PN1 {ECO:0000250|UniProtKB:O08562};
DE   AltName: Full=Sodium channel protein type IX subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.7;
GN   Name=SCN9A {ECO:0000312|HGNC:HGNC:10597}; Synonyms=NENA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION IN VOLTAGE-EVOKED
RP   DEPOLARIZATION, SUBCELLULAR LOCATION, SUBUNIT, TISSUE SPECIFICITY, AND
RP   VARIANT ARG-1161.
RC   TISSUE=Thyroid;
RX   PubMed=7720699; DOI=10.1002/j.1460-2075.1995.tb07091.x;
RA   Klugbauer N., Lacinova L., Flockerzi V., Hofmann F.;
RT   "Structure and functional expression of a new member of the tetrodotoxin-
RT   sensitive voltage-activated sodium channel family from human neuroendocrine
RT   cells.";
RL   EMBO J. 14:1084-1090(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INVOLVEMENT IN CONGENITAL
RP   INSENSITIVITY TO PAIN, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND VARIANT
RP   ARG-1161.
RX   PubMed=17167479; DOI=10.1038/nature05413;
RA   Cox J.J., Reimann F., Nicholas A.K., Thornton G., Roberts E., Springell K.,
RA   Karbani G., Jafri H., Mannan J., Raashid Y., Al-Gazali L., Hamamy H.,
RA   Valente E.M., Gorman S., Williams R., McHale D.P., Wood J.N., Gribble F.M.,
RA   Woods C.G.;
RT   "An SCN9A channelopathy causes congenital inability to experience pain.";
RL   Nature 444:894-898(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 136-674 (ISOFORMS 1; 2; 3 AND 4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=15302875; DOI=10.1074/jbc.m406387200;
RA   Raymond C.K., Castle J.C., Garrett-Engele P.W., Armour C.D., Kan Z.G.,
RA   Tsinoremas N.T., Johnson J.M.;
RT   "Expression of alternatively spliced sodium channel alpha-subunit genes:
RT   unique splicing patterns are observed in dorsal root ganglia.";
RL   J. Biol. Chem. 279:46234-46241(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 150-264 AND 1340-1400.
RA   Diss J.K.J., Fraser S.P., Coombes R.C., Djamgoz M.B.A.;
RT   "Upregulation of voltage-gated Na+ channel expression and metastatic
RT   potential in human breast cancer: correlative studies on cell lines and
RT   biopsy tissues.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 840-958, AND VARIANTS PERYTHM THR-859
RP   AND HIS-869.
RX   PubMed=14985375; DOI=10.1136/jmg.2003.012153;
RA   Yang Y., Wang Y., Li S., Xu Z., Li H., Ma L., Fan J., Bu D., Liu B.,
RA   Fan Z., Wu G., Jin J., Ding B., Zhu X., Shen Y.;
RT   "Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients
RT   with primary erythermalgia.";
RL   J. Med. Genet. 41:171-174(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=9169448; DOI=10.1074/jbc.272.23.14805;
RA   Sangameswaran L., Fish L.M., Koch B.D., Rabert D.K., Delgado S.G.,
RA   Ilnicka M., Jakeman L.B., Novakovic S., Wong K., Sze P., Tzoumaka E.,
RA   Stewart G.R., Herman R.C., Chan H., Eglen R.M., Hunter J.C.;
RT   "A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in
RT   rat and human dorsal root ganglia.";
RL   J. Biol. Chem. 272:14805-14809(1997).
RN   [8]
RP   FUNCTION IN VOLTAGE-EVOKED DEPOLARIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=15178348; DOI=10.1016/j.febslet.2004.04.092;
RA   Jo T., Nagata T., Iida H., Imuta H., Iwasawa K., Ma J., Hara K., Omata M.,
RA   Nagai R., Takizawa H., Nagase T., Nakajima T.;
RT   "Voltage-gated sodium channel expressed in cultured human smooth muscle
RT   cells: involvement of SCN9A.";
RL   FEBS Lett. 567:339-343(2004).
RN   [9]
RP   SUBUNIT, INTERACTION WITH THE SPIDER TOXINS HUWENTOXIN-IV AND PROTOXIN-II,
RP   AND MUTAGENESIS OF GLU-829.
RX   PubMed=20855463; DOI=10.1124/mol.110.066332;
RA   Xiao Y., Blumenthal K., Jackson J.O. II, Liang S., Cummins T.R.;
RT   "The tarantula toxins ProTx-II and huwentoxin-IV differentially interact
RT   with human Nav1.7 voltage sensors to inhibit channel activation and
RT   inactivation.";
RL   Mol. Pharmacol. 78:1124-1134(2010).
RN   [10]
RP   SUBUNIT, INTERACTION WITH THE SPIDER HUWENTOXIN-IV, AND MUTAGENESIS OF
RP   GLU-764; GLU-822; LEU-825 AND ASP-827.
RX   PubMed=21659528; DOI=10.1074/jbc.m111.246876;
RA   Xiao Y., Jackson J.O. II, Liang S., Cummins T.R.;
RT   "Common molecular determinants of tarantula huwentoxin-IV inhibition of Na+
RT   channel voltage sensors in domains II and IV.";
RL   J. Biol. Chem. 286:27301-27310(2011).
RN   [11]
RP   SUBUNIT, INTERACTION WITH THE SCORPION ALPHA-TOXIN CVIV4, AND MUTAGENESIS
RP   OF ASP-1597 AND GLU-1600.
RX   PubMed=21887265; DOI=10.1371/journal.pone.0023520;
RA   Rowe A.H., Xiao Y., Scales J., Linse K.D., Rowe M.P., Cummins T.R.,
RA   Zakon H.H.;
RT   "Isolation and characterization of CvIV4: a pain inducing alpha-scorpion
RT   toxin.";
RL   PLoS ONE 6:E23520-E23520(2011).
RN   [12]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF 1409-THR-ILE-1410.
RX   PubMed=23077250; DOI=10.1073/pnas.1206952109;
RA   Walker J.R., Novick P.A., Parsons W.H., McGregor M., Zablocki J.,
RA   Pande V.S., Du Bois J.;
RT   "Marked difference in saxitoxin and tetrodotoxin affinity for the human
RT   nociceptive voltage-gated sodium channel (Nav1.7) [corrected].";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:18102-18107(2012).
RN   [13]
RP   ERRATUM OF PUBMED:23077250.
RA   Walker J.R., Novick P.A., Parsons W.H., McGregor M., Zablocki J.,
RA   Pande V.S., Du Bois J.;
RL   Proc. Natl. Acad. Sci. U.S.A. 109:21551-21551(2012).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, PHOSPHORYLATION AT SER-1490, AND
RP   MUTAGENESIS OF SER-1490.
RX   PubMed=25240195; DOI=10.1016/j.febslet.2014.09.011;
RA   Tan Z.Y., Priest B.T., Krajewski J.L., Knopp K.L., Nisenbaum E.S.,
RA   Cummins T.R.;
RT   "Protein kinase C enhances human sodium channel hNav1.7 resurgent currents
RT   via a serine residue in the domain III-IV linker.";
RL   FEBS Lett. 588:3964-3969(2014).
RN   [15]
RP   SUBUNIT, AND INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G., Wickenden A.D.,
RA   Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [16]
RP   SUBUNIT, AND INTERACTION WITH THE SPIDER BETA/DELTA-THERAPHOTOXIN-PRE1A.
RX   PubMed=28428547; DOI=10.1038/s41598-017-01129-0;
RA   Wingerd J.S., Mozar C.A., Ussing C.A., Murali S.S., Chin Y.K.,
RA   Cristofori-Armstrong B., Durek T., Gilchrist J., Vaughan C.W., Bosmans F.,
RA   Adams D.J., Lewis R.J., Alewood P.F., Mobli M., Christie M.J., Rash L.D.;
RT   "The tarantula toxin beta/delta-TRTX-Pre1a highlights the importance of the
RT   S1-S2 voltage-sensor region for sodium channel subtype selectivity.";
RL   Sci. Rep. 7:974-988(2017).
RN   [17]
RP   TISSUE SPECIFICITY.
RX   PubMed=31647222; DOI=10.1021/acs.bioconjchem.9b00612;
RA   Gonzales J., Demetrio de Souza Franca P., Jiang Y., Pirovano G.,
RA   Kossatz S., Guru N., Yarilin D., Agwa A.J., Schroeder C.I., Patel S.G.,
RA   Ganly I., King G.F., Reiner T.;
RT   "Fluorescence imaging of peripheral nerves by a Nav1.7-targeted inhibitor
RT   cystine knot peptide.";
RL   Bioconj. Chem. 30:2879-2888(2019).
RN   [18] {ECO:0000312|PDB:5EK0}
RP   X-RAY CRYSTALLOGRAPHY (3.53 ANGSTROMS) OF 1527-1559 AND 1581-1622,
RP   FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=26680203; DOI=10.1126/science.aac5464;
RA   Ahuja S., Mukund S., Deng L., Khakh K., Chang E., Ho H., Shriver S.,
RA   Young C., Lin S., Johnson J.P. Jr., Wu P., Li J., Coons M., Tam C.,
RA   Brillantes B., Sampang H., Mortara K., Bowman K.K., Clark K.R., Estevez A.,
RA   Xie Z., Verschoof H., Grimwood M., Dehnhardt C., Andrez J.C., Focken T.,
RA   Sutherlin D.P., Safina B.S., Starovasnik M.A., Ortwine D.F., Franke Y.,
RA   Cohen C.J., Hackos D.H., Koth C.M., Payandeh J.;
RT   "Structural basis of Nav1.7 inhibition by an isoform-selective small-
RT   molecule antagonist.";
RL   Science 350:0-0(2015).
RN   [19] {ECO:0000312|PDB:6N4Q, ECO:0000312|PDB:6N4R}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.60 ANGSTROMS) OF 758-788 AND 813-843 IN
RP   COMPLEX WITH THE SPIDER PROTOXIN-II, AND MUTAGENESIS OF ILE-778; LEU-823;
RP   PHE-824; LEU-825; ALA-826 AND ASP-827.
RX   PubMed=30661758; DOI=10.1016/j.cell.2018.12.018;
RA   Xu H., Li T., Rohou A., Arthur C.P., Tzakoniati F., Wong E., Estevez A.,
RA   Kugel C., Franke Y., Chen J., Ciferri C., Hackos D.H., Koth C.M.,
RA   Payandeh J.;
RT   "Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin.";
RL   Cell 176:702-715(2019).
RN   [20] {ECO:0000312|PDB:6J8G, ECO:0000312|PDB:6J8H, ECO:0000312|PDB:6J8I, ECO:0000312|PDB:6J8J}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.2 ANGSTROMS) OF MUTANT LYS-406 IN
RP   COMPLEX WITH SCN1B; SCN2B; PROTOTOXIN-II; TETRODOTOXIN; HUWENTOXIN-IV AND
RP   SAXITOXIN, GLYCOSYLATION AT ASN-283; ASN-1352; ASN-1366 AND ASN-1375,
RP   SUBUNIT, DISULFIDE BOND, AND MUTAGENESIS OF GLU-406.
RX   PubMed=30765606; DOI=10.1126/science.aaw2493;
RA   Shen H., Liu D., Wu K., Lei J., Yan N.;
RT   "Structures of human Nav1.7 channel in complex with auxiliary subunits and
RT   animal toxins.";
RL   Science 363:1303-1308(2019).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS PERYTHM THR-859 AND HIS-869, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15385606; DOI=10.1523/jneurosci.2695-04.2004;
RA   Cummins T.R., Dib-Hajj S.D., Waxman S.G.;
RT   "Electrophysiological properties of mutant Nav1.7 sodium channels in a
RT   painful inherited neuropathy.";
RL   J. Neurosci. 24:8232-8236(2004).
RN   [22]
RP   VARIANT PERYTHM THR-241.
RX   PubMed=16216943; DOI=10.1001/archneur.62.10.1587;
RA   Michiels J.J., te Morsche R.H.M., Jansen J.B.M.J., Drenth J.P.H.;
RT   "Autosomal dominant erythermalgia associated with a novel mutation in the
RT   voltage-gated sodium channel alpha subunit Nav1.7.";
RL   Arch. Neurol. 62:1587-1590(2005).
RN   [23]
RP   VARIANT PERYTHM VAL-1460, AND CHARACTERIZATION OF VARIANT PERYTHM VAL-1460.
RX   PubMed=15958509; DOI=10.1093/brain/awh514;
RA   Dib-Hajj S.D., Rush A.M., Cummins T.R., Hisama F.M., Novella S.,
RA   Tyrrell L., Marshall L., Waxman S.G.;
RT   "Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces
RT   bursting of sensory neurons.";
RL   Brain 128:1847-1854(2005).
RN   [24]
RP   VARIANTS PERYTHM SER-216; LYS-395; THR-859 AND PHE-869, AND VARIANT
RP   ARG-1161.
RX   PubMed=15955112; DOI=10.1111/j.0022-202x.2005.23737.x;
RA   Drenth J.P., te Morsche R.H., Guillet G., Taieb A., Kirby R.L.,
RA   Jansen J.B.;
RT   "SCN9A mutations define primary erythermalgia as a neuropathic disorder of
RT   voltage gated sodium channels.";
RL   J. Invest. Dermatol. 124:1333-1338(2005).
RN   [25]
RP   VARIANT PERYTHM PHE-869, AND CHARACTERIZATION OF VARIANT PERYTHM PHE-869.
RX   PubMed=16392115; DOI=10.1002/ana.20776;
RA   Han C., Rush A.M., Dib-Hajj S.D., Li S., Xu Z., Wang Y., Tyrrell L.,
RA   Wang X., Yang Y., Waxman S.G.;
RT   "Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7.";
RL   Ann. Neurol. 59:553-558(2006).
RN   [26]
RP   CHARACTERIZATION OF VARIANT PERYTHM SER-216, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16988069; DOI=10.1212/01.wnl.0000231514.33603.1e;
RA   Choi J.S., Dib-Hajj S.D., Waxman S.G.;
RT   "Inherited erythermalgia: limb pain from an S4 charge-neutral Na
RT   channelopathy.";
RL   Neurology 67:1563-1567(2006).
RN   [27]
RP   VARIANTS PEPD CYS-1007; PHE-1309; ASP-1309; PHE-1310; THR-1472; VAL-1473;
RP   ILE-1475 AND LYS-1638, CHARACTERIZATION OF VARIANTS PEPD THR-1472; ILE-1475
RP   AND LYS-1638, AND FUNCTION.
RX   PubMed=17145499; DOI=10.1016/j.neuron.2006.10.006;
RA   Fertleman C.R., Baker M.D., Parker K.A., Moffatt S., Elmslie F.V.,
RA   Abrahamsen B., Ostman J., Klugbauer N., Wood J.N., Gardiner R.M., Rees M.;
RT   "SCN9A mutations in paroxysmal extreme pain disorder: allelic variants
RT   underlie distinct channel defects and phenotypes.";
RL   Neuron 52:767-774(2006).
RN   [28]
RP   CHARACTERIZATION OF VARIANT PERYTHM HIS-869.
RX   PubMed=16702558; DOI=10.1073/pnas.0602813103;
RA   Rush A.M., Dib-Hajj S.D., Liu S., Cummins T.R., Black J.A., Waxman S.G.;
RT   "A single sodium channel mutation produces hyper- or hypoexcitability in
RT   different types of neurons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:8245-8250(2006).
RN   [29]
RP   VARIANT PERYTHM GLU-1643, CHARACTERIZATION OF VARIANT PERYTHM GLU-1643,
RP   VARIANT PEPD GLU-1643, AND CHARACTERIZATION OF VARIANT PEPD GLU-1643.
RX   PubMed=18945915; DOI=10.1523/jneurosci.3443-08.2008;
RA   Estacion M., Dib-Hajj S.D., Benke P.J., Te Morsche R.H., Eastman E.M.,
RA   Macala L.J., Drenth J.P., Waxman S.G.;
RT   "NaV1.7 gain-of-function mutations as a continuum: A1632E displays
RT   physiological changes associated with erythromelalgia and paroxysmal
RT   extreme pain disorder mutations and produces symptoms of both disorders.";
RL   J. Neurosci. 28:11079-11088(2008).
RN   [30]
RP   VARIANT PERYTHM ARG-10, CHARACTERIZATION OF VARIANTS PERYTHM ARG-10 AND
RP   THR-859, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19369487; DOI=10.1093/brain/awp078;
RA   Han C., Dib-Hajj S.D., Lin Z., Li Y., Eastman E.M., Tyrrell L., Cao X.,
RA   Yang Y., Waxman S.G.;
RT   "Early- and late-onset inherited erythromelalgia: genotype-phenotype
RT   correlation.";
RL   Brain 132:1711-1722(2009).
RN   [31]
RP   VARIANTS VAL-62; GLN-149; MET-228; ASN-490; LYS-519; TYR-641; ARG-666;
RP   MET-695; TYR-710; VAL-750; PHE-1134; GLN-1171 AND VAL-1278.
RX   PubMed=19763161; DOI=10.1371/journal.pgen.1000649;
RA   Singh N.A., Pappas C., Dahle E.J., Claes L.R., Pruess T.H., De Jonghe P.,
RA   Thompson J., Dixon M., Gurnett C., Peiffer A., White H.S., Filloux F.,
RA   Leppert M.F.;
RT   "A role of SCN9A in human epilepsies, as a cause of febrile seizures and as
RT   a potential modifier of Dravet syndrome.";
RL   PLoS Genet. 5:E1000649-E1000649(2009).
RN   [32]
RP   VARIANTS CIP GLN-907 AND 1381-ARG--LEU-1385 DEL, AND CHARACTERIZATION OF
RP   VARIANTS CIP GLN-907 AND 1381-ARG--LEU-1385 DEL.
RX   PubMed=20635406; DOI=10.1002/humu.21325;
RA   Cox J.J., Sheynin J., Shorer Z., Reimann F., Nicholas A.K., Zubovic L.,
RA   Baralle M., Wraige E., Manor E., Levy J., Woods C.G., Parvari R.;
RT   "Congenital insensitivity to pain: novel SCN9A missense and in-frame
RT   deletion mutations.";
RL   Hum. Mutat. 31:E1670-E1686(2010).
RN   [33]
RP   VARIANT PEPD PRO-1623, AND CHARACTERIZATION OF VARIANT PEPD PRO-1623.
RX   PubMed=25285947; DOI=10.1097/aln.0000000000000476;
RA   Suter M.R., Bhuiyan Z.A., Laedermann C.J., Kuntzer T., Schaller M.,
RA   Stauffacher M.W., Roulet E., Abriel H., Decosterd I., Wider C.;
RT   "p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a
RT   cold sensitive paroxysmal extreme pain disorder.";
RL   Anesthesiology 122:414-423(2015).
RN   [34]
RP   VARIANT PERYTHM THR-1643, CHARACTERIZATION OF VARIANT PERYTHM THR-1643,
RP   MUTAGENESIS OF ALA-1643, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24311784; DOI=10.1074/jbc.m113.502211;
RA   Eberhardt M., Nakajima J., Klinger A.B., Neacsu C., Huhne K.,
RA   O'Reilly A.O., Kist A.M., Lampe A.K., Fischer K., Gibson J., Nau C.,
RA   Winterpacht A., Lampert A.;
RT   "Inherited pain: sodium channel Nav1.7 A1632T mutation causes
RT   erythromelalgia due to a shift of fast inactivation.";
RL   J. Biol. Chem. 289:1971-1980(2014).
RN   [35]
RP   LACK OF INVOLVEMENT IN EPILEPSY AND FEBRILE SEIZURES, AND VARIANT TYR-641.
RX   PubMed=33216760; DOI=10.1371/journal.pgen.1009161;
RA   Fasham J., Leslie J.S., Harrison J.W., Deline J., Williams K.B., Kuhl A.,
RA   Scott Schwoerer J., Cross H.E., Crosby A.H., Baple E.L.;
RT   "No association between SCN9A and monogenic human epilepsy disorders.";
RL   PLoS Genet. 16:e1009161-e1009161(2020).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability of
CC       excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the protein
CC       forms a sodium-selective channel through which Na(+) ions may pass in
CC       accordance with their electrochemical gradient (PubMed:7720699,
CC       PubMed:17167479, PubMed:25240195, PubMed:26680203, PubMed:15385606,
CC       PubMed:16988069, PubMed:17145499, PubMed:19369487, PubMed:24311784). It
CC       is a tetrodotoxin-sensitive Na(+) channel isoform (PubMed:7720699).
CC       Plays a role in pain mechanisms, especially in the development of
CC       inflammatory pain (PubMed:17167479, PubMed:17145499, PubMed:19369487,
CC       PubMed:24311784). {ECO:0000269|PubMed:15178348,
CC       ECO:0000269|PubMed:15385606, ECO:0000269|PubMed:16988069,
CC       ECO:0000269|PubMed:17145499, ECO:0000269|PubMed:17167479,
CC       ECO:0000269|PubMed:19369487, ECO:0000269|PubMed:24311784,
CC       ECO:0000269|PubMed:25240195, ECO:0000269|PubMed:26680203,
CC       ECO:0000269|PubMed:7720699}.
CC   -!- ACTIVITY REGULATION: Inhibited by tetrodotoxin (PubMed:23077250).
CC       Weakly inhibited by saxitoxin (PubMed:23077250).
CC       {ECO:0000269|PubMed:23077250}.
CC   -!- SUBUNIT: The sodium channel complex consists of a large, channel-
CC       forming alpha subunit (SCN9A) regulated by one or more beta subunits
CC       (SCN1B, SCN2B, SCN3B and SCN4B) (PubMed:7720699, PubMed:17167479,
CC       PubMed:25240195). SCN1B and SCN3B are non-covalently associated with
CC       SCN2A. SCN2B and SCN4B are disulfide-linked to SCN2A. Interacts with
CC       NEDD4 and NEDD4L (By similarity). Interacts with the scorpion alpha-
CC       toxin CvIV4 (PubMed:21887265). Interacts with the conotoxin GVIIJ
CC       (PubMed:24497506). Interacts with the spider huwentoxin-IV (through the
CC       extracellular loop S3-S4 of repeat II) (PubMed:20855463,
CC       PubMed:21659528, PubMed:30661758, PubMed:30765606). Interacts with the
CC       spider protoxin-II (through the extracellular loop S3-S4 of repeats II
CC       and IV) (PubMed:20855463, PubMed:21659528, PubMed:30661758,
CC       PubMed:30765606). Interacts with the spider beta/delta-theraphotoxin-
CC       Pre1a (PubMed:28428547). {ECO:0000250|UniProtKB:Q62205,
CC       ECO:0000269|PubMed:17167479, ECO:0000269|PubMed:21659528,
CC       ECO:0000269|PubMed:21887265, ECO:0000269|PubMed:24497506,
CC       ECO:0000269|PubMed:25240195, ECO:0000269|PubMed:28428547,
CC       ECO:0000269|PubMed:30661758, ECO:0000269|PubMed:30765606,
CC       ECO:0000269|PubMed:7720699}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15385606,
CC       ECO:0000269|PubMed:17167479, ECO:0000269|PubMed:19369487,
CC       ECO:0000269|PubMed:24311784, ECO:0000269|PubMed:25240195,
CC       ECO:0000269|PubMed:26680203, ECO:0000269|PubMed:7720699}; Multi-pass
CC       membrane protein {ECO:0000250|UniProtKB:D0E0C2}. Cell projection,
CC       neuron projection {ECO:0000250|UniProtKB:O08562}. Note=In neurite
CC       terminals. {ECO:0000250|UniProtKB:O08562}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15858-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15858-2; Sequence=VSP_012028;
CC       Name=3;
CC         IsoId=Q15858-3; Sequence=VSP_012029;
CC       Name=4;
CC         IsoId=Q15858-4; Sequence=VSP_012028, VSP_012029;
CC   -!- TISSUE SPECIFICITY: Expressed strongly in dorsal root ganglion, with
CC       only minor levels elsewhere in the body, smooth muscle cells, MTC cell
CC       line and C-cell carcinoma. Also expressed in vagus nerves within the
CC       head and neck region (PubMed:31647222). Isoform 1 is expressed
CC       preferentially in the central and peripheral nervous system. Isoform 2
CC       is expressed preferentially in the dorsal root ganglion.
CC       {ECO:0000269|PubMed:15178348, ECO:0000269|PubMed:15302875,
CC       ECO:0000269|PubMed:31647222, ECO:0000269|PubMed:7720699,
CC       ECO:0000269|PubMed:9169448}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1, S2, S3, S5, S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at every
CC       third position. {ECO:0000305}.
CC   -!- PTM: Phosphorylation at Ser-1490 by PKC in a highly conserved
CC       cytoplasmic loop increases peak sodium currents.
CC       {ECO:0000269|PubMed:25240195}.
CC   -!- PTM: Ubiquitinated by NEDD4L; which may promote its endocytosis. Does
CC       not seem to be ubiquitinated by NEDD4. {ECO:0000250|UniProtKB:Q62205}.
CC   -!- DISEASE: Primary erythermalgia (PERYTHM) [MIM:133020]: Autosomal
CC       dominant disease characterized by recurrent episodes of severe pain
CC       associated with redness and warmth in the feet or hands.
CC       {ECO:0000269|PubMed:14985375, ECO:0000269|PubMed:15385606,
CC       ECO:0000269|PubMed:15955112, ECO:0000269|PubMed:15958509,
CC       ECO:0000269|PubMed:16216943, ECO:0000269|PubMed:16392115,
CC       ECO:0000269|PubMed:16702558, ECO:0000269|PubMed:16988069,
CC       ECO:0000269|PubMed:18945915, ECO:0000269|PubMed:19369487,
CC       ECO:0000269|PubMed:24311784}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Indifference to pain, congenital, autosomal recessive (CIP)
CC       [MIM:243000]: A disorder characterized by congenital inability to
CC       perceive any form of pain, in any part of the body. All other sensory
CC       modalities are preserved and the peripheral and central nervous systems
CC       are apparently intact. Patients perceive the sensations of touch, warm
CC       and cold temperature, proprioception, tickle and pressure, but not
CC       painful stimuli. There is no evidence of a motor or sensory neuropathy,
CC       either axonal or demyelinating. {ECO:0000269|PubMed:20635406}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Paroxysmal extreme pain disorder (PEPD) [MIM:167400]:
CC       Autosomal dominant paroxysmal disorder of pain and autonomic
CC       dysfunction. The distinctive features are paroxysmal episodes of
CC       burning pain in the rectal, ocular, and mandibular areas accompanied by
CC       autonomic manifestations such as skin flushing.
CC       {ECO:0000269|PubMed:17145499, ECO:0000269|PubMed:18945915,
CC       ECO:0000269|PubMed:25285947}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.7/SCN9A subfamily. {ECO:0000305}.
CC   -!- CAUTION: SCN9A has been originally reported to be involved in
CC       generalized epilepsy with febrile seizures plus
CC       (GEFS+)(PubMed:19763161). However, it has later been shown that SCN9A
CC       variants are not a likely cause of autosomal dominant febrile
CC       seizures/febrile seizures plus and other monogenic seizure phenotypes
CC       (PubMed:33216760). {ECO:0000269|PubMed:19763161,
CC       ECO:0000269|PubMed:33216760}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SCN9A entry;
CC       URL="https://en.wikipedia.org/wiki/SCN9A";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Silent pain - Issue 102 of
CC       February 2009;
CC       URL="https://web.expasy.org/spotlight/back_issues/102";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X82835; CAA58042.1; -; mRNA.
DR   EMBL; DQ857292; ABI51981.1; -; mRNA.
DR   EMBL; AC074101; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107082; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108146; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY682084; AAT85833.1; -; mRNA.
DR   EMBL; AY682085; AAT85834.1; -; mRNA.
DR   EMBL; AY682086; AAT85835.1; -; mRNA.
DR   EMBL; AJ310882; CAC84550.1; -; mRNA.
DR   EMBL; AJ310883; CAC84551.1; -; mRNA.
DR   EMBL; AJ310897; CAC84537.1; -; mRNA.
DR   EMBL; AJ580918; CAE45644.1; -; Genomic_DNA.
DR   EMBL; AJ580919; CAE45645.1; -; Genomic_DNA.
DR   CCDS; CCDS46441.1; -. [Q15858-3]
DR   PIR; S54771; S54771.
DR   RefSeq; NP_002968.1; NM_002977.3.
DR   RefSeq; XP_005246814.1; XM_005246757.2.
DR   RefSeq; XP_011509918.1; XM_011511616.2. [Q15858-1]
DR   RefSeq; XP_011509919.1; XM_011511617.2. [Q15858-2]
DR   RefSeq; XP_011509920.1; XM_011511618.2. [Q15858-4]
DR   PDB; 5EK0; X-ray; 3.53 A; A/B/C/D=1527-1559, A/B/C/D=1581-1622.
DR   PDB; 6J8G; EM; 3.20 A; A=1-1988.
DR   PDB; 6J8H; EM; 3.20 A; A=1-1988.
DR   PDB; 6J8I; EM; 3.20 A; A=1-1988.
DR   PDB; 6J8J; EM; 3.20 A; A=1-1988.
DR   PDB; 6N4Q; EM; 3.60 A; A/B/C/D=758-788, A/B/C/D=813-843.
DR   PDB; 6N4R; EM; 4.20 A; A/B/C/D=758-788, A/B/C/D=813-843.
DR   PDB; 6NT3; EM; 3.40 A; A=257-275, A=1501-1631.
DR   PDB; 6NT4; EM; 3.50 A; A=257-275, A=1501-1631.
DR   PDB; 6VXO; EM; 3.50 A; A/C/D/E=817-835.
DR   PDB; 6W6O; EM; 3.20 A; A/D/F/H=817-835.
DR   PDB; 7K48; EM; 3.60 A; A/B/C/D=751-790, A/B/C/D=817-841.
DR   PDBsum; 5EK0; -.
DR   PDBsum; 6J8G; -.
DR   PDBsum; 6J8H; -.
DR   PDBsum; 6J8I; -.
DR   PDBsum; 6J8J; -.
DR   PDBsum; 6N4Q; -.
DR   PDBsum; 6N4R; -.
DR   PDBsum; 6NT3; -.
DR   PDBsum; 6NT4; -.
DR   PDBsum; 6VXO; -.
DR   PDBsum; 6W6O; -.
DR   PDBsum; 7K48; -.
DR   SMR; Q15858; -.
DR   BioGRID; 112239; 6.
DR   IntAct; Q15858; 3.
DR   MINT; Q15858; -.
DR   STRING; 9606.ENSP00000386306; -.
DR   BindingDB; Q15858; -.
DR   ChEMBL; CHEMBL4296; -.
DR   DrugBank; DB09088; Amylocaine.
DR   DrugBank; DB13746; Bioallethrin.
DR   DrugBank; DB05541; Brivaracetam.
DR   DrugBank; DB00564; Carbamazepine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB13269; Dichlorobenzyl alcohol.
DR   DrugBank; DB13961; Fish oil.
DR   DrugBank; DB06218; Lacosamide.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB11186; Pentoxyverine.
DR   DrugBank; DB09345; Pramocaine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB09342; Propoxycaine.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB06201; Rufinamide.
DR   DrugBank; DB09085; Tetracaine.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB00313; Valproic acid.
DR   DrugBank; DB00909; Zonisamide.
DR   DrugCentral; Q15858; -.
DR   GuidetoPHARMACOLOGY; 584; -.
DR   TCDB; 1.A.1.10.5; the voltage-gated ion channel (vic) superfamily.
DR   GlyGen; Q15858; 5 sites.
DR   iPTMnet; Q15858; -.
DR   PhosphoSitePlus; Q15858; -.
DR   BioMuta; SCN9A; -.
DR   DMDM; 327478559; -.
DR   jPOST; Q15858; -.
DR   MassIVE; Q15858; -.
DR   PaxDb; Q15858; -.
DR   PeptideAtlas; Q15858; -.
DR   PRIDE; Q15858; -.
DR   ProteomicsDB; 60797; -. [Q15858-1]
DR   ProteomicsDB; 60798; -. [Q15858-2]
DR   ProteomicsDB; 60799; -. [Q15858-3]
DR   ABCD; Q15858; 2 sequenced antibodies.
DR   Antibodypedia; 33781; 517 antibodies from 38 providers.
DR   DNASU; 6335; -.
DR   Ensembl; ENST00000303354; ENSP00000304748; ENSG00000169432.
DR   Ensembl; ENST00000409435; ENSP00000386330; ENSG00000169432. [Q15858-2]
DR   Ensembl; ENST00000409672; ENSP00000386306; ENSG00000169432. [Q15858-3]
DR   Ensembl; ENST00000642356; ENSP00000495601; ENSG00000169432.
DR   Ensembl; ENST00000645907; ENSP00000495983; ENSG00000169432. [Q15858-4]
DR   GeneID; 6335; -.
DR   KEGG; hsa:6335; -.
DR   MANE-Select; ENST00000642356.2; ENSP00000495601.1; NM_001365536.1; NP_001352465.1.
DR   UCSC; uc002udr.2; human. [Q15858-1]
DR   CTD; 6335; -.
DR   DisGeNET; 6335; -.
DR   GeneCards; SCN9A; -.
DR   GeneReviews; SCN9A; -.
DR   HGNC; HGNC:10597; SCN9A.
DR   HPA; ENSG00000169432; Tissue enhanced (brain).
DR   MalaCards; SCN9A; -.
DR   MIM; 133020; phenotype.
DR   MIM; 167400; phenotype.
DR   MIM; 243000; phenotype.
DR   MIM; 603415; gene.
DR   neXtProt; NX_Q15858; -.
DR   OpenTargets; ENSG00000169432; -.
DR   Orphanet; 88642; Channelopathy-associated congenital insensitivity to pain.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus.
DR   Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2.
DR   Orphanet; 46348; Paroxysmal extreme pain disorder.
DR   Orphanet; 90026; Primary erythromelalgia.
DR   Orphanet; 306577; Sodium channelopathy-related small fiber neuropathy.
DR   PharmGKB; PA35010; -.
DR   VEuPathDB; HostDB:ENSG00000169432; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   GeneTree; ENSGT00940000161368; -.
DR   HOGENOM; CLU_000540_5_0_1; -.
DR   InParanoid; Q15858; -.
DR   OMA; QSKYMTD; -.
DR   OrthoDB; 56920at2759; -.
DR   PhylomeDB; Q15858; -.
DR   TreeFam; TF323985; -.
DR   PathwayCommons; Q15858; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-9717207; Sensory perception of sweet, bitter, and umami (glutamate) taste.
DR   SignaLink; Q15858; -.
DR   SIGNOR; Q15858; -.
DR   BioGRID-ORCS; 6335; 4 hits in 1042 CRISPR screens.
DR   ChiTaRS; SCN9A; human.
DR   GeneWiki; Nav1.7; -.
DR   GenomeRNAi; 6335; -.
DR   Pharos; Q15858; Tclin.
DR   PRO; PR:Q15858; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q15858; protein.
DR   Bgee; ENSG00000169432; Expressed in sural nerve and 164 other tissues.
DR   ExpressionAtlas; Q15858; baseline and differential.
DR   Genevisible; Q15858; HS.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IBA:GO_Central.
DR   GO; GO:0031402; F:sodium ion binding; IEA:Ensembl.
DR   GO; GO:0005244; F:voltage-gated ion channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IDA:UniProtKB.
DR   GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IEA:UniProtKB-KW.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:UniProtKB.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   CDD; cd13433; Na_channel_gate; 1.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR044564; Na_chnl_inactivation_gate.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   InterPro; IPR028803; SCN9A.
DR   InterPro; IPR043203; VGCC_Ca_Na.
DR   InterPro; IPR027359; Volt_channel_dom_sf.
DR   PANTHER; PTHR10037; PTHR10037; 1.
DR   PANTHER; PTHR10037:SF221; PTHR10037:SF221; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   SMART; SM00015; IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   Disease variant; Disulfide bond; Epilepsy; Glycoprotein; Ion channel;
KW   Ion transport; Membrane; Phosphoprotein; Reference proteome; Repeat;
KW   Sodium; Sodium channel; Sodium transport; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation; Voltage-gated channel.
FT   CHAIN           1..1988
FT                   /note="Sodium channel protein type 9 subunit alpha"
FT                   /id="PRO_0000048502"
FT   TOPO_DOM        1..126
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        127..145
FT                   /note="Helical; Name=S1 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        146..152
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        153..173
FT                   /note="Helical; Name=S2 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        174..187
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        188..205
FT                   /note="Helical; Name=S3 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        206..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        212..228
FT                   /note="Helical; Name=S4 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        229..247
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        248..267
FT                   /note="Helical; Name=S5 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        268..346
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        347..371
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        372..378
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        379..399
FT                   /note="Helical; Name=S6 of repeat I"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        400..744
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        745..763
FT                   /note="Helical; Name=S1 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        764..774
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        775..794
FT                   /note="Helical; Name=S2 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        795..808
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        809..828
FT                   /note="Helical; Name=S3 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        829..830
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        831..848
FT                   /note="Helical; Name=S4 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        849..864
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        865..883
FT                   /note="Helical; Name=S5 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        884..912
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        913..933
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        934..946
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        947..967
FT                   /note="Helical; Name=S6 of repeat II"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        968..1193
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1194..1211
FT                   /note="Helical; Name=S1 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1212..1224
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1225..1243
FT                   /note="Helical; Name=S2 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1244..1257
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1258..1276
FT                   /note="Helical; Name=S3 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1277..1284
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1285..1303
FT                   /note="Helical; Name=S4 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1304..1320
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1321..1340
FT                   /note="Helical; Name=S5 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1341..1392
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1393..1414
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1415..1431
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1432..1453
FT                   /note="Helical; Name=S6 of repeat III"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1454..1516
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1517..1534
FT                   /note="Helical; Name=S1 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1535..1545
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1546..1564
FT                   /note="Helical; Name=S2 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1565..1576
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1577..1594
FT                   /note="Helical; Name=S3 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1595..1607
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1608..1624
FT                   /note="Helical; Name=S4 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1625..1643
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1644..1661
FT                   /note="Helical; Name=S5 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1662..1683
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        1684..1706
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1707..1736
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1737..1759
FT                   /note="Helical; Name=S6 of repeat IV"
FT                   /evidence="ECO:0000250|UniProtKB:D0E0C2"
FT   TOPO_DOM        1760..1988
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REPEAT          112..410
FT                   /note="I"
FT                   /evidence="ECO:0000305"
FT   REPEAT          726..989
FT                   /note="II"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1180..1488
FT                   /note="III"
FT                   /evidence="ECO:0000305"
FT   REPEAT          1497..1795
FT                   /note="IV"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1889..1918
FT                   /note="IQ"
FT   REGION          26..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          461..543
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          565..611
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1102..1148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1934..1988
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        26..51
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        486..529
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        565..592
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        594..610
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1117..1131
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1934..1960
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1961..1988
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            822
FT                   /note="Is directly targeted by the spider protoxin-II"
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   SITE            827
FT                   /note="Is directly targeted by the spider protoxin-II"
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MOD_RES         1490
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:25240195"
FT   CARBOHYD        209
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        283
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   CARBOHYD        1352
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   CARBOHYD        1366
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   CARBOHYD        1375
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        275..324
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        895
FT                   /note="Interchain; with SCN2B or SCN4B"
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        895
FT                   /note="Interchain; with the conotoxin GVIIJ (when the
FT                   channel is not linked to SCN2B or SCN4B; the bond to SCN2B
FT                   or SCN4B protects the channel from the inhibition by
FT                   toxin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04775"
FT   DISULFID        897..903
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        935..944
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        1350..1370
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   DISULFID        1715..1730
FT                   /evidence="ECO:0000269|PubMed:30765606,
FT                   ECO:0007744|PDB:6J8G, ECO:0007744|PDB:6J8H,
FT                   ECO:0007744|PDB:6J8I, ECO:0007744|PDB:6J8J"
FT   VAR_SEQ         200..229
FT                   /note="YLTEFVNLGNVSALRTFRVLRALKTISVIP -> YVTEFVDLGNVSALRTFR
FT                   VLRALKTISVIP (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15302875"
FT                   /id="VSP_012028"
FT   VAR_SEQ         648..658
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15302875,
FT                   ECO:0000303|PubMed:17167479, ECO:0000303|PubMed:7720699"
FT                   /id="VSP_012029"
FT   VARIANT         10
FT                   /note="Q -> R (in PERYTHM; causes a hyperpolarizing shift
FT                   of -5.3 mV for the midpoint of activation which is smaller
FT                   than that seen in other mutations causing early-onset
FT                   erythromelalgia mutations; also causes a faster rate of
FT                   activation and slower deactivation compared to wild-type;
FT                   expression of the mutant protein induced hyperexcitability
FT                   in dorsal root ganglion neurons but the increase is smaller
FT                   than that produced by Thr-859; dbSNP:rs267607030)"
FT                   /evidence="ECO:0000269|PubMed:19369487"
FT                   /id="VAR_064595"
FT   VARIANT         62
FT                   /note="I -> V (found in a patient with febrile seizures;
FT                   unknown pathological significance; dbSNP:rs121908920)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064596"
FT   VARIANT         149
FT                   /note="P -> Q (found in a patient with febrile seizures;
FT                   unknown pathological significance; dbSNP:rs121908921)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064597"
FT   VARIANT         216
FT                   /note="F -> S (in PERYTHM; hyperpolarizes the voltage
FT                   dependence of activation by 11 mV, accelerates activation,
FT                   slows deactivation and enhances the response to slow, small
FT                   depolarizations; dbSNP:rs80356469)"
FT                   /evidence="ECO:0000269|PubMed:15955112,
FT                   ECO:0000269|PubMed:16988069"
FT                   /id="VAR_064598"
FT   VARIANT         228
FT                   /note="I -> M (in dbSNP:rs71428908)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064599"
FT   VARIANT         241
FT                   /note="S -> T (in PERYTHM; dbSNP:rs80356470)"
FT                   /evidence="ECO:0000269|PubMed:16216943"
FT                   /id="VAR_032014"
FT   VARIANT         395
FT                   /note="N -> K (in PERYTHM; dbSNP:rs80356471)"
FT                   /evidence="ECO:0000269|PubMed:15955112"
FT                   /id="VAR_064600"
FT   VARIANT         490
FT                   /note="S -> N (in dbSNP:rs58022607)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064602"
FT   VARIANT         519
FT                   /note="E -> K (in dbSNP:rs187453572)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064603"
FT   VARIANT         641
FT                   /note="N -> Y (found in patients with febrile seizures
FT                   plus; unknown pathological significance;
FT                   dbSNP:rs121908918)"
FT                   /evidence="ECO:0000269|PubMed:19763161,
FT                   ECO:0000269|PubMed:33216760"
FT                   /id="VAR_064604"
FT   VARIANT         666
FT                   /note="K -> R (in dbSNP:rs121908919)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064605"
FT   VARIANT         695
FT                   /note="I -> M (in dbSNP:rs199588089)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064606"
FT   VARIANT         710
FT                   /note="C -> Y (found in a patient with severe myoclonic
FT                   epilepsy in infancy; unknown pathological significance;
FT                   dbSNP:rs201709980)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064607"
FT   VARIANT         750
FT                   /note="I -> V (in dbSNP:rs182650126)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064608"
FT   VARIANT         859
FT                   /note="I -> T (in PERYTHM; sporadic; activated at more
FT                   negative potentials; slower inactivation kinetics than
FT                   wild-type channels; dbSNP:rs80356474)"
FT                   /evidence="ECO:0000269|PubMed:14985375,
FT                   ECO:0000269|PubMed:15385606, ECO:0000269|PubMed:15955112,
FT                   ECO:0000269|PubMed:19369487"
FT                   /id="VAR_019947"
FT   VARIANT         869
FT                   /note="L -> F (in PERYTHM; causes a hyperpolarizing shift
FT                   in channel activation, a depolarizing shift of inactivation
FT                   and an 18-fold increase in deactivation time compared to
FT                   wild-type; the mean ramp current amplitude in response to
FT                   slow depolarization is higher in the mutant channels;
FT                   dbSNP:rs80356476)"
FT                   /evidence="ECO:0000269|PubMed:15955112,
FT                   ECO:0000269|PubMed:16392115"
FT                   /id="VAR_064609"
FT   VARIANT         869
FT                   /note="L -> H (in PERYTHM; activated at more negative
FT                   potentials; slower inactivation kinetics than wild-type
FT                   channels; dbSNP:rs80356475)"
FT                   /evidence="ECO:0000269|PubMed:14985375,
FT                   ECO:0000269|PubMed:15385606, ECO:0000269|PubMed:16702558"
FT                   /id="VAR_019948"
FT   VARIANT         907
FT                   /note="R -> Q (in CIP; significant reduction in membrane
FT                   localization of the mutant protein compared to the wild-
FT                   type; complete loss of function of the sodium channel;
FT                   dbSNP:rs1024152367)"
FT                   /evidence="ECO:0000269|PubMed:20635406"
FT                   /id="VAR_064610"
FT   VARIANT         932
FT                   /note="M -> L (in dbSNP:rs12478318)"
FT                   /id="VAR_030444"
FT   VARIANT         943
FT                   /note="M -> L (in dbSNP:rs12478318)"
FT                   /id="VAR_055646"
FT   VARIANT         1007
FT                   /note="R -> C (in PEPD; dbSNP:rs121908910)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032015"
FT   VARIANT         1134
FT                   /note="L -> F (in dbSNP:rs200160858)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064611"
FT   VARIANT         1161
FT                   /note="W -> R (in dbSNP:rs6746030)"
FT                   /evidence="ECO:0000269|PubMed:15955112,
FT                   ECO:0000269|PubMed:17167479, ECO:0000269|PubMed:7720699"
FT                   /id="VAR_019949"
FT   VARIANT         1171
FT                   /note="E -> Q (found in a patient with severe myoclonic
FT                   epilepsy in infancy; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064612"
FT   VARIANT         1278
FT                   /note="L -> V (in dbSNP:rs180922748)"
FT                   /evidence="ECO:0000269|PubMed:19763161"
FT                   /id="VAR_064613"
FT   VARIANT         1309
FT                   /note="V -> D (in PEPD; dbSNP:rs121908911)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032016"
FT   VARIANT         1309
FT                   /note="V -> F (in PEPD; dbSNP:rs121908912)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032017"
FT   VARIANT         1310
FT                   /note="V -> F (in PEPD; dbSNP:rs121908913)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032018"
FT   VARIANT         1381..1385
FT                   /note="Missing (in CIP; significant reduction in membrane
FT                   localization of the mutant protein compared to the wild-
FT                   type; complete loss of function of the sodium channel)"
FT                   /evidence="ECO:0000269|PubMed:20635406"
FT                   /id="VAR_064614"
FT   VARIANT         1460
FT                   /note="F -> V (in PERYTHM; produces a hyperpolarizing shift
FT                   in channel activation and a depolarizing shift in steady-
FT                   state activation; dbSNP:rs80356478)"
FT                   /evidence="ECO:0000269|PubMed:15958509"
FT                   /id="VAR_032019"
FT   VARIANT         1472
FT                   /note="I -> T (in PEPD; reduction in fast inactivation
FT                   leading to persistent sodium current; dbSNP:rs121908914)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032020"
FT   VARIANT         1473
FT                   /note="F -> V (in PEPD; dbSNP:rs1553474394)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032021"
FT   VARIANT         1475
FT                   /note="T -> I (in PEPD; reduction in fast inactivation
FT                   leading to persistent sodium current; dbSNP:rs121908915)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032022"
FT   VARIANT         1623
FT                   /note="L -> P (in PEPD; depolarizes the voltage-dependence
FT                   of channel activation and steady-state fast inactivation;
FT                   increases ramp current; dbSNP:rs1131691776)"
FT                   /evidence="ECO:0000269|PubMed:25285947"
FT                   /id="VAR_072279"
FT   VARIANT         1638
FT                   /note="M -> K (in PEPD; reduction in fast inactivation
FT                   leading to persistent sodium current)"
FT                   /evidence="ECO:0000269|PubMed:17145499"
FT                   /id="VAR_032023"
FT   VARIANT         1643
FT                   /note="A -> E (in PERYTHM and PEPD; hyperpolarizes voltage-
FT                   dependence of channel activation; depolarizes the voltage-
FT                   dependence of steady-state fast inactivation; slows channel
FT                   deactivation; enhances persistent and resurgent current;
FT                   enhances neuronal hyperexcitability in dorsal root ganglion
FT                   neurons; dbSNP:rs879253994)"
FT                   /evidence="ECO:0000269|PubMed:18945915,
FT                   ECO:0000269|PubMed:24311784"
FT                   /id="VAR_072280"
FT   VARIANT         1643
FT                   /note="A -> T (in PERYTHM; no effect on voltage-dependence
FT                   of channel activation; depolarizes the voltage dependence
FT                   of steady-state fast inactivation; accelerates channel
FT                   deactivation; no increase in persistent and resurgent
FT                   currents; enhances neuronal hyperexcitability in dorsal
FT                   root ganglion neurons)"
FT                   /evidence="ECO:0000269|PubMed:24311784"
FT                   /id="VAR_072281"
FT   VARIANT         1919
FT                   /note="D -> G (in dbSNP:rs3750904)"
FT                   /id="VAR_019950"
FT   MUTAGEN         406
FT                   /note="E->K: Hyperpolarizes the voltage dependence of
FT                   activation by 10.6 mV and prolonges fast-inactivation
FT                   duration when coexpressed with SCN1B and SCN2B."
FT                   /evidence="ECO:0000269|PubMed:30765606"
FT   MUTAGEN         764
FT                   /note="E->Q: 5-fold less blocked by the spider huwentoxin-
FT                   IV."
FT                   /evidence="ECO:0000269|PubMed:21659528"
FT   MUTAGEN         778
FT                   /note="I->A: 5-fold less inhibited by the spider protoxin-
FT                   II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         822
FT                   /note="E->A: No change in inhibition (IC(50)) by the spider
FT                   protoxin-II, but has a significant impact on channel
FT                   activation by shifiting the V(50) towart 0 mV when targeted
FT                   by protoxin-II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         822
FT                   /note="E->Q: 18-fold less blocked by the spider huwentoxin-
FT                   IV."
FT                   /evidence="ECO:0000269|PubMed:21659528"
FT   MUTAGEN         823
FT                   /note="L->A: 9-fold less inhibited by the spider protoxin-
FT                   II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         824
FT                   /note="F->A: 4-fold less inhibited by the spider protoxin-
FT                   II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         824
FT                   /note="F->C: Less inhibited by the spider protoxin-II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         825
FT                   /note="L->A: No change in inhibition by the spider
FT                   protoxin-II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         825
FT                   /note="L->C: 19-fold less blocked by the spider huwentoxin-
FT                   IV."
FT                   /evidence="ECO:0000269|PubMed:21659528"
FT   MUTAGEN         826
FT                   /note="A->L: 8-fold less inhibited by the spider protoxin-
FT                   II."
FT                   /evidence="ECO:0000269|PubMed:30661758"
FT   MUTAGEN         827
FT                   /note="D->A: 13-fold less blocked by the spider huwentoxin-
FT                   IV, 3-fold less inhibited by the spider protoxin-II, and
FT                   has a significant impact on channel activation by shifiting
FT                   the V(50) towart 0 mV when targeted by protoxin-II."
FT                   /evidence="ECO:0000269|PubMed:21659528,
FT                   ECO:0000269|PubMed:30661758"
FT   MUTAGEN         829
FT                   /note="E->C: 400-fold less blocked by the spider
FT                   huwentoxin-IV."
FT                   /evidence="ECO:0000269|PubMed:20855463"
FT   MUTAGEN         1409..1410
FT                   /note="TI->MD: Important increase in inhibition by
FT                   saxitoxin and little increase in inhibition by
FT                   tetrodotoxin."
FT                   /evidence="ECO:0000269|PubMed:23077250"
FT   MUTAGEN         1490
FT                   /note="S->A: Abolishes stimulation by agents that stimulate
FT                   PKC activity."
FT                   /evidence="ECO:0000269|PubMed:25240195"
FT   MUTAGEN         1490
FT                   /note="S->D,E: Increases current amplitude."
FT                   /evidence="ECO:0000269|PubMed:25240195"
FT   MUTAGEN         1597
FT                   /note="D->A: Decrease of the inhibition of fast
FT                   inactivation produced by the scorpion alpha-toxin CvIV4 on
FT                   this channel."
FT                   /evidence="ECO:0000269|PubMed:21887265"
FT   MUTAGEN         1600
FT                   /note="E->Q: Decrease of the inhibition of fast
FT                   inactivation produced by the scorpion alpha-toxin CvIV4 on
FT                   this channel."
FT                   /evidence="ECO:0000269|PubMed:21887265"
FT   MUTAGEN         1643
FT                   /note="A->D: Depolarizes the voltage-dependence of steady-
FT                   state fast inactivation; enhances persistent current."
FT                   /evidence="ECO:0000269|PubMed:24311784"
FT   MUTAGEN         1643
FT                   /note="A->K: No effect on voltage-dependence of steady-
FT                   state fast inactivation."
FT                   /evidence="ECO:0000269|PubMed:24311784"
FT   MUTAGEN         1643
FT                   /note="A->V: No effect on voltage-dependence of steady-
FT                   state fast inactivation."
FT                   /evidence="ECO:0000269|PubMed:24311784"
FT   CONFLICT        267
FT                   /note="F -> S (in Ref. 4; AAT85834)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        301
FT                   /note="K -> R (in Ref. 4; AAT85835)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        309
FT                   /note="S -> P (in Ref. 4; AAT85834)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        420
FT                   /note="E -> G (in Ref. 4; AAT85834)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        430
FT                   /note="L -> P (in Ref. 4; AAT85834)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        501
FT                   /note="S -> P (in Ref. 4; AAT85835)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        610
FT                   /note="P -> T (in Ref. 4; AAT85835)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        642
FT                   /note="G -> R (in Ref. 4; AAT85835)"
FT                   /evidence="ECO:0000305"
FT   HELIX           115..123
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           126..143
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           152..175
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          178..180
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           181..185
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           187..203
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           210..214
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           215..218
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           219..227
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           231..244
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           246..267
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           270..272
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          273..278
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           281..283
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           286..292
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           296..302
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          317..321
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          328..332
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            337..341
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          344..346
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           347..358
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           363..374
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           376..378
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           379..389
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           391..416
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           727..739
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            743..745
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           746..761
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           770..798
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           800..805
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           807..822
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           833..836
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           837..846
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           850..863
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            864..866
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           867..895
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            896..899
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          901..904
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          910..912
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           913..924
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           928..939
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           941..971
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1177..1190
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1192..1211
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1214..1217
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1220..1254
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1257..1278
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1287..1290
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1291..1299
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1300..1303
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1305..1343
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1349..1352
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            1353..1356
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1361..1363
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1367..1376
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1378..1383
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1386..1391
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1392..1404
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1408..1417
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1434..1444
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1446..1466
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            1467..1469
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1472..1474
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1476..1487
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1503..1513
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1515..1533
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1541..1569
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1571..1575
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1577..1602
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1606..1613
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1614..1616
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1617..1620
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1623..1626
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1628..1639
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1641..1666
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   STRAND          1676..1683
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1684..1695
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            1696..1699
FT                   /evidence="ECO:0007829|PDB:6J8I"
FT   HELIX           1700..1708
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   TURN            1712..1714
FT                   /evidence="ECO:0007829|PDB:6J8G"
FT   HELIX           1733..1767
FT                   /evidence="ECO:0007829|PDB:6J8G"
SQ   SEQUENCE   1988 AA;  226372 MW;  1BAEB8F32EBF5438 CRC64;
     MAMLPPPGPQ SFVHFTKQSL ALIEQRIAER KSKEPKEEKK DDDEEAPKPS SDLEAGKQLP
     FIYGDIPPGM VSEPLEDLDP YYADKKTFIV LNKGKTIFRF NATPALYMLS PFSPLRRISI
     KILVHSLFSM LIMCTILTNC IFMTMNNPPD WTKNVEYTFT GIYTFESLVK ILARGFCVGE
     FTFLRDPWNW LDFVVIVFAY LTEFVNLGNV SALRTFRVLR ALKTISVIPG LKTIVGALIQ
     SVKKLSDVMI LTVFCLSVFA LIGLQLFMGN LKHKCFRNSL ENNETLESIM NTLESEEDFR
     KYFYYLEGSK DALLCGFSTD SGQCPEGYTC VKIGRNPDYG YTSFDTFSWA FLALFRLMTQ
     DYWENLYQQT LRAAGKTYMI FFVVVIFLGS FYLINLILAV VAMAYEEQNQ ANIEEAKQKE
     LEFQQMLDRL KKEQEEAEAI AAAAAEYTSI RRSRIMGLSE SSSETSKLSS KSAKERRNRR
     KKKNQKKLSS GEEKGDAEKL SKSESEDSIR RKSFHLGVEG HRRAHEKRLS TPNQSPLSIR
     GSLFSARRSS RTSLFSFKGR GRDIGSETEF ADDEHSIFGD NESRRGSLFV PHRPQERRSS
     NISQASRSPP MLPVNGKMHS AVDCNGVVSL VDGRSALMLP NGQLLPEVII DKATSDDSGT
     TNQIHKKRRC SSYLLSEDML NDPNLRQRAM SRASILTNTV EELEESRQKC PPWWYRFAHK
     FLIWNCSPYW IKFKKCIYFI VMDPFVDLAI TICIVLNTLF MAMEHHPMTE EFKNVLAIGN
     LVFTGIFAAE MVLKLIAMDP YEYFQVGWNI FDSLIVTLSL VELFLADVEG LSVLRSFRLL
     RVFKLAKSWP TLNMLIKIIG NSVGALGNLT LVLAIIVFIF AVVGMQLFGK SYKECVCKIN
     DDCTLPRWHM NDFFHSFLIV FRVLCGEWIE TMWDCMEVAG QAMCLIVYMM VMVIGNLVVL
     NLFLALLLSS FSSDNLTAIE EDPDANNLQI AVTRIKKGIN YVKQTLREFI LKAFSKKPKI
     SREIRQAEDL NTKKENYISN HTLAEMSKGH NFLKEKDKIS GFGSSVDKHL MEDSDGQSFI
     HNPSLTVTVP IAPGESDLEN MNAEELSSDS DSEYSKVRLN RSSSSECSTV DNPLPGEGEE
     AEAEPMNSDE PEACFTDGCV WRFSCCQVNI ESGKGKIWWN IRKTCYKIVE HSWFESFIVL
     MILLSSGALA FEDIYIERKK TIKIILEYAD KIFTYIFILE MLLKWIAYGY KTYFTNAWCW
     LDFLIVDVSL VTLVANTLGY SDLGPIKSLR TLRALRPLRA LSRFEGMRVV VNALIGAIPS
     IMNVLLVCLI FWLIFSIMGV NLFAGKFYEC INTTDGSRFP ASQVPNRSEC FALMNVSQNV
     RWKNLKVNFD NVGLGYLSLL QVATFKGWTI IMYAAVDSVN VDKQPKYEYS LYMYIYFVVF
     IIFGSFFTLN LFIGVIIDNF NQQKKKLGGQ DIFMTEEQKK YYNAMKKLGS KKPQKPIPRP
     GNKIQGCIFD LVTNQAFDIS IMVLICLNMV TMMVEKEGQS QHMTEVLYWI NVVFIILFTG
     ECVLKLISLR HYYFTVGWNI FDFVVVIISI VGMFLADLIE TYFVSPTLFR VIRLARIGRI
     LRLVKGAKGI RTLLFALMMS LPALFNIGLL LFLVMFIYAI FGMSNFAYVK KEDGINDMFN
     FETFGNSMIC LFQITTSAGW DGLLAPILNS KPPDCDPKKV HPGSSVEGDC GNPSVGIFYF
     VSYIIISFLV VVNMYIAVIL ENFSVATEES TEPLSEDDFE MFYEVWEKFD PDATQFIEFS
     KLSDFAAALD PPLLIAKPNK VQLIAMDLPM VSGDRIHCLD ILFAFTKRVL GESGEMDSLR
     SQMEERFMSA NPSKVSYEPI TTTLKRKQED VSATVIQRAY RRYRLRQNVK NISSIYIKDG
     DRDDDLLNKK DMAFDNVNEN SSPEKTDATS STTSPPSYDS VTKPDKEKYE QDRTEKEDKG
     KDSKESKK
//
ID   SP4_HUMAN               Reviewed;         784 AA.
AC   Q02446; O60402; Q32M52;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   23-FEB-2022, entry version 182.
DE   RecName: Full=Transcription factor Sp4;
DE   AltName: Full=SPR-1;
GN   Name=SP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-197.
RC   TISSUE=Uterus;
RX   PubMed=1454515; DOI=10.1093/nar/20.21.5519;
RA   Hagen G., Mueller S., Beato M., Suske G.;
RT   "Cloning by recognition site screening of two novel GT box binding
RT   proteins: a family of Sp1 related genes.";
RL   Nucleic Acids Res. 20:5519-5525(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   INACTIVATION OF 9AATAD MOTIF.
RX   PubMed=31375868; DOI=10.1007/s00018-019-03251-w;
RA   Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.;
RT   "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with
RT   valines and intron reservoirs.";
RL   Cell. Mol. Life Sci. 77:1793-1810(2020).
CC   -!- FUNCTION: Binds to GT and GC boxes promoters elements. Probable
CC       transcriptional activator.
CC   -!- INTERACTION:
CC       Q02446; Q13444: ADAM15; NbExp=3; IntAct=EBI-10198587, EBI-77818;
CC       Q02446; Q9BXS5: AP1M1; NbExp=3; IntAct=EBI-10198587, EBI-541426;
CC       Q02446; Q9BTQ8: ATXN7L1; NbExp=3; IntAct=EBI-10198587, EBI-10298510;
CC       Q02446; A0A0S2Z5G4: BANP; NbExp=3; IntAct=EBI-10198587, EBI-16429704;
CC       Q02446; B4DE54: BANP; NbExp=3; IntAct=EBI-10198587, EBI-16429313;
CC       Q02446; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-10198587, EBI-11524452;
CC       Q02446; Q8N9N5-7: BANP; NbExp=3; IntAct=EBI-10198587, EBI-16429296;
CC       Q02446; Q96Q77: CIB3; NbExp=6; IntAct=EBI-10198587, EBI-10292696;
CC       Q02446; P27658: COL8A1; NbExp=3; IntAct=EBI-10198587, EBI-747133;
CC       Q02446; P41970: ELK3; NbExp=3; IntAct=EBI-10198587, EBI-1758534;
CC       Q02446; Q75MZ5: FOXP2; NbExp=4; IntAct=EBI-10198587, EBI-10255915;
CC       Q02446; P52655: GTF2A1; NbExp=3; IntAct=EBI-10198587, EBI-389518;
CC       Q02446; A0A024R5S0: hCG_2003792; NbExp=6; IntAct=EBI-10198587, EBI-10188461;
CC       Q02446; Q8TAP4: LMO3; NbExp=3; IntAct=EBI-10198587, EBI-742259;
CC       Q02446; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-10198587, EBI-739832;
CC       Q02446; Q4G0S1: LOC730441; NbExp=3; IntAct=EBI-10198587, EBI-10241801;
CC       Q02446; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-10198587, EBI-348259;
CC       Q02446; Q13952-2: NFYC; NbExp=3; IntAct=EBI-10198587, EBI-11956831;
CC       Q02446; Q16656: NRF1; NbExp=3; IntAct=EBI-10198587, EBI-2547810;
CC       Q02446; Q16656-4: NRF1; NbExp=3; IntAct=EBI-10198587, EBI-11742836;
CC       Q02446; Q9HAT8: PELI2; NbExp=3; IntAct=EBI-10198587, EBI-448407;
CC       Q02446; Q96T60: PNKP; NbExp=3; IntAct=EBI-10198587, EBI-1045072;
CC       Q02446; Q7Z3K3: POGZ; NbExp=3; IntAct=EBI-10198587, EBI-1389308;
CC       Q02446; P14859: POU2F1; NbExp=5; IntAct=EBI-10198587, EBI-624770;
CC       Q02446; P14859-6: POU2F1; NbExp=3; IntAct=EBI-10198587, EBI-11526590;
CC       Q02446; P86479: PRR20C; NbExp=5; IntAct=EBI-10198587, EBI-10172814;
CC       Q02446; P86480: PRR20D; NbExp=3; IntAct=EBI-10198587, EBI-12754095;
CC       Q02446; Q02446: SP4; NbExp=3; IntAct=EBI-10198587, EBI-10198587;
CC       Q02446; Q5MJ10: SPANXN2; NbExp=3; IntAct=EBI-10198587, EBI-12023934;
CC       Q02446; Q5MJ09: SPANXN3; NbExp=3; IntAct=EBI-10198587, EBI-12037215;
CC       Q02446; Q14119: VEZF1; NbExp=3; IntAct=EBI-10198587, EBI-11980193;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- TISSUE SPECIFICITY: Abundant in brain.
CC   -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors. In SP4, the motif is
CC       inactive. {ECO:0000269|PubMed:31375868}.
CC   -!- SIMILARITY: Belongs to the Sp1 C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X68561; CAA48563.1; -; mRNA.
DR   EMBL; AK289728; BAF82417.1; -; mRNA.
DR   EMBL; AC004595; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471073; EAW93733.1; -; Genomic_DNA.
DR   EMBL; BC109300; AAI09301.1; -; mRNA.
DR   CCDS; CCDS5373.1; -.
DR   PIR; S26638; S26638.
DR   RefSeq; NP_001313472.1; NM_001326543.1.
DR   RefSeq; NP_003103.2; NM_003112.4.
DR   SMR; Q02446; -.
DR   BioGRID; 112554; 43.
DR   IntAct; Q02446; 30.
DR   STRING; 9606.ENSP00000222584; -.
DR   GlyGen; Q02446; 22 sites, 2 O-linked glycans (22 sites).
DR   iPTMnet; Q02446; -.
DR   PhosphoSitePlus; Q02446; -.
DR   BioMuta; SP4; -.
DR   DMDM; 218511800; -.
DR   EPD; Q02446; -.
DR   jPOST; Q02446; -.
DR   MassIVE; Q02446; -.
DR   MaxQB; Q02446; -.
DR   PaxDb; Q02446; -.
DR   PeptideAtlas; Q02446; -.
DR   PRIDE; Q02446; -.
DR   ProteomicsDB; 58090; -.
DR   Antibodypedia; 4135; 69 antibodies from 21 providers.
DR   DNASU; 6671; -.
DR   Ensembl; ENST00000222584; ENSP00000222584; ENSG00000105866.
DR   GeneID; 6671; -.
DR   KEGG; hsa:6671; -.
DR   MANE-Select; ENST00000222584.8; ENSP00000222584.3; NM_003112.5; NP_003103.2.
DR   UCSC; uc003sva.4; human.
DR   CTD; 6671; -.
DR   DisGeNET; 6671; -.
DR   GeneCards; SP4; -.
DR   HGNC; HGNC:11209; SP4.
DR   HPA; ENSG00000105866; Low tissue specificity.
DR   MIM; 600540; gene.
DR   neXtProt; NX_Q02446; -.
DR   OpenTargets; ENSG00000105866; -.
DR   PharmGKB; PA36046; -.
DR   VEuPathDB; HostDB:ENSG00000105866; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000157827; -.
DR   HOGENOM; CLU_019688_2_0_1; -.
DR   InParanoid; Q02446; -.
DR   OMA; HINPQPA; -.
DR   OrthoDB; 1085860at2759; -.
DR   PhylomeDB; Q02446; -.
DR   TreeFam; TF350150; -.
DR   PathwayCommons; Q02446; -.
DR   SignaLink; Q02446; -.
DR   SIGNOR; Q02446; -.
DR   BioGRID-ORCS; 6671; 6 hits in 1070 CRISPR screens.
DR   ChiTaRS; SP4; human.
DR   GeneWiki; Sp4_transcription_factor; -.
DR   GenomeRNAi; 6671; -.
DR   Pharos; Q02446; Tbio.
DR   PRO; PR:Q02446; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q02446; protein.
DR   Bgee; ENSG00000105866; Expressed in endometrium and 226 other tissues.
DR   ExpressionAtlas; Q02446; baseline and differential.
DR   Genevisible; Q02446; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   InterPro; IPR030453; SP4.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR23235:SF17; PTHR23235:SF17; 2.
DR   Pfam; PF00096; zf-C2H2; 2.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3.
PE   1: Evidence at protein level;
KW   Activator; DNA-binding; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..784
FT                   /note="Transcription factor Sp4"
FT                   /id="PRO_0000047144"
FT   ZN_FING         647..671
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         677..701
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         707..729
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..68
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          109..150
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          281..390
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           467..475
FT                   /note="9aaTAD; inactive"
FT                   /evidence="ECO:0000269|PubMed:31375868"
FT   COMPBIAS        32..50
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        285..390
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         197
FT                   /note="Q -> K (in dbSNP:rs1042848)"
FT                   /evidence="ECO:0000269|PubMed:1454515"
FT                   /id="VAR_047975"
FT   CONFLICT        379..380
FT                   /note="QP -> HA (in Ref. 1; CAA48563)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        386
FT                   /note="A -> Q (in Ref. 1; CAA48563)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   784 AA;  81985 MW;  5B0B03EC03657993 CRC64;
     MSDQKKEEEE EAAAAAAMAT EGGKTSEPEN NNKKPKTSGS QDSQPSPLAL LAATCSKIGT
     PGENQATGQQ QIIIDPSQGL VQLQNQPQQL ELVTTQLAGN AWQLVASTPP ASKENNVSQP
     ASSSSSSSSS NNGSASPTKT KSGNSSTPGQ FQVIQVQNPS GSVQYQVIPQ LQTVEGQQIQ
     INPTSSSSLQ DLQGQIQLIS AGNNQAILTA ANRTASGNIL AQNLANQTVP VQIRPGVSIP
     LQLQTLPGTQ AQVVTTLPIN IGGVTLALPV INNVAAGGGT GQVGQPAATA DSGTSNGNQL
     VSTPTNTTTS ASTMPESPSS STTCTTTAST SLTSSDTLVS SADTGQYAST SASSSERTIE
     ESQTPAATES EAQSSSQLQP NGMQNAQDQS NSLQQVQIVG QPILQQIQIQ QPQQQIIQAI
     PPQSFQLQSG QTIQTIQQQP LQNVQLQAVN PTQVLIRAPT LTPSGQISWQ TVQVQNIQSL
     SNLQVQNAGL SQQLTITPVS SSGGTTLAQI APVAVAGAPI TLNTAQLASV PNLQTVSVAN
     LGAAGVQVQG VPVTITSVAG QQQGQDGVKV QQATIAPVTV AVGGIANATI GAVSPDQLTQ
     VHLQQGQQTS DQEVQPGKRL RRVACSCPNC REGEGRGSNE PGKKKQHICH IEGCGKVYGK
     TSHLRAHLRW HTGERPFICN WMFCGKRFTR SDELQRHRRT HTGEKRFECP ECSKRFMRSD
     HLSKHVKTHQ NKKGGGTALA IVTSGELDSS VTEVLGSPRI VTVAAISQDS NPATPNVSTN
     MEEF
//
ID   ITF2_HUMAN              Reviewed;         667 AA.
AC   P15884; B3KT62; B3KUC0; B4DT37; B4DUG3; B7Z5M6; B7Z6Y1; G0LNT9; G0LNU0;
AC   G0LNU1; G0LNU2; G0LNU4; G0LNU5; G0LNU8; G0LNU9; G0LNV0; G0LNV1; G0LNV2;
AC   H3BPQ1; Q08AP2; Q08AP3; Q15439; Q15440; Q15441;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 3.
DT   23-FEB-2022, entry version 223.
DE   RecName: Full=Transcription factor 4;
DE            Short=TCF-4;
DE   AltName: Full=Class B basic helix-loop-helix protein 19;
DE            Short=bHLHb19;
DE   AltName: Full=Immunoglobulin transcription factor 2;
DE            Short=ITF-2;
DE   AltName: Full=SL3-3 enhancer factor 2;
DE            Short=SEF-2;
GN   Name=TCF4; Synonyms=BHLHB19, ITF2, SEF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SEF2-1A; SEF2-1B AND SEF2-1D), AND
RP   ALTERNATIVE SPLICING (ISOFORM SEF2-1C).
RC   TISSUE=Thymocyte, and Thymus;
RX   PubMed=1681116; DOI=10.1128/jvi.65.11.6084-6093.1991;
RA   Corneliussen B., Thornell A., Hallberg B., Grundstroem T.;
RT   "Helix-loop-helix transcriptional activators bind to a sequence in
RT   glucocorticoid response elements of retrovirus enhancers.";
RL   J. Virol. 65:6084-6093(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A-; B-DELTA; B+DELTA; C-; C-DELTA; D-;
RP   E-; F-; G-; H-; I-; SEF2-1A; SEF2-1B AND SEF2-1D), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=21789225; DOI=10.1371/journal.pone.0022138;
RA   Sepp M., Kannike K., Eesmaa A., Urb M., Timmusk T.;
RT   "Functional diversity of human basic helix-loop-helix transcription factor
RT   TCF4 isoforms generated by alternative 5' exon usage and splicing.";
RL   PLoS ONE 6:E22138-E22138(2011).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SEF2-1A; C-; D-; F-; 11
RP   AND 13).
RC   TISSUE=Brain, Hippocampus, Spleen, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SEF2-1B AND SEF2-1D).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-278 (ISOFORM SEF2-1A).
RA   Gu J., Zhao M., Huang Q., Xu X., Li Y., Peng Y., Song H., Xiao H., Gu Y.,
RA   Li N., Qian B., Liu F., Qu J., Gao X., Cheng Z., Xu Z., Zeng L., Xu S.,
RA   Gu W., Tu Y., Jia J., Fu G., Ren S., Zhong M., Lu G., Yang Y., Gao G.,
RA   Zhang Q., Chen S., Han Z., Chen Z.;
RT   "MDSDCE06_MDS Homo sapiens cDNA clone MDSDCE06 5',mRNA sequence.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-48.
RC   TISSUE=Skin fibroblast;
RX   PubMed=9302263; DOI=10.1093/hmg/6.11.1855;
RA   Breschel T.S., McInnis M.G., Margolis R.L., Sirugo G., Corneliussen B.,
RA   Simpson S.G., McMahon F.J., Mackinnon D.F., Xu J.F., Pleasant N., Huo Y.,
RA   Ashworth R.G., Grundstrom C., Grundstrom T., Kidd K.K., Depaulo J.R.,
RA   Ross C.A.;
RT   "A novel, heritable, expanding CTG repeat in an intron of the SEF2-1 gene
RT   on chromosome 18q21.1.";
RL   Hum. Mol. Genet. 6:1855-1863(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 46-667 (ISOFORM SEF2-1B).
RX   PubMed=2308860; DOI=10.1093/nar/18.3.678;
RA   Henthorn P., McCarrick-Walmsley R., Kadesch T.;
RT   "Sequence of the cDNA encoding ITF-2, a positive-acting transcription
RT   factor.";
RL   Nucleic Acids Res. 18:678-678(1990).
RN   [10]
RP   DISCUSSION OF SEQUENCE.
RX   PubMed=2105528; DOI=10.1126/science.2105528;
RA   Henthorn P., Kiledjian M., Kadesch T.;
RT   "Two distinct transcription factors that bind the immunoglobulin enhancer
RT   microE5/kappa 2 motif.";
RL   Science 247:467-470(1990).
RN   [11]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS PTHS VAL-358;
RP   GLY-535; PRO-574; TRP-576 AND VAL-610.
RX   PubMed=22777675; DOI=10.1002/humu.22160;
RA   Forrest M., Chapman R.M., Doyle A.M., Tinsley C.L., Waite A., Blake D.J.;
RT   "Functional analysis of TCF4 missense mutations that cause Pitt-Hopkins
RT   syndrome.";
RL   Hum. Mutat. 33:1676-1686(2012).
RN   [14]
RP   INTERACTION WITH AGBL1.
RX   PubMed=24094747; DOI=10.1016/j.ajhg.2013.08.010;
RA   Riazuddin S.A., Vasanth S., Katsanis N., Gottsch J.D.;
RT   "Mutations in AGBL1 cause dominant late-onset Fuchs corneal dystrophy and
RT   alter protein-protein interaction with TCF4.";
RL   Am. J. Hum. Genet. 93:758-764(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-66; SER-87 AND SER-92, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INTERACTION WITH BHLHA9.
RX   PubMed=25466284; DOI=10.1016/j.ajhg.2014.10.012;
RA   Malik S., Percin F.E., Bornholdt D., Albrecht B., Percesepe A., Koch M.C.,
RA   Landi A., Fritz B., Khan R., Mumtaz S., Akarsu N.A., Grzeschik K.H.;
RT   "Mutations affecting the BHLHA9 DNA-binding domain cause MSSD, mesoaxial
RT   synostotic syndactyly with phalangeal reduction, Malik-Percin type.";
RL   Am. J. Hum. Genet. 95:649-659(2014).
RN   [17]
RP   INVOLVEMENT IN FECD3.
RX   PubMed=24255041; DOI=10.1167/iovs.13-12611;
RA   Mootha V.V., Gong X., Ku H.C., Xing C.;
RT   "Association and familial segregation of CTG18.1 trinucleotide repeat
RT   expansion of TCF4 gene in Fuchs' endothelial corneal dystrophy.";
RL   Invest. Ophthalmol. Vis. Sci. 55:33-42(2014).
RN   [18]
RP   INVOLVEMENT IN FECD3.
RX   PubMed=25168903; DOI=10.1167/iovs.14-14958;
RA   Wieben E.D., Aleff R.A., Eckloff B.W., Atkinson E.J., Baheti S., Middha S.,
RA   Brown W.L., Patel S.V., Kocher J.P., Baratz K.H.;
RT   "Comprehensive assessment of genetic variants within TCF4 in Fuchs'
RT   endothelial corneal dystrophy.";
RL   Invest. Ophthalmol. Vis. Sci. 55:6101-6107(2014).
RN   [19]
RP   INVOLVEMENT IN FECD3.
RX   PubMed=25593321; DOI=10.1074/jbc.m114.621607;
RA   Du J., Aleff R.A., Soragni E., Kalari K., Nie J., Tang X., Davila J.,
RA   Kocher J.P., Patel S.V., Gottesfeld J.M., Baratz K.H., Wieben E.D.;
RT   "RNA toxicity and missplicing in the common eye disease fuchs endothelial
RT   corneal dystrophy.";
RL   J. Biol. Chem. 290:5979-5990(2015).
RN   [20]
RP   POSSIBLE INVOLVEMENT IN SYMMETRICAL ACRAL KERATODERMA, AND VARIANT THR-29.
RX   PubMed=28921696; DOI=10.1111/jdv.14591;
RA   Chen P., Sun S., Zeng K., Li C., Wen J., Liang J., Tian X., Jiang Y.,
RA   Zhang J., Zhang S., Han K., Han C., Zhang X.;
RT   "Exome sequencing identifies a TCF4 mutation in a Chinese pedigree with
RT   symmetrical acral keratoderma.";
RL   J. Eur. Acad. Dermatol. Venereol. 32:1204-1208(2018).
RN   [21]
RP   VARIANTS PTHS TRP-576 AND GLN-576.
RX   PubMed=17436254; DOI=10.1086/515582;
RA   Amiel J., Rio M., de Pontual L., Redon R., Malan V., Boddaert N.,
RA   Plouin P., Carter N.P., Lyonnet S., Munnich A., Colleaux L.;
RT   "Mutations in TCF4, encoding a class I basic helix-loop-helix transcription
RT   factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic
RT   encephalopathy associated with autonomic dysfunction.";
RL   Am. J. Hum. Genet. 80:988-993(2007).
RN   [22]
RP   VARIANT PTHS TRP-576.
RX   PubMed=17436255; DOI=10.1086/515583;
RA   Zweier C., Peippo M.M., Hoyer J., Sousa S., Bottani A., Clayton-Smith J.,
RA   Reardon W., Saraiva J., Cabral A., Goehring I., Devriendt K., de Ravel T.,
RA   Bijlsma E.K., Hennekam R.C.M., Orrico A., Cohen M., Dreweke A., Reis A.,
RA   Nuernberg P., Rauch A.;
RT   "Haploinsufficiency of TCF4 causes syndromal mental retardation with
RT   intermittent hyperventilation (Pitt-Hopkins syndrome).";
RL   Am. J. Hum. Genet. 80:994-1001(2007).
RN   [23]
RP   VARIANTS PTHS VAL-358; PRO-574 AND HIS-578.
RX   PubMed=18728071; DOI=10.1136/jmg.2008.060129;
RA   Zweier C., Sticht H., Bijlsma E.K., Clayton-Smith J., Boonen S.E.,
RA   Fryer A., Greally M.T., Hoffmann L., den Hollander N.S., Jongmans M.,
RA   Kant S.G., King M.D., Lynch S.A., McKee S., Midro A.T., Park S.M.,
RA   Ricotti V., Tarantino E., Wessels M., Peippo M., Rauch A.;
RT   "Further delineation of Pitt-Hopkins syndrome: phenotypic and genotypic
RT   description of 16 novel patients.";
RL   J. Med. Genet. 45:738-744(2008).
RN   [24]
RP   VARIANTS PTHS GLY-535; GLY-572; GLN-576 AND VAL-610, AND CHARACTERIZATION
RP   OF VARIANTS PTHS GLY-535; GLY-572; GLN-576 AND VAL-610.
RX   PubMed=19235238; DOI=10.1002/humu.20935;
RA   de Pontual L., Mathieu Y., Golzio C., Rio M., Malan V., Boddaert N.,
RA   Soufflet C., Picard C., Durandy A., Dobbie A., Heron D., Isidor B.,
RA   Motte J., Newburry-Ecob R., Pasquier L., Tardieu M., Viot G., Jaubert F.,
RA   Munnich A., Colleaux L., Vekemans M., Etchevers H., Lyonnet S., Amiel J.;
RT   "Mutational, functional, and expression studies of the TCF4 gene in Pitt-
RT   Hopkins syndrome.";
RL   Hum. Mutat. 30:669-676(2009).
RN   [25]
RP   VARIANT PTHS PRO-578.
RX   PubMed=20184619; DOI=10.1111/j.1399-0004.2010.01380.x;
RA   Takano K., Lyons M., Moyes C., Jones J., Schwartz C.E.;
RT   "Two percent of patients suspected of having Angelman syndrome have TCF4
RT   mutations.";
RL   Clin. Genet. 78:282-288(2010).
RN   [26]
RP   VARIANTS PTHS TRP-565; GLY-572; GLN-572; HIS-574; PRO-574; TRP-576;
RP   GLN-576; PRO-578; PRO-583 AND VAL-610.
RX   PubMed=22045651; DOI=10.1002/humu.21639;
RA   Whalen S., Heron D., Gaillon T., Moldovan O., Rossi M., Devillard F.,
RA   Giuliano F., Soares G., Mathieu-Dramard M., Afenjar A., Charles P.,
RA   Mignot C., Burglen L., Van Maldergem L., Piard J., Aftimos S., Mancini G.,
RA   Dias P., Philip N., Goldenberg A., Le Merrer M., Rio M., Josifova D.,
RA   Van Hagen J.M., Lacombe D., Edery P., Dupuis-Girod S., Putoux A.,
RA   Sanlaville D., Fischer R., Drevillon L., Briand-Suleau A., Metay C.,
RA   Goossens M., Amiel J., Jacquette A., Giurgea I.;
RT   "Novel comprehensive diagnostic strategy in Pitt-Hopkins syndrome: clinical
RT   score and further delineation of the TCF4 mutational spectrum.";
RL   Hum. Mutat. 33:64-72(2012).
RN   [27]
RP   VARIANT PTHS 385-ARG--MET-667 DEL.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
CC   -!- FUNCTION: Transcription factor that binds to the immunoglobulin
CC       enhancer Mu-E5/KE5-motif. Involved in the initiation of neuronal
CC       differentiation. Activates transcription by binding to the E box (5'-
CC       CANNTG-3'). Binds to the E-box present in the somatostatin receptor 2
CC       initiator element (SSTR2-INR) to activate transcription (By
CC       similarity). Preferentially binds to either 5'-ACANNTGT-3' or 5'-
CC       CCANNTGG-3'. {ECO:0000250}.
CC   -!- SUBUNIT: Efficient DNA binding requires dimerization with another bHLH
CC       protein. Forms homo- or heterooligomers with myogenin. Interacts with
CC       HIVEP2. Interacts with NEUROD2 (By similarity). Interacts with AGBL1.
CC       Interacts with BHLHA9. {ECO:0000250, ECO:0000269|PubMed:24094747,
CC       ECO:0000269|PubMed:25466284}.
CC   -!- INTERACTION:
CC       P15884; P29972: AQP1; NbExp=3; IntAct=EBI-533224, EBI-745213;
CC       P15884; Q92888: ARHGEF1; NbExp=3; IntAct=EBI-533224, EBI-465400;
CC       P15884; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-533224, EBI-742909;
CC       P15884; P50553: ASCL1; NbExp=7; IntAct=EBI-533224, EBI-957042;
CC       P15884; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-533224, EBI-10254793;
CC       P15884; Q9BZE9: ASPSCR1; NbExp=3; IntAct=EBI-533224, EBI-1993677;
CC       P15884; P21281: ATP6V1B2; NbExp=3; IntAct=EBI-533224, EBI-4290814;
CC       P15884; O75934: BCAS2; NbExp=4; IntAct=EBI-533224, EBI-1050106;
CC       P15884; Q92843: BCL2L2; NbExp=3; IntAct=EBI-533224, EBI-707714;
CC       P15884; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-533224, EBI-8643161;
CC       P15884; Q9NP86: CABP5; NbExp=5; IntAct=EBI-533224, EBI-10311131;
CC       P15884; P38936: CDKN1A; NbExp=3; IntAct=EBI-533224, EBI-375077;
CC       P15884; P42773: CDKN2C; NbExp=4; IntAct=EBI-533224, EBI-711290;
CC       P15884; Q6ZQR2: CFAP77; NbExp=3; IntAct=EBI-533224, EBI-10255140;
CC       P15884; Q13111: CHAF1A; NbExp=3; IntAct=EBI-533224, EBI-1020839;
CC       P15884; Q9Y6H1: CHCHD2; NbExp=3; IntAct=EBI-533224, EBI-2321769;
CC       P15884; Q9UKJ5: CHIC2; NbExp=3; IntAct=EBI-533224, EBI-741528;
CC       P15884; P61024: CKS1B; NbExp=3; IntAct=EBI-533224, EBI-456371;
CC       P15884; P35222: CTNNB1; NbExp=22; IntAct=EBI-533224, EBI-491549;
CC       P15884; P26196: DDX6; NbExp=3; IntAct=EBI-533224, EBI-351257;
CC       P15884; Q9H4E7: DEF6; NbExp=4; IntAct=EBI-533224, EBI-745369;
CC       P15884; Q9NQL9: DMRT3; NbExp=3; IntAct=EBI-533224, EBI-9679045;
CC       P15884; Q5JVL4: EFHC1; NbExp=7; IntAct=EBI-533224, EBI-743105;
CC       P15884; O60573: EIF4E2; NbExp=3; IntAct=EBI-533224, EBI-398610;
CC       P15884; Q13541: EIF4EBP1; NbExp=3; IntAct=EBI-533224, EBI-74090;
CC       P15884; Q9Y2J2-3: EPB41L3; NbExp=3; IntAct=EBI-533224, EBI-10326138;
CC       P15884; O15197-2: EPHB6; NbExp=3; IntAct=EBI-533224, EBI-10182490;
CC       P15884; Q9Y3B2: EXOSC1; NbExp=4; IntAct=EBI-533224, EBI-371892;
CC       P15884; P16930: FAH; NbExp=3; IntAct=EBI-533224, EBI-4397076;
CC       P15884; Q9H5Z6: FAM124B; NbExp=3; IntAct=EBI-533224, EBI-741626;
CC       P15884; Q5TZK3: FAM74A6; NbExp=3; IntAct=EBI-533224, EBI-10247271;
CC       P15884; Q96RJ6: FERD3L; NbExp=4; IntAct=EBI-533224, EBI-10183007;
CC       P15884; Q96AC1: FERMT2; NbExp=6; IntAct=EBI-533224, EBI-4399465;
CC       P15884; Q8NFF5: FLAD1; NbExp=3; IntAct=EBI-533224, EBI-742815;
CC       P15884; P21333-2: FLNA; NbExp=3; IntAct=EBI-533224, EBI-9641086;
CC       P15884; O43559: FRS3; NbExp=3; IntAct=EBI-533224, EBI-725515;
CC       P15884; P55040: GEM; NbExp=3; IntAct=EBI-533224, EBI-744104;
CC       P15884; O76003: GLRX3; NbExp=3; IntAct=EBI-533224, EBI-374781;
CC       P15884; P50151: GNG10; NbExp=3; IntAct=EBI-533224, EBI-10211741;
CC       P15884; Q0D2H9: GOLGA8DP; NbExp=3; IntAct=EBI-533224, EBI-10181276;
CC       P15884; Q08AF8: GOLGA8G; NbExp=3; IntAct=EBI-533224, EBI-10181260;
CC       P15884; Q9H8Y8: GORASP2; NbExp=4; IntAct=EBI-533224, EBI-739467;
CC       P15884; Q96NT3: GUCD1; NbExp=3; IntAct=EBI-533224, EBI-8293751;
CC       P15884; P61296: HAND2; NbExp=3; IntAct=EBI-533224, EBI-10218584;
CC       P15884; O14929: HAT1; NbExp=3; IntAct=EBI-533224, EBI-2339359;
CC       P15884; V9HWF5: HEL-S-69p; NbExp=3; IntAct=EBI-533224, EBI-10330249;
CC       P15884; Q9UBY9: HSPB7; NbExp=3; IntAct=EBI-533224, EBI-739361;
CC       P15884; P41134: ID1; NbExp=3; IntAct=EBI-533224, EBI-1215527;
CC       P15884; Q02363: ID2; NbExp=3; IntAct=EBI-533224, EBI-713450;
CC       P15884; Q02535: ID3; NbExp=5; IntAct=EBI-533224, EBI-1387094;
CC       P15884; I3WAC9: INS; NbExp=3; IntAct=EBI-533224, EBI-10178524;
CC       P15884; Q92993: KAT5; NbExp=3; IntAct=EBI-533224, EBI-399080;
CC       P15884; Q9BQ13: KCTD14; NbExp=3; IntAct=EBI-533224, EBI-10189448;
CC       P15884; Q6P597: KLC3; NbExp=3; IntAct=EBI-533224, EBI-1643885;
CC       P15884; Q5THT1: KLHL32; NbExp=3; IntAct=EBI-533224, EBI-10247181;
CC       P15884; Q14847: LASP1; NbExp=3; IntAct=EBI-533224, EBI-742828;
CC       P15884; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-533224, EBI-726510;
CC       P15884; Q8TCE9: LGALS14; NbExp=4; IntAct=EBI-533224, EBI-10274069;
CC       P15884; P25800: LMO1; NbExp=3; IntAct=EBI-533224, EBI-8639312;
CC       P15884; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-533224, EBI-11742507;
CC       P15884; P61968: LMO4; NbExp=3; IntAct=EBI-533224, EBI-2798728;
CC       P15884; Q9UIQ6: LNPEP; NbExp=3; IntAct=EBI-533224, EBI-2805360;
CC       P15884; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-533224, EBI-77889;
CC       P15884; Q96A72: MAGOHB; NbExp=3; IntAct=EBI-533224, EBI-746778;
CC       P15884; O60336: MAPKBP1; NbExp=3; IntAct=EBI-533224, EBI-947402;
CC       P15884; O15232: MATN3; NbExp=3; IntAct=EBI-533224, EBI-6262458;
CC       P15884; Q9Y316: MEMO1; NbExp=3; IntAct=EBI-533224, EBI-1104564;
CC       P15884; Q6P2C6: MLLT6; NbExp=3; IntAct=EBI-533224, EBI-5773143;
CC       P15884; Q8NDC4: MORN4; NbExp=3; IntAct=EBI-533224, EBI-10269566;
CC       P15884; Q96HT8: MRFAP1L1; NbExp=3; IntAct=EBI-533224, EBI-748896;
CC       P15884; Q7Z7H8: MRPL10; NbExp=3; IntAct=EBI-533224, EBI-723524;
CC       P15884; Q8IXL7: MSRB3; NbExp=3; IntAct=EBI-533224, EBI-8634060;
CC       P15884; Q9ULV0: MYO5B; NbExp=3; IntAct=EBI-533224, EBI-311356;
CC       P15884; O43639: NCK2; NbExp=3; IntAct=EBI-533224, EBI-713635;
CC       P15884; Q9UHB4: NDOR1; NbExp=4; IntAct=EBI-533224, EBI-10249760;
CC       P15884; Q9HC98: NEK6; NbExp=4; IntAct=EBI-533224, EBI-740364;
CC       P15884; Q86SG6: NEK8; NbExp=3; IntAct=EBI-533224, EBI-1752987;
CC       P15884; Q8WWR8-2: NEU4; NbExp=3; IntAct=EBI-533224, EBI-10277551;
CC       P15884; Q92886: NEUROG1; NbExp=3; IntAct=EBI-533224, EBI-10279647;
CC       P15884; Q9Y5B8: NME7; NbExp=3; IntAct=EBI-533224, EBI-744782;
CC       P15884; Q9GZQ4: NMUR2; NbExp=3; IntAct=EBI-533224, EBI-10303844;
CC       P15884; Q5SY16: NOL9; NbExp=3; IntAct=EBI-533224, EBI-1055462;
CC       P15884; Q86WQ0: NR2C2AP; NbExp=3; IntAct=EBI-533224, EBI-10260040;
CC       P15884; Q8NFP7: NUDT10; NbExp=3; IntAct=EBI-533224, EBI-726826;
CC       P15884; O43929: ORC4; NbExp=3; IntAct=EBI-533224, EBI-374889;
CC       P15884; Q9UJX0: OSGIN1; NbExp=4; IntAct=EBI-533224, EBI-9057006;
CC       P15884; Q01804: OTUD4; NbExp=3; IntAct=EBI-533224, EBI-1054396;
CC       P15884; Q8WXA2: PATE1; NbExp=3; IntAct=EBI-533224, EBI-10277790;
CC       P15884; P30039: PBLD; NbExp=3; IntAct=EBI-533224, EBI-750589;
CC       P15884; Q13526: PIN1; NbExp=3; IntAct=EBI-533224, EBI-714158;
CC       P15884; Q494U1: PLEKHN1; NbExp=4; IntAct=EBI-533224, EBI-10241513;
CC       P15884; O95602: POLR1A; NbExp=3; IntAct=EBI-533224, EBI-359472;
CC       P15884; O15160: POLR1C; NbExp=3; IntAct=EBI-533224, EBI-1055079;
CC       P15884; P62937-2: PPIA; NbExp=3; IntAct=EBI-533224, EBI-25884072;
CC       P15884; Q9Y3C6: PPIL1; NbExp=3; IntAct=EBI-533224, EBI-2557649;
CC       P15884; Q6NYC8: PPP1R18; NbExp=3; IntAct=EBI-533224, EBI-2557469;
CC       P15884; P54646: PRKAA2; NbExp=3; IntAct=EBI-533224, EBI-1383852;
CC       P15884; P17252: PRKCA; NbExp=3; IntAct=EBI-533224, EBI-1383528;
CC       P15884; P25786: PSMA1; NbExp=3; IntAct=EBI-533224, EBI-359352;
CC       P15884; Q969U7: PSMG2; NbExp=3; IntAct=EBI-533224, EBI-723276;
CC       P15884; P43115-12: PTGER3; NbExp=3; IntAct=EBI-533224, EBI-10234038;
CC       P15884; Q5JT25: RAB41; NbExp=3; IntAct=EBI-533224, EBI-10244509;
CC       P15884; P47224: RABIF; NbExp=3; IntAct=EBI-533224, EBI-713992;
CC       P15884; Q6P9E2: RECK; NbExp=3; IntAct=EBI-533224, EBI-10253121;
CC       P15884; Q04206-3: RELA; NbExp=3; IntAct=EBI-533224, EBI-10223388;
CC       P15884; Q8IX06: REXO1L1P; NbExp=3; IntAct=EBI-533224, EBI-10262361;
CC       P15884; Q9UHP6: RSPH14; NbExp=3; IntAct=EBI-533224, EBI-748350;
CC       P15884; Q9UIL1: SCOC; NbExp=3; IntAct=EBI-533224, EBI-2686537;
CC       P15884; Q9UDX3: SEC14L4; NbExp=3; IntAct=EBI-533224, EBI-10320311;
CC       P15884; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-533224, EBI-9090795;
CC       P15884; Q6NXQ0: SFRS2; NbExp=3; IntAct=EBI-533224, EBI-10251550;
CC       P15884; Q96ES7: SGF29; NbExp=5; IntAct=EBI-533224, EBI-743117;
CC       P15884; Q9NUL5: SHFL; NbExp=3; IntAct=EBI-533224, EBI-10313866;
CC       P15884; O43699: SIGLEC6; NbExp=3; IntAct=EBI-533224, EBI-2814604;
CC       P15884; Q96H72: SLC39A13; NbExp=3; IntAct=EBI-533224, EBI-10287091;
CC       P15884; Q9BWU0: SLC4A1AP; NbExp=3; IntAct=EBI-533224, EBI-1999704;
CC       P15884; P49901: SMCP; NbExp=3; IntAct=EBI-533224, EBI-750494;
CC       P15884; Q9H4F8: SMOC1; NbExp=3; IntAct=EBI-533224, EBI-2801103;
CC       P15884; Q9H0A9: SPATC1L; NbExp=3; IntAct=EBI-533224, EBI-372911;
CC       P15884; Q9NZD8: SPG21; NbExp=3; IntAct=EBI-533224, EBI-742688;
CC       P15884; Q96FJ0: STAMBPL1; NbExp=3; IntAct=EBI-533224, EBI-745021;
CC       P15884; O75716: STK16; NbExp=3; IntAct=EBI-533224, EBI-749295;
CC       P15884; O75558: STX11; NbExp=3; IntAct=EBI-533224, EBI-714135;
CC       P15884; Q5T011-5: SZT2; NbExp=3; IntAct=EBI-533224, EBI-10245139;
CC       P15884; Q16559: TAL2; NbExp=3; IntAct=EBI-533224, EBI-10237959;
CC       P15884; Q15560: TCEA2; NbExp=3; IntAct=EBI-533224, EBI-710310;
CC       P15884; P15884: TCF4; NbExp=3; IntAct=EBI-533224, EBI-533224;
CC       P15884; P56279: TCL1A; NbExp=3; IntAct=EBI-533224, EBI-749995;
CC       P15884; Q08117: TLE5; NbExp=3; IntAct=EBI-533224, EBI-717810;
CC       P15884; P04637: TP53; NbExp=2; IntAct=EBI-533224, EBI-366083;
CC       P15884; Q9UL33: TRAPPC2L; NbExp=3; IntAct=EBI-533224, EBI-747601;
CC       P15884; Q96PN8: TSSK3; NbExp=3; IntAct=EBI-533224, EBI-3918381;
CC       P15884; Q15672: TWIST1; NbExp=8; IntAct=EBI-533224, EBI-1797287;
CC       P15884; Q8WVJ9: TWIST2; NbExp=4; IntAct=EBI-533224, EBI-1797313;
CC       P15884; Q9NX01: TXNL4B; NbExp=4; IntAct=EBI-533224, EBI-10309345;
CC       P15884; Q9BRU9: UTP23; NbExp=3; IntAct=EBI-533224, EBI-5457544;
CC       P15884; Q548N1: VPS28; NbExp=3; IntAct=EBI-533224, EBI-10243107;
CC       P15884; P61981: YWHAG; NbExp=3; IntAct=EBI-533224, EBI-359832;
CC       P15884; Q6UX98: ZDHHC24; NbExp=3; IntAct=EBI-533224, EBI-10254561;
CC       P15884; Q15973: ZNF124; NbExp=3; IntAct=EBI-533224, EBI-2555767;
CC       P15884; Q8TAU3: ZNF417; NbExp=3; IntAct=EBI-533224, EBI-740727;
CC       P15884; Q96SQ5: ZNF587; NbExp=3; IntAct=EBI-533224, EBI-6427977;
CC       P15884; Q53FW8; NbExp=3; IntAct=EBI-533224, EBI-10242473;
CC       P15884; P26233: ctnnb1; Xeno; NbExp=2; IntAct=EBI-533224, EBI-7373758;
CC       P15884; PRO_0000449627 [P0DTD1]: rep; Xeno; NbExp=3; IntAct=EBI-533224, EBI-25475877;
CC       P15884; Q61473: Sox17; Xeno; NbExp=5; IntAct=EBI-533224, EBI-9106822;
CC       P15884; Q06831: Sox4; Xeno; NbExp=2; IntAct=EBI-533224, EBI-6262177;
CC       P15884-3; Q9NXW9: ALKBH4; NbExp=3; IntAct=EBI-13636688, EBI-8637516;
CC       P15884-3; Q12774: ARHGEF5; NbExp=3; IntAct=EBI-13636688, EBI-602199;
CC       P15884-3; Q0P5N6: ARL16; NbExp=3; IntAct=EBI-13636688, EBI-10186132;
CC       P15884-3; Q8TDY4: ASAP3; NbExp=3; IntAct=EBI-13636688, EBI-2609717;
CC       P15884-3; Q9NQ33: ASCL3; NbExp=3; IntAct=EBI-13636688, EBI-12108222;
CC       P15884-3; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-13636688, EBI-10254793;
CC       P15884-3; Q7Z3C6-3: ATG9A; NbExp=3; IntAct=EBI-13636688, EBI-12006308;
CC       P15884-3; Q8N100: ATOH7; NbExp=3; IntAct=EBI-13636688, EBI-11976887;
CC       P15884-3; A0A0C4DG94: ATP11B; NbExp=3; IntAct=EBI-13636688, EBI-11990784;
CC       P15884-3; Q9H503-2: BANF2; NbExp=3; IntAct=EBI-13636688, EBI-11977289;
CC       P15884-3; Q5TBC7: BCL2L15; NbExp=3; IntAct=EBI-13636688, EBI-10247136;
CC       P15884-3; Q9BV19: C1orf50; NbExp=3; IntAct=EBI-13636688, EBI-2874661;
CC       P15884-3; O43439-4: CBFA2T2; NbExp=3; IntAct=EBI-13636688, EBI-11954144;
CC       P15884-3; P51946: CCNH; NbExp=3; IntAct=EBI-13636688, EBI-741406;
CC       P15884-3; Q16543: CDC37; NbExp=3; IntAct=EBI-13636688, EBI-295634;
CC       P15884-3; P42773: CDKN2C; NbExp=3; IntAct=EBI-13636688, EBI-711290;
CC       P15884-3; Q13111: CHAF1A; NbExp=3; IntAct=EBI-13636688, EBI-1020839;
CC       P15884-3; P61024: CKS1B; NbExp=3; IntAct=EBI-13636688, EBI-456371;
CC       P15884-3; P51800-3: CLCNKA; NbExp=3; IntAct=EBI-13636688, EBI-11980535;
CC       P15884-3; Q86WW8: COA5; NbExp=3; IntAct=EBI-13636688, EBI-5458774;
CC       P15884-3; Q96FN4: CPNE2; NbExp=3; IntAct=EBI-13636688, EBI-7097057;
CC       P15884-3; P26196: DDX6; NbExp=3; IntAct=EBI-13636688, EBI-351257;
CC       P15884-3; P04053: DNTT; NbExp=3; IntAct=EBI-13636688, EBI-1220259;
CC       P15884-3; Q9BVJ7: DUSP23; NbExp=3; IntAct=EBI-13636688, EBI-724940;
CC       P15884-3; Q68J44: DUSP29; NbExp=3; IntAct=EBI-13636688, EBI-1054321;
CC       P15884-3; Q5JVL4: EFHC1; NbExp=6; IntAct=EBI-13636688, EBI-743105;
CC       P15884-3; O15197-2: EPHB6; NbExp=3; IntAct=EBI-13636688, EBI-10182490;
CC       P15884-3; Q8IYI6: EXOC8; NbExp=3; IntAct=EBI-13636688, EBI-742102;
CC       P15884-3; Q9BQ89: FAM110A; NbExp=3; IntAct=EBI-13636688, EBI-1752811;
CC       P15884-3; Q6QHK4: FIGLA; NbExp=3; IntAct=EBI-13636688, EBI-11976617;
CC       P15884-3; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-13636688, EBI-14103818;
CC       P15884-3; Q9UBY9: HSPB7; NbExp=3; IntAct=EBI-13636688, EBI-739361;
CC       P15884-3; P41134: ID1; NbExp=3; IntAct=EBI-13636688, EBI-1215527;
CC       P15884-3; Q02535: ID3; NbExp=3; IntAct=EBI-13636688, EBI-1387094;
CC       P15884-3; Q2WGJ6: KLHL38; NbExp=3; IntAct=EBI-13636688, EBI-6426443;
CC       P15884-3; A0A0S2Z5S9: LHX4; NbExp=3; IntAct=EBI-13636688, EBI-16429099;
CC       P15884-3; P61968: LMO4; NbExp=3; IntAct=EBI-13636688, EBI-2798728;
CC       P15884-3; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-13636688, EBI-77889;
CC       P15884-3; O60336: MAPKBP1; NbExp=3; IntAct=EBI-13636688, EBI-947402;
CC       P15884-3; Q9Y4F3: MARF1; NbExp=3; IntAct=EBI-13636688, EBI-5235902;
CC       P15884-3; O15232: MATN3; NbExp=3; IntAct=EBI-13636688, EBI-6262458;
CC       P15884-3; Q9Y316: MEMO1; NbExp=3; IntAct=EBI-13636688, EBI-1104564;
CC       P15884-3; Q9BUN1: MENT; NbExp=3; IntAct=EBI-13636688, EBI-12022316;
CC       P15884-3; Q8NDC4: MORN4; NbExp=3; IntAct=EBI-13636688, EBI-10269566;
CC       P15884-3; O60682: MSC; NbExp=3; IntAct=EBI-13636688, EBI-740310;
CC       P15884-3; A6NI15: MSGN1; NbExp=3; IntAct=EBI-13636688, EBI-11991020;
CC       P15884-3; Q9ULV0-2: MYO5B; NbExp=3; IntAct=EBI-13636688, EBI-14093244;
CC       P15884-3; Q9UHB4: NDOR1; NbExp=3; IntAct=EBI-13636688, EBI-10249760;
CC       P15884-3; Q92692-2: NECTIN2; NbExp=3; IntAct=EBI-13636688, EBI-6979889;
CC       P15884-3; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-13636688, EBI-11750983;
CC       P15884-3; Q13562: NEUROD1; NbExp=3; IntAct=EBI-13636688, EBI-3908303;
CC       P15884-3; Q9HD90: NEUROD4; NbExp=3; IntAct=EBI-13636688, EBI-3917781;
CC       P15884-3; Q9Y4Z2: NEUROG3; NbExp=4; IntAct=EBI-13636688, EBI-10328570;
CC       P15884-3; Q8NET5: NFAM1; NbExp=3; IntAct=EBI-13636688, EBI-11990542;
CC       P15884-3; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-13636688, EBI-10271199;
CC       P15884-3; Q02577: NHLH2; NbExp=3; IntAct=EBI-13636688, EBI-5378683;
CC       P15884-3; Q9Y5B8: NME7; NbExp=3; IntAct=EBI-13636688, EBI-744782;
CC       P15884-3; Q86UR1-2: NOXA1; NbExp=3; IntAct=EBI-13636688, EBI-12025760;
CC       P15884-3; Q9BRQ3: NUDT22; NbExp=3; IntAct=EBI-13636688, EBI-10297093;
CC       P15884-3; Q96DL1-3: NXPE2; NbExp=3; IntAct=EBI-13636688, EBI-12128194;
CC       P15884-3; Q9NPJ8-3: NXT2; NbExp=3; IntAct=EBI-13636688, EBI-10698339;
CC       P15884-3; Q96PB7-3: OLFM3; NbExp=3; IntAct=EBI-13636688, EBI-12005356;
CC       P15884-3; Q8WXA2-2: PATE1; NbExp=3; IntAct=EBI-13636688, EBI-12837654;
CC       P15884-3; Q9Y3C6: PPIL1; NbExp=3; IntAct=EBI-13636688, EBI-2557649;
CC       P15884-3; O75771: RAD51D; NbExp=3; IntAct=EBI-13636688, EBI-1055693;
CC       P15884-3; Q6P9E2: RECK; NbExp=3; IntAct=EBI-13636688, EBI-10253121;
CC       P15884-3; A0A0S2Z4G9: RNF6; NbExp=3; IntAct=EBI-13636688, EBI-16428950;
CC       P15884-3; Q9UHP6: RSPH14; NbExp=3; IntAct=EBI-13636688, EBI-748350;
CC       P15884-3; Q7RTU7: SCX; NbExp=3; IntAct=EBI-13636688, EBI-17492262;
CC       P15884-3; O00560: SDCBP; NbExp=3; IntAct=EBI-13636688, EBI-727004;
CC       P15884-3; Q9UDX3: SEC14L4; NbExp=3; IntAct=EBI-13636688, EBI-10320311;
CC       P15884-3; Q96ES7: SGF29; NbExp=3; IntAct=EBI-13636688, EBI-743117;
CC       P15884-3; Q9H0W8: SMG9; NbExp=3; IntAct=EBI-13636688, EBI-2872322;
CC       P15884-3; Q9Y5K1-2: SPO11; NbExp=3; IntAct=EBI-13636688, EBI-12354035;
CC       P15884-3; Q9BX59: TAPBPL; NbExp=3; IntAct=EBI-13636688, EBI-12017416;
CC       P15884-3; Q7RTU1: TCF23; NbExp=3; IntAct=EBI-13636688, EBI-12127592;
CC       P15884-3; Q7RTU0: TCF24; NbExp=3; IntAct=EBI-13636688, EBI-18239606;
CC       P15884-3; Q9UL33-2: TRAPPC2L; NbExp=3; IntAct=EBI-13636688, EBI-11119202;
CC       P15884-3; Q6AZZ1: TRIM68; NbExp=3; IntAct=EBI-13636688, EBI-2130449;
CC       P15884-3; Q8N7C3: TRIML2; NbExp=3; IntAct=EBI-13636688, EBI-11059915;
CC       P15884-3; Q5T7W7: TSTD2; NbExp=3; IntAct=EBI-13636688, EBI-8994397;
CC       P15884-3; Q9UNY4-2: TTF2; NbExp=3; IntAct=EBI-13636688, EBI-11980463;
CC       P15884-3; Q8TF42: UBASH3B; NbExp=3; IntAct=EBI-13636688, EBI-1380492;
CC       P15884-3; Q6UX98: ZDHHC24; NbExp=3; IntAct=EBI-13636688, EBI-10254561;
CC       P15884-3; O75800: ZMYND10; NbExp=3; IntAct=EBI-13636688, EBI-747061;
CC       P15884-3; Q15973: ZNF124; NbExp=3; IntAct=EBI-13636688, EBI-2555767;
CC       P15884-3; Q96SQ5: ZNF587; NbExp=3; IntAct=EBI-13636688, EBI-6427977;
CC       P15884-3; A0A0S2Z5X4: ZNF688; NbExp=3; IntAct=EBI-13636688, EBI-16429014;
CC       P15884-3; A0A0S2Z6P0: ZNF688; NbExp=3; IntAct=EBI-13636688, EBI-16429989;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00981,
CC       ECO:0000269|PubMed:22777675}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=16;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=SEF2-1B; Synonyms=B-;
CC         IsoId=P15884-1; Sequence=Displayed;
CC       Name=SEF2-1A; Synonyms=A+;
CC         IsoId=P15884-2; Sequence=VSP_030819, VSP_002111, VSP_002112;
CC       Name=SEF2-1D; Synonyms=B+;
CC         IsoId=P15884-3; Sequence=VSP_002112;
CC       Name=B+delta;
CC         IsoId=P15884-4; Sequence=VSP_044340, VSP_002112;
CC       Name=B-delta;
CC         IsoId=P15884-5; Sequence=VSP_044340;
CC       Name=A-;
CC         IsoId=P15884-6; Sequence=VSP_044336, VSP_044337, VSP_044340;
CC       Name=G-;
CC         IsoId=P15884-7; Sequence=VSP_044334, VSP_044338, VSP_044339;
CC       Name=H-;
CC         IsoId=P15884-8; Sequence=VSP_044335, VSP_057364;
CC       Name=D-;
CC         IsoId=P15884-9; Sequence=VSP_045149;
CC       Name=F-;
CC         IsoId=P15884-10; Sequence=VSP_045151;
CC       Name=11;
CC         IsoId=P15884-11; Sequence=VSP_045150, VSP_044339, VSP_002112;
CC       Name=E-;
CC         IsoId=P15884-12; Sequence=VSP_047082, VSP_047083;
CC       Name=13;
CC         IsoId=P15884-13; Sequence=VSP_047081, VSP_002112;
CC       Name=C-;
CC         IsoId=P15884-14; Sequence=VSP_047081;
CC       Name=C-delta;
CC         IsoId=P15884-15; Sequence=VSP_047081, VSP_044340;
CC       Name=I-;
CC         IsoId=P15884-16; Sequence=VSP_054279;
CC   -!- TISSUE SPECIFICITY: Expressed in adult heart, brain, placenta, skeletal
CC       muscle and to a lesser extent in the lung. In developing embryonic
CC       tissues, expression mostly occurs in the brain.
CC   -!- DOMAIN: the 9aaTAD motif is a transactivation domain present in a large
CC       number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953}.
CC   -!- DISEASE: Pitt-Hopkins syndrome (PTHS) [MIM:610954]: A syndrome
CC       characterized by mental retardation, wide mouth and distinctive facial
CC       features, and intermittent hyperventilation followed by apnea. Features
CC       include intellectual disability with severe speech impairment, normal
CC       growth parameters at birth, postnatal microcephaly, breathing
CC       anomalies, severe motor developmental delay, motor incoordination,
CC       ocular anomalies, constipation, seizures, typical behavior and subtle
CC       brain abnormalities. {ECO:0000269|PubMed:17436254,
CC       ECO:0000269|PubMed:17436255, ECO:0000269|PubMed:18728071,
CC       ECO:0000269|PubMed:19235238, ECO:0000269|PubMed:20184619,
CC       ECO:0000269|PubMed:22045651, ECO:0000269|PubMed:22777675,
CC       ECO:0000269|PubMed:25356899}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Corneal dystrophy, Fuchs endothelial, 3 (FECD3) [MIM:613267]:
CC       A late-onset form of Fuchs endothelial corneal dystrophy, a disease
CC       caused by loss of endothelium of the central cornea. It is
CC       characterized by focal wart-like guttata that arise from Descemet
CC       membrane and develop in the central cornea, epithelial blisters,
CC       reduced vision and pain. Descemet membrane is thickened by abnormal
CC       collagenous deposition. {ECO:0000269|PubMed:24255041,
CC       ECO:0000269|PubMed:25168903, ECO:0000269|PubMed:25593321}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. Causative mutations are heterozygous TCF4 intronic trinucleotide
CC       repeat expansions (CTG)n. {ECO:0000269|PubMed:24255041,
CC       ECO:0000269|PubMed:25168903, ECO:0000269|PubMed:25593321}.
CC   -!- DISEASE: Note=Defects in TCF4 may cause autosomal dominant symmetrical
CC       acral keratoderma (SAK)syndrome. Symmetrical acral keratodermadefines
CC       is characterized by brown/black hyperkeratotic patches symmetrically
CC       distributed on the acral regions, especially the wrists, ankles, dorsa
CC       of hands, fingers and feet affects young and middle aged men. Patients
CC       have epidermis thickened by acanthosis and compact stratum
CC       corneum(PubMed:28921696). {ECO:0000269|PubMed:28921696}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60310.1; Type=Miscellaneous discrepancy; Note=Incomplete and probable erroneous sequence.; Evidence={ECO:0000305};
CC       Sequence=AAA60312.1; Type=Miscellaneous discrepancy; Note=Incomplete and probable erroneous sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M74718; AAA60310.1; ALT_SEQ; mRNA.
DR   EMBL; M74719; AAA60311.1; -; mRNA.
DR   EMBL; M74720; AAA60312.1; ALT_SEQ; mRNA.
DR   EMBL; FR748210; CBY80189.1; -; mRNA.
DR   EMBL; FR748211; CBY80190.1; -; mRNA.
DR   EMBL; FR748212; CBY80191.1; -; mRNA.
DR   EMBL; FR748213; CBY80192.1; -; mRNA.
DR   EMBL; FR748214; CBY80193.1; -; mRNA.
DR   EMBL; FR748215; CBY80194.1; -; mRNA.
DR   EMBL; FR748216; CBY80195.1; -; mRNA.
DR   EMBL; FR748217; CBY80196.1; -; mRNA.
DR   EMBL; FR748218; CBY80197.1; -; mRNA.
DR   EMBL; FR748219; CBY80198.1; -; mRNA.
DR   EMBL; FR748220; CBY80199.1; -; mRNA.
DR   EMBL; FR748221; CBY80200.1; -; mRNA.
DR   EMBL; FR748222; CBY80201.1; -; mRNA.
DR   EMBL; FR748223; CBY80202.1; -; mRNA.
DR   EMBL; AK095041; BAG52974.1; -; mRNA.
DR   EMBL; AK096862; BAG53382.1; -; mRNA.
DR   EMBL; AK299169; BAH12962.1; -; mRNA.
DR   EMBL; AK300636; BAG62325.1; -; mRNA.
DR   EMBL; AK300038; BAG61849.1; -; mRNA.
DR   EMBL; AK301144; BAH13417.1; -; mRNA.
DR   EMBL; AK300612; BAH13314.1; -; mRNA.
DR   EMBL; AK316165; BAH14536.1; -; mRNA.
DR   EMBL; AC013587; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC018994; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090383; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090684; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471096; EAW63017.1; -; Genomic_DNA.
DR   EMBL; CH471096; EAW63018.1; -; Genomic_DNA.
DR   EMBL; BC125084; AAI25085.1; -; mRNA.
DR   EMBL; BC125085; AAI25086.1; -; mRNA.
DR   EMBL; AV761952; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U75701; AAC51824.1; -; Genomic_DNA.
DR   EMBL; X52079; CAA36298.1; -; mRNA.
DR   CCDS; CCDS11960.1; -. [P15884-1]
DR   CCDS; CCDS42438.1; -. [P15884-3]
DR   CCDS; CCDS58623.1; -. [P15884-8]
DR   CCDS; CCDS58624.1; -. [P15884-2]
DR   CCDS; CCDS58625.1; -. [P15884-6]
DR   CCDS; CCDS58626.1; -. [P15884-9]
DR   CCDS; CCDS58627.1; -. [P15884-11]
DR   CCDS; CCDS58628.1; -. [P15884-10]
DR   CCDS; CCDS58629.1; -. [P15884-13]
DR   CCDS; CCDS59321.1; -. [P15884-12]
DR   CCDS; CCDS77191.1; -. [P15884-7]
DR   CCDS; CCDS77192.1; -. [P15884-14]
DR   PIR; A41311; A41311.
DR   RefSeq; NP_001077431.1; NM_001083962.1. [P15884-3]
DR   RefSeq; NP_001230155.2; NM_001243226.2.
DR   RefSeq; NP_001230156.1; NM_001243227.1. [P15884-13]
DR   RefSeq; NP_001230157.1; NM_001243228.1.
DR   RefSeq; NP_001230159.1; NM_001243230.1. [P15884-12]
DR   RefSeq; NP_001230160.1; NM_001243231.1. [P15884-10]
DR   RefSeq; NP_001230161.1; NM_001243232.1. [P15884-11]
DR   RefSeq; NP_001230162.1; NM_001243233.1. [P15884-9]
DR   RefSeq; NP_001230163.1; NM_001243234.1. [P15884-2]
DR   RefSeq; NP_001230164.1; NM_001243235.1. [P15884-6]
DR   RefSeq; NP_001230165.1; NM_001243236.1. [P15884-8]
DR   RefSeq; NP_001293136.1; NM_001306207.1. [P15884-14]
DR   RefSeq; NP_001293137.1; NM_001306208.1. [P15884-7]
DR   RefSeq; NP_001335140.1; NM_001348211.1.
DR   RefSeq; NP_001335141.1; NM_001348212.1. [P15884-9]
DR   RefSeq; NP_001335142.1; NM_001348213.1.
DR   RefSeq; NP_001335143.1; NM_001348214.1.
DR   RefSeq; NP_001335144.1; NM_001348215.1.
DR   RefSeq; NP_001335145.1; NM_001348216.1.
DR   RefSeq; NP_001335146.1; NM_001348217.1. [P15884-13]
DR   RefSeq; NP_001335147.1; NM_001348218.1. [P15884-13]
DR   RefSeq; NP_001335148.1; NM_001348219.1. [P15884-14]
DR   RefSeq; NP_001335149.1; NM_001348220.1.
DR   RefSeq; NP_003190.1; NM_003199.2. [P15884-1]
DR   RefSeq; XP_005266796.2; XM_005266739.3.
DR   RefSeq; XP_006722599.1; XM_006722536.2.
DR   RefSeq; XP_006722600.1; XM_006722537.2.
DR   RefSeq; XP_016881425.1; XM_017025936.1.
DR   RefSeq; XP_016881429.1; XM_017025940.1.
DR   RefSeq; XP_016881430.1; XM_017025941.1.
DR   RefSeq; XP_016881435.1; XM_017025946.1.
DR   RefSeq; XP_016881445.1; XM_017025956.1. [P15884-9]
DR   PDB; 2KWF; NMR; -; B=11-27.
DR   PDB; 6OD3; X-ray; 1.49 A; A/B/E/F/G/H/I/J=565-624.
DR   PDB; 6OD4; X-ray; 1.70 A; A/B/G/H=565-624.
DR   PDB; 6OD5; X-ray; 2.05 A; A/B/C/D=565-624.
DR   PDBsum; 2KWF; -.
DR   PDBsum; 6OD3; -.
DR   PDBsum; 6OD4; -.
DR   PDBsum; 6OD5; -.
DR   BMRB; P15884; -.
DR   SMR; P15884; -.
DR   BioGRID; 112787; 280.
DR   CORUM; P15884; -.
DR   DIP; DIP-163N; -.
DR   IntAct; P15884; 276.
DR   MINT; P15884; -.
DR   STRING; 9606.ENSP00000381382; -.
DR   BindingDB; P15884; -.
DR   ChEMBL; CHEMBL3885541; -.
DR   GlyConnect; 2086; 1 N-Linked glycan (1 site).
DR   GlyGen; P15884; 1 site, 2 N-linked glycans (1 site).
DR   iPTMnet; P15884; -.
DR   PhosphoSitePlus; P15884; -.
DR   BioMuta; TCF4; -.
DR   EPD; P15884; -.
DR   jPOST; P15884; -.
DR   MassIVE; P15884; -.
DR   MaxQB; P15884; -.
DR   PaxDb; P15884; -.
DR   PeptideAtlas; P15884; -.
DR   PRIDE; P15884; -.
DR   ProteomicsDB; 32164; -.
DR   ProteomicsDB; 32165; -.
DR   ProteomicsDB; 32166; -.
DR   ProteomicsDB; 32167; -.
DR   ProteomicsDB; 32168; -.
DR   ProteomicsDB; 3668; -.
DR   ProteomicsDB; 3707; -.
DR   ProteomicsDB; 41559; -.
DR   ProteomicsDB; 5186; -.
DR   ProteomicsDB; 53237; -. [P15884-1]
DR   ProteomicsDB; 53238; -. [P15884-2]
DR   ProteomicsDB; 53239; -. [P15884-3]
DR   ProteomicsDB; 6700; -.
DR   ProteomicsDB; 6818; -.
DR   Antibodypedia; 9596; 419 antibodies from 36 providers.
DR   DNASU; 6925; -.
DR   Ensembl; ENST00000354452; ENSP00000346440; ENSG00000196628. [P15884-3]
DR   Ensembl; ENST00000356073; ENSP00000348374; ENSG00000196628.
DR   Ensembl; ENST00000457482; ENSP00000409447; ENSG00000196628. [P15884-2]
DR   Ensembl; ENST00000537578; ENSP00000440731; ENSG00000196628. [P15884-13]
DR   Ensembl; ENST00000537856; ENSP00000439827; ENSG00000196628. [P15884-9]
DR   Ensembl; ENST00000540999; ENSP00000445202; ENSG00000196628. [P15884-14]
DR   Ensembl; ENST00000543082; ENSP00000439656; ENSG00000196628. [P15884-10]
DR   Ensembl; ENST00000544241; ENSP00000441562; ENSG00000196628. [P15884-11]
DR   Ensembl; ENST00000561831; ENSP00000457765; ENSG00000196628. [P15884-8]
DR   Ensembl; ENST00000561992; ENSP00000455179; ENSG00000196628. [P15884-9]
DR   Ensembl; ENST00000564228; ENSP00000455261; ENSG00000196628. [P15884-7]
DR   Ensembl; ENST00000564999; ENSP00000457649; ENSG00000196628.
DR   Ensembl; ENST00000565018; ENSP00000455984; ENSG00000196628. [P15884-15]
DR   Ensembl; ENST00000566279; ENSP00000456125; ENSG00000196628. [P15884-4]
DR   Ensembl; ENST00000566286; ENSP00000455418; ENSG00000196628. [P15884-12]
DR   Ensembl; ENST00000567880; ENSP00000454366; ENSG00000196628. [P15884-5]
DR   Ensembl; ENST00000568673; ENSP00000455135; ENSG00000196628. [P15884-13]
DR   Ensembl; ENST00000570177; ENSP00000454647; ENSG00000196628. [P15884-9]
DR   Ensembl; ENST00000570287; ENSP00000455763; ENSG00000196628. [P15884-6]
DR   Ensembl; ENST00000616053; ENSP00000478549; ENSG00000196628. [P15884-15]
DR   Ensembl; ENST00000626584; ENSP00000486072; ENSG00000196628. [P15884-16]
DR   Ensembl; ENST00000629387; ENSP00000486670; ENSG00000196628. [P15884-3]
DR   Ensembl; ENST00000636400; ENSP00000490006; ENSG00000196628. [P15884-13]
DR   GeneID; 6925; -.
DR   KEGG; hsa:6925; -.
DR   MANE-Select; ENST00000354452.8; ENSP00000346440.3; NM_001083962.2; NP_001077431.1. [P15884-3]
DR   UCSC; uc002lfw.5; human. [P15884-1]
DR   CTD; 6925; -.
DR   DisGeNET; 6925; -.
DR   GeneCards; TCF4; -.
DR   GeneReviews; TCF4; -.
DR   HGNC; HGNC:11634; TCF4.
DR   HPA; ENSG00000196628; Tissue enhanced (brain).
DR   MalaCards; TCF4; -.
DR   MIM; 602272; gene.
DR   MIM; 610954; phenotype.
DR   MIM; 613267; phenotype.
DR   neXtProt; NX_P15884; -.
DR   OpenTargets; ENSG00000196628; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   Orphanet; 98974; Fuchs endothelial corneal dystrophy.
DR   Orphanet; 2896; Pitt-Hopkins syndrome.
DR   Orphanet; 171; Primary sclerosing cholangitis.
DR   PharmGKB; PA164742621; -.
DR   VEuPathDB; HostDB:ENSG00000196628; -.
DR   eggNOG; KOG3910; Eukaryota.
DR   GeneTree; ENSGT00940000159129; -.
DR   InParanoid; P15884; -.
DR   OrthoDB; 571132at2759; -.
DR   PhylomeDB; P15884; -.
DR   TreeFam; TF321672; -.
DR   BRENDA; 7.6.2.3; 2681.
DR   PathwayCommons; P15884; -.
DR   Reactome; R-HSA-525793; Myogenesis.
DR   SignaLink; P15884; -.
DR   SIGNOR; P15884; -.
DR   BioGRID-ORCS; 6925; 13 hits in 1071 CRISPR screens.
DR   ChiTaRS; TCF4; human.
DR   EvolutionaryTrace; P15884; -.
DR   GeneWiki; TCF4; -.
DR   GenomeRNAi; 6925; -.
DR   Pharos; P15884; Tbio.
DR   PRO; PR:P15884; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; P15884; protein.
DR   Bgee; ENSG00000196628; Expressed in cerebellum and 260 other tissues.
DR   ExpressionAtlas; P15884; baseline and differential.
DR   Genevisible; P15884; HS.
DR   GO; GO:1990907; C:beta-catenin-TCF complex; IPI:FlyBase.
DR   GO; GO:0070369; C:beta-catenin-TCF7L2 complex; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IDA:ARUK-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; ISS:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:BHF-UCL.
DR   GO; GO:0070888; F:E-box binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0001093; F:TFIIB-class transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0065004; P:protein-DNA complex assembly; ISS:BHF-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 4.10.280.10; -; 1.
DR   IDEAL; IID00622; -.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Corneal dystrophy;
KW   Differentiation; Disease variant; DNA-binding; Epilepsy;
KW   Mental retardation; Neurogenesis; Nucleus; Phosphoprotein;
KW   Primary microcephaly; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..667
FT                   /note="Transcription factor 4"
FT                   /id="PRO_0000127256"
FT   DOMAIN          564..617
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          1..83
FT                   /note="Essential for MYOD1 inhibition"
FT                   /evidence="ECO:0000250"
FT   REGION          24..245
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          263..321
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          336..379
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          379..400
FT                   /note="Leucine-zipper"
FT   REGION          466..570
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          619..642
FT                   /note="Class A specific domain"
FT   REGION          634..667
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           18..26
FT                   /note="9aaTAD"
FT   COMPBIAS        28..65
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        86..124
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        139..160
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        184..245
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        267..319
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        469..488
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        513..570
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         66
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         87
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         92
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62655"
FT   MOD_RES         515
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   VAR_SEQ         1..216
FT                   /note="Missing (in isoform I-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_054279"
FT   VAR_SEQ         1..160
FT                   /note="Missing (in isoform SEF2-1A)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:1681116, ECO:0000303|PubMed:21789225,
FT                   ECO:0000303|Ref.7"
FT                   /id="VSP_030819"
FT   VAR_SEQ         1..130
FT                   /note="Missing (in isoform D-)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:21789225"
FT                   /id="VSP_045149"
FT   VAR_SEQ         1..102
FT                   /note="MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVED
FT                   RSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQS -> MKDIF
FT                   FQFIIARVRKCYSLSCLHTLPVVPTLR (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045150"
FT   VAR_SEQ         1..49
FT                   /note="MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSN ->
FT                   MEEDSRD (in isoform F-)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:21789225"
FT                   /id="VSP_045151"
FT   VAR_SEQ         1..32
FT                   /note="MHHQQRMAALGTDKELSDLLDFSAMFSPPVSS -> MKDIFFQFIIARVRKC
FT                   YSLSCLHTLPVVPTLR (in isoform G-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044334"
FT   VAR_SEQ         1..24
FT                   /note="Missing (in isoform 13, isoform C- and isoform C-
FT                   delta)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:21789225"
FT                   /id="VSP_047081"
FT   VAR_SEQ         1..24
FT                   /note="MHHQQRMAALGTDKELSDLLDFSA -> MQRAKTELFRLQIVTDDLRKNE
FT                   (in isoform E-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_047082"
FT   VAR_SEQ         1..23
FT                   /note="MHHQQRMAALGTDKELSDLLDFS -> MYCAYTIPGMGGNSLMYYYNGKA
FT                   (in isoform A-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044336"
FT   VAR_SEQ         1..23
FT                   /note="MHHQQRMAALGTDKELSDLLDFS -> MKFKQCRCSDTGLCCLDHEGKAE
FT                   (in isoform H-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044335"
FT   VAR_SEQ         24..183
FT                   /note="Missing (in isoform H-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_057364"
FT   VAR_SEQ         24..123
FT                   /note="Missing (in isoform A-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044337"
FT   VAR_SEQ         33..102
FT                   /note="Missing (in isoform G-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044338"
FT   VAR_SEQ         123
FT                   /note="Missing (in isoform G- and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044339"
FT   VAR_SEQ         124..183
FT                   /note="Missing (in isoform A-, isoform B-delta, isoform
FT                   B+delta and isoform C-delta)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_044340"
FT   VAR_SEQ         161..183
FT                   /note="LHSSAMEVQTKKVRKVPPGLPSS -> MYCAYTIPGMGGNSLMYYYNGKA
FT                   (in isoform SEF2-1A)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:1681116, ECO:0000303|PubMed:21789225,
FT                   ECO:0000303|Ref.7"
FT                   /id="VSP_002111"
FT   VAR_SEQ         357
FT                   /note="Missing (in isoform E-)"
FT                   /evidence="ECO:0000303|PubMed:21789225"
FT                   /id="VSP_047083"
FT   VAR_SEQ         545
FT                   /note="T -> TRSRS (in isoform B+delta, isoform SEF2-1A,
FT                   isoform SEF2-1D, isoform 11 and isoform 13)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:1681116,
FT                   ECO:0000303|PubMed:21789225, ECO:0000303|Ref.7"
FT                   /id="VSP_002112"
FT   VARIANT         29
FT                   /note="P -> T (probable disease-associated variant found in
FT                   a family with symmetrical acral keratoderma)"
FT                   /evidence="ECO:0000269|PubMed:28921696"
FT                   /id="VAR_079726"
FT   VARIANT         358
FT                   /note="G -> V (in PTHS; also expressed in the nucleus with
FT                   a pattern indistinguishable from the wild-type; does not
FT                   have a major impact on homodimer formation; affects
FT                   transcriptional activity in a context-dependent manner)"
FT                   /evidence="ECO:0000269|PubMed:18728071,
FT                   ECO:0000269|PubMed:22777675"
FT                   /id="VAR_066839"
FT   VARIANT         385..667
FT                   /note="Missing (in PTHS)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078644"
FT   VARIANT         450
FT                   /note="M -> I (in dbSNP:rs11660217)"
FT                   /id="VAR_049545"
FT   VARIANT         535
FT                   /note="D -> G (in PTHS; loss of function; also expressed in
FT                   the nucleus with a pattern indistinguishable from the wild-
FT                   type; does not have a major impact on homodimer formation;
FT                   affects transcriptional activity in a context-dependent
FT                   manner)"
FT                   /evidence="ECO:0000269|PubMed:19235238,
FT                   ECO:0000269|PubMed:22777675"
FT                   /id="VAR_058632"
FT   VARIANT         565
FT                   /note="R -> W (in PTHS)"
FT                   /evidence="ECO:0000269|PubMed:22045651"
FT                   /id="VAR_066970"
FT   VARIANT         572
FT                   /note="R -> G (in PTHS; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:19235238,
FT                   ECO:0000269|PubMed:22045651"
FT                   /id="VAR_058633"
FT   VARIANT         572
FT                   /note="R -> Q (in PTHS; dbSNP:rs1057521070)"
FT                   /evidence="ECO:0000269|PubMed:22045651"
FT                   /id="VAR_066971"
FT   VARIANT         574
FT                   /note="R -> H (in PTHS; dbSNP:rs121909123)"
FT                   /evidence="ECO:0000269|PubMed:22045651"
FT                   /id="VAR_066972"
FT   VARIANT         574
FT                   /note="R -> P (in PTHS; mislocalized to small spherical
FT                   punctae that are dispersed throughout the nucleus; can
FT                   attenuate homo- and heterodimer formation; affects
FT                   transcriptional activity in a context-dependent manner;
FT                   dbSNP:rs121909123)"
FT                   /evidence="ECO:0000269|PubMed:18728071,
FT                   ECO:0000269|PubMed:22045651, ECO:0000269|PubMed:22777675"
FT                   /id="VAR_066840"
FT   VARIANT         576
FT                   /note="R -> Q (in PTHS; loss of function;
FT                   dbSNP:rs121909121)"
FT                   /evidence="ECO:0000269|PubMed:17436254,
FT                   ECO:0000269|PubMed:19235238, ECO:0000269|PubMed:22045651"
FT                   /id="VAR_034704"
FT   VARIANT         576
FT                   /note="R -> W (in PTHS; mislocalized to small spherical
FT                   punctae that are dispersed throughout the nucleus; can
FT                   attenuate homo- and heterodimer formation; affects
FT                   transcriptional activity in a context-dependent manner;
FT                   dbSNP:rs121909120)"
FT                   /evidence="ECO:0000269|PubMed:17436254,
FT                   ECO:0000269|PubMed:17436255, ECO:0000269|PubMed:22045651,
FT                   ECO:0000269|PubMed:22777675"
FT                   /id="VAR_034705"
FT   VARIANT         578
FT                   /note="R -> H (in PTHS)"
FT                   /evidence="ECO:0000269|PubMed:18728071"
FT                   /id="VAR_066841"
FT   VARIANT         578
FT                   /note="R -> P (in PTHS)"
FT                   /evidence="ECO:0000269|PubMed:20184619,
FT                   ECO:0000269|PubMed:22045651"
FT                   /id="VAR_066973"
FT   VARIANT         583
FT                   /note="A -> P (in PTHS)"
FT                   /evidence="ECO:0000269|PubMed:22045651"
FT                   /id="VAR_066974"
FT   VARIANT         610
FT                   /note="A -> V (in PTHS; loss of function; mislocalized to
FT                   small spherical punctae that are dispersed throughout the
FT                   nucleus; can attenuate homo- and heterodimer formation;
FT                   affects transcriptional activity in a context-dependent
FT                   manner)"
FT                   /evidence="ECO:0000269|PubMed:19235238,
FT                   ECO:0000269|PubMed:22045651, ECO:0000269|PubMed:22777675"
FT                   /id="VAR_058634"
FT   CONFLICT        46..49
FT                   /note="TGSN -> EFGG (in Ref. 9; CAA36298)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        205
FT                   /note="Missing (in Ref. 7; AV761952)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        334
FT                   /note="P -> S (in Ref. 9; CAA36298)"
FT                   /evidence="ECO:0000305"
FT   HELIX           15..25
FT                   /evidence="ECO:0007829|PDB:2KWF"
FT   HELIX           565..594
FT                   /evidence="ECO:0007829|PDB:6OD3"
FT   HELIX           603..622
FT                   /evidence="ECO:0007829|PDB:6OD3"
SQ   SEQUENCE   667 AA;  71308 MW;  53459FC7989D9487 CRC64;
     MHHQQRMAAL GTDKELSDLL DFSAMFSPPV SSGKNGPTSL ASGHFTGSNV EDRSSSGSWG
     NGGHPSPSRN YGDGTPYDHM TSRDLGSHDN LSPPFVNSRI QSKTERGSYS SYGRESNLQG
     CHQQSLLGGD MDMGNPGTLS PTKPGSQYYQ YSSNNPRRRP LHSSAMEVQT KKVRKVPPGL
     PSSVYAPSAS TADYNRDSPG YPSSKPATST FPSSFFMQDG HHSSDPWSSS SGMNQPGYAG
     MLGNSSHIPQ SSSYCSLHPH ERLSYPSHSS ADINSSLPPM STFHRSGTNH YSTSSCTPPA
     NGTDSIMANR GSGAAGSSQT GDALGKALAS IYSPDHTNNS FSSNPSTPVG SPPSLSAGTA
     VWSRNGGQAS SSPNYEGPLH SLQSRIEDRL ERLDDAIHVL RNHAVGPSTA MPGGHGDMHG
     IIGPSHNGAM GGLGSGYGTG LLSANRHSLM VGTHREDGVA LRGSHSLLPN QVPVPQLPVQ
     SATSPDLNPP QDPYRGMPPG LQGQSVSSGS SEIKSDDEGD ENLQDTKSSE DKKLDDDKKD
     IKSITSNNDD EDLTPEQKAE REKERRMANN ARERLRVRDI NEAFKELGRM VQLHLKSDKP
     QTKLLILHQA VAVILSLEQQ VRERNLNPKA ACLKRREEEK VSSEPPPLSL AGPHPGMGDA
     SNHMGQM
//
ID   TSN6_HUMAN              Reviewed;         245 AA.
AC   O43657; Q54A42; Q6IAN9;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   23-FEB-2022, entry version 176.
DE   RecName: Full=Tetraspanin-6;
DE            Short=Tspan-6;
DE   AltName: Full=A15 homolog;
DE   AltName: Full=Putative NF-kappa-B-activating protein 321;
DE   AltName: Full=T245 protein;
DE   AltName: Full=Tetraspanin TM4-D;
DE   AltName: Full=Transmembrane 4 superfamily member 6;
GN   Name=TSPAN6; Synonyms=TM4SF6; ORFNames=UNQ767/PRO1560;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9714763; DOI=10.1016/s0167-4781(98)00087-6;
RA   Todd S.C., Doctor V.S., Levy S.;
RT   "Sequences and expression of six new members of the tetraspanin/TM4SF
RT   family.";
RL   Biochim. Biophys. Acta 1399:101-104(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9782095; DOI=10.1006/geno.1998.5415;
RA   Maeda K., Matsuhashi S., Hori K., Xin Z., Mukai T., Tabuchi K.,
RA   Egashira M., Niikawa N.;
RT   "Cloning and characterization of a novel human gene, TM4SF6, encoding a
RT   protein belonging to the transmembrane 4 superfamily, and mapped to Xq22.";
RL   Genomics 52:240-242(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Maeda K., Matsuhashi Y.;
RT   "The cDNA cloning of a novel gene A15 homologue which encodes a new member
RT   of the transmembrane 4 superfamily.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Puls K.L., Ni J., Liu D., Morahan G., Wright M.D.;
RT   "The molecular characterization of four tetraspanins.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-108.
RC   TISSUE=Lung;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y.,
RA   Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the tetraspanin (TM4SF) family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF053453; AAC69710.1; -; mRNA.
DR   EMBL; AF043906; AAC64257.1; -; mRNA.
DR   EMBL; U84895; AAD00560.1; -; mRNA.
DR   EMBL; AF133426; AAF08365.1; -; mRNA.
DR   EMBL; AY358825; AAQ89184.1; -; mRNA.
DR   EMBL; AB097016; BAC77369.1; -; mRNA.
DR   EMBL; BT006977; AAP35623.1; -; mRNA.
DR   EMBL; CR457115; CAG33396.1; -; mRNA.
DR   EMBL; AL035608; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471115; EAX02811.1; -; Genomic_DNA.
DR   EMBL; BC012389; AAH12389.1; -; mRNA.
DR   CCDS; CCDS14470.1; -.
DR   PIR; A59258; A59258.
DR   RefSeq; NP_001265672.1; NM_001278743.1.
DR   RefSeq; NP_003261.1; NM_003270.3.
DR   SMR; O43657; -.
DR   BioGRID; 112960; 59.
DR   IntAct; O43657; 16.
DR   MINT; O43657; -.
DR   STRING; 9606.ENSP00000362111; -.
DR   GlyGen; O43657; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O43657; -.
DR   PhosphoSitePlus; O43657; -.
DR   SwissPalm; O43657; -.
DR   BioMuta; TSPAN6; -.
DR   CPTAC; CPTAC-1285; -.
DR   EPD; O43657; -.
DR   jPOST; O43657; -.
DR   MassIVE; O43657; -.
DR   MaxQB; O43657; -.
DR   PaxDb; O43657; -.
DR   PeptideAtlas; O43657; -.
DR   PRIDE; O43657; -.
DR   ProteomicsDB; 49090; -.
DR   Antibodypedia; 478; 246 antibodies from 26 providers.
DR   DNASU; 7105; -.
DR   Ensembl; ENST00000373020; ENSP00000362111; ENSG00000000003.
DR   GeneID; 7105; -.
DR   KEGG; hsa:7105; -.
DR   MANE-Select; ENST00000373020.9; ENSP00000362111.4; NM_003270.4; NP_003261.1.
DR   UCSC; uc004ega.3; human.
DR   CTD; 7105; -.
DR   DisGeNET; 7105; -.
DR   GeneCards; TSPAN6; -.
DR   HGNC; HGNC:11858; TSPAN6.
DR   HPA; ENSG00000000003; Low tissue specificity.
DR   MIM; 300191; gene.
DR   neXtProt; NX_O43657; -.
DR   OpenTargets; ENSG00000000003; -.
DR   PharmGKB; PA36559; -.
DR   VEuPathDB; HostDB:ENSG00000000003; -.
DR   eggNOG; KOG3882; Eukaryota.
DR   GeneTree; ENSGT00940000159092; -.
DR   HOGENOM; CLU_055524_3_0_1; -.
DR   InParanoid; O43657; -.
DR   OMA; FLFRHEI; -.
DR   OrthoDB; 1145558at2759; -.
DR   PhylomeDB; O43657; -.
DR   TreeFam; TF352891; -.
DR   PathwayCommons; O43657; -.
DR   SignaLink; O43657; -.
DR   BioGRID-ORCS; 7105; 6 hits in 665 CRISPR screens.
DR   ChiTaRS; TSPAN6; human.
DR   GeneWiki; TSPAN6; -.
DR   GenomeRNAi; 7105; -.
DR   Pharos; O43657; Tbio.
DR   PRO; PR:O43657; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O43657; protein.
DR   Bgee; ENSG00000000003; Expressed in sperm and 228 other tissues.
DR   ExpressionAtlas; O43657; baseline and differential.
DR   Genevisible; O43657; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:1901223; P:negative regulation of NIK/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0039532; P:negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; HMP:UniProtKB.
DR   Gene3D; 1.10.1450.10; -; 1.
DR   InterPro; IPR018499; Tetraspanin/Peripherin.
DR   InterPro; IPR000301; Tetraspanin_animals.
DR   InterPro; IPR018503; Tetraspanin_CS.
DR   InterPro; IPR008952; Tetraspanin_EC2_sf.
DR   PANTHER; PTHR19282; PTHR19282; 1.
DR   Pfam; PF00335; Tetraspanin; 1.
DR   PIRSF; PIRSF002419; Tetraspanin; 1.
DR   SUPFAM; SSF48652; SSF48652; 1.
DR   PROSITE; PS00421; TM4_1; 1.
PE   1: Evidence at protein level;
KW   Glycoprotein; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..245
FT                   /note="Tetraspanin-6"
FT                   /id="PRO_0000219246"
FT   TOPO_DOM        1..19
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        20..40
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        41..59
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        60..80
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        81..93
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        94..114
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        115..208
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        209..229
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        230..245
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        134
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         108
FT                   /note="A -> T (in dbSNP:rs1802288)"
FT                   /evidence="ECO:0000269|PubMed:12761501"
FT                   /id="VAR_014494"
SQ   SEQUENCE   245 AA;  27563 MW;  811FAB19C2805BE2 CRC64;
     MASPSRRLQT KPVITCFKSV LLIYTFIFWI TGVILLAVGI WGKVSLENYF SLLNEKATNV
     PFVLIATGTV IILLGTFGCF ATCRASAWML KLYAMFLTLV FLVELVAAIV GFVFRHEIKN
     SFKNNYEKAL KQYNSTGDYR SHAVDKIQNT LHCCGVTDYR DWTDTNYYSE KGFPKSCCKL
     EDCTPQRDAD KVNNEGCFIK VMTIIESEMG VVAGISFGVA CFQLIGIFLA YCLSRAITNN
     QYEIV
//
ID   CUL2_HUMAN              Reviewed;         745 AA.
AC   Q13617; B3KT95; B7Z6K8; D3DRY6; G3V1S2; O00200; Q5T2B6; Q9UNF9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-AUG-2001, sequence version 2.
DT   23-FEB-2022, entry version 198.
DE   RecName: Full=Cullin-2;
DE            Short=CUL-2;
GN   Name=CUL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT SER-109, IDENTIFICATION IN
RP   COMPLEX WITH VHL AND ELONGIN BC, AND FUNCTION.
RC   TISSUE=Kidney;
RX   PubMed=9122164; DOI=10.1073/pnas.94.6.2156;
RA   Pause A., Lee S., Worrel R., Chen D.Y.T., Burgess W.H., Linehan W.M.,
RA   Klausner R.D.;
RT   "The von Hippel-Lindau tumor-suppressor gene product forms a stable complex
RT   with human CUL-2, a member of the Cdc53 family of proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2156-2161(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT SER-109, MUTAGENESIS OF
RP   LYS-621; LYS-689 AND LYS-719, AND NEDDYLATION AT LYS-689.
RC   TISSUE=Brain;
RX   PubMed=10092517; DOI=10.1006/bbrc.1999.0339;
RA   Wada H., Yeh E.T.H., Kamitani T.;
RT   "Identification of NEDD8-conjugation site in human cullin-2.";
RL   Biochem. Biophys. Res. Commun. 257:100-105(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 95-745.
RX   PubMed=8681378; DOI=10.1016/s0092-8674(00)81267-2;
RA   Kipreos E.T., Lander L.E., Wing J.P., He W.W., Hedgecock E.M.;
RT   "cul-1 is required for cell cycle exit in C. elegans and identifies a novel
RT   gene family.";
RL   Cell 85:829-839(1996).
RN   [8]
RP   INTERACTION WITH RBX1 AND RNF7.
RX   PubMed=10230407; DOI=10.1016/s1097-2765(00)80482-7;
RA   Ohta T., Michel J.J., Schottelius A.J., Xiong Y.;
RT   "ROC1, a homolog of APC11, represents a family of cullin partners with an
RT   associated ubiquitin ligase activity.";
RL   Mol. Cell 3:535-541(1999).
RN   [9]
RP   FUNCTION, AND IDENTIFICATION IN CBC(VHL) COMPLEX.
RX   PubMed=10973499; DOI=10.1073/pnas.190332597;
RA   Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W.;
RT   "Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-
RT   Lindau (VHL) tumor suppressor complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:10430-10435(2000).
RN   [10]
RP   IDENTIFICATION IN COMPLEX WITH VHL; ELONGIN BC AND RBX1, AND FUNCTION.
RX   PubMed=11384984; DOI=10.1074/jbc.m103093200;
RA   Kamura T., Burian D., Yan Q., Schmidt S.L., Lane W.S., Querido E.,
RA   Branton P.E., Shilatifard A., Conaway R.C., Conaway J.W.;
RT   "Muf1, a novel elongin BC-interacting leucine-rich repeat protein that can
RT   assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase.";
RL   J. Biol. Chem. 276:29748-29753(2001).
RN   [11]
RP   IDENTIFICATION IN E3 UBIQUITIN-PROTEIN LIGASE COMPLEX WITH MED8.
RX   PubMed=12149480; DOI=10.1073/pnas.162424199;
RA   Brower C.S., Sato S., Tomomori-Sato C., Kamura T., Pause A., Stearman R.,
RA   Klausner R.D., Malik S., Lane W.S., Sorokina I., Roeder R.G., Conaway J.W.,
RA   Conaway R.C.;
RT   "Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that
RT   can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:10353-10358(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TIP120A.
RX   PubMed=12609982; DOI=10.1074/jbc.m213070200;
RA   Min K.-W., Hwang J.-W., Lee J.-S., Park Y., Tamura T.-A., Yoon J.-B.;
RT   "TIP120A associates with cullins and modulates ubiquitin ligase activity.";
RL   J. Biol. Chem. 278:15905-15910(2003).
RN   [13]
RP   NEDDYLATION.
RX   PubMed=10597293; DOI=10.1038/sj.onc.1203093;
RA   Hori T., Osaka F., Chiba T., Miyamoto C., Okabayashi K., Shimbara N.,
RA   Kato S., Tanaka K.;
RT   "Covalent modification of all members of human cullin family proteins by
RT   NEDD8.";
RL   Oncogene 18:6829-6834(1999).
RN   [14]
RP   INTERACTION WITH LRR1 AND FEM1B.
RX   PubMed=15601820; DOI=10.1101/gad.1252404;
RA   Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C.,
RA   Conaway J.W., Nakayama K.I.;
RT   "VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1
RT   and Cul5-Rbx2 modules of ubiquitin ligases.";
RL   Genes Dev. 18:3055-3065(2004).
RN   [15]
RP   IDENTIFICATION IN COMPLEX WITH ELOC AND ZYG11B, AND IDENTIFICATION IN
RP   COMPLEX WITH ELOB; ELOC AND ZER1.
RX   PubMed=17304241; DOI=10.1038/sj.embor.7400895;
RA   Vasudevan S., Starostina N.G., Kipreos E.T.;
RT   "The Caenorhabditis elegans cell-cycle regulator ZYG-11 defines a conserved
RT   family of CUL-2 complex components.";
RL   EMBO Rep. 8:279-286(2007).
RN   [16]
RP   INTERACTION WITH HRSV VIRUS PROTEIN NS1 (MICROBIAL INFECTION).
RX   PubMed=17251292; DOI=10.1128/jvi.02303-06;
RA   Elliott J., Lynch O.T., Suessmuth Y., Qian P., Boyd C.R., Burrows J.F.,
RA   Buick R., Stevenson N.J., Touzelet O., Gadina M., Power U.F.,
RA   Johnston J.A.;
RT   "Respiratory syncytial virus NS1 protein degrades STAT2 by using the
RT   Elongin-Cullin E3 ligase.";
RL   J. Virol. 81:3428-3436(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-661, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-393, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   INTERACTS WITH KLHDC10.
RX   PubMed=23102700; DOI=10.1016/j.molcel.2012.09.018;
RA   Sekine Y., Hatanaka R., Watanabe T., Sono N., Iemura S., Natsume T.,
RA   Kuranaga E., Miura M., Takeda K., Ichijo H.;
RT   "The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1
RT   activation by suppressing PP5.";
RL   Mol. Cell 48:692-704(2012).
RN   [21]
RP   IDENTIFICATION IN A COMPLEX WITH LIMD1; EGLN1/PHD2; VHL AND ELOB.
RX   PubMed=22286099; DOI=10.1038/ncb2424;
RA   Foxler D.E., Bridge K.S., James V., Webb T.M., Mee M., Wong S.C., Feng Y.,
RA   Constantin-Teodosiu D., Petursdottir T.E., Bjornsson J., Ingvarsson S.,
RA   Ratcliffe P.J., Longmore G.D., Sharp T.V.;
RT   "The LIMD1 protein bridges an association between the prolyl hydroxylases
RT   and VHL to repress HIF-1 activity.";
RL   Nat. Cell Biol. 14:201-208(2012).
RN   [22]
RP   FUNCTION, INTERACTION WITH ARIH1, AND NEDDYLATION.
RX   PubMed=24076655; DOI=10.1038/emboj.2013.209;
RA   Kelsall I.R., Duda D.M., Olszewski J.L., Hofmann K., Knebel A.,
RA   Langevin F., Wood N., Wightman M., Schulman B.A., Alpi A.F.;
RT   "TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-
RT   RING ligase complexes.";
RL   EMBO J. 32:2848-2860(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-661, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   INTERACTION WITH DCUN1D1, AND COMPONENT OF VCB COMPLEX.
RX   PubMed=23401859; DOI=10.1128/mcb.01342-12;
RA   Heir P., Sufan R.I., Greer S.N., Poon B.P., Lee J.E., Ohh M.;
RT   "DCNL1 functions as a substrate sensor and activator of cullin 2-RING
RT   ligase.";
RL   Mol. Cell. Biol. 33:1621-1631(2013).
RN   [25]
RP   INTERACTION WITH DCUN1D1; DCUN1D2; DCUN1D3; DCUN1D4 AND DCUN1D5.
RX   PubMed=23201271; DOI=10.1016/j.str.2012.10.013;
RA   Monda J.K., Scott D.C., Miller D.J., Lydeard J., King D., Harper J.W.,
RA   Bennett E.J., Schulman B.A.;
RT   "Structural conservation of distinctive N-terminal acetylation-dependent
RT   interactions across a family of mammalian NEDD8 ligation enzymes.";
RL   Structure 21:42-53(2013).
RN   [26]
RP   INTERACTION WITH DCUN1D5.
RX   PubMed=24192928; DOI=10.1158/1078-0432.ccr-13-1252;
RA   Bommelje C.C., Weeda V.B., Huang G., Shah K., Bains S., Buss E., Shaha M.,
RA   Goenen M., Ghossein R., Ramanathan S.Y., Singh B.;
RT   "Oncogenic function of SCCRO5/DCUN1D5 requires its Neddylation E3 activity
RT   and nuclear localization.";
RL   Clin. Cancer Res. 20:372-381(2014).
RN   [27]
RP   FUNCTION, INTERACTION WITH ARIH1, AND NEDDYLATION.
RX   PubMed=27565346; DOI=10.1016/j.cell.2016.07.027;
RA   Scott D.C., Rhee D.Y., Duda D.M., Kelsall I.R., Olszewski J.L., Paulo J.A.,
RA   de Jong A., Ovaa H., Alpi A.F., Harper J.W., Schulman B.A.;
RT   "Two distinct types of E3 ligases work in unison to regulate substrate
RT   ubiquitylation.";
RL   Cell 166:1198-1214(2016).
RN   [28]
RP   INTERACTION WITH DCUN1D1; DCUN1D2; DCUN1D3; DCUN1D4 AND DCUN1D5.
RX   PubMed=26906416; DOI=10.1242/jcs.181784;
RA   Keuss M.J., Thomas Y., Mcarthur R., Wood N.T., Knebel A., Kurz T.;
RT   "Characterization of the mammalian family of DCN-type NEDD8 E3 ligases.";
RL   J. Cell Sci. 129:1441-1454(2016).
RN   [29]
RP   FUNCTION, AND PATHWAY.
RX   PubMed=26138980; DOI=10.1126/science.aab0515;
RA   Lin H.C., Ho S.C., Chen Y.Y., Khoo K.H., Hsu P.H., Yen H.C.;
RT   "SELENOPROTEINS. CRL2 aids elimination of truncated selenoproteins produced
RT   by failed UGA/Sec decoding.";
RL   Science 349:91-95(2015).
RN   [30]
RP   FUNCTION, PATHWAY, AND IDENTIFICATION IN A CRL2 E3 UBIQUITIN-PROTEIN LIGASE
RP   COMPLEX.
RX   PubMed=29779948; DOI=10.1016/j.cell.2018.04.028;
RA   Koren I., Timms R.T., Kula T., Xu Q., Li M.Z., Elledge S.J.;
RT   "The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting C-
RT   terminal degrons.";
RL   Cell 173:1622-1635(2018).
RN   [31]
RP   FUNCTION, PATHWAY, AND IDENTIFICATION IN A CRL2 E3 UBIQUITIN-PROTEIN LIGASE
RP   COMPLEX.
RX   PubMed=29775578; DOI=10.1016/j.molcel.2018.04.006;
RA   Lin H.C., Yeh C.W., Chen Y.F., Lee T.T., Hsieh P.Y., Rusnac D.V., Lin S.Y.,
RA   Elledge S.J., Zheng N., Yen H.S.;
RT   "C-terminal end-directed protein elimination by CRL2 ubiquitin ligases.";
RL   Mol. Cell 70:602-613(2018).
CC   -!- FUNCTION: Core component of multiple cullin-RING-based ECS (ElonginB/C-
CC       CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which
CC       mediate the ubiquitination of target proteins (PubMed:11384984,
CC       PubMed:26138980, PubMed:29779948, PubMed:29775578). CUL2 may serve as a
CC       rigid scaffold in the complex and may contribute to catalysis through
CC       positioning of the substrate and the ubiquitin-conjugating enzyme
CC       (PubMed:9122164, PubMed:10973499, PubMed:11384984, PubMed:12609982,
CC       PubMed:24076655). The E3 ubiquitin-protein ligase activity of the
CC       complex is dependent on the neddylation of the cullin subunit and is
CC       inhibited by the association of the deneddylated cullin subunit with
CC       TIP120A/CAND1 (PubMed:12609982, PubMed:24076655, PubMed:27565346). The
CC       functional specificity of the ECS complex depends on the substrate
CC       recognition component (PubMed:9122164, PubMed:10973499,
CC       PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS(VHL) mediates
CC       the ubiquitination of hypoxia-inducible factor (HIF) (PubMed:9122164,
CC       PubMed:10973499). A number of ECS complexes (containing either KLHDC2,
CC       KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition
CC       component) are part of the DesCEND (destruction via C-end degrons)
CC       pathway, which recognizes a C-degron located at the extreme C terminus
CC       of target proteins, leading to their ubiquitination and degradation
CC       (PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS complexes and
CC       ARIH1 collaborate in tandem to mediate ubiquitination of target
CC       proteins (PubMed:27565346). {ECO:0000269|PubMed:10973499,
CC       ECO:0000269|PubMed:11384984, ECO:0000269|PubMed:12609982,
CC       ECO:0000269|PubMed:24076655, ECO:0000269|PubMed:26138980,
CC       ECO:0000269|PubMed:27565346, ECO:0000269|PubMed:29775578,
CC       ECO:0000269|PubMed:29779948, ECO:0000269|PubMed:9122164}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:26138980, ECO:0000269|PubMed:29775578,
CC       ECO:0000269|PubMed:29779948}.
CC   -!- SUBUNIT: Component of multiple ECS (Elongin BC-CUL2/5-SOCS-box protein)
CC       E3 ubiquitin-protein ligase complexes formed of CUL2, Elongin BC (ELOB
CC       and ELOC), RBX1 and a variable substrate-specific adapter
CC       (PubMed:9122164, PubMed:10973499, PubMed:11384984, PubMed:26138980,
CC       PubMed:29779948, PubMed:29775578). Component of the ECS(VHL) or
CC       CBC(VHL) complex containing VHL (PubMed:9122164, PubMed:10973499,
CC       PubMed:11384984). Component of the ECS(MED8) complex with the probable
CC       substrate recognition component MED8 (PubMed:12149480). Component of
CC       multiple ECS complexes part of the DesCEND (destruction via C-end
CC       degrons) pathway, which contain either KLHDC2, KLHDC3, KLHDC10, APPBP2,
CC       FEM1A, FEM1B or FEM1C as substrate-recognition component
CC       (PubMed:23102700, PubMed:26138980, PubMed:29779948, PubMed:29775578).
CC       Component of the ECS(LRR1) complex with the probable substrate
CC       recognition component LRR1 (PubMed:15601820). Component of a probable
CC       ECS E3 ubiquitin-protein ligase complex containing CUL2, RBX1, ELOB,
CC       ELOC and FEM1B (PubMed:15601820). Part of an E3 ubiquitin-protein
CC       ligase complex including ZYG11B, CUL2 and Elongin BC (PubMed:17304241).
CC       Part of an E3 ubiquitin-protein ligase complex including ZER1, CUL2 and
CC       Elongin BC (PubMed:17304241). Interacts with RBX1, RNF7, FEM1B and
CC       TIP120A/CAND1 (PubMed:10230407, PubMed:12609982). Found in a complex
CC       composed of LIMD1, VHL, EGLN1/PHD2, ELOB and CUL2 (PubMed:22286099).
CC       Interacts (when neddylated) with ARIH1; leading to activate the E3
CC       ligase activity of ARIH1 (PubMed:24076655, PubMed:27565346). Interacts
CC       (unneddylated form) with DCUN1D1, DCUN1D2, DCUN1D3, DCUN1D4 and
CC       DCUN1D5; these interactions promote the cullin neddylation
CC       (PubMed:23401859, PubMed:23201271, PubMed:24192928, PubMed:26906416).
CC       Component of VCB (elongins BC/CUL2/VHL) complex that contains at least
CC       DCUN1D1, CUL2 and VHL; this complex triggers CUL2 neddylation and
CC       consequently cullin ring ligase (CRL) substrates polyubiquitylation
CC       (PubMed:23401859). {ECO:0000269|PubMed:10230407,
CC       ECO:0000269|PubMed:10973499, ECO:0000269|PubMed:11384984,
CC       ECO:0000269|PubMed:12149480, ECO:0000269|PubMed:12609982,
CC       ECO:0000269|PubMed:15601820, ECO:0000269|PubMed:17304241,
CC       ECO:0000269|PubMed:22286099, ECO:0000269|PubMed:23102700,
CC       ECO:0000269|PubMed:23201271, ECO:0000269|PubMed:23401859,
CC       ECO:0000269|PubMed:24076655, ECO:0000269|PubMed:24192928,
CC       ECO:0000269|PubMed:26138980, ECO:0000269|PubMed:26906416,
CC       ECO:0000269|PubMed:27565346, ECO:0000269|PubMed:29775578,
CC       ECO:0000269|PubMed:29779948, ECO:0000269|PubMed:9122164}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human respiratory
CC       syncytial virus (HRSV) protein NS1. {ECO:0000269|PubMed:17251292}.
CC   -!- INTERACTION:
CC       Q13617; Q86VP6: CAND1; NbExp=3; IntAct=EBI-456179, EBI-456077;
CC       Q13617; Q8N668: COMMD1; NbExp=6; IntAct=EBI-456179, EBI-1550112;
CC       Q13617; Q15369: ELOC; NbExp=10; IntAct=EBI-456179, EBI-301231;
CC       Q13617; P08238: HSP90AB1; NbExp=2; IntAct=EBI-456179, EBI-352572;
CC       Q13617; Q9BQ90: KLHDC3; NbExp=8; IntAct=EBI-456179, EBI-1055396;
CC       Q13617; Q15048: LRRC14; NbExp=6; IntAct=EBI-456179, EBI-2510124;
CC       Q13617; P62877: RBX1; NbExp=8; IntAct=EBI-456179, EBI-398523;
CC       Q13617; O94888: UBXN7; NbExp=20; IntAct=EBI-456179, EBI-1993627;
CC       Q13617; P40337: VHL; NbExp=16; IntAct=EBI-456179, EBI-301246;
CC       Q13617; Q9C0D3: ZYG11B; NbExp=4; IntAct=EBI-456179, EBI-1811414;
CC       Q13617; P12504: vif; Xeno; NbExp=6; IntAct=EBI-456179, EBI-779991;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13617-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13617-2; Sequence=VSP_044498;
CC   -!- PTM: Neddylated; which enhances the ubiquitination activity of ECS
CC       (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase
CC       complexes. CBC(VHL) complex formation seems to promote neddylation.
CC       Deneddylated via its interaction with the COP9 signalosome (CSN)
CC       complex (By similarity). {ECO:0000250|UniProtKB:Q9D4H8,
CC       ECO:0000269|PubMed:24076655, ECO:0000269|PubMed:27565346}.
CC   -!- SIMILARITY: Belongs to the cullin family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00330}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U83410; AAC51190.1; -; mRNA.
DR   EMBL; AF126404; AAD23581.1; -; mRNA.
DR   EMBL; AK095217; BAG53007.1; -; mRNA.
DR   EMBL; AK300491; BAH13294.1; -; mRNA.
DR   EMBL; AL392046; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW85924.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85925.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85926.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85927.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85928.1; -; Genomic_DNA.
DR   EMBL; BC009591; AAH09591.1; -; mRNA.
DR   EMBL; BC110901; AAI10902.1; -; mRNA.
DR   EMBL; U58088; AAC50545.1; -; mRNA.
DR   CCDS; CCDS55709.1; -. [Q13617-2]
DR   CCDS; CCDS7179.1; -. [Q13617-1]
DR   RefSeq; NP_001185706.1; NM_001198777.1. [Q13617-1]
DR   RefSeq; NP_001185707.1; NM_001198778.1. [Q13617-2]
DR   RefSeq; NP_001185708.1; NM_001198779.1.
DR   RefSeq; NP_003582.2; NM_003591.3. [Q13617-1]
DR   RefSeq; XP_011518049.1; XM_011519747.1. [Q13617-1]
DR   PDB; 4WQO; X-ray; 3.20 A; D=1-163.
DR   PDB; 5N4W; X-ray; 3.90 A; A=1-745.
DR   PDB; 6R6H; EM; 8.40 A; O=1-745.
DR   PDB; 6R7F; EM; 8.20 A; O=1-745.
DR   PDB; 6R7H; EM; 8.80 A; O=1-654.
DR   PDB; 6R7I; EM; 5.90 A; O=1-745.
DR   PDB; 6R7N; EM; 6.50 A; O=1-745.
DR   PDBsum; 4WQO; -.
DR   PDBsum; 5N4W; -.
DR   PDBsum; 6R6H; -.
DR   PDBsum; 6R7F; -.
DR   PDBsum; 6R7H; -.
DR   PDBsum; 6R7I; -.
DR   PDBsum; 6R7N; -.
DR   SMR; Q13617; -.
DR   BioGRID; 114031; 531.
DR   CORUM; Q13617; -.
DR   DIP; DIP-31612N; -.
DR   IntAct; Q13617; 379.
DR   MINT; Q13617; -.
DR   STRING; 9606.ENSP00000444856; -.
DR   GlyGen; Q13617; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13617; -.
DR   MetOSite; Q13617; -.
DR   PhosphoSitePlus; Q13617; -.
DR   SwissPalm; Q13617; -.
DR   BioMuta; CUL2; -.
DR   DMDM; 19863260; -.
DR   EPD; Q13617; -.
DR   jPOST; Q13617; -.
DR   MassIVE; Q13617; -.
DR   MaxQB; Q13617; -.
DR   PaxDb; Q13617; -.
DR   PeptideAtlas; Q13617; -.
DR   PRIDE; Q13617; -.
DR   ProteomicsDB; 32423; -.
DR   ProteomicsDB; 59605; -. [Q13617-1]
DR   Antibodypedia; 3631; 492 antibodies from 42 providers.
DR   DNASU; 8453; -.
DR   Ensembl; ENST00000374748; ENSP00000363880; ENSG00000108094.
DR   Ensembl; ENST00000374749; ENSP00000363881; ENSG00000108094.
DR   Ensembl; ENST00000374751; ENSP00000363883; ENSG00000108094.
DR   Ensembl; ENST00000421317; ENSP00000414095; ENSG00000108094. [Q13617-2]
DR   Ensembl; ENST00000673636; ENSP00000501215; ENSG00000108094.
DR   GeneID; 8453; -.
DR   KEGG; hsa:8453; -.
DR   MANE-Select; ENST00000374749.8; ENSP00000363881.3; NM_003591.4; NP_003582.2.
DR   UCSC; uc001ixv.4; human. [Q13617-1]
DR   CTD; 8453; -.
DR   DisGeNET; 8453; -.
DR   GeneCards; CUL2; -.
DR   HGNC; HGNC:2552; CUL2.
DR   HPA; ENSG00000108094; Low tissue specificity.
DR   MIM; 603135; gene.
DR   neXtProt; NX_Q13617; -.
DR   OpenTargets; ENSG00000108094; -.
DR   PharmGKB; PA27048; -.
DR   VEuPathDB; HostDB:ENSG00000108094; -.
DR   eggNOG; KOG2284; Eukaryota.
DR   GeneTree; ENSGT00940000154926; -.
DR   HOGENOM; CLU_004747_6_1_1; -.
DR   InParanoid; Q13617; -.
DR   OrthoDB; 1040292at2759; -.
DR   PhylomeDB; Q13617; -.
DR   TreeFam; TF101152; -.
DR   BRENDA; 2.3.2.32; 2681.
DR   PathwayCommons; Q13617; -.
DR   Reactome; R-HSA-1234176; Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-9010553; Regulation of expression of SLITs and ROBOs.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q13617; -.
DR   SIGNOR; Q13617; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 8453; 448 hits in 1110 CRISPR screens.
DR   ChiTaRS; CUL2; human.
DR   GeneWiki; CUL2; -.
DR   GenomeRNAi; 8453; -.
DR   Pharos; Q13617; Tbio.
DR   PRO; PR:Q13617; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q13617; protein.
DR   Bgee; ENSG00000108094; Expressed in sperm and 241 other tissues.
DR   ExpressionAtlas; Q13617; baseline and differential.
DR   Genevisible; Q13617; HS.
DR   GO; GO:0031462; C:Cul2-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0031461; C:cullin-RING ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005730; C:nucleolus; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0019005; C:SCF ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:0030891; C:VCB complex; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IBA:GO_Central.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0016567; P:protein ubiquitination; IBA:GO_Central.
DR   GO; GO:0031146; P:SCF-dependent proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR045093; Cullin.
DR   InterPro; IPR016157; Cullin_CS.
DR   InterPro; IPR016158; Cullin_homology.
DR   InterPro; IPR036317; Cullin_homology_sf.
DR   InterPro; IPR001373; Cullin_N.
DR   InterPro; IPR019559; Cullin_neddylation_domain.
DR   InterPro; IPR016159; Cullin_repeat-like_dom_sf.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11932; PTHR11932; 1.
DR   Pfam; PF00888; Cullin; 1.
DR   Pfam; PF10557; Cullin_Nedd8; 1.
DR   SMART; SM00182; CULLIN; 1.
DR   SMART; SM00884; Cullin_Nedd8; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF74788; SSF74788; 1.
DR   SUPFAM; SSF75632; SSF75632; 1.
DR   PROSITE; PS01256; CULLIN_1; 1.
DR   PROSITE; PS50069; CULLIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Host-virus interaction;
KW   Isopeptide bond; Phosphoprotein; Reference proteome; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN           1..745
FT                   /note="Cullin-2"
FT                   /id="PRO_0000119790"
FT   MOD_RES         393
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         661
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        689
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in NEDD8)"
FT                   /evidence="ECO:0000269|PubMed:10092517,
FT                   ECO:0000269|PubMed:10597293"
FT   VAR_SEQ         1
FT                   /note="M -> MYRVTWSTFWLRFQHYTCTM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044498"
FT   VARIANT         109
FT                   /note="N -> S"
FT                   /evidence="ECO:0000269|PubMed:10092517,
FT                   ECO:0000269|PubMed:9122164"
FT                   /id="VAR_011374"
FT   MUTAGEN         621
FT                   /note="K->R: No effect on conjugation with NEDD8."
FT                   /evidence="ECO:0000269|PubMed:10092517"
FT   MUTAGEN         689
FT                   /note="K->R: Loss of conjugation with NEDD8."
FT                   /evidence="ECO:0000269|PubMed:10092517"
FT   MUTAGEN         719
FT                   /note="K->R: No effect on conjugation with NEDD8."
FT                   /evidence="ECO:0000269|PubMed:10092517"
FT   CONFLICT        20
FT                   /note="T -> I (in Ref. 3; BAH13294)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95..98
FT                   /note="SKGA -> IRHE (in Ref. 7; AAC50545)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        681
FT                   /note="Q -> H (in Ref. 7; AAC50545)"
FT                   /evidence="ECO:0000305"
FT   HELIX           10..25
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   HELIX           32..47
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   HELIX           54..77
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   HELIX           85..104
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   HELIX           106..112
FT                   /evidence="ECO:0007829|PDB:4WQO"
FT   HELIX           139..156
FT                   /evidence="ECO:0007829|PDB:4WQO"
SQ   SEQUENCE   745 AA;  86983 MW;  30647248F671AB0E CRC64;
     MSLKPRVVDF DETWNKLLTT IKAVVMLEYV ERATWNDRFS DIYALCVAYP EPLGERLYTE
     TKIFLENHVR HLHKRVLESE EQVLVMYHRY WEEYSKGADY MDCLYRYLNT QFIKKNKLTE
     ADLQYGYGGV DMNEPLMEIG ELALDMWRKL MVEPLQAILI RMLLREIKND RGGEDPNQKV
     IHGVINSFVH VEQYKKKFPL KFYQEIFESP FLTETGEYYK QEASNLLQES NCSQYMEKVL
     GRLKDEEIRC RKYLHPSSYT KVIHECQQRM VADHLQFLHA ECHNIIRQEK KNDMANMYVL
     LRAVSTGLPH MIQELQNHIH DEGLRATSNL TQENMPTLFV ESVLEVHGKF VQLINTVLNG
     DQHFMSALDK ALTSVVNYRE PKSVCKAPEL LAKYCDNLLK KSAKGMTENE VEDRLTSFIT
     VFKYIDDKDV FQKFYARMLA KRLIHGLSMS MDSEEAMINK LKQACGYEFT SKLHRMYTDM
     SVSADLNNKF NNFIKNQDTV IDLGISFQIY VLQAGAWPLT QAPSSTFAIP QELEKSVQMF
     ELFYSQHFSG RKLTWLHYLC TGEVKMNYLG KPYVAMVTTY QMAVLLAFNN SETVSYKELQ
     DSTQMNEKEL TKTIKSLLDV KMINHDSEKE DIDAESSFSL NMNFSSKRTK FKITTSMQKD
     TPQEMEQTRS AVDEDRKMYL QAAIVRIMKA RKVLRHNALI QEVISQSRAR FNPSISMIKK
     CIEVLIDKQY IERSQASADE YSYVA
//
ID   DGKE_HUMAN              Reviewed;         567 AA.
AC   P52429; Q8TBM4; Q9UKQ3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   23-FEB-2022, entry version 187.
DE   RecName: Full=Diacylglycerol kinase epsilon;
DE            Short=DAG kinase epsilon;
DE            EC=2.7.1.107 {ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:23949095};
DE   AltName: Full=Diglyceride kinase epsilon;
DE            Short=DGK-epsilon;
GN   Name=DGKE; Synonyms=DAGK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=8626589; DOI=10.1074/jbc.271.17.10230;
RA   Tang W., Bunting M., Zimmerman G.A., McIntyre T.M., Prescott S.M.;
RT   "Molecular cloning of a novel human diacylglycerol kinase highly selective
RT   for arachidonate-containing substrates.";
RL   J. Biol. Chem. 271:10237-10241(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-154.
RX   PubMed=10571048; DOI=10.1016/s0378-1119(99)00345-5;
RA   Tang W., Bardien S., Bhattacharya S.S., Prescott S.M.;
RT   "Characterization of the human diacylglycerol kinase epsilon gene and its
RT   assessment as a candidate for inherited retinitis pigmentosa.";
RL   Gene 239:185-192(1999).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND PATHWAY.
RX   PubMed=15544348; DOI=10.1021/bi0484724;
RA   Epand R.M., Kam A., Bridgelal N., Saiga A., Topham M.K.;
RT   "The alpha isoform of diacylglycerol kinase exhibits arachidonoyl
RT   specificity with alkylacylglycerol.";
RL   Biochemistry 43:14778-14783(2004).
RN   [6]
RP   CATALYTIC ACTIVITY.
RX   PubMed=18004883; DOI=10.1021/bi701584v;
RA   Epand R.M., Shulga Y.V., Timmons H.C., Perri A.L., Belani J.D.,
RA   Perinpanathan K., Johnson-McIntire L.B., Bajjalieh S., Dicu A.O., Elias C.,
RA   Rychnovsky S.D., Topham M.K.;
RT   "Substrate chirality and specificity of diacylglycerol kinases and the
RT   multisubstrate lipid kinase.";
RL   Biochemistry 46:14225-14231(2007).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND ACTIVITY
RP   REGULATION.
RX   PubMed=19744926; DOI=10.1074/jbc.m109.050617;
RA   Lung M., Shulga Y.V., Ivanova P.T., Myers D.S., Milne S.B., Brown H.A.,
RA   Topham M.K., Epand R.M.;
RT   "Diacylglycerol kinase epsilon is selective for both acyl chains of
RT   phosphatidic acid or diacylglycerol.";
RL   J. Biol. Chem. 284:31062-31073(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBSTRATE SPECIFICITY.
RX   PubMed=22108654; DOI=10.1016/j.febslet.2011.11.016;
RA   Shulga Y.V., Topham M.K., Epand R.M.;
RT   "Substrate specificity of diacylglycerol kinase-epsilon and the
RT   phosphatidylinositol cycle.";
RL   FEBS Lett. 585:4025-4028(2011).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LEU-431; LEU-438 AND
RP   PRO-439.
RX   PubMed=21477596; DOI=10.1016/j.jmb.2011.03.071;
RA   Shulga Y.V., Topham M.K., Epand R.M.;
RT   "Study of arachidonoyl specificity in two enzymes of the PI cycle.";
RL   J. Mol. Biol. 409:101-112(2011).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=23949095; DOI=10.1159/000351849;
RA   Sato M., Liu K., Sasaki S., Kunii N., Sakai H., Mizuno H., Saga H.,
RA   Sakane F.;
RT   "Evaluations of the selectivities of the diacylglycerol kinase inhibitors
RT   R59022 and R59949 among diacylglycerol kinase isozymes using a new non-
RT   radioactive assay method.";
RL   Pharmacology 92:99-107(2013).
RN   [11]
RP   INVOLVEMENT IN NPHS7.
RX   PubMed=23274426; DOI=10.1681/asn.2012090903;
RA   Ozaltin F., Li B., Rauhauser A., An S.W., Soylemezoglu O., Gonul I.I.,
RA   Taskiran E.Z., Ibsirlioglu T., Korkmaz E., Bilginer Y., Duzova A., Ozen S.,
RA   Topaloglu R., Besbas N., Ashraf S., Du Y., Liang C., Chen P., Lu D.,
RA   Vadnagara K., Arbuckle S., Lewis D., Wakeland B., Quigg R.J., Ransom R.F.,
RA   Wakeland E.K., Topham M.K., Bazan N.G., Mohan C., Hildebrandt F.,
RA   Bakkaloglu A., Huang C.L., Attanasio M.;
RT   "DGKE variants cause a glomerular microangiopathy that mimics
RT   membranoproliferative GN.";
RL   J. Am. Soc. Nephrol. 24:377-384(2013).
RN   [12]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND VARIANTS AHUS7 PRO-63 AND
RP   PRO-273.
RX   PubMed=23542698; DOI=10.1038/ng.2590;
RA   Lemaire M., Fremeaux-Bacchi V., Schaefer F., Choi M., Tang W.H.,
RA   Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W.,
RA   Overton J.D., Mane S.M., Nuernberg G., Altmueller J., Thiele H., Morin D.,
RA   Deschenes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E.,
RA   Nuernberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J.,
RA   Loirat C., Lifton R.P.;
RT   "Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.";
RL   Nat. Genet. 45:531-536(2013).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-99.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Membrane-bound diacylglycerol kinase that converts
CC       diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and
CC       regulates the respective levels of these two bioactive lipids
CC       (PubMed:15544348, PubMed:19744926, PubMed:22108654, PubMed:21477596,
CC       PubMed:23949095). Thereby, acts as a central switch between the
CC       signaling pathways activated by these second messengers with different
CC       cellular targets and opposite effects in numerous biological processes
CC       (PubMed:8626589, PubMed:15544348). Also plays an important role in the
CC       biosynthesis of complex lipids (PubMed:8626589). Displays specificity
CC       for diacylglycerol substrates with an arachidonoyl acyl chain at the
CC       sn-2 position, with the highest activity toward 1-octadecanoyl-2-
CC       (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol the main diacylglycerol
CC       intermediate within the phosphatidylinositol turnover cycle
CC       (PubMed:19744926, PubMed:22108654, PubMed:23274426). Can also
CC       phosphorylate diacylglycerol substrates with a linoleoyl acyl chain at
CC       the sn-2 position but much less efficiently (PubMed:22108654).
CC       {ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:19744926,
CC       ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654,
CC       ECO:0000269|PubMed:23274426, ECO:0000269|PubMed:23949095,
CC       ECO:0000303|PubMed:15544348, ECO:0000303|PubMed:8626589}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycerol + ATP = a 1,2-diacyl-sn-glycero-3-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:10272, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17815, ChEBI:CHEBI:30616, ChEBI:CHEBI:58608,
CC         ChEBI:CHEBI:456216; EC=2.7.1.107;
CC         Evidence={ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:18004883,
CC         ECO:0000269|PubMed:19744926, ECO:0000269|PubMed:21477596,
CC         ECO:0000269|PubMed:22108654, ECO:0000269|PubMed:23949095};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10273;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol
CC         + ATP = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + ADP + H(+); Xref=Rhea:RHEA:40335, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:72864, ChEBI:CHEBI:77096,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40336;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol
CC         + ATP = 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphate + ADP + H(+); Xref=Rhea:RHEA:40323, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:75728, ChEBI:CHEBI:77091,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:15544348,
CC         ECO:0000269|PubMed:18004883, ECO:0000269|PubMed:19744926,
CC         ECO:0000269|PubMed:21477596, ECO:0000269|PubMed:22108654,
CC         ECO:0000269|PubMed:23949095};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40324;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycerol +
CC         ATP = 1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-
CC         phosphate + ADP + H(+); Xref=Rhea:RHEA:40331, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:77093, ChEBI:CHEBI:77094,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40332;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycerol + ATP =
CC         1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate + ADP
CC         + H(+); Xref=Rhea:RHEA:40351, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:77125, ChEBI:CHEBI:77126, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40352;
CC         Evidence={ECO:0000305|PubMed:22108654};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycerol + ATP =
CC         1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate +
CC         ADP + H(+); Xref=Rhea:RHEA:40339, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:77097, ChEBI:CHEBI:77098,
CC         ChEBI:CHEBI:456216; Evidence={ECO:0000269|PubMed:19744926,
CC         ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40340;
CC         Evidence={ECO:0000305|PubMed:19744926};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycerol + ATP = 1,2-di-
CC         (9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:40355, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:77127, ChEBI:CHEBI:77128, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:22108654};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40356;
CC         Evidence={ECO:0000305|PubMed:22108654};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycerol + ATP = 1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:40327, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:52333, ChEBI:CHEBI:74546, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:15544348, ECO:0000269|PubMed:19744926};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40328;
CC         Evidence={ECO:0000305|PubMed:15544348};
CC   -!- ACTIVITY REGULATION: Undergoes competitive inhibition by its own
CC       product 1,2-diacyl-sn-glycero-3-phosphate/phosphatidic acid. The
CC       strongest inhibition being observed in vitro with 1-octadecanoyl-2-
CC       (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate, a major
CC       intermediate in the phosphatidylinositol turnover cycle and more
CC       generally by diacylglycerols with an arachidonoyl acyl chain at the sn-
CC       2 position. {ECO:0000269|PubMed:19744926}.
CC   -!- PATHWAY: Lipid metabolism; glycerolipid metabolism.
CC       {ECO:0000305|PubMed:15544348}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:23542698}; Single-
CC       pass membrane protein {ECO:0000255}. Cytoplasm
CC       {ECO:0000269|PubMed:23542698}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P52429-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P52429-2; Sequence=VSP_056957, VSP_056958;
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in testis. Expressed in
CC       endothelium, platelets and podocytes (at protein level).
CC       {ECO:0000269|PubMed:23542698}.
CC   -!- DISEASE: Nephrotic syndrome 7 (NPHS7) [MIM:615008]: A form of nephrotic
CC       syndrome, a renal disease clinically characterized by severe
CC       proteinuria, resulting in complications such as hypoalbuminemia,
CC       hyperlipidemia and edema. NPHS7 is an autosomal recessive form
CC       characterized by onset of proteinuria usually in the first decade of
CC       life. The disorder is progressive, and some patients develop end-stage
CC       renal disease within several years. Renal biopsy typically shows
CC       membranoproliferative glomerulonephritis.
CC       {ECO:0000269|PubMed:23274426}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hemolytic uremic syndrome atypical 7 (AHUS7) [MIM:615008]: An
CC       atypical form of hemolytic uremic syndrome characterized by acute onset
CC       in the first year of life of microangiopathic hemolytic anemia,
CC       thrombocytopenia, and renal failure. After the acute episode, most
CC       patients develop chronic renal insufficiency. Unlike other genetic
CC       forms of aHUS, AHUS7 is not related to abnormal activation of the
CC       complement system. {ECO:0000269|PubMed:23542698}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the eukaryotic diacylglycerol kinase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U49379; AAC50497.1; -; mRNA.
DR   EMBL; AC015912; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC106858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022297; AAH22297.1; -; mRNA.
DR   EMBL; AF136745; AAD45666.1; -; Genomic_DNA.
DR   CCDS; CCDS11590.1; -. [P52429-1]
DR   RefSeq; NP_003638.1; NM_003647.2. [P52429-1]
DR   SMR; P52429; -.
DR   BioGRID; 114096; 51.
DR   IntAct; P52429; 12.
DR   STRING; 9606.ENSP00000284061; -.
DR   ChEMBL; CHEMBL1075187; -.
DR   DrugBank; DB14001; alpha-Tocopherol succinate.
DR   SwissLipids; SLP:000000546; -.
DR   iPTMnet; P52429; -.
DR   PhosphoSitePlus; P52429; -.
DR   SwissPalm; P52429; -.
DR   BioMuta; DGKE; -.
DR   DMDM; 1708625; -.
DR   EPD; P52429; -.
DR   jPOST; P52429; -.
DR   MassIVE; P52429; -.
DR   MaxQB; P52429; -.
DR   PaxDb; P52429; -.
DR   PeptideAtlas; P52429; -.
DR   PRIDE; P52429; -.
DR   ProteomicsDB; 56484; -. [P52429-1]
DR   ProteomicsDB; 74029; -.
DR   Antibodypedia; 2548; 243 antibodies from 30 providers.
DR   DNASU; 8526; -.
DR   Ensembl; ENST00000284061; ENSP00000284061; ENSG00000153933.
DR   Ensembl; ENST00000572810; ENSP00000459295; ENSG00000153933. [P52429-2]
DR   GeneID; 8526; -.
DR   KEGG; hsa:8526; -.
DR   MANE-Select; ENST00000284061.8; ENSP00000284061.3; NM_003647.3; NP_003638.1.
DR   UCSC; uc002iur.4; human. [P52429-1]
DR   CTD; 8526; -.
DR   DisGeNET; 8526; -.
DR   GeneCards; DGKE; -.
DR   GeneReviews; DGKE; -.
DR   HGNC; HGNC:2852; DGKE.
DR   HPA; ENSG00000153933; Tissue enhanced (retina).
DR   MalaCards; DGKE; -.
DR   MIM; 601440; gene.
DR   MIM; 615008; phenotype.
DR   neXtProt; NX_P52429; -.
DR   OpenTargets; ENSG00000153933; -.
DR   Orphanet; 357008; Hemolytic uremic syndrome with DGKE deficiency.
DR   Orphanet; 329903; Immunoglobulin-mediated membranoproliferative glomerulonephritis.
DR   PharmGKB; PA27313; -.
DR   VEuPathDB; HostDB:ENSG00000153933; -.
DR   eggNOG; KOG1169; Eukaryota.
DR   GeneTree; ENSGT00940000158604; -.
DR   HOGENOM; CLU_1517427_0_0_1; -.
DR   InParanoid; P52429; -.
DR   OMA; WVLNTIY; -.
DR   OrthoDB; 1275907at2759; -.
DR   PhylomeDB; P52429; -.
DR   TreeFam; TF313104; -.
DR   BRENDA; 2.7.1.107; 2681.
DR   PathwayCommons; P52429; -.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   SignaLink; P52429; -.
DR   UniPathway; UPA00230; -.
DR   BioGRID-ORCS; 8526; 8 hits in 1046 CRISPR screens.
DR   ChiTaRS; DGKE; human.
DR   GenomeRNAi; 8526; -.
DR   Pharos; P52429; Tbio.
DR   PRO; PR:P52429; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P52429; protein.
DR   Bgee; ENSG00000153933; Expressed in middle temporal gyrus and 207 other tissues.
DR   ExpressionAtlas; P52429; baseline and differential.
DR   Genevisible; P52429; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004143; F:diacylglycerol kinase activity; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003951; F:NAD+ kinase activity; IEA:InterPro.
DR   GO; GO:0046339; P:diacylglycerol metabolic process; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0046834; P:lipid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; IEA:InterPro.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 3.40.50.10330; -; 1.
DR   InterPro; IPR017438; ATP-NAD_kinase_N.
DR   InterPro; IPR037607; DGK.
DR   InterPro; IPR000756; Diacylglycerol_kin_accessory.
DR   InterPro; IPR001206; Diacylglycerol_kinase_cat_dom.
DR   InterPro; IPR016064; NAD/diacylglycerol_kinase_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   PANTHER; PTHR11255; PTHR11255; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00609; DAGK_acc; 1.
DR   Pfam; PF00781; DAGK_cat; 1.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00045; DAGKa; 1.
DR   SMART; SM00046; DAGKc; 1.
DR   SUPFAM; SSF111331; SSF111331; 1.
DR   PROSITE; PS50146; DAGK; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Disease variant;
KW   Hemolytic uremic syndrome; Kinase; Lipid metabolism; Membrane;
KW   Metal-binding; Nucleotide-binding; Reference proteome; Repeat; Transferase;
KW   Transmembrane; Transmembrane helix; Zinc; Zinc-finger.
FT   CHAIN           1..567
FT                   /note="Diacylglycerol kinase epsilon"
FT                   /id="PRO_0000218464"
FT   TRANSMEM        22..42
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          215..356
FT                   /note="DAGKc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00783"
FT   ZN_FING         59..108
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         124..177
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   VAR_SEQ         156..177
FT                   /note="CIWCQKTVHDECMKNSLKNEKC -> YGLRGHSLSQNAPWESGFHRVV (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056957"
FT   VAR_SEQ         178..567
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056958"
FT   VARIANT         63
FT                   /note="R -> P (in AHUS7; dbSNP:rs312262694)"
FT                   /evidence="ECO:0000269|PubMed:23542698"
FT                   /id="VAR_069804"
FT   VARIANT         99
FT                   /note="L -> R (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036120"
FT   VARIANT         273
FT                   /note="R -> P (in AHUS7; dbSNP:rs312262695)"
FT                   /evidence="ECO:0000269|PubMed:23542698"
FT                   /id="VAR_069805"
FT   MUTAGEN         431
FT                   /note="L->I: Decreased diacylglycerol kinase activity
FT                   toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
FT                   sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         431
FT                   /note="L->S: Loss of diacylglycerol kinase activity toward
FT                   1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
FT                   glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->I: Decreased diacylglycerol kinase activity
FT                   toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
FT                   sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->M: Decreased protein abundance and diacylglycerol
FT                   kinase activity toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-
FT                   eicosatetraenoyl)-sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         438
FT                   /note="L->S,A,G: Loss of diacylglycerol kinase activity
FT                   toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
FT                   sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
FT   MUTAGEN         439
FT                   /note="P->G: Decreased diacylglycerol kinase activity
FT                   toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-
FT                   sn-glycerol."
FT                   /evidence="ECO:0000269|PubMed:21477596"
SQ   SEQUENCE   567 AA;  63927 MW;  BC334AD15FB4D0B4 CRC64;
     MEAERRPAPG SPSEGLFADG HLILWTLCSV LLPVFITFWC SLQRSRRQLH RRDIFRKSKH
     GWRDTDLFSQ PTYCCVCAQH ILQGAFCDCC GLRVDEGCLR KADKRFQCKE IMLKNDTKVL
     DAMPHHWIRG NVPLCSYCMV CKQQCGCQPK LCDYRCIWCQ KTVHDECMKN SLKNEKCDFG
     EFKNLIIPPS YLTSINQMRK DKKTDYEVLA SKLGKQWTPL IILANSRSGT NMGEGLLGEF
     RILLNPVQVF DVTKTPPIKA LQLCTLLPYY SARVLVCGGD GTVGWVLDAV DDMKIKGQEK
     YIPQVAVLPL GTGNDLSNTL GWGTGYAGEI PVAQVLRNVM EADGIKLDRW KVQVTNKGYY
     NLRKPKEFTM NNYFSVGPDA LMALNFHAHR EKAPSLFSSR ILNKAVYLFY GTKDCLVQEC
     KDLNKKVELE LDGERVALPS LEGIIVLNIG YWGGGCRLWE GMGDETYPLA RHDDGLLEVV
     GVYGSFHCAQ IQVKLANPFR IGQAHTVRLI LKCSMMPMQV DGEPWAQGPC TVTITHKTHA
     MMLYFSGEQT DDDISSTSDQ EDIKATE
//
ID   TRDMT_HUMAN             Reviewed;         391 AA.
AC   O14717; B0YJ02; B0YJ03; B0YJ07; B0YJ08; O43669; Q86WW6;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   23-FEB-2022, entry version 179.
DE   RecName: Full=tRNA (cytosine(38)-C(5))-methyltransferase;
DE            EC=2.1.1.204 {ECO:0000269|PubMed:16424344};
DE   AltName: Full=DNA (cytosine-5)-methyltransferase-like protein 2 {ECO:0000303|PubMed:16424344};
DE            Short=Dnmt2 {ECO:0000303|PubMed:16424344};
DE   AltName: Full=DNA methyltransferase homolog HsaIIP;
DE            Short=DNA MTase homolog HsaIIP;
DE            Short=M.HsaIIP;
DE   AltName: Full=PuMet;
GN   Name=TRDMT1; Synonyms=DNMT2 {ECO:0000303|PubMed:16424344};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=9425235; DOI=10.1093/hmg/7.2.279;
RA   Yoder J.A., Bestor T.H.;
RT   "A candidate mammalian DNA methyltransferase related to pmt1p of fission
RT   yeast.";
RL   Hum. Mol. Genet. 7:279-284(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=9599025; DOI=10.1016/s0014-5793(98)00362-7;
RA   Van den Wyngaert I., Sprengel J., Kass S.U., Luyten W.H.M.L.;
RT   "Cloning and analysis of a novel human putative DNA methyltransferase.";
RL   FEBS Lett. 426:283-289(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Heart;
RX   PubMed=9592134; DOI=10.1093/nar/26.11.2536;
RA   Okano M., Xie S., Li E.;
RT   "Dnmt2 is not required for de novo and maintenance methylation of viral DNA
RT   in embryonic stem cells.";
RL   Nucleic Acids Res. 26:2536-2540(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A), AND VARIANT TYR-101.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 19-179 (ISOFORMS A; B; C; D; E AND F).
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=11551826; DOI=10.1016/s1357-2725(01)00074-7;
RA   Franchina M., Hooper J., Kay P.H.;
RT   "Five novel alternatively spliced transcripts of DNA (cytosine-5)
RT   methyltransferase 2 in human peripheral blood leukocytes.";
RL   Int. J. Biochem. Cell Biol. 33:1104-1115(2001).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=16424344; DOI=10.1126/science.1120976;
RA   Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X.,
RA   Golic K.G., Jacobsen S.E., Bestor T.H.;
RT   "Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2.";
RL   Science 311:395-398(2006).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE.
RX   PubMed=11139614; DOI=10.1093/nar/29.2.439;
RA   Dong A., Yoder J.A., Zhang X., Zhou L., Bestor T.H., Cheng X.;
RT   "Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that
RT   displays denaturant-resistant binding to DNA.";
RL   Nucleic Acids Res. 29:439-448(2001).
CC   -!- FUNCTION: Specifically methylates cytosine 38 in the anticodon loop of
CC       tRNA(Asp). {ECO:0000269|PubMed:16424344}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=cytidine(38) in tRNA + S-adenosyl-L-methionine = 5-
CC         methylcytidine(38) in tRNA + H(+) + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:42956, Rhea:RHEA-COMP:10299, Rhea:RHEA-COMP:10300,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789,
CC         ChEBI:CHEBI:74483, ChEBI:CHEBI:82748; EC=2.1.1.204;
CC         Evidence={ECO:0000269|PubMed:16424344};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42957;
CC         Evidence={ECO:0000269|PubMed:16424344};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16424344}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=A;
CC         IsoId=O14717-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=O14717-2; Sequence=VSP_005628;
CC       Name=C;
CC         IsoId=O14717-3; Sequence=VSP_005629;
CC       Name=D;
CC         IsoId=O14717-4; Sequence=VSP_005630, VSP_005631;
CC       Name=E;
CC         IsoId=O14717-5; Sequence=VSP_005632, VSP_005633;
CC       Name=F;
CC         IsoId=O14717-6; Sequence=VSP_005634, VSP_005635;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Higher expression in testis, ovary and
CC       thymus and at much lower levels in spleen, prostate, colon, small
CC       intestine, and peripheral blood leukocytes.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC       superfamily. C5-methyltransferase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01016}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF012128; AAC51939.1; -; mRNA.
DR   EMBL; AJ223333; CAA11272.1; -; mRNA.
DR   EMBL; AF045888; AAC39764.1; -; mRNA.
DR   EMBL; EF444974; ACA05980.1; -; Genomic_DNA.
DR   EMBL; EF444974; ACA05984.1; -; Genomic_DNA.
DR   EMBL; EF444974; ACA05985.1; -; Genomic_DNA.
DR   EMBL; EF444974; ACA05986.1; -; Genomic_DNA.
DR   EMBL; AC067747; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133415; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86218.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86219.1; -; Genomic_DNA.
DR   EMBL; BC047733; AAH47733.1; -; mRNA.
DR   EMBL; AF329940; AAK68034.1; -; mRNA.
DR   EMBL; AF329941; AAK68035.1; -; mRNA.
DR   EMBL; AF329942; AAK68036.1; -; mRNA.
DR   EMBL; AF329943; AAK68037.1; -; mRNA.
DR   EMBL; AF329944; AAK68033.1; -; mRNA.
DR   CCDS; CCDS7114.1; -. [O14717-1]
DR   RefSeq; NP_001307935.1; NM_001321006.1.
DR   RefSeq; NP_001307936.1; NM_001321007.1.
DR   RefSeq; NP_004403.1; NM_004412.6. [O14717-1]
DR   RefSeq; XP_005252432.1; XM_005252375.4. [O14717-3]
DR   PDB; 1G55; X-ray; 1.80 A; A=2-391.
DR   PDBsum; 1G55; -.
DR   SMR; O14717; -.
DR   BioGRID; 108124; 20.
DR   IntAct; O14717; 15.
DR   STRING; 9606.ENSP00000367030; -.
DR   ChEMBL; CHEMBL4523124; -.
DR   DrugBank; DB09462; Glycerin.
DR   DrugBank; DB00738; Pentamidine.
DR   DrugBank; DB01752; S-adenosyl-L-homocysteine.
DR   iPTMnet; O14717; -.
DR   PhosphoSitePlus; O14717; -.
DR   BioMuta; TRDMT1; -.
DR   EPD; O14717; -.
DR   MassIVE; O14717; -.
DR   MaxQB; O14717; -.
DR   PaxDb; O14717; -.
DR   PeptideAtlas; O14717; -.
DR   PRIDE; O14717; -.
DR   ProteomicsDB; 48175; -. [O14717-1]
DR   ProteomicsDB; 48176; -. [O14717-2]
DR   ProteomicsDB; 48177; -. [O14717-3]
DR   ProteomicsDB; 48178; -. [O14717-4]
DR   ProteomicsDB; 48179; -. [O14717-5]
DR   ProteomicsDB; 48180; -. [O14717-6]
DR   Antibodypedia; 4005; 463 antibodies from 36 providers.
DR   DNASU; 1787; -.
DR   Ensembl; ENST00000377799; ENSP00000367030; ENSG00000107614.
DR   Ensembl; ENST00000495022; ENSP00000417594; ENSG00000107614. [O14717-4]
DR   GeneID; 1787; -.
DR   KEGG; hsa:1787; -.
DR   MANE-Select; ENST00000377799.8; ENSP00000367030.3; NM_004412.7; NP_004403.1.
DR   UCSC; uc057sar.1; human. [O14717-1]
DR   CTD; 1787; -.
DR   DisGeNET; 1787; -.
DR   GeneCards; TRDMT1; -.
DR   HGNC; HGNC:2977; TRDMT1.
DR   HPA; ENSG00000107614; Low tissue specificity.
DR   MIM; 602478; gene.
DR   neXtProt; NX_O14717; -.
DR   OpenTargets; ENSG00000107614; -.
DR   PharmGKB; PA162406922; -.
DR   VEuPathDB; HostDB:ENSG00000107614; -.
DR   eggNOG; KOG0919; Eukaryota.
DR   GeneTree; ENSGT00390000016416; -.
DR   HOGENOM; CLU_049101_0_0_1; -.
DR   InParanoid; O14717; -.
DR   OMA; VMDIIHP; -.
DR   PhylomeDB; O14717; -.
DR   TreeFam; TF300024; -.
DR   BRENDA; 2.1.1.202; 2681.
DR   BRENDA; 2.1.1.204; 2681.
DR   PathwayCommons; O14717; -.
DR   Reactome; R-HSA-6782315; tRNA modification in the nucleus and cytosol.
DR   SignaLink; O14717; -.
DR   BioGRID-ORCS; 1787; 6 hits in 1050 CRISPR screens.
DR   ChiTaRS; TRDMT1; human.
DR   EvolutionaryTrace; O14717; -.
DR   GeneWiki; TRDMT1; -.
DR   GenomeRNAi; 1787; -.
DR   Pharos; O14717; Tbio.
DR   PRO; PR:O14717; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; O14717; protein.
DR   Bgee; ENSG00000107614; Expressed in caput epididymis and 172 other tissues.
DR   ExpressionAtlas; O14717; baseline and differential.
DR   Genevisible; O14717; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0016428; F:tRNA (cytosine-5-)-methyltransferase activity; EXP:Reactome.
DR   GO; GO:0008175; F:tRNA methyltransferase activity; IDA:MGI.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0030488; P:tRNA methylation; IDA:MGI.
DR   GO; GO:0006400; P:tRNA modification; TAS:Reactome.
DR   GO; GO:0036416; P:tRNA stabilization; ISS:UniProtKB.
DR   IDEAL; IID00004; -.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR031303; C5_meth_CS.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF00145; DNA_methylase; 1.
DR   PRINTS; PR00105; C5METTRFRASE.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   TIGRFAMs; TIGR00675; dcm; 1.
DR   PROSITE; PS00095; C5_MTASE_2; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Methyltransferase;
KW   Reference proteome; RNA-binding; S-adenosyl-L-methionine; Transferase;
KW   tRNA processing.
FT   CHAIN           1..391
FT                   /note="tRNA (cytosine(38)-C(5))-methyltransferase"
FT                   /id="PRO_0000088040"
FT   DOMAIN          4..391
FT                   /note="SAM-dependent MTase C5-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01016"
FT   REGION          13..15
FT                   /note="S-adenosyl-L-methionine binding"
FT                   /evidence="ECO:0000269|PubMed:11139614,
FT                   ECO:0007744|PDB:1G55"
FT   REGION          57..58
FT                   /note="S-adenosyl-L-methionine binding"
FT                   /evidence="ECO:0000269|PubMed:11139614,
FT                   ECO:0007744|PDB:1G55"
FT   ACT_SITE        79
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01016"
FT   BINDING         34
FT                   /note="S-adenosyl-L-methionine"
FT                   /evidence="ECO:0000269|PubMed:11139614,
FT                   ECO:0007744|PDB:1G55"
FT   BINDING         76
FT                   /note="S-adenosyl-L-methionine"
FT                   /evidence="ECO:0000269|PubMed:11139614,
FT                   ECO:0007744|PDB:1G55"
FT   BINDING         376
FT                   /note="S-adenosyl-L-methionine"
FT                   /evidence="ECO:0000269|PubMed:11139614,
FT                   ECO:0007744|PDB:1G55"
FT   VAR_SEQ         59..107
FT                   /note="GITLEEFDRLSFDMILMSPPCQPFTRIGRQGDMTDSRTNSFLHILDILP ->
FT                   RPLDTNNRKLWLSVPRVYIISNLSWHSKFKATIFSYCKASVRAITLSSP (in
FT                   isoform F)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005634"
FT   VAR_SEQ         59..71
FT                   /note="GITLEEFDRLSFD -> ITKITKVYSFGKC (in isoform E)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005632"
FT   VAR_SEQ         59..63
FT                   /note="GITLE -> DWPAG (in isoform D)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005630"
FT   VAR_SEQ         64..391
FT                   /note="Missing (in isoform D)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005631"
FT   VAR_SEQ         72..391
FT                   /note="Missing (in isoform E)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005633"
FT   VAR_SEQ         84..129
FT                   /note="Missing (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005629"
FT   VAR_SEQ         84..107
FT                   /note="Missing (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005628"
FT   VAR_SEQ         108..391
FT                   /note="Missing (in isoform F)"
FT                   /evidence="ECO:0000303|PubMed:11551826"
FT                   /id="VSP_005635"
FT   VARIANT         101
FT                   /note="H -> Y (in dbSNP:rs11254413)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_051961"
FT   CONFLICT        148
FT                   /note="L -> I (in Ref. 3; AAC39764)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..9
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           15..23
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          26..33
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           37..46
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           57..59
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           62..68
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          71..75
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           98..105
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           106..108
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          114..121
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           124..126
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           128..139
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          142..149
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           151..154
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          162..172
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          182..185
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           253..256
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           263..266
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           270..276
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   TURN            295..299
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           316..321
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   TURN            322..325
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           328..336
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           345..351
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           366..375
FT                   /evidence="ECO:0007829|PDB:1G55"
FT   HELIX           379..390
FT                   /evidence="ECO:0007829|PDB:1G55"
SQ   SEQUENCE   391 AA;  44597 MW;  BCA549E4EB2E6950 CRC64;
     MEPLRVLELY SGVGGMHHAL RESCIPAQVV AAIDVNTVAN EVYKYNFPHT QLLAKTIEGI
     TLEEFDRLSF DMILMSPPCQ PFTRIGRQGD MTDSRTNSFL HILDILPRLQ KLPKYILLEN
     VKGFEVSSTR DLLIQTIENC GFQYQEFLLS PTSLGIPNSR LRYFLIAKLQ SEPLPFQAPG
     QVLMEFPKIE SVHPQKYAMD VENKIQEKNV EPNISFDGSI QCSGKDAILF KLETAEEIHR
     KNQQDSDLSV KMLKDFLEDD TDVNQYLLPP KSLLRYALLL DIVQPTCRRS VCFTKGYGSY
     IEGTGSVLQT AEDVQVENIY KSLTNLSQEE QITKLLILKL RYFTPKEIAN LLGFPPEFGF
     PEKITVKQRY RLLGNSLNVH VVAKLIKILY E
//
ID   USP9Y_HUMAN             Reviewed;        2555 AA.
AC   O00507; O14601;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   23-FEB-2022, entry version 196.
DE   RecName: Full=Probable ubiquitin carboxyl-terminal hydrolase FAF-Y;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme FAF-Y;
DE   AltName: Full=Fat facets protein-related, Y-linked;
DE   AltName: Full=Ubiquitin thioesterase FAF-Y;
DE   AltName: Full=Ubiquitin-specific protease 9, Y chromosome;
DE   AltName: Full=Ubiquitin-specific-processing protease FAF-Y;
GN   Name=USP9Y; Synonyms=DFFRY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=8922996; DOI=10.1093/hmg/5.11.1695;
RA   Jones M.H., Furlong R.A., Burkin H., Chalmers I.J., Brown G.M., Khwaja O.,
RA   Affara N.A.;
RT   "The Drosophila developmental gene fat facets has a human homologue in
RT   Xp11.4 which escapes X-inactivation and has related sequences on Yq11.2.";
RL   Hum. Mol. Genet. 5:1695-1701(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9381176; DOI=10.1126/science.278.5338.675;
RA   Lahn B.T., Page D.C.;
RT   "Functional coherence of the human Y chromosome.";
RL   Science 278:675-680(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], GENE MAPPING, AND VARIANT THR-1060.
RC   TISSUE=Fetal brain, Retina, and Testis;
RX   PubMed=9384609; DOI=10.1093/hmg/7.1.97;
RA   Brown G.M., Furlong R.A., Sargent C.A., Erickson R.P., Longepied G.,
RA   Mitchell M., Jones M.H., Hargreave T.B., Cooke H.J., Affara N.A.;
RT   "Characterisation of the coding sequence and fine mapping of the human
RT   DFFRY gene and comparative expression analysis and mapping to the Sxrb
RT   interval of the mouse Y chromosome of the Dffry gene.";
RL   Hum. Mol. Genet. 7:97-107(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12815422; DOI=10.1038/nature01722;
RA   Skaletsky H., Kuroda-Kawaguchi T., Minx P.J., Cordum H.S., Hillier L.W.,
RA   Brown L.G., Repping S., Pyntikova T., Ali J., Bieri T., Chinwalla A.,
RA   Delehaunty A., Delehaunty K., Du H., Fewell G., Fulton L., Fulton R.,
RA   Graves T.A., Hou S.-F., Latrielle P., Leonard S., Mardis E., Maupin R.,
RA   McPherson J., Miner T., Nash W., Nguyen C., Ozersky P., Pepin K., Rock S.,
RA   Rohlfing T., Scott K., Schultz B., Strong C., Tin-Wollam A., Yang S.-P.,
RA   Waterston R.H., Wilson R.K., Rozen S., Page D.C.;
RT   "The male-specific region of the human Y chromosome is a mosaic of discrete
RT   sequence classes.";
RL   Nature 423:825-837(2003).
RN   [5]
RP   POSSIBLE INVOLVEMENT IN SPGFY2.
RX   PubMed=10581029; DOI=10.1038/70539;
RA   Sun C., Skaletsky H., Birren B., Devon K., Tang Z., Silber S., Oates R.,
RA   Page D.C.;
RT   "An azoospermic man with a de novo point mutation in the Y-chromosomal gene
RT   USP9Y.";
RL   Nat. Genet. 23:429-432(1999).
RN   [6]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [7]
RP   LACK OF INVOLVEMENT IN SPERMATOGENIC FAILURE.
RX   PubMed=19246359; DOI=10.1056/nejmoa0806218;
RA   Luddi A., Margollicci M., Gambera L., Serafini F., Cioni M., De Leo V.,
RA   Balestri P., Piomboni P.;
RT   "Spermatogenesis in a man with complete deletion of USP9Y.";
RL   N. Engl. J. Med. 360:881-885(2009).
CC   -!- FUNCTION: May function as a ubiquitin-protein or polyubiquitin
CC       hydrolase involved both in the processing of ubiquitin precursors and
CC       of ubiquitinated proteins. May therefore play an important regulatory
CC       role at the level of protein turnover by preventing degradation of
CC       proteins through the removal of conjugated ubiquitin. Essential
CC       component of TGF-beta/BMP signaling cascade. Deubiquitinates
CC       monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein
CC       ligase TRIM33. Monoubiquitination of SMAD4 hampers its ability to form
CC       a stable complex with activated SMAD2/3 resulting in inhibition of TGF-
CC       beta/BMP signaling cascade. Deubiquitination of SMAD4 by USP9X re-
CC       empowers its competence to mediate TGF-beta signaling (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- SUBUNIT: Interacts with SMAD4. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=O00507-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O00507-2; Sequence=VSP_005272;
CC   -!- TISSUE SPECIFICITY: Widely expressed in embryonic and adult tissues.
CC   -!- DISEASE: Note=USP9Y is located in the 'azoospermia factor a' (AZFa)
CC       region on chromosome Y which is deleted in Sertoli cell-only syndrome.
CC       This is an infertility disorder in which no germ cells are visible in
CC       seminiferous tubules leading to azoospermia. However, AZFa deletions
CC       resulting in complete loss of USP9Y have also been found in
CC       normospermic men (PubMed:19246359). {ECO:0000269|PubMed:19246359}.
CC   -!- DISEASE: Spermatogenic failure Y-linked 2 (SPGFY2) [MIM:415000]: A
CC       disorder resulting in the absence (azoospermia) or reduction
CC       (oligozoospermia) of sperm in the semen, leading to male infertility.
CC       {ECO:0000269|PubMed:10581029}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry. The role of
CC       USP9Y in spermatogenesis failure is uncertain (PubMed:19246359). A 4-bp
CC       deletion in a splice-donor site, causing exon skipping and protein
CC       truncation has been observed in non-obstructive azoospermia
CC       (PubMed:10581029). However, complete USP9Y deletion has been detected
CC       in individuals with no spermatogenic defects (PubMed:19246359).
CC       {ECO:0000269|PubMed:10581029, ECO:0000269|PubMed:19246359}.
CC   -!- MISCELLANEOUS: [Isoform Short]: May be produced at very low levels due
CC       to a premature stop codon in the mRNA, leading to nonsense-mediated
CC       mRNA decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF000986; AAC51833.1; -; mRNA.
DR   EMBL; Y13618; CAA73940.1; -; mRNA.
DR   EMBL; Y13619; CAA73941.1; -; mRNA.
DR   EMBL; AC002531; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS14781.1; -. [O00507-1]
DR   RefSeq; NP_004645.2; NM_004654.3. [O00507-1]
DR   SMR; O00507; -.
DR   BioGRID; 113892; 40.
DR   IntAct; O00507; 16.
DR   MINT; O00507; -.
DR   MEROPS; C19.028; -.
DR   CarbonylDB; O00507; -.
DR   iPTMnet; O00507; -.
DR   PhosphoSitePlus; O00507; -.
DR   BioMuta; USP9Y; -.
DR   EPD; O00507; -.
DR   jPOST; O00507; -.
DR   MassIVE; O00507; -.
DR   MaxQB; O00507; -.
DR   PaxDb; O00507; -.
DR   PeptideAtlas; O00507; -.
DR   PRIDE; O00507; -.
DR   ProteomicsDB; 47948; -. [O00507-1]
DR   ProteomicsDB; 47949; -. [O00507-2]
DR   Antibodypedia; 21866; 35 antibodies from 14 providers.
DR   DNASU; 8287; -.
DR   Ensembl; ENST00000338981; ENSP00000342812; ENSG00000114374.
DR   Ensembl; ENST00000651177; ENSP00000498372; ENSG00000114374.
DR   GeneID; 8287; -.
DR   KEGG; hsa:8287; -.
DR   MANE-Select; ENST00000338981.7; ENSP00000342812.3; NM_004654.4; NP_004645.2.
DR   UCSC; uc004fst.2; human. [O00507-1]
DR   CTD; 8287; -.
DR   DisGeNET; 8287; -.
DR   GeneCards; USP9Y; -.
DR   GeneReviews; USP9Y; -.
DR   HGNC; HGNC:12633; USP9Y.
DR   HPA; ENSG00000114374; Low tissue specificity.
DR   MalaCards; USP9Y; -.
DR   MIM; 400005; gene.
DR   MIM; 415000; phenotype.
DR   neXtProt; NX_O00507; -.
DR   OpenTargets; ENSG00000114374; -.
DR   Orphanet; 1646; Partial chromosome Y deletion.
DR   PharmGKB; PA37258; -.
DR   VEuPathDB; HostDB:ENSG00000114374; -.
DR   GeneTree; ENSGT00940000155375; -.
DR   HOGENOM; CLU_000331_1_0_1; -.
DR   InParanoid; O00507; -.
DR   OMA; TGRIRMQ; -.
DR   OrthoDB; 625455at2759; -.
DR   PhylomeDB; O00507; -.
DR   TreeFam; TF323966; -.
DR   PathwayCommons; O00507; -.
DR   SignaLink; O00507; -.
DR   BioGRID-ORCS; 8287; 8 hits in 672 CRISPR screens.
DR   ChiTaRS; USP9Y; human.
DR   GeneWiki; USP9Y; -.
DR   GenomeRNAi; 8287; -.
DR   Pharos; O00507; Tdark.
DR   PRO; PR:O00507; -.
DR   Proteomes; UP000005640; Chromosome Y.
DR   RNAct; O00507; protein.
DR   Bgee; ENSG00000114374; Expressed in small intestine Peyer's patch and 184 other tissues.
DR   ExpressionAtlas; O00507; baseline and differential.
DR   Genevisible; O00507; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0070410; F:co-SMAD binding; ISS:BHF-UCL.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; TAS:ProtInc.
DR   GO; GO:0004843; F:thiol-dependent deubiquitinase; IBA:GO_Central.
DR   GO; GO:0030509; P:BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0016579; P:protein deubiquitination; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR021905; DUF3517.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF12030; DUF3517; 1.
DR   Pfam; PF00443; UCH; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Cytoplasm; Hydrolase; Phosphoprotein; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..2555
FT                   /note="Probable ubiquitin carboxyl-terminal hydrolase FAF-
FT                   Y"
FT                   /id="PRO_0000080690"
FT   DOMAIN          1559..1958
FT                   /note="USP"
FT   REGION          1..66
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          972..997
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2476..2555
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..49
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        972..994
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2503..2517
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2524..2548
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1568
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   ACT_SITE        1881
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   MOD_RES         589
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q93008"
FT   MOD_RES         591
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q93008"
FT   MOD_RES         2444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q93008"
FT   MOD_RES         2541
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q93008"
FT   MOD_RES         2548
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q93008"
FT   VAR_SEQ         2071..2555
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005272"
FT   VARIANT         65
FT                   /note="E -> D (in dbSNP:rs7067496)"
FT                   /id="VAR_055350"
FT   VARIANT         211
FT                   /note="R -> C (in dbSNP:rs2032596)"
FT                   /id="VAR_055351"
FT   VARIANT         1035
FT                   /note="P -> S (in dbSNP:rs20319)"
FT                   /id="VAR_029328"
FT   VARIANT         1060
FT                   /note="A -> T (in dbSNP:rs20320)"
FT                   /evidence="ECO:0000269|PubMed:9384609"
FT                   /id="VAR_016194"
FT   VARIANT         1705
FT                   /note="A -> S (in dbSNP:rs2032606)"
FT                   /id="VAR_055352"
FT   CONFLICT        206
FT                   /note="D -> E (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        282
FT                   /note="I -> M (in Ref. 2; AAC51833)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        524
FT                   /note="D -> Y (in Ref. 2; AAC51833)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        542
FT                   /note="S -> A (in Ref. 2; AAC51833)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        666
FT                   /note="L -> V (in Ref. 2; AAC51833)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        883
FT                   /note="R -> C (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        907
FT                   /note="S -> F (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        946
FT                   /note="D -> N (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1002
FT                   /note="E -> K (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1017
FT                   /note="R -> K (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1025..1027
FT                   /note="VAD -> FAN (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1038..1039
FT                   /note="RD -> KN (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1067
FT                   /note="K -> N (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1258
FT                   /note="V -> F (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1733
FT                   /note="Y -> F (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1953
FT                   /note="L -> P (in Ref. 3; CAA73940/CAA73941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2086
FT                   /note="R -> G (in Ref. 2; AAC51833)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2555 AA;  291077 MW;  421D47D5899F4415 CRC64;
     MTAITHGSPV GGNDSQGQVL DGQSQHLFQQ NQTSSPDSSN ENSVATPPPE EQGQGDAPPQ
     HEDEEPAFPH TELANLDDMI NRPRWVVPVL PKGELEVLLE AAIDLSVKGL DVKSEACQRF
     FRDGLTISFT KILMDEAVSG WKFEIHRCII NNTHRLVELC VAKLSQDWFP LLELLAMALN
     PHCKFHIYNG TRPCELISSN AQLPEDELFA RSSDPRSPKG WLVDLINKFG TLNGFQILHD
     RFFNGSALNI QIIAALIKPF GQCYEFLSQH TLKKYFIPVI EIVPHLLENL TDEELKKEAK
     NEAKNDALSM IIKSLKNLAS RISGQDETIK NLEIFRLKMI LRLLQISSFN GKMNALNEIN
     KVISSVSYYT HRHSNPEEEE WLTAERMAEW IQQNNILSIV LQDSLHQPQY VEKLEKILRF
     VIKEKALTLQ DLDNIWAAQA GKHEAIVKNV HDLLAKLAWD FSPGQLDHLF DCFKASWTNA
     SKKQREKLLE LIRRLAEDDK DGVMAHKVLN LLWNLAQSDD VPVDIMDLAL SAHIKILDYS
     CSQDRDAQKI QWIDHFIEEL RTNDKWVIPA LKQIREICSL FGEASQNLSQ TQRSPHIFYR
     HDLINQLQQN HALVTLVAEN LATYMNSIRL YAGDHEDYDP QTVRLGSRYS HVQEVQERLN
     FLRFLLKDGQ LWLCAPQAKQ IWKCLAENAV YLCDREACFK WYSKLMGDEP DLDPDINKDF
     FESNVLQLDP SLLTENGMKC FERFFKAVNC RERKLIAKRR SYMMDDLELI GLDYLWRVVI
     QSSDEIANRA IDLLKEIYTN LGPRLKANQV VIHEDFIQSC FDRLKASYDT LCVFDGDKNS
     INCARQEAIR MVRVLTVIKE YINECDSDYH KERMILPMSR AFRGKHLSLI VRFPNQGRQV
     DELDIWSHTN DTIGSVRRCI VNRIKANVAH KKIELFVGGE LIDSEDDRKL IGQLNLKDKS
     LITAKLTQIN FNMPSSPDSS SDSSTASPGN HRNHYNDGPN LEVESCLPGV IMSVHPRYIS
     FLWQVADLGS NLNMPPLRDG ARVLMKLMPP DRTAVEKLRA VCLDHAKLGE GKLSPPLDSL
     FFGPSASQVL YLTEVVYALL MPAGVPLTDG SSDFQVHFLK SGGLPLVLSM LIRNNFLPNT
     DMETRRGAYL NALKIAKLLL TAIGYGHVRA VAEACQPVVD GTDPITQINQ VTHDQAVVLQ
     SALQSIPNPS SECVLRNESI LLAQEISNEA SRYMPDICVI RAIQKIIWAS ACGALGLVFS
     PNEEITKIYQ MTTNGSNKLE VEDEQVCCEA LEVMTLCFAL LPTALDALSK EKAWQTFIID
     LLLHCPSKTV RQLAQEQFFL MCTRCCMGHR PLLFFITLLF TILGSTAREK GKYSGDYFTL
     LRHLLNYAYN GNINIPNAEV LLVSEIDWLK RIRDNVKNTG ETGVEEPILE GHLGVTKELL
     AFQTSEKKYH FGCEKGGANL IKELIDDFIF PASKVYLQYL RSGELPAEQA IPVCSSPVTI
     NAGFELLVAL AIGCVRNLKQ IVDCLTEMYY MGTAITTCEA LTEWEYLPPV GPRPPKGFVG
     LKNAGATCYM NSVIQQLYMI PSIRNSILAI EGTGSDLHDD MFGDEKQDSE SNVDPRDDVF
     GYPHQFEDKP ALSKTEDRKE YNIGVLRHLQ VIFGHLAASQ LQYYVPRGFW KQFRLWGEPV
     NLREQHDALE FFNSLVDSLD EALKALGHPA ILSKVLGGSF ADQKICQGCP HRYECEESFT
     TLNVDIRNHQ NLLDSLEQYI KGDLLEGANA YHCEKCDKKV DTVKRLLIKK LPRVLAIQLK
     RFDYDWEREC AIKFNDYFEF PRELDMGPYT VAGVANLERD NVNSENELIE QKEQSDNETA
     GGTKYRLVGV LVHSGQASGG HYYSYIIQRN GKDDQTDHWY KFDDGDVTEC KMDDDEEMKN
     QCFGGEYMGE VFDHMMKRMS YRRQKRWWNA YILFYEQMDM IDEDDEMIRY ISELTIARPH
     QIIMSPAIER SVRKQNVKFM HNRLQYSLEY FQFVKKLLTC NGVYLNPAPG QDYLLPEAEE
     ITMISIQLAA RFLFTTGFHT KKIVRGPASD WYDALCVLLR HSKNVRFWFT HNVLFNVSNR
     FSEYLLECPS AEVRGAFAKL IVFIAHFSLQ DGSCPSPFAS PGPSSQACDN LSLSDHLLRA
     TLNLLRREVS EHGHHLQQYF NLFVMYANLG VAEKTQLLKL NVPATFMLVS LDEGPGPPIK
     YQYAELGKLY SVVSQLIRCC NVSSTMQSSI NGNPPLPNPF GDLNLSQPIM PIQQNVLDIL
     FVRTSYVKKI IEDCSNSEDT IKLLRFCSWE NPQFSSTVLS ELLWQVAYSY TYELRPYLDL
     LFQILLIEDS WQTHRIHNAL KGIPDDRDGL FDTIQRSKNH YQKRAYQCIK CMVALFSSCP
     VAYQILQGNG DLKRKWTWAV EWLGDELERR PYTGNPQYSY NNWSPPVQSN ETANGYFLER
     SHSARMTLAK ACELCPEEEP DDQDAPDEHE PSPSEDAPLY PHSPASQYQQ NNHVHGQPYT
     GPAAHHLNNP QKTGQRTQEN YEGNEEVSSP QMKDQ
//
ID   PIAS2_HUMAN             Reviewed;         621 AA.
AC   O75928; O75927; Q96BT5; Q96KE3;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   23-FEB-2022, entry version 201.
DE   RecName: Full=E3 SUMO-protein ligase PIAS2;
DE            EC=2.3.2.-;
DE   AltName: Full=Androgen receptor-interacting protein 3;
DE            Short=ARIP3;
DE   AltName: Full=DAB2-interacting protein;
DE            Short=DIP;
DE   AltName: Full=E3 SUMO-protein transferase PIAS2 {ECO:0000305};
DE   AltName: Full=Msx-interacting zinc finger protein;
DE            Short=Miz1;
DE   AltName: Full=PIAS-NY protein;
DE   AltName: Full=Protein inhibitor of activated STAT x;
DE   AltName: Full=Protein inhibitor of activated STAT2;
GN   Name=PIAS2; Synonyms=PIASX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS PIAS2-ALPHA AND PIAS2-BETA).
RC   TISSUE=B-cell;
RX   PubMed=9724754; DOI=10.1073/pnas.95.18.10626;
RA   Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D., Shuai K.;
RT   "Inhibition of Stat1-mediated gene activation by PIAS1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10626-10631(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Testis;
RX   PubMed=15301740;
RA   Zheng Y., Zhou Z.-M., Yin L.-L., Li J.-M., Sha J.-H.;
RT   "Molecular cloning and characterization of a novel splicing variant of
RT   PIASx.";
RL   Acta Pharmacol. Sin. 25:1058-1064(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PIAS2-ALPHA).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=9920921; DOI=10.1074/jbc.274.6.3700;
RA   Moilanen A.-M., Karvonen U., Poukka H., Yan W., Toppari J., Jaenne O.A.,
RA   Palvimo J.J.;
RT   "A testis-specific androgen receptor coregulator that belongs to a novel
RT   family of nuclear proteins.";
RL   J. Biol. Chem. 274:3700-3704(1999).
RN   [6]
RP   INTERACTION WITH SUMO1; TP73 AND TP53.
RX   PubMed=10961991; DOI=10.1074/jbc.m004293200;
RA   Minty A., Dumont X., Kaghad M., Caput D.;
RT   "Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73
RT   identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction
RT   motif.";
RL   J. Biol. Chem. 275:36316-36323(2000).
RN   [7]
RP   INTERACTION WITH PARK7, AND SUBCELLULAR LOCATION.
RX   PubMed=11477070; DOI=10.1074/jbc.m101730200;
RA   Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M.M., Ariga H.;
RT   "DJ-1 positively regulates the androgen receptor by impairing the binding
RT   of PIASx alpha to the receptor.";
RL   J. Biol. Chem. 276:37556-37563(2001).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=11439351; DOI=10.1038/sj.onc.1204489;
RA   Gross M., Liu B., Tan J.-A., French F.S., Carey M., Shuai K.;
RT   "Distinct effects of PIAS proteins on androgen-mediated gene activation in
RT   prostate cancer cells.";
RL   Oncogene 20:3880-3887(2001).
RN   [9]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.m208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK
RT   activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [10]
RP   SUMOYLATION OF MDM2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-362.
RX   PubMed=12393906; DOI=10.1074/jbc.m208319200;
RA   Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H.;
RT   "Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and
RT   RanBP2 enzymes.";
RL   J. Biol. Chem. 277:50131-50136(2002).
RN   [11]
RP   INTERACTION WITH JUN; TP53 AND UBE2I, SUMOYLATION, AND MUTAGENESIS OF
RP   CYS-362.
RX   PubMed=11867732; DOI=10.1073/pnas.052559499;
RA   Schmidt D., Mueller S.;
RT   "Members of the PIAS family act as SUMO ligases for c-Jun and p53 and
RT   repress p53 activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:2872-2877(2002).
RN   [12]
RP   INTERACTION WITH STAT4, AND SUBCELLULAR LOCATION.
RX   PubMed=12716907; DOI=10.1074/jbc.c300119200;
RA   Arora T., Liu B., He H., Kim J., Murphy T.L., Murphy K.M., Modlin R.L.,
RA   Shuai K.;
RT   "PIASx is a transcriptional co-repressor of signal transducer and activator
RT   of transcription 4.";
RL   J. Biol. Chem. 278:21327-21330(2003).
RN   [13]
RP   INTERACTION WITH PLAG1.
RX   PubMed=15208321; DOI=10.1074/jbc.m401753200;
RA   Van Dyck F., Delvaux E.L.D., Van de Ven W.J.M., Chavez M.V.;
RT   "Repression of the transactivating capacity of the oncoprotein PLAG1 by
RT   SUMOylation.";
RL   J. Biol. Chem. 279:36121-36131(2004).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH ELK1.
RX   PubMed=15920481; DOI=10.1038/sj.emboj.7600690;
RA   Yang S.-H., Sharrocks A.D.;
RT   "PIASx acts as an Elk-1 coactivator by facilitating derepression.";
RL   EMBO J. 24:2161-2171(2005).
RN   [15]
RP   FUNCTION IN PARK7 SUMOYLATION.
RX   PubMed=15976810; DOI=10.1038/sj.cdd.4401704;
RA   Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C.,
RA   Seino C., Iguchi-Ariga S.M.M., Ariga H.;
RT   "Proper SUMO-1 conjugation is essential to DJ-1 to exert its full
RT   activities.";
RL   Cell Death Differ. 13:96-108(2006).
RN   [16]
RP   INTERACTION WITH KLF8.
RX   PubMed=16617055; DOI=10.1074/jbc.m513135200;
RA   Wei H., Wang X., Gan B., Urvalek A.M., Melkoumian Z.K., Guan J.-L.,
RA   Zhao J.;
RT   "Sumoylation delimits KLF8 transcriptional activity associated with the
RT   cell cycle regulation.";
RL   J. Biol. Chem. 281:16664-16671(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   INTERACTION WITH IFIH1/MDA5.
RX   PubMed=21156324; DOI=10.1016/j.molimm.2010.09.003;
RA   Fu J., Xiong Y., Xu Y., Cheng G., Tang H.;
RT   "MDA5 is SUMOylated by PIAS2? in the upregulation of type I interferon
RT   signaling.";
RL   Mol. Immunol. 48:415-422(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-476; SER-477 AND SER-478, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=22406621; DOI=10.1158/0008-5472.can-11-3159;
RA   Rabellino A., Carter B., Konstantinidou G., Wu S.Y., Rimessi A.,
RA   Byers L.A., Heymach J.V., Girard L., Chiang C.M., Teruya-Feldstein J.,
RA   Scaglioni P.P.;
RT   "The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its
RT   oncogenic counterpart PML-RARA.";
RL   Cancer Res. 72:2275-2284(2012).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-249 AND LYS-443, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-249; LYS-430; LYS-443 AND
RP   LYS-489, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-249, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [24]
RP   INTERACTION WITH PRDM1.
RX   PubMed=28842558; DOI=10.1038/s41467-017-00476-w;
RA   Wang W.F., Yan L., Liu Z., Liu L.X., Lin J., Liu Z.Y., Chen X.P., Zhang W.,
RA   Xu Z.Z., Shi T., Li J.M., Zhao Y.L., Meng G., Xia Y., Li J.Y., Zhu J.;
RT   "HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal
RT   misfolded Blimp-1s in lymphoma cells.";
RL   Nat. Commun. 8:363-363(2017).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-46; LYS-249; LYS-430; LYS-435;
RP   LYS-443; LYS-452; LYS-489 AND LYS-502, SUMOYLATION [LARGE SCALE ANALYSIS]
RP   AT LYS-562 (ISOFORM PIAS2-ALPHA), AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [26]
RP   STRUCTURE BY NMR OF 466-488 IN COMPLEX WITH SUMO1, AND MUTAGENESIS OF
RP   VAL-467; VAL-469; ILE-470; LEU-472 AND THR-473.
RX   PubMed=16204249; DOI=10.1074/jbc.m507059200;
RA   Song J., Zhang Z., Hu W., Chen Y.;
RT   "Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif:
RT   a reversal of the bound orientation.";
RL   J. Biol. Chem. 280:40122-40129(2005).
CC   -!- FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO)
CC       ligase, stabilizing the interaction between UBE2I and the substrate,
CC       and as a SUMO-tethering factor. Plays a crucial role as a
CC       transcriptional coregulator in various cellular pathways, including the
CC       STAT pathway, the p53 pathway and the steroid hormone signaling
CC       pathway. The effects of this transcriptional coregulation,
CC       transactivation or silencing may vary depending upon the biological
CC       context and the PIAS2 isoform studied. However, it seems to be mostly
CC       involved in gene silencing. Binds to sumoylated ELK1 and enhances its
CC       transcriptional activity by preventing recruitment of HDAC2 by ELK1,
CC       thus reversing SUMO-mediated repression of ELK1 transactivation
CC       activity. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes
CC       MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation.
CC       Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than
CC       isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at'Lys-65' and
CC       'Lys-160'. {ECO:0000269|PubMed:15920481, ECO:0000269|PubMed:15976810,
CC       ECO:0000269|PubMed:22406621}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Binds SUMO1 and UBE2I. Interacts with AXIN1, JUN, MDM2, PARK7,
CC       TP53 and TP73 isoform alpha, but not TP73 isoform beta. Interacts with
CC       STAT4 following IL12 and IFN-alpha stimulation of T-cells. Interacts
CC       also with GTF2I, GTF2IRD1, IKFZ1, DAB2 and MSX2, as well as with
CC       several steroid receptors, including ESR1, ESR2, NR3C1, PGR, AR, and
CC       with NCOA2 (By similarity). Sumoylation of a target protein seems to
CC       enhance the interaction. Binds to sumoylated ELK1. Binds DNA, such as
CC       CDKN1A promoter, in a sequence-specific manner. Interacts with PLAG1.
CC       Interacts with KLF8; the interaction results in SUMO ligation and
CC       repression of KLF8 transcriptional activity and of its cell cycle
CC       progression into G(1) phase. PIAS2-beta interacts with IFIH1/MDA5.
CC       Isoform PIAS2-alpha interacts with PML (isoform PML-12). Interacts with
CC       PRDM1/Blimp-1 (PubMed:28842558). {ECO:0000250,
CC       ECO:0000269|PubMed:10961991, ECO:0000269|PubMed:11477070,
CC       ECO:0000269|PubMed:11867732, ECO:0000269|PubMed:12223491,
CC       ECO:0000269|PubMed:12716907, ECO:0000269|PubMed:15208321,
CC       ECO:0000269|PubMed:15920481, ECO:0000269|PubMed:16204249,
CC       ECO:0000269|PubMed:16617055, ECO:0000269|PubMed:21156324,
CC       ECO:0000269|PubMed:22406621, ECO:0000269|PubMed:28842558}.
CC   -!- INTERACTION:
CC       O75928; Q96HD9: ACY3; NbExp=3; IntAct=EBI-348555, EBI-3916242;
CC       O75928; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-348555, EBI-10175300;
CC       O75928; O95273: CCNDBP1; NbExp=4; IntAct=EBI-348555, EBI-748961;
CC       O75928; P14136: GFAP; NbExp=3; IntAct=EBI-348555, EBI-744302;
CC       O75928; Q08379: GOLGA2; NbExp=3; IntAct=EBI-348555, EBI-618309;
CC       O75928; P20592: MX2; NbExp=3; IntAct=EBI-348555, EBI-10200618;
CC       O75928; P01106: MYC; NbExp=4; IntAct=EBI-348555, EBI-447544;
CC       O75928; Q8IVL1: NAV2; NbExp=4; IntAct=EBI-348555, EBI-741200;
CC       O75928; O43741: PRKAB2; NbExp=3; IntAct=EBI-348555, EBI-1053424;
CC       O75928; P63244: RACK1; NbExp=2; IntAct=EBI-348555, EBI-296739;
CC       O75928; Q96T51: RUFY1; NbExp=3; IntAct=EBI-348555, EBI-3941207;
CC       O75928; P63165: SUMO1; NbExp=8; IntAct=EBI-348555, EBI-80140;
CC       O75928; G2XKQ0: SUMO1P1; NbExp=3; IntAct=EBI-348555, EBI-10175576;
CC       O75928; P36406: TRIM23; NbExp=3; IntAct=EBI-348555, EBI-740098;
CC       O75928; Q969E8: TSR2; NbExp=3; IntAct=EBI-348555, EBI-746981;
CC       O75928; P63279: UBE2I; NbExp=8; IntAct=EBI-348555, EBI-80168;
CC       O75928; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-348555, EBI-10180829;
CC       O75928; O96006: ZBED1; NbExp=3; IntAct=EBI-348555, EBI-740037;
CC       O75928; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-348555, EBI-742740;
CC       O75928; Q59GP6; NbExp=3; IntAct=EBI-348555, EBI-10243413;
CC       O75928-2; P15336: ATF2; NbExp=3; IntAct=EBI-348567, EBI-1170906;
CC       O75928-2; Q7Z6I8: C5orf24; NbExp=3; IntAct=EBI-348567, EBI-9995695;
CC       O75928-2; P0DN79: CBSL; NbExp=3; IntAct=EBI-348567, EBI-14245939;
CC       O75928-2; Q9UFW8: CGGBP1; NbExp=3; IntAct=EBI-348567, EBI-723153;
CC       O75928-2; P16220: CREB1; NbExp=3; IntAct=EBI-348567, EBI-711855;
CC       O75928-2; P17661: DES; NbExp=3; IntAct=EBI-348567, EBI-1055572;
CC       O75928-2; Q05D60: DEUP1; NbExp=3; IntAct=EBI-348567, EBI-748597;
CC       O75928-2; Q14565: DMC1; NbExp=3; IntAct=EBI-348567, EBI-930865;
CC       O75928-2; Q96F86: EDC3; NbExp=3; IntAct=EBI-348567, EBI-997311;
CC       O75928-2; Q96B26: EXOSC8; NbExp=3; IntAct=EBI-348567, EBI-371922;
CC       O75928-2; Q9BPY3: FAM118B; NbExp=3; IntAct=EBI-348567, EBI-726822;
CC       O75928-2; O75344: FKBP6; NbExp=5; IntAct=EBI-348567, EBI-744771;
CC       O75928-2; P14136: GFAP; NbExp=6; IntAct=EBI-348567, EBI-744302;
CC       O75928-2; Q6ISB3: GRHL2; NbExp=3; IntAct=EBI-348567, EBI-10219092;
CC       O75928-2; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-348567, EBI-2549423;
CC       O75928-2; Q9NP66: HMG20A; NbExp=3; IntAct=EBI-348567, EBI-740641;
CC       O75928-2; Q9P0W2: HMG20B; NbExp=5; IntAct=EBI-348567, EBI-713401;
CC       O75928-2; Q9UGU5: HMGXB4; NbExp=3; IntAct=EBI-348567, EBI-7261162;
CC       O75928-2; O60812: HNRNPCL1; NbExp=3; IntAct=EBI-348567, EBI-1046507;
CC       O75928-2; Q9BUJ2: HNRNPUL1; NbExp=3; IntAct=EBI-348567, EBI-1018153;
CC       O75928-2; Q86YM7: HOMER1; NbExp=3; IntAct=EBI-348567, EBI-746815;
CC       O75928-2; Q9UJC3: HOOK1; NbExp=3; IntAct=EBI-348567, EBI-746704;
CC       O75928-2; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-348567, EBI-11522367;
CC       O75928-2; P20839-3: IMPDH1; NbExp=3; IntAct=EBI-348567, EBI-12188657;
CC       O75928-2; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-348567, EBI-14069005;
CC       O75928-2; Q5T753: LCE1E; NbExp=3; IntAct=EBI-348567, EBI-11955335;
CC       O75928-2; Q5TA81: LCE2C; NbExp=3; IntAct=EBI-348567, EBI-11973993;
CC       O75928-2; Q9UH92-3: MLX; NbExp=3; IntAct=EBI-348567, EBI-8852072;
CC       O75928-2; P20591: MX1; NbExp=3; IntAct=EBI-348567, EBI-929476;
CC       O75928-2; Q9Y5B8: NME7; NbExp=3; IntAct=EBI-348567, EBI-744782;
CC       O75928-2; P22234: PAICS; NbExp=3; IntAct=EBI-348567, EBI-712261;
CC       O75928-2; O75569: PRKRA; NbExp=3; IntAct=EBI-348567, EBI-713955;
CC       O75928-2; P41219: PRPH; NbExp=3; IntAct=EBI-348567, EBI-752074;
CC       O75928-2; P48378: RFX2; NbExp=3; IntAct=EBI-348567, EBI-746731;
CC       O75928-2; Q06455-2: RUNX1T1; NbExp=5; IntAct=EBI-348567, EBI-11984663;
CC       O75928-2; Q15436: SEC23A; NbExp=3; IntAct=EBI-348567, EBI-81088;
CC       O75928-2; P35711-4: SOX5; NbExp=3; IntAct=EBI-348567, EBI-11954419;
CC       O75928-2; Q9H0A9-2: SPATC1L; NbExp=3; IntAct=EBI-348567, EBI-11995806;
CC       O75928-2; Q9BUA3: SPINDOC; NbExp=3; IntAct=EBI-348567, EBI-1773488;
CC       O75928-2; P63165: SUMO1; NbExp=3; IntAct=EBI-348567, EBI-80140;
CC       O75928-2; Q17R54: SYN3; NbExp=3; IntAct=EBI-348567, EBI-12820047;
CC       O75928-2; P07101-3: TH; NbExp=3; IntAct=EBI-348567, EBI-12001016;
CC       O75928-2; Q12933: TRAF2; NbExp=3; IntAct=EBI-348567, EBI-355744;
CC       O75928-2; Q13114: TRAF3; NbExp=3; IntAct=EBI-348567, EBI-357631;
CC       O75928-2; O00463: TRAF5; NbExp=3; IntAct=EBI-348567, EBI-523498;
CC       O75928-2; Q86XT4: TRIM50; NbExp=3; IntAct=EBI-348567, EBI-9867283;
CC       O75928-2; Q969E8: TSR2; NbExp=3; IntAct=EBI-348567, EBI-746981;
CC       O75928-2; P40222: TXLNA; NbExp=3; IntAct=EBI-348567, EBI-359793;
CC       O75928-2; Q8TF42: UBASH3B; NbExp=3; IntAct=EBI-348567, EBI-1380492;
CC       O75928-2; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-348567, EBI-10180829;
CC       O75928-2; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-348567, EBI-741480;
CC       O75928-2; Q05516: ZBTB16; NbExp=3; IntAct=EBI-348567, EBI-711925;
CC       O75928-2; Q96K80: ZC3H10; NbExp=3; IntAct=EBI-348567, EBI-742550;
CC       O75928-2; Q96MM3: ZFP42; NbExp=3; IntAct=EBI-348567, EBI-12151755;
CC       O75928-2; Q9P2F9: ZNF319; NbExp=3; IntAct=EBI-348567, EBI-11993110;
CC       O75928-2; O60232: ZNRD2; NbExp=3; IntAct=EBI-348567, EBI-741415;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000250|UniProtKB:Q8C5D8}.
CC       Nucleus, PML body {ECO:0000269|PubMed:12716907,
CC       ECO:0000269|PubMed:22406621}. Nucleus {ECO:0000269|PubMed:11477070,
CC       ECO:0000269|PubMed:12393906}. Note=Colocalizes at least partially with
CC       promyelocytic leukemia nuclear bodies (PML NBs) (PubMed:22406621).
CC       Colocalizes with SUMO1 in nuclear granules (By similarity).
CC       {ECO:0000250|UniProtKB:Q8C5D8, ECO:0000269|PubMed:22406621}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=PIAS2-beta; Synonyms=PIASx-beta, Miz1;
CC         IsoId=O75928-1; Sequence=Displayed;
CC       Name=PIAS2-alpha; Synonyms=PIASx-alpha, ARIP3;
CC         IsoId=O75928-2; Sequence=VSP_050008, VSP_050009;
CC       Name=3;
CC         IsoId=O75928-3; Sequence=VSP_012196, VSP_012197;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in testis. Isoform 3 is expressed
CC       predominantly in adult testis, weakly in pancreas, embryonic testis and
CC       sperm, and at very low levels in other organs.
CC       {ECO:0000269|PubMed:11439351, ECO:0000269|PubMed:15301740,
CC       ECO:0000269|PubMed:9920921}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 3 expression in adult testis is 14.2-fold
CC       stronger than in embryonic testis. {ECO:0000269|PubMed:15301740}.
CC   -!- INDUCTION: Up-regulated transiently during myeloid differentiation in
CC       various cells lines, such as HL-60, U-937, K-562, induced by either
CC       phorbol ester (TPA) or retinoic acid.
CC   -!- DOMAIN: The LXXLL motif is a transcriptional coregulator signature.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:11867732,
CC       ECO:0000269|PubMed:12393906}.
CC   -!- SIMILARITY: Belongs to the PIAS family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF077953; AAC36704.1; -; mRNA.
DR   EMBL; AF077954; AAC36705.1; -; mRNA.
DR   EMBL; AF361054; AAK48938.1; -; mRNA.
DR   EMBL; AC090241; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090373; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015190; AAH15190.1; -; mRNA.
DR   CCDS; CCDS32824.1; -. [O75928-1]
DR   CCDS; CCDS32825.1; -. [O75928-2]
DR   RefSeq; NP_001310989.1; NM_001324060.1. [O75928-3]
DR   RefSeq; NP_004662.2; NM_004671.4. [O75928-1]
DR   RefSeq; NP_775298.1; NM_173206.3. [O75928-2]
DR   PDB; 2ASQ; NMR; -; B=466-488.
DR   PDB; 4FO9; X-ray; 2.39 A; A=147-488.
DR   PDBsum; 2ASQ; -.
DR   PDBsum; 4FO9; -.
DR   SMR; O75928; -.
DR   BioGRID; 114523; 146.
DR   ELM; O75928; -.
DR   IntAct; O75928; 105.
DR   MINT; O75928; -.
DR   STRING; 9606.ENSP00000465676; -.
DR   iPTMnet; O75928; -.
DR   PhosphoSitePlus; O75928; -.
DR   BioMuta; PIAS2; -.
DR   EPD; O75928; -.
DR   jPOST; O75928; -.
DR   MassIVE; O75928; -.
DR   MaxQB; O75928; -.
DR   PaxDb; O75928; -.
DR   PeptideAtlas; O75928; -.
DR   PRIDE; O75928; -.
DR   ProteomicsDB; 50294; -. [O75928-1]
DR   ProteomicsDB; 50295; -. [O75928-2]
DR   ProteomicsDB; 50296; -. [O75928-3]
DR   Antibodypedia; 9110; 528 antibodies from 41 providers.
DR   DNASU; 9063; -.
DR   Ensembl; ENST00000324794; ENSP00000317163; ENSG00000078043. [O75928-2]
DR   Ensembl; ENST00000585916; ENSP00000465676; ENSG00000078043.
DR   GeneID; 9063; -.
DR   KEGG; hsa:9063; -.
DR   MANE-Select; ENST00000585916.6; ENSP00000465676.1; NM_004671.5; NP_004662.2.
DR   UCSC; uc002lck.4; human. [O75928-1]
DR   CTD; 9063; -.
DR   DisGeNET; 9063; -.
DR   GeneCards; PIAS2; -.
DR   HGNC; HGNC:17311; PIAS2.
DR   HPA; ENSG00000078043; Tissue enhanced (testis).
DR   MIM; 603567; gene.
DR   neXtProt; NX_O75928; -.
DR   OpenTargets; ENSG00000078043; -.
DR   PharmGKB; PA134933292; -.
DR   VEuPathDB; HostDB:ENSG00000078043; -.
DR   eggNOG; KOG2169; Eukaryota.
DR   GeneTree; ENSGT01030000234539; -.
DR   HOGENOM; CLU_020768_3_0_1; -.
DR   InParanoid; O75928; -.
DR   OMA; DPQQYCP; -.
DR   OrthoDB; 1205949at2759; -.
DR   PhylomeDB; O75928; -.
DR   PathwayCommons; O75928; -.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins. [O75928-1]
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors. [O75928-1]
DR   Reactome; R-HSA-3232142; SUMOylation of ubiquitinylation proteins. [O75928-1]
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors. [O75928-1]
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins. [O75928-2]
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SignaLink; O75928; -.
DR   SIGNOR; O75928; -.
DR   UniPathway; UPA00886; -.
DR   BioGRID-ORCS; 9063; 8 hits in 1079 CRISPR screens.
DR   ChiTaRS; PIAS2; human.
DR   EvolutionaryTrace; O75928; -.
DR   GeneWiki; Protein_inhibitor_of_activated_STAT2; -.
DR   GenomeRNAi; 9063; -.
DR   Pharos; O75928; Tbio.
DR   PRO; PR:O75928; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; O75928; protein.
DR   Bgee; ENSG00000078043; Expressed in testis and 237 other tissues.
DR   ExpressionAtlas; O75928; baseline and differential.
DR   Genevisible; O75928; HS.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0061665; F:SUMO ligase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016925; P:protein sumoylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:Ensembl.
DR   DisProt; DP01675; -.
DR   Gene3D; 1.10.720.30; -; 1.
DR   Gene3D; 2.60.120.780; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   IDEAL; IID00136; -.
DR   InterPro; IPR027228; PIAS2.
DR   InterPro; IPR023321; PINIT.
DR   InterPro; IPR038654; PINIT_sf.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   InterPro; IPR004181; Znf_MIZ.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10782:SF12; PTHR10782:SF12; 1.
DR   Pfam; PF14324; PINIT; 1.
DR   Pfam; PF02891; zf-MIZ; 1.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51466; PINIT; 1.
DR   PROSITE; PS50800; SAP; 1.
DR   PROSITE; PS51044; ZF_SP_RING; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..621
FT                   /note="E3 SUMO-protein ligase PIAS2"
FT                   /id="PRO_0000218976"
FT   DOMAIN          11..45
FT                   /note="SAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00186"
FT   DOMAIN          134..299
FT                   /note="PINIT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00799"
FT   ZN_FING         331..412
FT                   /note="SP-RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   REGION          467..473
FT                   /note="SUMO1-binding"
FT   REGION          579..621
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           19..23
FT                   /note="LXXLL motif"
FT   MOTIF           484..492
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   METAL           362
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           364
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           385
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   METAL           388
FT                   /note="Zinc"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   MOD_RES         476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         477
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         499
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C5D8"
FT   CROSSLNK        46
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        249
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        430
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        435
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        443
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        452
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        489
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        502
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..8
FT                   /note="MADFEELR -> MNAGKQLQRTLH (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15301740"
FT                   /id="VSP_012196"
FT   VAR_SEQ         402..621
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15301740"
FT                   /id="VSP_012197"
FT   VAR_SEQ         551..572
FT                   /note="LDFLSLIPVDPQYCPPMFLDSL -> EQRRNDINNELKLGTSSDTVQQ (in
FT                   isoform PIAS2-alpha)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9724754"
FT                   /id="VSP_050008"
FT   VAR_SEQ         573..621
FT                   /note="Missing (in isoform PIAS2-alpha)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9724754"
FT                   /id="VSP_050009"
FT   VARIANT         207
FT                   /note="V -> A (in dbSNP:rs16940108)"
FT                   /id="VAR_056693"
FT   MUTAGEN         362
FT                   /note="C->S,A: Loss of MDM2 and TP53 sumoylation and of
FT                   autosumoylation; no loss of JUN- and TP53-binding."
FT                   /evidence="ECO:0000269|PubMed:11867732,
FT                   ECO:0000269|PubMed:12393906"
FT   MUTAGEN         467
FT                   /note="V->A: Reduces affinity for SUMO1."
FT                   /evidence="ECO:0000269|PubMed:16204249"
FT   MUTAGEN         469
FT                   /note="V->A: Abolishes binding to SUMO1."
FT                   /evidence="ECO:0000269|PubMed:16204249"
FT   MUTAGEN         470
FT                   /note="I->A: Abolishes binding to SUMO1."
FT                   /evidence="ECO:0000269|PubMed:16204249"
FT   MUTAGEN         472
FT                   /note="L->A: Abolishes binding to SUMO1."
FT                   /evidence="ECO:0000269|PubMed:16204249"
FT   MUTAGEN         473
FT                   /note="T->A: Reduces affinity for SUMO1."
FT                   /evidence="ECO:0000269|PubMed:16204249"
FT   CONFLICT        144
FT                   /note="P -> L (in Ref. 2; AAK48938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        616
FT                   /note="D -> E (in Ref. 1; AAC36705)"
FT                   /evidence="ECO:0000305"
FT   STRAND          154..165
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          173..181
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           185..192
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          195..197
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          203..215
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          231..234
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           264..266
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          275..282
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          289..298
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           301..309
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           316..327
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          340..345
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   TURN            347..349
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          354..359
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           370..379
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   TURN            386..388
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           394..396
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          397..400
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   HELIX           401..407
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          415..418
FT                   /evidence="ECO:0007829|PDB:4FO9"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:2ASQ"
FT   CROSSLNK        O75928-2:562
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
SQ   SEQUENCE   621 AA;  68240 MW;  6422B383345AD883 CRC64;
     MADFEELRNM VSSFRVSELQ VLLGFAGRNK SGRKHDLLMR ALHLLKSGCS PAVQIKIREL
     YRRRYPRTLE GLSDLSTIKS SVFSLDGGSS PVEPDLAVAG IHSLPSTSVT PHSPSSPVGS
     VLLQDTKPTF EMQQPSPPIP PVHPDVQLKN LPFYDVLDVL IKPTSLVQSS IQRFQEKFFI
     FALTPQQVRE ICISRDFLPG GRRDYTVQVQ LRLCLAETSC PQEDNYPNSL CIKVNGKLFP
     LPGYAPPPKN GIEQKRPGRP LNITSLVRLS SAVPNQISIS WASEIGKNYS MSVYLVRQLT
     SAMLLQRLKM KGIRNPDHSR ALIKEKLTAD PDSEIATTSL RVSLMCPLGK MRLTIPCRAV
     TCTHLQCFDA ALYLQMNEKK PTWICPVCDK KAAYESLILD GLFMEILNDC SDVDEIKFQE
     DGSWCPMRPK KEAMKVSSQP CTKIESSSVL SKPCSVTVAS EASKKKVDVI DLTIESSSDE
     EEDPPAKRKC IFMSETQSSP TKGVLMYQPS SVRVPSVTSV DPAAIPPSLT DYSVPFHHTP
     ISSMSSDLPG LDFLSLIPVD PQYCPPMFLD SLTSPLTASS TSVTTTSSHE SSTHVSSSSS
     RSETGVITSS GSNIPDIISL D
//
ID   ETV1_HUMAN              Reviewed;         477 AA.
AC   P50549; A4D118; B2R768; B7Z2I4; B7Z618; B7Z9P2; C9JT37; E9PHB1; F5GXR2;
AC   O75849; Q4KMQ6; Q59GA7; Q6AI30; Q9UQ71; Q9Y636;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   23-FEB-2022, entry version 190.
DE   RecName: Full=ETS translocation variant 1 {ECO:0000305};
DE   AltName: Full=Ets-related protein 81 {ECO:0000312|HGNC:HGNC:3490};
GN   Name=ETV1 {ECO:0000312|HGNC:HGNC:3490};
GN   Synonyms=ER81 {ECO:0000303|PubMed:7651741};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|Proteomes:UP000005640};
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL TRANSLOCATION WITH
RP   EWSR1.
RX   PubMed=7700648;
RA   Jeon I.-S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F., Denny C.T.,
RA   Shapiro D.N.;
RT   "A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the
RT   ETS gene ETV1.";
RL   Oncogene 10:1229-1234(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.
RC   TISSUE=Kidney;
RX   PubMed=7651741;
RA   Monte D., Coutte L., Baert J.-L., Angeli I., Stehelin D., de Launoit Y.;
RT   "Molecular characterization of the ets-related human transcription factor
RT   ER81.";
RL   Oncogene 11:771-779(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).
RA   Coutte L., Monte D., Pouilly L., Dewitte F., Vidaud M., Baert J.-L.,
RA   de Launoit Y.;
RT   "Characterization of the human and mouse ER81/ETV1 transcription factor
RT   genes. Role of the two human alternatively spliced isoforms.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 4 AND 5), AND
RP   VARIANT GLY-100.
RC   TISSUE=Brain, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLY-100.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Seminoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION AT SER-191 AND SER-216.
RX   PubMed=12213813; DOI=10.1074/jbc.m205501200;
RA   Wu J., Janknecht R.;
RT   "Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6
RT   kinase 1 and protein kinase A.";
RL   J. Biol. Chem. 277:42669-42679(2002).
RN   [11]
RP   PHOSPHORYLATION AT SER-191 AND SER-216, AND MUTAGENESIS OF SER-191 AND
RP   SER-216.
RX   PubMed=12569367; DOI=10.1038/sj.onc.1206185;
RA   Janknecht R.;
RT   "Regulation of the ER81 transcription factor and its coactivators by
RT   mitogen- and stress-activated protein kinase 1 (MSK1).";
RL   Oncogene 22:746-755(2003).
RN   [12]
RP   SUMOYLATION.
RX   PubMed=15561718; DOI=10.1074/jbc.m411718200;
RA   Gocke C.B., Yu H., Kang J.;
RT   "Systematic identification and analysis of mammalian small ubiquitin-like
RT   modifier substrates.";
RL   J. Biol. Chem. 280:5004-5012(2005).
RN   [13]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-317, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Transcriptional activator that binds to DNA sequences
CC       containing the consensus pentanucleotide 5'-CGGA[AT]-3'
CC       (PubMed:7651741). Required for olfactory dopaminergic neuron
CC       differentiation; may directly activate expression of tyrosine
CC       hydroxylase (TH) (By similarity). {ECO:0000250|UniProtKB:P41164,
CC       ECO:0000269|PubMed:7651741}.
CC   -!- INTERACTION:
CC       P50549; Q8NHY2: COP1; NbExp=2; IntAct=EBI-3905068, EBI-1176214;
CC       P50549; Q16236: NFE2L2; NbExp=4; IntAct=EBI-3905068, EBI-2007911;
CC       P50549; P78527: PRKDC; NbExp=2; IntAct=EBI-3905068, EBI-352053;
CC       P50549-1; Q8NHY2-1: COP1; NbExp=2; IntAct=EBI-15926557, EBI-9698228;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00237}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=P50549-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P50549-2; Sequence=VSP_001472;
CC       Name=3;
CC         IsoId=P50549-3; Sequence=VSP_043750;
CC       Name=4;
CC         IsoId=P50549-4; Sequence=VSP_043808, VSP_043809;
CC       Name=5;
CC         IsoId=P50549-5; Sequence=VSP_043808, VSP_001472;
CC       Name=6;
CC         IsoId=P50549-6; Sequence=VSP_043808;
CC   -!- TISSUE SPECIFICITY: Very highly expressed in brain, highly expressed in
CC       testis, lung and heart, moderately in spleen, small intestine, pancreas
CC       and colon, weakly in liver, prostate and thymus, very weakly in
CC       skeletal muscle, kidney and ovary and not in placenta and peripheral
CC       blood leukocytes. {ECO:0000269|PubMed:7651741}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:15561718}.
CC   -!- PTM: Phosphorylated at Ser-191 and Ser-216 by RPS6KA1 and RPS6KA5;
CC       phosphorylation activates transcriptional activity.
CC       {ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:12569367}.
CC   -!- DISEASE: Ewing sarcoma (ES) [MIM:612219]: A highly malignant,
CC       metastatic, primitive small round cell tumor of bone and soft tissue
CC       that affects children and adolescents. It belongs to the Ewing sarcoma
CC       family of tumors, a group of morphologically heterogeneous neoplasms
CC       that share the same cytogenetic features. They are considered neural
CC       tumors derived from cells of the neural crest. Ewing sarcoma represents
CC       the less differentiated form of the tumors.
CC       {ECO:0000269|PubMed:7700648}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis. A chromosomal aberration involving
CC       ETV1 is found in patients with Ewing sarcoma. Translocation
CC       t(7;22)(p22;q12) with EWSR1. {ECO:0000269|PubMed:7700648}.
CC   -!- SIMILARITY: Belongs to the ETS family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92439.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U17163; AAA79844.1; -; mRNA.
DR   EMBL; X87175; CAA60642.1; -; mRNA.
DR   EMBL; AF109632; AAD29877.1; -; Genomic_DNA.
DR   EMBL; AF109621; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109622; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109623; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109624; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109625; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109626; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109627; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109628; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109629; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109630; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109631; AAD29877.1; JOINED; Genomic_DNA.
DR   EMBL; AF109632; AAD29878.1; -; Genomic_DNA.
DR   EMBL; AF109621; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109622; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109623; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109625; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109626; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109627; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109628; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109629; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109630; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AF109631; AAD29878.1; JOINED; Genomic_DNA.
DR   EMBL; AK294755; BAH11870.1; -; mRNA.
DR   EMBL; AK299693; BAH13104.1; -; mRNA.
DR   EMBL; AK312863; BAG35715.1; -; mRNA.
DR   EMBL; AK316007; BAH14378.1; -; mRNA.
DR   EMBL; AB209202; BAD92439.1; ALT_INIT; mRNA.
DR   EMBL; CR627389; CAH10484.1; -; mRNA.
DR   EMBL; AC004857; AAC62435.1; -; Genomic_DNA.
DR   EMBL; AC004909; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24294.1; -; Genomic_DNA.
DR   EMBL; BC098403; AAH98403.1; -; mRNA.
DR   EMBL; BC106762; AAI06763.1; -; mRNA.
DR   EMBL; BC106763; AAI06764.1; -; mRNA.
DR   CCDS; CCDS55083.1; -. [P50549-5]
DR   CCDS; CCDS55084.1; -. [P50549-4]
DR   CCDS; CCDS55085.1; -. [P50549-6]
DR   CCDS; CCDS55086.1; -. [P50549-2]
DR   CCDS; CCDS55087.1; -. [P50549-3]
DR   CCDS; CCDS55088.1; -. [P50549-1]
DR   PIR; I38893; I38893.
DR   RefSeq; NP_001156619.1; NM_001163147.1. [P50549-3]
DR   RefSeq; NP_001156620.1; NM_001163148.1. [P50549-2]
DR   RefSeq; NP_001156621.1; NM_001163149.1. [P50549-2]
DR   RefSeq; NP_001156622.1; NM_001163150.1. [P50549-6]
DR   RefSeq; NP_001156623.1; NM_001163151.1. [P50549-5]
DR   RefSeq; NP_001156624.1; NM_001163152.1. [P50549-4]
DR   RefSeq; NP_004947.2; NM_004956.4. [P50549-1]
DR   RefSeq; XP_005249692.1; XM_005249635.4. [P50549-1]
DR   RefSeq; XP_005249693.1; XM_005249636.4.
DR   RefSeq; XP_011513470.1; XM_011515168.2. [P50549-1]
DR   PDB; 4AVP; X-ray; 1.82 A; A/B/C/D=326-429.
DR   PDB; 4BNC; X-ray; 2.90 A; A=326-429.
DR   PDB; 5ILS; X-ray; 1.40 A; A=334-434.
DR   PDBsum; 4AVP; -.
DR   PDBsum; 4BNC; -.
DR   PDBsum; 5ILS; -.
DR   SMR; P50549; -.
DR   BioGRID; 108416; 24.
DR   DIP; DIP-60463N; -.
DR   IntAct; P50549; 9.
DR   STRING; 9606.ENSP00000405327; -.
DR   BindingDB; P50549; -.
DR   ChEMBL; CHEMBL2010626; -.
DR   GlyGen; P50549; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P50549; -.
DR   PhosphoSitePlus; P50549; -.
DR   BioMuta; ETV1; -.
DR   DMDM; 12643411; -.
DR   MassIVE; P50549; -.
DR   MaxQB; P50549; -.
DR   PaxDb; P50549; -.
DR   PeptideAtlas; P50549; -.
DR   PRIDE; P50549; -.
DR   ProteomicsDB; 20494; -.
DR   ProteomicsDB; 24498; -.
DR   ProteomicsDB; 56244; -. [P50549-1]
DR   ProteomicsDB; 56245; -. [P50549-2]
DR   ProteomicsDB; 56246; -. [P50549-3]
DR   ProteomicsDB; 56247; -. [P50549-4]
DR   Antibodypedia; 25156; 330 antibodies from 32 providers.
DR   DNASU; 2115; -.
DR   Ensembl; ENST00000242066; ENSP00000242066; ENSG00000006468. [P50549-2]
DR   Ensembl; ENST00000399357; ENSP00000382293; ENSG00000006468. [P50549-4]
DR   Ensembl; ENST00000403527; ENSP00000384138; ENSG00000006468. [P50549-6]
DR   Ensembl; ENST00000403685; ENSP00000385686; ENSG00000006468. [P50549-2]
DR   Ensembl; ENST00000405192; ENSP00000385381; ENSG00000006468. [P50549-3]
DR   Ensembl; ENST00000405218; ENSP00000385551; ENSG00000006468.
DR   Ensembl; ENST00000420159; ENSP00000411626; ENSG00000006468. [P50549-5]
DR   Ensembl; ENST00000430479; ENSP00000405327; ENSG00000006468.
DR   GeneID; 2115; -.
DR   KEGG; hsa:2115; -.
DR   MANE-Select; ENST00000430479.6; ENSP00000405327.1; NM_004956.5; NP_004947.2.
DR   UCSC; uc003ssw.5; human. [P50549-1]
DR   CTD; 2115; -.
DR   DisGeNET; 2115; -.
DR   GeneCards; ETV1; -.
DR   HGNC; HGNC:3490; ETV1.
DR   HPA; ENSG00000006468; Tissue enhanced (brain, salivary gland).
DR   MalaCards; ETV1; -.
DR   MIM; 600541; gene.
DR   MIM; 612219; phenotype.
DR   neXtProt; NX_P50549; -.
DR   OpenTargets; ENSG00000006468; -.
DR   Orphanet; 319; Skeletal Ewing sarcoma.
DR   PharmGKB; PA27904; -.
DR   VEuPathDB; HostDB:ENSG00000006468; -.
DR   eggNOG; KOG3806; Eukaryota.
DR   GeneTree; ENSGT00940000157123; -.
DR   HOGENOM; CLU_030025_1_0_1; -.
DR   InParanoid; P50549; -.
DR   OMA; QVPYCNS; -.
DR   PhylomeDB; P50549; -.
DR   TreeFam; TF316214; -.
DR   PathwayCommons; P50549; -.
DR   SignaLink; P50549; -.
DR   SIGNOR; P50549; -.
DR   BioGRID-ORCS; 2115; 12 hits in 1065 CRISPR screens.
DR   ChiTaRS; ETV1; human.
DR   GeneWiki; ETV1; -.
DR   GenomeRNAi; 2115; -.
DR   Pharos; P50549; Tbio.
DR   PRO; PR:P50549; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P50549; protein.
DR   Bgee; ENSG00000006468; Expressed in cerebellum and 209 other tissues.
DR   ExpressionAtlas; P50549; baseline and differential.
DR   Genevisible; P50549; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0007638; P:mechanosensory behavior; IEA:Ensembl.
DR   GO; GO:0007517; P:muscle organ development; IEA:Ensembl.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; TAS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR000418; Ets_dom.
DR   InterPro; IPR006715; ETS_PEA3_N.
DR   InterPro; IPR032928; ETS_V1.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11849:SF196; PTHR11849:SF196; 1.
DR   Pfam; PF00178; Ets; 1.
DR   Pfam; PF04621; ETS_PEA3_N; 1.
DR   PRINTS; PR00454; ETSDOMAIN.
DR   SMART; SM00413; ETS; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00345; ETS_DOMAIN_1; 1.
DR   PROSITE; PS00346; ETS_DOMAIN_2; 1.
DR   PROSITE; PS50061; ETS_DOMAIN_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Chromosomal rearrangement;
KW   Disease variant; DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..477
FT                   /note="ETS translocation variant 1"
FT                   /id="PRO_0000204110"
FT   DNA_BIND        335..415
FT                   /note="ETS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00237"
FT   REGION          128..179
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        145..159
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         94
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P43268"
FT   MOD_RES         191
FT                   /note="Phosphoserine; by RPS6KA1 and RPS6KA5"
FT                   /evidence="ECO:0000269|PubMed:12213813,
FT                   ECO:0000269|PubMed:12569367"
FT   MOD_RES         216
FT                   /note="Phosphoserine; by RPS6KA1 and RPS6KA5"
FT                   /evidence="ECO:0000269|PubMed:12213813,
FT                   ECO:0000269|PubMed:12569367"
FT   CROSSLNK        317
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..60
FT                   /note="MDGFYDQQVPYMVTNSQRGRNCNEKPTNVRKRKFINRDLAHDSEELFQDLSQ
FT                   LQETWLAE -> MLQDLSASVFFPPCSQHRTL (in isoform 4, isoform 5
FT                   and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_043808"
FT   VAR_SEQ         61..79
FT                   /note="AQVPDNDEQFVPDYQAESL -> V (in isoform 2 and isoform
FT                   5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:7651741"
FT                   /id="VSP_001472"
FT   VAR_SEQ         122..184
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043809"
FT   VAR_SEQ         268..290
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_043750"
FT   VARIANT         100
FT                   /note="S -> G (in dbSNP:rs9639168)"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.5"
FT                   /id="VAR_048948"
FT   MUTAGEN         191
FT                   /note="S->A: Loss of phosphorylation by RPS6KA5."
FT                   /evidence="ECO:0000269|PubMed:12569367"
FT   MUTAGEN         216
FT                   /note="S->A: Loss of phosphorylation by RPS6KA5."
FT                   /evidence="ECO:0000269|PubMed:12569367"
FT   CONFLICT        39
FT                   /note="L -> V (in Ref. 2; CAA60642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        117
FT                   /note="C -> S (in Ref. 1; AAA79844)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        127
FT                   /note="K -> N (in Ref. 1; AAA79844)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        253
FT                   /note="Missing (in Ref. 2; CAA60642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        349
FT                   /note="S -> A (in Ref. 2; CAA60642)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        445
FT                   /note="E -> G (in Ref. 6; CAH10484)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        471
FT                   /note="Y -> C (in Ref. 4; BAH13104)"
FT                   /evidence="ECO:0000305"
FT   HELIX           337..346
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   HELIX           348..350
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   TURN            351..353
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   STRAND          354..356
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   STRAND          362..367
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   HELIX           368..379
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   HELIX           386..398
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   STRAND          401..404
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   STRAND          409..414
FT                   /evidence="ECO:0007829|PDB:5ILS"
FT   HELIX           418..425
FT                   /evidence="ECO:0007829|PDB:5ILS"
SQ   SEQUENCE   477 AA;  55131 MW;  BE95FA3F07196F06 CRC64;
     MDGFYDQQVP YMVTNSQRGR NCNEKPTNVR KRKFINRDLA HDSEELFQDL SQLQETWLAE
     AQVPDNDEQF VPDYQAESLA FHGLPLKIKK EPHSPCSEIS SACSQEQPFK FSYGEKCLYN
     VSAYDQKPQV GMRPSNPPTP SSTPVSPLHH ASPNSTHTPK PDRAFPAHLP PSQSIPDSSY
     PMDHRFRRQL SEPCNSFPPL PTMPREGRPM YQRQMSEPNI PFPPQGFKQE YHDPVYEHNT
     MVGSAASQSF PPPLMIKQEP RDFAYDSEVP SCHSIYMRQE GFLAHPSRTE GCMFEKGPRQ
     FYDDTCVVPE KFDGDIKQEP GMYREGPTYQ RRGSLQLWQF LVALLDDPSN SHFIAWTGRG
     MEFKLIEPEE VARRWGIQKN RPAMNYDKLS RSLRYYYEKG IMQKVAGERY VYKFVCDPEA
     LFSMAFPDNQ RPLLKTDMER HINEEDTVPL SHFDESMAYM PEGGCCNPHP YNEGYVY
//
ID   LIMS1_HUMAN             Reviewed;         325 AA.
AC   P48059; B2RAJ4; B7Z483; B7Z7R3; B7Z907; Q53TE0; Q9BS44;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   23-FEB-2022, entry version 211.
DE   RecName: Full=LIM and senescent cell antigen-like-containing domain protein 1;
DE   AltName: Full=Particularly interesting new Cys-His protein 1;
DE            Short=PINCH-1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-48;
GN   Name=LIMS1; Synonyms=PINCH, PINCH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=7517666; DOI=10.1006/bbrc.1994.1822;
RA   Rearden A.;
RT   "A new LIM protein containing an autoepitope homologous to 'senescent cell
RT   antigen'.";
RL   Biochem. Biophys. Res. Commun. 201:1124-1131(1994).
RN   [2]
RP   SEQUENCE REVISION TO C-TERMINUS.
RA   Rearden A.;
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 5).
RC   TISSUE=Testis, Tongue, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-12, AND ACETYLATION AT ALA-2.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   INTERACTION WITH NCK2.
RX   PubMed=9843575; DOI=10.1091/mbc.9.12.3367;
RA   Tu Y., Li F., Wu C.;
RT   "Nck-2, a novel Src homology2/3-containing adaptor protein that interacts
RT   with the LIM-only protein PINCH and components of growth factor receptor
RT   kinase-signaling pathways.";
RL   Mol. Biol. Cell 9:3367-3382(1998).
RN   [8]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [9]
RP   INTERACTION WITH ILK AND NCK2, AND SUBCELLULAR LOCATION.
RX   PubMed=10022929; DOI=10.1128/mcb.19.3.2425;
RA   Tu Y., Li F., Goicoechea S., Wu C.;
RT   "The LIM-only protein PINCH directly interacts with integrin-linked kinase
RT   and is recruited to integrin-rich sites in spreading cells.";
RL   Mol. Cell. Biol. 19:2425-2434(1999).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   STRUCTURE BY NMR OF 1-70.
RX   PubMed=11078733; DOI=10.1074/jbc.m007632200;
RA   Velyvis A., Yang Y., Wu C., Qin J.;
RT   "Solution structure of the focal adhesion adaptor PINCH LIM1 domain and
RT   characterization of its interaction with the integrin-linked kinase ankyrin
RT   repeat domain.";
RL   J. Biol. Chem. 276:4932-4939(2001).
RN   [12]
RP   STRUCTURE BY NMR OF 188-251.
RX   PubMed=12794636; DOI=10.1038/nsb938;
RA   Velyvis A., Vaynberg J., Yang Y., Vinogradova O., Zhang Y., Wu C., Qin J.;
RT   "Structural and functional insights into PINCH LIM4 domain-mediated
RT   integrin signaling.";
RL   Nat. Struct. Biol. 10:558-564(2003).
RN   [13]
RP   STRUCTURE BY NMR OF 71-190.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second and third LIM domain of particularly
RT   interesting new Cys-His protein (PINCH).";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 6-68 IN COMPLEX WITH ILK, AND
RP   MUTAGENESIS OF PHE-42; HIS-61; ASP-62 AND LEU-66.
RX   PubMed=19074270; DOI=10.1073/pnas.0811415106;
RA   Chiswell B.P., Zhang R., Murphy J.W., Boggon T.J., Calderwood D.A.;
RT   "The structural basis of integrin-linked kinase-PINCH interactions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:20677-20682(2008).
RN   [15]
RP   STRUCTURE BY NMR OF 1-70 IN COMPLEX WITH ILK, MUTAGENESIS OF PHE-42 AND
RP   ARG-56, AND SUBCELLULAR LOCATION.
RX   PubMed=19117955; DOI=10.1074/jbc.m805319200;
RA   Yang Y., Wang X., Hawkins C.A., Chen K., Vaynberg J., Mao X., Tu Y.,
RA   Zuo X., Wang J., Wang Y.-X., Wu C., Tjandra N., Qin J.;
RT   "Structural basis of focal adhesion localization of LIM-only adaptor PINCH
RT   by integrin-linked kinase.";
RL   J. Biol. Chem. 284:5836-5844(2009).
CC   -!- FUNCTION: Adapter protein in a cytoplasmic complex linking beta-
CC       integrins to the actin cytoskeleton, bridges the complex to cell
CC       surface receptor tyrosine kinases and growth factor receptors. Involved
CC       in the regulation of cell survival, cell proliferation and cell
CC       differentiation.
CC   -!- SUBUNIT: Interacts (via LIM zinc-binding 5) with TGFB1I1 (By
CC       similarity). Interacts with integrin-linked protein kinase 1 (ILK) via
CC       the first LIM domain, and in competition with LIMS2. Part of the
CC       heterotrimeric IPP complex composed of integrin-linked kinase (ILK),
CC       LIMS1 or LIMS2, and PARVA. Interacts with SH3/SH2 adapter NCK2, thereby
CC       linking the complex to cell surface receptors. {ECO:0000250,
CC       ECO:0000269|PubMed:10022929, ECO:0000269|PubMed:19074270,
CC       ECO:0000269|PubMed:19117955, ECO:0000269|PubMed:9843575}.
CC   -!- INTERACTION:
CC       P48059; Q13418: ILK; NbExp=13; IntAct=EBI-306928, EBI-747644;
CC       P48059; O43639: NCK2; NbExp=2; IntAct=EBI-306928, EBI-713635;
CC       P48059; Q15404: RSU1; NbExp=6; IntAct=EBI-306928, EBI-1057132;
CC       P48059; P09022: Hoxa1; Xeno; NbExp=3; IntAct=EBI-306928, EBI-3957603;
CC       P48059; O55222: Ilk; Xeno; NbExp=4; IntAct=EBI-306928, EBI-6690138;
CC       P48059-3; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-12864460, EBI-744545;
CC       P48059-3; P27658: COL8A1; NbExp=3; IntAct=EBI-12864460, EBI-747133;
CC       P48059-3; Q2TBE0: CWF19L2; NbExp=3; IntAct=EBI-12864460, EBI-5453285;
CC       P48059-3; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-12864460, EBI-6658203;
CC       P48059-3; P55040: GEM; NbExp=3; IntAct=EBI-12864460, EBI-744104;
CC       P48059-3; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-12864460, EBI-14103818;
CC       P48059-3; Q13418: ILK; NbExp=3; IntAct=EBI-12864460, EBI-747644;
CC       P48059-3; Q9C086: INO80B; NbExp=3; IntAct=EBI-12864460, EBI-715611;
CC       P48059-3; Q5T749: KPRP; NbExp=3; IntAct=EBI-12864460, EBI-10981970;
CC       P48059-3; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-12864460, EBI-11742507;
CC       P48059-3; O75771: RAD51D; NbExp=3; IntAct=EBI-12864460, EBI-1055693;
CC       P48059-3; Q9BWG6: SCNM1; NbExp=3; IntAct=EBI-12864460, EBI-748391;
CC       P48059-3; Q9NU19: TBC1D22B; NbExp=3; IntAct=EBI-12864460, EBI-8787464;
CC       P48059-3; Q15560: TCEA2; NbExp=3; IntAct=EBI-12864460, EBI-710310;
CC       P48059-3; Q9NZV7: ZIM2; NbExp=3; IntAct=EBI-12864460, EBI-11962760;
CC       P48059-3; Q86VK4-3: ZNF410; NbExp=3; IntAct=EBI-12864460, EBI-11741890;
CC       P48059-3; Q8TAU3: ZNF417; NbExp=3; IntAct=EBI-12864460, EBI-740727;
CC       P48059-3; Q8TBZ8: ZNF564; NbExp=3; IntAct=EBI-12864460, EBI-10273713;
CC       P48059-3; Q96SQ5: ZNF587; NbExp=3; IntAct=EBI-12864460, EBI-6427977;
CC   -!- SUBCELLULAR LOCATION: Cell junction, focal adhesion. Cell membrane;
CC       Peripheral membrane protein; Cytoplasmic side.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P48059-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48059-2; Sequence=VSP_042672;
CC       Name=3;
CC         IsoId=P48059-3; Sequence=VSP_043210;
CC       Name=4;
CC         IsoId=P48059-4; Sequence=VSP_043211;
CC       Name=5;
CC         IsoId=P48059-5; Sequence=VSP_043212;
CC   -!- TISSUE SPECIFICITY: Expressed in most tissues except in the brain.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U09284; AAA20086.2; -; mRNA.
DR   EMBL; AK296992; BAH12469.1; -; mRNA.
DR   EMBL; AK302411; BAH13699.1; -; mRNA.
DR   EMBL; AK304260; BAH14143.1; -; mRNA.
DR   EMBL; AK314217; BAG36891.1; -; mRNA.
DR   EMBL; AC010095; AAY14983.1; -; Genomic_DNA.
DR   EMBL; AC012487; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC005341; AAH05341.1; -; mRNA.
DR   CCDS; CCDS2078.1; -. [P48059-1]
DR   CCDS; CCDS54382.1; -. [P48059-2]
DR   CCDS; CCDS54383.1; -. [P48059-4]
DR   CCDS; CCDS54384.1; -. [P48059-5]
DR   CCDS; CCDS54385.1; -. [P48059-3]
DR   PIR; JC2324; JC2324.
DR   RefSeq; NP_001180411.1; NM_001193482.1. [P48059-4]
DR   RefSeq; NP_001180412.1; NM_001193483.2. [P48059-2]
DR   RefSeq; NP_001180413.1; NM_001193484.1. [P48059-5]
DR   RefSeq; NP_001180414.1; NM_001193485.2. [P48059-3]
DR   RefSeq; NP_001180417.1; NM_001193488.1. [P48059-1]
DR   RefSeq; NP_004978.2; NM_004987.5. [P48059-1]
DR   PDB; 1G47; NMR; -; A=1-70.
DR   PDB; 1NYP; NMR; -; A=188-251.
DR   PDB; 1U5S; NMR; -; B=188-251.
DR   PDB; 2COR; NMR; -; A=125-190.
DR   PDB; 2D8X; NMR; -; A=71-127.
DR   PDB; 2KBX; NMR; -; B=1-70.
DR   PDB; 3F6Q; X-ray; 1.60 A; B=6-68.
DR   PDB; 4HI8; X-ray; 1.20 A; B=6-68.
DR   PDB; 4HI9; X-ray; 1.20 A; B=6-68.
DR   PDB; 6MIF; NMR; -; A=249-325.
DR   PDB; 7D2S; X-ray; 1.65 A; B=249-325.
DR   PDB; 7D2T; X-ray; 2.20 A; B/D=188-325.
DR   PDB; 7D2U; X-ray; 3.15 A; B=188-325.
DR   PDB; 7LT9; X-ray; 3.05 A; B=189-325.
DR   PDBsum; 1G47; -.
DR   PDBsum; 1NYP; -.
DR   PDBsum; 1U5S; -.
DR   PDBsum; 2COR; -.
DR   PDBsum; 2D8X; -.
DR   PDBsum; 2KBX; -.
DR   PDBsum; 3F6Q; -.
DR   PDBsum; 4HI8; -.
DR   PDBsum; 4HI9; -.
DR   PDBsum; 6MIF; -.
DR   PDBsum; 7D2S; -.
DR   PDBsum; 7D2T; -.
DR   PDBsum; 7D2U; -.
DR   PDBsum; 7LT9; -.
DR   SMR; P48059; -.
DR   BioGRID; 110175; 81.
DR   CORUM; P48059; -.
DR   DIP; DIP-40671N; -.
DR   IntAct; P48059; 66.
DR   MINT; P48059; -.
DR   STRING; 9606.ENSP00000446121; -.
DR   iPTMnet; P48059; -.
DR   PhosphoSitePlus; P48059; -.
DR   SwissPalm; P48059; -.
DR   BioMuta; LIMS1; -.
DR   DMDM; 18266876; -.
DR   OGP; P48059; -.
DR   EPD; P48059; -.
DR   jPOST; P48059; -.
DR   MassIVE; P48059; -.
DR   MaxQB; P48059; -.
DR   PaxDb; P48059; -.
DR   PeptideAtlas; P48059; -.
DR   PRIDE; P48059; -.
DR   ProteomicsDB; 55846; -. [P48059-1]
DR   ProteomicsDB; 55847; -. [P48059-2]
DR   ProteomicsDB; 55848; -. [P48059-3]
DR   ProteomicsDB; 55849; -. [P48059-4]
DR   ProteomicsDB; 55850; -. [P48059-5]
DR   Antibodypedia; 33091; 288 antibodies from 33 providers.
DR   DNASU; 3987; -.
DR   Ensembl; ENST00000332345; ENSP00000331775; ENSG00000169756.
DR   Ensembl; ENST00000338045; ENSP00000337598; ENSG00000169756. [P48059-3]
DR   Ensembl; ENST00000393310; ENSP00000376987; ENSG00000169756.
DR   Ensembl; ENST00000409441; ENSP00000387264; ENSG00000169756. [P48059-5]
DR   Ensembl; ENST00000410093; ENSP00000386926; ENSG00000169756. [P48059-4]
DR   Ensembl; ENST00000544547; ENSP00000437912; ENSG00000169756. [P48059-2]
DR   GeneID; 3987; -.
DR   KEGG; hsa:3987; -.
DR   UCSC; uc002teg.4; human. [P48059-1]
DR   CTD; 3987; -.
DR   DisGeNET; 3987; -.
DR   GeneCards; LIMS1; -.
DR   HGNC; HGNC:6616; LIMS1.
DR   HPA; ENSG00000169756; Low tissue specificity.
DR   MIM; 602567; gene.
DR   neXtProt; NX_P48059; -.
DR   OpenTargets; ENSG00000169756; -.
DR   PharmGKB; PA30389; -.
DR   VEuPathDB; HostDB:ENSG00000169756; -.
DR   eggNOG; KOG2272; Eukaryota.
DR   GeneTree; ENSGT00940000153518; -.
DR   HOGENOM; CLU_001357_0_0_1; -.
DR   InParanoid; P48059; -.
DR   OMA; PFPDGIY; -.
DR   OrthoDB; 1593918at2759; -.
DR   PhylomeDB; P48059; -.
DR   TreeFam; TF314113; -.
DR   PathwayCommons; P48059; -.
DR   Reactome; R-HSA-446353; Cell-extracellular matrix interactions.
DR   Reactome; R-HSA-446388; Regulation of cytoskeletal remodeling and cell spreading by IPP complex components.
DR   SignaLink; P48059; -.
DR   SIGNOR; P48059; -.
DR   BioGRID-ORCS; 3987; 227 hits in 1042 CRISPR screens.
DR   ChiTaRS; LIMS1; human.
DR   EvolutionaryTrace; P48059; -.
DR   GeneWiki; LIMS1; -.
DR   GenomeRNAi; 3987; -.
DR   Pharos; P48059; Tbio.
DR   PRO; PR:P48059; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P48059; protein.
DR   Bgee; ENSG00000169756; Expressed in endometrium and 222 other tissues.
DR   ExpressionAtlas; P48059; baseline and differential.
DR   Genevisible; P48059; HS.
DR   GO; GO:0005911; C:cell-cell junction; IMP:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007569; P:cell aging; TAS:ProtInc.
DR   GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central.
DR   GO; GO:0045216; P:cell-cell junction organization; IBA:GO_Central.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB.
DR   GO; GO:0045184; P:establishment of protein localization; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IMP:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:2001046; P:positive regulation of integrin-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:CAFA.
DR   InterPro; IPR017351; PINCH_1-like.
DR   InterPro; IPR001781; Znf_LIM.
DR   PANTHER; PTHR24210; PTHR24210; 1.
DR   Pfam; PF00412; LIM; 5.
DR   PIRSF; PIRSF038003; PINCH; 1.
DR   SMART; SM00132; LIM; 5.
DR   PROSITE; PS00478; LIM_DOMAIN_1; 4.
DR   PROSITE; PS50023; LIM_DOMAIN_2; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell junction;
KW   Cell membrane; Direct protein sequencing; LIM domain; Membrane;
KW   Metal-binding; Reference proteome; Repeat; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   CHAIN           2..325
FT                   /note="LIM and senescent cell antigen-like-containing
FT                   domain protein 1"
FT                   /id="PRO_0000075888"
FT   DOMAIN          10..62
FT                   /note="LIM zinc-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          71..121
FT                   /note="LIM zinc-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          135..184
FT                   /note="LIM zinc-binding 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          193..243
FT                   /note="LIM zinc-binding 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          252..303
FT                   /note="LIM zinc-binding 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   VAR_SEQ         1
FT                   /note="M -> MLGVAAGMTHSNM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042672"
FT   VAR_SEQ         1
FT                   /note="M -> MAFSGRARPCIIPENEEIPRAALNTVHEANGTEDERAVSKLQRRHSD
FT                   VKVYKEFCDFYAKFNM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043210"
FT   VAR_SEQ         1
FT                   /note="M -> MTCNM (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_043211"
FT   VAR_SEQ         1
FT                   /note="M -> MTALQLKELSHSGLYRRRRDRPDSLRVNGLPEEELSNM (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043212"
FT   MUTAGEN         42
FT                   /note="F->A: Loss of interaction with ILK and loss of
FT                   localization to focal adhesion."
FT                   /evidence="ECO:0000269|PubMed:19074270,
FT                   ECO:0000269|PubMed:19117955"
FT   MUTAGEN         56
FT                   /note="R->A: Alters interaction with ILK."
FT                   /evidence="ECO:0000269|PubMed:19117955"
FT   MUTAGEN         61
FT                   /note="H->D: Alters interaction with ILK."
FT                   /evidence="ECO:0000269|PubMed:19074270"
FT   MUTAGEN         62
FT                   /note="D->A: Alters interaction with ILK."
FT                   /evidence="ECO:0000269|PubMed:19074270"
FT   MUTAGEN         66
FT                   /note="L->D: Alters interaction with ILK."
FT                   /evidence="ECO:0000269|PubMed:19074270"
FT   CONFLICT        78
FT                   /note="I -> T (in Ref. 5; AAH05341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        262
FT                   /note="D -> G (in Ref. 5; AAH05341)"
FT                   /evidence="ECO:0000305"
FT   TURN            11..13
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   STRAND          22..26
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   STRAND          29..32
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   TURN            33..35
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   TURN            39..41
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   HELIX           46..48
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   STRAND          51..53
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   STRAND          56..58
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   HELIX           60..66
FT                   /evidence="ECO:0007829|PDB:4HI8"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          83..85
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   TURN            92..94
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          98..100
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          110..112
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   STRAND          115..117
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   HELIX           119..126
FT                   /evidence="ECO:0007829|PDB:2D8X"
FT   TURN            136..138
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   TURN            156..158
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   STRAND          173..175
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   STRAND          178..180
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   HELIX           182..186
FT                   /evidence="ECO:0007829|PDB:2COR"
FT   TURN            194..197
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   STRAND          210..213
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   TURN            214..216
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   TURN            220..222
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:1NYP"
FT   HELIX           241..247
FT                   /evidence="ECO:0007829|PDB:1NYP"
SQ   SEQUENCE   325 AA;  37251 MW;  E665FEB11D849CAE CRC64;
     MANALASATC ERCKGGFAPA EKIVNSNGEL YHEQCFVCAQ CFQQFPEGLF YEFEGRKYCE
     HDFQMLFAPC CHQCGEFIIG RVIKAMNNSW HPECFRCDLC QEVLADIGFV KNAGRHLCRP
     CHNREKARGL GKYICQKCHA IIDEQPLIFK NDPYHPDHFN CANCGKELTA DARELKGELY
     CLPCHDKMGV PICGACRRPI EGRVVNAMGK QWHVEHFVCA KCEKPFLGHR HYERKGLAYC
     ETHYNQLFGD VCFHCNRVIE GDVVSALNKA WCVNCFACST CNTKLTLKNK FVEFDMKPVC
     KKCYEKFPLE LKKRLKKLAE TLGRK
//
ID   UBP14_HUMAN             Reviewed;         494 AA.
AC   P54578; B7Z4N8; J3QRZ5; Q53XY5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   23-FEB-2022, entry version 205.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 14;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 14;
DE   AltName: Full=Ubiquitin thioesterase 14;
DE   AltName: Full=Ubiquitin-specific-processing protease 14;
GN   Name=USP14; Synonyms=TGT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RA   Deshpande K.L., Katze J.R.;
RT   "tRNA-guanine transglycosylase cDNA from human placenta.";
RL   Submitted (AUG-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D.,
RA   Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J.,
RA   Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L.,
RA   Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A.,
RA   Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C.,
RA   Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-308 (ISOFORM 2).
RC   TISSUE=T-cell;
RA   Heil O., Ebert L., Hennig S., Henze S., Radelof U., Schneider D., Korn B.;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   INTERACTION WITH FANCC.
RX   PubMed=14499622; DOI=10.1016/s0014-4827(03)00261-1;
RA   Reuter T.Y., Medhurst A.L., Waisfisz Q., Zhi Y., Herterich S., Hoehn H.,
RA   Gross H.J., Joenje H., Hoatlin M.E., Mathew C.G., Huber P.A.;
RT   "Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in
RT   transcription regulation, cell signaling, oxidative metabolism, and
RT   cellular transport.";
RL   Exp. Cell Res. 289:211-221(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [9]
RP   ASSOCIATION WITH THE 26S PROTEASOME, AND FUNCTION.
RX   PubMed=18162577; DOI=10.1091/mbc.e07-10-1040;
RA   Koulich E., Li X., DeMartino G.N.;
RT   "Relative structural and functional roles of multiple deubiquitylating
RT   proteins associated with mammalian 26S proteasome.";
RL   Mol. Biol. Cell 19:1072-1082(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH ERN1.
RX   PubMed=19135427; DOI=10.1016/j.bbrc.2008.12.182;
RA   Nagai A., Kadowaki H., Maruyama T., Takeda K., Nishitoh H., Ichijo H.;
RT   "USP14 inhibits ER-associated degradation via interaction with IRE1alpha.";
RL   Biochem. Biophys. Res. Commun. 379:995-1000(2009).
RN   [12]
RP   INTERACTION WITH CXCR4, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19106094; DOI=10.1074/jbc.m808507200;
RA   Mines M.A., Goodwin J.S., Limbird L.E., Cui F.F., Fan G.H.;
RT   "Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced
RT   CXCR4 degradation and chemotaxis but not ERK activation.";
RL   J. Biol. Chem. 284:5742-5752(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-449, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143 AND THR-235, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-52; SER-143; SER-237; SER-302
RP   AND SER-432, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-143 AND THR-235, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH TRIM14.
RX   PubMed=27666593; DOI=10.1016/j.molcel.2016.08.025;
RA   Chen M., Meng Q., Qin Y., Liang P., Tan P., He L., Zhou Y., Chen Y.,
RA   Huang J., Wang R.F., Cui J.;
RT   "TRIM14 inhibits cGAS degradation mediated by selective autophagy receptor
RT   p62 to promote innate immune responses.";
RL   Mol. Cell 64:105-119(2016).
RN   [21]
RP   FUNCTION.
RX   PubMed=28396413; DOI=10.1073/pnas.1701734114;
RA   Kuo C.L., Goldberg A.L.;
RT   "Ubiquitinated proteins promote the association of proteasomes with the
RT   deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E3404-E3413(2017).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 91-494, CATALYTIC ACTIVITY, AND
RP   ACTIVE SITE.
RX   PubMed=16211010; DOI=10.1038/sj.emboj.7600832;
RA   Hu M., Li P., Song L., Jeffrey P.D., Chenova T.A., Wilkinson K.D.,
RA   Cohen R.E., Shi Y.;
RT   "Structure and mechanisms of the proteasome-associated deubiquitinating
RT   enzyme USP14.";
RL   EMBO J. 24:3747-3756(2005).
CC   -!- FUNCTION: Proteasome-associated deubiquitinase which releases ubiquitin
CC       from the proteasome targeted ubiquitinated proteins. Ensures the
CC       regeneration of ubiquitin at the proteasome (PubMed:18162577,
CC       PubMed:28396413). Is a reversibly associated subunit of the proteasome
CC       and a large fraction of proteasome-free protein exists within the cell
CC       (PubMed:18162577). Required for the degradation of the chemokine
CC       receptor CXCR4 which is critical for CXCL12-induced cell chemotaxis
CC       (PubMed:19106094). Serves also as a physiological inhibitor of
CC       endoplasmic reticulum-associated degradation (ERAD) under the non-
CC       stressed condition by inhibiting the degradation of unfolded
CC       endoplasmic reticulum proteins via interaction with ERN1
CC       (PubMed:19135427). Indispensable for synaptic development and function
CC       at neuromuscular junctions (NMJs) (By similarity). Plays a role in the
CC       innate immune defense against viruses by stabilizing the viral DNA
CC       sensor CGAS and thus inhibiting its autophagic degradation
CC       (PubMed:27666593). {ECO:0000250|UniProtKB:Q9JMA1,
CC       ECO:0000269|PubMed:18162577, ECO:0000269|PubMed:19106094,
CC       ECO:0000269|PubMed:19135427, ECO:0000269|PubMed:27666593,
CC       ECO:0000269|PubMed:28396413}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:16211010};
CC   -!- SUBUNIT: Homodimer (Potential). Associates with the 26S proteasome.
CC       Interacts with FANCC, CXCR4 and ERN1. Interacts with TRIM14; this
CC       interaction recruits USP14 to cleave ubiquitin chains of CGAS.
CC       {ECO:0000269|PubMed:14499622, ECO:0000269|PubMed:19106094,
CC       ECO:0000269|PubMed:19135427, ECO:0000269|PubMed:27666593, ECO:0000305}.
CC   -!- INTERACTION:
CC       P54578; Q08209: PPP3CA; NbExp=3; IntAct=EBI-1048016, EBI-352922;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19106094}. Cell
CC       membrane {ECO:0000269|PubMed:19106094}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:19106094}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P54578-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54578-2; Sequence=VSP_047343;
CC       Name=3;
CC         IsoId=P54578-3; Sequence=VSP_057292;
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. USP14/UBP6 subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be a guanine tRNA-
CC       ribosyltransferase. {ECO:0000305, ECO:0000305|Ref.1}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CR976282; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U30888; AAB60365.1; -; mRNA.
DR   EMBL; BT007183; AAP35847.1; -; mRNA.
DR   EMBL; AK297605; BAH12624.1; -; mRNA.
DR   EMBL; AP000845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC003556; AAH03556.1; -; mRNA.
DR   EMBL; CR976282; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS32780.1; -. [P54578-1]
DR   CCDS; CCDS32781.1; -. [P54578-2]
DR   PIR; G01932; G01932.
DR   RefSeq; NP_001032411.1; NM_001037334.1. [P54578-2]
DR   RefSeq; NP_005142.1; NM_005151.3. [P54578-1]
DR   PDB; 2AYN; X-ray; 3.20 A; A/B/C=91-494.
DR   PDB; 2AYO; X-ray; 3.50 A; A=91-494.
DR   PDB; 5GJQ; EM; 4.50 A; x=1-494.
DR   PDB; 6IIK; X-ray; 1.97 A; A/B=96-494.
DR   PDB; 6IIL; X-ray; 2.20 A; A/B=96-494.
DR   PDB; 6IIM; X-ray; 2.21 A; A/B=96-494.
DR   PDB; 6IIN; X-ray; 2.53 A; A/B=101-485.
DR   PDB; 6LVS; X-ray; 2.73 A; A/B/C/D/E/F=92-494.
DR   PDBsum; 2AYN; -.
DR   PDBsum; 2AYO; -.
DR   PDBsum; 5GJQ; -.
DR   PDBsum; 6IIK; -.
DR   PDBsum; 6IIL; -.
DR   PDBsum; 6IIM; -.
DR   PDBsum; 6IIN; -.
DR   PDBsum; 6LVS; -.
DR   BMRB; P54578; -.
DR   SMR; P54578; -.
DR   BioGRID; 114551; 431.
DR   IntAct; P54578; 49.
DR   MINT; P54578; -.
DR   STRING; 9606.ENSP00000261601; -.
DR   BindingDB; P54578; -.
DR   ChEMBL; CHEMBL1293295; -.
DR   DrugBank; DB12695; Phenethyl Isothiocyanate.
DR   GuidetoPHARMACOLOGY; 2429; -.
DR   MEROPS; C19.015; -.
DR   GlyGen; P54578; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P54578; -.
DR   MetOSite; P54578; -.
DR   PhosphoSitePlus; P54578; -.
DR   SwissPalm; P54578; -.
DR   BioMuta; USP14; -.
DR   DMDM; 1729927; -.
DR   OGP; P54578; -.
DR   EPD; P54578; -.
DR   jPOST; P54578; -.
DR   MassIVE; P54578; -.
DR   MaxQB; P54578; -.
DR   PaxDb; P54578; -.
DR   PeptideAtlas; P54578; -.
DR   PRIDE; P54578; -.
DR   ProteomicsDB; 56687; -. [P54578-1]
DR   ProteomicsDB; 6620; -.
DR   Antibodypedia; 676; 313 antibodies from 35 providers.
DR   DNASU; 9097; -.
DR   Ensembl; ENST00000261601; ENSP00000261601; ENSG00000101557.
DR   Ensembl; ENST00000400266; ENSP00000383125; ENSG00000101557. [P54578-3]
DR   Ensembl; ENST00000582707; ENSP00000464447; ENSG00000101557. [P54578-2]
DR   GeneID; 9097; -.
DR   KEGG; hsa:9097; -.
DR   MANE-Select; ENST00000261601.8; ENSP00000261601.6; NM_005151.4; NP_005142.1.
DR   UCSC; uc002kkf.2; human. [P54578-1]
DR   CTD; 9097; -.
DR   DisGeNET; 9097; -.
DR   GeneCards; USP14; -.
DR   HGNC; HGNC:12612; USP14.
DR   HPA; ENSG00000101557; Low tissue specificity.
DR   MIM; 607274; gene.
DR   neXtProt; NX_P54578; -.
DR   OpenTargets; ENSG00000101557; -.
DR   PharmGKB; PA37238; -.
DR   VEuPathDB; HostDB:ENSG00000101557; -.
DR   eggNOG; KOG1872; Eukaryota.
DR   GeneTree; ENSGT00390000009615; -.
DR   InParanoid; P54578; -.
DR   OMA; MCKGGIL; -.
DR   OrthoDB; 600543at2759; -.
DR   PhylomeDB; P54578; -.
DR   TreeFam; TF314494; -.
DR   PathwayCommons; P54578; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; P54578; -.
DR   SIGNOR; P54578; -.
DR   BioGRID-ORCS; 9097; 94 hits in 1053 CRISPR screens.
DR   ChiTaRS; USP14; human.
DR   EvolutionaryTrace; P54578; -.
DR   GeneWiki; USP14; -.
DR   GenomeRNAi; 9097; -.
DR   Pharos; P54578; Tchem.
DR   PRO; PR:P54578; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; P54578; protein.
DR   Bgee; ENSG00000101557; Expressed in secondary oocyte and 259 other tissues.
DR   ExpressionAtlas; P54578; baseline and differential.
DR   Genevisible; P54578; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0000502; C:proteasome complex; IEA:UniProtKB-KW.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IMP:UniProtKB.
DR   GO; GO:0070628; F:proteasome binding; IDA:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent deubiquitinase; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:1903070; P:negative regulation of ER-associated ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:FlyBase.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IMP:UniProtKB.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR000626; Ubiquitin-like_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   InterPro; IPR019954; Ubiquitin_CS.
DR   InterPro; IPR044635; UBP14-like.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   PANTHER; PTHR43982; PTHR43982; 1.
DR   Pfam; PF00443; UCH; 1.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS00299; UBIQUITIN_1; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane; Cytoplasm;
KW   Hydrolase; Immunity; Innate immunity; Membrane; Phosphoprotein; Protease;
KW   Proteasome; Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..494
FT                   /note="Ubiquitin carboxyl-terminal hydrolase 14"
FT                   /id="PRO_0000080636"
FT   DOMAIN          4..80
FT                   /note="Ubiquitin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00214"
FT   DOMAIN          105..483
FT                   /note="USP"
FT   ACT_SITE        114
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000305|PubMed:16211010"
FT   ACT_SITE        435
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   MOD_RES         52
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19367720,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JMA1"
FT   MOD_RES         235
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         237
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         302
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         432
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         449
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   VAR_SEQ         55..65
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_057292"
FT   VAR_SEQ         66..100
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_047343"
FT   STRAND          110..112
FT                   /evidence="ECO:0007829|PDB:6IIL"
FT   HELIX           114..124
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           127..135
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          142..144
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   HELIX           147..165
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          167..170
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           173..182
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           184..187
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          191..193
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   HELIX           200..214
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           242..247
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          249..259
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          261..263
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          266..273
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          275..278
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:2AYN"
FT   HELIX           286..293
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          295..302
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   TURN            303..306
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          307..319
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          321..329
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          331..334
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   TURN            335..338
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   STRAND          339..342
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   STRAND          351..354
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           356..358
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           361..376
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          404..406
FT                   /evidence="ECO:0007829|PDB:6LVS"
FT   TURN            409..412
FT                   /evidence="ECO:0007829|PDB:2AYN"
FT   STRAND          414..429
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          435..443
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          446..451
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          454..458
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           460..464
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   HELIX           465..467
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          469..472
FT                   /evidence="ECO:0007829|PDB:6IIK"
FT   STRAND          474..482
FT                   /evidence="ECO:0007829|PDB:6IIK"
SQ   SEQUENCE   494 AA;  56069 MW;  E6D4679A86E9DF00 CRC64;
     MPLYSVTVKW GKEKFEGVEL NTDEPPMVFK AQLFALTGVQ PARQKVMVKG GTLKDDDWGN
     IKIKNGMTLL MMGSADALPE EPSAKTVFVE DMTEEQLASA MELPCGLTNL GNTCYMNATV
     QCIRSVPELK DALKRYAGAL RASGEMASAQ YITAALRDLF DSMDKTSSSI PPIILLQFLH
     MAFPQFAEKG EQGQYLQQDA NECWIQMMRV LQQKLEAIED DSVKETDSSS ASAATPSKKK
     SLIDQFFGVE FETTMKCTES EEEEVTKGKE NQLQLSCFIN QEVKYLFTGL KLRLQEEITK
     QSPTLQRNAL YIKSSKISRL PAYLTIQMVR FFYKEKESVN AKVLKDVKFP LMLDMYELCT
     PELQEKMVSF RSKFKDLEDK KVNQQPNTSD KKSSPQKEVK YEPFSFADDI GSNNCGYYDL
     QAVLTHQGRS SSSGHYVSWV KRKQDEWIKF DDDKVSIVTP EDILRLSGGG DWHIAYVLLY
     GPRRVEIMEE ESEQ
//
ID   LPP_HUMAN               Reviewed;         612 AA.
AC   Q93052; A1L4L6; D3DNV6; Q8NFX5;
DT   22-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   23-FEB-2022, entry version 181.
DE   RecName: Full=Lipoma-preferred partner;
DE   AltName: Full=LIM domain-containing preferred translocation partner in lipoma;
GN   Name=LPP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], CHROMOSOMAL TRANSLOCATION WITH
RP   HMGA2, AND TISSUE SPECIFICITY.
RC   TISSUE=Small intestine;
RX   PubMed=8812423; DOI=10.1006/geno.1996.0432;
RA   Petit M.M.R., Mols R., Schoenmakers E.F., Mandahl N., Van de Ven W.J.M.;
RT   "LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel
RT   member of the LIM protein gene family.";
RL   Genomics 36:118-129(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 276-371.
RX   PubMed=12063392; DOI=10.1159/000059338;
RA   Lemke I., Rogalla P., Bullerdiek J.;
RT   "A novel LPP fusion gene indicates the crucial role of truncated LPP
RT   proteins in lipomas and pulmonary chondroid hamartomas.";
RL   Cytogenet. Cell Genet. 95:153-156(2001).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH HMGA2.
RX   PubMed=9772904; DOI=10.1016/s0165-4608(98)00038-7;
RA   Petit M.M., Swarts S., Bridge J.A., Van de Ven W.J.M.;
RT   "Expression of reciprocal fusion transcripts of the HMGIC and LPP genes in
RT   parosteal lipoma.";
RL   Cancer Genet. Cytogenet. 106:18-23(1998).
RN   [7]
RP   CHROMOSOMAL TRANSLOCATION WITH HMGA2.
RX   PubMed=11066083;
RX   DOI=10.1002/1098-2264(2000)9999:9999<1::aid-gcc1043>3.0.co;2-n;
RA   Rogalla P., Lemke I., Kazmierczak B., Bullerdiek J.;
RT   "An identical HMGIC-LPP fusion transcript is consistently expressed in
RT   pulmonary chondroid hamartomas with t(3;12)(q27-28;q14-15).";
RL   Genes Chromosomes Cancer 29:363-366(2000).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH
RP   VASP.
RX   PubMed=10637295; DOI=10.1091/mbc.11.1.117;
RA   Petit M.M., Fradelizi J., Golsteyn R.M., Ayoubi T.A., Menichi B.,
RA   Louvard D., Van de Ven W.J.M., Friederich E.;
RT   "LPP, an actin cytoskeleton protein related to zyxin, harbors a nuclear
RT   export signal and transcriptional activation capacity.";
RL   Mol. Biol. Cell 11:117-129(2000).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH KMT2A/MLL1.
RX   PubMed=11433529; DOI=10.1002/gcc.1157;
RA   Daheron L., Veinstein A., Brizard F., Drabkin H., Lacotte L., Guilhot F.,
RA   Larsen C.J., Brizard A., Roche J.;
RT   "Human LPP gene is fused to MLL in a secondary acute leukemia with a
RT   t(3;11) (q28;q23).";
RL   Genes Chromosomes Cancer 31:382-389(2001).
RN   [10]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH VASP AND ACTN1.
RX   PubMed=12441356; DOI=10.1074/jbc.m206106200;
RA   Petit M.M., Meulemans S.M., Van de Ven W.J.M.;
RT   "The focal adhesion and nuclear targeting capacity of the LIM-containing
RT   lipoma-preferred partner (LPP) protein.";
RL   J. Biol. Chem. 278:2157-2168(2003).
RN   [11]
RP   INTERACTION WITH ACTN1.
RX   PubMed=12615977; DOI=10.1242/jcs.00309;
RA   Li B., Zhuang L., Reinhard M., Trueb B.;
RT   "The lipoma preferred partner LPP interacts with alpha-actinin.";
RL   J. Cell Sci. 116:1359-1366(2003).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C.,
RA   Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using mass
RT   spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [14]
RP   INTERACTION WITH SCRIB, AND MUTAGENESIS.
RX   PubMed=15649318; DOI=10.1186/1471-2121-6-1;
RA   Petit M.M.R., Meulemans S.M.P., Alen P., Ayoubi T.A.Y., Jansen E.,
RA   Van de Ven W.J.M.;
RT   "The tumor suppressor Scrib interacts with the zyxin-related protein LPP,
RT   which shuttles between cell adhesion sites and the nucleus.";
RL   BMC Cell Biol. 6:1-1(2005).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-327, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
CC   -!- FUNCTION: May play a structural role at sites of cell adhesion in
CC       maintaining cell shape and motility. In addition to these structural
CC       functions, it may also be implicated in signaling events and activation
CC       of gene transcription. May be involved in signal transduction from cell
CC       adhesion sites to the nucleus allowing successful integration of
CC       signals arising from soluble factors and cell-cell adhesion sites. Also
CC       suggested to serve as a scaffold protein upon which distinct protein
CC       complexes are assembled in the cytoplasm and in the nucleus.
CC       {ECO:0000269|PubMed:10637295}.
CC   -!- SUBUNIT: Interacts with VASP, with PDZ domains of SCRIB and with
CC       ACTN1/alpha-actinin. {ECO:0000269|PubMed:10637295,
CC       ECO:0000269|PubMed:12441356, ECO:0000269|PubMed:12615977,
CC       ECO:0000269|PubMed:15649318}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cell junction. Cell membrane.
CC       Note=Found in the nucleus, in the cytoplasm and at cell adhesion sites.
CC       Shuttles between the cytoplasm and the nucleus. It has been found in
CC       sites of cell adhesion such as cell-to-cell contact and focal adhesion
CC       which are membrane attachment sites of cells to the extracellular
CC       matrix. Mainly nuclear when fused with HMGA2/HMGIC and KMT2A/MLL1.
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues but no or
CC       very low expression in brain and peripheral leukocytes.
CC       {ECO:0000269|PubMed:10637295, ECO:0000269|PubMed:8812423}.
CC   -!- DISEASE: Note=A chromosomal aberration involving LPP is associated with
CC       a subclass of benign mesenchymal tumors known as lipomas. Translocation
CC       t(3;12)(q27-q28;q13-q15) with HMGA2 is shown in lipomas.
CC   -!- DISEASE: Note=A chromosomal aberration involving LPP is associated with
CC       pulmonary chondroid hamartomas. Translocation t(3;12)(q27-q28;q14-q15)
CC       with HMGA2 is detected in pulmonary chondroid hamartomas.
CC   -!- DISEASE: Note=A chromosomal aberration involving LPP is associated with
CC       parosteal lipomas. Translocation t(3;12)(q28;q14) with HMGA2 is also
CC       shown in one parosteal lipoma.
CC   -!- DISEASE: Note=A chromosomal aberration involving LPP is associated with
CC       acute monoblastic leukemia. Translocation t(3;11)(q28;q23) with
CC       KMT2A/MLL1 is associated with acute monoblastic leukemia.
CC   -!- SIMILARITY: Belongs to the zyxin/ajuba family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LPPID72.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U49957; AAC50738.1; -; mRNA.
DR   EMBL; U49968; AAC50739.1; -; Genomic_DNA.
DR   EMBL; U49960; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49961; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49962; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49963; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49964; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49965; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49966; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; U49967; AAC50739.1; JOINED; Genomic_DNA.
DR   EMBL; CR457074; CAG33355.1; -; mRNA.
DR   EMBL; CH471052; EAW78127.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78128.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78133.1; -; Genomic_DNA.
DR   EMBL; BC130584; AAI30585.1; -; mRNA.
DR   EMBL; AF393503; AAM73685.1; ALT_TERM; mRNA.
DR   CCDS; CCDS3291.1; -.
DR   RefSeq; NP_001161143.1; NM_001167671.2.
DR   RefSeq; NP_005569.1; NM_005578.4.
DR   RefSeq; XP_005247503.1; XM_005247446.4.
DR   RefSeq; XP_005247507.1; XM_005247450.4.
DR   RefSeq; XP_005247508.1; XM_005247451.4.
DR   RefSeq; XP_005247510.1; XM_005247453.2.
DR   RefSeq; XP_011511122.1; XM_011512820.2.
DR   RefSeq; XP_011511129.1; XM_011512827.2.
DR   RefSeq; XP_011511130.1; XM_011512828.2.
DR   RefSeq; XP_011511133.1; XM_011512831.2.
DR   RefSeq; XP_011511135.1; XM_011512833.2.
DR   RefSeq; XP_011511136.1; XM_011512834.2.
DR   RefSeq; XP_016861866.1; XM_017006377.1.
DR   RefSeq; XP_016861867.1; XM_017006378.1.
DR   RefSeq; XP_016861868.1; XM_017006379.1.
DR   RefSeq; XP_016861869.1; XM_017006380.1.
DR   SMR; Q93052; -.
DR   BioGRID; 110208; 92.
DR   CORUM; Q93052; -.
DR   IntAct; Q93052; 23.
DR   MINT; Q93052; -.
DR   STRING; 9606.ENSP00000482472; -.
DR   GlyGen; Q93052; 11 sites, 2 O-linked glycans (11 sites).
DR   iPTMnet; Q93052; -.
DR   MetOSite; Q93052; -.
DR   PhosphoSitePlus; Q93052; -.
DR   BioMuta; LPP; -.
DR   DMDM; 74751663; -.
DR   EPD; Q93052; -.
DR   jPOST; Q93052; -.
DR   MassIVE; Q93052; -.
DR   MaxQB; Q93052; -.
DR   PaxDb; Q93052; -.
DR   PeptideAtlas; Q93052; -.
DR   PRIDE; Q93052; -.
DR   ProteomicsDB; 75690; -.
DR   Antibodypedia; 2772; 265 antibodies from 41 providers.
DR   DNASU; 4026; -.
DR   Ensembl; ENST00000617246; ENSP00000478901; ENSG00000145012.
DR   Ensembl; ENST00000640853; ENSP00000491657; ENSG00000145012.
DR   GeneID; 4026; -.
DR   KEGG; hsa:4026; -.
DR   MANE-Select; ENST00000617246.5; ENSP00000478901.1; NM_001375462.1; NP_001362391.1.
DR   UCSC; uc032sne.1; human.
DR   CTD; 4026; -.
DR   DisGeNET; 4026; -.
DR   GeneCards; LPP; -.
DR   HGNC; HGNC:6679; LPP.
DR   HPA; ENSG00000145012; Low tissue specificity.
DR   MalaCards; LPP; -.
DR   MIM; 600700; gene.
DR   neXtProt; NX_Q93052; -.
DR   OpenTargets; ENSG00000145012; -.
DR   PharmGKB; PA30440; -.
DR   VEuPathDB; HostDB:ENSG00000145012; -.
DR   eggNOG; KOG1701; Eukaryota.
DR   GeneTree; ENSGT00940000156022; -.
DR   InParanoid; Q93052; -.
DR   OMA; ACNSARI; -.
DR   PhylomeDB; Q93052; -.
DR   TreeFam; TF320310; -.
DR   PathwayCommons; Q93052; -.
DR   SignaLink; Q93052; -.
DR   SIGNOR; Q93052; -.
DR   BioGRID-ORCS; 4026; 7 hits in 1049 CRISPR screens.
DR   ChiTaRS; LPP; human.
DR   GeneWiki; LPP_(gene); -.
DR   GenomeRNAi; 4026; -.
DR   Pharos; Q93052; Tbio.
DR   PRO; PR:Q93052; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q93052; protein.
DR   Bgee; ENSG00000145012; Expressed in saphenous vein and 254 other tissues.
DR   ExpressionAtlas; Q93052; baseline and differential.
DR   Genevisible; Q93052; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001725; C:stress fiber; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central.
DR   InterPro; IPR028771; LPP.
DR   InterPro; IPR001781; Znf_LIM.
DR   PANTHER; PTHR24207:SF0; PTHR24207:SF0; 1.
DR   Pfam; PF00412; LIM; 3.
DR   SMART; SM00132; LIM; 3.
DR   PROSITE; PS00478; LIM_DOMAIN_1; 2.
DR   PROSITE; PS50023; LIM_DOMAIN_2; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Cell adhesion; Cell junction; Cell membrane;
KW   Chromosomal rearrangement; Cytoplasm; Isopeptide bond; LIM domain;
KW   Membrane; Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Ubl conjugation; Zinc.
FT   CHAIN           1..612
FT                   /note="Lipoma-preferred partner"
FT                   /id="PRO_0000075832"
FT   DOMAIN          414..473
FT                   /note="LIM zinc-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          474..534
FT                   /note="LIM zinc-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   DOMAIN          535..603
FT                   /note="LIM zinc-binding 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00125"
FT   REGION          1..118
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          132..219
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          307..387
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        26..42
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        64..78
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        138..156
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        185..202
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        204..219
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            371..372
FT                   /note="Breakpoint for translocation to form HMGA2-LPP"
FT   SITE            470..471
FT                   /note="Breakpoint for translocation to form HMGA2-LPP and
FT                   KMT2A/MLL1-LPP"
FT   MOD_RES         108
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BFW7"
FT   MOD_RES         116
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5XI07"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5XI07"
FT   MOD_RES         244
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BFW7"
FT   MOD_RES         301
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BFW7"
FT   MOD_RES         333
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CROSSLNK        327
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   VARIANT         146
FT                   /note="T -> A (in dbSNP:rs35417432)"
FT                   /id="VAR_050150"
FT   VARIANT         259
FT                   /note="S -> P (in dbSNP:rs35940579)"
FT                   /id="VAR_050151"
FT   VARIANT         346
FT                   /note="Y -> H (in dbSNP:rs7645635)"
FT                   /id="VAR_034070"
FT   MUTAGEN         610
FT                   /note="T->A: Abolishes binding to SCRIB."
FT                   /evidence="ECO:0000269|PubMed:15649318"
FT   MUTAGEN         612
FT                   /note="L->A: Abolishes binding to SCRIB."
FT                   /evidence="ECO:0000269|PubMed:15649318"
SQ   SEQUENCE   612 AA;  65746 MW;  439CE0101FDE4DDD CRC64;
     MSHPSWLPPK STGEPLGHVP ARMETTHSFG NPSISVSTQQ PPKKFAPVVA PKPKYNPYKQ
     PGGEGDFLPP PPPPLDDSSA LPSISGNFPP PPPLDEEAFK VQGNPGGKTL EERRSSLDAE
     IDSLTSILAD LECSSPYKPR PPQSSTGSTA SPPVSTPVTG HKRMVIPNQP PLTATKKSTL
     KPQPAPQAGP IPVAPIGTLK PQPQPVPASY TTASTSSRPT FNVQVKSAQP SPHYMAAPSS
     GQIYGSGPQG YNTQPVPVSG QCPPPSTRGG MDYAYIPPPG LQPEPGYGYA PNQGRYYEGY
     YAAGPGYGGR NDSDPTYGQQ GHPNTWKREP GYTPPGAGNQ NPPGMYPVTG PKKTYITDPV
     SAPCAPPLQP KGGHSGQLGP SSVAPSFRPE DELEHLTKKM LYDMENPPAD EYFGRCARCG
     ENVVGEGTGC TAMDQVFHVD CFTCIICNNK LRGQPFYAVE KKAYCEPCYI NTLEQCNVCS
     KPIMERILRA TGKAYHPHCF TCVMCHRSLD GIPFTVDAGG LIHCIEDFHK KFAPRCSVCK
     EPIMPAPGQE ETVRIVALDR DFHVHCYRCE DCGGLLSEGD NQGCYPLDGH ILCKTCNSAR
     IRVLTAKAST DL
//
ID   ABI2_HUMAN              Reviewed;         513 AA.
AC   Q9NYB9; B4DSN1; Q13147; Q13249; Q13801; Q9BV70;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 187.
DE   RecName: Full=Abl interactor 2 {ECO:0000303|Ref.16};
DE   AltName: Full=Abelson interactor 2 {ECO:0000303|Ref.16};
DE            Short=Abi-2 {ECO:0000303|PubMed:7590236};
DE   AltName: Full=Abl-binding protein 3;
DE            Short=AblBP3;
DE   AltName: Full=Arg-binding protein 1 {ECO:0000303|PubMed:8649853};
DE            Short=ArgBP1 {ECO:0000303|PubMed:8649853};
GN   Name=ABI2 {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:24011};
GN   Synonyms=ARGBPIA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, INTERACTION WITH ABL1, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=7590236; DOI=10.1101/gad.9.21.2569;
RA   Dai Z., Pendergast A.M.;
RT   "Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine
RT   kinase and modulates c-Abl transforming activity.";
RL   Genes Dev. 9:2569-2582(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Ren R.;
RT   "Cloning of a binding substrate of the Abl protein tyrosine kinase.";
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH ABL2, AND DOMAIN.
RC   TISSUE=Brain;
RX   PubMed=8649853;
RA   Wang B., Mysliwiec T., Krainc D., Jensen R.A., Sonoda G., Testa J.R.,
RA   Golemis E.A., Kruh G.D.;
RT   "Identification of ArgBP1, an Arg protein tyrosine kinase binding protein
RT   that is the human homologue of a CNS-specific Xenopus gene.";
RL   Oncogene 12:1921-1929(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=10498863; DOI=10.1038/sj.onc.1202911;
RA   Juang J.L., Hoffmann F.M.;
RT   "Drosophila abelson interacting protein (dAbi) is a positive regulator of
RT   abelson tyrosine kinase activity.";
RL   Oncogene 18:5138-5147(1999).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11516653; DOI=10.1016/s0960-9822(01)00239-1;
RA   Stradal T.E.B., Courtney K.D., Rottner K., Hahne P., Small J.V.,
RA   Pendergast A.M.;
RT   "The Abl interactor proteins localize to sites of actin polymerization at
RT   the tips of lamellipodia and filopodia.";
RL   Curr. Biol. 11:891-895(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15572692; DOI=10.1128/mcb.24.24.10905-10922.2004;
RA   Grove M., Demyanenko G., Echarri A., Zipfel P.A., Quiroz M.E.,
RA   Rodriguiz R.M., Playford M., Martensen S.A., Robinson M.R., Wetsel W.C.,
RA   Maness P.F., Pendergast A.M.;
RT   "ABI2-deficient mice exhibit defective cell migration, aberrant dendritic
RT   spine morphogenesis, and deficits in learning and memory.";
RL   Mol. Cell. Biol. 24:10905-10922(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227 AND SER-368, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-227, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-183; SER-227 AND SER-368, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL135 (MICROBIAL INFECTION).
RX   PubMed=25121749; DOI=10.1016/j.chom.2014.07.005;
RA   Stanton R.J., Prod'homme V., Purbhoo M.A., Moore M., Aicheler R.J.,
RA   Heinzmann M., Bailer S.M., Haas J., Antrobus R., Weekes M.P., Lehner P.J.,
RA   Vojtesek B., Miners K.L., Man S., Wilkie G.S., Davison A.J., Wang E.C.,
RA   Tomasec P., Wilkinson G.W.;
RT   "HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition
RT   of infected cells.";
RL   Cell Host Microbe 16:201-214(2014).
RN   [16]
RP   STRUCTURE BY NMR OF 444-508.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH3 domain of Abl interactor 2 (Abelson
RT   interactor 2).";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.29 ANGSTROMS) OF 1-164, SUBUNIT, AND FUNCTION.
RX   PubMed=21107423; DOI=10.1038/nature09623;
RA   Chen Z., Borek D., Padrick S.B., Gomez T.S., Metlagel Z., Ismail A.M.,
RA   Umetani J., Billadeau D.D., Otwinowski Z., Rosen M.K.;
RT   "Structure and control of the actin regulatory WAVE complex.";
RL   Nature 468:533-538(2010).
RN   [18]
RP   VARIANT 132-ARG--GLU-513 DEL.
RX   PubMed=28397838; DOI=10.1038/mp.2017.60;
RA   Harripaul R., Vasli N., Mikhailov A., Rafiq M.A., Mittal K.,
RA   Windpassinger C., Sheikh T.I., Noor A., Mahmood H., Downey S., Johnson M.,
RA   Vleuten K., Bell L., Ilyas M., Khan F.S., Khan V., Moradi M., Ayaz M.,
RA   Naeem F., Heidari A., Ahmed I., Ghadami S., Agha Z., Zeinali S., Qamar R.,
RA   Mozhdehipanah H., John P., Mir A., Ansar M., French L., Ayub M.,
RA   Vincent J.B.;
RT   "Mapping autosomal recessive intellectual disability: combined microarray
RT   and exome sequencing identifies 26 novel candidate genes in 192
RT   consanguineous families.";
RL   Mol. Psychiatry 23:973-984(2018).
CC   -!- FUNCTION: Regulator of actin cytoskeleton dynamics underlying cell
CC       motility and adhesion. Functions as a component of the WAVE complex,
CC       which activates actin nucleating machinery Arp2/3 to drive lamellipodia
CC       formation (PubMed:21107423). Acts as regulator and substrate of
CC       nonreceptor tyrosine kinases ABL1 and ABL2 involved in processes linked
CC       to cell growth and differentiation. Positively regulates ABL1-mediated
CC       phosphorylation of ENAH, which is required for proper polymerization of
CC       nucleated actin filaments at the leading edge (PubMed:7590236,
CC       PubMed:8649853, PubMed:10498863). Contributes to the regulation of
CC       actin assembly at the tips of neuron projections. In particular,
CC       controls dendritic spine morphogenesis and may promote dendritic spine
CC       specification toward large mushroom-type spines known as repositories
CC       of memory in the brain (By similarity). In hippocampal neurons, may
CC       mediate actin-dependent BDNF-NTRK2 early endocytic trafficking that
CC       triggers dendrite outgrowth (By similarity). Participates in ocular
CC       lens morphogenesis, likely by regulating lamellipodia-driven adherens
CC       junction formation at the epithelial cell-secondary lens fiber
CC       interface (By similarity). Also required for nascent adherens junction
CC       assembly in epithelial cells (PubMed:15572692).
CC       {ECO:0000250|UniProtKB:P62484, ECO:0000269|PubMed:10498863,
CC       ECO:0000269|PubMed:15572692, ECO:0000269|PubMed:21107423,
CC       ECO:0000269|PubMed:7590236, ECO:0000269|PubMed:8649853}.
CC   -!- SUBUNIT: Component of the WAVE complex composed of ABI2, CYFIP1 or
CC       CYFIP2, BRK1, NCKAP1 and WASF1/WAVE1. Within the complex, a heterodimer
CC       containing NCKAP1 and CYFIP1 interacts with a heterotrimer formed by
CC       WAVE1, ABI2 and BRK1. CYFIP2 binds to activated RAC1 which causes the
CC       complex to dissociate, releasing activated WASF1 (PubMed:21107423).
CC       Interacts (via SH3 domain) with ABL1 and ABL2 (PubMed:7590236,
CC       PubMed:8649853). {ECO:0000269|PubMed:21107423,
CC       ECO:0000269|PubMed:7590236, ECO:0000269|PubMed:8649853}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       UL135. {ECO:0000269|PubMed:25121749}.
CC   -!- INTERACTION:
CC       Q9NYB9; Q9NYB9: ABI2; NbExp=3; IntAct=EBI-743598, EBI-743598;
CC       Q9NYB9; P00519: ABL1; NbExp=2; IntAct=EBI-743598, EBI-375543;
CC       Q9NYB9; A7KAX9: ARHGAP32; NbExp=4; IntAct=EBI-743598, EBI-308663;
CC       Q9NYB9; Q9H6L4: ARMC7; NbExp=4; IntAct=EBI-743598, EBI-742909;
CC       Q9NYB9; Q9UL45: BLOC1S6; NbExp=5; IntAct=EBI-743598, EBI-465781;
CC       Q9NYB9; Q68D86: CCDC102B; NbExp=5; IntAct=EBI-743598, EBI-10171570;
CC       Q9NYB9; Q8TD31: CCHCR1; NbExp=3; IntAct=EBI-743598, EBI-949834;
CC       Q9NYB9; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-743598, EBI-10175300;
CC       Q9NYB9; O43186: CRX; NbExp=5; IntAct=EBI-743598, EBI-748171;
CC       Q9NYB9; O60941: DTNB; NbExp=6; IntAct=EBI-743598, EBI-740402;
CC       Q9NYB9; O43281: EFS; NbExp=6; IntAct=EBI-743598, EBI-718488;
CC       Q9NYB9; Q9H6Z9: EGLN3; NbExp=3; IntAct=EBI-743598, EBI-1175354;
CC       Q9NYB9; Q6IB98: EIF3S3; NbExp=3; IntAct=EBI-743598, EBI-10184995;
CC       Q9NYB9; Q96CN9: GCC1; NbExp=4; IntAct=EBI-743598, EBI-746252;
CC       Q9NYB9; O14964: HGS; NbExp=5; IntAct=EBI-743598, EBI-740220;
CC       Q9NYB9; P61978: HNRNPK; NbExp=6; IntAct=EBI-743598, EBI-304185;
CC       Q9NYB9; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-743598, EBI-748420;
CC       Q9NYB9; Q8IY31: IFT20; NbExp=6; IntAct=EBI-743598, EBI-744203;
CC       Q9NYB9; Q8IYA8: IHO1; NbExp=6; IntAct=EBI-743598, EBI-8638439;
CC       Q9NYB9; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-743598, EBI-10188326;
CC       Q9NYB9; Q9BVG8: KIFC3; NbExp=5; IntAct=EBI-743598, EBI-2125614;
CC       Q9NYB9; A1A4E9: KRT13; NbExp=3; IntAct=EBI-743598, EBI-10171552;
CC       Q9NYB9; P19012: KRT15; NbExp=6; IntAct=EBI-743598, EBI-739566;
CC       Q9NYB9; P08727: KRT19; NbExp=3; IntAct=EBI-743598, EBI-742756;
CC       Q9NYB9; P35900: KRT20; NbExp=3; IntAct=EBI-743598, EBI-742094;
CC       Q9NYB9; Q15323: KRT31; NbExp=5; IntAct=EBI-743598, EBI-948001;
CC       Q9NYB9; Q14525: KRT33B; NbExp=3; IntAct=EBI-743598, EBI-1049638;
CC       Q9NYB9; P25791: LMO2; NbExp=5; IntAct=EBI-743598, EBI-739696;
CC       Q9NYB9; Q96HT8: MRFAP1L1; NbExp=7; IntAct=EBI-743598, EBI-748896;
CC       Q9NYB9; Q9H9J2: MRPL44; NbExp=3; IntAct=EBI-743598, EBI-713619;
CC       Q9NYB9; O43639: NCK2; NbExp=6; IntAct=EBI-743598, EBI-713635;
CC       Q9NYB9; P37198: NUP62; NbExp=6; IntAct=EBI-743598, EBI-347978;
CC       Q9NYB9; Q15154: PCM1; NbExp=3; IntAct=EBI-743598, EBI-741421;
CC       Q9NYB9; Q13526: PIN1; NbExp=5; IntAct=EBI-743598, EBI-714158;
CC       Q9NYB9; P30405: PPIF; NbExp=4; IntAct=EBI-743598, EBI-5544229;
CC       Q9NYB9; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-743598, EBI-2860740;
CC       Q9NYB9; Q13131: PRKAA1; NbExp=5; IntAct=EBI-743598, EBI-1181405;
CC       Q9NYB9; P54646: PRKAA2; NbExp=5; IntAct=EBI-743598, EBI-1383852;
CC       Q9NYB9; Q569H4: PRR16; NbExp=4; IntAct=EBI-743598, EBI-5564642;
CC       Q9NYB9; O00560: SDCBP; NbExp=5; IntAct=EBI-743598, EBI-727004;
CC       Q9NYB9; O75886: STAM2; NbExp=5; IntAct=EBI-743598, EBI-373258;
CC       Q9NYB9; Q9UBB9: TFIP11; NbExp=6; IntAct=EBI-743598, EBI-1105213;
CC       Q9NYB9; Q08117: TLE5; NbExp=5; IntAct=EBI-743598, EBI-717810;
CC       Q9NYB9; Q13049: TRIM32; NbExp=6; IntAct=EBI-743598, EBI-742790;
CC       Q9NYB9; Q15654: TRIP6; NbExp=5; IntAct=EBI-743598, EBI-742327;
CC       Q9NYB9; Q5ST30-4: VARS2; NbExp=3; IntAct=EBI-743598, EBI-10244997;
CC       Q9NYB9; P50552: VASP; NbExp=5; IntAct=EBI-743598, EBI-748201;
CC       Q9NYB9; P18206: VCL; NbExp=3; IntAct=EBI-743598, EBI-716775;
CC       Q9NYB9; Q9Y3C0: WASHC3; NbExp=4; IntAct=EBI-743598, EBI-712969;
CC       Q9NYB9; O43516: WIPF1; NbExp=4; IntAct=EBI-743598, EBI-346356;
CC       Q9NYB9; Q8VHK2: Caskin1; Xeno; NbExp=3; IntAct=EBI-743598, EBI-7049475;
CC       Q9NYB9-2; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-11096309, EBI-11743294;
CC       Q9NYB9-2; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-11096309, EBI-11096309;
CC       Q9NYB9-2; Q9P2A4: ABI3; NbExp=5; IntAct=EBI-11096309, EBI-742038;
CC       Q9NYB9-2; P42684-3: ABL2; NbExp=3; IntAct=EBI-11096309, EBI-10693977;
CC       Q9NYB9-2; O94929-2: ABLIM3; NbExp=3; IntAct=EBI-11096309, EBI-11961672;
CC       Q9NYB9-2; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-11096309, EBI-357530;
CC       Q9NYB9-2; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-11096309, EBI-11745576;
CC       Q9NYB9-2; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-11096309, EBI-14493093;
CC       Q9NYB9-2; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-11096309, EBI-11954519;
CC       Q9NYB9-2; Q9Y6H3: ATP23; NbExp=3; IntAct=EBI-11096309, EBI-12811889;
CC       Q9NYB9-2; O95429: BAG4; NbExp=5; IntAct=EBI-11096309, EBI-2949658;
CC       Q9NYB9-2; Q9NQY0: BIN3; NbExp=7; IntAct=EBI-11096309, EBI-2653038;
CC       Q9NYB9-2; Q8TDH9: BLOC1S5; NbExp=3; IntAct=EBI-11096309, EBI-465861;
CC       Q9NYB9-2; Q9UL45: BLOC1S6; NbExp=6; IntAct=EBI-11096309, EBI-465781;
CC       Q9NYB9-2; Q96GS4: BORCS6; NbExp=5; IntAct=EBI-11096309, EBI-10193358;
CC       Q9NYB9-2; Q5BKX5-3: C19orf54; NbExp=5; IntAct=EBI-11096309, EBI-11976299;
CC       Q9NYB9-2; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-11096309, EBI-8643161;
CC       Q9NYB9-2; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-11096309, EBI-747505;
CC       Q9NYB9-2; A1L168: C20orf202; NbExp=3; IntAct=EBI-11096309, EBI-18396958;
CC       Q9NYB9-2; Q53FE4: C4orf17; NbExp=3; IntAct=EBI-11096309, EBI-715110;
CC       Q9NYB9-2; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-11096309, EBI-10171570;
CC       Q9NYB9-2; Q96NT0: CCDC115; NbExp=5; IntAct=EBI-11096309, EBI-2810325;
CC       Q9NYB9-2; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-11096309, EBI-10961624;
CC       Q9NYB9-2; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-11096309, EBI-17967022;
CC       Q9NYB9-2; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-11096309, EBI-10175300;
CC       Q9NYB9-2; Q9H3R5: CENPH; NbExp=6; IntAct=EBI-11096309, EBI-1003700;
CC       Q9NYB9-2; Q7L2Z9: CENPQ; NbExp=3; IntAct=EBI-11096309, EBI-2350265;
CC       Q9NYB9-2; Q9C0F1: CEP44; NbExp=3; IntAct=EBI-11096309, EBI-744115;
CC       Q9NYB9-2; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-11096309, EBI-11752486;
CC       Q9NYB9-2; Q16740: CLPP; NbExp=3; IntAct=EBI-11096309, EBI-1056029;
CC       Q9NYB9-2; Q96JB2-2: COG3; NbExp=3; IntAct=EBI-11096309, EBI-9091495;
CC       Q9NYB9-2; Q9NWM3: CUEDC1; NbExp=3; IntAct=EBI-11096309, EBI-5838167;
CC       Q9NYB9-2; Q13561: DCTN2; NbExp=3; IntAct=EBI-11096309, EBI-715074;
CC       Q9NYB9-2; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-11096309, EBI-11988027;
CC       Q9NYB9-2; Q9P1A6-3: DLGAP2; NbExp=3; IntAct=EBI-11096309, EBI-12019838;
CC       Q9NYB9-2; Q9Y2H0-1: DLGAP4; NbExp=3; IntAct=EBI-11096309, EBI-12000556;
CC       Q9NYB9-2; Q6TDU7: DNAI7; NbExp=3; IntAct=EBI-11096309, EBI-5235378;
CC       Q9NYB9-2; O60941-5: DTNB; NbExp=5; IntAct=EBI-11096309, EBI-11984733;
CC       Q9NYB9-2; O43281-2: EFS; NbExp=5; IntAct=EBI-11096309, EBI-11525448;
CC       Q9NYB9-2; Q05215: EGR4; NbExp=3; IntAct=EBI-11096309, EBI-19949420;
CC       Q9NYB9-2; Q9H0I2: ENKD1; NbExp=6; IntAct=EBI-11096309, EBI-744099;
CC       Q9NYB9-2; Q8TE68-2: EPS8L1; NbExp=3; IntAct=EBI-11096309, EBI-12003490;
CC       Q9NYB9-2; Q96MY7: FAM161B; NbExp=3; IntAct=EBI-11096309, EBI-7225287;
CC       Q9NYB9-2; A8MTA8-2: FAM166B; NbExp=3; IntAct=EBI-11096309, EBI-12160437;
CC       Q9NYB9-2; Q7L5A3: FAM214B; NbExp=3; IntAct=EBI-11096309, EBI-745689;
CC       Q9NYB9-2; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-11096309, EBI-6658203;
CC       Q9NYB9-2; Q8IZT9: FAM9C; NbExp=3; IntAct=EBI-11096309, EBI-2870039;
CC       Q9NYB9-2; Q6PCT2-2: FBXL19; NbExp=3; IntAct=EBI-11096309, EBI-11959077;
CC       Q9NYB9-2; Q5TD97: FHL5; NbExp=3; IntAct=EBI-11096309, EBI-750641;
CC       Q9NYB9-2; Q0VDC6: FKBP1A; NbExp=3; IntAct=EBI-11096309, EBI-10226858;
CC       Q9NYB9-2; Q9NU39: FOXD4L1; NbExp=3; IntAct=EBI-11096309, EBI-11320806;
CC       Q9NYB9-2; Q8NHY3: GAS2L2; NbExp=3; IntAct=EBI-11096309, EBI-7960826;
CC       Q9NYB9-2; P14136: GFAP; NbExp=6; IntAct=EBI-11096309, EBI-744302;
CC       Q9NYB9-2; Q86UU5: GGN; NbExp=3; IntAct=EBI-11096309, EBI-10259069;
CC       Q9NYB9-2; O95872: GPANK1; NbExp=3; IntAct=EBI-11096309, EBI-751540;
CC       Q9NYB9-2; A0A024R8L2: hCG_1987119; NbExp=3; IntAct=EBI-11096309, EBI-14103818;
CC       Q9NYB9-2; Q03014: HHEX; NbExp=3; IntAct=EBI-11096309, EBI-747421;
CC       Q9NYB9-2; P61978-2: HNRNPK; NbExp=6; IntAct=EBI-11096309, EBI-7060731;
CC       Q9NYB9-2; Q9NSC5: HOMER3; NbExp=3; IntAct=EBI-11096309, EBI-748420;
CC       Q9NYB9-2; O75031: HSF2BP; NbExp=3; IntAct=EBI-11096309, EBI-7116203;
CC       Q9NYB9-2; Q8IY31-3: IFT20; NbExp=7; IntAct=EBI-11096309, EBI-9091197;
CC       Q9NYB9-2; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-11096309, EBI-8638439;
CC       Q9NYB9-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-11096309, EBI-6509505;
CC       Q9NYB9-2; Q9C086: INO80B; NbExp=3; IntAct=EBI-11096309, EBI-715611;
CC       Q9NYB9-2; Q2T9L4: INSYN1; NbExp=3; IntAct=EBI-11096309, EBI-4311436;
CC       Q9NYB9-2; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-11096309, EBI-1055254;
CC       Q9NYB9-2; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-11096309, EBI-10188326;
CC       Q9NYB9-2; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-11096309, EBI-14069005;
CC       Q9NYB9-2; Q9Y448: KNSTRN; NbExp=3; IntAct=EBI-11096309, EBI-373334;
CC       Q9NYB9-2; P02533: KRT14; NbExp=3; IntAct=EBI-11096309, EBI-702178;
CC       Q9NYB9-2; P19012: KRT15; NbExp=3; IntAct=EBI-11096309, EBI-739566;
CC       Q9NYB9-2; P08727: KRT19; NbExp=3; IntAct=EBI-11096309, EBI-742756;
CC       Q9NYB9-2; Q2M2I5: KRT24; NbExp=3; IntAct=EBI-11096309, EBI-2952736;
CC       Q9NYB9-2; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-11096309, EBI-3044087;
CC       Q9NYB9-2; O76011: KRT34; NbExp=3; IntAct=EBI-11096309, EBI-1047093;
CC       Q9NYB9-2; O76013-2: KRT36; NbExp=3; IntAct=EBI-11096309, EBI-11958506;
CC       Q9NYB9-2; O95678: KRT75; NbExp=3; IntAct=EBI-11096309, EBI-2949715;
CC       Q9NYB9-2; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-11096309, EBI-726510;
CC       Q9NYB9-2; Q3B8N2: LGALS9B; NbExp=3; IntAct=EBI-11096309, EBI-10240775;
CC       Q9NYB9-2; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-11096309, EBI-12039345;
CC       Q9NYB9-2; Q68G74: LHX8; NbExp=3; IntAct=EBI-11096309, EBI-8474075;
CC       Q9NYB9-2; P25800: LMO1; NbExp=8; IntAct=EBI-11096309, EBI-8639312;
CC       Q9NYB9-2; P25791-3: LMO2; NbExp=6; IntAct=EBI-11096309, EBI-11959475;
CC       Q9NYB9-2; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-11096309, EBI-11742507;
CC       Q9NYB9-2; P61968: LMO4; NbExp=3; IntAct=EBI-11096309, EBI-2798728;
CC       Q9NYB9-2; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-11096309, EBI-739832;
CC       Q9NYB9-2; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-11096309, EBI-741355;
CC       Q9NYB9-2; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-11096309, EBI-741037;
CC       Q9NYB9-2; P43355: MAGEA1; NbExp=3; IntAct=EBI-11096309, EBI-740978;
CC       Q9NYB9-2; Q9BTT4: MED10; NbExp=3; IntAct=EBI-11096309, EBI-394354;
CC       Q9NYB9-2; Q9P086: MED11; NbExp=3; IntAct=EBI-11096309, EBI-394704;
CC       Q9NYB9-2; Q9NX70: MED29; NbExp=3; IntAct=EBI-11096309, EBI-394656;
CC       Q9NYB9-2; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11096309, EBI-16439278;
CC       Q9NYB9-2; Q9Y605: MRFAP1; NbExp=5; IntAct=EBI-11096309, EBI-995714;
CC       Q9NYB9-2; Q13084: MRPL28; NbExp=3; IntAct=EBI-11096309, EBI-723426;
CC       Q9NYB9-2; P15173: MYOG; NbExp=3; IntAct=EBI-11096309, EBI-3906629;
CC       Q9NYB9-2; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-11096309, EBI-5662487;
CC       Q9NYB9-2; A0A0S2Z4D7: NCK1; NbExp=3; IntAct=EBI-11096309, EBI-16429340;
CC       Q9NYB9-2; A0A0S2Z4E4: NCK1; NbExp=3; IntAct=EBI-11096309, EBI-16432934;
CC       Q9NYB9-2; O43639: NCK2; NbExp=10; IntAct=EBI-11096309, EBI-713635;
CC       Q9NYB9-2; Q9NZQ3-3: NCKIPSD; NbExp=3; IntAct=EBI-11096309, EBI-10963850;
CC       Q9NYB9-2; O94856-3: NFASC; NbExp=3; IntAct=EBI-11096309, EBI-12035911;
CC       Q9NYB9-2; Q5HYW2: NHSL2; NbExp=9; IntAct=EBI-11096309, EBI-2859639;
CC       Q9NYB9-2; O00746: NME4; NbExp=3; IntAct=EBI-11096309, EBI-744871;
CC       Q9NYB9-2; O43482: OIP5; NbExp=3; IntAct=EBI-11096309, EBI-536879;
CC       Q9NYB9-2; A6NGQ2: OOEP; NbExp=3; IntAct=EBI-11096309, EBI-18583589;
CC       Q9NYB9-2; Q13177: PAK2; NbExp=3; IntAct=EBI-11096309, EBI-1045887;
CC       Q9NYB9-2; Q15154-3: PCM1; NbExp=3; IntAct=EBI-11096309, EBI-11742977;
CC       Q9NYB9-2; Q9NR12: PDLIM7; NbExp=3; IntAct=EBI-11096309, EBI-350517;
CC       Q9NYB9-2; Q99471: PFDN5; NbExp=3; IntAct=EBI-11096309, EBI-357275;
CC       Q9NYB9-2; Q8N4B1-4: PHETA1; NbExp=8; IntAct=EBI-11096309, EBI-14131832;
CC       Q9NYB9-2; O43189: PHF1; NbExp=3; IntAct=EBI-11096309, EBI-530034;
CC       Q9NYB9-2; Q13526: PIN1; NbExp=3; IntAct=EBI-11096309, EBI-714158;
CC       Q9NYB9-2; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-11096309, EBI-12014286;
CC       Q9NYB9-2; P01189: POMC; NbExp=3; IntAct=EBI-11096309, EBI-12219503;
CC       Q9NYB9-2; P30405: PPIF; NbExp=3; IntAct=EBI-11096309, EBI-5544229;
CC       Q9NYB9-2; Q08209-2: PPP3CA; NbExp=3; IntAct=EBI-11096309, EBI-11959013;
CC       Q9NYB9-2; Q9GZV8: PRDM14; NbExp=3; IntAct=EBI-11096309, EBI-3957793;
CC       Q9NYB9-2; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-11096309, EBI-11320284;
CC       Q9NYB9-2; P54646: PRKAA2; NbExp=3; IntAct=EBI-11096309, EBI-1383852;
CC       Q9NYB9-2; Q569H4: PRR16; NbExp=8; IntAct=EBI-11096309, EBI-5564642;
CC       Q9NYB9-2; P86480: PRR20D; NbExp=3; IntAct=EBI-11096309, EBI-12754095;
CC       Q9NYB9-2; P25786: PSMA1; NbExp=3; IntAct=EBI-11096309, EBI-359352;
CC       Q9NYB9-2; Q6NUJ5: PWWP2B; NbExp=3; IntAct=EBI-11096309, EBI-10251192;
CC       Q9NYB9-2; Q15276: RABEP1; NbExp=3; IntAct=EBI-11096309, EBI-447043;
CC       Q9NYB9-2; Q9UJ41-4: RABGEF1; NbExp=3; IntAct=EBI-11096309, EBI-14093916;
CC       Q9NYB9-2; Q9Y272: RASD1; NbExp=3; IntAct=EBI-11096309, EBI-740818;
CC       Q9NYB9-2; Q15287: RNPS1; NbExp=3; IntAct=EBI-11096309, EBI-395959;
CC       Q9NYB9-2; Q9BUL9: RPP25; NbExp=3; IntAct=EBI-11096309, EBI-366570;
CC       Q9NYB9-2; Q9UHP6: RSPH14; NbExp=3; IntAct=EBI-11096309, EBI-748350;
CC       Q9NYB9-2; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-11096309, EBI-6257312;
CC       Q9NYB9-2; O76038: SCGN; NbExp=3; IntAct=EBI-11096309, EBI-749420;
CC       Q9NYB9-2; Q9Y3L3: SH3BP1; NbExp=3; IntAct=EBI-11096309, EBI-346869;
CC       Q9NYB9-2; Q13239-3: SLA; NbExp=3; IntAct=EBI-11096309, EBI-17630587;
CC       Q9NYB9-2; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-11096309, EBI-358489;
CC       Q9NYB9-2; O60641-3: SNAP91; NbExp=3; IntAct=EBI-11096309, EBI-12854506;
CC       Q9NYB9-2; O95295: SNAPIN; NbExp=5; IntAct=EBI-11096309, EBI-296723;
CC       Q9NYB9-2; Q96RF0: SNX18; NbExp=3; IntAct=EBI-11096309, EBI-298169;
CC       Q9NYB9-2; Q9UNH6-3: SNX7; NbExp=3; IntAct=EBI-11096309, EBI-12424584;
CC       Q9NYB9-2; O60504: SORBS3; NbExp=3; IntAct=EBI-11096309, EBI-741237;
CC       Q9NYB9-2; O75886: STAM2; NbExp=3; IntAct=EBI-11096309, EBI-373258;
CC       Q9NYB9-2; Q8N4C7: STX19; NbExp=3; IntAct=EBI-11096309, EBI-8484990;
CC       Q9NYB9-2; Q12846: STX4; NbExp=3; IntAct=EBI-11096309, EBI-744942;
CC       Q9NYB9-2; Q08117-2: TLE5; NbExp=6; IntAct=EBI-11096309, EBI-11741437;
CC       Q9NYB9-2; P07951-2: TPM2; NbExp=3; IntAct=EBI-11096309, EBI-10977815;
CC       Q9NYB9-2; Q13049: TRIM32; NbExp=8; IntAct=EBI-11096309, EBI-742790;
CC       Q9NYB9-2; Q6ZMU5: TRIM72; NbExp=3; IntAct=EBI-11096309, EBI-2341648;
CC       Q9NYB9-2; Q8N7C3: TRIML2; NbExp=3; IntAct=EBI-11096309, EBI-11059915;
CC       Q9NYB9-2; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-11096309, EBI-947187;
CC       Q9NYB9-2; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-11096309, EBI-739895;
CC       Q9NYB9-2; O75604: USP2; NbExp=3; IntAct=EBI-11096309, EBI-743272;
CC       Q9NYB9-2; Q5ST30: VARS2; NbExp=3; IntAct=EBI-11096309, EBI-2116622;
CC       Q9NYB9-2; Q9UK41-2: VPS28; NbExp=3; IntAct=EBI-11096309, EBI-12146727;
CC       Q9NYB9-2; Q9UPY6-2: WASF3; NbExp=3; IntAct=EBI-11096309, EBI-12026286;
CC       Q9NYB9-2; Q9Y3C0: WASHC3; NbExp=5; IntAct=EBI-11096309, EBI-712969;
CC       Q9NYB9-2; O00401: WASL; NbExp=5; IntAct=EBI-11096309, EBI-957615;
CC       Q9NYB9-2; O43516-4: WIPF1; NbExp=3; IntAct=EBI-11096309, EBI-12052927;
CC       Q9NYB9-2; Q9NZC7-5: WWOX; NbExp=5; IntAct=EBI-11096309, EBI-12040603;
CC       Q9NYB9-2; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-11096309, EBI-11419867;
CC       Q9NYB9-2; Q9H0C1: ZMYND12; NbExp=5; IntAct=EBI-11096309, EBI-12030590;
CC       Q9NYB9-2; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-11096309, EBI-17269964;
CC       Q9NYB9-2; A0A0S2Z5X4: ZNF688; NbExp=3; IntAct=EBI-11096309, EBI-16429014;
CC       Q9NYB9-2; P0C7X2: ZNF688; NbExp=3; IntAct=EBI-11096309, EBI-4395732;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11516653,
CC       ECO:0000269|PubMed:7590236, ECO:0000269|PubMed:8649853}. Nucleus
CC       {ECO:0000269|PubMed:7590236}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:11516653, ECO:0000269|PubMed:15572692}. Cell
CC       projection, filopodium {ECO:0000269|PubMed:11516653}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:15572692}. Cell junction, adherens
CC       junction {ECO:0000269|PubMed:15572692}. Note=Isoform 1 but not isoform
CC       3 is localized to protruding lamellipodia and filopodia tips
CC       (PubMed:11516653, PubMed:15572692). Present at nascent adherens
CC       junctions, where it clusters adjacent to the tips of F-actin
CC       protrusions (PubMed:15572692). {ECO:0000269|PubMed:11516653,
CC       ECO:0000269|PubMed:15572692}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Abi-2b;
CC         IsoId=Q9NYB9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYB9-2; Sequence=VSP_010761, VSP_010762, VSP_010763;
CC       Name=3; Synonyms=Abi-2a;
CC         IsoId=Q9NYB9-3; Sequence=VSP_010759, VSP_010760, VSP_010761,
CC                                  VSP_010762;
CC       Name=4;
CC         IsoId=Q9NYB9-4; Sequence=VSP_010761;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Abundant in testes, ovary,
CC       thymus, and colon, with lower but detectable levels in prostate,
CC       peripheral blood leukocytes, and spleen. {ECO:0000269|PubMed:7590236}.
CC   -!- DOMAIN: The SH3 domain is critical for binding to ABL1 and ABL2.
CC       {ECO:0000269|PubMed:7590236, ECO:0000269|PubMed:8649853}.
CC   -!- PTM: Phosphorylated by ABL1. {ECO:0000269|PubMed:7590236}.
CC   -!- SIMILARITY: Belongs to the ABI family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U23435; AAA92289.1; -; mRNA.
DR   EMBL; U31089; AAA75446.1; -; mRNA.
DR   EMBL; AF260261; AAF70308.1; -; mRNA.
DR   EMBL; X95632; CAA64885.1; -; mRNA.
DR   EMBL; BT009920; AAP88922.1; -; mRNA.
DR   EMBL; AK299824; BAG61693.1; -; mRNA.
DR   EMBL; BC001439; AAH01439.1; -; mRNA.
DR   CCDS; CCDS2358.1; -. [Q9NYB9-2]
DR   CCDS; CCDS63093.1; -. [Q9NYB9-1]
DR   CCDS; CCDS63094.1; -. [Q9NYB9-4]
DR   PIR; G01936; G01936.
DR   RefSeq; NP_001269854.1; NM_001282925.1.
DR   RefSeq; NP_001269855.1; NM_001282926.1.
DR   RefSeq; NP_001269856.1; NM_001282927.1. [Q9NYB9-3]
DR   RefSeq; NP_005750.4; NM_005759.5. [Q9NYB9-2]
DR   RefSeq; XP_006712248.1; XM_006712185.1.
DR   PDB; 2ED0; NMR; -; A=444-508.
DR   PDB; 3P8C; X-ray; 2.29 A; F=1-154.
DR   PDB; 4N78; X-ray; 2.43 A; F=1-513.
DR   PDBsum; 2ED0; -.
DR   PDBsum; 3P8C; -.
DR   PDBsum; 4N78; -.
DR   BMRB; Q9NYB9; -.
DR   SMR; Q9NYB9; -.
DR   BioGRID; 115454; 270.
DR   DIP; DIP-37566N; -.
DR   IntAct; Q9NYB9; 239.
DR   MINT; Q9NYB9; -.
DR   STRING; 9606.ENSP00000295851; -.
DR   MoonDB; Q9NYB9; Predicted.
DR   iPTMnet; Q9NYB9; -.
DR   PhosphoSitePlus; Q9NYB9; -.
DR   BioMuta; ABI2; -.
DR   DMDM; 50400673; -.
DR   CPTAC; CPTAC-1593; -.
DR   EPD; Q9NYB9; -.
DR   jPOST; Q9NYB9; -.
DR   MassIVE; Q9NYB9; -.
DR   MaxQB; Q9NYB9; -.
DR   PeptideAtlas; Q9NYB9; -.
DR   PRIDE; Q9NYB9; -.
DR   ProteomicsDB; 83209; -. [Q9NYB9-1]
DR   ProteomicsDB; 83210; -. [Q9NYB9-2]
DR   ProteomicsDB; 83211; -. [Q9NYB9-3]
DR   ProteomicsDB; 83212; -. [Q9NYB9-4]
DR   Antibodypedia; 34165; 226 antibodies from 31 providers.
DR   DNASU; 10152; -.
DR   Ensembl; ENST00000261017; ENSP00000261017; ENSG00000138443. [Q9NYB9-2]
DR   GeneID; 10152; -.
DR   KEGG; hsa:10152; -.
DR   UCSC; uc002uzz.5; human. [Q9NYB9-1]
DR   CTD; 10152; -.
DR   DisGeNET; 10152; -.
DR   GeneCards; ABI2; -.
DR   HGNC; HGNC:24011; ABI2.
DR   HPA; ENSG00000138443; Low tissue specificity.
DR   MIM; 606442; gene.
DR   neXtProt; NX_Q9NYB9; -.
DR   OpenTargets; ENSG00000138443; -.
DR   PharmGKB; PA134977642; -.
DR   VEuPathDB; HostDB:ENSG00000138443; -.
DR   eggNOG; KOG2546; Eukaryota.
DR   GeneTree; ENSGT00940000156089; -.
DR   InParanoid; Q9NYB9; -.
DR   OrthoDB; 1478981at2759; -.
DR   PhylomeDB; Q9NYB9; -.
DR   TreeFam; TF314303; -.
DR   PathwayCommons; Q9NYB9; -.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SignaLink; Q9NYB9; -.
DR   SIGNOR; Q9NYB9; -.
DR   BioGRID-ORCS; 10152; 5 hits in 1048 CRISPR screens.
DR   ChiTaRS; ABI2; human.
DR   EvolutionaryTrace; Q9NYB9; -.
DR   GeneWiki; ABI2; -.
DR   GenomeRNAi; 10152; -.
DR   Pharos; Q9NYB9; Tbio.
DR   PRO; PR:Q9NYB9; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NYB9; protein.
DR   Bgee; ENSG00000138443; Expressed in dorsolateral prefrontal cortex and 239 other tissues.
DR   ExpressionAtlas; Q9NYB9; baseline and differential.
DR   Genevisible; Q9NYB9; HS.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0043197; C:dendritic spine; ISS:UniProtKB.
DR   GO; GO:0032433; C:filopodium tip; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0031209; C:SCAR complex; IDA:UniProtKB.
DR   GO; GO:0008093; F:cytoskeletal anchor activity; TAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; NAS:UniProtKB.
DR   GO; GO:0070064; F:proline-rich region binding; IPI:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0035591; F:signaling adaptor activity; IDA:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0008154; P:actin polymerization or depolymerization; NAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:2000601; P:positive regulation of Arp2/3 complex-mediated actin nucleation; IDA:UniProtKB.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; IDA:ARUK-UCL.
DR   GO; GO:0016601; P:Rac protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045186; P:zonula adherens assembly; IMP:UniProtKB.
DR   CDD; cd11972; SH3_Abi2; 1.
DR   DisProt; DP02386; -.
DR   InterPro; IPR028457; ABI.
DR   InterPro; IPR036993; ABI2.
DR   InterPro; IPR035726; Abi2_SH3.
DR   InterPro; IPR012849; Abl-interactor_HHR_dom.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR000727; T_SNARE_dom.
DR   PANTHER; PTHR10460; PTHR10460; 2.
DR   PANTHER; PTHR10460:SF26; PTHR10460:SF26; 2.
DR   Pfam; PF07815; Abi_HHR; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS50192; T_SNARE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell projection;
KW   Coiled coil; Cytoplasm; Cytoskeleton; Disease variant;
KW   Host-virus interaction; Mental retardation; Neurogenesis; Nucleus;
KW   Phosphoprotein; Reference proteome; SH3 domain.
FT   CHAIN           1..513
FT                   /note="Abl interactor 2"
FT                   /id="PRO_0000191790"
FT   DOMAIN          45..107
FT                   /note="t-SNARE coiled-coil homology"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00202"
FT   DOMAIN          451..510
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REGION          167..431
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        217..265
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        272..290
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        373..396
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        397..420
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         40
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P62484"
FT   MOD_RES         183
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         227
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         361
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P62484"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..45
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7590236"
FT                   /id="VSP_010759"
FT   VAR_SEQ         46..95
FT                   /note="ALEETKAYTTQSLASVAYLINTLANNVLQMLDIQASQLRRMESSINHISQ
FT                   -> MSCRCWISRHPSYEGWNLQSIIFHKQIRGVDLESTFVTKFGNNCSLRLNE (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7590236"
FT                   /id="VSP_010760"
FT   VAR_SEQ         154..159
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:7590236,
FT                   ECO:0000303|PubMed:8649853, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_010761"
FT   VAR_SEQ         284..344
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7590236, ECO:0000303|PubMed:8649853,
FT                   ECO:0000303|Ref.2, ECO:0000303|Ref.4"
FT                   /id="VSP_010762"
FT   VAR_SEQ         399
FT                   /note="S -> SLAPPPPSILQVTPQLPLMGFVARVQENIS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8649853, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_010763"
FT   VARIANT         132..513
FT                   /note="Missing (probable disease-associated variant found
FT                   in a consanguineous family with intellectual disability)"
FT                   /evidence="ECO:0000269|PubMed:28397838"
FT                   /id="VAR_080776"
FT   CONFLICT        22
FT                   /note="S -> R (in Ref. 3; CAA64885)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="A -> D (in Ref. 3; CAA64885)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        243
FT                   /note="S -> T (in Ref. 2; AAA75446)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        249
FT                   /note="G -> P (in Ref. 1; AAA92289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        317
FT                   /note="N -> D (in Ref. 5; BAG61693)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324..325
FT                   /note="PN -> QT (in Ref. 5; BAG61693)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        432
FT                   /note="A -> V (in Ref. 2; AAA75446)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        500
FT                   /note="F -> S (in Ref. 2; AAA75446)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1..9
FT                   /evidence="ECO:0007829|PDB:3P8C"
FT   HELIX           11..39
FT                   /evidence="ECO:0007829|PDB:3P8C"
FT   HELIX           43..110
FT                   /evidence="ECO:0007829|PDB:3P8C"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:3P8C"
FT   TURN            143..151
FT                   /evidence="ECO:0007829|PDB:3P8C"
FT   STRAND          453..458
FT                   /evidence="ECO:0007829|PDB:2ED0"
FT   STRAND          477..483
FT                   /evidence="ECO:0007829|PDB:2ED0"
FT   STRAND          485..493
FT                   /evidence="ECO:0007829|PDB:2ED0"
FT   STRAND          496..501
FT                   /evidence="ECO:0007829|PDB:2ED0"
FT   STRAND          504..507
FT                   /evidence="ECO:0007829|PDB:2ED0"
SQ   SEQUENCE   513 AA;  55663 MW;  822983A69E5EA512 CRC64;
     MAELQMLLEE EIPGGRRALF DSYTNLERVA DYCENNYIQS ADKQRALEET KAYTTQSLAS
     VAYLINTLAN NVLQMLDIQA SQLRRMESSI NHISQTVDIH KEKVARREIG ILTTNKNTSR
     THKIIAPANL ERPVRYIRKP IDYTILDDIG HGVKWLLRFK VSTQNMKMGG LPRTTPPTQK
     PPSPPMSGKG TLGRHSPYRT LEPVRPPVVP NDYVPSPTRN MAPSQQSPVR TASVNQRNRT
     YSSSGSSGGS HPSSRSSSRE NSGSGSVGVP IAVPTPSPPS VFPAPAGSAG TPPLPATSAS
     APAPLVPATV PSSTAPNAAA GGAPNLADGF TSPTPPVVSS TPPTGHPVQF YSMNRPASRH
     TPPTIGGSLP YRRPPSITSQ TSLQNQMNGG PFYSQNPVSD TPPPPPPVEE PVFDESPPPP
     PPPEDYEEEE AAVVEYSDPY AEEDPPWAPR SYLEKVVAIY DYTKDKEDEL SFQEGAIIYV
     IKKNDDGWYE GVMNGVTGLF PGNYVESIMH YSE
//
ID   SMAD5_HUMAN             Reviewed;         465 AA.
AC   Q99717; O14688; Q15798; Q9UQA1;
DT   04-MAY-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   23-FEB-2022, entry version 213.
DE   RecName: Full=Mothers against decapentaplegic homolog 5;
DE            Short=MAD homolog 5;
DE            Short=Mothers against DPP homolog 5;
DE   AltName: Full=JV5-1;
DE   AltName: Full=SMAD family member 5;
DE            Short=SMAD 5;
DE            Short=Smad5;
DE            Short=hSmad5;
GN   Name=SMAD5; Synonyms=MADH5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8673135; DOI=10.1038/ng0796-347;
RA   Riggins G.J., Thiagalingam S., Rosenblum E., Weinstein C.L., Kern S.E.,
RA   Hamilton S.R., Willson J.K.V., Markowitz S.D., Kinzler K.W.,
RA   Vogelstein B.V.;
RT   "Mad-related genes in the human.";
RL   Nat. Genet. 13:347-349(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=9288787;
RA   Hejlik D.P., Kottickal L.V., Liang H., Fairman J., Davis T., Janecki T.,
RA   Sexton D., Perry W. III, Tavtigian S.V., Teng D.H., Nagarajan L.;
RT   "Localization of SMAD5 and its evaluation as a candidate myeloid tumor
RT   suppressor.";
RL   Cancer Res. 57:3779-3783(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9264367; DOI=10.1038/sj.leu.2400750;
RA   Zavadil J., Brezinova J., Svoboda P., Zemanova Z., Michalova K.;
RT   "Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and
RT   not mutated in the retained allele in human leukemia cell line HL60.";
RL   Leukemia 11:1187-1192(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9484787; DOI=10.1038/sj.onc.1201614;
RA   Gemma A., Hagiwara K., Vincent F., Ke Y., Hancock A.R., Nagashima M.,
RA   Bennett W.P., Harris C.C.;
RT   "hSmad5 gene, a human hSmad family member: its full length cDNA, genomic
RT   structure, promoter region and mutation analysis in human tumors.";
RL   Oncogene 16:951-956(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF GLY-419.
RX   PubMed=9442019; DOI=10.1074/jbc.273.4.1872;
RA   Nishimura R., Kato Y., Chen D., Harris S.E., Mundy G.R., Yoneda T.;
RT   "Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic
RT   differentiation of the pluripotent mesenchymal precursor cell line C2C12.";
RL   J. Biol. Chem. 273:1872-1879(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-16; 34-40; 130-158; 283-306 AND 309-319, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT THR-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lempens A., Norman J.C.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [8]
RP   REVIEW.
RX   PubMed=9759503; DOI=10.1146/annurev.biochem.67.1.753;
RA   Massague J.;
RT   "TGF-beta signal transduction.";
RL   Annu. Rev. Biochem. 67:753-791(1998).
RN   [9]
RP   REVIEW.
RX   PubMed=10647776; DOI=10.1016/s1359-6101(99)00012-x;
RA   Verschueren K., Huylebroeck D.;
RT   "Remarkable versatility of Smad proteins in the nucleus of transforming
RT   growth factor-beta activated cells.";
RL   Cytokine Growth Factor Rev. 10:187-199(1999).
RN   [10]
RP   REVIEW.
RX   PubMed=10708948; DOI=10.1016/s1359-6101(99)00024-6;
RA   Wrana J.L., Attisano L.;
RT   "The Smad pathway.";
RL   Cytokine Growth Factor Rev. 11:5-13(2000).
RN   [11]
RP   REVIEW.
RX   PubMed=10708949; DOI=10.1016/s1359-6101(99)00025-8;
RA   Miyazono K.;
RT   "TGF-beta signaling by Smad proteins.";
RL   Cytokine Growth Factor Rev. 11:15-22(2000).
RN   [12]
RP   INTERACTION WITH ZNF8.
RX   PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002;
RA   Jiao K., Zhou Y., Hogan B.L.M.;
RT   "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor,
RT   as a novel nuclear interaction partner of Smad1.";
RL   Mol. Cell. Biol. 22:7633-7644(2002).
RN   [13]
RP   INTERACTION WITH SUV39H1 AND SUV39H2.
RX   PubMed=15107829; DOI=10.1038/sj.onc.1207660;
RA   Frontelo P., Leader J.E., Yoo N., Potocki A.C., Crawford M., Kulik M.,
RA   Lechleider R.J.;
RT   "Suv39h histone methyltransferases interact with Smads and cooperate in
RT   BMP-induced repression.";
RL   Oncogene 23:5242-5251(2004).
RN   [14]
RP   INTERACTION WITH LEMD3.
RX   PubMed=15647271; DOI=10.1074/jbc.m411234200;
RA   Pan D., Estevez-Salmeron L.D., Stroschein S.L., Zhu X., He J., Zhou S.,
RA   Luo K.;
RT   "The integral inner nuclear membrane protein MAN1 physically interacts with
RT   the R-Smad proteins to repress signaling by the transforming growth
RT   factor-{beta} superfamily of cytokines.";
RL   J. Biol. Chem. 280:15992-16001(2005).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-463 AND SER-465, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   INTERACTION WITH RANBP3L.
RX   PubMed=25755279; DOI=10.1128/mcb.00121-15;
RA   Chen F., Lin X., Xu P., Zhang Z., Chen Y., Wang C., Han J., Zhao B.,
RA   Xiao M., Feng X.H.;
RT   "Nuclear export of Smads by RanBP3L regulates bone morphogenetic protein
RT   signaling and mesenchymal stem cell differentiation.";
RL   Mol. Cell. Biol. 35:1700-1711(2015).
CC   -!- FUNCTION: Transcriptional modulator activated by BMP (bone
CC       morphogenetic proteins) type 1 receptor kinase. SMAD5 is a receptor-
CC       regulated SMAD (R-SMAD).
CC   -!- SUBUNIT: May form trimers with the co-SMAD SMAD4. Interacts with PEBP2-
CC       alpha subunit and SMURF1. Interacts with SUV39H1 and SUV39H2. Interacts
CC       (via MH2 domain) with LEMD3. Interacts with WWP1. Interacts with
CC       TMEM119 (By similarity). Interacts with ZNF8 (PubMed:12370310).
CC       Interacts with RANBP3L (PubMed:25755279).
CC       {ECO:0000250|UniProtKB:P97454, ECO:0000269|PubMed:12370310,
CC       ECO:0000269|PubMed:15107829, ECO:0000269|PubMed:15647271,
CC       ECO:0000269|PubMed:25755279}.
CC   -!- INTERACTION:
CC       Q99717; P17844: DDX5; NbExp=3; IntAct=EBI-6391136, EBI-351962;
CC       Q99717; Q92876: KLK6; NbExp=3; IntAct=EBI-6391136, EBI-2432309;
CC       Q99717; Q99732: LITAF; NbExp=3; IntAct=EBI-6391136, EBI-725647;
CC       Q99717; P78424: POU6F2; NbExp=3; IntAct=EBI-6391136, EBI-12029004;
CC       Q99717; Q969T9: WBP2; NbExp=3; IntAct=EBI-6391136, EBI-727055;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Cytoplasmic in the
CC       absence of ligand. Migrates to the nucleus when complexed with SMAD4.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylated on serine by BMP (bone morphogenetic proteins) type
CC       1 receptor kinase.
CC   -!- PTM: Ubiquitin-mediated proteolysis by SMAD-specific E3 ubiquitin
CC       ligase SMURF1.
CC   -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U59913; AAC50791.1; -; mRNA.
DR   EMBL; AF010601; AAB66353.1; -; mRNA.
DR   EMBL; AF010607; AAB92396.1; -; Genomic_DNA.
DR   EMBL; AF010602; AAB92396.1; JOINED; Genomic_DNA.
DR   EMBL; AF010603; AAB92396.1; JOINED; Genomic_DNA.
DR   EMBL; AF010604; AAB92396.1; JOINED; Genomic_DNA.
DR   EMBL; AF010605; AAB92396.1; JOINED; Genomic_DNA.
DR   EMBL; AF010606; AAB92396.1; JOINED; Genomic_DNA.
DR   EMBL; U73825; AAB95090.1; -; mRNA.
DR   EMBL; AF009744; AAB82655.1; -; Genomic_DNA.
DR   EMBL; AF009739; AAB82655.1; JOINED; Genomic_DNA.
DR   EMBL; AF009740; AAB82655.1; JOINED; Genomic_DNA.
DR   EMBL; AF009741; AAB82655.1; JOINED; Genomic_DNA.
DR   EMBL; AF009742; AAB82655.1; JOINED; Genomic_DNA.
DR   EMBL; AF009743; AAB82655.1; JOINED; Genomic_DNA.
DR   EMBL; AF009678; AAB72180.1; -; mRNA.
DR   EMBL; BC009682; AAH09682.1; -; mRNA.
DR   CCDS; CCDS75308.1; -.
DR   RefSeq; NP_001001419.1; NM_001001419.2.
DR   RefSeq; NP_001001420.1; NM_001001420.2.
DR   RefSeq; NP_005894.3; NM_005903.6.
DR   RefSeq; XP_016864959.1; XM_017009470.1.
DR   PDB; 6FZS; X-ray; 2.31 A; A/B=9-138.
DR   PDB; 6TCE; X-ray; 2.92 A; A=9-138.
DR   PDBsum; 6FZS; -.
DR   PDBsum; 6TCE; -.
DR   SASBDB; Q99717; -.
DR   SMR; Q99717; -.
DR   BioGRID; 110265; 75.
DR   DIP; DIP-57571N; -.
DR   IntAct; Q99717; 39.
DR   MINT; Q99717; -.
DR   STRING; 9606.ENSP00000441954; -.
DR   iPTMnet; Q99717; -.
DR   PhosphoSitePlus; Q99717; -.
DR   BioMuta; SMAD5; -.
DR   DMDM; 13959566; -.
DR   EPD; Q99717; -.
DR   jPOST; Q99717; -.
DR   MassIVE; Q99717; -.
DR   MaxQB; Q99717; -.
DR   PaxDb; Q99717; -.
DR   PeptideAtlas; Q99717; -.
DR   PRIDE; Q99717; -.
DR   ProteomicsDB; 78432; -.
DR   Antibodypedia; 7303; 609 antibodies from 41 providers.
DR   DNASU; 4090; -.
DR   Ensembl; ENST00000509297; ENSP00000426696; ENSG00000113658.
DR   Ensembl; ENST00000545279; ENSP00000441954; ENSG00000113658.
DR   Ensembl; ENST00000545620; ENSP00000446474; ENSG00000113658.
DR   GeneID; 4090; -.
DR   KEGG; hsa:4090; -.
DR   MANE-Select; ENST00000545279.6; ENSP00000441954.2; NM_005903.7; NP_005894.3.
DR   UCSC; uc032vlw.2; human.
DR   CTD; 4090; -.
DR   DisGeNET; 4090; -.
DR   GeneCards; SMAD5; -.
DR   HGNC; HGNC:6771; SMAD5.
DR   HPA; ENSG00000113658; Low tissue specificity.
DR   MIM; 603110; gene.
DR   neXtProt; NX_Q99717; -.
DR   OpenTargets; ENSG00000113658; -.
DR   PharmGKB; PA30528; -.
DR   VEuPathDB; HostDB:ENSG00000113658; -.
DR   eggNOG; KOG3701; Eukaryota.
DR   GeneTree; ENSGT00940000155437; -.
DR   HOGENOM; CLU_026736_0_2_1; -.
DR   InParanoid; Q99717; -.
DR   OMA; MPRGDVQ; -.
DR   OrthoDB; 608001at2759; -.
DR   PhylomeDB; Q99717; -.
DR   PathwayCommons; Q99717; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q99717; -.
DR   SIGNOR; Q99717; -.
DR   BioGRID-ORCS; 4090; 10 hits in 259 CRISPR screens.
DR   ChiTaRS; SMAD5; human.
DR   GeneWiki; Mothers_against_decapentaplegic_homolog_5; -.
DR   GenomeRNAi; 4090; -.
DR   Pharos; Q99717; Tbio.
DR   PRO; PR:Q99717; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q99717; protein.
DR   Bgee; ENSG00000113658; Expressed in female gonad and 243 other tissues.
DR   ExpressionAtlas; Q99717; baseline and differential.
DR   Genevisible; Q99717; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0071144; C:heteromeric SMAD protein complex; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0071141; C:SMAD protein complex; NAS:BHF-UCL.
DR   GO; GO:0017151; F:DEAD/H-box RNA helicase binding; IPI:BHF-UCL.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0070411; F:I-SMAD binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0030509; P:BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0003161; P:cardiac conduction system development; NAS:BHF-UCL.
DR   GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl.
DR   GO; GO:0002051; P:osteoblast fate commitment; IEA:Ensembl.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:1901522; P:positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0060395; P:SMAD protein signal transduction; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   Gene3D; 2.60.200.10; -; 1.
DR   Gene3D; 3.90.520.10; -; 1.
DR   InterPro; IPR013790; Dwarfin.
DR   InterPro; IPR003619; MAD_homology1_Dwarfin-type.
DR   InterPro; IPR013019; MAD_homology_MH1.
DR   InterPro; IPR017855; SMAD-like_dom_sf.
DR   InterPro; IPR001132; SMAD_dom_Dwarfin-type.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR036578; SMAD_MH1_sf.
DR   PANTHER; PTHR13703; PTHR13703; 1.
DR   Pfam; PF03165; MH1; 1.
DR   Pfam; PF03166; MH2; 1.
DR   SMART; SM00523; DWA; 1.
DR   SMART; SM00524; DWB; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   SUPFAM; SSF56366; SSF56366; 1.
DR   PROSITE; PS51075; MH1; 1.
DR   PROSITE; PS51076; MH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   DNA-binding; Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:22223895"
FT   CHAIN           2..465
FT                   /note="Mothers against decapentaplegic homolog 5"
FT                   /id="PRO_0000090865"
FT   DOMAIN          13..137
FT                   /note="MH1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00438"
FT   DOMAIN          271..465
FT                   /note="MH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00439"
FT   REGION          163..249
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        163..184
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        185..201
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        232..249
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   METAL           65
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           110
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           122
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           127
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylthreonine"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:22223895"
FT   MOD_RES         463
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         465
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MUTAGEN         419
FT                   /note="G->S: Loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:9442019"
FT   CONFLICT        175
FT                   /note="D -> H (in Ref. 1; AAC50791)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        237
FT                   /note="N -> P (in Ref. 1; AAC50791)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        293
FT                   /note="S -> R (in Ref. 1; AAC50791)"
FT                   /evidence="ECO:0000305"
FT   HELIX           13..20
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           26..42
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           48..57
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          67..69
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          76..78
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          81..83
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           85..93
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          104..106
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          119..122
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   HELIX           125..127
FT                   /evidence="ECO:0007829|PDB:6FZS"
FT   STRAND          128..130
FT                   /evidence="ECO:0007829|PDB:6FZS"
SQ   SEQUENCE   465 AA;  52258 MW;  4A1FD7EC7BD06728 CRC64;
     MTSMASLFSF TSPAVKRLLG WKQGDEEEKW AEKAVDALVK KLKKKKGAME ELEKALSSPG
     QPSKCVTIPR SLDGRLQVSH RKGLPHVIYC RVWRWPDLQS HHELKPLDIC EFPFGSKQKE
     VCINPYHYKR VESPVLPPVL VPRHNEFNPQ HSLLVQFRNL SHNEPHMPQN ATFPDSFHQP
     NNTPFPLSPN SPYPPSPASS TYPNSPASSG PGSPFQLPAD TPPPAYMPPD DQMGQDNSQP
     MDTSNNMIPQ IMPSISSRDV QPVAYEEPKH WCSIVYYELN NRVGEAFHAS STSVLVDGFT
     DPSNNKSRFC LGLLSNVNRN STIENTRRHI GKGVHLYYVG GEVYAECLSD SSIFVQSRNC
     NFHHGFHPTT VCKIPSSCSL KIFNNQEFAQ LLAQSVNHGF EAVYELTKMC TIRMSFVKGW
     GAEYHRQDVT STPCWIEIHL HGPLQWLDKV LTQMGSPLNP ISSVS
//
ID   AAPK2_HUMAN             Reviewed;         552 AA.
AC   P54646; Q9H1E8; Q9UD43;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   23-FEB-2022, entry version 212.
DE   RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2;
DE            Short=AMPK subunit alpha-2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:32029622};
DE   AltName: Full=Acetyl-CoA carboxylase kinase;
DE            Short=ACACA kinase;
DE            EC=2.7.11.27 {ECO:0000250|UniProtKB:Q09137};
DE   AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase;
DE            Short=HMGCR kinase;
DE            EC=2.7.11.31 {ECO:0000250|UniProtKB:Q09137};
GN   Name=PRKAA2; Synonyms=AMPK, AMPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Heart;
RX   PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0;
RA   Aguan K., Scott J., See C.G., Sarkar N.H.;
RT   "Characterization and chromosomal localization of the human homologue of a
RT   rat AMP-activated protein kinase-encoding gene: a major regulator of lipid
RT   metabolism in mammals.";
RL   Gene 149:345-350(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4;
RA   Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D.,
RA   Scott J., Carey F.;
RT   "Molecular cloning, expression and chromosomal localisation of human AMP-
RT   activated protein kinase.";
RL   FEBS Lett. 356:117-121(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF EP300.
RX   PubMed=11518699; DOI=10.1074/jbc.c100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [7]
RP   ACTIVITY REGULATION.
RX   PubMed=11602624; DOI=10.1172/jci13505;
RA   Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M.,
RA   Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J.,
RA   Moller D.E.;
RT   "Role of AMP-activated protein kinase in mechanism of metformin action.";
RL   J. Clin. Invest. 108:1167-1174(2001).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF CFTR.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein kinase
RT   in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [10]
RP   PHOSPHORYLATION AT THR-172, AND ACTIVITY REGULATION.
RX   PubMed=15980064; DOI=10.1074/jbc.m503824200;
RA   Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R.,
RA   Witters L.A.;
RT   "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated
RT   protein kinase kinases.";
RL   J. Biol. Chem. 280:29060-29066(2005).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J.,
RA   Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3.
RX   PubMed=17711846; DOI=10.1074/jbc.m705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P.,
RA   Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [13]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=17486097; DOI=10.1038/nature05828;
RA   Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H.,
RA   Shong M., Kim J.M., Kim J., Chung J.;
RT   "Energy-dependent regulation of cell structure by AMP-activated protein
RT   kinase.";
RL   Nature 447:1017-1020(2007).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5.
RX   PubMed=18184930; DOI=10.2337/db07-0843;
RA   McGee S.L., van Denderen B.J., Howlett K.F., Mollica J., Schertzer J.D.,
RA   Kemp B.E., Hargreaves M.;
RT   "AMP-activated protein kinase regulates GLUT4 transcription by
RT   phosphorylating histone deacetylase 5.";
RL   Diabetes 57:860-867(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KLC1.
RX   PubMed=20074060; DOI=10.1042/bst0380205;
RA   McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A.;
RT   "Cell-wide analysis of secretory granule dynamics in three dimensions in
RT   living pancreatic beta-cells: evidence against a role for AMPK-dependent
RT   phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin
RT   granule movement.";
RL   Biochem. Soc. Trans. 38:205-208(2010).
RN   [19]
RP   FUNCTION.
RX   PubMed=20160076; DOI=10.1073/pnas.0913860107;
RA   Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K.,
RA   Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B.,
RA   Walker C.L.;
RT   "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to
RT   ROS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010).
RN   [20]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory
RT   feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF ULK1.
RX   PubMed=21205641; DOI=10.1126/science.1196371;
RA   Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A.,
RA   Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M.,
RA   Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.;
RT   "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects
RT   energy sensing to mitophagy.";
RL   Science 331:456-461(2011).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [25]
RP   ACTIVITY REGULATION BY SALICYLATE.
RX   PubMed=22517326; DOI=10.1126/science.1215327;
RA   Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C.,
RA   Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J., Kemp B.E.,
RA   Sakamoto K., Steinberg G.R., Hardie D.G.;
RT   "The ancient drug salicylate directly activates AMP-activated protein
RT   kinase.";
RL   Science 336:918-922(2012).
RN   [26]
RP   DEPHOSPHORYLATION AT THR-172.
RX   PubMed=23088624; DOI=10.1042/bj20121201;
RA   Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y., Takano-Yamamoto T.,
RA   Tamura S., Kobayashi T.;
RT   "N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to
RT   dephosphorylate their physiological substrates in cells.";
RL   Biochem. J. 449:741-749(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION AT THR-172.
RX   PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065;
RA   Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J.,
RA   DeBerardinis R.J., MacKeigan J.P.;
RT   "A mitochondrial RNAi screen defines cellular bioenergetic determinants and
RT   identifies an adenylate kinase as a key regulator of ATP levels.";
RL   Cell Rep. 7:907-917(2014).
RN   [29]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=25687571; DOI=10.1074/mcp.m114.047159;
RA   Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S.,
RA   Kelly I., Landry C.R., Faure R.L.;
RT   "The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole-
RT   4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC)
RT   plays a central role in insulin signaling and the Golgi/endosomes protein
RT   network.";
RL   Mol. Cell. Proteomics 14:1079-1092(2015).
RN   [30]
RP   FUNCTION.
RX   PubMed=28561066; DOI=10.1038/ncomms15637;
RA   Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M.,
RA   Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B.,
RA   Proikas-Cezanne T.;
RT   "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling
RT   circuits in the control of autophagy.";
RL   Nat. Commun. 8:15637-15637(2017).
RN   [31]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=32029622; DOI=10.1126/science.aay0542;
RA   Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S.,
RA   Loomba R., Karin M., Witztum J.L., Saltiel A.R.;
RT   "An AMPK-caspase-6 axis controls liver damage in nonalcoholic
RT   steatohepatitis.";
RL   Science 367:652-660(2020).
RN   [32]
RP   FUNCTION.
RX   PubMed=34077757; DOI=10.1016/j.molcel.2021.05.005;
RA   Liu R., Lee J.H., Li J., Yu R., Tan L., Xia Y., Zheng Y., Bian X.L.,
RA   Lorenzi P.L., Chen Q., Lu Z.;
RT   "Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of
RT   lipid droplets.";
RL   Mol. Cell 81:2722-2735(2021).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279.
RX   PubMed=20124709; DOI=10.1107/s1744309109052543;
RA   Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E., Finerty P.J. Jr.,
RA   Newman E., Mackenzie F., Dhe-Paganon S.;
RT   "A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-
RT   binding site and catalytic loop refolding as a means of regulation.";
RL   Acta Crystallogr. F 66:143-151(2010).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN
RP   COMPLEX WITH COMPOUND C, AND ACTIVITY REGULATION.
RX   PubMed=21543851; DOI=10.1107/s0907444911010201;
RA   Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M.,
RA   Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T., Okada-Iwabu M.,
RA   Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.;
RT   "Structural basis for compound C inhibition of the human AMP-activated
RT   protein kinase alpha2 subunit kinase domain.";
RL   Acta Crystallogr. D 67:480-487(2011).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase (AMPK), an
CC       energy sensor protein kinase that plays a key role in regulating
CC       cellular energy metabolism (PubMed:17307971, PubMed:17712357). In
CC       response to reduction of intracellular ATP levels, AMPK activates
CC       energy-producing pathways and inhibits energy-consuming processes:
CC       inhibits protein, carbohydrate and lipid biosynthesis, as well as cell
CC       growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts
CC       via direct phosphorylation of metabolic enzymes, and by longer-term
CC       effects via phosphorylation of transcription regulators
CC       (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by
CC       phosphorylating and inactivating lipid metabolic enzymes such as ACACA,
CC       ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol
CC       synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB)
CC       and hormone-sensitive lipase (LIPE) enzymes, respectively
CC       (PubMed:7959015). Promotes lipolysis of lipid droplets by mediating
CC       phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757).
CC       Regulates insulin-signaling and glycolysis by phosphorylating IRS1,
CC       PFKFB2 and PFKFB3 (By similarity). Involved in insulin receptor/INSR
CC       internalization (PubMed:25687571). AMPK stimulates glucose uptake in
CC       muscle by increasing the translocation of the glucose transporter
CC       SLC2A4/GLUT4 to the plasma membrane, possibly by mediating
CC       phosphorylation of TBC1D4/AS160 (By similarity). Regulates
CC       transcription and chromatin structure by phosphorylating transcription
CC       regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3,
CC       histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53,
CC       SREBF1, SREBF2 and PPARGC1A (PubMed:11554766, PubMed:11518699,
CC       PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key
CC       regulator of glucose homeostasis in liver by phosphorylating
CC       CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By
CC       similarity). In response to stress, phosphorylates 'Ser-36' of histone
CC       H2B (H2BS36ph), leading to promote transcription (By similarity). Acts
CC       as a key regulator of cell growth and proliferation by phosphorylating
CC       TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation,
CC       negatively regulates the mTORC1 complex by phosphorylating RPTOR
CC       component of the mTORC1 complex and by phosphorylating and activating
CC       TSC2 (PubMed:14651849, PubMed:20160076, PubMed:21205641). In response
CC       to nutrient limitation, promotes autophagy by phosphorylating and
CC       activating ATG1/ULK1 (PubMed:21205641). In that process also activates
CC       WDR45/WIPI4 (PubMed:28561066). Phosphorylates CASP6, thereby preventing
CC       its autoprocessing and subsequent activation (PubMed:32029622). AMPK
CC       also acts as a regulator of circadian rhythm by mediating
CC       phosphorylation of CRY1, leading to destabilize it (By similarity). May
CC       regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading
CC       to stabilize it (By similarity). Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by indirectly
CC       activating myosin (PubMed:17486097). Also phosphorylates CFTR, EEF2K,
CC       KLC1, NOS3 and SLC12A1 (PubMed:12519745, PubMed:20074060). Plays an
CC       important role in the differential regulation of pro-autophagy
CC       (composed of PIK3C3, BECN1, PIK3R4 and UVRAG or ATG14) and non-
CC       autophagy (composed of PIK3C3, BECN1 and PIK3R4) complexes, in response
CC       to glucose starvation (By similarity). Can inhibit the non-autophagy
CC       complex by phosphorylating PIK3C3 and can activate the pro-autophagy
CC       complex by phosphorylating BECN1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q09137, ECO:0000250|UniProtKB:Q8BRK8,
CC       ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766,
CC       ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849,
CC       ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097,
CC       ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930,
CC       ECO:0000269|PubMed:20074060, ECO:0000269|PubMed:20160076,
CC       ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25687571,
CC       ECO:0000269|PubMed:28561066, ECO:0000269|PubMed:32029622,
CC       ECO:0000269|PubMed:34077757, ECO:0000269|PubMed:7959015,
CC       ECO:0000303|PubMed:17307971, ECO:0000303|PubMed:17712357}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:32029622};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:Q09137};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[acetyl-CoA carboxylase] = ADP + H(+) + O-
CC         phospho-L-seryl-[acetyl-CoA carboxylase]; Xref=Rhea:RHEA:20333,
CC         Rhea:RHEA-COMP:13722, Rhea:RHEA-COMP:13723, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.27;
CC         Evidence={ECO:0000250|UniProtKB:Q09137};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A
CC         reductase] = ADP + H(+) + O-phospho-L-seryl-[3-hydroxy-3-
CC         methylglutaryl-coenzyme A reductase]; Xref=Rhea:RHEA:23172,
CC         Rhea:RHEA-COMP:13692, Rhea:RHEA-COMP:13693, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.31;
CC         Evidence={ECO:0000250|UniProtKB:Q09137};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-172
CC       (PubMed:15980064). Binding of AMP to non-catalytic gamma subunit
CC       (PRKAG1, PRKAG2 or PRKAG3) results in allosteric activation, inducing
CC       phosphorylation on Thr-172 (PubMed:15980064). AMP-binding to gamma
CC       subunit also sustains activity by preventing dephosphorylation of Thr-
CC       172 (PubMed:15980064). ADP also stimulates Thr-172 phosphorylation,
CC       without stimulating already phosphorylated AMPK (PubMed:15980064). ATP
CC       promotes dephosphorylation of Thr-172, rendering the enzyme inactive
CC       (PubMed:15980064). Under physiological conditions AMPK mainly exists in
CC       its inactive form in complex with ATP, which is much more abundant than
CC       AMP. AMPK is activated by antihyperglycemic drug metformin, a drug
CC       prescribed to patients with type 2 diabetes: in vivo, metformin seems
CC       to mainly inhibit liver gluconeogenesis. However, metformin can be used
CC       to activate AMPK in muscle and other cells in culture or ex vivo
CC       (PubMed:11602624). Selectively inhibited by compound C (6-[4-(2-
CC       Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a]
CC       pyrimidine. Activated by resveratrol, a natural polyphenol present in
CC       red wine, and S17834, a synthetic polyphenol. Salicylate/aspirin
CC       directly activates kinase activity, primarily by inhibiting Thr-172
CC       dephosphorylation. {ECO:0000269|PubMed:11602624,
CC       ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21543851,
CC       ECO:0000269|PubMed:22517326}.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1
CC       or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic
CC       subunits (PRKAG1, PRKAG2 or PRKAG3) (PubMed:21543851). Interacts with
CC       FNIP1 and FNIP2. Associates with internalized insulin receptor/INSR
CC       complexes on Golgi/endosomal membranes; PRKAA2/AMPK2 together with ATIC
CC       and HACD3/PTPLAD1 is proposed to be part of a signaling network
CC       regulating INSR autophosphorylation and endocytosis (PubMed:25687571).
CC       {ECO:0000269|PubMed:21543851, ECO:0000269|PubMed:25687571}.
CC   -!- INTERACTION:
CC       P54646; Q8IZP0-5: ABI1; NbExp=3; IntAct=EBI-1383852, EBI-11743294;
CC       P54646; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-1383852, EBI-743598;
CC       P54646; Q9NYB9-2: ABI2; NbExp=3; IntAct=EBI-1383852, EBI-11096309;
CC       P54646; Q13155: AIMP2; NbExp=3; IntAct=EBI-1383852, EBI-745226;
CC       P54646; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-1383852, EBI-357530;
CC       P54646; A2BDD9: AMOT; NbExp=3; IntAct=EBI-1383852, EBI-17286414;
CC       P54646; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-1383852, EBI-746752;
CC       P54646; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-1383852, EBI-12224467;
CC       P54646; Q92624: APPBP2; NbExp=3; IntAct=EBI-1383852, EBI-743771;
CC       P54646; Q96B67: ARRDC3; NbExp=3; IntAct=EBI-1383852, EBI-2875665;
CC       P54646; Q5T686: AVPI1; NbExp=3; IntAct=EBI-1383852, EBI-8640233;
CC       P54646; Q9P1Z2: CALCOCO1; NbExp=3; IntAct=EBI-1383852, EBI-749920;
CC       P54646; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-1383852, EBI-739580;
CC       P54646; P0C7W6: CCDC172; NbExp=3; IntAct=EBI-1383852, EBI-2548868;
CC       P54646; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-1383852, EBI-745269;
CC       P54646; Q00587-2: CDC42EP1; NbExp=3; IntAct=EBI-1383852, EBI-11027409;
CC       P54646; Q01850: CDR2; NbExp=3; IntAct=EBI-1383852, EBI-1181367;
CC       P54646; O14627: CDX4; NbExp=3; IntAct=EBI-1383852, EBI-10181162;
CC       P54646; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-1383852, EBI-11523759;
CC       P54646; O75638-2: CTAG2; NbExp=3; IntAct=EBI-1383852, EBI-12265122;
CC       P54646; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-1383852, EBI-3867333;
CC       P54646; Q9NQM4: DNAAF6; NbExp=3; IntAct=EBI-1383852, EBI-10239299;
CC       P54646; P50570: DNM2; NbExp=3; IntAct=EBI-1383852, EBI-346547;
CC       P54646; Q92997: DVL3; NbExp=3; IntAct=EBI-1383852, EBI-739789;
CC       P54646; Q9Y6C2-2: EMILIN1; NbExp=3; IntAct=EBI-1383852, EBI-11748557;
CC       P54646; O95208-2: EPN2; NbExp=3; IntAct=EBI-1383852, EBI-12135243;
CC       P54646; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-1383852, EBI-10242151;
CC       P54646; Q6FG41: FOS; NbExp=3; IntAct=EBI-1383852, EBI-10198738;
CC       P54646; O75420: GIGYF1; NbExp=3; IntAct=EBI-1383852, EBI-947774;
CC       P54646; P08151: GLI1; NbExp=3; IntAct=EBI-1383852, EBI-308084;
CC       P54646; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1383852, EBI-618309;
CC       P54646; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1383852, EBI-11163335;
CC       P54646; O75791: GRAP2; NbExp=3; IntAct=EBI-1383852, EBI-740418;
CC       P54646; P28799: GRN; NbExp=3; IntAct=EBI-1383852, EBI-747754;
CC       P54646; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-1383852, EBI-2549423;
CC       P54646; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-1383852, EBI-10172004;
CC       P54646; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1383852, EBI-11522367;
CC       P54646; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383852, EBI-747204;
CC       P54646; Q719H9: KCTD1; NbExp=3; IntAct=EBI-1383852, EBI-9027502;
CC       P54646; Q7L273: KCTD9; NbExp=3; IntAct=EBI-1383852, EBI-4397613;
CC       P54646; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-1383852, EBI-3437878;
CC       P54646; Q96L93-6: KIF16B; NbExp=3; IntAct=EBI-1383852, EBI-10988217;
CC       P54646; Q5T7B8-2: KIF24; NbExp=3; IntAct=EBI-1383852, EBI-10213781;
CC       P54646; Q9BVG8: KIFC3; NbExp=4; IntAct=EBI-1383852, EBI-2125614;
CC       P54646; P08779: KRT16; NbExp=3; IntAct=EBI-1383852, EBI-356410;
CC       P54646; Q15323: KRT31; NbExp=3; IntAct=EBI-1383852, EBI-948001;
CC       P54646; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-1383852, EBI-10172052;
CC       P54646; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-2686809;
CC       P54646; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-11985629;
CC       P54646; P80188: LCN2; NbExp=3; IntAct=EBI-1383852, EBI-11911016;
CC       P54646; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1383852, EBI-741037;
CC       P54646; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383852, EBI-2340269;
CC       P54646; Q6PF18: MORN3; NbExp=3; IntAct=EBI-1383852, EBI-9675802;
CC       P54646; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-1383852, EBI-995714;
CC       P54646; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1383852, EBI-11522433;
CC       P54646; P12524-2: MYCL; NbExp=3; IntAct=EBI-1383852, EBI-18936665;
CC       P54646; Q15742: NAB2; NbExp=3; IntAct=EBI-1383852, EBI-8641936;
CC       P54646; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-1383852, EBI-10172876;
CC       P54646; Q15233-2: NONO; NbExp=3; IntAct=EBI-1383852, EBI-10203843;
CC       P54646; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-1383852, EBI-945833;
CC       P54646; Q96F24: NRBF2; NbExp=3; IntAct=EBI-1383852, EBI-2362014;
CC       P54646; Q86Y26: NUTM1; NbExp=3; IntAct=EBI-1383852, EBI-10178410;
CC       P54646; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-1383852, EBI-12014286;
CC       P54646; Q7Z5V6-2: PPP1R32; NbExp=3; IntAct=EBI-1383852, EBI-12000762;
CC       P54646; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383852, EBI-11320284;
CC       P54646; Q9Y478: PRKAB1; NbExp=7; IntAct=EBI-1383852, EBI-719769;
CC       P54646; O43741: PRKAB2; NbExp=12; IntAct=EBI-1383852, EBI-1053424;
CC       P54646; P54619: PRKAG1; NbExp=12; IntAct=EBI-1383852, EBI-1181439;
CC       P54646; P31321: PRKAR1B; NbExp=3; IntAct=EBI-1383852, EBI-2805516;
CC       P54646; P41219: PRPH; NbExp=3; IntAct=EBI-1383852, EBI-752074;
CC       P54646; Q86YV0: RASAL3; NbExp=3; IntAct=EBI-1383852, EBI-3437896;
CC       P54646; Q93062: RBPMS; NbExp=3; IntAct=EBI-1383852, EBI-740322;
CC       P54646; Q04864-2: REL; NbExp=4; IntAct=EBI-1383852, EBI-10829018;
CC       P54646; Q8HWS3: RFX6; NbExp=3; IntAct=EBI-1383852, EBI-746118;
CC       P54646; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-1383852, EBI-396669;
CC       P54646; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-1383852, EBI-748621;
CC       P54646; Q15477: SKIV2L; NbExp=3; IntAct=EBI-1383852, EBI-373226;
CC       P54646; Q9H6Q3: SLA2; NbExp=3; IntAct=EBI-1383852, EBI-1222854;
CC       P54646; Q5JUK2: SOHLH1; NbExp=3; IntAct=EBI-1383852, EBI-12288855;
CC       P54646; O43609: SPRY1; NbExp=3; IntAct=EBI-1383852, EBI-3866665;
CC       P54646; Q6ZMT1: STAC2; NbExp=3; IntAct=EBI-1383852, EBI-948802;
CC       P54646; Q15831: STK11; NbExp=3; IntAct=EBI-1383852, EBI-306838;
CC       P54646; P15884: TCF4; NbExp=3; IntAct=EBI-1383852, EBI-533224;
CC       P54646; Q96CG3: TIFA; NbExp=3; IntAct=EBI-1383852, EBI-740711;
CC       P54646; Q08117: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-717810;
CC       P54646; Q08117-2: TLE5; NbExp=3; IntAct=EBI-1383852, EBI-11741437;
CC       P54646; Q15645: TRIP13; NbExp=3; IntAct=EBI-1383852, EBI-358993;
CC       P54646; Q15654: TRIP6; NbExp=3; IntAct=EBI-1383852, EBI-742327;
CC       P54646; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-1383852, EBI-739485;
CC       P54646; O75385: ULK1; NbExp=2; IntAct=EBI-1383852, EBI-908831;
CC       P54646; Q9Y6N9-4: USH1C; NbExp=3; IntAct=EBI-1383852, EBI-11523636;
CC       P54646; Q495M9: USH1G; NbExp=3; IntAct=EBI-1383852, EBI-8601749;
CC       P54646; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-1383852, EBI-739895;
CC       P54646; Q9UK41-2: VPS28; NbExp=3; IntAct=EBI-1383852, EBI-12146727;
CC       P54646; Q9H9H4: VPS37B; NbExp=3; IntAct=EBI-1383852, EBI-4400866;
CC       P54646; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1383852, EBI-2799833;
CC       P54646; O76024: WFS1; NbExp=3; IntAct=EBI-1383852, EBI-720609;
CC       P54646; O00308: WWP2; NbExp=3; IntAct=EBI-1383852, EBI-743923;
CC       P54646; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-1383852, EBI-742740;
CC       P54646; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-1383852, EBI-12030590;
CC       P54646; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-1383852, EBI-1640204;
CC       P54646; Q8NF99: ZNF397; NbExp=3; IntAct=EBI-1383852, EBI-10213894;
CC       P54646; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-1383852, EBI-5667532;
CC       P54646; Q9WTK7: Stk11; Xeno; NbExp=2; IntAct=EBI-1383852, EBI-8627450;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q8BRK8}. Nucleus
CC       {ECO:0000269|PubMed:15866171}. Note=In response to stress, recruited by
CC       p53/TP53 to specific promoters. {ECO:0000269|PubMed:15866171}.
CC   -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some sequence
CC       similarity with the ubiquitin-associated domains and represses kinase
CC       activity. {ECO:0000250|UniProtKB:Q13131}.
CC   -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q8BRK8}.
CC   -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39. Also
CC       phosphorylated at Thr-172 by CAMKK2; triggered by a rise in
CC       intracellular calcium ions, without detectable changes in the AMP/ATP
CC       ratio. CAMKK1 can also phosphorylate Thr-172, but at much lower level.
CC       Dephosphorylated by protein phosphatase 2A and 2C (PP2A and PP2C).
CC       Phosphorylated by ULK1; leading to negatively regulate AMPK activity
CC       and suggesting the existence of a regulatory feedback loop between ULK1
CC       and AMPK. Dephosphorylated by PPM1A and PPM1B at Thr-172 (mediated by
CC       STK11/LKB1). {ECO:0000269|PubMed:15980064,
CC       ECO:0000269|PubMed:21460634}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U06454; AAA64745.1; -; mRNA.
DR   EMBL; AL035705; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069680; AAH69680.1; -; mRNA.
DR   EMBL; BC069740; AAH69740.1; -; mRNA.
DR   EMBL; BC069823; AAH69823.1; -; mRNA.
DR   CCDS; CCDS605.1; -.
DR   PIR; S51025; S51025.
DR   RefSeq; NP_006243.2; NM_006252.3.
DR   PDB; 2H6D; X-ray; 1.85 A; A=6-279.
DR   PDB; 2LTU; NMR; -; A=282-339.
DR   PDB; 2YZA; X-ray; 3.02 A; A=6-279.
DR   PDB; 3AQV; X-ray; 2.08 A; A=6-279.
DR   PDB; 4CFE; X-ray; 3.02 A; A/C=1-552.
DR   PDB; 4CFF; X-ray; 3.92 A; A/C=1-552.
DR   PDB; 4ZHX; X-ray; 2.99 A; A/C=2-552.
DR   PDB; 5EZV; X-ray; 2.99 A; A/C=2-347, A/C=397-552.
DR   PDB; 5ISO; X-ray; 2.63 A; A/C=1-552.
DR   PDB; 6B1U; X-ray; 2.77 A; A/C=2-552.
DR   PDB; 6B2E; X-ray; 3.80 A; A=2-552.
DR   PDB; 6BX6; X-ray; 2.90 A; A=6-279.
DR   PDBsum; 2H6D; -.
DR   PDBsum; 2LTU; -.
DR   PDBsum; 2YZA; -.
DR   PDBsum; 3AQV; -.
DR   PDBsum; 4CFE; -.
DR   PDBsum; 4CFF; -.
DR   PDBsum; 4ZHX; -.
DR   PDBsum; 5EZV; -.
DR   PDBsum; 5ISO; -.
DR   PDBsum; 6B1U; -.
DR   PDBsum; 6B2E; -.
DR   PDBsum; 6BX6; -.
DR   BMRB; P54646; -.
DR   SMR; P54646; -.
DR   BioGRID; 111550; 190.
DR   ComplexPortal; CPX-5787; AMPK complex, alpha2-beta1-gamma1 variant.
DR   ComplexPortal; CPX-5790; AMPK complex, alpha2-beta2-gamma1 variant.
DR   ComplexPortal; CPX-5840; AMPK complex, alpha2-beta2-gamma3 variant.
DR   ComplexPortal; CPX-5843; AMPK complex, alpha2-beta1-gamma3 variant.
DR   ComplexPortal; CPX-5844; AMPK complex, alpha2-beta1-gamma2 variant.
DR   ComplexPortal; CPX-5845; AMPK complex, alpha2-beta2-gamma2 variant.
DR   CORUM; P54646; -.
DR   DIP; DIP-39796N; -.
DR   IntAct; P54646; 142.
DR   MINT; P54646; -.
DR   STRING; 9606.ENSP00000360290; -.
DR   BindingDB; P54646; -.
DR   ChEMBL; CHEMBL2116; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00131; Adenosine phosphate.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00273; Topiramate.
DR   DrugCentral; P54646; -.
DR   TCDB; 8.A.104.1.1; the 5'-amp-activated protein kinase (ampk) family.
DR   GlyConnect; 985; 2 N-Linked glycans (1 site).
DR   GlyGen; P54646; 2 sites, 3 N-linked glycans (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; P54646; -.
DR   PhosphoSitePlus; P54646; -.
DR   BioMuta; PRKAA2; -.
DR   DMDM; 20178276; -.
DR   EPD; P54646; -.
DR   jPOST; P54646; -.
DR   MassIVE; P54646; -.
DR   MaxQB; P54646; -.
DR   PaxDb; P54646; -.
DR   PeptideAtlas; P54646; -.
DR   PRIDE; P54646; -.
DR   ProteomicsDB; 56689; -.
DR   Antibodypedia; 3399; 823 antibodies from 43 providers.
DR   DNASU; 5563; -.
DR   Ensembl; ENST00000371244; ENSP00000360290; ENSG00000162409.
DR   GeneID; 5563; -.
DR   KEGG; hsa:5563; -.
DR   MANE-Select; ENST00000371244.9; ENSP00000360290.4; NM_006252.4; NP_006243.2.
DR   UCSC; uc001cyk.5; human.
DR   CTD; 5563; -.
DR   DisGeNET; 5563; -.
DR   GeneCards; PRKAA2; -.
DR   HGNC; HGNC:9377; PRKAA2.
DR   HPA; ENSG00000162409; Tissue enhanced (heart muscle, skeletal muscle, tongue).
DR   MIM; 600497; gene.
DR   neXtProt; NX_P54646; -.
DR   OpenTargets; ENSG00000162409; -.
DR   PharmGKB; PA33745; -.
DR   VEuPathDB; HostDB:ENSG00000162409; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   GeneTree; ENSGT00940000156945; -.
DR   HOGENOM; CLU_000288_59_3_1; -.
DR   OrthoDB; 1127668at2759; -.
DR   PhylomeDB; P54646; -.
DR   TreeFam; TF314032; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.11.31; 2681.
DR   PathwayCommons; P54646; -.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity.
DR   Reactome; R-HSA-200425; Carnitine metabolism.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-9613354; Lipophagy.
DR   Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs.
DR   SignaLink; P54646; -.
DR   SIGNOR; P54646; -.
DR   BioGRID-ORCS; 5563; 7 hits in 1068 CRISPR screens.
DR   ChiTaRS; PRKAA2; human.
DR   EvolutionaryTrace; P54646; -.
DR   GeneWiki; PRKAA2; -.
DR   GenomeRNAi; 5563; -.
DR   Pharos; P54646; Tchem.
DR   PRO; PR:P54646; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P54646; protein.
DR   Bgee; ENSG00000162409; Expressed in biceps brachii and 220 other tissues.
DR   ExpressionAtlas; P54646; baseline and differential.
DR   Genevisible; P54646; HS.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0010494; C:cytoplasmic stress granule; ISS:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:ARUK-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IPI:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IDA:ComplexPortal.
DR   GO; GO:0050405; F:[acetyl-CoA carboxylase] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0035174; F:histone serine kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISS:ARUK-UCL.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISS:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:ARUK-UCL.
DR   GO; GO:0031669; P:cellular response to nutrient levels; IDA:ComplexPortal.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:ARUK-UCL.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:1904428; P:negative regulation of tubulin deacetylation; ISS:ARUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:2000758; P:positive regulation of peptidyl-lysine acetylation; ISS:ARUK-UCL.
DR   GO; GO:1903829; P:positive regulation of protein localization; ISS:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; ISS:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL.
DR   GO; GO:0062028; P:regulation of stress granule assembly; IEA:Ensembl.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd12200; AMPKA2_C; 1.
DR   CDD; cd14404; UBA_AID_AAPK2; 1.
DR   IDEAL; IID00661; -.
DR   InterPro; IPR032270; AMPK_C.
DR   InterPro; IPR039148; AMPKA2_C.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR028783; PRKAA2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF16579; AdenylateSensor; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Autophagy; Biological rhythms;
KW   Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator;
KW   Cytoplasm; Fatty acid biosynthesis; Fatty acid metabolism; Kinase;
KW   Lipid biosynthesis; Lipid metabolism; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Steroid biosynthesis; Steroid metabolism;
KW   Sterol biosynthesis; Sterol metabolism; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Wnt signaling pathway.
FT   CHAIN           1..552
FT                   /note="5'-AMP-activated protein kinase catalytic subunit
FT                   alpha-2"
FT                   /id="PRO_0000085594"
FT   DOMAIN          16..268
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         22..30
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          291..376
FT                   /note="AIS"
FT                   /evidence="ECO:0000250|UniProtKB:Q13131"
FT   REGION          477..521
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        498..521
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        139
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         45
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         172
FT                   /note="Phosphothreonine; by LKB1 and CaMKK2"
FT                   /evidence="ECO:0000269|PubMed:15980064,
FT                   ECO:0000269|PubMed:24767988"
FT   MOD_RES         258
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q09137"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         491
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q09137"
FT   VARIANT         371
FT                   /note="P -> T (in breast cancer samples; infiltrating
FT                   ductal carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_035623"
FT   VARIANT         407
FT                   /note="R -> Q (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040355"
FT   VARIANT         523
FT                   /note="S -> G (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035624"
FT   MUTAGEN         172
FT                   /note="T->D: Phosphomimetic mutant."
FT   CONFLICT        180
FT                   /note="A -> T (in Ref. 1; AAA64745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="D -> G (in Ref. 1; AAA64745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        403..404
FT                   /note="HL -> RQ (in Ref. 1; AAA64745)"
FT                   /evidence="ECO:0000305"
FT   STRAND          16..24
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          26..35
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   TURN            36..38
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          41..48
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           49..54
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           58..69
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          79..84
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          86..94
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           101..108
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           113..133
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           142..144
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           160..162
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           192..209
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           219..228
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   STRAND          235..237
FT                   /evidence="ECO:0007829|PDB:6BX6"
FT   HELIX           239..248
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           253..255
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           259..264
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           266..269
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           274..276
FT                   /evidence="ECO:0007829|PDB:2H6D"
FT   HELIX           283..286
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           290..299
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           304..312
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           319..335
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           338..341
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          403..408
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           412..426
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          429..434
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          437..443
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   TURN            445..447
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          450..459
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          461..463
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   STRAND          465..472
FT                   /evidence="ECO:0007829|PDB:5ISO"
FT   HELIX           535..549
FT                   /evidence="ECO:0007829|PDB:5ISO"
SQ   SEQUENCE   552 AA;  62320 MW;  C46AAFC1D5104975 CRC64;
     MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK
     IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF
     QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA
     APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS
     VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF
     ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP
     PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY
     RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR
     SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF
     EMCASLITTL AR
//
ID   CLN5_HUMAN              Reviewed;         358 AA.
AC   O75503; B3KQK7;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   29-APR-2008, sequence version 2.
DT   23-FEB-2022, entry version 174.
DE   RecName: Full=Ceroid-lipofuscinosis neuronal protein 5;
DE            Short=Protein CLN5;
DE   Contains:
DE     RecName: Full=Ceroid-lipofuscinosis neuronal protein 5, secreted form;
GN   Name=CLN5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT CLN5 ASN-230, AND VARIANT ARG-319.
RC   TISSUE=Fetal brain;
RX   PubMed=9662406; DOI=10.1038/975;
RA   Savukoski M., Klockars T., Holmberg V., Santavuori P., Lander E.S.,
RA   Peltonen L.;
RT   "CLN5, a novel gene encoding a putative transmembrane protein mutated in
RT   Finnish variant late infantile neuronal ceroid lipofuscinosis.";
RL   Nat. Genet. 19:286-288(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=11971870; DOI=10.1093/hmg/11.8.885;
RA   Isosomppi J., Vesa J., Jalanko A., Peltonen L.;
RT   "Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5
RT   protein.";
RL   Hum. Mol. Genet. 11:885-891(2002).
RN   [5]
RP   FUNCTION (SECRETED FORM), INTERACTION WITH SORT1; RAB5A AND RAB7A, AND
RP   SUBCELLULAR LOCATION (SECRETED FORM).
RX   PubMed=22431521; DOI=10.1128/mcb.06726-11;
RA   Mamo A., Jules F., Dumaresq-Doiron K., Costantino S., Lefrancois S.;
RT   "The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal
RT   sorting.";
RL   Mol. Cell. Biol. 32:1855-1866(2012).
RN   [6]
RP   VARIANT CLN5 HIS-63.
RX   PubMed=15728307; DOI=10.1212/01.wnl.0000151974.44980.f1;
RA   Pineda-Trujillo N., Cornejo W., Carrizosa J., Wheeler R.B., Munera S.,
RA   Valencia A., Agudelo-Arango J., Cogollo A., Anderson G., Bedoya G.,
RA   Mole S.E., Ruiz-Linares A.;
RT   "A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of
RT   juvenile onset.";
RL   Neurology 64:740-742(2005).
RN   [7]
RP   VARIANTS CLN5 PRO-63 AND ASN-230.
RX   PubMed=16814585; DOI=10.1016/j.ymgme.2006.04.010;
RA   Bessa C., Teixeira C.A., Mangas M., Dias A., Sa Miranda M.C., Guimaraes A.,
RA   Ferreira J.C., Canas N., Cabral P., Ribeiro M.G.;
RT   "Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights
RT   into molecular mechanisms of CLN5 deficiency.";
RL   Mol. Genet. Metab. 89:245-253(2006).
RN   [8]
RP   VARIANT CLN5 ASP-209.
RX   PubMed=17607606; DOI=10.1055/s-2007-981449;
RA   Cannelli N., Nardocci N., Cassandrini D., Morbin M., Aiello C., Bugiani M.,
RA   Criscuolo L., Zara F., Striano P., Granata T., Bertini E., Simonati A.,
RA   Santorelli F.M.;
RT   "Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid
RT   lipofuscinosis.";
RL   Neuropediatrics 38:46-49(2007).
RN   [9]
RP   VARIANT CLN5 CYS-330, AND CHARACTERIZATION OF VARIANT CLN5 CYS-330.
RX   PubMed=19309691; DOI=10.1002/humu.21010;
RA   Lebrun A.-H., Storch S., Rueschendorf F., Schmiedt M.-L., Kyttaelae A.,
RA   Mole S.E., Kitzmueller C., Saar K., Mewasingh L.D., Boda V.,
RA   Kohlschuetter A., Ullrich K., Braulke T., Schulz A.;
RT   "Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes
RT   neuronal ceroid lipofuscinosis in Asian sibship.";
RL   Hum. Mutat. 30:E651-E661(2009).
RN   [10]
RP   CHARACTERIZATION OF VARIANTS CLN5 PRO-63; HIS-63 AND ASN-230, PROTEOLYTIC
RP   CLEAVAGE, SUBCELLULAR LOCATION (SECRETED FORM), AND GLYCOSYLATION.
RX   PubMed=20052765; DOI=10.1002/humu.21195;
RA   Schmiedt M.L., Bessa C., Heine C., Ribeiro M.G., Jalanko A., Kyttaelae A.;
RT   "The neuronal ceroid lipofuscinosis protein CLN5: new insights into
RT   cellular maturation, transport, and consequences of mutations.";
RL   Hum. Mutat. 31:356-365(2010).
RN   [11]
RP   VARIANTS CLN5 HIS-63; TYR-77; SER-143; PRO-149; SER-156; ARG-158; SER-158;
RP   ASP-209 AND CYS-325, AND VARIANTS ARG-26 AND LYS-193.
RX   PubMed=21990111; DOI=10.1002/humu.21624;
RA   Kousi M., Lehesjoki A.E., Mole S.E.;
RT   "Update of the mutation spectrum and clinical correlations of over 360
RT   mutations in eight genes that underlie the neuronal ceroid
RT   lipofuscinoses.";
RL   Hum. Mutat. 33:42-63(2012).
RN   [12]
RP   CHARACTERIZATION OF VARIANT CLN5 ASN-230, SUBCELLULAR LOCATION (MEMBRANE
RP   FORM), TOPOLOGY, PROTEOLYTIC CLEAVAGE, AND GLYCOSYLATION.
RX   PubMed=24038957; DOI=10.1002/humu.22443;
RA   Larkin H., Ribeiro M.G., Lavoie C.;
RT   "Topology and membrane anchoring of the lysosomal storage disease-related
RT   protein CLN5.";
RL   Hum. Mutat. 34:1688-1697(2013).
RN   [13]
RP   CHARACTERIZATION OF VARIANTS CLN5 SER-143 AND ASN-230, GLYCOSYLATION AT
RP   ASN-130; ASN-143; ASN-178; ASN-203; ASN-255; ASN-271; ASN-281 AND ASN-352,
RP   MUTAGENESIS OF ASN-130; ASN-143; ASN-178; ASN-203; ASN-255; ASN-271;
RP   ASN-281 AND ASN-352, AND SUBCELLULAR LOCATION (SECRETED FORM).
RX   PubMed=24058541; DOI=10.1371/journal.pone.0074299;
RA   Moharir A., Peck S.H., Budden T., Lee S.Y.;
RT   "The role of N-glycosylation in folding, trafficking, and functionality of
RT   lysosomal protein CLN5.";
RL   PLoS ONE 8:E74299-E74299(2013).
RN   [14]
RP   CHARACTERIZATION OF VARIANT CLN5 ASN-230, AND PROTEOLYTIC CLEAVAGE AT
RP   C-TERMINUS.
RX   PubMed=26342652; DOI=10.1016/j.yexcr.2015.08.021;
RA   De Silva B., Adams J., Lee S.Y.;
RT   "Proteolytic processing of the neuronal ceroid lipofuscinosis related
RT   lysosomal protein CLN5.";
RL   Exp. Cell Res. 338:45-53(2015).
CC   -!- FUNCTION: Plays a role in influencing the retrograde trafficking of
CC       lysosomal sorting receptors SORT1 and IGF2R from the endosomes to the
CC       trans-Golgi network by controlling the recruitment of retromer complex
CC       to the endosomal membrane. Regulates the localization and activation of
CC       RAB7A which is required to recruit the retromer complex to the
CC       endosomal membrane (PubMed:22431521). {ECO:0000269|PubMed:22431521}.
CC   -!- SUBUNIT: Interacts with SORT1, RAB5A and RAB7A (PubMed:22431521).
CC       Interacts with PPT1, TPP1, CLN3, CLN6, CLN8, ATP5F1A and ATP5F1B (By
CC       similarity). {ECO:0000250|UniProtKB:Q3UMW8,
CC       ECO:0000269|PubMed:22431521}.
CC   -!- INTERACTION:
CC       O75503; Q13286: CLN3; NbExp=2; IntAct=EBI-1043514, EBI-3248760;
CC   -!- SUBCELLULAR LOCATION: [Ceroid-lipofuscinosis neuronal protein 5,
CC       secreted form]: Lysosome {ECO:0000269|PubMed:11971870,
CC       ECO:0000269|PubMed:20052765, ECO:0000269|PubMed:22431521,
CC       ECO:0000269|PubMed:24038957, ECO:0000269|PubMed:24058541}.
CC   -!- SUBCELLULAR LOCATION: [Ceroid-lipofuscinosis neuronal protein 5]:
CC       Membrane {ECO:0000269|PubMed:24038957}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:24038957}. Note=An amphipathic anchor
CC       region facilitates its association with the membrane.
CC       {ECO:0000269|PubMed:24038957}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: N-glycosylated with both high mannose and complex type sugars.
CC       Glycosylation is important for proper folding and trafficking to the
CC       lysosomes. {ECO:0000269|PubMed:11971870, ECO:0000269|PubMed:20052765,
CC       ECO:0000269|PubMed:24038957, ECO:0000269|PubMed:24058541}.
CC   -!- PTM: [Ceroid-lipofuscinosis neuronal protein 5]: The type II membrane
CC       signal anchor is proteolytically cleaved to produce a mature form that
CC       is transported to the lysosomes (Ceroid-lipofuscinosis neuronal protein
CC       5, secreted form) (PubMed:24038957, PubMed:20052765).
CC       {ECO:0000269|PubMed:20052765, ECO:0000269|PubMed:24038957}.
CC   -!- PTM: Can undergo proteolytic cleavage at the C-terminus, probably by a
CC       cysteine protease and may involve the removal of approximately 10-15
CC       residues from the C-terminal end (PubMed:26342652).
CC       {ECO:0000269|PubMed:26342652}.
CC   -!- DISEASE: Ceroid lipofuscinosis, neuronal, 5 (CLN5) [MIM:256731]: A form
CC       of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are
CC       progressive neurodegenerative, lysosomal storage diseases characterized
CC       by intracellular accumulation of autofluorescent liposomal material,
CC       and clinically by seizures, dementia, visual loss, and/or cerebral
CC       atrophy. The lipopigment patterns observed most often in neuronal
CC       ceroid lipofuscinosis type 5 comprise mixed combinations of granular,
CC       curvilinear, and fingerprint profiles. {ECO:0000269|PubMed:15728307,
CC       ECO:0000269|PubMed:16814585, ECO:0000269|PubMed:17607606,
CC       ECO:0000269|PubMed:19309691, ECO:0000269|PubMed:20052765,
CC       ECO:0000269|PubMed:21990111, ECO:0000269|PubMed:24038957,
CC       ECO:0000269|PubMed:24058541, ECO:0000269|PubMed:26342652,
CC       ECO:0000269|PubMed:9662406}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the CLN5 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC27614.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NCL CLN5; Note=Neural Ceroid Lipofuscinoses mutation
CC       db;
CC       URL="https://www.ucl.ac.uk/ncl/cln5.shtml";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF068227; AAC27614.1; ALT_INIT; mRNA.
DR   EMBL; AK075109; BAG52069.1; -; mRNA.
DR   EMBL; AC001226; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS9456.1; -.
DR   RefSeq; NP_006484.1; NM_006493.2.
DR   SMR; O75503; -.
DR   BioGRID; 107614; 66.
DR   IntAct; O75503; 11.
DR   MINT; O75503; -.
DR   STRING; 9606.ENSP00000366673; -.
DR   GlyConnect; 1108; 17 N-Linked glycans (4 sites).
DR   GlyGen; O75503; 8 sites, 16 N-linked glycans (4 sites).
DR   iPTMnet; O75503; -.
DR   PhosphoSitePlus; O75503; -.
DR   BioMuta; CLN5; -.
DR   EPD; O75503; -.
DR   jPOST; O75503; -.
DR   MassIVE; O75503; -.
DR   MaxQB; O75503; -.
DR   PaxDb; O75503; -.
DR   PeptideAtlas; O75503; -.
DR   PRIDE; O75503; -.
DR   ProteomicsDB; 50054; -.
DR   Antibodypedia; 50072; 177 antibodies from 24 providers.
DR   DNASU; 1203; -.
DR   Ensembl; ENST00000377453; ENSP00000366673; ENSG00000102805.
DR   Ensembl; ENST00000636183; ENSP00000490181; ENSG00000102805.
DR   GeneID; 1203; -.
DR   KEGG; hsa:1203; -.
DR   MANE-Select; ENST00000377453.9; ENSP00000366673.5; NM_006493.4; NP_006484.2.
DR   UCSC; uc058xoc.1; human.
DR   CTD; 1203; -.
DR   DisGeNET; 1203; -.
DR   GeneCards; CLN5; -.
DR   HGNC; HGNC:2076; CLN5.
DR   HPA; ENSG00000102805; Low tissue specificity.
DR   MalaCards; CLN5; -.
DR   MIM; 256731; phenotype.
DR   MIM; 608102; gene.
DR   neXtProt; NX_O75503; -.
DR   OpenTargets; ENSG00000102805; -.
DR   Orphanet; 228360; CLN5 disease.
DR   PharmGKB; PA26603; -.
DR   VEuPathDB; HostDB:ENSG00000102805; -.
DR   eggNOG; ENOG502QPQ5; Eukaryota.
DR   GeneTree; ENSGT00390000010065; -.
DR   HOGENOM; CLU_050387_0_0_1; -.
DR   InParanoid; O75503; -.
DR   OMA; ITYEEVP; -.
DR   OrthoDB; 1227965at2759; -.
DR   PhylomeDB; O75503; -.
DR   TreeFam; TF330864; -.
DR   PathwayCommons; O75503; -.
DR   SignaLink; O75503; -.
DR   BioGRID-ORCS; 1203; 7 hits in 1042 CRISPR screens.
DR   ChiTaRS; CLN5; human.
DR   GeneWiki; CLN5; -.
DR   GenomeRNAi; 1203; -.
DR   Pharos; O75503; Tbio.
DR   PRO; PR:O75503; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; O75503; protein.
DR   Bgee; ENSG00000102805; Expressed in thyroid gland and 238 other tissues.
DR   ExpressionAtlas; O75503; baseline and differential.
DR   Genevisible; O75503; HS.
DR   GO; GO:0005829; C:cytosol; IEA:GOC.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016798; F:hydrolase activity, acting on glycosyl bonds; IBA:GO_Central.
DR   GO; GO:0005537; F:mannose binding; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEP:UniProtKB.
DR   GO; GO:0070085; P:glycosylation; IDA:UniProtKB.
DR   GO; GO:0007042; P:lysosomal lumen acidification; IMP:UniProtKB.
DR   GO; GO:0007040; P:lysosome organization; IBA:GO_Central.
DR   GO; GO:0022008; P:neurogenesis; IEP:UniProtKB.
DR   GO; GO:0042551; P:neuron maturation; NAS:UniProtKB.
DR   GO; GO:1904426; P:positive regulation of GTP binding; IMP:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0042147; P:retrograde transport, endosome to Golgi; IMP:UniProtKB.
DR   GO; GO:0006465; P:signal peptide processing; IDA:UniProtKB.
DR   InterPro; IPR026138; CLN5.
DR   PANTHER; PTHR15380; PTHR15380; 1.
DR   Pfam; PF15014; CLN5; 1.
PE   1: Evidence at protein level;
KW   Disease variant; Epilepsy; Glycoprotein; Lysosome; Membrane;
KW   Neurodegeneration; Neuronal ceroid lipofuscinosis; Reference proteome;
KW   Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..358
FT                   /note="Ceroid-lipofuscinosis neuronal protein 5"
FT                   /id="PRO_0000089860"
FT   CHAIN           ?..358
FT                   /note="Ceroid-lipofuscinosis neuronal protein 5, secreted
FT                   form"
FT                   /id="PRO_0000438009"
FT   TOPO_DOM        1..23
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24038957"
FT   TRANSMEM        24..41
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        42..358
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:24038957"
FT   REGION          304..343
FT                   /note="Membrane-anchoring"
FT                   /evidence="ECO:0000269|PubMed:24038957"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        143
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        255
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        271
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        281
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CARBOHYD        352
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   VARIANT         26
FT                   /note="W -> R (in dbSNP:rs199727787)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066895"
FT   VARIANT         63
FT                   /note="R -> H (in CLN5; retained in the endoplasmic
FT                   reticulum rather than reaching the lysosome;
FT                   dbSNP:rs104894386)"
FT                   /evidence="ECO:0000269|PubMed:15728307,
FT                   ECO:0000269|PubMed:20052765, ECO:0000269|PubMed:21990111"
FT                   /id="VAR_042700"
FT   VARIANT         63
FT                   /note="R -> P (in CLN5; Retained in the endoplasmic
FT                   reticulum rather than reaching the lysosome;
FT                   dbSNP:rs104894386)"
FT                   /evidence="ECO:0000269|PubMed:16814585,
FT                   ECO:0000269|PubMed:20052765"
FT                   /id="VAR_042702"
FT   VARIANT         77
FT                   /note="C -> Y (in CLN5; dbSNP:rs267606738)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066896"
FT   VARIANT         143
FT                   /note="N -> S (in CLN5; loss of glycosylation; effectively
FT                   transported to the lysosome; dbSNP:rs386833975)"
FT                   /evidence="ECO:0000269|PubMed:21990111,
FT                   ECO:0000269|PubMed:24058541"
FT                   /id="VAR_066897"
FT   VARIANT         149
FT                   /note="L -> P (in CLN5; dbSNP:rs386833976)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066898"
FT   VARIANT         156
FT                   /note="P -> S (in CLN5; dbSNP:rs386833977)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066899"
FT   VARIANT         158
FT                   /note="W -> R (in CLN5; dbSNP:rs147065248)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066900"
FT   VARIANT         158
FT                   /note="W -> S (in CLN5; dbSNP:rs386833978)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066901"
FT   VARIANT         193
FT                   /note="N -> K (in dbSNP:rs138611001)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066902"
FT   VARIANT         209
FT                   /note="Y -> D (in CLN5; dbSNP:rs386833981)"
FT                   /evidence="ECO:0000269|PubMed:17607606,
FT                   ECO:0000269|PubMed:21990111"
FT                   /id="VAR_042701"
FT   VARIANT         219
FT                   /note="E -> A (in dbSNP:rs11842935)"
FT                   /id="VAR_059031"
FT   VARIANT         230
FT                   /note="D -> N (in CLN5; creates a new N-glycosylation site;
FT                   retained in the endoplasmic reticulum rather than reaching
FT                   the lysosome; dbSNP:rs28940280)"
FT                   /evidence="ECO:0000269|PubMed:16814585,
FT                   ECO:0000269|PubMed:20052765, ECO:0000269|PubMed:24038957,
FT                   ECO:0000269|PubMed:24058541, ECO:0000269|PubMed:26342652,
FT                   ECO:0000269|PubMed:9662406"
FT                   /id="VAR_005137"
FT   VARIANT         319
FT                   /note="K -> R (in dbSNP:rs1800209)"
FT                   /evidence="ECO:0000269|PubMed:9662406"
FT                   /id="VAR_005138"
FT   VARIANT         325
FT                   /note="Y -> C (in CLN5; dbSNP:rs148862100)"
FT                   /evidence="ECO:0000269|PubMed:21990111"
FT                   /id="VAR_066903"
FT   VARIANT         330
FT                   /note="W -> C (in CLN5; retained in the endoplasmic
FT                   reticulum rather than reaching the lysosome;
FT                   dbSNP:rs386833968)"
FT                   /evidence="ECO:0000269|PubMed:19309691"
FT                   /id="VAR_059032"
FT   MUTAGEN         130
FT                   /note="N->Q: Loss of glycosylation. Retained in the
FT                   endoplasmic reticulum rather than reaching the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         143
FT                   /note="N->Q: Loss of glycosylation. Effectively transported
FT                   to the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         178
FT                   /note="N->Q: Loss of glycosylation. Effectively transported
FT                   to the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         203
FT                   /note="N->Q: Loss of glycosylation. Retained in the
FT                   endoplasmic reticulum rather than reaching the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         255
FT                   /note="N->Q: Loss of glycosylation. Retained in the
FT                   endoplasmic reticulum rather than reaching the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         271
FT                   /note="N->Q: Loss of glycosylation. Retained in the
FT                   endoplasmic reticulum rather than reaching the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         281
FT                   /note="N->Q: Loss of glycosylation. Partially retained in
FT                   the endoplasmic reticulum."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   MUTAGEN         352
FT                   /note="N->Q: Loss of glycosylation. Retained in the Golgi
FT                   apparatus rather than reaching the lysosome."
FT                   /evidence="ECO:0000269|PubMed:24058541"
FT   CONFLICT        57
FT                   /note="Y -> C (in Ref. 2; BAG52069)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        92
FT                   /note="I -> T (in Ref. 2; BAG52069)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   358 AA;  41497 MW;  07E49D4913685190 CRC64;
     MAQEVDTAQG AEMRRGAGAA RGRASWCWAL ALLWLAVVPG WSRVSGIPSR RHWPVPYKRF
     DFRPKPDPYC QAKYTFCPTG SPIPVMEGDD DIEVFRLQAP VWEFKYGDLL GHLKIMHDAI
     GFRSTLTGKN YTMEWYELFQ LGNCTFPHLR PEMDAPFWCN QGAACFFEGI DDVHWKENGT
     LVQVATISGN MFNQMAKWVK QDNETGIYYE TWNVKASPEK GAETWFDSYD CSKFVLRTFN
     KLAEFGAEFK NIETNYTRIF LYSGEPTYLG NETSVFGPTG NKTLGLAIKR FYYPFKPHLP
     TKEFLLSLLQ IFDAVIVHKQ FYLFYNFEYW FLPMKFPFIK ITYEEIPLPI RNKTLSGL
//
ID   DDX52_HUMAN             Reviewed;         599 AA.
AC   Q9Y2R4; Q86YG1; Q8N213; Q9NVE0; Q9Y482;
DT   09-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 4.
DT   23-FEB-2022, entry version 185.
DE   RecName: Full=Probable ATP-dependent RNA helicase DDX52;
DE            EC=3.6.4.13;
DE   AltName: Full=ATP-dependent RNA helicase ROK1-like;
DE   AltName: Full=DEAD box protein 52;
GN   Name=DDX52; Synonyms=ROK1; ORFNames=HUSSY-19;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Mao M., Liu T., Zhang J., Zhang Q., Fu G., Zhou J., Wu J., Shen Y., Yu M.,
RA   Ye M., Chen S., Chen Z.;
RT   "Human putative ATP-dependent RNA helicase rok1 mRNA.";
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Teratocarcinoma, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 180-599.
RC   TISSUE=Liver, and Spleen;
RX   PubMed=11124703;
RX   DOI=10.1002/1097-0061(200101)18:1<69::aid-yea647>3.0.co;2-h;
RA   Stanchi F., Bertocco E., Toppo S., Dioguardi R., Simionati B., Cannata N.,
RA   Zimbello R., Lanfranchi G., Valle G.;
RT   "Characterization of 16 novel human genes showing high similarity to yeast
RT   sequences.";
RL   Yeast 18:69-80(2001).
RN   [6]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-15, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 139-381 IN COMPLEX WITH ADP.
RX   PubMed=20941364; DOI=10.1371/journal.pone.0012791;
RA   Schutz P., Karlberg T., van den Berg S., Collins R., Lehtio L., Hogbom M.,
RA   Holmberg-Schiavone L., Tempel W., Park H.W., Hammarstrom M., Moche M.,
RA   Thorsell A.G., Schuler H.;
RT   "Comparative structural analysis of human DEAD-box RNA helicases.";
RL   PLoS ONE 5:E12791-E12791(2010).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:12429849}.
CC   -!- SIMILARITY: Belongs to the DEAD box helicase family. DDX52/ROK1
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD27766.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AK093661; Type=Miscellaneous discrepancy; Note=Cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAA91812.1; Type=Miscellaneous discrepancy; Note=Cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=CAA09374.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF077033; AAD27766.1; ALT_FRAME; mRNA.
DR   EMBL; AK001652; BAA91812.1; ALT_SEQ; mRNA.
DR   EMBL; AK093661; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC091199; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC041785; AAH41785.1; -; mRNA.
DR   EMBL; AJ010840; CAA09374.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS11323.1; -.
DR   RefSeq; NP_001278405.1; NM_001291476.1.
DR   RefSeq; NP_008941.3; NM_007010.4.
DR   PDB; 3DKP; X-ray; 2.10 A; A=139-381.
DR   PDBsum; 3DKP; -.
DR   SMR; Q9Y2R4; -.
DR   BioGRID; 116241; 119.
DR   IntAct; Q9Y2R4; 43.
DR   MINT; Q9Y2R4; -.
DR   STRING; 9606.ENSP00000479504; -.
DR   iPTMnet; Q9Y2R4; -.
DR   PhosphoSitePlus; Q9Y2R4; -.
DR   SwissPalm; Q9Y2R4; -.
DR   BioMuta; DDX52; -.
DR   DMDM; 296439375; -.
DR   SWISS-2DPAGE; Q9Y2R4; -.
DR   EPD; Q9Y2R4; -.
DR   jPOST; Q9Y2R4; -.
DR   MassIVE; Q9Y2R4; -.
DR   MaxQB; Q9Y2R4; -.
DR   PaxDb; Q9Y2R4; -.
DR   PeptideAtlas; Q9Y2R4; -.
DR   PRIDE; Q9Y2R4; -.
DR   ProteomicsDB; 85879; -.
DR   Antibodypedia; 74465; 110 antibodies from 23 providers.
DR   DNASU; 11056; -.
DR   Ensembl; ENST00000615769; ENSP00000480030; ENSG00000277594.
DR   Ensembl; ENST00000617633; ENSP00000479504; ENSG00000278053.
DR   GeneID; 11056; -.
DR   KEGG; hsa:11056; -.
DR   MANE-Select; ENST00000617633.5; ENSP00000479504.1; NM_007010.5; NP_008941.3.
DR   UCSC; uc002hoi.3; human.
DR   CTD; 11056; -.
DR   DisGeNET; 11056; -.
DR   GeneCards; DDX52; -.
DR   HGNC; HGNC:20038; DDX52.
DR   HPA; ENSG00000278053; Low tissue specificity.
DR   MIM; 612500; gene.
DR   neXtProt; NX_Q9Y2R4; -.
DR   PharmGKB; PA134904836; -.
DR   VEuPathDB; HostDB:ENSG00000278053; -.
DR   eggNOG; KOG0344; Eukaryota.
DR   HOGENOM; CLU_003041_1_4_1; -.
DR   InParanoid; Q9Y2R4; -.
DR   OrthoDB; 400908at2759; -.
DR   PhylomeDB; Q9Y2R4; -.
DR   TreeFam; TF314448; -.
DR   PathwayCommons; Q9Y2R4; -.
DR   Reactome; R-HSA-6790901; rRNA modification in the nucleus and cytosol.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; Q9Y2R4; -.
DR   BioGRID-ORCS; 11056; 494 hits in 1011 CRISPR screens.
DR   ChiTaRS; DDX52; human.
DR   EvolutionaryTrace; Q9Y2R4; -.
DR   GeneWiki; DDX52; -.
DR   GenomeRNAi; 11056; -.
DR   Pharos; Q9Y2R4; Tbio.
DR   PRO; PR:Q9Y2R4; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9Y2R4; protein.
DR   Bgee; ENSG00000278053; Expressed in sural nerve and 231 other tissues.
DR   ExpressionAtlas; Q9Y2R4; baseline and differential.
DR   Genevisible; Q9Y2R4; HS.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0030490; P:maturation of SSU-rRNA; IBA:GO_Central.
DR   CDD; cd17957; DEADc_DDX52; 1.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR044764; DDX52/Rok1_DEADc.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR014014; RNA_helicase_DEAD_Q_motif.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51195; Q_MOTIF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Helicase; Hydrolase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   RNA-binding.
FT   CHAIN           1..599
FT                   /note="Probable ATP-dependent RNA helicase DDX52"
FT                   /id="PRO_0000055060"
FT   DOMAIN          196..374
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          385..546
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   NP_BIND         209..216
FT                   /note="ATP"
FT   REGION          59..100
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          577..599
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           165..193
FT                   /note="Q motif"
FT   MOTIF           318..321
FT                   /note="DEAD box"
FT   COMPBIAS        68..96
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         15
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         39
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VARIANT         403
FT                   /note="V -> M (in dbSNP:rs7216445)"
FT                   /id="VAR_060235"
FT   CONFLICT        299
FT                   /note="L -> S (in Ref. 2; AK093661)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        582
FT                   /note="K -> R (in Ref. 2; BAA91812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        584
FT                   /note="V -> F (in Ref. 4; CAA09374)"
FT                   /evidence="ECO:0000305"
FT   HELIX           139..146
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          149..155
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           163..170
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           174..182
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           190..200
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          205..208
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           215..227
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          237..240
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           244..257
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   TURN            258..260
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           270..275
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   TURN            276..278
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          288..291
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           293..301
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          314..319
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           320..326
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           331..341
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          348..355
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   HELIX           358..367
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          368..370
FT                   /evidence="ECO:0007829|PDB:3DKP"
FT   STRAND          372..376
FT                   /evidence="ECO:0007829|PDB:3DKP"
SQ   SEQUENCE   599 AA;  67466 MW;  0EA504577A8BB7DB CRC64;
     MDVHDLFRRL GAGAKFDTRR FSADAARFQI GKRKYDFDSS EVLQGLDFFG NKKSVPGVCG
     ASQTHQKPQN GEKKEESLTE RKREQSKKKR KTMTSEIASQ EEGATIQWMS SVEAKIEDKK
     VQRESKLTSG KLENLRKEKI NFLRNKHKIH VQGTDLPDPI ATFQQLDQEY KINSRLLQNI
     LDAGFQMPTP IQMQAIPVML HGRELLASAP TGSGKTLAFS IPILMQLKQP ANKGFRALII
     SPTRELASQI HRELIKISEG TGFRIHMIHK AAVAAKKFGP KSSKKFDILV TTPNRLIYLL
     KQDPPGIDLA SVEWLVVDES DKLFEDGKTG FRDQLASIFL ACTSHKVRRA MFSATFAYDV
     EQWCKLNLDN VISVSIGARN SAVETVEQEL LFVGSETGKL LAVRELVKKG FNPPVLVFVQ
     SIERAKELFH ELIYEGINVD VIHAERTQQQ RDNTVHSFRA GKIWVLICTA LLARGIDFKG
     VNLVINYDFP TSSVEYIHRI GRTGRAGNKG KAITFFTEDD KPLLRSVANV IQQAGCPVPE
     YIKGFQKLLS KQKKKMIKKP LERESISTTP KCFLEKAKDK QKKVTGQNSK KKVALEDKS
//
ID   MTF2_HUMAN              Reviewed;         593 AA.
AC   Q9Y483; A6NGQ9; A8K2Q3; B1AKT5; B1AKT6; Q96G26; Q9UES9; Q9UP40;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 3.
DT   23-FEB-2022, entry version 174.
DE   RecName: Full=Metal-response element-binding transcription factor 2;
DE   AltName: Full=Metal regulatory transcription factor 2;
DE   AltName: Full=Metal-response element DNA-binding protein M96;
DE   AltName: Full=Polycomb-like protein 2;
DE            Short=hPCl2;
GN   Name=MTF2; Synonyms=PCL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RA   Tao B., Wang J., Yuan J., Qiang B.;
RT   "Isolation and cloning of a novel human M96 cDNA, spliced isoforms.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Holen T., Aasland R.;
RT   "The polycomblike protein family.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Pre-B cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-24, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   FUNCTION, AND H3K36ME3-BINDING.
RX   PubMed=23142980; DOI=10.1038/nsmb.2435;
RA   Musselman C.A., Avvakumov N., Watanabe R., Abraham C.G., Lalonde M.E.,
RA   Hong Z., Allen C., Roy S., Nunez J.K., Nickoloff J., Kulesza C.A.,
RA   Yasui A., Cote J., Kutateladze T.G.;
RT   "Molecular basis for H3K36me3 recognition by the Tudor domain of PHF1.";
RL   Nat. Struct. Mol. Biol. 19:1266-1272(2012).
RN   [8]
RP   FUNCTION, AND H3K36ME3-BINDING.
RX   PubMed=23228662; DOI=10.1016/j.bbrc.2012.11.116;
RA   Qin S., Guo Y., Xu C., Bian C., Fu M., Gong S., Min J.;
RT   "Tudor domains of the PRC2 components PHF1 and PHF19 selectively bind to
RT   histone H3K36me3.";
RL   Biochem. Biophys. Res. Commun. 430:547-553(2013).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-360 AND LYS-522, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [11] {ECO:0000305}
RP   FUNCTION, ASSOCIATION WITH THE PRC2 COMPLEX, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 338-LYS-LYS-339 AND 544-GLN--GLY-557.
RX   PubMed=31959557; DOI=10.1016/j.molcel.2019.12.019;
RA   Chen S., Jiao L., Liu X., Yang X., Liu X.;
RT   "A Dimeric Structural Scaffold for PRC2-PCL Targeting to CpG Island
RT   Chromatin.";
RL   Mol. Cell 77:1265-1278.e7(2020).
CC   -!- FUNCTION: Polycomb group (PcG) protein that specifically binds histone
CC       H3 trimethylated at 'Lys-36' (H3K36me3) and recruits the PRC2 complex,
CC       thus enhancing PRC2 H3K27me3 methylation activity (PubMed:23142980,
CC       PubMed:23228662, PubMed:31959557). Regulates the transcriptional
CC       networks during embryonic stem cell self-renewal and differentiation
CC       (By similarity). Promotes recruitment of the PRC2 complex to the
CC       inactive X chromosome in differentiating XX ES cells and PRC2
CC       recruitment to target genes in undifferentiated ES cells (By
CC       similarity). Required to repress Hox genes by enhancing H3K27me3
CC       methylation of the PRC2 complex (By similarity). In some conditions may
CC       act as an inhibitor of PRC2 activity: able to activate the CDKN2A gene
CC       and promote cellular senescence by suppressing the catalytic activity
CC       of the PRC2 complex locally (By similarity). Binds to the metal-
CC       regulating-element (MRE) of MT1A gene promoter (By similarity).
CC       {ECO:0000250|UniProtKB:Q02395, ECO:0000269|PubMed:23142980,
CC       ECO:0000269|PubMed:23228662, ECO:0000269|PubMed:31959557}.
CC   -!- SUBUNIT: Associates with the PRC2 complex, which consists of the core
CC       components EED, EZH1 or EZH2, SUZ12, and RBBP4, and various
CC       combinations of accessory subunits including AEBP2, JARID2, PHF19, MTF2
CC       and EPOP (PubMed:31959557). Forms a dimeric PRC2.1 (class 1, PRC-PCL)
CC       complex consisting of at least SUZ12, RBBP4, and PHF19 or MTF2; PHF19
CC       and MTF2 stabilize the dimeric structure which enhances PRC2
CC       interaction with chromatin (PubMed:31959557).
CC       {ECO:0000269|PubMed:31959557}.
CC   -!- INTERACTION:
CC       Q9Y483-4; P54252: ATXN3; NbExp=3; IntAct=EBI-10698053, EBI-946046;
CC       Q9Y483-4; P55273: CDKN2D; NbExp=3; IntAct=EBI-10698053, EBI-745859;
CC       Q9Y483-4; Q9NX09: DDIT4; NbExp=3; IntAct=EBI-10698053, EBI-715104;
CC       Q9Y483-4; G5E9A7: DMWD; NbExp=3; IntAct=EBI-10698053, EBI-10976677;
CC       Q9Y483-4; P14136: GFAP; NbExp=3; IntAct=EBI-10698053, EBI-744302;
CC       Q9Y483-4; Q53GS7: GLE1; NbExp=3; IntAct=EBI-10698053, EBI-1955541;
CC       Q9Y483-4; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-10698053, EBI-1055254;
CC       Q9Y483-4; O60260-5: PRKN; NbExp=3; IntAct=EBI-10698053, EBI-21251460;
CC       Q9Y483-4; P37840: SNCA; NbExp=3; IntAct=EBI-10698053, EBI-985879;
CC       Q9Y483-4; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-10698053, EBI-5235340;
CC       Q9Y483-4; Q13148: TARDBP; NbExp=3; IntAct=EBI-10698053, EBI-372899;
CC       Q9Y483-4; Q96BH6; NbExp=3; IntAct=EBI-10698053, EBI-25872486;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:31959557}.
CC       Note=Localizes to chromatin as part of the PRC2 complex.
CC       {ECO:0000269|PubMed:31959557}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9Y483-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y483-2; Sequence=VSP_004696;
CC       Name=3;
CC         IsoId=Q9Y483-3; Sequence=VSP_040329;
CC       Name=4;
CC         IsoId=Q9Y483-4; Sequence=VSP_053348;
CC   -!- DOMAIN: The Tudor domain recognizes and binds H3K36me3
CC       (PubMed:23142980, PubMed:23228662). {ECO:0000269|PubMed:23142980,
CC       ECO:0000269|PubMed:23228662}.
CC   -!- SIMILARITY: Belongs to the Polycomblike family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF072814; AAC27618.1; -; mRNA.
DR   EMBL; AF073293; AAC27080.1; -; mRNA.
DR   EMBL; AJ010014; CAA08970.1; -; mRNA.
DR   EMBL; AK290318; BAF83007.1; -; mRNA.
DR   EMBL; AC093577; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL117354; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF459519; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010013; AAH10013.1; -; mRNA.
DR   CCDS; CCDS53340.1; -. [Q9Y483-4]
DR   CCDS; CCDS53341.1; -. [Q9Y483-3]
DR   CCDS; CCDS742.1; -. [Q9Y483-1]
DR   RefSeq; NP_001157863.1; NM_001164391.1. [Q9Y483-3]
DR   RefSeq; NP_001157864.1; NM_001164392.1. [Q9Y483-4]
DR   RefSeq; NP_001157865.1; NM_001164393.1. [Q9Y483-3]
DR   RefSeq; NP_031384.1; NM_007358.3. [Q9Y483-1]
DR   RefSeq; XP_011539318.1; XM_011541016.1.
DR   RefSeq; XP_016856165.1; XM_017000676.1.
DR   PDB; 5XFR; X-ray; 2.25 A; A/B=43-358.
DR   PDBsum; 5XFR; -.
DR   SMR; Q9Y483; -.
DR   BioGRID; 116499; 102.
DR   IntAct; Q9Y483; 44.
DR   MINT; Q9Y483; -.
DR   STRING; 9606.ENSP00000359321; -.
DR   iPTMnet; Q9Y483; -.
DR   PhosphoSitePlus; Q9Y483; -.
DR   BioMuta; MTF2; -.
DR   DMDM; 317373393; -.
DR   EPD; Q9Y483; -.
DR   jPOST; Q9Y483; -.
DR   MassIVE; Q9Y483; -.
DR   MaxQB; Q9Y483; -.
DR   PaxDb; Q9Y483; -.
DR   PeptideAtlas; Q9Y483; -.
DR   PRIDE; Q9Y483; -.
DR   ProteomicsDB; 3108; -.
DR   ProteomicsDB; 86123; -. [Q9Y483-1]
DR   ProteomicsDB; 86124; -. [Q9Y483-2]
DR   ProteomicsDB; 86125; -. [Q9Y483-3]
DR   ABCD; Q9Y483; 1 sequenced antibody.
DR   Antibodypedia; 19938; 183 antibodies from 29 providers.
DR   DNASU; 22823; -.
DR   Ensembl; ENST00000370298; ENSP00000359321; ENSG00000143033.
DR   Ensembl; ENST00000370303; ENSP00000359326; ENSG00000143033. [Q9Y483-4]
DR   Ensembl; ENST00000540243; ENSP00000443295; ENSG00000143033. [Q9Y483-3]
DR   Ensembl; ENST00000545708; ENSP00000444962; ENSG00000143033. [Q9Y483-3]
DR   GeneID; 22823; -.
DR   KEGG; hsa:22823; -.
DR   MANE-Select; ENST00000370298.9; ENSP00000359321.4; NM_007358.4; NP_031384.1.
DR   UCSC; uc009wdj.4; human. [Q9Y483-1]
DR   UCSC; uc009wdk.4; human.
DR   CTD; 22823; -.
DR   DisGeNET; 22823; -.
DR   GeneCards; MTF2; -.
DR   HGNC; HGNC:29535; MTF2.
DR   HPA; ENSG00000143033; Low tissue specificity.
DR   MIM; 609882; gene.
DR   neXtProt; NX_Q9Y483; -.
DR   OpenTargets; ENSG00000143033; -.
DR   PharmGKB; PA128394586; -.
DR   VEuPathDB; HostDB:ENSG00000143033; -.
DR   eggNOG; KOG4323; Eukaryota.
DR   GeneTree; ENSGT00950000183180; -.
DR   InParanoid; Q9Y483; -.
DR   OMA; ELELMAY; -.
DR   PhylomeDB; Q9Y483; -.
DR   TreeFam; TF106420; -.
DR   PathwayCommons; Q9Y483; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   SignaLink; Q9Y483; -.
DR   BioGRID-ORCS; 22823; 14 hits in 1058 CRISPR screens.
DR   ChiTaRS; MTF2; human.
DR   GenomeRNAi; 22823; -.
DR   Pharos; Q9Y483; Tbio.
DR   PRO; PR:Q9Y483; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9Y483; protein.
DR   Bgee; ENSG00000143033; Expressed in secondary oocyte and 248 other tissues.
DR   ExpressionAtlas; Q9Y483; baseline and differential.
DR   Genevisible; Q9Y483; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:ARUK-UCL.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; IBA:GO_Central.
DR   GO; GO:0061086; P:negative regulation of histone H3-K27 methylation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0061087; P:positive regulation of histone H3-K27 methylation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0007379; P:segment specification; ISS:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   CDD; cd15578; PHD1_MTF2; 1.
DR   CDD; cd15580; PHD2_MTF2; 1.
DR   CDD; cd04508; TUDOR; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR040477; KDM4_Tudor_2.
DR   InterPro; IPR025894; Mtf2_C_dom.
DR   InterPro; IPR042014; MTF2_PHD1.
DR   InterPro; IPR042015; MTF2_PHD2.
DR   InterPro; IPR002999; Tudor.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF14061; Mtf2_C; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF18104; Tudor_2; 1.
DR   SMART; SM00249; PHD; 2.
DR   SMART; SM00333; TUDOR; 1.
DR   SUPFAM; SSF57903; SSF57903; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 2.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator; DNA-binding;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..593
FT                   /note="Metal-response element-binding transcription factor
FT                   2"
FT                   /id="PRO_0000059317"
FT   DOMAIN          44..101
FT                   /note="Tudor"
FT   ZN_FING         102..157
FT                   /note="PHD-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   ZN_FING         201..255
FT                   /note="PHD-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          360..411
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          424..486
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        363..401
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        442..474
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         24
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        360
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        522
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..331
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_004696"
FT   VAR_SEQ         1..102
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_040329"
FT   VAR_SEQ         331..387
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_053348"
FT   VARIANT         140
FT                   /note="S -> C (in dbSNP:rs2815427)"
FT                   /id="VAR_054765"
FT   MUTAGEN         338..339
FT                   /note="KK->AA: Abolishes chromatin binding activity of the
FT                   PRC2.1 complex."
FT                   /evidence="ECO:0000269|PubMed:31959557"
FT   MUTAGEN         544..557
FT                   /note="Missing: Reduced chromatin binding activity of the
FT                   PRC2.1 complex, probably due to loss of dimer stability."
FT                   /evidence="ECO:0000269|PubMed:31959557"
FT   STRAND          51..55
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          61..70
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            71..74
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          75..80
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          85..89
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           90..92
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            106..108
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          128..130
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            131..133
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          134..136
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            140..144
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           152..159
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           170..178
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           186..188
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            204..207
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            212..215
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          216..219
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            220..222
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          225..227
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           228..230
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          245..248
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           250..253
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          258..261
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           266..281
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            288..291
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           292..298
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           300..303
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           307..310
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           313..326
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   TURN            328..330
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          331..333
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   HELIX           334..337
FT                   /evidence="ECO:0007829|PDB:5XFR"
FT   STRAND          343..348
FT                   /evidence="ECO:0007829|PDB:5XFR"
SQ   SEQUENCE   593 AA;  67090 MW;  4517B5DD61BB1AF4 CRC64;
     MRDSTGAGNS LVHKRSPLRR NQKTPTSLTK LSLQDGHKAK KPACKFEEGQ DVLARWSDGL
     FYLGTIKKIN ILKQSCFIIF EDSSKSWVLW KDIQTGATGS GEMVCTICQE EYSEAPNEMV
     ICDKCGQGYH QLCHTPHIDS SVIDSDEKWL CRQCVFATTT KRGGALKKGP NAKALQVMKQ
     TLPYSVADLE WDAGHKTNVQ QCYCYCGGPG DWYLKMLQCC KCKQWFHEAC VQCLQKPMLF
     GDRFYTFICS VCSSGPEYLK RLPLQWVDIA HLCLYNLSVI HKKKYFDSEL ELMTYINENW
     DRLHPGELAD TPKSERYEHV LEALNDYKTM FMSGKEIKKK KHLFGLRIRV PPVPPNVAFK
     AEKEPEGTSH EFKIKGRKAS KPISDSREVS NGIEKKGKKK SVGRPPGPYT RKMIQKTAEP
     LLDKESISEN PTLDLPCSIG RTEGTAHSSN TSDVDFTGAS SAKETTSSSI SRHYGLSDSR
     KRTRTGRSWP AAIPHLRRRR GRLPRRALQT QNSEIVKDDE GKEDYQFDEL NTEILNNLAD
     QELQLNHLKN SITSYFGAAG RIACGEKYRV LARRVTLDGK VQYLVEWEGA TAS
//
ID   PLA2R_HUMAN             Reviewed;        1463 AA.
AC   Q13018; B2RTU9; D3DPB1; Q13019; Q15095; Q53R45; Q53RR7;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 2.
DT   23-FEB-2022, entry version 169.
DE   RecName: Full=Secretory phospholipase A2 receptor;
DE            Short=PLA2-R;
DE            Short=PLA2R;
DE   AltName: Full=180 kDa secretory phospholipase A2 receptor;
DE   AltName: Full=C-type lectin domain family 13 member C;
DE   AltName: Full=M-type receptor;
DE   Contains:
DE     RecName: Full=Soluble secretory phospholipase A2 receptor;
DE              Short=Soluble PLA2-R;
DE              Short=Soluble PLA2R;
DE   Flags: Precursor;
GN   Name=PLA2R1; Synonyms=CLEC13C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, VARIANTS VAL-292 AND ASP-300, AND INTERACTION WITH PLA2G1B.
RC   TISSUE=Kidney;
RX   PubMed=7721806; DOI=10.1074/jbc.270.15.8963;
RA   Ancian P., Lambeau G., Mattei M.-G., Lazdunski M.;
RT   "The human 180-kDa receptor for secretory phospholipases A2. Molecular
RT   cloning, identification of a secreted soluble form, expression, and
RT   chromosomal localization.";
RL   J. Biol. Chem. 270:8963-8970(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 532-942, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=7925459; DOI=10.1111/j.1432-1033.1994.00375.x;
RA   Higashino K., Ishizaki J., Kishino J., Ohara O., Arita H.;
RT   "Structural comparison of phospholipase-A2-binding regions in
RT   phospholipase-A2 receptors from various mammals.";
RL   Eur. J. Biochem. 225:375-382(1994).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=9481783; DOI=10.1016/s0143-4004(98)90096-0;
RA   Moses E.K., Freed K.A., Brennecke S.P., Rice G.E.;
RT   "Distribution of the phospholipase A2 receptor messenger RNA in human
RT   gestational tissues.";
RL   Placenta 19:35-40(1998).
RN   [7]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15611272; DOI=10.4049/jimmunol.174.1.464;
RA   Granata F., Petraroli A., Boilard E., Bezzine S., Bollinger J.,
RA   Del Vecchio L., Gelb M.H., Lambeau G., Marone G., Triggiani M.;
RT   "Activation of cytokine production by secreted phospholipase A2 in human
RT   lung macrophages expressing the M-type receptor.";
RL   J. Immunol. 174:464-474(2005).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=25335547; DOI=10.1038/srep06660;
RA   Pan Y., Wan J., Liu Y., Yang Q., Liang W., Singhal P.C., Saleem M.A.,
RA   Ding G.;
RT   "sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2
RT   receptor.";
RL   Sci. Rep. 4:6660-6660(2014).
CC   -!- FUNCTION: Receptor for secretory phospholipase A2 (sPLA2). Acts as a
CC       receptor for phospholipase sPLA2-IB/PLA2G1B but not sPLA2-IIA/PLA2G2A.
CC       Also able to bind to snake PA2-like toxins. Although its precise
CC       function remains unclear, binding of sPLA2 to its receptor participates
CC       in both positive and negative regulation of sPLA2 functions as well as
CC       clearance of sPLA2. Binding of sPLA2-IB/PLA2G1B induces various effects
CC       depending on the cell type, such as activation of the mitogen-activated
CC       protein kinase (MAPK) cascade to induce cell proliferation, the
CC       production of lipid mediators, selective release of arachidonic acid in
CC       bone marrow-derived mast cells. In neutrophils, binding of sPLA2-
CC       IB/PLA2G1B can activate p38 MAPK to stimulate elastase release and cell
CC       adhesion. May be involved in responses in proinflammatory cytokine
CC       productions during endotoxic shock. Also has endocytic properties and
CC       rapidly internalizes sPLA2 ligands, which is particularly important for
CC       the clearance of extracellular sPLA2s to protect their potent enzymatic
CC       activities. The soluble secretory phospholipase A2 receptor form is
CC       circulating and acts as a negative regulator of sPLA2 functions by
CC       blocking the biological functions of sPLA2-IB/PLA2G1B (PubMed:15611272,
CC       PubMed:7721806). In podocytes, binding of sPLA2-IB/PLA2G1B can regulate
CC       podocyte survival and glomerular homeostasis (PubMed:25335547).
CC       {ECO:0000269|PubMed:15611272, ECO:0000269|PubMed:25335547,
CC       ECO:0000269|PubMed:7721806}.
CC   -!- SUBUNIT: Interacts with sPLA2-IB/PLA2G1B; this interaction mediates
CC       intracellular signaling as well as clearance of extracellular sPLA2-
CC       IB/PLA2G1B via endocytotic pathway (PubMed:7721806). Interacts with
CC       sPLA2-X/PLA2G10; this interaction mediates sPLA2-X/PLA2G10 clearance
CC       and inactivation (By similarity). {ECO:0000250|UniProtKB:Q62028,
CC       ECO:0000269|PubMed:7721806}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Soluble secretory phospholipase A2 receptor]:
CC       Secreted {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13018-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13018-2; Sequence=VSP_029493, VSP_029494;
CC   -!- TISSUE SPECIFICITY: Expressed in podocytes (at protein level)
CC       (PubMed:25335547). Present in lung macrophage (at protein level).
CC       Highly expressed in kidney. Also expressed in pancreas, amnion,
CC       choriodecidua and placenta. Isoform 2 is expressed at much lower level.
CC       {ECO:0000269|PubMed:15611272, ECO:0000269|PubMed:25335547,
CC       ECO:0000269|PubMed:7721806, ECO:0000269|PubMed:7925459,
CC       ECO:0000269|PubMed:9481783}.
CC   -!- DOMAIN: C-type lectin domains 3-5 mediate the interaction with
CC       phospholipase PLA2G1B.
CC   -!- DOMAIN: The endocytosis signal probably mediates endocytosis via
CC       clathrin-coated pits. {ECO:0000250}.
CC   -!- PTM: The secretory phospholipase A2 receptor form may be produced by
CC       the action of metalloproteinases. It contains all extracellular domains
CC       and only lacks transmembrane and cytosolic regions. It is however
CC       unclear whether this form is produced by proteolytic cleavage as
CC       suggested by some experiments, or by alternative splicing, as in the
CC       case of isoform 2 that shares all characteristics of secretory
CC       phospholipase A2 receptor form (By similarity). {ECO:0000250}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Phospholipase A2 receptor;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_253";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U17033; AAA70110.1; -; mRNA.
DR   EMBL; U17034; AAC50163.1; -; mRNA.
DR   EMBL; AC080166; AAY24052.1; -; Genomic_DNA.
DR   EMBL; AC093873; AAY24190.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11392.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11393.1; -; Genomic_DNA.
DR   EMBL; BC140823; AAI40824.1; -; mRNA.
DR   EMBL; D30780; BAA06444.1; -; mRNA.
DR   CCDS; CCDS33309.1; -. [Q13018-1]
DR   CCDS; CCDS42767.1; -. [Q13018-2]
DR   PIR; A56395; A56395.
DR   PIR; B56395; B56395.
DR   RefSeq; NP_001007268.1; NM_001007267.2. [Q13018-2]
DR   RefSeq; NP_001182570.1; NM_001195641.1.
DR   RefSeq; NP_031392.3; NM_007366.4. [Q13018-1]
DR   RefSeq; XP_005246449.1; XM_005246392.3. [Q13018-1]
DR   RefSeq; XP_011509122.1; XM_011510820.2. [Q13018-1]
DR   RefSeq; XP_016859087.1; XM_017003598.1. [Q13018-1]
DR   PDB; 6JLI; X-ray; 1.78 A; A=1108-1234.
DR   PDBsum; 6JLI; -.
DR   SMR; Q13018; -.
DR   BioGRID; 116585; 2.
DR   IntAct; Q13018; 2.
DR   STRING; 9606.ENSP00000283243; -.
DR   ChEMBL; CHEMBL3713395; -.
DR   GlyConnect; 674; 1 N-Linked glycan (1 site).
DR   GlyGen; Q13018; 3 sites, 2 N-linked glycans (1 site).
DR   iPTMnet; Q13018; -.
DR   PhosphoSitePlus; Q13018; -.
DR   BioMuta; PLA2R1; -.
DR   DMDM; 160419241; -.
DR   EPD; Q13018; -.
DR   jPOST; Q13018; -.
DR   MassIVE; Q13018; -.
DR   PaxDb; Q13018; -.
DR   PeptideAtlas; Q13018; -.
DR   PRIDE; Q13018; -.
DR   ProteomicsDB; 59106; -. [Q13018-1]
DR   ProteomicsDB; 59107; -. [Q13018-2]
DR   Antibodypedia; 2544; 241 antibodies from 25 providers.
DR   DNASU; 22925; -.
DR   Ensembl; ENST00000283243; ENSP00000283243; ENSG00000153246.
DR   Ensembl; ENST00000392771; ENSP00000376524; ENSG00000153246. [Q13018-2]
DR   GeneID; 22925; -.
DR   KEGG; hsa:22925; -.
DR   MANE-Select; ENST00000283243.13; ENSP00000283243.7; NM_007366.5; NP_031392.3.
DR   UCSC; uc002ube.3; human. [Q13018-1]
DR   CTD; 22925; -.
DR   DisGeNET; 22925; -.
DR   GeneCards; PLA2R1; -.
DR   HGNC; HGNC:9042; PLA2R1.
DR   HPA; ENSG00000153246; Tissue enhanced (salivary gland, thyroid gland).
DR   MIM; 604939; gene.
DR   neXtProt; NX_Q13018; -.
DR   OpenTargets; ENSG00000153246; -.
DR   PharmGKB; PA33369; -.
DR   VEuPathDB; HostDB:ENSG00000153246; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   GeneTree; ENSGT01040000240381; -.
DR   HOGENOM; CLU_002069_2_0_1; -.
DR   InParanoid; Q13018; -.
DR   OMA; KYHATHC; -.
DR   OrthoDB; 29241at2759; -.
DR   PhylomeDB; Q13018; -.
DR   TreeFam; TF316663; -.
DR   PathwayCommons; Q13018; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   Reactome; R-HSA-1482925; Acyl chain remodelling of PG.
DR   Reactome; R-HSA-1483166; Synthesis of PA.
DR   SignaLink; Q13018; -.
DR   BioGRID-ORCS; 22925; 6 hits in 1040 CRISPR screens.
DR   ChiTaRS; PLA2R1; human.
DR   GenomeRNAi; 22925; -.
DR   Pharos; Q13018; Tbio.
DR   PRO; PR:Q13018; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q13018; protein.
DR   Bgee; ENSG00000153246; Expressed in metanephros and 177 other tissues.
DR   Genevisible; Q13018; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0043274; F:phospholipase binding; IPI:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; IDA:UniProtKB.
DR   GO; GO:1900139; P:negative regulation of arachidonic acid secretion; ISS:UniProtKB.
DR   GO; GO:1900138; P:negative regulation of phospholipase A2 activity; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:UniProtKB.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; ISS:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IMP:UniProtKB.
DR   GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:1904635; P:positive regulation of glomerular visceral epithelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; IMP:UniProtKB.
DR   CDD; cd00062; FN2; 1.
DR   CDD; cd00161; RICIN; 1.
DR   Gene3D; 2.10.10.10; -; 1.
DR   Gene3D; 3.10.100.10; -; 8.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR000562; FN_type2_dom.
DR   InterPro; IPR036943; FN_type2_sf.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00040; fn2; 1.
DR   Pfam; PF00059; Lectin_C; 8.
DR   SMART; SM00034; CLECT; 8.
DR   SMART; SM00059; FN2; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF56436; SSF56436; 8.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 3.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 8.
DR   PROSITE; PS00023; FN2_1; 1.
DR   PROSITE; PS51092; FN2_2; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   Endocytosis; Glycoprotein; Lectin; Membrane; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000250"
FT   CHAIN           21..1463
FT                   /note="Secretory phospholipase A2 receptor"
FT                   /id="PRO_5000144349"
FT   CHAIN           21..?
FT                   /note="Soluble secretory phospholipase A2 receptor"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000311250"
FT   TOPO_DOM        21..1397
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1398..1418
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1419..1463
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          38..161
FT                   /note="Ricin B-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DOMAIN          173..221
FT                   /note="Fibronectin type-II"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          238..355
FT                   /note="C-type lectin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          385..502
FT                   /note="C-type lectin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          522..643
FT                   /note="C-type lectin 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          673..797
FT                   /note="C-type lectin 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          819..938
FT                   /note="C-type lectin 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          965..1096
FT                   /note="C-type lectin 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          1121..1232
FT                   /note="C-type lectin 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          1257..1378
FT                   /note="C-type lectin 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   MOTIF           1436..1442
FT                   /note="Endocytosis signal"
FT   CARBOHYD        93
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        454
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1123
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   DISULFID        51..64
FT                   /evidence="ECO:0000250"
FT   DISULFID        89..106
FT                   /evidence="ECO:0000250"
FT   DISULFID        178..204
FT                   /evidence="ECO:0000250"
FT   DISULFID        192..219
FT                   /evidence="ECO:0000250"
FT   DISULFID        260..354
FT                   /evidence="ECO:0000250"
FT   DISULFID        330..346
FT                   /evidence="ECO:0000250"
FT   DISULFID        406..501
FT                   /evidence="ECO:0000250"
FT   DISULFID        478..493
FT                   /evidence="ECO:0000250"
FT   DISULFID        617..634
FT                   /evidence="ECO:0000250"
FT   DISULFID        699..796
FT                   /evidence="ECO:0000250"
FT   DISULFID        774..788
FT                   /evidence="ECO:0000250"
FT   DISULFID        840..937
FT                   /evidence="ECO:0000250"
FT   DISULFID        914..929
FT                   /evidence="ECO:0000250"
FT   DISULFID        1067..1087
FT                   /evidence="ECO:0000250"
FT   DISULFID        1209..1223
FT                   /evidence="ECO:0000250"
FT   DISULFID        1280..1377
FT                   /evidence="ECO:0000250"
FT   DISULFID        1354..1369
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1323..1324
FT                   /note="NE -> SK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7721806"
FT                   /id="VSP_029493"
FT   VAR_SEQ         1325..1463
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7721806"
FT                   /id="VSP_029494"
FT   VARIANT         142
FT                   /note="R -> Q (in dbSNP:rs12327936)"
FT                   /id="VAR_037203"
FT   VARIANT         177
FT                   /note="P -> S (in dbSNP:rs13394676)"
FT                   /id="VAR_037204"
FT   VARIANT         279
FT                   /note="I -> V (in dbSNP:rs965290)"
FT                   /id="VAR_037205"
FT   VARIANT         292
FT                   /note="M -> V (in dbSNP:rs3749117)"
FT                   /evidence="ECO:0000269|PubMed:7721806"
FT                   /id="VAR_037206"
FT   VARIANT         300
FT                   /note="H -> D (in dbSNP:rs35771982)"
FT                   /evidence="ECO:0000269|PubMed:7721806"
FT                   /id="VAR_037207"
FT   VARIANT         370
FT                   /note="A -> E (in dbSNP:rs34916310)"
FT                   /id="VAR_061354"
FT   VARIANT         404
FT                   /note="R -> H (in dbSNP:rs33985939)"
FT                   /id="VAR_037208"
FT   VARIANT         1106
FT                   /note="G -> S (in dbSNP:rs3828323)"
FT                   /id="VAR_037209"
FT   CONFLICT        15..17
FT                   /note="APR -> GAA (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        62..64
FT                   /note="ENC -> GRTGS (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        521..523
FT                   /note="RHG -> ETC (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        724
FT                   /note="S -> P (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        779
FT                   /note="A -> P (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1224
FT                   /note="E -> D (in Ref. 1; AAA70110/AAC50163)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1263
FT                   /note="S -> K (in Ref. 1; AAA70110)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1118..1121
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1124..1133
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   HELIX           1135..1144
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   HELIX           1155..1168
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1172..1177
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1198..1200
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   HELIX           1202..1204
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1208..1212
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1218..1221
FT                   /evidence="ECO:0007829|PDB:6JLI"
FT   STRAND          1227..1233
FT                   /evidence="ECO:0007829|PDB:6JLI"
SQ   SEQUENCE   1463 AA;  168600 MW;  4E65EA5AC5D597E2 CRC64;
     MLLSPSLLLL LLLGAPRGCA EGVAAALTPE RLLEWQDKGI FVIQSESLKK CIQAGKSVLT
     LENCKQANKH MLWKWVSNHG LFNIGGSGCL GLNFSAPEQP LSLYECDSTL VSLRWRCNRK
     MITGPLQYSV QVAHDNTVVA SRKYIHKWIS YGSGGGDICE YLHKDLHTIK GNTHGMPCMF
     PFQYNHQWHH ECTREGREDD LLWCATTSRY ERDEKWGFCP DPTSAEVGCD TIWEKDLNSH
     ICYQFNLLSS LSWSEAHSSC QMQGGTLLSI TDETEENFIR EHMSSKTVEV WMGLNQLDEH
     AGWQWSDGTP LNYLNWSPEV NFEPFVEDHC GTFSSFMPSA WRSRDCESTL PYICKKYLNH
     IDHEIVEKDA WKYYATHCEP GWNPYNRNCY KLQKEEKTWH EALRSCQADN SALIDITSLA
     EVEFLVTLLG DENASETWIG LSSNKIPVSF EWSNDSSVIF TNWHTLEPHI FPNRSQLCVS
     AEQSEGHWKV KNCEERLFYI CKKAGHVLSD AESGCQEGWE RHGGFCYKID TVLRSFDQAS
     SGYYCPPALV TITNRFEQAF ITSLISSVVK MKDSYFWIAL QDQNDTGEYT WKPVGQKPEP
     VQYTHWNTHQ PRYSGGCVAM RGRHPLGRWE VKHCRHFKAM SLCKQPVENQ EKAEYEERWP
     FHPCYLDWES EPGLASCFKV FHSEKVLMKR TWREAEAFCE EFGAHLASFA HIEEENFVNE
     LLHSKFNWTE ERQFWIGFNK RNPLNAGSWE WSDRTPVVSS FLDNTYFGED ARNCAVYKAN
     KTLLPLHCGS KREWICKIPR DVKPKIPFWY QYDVPWLFYQ DAEYLFHTFA SEWLNFEFVC
     SWLHSDLLTI HSAHEQEFIH SKIKALSKYG ASWWIGLQEE RANDEFRWRD GTPVIYQNWD
     TGRERTVNNQ SQRCGFISSI TGLWGSEECS VSMPSICKRK KVWLIEKKKD TPKQHGTCPK
     GWLYFNYKCL LLNIPKDPSS WKNWTHAQHF CAEEGGTLVA IESEVEQAFI TMNLFGQTTS
     VWIGLQNDDY ETWLNGKPVV YSNWSPFDII NIPSHNTTEV QKHIPLCALL SSNPNFHFTG
     KWYFEDCGKE GYGFVCEKMQ DTSGHGVNTS DMYPMPNTLE YGNRTYKIIN ANMTWYAAIK
     TCLMHKAQLV SITDQYHQSF LTVVLNRLGY AHWIGLFTTD NGLNFDWSDG TKSSFTFWKD
     EESSLLGDCV FADSNGRWHS TACESFLQGA ICHVPPETRQ SEHPELCSET SIPWIKFKSN
     CYSFSTVLDS MSFEAAHEFC KKEGSNLLTI KDEAENAFLL EELFAFGSSV QMVWLNAQFD
     GNNETIKWFD GTPTDQSNWG IRKPDTDYFK PHHCVALRIP EGLWQLSPCQ EKKGFICKME
     ADIHTAEALP EKGPSHSIIP LAVVLTLIVI VAICTLSFCI YKHNGGFFRR LAGFRNPYYP
     ATNFSTVYLE ENILISDLEK SDQ
//
ID   RYBP_HUMAN              Reviewed;         228 AA.
AC   Q8N488; Q9P2W5; Q9UMW4;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   23-FEB-2022, entry version 168.
DE   RecName: Full=RING1 and YY1-binding protein;
DE   AltName: Full=Apoptin-associating protein 1;
DE            Short=APAP-1;
DE   AltName: Full=Death effector domain-associated factor;
DE            Short=DED-associated factor;
DE   AltName: Full=YY1 and E4TF1-associated factor 1;
GN   Name=RYBP; Synonyms=DEDAF, YEAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH DEDD; FADD; CASP8 AND CASP10.
RX   PubMed=11395500; DOI=10.1074/jbc.m102799200;
RA   Zheng L., Schickling O., Peter M.E., Lenardo M.J.;
RT   "The death effector domain-associated factor plays distinct regulatory
RT   roles in the nucleus and cytoplasm.";
RL   J. Biol. Chem. 276:31945-31952(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, INTERACTION WITH YY1 AND GABPB1, AND REGION.
RX   PubMed=11953439; DOI=10.1074/jbc.m203060200;
RA   Sawa C., Yoshikawa T., Matsuda-Suzuki F., Delehouzee S., Goto M.,
RA   Watanabe H., Sawada J., Kataoka K., Handa H.;
RT   "YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor
RT   family for the YY1 and E4TF1/hGABP transcription factors.";
RL   J. Biol. Chem. 277:22484-22490(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH APOPTIN.
RX   PubMed=14765135; DOI=10.1038/sj.cdd.4401391;
RA   Danen-van Oorschot A.A.M.M., Voskamp P., Seelen M.C.M.J.,
RA   van Miltenburg M.H.A.M., Bolk M.W., Tait S.W., Boesen-de Cock J.G.R.,
RA   Rohn J.L., Borst J., Noteborn M.H.M.;
RT   "Human death effector domain-associated factor interacts with the viral
RT   apoptosis agonist Apoptin and exerts tumor-preferential cell killing.";
RL   Cell Death Differ. 11:564-573(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Cheng C.M., Yuo C.Y.;
RT   "The chicken anemia virus protein apoptin is associated with a human
RT   apoptotic protein, APAP1.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH BCOR; PCGF1; RING1 AND RNF2.
RX   PubMed=16943429; DOI=10.1128/mcb.00630-06;
RA   Gearhart M.D., Corcoran C.M., Wamstad J.A., Bardwell V.J.;
RT   "Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex
RT   that is recruited to BCL6 targets.";
RL   Mol. Cell. Biol. 26:6880-6889(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH MDM2, AND IDENTIFICATION IN A COMPLEX WITH MDM2
RP   AND TP53.
RX   PubMed=19098711; DOI=10.1038/embor.2008.231;
RA   Chen D., Zhang J., Li M., Rayburn E.R., Wang H., Zhang R.;
RT   "RYBP stabilizes p53 by modulating MDM2.";
RL   EMBO Rep. 10:166-172(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127 AND SER-130, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99 AND SER-227, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99; SER-123; SER-127 AND
RP   SER-130, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION IN A COMPLEX WITH PCGF5; AUTS2; CSNK2B AND RYBP, AND
RP   FUNCTION.
RX   PubMed=25519132; DOI=10.1038/nature13921;
RA   Gao Z., Lee P., Stafford J.M., von Schimmelmann M., Schaefer A.,
RA   Reinberg D.;
RT   "An AUTS2-polycomb complex activates gene expression in the CNS.";
RL   Nature 516:349-354(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH PCGF1.
RX   PubMed=26687479; DOI=10.1038/srep18388;
RA   Oliviero G., Munawar N., Watson A., Streubel G., Manning G., Bardwell V.,
RA   Bracken A.P., Cagney G.;
RT   "The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a
RT   pluripotency sub-network that includes DPPA4, a regulator of
RT   embryogenesis.";
RL   Sci. Rep. 5:18388-18388(2015).
RN   [17]
RP   FUNCTION, INTERACTION WITH FANK1, SUBCELLULAR LOCATION, AND REGION.
RX   PubMed=27060496; DOI=10.1016/j.cellsig.2016.03.012;
RA   Ma W., Zhang X., Li M., Ma X., Huang B., Chen H., Chen D.;
RT   "Proapoptotic RYBP interacts with FANK1 and induces tumor cell apoptosis
RT   through the AP-1 signaling pathway.";
RL   Cell. Signal. 28:779-787(2016).
RN   [18]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=27748911; DOI=10.3892/ijo.2016.3718;
RA   Zhou H., Li J., Zhang Z., Ye R., Shao N., Cheang T., Wang S.;
RT   "RING1 and YY1 binding protein suppresses breast cancer growth and
RT   metastasis.";
RL   Int. J. Oncol. 49:2442-2452(2016).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-77, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 145-179 IN COMPLEX WITH
RP   RNF2/RING1B, AND INTERACTION WITH RNF2.
RX   PubMed=20696397; DOI=10.1016/j.str.2010.04.013;
RA   Wang R., Taylor A.B., Leal B.Z., Chadwell L.V., Ilangovan U.,
RA   Robinson A.K., Schirf V., Hart P.J., Lafer E.M., Demeler B., Hinck A.P.,
RA   McEwen D.G., Kim C.A.;
RT   "Polycomb group targeting through different binding partners of RING1B C-
RT   terminal domain.";
RL   Structure 18:966-975(2010).
CC   -!- FUNCTION: Component of a Polycomb group (PcG) multiprotein PRC1-like
CC       complex, a complex class required to maintain the transcriptionally
CC       repressive state of many genes, including Hox genes, throughout
CC       development. PcG PRC1-like complex acts via chromatin remodeling and
CC       modification of histones; it mediates monoubiquitination of histone H2A
CC       'Lys-119', rendering chromatin heritably changed in its expressibility
CC       (PubMed:25519132). Component of a PRC1-like complex that mediates
CC       monoubiquitination of histone H2A 'Lys-119' on the X chromosome and is
CC       required for normal silencing of one copy of the X chromosome in XX
CC       females. May stimulate ubiquitination of histone H2A 'Lys-119' by
CC       recruiting the complex to target sites (By similarity). Inhibits
CC       ubiquitination and subsequent degradation of TP53, and thereby plays a
CC       role in regulating transcription of TP53 target genes
CC       (PubMed:19098711). May also regulate the ubiquitin-mediated proteasomal
CC       degradation of other proteins like FANK1 to regulate apoptosis
CC       (PubMed:14765135, PubMed:27060496). May be implicated in the regulation
CC       of the transcription as a repressor of the transcriptional activity of
CC       E4TF1 (PubMed:11953439). May bind to DNA (By similarity). May play a
CC       role in the repression of tumor growth and metastasis in breast cancer
CC       by down-regulating SRRM3 (PubMed:27748911).
CC       {ECO:0000250|UniProtKB:Q8CCI5, ECO:0000269|PubMed:11953439,
CC       ECO:0000269|PubMed:14765135, ECO:0000269|PubMed:19098711,
CC       ECO:0000269|PubMed:27060496, ECO:0000269|PubMed:27748911}.
CC   -!- SUBUNIT: Monomer. Component of repressive BCOR complex containing
CC       Polycomb group subcomplex at least composed of BCOR, PCGF1, RING1 and
CC       RNF2/RING2 (PubMed:16943429). Component of PCR1-like complexes
CC       (PubMed:26687479, PubMed:20696397). Interacts with PCGF1
CC       (PubMed:26687479). Part of a PCR1-like complex that contains AUTS2,
CC       PCGF5, RNF2, CSNK2B AND RYBP (PubMed:25519132). Interacts with RNF2;
CC       the interaction is direct (PubMed:20696397). Interacts with CBX2, YAF2,
CC       RING1 and RNF2 (By similarity). Interacts with ubiquitin and
CC       ubiquitinated proteins (By similarity). Interacts with ubiquitinated
CC       histone H2A (By similarity). Interacts with apoptin, DEDD, FADD, CASP8,
CC       CASP10, YY1 and GABPB1 (PubMed:11395500, PubMed:11953439,
CC       PubMed:14765135). Together with GABPB1 and YY1, it forms a ternary
CC       complex, probably being the bridge factor between these two
CC       transcription factors (PubMed:11953439). Interacts with MDM2, and
CC       thereby inhibits ubiquitination of TP53 (PubMed:19098711). Identified
CC       in a ternary complex containing MDM2, TP53 and RYBP (PubMed:19098711).
CC       Interacts with FANK1; may prevent the ubiquitin-mediated proteasomal
CC       degradation of FANK1 (PubMed:27060496). Interacts with IFT57 (By
CC       similarity). {ECO:0000250|UniProtKB:Q8CCI5,
CC       ECO:0000269|PubMed:11395500, ECO:0000269|PubMed:11953439,
CC       ECO:0000269|PubMed:14765135, ECO:0000269|PubMed:16943429,
CC       ECO:0000269|PubMed:19098711, ECO:0000269|PubMed:20696397,
CC       ECO:0000269|PubMed:25519132, ECO:0000269|PubMed:26687479,
CC       ECO:0000269|PubMed:27060496}.
CC   -!- INTERACTION:
CC       Q8N488; P54253: ATXN1; NbExp=6; IntAct=EBI-752324, EBI-930964;
CC       Q8N488; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-752324, EBI-11524452;
CC       Q8N488; Q8WUW1: BRK1; NbExp=3; IntAct=EBI-752324, EBI-2837444;
CC       Q8N488; P21964-2: COMT; NbExp=3; IntAct=EBI-752324, EBI-10200977;
CC       Q8N488; A0A140G945: CRYAA2; NbExp=3; IntAct=EBI-752324, EBI-25838900;
CC       Q8N488; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-752324, EBI-25840379;
CC       Q8N488; G5E9A7: DMWD; NbExp=3; IntAct=EBI-752324, EBI-10976677;
CC       Q8N488; Q01658: DR1; NbExp=3; IntAct=EBI-752324, EBI-750300;
CC       Q8N488; Q96JC9: EAF1; NbExp=3; IntAct=EBI-752324, EBI-769261;
CC       Q8N488; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-752324, EBI-21603100;
CC       Q8N488; P00451-2: F8; NbExp=3; IntAct=EBI-752324, EBI-25852704;
CC       Q8N488; P21333-2: FLNA; NbExp=3; IntAct=EBI-752324, EBI-9641086;
CC       Q8N488; P35637: FUS; NbExp=3; IntAct=EBI-752324, EBI-400434;
CC       Q8N488; P14136: GFAP; NbExp=3; IntAct=EBI-752324, EBI-744302;
CC       Q8N488; O14908-2: GIPC1; NbExp=3; IntAct=EBI-752324, EBI-25913156;
CC       Q8N488; P78333: GPC5; NbExp=3; IntAct=EBI-752324, EBI-2558325;
CC       Q8N488; P28799: GRN; NbExp=3; IntAct=EBI-752324, EBI-747754;
CC       Q8N488; Q00403: GTF2B; NbExp=3; IntAct=EBI-752324, EBI-389564;
CC       Q8N488; Q9Y5Q9: GTF3C3; NbExp=3; IntAct=EBI-752324, EBI-1054873;
CC       Q8N488; O43464: HTRA2; NbExp=3; IntAct=EBI-752324, EBI-517086;
CC       Q8N488; P42858: HTT; NbExp=9; IntAct=EBI-752324, EBI-466029;
CC       Q8N488; O60333-2: KIF1B; NbExp=3; IntAct=EBI-752324, EBI-10975473;
CC       Q8N488; P02545: LMNA; NbExp=3; IntAct=EBI-752324, EBI-351935;
CC       Q8N488; P31153: MAT2A; NbExp=3; IntAct=EBI-752324, EBI-1050743;
CC       Q8N488; Q00987: MDM2; NbExp=11; IntAct=EBI-752324, EBI-389668;
CC       Q8N488; Q92597: NDRG1; NbExp=3; IntAct=EBI-752324, EBI-716486;
CC       Q8N488; P07196: NEFL; NbExp=3; IntAct=EBI-752324, EBI-475646;
CC       Q8N488; P35240-4: NF2; NbExp=3; IntAct=EBI-752324, EBI-1014514;
CC       Q8N488; O43933: PEX1; NbExp=3; IntAct=EBI-752324, EBI-988601;
CC       Q8N488; P14618: PKM; NbExp=3; IntAct=EBI-752324, EBI-353408;
CC       Q8N488; O60260-5: PRKN; NbExp=6; IntAct=EBI-752324, EBI-21251460;
CC       Q8N488; P49768-2: PSEN1; NbExp=6; IntAct=EBI-752324, EBI-11047108;
CC       Q8N488; P49810: PSEN2; NbExp=3; IntAct=EBI-752324, EBI-2010251;
CC       Q8N488; P20618: PSMB1; NbExp=3; IntAct=EBI-752324, EBI-372273;
CC       Q8N488; Q06587: RING1; NbExp=18; IntAct=EBI-752324, EBI-752313;
CC       Q8N488; Q06587-2: RING1; NbExp=3; IntAct=EBI-752324, EBI-7065222;
CC       Q8N488; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-752324, EBI-396669;
CC       Q8N488; Q99496: RNF2; NbExp=18; IntAct=EBI-752324, EBI-722416;
CC       Q8N488; Q99719: SEPTIN5; NbExp=3; IntAct=EBI-752324, EBI-373345;
CC       Q8N488; P37840: SNCA; NbExp=3; IntAct=EBI-752324, EBI-985879;
CC       Q8N488; Q16143: SNCB; NbExp=3; IntAct=EBI-752324, EBI-727106;
CC       Q8N488; P00441: SOD1; NbExp=3; IntAct=EBI-752324, EBI-990792;
CC       Q8N488; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-752324, EBI-5235340;
CC       Q8N488; P49458: SRP9; NbExp=3; IntAct=EBI-752324, EBI-350743;
CC       Q8N488; Q13148: TARDBP; NbExp=6; IntAct=EBI-752324, EBI-372899;
CC       Q8N488; Q9NUW8: TDP1; NbExp=3; IntAct=EBI-752324, EBI-2902553;
CC       Q8N488; P21980-2: TGM2; NbExp=3; IntAct=EBI-752324, EBI-25842075;
CC       Q8N488; P04637: TP53; NbExp=3; IntAct=EBI-752324, EBI-366083;
CC       Q8N488; P0CG47: UBB; NbExp=3; IntAct=EBI-752324, EBI-413034;
CC       Q8N488; P0CG48: UBC; NbExp=3; IntAct=EBI-752324, EBI-3390054;
CC       Q8N488; Q9HD64: XAGE1B; NbExp=3; IntAct=EBI-752324, EBI-2340004;
CC       Q8N488; Q9P1N4; NbExp=3; IntAct=EBI-752324, EBI-25878161;
CC       Q8N488; PRO_0000037319 [P0C6X7]: rep; Xeno; NbExp=2; IntAct=EBI-752324, EBI-25487926;
CC       Q8N488; Q923J1: Trpm7; Xeno; NbExp=3; IntAct=EBI-752324, EBI-8010314;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11395500,
CC       ECO:0000269|PubMed:11953439, ECO:0000269|PubMed:14765135,
CC       ECO:0000269|PubMed:27060496}. Cytoplasm {ECO:0000269|PubMed:11395500,
CC       ECO:0000269|PubMed:14765135}. Nucleus, nucleoplasm
CC       {ECO:0000250|UniProtKB:Q8CCI5}. Note=Primarily found in the nucleus.
CC       Detected in a punctate pattern likely to represent Polycomb group (PcG)
CC       bodies (By similarity). {ECO:0000250|UniProtKB:Q8CCI5}.
CC   -!- TISSUE SPECIFICITY: Down-regulated in breast cancer tissues and in
CC       several breast cancer cell lines (at protein level) (PubMed:27748911).
CC       Widely expressed with highest levels in lymphoid tissues and placenta.
CC       {ECO:0000269|PubMed:11395500, ECO:0000269|PubMed:11953439,
CC       ECO:0000269|PubMed:14765135, ECO:0000269|PubMed:27748911}.
CC   -!- DOMAIN: Intrinsically unstructured in the absence of binding partners.
CC       Folds upon binding to DNA or RNF2 (By similarity). {ECO:0000250}.
CC   -!- PTM: Monoubiquitinated. {ECO:0000250}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK63197.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAO73587.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA89486.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF179286; AAD51858.1; -; mRNA.
DR   EMBL; AB029551; BAA89486.1; ALT_INIT; mRNA.
DR   EMBL; AY228125; AAO73587.1; ALT_INIT; mRNA.
DR   EMBL; AF227959; AAK63197.1; ALT_INIT; mRNA.
DR   EMBL; BC014959; AAH14959.1; -; mRNA.
DR   EMBL; BC036459; AAH36459.1; -; mRNA.
DR   RefSeq; NP_036366.3; NM_012234.6.
DR   PDB; 3IXS; X-ray; 1.70 A; B/D/F/H/J/L=145-179.
DR   PDBsum; 3IXS; -.
DR   SMR; Q8N488; -.
DR   BioGRID; 116997; 104.
DR   CORUM; Q8N488; -.
DR   DIP; DIP-41435N; -.
DR   IntAct; Q8N488; 99.
DR   MINT; Q8N488; -.
DR   STRING; 9606.ENSP00000419494; -.
DR   iPTMnet; Q8N488; -.
DR   PhosphoSitePlus; Q8N488; -.
DR   BioMuta; RYBP; -.
DR   DMDM; 78102506; -.
DR   EPD; Q8N488; -.
DR   jPOST; Q8N488; -.
DR   MassIVE; Q8N488; -.
DR   MaxQB; Q8N488; -.
DR   PaxDb; Q8N488; -.
DR   PeptideAtlas; Q8N488; -.
DR   PRIDE; Q8N488; -.
DR   ProteomicsDB; 71895; -.
DR   Antibodypedia; 7772; 466 antibodies from 36 providers.
DR   DNASU; 23429; -.
DR   Ensembl; ENST00000477973; ENSP00000419494; ENSG00000163602.
DR   GeneID; 23429; -.
DR   KEGG; hsa:23429; -.
DR   UCSC; uc003dpe.4; human.
DR   CTD; 23429; -.
DR   DisGeNET; 23429; -.
DR   GeneCards; RYBP; -.
DR   HGNC; HGNC:10480; RYBP.
DR   HPA; ENSG00000163602; Low tissue specificity.
DR   MIM; 607535; gene.
DR   neXtProt; NX_Q8N488; -.
DR   PharmGKB; PA34893; -.
DR   VEuPathDB; HostDB:ENSG00000163602; -.
DR   eggNOG; KOG4477; Eukaryota.
DR   HOGENOM; CLU_095374_0_0_1; -.
DR   InParanoid; Q8N488; -.
DR   OrthoDB; 1634090at2759; -.
DR   PhylomeDB; Q8N488; -.
DR   TreeFam; TF350501; -.
DR   PathwayCommons; Q8N488; -.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   SignaLink; Q8N488; -.
DR   SIGNOR; Q8N488; -.
DR   BioGRID-ORCS; 23429; 8 hits in 173 CRISPR screens.
DR   ChiTaRS; RYBP; human.
DR   EvolutionaryTrace; Q8N488; -.
DR   GeneWiki; RYBP; -.
DR   GenomeRNAi; 23429; -.
DR   Pharos; Q8N488; Tbio.
DR   PRO; PR:Q8N488; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q8N488; protein.
DR   Bgee; ENSG00000163602; Expressed in chorionic villus and 252 other tissues.
DR   Genevisible; Q8N488; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central.
DR   GO; GO:0003714; F:transcription corepressor activity; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0035518; P:histone H2A monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   DisProt; DP00694; -.
DR   InterPro; IPR039958; RYBP/YAF2.
DR   InterPro; IPR033774; YAF2_RYBP.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR036443; Znf_RanBP2_sf.
DR   PANTHER; PTHR12920; PTHR12920; 1.
DR   Pfam; PF17219; YAF2_RYBP; 1.
DR   Pfam; PF00641; zf-RanBP; 1.
DR   SMART; SM00547; ZnF_RBZ; 1.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 1.
DR   PROSITE; PS50199; ZF_RANBP2_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Cytoplasm; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..228
FT                   /note="RING1 and YY1-binding protein"
FT                   /id="PRO_0000097550"
FT   ZN_FING         21..50
FT                   /note="RanBP2-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00322"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          65..156
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          143..226
FT                   /note="Interaction with GABPB1 and FANK1"
FT                   /evidence="ECO:0000269|PubMed:11953439,
FT                   ECO:0000269|PubMed:27060496"
FT   REGION          172..228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..20
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        75..119
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        122..141
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         99
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         123
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         227
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        77
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CONFLICT        20
FT                   /note="A -> T (in Ref. 5; AAH36459)"
FT                   /evidence="ECO:0000305"
FT   STRAND          149..163
FT                   /evidence="ECO:0007829|PDB:3IXS"
FT   STRAND          166..175
FT                   /evidence="ECO:0007829|PDB:3IXS"
SQ   SEQUENCE   228 AA;  24822 MW;  EB9593460A3F0F4C CRC64;
     MTMGDKKSPT RPKRQAKPAA DEGFWDCSVC TFRNSAEAFK CSICDVRKGT STRKPRINSQ
     LVAQQVAQQY ATPPPPKKEK KEKVEKQDKE KPEKDKEISP SVTKKNTNKK TKPKSDILKD
     PPSEANSIQS ANATTKTSET NHTSRPRLKN VDRSTAQQLA VTVGNVTVII TDFKEKTRSS
     STSSSTVTSS AGSEQQNQSS SGSESTDKGS SRSSTPKGDM SAVNDESF
//
ID   O52A1_HUMAN             Reviewed;         312 AA.
AC   Q9UKL2; Q6IF31;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   23-FEB-2022, entry version 165.
DE   RecName: Full=Olfactory receptor 52A1;
DE   AltName: Full=HPFH1OR;
DE   AltName: Full=Odorant receptor HOR3'beta4;
DE   AltName: Full=Olfactory receptor OR11-319;
GN   Name=OR52A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10512676; DOI=10.1006/geno.1999.5935;
RA   Feingold E.A., Penny L.A., Nienhuis A.W., Forget B.G.;
RT   "An olfactory receptor gene is located in the extended human beta-globin
RT   gene cluster and is expressed in erythroid cells.";
RL   Genomics 61:15-23(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11121057; DOI=10.1073/pnas.97.26.14560;
RA   Bulger M., Bender M.A., van Doorninck J.H., Wertman B., Farrell C.M.,
RA   Felsenfeld G., Groudine M., Hardison R.;
RT   "Comparative structural and functional analysis of the olfactory receptor
RT   genes flanking the human and mouse beta-globin gene clusters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:14560-14565(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION.
RX   PubMed=14983052; DOI=10.1073/pnas.0307882100;
RA   Malnic B., Godfrey P.A., Buck L.B.;
RT   "The human olfactory receptor gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2584-2589(2004).
RN   [6]
RP   ERRATUM OF PUBMED:14983052.
RA   Malnic B., Godfrey P.A., Buck L.B.;
RL   Proc. Natl. Acad. Sci. U.S.A. 101:7205-7205(2004).
CC   -!- FUNCTION: Odorant receptor. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Human Olfactory Receptor Data Exploratorium (HORDE);
CC       URL="http://genome.weizmann.ac.il/horde/card/index/symbol:OR52A1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF154673; AAD51279.1; -; Genomic_DNA.
DR   EMBL; AF289204; AAG42367.1; -; Genomic_DNA.
DR   EMBL; AC129505; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC111722; AAI11723.1; -; mRNA.
DR   EMBL; BK004431; DAA04829.1; -; Genomic_DNA.
DR   CCDS; CCDS31374.1; -.
DR   RefSeq; NP_036507.2; NM_012375.2.
DR   SMR; Q9UKL2; -.
DR   STRING; 9606.ENSP00000369725; -.
DR   GlyGen; Q9UKL2; 1 site.
DR   BioMuta; OR52A1; -.
DR   DMDM; 296439247; -.
DR   MassIVE; Q9UKL2; -.
DR   PaxDb; Q9UKL2; -.
DR   PeptideAtlas; Q9UKL2; -.
DR   PRIDE; Q9UKL2; -.
DR   Antibodypedia; 55354; 110 antibodies from 21 providers.
DR   DNASU; 23538; -.
DR   Ensembl; ENST00000380367; ENSP00000369725; ENSG00000182070.
DR   GeneID; 23538; -.
DR   KEGG; hsa:23538; -.
DR   MANE-Select; ENST00000380367.3; ENSP00000369725.1; NM_012375.3; NP_036507.2.
DR   UCSC; uc010qyy.2; human.
DR   CTD; 23538; -.
DR   GeneCards; OR52A1; -.
DR   HGNC; HGNC:8318; OR52A1.
DR   HPA; ENSG00000182070; Not detected.
DR   neXtProt; NX_Q9UKL2; -.
DR   OpenTargets; ENSG00000182070; -.
DR   PharmGKB; PA32392; -.
DR   VEuPathDB; HostDB:ENSG00000182070; -.
DR   eggNOG; ENOG502SITM; Eukaryota.
DR   GeneTree; ENSGT01040000240377; -.
DR   HOGENOM; CLU_012526_0_0_1; -.
DR   InParanoid; Q9UKL2; -.
DR   OMA; VIQIGTV; -.
DR   OrthoDB; 912949at2759; -.
DR   PhylomeDB; Q9UKL2; -.
DR   TreeFam; TF352744; -.
DR   PathwayCommons; Q9UKL2; -.
DR   BioGRID-ORCS; 23538; 3 hits in 646 CRISPR screens.
DR   GeneWiki; OR52A1; -.
DR   GenomeRNAi; 23538; -.
DR   Pharos; Q9UKL2; Tdark.
DR   PRO; PR:Q9UKL2; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9UKL2; protein.
DR   Bgee; ENSG00000182070; Expressed in anatomical system and 2 other tissues.
DR   Genevisible; Q9UKL2; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0004984; F:olfactory receptor activity; IEA:InterPro.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007608; P:sensory perception of smell; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000725; Olfact_rcpt.
DR   Pfam; PF13853; 7tm_4; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00245; OLFACTORYR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   2: Evidence at transcript level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Olfaction; Receptor; Reference proteome; Sensory transduction;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..312
FT                   /note="Olfactory receptor 52A1"
FT                   /id="PRO_0000150765"
FT   TOPO_DOM        1..27
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        28..48
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        49..56
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        57..77
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        78..101
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        102..122
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        123..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..162
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..199
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        200..220
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        221..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        241..261
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        262..276
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        277..297
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        298..312
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        99..182
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        272
FT                   /note="S -> P (in Ref. 1; AAD51279, 2; AAG42367 and 4;
FT                   AAI11723)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   312 AA;  35322 MW;  B05AFD46352D513C CRC64;
     MSISNITVYM PSVLTLVGIP GLESVQCWIG IPFCAIYLIA MIGNSLLLSI IKSERSLHEP
     LYIFLGMLGA TDIALASSIM PKMLGIFWFN VPEIYFDSCL LQMWFIHTLQ GIESGILVAM
     ALDRYVAICY PLRHANIFTH QLVIQIGTMV VLRAAILVAP CLVLIKCRFQ FYHTTVISHS
     YCEHMAIVKL AAANVQVNKI YGLFVAFTVA GFDLTFITLS YIQIFITVFR LPQKEARFKA
     FNTCIAHICV FLQFYLLAFF SFFTHRFGSH ISPYIHILFS SIYLLVPPFL NPLVYGAKTT
     QIRIHVVKMF CS
//
ID   BL1S6_HUMAN             Reviewed;         172 AA.
AC   Q9UL45;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   23-FEB-2022, entry version 172.
DE   RecName: Full=Biogenesis of lysosome-related organelles complex 1 subunit 6;
DE            Short=BLOC-1 subunit 6;
DE   AltName: Full=Pallid protein homolog;
DE   AltName: Full=Pallidin;
DE   AltName: Full=Syntaxin 13-interacting protein;
GN   Name=BLOC1S6; Synonyms=PA, PLDN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10610180; DOI=10.1038/15507;
RA   Huang L., Kuo Y.-M., Gitschier J.;
RT   "The pallid gene encodes a novel, syntaxin 13-interacting protein involved
RT   in platelet storage pool deficiency.";
RL   Nat. Genet. 23:329-332(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   REVIEW, AND ALTERNATIVE SPLICING.
RX   PubMed=11936273; DOI=10.1034/j.1600-0749.2002.1r082.x;
RA   Falcon-Perez J.M., Dell'Angelica E.C.;
RT   "The pallidin (Pldn) gene and the role of SNARE proteins in melanosome
RT   biogenesis.";
RL   Pigment Cell Res. 15:82-86(2002).
RN   [5]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION, INTERACTION WITH
RP   STX12 AND BLOC1S5, AND HOMODIMERIZATION.
RX   PubMed=12191018; DOI=10.1034/j.1600-0854.2002.30908.x;
RA   Moriyama K., Bonifacino J.S.;
RT   "Pallidin is a component of a multi-protein complex involved in the
RT   biogenesis of lysosome-related organelles.";
RL   Traffic 3:666-677(2002).
RN   [6]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INTERACTION WITH BLOC1S5 AND
RP   F-ACTIN, AND HOMODIMERIZATION.
RX   PubMed=12019270; DOI=10.1074/jbc.m204011200;
RA   Falcon-Perez J.M., Starcevic M., Gautam R., Dell'Angelica E.C.;
RT   "BLOC-1, a novel complex containing the pallidin and muted proteins
RT   involved in the biogenesis of melanosomes and platelet-dense granules.";
RL   J. Biol. Chem. 277:28191-28199(2002).
RN   [7]
RP   IDENTIFICATION IN THE BLOC-1 COMPLEX, AND FUNCTION.
RX   PubMed=17182842; DOI=10.1091/mbc.e06-12-1066;
RA   Setty S.R., Tenza D., Truschel S.T., Chou E., Sviderskaya E.V., Theos A.C.,
RA   Lamoreux M.L., Di Pietro S.M., Starcevic M., Bennett D.C.,
RA   Dell'Angelica E.C., Raposo G., Marks M.S.;
RT   "BLOC-1 is required for cargo-specific sorting from vacuolar early
RT   endosomes toward lysosome-related organelles.";
RL   Mol. Biol. Cell 18:768-780(2007).
RN   [8]
RP   IDENTIFICATION IN THE BLOC-1 COMPLEX, AND INTERACTION WITH SNAP25; SNAP47
RP   AND STX12.
RX   PubMed=19546860; DOI=10.1038/mp.2009.58;
RA   Ghiani C.A., Starcevic M., Rodriguez-Fernandez I.A., Nazarian R.,
RA   Cheli V.T., Chan L.N., Malvar J.S., de Vellis J., Sabatti C.,
RA   Dell'Angelica E.C.;
RT   "The dysbindin-containing complex (BLOC-1) in brain: developmental
RT   regulation, interaction with SNARE proteins and role in neurite
RT   outgrowth.";
RL   Mol. Psychiatry 15:204-215(2010).
RN   [9]
RP   RETRACTED PAPER.
RX   PubMed=21665000; DOI=10.1016/j.ajhg.2011.05.009;
RA   Cullinane A.R., Curry J.A., Carmona-Rivera C., Summers C.G., Ciccone C.,
RA   Cardillo N.D., Dorward H., Hess R.A., White J.G., Adams D., Huizing M.,
RA   Gahl W.A.;
RT   "A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak
RT   Syndrome type 9.";
RL   Am. J. Hum. Genet. 88:778-787(2011).
RN   [10]
RP   RETRACTION NOTICE OF PUBMED:21665000.
RX   PubMed=28475864; DOI=10.1016/j.ajhg.2017.04.011;
RA   Cullinane A.R., Curry J.A., Carmona-Rivera C., Summers C.G., Ciccone C.,
RA   Cardillo N.D., Dorward H., Hess R.A., White J.G., Adams D., Huizing M.,
RA   Gahl W.A.;
RT   "Retraction Notice to: A BLOC-1 Mutation Screen Reveals that PLDN Is
RT   Mutated in Hermansky-Pudlak Syndrome Type 9.";
RL   Am. J. Hum. Genet. 100:837-837(2017).
RN   [11]
RP   FUNCTION, ASSOCIATION WITH THE AP-3 COMPLEX, AND INTERACTION WITH BLOC1S5.
RX   PubMed=21998198; DOI=10.1091/mbc.e11-07-0592;
RA   Larimore J., Tornieri K., Ryder P.V., Gokhale A., Zlatic S.A., Craige B.,
RA   Lee J.D., Talbot K., Pare J.F., Smith Y., Faundez V.;
RT   "The schizophrenia susceptibility factor dysbindin and its associated
RT   complex sort cargoes from cell bodies to the synapse.";
RL   Mol. Biol. Cell 22:4854-4867(2011).
RN   [12]
RP   INVOLVEMENT IN HPS9, VARIANT HPS9 78-GLN--MET-172 DEL, AND CHARACTERIZATION
RP   OF VARIANT HPS9 78-GLN--MET-172 DEL.
RX   PubMed=22461475; DOI=10.1182/blood-2012-01-404350;
RA   Badolato R., Prandini A., Caracciolo S., Colombo F., Tabellini G.,
RA   Giacomelli M., Cantarini M.E., Pession A., Bell C.J., Dinwiddie D.L.,
RA   Miller N.A., Hateley S.L., Saunders C.J., Zhang L., Schroth G.P.,
RA   Plebani A., Parolini S., Kingsmore S.F.;
RT   "Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak-like
RT   primary immunodeficiency syndrome.";
RL   Blood 119:3185-3187(2012).
RN   [13]
RP   IDENTIFICATION IN THE BLOC-1 COMPLEX, AND COMPOSITION OF THE BLOC-1
RP   COMPLEX.
RX   PubMed=22203680; DOI=10.1074/jbc.m111.325746;
RA   Lee H.H., Nemecek D., Schindler C., Smith W.J., Ghirlando R., Steven A.C.,
RA   Bonifacino J.S., Hurley J.H.;
RT   "Assembly and architecture of biogenesis of lysosome-related organelles
RT   complex-1 (BLOC-1).";
RL   J. Biol. Chem. 287:5882-5890(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the BLOC-1 complex, a complex that is required
CC       for normal biogenesis of lysosome-related organelles (LRO), such as
CC       platelet dense granules and melanosomes. In concert with the AP-3
CC       complex, the BLOC-1 complex is required to target membrane protein
CC       cargos into vesicles assembled at cell bodies for delivery into
CC       neurites and nerve terminals. The BLOC-1 complex, in association with
CC       SNARE proteins, is also proposed to be involved in neurite extension.
CC       May play a role in intracellular vesicle trafficking, particularly in
CC       the vesicle-docking and fusion process. {ECO:0000269|PubMed:17182842,
CC       ECO:0000269|PubMed:21998198}.
CC   -!- SUBUNIT: Interacts with BLOC1S4 and DTNBP1/BLOC1S7 (By similarity).
CC       Homodimer. Component of the biogenesis of lysosome-related organelles
CC       complex 1 (BLOC-1) composed of BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S4,
CC       BLOC1S5, BLOC1S6, DTNBP1/BLOC1S7 and SNAPIN/BLOC1S8. Octamer composed
CC       of one copy each BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S4, BLOC1S5, BLOC1S6,
CC       DTNBP1/BLOC1S7 and SNAPIN/BLOC1S8. The BLOC-1 complex associates with
CC       the AP-3 protein complex and membrane protein cargos. Interacts with
CC       BLOC1S5, F-actin, SNAP25 isoform 1 and isoform 2, SNAP47 and STX12.
CC       {ECO:0000250, ECO:0000269|PubMed:12019270, ECO:0000269|PubMed:12191018,
CC       ECO:0000269|PubMed:17182842, ECO:0000269|PubMed:19546860,
CC       ECO:0000269|PubMed:21998198, ECO:0000269|PubMed:22203680}.
CC   -!- INTERACTION:
CC       Q9UL45; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-465781, EBI-743598;
CC       Q9UL45; Q9NYB9-2: ABI2; NbExp=6; IntAct=EBI-465781, EBI-11096309;
CC       Q9UL45; P78537: BLOC1S1; NbExp=17; IntAct=EBI-465781, EBI-348630;
CC       Q9UL45; Q9NUP1: BLOC1S4; NbExp=5; IntAct=EBI-465781, EBI-465852;
CC       Q9UL45; Q9UL45: BLOC1S6; NbExp=3; IntAct=EBI-465781, EBI-465781;
CC       Q9UL45; Q504U0: C4orf46; NbExp=3; IntAct=EBI-465781, EBI-6657981;
CC       Q9UL45; Q96JN2-2: CCDC136; NbExp=3; IntAct=EBI-465781, EBI-10171416;
CC       Q9UL45; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-465781, EBI-10175300;
CC       Q9UL45; Q8N619: CDK5R1; NbExp=3; IntAct=EBI-465781, EBI-10266998;
CC       Q9UL45; Q9C0F1: CEP44; NbExp=3; IntAct=EBI-465781, EBI-744115;
CC       Q9UL45; Q6QEF8: CORO6; NbExp=3; IntAct=EBI-465781, EBI-10254194;
CC       Q9UL45; Q13561: DCTN2; NbExp=3; IntAct=EBI-465781, EBI-715074;
CC       Q9UL45; Q96EV8: DTNBP1; NbExp=9; IntAct=EBI-465781, EBI-465804;
CC       Q9UL45; Q8IYI6: EXOC8; NbExp=4; IntAct=EBI-465781, EBI-742102;
CC       Q9UL45; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-465781, EBI-2514791;
CC       Q9UL45; Q8IY31-3: IFT20; NbExp=3; IntAct=EBI-465781, EBI-9091197;
CC       Q9UL45; Q2T9L4: INSYN1; NbExp=7; IntAct=EBI-465781, EBI-4311436;
CC       Q9UL45; A1A4E9: KRT13; NbExp=3; IntAct=EBI-465781, EBI-10171552;
CC       Q9UL45; Q14CN4: KRT72; NbExp=3; IntAct=EBI-465781, EBI-1221280;
CC       Q9UL45; Q13503: MED21; NbExp=3; IntAct=EBI-465781, EBI-394678;
CC       Q9UL45; Q9BV36: MLPH; NbExp=3; IntAct=EBI-465781, EBI-7042162;
CC       Q9UL45; P37198: NUP62; NbExp=6; IntAct=EBI-465781, EBI-347978;
CC       Q9UL45; Q9H8W4: PLEKHF2; NbExp=4; IntAct=EBI-465781, EBI-742388;
CC       Q9UL45; Q9UJ41: RABGEF1; NbExp=3; IntAct=EBI-465781, EBI-913954;
CC       Q9UL45; Q9UJ41-4: RABGEF1; NbExp=6; IntAct=EBI-465781, EBI-14093916;
CC       Q9UL45; Q6NUQ1: RINT1; NbExp=3; IntAct=EBI-465781, EBI-726876;
CC       Q9UL45; Q96BD8: SKA1; NbExp=8; IntAct=EBI-465781, EBI-741854;
CC       Q9UL45; Q16637: SMN2; NbExp=6; IntAct=EBI-465781, EBI-395421;
CC       Q9UL45; O75558: STX11; NbExp=6; IntAct=EBI-465781, EBI-714135;
CC       Q9UL45; Q16623: STX1A; NbExp=3; IntAct=EBI-465781, EBI-712466;
CC       Q9UL45; A1L190: SYCE3; NbExp=3; IntAct=EBI-465781, EBI-10283466;
CC       Q9UL45; P09493-10: TPM1; NbExp=5; IntAct=EBI-465781, EBI-12123928;
CC       Q9UL45; Q5VU62: TPM3; NbExp=3; IntAct=EBI-465781, EBI-10184033;
CC       Q9UL45; Q9Y3C0: WASHC3; NbExp=8; IntAct=EBI-465781, EBI-712969;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12019270,
CC       ECO:0000269|PubMed:12191018}. Membrane {ECO:0000269|PubMed:12019270,
CC       ECO:0000269|PubMed:12191018}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:12019270}. Note=It can exist as a soluble protein
CC       as well as a peripheral membrane protein (PubMed:12019270).
CC       {ECO:0000269|PubMed:12019270}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UL45-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UL45-2; Sequence=VSP_009293, VSP_009294;
CC       Name=3;
CC         IsoId=Q9UL45-3; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:12019270,
CC       ECO:0000269|PubMed:12191018}.
CC   -!- PTM: Phosphorylated. {ECO:0000269|PubMed:12191018}.
CC   -!- DISEASE: Hermansky-Pudlak syndrome 9 (HPS9) [MIM:614171]: A form of
CC       Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal
CC       recessive disorder characterized by oculocutaneous albinism, bleeding
CC       due to platelet storage pool deficiency, and lysosomal storage defects.
CC       This syndrome results from defects of diverse cytoplasmic organelles
CC       including melanosomes, platelet dense granules and lysosomes. Ceroid
CC       storage in the lungs is associated with pulmonary fibrosis, a common
CC       cause of premature death in individuals with HPS.
CC       {ECO:0000269|PubMed:22461475}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing acceptor splice
CC       site. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be due to exons 2 and 3 skipping.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the BLOC1S6 family. {ECO:0000305}.
CC   -!- CAUTION: A paper showing involvement in Hermansky-Pudlak syndrome 9 was
CC       retracted due to image duplication. {ECO:0000269|PubMed:21665000,
CC       ECO:0000305|PubMed:28475864}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF080470; AAF08343.1; -; mRNA.
DR   EMBL; AK057545; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC004819; AAH04819.1; -; mRNA.
DR   CCDS; CCDS10126.1; -. [Q9UL45-1]
DR   RefSeq; NP_036520.1; NM_012388.3. [Q9UL45-1]
DR   SMR; Q9UL45; -.
DR   BioGRID; 117644; 76.
DR   ComplexPortal; CPX-1910; BLOC-1 complex.
DR   CORUM; Q9UL45; -.
DR   IntAct; Q9UL45; 49.
DR   MINT; Q9UL45; -.
DR   STRING; 9606.ENSP00000220531; -.
DR   iPTMnet; Q9UL45; -.
DR   PhosphoSitePlus; Q9UL45; -.
DR   BioMuta; BLOC1S6; -.
DR   DMDM; 41017511; -.
DR   EPD; Q9UL45; -.
DR   jPOST; Q9UL45; -.
DR   MassIVE; Q9UL45; -.
DR   MaxQB; Q9UL45; -.
DR   PaxDb; Q9UL45; -.
DR   PeptideAtlas; Q9UL45; -.
DR   PRIDE; Q9UL45; -.
DR   ProteomicsDB; 84945; -. [Q9UL45-1]
DR   ProteomicsDB; 84946; -. [Q9UL45-2]
DR   Antibodypedia; 24448; 205 antibodies from 31 providers.
DR   DNASU; 26258; -.
DR   Ensembl; ENST00000220531; ENSP00000220531; ENSG00000104164.
DR   Ensembl; ENST00000567523; ENSP00000456624; ENSG00000104164. [Q9UL45-2]
DR   GeneID; 26258; -.
DR   KEGG; hsa:26258; -.
DR   MANE-Select; ENST00000220531.9; ENSP00000220531.4; NM_012388.4; NP_036520.1.
DR   UCSC; uc001zvq.4; human. [Q9UL45-1]
DR   CTD; 26258; -.
DR   DisGeNET; 26258; -.
DR   GeneCards; BLOC1S6; -.
DR   GeneReviews; BLOC1S6; -.
DR   HGNC; HGNC:8549; BLOC1S6.
DR   HPA; ENSG00000104164; Low tissue specificity.
DR   MalaCards; BLOC1S6; -.
DR   MIM; 604310; gene.
DR   MIM; 614171; phenotype.
DR   neXtProt; NX_Q9UL45; -.
DR   OpenTargets; ENSG00000104164; -.
DR   PharmGKB; PA33398; -.
DR   VEuPathDB; HostDB:ENSG00000104164; -.
DR   eggNOG; ENOG502RZNC; Eukaryota.
DR   GeneTree; ENSGT00510000047812; -.
DR   HOGENOM; CLU_115118_1_0_1; -.
DR   InParanoid; Q9UL45; -.
DR   OMA; MMSDVKR; -.
DR   PhylomeDB; Q9UL45; -.
DR   TreeFam; TF325188; -.
DR   PathwayCommons; Q9UL45; -.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   SignaLink; Q9UL45; -.
DR   SIGNOR; Q9UL45; -.
DR   BioGRID-ORCS; 26258; 21 hits in 1051 CRISPR screens.
DR   ChiTaRS; BLOC1S6; human.
DR   GeneWiki; PLDN; -.
DR   GenomeRNAi; 26258; -.
DR   Pharos; Q9UL45; Tbio.
DR   PRO; PR:Q9UL45; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q9UL45; protein.
DR   Bgee; ENSG00000104164; Expressed in epithelial cell of pancreas and 225 other tissues.
DR   ExpressionAtlas; Q9UL45; baseline and differential.
DR   Genevisible; Q9UL45; HS.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0031083; C:BLOC-1 complex; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0019898; C:extrinsic component of membrane; IDA:UniProtKB.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0051015; F:actin filament binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019905; F:syntaxin binding; TAS:UniProtKB.
DR   GO; GO:0046085; P:adenosine metabolic process; IEA:Ensembl.
DR   GO; GO:0008089; P:anterograde axonal transport; ISS:UniProtKB.
DR   GO; GO:0048490; P:anterograde synaptic vesicle transport; ISS:UniProtKB.
DR   GO; GO:0006531; P:aspartate metabolic process; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0042745; P:circadian sleep/wake cycle; IEA:Ensembl.
DR   GO; GO:0007010; P:cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0021542; P:dentate gyrus development; IEA:Ensembl.
DR   GO; GO:0016197; P:endosomal transport; IEA:Ensembl.
DR   GO; GO:0007032; P:endosome organization; IEA:Ensembl.
DR   GO; GO:0035646; P:endosome to melanosome transport; IDA:UniProtKB.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0006536; P:glutamate metabolic process; IEA:Ensembl.
DR   GO; GO:0006541; P:glutamine metabolic process; IEA:Ensembl.
DR   GO; GO:0006547; P:histidine metabolic process; IEA:Ensembl.
DR   GO; GO:0021854; P:hypothalamus development; IEA:Ensembl.
DR   GO; GO:0046907; P:intracellular transport; IBA:GO_Central.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0006558; P:L-phenylalanine metabolic process; IEA:Ensembl.
DR   GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl.
DR   GO; GO:0035641; P:locomotory exploration behavior; IEA:Ensembl.
DR   GO; GO:0006553; P:lysine metabolic process; IEA:Ensembl.
DR   GO; GO:0030318; P:melanocyte differentiation; IEA:Ensembl.
DR   GO; GO:0032438; P:melanosome organization; NAS:UniProtKB.
DR   GO; GO:0032402; P:melanosome transport; IDA:UniProtKB.
DR   GO; GO:0061025; P:membrane fusion; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:Ensembl.
DR   GO; GO:0060155; P:platelet dense granule organization; IEA:Ensembl.
DR   GO; GO:0032816; P:positive regulation of natural killer cell activation; IEA:Ensembl.
DR   GO; GO:0050942; P:positive regulation of pigment cell differentiation; IDA:UniProtKB.
DR   GO; GO:1903441; P:protein localization to ciliary membrane; IEA:Ensembl.
DR   GO; GO:0033299; P:secretion of lysosomal enzymes; IEA:Ensembl.
DR   GO; GO:0016081; P:synaptic vesicle docking; NAS:UniProtKB.
DR   GO; GO:0006568; P:tryptophan metabolic process; IEA:Ensembl.
DR   GO; GO:0001944; P:vasculature development; IEA:Ensembl.
DR   InterPro; IPR017242; BLOC-1_pallidin.
DR   InterPro; IPR028119; Snapin/Pallidin/Snn1.
DR   Pfam; PF14712; Snapin_Pallidin; 1.
DR   PIRSF; PIRSF037609; BLOC-1_complex_pallidin; 1.
PE   1: Evidence at protein level;
KW   Albinism; Alternative splicing; Coiled coil; Cytoplasm; Disease variant;
KW   Hermansky-Pudlak syndrome; Membrane; Phosphoprotein; Reference proteome.
FT   CHAIN           1..172
FT                   /note="Biogenesis of lysosome-related organelles complex 1
FT                   subunit 6"
FT                   /id="PRO_0000058458"
FT   REGION          1..36
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          135..172
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          63..167
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        140..172
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         76..80
FT                   /note="QNQVV -> TKLYC (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_009293"
FT   VAR_SEQ         81..172
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_009294"
FT   VARIANT         78..172
FT                   /note="Missing (in HPS9; reduces NK cell cytolytic
FT                   activity; increases LAMP1/CD107A and CD63 levels at the
FT                   cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:22461475"
FT                   /id="VAR_081117"
SQ   SEQUENCE   172 AA;  19744 MW;  37902FCFD4802294 CRC64;
     MSVPGPSSPD GALTRPPYCL EAGEPTPGLS DTSPDEGLIE DLTIEDKAVE QLAEGLLSHY
     LPDLQRSKQA LQELTQNQVV LLDTLEQEIS KFKECHSMLD INALFAEAKH YHAKLVNIRK
     EMLMLHEKTS KLKKRALKLQ QKRQKEELER EQQREKEFER EKQLTARPAK RM
//
ID   PCDB1_HUMAN             Reviewed;         818 AA.
AC   Q9Y5F3; Q2M257;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   23-FEB-2022, entry version 162.
DE   RecName: Full=Protocadherin beta-1;
DE            Short=PCDH-beta-1;
DE   Flags: Precursor;
GN   Name=PCDHB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-778.
RX   PubMed=10380929; DOI=10.1016/s0092-8674(00)80789-8;
RA   Wu Q., Maniatis T.;
RT   "A striking organization of a large family of human neural cadherin-like
RT   cell adhesion genes.";
RL   Cell 97:779-790(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Potential calcium-dependent cell-adhesion protein. May be
CC       involved in the establishment and maintenance of specific neuronal
CC       connections in the brain.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF152488; AAD43749.1; -; mRNA.
DR   EMBL; CH471062; EAW61985.1; -; Genomic_DNA.
DR   EMBL; BC112096; AAI12097.1; -; mRNA.
DR   EMBL; BC112098; AAI12099.1; -; mRNA.
DR   CCDS; CCDS4243.1; -.
DR   RefSeq; NP_037472.2; NM_013340.3.
DR   SMR; Q9Y5F3; -.
DR   BioGRID; 118971; 19.
DR   IntAct; Q9Y5F3; 1.
DR   STRING; 9606.ENSP00000307234; -.
DR   GlyGen; Q9Y5F3; 5 sites.
DR   iPTMnet; Q9Y5F3; -.
DR   PhosphoSitePlus; Q9Y5F3; -.
DR   BioMuta; PCDHB1; -.
DR   DMDM; 205371811; -.
DR   jPOST; Q9Y5F3; -.
DR   MassIVE; Q9Y5F3; -.
DR   PaxDb; Q9Y5F3; -.
DR   PeptideAtlas; Q9Y5F3; -.
DR   PRIDE; Q9Y5F3; -.
DR   ProteomicsDB; 86352; -.
DR   Antibodypedia; 27174; 86 antibodies from 16 providers.
DR   DNASU; 29930; -.
DR   Ensembl; ENST00000306549; ENSP00000307234; ENSG00000171815.
DR   GeneID; 29930; -.
DR   KEGG; hsa:29930; -.
DR   MANE-Select; ENST00000306549.6; ENSP00000307234.4; NM_013340.4; NP_037472.2.
DR   UCSC; uc003lik.3; human.
DR   CTD; 29930; -.
DR   DisGeNET; 29930; -.
DR   GeneCards; PCDHB1; -.
DR   HGNC; HGNC:8680; PCDHB1.
DR   HPA; ENSG00000171815; Tissue enhanced (skeletal).
DR   MIM; 604967; gene.
DR   MIM; 606327; gene.
DR   neXtProt; NX_Q9Y5F3; -.
DR   OpenTargets; ENSG00000171815; -.
DR   PharmGKB; PA33025; -.
DR   VEuPathDB; HostDB:ENSG00000171815; -.
DR   eggNOG; KOG3594; Eukaryota.
DR   GeneTree; ENSGT00940000162745; -.
DR   HOGENOM; CLU_006480_3_2_1; -.
DR   InParanoid; Q9Y5F3; -.
DR   OMA; QDHGQPA; -.
DR   OrthoDB; 300321at2759; -.
DR   PhylomeDB; Q9Y5F3; -.
DR   TreeFam; TF332299; -.
DR   PathwayCommons; Q9Y5F3; -.
DR   BioGRID-ORCS; 29930; 4 hits in 997 CRISPR screens.
DR   GenomeRNAi; 29930; -.
DR   Pharos; Q9Y5F3; Tdark.
DR   PRO; PR:Q9Y5F3; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9Y5F3; protein.
DR   Bgee; ENSG00000171815; Expressed in skeletal muscle tissue and 7 other tissues.
DR   Genevisible; Q9Y5F3; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   InterPro; IPR002126; Cadherin-like_dom.
DR   InterPro; IPR015919; Cadherin-like_sf.
DR   InterPro; IPR032455; Cadherin_C.
DR   InterPro; IPR020894; Cadherin_CS.
DR   InterPro; IPR013164; Cadherin_N.
DR   InterPro; IPR030723; PCDHB1.
DR   PANTHER; PTHR24028:SF12; PTHR24028:SF12; 1.
DR   Pfam; PF00028; Cadherin; 5.
DR   Pfam; PF08266; Cadherin_2; 1.
DR   Pfam; PF16492; Cadherin_C_2; 1.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 6.
DR   SUPFAM; SSF49313; SSF49313; 6.
DR   PROSITE; PS00232; CADHERIN_1; 5.
DR   PROSITE; PS50268; CADHERIN_2; 6.
PE   2: Evidence at transcript level;
KW   Calcium; Cell adhesion; Cell membrane; Glycoprotein; Membrane;
KW   Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000255"
FT   CHAIN           29..818
FT                   /note="Protocadherin beta-1"
FT                   /id="PRO_0000003914"
FT   TOPO_DOM        29..691
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        692..712
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        713..818
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          35..133
FT                   /note="Cadherin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          138..242
FT                   /note="Cadherin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          243..347
FT                   /note="Cadherin 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          348..452
FT                   /note="Cadherin 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          457..562
FT                   /note="Cadherin 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          577..672
FT                   /note="Cadherin 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   REGION          789..818
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        803..818
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        169
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        209
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        257
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        419
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        568
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         385
FT                   /note="F -> L (in dbSNP:rs2233591)"
FT                   /id="VAR_048541"
FT   VARIANT         390
FT                   /note="L -> F (in dbSNP:rs2233592)"
FT                   /id="VAR_048542"
FT   VARIANT         524
FT                   /note="A -> V (in dbSNP:rs17208383)"
FT                   /id="VAR_048543"
FT   VARIANT         611
FT                   /note="T -> I (in dbSNP:rs10476822)"
FT                   /id="VAR_048544"
FT   VARIANT         712
FT                   /note="I -> T (in dbSNP:rs31738)"
FT                   /id="VAR_048545"
FT   VARIANT         719
FT                   /note="K -> I (in dbSNP:rs2233595)"
FT                   /id="VAR_048546"
FT   VARIANT         778
FT                   /note="F -> L (in dbSNP:rs246679)"
FT                   /evidence="ECO:0000269|PubMed:10380929"
FT                   /id="VAR_048547"
SQ   SEQUENCE   818 AA;  90491 MW;  4697DC76EDB7D604 CRC64;
     MAGTRRKSLQ NRQVGSLLIF LCISVGDATT IRYSVAEEME SGSFVANVAK DLGLEVGKLA
     ARGARLVSEG NKMHFRLHRK TGDLFVKEKL DRESLCGKAD PCVLHFEVVL VEPLQSFRAE
     VRVFDINDNA PVFLNKEPLL KIPESTPLGS RFPLQSAQDL DVGLNGLQNY TLSANGYFHL
     HTRFCSHGPK YAELVLNKPL DREEQPEVNL TITAVDGGSP PKSGTAHIHV VVLDVNDHVP
     QFSRLVYRAQ VSENSPNGSL VATVTAVDLD EGTNKAITYS LAQNPEAILK TFQIDPQNGE
     VRLRGPLDFE AIETYDIDIQ ATDGGGLSAH SKVLVEVVDV NDNPPEVMVS SVSSPLPEDS
     PPQTVVALFT IRDRDIRVGG KVTCFLREDL PFVIKPTFGN SYSLVTDRSL DREEVSGYNI
     TIVAMDTGPP SLSAETMIEV LISDVNDNPP IFREDSYILT VRENNSPAVF IGKVHAEDLD
     LGENAQITYS LLPPKNGDLS VFAYISINSG NGKLYALRTM DYEAIQDFQF VVKATDGGFL
     SLSSQVTVRV VVLDDNDNRP MILYPLQNGT LPCNDLVPRS AEAGYLVTKV VAVDGDSGQN
     SWLSYHLLKA TDLGLFSVQR QNGEIHTLRQ ISERDPMMQK LIILVQDHGQ PALSTTVSLN
     ILLVDGFSEP YLQFQDPTKH SRKVNPSTKY LVISLVILSF LFLLSVIVIF IIHVYQKIKY
     REKFTIQEHF YDDCNFSNNL VQGQGNGSLS RPCPYEMCSA TGTGNSEFRF LKRFMPNFPF
     PHATGEIKME AGSSLPPNSD RNKSQRLEGH DQVSDDYM
//
ID   CNOT7_HUMAN             Reviewed;         285 AA.
AC   Q9UIV1; A8MZM5; B3KMP1; B3KN35; D3DSP6; G3V108; Q7Z530;
DT   14-AUG-2001, integrated into UniProtKB/Swiss-Prot.
DT   02-FEB-2004, sequence version 3.
DT   23-FEB-2022, entry version 187.
DE   RecName: Full=CCR4-NOT transcription complex subunit 7;
DE            EC=3.1.13.4;
DE   AltName: Full=BTG1-binding factor 1;
DE   AltName: Full=CCR4-associated factor 1;
DE            Short=CAF-1;
DE   AltName: Full=Caf1a;
GN   Name=CNOT7; Synonyms=CAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9820826; DOI=10.1042/bj3360471;
RA   Bogdan J.A., Adams-Burton C., Pedicord D.L., Sukovich D.A., Benfield P.A.,
RA   Corjay M.H., Stoltenborg J.K., Dicker I.B.;
RT   "Human carbon catabolite repressor protein (CCR4)-associative factor 1:
RT   cloning, expression and characterization of its interaction with the B-cell
RT   translocation protein BTG1.";
RL   Biochem. J. 336:471-481(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wan Y.Z., Yu L., Zhang H.L., Liu Q., Chen S.Y., Zhao S.Y.;
RT   "Cloning and expression of a new human cDNA homology to mouse mCAF1 protein
RT   mRNA.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Embryo, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Prostate, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY.
RX   PubMed=15769875; DOI=10.1261/rna.7135305;
RA   Bianchin C., Mauxion F., Sentis S., Seraphin B., Corbo L.;
RT   "Conservation of the deadenylase activity of proteins of the Caf1 family in
RT   human.";
RL   RNA 11:487-494(2005).
RN   [8]
RP   IDENTIFICATION IN THE CCR4-NOT COMPLEX, AND COMPOSITION OF THE CCR4-NOT
RP   COMPLEX.
RX   PubMed=19558367; DOI=10.1042/bj20090500;
RA   Lau N.C., Kolkman A., van Schaik F.M., Mulder K.W., Pijnappel W.W.,
RA   Heck A.J., Timmers H.T.;
RT   "Human Ccr4-Not complexes contain variable deadenylase subunits.";
RL   Biochem. J. 422:443-453(2009).
RN   [9]
RP   FUNCTION.
RX   PubMed=19605561; DOI=10.1091/mbc.e09-02-0146;
RA   Aslam A., Mittal S., Koch F., Andrau J.C., Winkler G.S.;
RT   "The Ccr4-NOT deadenylase subunits CNOT7 and CNOT8 have overlapping roles
RT   and modulate cell proliferation.";
RL   Mol. Biol. Cell 20:3840-3850(2009).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20634287; DOI=10.1074/jbc.m110.150763;
RA   Cooke A., Prigge A., Wickens M.;
RT   "Translational repression by deadenylases.";
RL   J. Biol. Chem. 285:28506-28513(2010).
RN   [11]
RP   FUNCTION.
RX   PubMed=20065043; DOI=10.1128/mcb.01481-09;
RA   Piao X., Zhang X., Wu L., Belasco J.G.;
RT   "CCR4-NOT deadenylates mRNA associated with complexes in human cells.";
RL   Mol. Cell. Biol. 30:1486-1494(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   INTERACTION WITH TOB1, AND MUTAGENESIS OF ASP-161.
RX   PubMed=21336257; DOI=10.1038/emboj.2011.37;
RA   Hosoda N., Funakoshi Y., Hirasawa M., Yamagishi R., Asano Y., Miyagawa R.,
RA   Ogami K., Tsujimoto M., Hoshino S.;
RT   "Anti-proliferative protein Tob negatively regulates CPEB3 target by
RT   recruiting Caf1 deadenylase.";
RL   EMBO J. 30:1311-1323(2011).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH TOB1 AND BTG2.
RX   PubMed=23236473; DOI=10.1371/journal.pone.0051331;
RA   Doidge R., Mittal S., Aslam A., Winkler G.S.;
RT   "The anti-proliferative activity of BTG/TOB proteins is mediated via the
RT   Caf1a (CNOT7) and Caf1b (CNOT8) deadenylase subunits of the Ccr4-not
RT   complex.";
RL   PLoS ONE 7:E51331-E51331(2012).
RN   [15]
RP   INTERACTION WITH ZFP36; ZFP36L1 AND ZFP36L2.
RX   PubMed=25106868; DOI=10.1093/nar/gku652;
RA   Adachi S., Homoto M., Tanaka R., Hioki Y., Murakami H., Suga H.,
RA   Matsumoto M., Nakayama K.I., Hatta T., Iemura S., Natsume T.;
RT   "ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway.";
RL   Nucleic Acids Res. 42:10037-10049(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   INTERACTION WITH TARDBP.
RX   PubMed=30520513; DOI=10.1002/1873-3468.13310;
RA   Fukushima M., Hosoda N., Chifu K., Hoshino S.I.;
RT   "TDP-43 accelerates deadenylation of target mRNAs by recruiting Caf1
RT   deadenylase.";
RL   FEBS Lett. 593:277-287(2019).
RN   [18]
RP   INTERACTION WITH BTG4.
RX   PubMed=32502391; DOI=10.1016/j.ajhg.2020.05.010;
RA   Zheng W., Zhou Z., Sha Q., Niu X., Sun X., Shi J., Zhao L., Zhang S.,
RA   Dai J., Cai S., Meng F., Hu L., Gong F., Li X., Fu J., Shi R., Lu G.,
RA   Chen B., Fan H., Wang L., Lin G., Sang Q.;
RT   "Homozygous mutations in BTG4 cause zygotic cleavage failure and female
RT   infertility.";
RL   Am. J. Hum. Genet. 107:24-33(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 11-262 IN COMPLEX WITH TOB1,
RP   CATALYTIC ACTIVITY, COFACTOR, AND MUTAGENESIS OF ASP-40; GLU-42; ASP-161;
RP   HIS-225 AND ASP-230.
RX   PubMed=19276069; DOI=10.1074/jbc.m809250200;
RA   Horiuchi M., Takeuchi K., Noda N., Muroya N., Suzuki T., Nakamura T.,
RA   Kawamura-Tsuzuku J., Takahasi K., Yamamoto T., Inagaki F.;
RT   "Structural basis for the antiproliferative activity of the Tob-hCaf1
RT   complex.";
RL   J. Biol. Chem. 284:13244-13255(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1-285 IN COMPLEX WITH CNOT1, AND
RP   MUTAGENESIS OF GLU-138; MET-141; THR-142 AND GLU-149.
RX   PubMed=22977175; DOI=10.1093/nar/gks883;
RA   Petit A.P., Wohlbold L., Bawankar P., Huntzinger E., Schmidt S.,
RA   Izaurralde E., Weichenrieder O.;
RT   "The structural basis for the interaction between the CAF1 nuclease and the
RT   NOT1 scaffold of the human CCR4-NOT deadenylase complex.";
RL   Nucleic Acids Res. 40:11058-11072(2012).
CC   -!- FUNCTION: Has 3'-5' poly(A) exoribonuclease activity for synthetic
CC       poly(A) RNA substrate. Its function seems to be partially redundant
CC       with that of CNOT8. Catalytic component of the CCR4-NOT complex which
CC       is one of the major cellular mRNA deadenylases and is linked to various
CC       cellular processes including bulk mRNA degradation, miRNA-mediated
CC       repression, translational repression during translational initiation
CC       and general transcription regulation. During miRNA-mediated repression
CC       the complex seems also to act as translational repressor during
CC       translational initiation. Additional complex functions may be a
CC       consequence of its influence on mRNA expression. Associates with
CC       members of the BTG family such as TOB1 and BTG2 and is required for
CC       their anti-proliferative activity. {ECO:0000269|PubMed:19605561,
CC       ECO:0000269|PubMed:20065043, ECO:0000269|PubMed:20634287,
CC       ECO:0000269|PubMed:23236473}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage of poly(A) to 5'-AMP.; EC=3.1.13.4;
CC         Evidence={ECO:0000269|PubMed:15769875, ECO:0000269|PubMed:19276069,
CC         ECO:0000269|PubMed:20634287};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:19276069};
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:19276069};
CC       Name=Co(2+); Xref=ChEBI:CHEBI:48828;
CC         Evidence={ECO:0000269|PubMed:19276069};
CC       Note=Binds 2 divalent metal cations per subunit with RNAase activity
CC       being higher in presence of Mn(2+) than of Mg(2+) or Co(2+).
CC       {ECO:0000269|PubMed:19276069};
CC   -!- SUBUNIT: Component of the CCR4-NOT complex; distinct complexes seem to
CC       exist that differ in the participation of probably mutually exclusive
CC       catalytic subunits; the complex contains two deadenylase subunits,
CC       CNOT6 or CNOT6L, and CNOT7 or CNOT8 (PubMed:19558367). In the complex,
CC       interacts directly with CNOT1 (PubMed:21336257). Interacts with AGO2
CC       (By similarity). Interacts with TOB1; recruited by TOB1 to a ternary
CC       complex with CPEB3 which is required for mRNA deadenylation and decay
CC       (PubMed:21336257, PubMed:23236473, PubMed:19276069). Interacts with
CC       BTG1 (By similarity). Interacts with BTG2 (PubMed:23236473). Interacts
CC       with NANOS2 (By similarity). Interacts with ZFP36, ZFP36L1 and ZFP36L2;
CC       these interactions are inhibited in response to phorbol 12-myristate
CC       13-acetate (PMA) treatment in a p38 MAPK-dependent manner
CC       (PubMed:25106868). Interacts with TARDBP (PubMed:30520513). Interacts
CC       with BTG4 (PubMed:32502391). Interacts with EIF4E; this interaction is
CC       increased by CNOT7 interaction with BTG4 (By similarity).
CC       {ECO:0000250|UniProtKB:Q60809, ECO:0000269|PubMed:19276069,
CC       ECO:0000269|PubMed:19558367, ECO:0000269|PubMed:21336257,
CC       ECO:0000269|PubMed:22977175, ECO:0000269|PubMed:23236473,
CC       ECO:0000269|PubMed:25106868, ECO:0000269|PubMed:30520513,
CC       ECO:0000269|PubMed:32502391}.
CC   -!- INTERACTION:
CC       Q9UIV1; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-2105113, EBI-528269;
CC       Q9UIV1; P62324: BTG1; NbExp=4; IntAct=EBI-2105113, EBI-742279;
CC       Q9UIV1; P78543: BTG2; NbExp=8; IntAct=EBI-2105113, EBI-1047576;
CC       Q9UIV1; A5YKK6: CNOT1; NbExp=7; IntAct=EBI-2105113, EBI-1222758;
CC       Q9UIV1; Q9ULM6: CNOT6; NbExp=2; IntAct=EBI-2105113, EBI-2104530;
CC       Q9UIV1; Q96LI5: CNOT6L; NbExp=6; IntAct=EBI-2105113, EBI-1046635;
CC       Q9UIV1; P42858: HTT; NbExp=13; IntAct=EBI-2105113, EBI-466029;
CC       Q9UIV1; Q86TB9: PATL1; NbExp=5; IntAct=EBI-2105113, EBI-2562092;
CC       Q9UIV1; Q9NUJ3: TCP11L1; NbExp=3; IntAct=EBI-2105113, EBI-2555179;
CC       Q9UIV1; Q9HCJ0: TNRC6C; NbExp=9; IntAct=EBI-2105113, EBI-6507625;
CC       Q9UIV1; P50616: TOB1; NbExp=9; IntAct=EBI-2105113, EBI-723281;
CC       Q9UIV1; Q14106: TOB2; NbExp=7; IntAct=EBI-2105113, EBI-2562000;
CC       Q9UIV1; P22893: Zfp36; Xeno; NbExp=3; IntAct=EBI-2105113, EBI-647803;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, P-body {ECO:0000250}.
CC       Note=NANOS2 promotes its localization to P-body. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UIV1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UIV1-2; Sequence=VSP_045497;
CC   -!- SIMILARITY: Belongs to the CAF1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF01500.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L46722; AAF01500.1; ALT_FRAME; mRNA.
DR   EMBL; AF086915; AAP97145.1; -; mRNA.
DR   EMBL; AK021808; BAG51053.1; -; mRNA.
DR   EMBL; AK023466; BAG51197.1; -; mRNA.
DR   EMBL; AC091050; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471080; EAW63820.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63821.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63822.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63823.1; -; Genomic_DNA.
DR   EMBL; BC060852; AAH60852.1; -; mRNA.
DR   EMBL; BC070187; AAH70187.1; -; mRNA.
DR   CCDS; CCDS55202.1; -. [Q9UIV1-2]
DR   CCDS; CCDS6000.2; -. [Q9UIV1-1]
DR   RefSeq; NP_001309016.1; NM_001322087.1. [Q9UIV1-2]
DR   RefSeq; NP_001309017.1; NM_001322088.1. [Q9UIV1-2]
DR   RefSeq; NP_001309018.1; NM_001322089.1. [Q9UIV1-2]
DR   RefSeq; NP_001309019.1; NM_001322090.1. [Q9UIV1-1]
DR   RefSeq; NP_001309020.1; NM_001322091.1. [Q9UIV1-1]
DR   RefSeq; NP_001309021.1; NM_001322092.1. [Q9UIV1-1]
DR   RefSeq; NP_001309022.1; NM_001322093.1.
DR   RefSeq; NP_001309023.1; NM_001322094.1.
DR   RefSeq; NP_001309024.1; NM_001322095.1.
DR   RefSeq; NP_001309025.1; NM_001322096.1.
DR   RefSeq; NP_001309026.1; NM_001322097.1.
DR   RefSeq; NP_001309027.1; NM_001322098.1.
DR   RefSeq; NP_001309028.1; NM_001322099.1.
DR   RefSeq; NP_001309029.1; NM_001322100.1.
DR   RefSeq; NP_037486.2; NM_013354.6. [Q9UIV1-1]
DR   RefSeq; NP_473367.2; NM_054026.3. [Q9UIV1-2]
DR   RefSeq; XP_005273538.1; XM_005273481.2. [Q9UIV1-1]
DR   PDB; 2D5R; X-ray; 2.50 A; A=11-262.
DR   PDB; 4GMJ; X-ray; 2.70 A; B/D/F=1-285.
DR   PDB; 7AX1; X-ray; 3.30 A; B=2-285.
DR   PDBsum; 2D5R; -.
DR   PDBsum; 4GMJ; -.
DR   PDBsum; 7AX1; -.
DR   SMR; Q9UIV1; -.
DR   BioGRID; 118938; 129.
DR   ComplexPortal; CPX-2522; CCR4-NOT mRNA deadenylase complex, CNOT6L-CNOT7 variant.
DR   ComplexPortal; CPX-707; CCR4-NOT mRNA deadenylase complex, CNOT6-CNOT7 variant.
DR   CORUM; Q9UIV1; -.
DR   DIP; DIP-41902N; -.
DR   IntAct; Q9UIV1; 58.
DR   MINT; Q9UIV1; -.
DR   STRING; 9606.ENSP00000355279; -.
DR   BindingDB; Q9UIV1; -.
DR   ChEMBL; CHEMBL3616361; -.
DR   iPTMnet; Q9UIV1; -.
DR   PhosphoSitePlus; Q9UIV1; -.
DR   BioMuta; CNOT7; -.
DR   DMDM; 41713629; -.
DR   EPD; Q9UIV1; -.
DR   jPOST; Q9UIV1; -.
DR   MassIVE; Q9UIV1; -.
DR   MaxQB; Q9UIV1; -.
DR   PaxDb; Q9UIV1; -.
DR   PeptideAtlas; Q9UIV1; -.
DR   PRIDE; Q9UIV1; -.
DR   ProteomicsDB; 32220; -.
DR   ProteomicsDB; 84569; -. [Q9UIV1-1]
DR   Antibodypedia; 22252; 202 antibodies from 28 providers.
DR   DNASU; 29883; -.
DR   Ensembl; ENST00000361272; ENSP00000355279; ENSG00000198791.
DR   Ensembl; ENST00000523917; ENSP00000429093; ENSG00000198791. [Q9UIV1-2]
DR   GeneID; 29883; -.
DR   KEGG; hsa:29883; -.
DR   MANE-Select; ENST00000361272.9; ENSP00000355279.4; NM_013354.7; NP_037486.2.
DR   UCSC; uc003wxg.2; human. [Q9UIV1-1]
DR   CTD; 29883; -.
DR   DisGeNET; 29883; -.
DR   GeneCards; CNOT7; -.
DR   HGNC; HGNC:14101; CNOT7.
DR   HPA; ENSG00000198791; Low tissue specificity.
DR   MIM; 604913; gene.
DR   neXtProt; NX_Q9UIV1; -.
DR   OpenTargets; ENSG00000198791; -.
DR   PharmGKB; PA26678; -.
DR   VEuPathDB; HostDB:ENSG00000198791; -.
DR   eggNOG; KOG0304; Eukaryota.
DR   GeneTree; ENSGT00390000000080; -.
DR   HOGENOM; CLU_027974_0_1_1; -.
DR   InParanoid; Q9UIV1; -.
DR   OMA; DTKWISF; -.
DR   OrthoDB; 931256at2759; -.
DR   PhylomeDB; Q9UIV1; -.
DR   TreeFam; TF314185; -.
DR   BRENDA; 3.1.13.4; 2681.
DR   PathwayCommons; Q9UIV1; -.
DR   Reactome; R-HSA-429947; Deadenylation of mRNA.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   SignaLink; Q9UIV1; -.
DR   BioGRID-ORCS; 29883; 200 hits in 1053 CRISPR screens.
DR   ChiTaRS; CNOT7; human.
DR   EvolutionaryTrace; Q9UIV1; -.
DR   GeneWiki; CNOT7; -.
DR   GenomeRNAi; 29883; -.
DR   Pharos; Q9UIV1; Tchem.
DR   PRO; PR:Q9UIV1; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q9UIV1; protein.
DR   Bgee; ENSG00000198791; Expressed in female gonad and 252 other tissues.
DR   ExpressionAtlas; Q9UIV1; baseline and differential.
DR   Genevisible; Q9UIV1; HS.
DR   GO; GO:0030014; C:CCR4-NOT complex; IDA:UniProtKB.
DR   GO; GO:0030015; C:CCR4-NOT core complex; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IMP:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000932; C:P-body; ISS:UniProtKB.
DR   GO; GO:0000175; F:3'-5'-exoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0004532; F:exoribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004535; F:poly(A)-specific ribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; IMP:UniProtKB.
DR   GO; GO:0000290; P:deadenylation-dependent decapping of nuclear-transcribed mRNA; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IMP:UniProtKB.
DR   GO; GO:0043928; P:exonucleolytic catabolism of deadenylated mRNA; IDA:UniProtKB.
DR   GO; GO:0035195; P:gene silencing by miRNA; TAS:UniProtKB.
DR   GO; GO:0031047; P:gene silencing by RNA; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl.
DR   GO; GO:0033962; P:P-body assembly; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0061014; P:positive regulation of mRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:1900153; P:positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; IMP:UniProtKB.
DR   GO; GO:0060213; P:positive regulation of nuclear-transcribed mRNA poly(A) tail shortening; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0042509; P:regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB.
DR   Gene3D; 3.30.420.10; -; 1.
DR   IDEAL; IID00504; -.
DR   InterPro; IPR039636; CNOT7.
DR   InterPro; IPR039637; CNOT7/CNOT8/Pop2.
DR   InterPro; IPR006941; RNase_CAF1.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR036397; RNaseH_sf.
DR   PANTHER; PTHR10797; PTHR10797; 1.
DR   PANTHER; PTHR10797:SF2; PTHR10797:SF2; 1.
DR   Pfam; PF04857; CAF1; 2.
DR   SUPFAM; SSF53098; SSF53098; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Exonuclease; Hydrolase;
KW   Magnesium; Metal-binding; Nuclease; Nucleus; Reference proteome; Repressor;
KW   RNA-binding; RNA-mediated gene silencing; Transcription;
KW   Transcription regulation; Translation regulation.
FT   CHAIN           1..285
FT                   /note="CCR4-NOT transcription complex subunit 7"
FT                   /id="PRO_0000212844"
FT   METAL           40
FT                   /note="Divalent metal cation 1; catalytic"
FT                   /evidence="ECO:0000305"
FT   METAL           40
FT                   /note="Divalent metal cation 2; catalytic"
FT                   /evidence="ECO:0000305"
FT   METAL           42
FT                   /note="Divalent metal cation 2; catalytic"
FT                   /evidence="ECO:0000305"
FT   METAL           161
FT                   /note="Divalent metal cation 1; catalytic"
FT                   /evidence="ECO:0000305"
FT   METAL           230
FT                   /note="Divalent metal cation 2; catalytic"
FT                   /evidence="ECO:0000305"
FT   METAL           278
FT                   /note="Divalent metal cation 1; catalytic"
FT                   /evidence="ECO:0000305"
FT   VAR_SEQ         244..285
FT                   /note="MFFEDHIDDAKYCGHLYGLGSGSSYVQNGTGNAYEEEANKQS -> V (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045497"
FT   MUTAGEN         40
FT                   /note="D->N: Abolishes RNA deadenylase activity."
FT                   /evidence="ECO:0000269|PubMed:19276069"
FT   MUTAGEN         42
FT                   /note="E->Q: Abolishes RNA deadenylase activity."
FT                   /evidence="ECO:0000269|PubMed:19276069"
FT   MUTAGEN         138
FT                   /note="E->K: Abolishes interaction with CNOT1; when
FT                   associated with Y-142 and K-149."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         141
FT                   /note="M->R: Abolishes interaction with CNOT1."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         142
FT                   /note="T->Y: Abolishes interaction with CNOT1; when
FT                   associated with K-138 and K-149."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         149
FT                   /note="E->K: Abolishes interaction with CNOT1; when
FT                   associated with K-138 and Y-142."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         161
FT                   /note="D->N: Abolishes RNA deadenylase activity.
FT                   Drastically reduces the rate of deadenylation and decay of
FT                   CBEP3-tethered mRNA."
FT                   /evidence="ECO:0000269|PubMed:19276069,
FT                   ECO:0000269|PubMed:21336257"
FT   MUTAGEN         203
FT                   /note="K->A: Abolishes interaction with TOB1."
FT   MUTAGEN         225
FT                   /note="H->A: Abolishes RNA deadenylase activity."
FT                   /evidence="ECO:0000269|PubMed:19276069"
FT   MUTAGEN         230
FT                   /note="D->N: Abolishes RNA deadenylase activity."
FT                   /evidence="ECO:0000269|PubMed:19276069"
FT   CONFLICT        4..5
FT                   /note="AT -> EL (in Ref. 3; AAP97145)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        241
FT                   /note="M -> V (in Ref. 4; BAG51197)"
FT                   /evidence="ECO:0000305"
FT   STRAND          12..15
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           17..19
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           20..33
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          36..42
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           57..69
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          76..82
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          94..99
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   TURN            103..105
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           110..119
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           123..129
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           133..141
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   TURN            142..144
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          145..150
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          152..157
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           159..170
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           178..188
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           195..198
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           199..201
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           209..216
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           227..244
FT                   /evidence="ECO:0007829|PDB:2D5R"
FT   HELIX           252..255
FT                   /evidence="ECO:0007829|PDB:2D5R"
SQ   SEQUENCE   285 AA;  32745 MW;  2AF23ED27E06EFDB CRC64;
     MPAATVDHSQ RICEVWACNL DEEMKKIRQV IRKYNYVAMD TEFPGVVARP IGEFRSNADY
     QYQLLRCNVD LLKIIQLGLT FMNEQGEYPP GTSTWQFNFK FNLTEDMYAQ DSIELLTTSG
     IQFKKHEEEG IETQYFAELL MTSGVVLCEG VKWLSFHSGY DFGYLIKILT NSNLPEEELD
     FFEILRLFFP VIYDVKYLMK SCKNLKGGLQ EVAEQLELER IGPQHQAGSD SLLTGMAFFK
     MREMFFEDHI DDAKYCGHLY GLGSGSSYVQ NGTGNAYEEE ANKQS
//
ID   CK054_HUMAN             Reviewed;         315 AA.
AC   Q9H0W9; A8K850; Q6FI88; Q6XYB0; Q96EI3; Q96IX1; Q9Y6B4;
DT   11-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   23-FEB-2022, entry version 148.
DE   RecName: Full=Ester hydrolase C11orf54;
DE            EC=3.1.-.-;
GN   Name=C11orf54; ORFNames=LP4947, PTD012;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Pituitary tumor;
RA   Mao Y., Song H., Peng Y., Huang Q., Dai M., Zhang Q., Mao M., Fu G.,
RA   Luo M., Chen J., Hu R.;
RT   "Human PTD012 mRNA, complete cds.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Esophagus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Colon, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 2-315, FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING.
RX   PubMed=16522806; DOI=10.1110/ps.052037006;
RA   Manjasetty B.A., Buessow K., Fieber-Erdmann M., Roske Y., Gobom J.,
RA   Scheich C., Goetz F., Niesen F.H., Heinemann U.;
RT   "Crystal structure of Homo sapiens PTD012 reveals a zinc-containing
RT   hydrolase fold.";
RL   Protein Sci. 15:914-920(2006).
CC   -!- FUNCTION: Exhibits ester hydrolase activity on the substrate p-
CC       nitrophenyl acetate. {ECO:0000269|PubMed:16522806}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:16522806}.
CC   -!- INTERACTION:
CC       Q9H0W9; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-740204, EBI-2212028;
CC       Q9H0W9; Q15645: TRIP13; NbExp=3; IntAct=EBI-740204, EBI-358993;
CC       Q9H0W9; Q08AM6: VAC14; NbExp=4; IntAct=EBI-740204, EBI-2107455;
CC       Q9H0W9-3; Q86V38: ATN1; NbExp=3; IntAct=EBI-12108466, EBI-11954292;
CC       Q9H0W9-3; P55212: CASP6; NbExp=3; IntAct=EBI-12108466, EBI-718729;
CC       Q9H0W9-3; A0A140G945: CRYAA2; NbExp=3; IntAct=EBI-12108466, EBI-25838900;
CC       Q9H0W9-3; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-12108466, EBI-12593112;
CC       Q9H0W9-3; O14901: KLF11; NbExp=3; IntAct=EBI-12108466, EBI-948266;
CC       Q9H0W9-3; Q92876: KLK6; NbExp=3; IntAct=EBI-12108466, EBI-2432309;
CC       Q9H0W9-3; P13473-2: LAMP2; NbExp=3; IntAct=EBI-12108466, EBI-21591415;
CC       Q9H0W9-3; Q13153: PAK1; NbExp=3; IntAct=EBI-12108466, EBI-1307;
CC       Q9H0W9-3; P62826: RAN; NbExp=3; IntAct=EBI-12108466, EBI-286642;
CC       Q9H0W9-3; Q15645: TRIP13; NbExp=3; IntAct=EBI-12108466, EBI-358993;
CC       Q9H0W9-3; Q08AM6: VAC14; NbExp=3; IntAct=EBI-12108466, EBI-2107455;
CC       Q9H0W9-4; P04792: HSPB1; NbExp=3; IntAct=EBI-25849710, EBI-352682;
CC       Q9H0W9-4; O60333-2: KIF1B; NbExp=3; IntAct=EBI-25849710, EBI-10975473;
CC       Q9H0W9-4; O76024: WFS1; NbExp=3; IntAct=EBI-25849710, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16522806}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9H0W9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H0W9-2; Sequence=VSP_019818;
CC       Name=3;
CC         IsoId=Q9H0W9-3; Sequence=VSP_019821;
CC       Name=4;
CC         IsoId=Q9H0W9-4; Sequence=VSP_019817;
CC   -!- MISCELLANEOUS: [Isoform 3]: Probably non-functional. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH07110.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAP34483.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF092133; AAD40375.1; -; mRNA.
DR   EMBL; AL136605; CAB66540.1; -; mRNA.
DR   EMBL; CR533538; CAG38569.1; -; mRNA.
DR   EMBL; AY203960; AAP34483.1; ALT_FRAME; mRNA.
DR   EMBL; AK292215; BAF84904.1; -; mRNA.
DR   EMBL; CH471065; EAW66915.1; -; Genomic_DNA.
DR   EMBL; BC007110; AAH07110.2; ALT_INIT; mRNA.
DR   EMBL; BC012298; AAH12298.1; -; mRNA.
DR   CCDS; CCDS66204.1; -. [Q9H0W9-1]
DR   CCDS; CCDS73366.1; -. [Q9H0W9-2]
DR   CCDS; CCDS8294.1; -. [Q9H0W9-3]
DR   RefSeq; NP_001272996.1; NM_001286067.1. [Q9H0W9-1]
DR   RefSeq; NP_001272997.1; NM_001286068.1. [Q9H0W9-1]
DR   RefSeq; NP_001272998.1; NM_001286069.1. [Q9H0W9-1]
DR   RefSeq; NP_001272999.1; NM_001286070.1. [Q9H0W9-2]
DR   RefSeq; NP_001273000.1; NM_001286071.1.
DR   RefSeq; NP_054758.2; NM_014039.3. [Q9H0W9-3]
DR   RefSeq; XP_006718887.1; XM_006718824.1.
DR   RefSeq; XP_011541083.1; XM_011542781.2. [Q9H0W9-1]
DR   RefSeq; XP_011541084.1; XM_011542782.2. [Q9H0W9-1]
DR   RefSeq; XP_016873102.1; XM_017017613.1.
DR   RefSeq; XP_016873103.1; XM_017017614.1.
DR   RefSeq; XP_016873104.1; XM_017017615.1.
DR   RefSeq; XP_016873105.1; XM_017017616.1.
DR   PDB; 1XCR; X-ray; 1.70 A; A/B=2-315.
DR   PDBsum; 1XCR; -.
DR   SMR; Q9H0W9; -.
DR   BioGRID; 118794; 38.
DR   IntAct; Q9H0W9; 17.
DR   STRING; 9606.ENSP00000331209; -.
DR   GlyGen; Q9H0W9; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q9H0W9; -.
DR   PhosphoSitePlus; Q9H0W9; -.
DR   BioMuta; C11orf54; -.
DR   DMDM; 74718025; -.
DR   EPD; Q9H0W9; -.
DR   jPOST; Q9H0W9; -.
DR   MassIVE; Q9H0W9; -.
DR   MaxQB; Q9H0W9; -.
DR   PeptideAtlas; Q9H0W9; -.
DR   PRIDE; Q9H0W9; -.
DR   ProteomicsDB; 80335; -. [Q9H0W9-1]
DR   ProteomicsDB; 80336; -. [Q9H0W9-2]
DR   ProteomicsDB; 80337; -. [Q9H0W9-3]
DR   ProteomicsDB; 80338; -. [Q9H0W9-4]
DR   Antibodypedia; 31588; 58 antibodies from 16 providers.
DR   DNASU; 28970; -.
DR   Ensembl; ENST00000331239; ENSP00000331209; ENSG00000182919.
DR   Ensembl; ENST00000354421; ENSP00000346403; ENSG00000182919.
DR   Ensembl; ENST00000528099; ENSP00000435113; ENSG00000182919.
DR   Ensembl; ENST00000528288; ENSP00000433721; ENSG00000182919. [Q9H0W9-3]
DR   Ensembl; ENST00000540113; ENSP00000442094; ENSG00000182919. [Q9H0W9-2]
DR   GeneID; 28970; -.
DR   KEGG; hsa:28970; -.
DR   MANE-Select; ENST00000354421.8; ENSP00000346403.3; NM_001286069.2; NP_001272998.1.
DR   UCSC; uc001pef.5; human. [Q9H0W9-1]
DR   CTD; 28970; -.
DR   DisGeNET; 28970; -.
DR   GeneCards; C11orf54; -.
DR   HGNC; HGNC:30204; C11orf54.
DR   HPA; ENSG00000182919; Group enriched (kidney, liver).
DR   MIM; 615810; gene.
DR   neXtProt; NX_Q9H0W9; -.
DR   OpenTargets; ENSG00000182919; -.
DR   PharmGKB; PA143485349; -.
DR   VEuPathDB; HostDB:ENSG00000182919; -.
DR   eggNOG; KOG4048; Eukaryota.
DR   GeneTree; ENSGT00390000017214; -.
DR   InParanoid; Q9H0W9; -.
DR   OMA; QLNFVTC; -.
DR   OrthoDB; 877242at2759; -.
DR   PhylomeDB; Q9H0W9; -.
DR   TreeFam; TF313169; -.
DR   PathwayCommons; Q9H0W9; -.
DR   SignaLink; Q9H0W9; -.
DR   BioGRID-ORCS; 28970; 14 hits in 1022 CRISPR screens.
DR   ChiTaRS; C11orf54; human.
DR   EvolutionaryTrace; Q9H0W9; -.
DR   GeneWiki; C11orf54; -.
DR   GenomeRNAi; 28970; -.
DR   Pharos; Q9H0W9; Tbio.
DR   PRO; PR:Q9H0W9; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9H0W9; protein.
DR   Bgee; ENSG00000182919; Expressed in kidney epithelium and 216 other tissues.
DR   ExpressionAtlas; Q9H0W9; baseline and differential.
DR   Genevisible; Q9H0W9; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:LIFEdb.
DR   GO; GO:0016788; F:hydrolase activity, acting on ester bonds; IDA:FlyBase.
DR   GO; GO:0008270; F:zinc ion binding; IDA:FlyBase.
DR   InterPro; IPR015021; DUF1907.
DR   PANTHER; PTHR13204; PTHR13204; 1.
DR   Pfam; PF08925; DUF1907; 1.
DR   SMART; SM01168; DUF1907; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Hydrolase; Metal-binding; Nucleus;
KW   Reference proteome; Zinc.
FT   CHAIN           1..315
FT                   /note="Ester hydrolase C11orf54"
FT                   /id="PRO_0000246029"
FT   METAL           266
FT                   /note="Zinc; catalytic"
FT   METAL           268
FT                   /note="Zinc; catalytic"
FT   METAL           278
FT                   /note="Zinc; catalytic"
FT   VAR_SEQ         1..111
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_019817"
FT   VAR_SEQ         1..19
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_019818"
FT   VAR_SEQ         170..219
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_019821"
FT   CONFLICT        10
FT                   /note="V -> A (in Ref. 3; CAG38569)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        184
FT                   /note="F -> L (in Ref. 3; CAG38569)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        304
FT                   /note="D -> G (in Ref. 1; AAD40375)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..7
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           13..27
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          28..37
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   TURN            44..46
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          58..63
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           65..67
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          69..71
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           80..86
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          93..99
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           102..105
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          110..112
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          114..116
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          129..133
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   TURN            135..137
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          140..144
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           145..148
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          153..163
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          169..178
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           184..196
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          202..218
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   HELIX           231..237
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          238..245
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          247..256
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          264..270
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          272..274
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          277..283
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   TURN            285..287
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          289..296
FT                   /evidence="ECO:0007829|PDB:1XCR"
FT   STRAND          298..304
FT                   /evidence="ECO:0007829|PDB:1XCR"
SQ   SEQUENCE   315 AA;  35117 MW;  F084671CC1E3F72A CRC64;
     MACAEFSFHV PSLEELAGVM QKGLKDNFAD VQVSVVDCPD LTKEPFTFPV KGICGKTRIA
     EVGGVPYLLP LVNQKKVYDL NKIAKEIKLP GAFILGAGAG PFQTLGFNSE FMPVIQTESE
     HKPPVNGSYF AHVNPADGGC LLEKYSEKCH DFQCALLANL FASEGQPGKV IEVKAKRRTG
     PLNFVTCMRE TLEKHYGNKP IGMGGTFIIQ KGKVKSHIMP AEFSSCPLNS DEEVNKWLHF
     YEMKAPLVCL PVFVSRDPGF DLRLEHTHFF SRHGEGGHYH YDTTPDIVEY LGYFLPAEFL
     YRIDQPKETH SIGRD
//
ID   HACD1_HUMAN             Reviewed;         288 AA.
AC   B0YJ81; B0YJ80; Q6JIC5; Q96FW7; Q9HB93; Q9UHX2;
DT   02-SEP-2008, integrated into UniProtKB/Swiss-Prot.
DT   08-APR-2008, sequence version 1.
DT   23-FEB-2022, entry version 112.
DE   RecName: Full=Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 {ECO:0000305};
DE            EC=4.2.1.134 {ECO:0000269|PubMed:18554506, ECO:0000269|PubMed:23933735};
DE   AltName: Full=3-hydroxyacyl-CoA dehydratase 1 {ECO:0000303|PubMed:18554506};
DE            Short=HACD1 {ECO:0000303|PubMed:15164054};
DE   AltName: Full=Cementum-attachment protein {ECO:0000303|PubMed:22067203};
DE            Short=CAP {ECO:0000303|PubMed:22067203};
DE   AltName: Full=Protein-tyrosine phosphatase-like member A {ECO:0000312|HGNC:HGNC:9639};
GN   Name=HACD1 {ECO:0000303|PubMed:15164054, ECO:0000312|HGNC:HGNC:9639};
GN   Synonyms=PTPLA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS LYS-64; GLN-64; PHE-70 AND
RP   TYR-227, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=11054553; DOI=10.1016/s0378-1119(00)00347-4;
RA   Li D., Gonzalez O., Bachinski L.L., Roberts R.;
RT   "Human protein tyrosine phosphatase-like gene: expression profile, genomic
RT   structure, and mutation analysis in families with ARVD.";
RL   Gene 256:237-243(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYS-64 AND TYR-227.
RX   PubMed=10644438; DOI=10.1006/geno.1999.5950;
RA   Uwanogho D.A., Hardcastle Z., Balogh P., Mirza G., Thornburg K.L.,
RA   Ragoussis J., Sharpe P.T.;
RT   "Molecular cloning, chromosomal mapping, and developmental expression of a
RT   novel protein tyrosine phosphatase-like gene.";
RL   Genomics 62:406-416(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=22067203; DOI=10.1177/0022034511428155;
RA   Valdes De Hoyos A., Hoz-Rodriguez L., Arzate H., Narayanan A.S.;
RT   "Isolation of protein-tyrosine phosphatase-like member-a variant from
RT   cementum.";
RL   J. Dent. Res. 91:203-209(2012).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS LYS-64 AND
RP   PHE-70.
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-288 (ISOFORM 1).
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, PATHWAY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=18554506; DOI=10.1016/j.febslet.2008.06.007;
RA   Ikeda M., Kanao Y., Yamanaka M., Sakuraba H., Mizutani Y., Igarashi Y.,
RA   Kihara A.;
RT   "Characterization of four mammalian 3-hydroxyacyl-CoA dehydratases involved
RT   in very long-chain fatty acid synthesis.";
RL   FEBS Lett. 582:2435-2440(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   INVOLVEMENT IN CFTD, GLYCOSYLATION, AND CATALYTIC ACTIVITY.
RX   PubMed=23933735; DOI=10.1093/hmg/ddt380;
RA   Muhammad E., Reish O., Ohno Y., Scheetz T., Deluca A., Searby C., Regev M.,
RA   Benyamini L., Fellig Y., Kihara A., Sheffield V.C., Parvari R.;
RT   "Congenital myopathy is caused by mutation of HACD1.";
RL   Hum. Mol. Genet. 22:5229-5236(2013).
RN   [11]
RP   FUNCTION (ISOFORM 2), AND SUBUNIT (ISOFORM 2).
RX   PubMed=25263524; DOI=10.1016/j.bone.2014.09.014;
RA   Montoya G., Arenas J., Romo E., Zeichner-David M., Alvarez M.,
RA   Narayanan A.S., Velazquez U., Mercado G., Arzate H.;
RT   "Human recombinant cementum attachment protein (hrPTPLa/CAP) promotes
RT   hydroxyapatite crystal formation in vitro and bone healing in vivo.";
RL   Bone 69:154-164(2014).
CC   -!- FUNCTION: [Isoform 1]: Catalyzes the third of the four reactions of the
CC       long-chain fatty acids elongation cycle. This endoplasmic reticulum-
CC       bound enzymatic process, allows the addition of two carbons to the
CC       chain of long- and very long-chain fatty acids/VLCFAs per cycle. This
CC       enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate
CC       into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation.
CC       Thereby, it participates in the production of VLCFAs of different chain
CC       lengths that are involved in multiple biological processes as
CC       precursors of membrane lipids and lipid mediators.
CC       {ECO:0000269|PubMed:18554506}.
CC   -!- FUNCTION: [Isoform 2]: In tooth development, may play a role in the
CC       recruitment and the differentiation of cells that contribute to
CC       cementum formation. May also bind hydroxyapatite and regulate its
CC       crystal nucleation to form cementum. {ECO:0000269|PubMed:22067203}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a very-long-chain (3R)-3-hydroxyacyl-CoA = a very-long-chain
CC         (2E)-enoyl-CoA + H2O; Xref=Rhea:RHEA:45812, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:83728, ChEBI:CHEBI:85440; EC=4.2.1.134;
CC         Evidence={ECO:0000269|PubMed:18554506, ECO:0000269|PubMed:23933735};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45813;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxyhexadecanoyl-CoA = (2E)-hexadecenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39159, ChEBI:CHEBI:15377, ChEBI:CHEBI:61526,
CC         ChEBI:CHEBI:74278; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39160;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxyoctadecanoyl-CoA = (2E)-octadecenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39155, ChEBI:CHEBI:15377, ChEBI:CHEBI:71412,
CC         ChEBI:CHEBI:76374; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39156;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxyeicosanoyl-CoA = (2E)-eicosenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39175, ChEBI:CHEBI:15377, ChEBI:CHEBI:74691,
CC         ChEBI:CHEBI:76373; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39176;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxydocosanoyl-CoA = (2E)-docosenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39187, ChEBI:CHEBI:15377, ChEBI:CHEBI:74692,
CC         ChEBI:CHEBI:76375; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39188;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxytetracosanoyl-CoA = (2E)-tetracosenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39199, ChEBI:CHEBI:15377, ChEBI:CHEBI:74693,
CC         ChEBI:CHEBI:76377; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39200;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3R)-hydroxyhexacosanoyl-CoA = (2E)-hexacosenoyl-CoA + H2O;
CC         Xref=Rhea:RHEA:39211, ChEBI:CHEBI:15377, ChEBI:CHEBI:74281,
CC         ChEBI:CHEBI:76378; Evidence={ECO:0000269|PubMed:18554506};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39212;
CC         Evidence={ECO:0000305|PubMed:18554506};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=33.6 uM for 3-hydroxypalmitoyl-CoA (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:18554506};
CC   -!- PATHWAY: Lipid metabolism; fatty acid biosynthesis.
CC       {ECO:0000269|PubMed:18554506}.
CC   -!- SUBUNIT: Isoform 1: May interact with enzymes of the ELO family
CC       (including ELOVL1); with those enzymes that mediate condensation, the
CC       first of the four steps of the reaction cycle responsible for fatty
CC       acids elongation, may be part of a larger fatty acids elongase complex
CC       (PubMed:18554506). Isoform 2: Homooligomer. Self-assembles into spheres
CC       which then aggregates to form strings and a meshwork that may support
CC       hydroxyapatite crystal nucleation (PubMed:25263524).
CC       {ECO:0000269|PubMed:18554506, ECO:0000269|PubMed:25263524}.
CC   -!- INTERACTION:
CC       B0YJ81; Q7Z7G2: CPLX4; NbExp=3; IntAct=EBI-12051643, EBI-18013275;
CC       B0YJ81; Q13651: IL10RA; NbExp=3; IntAct=EBI-12051643, EBI-1031656;
CC       B0YJ81; Q96K19-5: RNF170; NbExp=3; IntAct=EBI-12051643, EBI-12055631;
CC       B0YJ81; Q9NZ01: TECR; NbExp=3; IntAct=EBI-12051643, EBI-2877718;
CC       B0YJ81; Q9BVX2: TMEM106C; NbExp=4; IntAct=EBI-12051643, EBI-2821497;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:18554506}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:18554506}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=B0YJ81-1; Sequence=Displayed;
CC       Name=2; Synonyms=CAP, cementum-attachment protein, PTPLA-CAP
CC       {ECO:0000303|PubMed:22067203};
CC         IsoId=B0YJ81-2; Sequence=VSP_035363, VSP_035364;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is highly expressed in the myocardium,
CC       and to a lesser extent in skeletal and smooth muscular tissues
CC       including those from stomach, jejunum, and bladder. Also detected in
CC       gingival fibroblasts, periodontal ligament cells, osteoblasts and
CC       cementoblasts (PubMed:11054553, PubMed:22067203). Isoform 2 is
CC       specifically expressed by cementoblasts but also detected in
CC       periodontal ligament cells, heart, liver and kidney (at protein level)
CC       (PubMed:22067203). {ECO:0000269|PubMed:11054553,
CC       ECO:0000269|PubMed:22067203}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is expressed in fetal heart.
CC       {ECO:0000269|PubMed:11054553}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:23933735}.
CC   -!- DISEASE: Myopathy, congenital, with fiber-type disproportion (CFTD)
CC       [MIM:255310]: A genetically heterogeneous disorder in which there is
CC       relative hypotrophy of type 1 muscle fibers compared to type 2 fibers
CC       on skeletal muscle biopsy. However, these findings are not specific and
CC       can be found in many different myopathic and neuropathic conditions.
CC       {ECO:0000269|PubMed:23933735}. Note=The gene represented in this entry
CC       may be involved in disease pathogenesis. A loss-of-function mutation
CC       that segregates with the disease was found in four members of a
CC       consanguineous family and not identified in unaffected controls. The
CC       mutation affects the expression of the mRNA and the produced protein is
CC       catalytically inactive. {ECO:0000269|PubMed:23933735}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Catalytically inactive since it lacks the
CC       active site but may have an alternative function.
CC       {ECO:0000269|PubMed:22067203}.
CC   -!- SIMILARITY: Belongs to the very long-chain fatty acids dehydratase HACD
CC       family. {ECO:0000305}.
CC   -!- CAUTION: Isoform 1 shares some similarity with tyrosine phosphatase
CC       proteins but it has probably no phosphatase activity.
CC       {ECO:0000250|UniProtKB:Q6Y1H2, ECO:0000305|PubMed:18554506}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG10713.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ACA06059.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF266852; AAG10713.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF266848; AAG10713.1; JOINED; Genomic_DNA.
DR   EMBL; AF266849; AAG10713.1; JOINED; Genomic_DNA.
DR   EMBL; AF266850; AAG10713.1; JOINED; Genomic_DNA.
DR   EMBL; AF266851; AAG10713.1; JOINED; Genomic_DNA.
DR   EMBL; AF114494; AAF21976.1; -; mRNA.
DR   EMBL; AY455942; AAR22554.1; -; mRNA.
DR   EMBL; EF445016; ACA06059.1; ALT_INIT; Genomic_DNA.
DR   EMBL; EF445016; ACA06060.1; -; Genomic_DNA.
DR   EMBL; EF445016; ACA06061.1; -; Genomic_DNA.
DR   EMBL; AC069542; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010353; AAH10353.1; -; mRNA.
DR   EMBL; CR608689; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS7121.1; -. [B0YJ81-1]
DR   RefSeq; NP_055056.3; NM_014241.3. [B0YJ81-1]
DR   BioGRID; 114634; 25.
DR   IntAct; B0YJ81; 21.
DR   STRING; 9606.ENSP00000355308; -.
DR   SwissLipids; SLP:000000435; -.
DR   GlyGen; B0YJ81; 1 site.
DR   iPTMnet; B0YJ81; -.
DR   PhosphoSitePlus; B0YJ81; -.
DR   BioMuta; HACD1; -.
DR   EPD; B0YJ81; -.
DR   jPOST; B0YJ81; -.
DR   MassIVE; B0YJ81; -.
DR   MaxQB; B0YJ81; -.
DR   PaxDb; B0YJ81; -.
DR   PeptideAtlas; B0YJ81; -.
DR   PRIDE; B0YJ81; -.
DR   ProteomicsDB; 2882; -. [B0YJ81-1]
DR   ProteomicsDB; 2883; -. [B0YJ81-2]
DR   Antibodypedia; 57457; 63 antibodies from 14 providers.
DR   DNASU; 9200; -.
DR   Ensembl; ENST00000361271; ENSP00000355308; ENSG00000165996.
DR   GeneID; 9200; -.
DR   KEGG; hsa:9200; -.
DR   MANE-Select; ENST00000361271.8; ENSP00000355308.3; NM_014241.4; NP_055056.3.
DR   UCSC; uc001ipg.4; human. [B0YJ81-1]
DR   CTD; 9200; -.
DR   DisGeNET; 9200; -.
DR   GeneCards; HACD1; -.
DR   HGNC; HGNC:9639; HACD1.
DR   HPA; ENSG00000165996; Tissue enhanced (heart).
DR   MalaCards; HACD1; -.
DR   MIM; 255310; phenotype.
DR   MIM; 610467; gene.
DR   neXtProt; NX_B0YJ81; -.
DR   OpenTargets; ENSG00000165996; -.
DR   Orphanet; 2020; Congenital fiber-type disproportion myopathy.
DR   PharmGKB; PA33982; -.
DR   VEuPathDB; HostDB:ENSG00000165996; -.
DR   eggNOG; KOG3187; Eukaryota.
DR   GeneTree; ENSGT00530000062962; -.
DR   HOGENOM; CLU_034302_2_0_1; -.
DR   InParanoid; B0YJ81; -.
DR   OMA; SYILWQL; -.
DR   OrthoDB; 1458293at2759; -.
DR   PhylomeDB; B0YJ81; -.
DR   TreeFam; TF313326; -.
DR   PathwayCommons; B0YJ81; -.
DR   Reactome; R-HSA-75876; Synthesis of very long-chain fatty acyl-CoAs.
DR   SABIO-RK; B0YJ81; -.
DR   SignaLink; B0YJ81; -.
DR   UniPathway; UPA00094; -.
DR   BioGRID-ORCS; 9200; 3 hits in 1041 CRISPR screens.
DR   ChiTaRS; HACD1; human.
DR   GenomeRNAi; 9200; -.
DR   Pharos; B0YJ81; Tbio.
DR   PRO; PR:B0YJ81; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; B0YJ81; protein.
DR   Bgee; ENSG00000165996; Expressed in heart and 211 other tissues.
DR   ExpressionAtlas; B0YJ81; baseline and differential.
DR   Genevisible; B0YJ81; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0102343; F:3-hydroxy-arachidoyl-CoA dehydratase activity; IEA:UniProtKB-EC.
DR   GO; GO:0102344; F:3-hydroxy-behenoyl-CoA dehydratase activity; IEA:UniProtKB-EC.
DR   GO; GO:0102345; F:3-hydroxy-lignoceroyl-CoA dehydratase activity; IEA:UniProtKB-EC.
DR   GO; GO:0018812; F:3-hydroxyacyl-CoA dehydratase activity; IDA:UniProtKB.
DR   GO; GO:0080023; F:3R-hydroxyacyl-CoA dehydratase activity; EXP:Reactome.
DR   GO; GO:0019899; F:enzyme binding; IDA:UniProtKB.
DR   GO; GO:0046848; F:hydroxyapatite binding; IDA:UniProtKB.
DR   GO; GO:0102158; F:very-long-chain 3-hydroxyacyl-CoA dehydratase activity; IEA:UniProtKB-EC.
DR   GO; GO:0034622; P:cellular protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0071529; P:cementum mineralization; IDA:UniProtKB.
DR   GO; GO:0030497; P:fatty acid elongation; IDA:UniProtKB.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IDA:UniProtKB.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IGI:UniProtKB.
DR   GO; GO:0042761; P:very long-chain fatty acid biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR007482; Tyr_Pase-like_PTPLA.
DR   PANTHER; PTHR11035; PTHR11035; 1.
DR   Pfam; PF04387; PTPLA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Developmental protein; Endoplasmic reticulum;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Glycoprotein;
KW   Lipid biosynthesis; Lipid metabolism; Lyase; Membrane; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..288
FT                   /note="Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase
FT                   1"
FT                   /id="PRO_0000349315"
FT   TOPO_DOM        1..75
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        76..95
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        96..114
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        115..131
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        132..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..159
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        160..165
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        166..180
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        181..203
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        204..221
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        222..251
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        252..269
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        270..288
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        35..49
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        210
FT                   /evidence="ECO:0000250|UniProtKB:P40857"
FT   ACT_SITE        217
FT                   /evidence="ECO:0000250|UniProtKB:P40857"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CARBOHYD        243
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         126..140
FT                   /note="IVHCLIGIVPTSVIV -> VSFPSCCFSIAVIFM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:22067203"
FT                   /id="VSP_035363"
FT   VAR_SEQ         141..288
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:22067203"
FT                   /id="VSP_035364"
FT   VARIANT         64
FT                   /note="E -> K (in dbSNP:rs7895850)"
FT                   /evidence="ECO:0000269|PubMed:10644438,
FT                   ECO:0000269|PubMed:11054553, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046366"
FT   VARIANT         64
FT                   /note="E -> Q (in dbSNP:rs7895850)"
FT                   /evidence="ECO:0000269|PubMed:11054553"
FT                   /id="VAR_046367"
FT   VARIANT         70
FT                   /note="V -> F (in dbSNP:rs11254692)"
FT                   /evidence="ECO:0000269|PubMed:11054553,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046368"
FT   VARIANT         227
FT                   /note="H -> Y (in dbSNP:rs1053926)"
FT                   /evidence="ECO:0000269|PubMed:10644438,
FT                   ECO:0000269|PubMed:11054553"
FT                   /id="VAR_046369"
FT   CONFLICT        80
FT                   /note="D -> N (in Ref. 2; AAF21976)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   288 AA;  32388 MW;  1CB64F23C3907F6E CRC64;
     MGRLTEAAAA GSGSRAAGWA GSPPTLLPLS PTSPRCAATM ASSDEDGTNG GASEAGEDRE
     APGERRRLGV LATAWLTFYD IAMTAGWLVL AIAMVRFYME KGTHRGLYKS IQKTLKFFQT
     FALLEIVHCL IGIVPTSVIV TGVQVSSRIF MVWLITHSIK PIQNEESVVL FLVAWTVTEI
     TRYSFYTFSL LDHLPYFIKW ARYNFFIILY PVGVAGELLT IYAALPHVKK TGMFSIRLPN
     KYNVSFDYYY FLLITMASYI PLFPQLYFHM LRQRRKVLHG EVIVEKDD
//
ID   TFIP8_HUMAN             Reviewed;         198 AA.
AC   O95379; B3KMH1; B3KMI2; B7Z713; Q9P1Q1; Q9UER5; Q9UP47;
DT   01-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   23-FEB-2022, entry version 154.
DE   RecName: Full=Tumor necrosis factor alpha-induced protein 8;
DE            Short=TNF alpha-induced protein 8;
DE   AltName: Full=Head and neck tumor and metastasis-related protein;
DE   AltName: Full=MDC-3.13;
DE   AltName: Full=NF-kappa-B-inducible DED-containing protein;
DE            Short=NDED;
DE   AltName: Full=SCC-S2;
DE   AltName: Full=TNF-induced protein GG2-1;
GN   Name=TNFAIP8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Umbilical vein;
RX   PubMed=10233894;
RA   Horrevoets A.J.G., Fontijn R.D., van Zonneveld A.J., de Vries C.J.M.,
RA   ten Cate J.W., Pannekoek H.;
RT   "Vascular endothelial genes that are responsive to tumor necrosis factor-
RT   alpha in vitro are expressed in atherosclerotic lesions, including
RT   inhibitor of apoptosis protein-1, stannin, and two novel genes.";
RL   Blood 93:3418-3431(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RA   Nietfeld W., Meyerhans A.F.;
RT   "Identification of cellular factors involved in the differentiation of
RT   dendritic cells.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   TISSUE=Stomach;
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 99-198 (ISOFORM 3), IDENTIFICATION, FUNCTION,
RP   INDUCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   TISSUE=Heart;
RX   PubMed=10644768; DOI=10.1074/jbc.275.4.2973;
RA   Kumar D., Whiteside T.L., Kasid U.;
RT   "Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-
RT   S2, containing the consensus sequence of a death effector domain of fas-
RT   associated death domain-like interleukin-1beta-converting enzyme-inhibitory
RT   protein.";
RL   J. Biol. Chem. 275:2973-2978(2000).
RN   [9]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=11346652; DOI=10.1074/jbc.m102464200;
RA   You Z., Ouyang H., Lopatin D., Polver P.J., Wang C.-Y.;
RT   "Nuclear factor-kappa B-inducible death effector domain-containing protein
RT   suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8
RT   activity.";
RL   J. Biol. Chem. 276:26398-26404(2001).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=14724590; DOI=10.1038/sj.onc.1207123;
RA   Kumar D., Gokhale P., Broustas C., Chakravarty D., Ahmad I., Kasid U.;
RT   "Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced
RT   proliferation and tumorigenicity of MDA-MB 435 cells.";
RL   Oncogene 23:612-616(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Acts as a negative mediator of apoptosis and may play a role
CC       in tumor progression. Suppresses the TNF-mediated apoptosis by
CC       inhibiting caspase-8 activity but not the processing of procaspase-8,
CC       subsequently resulting in inhibition of BID cleavage and caspase-3
CC       activation. {ECO:0000269|PubMed:10644768, ECO:0000269|PubMed:11346652,
CC       ECO:0000269|PubMed:14724590}.
CC   -!- INTERACTION:
CC       O95379; Q86V38: ATN1; NbExp=3; IntAct=EBI-1049336, EBI-11954292;
CC       O95379; Q96JC9: EAF1; NbExp=3; IntAct=EBI-1049336, EBI-769261;
CC       O95379; Q56P03: EAPP; NbExp=3; IntAct=EBI-1049336, EBI-748732;
CC       O95379; Q8NBZ0: INO80E; NbExp=3; IntAct=EBI-1049336, EBI-769401;
CC       O95379; Q9NPJ6: MED4; NbExp=7; IntAct=EBI-1049336, EBI-394607;
CC       O95379; Q96S99: PLEKHF1; NbExp=3; IntAct=EBI-1049336, EBI-745767;
CC       O95379; Q9H8W4: PLEKHF2; NbExp=4; IntAct=EBI-1049336, EBI-742388;
CC       O95379; Q9NZ81: PRR13; NbExp=6; IntAct=EBI-1049336, EBI-740924;
CC       O95379; O00560: SDCBP; NbExp=6; IntAct=EBI-1049336, EBI-727004;
CC       O95379; Q96CG3: TIFA; NbExp=3; IntAct=EBI-1049336, EBI-740711;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14724590}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O95379-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95379-2; Sequence=VSP_024899;
CC       Name=3;
CC         IsoId=O95379-3; Sequence=VSP_024898;
CC       Name=4;
CC         IsoId=O95379-4; Sequence=VSP_054827;
CC   -!- TISSUE SPECIFICITY: Expressed at high levels in the spleen, lymph node,
CC       thymus, thyroid, bone marrow and placenta. Expressed at high levels
CC       both in various tumor tissues, unstimulated and cytokine-activated
CC       cultured cells. Expressed at low levels in the spinal cord, ovary,
CC       lung, adrenal glands, heart, brain, testis and skeletal muscle.
CC       {ECO:0000269|PubMed:10233894, ECO:0000269|PubMed:10644768,
CC       ECO:0000269|PubMed:14724590}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at high levels in the fetal liver, lung
CC       and kidney. {ECO:0000269|PubMed:10644768}.
CC   -!- INDUCTION: By nuclear factor-KB (NF-KB) and TNF. Induction by TNF
CC       depends upon activation of NF-KB. {ECO:0000269|PubMed:10644768,
CC       ECO:0000269|PubMed:11346652}.
CC   -!- SIMILARITY: Belongs to the TNFAIP8 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF070671; AAC83229.1; -; mRNA.
DR   EMBL; AF099935; AAC72975.1; -; mRNA.
DR   EMBL; AF099936; AAC72976.1; -; mRNA.
DR   EMBL; CR457137; CAG33418.1; -; mRNA.
DR   EMBL; AK001850; BAG50983.1; -; mRNA.
DR   EMBL; AK001931; BAG50994.1; -; mRNA.
DR   EMBL; AK301281; BAH13449.1; -; mRNA.
DR   EMBL; AC008475; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC027320; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC035144; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471086; EAW48914.1; -; Genomic_DNA.
DR   EMBL; BC005352; AAH05352.1; -; mRNA.
DR   EMBL; BC007014; AAH07014.1; -; mRNA.
DR   EMBL; AF098933; AAF29435.1; -; mRNA.
DR   CCDS; CCDS47257.1; -. [O95379-3]
DR   CCDS; CCDS47258.1; -. [O95379-1]
DR   CCDS; CCDS68933.1; -. [O95379-4]
DR   RefSeq; NP_001071122.1; NM_001077654.2. [O95379-3]
DR   RefSeq; NP_001273742.1; NM_001286813.1. [O95379-1]
DR   RefSeq; NP_001273743.1; NM_001286814.1. [O95379-4]
DR   RefSeq; NP_001273744.1; NM_001286815.1.
DR   RefSeq; NP_001273746.1; NM_001286817.1.
DR   RefSeq; NP_055165.2; NM_014350.3. [O95379-1]
DR   SMR; O95379; -.
DR   BioGRID; 117344; 31.
DR   IntAct; O95379; 14.
DR   MINT; O95379; -.
DR   STRING; 9606.ENSP00000427424; -.
DR   iPTMnet; O95379; -.
DR   PhosphoSitePlus; O95379; -.
DR   BioMuta; TNFAIP8; -.
DR   EPD; O95379; -.
DR   jPOST; O95379; -.
DR   MassIVE; O95379; -.
DR   MaxQB; O95379; -.
DR   PaxDb; O95379; -.
DR   PeptideAtlas; O95379; -.
DR   PRIDE; O95379; -.
DR   ProteomicsDB; 50831; -. [O95379-1]
DR   ProteomicsDB; 50832; -. [O95379-2]
DR   ProteomicsDB; 50833; -. [O95379-3]
DR   ProteomicsDB; 6823; -.
DR   Antibodypedia; 25539; 263 antibodies from 32 providers.
DR   DNASU; 25816; -.
DR   Ensembl; ENST00000274456; ENSP00000274456; ENSG00000145779. [O95379-3]
DR   Ensembl; ENST00000503646; ENSP00000421848; ENSG00000145779.
DR   Ensembl; ENST00000504771; ENSP00000422245; ENSG00000145779.
DR   Ensembl; ENST00000513374; ENSP00000427424; ENSG00000145779. [O95379-4]
DR   GeneID; 25816; -.
DR   KEGG; hsa:25816; -.
DR   MANE-Select; ENST00000504771.3; ENSP00000422245.1; NM_014350.4; NP_055165.2.
DR   UCSC; uc003ksg.5; human. [O95379-1]
DR   CTD; 25816; -.
DR   DisGeNET; 25816; -.
DR   GeneCards; TNFAIP8; -.
DR   HGNC; HGNC:17260; TNFAIP8.
DR   HPA; ENSG00000145779; Tissue enhanced (lymphoid).
DR   MIM; 612111; gene.
DR   neXtProt; NX_O95379; -.
DR   OpenTargets; ENSG00000145779; -.
DR   PharmGKB; PA134957136; -.
DR   VEuPathDB; HostDB:ENSG00000145779; -.
DR   eggNOG; ENOG502S00N; Eukaryota.
DR   GeneTree; ENSGT00390000003488; -.
DR   HOGENOM; CLU_085918_1_0_1; -.
DR   InParanoid; O95379; -.
DR   OMA; LYNPFGT; -.
DR   OrthoDB; 1284744at2759; -.
DR   PhylomeDB; O95379; -.
DR   TreeFam; TF323415; -.
DR   PathwayCommons; O95379; -.
DR   Reactome; R-HSA-1483255; PI Metabolism.
DR   SignaLink; O95379; -.
DR   SIGNOR; O95379; -.
DR   BioGRID-ORCS; 25816; 4 hits in 1046 CRISPR screens.
DR   ChiTaRS; TNFAIP8; human.
DR   GeneWiki; TNFAIP8; -.
DR   GenomeRNAi; 25816; -.
DR   Pharos; O95379; Tbio.
DR   PRO; PR:O95379; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; O95379; protein.
DR   Bgee; ENSG00000145779; Expressed in bone marrow and 214 other tissues.
DR   ExpressionAtlas; O95379; baseline and differential.
DR   Genevisible; O95379; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   Gene3D; 1.20.1440.160; -; 1.
DR   InterPro; IPR008477; TNFAIP8-like.
DR   InterPro; IPR038355; TNFAIP8_sf.
DR   PANTHER; PTHR12757; PTHR12757; 1.
DR   Pfam; PF05527; DUF758; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Coiled coil; Cytoplasm;
KW   Reference proteome.
FT   CHAIN           1..198
FT                   /note="Tumor necrosis factor alpha-induced protein 8"
FT                   /id="PRO_0000285718"
FT   COILED          49..83
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..11
FT                   /note="MHSEAEESKEV -> M (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10233894,
FT                   ECO:0000303|PubMed:10644768, ECO:0000303|PubMed:14702039"
FT                   /id="VSP_024898"
FT   VAR_SEQ         1..10
FT                   /note="MHSEAEESKE -> MA (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3"
FT                   /id="VSP_024899"
FT   VAR_SEQ         1..10
FT                   /note="MHSEAEESKE -> MTLPRYCEVVLLIAHGEKMLKL (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054827"
FT   VARIANT         151
FT                   /note="S -> C (in dbSNP:rs3203922)"
FT                   /id="VAR_032047"
SQ   SEQUENCE   198 AA;  23003 MW;  D9B8F6FCF9AFC2C3 CRC64;
     MHSEAEESKE VATDVFNSKN LAVQAQKKIL GKMVSKSIAT TLIDDTSSEV LDELYRVTRE
     YTQNKKEAEK IIKNLIKTVI KLAILYRNNQ FNQDELALME KFKKKVHQLA MTVVSFHQVD
     YTFDRNVLSR LLNECREMLH QIIQRHLTAK SHGRVNNVFD HFSDCEFLAA LYNPFGNFKP
     HLQKLCDGIN KMLDEENI
//
ID   KS6A6_HUMAN             Reviewed;         745 AA.
AC   Q9UK32; B2R854; B7ZL90; Q6FHX2; Q8WX28; Q9H4S6;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   23-FEB-2022, entry version 188.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-6;
DE            Short=S6K-alpha-6;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 6;
DE            Short=p90-RSK 6;
DE            Short=p90RSK6;
DE   AltName: Full=Ribosomal S6 kinase 4;
DE            Short=RSK-4;
DE   AltName: Full=pp90RSK4;
GN   Name=RPS6KA6; Synonyms=RSK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10644430; DOI=10.1006/geno.1999.6004;
RA   Yntema H.G., van den Helm B., Kissing J., van Duijnhoven G., Poppelaars F.,
RA   Chelly J., Moraine C., Fryns J.-P., Hamel B.C.J., Heilbronner H.,
RA   Pander H.-J., Brunner H.G., Ropers H.-H., Cremers F.P.M., van Bokhoven H.;
RT   "A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in
RT   patients with complex X-linked mental retardation.";
RL   Genomics 62:332-343(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN P53/TP53 SIGNALING.
RX   PubMed=15042092; DOI=10.1038/nature02371;
RA   Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A.,
RA   Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B.,
RA   Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., Bernards R.;
RT   "A large-scale RNAi screen in human cells identifies new components of the
RT   p53 pathway.";
RL   Nature 428:431-437(2004).
RN   [8]
RP   FUNCTION, ACTIVITY REGULATION, INTERACTION WITH MAPK3, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION AT SER-232; SER-372; SER-389 AND THR-581, AND
RP   MUTAGENESIS OF SER-372; SER-389 AND THR-581.
RX   PubMed=15632195; DOI=10.1074/jbc.m408194200;
RA   Duemmler B.A., Hauge C., Silber J., Yntema H.G., Kruse L.S., Kofoed B.,
RA   Hemmings B.A., Alessi D.R., Froedin M.;
RT   "Functional characterization of human RSK4, a new 90-kDa ribosomal S6
RT   kinase, reveals constitutive activation in most cell types.";
RL   J. Biol. Chem. 280:13304-13314(2005).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=18813292; DOI=10.1038/nrm2509;
RA   Anjum R., Blenis J.;
RT   "The RSK family of kinases: emerging roles in cellular signalling.";
RL   Nat. Rev. Mol. Cell Biol. 9:747-758(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-140; THR-258 AND ASN-692.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Constitutively active serine/threonine-protein kinase that
CC       exhibits growth-factor-independent kinase activity and that may
CC       participate in p53/TP53-dependent cell growth arrest signaling and play
CC       an inhibitory role during embryogenesis. {ECO:0000269|PubMed:15042092,
CC       ECO:0000269|PubMed:15632195}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Constitutively activated by phosphorylation at
CC       Ser-232, Ser-372, and Ser-389 in serum-starved cells. Does not require
CC       growth factor stimulation for significant kinase activity.
CC       {ECO:0000269|PubMed:15632195}.
CC   -!- SUBUNIT: Forms a complex with MAPK3/ERK1 but not with MAPK9 or MAPK14
CC       in serum-starved cells.
CC   -!- INTERACTION:
CC       Q9UK32; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-722467, EBI-7082156;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:15632195}.
CC       Nucleus {ECO:0000269|PubMed:15632195}. Note=Predominantly cytosolic.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UK32-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UK32-2; Sequence=VSP_056181;
CC   -!- PTM: Phosphorylated at Ser-232, Ser-372, and Ser-389 in serum-starved
CC       cells. {ECO:0000269|PubMed:15632195}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF184965; AAF13190.1; -; mRNA.
DR   EMBL; CR536566; CAG38803.1; -; mRNA.
DR   EMBL; AK313240; BAG36051.1; -; mRNA.
DR   EMBL; AL389887; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354653; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471104; EAW98575.1; -; Genomic_DNA.
DR   EMBL; BC143648; AAI43649.1; -; mRNA.
DR   CCDS; CCDS14451.1; -. [Q9UK32-1]
DR   CCDS; CCDS83480.1; -. [Q9UK32-2]
DR   RefSeq; NP_001317441.1; NM_001330512.1. [Q9UK32-2]
DR   RefSeq; NP_055311.1; NM_014496.4. [Q9UK32-1]
DR   RefSeq; XP_011529219.1; XM_011530917.2. [Q9UK32-2]
DR   PDB; 6G76; X-ray; 3.00 A; A/B=48-349.
DR   PDB; 6G77; X-ray; 2.50 A; A/B=48-349.
DR   PDB; 6G78; X-ray; 2.50 A; A/B=48-349.
DR   PDBsum; 6G76; -.
DR   PDBsum; 6G77; -.
DR   PDBsum; 6G78; -.
DR   SMR; Q9UK32; -.
DR   BioGRID; 118144; 48.
DR   IntAct; Q9UK32; 30.
DR   MINT; Q9UK32; -.
DR   STRING; 9606.ENSP00000262752; -.
DR   BindingDB; Q9UK32; -.
DR   ChEMBL; CHEMBL4924; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9UK32; -.
DR   GuidetoPHARMACOLOGY; 1530; -.
DR   iPTMnet; Q9UK32; -.
DR   PhosphoSitePlus; Q9UK32; -.
DR   BioMuta; RPS6KA6; -.
DR   DMDM; 11133131; -.
DR   EPD; Q9UK32; -.
DR   jPOST; Q9UK32; -.
DR   MassIVE; Q9UK32; -.
DR   MaxQB; Q9UK32; -.
DR   PaxDb; Q9UK32; -.
DR   PeptideAtlas; Q9UK32; -.
DR   PRIDE; Q9UK32; -.
DR   ProteomicsDB; 7217; -.
DR   ProteomicsDB; 84712; -. [Q9UK32-1]
DR   Antibodypedia; 489; 245 antibodies from 31 providers.
DR   DNASU; 27330; -.
DR   Ensembl; ENST00000262752; ENSP00000262752; ENSG00000072133.
DR   Ensembl; ENST00000620340; ENSP00000483896; ENSG00000072133. [Q9UK32-2]
DR   GeneID; 27330; -.
DR   KEGG; hsa:27330; -.
DR   MANE-Select; ENST00000262752.5; ENSP00000262752.2; NM_014496.5; NP_055311.1.
DR   UCSC; uc004eej.3; human. [Q9UK32-1]
DR   CTD; 27330; -.
DR   DisGeNET; 27330; -.
DR   GeneCards; RPS6KA6; -.
DR   HGNC; HGNC:10435; RPS6KA6.
DR   HPA; ENSG00000072133; Low tissue specificity.
DR   MIM; 300303; gene.
DR   neXtProt; NX_Q9UK32; -.
DR   OpenTargets; ENSG00000072133; -.
DR   PharmGKB; PA34850; -.
DR   VEuPathDB; HostDB:ENSG00000072133; -.
DR   eggNOG; KOG0603; Eukaryota.
DR   GeneTree; ENSGT00940000159242; -.
DR   HOGENOM; CLU_000288_58_3_1; -.
DR   InParanoid; Q9UK32; -.
DR   OMA; FVITKTV; -.
DR   OrthoDB; 1132245at2759; -.
DR   PhylomeDB; Q9UK32; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q9UK32; -.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling.
DR   Reactome; R-HSA-444257; RSK activation.
DR   SignaLink; Q9UK32; -.
DR   BioGRID-ORCS; 27330; 9 hits in 694 CRISPR screens.
DR   ChiTaRS; RPS6KA6; human.
DR   GenomeRNAi; 27330; -.
DR   Pharos; Q9UK32; Tchem.
DR   PRO; PR:Q9UK32; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9UK32; protein.
DR   Bgee; ENSG00000072133; Expressed in buccal mucosa cell and 179 other tissues.
DR   Genevisible; Q9UK32; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:RHEA.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:UniProtKB.
DR   GO; GO:0045992; P:negative regulation of embryonic development; ISS:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd05582; STKc_RSK_N; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR041906; RSK_N.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..745
FT                   /note="Ribosomal protein S6 kinase alpha-6"
FT                   /id="PRO_0000086209"
FT   DOMAIN          73..330
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          331..400
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          426..683
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         79..87
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         432..440
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..28
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        198
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        543
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         105
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         455
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         232
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   MOD_RES         372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   MOD_RES         389
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15632195,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         581
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   VAR_SEQ         1..27
FT                   /note="MLPFAPQDEPWDREMEVFSGGGASSGE -> MGLSTSAIWKNTRVEIVNPYE
FT                   VKRKVK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056181"
FT   VARIANT         140
FT                   /note="Y -> C (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040637"
FT   VARIANT         258
FT                   /note="S -> T (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040638"
FT   VARIANT         692
FT                   /note="D -> N (in dbSNP:rs6616890)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_030670"
FT   MUTAGEN         372
FT                   /note="S->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   MUTAGEN         389
FT                   /note="S->A: Strongly decreases activity."
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   MUTAGEN         581
FT                   /note="T->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15632195"
FT   CONFLICT        116
FT                   /note="D -> G (in Ref. 2; CAG38803)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        295
FT                   /note="F -> L (in Ref. 2; CAG38803)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        341
FT                   /note="R -> G (in Ref. 2; CAG38803)"
FT                   /evidence="ECO:0000305"
FT   STRAND          52..56
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          73..81
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          86..92
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   TURN            96..99
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          101..115
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           126..129
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          138..144
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          147..152
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           160..165
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           172..191
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           226..230
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           237..239
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           242..245
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           252..268
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           278..287
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           298..307
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   TURN            312..314
FT                   /evidence="ECO:0007829|PDB:6G78"
FT   TURN            316..319
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           322..325
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:6G77"
FT   HELIX           335..339
FT                   /evidence="ECO:0007829|PDB:6G77"
SQ   SEQUENCE   745 AA;  83872 MW;  5EC5AB2FA1C19DE8 CRC64;
     MLPFAPQDEP WDREMEVFSG GGASSGEVNG LKMVDEPMEE GEADSCHDEG VVKEIPITHH
     VKEGYEKADP AQFELLKVLG QGSFGKVFLV RKKTGPDAGQ LYAMKVLKKA SLKVRDRVRT
     KMERDILVEV NHPFIVKLHY AFQTEGKLYL ILDFLRGGDV FTRLSKEVLF TEEDVKFYLA
     ELALALDHLH QLGIVYRDLK PENILLDEIG HIKLTDFGLS KESVDQEKKA YSFCGTVEYM
     APEVVNRRGH SQSADWWSYG VLMFEMLTGT LPFQGKDRNE TMNMILKAKL GMPQFLSAEA
     QSLLRMLFKR NPANRLGSEG VEEIKRHLFF ANIDWDKLYK REVQPPFKPA SGKPDDTFCF
     DPEFTAKTPK DSPGLPASAN AHQLFKGFSF VATSIAEEYK ITPITSANVL PIVQINGNAA
     QFGEVYELKE DIGVGSYSVC KRCIHATTNM EFAVKIIDKS KRDPSEEIEI LMRYGQHPNI
     ITLKDVFDDG RYVYLVTDLM KGGELLDRIL KQKCFSEREA SDILYVISKT VDYLHCQGVV
     HRDLKPSNIL YMDESASADS IRICDFGFAK QLRGENGLLL TPCYTANFVA PEVLMQQGYD
     AACDIWSLGV LFYTMLAGYT PFANGPNDTP EEILLRIGNG KFSLSGGNWD NISDGAKDLL
     SHMLHMDPHQ RYTAEQILKH SWITHRDQLP NDQPKRNDVS HVVKGAMVAT YSALTHKTFQ
     PVLEPVAASS LAQRRSMKKR TSTGL
//
ID   TALD3_HUMAN             Reviewed;        1533 AA.
AC   Q9BVV6; B4DZB6; E7EWM8; J3KQH9; O60328; Q6NYC6; Q6UV20;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 4.
DT   23-FEB-2022, entry version 150.
DE   RecName: Full=Protein TALPID3;
GN   Name=KIAA0586; Synonyms=TALPID3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT PRO-828.
RA   Zhen Y., Huo R., Lu L., Xu M., Yin L.L., Xu Z.Y., Li J.M., Zhou Z.M.,
RA   Sha J.H.;
RT   "Cloning an isoform of KIAA0586 gene related to spermatogenesis.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-828.
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT PRO-828.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-828.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   PRO-828.
RC   TISSUE=Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19144723; DOI=10.1242/dev.028464;
RA   Yin Y., Bangs F., Paton I.R., Prescott A., James J., Davey M.G.,
RA   Whitley P., Genikhovich G., Technau U., Burt D.W., Tickle C.;
RT   "The Talpid3 gene (KIAA0586) encodes a centrosomal protein that is
RT   essential for primary cilia formation.";
RL   Development 136:655-664(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-406, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH CCP110; CEP290; CEP97 AND KIF24.
RX   PubMed=24421332; DOI=10.1083/jcb.201304153;
RA   Kobayashi T., Kim S., Lin Y.C., Inoue T., Dynlacht B.D.;
RT   "The CP110-interacting proteins Talpid3 and Cep290 play overlapping and
RT   distinct roles in cilia assembly.";
RL   J. Cell Biol. 204:215-229(2014).
RN   [10]
RP   DEVELOPMENTAL STAGE, AND INVOLVEMENT IN SRTD14.
RX   PubMed=26166481; DOI=10.1016/j.ajhg.2015.06.003;
RA   Alby C., Piquand K., Huber C., Megarbane A., Ichkou A., Legendre M.,
RA   Pelluard F., Encha-Ravazi F., Abi-Tayeh G., Bessieres B.,
RA   El Chehadeh-Djebbar S., Laurent N., Faivre L., Sztriha L., Zombor M.,
RA   Szabo H., Failler M., Garfa-Traore M., Bole C., Nitschke P., Nizon M.,
RA   Elkhartoufi N., Clerget-Darpoux F., Munnich A., Lyonnet S., Vekemans M.,
RA   Saunier S., Cormier-Daire V., Attie-Bitach T., Thomas S.;
RT   "Mutations in KIAA0586 cause lethal ciliopathies ranging from a
RT   hydrolethalus phenotype to short-rib polydactyly syndrome.";
RL   Am. J. Hum. Genet. 97:311-318(2015).
RN   [11]
RP   INVOLVEMENT IN JBTS23.
RX   PubMed=26026149; DOI=10.7554/elife.06602;
RA   Roosing S., Hofree M., Kim S., Scott E., Copeland B., Romani M.,
RA   Silhavy J.L., Rosti R.O., Schroth J., Mazza T., Miccinilli E., Zaki M.S.,
RA   Swoboda K.J., Milisa-Drautz J., Dobyns W.B., Mikati M.A., Incecik F.,
RA   Azam M., Borgatti R., Romaniello R., Boustany R.M., Clericuzio C.L.,
RA   D'Arrigo S., Stroemme P., Boltshauser E., Stanzial F.,
RA   Mirabelli-Badenier M., Moroni I., Bertini E., Emma F., Steinlin M.,
RA   Hildebrandt F., Johnson C.A., Freilinger M., Vaux K.K., Gabriel S.B.,
RA   Aza-Blanc P., Heynen-Genel S., Ideker T., Dynlacht B.D., Lee J.E.,
RA   Valente E.M., Kim J., Gleeson J.G.;
RT   "Functional genome-wide siRNA screen identifies KIAA0586 as mutated in
RT   Joubert syndrome.";
RL   Elife 4:E06602-E06602(2015).
RN   [12]
RP   SUBCELLULAR LOCATION, AND INVOLVEMENT IN JBTS23.
RX   PubMed=26386247; DOI=10.7554/elife.08077;
RA   Stephen L.A., Tawamie H., Davis G.M., Tebbe L., Nuernberg P., Nuernberg G.,
RA   Thiele H., Thoenes M., Boltshauser E., Uebe S., Rompel O., Reis A.,
RA   Ekici A.B., McTeir L., Fraser A.M., Hall E.A., Mill P., Daudet N.,
RA   Cross C., Wolfrum U., Jamra R.A., Davey M.G., Bolz H.J.;
RT   "TALPID3 controls centrosome and cell polarity and the human ortholog
RT   KIAA0586 is mutated in Joubert syndrome (JBTS23).";
RL   Elife 4:0-0(2015).
RN   [13]
RP   INVOLVEMENT IN JBTS23, AND VARIANT JBTS23 VAL-566.
RX   PubMed=26096313; DOI=10.1002/humu.22821;
RG   University of Washington Center for Mendelian Genomics;
RA   Bachmann-Gagescu R., Phelps I.G., Dempsey J.C., Sharma V.A., Ishak G.E.,
RA   Boyle E.A., Wilson M., Marques Lourenco C., Arslan M., Shendure J.,
RA   Doherty D.;
RT   "KIAA0586 is Mutated in Joubert Syndrome.";
RL   Hum. Mutat. 36:831-835(2015).
RN   [14]
RP   TISSUE SPECIFICITY, AND INVOLVEMENT IN JBTS23.
RX   PubMed=26386044; DOI=10.1136/jmedgenet-2015-103316;
RG   NISC Comparative Sequencing Program;
RA   Malicdan M.C., Vilboux T., Stephen J., Maglic D., Mian L., Konzman D.,
RA   Guo J., Yildirimli D., Bryant J., Fischer R., Zein W.M., Snow J.,
RA   Vemulapalli M., Mullikin J.C., Toro C., Solomon B.D., Niederhuber J.E.,
RA   Gahl W.A., Gunay-Aygun M.;
RT   "Mutations in human homologue of chicken talpid3 gene (KIAA0586) cause a
RT   hybrid ciliopathy with overlapping features of Jeune and Joubert
RT   syndromes.";
RL   J. Med. Genet. 52:830-839(2015).
RN   [15]
RP   INVOLVEMENT IN JBTS23, AND VARIANT JBTS23 LYS-403.
RX   PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336;
RA   Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L., Edvardson S.,
RA   Rein A.J., Elpeleg O., Katsanis N.;
RT   "A human laterality disorder caused by a homozygous deleterious mutation in
RT   MMP21.";
RL   J. Med. Genet. 52:840-847(2015).
CC   -!- FUNCTION: Required for ciliogenesis and sonic hedgehog/SHH signaling.
CC       Required for the centrosomal recruitment of RAB8A and for the targeting
CC       of centriole satellite proteins to centrosomes such as of PCM1. May
CC       play a role in early ciliogenesis in the disappearance of centriolar
CC       satellites that preceeds ciliary vesicle formation (PubMed:24421332).
CC       Involved in regulation of cell intracellular organization. Involved in
CC       regulation of cell polarity (By similarity). Required for asymmetrical
CC       localization of CEP120 to daughter centrioles (By similarity).
CC       {ECO:0000250|UniProtKB:E9PV87, ECO:0000250|UniProtKB:Q1G7G9,
CC       ECO:0000269|PubMed:24421332}.
CC   -!- SUBUNIT: Interacts with CCP110, CEP290, CEP97, KIF24.
CC       {ECO:0000269|PubMed:24421332}.
CC   -!- INTERACTION:
CC       Q9BVV6; O43303: CCP110; NbExp=6; IntAct=EBI-11286926, EBI-1566217;
CC       Q9BVV6; Q8TAP6: CEP76; NbExp=2; IntAct=EBI-11286926, EBI-742887;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:19144723}. Photoreceptor inner
CC       segment {ECO:0000269|PubMed:26386247}. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome, centriole
CC       {ECO:0000269|PubMed:24421332, ECO:0000269|PubMed:26386247}. Cytoplasm,
CC       cytoskeleton, cilium basal body {ECO:0000269|PubMed:26386247}.
CC       Note=Forms a ring-like structure at the extreme distal end of both
CC       mother and daughter centrioles (PubMed:24421332). In photoreceptor
CC       cells localized to the joint between the inner and outer segments,
CC       specifically localized at the mother centriole (basal body) and the
CC       adjacent centriole as well as between the two centrioles but not in the
CC       connecting cilium (PubMed:26386247). {ECO:0000269|PubMed:24421332,
CC       ECO:0000269|PubMed:26386247}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9BVV6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BVV6-2; Sequence=VSP_040642, VSP_040643;
CC       Name=3;
CC         IsoId=Q9BVV6-3; Sequence=VSP_046005, VSP_046006, VSP_046007;
CC       Name=4;
CC         IsoId=Q9BVV6-4; Sequence=VSP_046387, VSP_046006;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed (PubMed:26386044). Expressed
CC       in photoreceptor cells (at protein level) (PubMed:26386247).
CC       {ECO:0000269|PubMed:26386044, ECO:0000269|PubMed:26386247}.
CC   -!- DEVELOPMENTAL STAGE: Expressed as early as 6 weeks of gestation
CC       (Carnegie stage 16). Ubiquitously expressed during fetal development
CC       and postnatally in all adult tissues tested.
CC       {ECO:0000269|PubMed:26166481}.
CC   -!- DISEASE: Joubert syndrome 23 (JBTS23) [MIM:616490]: A mild form of
CC       Joubert syndrome, a disorder presenting with cerebellar ataxia,
CC       oculomotor apraxia, hypotonia, neonatal breathing abnormalities and
CC       psychomotor delay. Neuroradiologically, it is characterized by
CC       cerebellar vermian hypoplasia/aplasia, thickened and reoriented
CC       superior cerebellar peduncles, and an abnormally large interpeduncular
CC       fossa, giving the appearance of a molar tooth on transaxial slices
CC       (molar tooth sign). Additional variable features include retinal
CC       dystrophy, renal disease, liver fibrosis, and polydactyly.
CC       {ECO:0000269|PubMed:26026149, ECO:0000269|PubMed:26096313,
CC       ECO:0000269|PubMed:26386044, ECO:0000269|PubMed:26386247,
CC       ECO:0000269|PubMed:26429889}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. Some patients with
CC       biallelic KIAA0586 mutations manifest a disease phenotype with features
CC       of Joubert syndrome and additional findings of a small thorax and
CC       respiratory problems consistent with Jeune syndrome (Joubert-Jeune
CC       ciliopathy). {ECO:0000269|PubMed:26386044}.
CC   -!- DISEASE: Short-rib thoracic dysplasia 14 with polydactyly (SRTD14)
CC       [MIM:616546]: A form of short-rib thoracic dysplasia, a group of
CC       autosomal recessive ciliopathies that are characterized by a
CC       constricted thoracic cage, short ribs, shortened tubular bones, and a
CC       'trident' appearance of the acetabular roof. Polydactyly is variably
CC       present. Non-skeletal involvement can include cleft lip/palate as well
CC       as anomalies of major organs such as the brain, eye, heart, kidneys,
CC       liver, pancreas, intestines, and genitalia. Some forms of the disease
CC       are lethal in the neonatal period due to respiratory insufficiency
CC       secondary to a severely restricted thoracic cage, whereas others are
CC       compatible with life. Disease spectrum encompasses Ellis-van Creveld
CC       syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-
CC       Saldino syndrome, and short rib-polydactyly syndrome.
CC       {ECO:0000269|PubMed:26166481}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TALPID3 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA25512.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY359881; AAQ63404.1; -; mRNA.
DR   EMBL; AB011158; BAA25512.2; ALT_INIT; mRNA.
DR   EMBL; AK302836; BAG64028.1; -; mRNA.
DR   EMBL; AL135752; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL139021; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW80740.1; -; Genomic_DNA.
DR   EMBL; BC000900; AAH00900.1; -; mRNA.
DR   EMBL; BC066647; AAH66647.2; -; mRNA.
DR   CCDS; CCDS45115.1; -. [Q9BVV6-2]
DR   CCDS; CCDS58320.1; -. [Q9BVV6-3]
DR   CCDS; CCDS58321.1; -. [Q9BVV6-1]
DR   CCDS; CCDS58322.1; -. [Q9BVV6-4]
DR   PIR; T00344; T00344.
DR   RefSeq; NP_001231118.1; NM_001244189.1. [Q9BVV6-3]
DR   RefSeq; NP_001231119.1; NM_001244190.1. [Q9BVV6-1]
DR   RefSeq; NP_001231120.1; NM_001244191.1.
DR   RefSeq; NP_001231121.1; NM_001244192.1. [Q9BVV6-4]
DR   RefSeq; NP_001231122.1; NM_001244193.1.
DR   RefSeq; NP_055564.3; NM_014749.4. [Q9BVV6-2]
DR   SMR; Q9BVV6; -.
DR   BioGRID; 115130; 23.
DR   IntAct; Q9BVV6; 15.
DR   MINT; Q9BVV6; -.
DR   STRING; 9606.ENSP00000346359; -.
DR   iPTMnet; Q9BVV6; -.
DR   PhosphoSitePlus; Q9BVV6; -.
DR   BioMuta; KIAA0586; -.
DR   DMDM; 327478601; -.
DR   jPOST; Q9BVV6; -.
DR   MassIVE; Q9BVV6; -.
DR   MaxQB; Q9BVV6; -.
DR   PeptideAtlas; Q9BVV6; -.
DR   PRIDE; Q9BVV6; -.
DR   ProteomicsDB; 18876; -.
DR   ProteomicsDB; 79236; -. [Q9BVV6-1]
DR   ProteomicsDB; 79237; -. [Q9BVV6-2]
DR   Antibodypedia; 21; 14 antibodies from 11 providers.
DR   DNASU; 9786; -.
DR   Ensembl; ENST00000261244; ENSP00000261244; ENSG00000100578. [Q9BVV6-2]
DR   Ensembl; ENST00000354386; ENSP00000346359; ENSG00000100578. [Q9BVV6-3]
DR   Ensembl; ENST00000423743; ENSP00000399427; ENSG00000100578. [Q9BVV6-4]
DR   Ensembl; ENST00000619416; ENSP00000478083; ENSG00000100578.
DR   GeneID; 9786; -.
DR   KEGG; hsa:9786; -.
DR   UCSC; uc001xdt.5; human. [Q9BVV6-1]
DR   CTD; 9786; -.
DR   DisGeNET; 9786; -.
DR   GeneCards; KIAA0586; -.
DR   GeneReviews; KIAA0586; -.
DR   HGNC; HGNC:19960; KIAA0586.
DR   HPA; ENSG00000100578; Low tissue specificity.
DR   MalaCards; KIAA0586; -.
DR   MIM; 610178; gene.
DR   MIM; 616490; phenotype.
DR   MIM; 616546; phenotype.
DR   neXtProt; NX_Q9BVV6; -.
DR   OpenTargets; ENSG00000100578; -.
DR   Orphanet; 475; Joubert syndrome.
DR   Orphanet; 397715; Joubert syndrome with Jeune asphyxiating thoracic dystrophy.
DR   PharmGKB; PA134992213; -.
DR   VEuPathDB; HostDB:ENSG00000100578; -.
DR   eggNOG; ENOG502QUXJ; Eukaryota.
DR   GeneTree; ENSGT00390000012397; -.
DR   InParanoid; Q9BVV6; -.
DR   OrthoDB; 66287at2759; -.
DR   PhylomeDB; Q9BVV6; -.
DR   TreeFam; TF332939; -.
DR   PathwayCommons; Q9BVV6; -.
DR   SignaLink; Q9BVV6; -.
DR   BioGRID-ORCS; 9786; 10 hits in 1051 CRISPR screens.
DR   ChiTaRS; KIAA0586; human.
DR   GenomeRNAi; 9786; -.
DR   Pharos; Q9BVV6; Tbio.
DR   PRO; PR:Q9BVV6; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9BVV6; protein.
DR   Bgee; ENSG00000100578; Expressed in testis and 206 other tissues.
DR   ExpressionAtlas; Q9BVV6; baseline and differential.
DR   Genevisible; Q9BVV6; HS.
DR   GO; GO:0005814; C:centriole; IBA:GO_Central.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:UniProtKB-SubCell.
DR   GO; GO:0060271; P:cilium assembly; IMP:MGI.
DR   GO; GO:0070201; P:regulation of establishment of protein localization; IMP:MGI.
DR   GO; GO:0007224; P:smoothened signaling pathway; ISS:UniProtKB.
DR   InterPro; IPR029246; TALPID3.
DR   PANTHER; PTHR15721; PTHR15721; 1.
DR   Pfam; PF15324; TALPID3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell projection; Ciliopathy;
KW   Cilium biogenesis/degradation; Coiled coil; Cytoplasm; Cytoskeleton;
KW   Disease variant; Joubert syndrome; Phosphoprotein; Reference proteome.
FT   CHAIN           1..1533
FT                   /note="Protein TALPID3"
FT                   /id="PRO_0000050766"
FT   REGION          32..57
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          309..339
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          377..400
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          467..554
FT                   /note="Required for centrosomal localization"
FT                   /evidence="ECO:0000250"
FT   REGION          546..575
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1129..1156
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          182..223
FT                   /evidence="ECO:0000255"
FT   COILED          467..501
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        38..57
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        377..399
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        546..563
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1042
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:E9PV87"
FT   MOD_RES         1046
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:E9PV87"
FT   MOD_RES         1050
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9PV87"
FT   MOD_RES         1063
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:E9PV87"
FT   MOD_RES         1066
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:E9PV87"
FT   VAR_SEQ         1..70
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_046387"
FT   VAR_SEQ         1
FT                   /note="M -> MKGSEVSLEKKKKIKM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040642"
FT   VAR_SEQ         1
FT                   /note="M -> MFWCGTCFVTNNMKGSEVSLEKKKKIKM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046005"
FT   VAR_SEQ         122
FT                   /note="K -> NVSLCLTGWSDHSGVITTHCSLYLLRLMRSSHLSLPSSWDYR (in
FT                   isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.1"
FT                   /id="VSP_046006"
FT   VAR_SEQ         538..613
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_040643"
FT   VAR_SEQ         1485..1532
FT                   /note="GKAVPLSASQMPPAKMSVMLPSVNLEDCSQSLSLSTMQEDMESSGADT ->
FT                   LGVHVKKVSCIGKLGLWRFVIQIISSPRWESSATLRFTDAPCQDVSDAAVSEPRGLLSV
FT                   SESQHNAGGHGVFGGRYLLNGKRQPAQCLCHW (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046007"
FT   VARIANT         403
FT                   /note="R -> K (in JBTS23; unknown pathological
FT                   significance; dbSNP:rs772739103)"
FT                   /evidence="ECO:0000269|PubMed:26429889"
FT                   /id="VAR_076328"
FT   VARIANT         566
FT                   /note="D -> V (in JBTS23)"
FT                   /evidence="ECO:0000269|PubMed:26096313"
FT                   /id="VAR_074596"
FT   VARIANT         828
FT                   /note="L -> P (in dbSNP:rs1748986)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:9628581,
FT                   ECO:0000269|Ref.1, ECO:0000269|Ref.5"
FT                   /id="VAR_069108"
FT   CONFLICT        1041
FT                   /note="P -> A (in Ref. 2; BAA25512, 3; BAG64028, 5;
FT                   EAW80740 and 6; AAH66647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q9BVV6-3:1568
FT                   /note="L -> P (in Ref. 3; BAG64028)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1533 AA;  169307 MW;  031F5F28D63FD612 CRC64;
     MPVKRLREVV SQNHGDHLVL LKDELPCVPP ALSANKRLPV GTGTSLNGTS RGSSDLTSAR
     NCYQPLLENP MVSESDFSKD VAVQVLPLDK IEENNKQKAN DIFISQYTMG QKDALRTVLK
     QKAQSMPVFK EVKVHLLEDA GIEKDAVTQE TRISPSGIDS ATTVAAATAA AIATAAPLIK
     VQSDLEAKVN SVTELLSKLQ ETDKHLQRVT EQQTSIQRKQ EKLHCHDHEK QMNVFMEQHI
     RHLEKLQQQQ IDIQTHFISA ALKTSSFQPV SMPSSRAVEK YSVKPEHPNL GSCNPSLYNT
     FASKQAPLKE VEDTSFDKQK SPLETPAPRR FAPVPVSRDD ELSKRENLLE EKENMEVSCH
     RGNVRLLEQI LNNNDSLTRK SESSNTTSLT RSKIGWTPEK TNRFPSCEEL ETTKVTMQKS
     DDVLHDLGQK EKETNSMVQP KESLSMLKLP DLPQNSVKLQ TTNTTRSVLK DAEKILRGVQ
     NNKKVLEENL EAIIRAKDGA AMYSLINALS TNREMSEKIR IRKTVDEWIK TISAEIQDEL
     SRTDYEQKRF DQKNQRTKKG QNMTKDIRTN TQDKTVNKSV IPRKHSQKQI EEHFRNLPMR
     GMPASSLQKE RKEGLLKATT VIQDEDYMLQ VYGKPVYQGH RSTLKKGPYL RFNSPSPKSR
     PQRPKVIERV KGTKVKSIRT QTDFYATKPK KMDSKMKHSV PVLPHGDQQY LFSPSREMPT
     FSGTLEGHLI PMAILLGQTQ SNSDTMPPAG VIVSKPHPVT VTTSIPPSSR KVETGVKKPN
     IAIVEMKSEK KDPPQLTVQV LPSVDIDSIS NSSADVLSPL SSPKEASLPP VQTWIKTPEI
     MKVDEEEVKF PGTNFDEIID VIQEEEKCDE IPDSEPILEF NRSVKADSTK YNGPPFPPVA
     STFQPTADIL DKVIERKETL ENSLIQWVEQ EIMSRIISGL FPVQQQIAPS ISVSVSETSE
     PLTSDIVEGT SSGALQLFVD AGVPVNSNVI KHFVNEALAE TIAVMLGDRE AKKQGPVATG
     VSGDASTNET YLPARVCTPL PTPQPTPPCS PSSPAKECVL VKTPDSSPCD SDHDMAFPVK
     EICAEKGDDM PAIMLVNTPT VTPTTTPPPA AAVFTPTLSD ISIDKLKVSS PELPKPWGDG
     DLPLEEENPN SPQEELHPRA IVMSVAKDEE PESMDFPAQP PPPEPVPFMP FPAGTKAPSP
     SQMPGSDSST LESTLSVTVT ETETLDKPIS EGEILFSCGQ KLAPKILEDI GLYLTNLNDS
     LSSTLHDAVE MEDDPPSEGQ VIRMSHKKFH ADAILSFAKQ NQESAVSQQA VYHSEDLENS
     VGELSEGQRP QLTAAAENIL MGHSLYMQPP VTNTQSLDQQ CDPKPLSRQF DTVSGSIYED
     SCASHGPMSL GELELEPNSK LVLPTTLLTA QENDVNLPVA AEDFSQYQLK QNQDVKQVEH
     KPSQSYLRVR NKSDIAPSQQ QVSPGDMDRT QIELNPYLTC VFSGGKAVPL SASQMPPAKM
     SVMLPSVNLE DCSQSLSLST MQEDMESSGA DTF
//
ID   FAKD2_HUMAN             Reviewed;         710 AA.
AC   Q9NYY8; Q9NVX6; Q9Y2H7;
DT   07-FEB-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 158.
DE   RecName: Full=FAST kinase domain-containing protein 2, mitochondrial;
DE   Flags: Precursor;
GN   Name=FASTKD2 {ECO:0000303|PubMed:27667664, ECO:0000312|HGNC:HGNC:29160};
GN   Synonyms=KIAA0971;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adrenal gland;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 442-710 (ISOFORM 1).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN COXPD44, AND VARIANT COXPD44
RP   432-ARG--GLN-710 DEL.
RX   PubMed=18771761; DOI=10.1016/j.ajhg.2008.08.009;
RA   Ghezzi D., Saada A., D'Adamo P., Fernandez-Vizarra E., Gasparini P.,
RA   Tiranti V., Elpeleg O., Zeviani M.;
RT   "FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy
RT   associated with cytochrome c oxidase deficiency.";
RL   Am. J. Hum. Genet. 83:415-423(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=20869947; DOI=10.1016/j.bbrc.2010.09.075;
RA   Simarro M., Gimenez-Cassina A., Kedersha N., Lazaro J.B., Adelmant G.O.,
RA   Marto J.A., Rhee K., Tisdale S., Danial N., Benarafa C., Orduna A.,
RA   Anderson P.;
RT   "Fast kinase domain-containing protein 3 is a mitochondrial protein
RT   essential for cellular respiration.";
RL   Biochem. Biophys. Res. Commun. 401:440-446(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126 AND SER-140, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-708, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH GRSF1; DDX28; DHX30 AND FASTKD5,
RP   SUBCELLULAR LOCATION, RNA-BINDING, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25683715; DOI=10.1016/j.celrep.2015.01.030;
RA   Antonicka H., Shoubridge E.A.;
RT   "Mitochondrial RNA granules are centers for post-transcriptional RNA
RT   processing and ribosome biogenesis.";
RL   Cell Rep. 10:920-932(2015).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   FUNCTION.
RX   PubMed=26370583; DOI=10.1261/rna.052365.115;
RA   Popow J., Alleaume A.-M., Curk T., Schwarzl T., Sauer S., Hentze M.W.;
RT   "FASTKD2 is an RNA-binding protein required for mitochondrial RNA
RT   processing and translation.";
RL   RNA 21:1873-1884(2015).
RN   [16]
RP   SUBUNIT, AND FUNCTION.
RX   PubMed=27667664; DOI=10.1016/j.cmet.2016.08.017;
RA   Arroyo J.D., Jourdain A.A., Calvo S.E., Ballarano C.A., Doench J.G.,
RA   Root D.E., Mootha V.K.;
RT   "A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative
RT   Phosphorylation.";
RL   Cell Metab. 24:875-885(2016).
RN   [17]
RP   VARIANTS COXPD44 205-ARG--GLN-710 DEL AND PRO-255.
RX   PubMed=28499982; DOI=10.1016/j.mito.2017.05.005;
RA   Yoo D.H., Choi Y.C., Nam D.E., Choi S.S., Kim J.W., Choi B.O., Chung K.W.;
RT   "Identification of FASTKD2 compound heterozygous mutations as the
RT   underlying cause of autosomal recessive MELAS-like syndrome.";
RL   Mitochondrion 35:54-58(2017).
RN   [18]
RP   VARIANT COXPD44 290-ARG--GLN-710 DEL, AND CHARACTERIZATION OF VARIANT
RP   COXPD44 290-ARG--GLN-710 DEL.
RX   PubMed=31944455; DOI=10.1002/humu.23985;
RA   Wei X., Du M., Li D., Wen S., Xie J., Li Y., Chen A., Zhang K., Xu P.,
RA   Jia M., Wen C., Zhou H., Lyu J., Yang Y., Fang H.;
RT   "Mutations in FASTKD2 are associated with mitochondrial disease with multi-
RT   OXPHOS deficiency.";
RL   Hum. Mutat. 41:961-972(2020).
CC   -!- FUNCTION: Plays an important role in assembly of the mitochondrial
CC       large ribosomal subunit (PubMed:25683715). As a component of a
CC       functional protein-RNA module, consisting of RCC1L, NGRN, RPUSD3,
CC       RPUSD4, TRUB2, FASTKD2 and 16S mitochondrial ribosomal RNA (16S mt-
CC       rRNA), controls 16S mt-rRNA abundance and is required for intra-
CC       mitochondrial translation (PubMed:27667664, PubMed:25683715,
CC       PubMed:26370583). May play a role in mitochondrial apoptosis.
CC       {ECO:0000269|PubMed:18771761, ECO:0000269|PubMed:25683715,
CC       ECO:0000269|PubMed:26370583, ECO:0000269|PubMed:27667664}.
CC   -!- SUBUNIT: Monomer. Found in a complex with GRSF1, DDX28, DHX30 and
CC       FASTKD5. Associates with the 16S mitochondrial rRNA (16S mt-rRNA)
CC       (PubMed:25683715). Forms a regulatory protein-RNA complex, consisting
CC       of RCC1L, NGRN, RPUSD3, RPUSD4, TRUB2, FASTKD2 and 16S mt-rRNA
CC       (PubMed:27667664). {ECO:0000269|PubMed:25683715,
CC       ECO:0000269|PubMed:27667664}.
CC   -!- INTERACTION:
CC       Q9NYY8; P13473-2: LAMP2; NbExp=3; IntAct=EBI-1055752, EBI-21591415;
CC       Q9NYY8; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-1055752, EBI-2623095;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix, mitochondrion nucleoid
CC       {ECO:0000269|PubMed:20869947, ECO:0000269|PubMed:25683715}.
CC       Mitochondrion matrix {ECO:0000305|PubMed:18771761}. Note=Localizes to
CC       mitochondrial RNA granules found in close proximity to the
CC       mitochondrial nucleoids. {ECO:0000269|PubMed:25683715}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NYY8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYY8-2; Sequence=VSP_017186, VSP_017187;
CC   -!- TISSUE SPECIFICITY: Expression detected in spleen, thymus, testis,
CC       ovary, colon, heart, smooth muscle, kidney, brain, lung, liver and
CC       white adipose tissue with highest expression in heart, smooth muscle
CC       and thyroid. {ECO:0000269|PubMed:20869947}.
CC   -!- DISEASE: Combined oxidative phosphorylation deficiency 44 (COXPD44)
CC       [MIM:618855]: An autosomal recessive mitochondrial disorder
CC       characterized by onset in infancy or early childhood of global
CC       developmental delay, hypotonia, and abnormal movements. Combined
CC       oxidative phosphorylation deficiency is present in skeletal muscle.
CC       Most patients have seizures associated with status epilepticus.
CC       Additional variable features include optic atrophy, hypertrophic
CC       cardiomyopathy, stroke-like episodes, and increased lactate levels in
CC       serum and cerebrospinal fluid. {ECO:0000269|PubMed:18771761,
CC       ECO:0000269|PubMed:28499982, ECO:0000269|PubMed:31944455}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the FAST kinase family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-17 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76815.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA91617.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB023188; BAA76815.2; ALT_INIT; mRNA.
DR   EMBL; AF223470; AAF64145.1; -; mRNA.
DR   EMBL; AL833877; CAD38734.1; -; mRNA.
DR   EMBL; AC008269; AAX93275.1; -; Genomic_DNA.
DR   EMBL; BC001544; AAH01544.1; -; mRNA.
DR   EMBL; AK001315; BAA91617.1; ALT_INIT; mRNA.
DR   CCDS; CCDS2371.1; -. [Q9NYY8-1]
DR   RefSeq; NP_001129665.1; NM_001136193.1. [Q9NYY8-1]
DR   RefSeq; NP_001129666.1; NM_001136194.1. [Q9NYY8-1]
DR   RefSeq; NP_055744.2; NM_014929.3. [Q9NYY8-1]
DR   BioGRID; 116535; 246.
DR   CORUM; Q9NYY8; -.
DR   IntAct; Q9NYY8; 32.
DR   MINT; Q9NYY8; -.
DR   STRING; 9606.ENSP00000236980; -.
DR   iPTMnet; Q9NYY8; -.
DR   MetOSite; Q9NYY8; -.
DR   PhosphoSitePlus; Q9NYY8; -.
DR   BioMuta; FASTKD2; -.
DR   DMDM; 74734717; -.
DR   EPD; Q9NYY8; -.
DR   jPOST; Q9NYY8; -.
DR   MassIVE; Q9NYY8; -.
DR   MaxQB; Q9NYY8; -.
DR   PaxDb; Q9NYY8; -.
DR   PeptideAtlas; Q9NYY8; -.
DR   PRIDE; Q9NYY8; -.
DR   ProteomicsDB; 83300; -. [Q9NYY8-1]
DR   ProteomicsDB; 83301; -. [Q9NYY8-2]
DR   Antibodypedia; 34183; 232 antibodies from 25 providers.
DR   DNASU; 22868; -.
DR   Ensembl; ENST00000236980; ENSP00000236980; ENSG00000118246.
DR   Ensembl; ENST00000402774; ENSP00000385990; ENSG00000118246.
DR   Ensembl; ENST00000403094; ENSP00000384929; ENSG00000118246.
DR   GeneID; 22868; -.
DR   KEGG; hsa:22868; -.
DR   MANE-Select; ENST00000402774.8; ENSP00000385990.3; NM_001136193.2; NP_001129665.1.
DR   UCSC; uc002vbu.4; human. [Q9NYY8-1]
DR   CTD; 22868; -.
DR   DisGeNET; 22868; -.
DR   GeneCards; FASTKD2; -.
DR   HGNC; HGNC:29160; FASTKD2.
DR   HPA; ENSG00000118246; Low tissue specificity.
DR   MalaCards; FASTKD2; -.
DR   MIM; 612322; gene.
DR   MIM; 618855; phenotype.
DR   neXtProt; NX_Q9NYY8; -.
DR   OpenTargets; ENSG00000118246; -.
DR   Orphanet; 166105; FASTKD2-related infantile mitochondrial encephalomyopathy.
DR   PharmGKB; PA134974924; -.
DR   VEuPathDB; HostDB:ENSG00000118246; -.
DR   eggNOG; ENOG502QVSD; Eukaryota.
DR   GeneTree; ENSGT01030000234607; -.
DR   HOGENOM; CLU_025270_0_0_1; -.
DR   InParanoid; Q9NYY8; -.
DR   OMA; FDIWKLK; -.
DR   PhylomeDB; Q9NYY8; -.
DR   TreeFam; TF352875; -.
DR   BRENDA; 2.7.11.8; 2681.
DR   PathwayCommons; Q9NYY8; -.
DR   SignaLink; Q9NYY8; -.
DR   SIGNOR; Q9NYY8; -.
DR   BioGRID-ORCS; 22868; 12 hits in 1048 CRISPR screens.
DR   ChiTaRS; FASTKD2; human.
DR   GenomeRNAi; 22868; -.
DR   Pharos; Q9NYY8; Tbio.
DR   PRO; PR:Q9NYY8; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NYY8; protein.
DR   Bgee; ENSG00000118246; Expressed in heart and 221 other tissues.
DR   ExpressionAtlas; Q9NYY8; baseline and differential.
DR   Genevisible; Q9NYY8; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; IBA:GO_Central.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0035770; C:ribonucleoprotein granule; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0019843; F:rRNA binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:1902775; P:mitochondrial large ribosomal subunit assembly; IMP:UniProtKB.
DR   GO; GO:0000963; P:mitochondrial RNA processing; IBA:GO_Central.
DR   GO; GO:0032543; P:mitochondrial translation; IDA:UniProtKB.
DR   GO; GO:0070131; P:positive regulation of mitochondrial translation; IMP:UniProtKB.
DR   GO; GO:0044528; P:regulation of mitochondrial mRNA stability; IBA:GO_Central.
DR   GO; GO:0006396; P:RNA processing; IDA:UniProtKB.
DR   InterPro; IPR013579; FAST_2.
DR   InterPro; IPR010622; FAST_Leu-rich.
DR   InterPro; IPR013584; RAP.
DR   Pfam; PF06743; FAST_1; 1.
DR   Pfam; PF08368; FAST_2; 1.
DR   Pfam; PF08373; RAP; 1.
DR   SMART; SM00952; RAP; 1.
DR   PROSITE; PS51286; RAP; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disease variant; Mitochondrion;
KW   Mitochondrion nucleoid; Phosphoprotein; Primary mitochondrial disease;
KW   Reference proteome; Ribosome biogenesis; RNA-binding; rRNA-binding;
KW   Transit peptide.
FT   TRANSIT         1..?
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000305"
FT   CHAIN           ?..710
FT                   /note="FAST kinase domain-containing protein 2,
FT                   mitochondrial"
FT                   /id="PRO_0000050783"
FT   DOMAIN          634..691
FT                   /note="RAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00619"
FT   MOD_RES         126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         708
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         634..648
FT                   /note="VAVLCVSRSAYCLGS -> LLTYISFAGLSELKS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10231032"
FT                   /id="VSP_017186"
FT   VAR_SEQ         649..710
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10231032"
FT                   /id="VSP_017187"
FT   VARIANT         15
FT                   /note="S -> N (in dbSNP:rs3762568)"
FT                   /id="VAR_053889"
FT   VARIANT         205..710
FT                   /note="Missing (in COXPD44)"
FT                   /evidence="ECO:0000269|PubMed:28499982"
FT                   /id="VAR_084340"
FT   VARIANT         255
FT                   /note="L -> P (in COXPD44; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28499982"
FT                   /id="VAR_084341"
FT   VARIANT         290..710
FT                   /note="Missing (in COXPD44; decreased mitochondrial large
FT                   ribosomal subunit assembly)"
FT                   /evidence="ECO:0000269|PubMed:31944455"
FT                   /id="VAR_084342"
FT   VARIANT         432..710
FT                   /note="Missing (in COXPD44)"
FT                   /evidence="ECO:0000269|PubMed:18771761"
FT                   /id="VAR_084343"
FT   VARIANT         445
FT                   /note="V -> E (in dbSNP:rs13003768)"
FT                   /id="VAR_053890"
SQ   SEQUENCE   710 AA;  81463 MW;  11BF1D5A0CF1DA15 CRC64;
     MLTTLKPFGS VSVESKMNNK AGSFFWNLRQ FSTLVSTSRT MRLCCLGLCK PKIVHSNWNI
     LNNFHNRMQS TDIIRYLFQD AFIFKSDVGF QTKGISTLTA LRIERLLYAK RLFFDSKQSL
     VPVDKSDDEL KKVNLNHEVS NEDVLTKETK PNRISSRKLS EECNSLSDVL DAFSKAPTFP
     SSNYFTAMWT IAKRLSDDQK RFEKRLMFSH PAFNQLCEHM MREAKIMQYK YLLFSLHAIV
     KLGIPQNTIL VQTLLRVTQE RINECDEICL SVLSTVLEAM EPCKNVHVLR TGFRILVDQQ
     VWKIEDVFTL QVVMKCIGKD APIALKRKLE MKALRELDRF SVLNSQHMFE VLAAMNHRSL
     ILLDECSKVV LDNIHGCPLR IMINILQSCK DLQYHNLDLF KGLADYVAAT FDIWKFRKVL
     FILILFENLG FRPVGLMDLF MKRIVEDPES LNMKNILSIL HTYSSLNHVY KCQNKEQFVE
     VMASALTGYL HTISSENLLD AVYSFCLMNY FPLAPFNQLL QKDIISELLT SDDMKNAYKL
     HTLDTCLKLD DTVYLRDIAL SLPQLPRELP SSHTNAKVAE VLSSLLGGEG HFSKDVHLPH
     NYHIDFEIRM DTNRNQVLPL SDVDTTSATD IQRVAVLCVS RSAYCLGSSH PRGFLAMKMR
     HLNAMGFHVI LVNNWEMDKL EMEDAVTFLK TKIYSVEALP VAAVNVQSTQ
//
ID   RRP44_HUMAN             Reviewed;         958 AA.
AC   Q9Y2L1; A6NI21; B2RBL2; Q5W0P7; Q5W0P8; Q658Z7; Q7Z481; Q8WWI2; Q9UG36;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   16-AUG-2005, sequence version 2.
DT   23-FEB-2022, entry version 211.
DE   RecName: Full=Exosome complex exonuclease RRP44;
DE            EC=3.1.13.-;
DE            EC=3.1.26.-;
DE   AltName: Full=Protein DIS3 homolog;
DE   AltName: Full=Ribosomal RNA-processing protein 44;
GN   Name=DIS3; Synonyms=KIAA1008, RRP44;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=9562621; DOI=10.1093/oxfordjournals.jbchem.a022020;
RA   Shiomi T., Fukushima K., Suzuki N., Nakashima N., Noguchi E., Nishimoto T.;
RT   "Human dis3p, which binds to either GTP- or GDP-Ran, complements
RT   Saccharomyces cerevisiae dis3.";
RL   J. Biochem. 123:883-890(1998).
RN   [2]
RP   ERRATUM OF PUBMED:9562621.
RA   Shiomi T., Fukushima K., Suzuki N., Nakashima N., Noguchi E., Nishimoto T.;
RL   J. Biochem. 124:250-250(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-269.
RC   TISSUE=Brain, and Peripheral blood leukocyte;
RX   PubMed=11935316; DOI=10.1007/s00439-001-0646-6;
RA   Rozenblum E., Vahteristo P., Sandberg T., Bergthorsson J.T., Syrjakoski K.,
RA   Weaver D., Haraldsson K., Johannsdottir H.K., Vehmanen P., Nigam S.,
RA   Golberger N., Robbins C., Pak E., Dutra A., Gillander E., Stephan D.A.,
RA   Bailey-Wilson J., Juo S.-H.H., Kainu T., Arason A., Barkardottir R.B.,
RA   Nevanlinna H., Borg A., Kallioniemi O.-P.;
RT   "A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer
RT   development: identification and characterization of candidate genes.";
RL   Hum. Genet. 110:111-121(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ARG-326.
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-269.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-269.
RC   TISSUE=Lymph node, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-326.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION IN PROMPT DEGRADATION.
RX   PubMed=19056938; DOI=10.1126/science.1164096;
RA   Preker P., Nielsen J., Kammler S., Lykke-Andersen S., Christensen M.S.,
RA   Mapendano C.K., Schierup M.H., Jensen T.H.;
RT   "RNA exosome depletion reveals transcription upstream of active human
RT   promoters.";
RL   Science 322:1851-1854(2008).
RN   [12]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-18, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   ASSOCIATION WITH THE RNA EXOSOME COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, FUNCTION, COFACTOR, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-146 AND ASP-487.
RX   PubMed=20531386; DOI=10.1038/emboj.2010.121;
RA   Tomecki R., Kristiansen M.S., Lykke-Andersen S., Chlebowski A.,
RA   Larsen K.M., Szczesny R.J., Drazkowska K., Pastula A., Andersen J.S.,
RA   Stepien P.P., Dziembowski A., Jensen T.H.;
RT   "The human core exosome interacts with differentially localized processive
RT   RNases: hDIS3 and hDIS3L.";
RL   EMBO J. 29:2342-2357(2010).
RN   [15]
RP   ASSOCIATION WITH THE RNA EXOSOME COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, SUBCELLULAR LOCATION, AND INTERACTION WITH EXOSC3.
RX   PubMed=20531389; DOI=10.1038/emboj.2010.122;
RA   Staals R.H., Bronkhorst A.W., Schilders G., Slomovic S., Schuster G.,
RA   Heck A.J., Raijmakers R., Pruijn G.J.;
RT   "Dis3-like 1: a novel exoribonuclease associated with the human exosome.";
RL   EMBO J. 29:2358-2367(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-215, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   INTERACTION WITH DHX34.
RX   PubMed=25220460; DOI=10.1016/j.celrep.2014.08.020;
RA   Hug N., Caceres J.F.;
RT   "The RNA helicase DHX34 activates NMD by promoting a transition from the
RT   surveillance to the decay-inducing complex.";
RL   Cell Rep. 8:1845-1856(2014).
RN   [20] {ECO:0007744|PDB:6D6Q, ECO:0007744|PDB:6D6R}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.45 ANGSTROMS), AND SUBUNIT.
RX   PubMed=29906447; DOI=10.1016/j.cell.2018.05.041;
RA   Weick E.M., Puno M.R., Januszyk K., Zinder J.C., DiMattia M.A., Lima C.D.;
RT   "Helicase-Dependent RNA Decay Illuminated by a Cryo-EM Structure of a Human
RT   Nuclear RNA Exosome-MTR4 Complex.";
RL   Cell 173:1663-1677.e21(2018).
CC   -!- FUNCTION: Putative catalytic component of the RNA exosome complex which
CC       has 3'->5' exoribonuclease activity and participates in a multitude of
CC       cellular RNA processing and degradation events. In the nucleus, the RNA
CC       exosome complex is involved in proper maturation of stable RNA species
CC       such as rRNA, snRNA and snoRNA, in the elimination of RNA processing
CC       by-products and non-coding 'pervasive' transcripts, such as antisense
CC       RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs
CC       with processing defects, thereby limiting or excluding their export to
CC       the cytoplasm. The RNA exosome may be involved in Ig class switch
CC       recombination (CSR) and/or Ig variable region somatic hypermutation
CC       (SHM) by targeting AICDA deamination activity to transcribed dsDNA
CC       substrates. In the cytoplasm, the RNA exosome complex is involved in
CC       general mRNA turnover and specifically degrades inherently unstable
CC       mRNAs containing AU-rich elements (AREs) within their 3' untranslated
CC       regions, and in RNA surveillance pathways, preventing translation of
CC       aberrant mRNAs. It seems to be involved in degradation of histone mRNA.
CC       DIS3 has both 3'-5' exonuclease and endonuclease activities.
CC       {ECO:0000269|PubMed:19056938, ECO:0000269|PubMed:20531386}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:20531386};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:20531386};
CC   -!- SUBUNIT: Component of the RNA exosome complex (PubMed:29906447). The
CC       catalytically inactive RNA exosome core (Exo-9) complex is believed to
CC       associate with catalytic subunits EXOSC10, and DIS3 or DIS3L in
CC       cytoplasmic- and nuclear-specific RNA exosome complex forms
CC       (PubMed:29906447). Interacts with DHX34; the interaction is RNA-
CC       independent (PubMed:25220460). {ECO:0000269|PubMed:25220460,
CC       ECO:0000269|PubMed:29906447}.
CC   -!- INTERACTION:
CC       Q9Y2L1; Q01780: EXOSC10; NbExp=4; IntAct=EBI-373539, EBI-358236;
CC       Q9Y2L1; Q9NQT5: EXOSC3; NbExp=3; IntAct=EBI-373539, EBI-371866;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20531386}. Nucleus,
CC       nucleolus {ECO:0000269|PubMed:12429849}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:20531389}. Nucleus {ECO:0000269|PubMed:20531386}.
CC       Note=Predominantly located in the nucleus (PubMed:20531386). According
CC       to PubMed:12429849, found in the nucleolus (PubMed:12429849). According
CC       to PubMed:20531386, excluded from nucleolus supporting the existence of
CC       a nucleolar RNA exosome complex devoid of DIS3 (PubMed:20531386).
CC       {ECO:0000269|PubMed:12429849, ECO:0000269|PubMed:20531386}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y2L1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y2L1-2; Sequence=VSP_014971;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- MISCELLANEOUS: The association of DIS3 with the RNA exosome complex
CC       appears to be weak explaining its absence in some complex
CC       purifications.
CC   -!- SIMILARITY: Belongs to the RNR ribonuclease family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA76852.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF330044; AAL37479.1; -; mRNA.
DR   EMBL; AB023225; BAA76852.2; ALT_INIT; mRNA.
DR   EMBL; AL832266; CAH56266.1; -; mRNA.
DR   EMBL; AK314715; BAG37259.1; -; mRNA.
DR   EMBL; AL080158; CAB45749.1; -; mRNA.
DR   EMBL; AL138695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391384; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471093; EAW80517.1; -; Genomic_DNA.
DR   EMBL; BC056143; AAH56143.1; -; mRNA.
DR   CCDS; CCDS45057.1; -. [Q9Y2L1-2]
DR   CCDS; CCDS9447.1; -. [Q9Y2L1-1]
DR   PIR; JE0110; JE0110.
DR   RefSeq; NP_001121698.1; NM_001128226.2. [Q9Y2L1-2]
DR   RefSeq; NP_055768.3; NM_014953.4. [Q9Y2L1-1]
DR   PDB; 6D6Q; EM; 3.45 A; K=1-958.
DR   PDB; 6D6R; EM; 3.45 A; K=1-958.
DR   PDB; 6H25; EM; 3.80 A; J=1-958.
DR   PDBsum; 6D6Q; -.
DR   PDBsum; 6D6R; -.
DR   PDBsum; 6H25; -.
DR   SMR; Q9Y2L1; -.
DR   BioGRID; 116559; 141.
DR   ComplexPortal; CPX-476; Nuclear exosome complex, DIS3-EXOSC10 variant.
DR   ComplexPortal; CPX-593; Exosome complex, DIS3 variant.
DR   CORUM; Q9Y2L1; -.
DR   IntAct; Q9Y2L1; 49.
DR   MINT; Q9Y2L1; -.
DR   STRING; 9606.ENSP00000366997; -.
DR   GlyGen; Q9Y2L1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Y2L1; -.
DR   MetOSite; Q9Y2L1; -.
DR   PhosphoSitePlus; Q9Y2L1; -.
DR   SwissPalm; Q9Y2L1; -.
DR   BioMuta; DIS3; -.
DR   DMDM; 73620993; -.
DR   SWISS-2DPAGE; Q9Y2L1; -.
DR   EPD; Q9Y2L1; -.
DR   jPOST; Q9Y2L1; -.
DR   MassIVE; Q9Y2L1; -.
DR   MaxQB; Q9Y2L1; -.
DR   PaxDb; Q9Y2L1; -.
DR   PeptideAtlas; Q9Y2L1; -.
DR   PRIDE; Q9Y2L1; -.
DR   ProteomicsDB; 85832; -. [Q9Y2L1-1]
DR   ProteomicsDB; 85833; -. [Q9Y2L1-2]
DR   Antibodypedia; 24401; 219 antibodies from 30 providers.
DR   DNASU; 22894; -.
DR   Ensembl; ENST00000377767; ENSP00000366997; ENSG00000083520.
DR   Ensembl; ENST00000377780; ENSP00000367011; ENSG00000083520. [Q9Y2L1-2]
DR   GeneID; 22894; -.
DR   KEGG; hsa:22894; -.
DR   MANE-Select; ENST00000377767.9; ENSP00000366997.4; NM_014953.5; NP_055768.3.
DR   UCSC; uc001vix.6; human. [Q9Y2L1-1]
DR   CTD; 22894; -.
DR   DisGeNET; 22894; -.
DR   GeneCards; DIS3; -.
DR   HGNC; HGNC:20604; DIS3.
DR   HPA; ENSG00000083520; Low tissue specificity.
DR   MIM; 607533; gene.
DR   neXtProt; NX_Q9Y2L1; -.
DR   OpenTargets; ENSG00000083520; -.
DR   PharmGKB; PA162383628; -.
DR   VEuPathDB; HostDB:ENSG00000083520; -.
DR   eggNOG; KOG2102; Eukaryota.
DR   GeneTree; ENSGT00530000063106; -.
DR   InParanoid; Q9Y2L1; -.
DR   OMA; VQYKPFP; -.
DR   OrthoDB; 1104619at2759; -.
DR   PhylomeDB; Q9Y2L1; -.
DR   TreeFam; TF105755; -.
DR   PathwayCommons; Q9Y2L1; -.
DR   Reactome; R-HSA-380994; ATF4 activates genes in response to endoplasmic reticulum stress.
DR   Reactome; R-HSA-429958; mRNA decay by 3' to 5' exoribonuclease.
DR   Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA.
DR   Reactome; R-HSA-450513; Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA.
DR   Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; Q9Y2L1; -.
DR   BioGRID-ORCS; 22894; 562 hits in 1057 CRISPR screens.
DR   ChiTaRS; DIS3; human.
DR   GeneWiki; DIS3; -.
DR   GenomeRNAi; 22894; -.
DR   Pharos; Q9Y2L1; Tbio.
DR   PRO; PR:Q9Y2L1; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q9Y2L1; protein.
DR   Bgee; ENSG00000083520; Expressed in calcaneal tendon and 224 other tissues.
DR   ExpressionAtlas; Q9Y2L1; baseline and differential.
DR   Genevisible; Q9Y2L1; HS.
DR   GO; GO:0000177; C:cytoplasmic exosome (RNase complex); IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000178; C:exosome (RNase complex); IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0000176; C:nuclear exosome (RNase complex); IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:ComplexPortal.
DR   GO; GO:0000175; F:3'-5'-exoribonuclease activity; IMP:UniProtKB.
DR   GO; GO:0004519; F:endonuclease activity; IMP:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0071034; P:CUT catabolic process; IMP:UniProtKB.
DR   GO; GO:0043928; P:exonucleolytic catabolism of deadenylated mRNA; TAS:Reactome.
DR   GO; GO:0006401; P:RNA catabolic process; IDA:ComplexPortal.
DR   GO; GO:0006396; P:RNA processing; IDA:ComplexPortal.
DR   GO; GO:0016075; P:rRNA catabolic process; IMP:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; TAS:UniProtKB.
DR   InterPro; IPR041505; Dis3_CSD2.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR029060; PIN-like_dom_sf.
DR   InterPro; IPR002716; PIN_dom.
DR   InterPro; IPR001900; RNase_II/R.
DR   InterPro; IPR022966; RNase_II/R_CS.
DR   InterPro; IPR033771; Rrp44_CSD1.
DR   InterPro; IPR033770; RRP44_S1.
DR   Pfam; PF17849; OB_Dis3; 1.
DR   Pfam; PF13638; PIN_4; 1.
DR   Pfam; PF00773; RNB; 1.
DR   Pfam; PF17216; Rrp44_CSD1; 1.
DR   Pfam; PF17215; Rrp44_S1; 1.
DR   SMART; SM00670; PINc; 1.
DR   SMART; SM00955; RNB; 1.
DR   SUPFAM; SSF50249; SSF50249; 3.
DR   SUPFAM; SSF88723; SSF88723; 1.
DR   PROSITE; PS01175; RIBONUCLEASE_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm; Endonuclease;
KW   Exonuclease; Exosome; Hydrolase; Magnesium; Manganese; Nuclease; Nucleus;
KW   Phosphoprotein; Reference proteome; RNA-binding; rRNA processing.
FT   CHAIN           1..958
FT                   /note="Exosome complex exonuclease RRP44"
FT                   /id="PRO_0000166419"
FT   DOMAIN          64..182
FT                   /note="PINc"
FT   REGION          938..958
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         18
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         215
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         78..129
FT                   /note="DVLEDPAIRNVIVLQTVLQEVRNRSAPVYKRIRDVTNNQEKHFYTFTNEHHR
FT                   -> VSAWRPGTWASVASSLRLPGSL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10231032"
FT                   /id="VSP_014971"
FT   VARIANT         269
FT                   /note="N -> S (in dbSNP:rs4883918)"
FT                   /evidence="ECO:0000269|PubMed:11935316,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17974005"
FT                   /id="VAR_023099"
FT   VARIANT         326
FT                   /note="T -> R (in dbSNP:rs7332388)"
FT                   /evidence="ECO:0000269|PubMed:10231032,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_023100"
FT   MUTAGEN         146
FT                   /note="D->N: Loss of endonuclease activity; when associated
FT                   with N-487."
FT                   /evidence="ECO:0000269|PubMed:20531386"
FT   MUTAGEN         487
FT                   /note="D->N: Loss of exonuclease activity. Loss of
FT                   endonuclease activity; when associated with N-146."
FT                   /evidence="ECO:0000269|PubMed:20531386"
FT   CONFLICT        635
FT                   /note="P -> S (in Ref. 7; CAH56266)"
FT                   /evidence="ECO:0000305"
FT   STRAND          2..10
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          12..14
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          16..24
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           70..75
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           77..81
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          87..90
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           93..101
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           103..113
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          116..122
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            129..131
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           141..163
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          166..168
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          173..177
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           178..186
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           194..200
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           206..209
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           234..243
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          247..252
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          261..265
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          274..277
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            280..282
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          291..296
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          342..350
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          356..361
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          371..377
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          383..385
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          391..393
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          396..404
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          413..422
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           426..436
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           446..451
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           463..465
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          466..469
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          489..494
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          500..506
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           509..511
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           518..525
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           542..546
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          555..566
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          574..585
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           590..598
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            604..606
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           607..626
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           658..681
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          683..685
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          688..691
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            696..699
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           700..708
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           718..725
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           737..745
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          752..754
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            756..758
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            765..767
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           783..795
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           802..804
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   HELIX           807..842
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          846..848
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          857..859
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          862..864
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   TURN            865..868
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          869..871
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          886..888
FT                   /evidence="ECO:0007829|PDB:6D6R"
FT   TURN            889..892
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          893..895
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          908..911
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          916..918
FT                   /evidence="ECO:0007829|PDB:6D6Q"
FT   STRAND          925..928
FT                   /evidence="ECO:0007829|PDB:6D6Q"
SQ   SEQUENCE   958 AA;  109003 MW;  92336BA0D06247FE CRC64;
     MLKSKTFLKK TRAGGVMKIV REHYLRDDIG CGAPGCAACG GAHEGPALEP QPQDPASSVC
     PQPHYLLPDT NVLLHQIDVL EDPAIRNVIV LQTVLQEVRN RSAPVYKRIR DVTNNQEKHF
     YTFTNEHHRE TYVEQEQGEN ANDRNDRAIR VAAKWYNEHL KKMSADNQLQ VIFITNDRRN
     KEKAIEEGIP AFTCEEYVKS LTANPELIDR LACLSEEGNE IESGKIIFSE HLPLSKLQQG
     IKSGTYLQGT FRASRENYLE ATVWIHGDNE ENKEIILQGL KHLNRAVHED IVAVELLPKS
     QWVAPSSVVL HDEGQNEEDV EKEEETERML KTAVSEKMLK PTGRVVGIIK RNWRPYCGML
     SKSDIKESRR HLFTPADKRI PRIRIETRQA STLEGRRIIV AIDGWPRNSR YPNGHFVRNL
     GDVGEKETET EVLLLEHDVP HQPFSQAVLS FLPKMPWSIT EKDMKNREDL RHLCICSVDP
     PGCTDIDDAL HCRELENGNL EVGVHIADVS HFIRPGNALD QESARRGTTV YLCEKRIDMV
     PELLSSNLCS LKCDVDRLAF SCIWEMNHNA EILKTKFTKS VINSKASLTY AEAQLRIDSA
     NMNDDITTSL RGLNKLAKIL KKRRIEKGAL TLSSPEVRFH MDSETHDPID LQTKELRETN
     SMVEEFMLLA NISVAKKIHE EFSEHALLRK HPAPPPSNYE ILVKAARSRN LEIKTDTAKS
     LAESLDQAES PTFPYLNTLL RILATRCMMQ AVYFCSGMDN DFHHYGLASP IYTHFTSPIR
     RYADVIVHRL LAVAIGADCT YPELTDKHKL ADICKNLNFR HKMAQYAQRA SVAFHTQLFF
     KSKGIVSEEA YILFVRKNAI VVLIPKYGLE GTVFFEEKDK PNPQLIYDDE IPSLKIEDTV
     FHVFDKVKVK IMLDSSNLQH QKIRMSLVEP QIPGISIPTD TSNMDLNGPK KKKMKLGK
//
ID   ZBT20_HUMAN             Reviewed;         741 AA.
AC   Q9HC78; Q63HP6; Q8N6R5; Q9Y410;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAR-2008, sequence version 3.
DT   23-FEB-2022, entry version 182.
DE   RecName: Full=Zinc finger and BTB domain-containing protein 20;
DE   AltName: Full=Dendritic-derived BTB/POZ zinc finger protein;
DE   AltName: Full=Zinc finger protein 288;
GN   Name=ZBTB20; Synonyms=DPZF, ZNF288;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11352661; DOI=10.1006/bbrc.2001.4689;
RA   Zhang W., Mi J., Li N., Sui L., Wan T., Zhang J., Chen T., Cao X.;
RT   "Identification and characterization of DPZF, a novel human BTB/POZ zinc
RT   finger protein sharing homology to BCL-6.";
RL   Biochem. Biophys. Res. Commun. 282:1067-1073(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-211 AND SER-353, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   INVOLVEMENT IN PRIMS, VARIANTS PRIMS GLN-590; ARG-596; ALA-602 AND PHE-621,
RP   AND CHARACTERIZATION OF VARIANTS PRIMS GLN-590; ARG-596; ALA-602 AND
RP   PHE-621.
RX   PubMed=25017102; DOI=10.1038/ng.3035;
RA   Cordeddu V., Redeker B., Stellacci E., Jongejan A., Fragale A.,
RA   Bradley T.E., Anselmi M., Ciolfi A., Cecchetti S., Muto V., Bernardini L.,
RA   Azage M., Carvalho D.R., Espay A.J., Male A., Molin A.M., Posmyk R.,
RA   Battisti C., Casertano A., Melis D., van Kampen A., Baas F., Mannens M.M.,
RA   Bocchinfuso G., Stella L., Tartaglia M., Hennekam R.C.;
RT   "Mutations in ZBTB20 cause Primrose syndrome.";
RL   Nat. Genet. 46:815-817(2014).
RN   [10]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-330, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-330, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [12]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-330, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [13]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-330, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-330; LYS-371 AND LYS-723, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: May be a transcription factor that may be involved in
CC       hematopoiesis, oncogenesis, and immune responses (PubMed:11352661).
CC       Plays a role in postnatal myogenesis, may be involved in the regulation
CC       of satellite cells self-renewal (By similarity).
CC       {ECO:0000250|UniProtKB:Q8K0L9, ECO:0000269|PubMed:11352661}.
CC   -!- SUBUNIT: Can homodimerize. Binds to DNA.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q8K0L9}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9HC78-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9HC78-2; Sequence=VSP_032503;
CC   -!- TISSUE SPECIFICITY: Expressed in spleen, lymph node, thymus, peripheral
CC       blood leukocytes, and fetal liver. {ECO:0000269|PubMed:11352661}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- DISEASE: Primrose syndrome (PRIMS) [MIM:259050]: A disease
CC       characterized by macrocephaly, intellectual disability, disturbed
CC       behavior, dysmorphic facial features, ectopic calcifications, large
CC       calcified ear auricles, and progressive muscle wasting.
CC       {ECO:0000269|PubMed:25017102}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF139460; AAG28340.2; -; mRNA.
DR   EMBL; AL050276; CAB43377.1; -; mRNA.
DR   EMBL; BX647778; CAH56190.1; -; mRNA.
DR   EMBL; CH471052; EAW79598.1; -; Genomic_DNA.
DR   EMBL; BC029041; AAH29041.1; -; mRNA.
DR   CCDS; CCDS2981.1; -. [Q9HC78-2]
DR   CCDS; CCDS54626.1; -. [Q9HC78-1]
DR   PIR; T08725; T08725.
DR   RefSeq; NP_001157814.1; NM_001164342.2. [Q9HC78-1]
DR   RefSeq; NP_001157815.1; NM_001164343.2. [Q9HC78-2]
DR   RefSeq; NP_001157816.1; NM_001164344.2. [Q9HC78-2]
DR   RefSeq; NP_001157817.1; NM_001164345.2. [Q9HC78-2]
DR   RefSeq; NP_001157818.1; NM_001164346.2. [Q9HC78-2]
DR   RefSeq; NP_001157819.1; NM_001164347.2. [Q9HC78-2]
DR   RefSeq; NP_001335729.1; NM_001348800.1. [Q9HC78-1]
DR   RefSeq; NP_001335731.1; NM_001348802.1. [Q9HC78-2]
DR   RefSeq; NP_001335732.1; NM_001348803.1. [Q9HC78-1]
DR   RefSeq; NP_001335733.1; NM_001348804.1. [Q9HC78-2]
DR   RefSeq; NP_001335734.1; NM_001348805.1. [Q9HC78-2]
DR   RefSeq; NP_056457.3; NM_015642.5. [Q9HC78-2]
DR   SMR; Q9HC78; -.
DR   BioGRID; 117573; 36.
DR   IntAct; Q9HC78; 15.
DR   STRING; 9606.ENSP00000419153; -.
DR   GlyGen; Q9HC78; 4 sites, 2 O-linked glycans (4 sites).
DR   iPTMnet; Q9HC78; -.
DR   PhosphoSitePlus; Q9HC78; -.
DR   BioMuta; ZBTB20; -.
DR   DMDM; 172045933; -.
DR   jPOST; Q9HC78; -.
DR   MassIVE; Q9HC78; -.
DR   MaxQB; Q9HC78; -.
DR   PaxDb; Q9HC78; -.
DR   PeptideAtlas; Q9HC78; -.
DR   PRIDE; Q9HC78; -.
DR   ProteomicsDB; 81647; -. [Q9HC78-1]
DR   ProteomicsDB; 81648; -. [Q9HC78-2]
DR   Antibodypedia; 16495; 160 antibodies from 25 providers.
DR   DNASU; 26137; -.
DR   Ensembl; ENST00000357258; ENSP00000349803; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000393785; ENSP00000377375; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000462705; ENSP00000420324; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000464560; ENSP00000417307; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000471418; ENSP00000419902; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000474710; ENSP00000419153; ENSG00000181722.
DR   Ensembl; ENST00000481632; ENSP00000418092; ENSG00000181722. [Q9HC78-2]
DR   Ensembl; ENST00000675478; ENSP00000501561; ENSG00000181722.
DR   Ensembl; ENST00000676079; ENSP00000502480; ENSG00000181722.
DR   GeneID; 26137; -.
DR   KEGG; hsa:26137; -.
DR   MANE-Select; ENST00000675478.1; ENSP00000501561.1; NM_001348800.3; NP_001335729.1.
DR   UCSC; uc003ebi.5; human. [Q9HC78-1]
DR   CTD; 26137; -.
DR   DisGeNET; 26137; -.
DR   GeneCards; ZBTB20; -.
DR   GeneReviews; ZBTB20; -.
DR   HGNC; HGNC:13503; ZBTB20.
DR   HPA; ENSG00000181722; Tissue enriched (brain).
DR   MalaCards; ZBTB20; -.
DR   MIM; 259050; phenotype.
DR   MIM; 606025; gene.
DR   neXtProt; NX_Q9HC78; -.
DR   OpenTargets; ENSG00000181722; -.
DR   Orphanet; 3042; Intellectual disability-cataracts-calcified pinnae-myopathy syndrome.
DR   PharmGKB; PA37789; -.
DR   VEuPathDB; HostDB:ENSG00000181722; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000158617; -.
DR   HOGENOM; CLU_019055_0_0_1; -.
DR   InParanoid; Q9HC78; -.
DR   OMA; EQQFMAG; -.
DR   OrthoDB; 1318335at2759; -.
DR   PhylomeDB; Q9HC78; -.
DR   TreeFam; TF335684; -.
DR   PathwayCommons; Q9HC78; -.
DR   SignaLink; Q9HC78; -.
DR   BioGRID-ORCS; 26137; 5 hits in 1099 CRISPR screens.
DR   ChiTaRS; ZBTB20; human.
DR   GeneWiki; ZBTB20; -.
DR   GenomeRNAi; 26137; -.
DR   Pharos; Q9HC78; Tbio.
DR   PRO; PR:Q9HC78; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9HC78; protein.
DR   Bgee; ENSG00000181722; Expressed in pituitary gland and 254 other tissues.
DR   ExpressionAtlas; Q9HC78; baseline and differential.
DR   Genevisible; Q9HC78; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0055088; P:lipid homeostasis; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   Gene3D; 3.30.710.10; -; 1.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF00096; zf-C2H2; 5.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00355; ZnF_C2H2; 5.
DR   SUPFAM; SSF54695; SSF54695; 1.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 5.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 5.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disease variant; DNA-binding; Isopeptide bond;
KW   Mental retardation; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..741
FT                   /note="Zinc finger and BTB domain-containing protein 20"
FT                   /id="PRO_0000047733"
FT   DOMAIN          104..167
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   ZN_FING         578..600
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         606..628
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         634..656
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         662..684
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         715..737
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..32
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          203..235
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          350..440
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        208..235
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        373..389
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        421..440
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         211
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         353
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         357
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0L9"
FT   MOD_RES         690
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0L9"
FT   MOD_RES         695
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K0L9"
FT   CROSSLNK        330
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        330
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        371
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..73
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11230166,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005"
FT                   /id="VSP_032503"
FT   VARIANT         590
FT                   /note="K -> Q (in PRIMS; does not affect subcellular
FT                   location; strongly reduced DNA binding; reduced ability to
FT                   repress transcription; dominant-negative effect of the
FT                   mutant on the wild-type allele; dbSNP:rs483353064)"
FT                   /evidence="ECO:0000269|PubMed:25017102"
FT                   /id="VAR_072583"
FT   VARIANT         596
FT                   /note="H -> R (in PRIMS; strongly reduced DNA binding;
FT                   strongly reduced ability to repress transcription;
FT                   dominant-negative effect of the mutant on the wild-type
FT                   allele; dbSNP:rs483353066)"
FT                   /evidence="ECO:0000269|PubMed:25017102"
FT                   /id="VAR_072584"
FT   VARIANT         602
FT                   /note="G -> A (in PRIMS; strongly reduced DNA binding;
FT                   strongly reduced ability to repress transcription;
FT                   dominant-negative effect of the mutant on the wild-type
FT                   allele; dbSNP:rs483353068)"
FT                   /evidence="ECO:0000269|PubMed:25017102"
FT                   /id="VAR_072585"
FT   VARIANT         621
FT                   /note="L -> F (in PRIMS; strongly reduced DNA binding;
FT                   reduced ability to repress transcription; dominant-negative
FT                   effect of the mutant on the wild-type allele;
FT                   dbSNP:rs483353070)"
FT                   /evidence="ECO:0000269|PubMed:25017102"
FT                   /id="VAR_072586"
FT   CONFLICT        224
FT                   /note="S -> G (in Ref. 1; AAG28340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        266
FT                   /note="V -> M (in Ref. 1; AAG28340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="E -> G (in Ref. 3; CAH56190)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337
FT                   /note="Y -> F (in Ref. 1; AAG28340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        465
FT                   /note="S -> F (in Ref. 1; AAG28340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        517
FT                   /note="A -> V (in Ref. 1; AAG28340)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        543
FT                   /note="S -> F (in Ref. 5; AAH29041)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   741 AA;  81083 MW;  913DDA9E6771C1EF CRC64;
     MLERKKPKTA ENQKASEENE ITQPGGSSAK PGLPCLNFEA VLSPDPALIH STHSLTNSHA
     HTGSSDCDIS CKGMTERIHS INLHNFSNSV LETLNEQRNR GHFCDVTVRI HGSMLRAHRC
     VLAAGSPFFQ DKLLLGYSDI EIPSVVSVQS VQKLIDFMYS GVLRVSQSEA LQILTAASIL
     QIKTVIDECT RIVSQNVGDV FPGIQDSGQD TPRGTPESGT SGQSSDTESG YLQSHPQHSV
     DRIYSALYAC SMQNGSGERS FYSGAVVSHH ETALGLPRDH HMEDPSWITR IHERSQQMER
     YLSTTPETTH CRKQPRPVRI QTLVGNIHIK QEMEDDYDYY GQQRVQILER NESEECTEDT
     DQAEGTESEP KGESFDSGVS SSIGTEPDSV EQQFGPGAAR DSQAEPTQPE QAAEAPAEGG
     PQTNQLETGA SSPERSNEVE MDSTVITVSN SSDKSVLQQP SVNTSIGQPL PSTQLYLRQT
     ETLTSNLRMP LTLTSNTQVI GTAGNTYLPA LFTTQPAGSG PKPFLFSLPQ PLAGQQTQFV
     TVSQPGLSTF TAQLPAPQPL ASSAGHSTAS GQGEKKPYEC TLCNKTFTAK QNYVKHMFVH
     TGEKPHQCSI CWRSFSLKDY LIKHMVTHTG VRAYQCSICN KRFTQKSSLN VHMRLHRGEK
     SYECYICKKK FSHKTLLERH VALHSASNGT PPAGTPPGAR AGPPGVVACT EGTTYVCSVC
     PAKFDQIEQF NDHMRMHVSD G
//
ID   SUH_HUMAN               Reviewed;         500 AA.
AC   Q06330; B4DY22; Q5XKH9; Q6P1N3;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2011, sequence version 3.
DT   23-FEB-2022, entry version 207.
DE   RecName: Full=Recombining binding protein suppressor of hairless;
DE   AltName: Full=CBF-1;
DE   AltName: Full=J kappa-recombination signal-binding protein;
DE   AltName: Full=RBP-J kappa;
DE            Short=RBP-J;
DE            Short=RBP-JK;
DE   AltName: Full=Renal carcinoma antigen NY-REN-30;
GN   Name=RBPJ {ECO:0000312|HGNC:HGNC:5724};
GN   Synonyms=IGKJRB, IGKJRB1, RBPJK, RBPSUH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS APCR-1; APCR-2 AND APCR-3), AND
RP   VARIANT VAL-456.
RC   TISSUE=Placenta;
RX   PubMed=8406481; DOI=10.1006/geno.1993.1326;
RA   Amakawa R., Jing W., Ozawa K., Matsunami N., Hamaguchi Y., Matsuda F.,
RA   Kawaichi M., Honjo T.;
RT   "Human Jk recombination signal binding protein gene (IGKJRB): comparison
RT   with its mouse homologue.";
RL   Genomics 17:306-315(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 5 AND 6).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH EBV EBNA2.
RX   PubMed=8016657; DOI=10.1126/science.8016657;
RA   Henkel T., Ling P.D., Hayward S.D., Peterson M.G.;
RT   "Mediation of Epstein-Barr virus EBNA2 transactivation by recombination
RT   signal-binding protein J kappa.";
RL   Science 265:92-95(1994).
RN   [6]
RP   INTERACTION WITH EBV EBNA3; EBV EBNA4 AND EBV EBNA6.
RX   PubMed=8627785; DOI=10.1128/jvi.70.5.3068-3074.1996;
RA   Robertson E.S., Lin J., Kieff E.;
RT   "The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B,
RT   and 3C interact with RBPJ(kappa).";
RL   J. Virol. 70:3068-3074(1996).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   INTERACTION WITH CIR1, AND SUBCELLULAR LOCATION.
RX   PubMed=9874765; DOI=10.1073/pnas.96.1.23;
RA   Hsieh J.J.-D., Zhou S., Chen L., Young D.B., Hayward S.D.;
RT   "CIR, a corepressor linking the DNA binding factor CBF1 to the histone
RT   deacetylase complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:23-28(1999).
RN   [9]
RP   INTERACTION WITH SNW1.
RX   PubMed=10644367; DOI=10.1128/jvi.74.4.1939-1947.2000;
RA   Zhou S., Fujimuro M., Hsieh J.J., Chen L., Hayward S.D.;
RT   "A role for SKIP in EBNA2 activation of CBF1-repressed promoters.";
RL   J. Virol. 74:1939-1947(2000).
RN   [10]
RP   INTERACTION WITH NOTCH1.
RX   PubMed=10637481; DOI=10.1038/sj.leu.2401630;
RA   Callahan J., Aster J., Sklar J., Kieff E., Robertson E.S.;
RT   "Intracellular forms of human NOTCH1 interact at distinctly different
RT   levels with RBP-jkappa in human B and T cells.";
RL   Leukemia 14:84-92(2000).
RN   [11]
RP   INTERACTION WITH MINT.
RX   PubMed=12374742; DOI=10.1093/emboj/cdf549;
RA   Oswald F., Kostezka U., Astrahantseff K., Bourteele S., Dillinger K.,
RA   Zechner U., Ludwig L., Wilda M., Hameister H., Knoechel W., Liptay S.,
RA   Schmid R.M.;
RT   "SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway.";
RL   EMBO J. 21:5417-5426(2002).
RN   [12]
RP   INTERACTION WITH C12ORF52, AND SUBCELLULAR LOCATION.
RX   PubMed=21102556; DOI=10.1038/emboj.2010.289;
RA   Wacker S.A., Alvarado C., von Wichert G., Knippschild U., Wiedenmann J.,
RA   Clauss K., Nienhaus G.U., Hameister H., Baumann B., Borggrefe T.,
RA   Knochel W., Oswald F.;
RT   "RITA, a novel modulator of Notch signalling, acts via nuclear export of
RT   RBP-J.";
RL   EMBO J. 30:43-56(2011).
RN   [13]
RP   FUNCTION, AND METHYLATED DNA-BINDING.
RX   PubMed=21991380; DOI=10.1371/journal.pone.0025884;
RA   Bartels S.J., Spruijt C.G., Brinkman A.B., Jansen P.W., Vermeulen M.,
RA   Stunnenberg H.G.;
RT   "A SILAC-based screen for Methyl-CpG binding proteins identifies RBP-J as a
RT   DNA methylation and sequence-specific binding protein.";
RL   PLoS ONE 6:E25884-E25884(2011).
RN   [14]
RP   INTERACTION WITH BEND6.
RX   PubMed=23571214; DOI=10.1242/dev.087502;
RA   Dai Q., Andreu-Agullo C., Insolera R., Wong L.C., Shi S.H., Lai E.C.;
RT   "BEND6 is a nuclear antagonist of Notch signaling during self-renewal of
RT   neural stem cells.";
RL   Development 140:1892-1902(2013).
RN   [15]
RP   FUNCTION IN COX4I2 TRANSCRIPTION, AND INTERACTION WITH CHCHD2 AND CXXC5.
RX   PubMed=23303788; DOI=10.1093/nar/gks1454;
RA   Aras S., Pak O., Sommer N., Finley R. Jr., Huttemann M., Weissmann N.,
RA   Grossman L.I.;
RT   "Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene
RT   expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2.";
RL   Nucleic Acids Res. 41:2255-2266(2013).
RN   [16]
RP   INTERACTION WITH ZMIZ1.
RX   PubMed=26522984; DOI=10.1016/j.immuni.2015.10.007;
RA   Pinnell N., Yan R., Cho H.J., Keeley T., Murai M.J., Liu Y., Alarcon A.S.,
RA   Qin J., Wang Q., Kuick R., Elenitoba-Johnson K.S., Maillard I.,
RA   Samuelson L.C., Cierpicki T., Chiang M.Y.;
RT   "The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of
RT   Notch1 in T cell development and leukemia.";
RL   Immunity 43:870-883(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-449 IN COMPLEX WITH DNA; MAML1
RP   AND NOTCH1.
RX   PubMed=16530044; DOI=10.1016/j.cell.2005.12.037;
RA   Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C.;
RT   "Structural basis for cooperativity in recruitment of MAML coactivators to
RT   Notch transcription complexes.";
RL   Cell 124:973-983(2006).
RN   [18]
RP   VARIANTS AOS3 GLY-63 AND GLU-169, AND CHARACTERIZATION OF VARIANTS AOS3
RP   GLY-63 AND GLU-169.
RX   PubMed=22883147; DOI=10.1016/j.ajhg.2012.07.005;
RA   Hassed S.J., Wiley G.B., Wang S., Lee J.Y., Li S., Xu W., Zhao Z.J.,
RA   Mulvihill J.J., Robertson J., Warner J., Gaffney P.M.;
RT   "RBPJ mutations identified in two families affected by Adams-Oliver
RT   syndrome.";
RL   Am. J. Hum. Genet. 91:391-395(2012).
CC   -!- FUNCTION: Transcriptional regulator that plays a central role in Notch
CC       signaling, a signaling pathway involved in cell-cell communication that
CC       regulates a broad spectrum of cell-fate determinations. Acts as a
CC       transcriptional repressor when it is not associated with Notch
CC       proteins. When associated with some NICD product of Notch proteins
CC       (Notch intracellular domain), it acts as a transcriptional activator
CC       that activates transcription of Notch target genes. Probably represses
CC       or activates transcription via the recruitment of chromatin remodeling
CC       complexes containing histone deacetylase or histone acetylase proteins,
CC       respectively. Specifically binds to the immunoglobulin kappa-type J
CC       segment recombination signal sequence. Binds specifically to methylated
CC       DNA (PubMed:21991380). Binds to the oxygen responsive element of COX4I2
CC       and activates its transcription under hypoxia conditions (4% oxygen)
CC       (PubMed:23303788). Negatively regulates the phagocyte oxidative burst
CC       in response to bacterial infection by repressing transcription of NADPH
CC       oxidase subunits (By similarity). {ECO:0000250|UniProtKB:P31266,
CC       ECO:0000269|PubMed:21991380, ECO:0000269|PubMed:23303788}.
CC   -!- SUBUNIT: Interacts with activated NOTCH1, NOTCH2 or NOTCH3. Interacts
CC       with MINT/SHARP. This interaction may mediate the recruitment of large
CC       corepressor complexes containing proteins such as HDAC1, HDAC2, NCOR2,
CC       SAP30, FHL1/KYOT2 and CIR1. Interacts with EP300, MAML1 and PTF1A.
CC       Interacts with Epstein-Barr virus EBNA2, EBNA3, EBNA4 and EBNA6.
CC       Interacts with RITA1/C12orf52, leading to nuclear export, prevent the
CC       interaction between RBPJ and NICD product and subsequent down-
CC       regulation of the Notch signaling pathway. Interacts with SNW1.
CC       Interacts with CHCHD2 and CXXC5 (PubMed:23303788). Interacts with BEND6
CC       (via BEN domain). Interacts with NKAPL (By similarity). Interacts with
CC       ZMIZ1. Interacts with RBM15 (By similarity).
CC       {ECO:0000250|UniProtKB:P31266, ECO:0000269|PubMed:10637481,
CC       ECO:0000269|PubMed:10644367, ECO:0000269|PubMed:12374742,
CC       ECO:0000269|PubMed:16530044, ECO:0000269|PubMed:21102556,
CC       ECO:0000269|PubMed:23303788, ECO:0000269|PubMed:23571214,
CC       ECO:0000269|PubMed:26522984, ECO:0000269|PubMed:8016657,
CC       ECO:0000269|PubMed:8627785, ECO:0000269|PubMed:9874765}.
CC   -!- INTERACTION:
CC       Q06330; P54253: ATXN1; NbExp=7; IntAct=EBI-632552, EBI-930964;
CC       Q06330; P0C7T5: ATXN1L; NbExp=7; IntAct=EBI-632552, EBI-8624731;
CC       Q06330; Q6P3S6: FBXO42; NbExp=3; IntAct=EBI-632552, EBI-2506081;
CC       Q06330; O60341: KDM1A; NbExp=4; IntAct=EBI-632552, EBI-710124;
CC       Q06330; Q9Y618: NCOR2; NbExp=3; IntAct=EBI-632552, EBI-80830;
CC       Q06330; P46531: NOTCH1; NbExp=12; IntAct=EBI-632552, EBI-636374;
CC       Q06330; Q9UPP1: PHF8; NbExp=2; IntAct=EBI-632552, EBI-1560800;
CC       Q06330; Q96K30: RITA1; NbExp=10; IntAct=EBI-632552, EBI-2836148;
CC       Q06330; P51532: SMARCA4; NbExp=2; IntAct=EBI-632552, EBI-302489;
CC       Q06330; Q13573: SNW1; NbExp=2; IntAct=EBI-632552, EBI-632715;
CC       Q06330; Q96T58: SPEN; NbExp=2; IntAct=EBI-632552, EBI-765739;
CC       Q06330; P04637: TP53; NbExp=5; IntAct=EBI-632552, EBI-366083;
CC       Q06330; P12978: EBNA2; Xeno; NbExp=2; IntAct=EBI-632552, EBI-8052923;
CC       Q06330; P12977: EBNA3; Xeno; NbExp=4; IntAct=EBI-632552, EBI-993115;
CC       Q06330; P03203: EBNA4; Xeno; NbExp=4; IntAct=EBI-632552, EBI-9346250;
CC       Q06330; P03204: EBNA6; Xeno; NbExp=3; IntAct=EBI-632552, EBI-9255985;
CC       Q06330; Q01705: Notch1; Xeno; NbExp=3; IntAct=EBI-632552, EBI-1392707;
CC       Q06330; P0CJ62: rita1; Xeno; NbExp=2; IntAct=EBI-632552, EBI-8517225;
CC       Q06330-6; P46531: NOTCH1; NbExp=6; IntAct=EBI-12599287, EBI-636374;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Mainly nuclear, upon
CC       interaction with RITA/C12orf52, translocates to the cytoplasm, down-
CC       regulating the Notch signaling pathway.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=APCR-2;
CC         IsoId=Q06330-1; Sequence=Displayed;
CC       Name=APCR-1;
CC         IsoId=Q06330-2; Sequence=VSP_002717;
CC       Name=APCR-3;
CC         IsoId=Q06330-3; Sequence=VSP_002718, VSP_002719;
CC       Name=4;
CC         IsoId=Q06330-4; Sequence=VSP_021573;
CC       Name=5;
CC         IsoId=Q06330-5; Sequence=VSP_021572;
CC       Name=6;
CC         IsoId=Q06330-6; Sequence=VSP_021574;
CC       Name=7;
CC         IsoId=Q06330-7; Sequence=VSP_042637;
CC   -!- DISEASE: Adams-Oliver syndrome 3 (AOS3) [MIM:614814]: An autosomal
CC       dominant form of Adams-Oliver syndrome, a disorder characterized by the
CC       congenital absence of skin (aplasia cutis congenita) in combination
CC       with transverse limb defects. Aplasia cutis congenita can be located
CC       anywhere on the body, but in the vast majority of the cases, it is
CC       present on the posterior parietal region where it is often associated
CC       with an underlying defect of the parietal bones. Limb abnormalities are
CC       typically limb truncation defects affecting the distal phalanges or
CC       entire digits (true ectrodactyly). Only rarely, metatarsals/metacarpals
CC       or more proximal limb structures are also affected. Apart from
CC       transverse limb defects, syndactyly, most commonly of second and third
CC       toes, can also be observed. The clinical features are highly variable
CC       and can also include cardiovascular malformations, brain abnormalities
CC       and vascular defects such as cutis marmorata and dilated scalp veins.
CC       AOS3 patients manifest characteristic vertex scalp defects and terminal
CC       limb defects, but without congenital heart defects, other associated
CC       defects, or immune defects. {ECO:0000269|PubMed:22883147}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the Su(H) family. {ECO:0000305}.
CC   -!- CAUTION: Despite some similarity with the 'phage' integrase family, it
CC       has no recombinase activity. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA16254.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L07872; AAA60258.1; -; mRNA.
DR   EMBL; L07874; AAA16253.1; -; mRNA.
DR   EMBL; L07875; AAA16254.1; ALT_INIT; mRNA.
DR   EMBL; L07876; AAA16356.1; -; mRNA.
DR   EMBL; AK302230; BAG63584.1; -; mRNA.
DR   EMBL; AC093637; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097109; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC097714; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC111003; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC020780; AAH20780.1; -; mRNA.
DR   EMBL; BC053531; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC064976; AAH64976.1; -; mRNA.
DR   CCDS; CCDS33969.1; -. [Q06330-6]
DR   CCDS; CCDS3436.1; -. [Q06330-5]
DR   CCDS; CCDS3437.1; -. [Q06330-1]
DR   CCDS; CCDS43219.1; -. [Q06330-7]
DR   CCDS; CCDS87214.1; -. [Q06330-5]
DR   PIR; A47214; A47214.
DR   RefSeq; NP_005340.2; NM_005349.3. [Q06330-1]
DR   RefSeq; NP_056958.3; NM_015874.4. [Q06330-7]
DR   RefSeq; NP_976028.1; NM_203283.2. [Q06330-4]
DR   RefSeq; NP_976029.1; NM_203284.2. [Q06330-6]
DR   RefSeq; XP_005248218.1; XM_005248161.3.
DR   RefSeq; XP_011512142.1; XM_011513840.2. [Q06330-6]
DR   RefSeq; XP_016863661.1; XM_017008172.1.
DR   RefSeq; XP_016863662.1; XM_017008173.1.
DR   RefSeq; XP_016863663.1; XM_017008174.1. [Q06330-6]
DR   RefSeq; XP_016863664.1; XM_017008175.1.
DR   PDB; 2F8X; X-ray; 3.25 A; C=23-449.
DR   PDB; 3NBN; X-ray; 3.45 A; A/D=23-448.
DR   PDB; 3V79; X-ray; 3.85 A; C=23-449.
DR   PDB; 6PY8; X-ray; 3.75 A; C/E=23-466.
DR   PDBsum; 2F8X; -.
DR   PDBsum; 3NBN; -.
DR   PDBsum; 3V79; -.
DR   PDBsum; 6PY8; -.
DR   SMR; Q06330; -.
DR   BioGRID; 109736; 150.
DR   CORUM; Q06330; -.
DR   DIP; DIP-33326N; -.
DR   ELM; Q06330; -.
DR   IntAct; Q06330; 125.
DR   MINT; Q06330; -.
DR   STRING; 9606.ENSP00000345206; -.
DR   BindingDB; Q06330; -.
DR   ChEMBL; CHEMBL4105709; -.
DR   GlyGen; Q06330; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q06330; -.
DR   PhosphoSitePlus; Q06330; -.
DR   BioMuta; RBPJ; -.
DR   DMDM; 338817983; -.
DR   EPD; Q06330; -.
DR   jPOST; Q06330; -.
DR   MassIVE; Q06330; -.
DR   MaxQB; Q06330; -.
DR   PaxDb; Q06330; -.
DR   PeptideAtlas; Q06330; -.
DR   PRIDE; Q06330; -.
DR   ProteomicsDB; 58432; -. [Q06330-1]
DR   ProteomicsDB; 58433; -. [Q06330-2]
DR   ProteomicsDB; 58434; -. [Q06330-3]
DR   ProteomicsDB; 58435; -. [Q06330-4]
DR   ProteomicsDB; 58436; -. [Q06330-5]
DR   ProteomicsDB; 58437; -. [Q06330-6]
DR   ProteomicsDB; 58438; -. [Q06330-7]
DR   TopDownProteomics; Q06330-3; -. [Q06330-3]
DR   Antibodypedia; 10265; 437 antibodies from 41 providers.
DR   DNASU; 3516; -.
DR   Ensembl; ENST00000342295; ENSP00000345206; ENSG00000168214.
DR   Ensembl; ENST00000342320; ENSP00000340124; ENSG00000168214. [Q06330-6]
DR   Ensembl; ENST00000345843; ENSP00000305815; ENSG00000168214. [Q06330-5]
DR   Ensembl; ENST00000348160; ENSP00000339699; ENSG00000168214. [Q06330-6]
DR   Ensembl; ENST00000355476; ENSP00000347659; ENSG00000168214. [Q06330-7]
DR   Ensembl; ENST00000361572; ENSP00000354528; ENSG00000168214.
DR   Ensembl; ENST00000504423; ENSP00000421804; ENSG00000168214. [Q06330-5]
DR   Ensembl; ENST00000505958; ENSP00000426872; ENSG00000168214. [Q06330-6]
DR   Ensembl; ENST00000507561; ENSP00000423907; ENSG00000168214. [Q06330-5]
DR   Ensembl; ENST00000512671; ENSP00000423644; ENSG00000168214.
DR   Ensembl; ENST00000680928; ENSP00000505493; ENSG00000168214. [Q06330-6]
DR   Ensembl; ENST00000681093; ENSP00000504964; ENSG00000168214. [Q06330-6]
DR   Ensembl; ENST00000681264; ENSP00000505255; ENSG00000168214. [Q06330-5]
DR   Ensembl; ENST00000681484; ENSP00000505636; ENSG00000168214. [Q06330-5]
DR   GeneID; 3516; -.
DR   KEGG; hsa:3516; -.
DR   MANE-Select; ENST00000355476.8; ENSP00000347659.4; NM_015874.6; NP_056958.3. [Q06330-7]
DR   UCSC; uc003grx.3; human. [Q06330-1]
DR   CTD; 3516; -.
DR   DisGeNET; 3516; -.
DR   GeneCards; RBPJ; -.
DR   GeneReviews; RBPJ; -.
DR   HGNC; HGNC:5724; RBPJ.
DR   HPA; ENSG00000168214; Low tissue specificity.
DR   MalaCards; RBPJ; -.
DR   MIM; 147183; gene.
DR   MIM; 614814; phenotype.
DR   neXtProt; NX_Q06330; -.
DR   OpenTargets; ENSG00000168214; -.
DR   Orphanet; 974; Adams-Oliver syndrome.
DR   PharmGKB; PA34292; -.
DR   VEuPathDB; HostDB:ENSG00000168214; -.
DR   eggNOG; KOG3743; Eukaryota.
DR   GeneTree; ENSGT00390000005197; -.
DR   HOGENOM; CLU_022207_2_1_1; -.
DR   InParanoid; Q06330; -.
DR   OMA; ISEVQWN; -.
DR   OrthoDB; 444988at2759; -.
DR   PhylomeDB; Q06330; -.
DR   TreeFam; TF314117; -.
DR   PathwayCommons; Q06330; -.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   SignaLink; Q06330; -.
DR   SIGNOR; Q06330; -.
DR   BioGRID-ORCS; 3516; 23 hits in 1051 CRISPR screens.
DR   ChiTaRS; RBPJ; human.
DR   EvolutionaryTrace; Q06330; -.
DR   GeneWiki; RBPJ; -.
DR   GenomeRNAi; 3516; -.
DR   Pharos; Q06330; Tbio.
DR   PRO; PR:Q06330; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q06330; protein.
DR   Bgee; ENSG00000168214; Expressed in corpus callosum and 255 other tissues.
DR   ExpressionAtlas; Q06330; baseline and differential.
DR   Genevisible; Q06330; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:CAFA.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; TAS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:MGI.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0003176; P:aortic valve development; IEA:Ensembl.
DR   GO; GO:0060844; P:arterial endothelial cell fate commitment; IEA:Ensembl.
DR   GO; GO:0036302; P:atrioventricular canal development; ISS:BHF-UCL.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0097101; P:blood vessel endothelial cell fate specification; ISS:BHF-UCL.
DR   GO; GO:0072554; P:blood vessel lumenization; ISS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060486; P:club cell differentiation; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003160; P:endocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009957; P:epidermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060716; P:labyrinthine layer blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0030279; P:negative regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IC:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:BHF-UCL.
DR   GO; GO:1901297; P:positive regulation of canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment; IEA:Ensembl.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000138; P:positive regulation of cell proliferation involved in heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1901189; P:positive regulation of ephrin receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:1901186; P:positive regulation of ERBB signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; IDA:UniProtKB.
DR   GO; GO:0003177; P:pulmonary valve development; IEA:Ensembl.
DR   GO; GO:0048505; P:regulation of timing of cell differentiation; IEA:Ensembl.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0048733; P:sebaceous gland development; IEA:Ensembl.
DR   GO; GO:0003139; P:secondary heart field specification; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   CDD; cd01176; IPT_RBP-Jkappa; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 2.60.40.1450; -; 1.
DR   IDEAL; IID00380; -.
DR   InterPro; IPR015350; Beta-trefoil_DNA-bd_dom.
DR   InterPro; IPR036358; BTD_sf.
DR   InterPro; IPR040159; CLS_fam.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR015351; RBP-J/Cbf11/Cbf12_DNA-bd.
DR   InterPro; IPR037095; RBP-J/Cbf11_DNA-bd_sf.
DR   InterPro; IPR038007; RBP-Jkappa_IPT.
DR   PANTHER; PTHR10665; PTHR10665; 2.
DR   Pfam; PF09270; BTD; 1.
DR   Pfam; PF09271; LAG1-DNAbind; 1.
DR   Pfam; PF20144; TIG_SUH; 1.
DR   SMART; SM01268; BTD; 1.
DR   SMART; SM01267; LAG1_DNAbind; 1.
DR   SUPFAM; SSF110217; SSF110217; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm;
KW   Disease variant; DNA-binding; Notch signaling pathway; Nucleus;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..500
FT                   /note="Recombining binding protein suppressor of hairless"
FT                   /id="PRO_0000208567"
FT   DOMAIN          355..445
FT                   /note="IPT/TIG"
FT   REGION          1..30
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          57..67
FT                   /note="DNA binding"
FT                   /evidence="ECO:0000269|PubMed:16530044"
FT   REGION          165..170
FT                   /note="DNA binding"
FT                   /evidence="ECO:0000269|PubMed:16530044"
FT   REGION          192..197
FT                   /note="DNA binding"
FT                   /evidence="ECO:0000269|PubMed:16530044"
FT   REGION          465..500
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         175
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P31266"
FT   VAR_SEQ         1..89
FT                   /note="Missing (in isoform APCR-3)"
FT                   /evidence="ECO:0000303|PubMed:8406481"
FT                   /id="VSP_002718"
FT   VAR_SEQ         1..75
FT                   /note="Missing (in isoform APCR-1)"
FT                   /evidence="ECO:0000303|PubMed:8406481"
FT                   /id="VSP_002717"
FT   VAR_SEQ         1..35
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021572"
FT   VAR_SEQ         1..20
FT                   /note="MDHTEGSPAEEPPAHAPSPG -> MGGCR (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021573"
FT   VAR_SEQ         1..20
FT                   /note="MDHTEGSPAEEPPAHAPSPG -> MAWIKR (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021574"
FT   VAR_SEQ         1..19
FT                   /note="MDHTEGSPAEEPPAHAPSP -> MAPVVT (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042637"
FT   VAR_SEQ         90..95
FT                   /note="DGCSEQ -> MAWIKR (in isoform APCR-3)"
FT                   /evidence="ECO:0000303|PubMed:8406481"
FT                   /id="VSP_002719"
FT   VARIANT         63
FT                   /note="E -> G (in AOS3; shows decreased binding to the HES1
FT                   promoter compared to wild-type; dbSNP:rs387907270)"
FT                   /evidence="ECO:0000269|PubMed:22883147"
FT                   /id="VAR_068929"
FT   VARIANT         169
FT                   /note="K -> E (in AOS3; shows decreased binding to the HES1
FT                   promoter compared to wild-type; dbSNP:rs387907271)"
FT                   /evidence="ECO:0000269|PubMed:22883147"
FT                   /id="VAR_068930"
FT   VARIANT         291
FT                   /note="K -> E (in dbSNP:rs1064372)"
FT                   /id="VAR_028994"
FT   VARIANT         334
FT                   /note="D -> H (in dbSNP:rs1064376)"
FT                   /id="VAR_028995"
FT   VARIANT         408
FT                   /note="I -> V (in dbSNP:rs1064381)"
FT                   /id="VAR_057244"
FT   VARIANT         419
FT                   /note="R -> Q (in dbSNP:rs1064384)"
FT                   /id="VAR_028996"
FT   VARIANT         425
FT                   /note="P -> S (in dbSNP:rs1064387)"
FT                   /id="VAR_028997"
FT   VARIANT         456
FT                   /note="A -> V (in dbSNP:rs1064402)"
FT                   /evidence="ECO:0000269|PubMed:8406481"
FT                   /id="VAR_028998"
FT   CONFLICT        7
FT                   /note="S -> L (in Ref. 1; AAA60258/AAA16253/AAA16254)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        140..141
FT                   /note="ML -> IF (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        240
FT                   /note="G -> V (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        248
FT                   /note="V -> C (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        265
FT                   /note="R -> M (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        270
FT                   /note="Q -> H (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        462
FT                   /note="R -> P (in Ref. 1; AAA60258)"
FT                   /evidence="ECO:0000305"
FT   HELIX           33..41
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          50..57
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   HELIX           79..88
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   TURN            89..91
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   TURN            94..96
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          118..121
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   STRAND          137..139
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          141..146
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          152..157
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          161..166
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          174..176
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          178..180
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          185..191
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   HELIX           193..195
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   TURN            197..199
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          220..225
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          231..234
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          246..255
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          262..268
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          271..275
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          284..289
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          291..295
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          297..299
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   STRAND          302..306
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          328..336
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          343..345
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   STRAND          356..362
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   HELIX           366..368
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          370..377
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          382..386
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          389..391
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          393..397
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          400..404
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   HELIX           408..411
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          412..414
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          426..430
FT                   /evidence="ECO:0007829|PDB:2F8X"
FT   STRAND          431..433
FT                   /evidence="ECO:0007829|PDB:3NBN"
FT   STRAND          435..437
FT                   /evidence="ECO:0007829|PDB:2F8X"
SQ   SEQUENCE   500 AA;  55637 MW;  91E50D2DE9087EDA CRC64;
     MDHTEGSPAE EPPAHAPSPG KFGERPPPKR LTREAMRNYL KERGDQTVLI LHAKVAQKSY
     GNEKRFFCPP PCVYLMGSGW KKKKEQMERD GCSEQESQPC AFIGIGNSDQ EMQQLNLEGK
     NYCTAKTLYI SDSDKRKHFM LSVKMFYGNS DDIGVFLSKR IKVISKPSKK KQSLKNADLC
     IASGTKVALF NRLRSQTVST RYLHVEGGNF HASSQQWGAF FIHLLDDDES EGEEFTVRDG
     YIHYGQTVKL VCSVTGMALP RLIIRKVDKQ TALLDADDPV SQLHKCAFYL KDTERMYLCL
     SQERIIQFQA TPCPKEPNKE MINDGASWTI ISTDKAEYTF YEGMGPVLAP VTPVPVVESL
     QLNGGGDVAM LELTGQNFTP NLRVWFGDVE AETMYRCGES MLCVVPDISA FREGWRWVRQ
     PVQVPVTLVR NDGIIYSTSL TFTYTPEPGP RPHCSAAGAI LRANSSQVPP NESNTNSEGS
     YTNASTNSTS VTSSTATVVS
//
ID   ABHD5_HUMAN             Reviewed;         349 AA.
AC   Q8WTS1; B2R9K0; Q9Y369;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   23-FEB-2022, entry version 169.
DE   RecName: Full=1-acylglycerol-3-phosphate O-acyltransferase ABHD5 {ECO:0000305};
DE            EC=2.3.1.51 {ECO:0000269|PubMed:18606822};
DE   AltName: Full=Abhydrolase domain-containing protein 5;
DE   AltName: Full=Lipid droplet-binding protein CGI-58;
GN   Name=ABHD5 {ECO:0000312|HGNC:HGNC:21396}; Synonyms=NCIE2; ORFNames=CGI-58;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND VARIANTS CDS
RP   LYS-7; PRO-130 AND LYS-260.
RX   PubMed=11590543; DOI=10.1086/324121;
RA   Lefevre C., Jobard F., Caux F., Bouadjar B., Karaduman A., Heilig R.,
RA   Lakhdar H., Wollenberg A., Verret J.-L., Weissenbach J., Oezguec M.,
RA   Lathrop M., Prud'homme J.-F., Fischer J.;
RT   "Mutations in CGI-58, the gene encoding a new protein of the
RT   esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome.";
RL   Am. J. Hum. Genet. 69:1002-1012(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS CDS PRO-130 AND LYS-260.
RX   PubMed=16679289; DOI=10.1016/j.cmet.2006.03.005;
RA   Lass A., Zimmermann R., Haemmerle G., Riederer M., Schoiswohl G.,
RA   Schweiger M., Kienesberger P., Strauss J.G., Gorkiewicz G., Zechner R.;
RT   "Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is
RT   activated by CGI-58 and defective in Chanarin-Dorfman Syndrome.";
RL   Cell Metab. 3:309-319(2006).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   AND INDUCTION.
RX   PubMed=18832586; DOI=10.2353/ajpath.2008.080005;
RA   Akiyama M., Sakai K., Takayama C., Yanagi T., Yamanaka Y., McMillan J.R.,
RA   Shimizu H.;
RT   "CGI-58 is an alpha/beta-hydrolase within lipid transporting lamellar
RT   granules of differentiated keratinocytes.";
RL   Am. J. Pathol. 173:1349-1360(2008).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS CDS PRO-130
RP   AND LYS-260.
RX   PubMed=18606822; DOI=10.1074/jbc.m801783200;
RA   Ghosh A.K., Ramakrishnan G., Chandramohan C., Rajasekharan R.;
RT   "CGI-58, the causative gene for Chanarin-Dorfman syndrome, mediates
RT   acylation of lysophosphatidic acid.";
RL   J. Biol. Chem. 283:24525-24533(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [11]
RP   VARIANT ARG-82.
RX   PubMed=15967942; DOI=10.1001/archderm.141.6.798;
RA   Schleinitz N., Fischer J., Sanchez A., Veit V., Harle J.-R.,
RA   Pelissier J.-F.;
RT   "Two new mutations of the ABHD5 gene in a new adult case of Chanarin
RT   Dorfman syndrome: an uncommon lipid storage disease.";
RL   Arch. Dermatol. 141:798-800(2005).
RN   [12]
RP   VARIANT CDS GLY-115.
RX   PubMed=17495960; DOI=10.1038/sj.jid.5700860;
RA   Ben Selma Z., Yilmaz S., Schischmanoff P.O., Blom A., Ozogul C.,
RA   Laroche L., Caux F.;
RT   "A novel S115G mutation of CGI-58 in a Turkish patient with Dorfman-
RT   Chanarin syndrome.";
RL   J. Invest. Dermatol. 127:2273-2276(2007).
CC   -!- FUNCTION: Coenzyme A-dependent lysophosphatidic acid acyltransferase
CC       that catalyzes the transfert of an acyl group on a lysophosphatidic
CC       acid (PubMed:18606822). Functions preferentially with 1-oleoyl-
CC       lysophosphatidic acid followed by 1-palmitoyl-lysophosphatidic acid, 1-
CC       stearoyl-lysophosphatidic acid and 1-arachidonoyl-lysophosphatidic acid
CC       as lipid acceptor. Functions preferentially with arachidonoyl-CoA
CC       followed by oleoyl-CoA as acyl group donors (By similarity). Functions
CC       in phosphatidic acid biosynthesis (PubMed:18606822). May regulate the
CC       cellular storage of triacylglycerol through activation of the
CC       phospholipase PNPLA2 (PubMed:16679289). Involved in keratinocyte
CC       differentiation (PubMed:18832586). Regulates lipid droplet fusion (By
CC       similarity). {ECO:0000250|UniProtKB:Q9DBL9,
CC       ECO:0000269|PubMed:16679289, ECO:0000269|PubMed:18606822,
CC       ECO:0000269|PubMed:18832586}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphate + an acyl-CoA = a 1,2-diacyl-
CC         sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:19709,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57970, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:58608; EC=2.3.1.51;
CC         Evidence={ECO:0000269|PubMed:18606822};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19710;
CC         Evidence={ECO:0000305|PubMed:18606822};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + hexadecanoyl-CoA
CC         = 1-(9Z)-octadecenoyl-2-hexadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37143, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74551;
CC         Evidence={ECO:0000269|PubMed:18606822};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37144;
CC         Evidence={ECO:0000305|PubMed:18606822};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + octadecanoyl-CoA
CC         = 1-(9Z-octadecenoyl)-2-octadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37147, ChEBI:CHEBI:57287, ChEBI:CHEBI:57394,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74552;
CC         Evidence={ECO:0000269|PubMed:18606822};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37148;
CC         Evidence={ECO:0000305|PubMed:18606822};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-octadecenoyl-CoA + 1-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphate = 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37131, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74546;
CC         Evidence={ECO:0000269|PubMed:18606822};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37132;
CC         Evidence={ECO:0000305|PubMed:18606822};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + 1-(9Z-octadecenoyl)-sn-
CC         glycero-3-phosphate = 1-(9Z)-octadecenoyl-2-(5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:37443,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:74544,
CC         ChEBI:CHEBI:74928; Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37444;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + eicosanoyl-CoA =
CC         1-(9Z)-octadecenoyl-2-eicosanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37451, ChEBI:CHEBI:57287, ChEBI:CHEBI:57380,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74937;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37452;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-octadecenoyl-CoA + 1-hexadecanoyl-sn-glycero-3-phosphate
CC         = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:33187, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:57518, ChEBI:CHEBI:64839;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33188;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-octadecenoyl-CoA + 1-octadecanoyl-sn-glycero-3-phosphate
CC         = 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37163, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:74560, ChEBI:CHEBI:74565;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37164;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-octadecenoyl-CoA + 1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
CC         glycero-3-phosphate = 1-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-2-(9Z)-
CC         octadecenoyl-sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:37455,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57387, ChEBI:CHEBI:74938,
CC         ChEBI:CHEBI:74941; Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37456;
CC         Evidence={ECO:0000250|UniProtKB:Q9DBL9};
CC   -!- ACTIVITY REGULATION: Acyltransferase activity is inhibited by
CC       detergents such as Triton X-100 and 3-[(3-
CC       cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).
CC       Acyltransferase activity is inhibited by the presence of magnesium and
CC       calcium. {ECO:0000250|UniProtKB:Q9DBL9}.
CC   -!- SUBUNIT: Interacts with ADRP, PLIN and PNPLA2. Interacts with PLIN5;
CC       promotes interaction with PNPLA2 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q8WTS1; Q5T4B2: CERCAM; NbExp=3; IntAct=EBI-2813554, EBI-12261896;
CC       Q8WTS1; P51793: CLCN4; NbExp=3; IntAct=EBI-2813554, EBI-22754239;
CC       Q8WTS1; Q8NI60: COQ8A; NbExp=3; IntAct=EBI-2813554, EBI-745535;
CC       Q8WTS1; Q6ZPD8: DGAT2L6; NbExp=3; IntAct=EBI-2813554, EBI-12831978;
CC       Q8WTS1; Q05329: GAD2; NbExp=3; IntAct=EBI-2813554, EBI-9304251;
CC       Q8WTS1; O00258: GET1; NbExp=3; IntAct=EBI-2813554, EBI-18908258;
CC       Q8WTS1; P48058-2: GRIA4; NbExp=3; IntAct=EBI-2813554, EBI-17517256;
CC       Q8WTS1; Q9NQG6: MIEF1; NbExp=5; IntAct=EBI-2813554, EBI-740987;
CC       Q8WTS1; A6NKB5-5: PCNX2; NbExp=3; IntAct=EBI-2813554, EBI-17616589;
CC       Q8WTS1; Q99541: PLIN2; NbExp=3; IntAct=EBI-2813554, EBI-2115275;
CC       Q8WTS1; O60664: PLIN3; NbExp=3; IntAct=EBI-2813554, EBI-725795;
CC       Q8WTS1; Q00G26: PLIN5; NbExp=3; IntAct=EBI-2813554, EBI-21732470;
CC       Q8WTS1; Q8N0V3: RBFA; NbExp=3; IntAct=EBI-2813554, EBI-3232108;
CC       Q8WTS1; Q9Y225-2: RNF24; NbExp=3; IntAct=EBI-2813554, EBI-13044680;
CC       Q8WTS1; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-2813554, EBI-6257312;
CC       Q8WTS1; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-2813554, EBI-2623095;
CC       Q8WTS1; Q8N4M1-3: SLC44A3; NbExp=3; IntAct=EBI-2813554, EBI-12056955;
CC       Q8WTS1; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-2813554, EBI-8638294;
CC       Q8WTS1; O43399: TPD52L2; NbExp=3; IntAct=EBI-2813554, EBI-782604;
CC       Q8WTS1; Q6PEW1: ZCCHC12; NbExp=3; IntAct=EBI-2813554, EBI-748373;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18832586}. Lipid
CC       droplet {ECO:0000250|UniProtKB:Q9DBL9}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q9DBL9}. Note=Colocalized with PLIN and ADRP on
CC       the surface of lipid droplets. The localization is dependent upon the
CC       metabolic status of the adipocytes and the activity of PKA (By
CC       similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely expressed in various tissues, including
CC       lymphocytes, liver, skeletal muscle and brain. Expressed by upper
CC       epidermal layers and dermal fibroblasts in skin, hepatocytes and
CC       neurons (at protein level). {ECO:0000269|PubMed:11590543,
CC       ECO:0000269|PubMed:18832586}.
CC   -!- DEVELOPMENTAL STAGE: Detected in fetal epidermis from 49 to 135 days
CC       estimated gestational age (at protein level).
CC       {ECO:0000269|PubMed:18832586}.
CC   -!- INDUCTION: Up-regulated upon keratinocyte differentiation (at protein
CC       level). {ECO:0000269|PubMed:18832586}.
CC   -!- DOMAIN: The HXXXXD motif is essential for acyltransferase activity and
CC       may constitute the binding site for the phosphate moiety of the
CC       glycerol-3-phosphate. {ECO:0000250}.
CC   -!- DISEASE: Chanarin-Dorfman syndrome (CDS) [MIM:275630]: An autosomal
CC       recessive inborn error of lipid metabolism with multisystemic
CC       accumulation of triglycerides although plasma concentrations are
CC       normal. Clinical characteristics are congenital generalized ichthyosis,
CC       vacuolated leukocytes, hepatomegaly, myopathy, cataracts, neurosensory
CC       hearing loss and developmental delay. The disorder presents at birth
CC       with generalized, fine, white scaling of the skin and a variable degree
CC       of erythema resembling non-bullous congenital ichthyosiform
CC       erythroderma. {ECO:0000269|PubMed:11590543,
CC       ECO:0000269|PubMed:16679289, ECO:0000269|PubMed:17495960,
CC       ECO:0000269|PubMed:18606822}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S33 family. ABHD4/ABHD5 subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL606838; CAD12731.1; -; Genomic_DNA.
DR   EMBL; AF151816; AAD34053.1; -; mRNA.
DR   EMBL; AK313811; BAG36547.1; -; mRNA.
DR   EMBL; AC105903; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW64699.1; -; Genomic_DNA.
DR   EMBL; BC021958; AAH21958.1; -; mRNA.
DR   CCDS; CCDS2711.1; -.
DR   RefSeq; NP_057090.2; NM_016006.4.
DR   SMR; Q8WTS1; -.
DR   BioGRID; 119288; 36.
DR   IntAct; Q8WTS1; 35.
DR   MINT; Q8WTS1; -.
DR   STRING; 9606.ENSP00000390849; -.
DR   SwissLipids; SLP:000000098; -.
DR   ESTHER; human-ABHD5; CGI-58_ABHD5_ABHD4.
DR   MEROPS; S33.975; -.
DR   GlyGen; Q8WTS1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8WTS1; -.
DR   PhosphoSitePlus; Q8WTS1; -.
DR   BioMuta; ABHD5; -.
DR   DMDM; 73921640; -.
DR   EPD; Q8WTS1; -.
DR   jPOST; Q8WTS1; -.
DR   MassIVE; Q8WTS1; -.
DR   MaxQB; Q8WTS1; -.
DR   PaxDb; Q8WTS1; -.
DR   PeptideAtlas; Q8WTS1; -.
DR   PRIDE; Q8WTS1; -.
DR   ProteomicsDB; 74594; -.
DR   Antibodypedia; 29395; 344 antibodies from 33 providers.
DR   DNASU; 51099; -.
DR   Ensembl; ENST00000644371; ENSP00000495778; ENSG00000011198.
DR   Ensembl; ENST00000649763; ENSP00000497701; ENSG00000011198.
DR   GeneID; 51099; -.
DR   KEGG; hsa:51099; -.
DR   MANE-Select; ENST00000644371.2; ENSP00000495778.1; NM_016006.6; NP_057090.2.
DR   UCSC; uc003cmx.4; human.
DR   CTD; 51099; -.
DR   DisGeNET; 51099; -.
DR   GeneCards; ABHD5; -.
DR   HGNC; HGNC:21396; ABHD5.
DR   HPA; ENSG00000011198; Low tissue specificity.
DR   MalaCards; ABHD5; -.
DR   MIM; 275630; phenotype.
DR   MIM; 604780; gene.
DR   neXtProt; NX_Q8WTS1; -.
DR   OpenTargets; ENSG00000011198; -.
DR   Orphanet; 98907; Neutral lipid storage disease with ichthyosis.
DR   PharmGKB; PA134891622; -.
DR   VEuPathDB; HostDB:ENSG00000011198; -.
DR   eggNOG; KOG4409; Eukaryota.
DR   GeneTree; ENSGT00390000016277; -.
DR   HOGENOM; CLU_017361_0_0_1; -.
DR   InParanoid; Q8WTS1; -.
DR   OMA; HAYCHGI; -.
DR   OrthoDB; 1555935at2759; -.
DR   PhylomeDB; Q8WTS1; -.
DR   TreeFam; TF314196; -.
DR   PathwayCommons; Q8WTS1; -.
DR   Reactome; R-HSA-163560; Triglyceride catabolism.
DR   SignaLink; Q8WTS1; -.
DR   BioGRID-ORCS; 51099; 5 hits in 1043 CRISPR screens.
DR   ChiTaRS; ABHD5; human.
DR   GeneWiki; ABHD5; -.
DR   GenomeRNAi; 51099; -.
DR   Pharos; Q8WTS1; Tbio.
DR   PRO; PR:Q8WTS1; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q8WTS1; protein.
DR   Bgee; ENSG00000011198; Expressed in blood and 207 other tissues.
DR   ExpressionAtlas; Q8WTS1; baseline and differential.
DR   Genevisible; Q8WTS1; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003841; F:1-acylglycerol-3-phosphate O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0052689; F:carboxylic ester hydrolase activity; IBA:GO_Central.
DR   GO; GO:0042171; F:lysophosphatidic acid acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0055088; P:lipid homeostasis; IBA:GO_Central.
DR   GO; GO:0010891; P:negative regulation of sequestering of triglyceride; IDA:UniProtKB.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IEA:Ensembl.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR000073; AB_hydrolase_1.
DR   Pfam; PF00561; Abhydrolase_1; 1.
DR   PRINTS; PR00111; ABHYDROLASE.
DR   SUPFAM; SSF53474; SSF53474; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Acyltransferase; Cataract; Cytoplasm; Deafness;
KW   Differentiation; Disease variant; Fatty acid metabolism; Ichthyosis;
KW   Lipid biosynthesis; Lipid droplet; Lipid metabolism;
KW   Phospholipid biosynthesis; Phospholipid metabolism; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..349
FT                   /note="1-acylglycerol-3-phosphate O-acyltransferase ABHD5"
FT                   /id="PRO_0000080866"
FT   DOMAIN          77..184
FT                   /note="AB hydrolase-1"
FT                   /evidence="ECO:0000255"
FT   MOTIF           327..332
FT                   /note="HXXXXD motif"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         122
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6QA69"
FT   VARIANT         7
FT                   /note="E -> K (in CDS; dbSNP:rs104893676)"
FT                   /evidence="ECO:0000269|PubMed:11590543"
FT                   /id="VAR_023387"
FT   VARIANT         72
FT                   /note="I -> T (in dbSNP:rs2302349)"
FT                   /id="VAR_037574"
FT   VARIANT         82
FT                   /note="H -> R (found in a patient with CDS but without
FT                   evidence it may cause the disease; dbSNP:rs145548259)"
FT                   /evidence="ECO:0000269|PubMed:15967942"
FT                   /id="VAR_057953"
FT   VARIANT         115
FT                   /note="S -> G (in CDS)"
FT                   /evidence="ECO:0000269|PubMed:17495960"
FT                   /id="VAR_057954"
FT   VARIANT         130
FT                   /note="Q -> P (in CDS; loss of PNPLA2-dependent
FT                   triacylclycerol hydrolysis but no effect on LPA
FT                   acyltransferase activity; dbSNP:rs28939077)"
FT                   /evidence="ECO:0000269|PubMed:11590543,
FT                   ECO:0000269|PubMed:16679289, ECO:0000269|PubMed:18606822"
FT                   /id="VAR_023388"
FT   VARIANT         260
FT                   /note="E -> K (in CDS; loss of PNPLA2-dependent
FT                   triacylclycerol hydrolysis but no effect on LPA
FT                   acyltransferase activity; dbSNP:rs28939078)"
FT                   /evidence="ECO:0000269|PubMed:11590543,
FT                   ECO:0000269|PubMed:16679289, ECO:0000269|PubMed:18606822"
FT                   /id="VAR_023389"
FT   CONFLICT        263
FT                   /note="F -> S (in Ref. 2; AAD34053)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   349 AA;  39096 MW;  85958A2DEC169C82 CRC64;
     MAAEEEEVDS ADTGERSGWL TGWLPTWCPT SISHLKEAEE KMLKCVPCTY KKEPVRISNG
     NKIWTLKFSH NISNKTPLVL LHGFGGGLGL WALNFGDLCT NRPVYAFDLL GFGRSSRPRF
     DSDAEEVENQ FVESIEEWRC ALGLDKMILL GHNLGGFLAA AYSLKYPSRV NHLILVEPWG
     FPERPDLADQ DRPIPVWIRA LGAALTPFNP LAGLRIAGPF GLSLVQRLRP DFKRKYSSMF
     EDDTVTEYIY HCNVQTPSGE TAFKNMTIPY GWAKRPMLQR IGKMHPDIPV SVIFGARSCI
     DGNSGTSIQS LRPHSYVKTI AILGAGHYVY ADQPEEFNQK VKEICDTVD
//
ID   NIP7_HUMAN              Reviewed;         180 AA.
AC   Q9Y221; B2RD04; Q9NZZ0;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   23-FEB-2022, entry version 176.
DE   RecName: Full=60S ribosome subunit biogenesis protein NIP7 homolog;
DE   AltName: Full=KD93;
DE   AltName: Full=Nucleolar pre-rRNA processing protein NIP7;
GN   Name=NIP7; ORFNames=CGI-37, HSPC031, HSPC180, OK/SW-cl.76, OK/SW-cl.78;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-reactive
RT   CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Periodontal ligament;
RA   Myokai F.;
RT   "Mechanical stress-induced gene 26-1, 26-2.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [9]
RP   INTERACTION WITH NOL8.
RX   PubMed=14660641; DOI=10.1074/jbc.m305935200;
RA   Sekiguchi T., Todaka Y., Wang Y., Hirose E., Nakashima N., Nishimoto T.;
RT   "A novel human nucleolar protein, Nop132, binds to the G proteins, RRAG
RT   A/C/D.";
RL   J. Biol. Chem. 279:8343-8350(2004).
RN   [10]
RP   INTERACTION WITH SBDS.
RX   PubMed=17643419; DOI=10.1016/j.yexcr.2007.06.024;
RA   Hesling C., Oliveira C.C., Castilho B.A., Zanchin N.I.;
RT   "The Shwachman-Bodian-Diamond syndrome associated protein interacts with
RT   HsNip7 and its down-regulation affects gene expression at the
RT   transcriptional and translational levels.";
RL   Exp. Cell Res. 313:4180-4195(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   FUNCTION, INTERACTION WITH FTSJ3, AND SUBCELLULAR LOCATION.
RX   PubMed=22195017; DOI=10.1371/journal.pone.0029174;
RA   Morello L.G., Coltri P.P., Quaresma A.J., Simabuco F.M., Silva T.C.,
RA   Singh G., Nickerson J.A., Oliveira C.C., Moore M.J., Zanchin N.I.;
RT   "The human nucleolar protein FTSJ3 associates with NIP7 and functions in
RT   pre-rRNA processing.";
RL   PLoS ONE 6:E29174-E29174(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS), DOMAINS, SUBUNIT STRUCTURE, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=15522784; DOI=10.1016/j.jsb.2004.06.010;
RA   Liu J.-F., Wang X.-Q., Wang Z.-X., Chen J.-R., Jiang T., An X.-M.,
RA   Chang W.-R., Liang D.-C.;
RT   "Crystal structure of KD93, a novel protein expressed in human
RT   hematopoietic stem/progenitor cells.";
RL   J. Struct. Biol. 148:370-374(2004).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RA   Kuzin A.P., Chen Y., Forouhar F., Acton T.B., Shastry R., Ma L.-C.,
RA   Cooper B., Xiao R., Montelione G., Tong L., Hunt J.F.;
RT   "Crystal structure of Northeast structural genomics consortium target
RT   HR2118: a human homolog of Saccharomyces cerevisiae NIP7p.";
RL   Submitted (JUN-2004) to the PDB data bank.
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-171.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Required for proper 34S pre-rRNA processing and 60S ribosome
CC       subunit assembly. {ECO:0000269|PubMed:22195017}.
CC   -!- SUBUNIT: Monomer. Interacts with pre-ribosome complex. May bind to RNA
CC       (By similarity). Interacts with NOL8. May interact with SBDS. Interacts
CC       with FTSJ3. {ECO:0000250, ECO:0000269|PubMed:14660641,
CC       ECO:0000269|PubMed:15522784, ECO:0000269|PubMed:17643419,
CC       ECO:0000269|PubMed:22195017}.
CC   -!- INTERACTION:
CC       Q9Y221; O43186: CRX; NbExp=3; IntAct=EBI-749003, EBI-748171;
CC       Q9Y221; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-749003, EBI-741037;
CC       Q9Y221; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-749003, EBI-10172876;
CC       Q9Y221; Q96CV9: OPTN; NbExp=3; IntAct=EBI-749003, EBI-748974;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:12429849,
CC       ECO:0000269|PubMed:22195017}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y221-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y221-2; Sequence=VSP_012094;
CC   -!- TISSUE SPECIFICITY: Expressed in hematopoietic stem/progenitor cells.
CC       {ECO:0000269|PubMed:15522784}.
CC   -!- SIMILARITY: Belongs to the NIP7 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF132971; AAD27746.1; -; mRNA.
DR   EMBL; AF085360; AAD40195.1; -; mRNA.
DR   EMBL; AF161528; AAF29143.1; -; mRNA.
DR   EMBL; AB062398; BAB93485.1; -; mRNA.
DR   EMBL; AB062479; BAB93504.1; -; mRNA.
DR   EMBL; AB112439; BAD05056.1; -; mRNA.
DR   EMBL; AK315355; BAG37751.1; -; mRNA.
DR   EMBL; CH471092; EAW83271.1; -; Genomic_DNA.
DR   EMBL; BC015941; AAH15941.1; -; mRNA.
DR   CCDS; CCDS10877.1; -. [Q9Y221-1]
DR   CCDS; CCDS56003.1; -. [Q9Y221-2]
DR   RefSeq; NP_001186363.1; NM_001199434.1. [Q9Y221-2]
DR   RefSeq; NP_057185.1; NM_016101.4. [Q9Y221-1]
DR   PDB; 1SQW; X-ray; 1.90 A; A=1-180.
DR   PDB; 1T5Y; X-ray; 2.50 A; A=1-180.
DR   PDBsum; 1SQW; -.
DR   PDBsum; 1T5Y; -.
DR   SMR; Q9Y221; -.
DR   BioGRID; 119517; 147.
DR   IntAct; Q9Y221; 31.
DR   MINT; Q9Y221; -.
DR   STRING; 9606.ENSP00000254940; -.
DR   DrugBank; DB12339; Radezolid.
DR   iPTMnet; Q9Y221; -.
DR   MetOSite; Q9Y221; -.
DR   PhosphoSitePlus; Q9Y221; -.
DR   SwissPalm; Q9Y221; -.
DR   BioMuta; NIP7; -.
DR   DMDM; 56404676; -.
DR   SWISS-2DPAGE; Q9Y221; -.
DR   EPD; Q9Y221; -.
DR   jPOST; Q9Y221; -.
DR   MassIVE; Q9Y221; -.
DR   MaxQB; Q9Y221; -.
DR   PaxDb; Q9Y221; -.
DR   PeptideAtlas; Q9Y221; -.
DR   PRIDE; Q9Y221; -.
DR   ProteomicsDB; 85597; -. [Q9Y221-1]
DR   ProteomicsDB; 85598; -. [Q9Y221-2]
DR   TopDownProteomics; Q9Y221-1; -. [Q9Y221-1]
DR   Antibodypedia; 16183; 230 antibodies from 31 providers.
DR   DNASU; 51388; -.
DR   Ensembl; ENST00000254940; ENSP00000254940; ENSG00000132603.
DR   Ensembl; ENST00000254941; ENSP00000254941; ENSG00000132603. [Q9Y221-2]
DR   GeneID; 51388; -.
DR   KEGG; hsa:51388; -.
DR   MANE-Select; ENST00000254940.10; ENSP00000254940.5; NM_016101.5; NP_057185.1.
DR   UCSC; uc002exa.4; human. [Q9Y221-1]
DR   CTD; 51388; -.
DR   DisGeNET; 51388; -.
DR   GeneCards; NIP7; -.
DR   HGNC; HGNC:24328; NIP7.
DR   HPA; ENSG00000132603; Low tissue specificity.
DR   MIM; 619204; gene.
DR   neXtProt; NX_Q9Y221; -.
DR   OpenTargets; ENSG00000132603; -.
DR   PharmGKB; PA142671264; -.
DR   VEuPathDB; HostDB:ENSG00000132603; -.
DR   eggNOG; KOG3492; Eukaryota.
DR   GeneTree; ENSGT00950000182971; -.
DR   HOGENOM; CLU_097217_0_0_1; -.
DR   InParanoid; Q9Y221; -.
DR   OMA; YKIWVKP; -.
DR   OrthoDB; 1405073at2759; -.
DR   PhylomeDB; Q9Y221; -.
DR   TreeFam; TF300081; -.
DR   PathwayCommons; Q9Y221; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; Q9Y221; -.
DR   BioGRID-ORCS; 51388; 803 hits in 1051 CRISPR screens.
DR   ChiTaRS; NIP7; human.
DR   EvolutionaryTrace; Q9Y221; -.
DR   GeneWiki; NIP7; -.
DR   GenomeRNAi; 51388; -.
DR   Pharos; Q9Y221; Tbio.
DR   PRO; PR:Q9Y221; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9Y221; protein.
DR   Bgee; ENSG00000132603; Expressed in secondary oocyte and 223 other tissues.
DR   ExpressionAtlas; Q9Y221; baseline and differential.
DR   Genevisible; Q9Y221; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0030687; C:preribosome, large subunit precursor; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0042273; P:ribosomal large subunit biogenesis; IBA:GO_Central.
DR   GO; GO:0042255; P:ribosome assembly; IEA:InterPro.
DR   Gene3D; 2.30.130.10; -; 1.
DR   InterPro; IPR002478; PUA.
DR   InterPro; IPR015947; PUA-like_sf.
DR   InterPro; IPR036974; PUA_sf.
DR   InterPro; IPR016686; Ribosomal_synth_fac_NIP7.
DR   InterPro; IPR040598; UPF0113_N.
DR   InterPro; IPR005155; UPF0113_PUA.
DR   Pfam; PF03657; UPF0113; 1.
DR   Pfam; PF17833; UPF0113_N; 1.
DR   PIRSF; PIRSF017190; Rbsml_synth_fac_NIP7; 1.
DR   SMART; SM00359; PUA; 1.
DR   SUPFAM; SSF88697; SSF88697; 1.
DR   PROSITE; PS50890; PUA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Nucleus; Reference proteome;
KW   Ribosome biogenesis; RNA-binding.
FT   CHAIN           1..180
FT                   /note="60S ribosome subunit biogenesis protein NIP7
FT                   homolog"
FT                   /id="PRO_0000218773"
FT   DOMAIN          94..170
FT                   /note="PUA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00161"
FT   REGION          1..92
FT                   /note="N-terminal domain"
FT   REGION          93..180
FT                   /note="C-terminal domain"
FT   VAR_SEQ         95..141
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11042152"
FT                   /id="VSP_012094"
FT   VARIANT         171
FT                   /note="E -> Q (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036488"
FT   HELIX           6..20
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           21..24
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           25..28
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          33..40
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          43..48
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           49..53
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   TURN            54..56
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           60..66
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          67..73
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          79..81
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           83..85
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           86..89
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           90..92
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          96..99
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           101..107
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           115..117
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          118..121
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          130..135
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          140..148
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           150..155
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   STRAND          160..168
FT                   /evidence="ECO:0007829|PDB:1SQW"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:1SQW"
SQ   SEQUENCE   180 AA;  20463 MW;  FC6CFB2250AA4FC9 CRC64;
     MRPLTEEETR VMFEKIAKYI GENLQLLVDR PDGTYCFRLH NDRVYYVSEK IMKLAANISG
     DKLVSLGTCF GKFTKTHKFR LHVTALDYLA PYAKYKVWIK PGAEQSFLYG NHVLKSGLGR
     ITENTSQYQG VVVYSMADIP LGFGVAAKST QDCRKVDPMA IVVFHQADIG EYVRHEETLT
//
ID   RAB9B_HUMAN             Reviewed;         201 AA.
AC   Q9NP90; B2R8M0; Q52LX2;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 178.
DE   RecName: Full=Ras-related protein Rab-9B;
DE   AltName: Full=Rab-9-like protein;
DE            Short=Rab-9L;
GN   Name=RAB9B; Synonyms=RAB9L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=11043518; DOI=10.1007/s100380070025;
RA   Seki N., Azuma T., Yoshikawa T., Masuho Y., Muramatsu M., Saito T.;
RT   "cDNA cloning of a new member of the Ras superfamily, RAB9-like, on the
RT   human chromosome Xq22.1-q22.3 region.";
RL   J. Hum. Genet. 45:318-322(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH HPS4 AND BLOC-3 COMPLEX, AND ABSENCE OF INTERACTION WITH
RP   HPS1.
RX   PubMed=20048159; DOI=10.1074/jbc.m109.069088;
RA   Kloer D.P., Rojas R., Ivan V., Moriyama K., van Vlijmen T., Murthy N.,
RA   Ghirlando R., van der Sluijs P., Hurley J.H., Bonifacino J.S.;
RT   "Assembly of the biogenesis of lysosome-related organelles complex-3 (BLOC-
RT   3) and its interaction with Rab9.";
RL   J. Biol. Chem. 285:7794-7804(2010).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21255211; DOI=10.1111/j.1600-0854.2011.01165.x;
RA   Seto S., Tsujimura K., Koide Y.;
RT   "Rab GTPases regulating phagosome maturation are differentially recruited
RT   to mycobacterial phagosomes.";
RL   Traffic 12:407-420(2011).
RN   [7]
RP   INTERACTION WITH SGSM1.
RX   PubMed=22637480; DOI=10.1074/jbc.m112.362558;
RA   Nottingham R.M., Pusapati G.V., Ganley I.G., Barr F.A., Lambright D.G.,
RA   Pfeffer S.R.;
RT   "RUTBC2 protein, a Rab9A effector and GTPase-activating protein for
RT   Rab36.";
RL   J. Biol. Chem. 287:22740-22748(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2-180 IN COMPLEX WITH GTP ANALOG.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human RAB9B in complex with a GTP analogue.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Involved in the transport of proteins between the endosomes
CC       and the trans Golgi network. {ECO:0000250|UniProtKB:P24408}.
CC   -!- SUBUNIT: Interacts (GTP-bound form) with SGSM1; the GDP-bound form has
CC       much lower affinity for SGSM1 (PubMed:22637480). The GTP-bound form but
CC       not the GDP-bound form interacts with HPS4 and the BLOC-3 complex
CC       (heterodimer of HPS1 and HPS4) but does not interact with HPS1 alone
CC       (PubMed:20048159). {ECO:0000269|PubMed:20048159,
CC       ECO:0000269|PubMed:22637480}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Lipid-anchor
CC       {ECO:0000305}; Cytoplasmic side {ECO:0000305}. Cytoplasmic vesicle,
CC       phagosome {ECO:0000269|PubMed:21255211}. Cytoplasmic vesicle, phagosome
CC       membrane {ECO:0000250}; Lipid-anchor {ECO:0000250}; Cytoplasmic side
CC       {ECO:0000250}. Note=Recruited to phagosomes containing S.aureus or
CC       M.tuberculosis.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:11043518}.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Rab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB036693; BAA89542.1; -; mRNA.
DR   EMBL; AK313425; BAG36217.1; -; mRNA.
DR   EMBL; AL139228; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC093756; AAH93756.1; -; mRNA.
DR   EMBL; BC093758; AAH93758.1; -; mRNA.
DR   CCDS; CCDS14515.1; -.
DR   RefSeq; NP_057454.1; NM_016370.2.
DR   PDB; 2OCB; X-ray; 2.20 A; A=2-180.
DR   PDBsum; 2OCB; -.
DR   SMR; Q9NP90; -.
DR   BioGRID; 119382; 24.
DR   IntAct; Q9NP90; 12.
DR   STRING; 9606.ENSP00000243298; -.
DR   iPTMnet; Q9NP90; -.
DR   PhosphoSitePlus; Q9NP90; -.
DR   BioMuta; RAB9B; -.
DR   DMDM; 13124471; -.
DR   EPD; Q9NP90; -.
DR   jPOST; Q9NP90; -.
DR   MassIVE; Q9NP90; -.
DR   MaxQB; Q9NP90; -.
DR   PaxDb; Q9NP90; -.
DR   PeptideAtlas; Q9NP90; -.
DR   PRIDE; Q9NP90; -.
DR   ProteomicsDB; 81933; -.
DR   Antibodypedia; 29164; 83 antibodies from 27 providers.
DR   DNASU; 51209; -.
DR   Ensembl; ENST00000243298; ENSP00000243298; ENSG00000123570.
DR   GeneID; 51209; -.
DR   KEGG; hsa:51209; -.
DR   MANE-Select; ENST00000243298.3; ENSP00000243298.2; NM_016370.4; NP_057454.1.
DR   UCSC; uc004ell.3; human.
DR   CTD; 51209; -.
DR   DisGeNET; 51209; -.
DR   GeneCards; RAB9B; -.
DR   HGNC; HGNC:14090; RAB9B.
DR   HPA; ENSG00000123570; Tissue enhanced (heart).
DR   MalaCards; RAB9B; -.
DR   MIM; 300285; gene.
DR   neXtProt; NX_Q9NP90; -.
DR   OpenTargets; ENSG00000123570; -.
DR   PharmGKB; PA34153; -.
DR   VEuPathDB; HostDB:ENSG00000123570; -.
DR   eggNOG; KOG0394; Eukaryota.
DR   GeneTree; ENSGT00940000160481; -.
DR   HOGENOM; CLU_041217_10_6_1; -.
DR   InParanoid; Q9NP90; -.
DR   OMA; NRKAPRS; -.
DR   PhylomeDB; Q9NP90; -.
DR   TreeFam; TF326442; -.
DR   PathwayCommons; Q9NP90; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6811440; Retrograde transport at the Trans-Golgi-Network.
DR   Reactome; R-HSA-8873719; RAB geranylgeranylation.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   Reactome; R-HSA-9706019; RHOBTB3 ATPase cycle.
DR   SignaLink; Q9NP90; -.
DR   BioGRID-ORCS; 51209; 3 hits in 661 CRISPR screens.
DR   ChiTaRS; RAB9B; human.
DR   EvolutionaryTrace; Q9NP90; -.
DR   GenomeRNAi; 51209; -.
DR   Pharos; Q9NP90; Tbio.
DR   PRO; PR:Q9NP90; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9NP90; protein.
DR   Bgee; ENSG00000123570; Expressed in left ventricle myocardium and 179 other tissues.
DR   Genevisible; Q9NP90; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005770; C:late endosome; IBA:GO_Central.
DR   GO; GO:0005764; C:lysosome; IBA:GO_Central.
DR   GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0019003; F:GDP binding; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0032482; P:Rab protein signal transduction; IEA:InterPro.
DR   GO; GO:0042147; P:retrograde transport, endosome to Golgi; IBA:GO_Central.
DR   CDD; cd04116; Rab9; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR041824; Rab9.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SMART; SM00174; RHO; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51419; RAB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cytoplasmic vesicle; GTP-binding; Lipoprotein;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Prenylation;
KW   Protein transport; Reference proteome; Transport.
FT   CHAIN           1..201
FT                   /note="Ras-related protein Rab-9B"
FT                   /id="PRO_0000121142"
FT   NP_BIND         14..22
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   NP_BIND         33..34
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   NP_BIND         38..39
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   NP_BIND         124..127
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   NP_BIND         155..156
FT                   /note="GTP"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   MOTIF           36..44
FT                   /note="Effector region"
FT                   /evidence="ECO:0000250"
FT   BINDING         65
FT                   /note="GTP; via amide nitrogen"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PDB:2OCB"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BHH2"
FT   LIPID           200
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           201
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000250"
FT   STRAND          6..13
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           20..29
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   STRAND          41..53
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   STRAND          55..63
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           67..69
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           70..73
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           74..76
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   STRAND          81..88
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           92..96
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           98..108
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   TURN            114..116
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   STRAND          119..124
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           135..144
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   TURN            155..158
FT                   /evidence="ECO:0007829|PDB:2OCB"
FT   HELIX           161..173
FT                   /evidence="ECO:0007829|PDB:2OCB"
SQ   SEQUENCE   201 AA;  22719 MW;  B35EDA8E8358C49C CRC64;
     MSGKSLLLKV ILLGDGGVGK SSLMNRYVTN KFDSQAFHTI GVEFLNRDLE VDGRFVTLQI
     WDTAGQERFK SLRTPFYRGA DCCLLTFSVD DRQSFENLGN WQKEFIYYAD VKDPEHFPFV
     VLGNKVDKED RQVTTEEAQT WCMENGDYPY LETSAKDDTN VTVAFEEAVR QVLAVEEQLE
     HCMLGHTIDL NSGSKAGSSC C
//
ID   TET5A_HUMAN             Reviewed;         442 AA.
AC   Q96IP4; A8K7U4; Q5TF86; Q8NFZ9; Q9BW32; Q9NXV5;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   23-FEB-2022, entry version 129.
DE   RecName: Full=Terminal nucleotidyltransferase 5A {ECO:0000305};
DE            EC=2.7.7.19 {ECO:0000269|PubMed:33882302};
DE   AltName: Full=HBV X-transactivated gene 11 protein {ECO:0000303|Ref.2};
DE   AltName: Full=HBV XAg-transactivated protein 11 {ECO:0000303|Ref.2};
GN   Name=TENT5A {ECO:0000312|HGNC:HGNC:18345};
GN   Synonyms=C6orf37 {ECO:0000312|HGNC:HGNC:18345},
GN   FAM46A {ECO:0000312|HGNC:HGNC:18345}, XTP11 {ECO:0000303|Ref.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT 39-GLY--GLY-43 DEL, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12054608; DOI=10.1016/s0006-291x(02)00228-0;
RA   Lagali P.S., Kakuk L.E., Griesinger I.B., Wong P.W., Ayyagari R.;
RT   "Identification and characterization of C6orf37, a novel candidate human
RT   retinal disease gene on chromosome 6q14.";
RL   Biochem. Biophys. Res. Commun. 293:356-365(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-ASP-PHE-GLY-GLY-24
RP   INS AND ALA-313.
RC   TISSUE=Synovium;
RA   Liu Y., Li J., Cheng J., Ji D., Gong M., Zhang L., Chen J.;
RT   "Homo sapiens HBV XAg-transactivated protein 11 (XTP11) mRNA.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   GLY-ASP-PHE-GLY-GLY-24 INS AND ALA-313.
RC   TISSUE=Colon, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   GLY-ASP-PHE-GLY-GLY-24 INS.
RC   TISSUE=Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, AND MUTAGENESIS OF ASP-139 AND ASP-141.
RX   PubMed=33882302; DOI=10.1016/j.celrep.2021.109015;
RA   Gewartowska O., Aranaz-Novaliches G., Krawczyk P.S., Mroczek S.,
RA   Kusio-Kobialka M., Tarkowski B., Spoutil F., Benada O., Kofronova O.,
RA   Szwedziak P., Cysewski D., Gruchota J., Szpila M., Chlebowski A.,
RA   Sedlacek R., Prochazka J., Dziembowski A.;
RT   "Cytoplasmic polyadenylation by TENT5A is required for proper bone
RT   formation.";
RL   Cell Rep. 35:109015-109015(2021).
RN   [8]
RP   INVOLVEMENT IN OI18, VARIANTS OI18 ARG-127 AND GLY-231, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=29358272; DOI=10.1136/jmedgenet-2017-104999;
RA   Doyard M., Bacrot S., Huber C., Di Rocco M., Goldenberg A., Aglan M.S.,
RA   Brunelle P., Temtamy S., Michot C., Otaify G.A., Haudry C., Castanet M.,
RA   Leroux J., Bonnefont J.P., Munnich A., Baujat G., Lapunzina P., Monnot S.,
RA   Ruiz-Perez V.L., Cormier-Daire V.;
RT   "FAM46A mutations are responsible for autosomal recessive osteogenesis
RT   imperfecta.";
RL   J. Med. Genet. 55:278-284(2018).
RN   [9]
RP   VARIANTS GLY-ASP-PHE-GLY-GLY-24 INS AND 39-GLY--GLY-43 DEL.
RX   PubMed=16545789; DOI=10.1016/j.cca.2005.12.043;
RA   Cui J., Wang W., Lai M.D., Xu E.P., Lv B.J., Lin J., Ruan W.J., Ma Y.,
RA   Yao C.;
RT   "Identification of a novel VNTR polymorphism in C6orf37 and its association
RT   with colorectal cancer risk in Chinese population.";
RL   Clin. Chim. Acta 368:155-159(2006).
CC   -!- FUNCTION: Cytoplasmic non-canonical poly(A) RNA polymerase that
CC       catalyzes the transfer of one adenosine molecule from an ATP to an mRNA
CC       poly(A) tail bearing a 3'-OH terminal group and participates in the
CC       cytoplasmic polyadenylation (PubMed:33882302). Polyadenylates mRNA
CC       encoding extracellular matrix constituents and other genes crucial for
CC       bone mineralization and during osteoblast mineralization, mainly
CC       focuses on ER-targeted mRNAs (By similarity).
CC       {ECO:0000250|UniProtKB:D3Z5S8, ECO:0000269|PubMed:33882302}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + RNA(n) = diphosphate + RNA(n)-3'-adenine ribonucleotide;
CC         Xref=Rhea:RHEA:11332, Rhea:RHEA-COMP:14527, Rhea:RHEA-COMP:17347,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:140395,
CC         ChEBI:CHEBI:173115; EC=2.7.7.19;
CC         Evidence={ECO:0000269|PubMed:33882302};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11333;
CC         Evidence={ECO:0000269|PubMed:33882302};
CC   -!- INTERACTION:
CC       Q96IP4; P54253: ATXN1; NbExp=5; IntAct=EBI-954084, EBI-930964;
CC       Q96IP4; Q9NP31: SH2D2A; NbExp=3; IntAct=EBI-954084, EBI-490630;
CC       Q96IP4; P43405: SYK; NbExp=3; IntAct=EBI-954084, EBI-78302;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:D3Z5S8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96IP4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96IP4-2; Sequence=VSP_035502;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with preferential expression
CC       observed in the retina compared to other ocular tissues
CC       (PubMed:12054608). Also expressed in osteoblasts (PubMed:29358272).
CC       {ECO:0000269|PubMed:12054608, ECO:0000269|PubMed:29358272}.
CC   -!- DISEASE: Osteogenesis imperfecta 18 (OI18) [MIM:617952]: An autosomal
CC       recessive form of osteogenesis imperfecta, a connective tissue disorder
CC       characterized by low bone mass, bone fragility and susceptibility to
CC       fractures after minimal trauma. Disease severity ranges from very mild
CC       forms without fractures to intrauterine fractures and perinatal
CC       lethality. Extraskeletal manifestations, which affect a variable number
CC       of patients, are dentinogenesis imperfecta, hearing loss, and blue
CC       sclerae. OI18 is a severe form characterized by congenital bowing of
CC       the lower limb, wormian bones, blue sclerae, vertebral collapses and
CC       multiple fractures in the first years of life.
CC       {ECO:0000269|PubMed:29358272}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TENT family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH00683.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF350451; AAM53071.1; -; mRNA.
DR   EMBL; AY740520; AAW66943.1; -; mRNA.
DR   EMBL; AK000044; BAA90903.1; -; mRNA.
DR   EMBL; AK056057; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK292109; BAF84798.1; -; mRNA.
DR   EMBL; AL078599; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48692.1; -; Genomic_DNA.
DR   EMBL; BC000683; AAH00683.1; ALT_INIT; mRNA.
DR   EMBL; BC007351; AAH07351.1; -; mRNA.
DR   CCDS; CCDS34489.1; -. [Q96IP4-1]
DR   PIR; JC7837; JC7837.
DR   RefSeq; NP_060103.2; NM_017633.2. [Q96IP4-1]
DR   SMR; Q96IP4; -.
DR   BioGRID; 120744; 80.
DR   IntAct; Q96IP4; 48.
DR   STRING; 9606.ENSP00000318298; -.
DR   iPTMnet; Q96IP4; -.
DR   PhosphoSitePlus; Q96IP4; -.
DR   BioMuta; FAM46A; -.
DR   DMDM; 209572613; -.
DR   EPD; Q96IP4; -.
DR   jPOST; Q96IP4; -.
DR   MassIVE; Q96IP4; -.
DR   MaxQB; Q96IP4; -.
DR   PaxDb; Q96IP4; -.
DR   PeptideAtlas; Q96IP4; -.
DR   PRIDE; Q96IP4; -.
DR   ProteomicsDB; 76841; -. [Q96IP4-1]
DR   ProteomicsDB; 76842; -. [Q96IP4-2]
DR   Antibodypedia; 46387; 106 antibodies from 20 providers.
DR   DNASU; 55603; -.
DR   Ensembl; ENST00000320172; ENSP00000318298; ENSG00000112773.
DR   Ensembl; ENST00000369754; ENSP00000358769; ENSG00000112773. [Q96IP4-2]
DR   GeneID; 55603; -.
DR   KEGG; hsa:55603; -.
DR   MANE-Select; ENST00000320172.11; ENSP00000318298.6; NM_017633.3; NP_060103.2.
DR   UCSC; uc003pjf.3; human. [Q96IP4-1]
DR   CTD; 55603; -.
DR   DisGeNET; 55603; -.
DR   GeneCards; TENT5A; -.
DR   HGNC; HGNC:18345; TENT5A.
DR   HPA; ENSG00000112773; Group enriched (bone marrow, salivary gland).
DR   MalaCards; TENT5A; -.
DR   MIM; 611357; gene.
DR   MIM; 617952; phenotype.
DR   neXtProt; NX_Q96IP4; -.
DR   OpenTargets; ENSG00000112773; -.
DR   Orphanet; 666; Osteogenesis imperfecta.
DR   PharmGKB; PA38531; -.
DR   VEuPathDB; HostDB:ENSG00000112773; -.
DR   eggNOG; KOG3852; Eukaryota.
DR   GeneTree; ENSGT00940000157191; -.
DR   HOGENOM; CLU_008115_2_1_1; -.
DR   InParanoid; Q96IP4; -.
DR   OrthoDB; 612201at2759; -.
DR   PhylomeDB; Q96IP4; -.
DR   TreeFam; TF315239; -.
DR   PathwayCommons; Q96IP4; -.
DR   SignaLink; Q96IP4; -.
DR   BioGRID-ORCS; 55603; 5 hits in 1045 CRISPR screens.
DR   ChiTaRS; FAM46A; human.
DR   GeneWiki; FAM46A; -.
DR   GenomeRNAi; 55603; -.
DR   Pharos; Q96IP4; Tbio.
DR   PRO; PR:Q96IP4; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q96IP4; protein.
DR   Bgee; ENSG00000112773; Expressed in chorionic villus and 234 other tissues.
DR   ExpressionAtlas; Q96IP4; baseline and differential.
DR   Genevisible; Q96IP4; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:1990817; F:RNA adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0048255; P:mRNA stabilization; IBA:GO_Central.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; ISS:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; IEA:Ensembl.
DR   InterPro; IPR012937; TET5.
DR   PANTHER; PTHR12974; PTHR12974; 1.
DR   Pfam; PF07984; NTP_transf_7; 1.
DR   SMART; SM01153; DUF1693; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasm; Disease variant; Nucleotidyltransferase;
KW   Osteogenesis imperfecta; Reference proteome; Repeat; Transferase.
FT   CHAIN           1..442
FT                   /note="Terminal nucleotidyltransferase 5A"
FT                   /id="PRO_0000259929"
FT   REPEAT          24..28
FT                   /note="1"
FT   REPEAT          29..33
FT                   /note="2"
FT   REPEAT          34..38
FT                   /note="3"
FT   REPEAT          39..43
FT                   /note="4"
FT   VAR_SEQ         1
FT                   /note="M -> MHQRYFWTDQGQVALGGHYM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035502"
FT   VARIANT         24
FT                   /note="G -> GGDFGG"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046649"
FT   VARIANT         39..43
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:12054608,
FT                   ECO:0000269|PubMed:16545789"
FT                   /id="VAR_028978"
FT   VARIANT         127
FT                   /note="H -> R (in OI18; unknown pathological significance;
FT                   dbSNP:rs1187611948)"
FT                   /evidence="ECO:0000269|PubMed:29358272"
FT                   /id="VAR_080798"
FT   VARIANT         231
FT                   /note="D -> G (in OI18; unknown pathological significance;
FT                   dbSNP:rs1554200371)"
FT                   /evidence="ECO:0000269|PubMed:29358272"
FT                   /id="VAR_080799"
FT   VARIANT         313
FT                   /note="T -> A"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.2"
FT                   /id="VAR_028979"
FT   MUTAGEN         139
FT                   /note="D->N: Does not elongate poly(A) tail; when
FT                   associated with N-141."
FT                   /evidence="ECO:0000269|PubMed:33882302"
FT   MUTAGEN         141
FT                   /note="D->N: Does not elongate poly(A) tail; when
FT                   associated with N-139."
FT                   /evidence="ECO:0000269|PubMed:33882302"
FT   CONFLICT        47
FT                   /note="S -> T (in Ref. 1; AAM53071)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145
FT                   /note="C -> S (in Ref. 1; AAM53071)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   442 AA;  49666 MW;  C72092C590C1E369 CRC64;
     MAEGEGYFAM SEDELACSPY IPLGGDFGGG DFGGGDFGGG DFGGGGSFGG HCLDYCESPT
     AHCNVLNWEQ VQRLDGILSE TIPIHGRGNF PTLELQPSLI VKVVRRRLAE KRIGVRDVRL
     NGSAASHVLH QDSGLGYKDL DLIFCADLRG EGEFQTVKDV VLDCLLDFLP EGVNKEKITP
     LTLKEAYVQK MVKVCNDSDR WSLISLSNNS GKNVELKFVD SLRRQFEFSV DSFQIKLDSL
     LLFYECSENP MTETFHPTII GESVYGDFQE AFDHLCNKII ATRNPEEIRG GGLLKYCNLL
     VRGFRPASDE IKTLQRYMCS RFFIDFSDIG EQQRKLESYL QNHFVGLEDR KYEYLMTLHG
     VVNESTVCLM GHERRQTLNL ITMLAIRVLA DQNVIPNVAN VTCYYQPAPY VADANFSNYY
     IAQVQPVFTC QQQTYSTWLP CN
//
ID   ELOV2_HUMAN             Reviewed;         296 AA.
AC   Q9NXB9; Q6P9E1; Q86W94;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   26-FEB-2008, sequence version 2.
DT   23-FEB-2022, entry version 153.
DE   RecName: Full=Elongation of very long chain fatty acids protein 2 {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000305};
DE            EC=2.3.1.199 {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:11734209, ECO:0000269|PubMed:12371743, ECO:0000269|PubMed:19575253, ECO:0000269|PubMed:20937905};
DE   AltName: Full=3-keto acyl-CoA synthase ELOVL2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=ELOVL fatty acid elongase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE            Short=ELOVL FA elongase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=Very long chain 3-ketoacyl-CoA synthase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=Very long chain 3-oxoacyl-CoA synthase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
GN   Name=ELOVL2 {ECO:0000255|HAMAP-Rule:MF_03202};
GN   Synonyms=ELG3 {ECO:0000303|PubMed:11734209}, SSC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-216.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=11734209; DOI=10.1016/s0014-5793(01)03135-0;
RA   de Antueno R.J., Knickle L.C., Smith H., Elliot M.L., Allen S.J., Nwaka S.,
RA   Winther M.D.;
RT   "Activity of human Delta5 and Delta6 desaturases on multiple n-3 and n-6
RT   polyunsaturated fatty acids.";
RL   FEBS Lett. 509:77-80(2001).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=12371743; DOI=10.1007/s11745-002-0955-6;
RA   Leonard A.E., Kelder B., Bobik E.G., Chuang L.-T., Lewis C.J.,
RA   Kopchick J.J., Mukerji P., Huang Y.-S.;
RT   "Identification and expression of mammalian long-chain PUFA elongation
RT   enzymes.";
RL   Lipids 37:733-740(2002).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=19575253; DOI=10.1007/s11745-009-3320-8;
RA   Kitazawa H., Miyamoto Y., Shimamura K., Nagumo A., Tokita S.;
RT   "Development of a high-density assay for long-chain fatty acyl-CoA
RT   elongases.";
RL   Lipids 44:765-773(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=20937905; DOI=10.1073/pnas.1005572107;
RA   Ohno Y., Suto S., Yamanaka M., Mizutani Y., Mitsutake S., Igarashi Y.,
RA   Sassa T., Kihara A.;
RT   "ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid
RT   synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18439-18444(2010).
CC   -!- FUNCTION: Catalyzes the first and rate-limiting reaction of the four
CC       reactions that constitute the long-chain fatty acids elongation cycle.
CC       This endoplasmic reticulum-bound enzymatic process allows the addition
CC       of 2 carbons to the chain of long- and very long-chain fatty acids
CC       (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of
CC       polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting
CC       specifically toward polyunsaturated acyl-CoA with the higher activity
CC       toward C20:4(n-6) acyl-CoA. May participate in the production of
CC       polyunsaturated VLCFAs of different chain lengths that are involved in
CC       multiple biological processes as precursors of membrane lipids and
CC       lipid mediators. {ECO:0000255|HAMAP-Rule:MF_03202,
CC       ECO:0000269|PubMed:11734209, ECO:0000269|PubMed:12371743,
CC       ECO:0000269|PubMed:19575253, ECO:0000269|PubMed:20937905}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a very-long-chain acyl-CoA + H(+) + malonyl-CoA = a very-long-
CC         chain 3-oxoacyl-CoA + CO2 + CoA; Xref=Rhea:RHEA:32727,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16526, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57384, ChEBI:CHEBI:90725, ChEBI:CHEBI:90736;
CC         EC=2.3.1.199; Evidence={ECO:0000255|HAMAP-Rule:MF_03202,
CC         ECO:0000269|PubMed:11734209, ECO:0000269|PubMed:12371743,
CC         ECO:0000269|PubMed:19575253, ECO:0000269|PubMed:20937905};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32728;
CC         Evidence={ECO:0000305|PubMed:11734209};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + H(+) + malonyl-CoA =
CC         (7Z,10Z,13Z,16Z)-3-oxodocosatetraenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36475, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:57384,
CC         ChEBI:CHEBI:73852; Evidence={ECO:0000269|PubMed:11734209,
CC         ECO:0000269|PubMed:12371743, ECO:0000269|PubMed:19575253,
CC         ECO:0000269|PubMed:20937905};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36476;
CC         Evidence={ECO:0000305|PubMed:11734209};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(7Z,10Z,13Z,16Z)-docosatetraenoyl-CoA + H(+) + malonyl-CoA =
CC         (9Z,12Z,15Z,18Z)-3-oxotetracosatetraenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36479, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73856,
CC         ChEBI:CHEBI:73857; Evidence={ECO:0000269|PubMed:11734209,
CC         ECO:0000269|PubMed:12371743};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36480;
CC         Evidence={ECO:0000305|PubMed:11734209};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA + H(+) + malonyl-CoA
CC         = (7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36483, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73862,
CC         ChEBI:CHEBI:73863; Evidence={ECO:0000269|PubMed:11734209,
CC         ECO:0000269|PubMed:12371743};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36484;
CC         Evidence={ECO:0000305|PubMed:11734209};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA + H(+) + malonyl-CoA
CC         = (9Z,12Z,15Z,18Z,21Z)-3-oxotetracosapentaenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36491, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73870,
CC         ChEBI:CHEBI:73871; Evidence={ECO:0000269|PubMed:11734209,
CC         ECO:0000269|PubMed:12371743};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36492;
CC         Evidence={ECO:0000305|PubMed:11734209};
CC   -!- PATHWAY: Lipid metabolism; polyunsaturated fatty acid biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:11734209,
CC       ECO:0000269|PubMed:12371743, ECO:0000269|PubMed:19575253,
CC       ECO:0000269|PubMed:20937905}.
CC   -!- INTERACTION:
CC       Q9NXB9; Q9H0Q3: FXYD6; NbExp=3; IntAct=EBI-17206972, EBI-713304;
CC       Q9NXB9; Q01628: IFITM3; NbExp=3; IntAct=EBI-17206972, EBI-7932862;
CC       Q9NXB9; Q13021: MALL; NbExp=3; IntAct=EBI-17206972, EBI-750078;
CC       Q9NXB9; A2RU14: TMEM218; NbExp=3; IntAct=EBI-17206972, EBI-10173151;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:20937905}; Multi-
CC       pass membrane protein {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   -!- TISSUE SPECIFICITY: Liver and testis. {ECO:0000269|PubMed:20937905}.
CC   -!- DOMAIN: The C-terminal di-lysine motif may confer endoplasmic reticulum
CC       localization. {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   -!- SIMILARITY: Belongs to the ELO family. ELOVL2 subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK000341; BAA91096.1; -; mRNA.
DR   EMBL; AL121955; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471087; EAW55291.1; -; Genomic_DNA.
DR   EMBL; BC050278; AAH50278.2; -; mRNA.
DR   EMBL; BC060809; AAH60809.1; -; mRNA.
DR   CCDS; CCDS4518.1; -.
DR   RefSeq; NP_060240.3; NM_017770.3.
DR   SMR; Q9NXB9; -.
DR   BioGRID; 120244; 54.
DR   IntAct; Q9NXB9; 12.
DR   STRING; 9606.ENSP00000346693; -.
DR   BindingDB; Q9NXB9; -.
DR   ChEMBL; CHEMBL5911; -.
DR   DrugBank; DB00132; alpha-Linolenic acid.
DR   SwissLipids; SLP:000000245; -.
DR   iPTMnet; Q9NXB9; -.
DR   PhosphoSitePlus; Q9NXB9; -.
DR   SwissPalm; Q9NXB9; -.
DR   BioMuta; ELOVL2; -.
DR   DMDM; 187472388; -.
DR   MassIVE; Q9NXB9; -.
DR   MaxQB; Q9NXB9; -.
DR   PaxDb; Q9NXB9; -.
DR   PeptideAtlas; Q9NXB9; -.
DR   PRIDE; Q9NXB9; -.
DR   ProteomicsDB; 83070; -.
DR   Antibodypedia; 44274; 174 antibodies from 26 providers.
DR   DNASU; 54898; -.
DR   Ensembl; ENST00000354666; ENSP00000346693; ENSG00000197977.
DR   GeneID; 54898; -.
DR   KEGG; hsa:54898; -.
DR   MANE-Select; ENST00000354666.4; ENSP00000346693.3; NM_017770.4; NP_060240.3.
DR   UCSC; uc003mzp.5; human.
DR   CTD; 54898; -.
DR   DisGeNET; 54898; -.
DR   GeneCards; ELOVL2; -.
DR   HGNC; HGNC:14416; ELOVL2.
DR   HPA; ENSG00000197977; Tissue enhanced (liver, placenta, retina).
DR   MIM; 611814; gene.
DR   neXtProt; NX_Q9NXB9; -.
DR   OpenTargets; ENSG00000197977; -.
DR   PharmGKB; PA27761; -.
DR   VEuPathDB; HostDB:ENSG00000197977; -.
DR   eggNOG; KOG3071; Eukaryota.
DR   GeneTree; ENSGT01030000234600; -.
DR   HOGENOM; CLU_048483_0_1_1; -.
DR   InParanoid; Q9NXB9; -.
DR   OMA; FHKDYFA; -.
DR   OrthoDB; 1094172at2759; -.
DR   PhylomeDB; Q9NXB9; -.
DR   TreeFam; TF323454; -.
DR   PathwayCommons; Q9NXB9; -.
DR   Reactome; R-HSA-2046105; Linoleic acid (LA) metabolism.
DR   Reactome; R-HSA-2046106; alpha-linolenic acid (ALA) metabolism.
DR   Reactome; R-HSA-75876; Synthesis of very long-chain fatty acyl-CoAs.
DR   SignaLink; Q9NXB9; -.
DR   UniPathway; UPA00658; -.
DR   BioGRID-ORCS; 54898; 5 hits in 1038 CRISPR screens.
DR   ChiTaRS; ELOVL2; human.
DR   GenomeRNAi; 54898; -.
DR   Pharos; Q9NXB9; Tbio.
DR   PRO; PR:Q9NXB9; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9NXB9; protein.
DR   Bgee; ENSG00000197977; Expressed in ventricular zone and 172 other tissues.
DR   ExpressionAtlas; Q9NXB9; baseline and differential.
DR   Genevisible; Q9NXB9; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0009922; F:fatty acid elongase activity; IDA:UniProtKB.
DR   GO; GO:0102756; F:very-long-chain 3-ketoacyl-CoA synthase activity; IEA:UniProtKB-EC.
DR   GO; GO:0036109; P:alpha-linolenic acid metabolic process; TAS:Reactome.
DR   GO; GO:0034625; P:fatty acid elongation, monounsaturated fatty acid; IBA:GO_Central.
DR   GO; GO:0034626; P:fatty acid elongation, polyunsaturated fatty acid; IDA:UniProtKB.
DR   GO; GO:0019367; P:fatty acid elongation, saturated fatty acid; IBA:GO_Central.
DR   GO; GO:0043651; P:linoleic acid metabolic process; TAS:Reactome.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006636; P:unsaturated fatty acid biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0042761; P:very long-chain fatty acid biosynthetic process; IDA:UniProtKB.
DR   HAMAP; MF_03202; VLCF_elongase_2; 1.
DR   InterPro; IPR030457; ELO_CS.
DR   InterPro; IPR002076; ELO_fam.
DR   InterPro; IPR033680; ELOVL2.
DR   PANTHER; PTHR11157; PTHR11157; 1.
DR   PANTHER; PTHR11157:SF16; PTHR11157:SF16; 1.
DR   Pfam; PF01151; ELO; 1.
DR   PROSITE; PS01188; ELO; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Fatty acid biosynthesis; Fatty acid metabolism;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Reference proteome;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..296
FT                   /note="Elongation of very long chain fatty acids protein 2"
FT                   /id="PRO_0000207538"
FT   TRANSMEM        29..49
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        67..87
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        115..135
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        153..173
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        175..195
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        208..225
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        230..250
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   MOTIF           293..296
FT                   /note="Di-lysine motif"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   VARIANT         216
FT                   /note="T -> A (in dbSNP:rs17855038)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_039039"
FT   VARIANT         225
FT                   /note="V -> M (in dbSNP:rs6919726)"
FT                   /id="VAR_039040"
FT   CONFLICT        31
FT                   /note="M -> T (in Ref. 1; BAA91096)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="I -> V (in Ref. 1; BAA91096)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   296 AA;  34585 MW;  CFB09952FBE90957 CRC64;
     MEHLKAFDDE INAFLDNMFG PRDSRVRGWF MLDSYLPTFF LTVMYLLSIW LGNKYMKNRP
     ALSLRGILTL YNLGITLLSA YMLAELILST WEGGYNLQCQ DLTSAGEADI RVAKVLWWYY
     FSKSVEFLDT IFFVLRKKTS QITFLHVYHH ASMFNIWWCV LNWIPCGQSF FGPTLNSFIH
     ILMYSYYGLS VFPSMHKYLW WKKYLTQAQL VQFVLTITHT MSAVVKPCGF PFGCLIFQSS
     YMLTLVILFL NFYVQTYRKK PMKKDMQEPP AGKEVKNGFS KAYFTAANGV MNKKAQ
//
ID   RN125_HUMAN             Reviewed;         232 AA.
AC   Q96EQ8; Q9NX39;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 4.
DT   23-FEB-2022, entry version 169.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF125 {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000269|PubMed:15843525, ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375};
DE   AltName: Full=RING finger protein 125 {ECO:0000312|HGNC:HGNC:21150};
DE   AltName: Full=T-cell RING activation protein 1 {ECO:0000303|PubMed:12974981};
DE            Short=TRAC-1 {ECO:0000303|PubMed:12974981};
GN   Name=RNF125 {ECO:0000312|HGNC:HGNC:21150};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION, AND TISSUE SPECIFICITY.
RX   PubMed=12974981; DOI=10.1186/1475-4924-2-21;
RA   Chu P., Pardo J., Zhao H., Li C.C., Pali E., Shen M.M., Qu K., Yu S.X.,
RA   Huang B.C.B., Yu P., Masuda E.S., Molineaux S.M., Kolbinger F., Aversa G.,
RA   de Vries J., Payan D.G., Liao X.C.;
RT   "Systematic identification of regulatory proteins critical for T-cell
RT   activation.";
RL   J. Biol. 2:21.1-21.16(2003).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND MUTAGENESIS OF GLY-2;
RP   CYS-37; CYS-40; HIS-54; CYS-57; CYS-72 AND CYS-75.
RX   PubMed=15843525; DOI=10.4049/jimmunol.174.9.5288;
RA   Zhao H., Li C.C., Pardo J., Chu P.C., Liao C.X., Huang J., Dong J.G.,
RA   Zhou X., Huang Q., Huang B.C.B., Bennett M.K., Molineaux S.M., Lu H.,
RA   Daniel-Issakani S., Payan D.G., Masuda E.S.;
RT   "A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell
RT   activation.";
RL   J. Immunol. 174:5288-5297(2005).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-72 AND CYS-75.
RX   PubMed=17460044; DOI=10.1073/pnas.0611551104;
RA   Arimoto K., Takahashi H., Hishiki T., Konishi H., Fujita T., Shimotohno K.;
RT   "Negative regulation of the RIG-I signaling by the ubiquitin ligase
RT   RNF125.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7500-7505(2007).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF CYS-37 AND CYS-40.
RX   PubMed=17643463; DOI=10.1016/j.virol.2007.06.028;
RA   Shoji-Kawata S., Zhong Q., Kameoka M., Iwabu Y., Sapsutthipas S.,
RA   Luftig R.B., Ikuta K.;
RT   "The RING finger ubiquitin ligase RNF125/TRAC-1 down-modulates HIV-1
RT   replication in primary human peripheral blood mononuclear cells.";
RL   Virology 368:191-204(2007).
RN   [7]
RP   SUBCELLULAR LOCATION, AUTOUBIQUITINATION, MYRISTOYLATION AT GLY-2, AND
RP   MUTAGENESIS OF GLY-2; CYS-37; CYS-40; VAL-217 AND SER-221.
RX   PubMed=17990982; DOI=10.1042/bj20070995;
RA   Giannini A.L., Gao Y., Bijlmakers M.J.;
RT   "T-cell regulator RNF125/TRAC-1 belongs to a novel family of ubiquitin
RT   ligases with zinc fingers and a ubiquitin-binding domain.";
RL   Biochem. J. 410:101-111(2008).
RN   [8]
RP   INVOLVEMENT IN TNORS, AND VARIANTS TNORS ILE-112; LEU-163 AND CYS-174.
RX   PubMed=25196541; DOI=10.1002/humu.22689;
RG   SOGRI Consortium;
RA   Tenorio J., Mansilla A., Valencia M., Martinez-Glez V., Romanelli V.,
RA   Arias P., Castrejon N., Poletta F., Guillen-Navarro E., Gordo G.,
RA   Mansilla E., Garcia-Santiago F., Gonzalez-Casado I., Vallespin E.,
RA   Palomares M., Mori M.A., Santos-Simarro F., Garcia-Minaur S., Fernandez L.,
RA   Mena R., Benito-Sanz S., del Pozo A., Silla J.C., Ibanez K.,
RA   Lopez-Granados E., Martin-Trujillo A., Montaner D., Heath K.E.,
RA   Campos-Barros A., Dopazo J., Nevado J., Monk D., Ruiz-Perez V.L.,
RA   Lapunzina P.;
RT   "A new overgrowth syndrome is due to mutations in RNF125.";
RL   Hum. Mutat. 35:1436-1441(2014).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-72 AND CYS-75.
RX   PubMed=25591766; DOI=10.1159/000369691;
RA   Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.;
RT   "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.";
RL   Cell. Physiol. Biochem. 35:237-245(2015).
RN   [10]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=26027934; DOI=10.1016/j.celrep.2015.04.049;
RA   Kim H., Frederick D.T., Levesque M.P., Cooper Z.A., Feng Y., Krepler C.,
RA   Brill L., Samuels Y., Hayward N.K., Perlina A., Piris A., Zhang T.,
RA   Halaban R., Herlyn M.M., Brown K.M., Wargo J.A., Dummer R., Flaherty K.T.,
RA   Ronai Z.A.;
RT   "Downregulation of the ubiquitin ligase RNF125 underlies resistance of
RT   melanoma cells to BRAF inhibitors via JAK1 deregulation.";
RL   Cell Rep. 11:1458-1473(2015).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH VCP.
RX   PubMed=26471729; DOI=10.15252/embj.201591888;
RA   Hao Q., Jiao S., Shi Z., Li C., Meng X., Zhang Z., Wang Y., Song X.,
RA   Wang W., Zhang R., Zhao Y., Wong C.C., Zhou Z.;
RT   "A non-canonical role of the p97 complex in RIG-I antiviral signaling.";
RL   EMBO J. 34:2903-2920(2015).
RN   [12]
RP   INDUCTION.
RX   PubMed=26202983; DOI=10.4049/jimmunol.1500370;
RA   Zhu B., Ye J., Nie Y., Ashraf U., Zohaib A., Duan X., Fu Z.F., Song Y.,
RA   Chen H., Cao S.;
RT   "MicroRNA-15b Modulates Japanese Encephalitis Virus-Mediated Inflammation
RT   via Targeting RNF125.";
RL   J. Immunol. 195:2251-2262(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEX WITH ZINC, FUNCTION,
RP   CATALYTIC ACTIVITY, INTERACTION WITH UBE2D1, DOMAIN, AND MUTAGENESIS OF
RP   100-CYS--CYS-103 AND 109-LEU--ARG-113.
RX   PubMed=27411375; DOI=10.1038/srep29232;
RA   Bijlmakers M.J., Teixeira J.M., Boer R., Mayzel M., Puig-Sarries P.,
RA   Karlsson G., Coll M., Pons M., Crosas B.;
RT   "A C2HC zinc finger is essential for the RING-E2 interaction of the
RT   ubiquitin ligase RNF125.";
RL   Sci. Rep. 6:29232-29232(2016).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination and
CC       subsequent proteasomal degradation of target proteins, such as
CC       DDX58/RIG-I, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53 (PubMed:15843525,
CC       PubMed:17460044, PubMed:17643463, PubMed:26027934, PubMed:26471729,
CC       PubMed:25591766, PubMed:27411375). Acts as a negative regulator of type
CC       I interferon production by mediating ubiquitination of DDX58/RIG-I at
CC       'Lys-181', leading to DDX58/RIG-I degradation (PubMed:17460044,
CC       PubMed:26471729). Mediates ubiquitination and subsequent degradation of
CC       p53/TP53 (PubMed:25591766). Mediates ubiquitination and subsequent
CC       degradation of JAK1 (PubMed:26027934). Acts as a positive regulator of
CC       T-cell activation (PubMed:15843525). {ECO:0000269|PubMed:15843525,
CC       ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:17643463,
CC       ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:26027934,
CC       ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:15843525,
CC         ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:17643463,
CC         ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:26027934,
CC         ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:15843525, ECO:0000269|PubMed:17460044,
CC       ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:25591766,
CC       ECO:0000269|PubMed:26027934, ECO:0000269|PubMed:26471729,
CC       ECO:0000269|PubMed:27411375}.
CC   -!- SUBUNIT: Interacts with UBE2D1 (PubMed:27411375). Interacts with
CC       VCP/p97; leading to recruit RNF125 to DDX58/RIG-I and promote
CC       ubiquitination of DDX58/RIG-I (PubMed:26471729).
CC       {ECO:0000269|PubMed:26471729, ECO:0000269|PubMed:27411375}.
CC   -!- INTERACTION:
CC       Q96EQ8; O95786-1: DDX58; NbExp=5; IntAct=EBI-2339208, EBI-15577823;
CC       Q96EQ8; Q9BYX4: IFIH1; NbExp=2; IntAct=EBI-2339208, EBI-6115771;
CC       Q96EQ8; Q7Z434-1: MAVS; NbExp=2; IntAct=EBI-2339208, EBI-15577799;
CC       Q96EQ8; Q96LR5: UBE2E2; NbExp=5; IntAct=EBI-2339208, EBI-2129763;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:17990982}; Lipid-anchor
CC       {ECO:0000269|PubMed:17990982}. Note=Shows a reticular staining pattern
CC       within the cell and is probably expressed at other intracellular
CC       membranes in addition to the Golgi membrane. Not detected at the plasma
CC       membrane. {ECO:0000269|PubMed:17990982}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in lymphoid tissues,
CC       including bone marrow, spleen and thymus. Also weakly expressed in
CC       other tissues. Predominant in the CD4(+) and CD8(+) T-cells, suggesting
CC       that it is preferentially confined to T-cells.
CC       {ECO:0000269|PubMed:12974981, ECO:0000269|PubMed:15843525}.
CC   -!- INDUCTION: Down-regulated by miR-15b (PubMed:26202983). Down-regulated
CC       in BRAFi resistant melanomas, leading to increased levels of JAK1 and
CC       possibly promoting BRAFi resistance. {ECO:0000269|PubMed:26027934,
CC       ECO:0000269|PubMed:26202983}.
CC   -!- DOMAIN: The C2HC RNF-type zinc finger and the linker region stabilize
CC       the RING-type zinc finger, leading to promote binding of the RING-type
CC       zinc finger to the ubiquitin-conjugating enzyme E2 (donor ubiquitin)
CC       (PubMed:27411375). {ECO:0000269|PubMed:27411375}.
CC   -!- PTM: Autoubiquitinated, leading to its subsequent proteasomal
CC       degradation. {ECO:0000269|PubMed:17990982}.
CC   -!- DISEASE: Tenorio syndrome (TNORS) [MIM:616260]: A disease characterized
CC       by overgrowth, macrocephaly, and intellectual disability. Some patients
CC       may have mild hydrocephaly, hypoglycemia, and inflammatory diseases
CC       resembling Sjogren syndrome. {ECO:0000269|PubMed:25196541}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK000463; BAA91182.1; -; mRNA.
DR   EMBL; BC012021; AAH12021.1; -; mRNA.
DR   CCDS; CCDS11902.1; -.
DR   RefSeq; NP_060301.2; NM_017831.3.
DR   PDB; 5DKA; X-ray; 1.55 A; A/B=1-232.
DR   PDBsum; 5DKA; -.
DR   SMR; Q96EQ8; -.
DR   BioGRID; 120281; 34.
DR   DIP; DIP-52778N; -.
DR   ELM; Q96EQ8; -.
DR   IntAct; Q96EQ8; 22.
DR   MINT; Q96EQ8; -.
DR   STRING; 9606.ENSP00000217740; -.
DR   iPTMnet; Q96EQ8; -.
DR   PhosphoSitePlus; Q96EQ8; -.
DR   BioMuta; RNF125; -.
DR   DMDM; 143811449; -.
DR   jPOST; Q96EQ8; -.
DR   MassIVE; Q96EQ8; -.
DR   PaxDb; Q96EQ8; -.
DR   PeptideAtlas; Q96EQ8; -.
DR   PRIDE; Q96EQ8; -.
DR   ProteomicsDB; 76441; -.
DR   Antibodypedia; 22188; 215 antibodies from 30 providers.
DR   DNASU; 54941; -.
DR   Ensembl; ENST00000217740; ENSP00000217740; ENSG00000101695.
DR   GeneID; 54941; -.
DR   KEGG; hsa:54941; -.
DR   MANE-Select; ENST00000217740.4; ENSP00000217740.3; NM_017831.4; NP_060301.2.
DR   UCSC; uc002kxf.2; human.
DR   CTD; 54941; -.
DR   DisGeNET; 54941; -.
DR   GeneCards; RNF125; -.
DR   HGNC; HGNC:21150; RNF125.
DR   HPA; ENSG00000101695; Tissue enhanced (bone).
DR   MalaCards; RNF125; -.
DR   MIM; 610432; gene.
DR   MIM; 616260; phenotype.
DR   neXtProt; NX_Q96EQ8; -.
DR   OpenTargets; ENSG00000101695; -.
DR   PharmGKB; PA134950383; -.
DR   VEuPathDB; HostDB:ENSG00000101695; -.
DR   eggNOG; ENOG502RYGV; Eukaryota.
DR   GeneTree; ENSGT00950000182909; -.
DR   HOGENOM; CLU_092448_2_0_1; -.
DR   InParanoid; Q96EQ8; -.
DR   OMA; NCTECNT; -.
DR   OrthoDB; 1097558at2759; -.
DR   PhylomeDB; Q96EQ8; -.
DR   TreeFam; TF331012; -.
DR   PathwayCommons; Q96EQ8; -.
DR   Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   SignaLink; Q96EQ8; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 54941; 8 hits in 1079 CRISPR screens.
DR   ChiTaRS; RNF125; human.
DR   GeneWiki; RNF125; -.
DR   GenomeRNAi; 54941; -.
DR   Pharos; Q96EQ8; Tbio.
DR   PRO; PR:Q96EQ8; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; Q96EQ8; protein.
DR   Bgee; ENSG00000101695; Expressed in prostate gland and 219 other tissues.
DR   ExpressionAtlas; Q96EQ8; baseline and differential.
DR   Genevisible; Q96EQ8; HS.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0034098; C:VCP-NPL4-UFD1 AAA ATPase complex; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0039536; P:negative regulation of RIG-I signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR008598; Di19_Zn-bd.
DR   InterPro; IPR034734; ZF_C2HC_RNF.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF05605; zf-Di19; 1.
DR   Pfam; PF18574; zf_C2HC_14; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51803; ZF_C2HC_RNF; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Disease variant; Golgi apparatus;
KW   Immunity; Lipoprotein; Membrane; Mental retardation; Metal-binding;
KW   Myristate; Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:17990982"
FT   CHAIN           2..232
FT                   /note="E3 ubiquitin-protein ligase RNF125"
FT                   /id="PRO_0000056090"
FT   ZN_FING         37..76
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         100..119
FT                   /note="C2HC RNF-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01144,
FT                   ECO:0000303|PubMed:17990982"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          43..45
FT                   /note="Interaction with the C2HC RNF-type zinc finger"
FT                   /evidence="ECO:0000269|PubMed:27411375"
FT   REGION          109..113
FT                   /note="Interaction with the RING-type zinc finger"
FT                   /evidence="ECO:0000269|PubMed:27411375"
FT   REGION          120..128
FT                   /note="Linker region"
FT                   /evidence="ECO:0000269|PubMed:27411375"
FT   REGION          210..224
FT                   /note="Required for interaction with ubiquitin and for
FT                   autoubiquitination"
FT                   /evidence="ECO:0000269|PubMed:17990982"
FT   METAL           37
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           40
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           52
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           54
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           57
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           60
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           72
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           75
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000269|PubMed:27411375,
FT                   ECO:0007744|PDB:5DKA"
FT   METAL           100
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01144,
FT                   ECO:0000269|PubMed:27411375, ECO:0007744|PDB:5DKA"
FT   METAL           103
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01144,
FT                   ECO:0000269|PubMed:27411375, ECO:0007744|PDB:5DKA"
FT   METAL           115
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01144,
FT                   ECO:0000269|PubMed:27411375, ECO:0007744|PDB:5DKA"
FT   METAL           119
FT                   /note="Zinc 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01144,
FT                   ECO:0000269|PubMed:27411375, ECO:0007744|PDB:5DKA"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:17990982"
FT   VARIANT         112
FT                   /note="M -> I (in TNORS; dbSNP:rs786201014)"
FT                   /evidence="ECO:0000269|PubMed:25196541"
FT                   /id="VAR_073353"
FT   VARIANT         163
FT                   /note="S -> L (in TNORS; dbSNP:rs373764886)"
FT                   /evidence="ECO:0000269|PubMed:25196541"
FT                   /id="VAR_073354"
FT   VARIANT         174
FT                   /note="R -> C (in TNORS; dbSNP:rs370242930)"
FT                   /evidence="ECO:0000269|PubMed:25196541"
FT                   /id="VAR_073355"
FT   MUTAGEN         2
FT                   /note="G->A: Abolishes ability to regulate T-cell
FT                   activation but not E3 ligase activity in vitro. Also
FT                   abolishes myristoylation and membrane localization."
FT                   /evidence="ECO:0000269|PubMed:15843525,
FT                   ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:17990982"
FT   MUTAGEN         37
FT                   /note="C->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-40."
FT                   /evidence="ECO:0000269|PubMed:15843525,
FT                   ECO:0000269|PubMed:17643463, ECO:0000269|PubMed:17990982"
FT   MUTAGEN         40
FT                   /note="C->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-37."
FT                   /evidence="ECO:0000269|PubMed:15843525,
FT                   ECO:0000269|PubMed:17990982"
FT   MUTAGEN         54
FT                   /note="H->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-57."
FT                   /evidence="ECO:0000269|PubMed:15843525"
FT   MUTAGEN         57
FT                   /note="C->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-54."
FT                   /evidence="ECO:0000269|PubMed:15843525"
FT   MUTAGEN         72
FT                   /note="C->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-75."
FT                   /evidence="ECO:0000269|PubMed:15843525,
FT                   ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:25591766"
FT   MUTAGEN         75
FT                   /note="C->A: Abolishes ability to regulate T-cell
FT                   activation and E3 ligase activity in vitro; when associated
FT                   with A-72."
FT                   /evidence="ECO:0000269|PubMed:15843525,
FT                   ECO:0000269|PubMed:17460044, ECO:0000269|PubMed:25591766"
FT   MUTAGEN         100..103
FT                   /note="CAEC->AAEA: Abolished E3 ubiquitin-protein ligase
FT                   activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:27411375"
FT   MUTAGEN         109..113
FT                   /note="LSEMR->ASEAA: Abolished E3 ubiquitin-protein ligase
FT                   activity in vitro."
FT                   /evidence="ECO:0000269|PubMed:27411375"
FT   MUTAGEN         217
FT                   /note="V->P: Reduced ubiquitination and reduced binding to
FT                   ubiquitinated proteins; when associated with Q-221."
FT                   /evidence="ECO:0000269|PubMed:17990982"
FT   MUTAGEN         221
FT                   /note="S->Q: Reduced ubiquitination and reduced binding to
FT                   ubiquitinated proteins; when associated with P-217."
FT                   /evidence="ECO:0000269|PubMed:17990982"
FT   CONFLICT        105..108
FT                   /note="TLVC -> IVLY (in Ref. 2; AAH12021)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="S -> N (in Ref. 1; BAA91182)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        232
FT                   /note="T -> A (in Ref. 2; AAH12021)"
FT                   /evidence="ECO:0000305"
FT   TURN            38..40
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   STRAND          45..49
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   HELIX           58..67
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   TURN            73..75
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   STRAND          80..82
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   HELIX           87..93
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   STRAND          97..99
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   TURN            101..103
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   HELIX           112..118
FT                   /evidence="ECO:0007829|PDB:5DKA"
FT   HELIX           120..126
FT                   /evidence="ECO:0007829|PDB:5DKA"
SQ   SEQUENCE   232 AA;  26454 MW;  E3D93D546AD99D81 CRC64;
     MGSVLSTDSG KSAPASATAR ALERRRDPEL PVTSFDCAVC LEVLHQPVRT RCGHVFCRSC
     IATSLKNNKW TCPYCRAYLP SEGVPATDVA KRMKSEYKNC AECDTLVCLS EMRAHIRTCQ
     KYIDKYGPLQ ELEETAARCV CPFCQRELYE DSLLDHCITH HRSERRPVFC PLCRLIPDEN
     PSSFSGSLIR HLQVSHTLFY DDFIDFNIIE EALIRRVLDR SLLEYVNHSN TT
//
ID   FKB14_HUMAN             Reviewed;         211 AA.
AC   Q9NWM8;
DT   10-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 181.
DE   RecName: Full=Peptidyl-prolyl cis-trans isomerase FKBP14;
DE            Short=PPIase FKBP14;
DE            EC=5.2.1.8 {ECO:0000269|PubMed:24821723};
DE   AltName: Full=22 kDa FK506-binding protein;
DE            Short=22 kDa FKBP;
DE            Short=FKBP-22;
DE   AltName: Full=FK506-binding protein 14;
DE            Short=FKBP-14;
DE   AltName: Full=Rotamase;
DE   Flags: Precursor;
GN   Name=FKBP14; Synonyms=FKBP22; ORFNames=UNQ322/PRO381;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 20-34.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [5]
RP   INVOLVEMENT IN EDSKSCL2, AND SUBCELLULAR LOCATION.
RX   PubMed=22265013; DOI=10.1016/j.ajhg.2011.12.004;
RA   Baumann M., Giunta C., Krabichler B., Ruschendorf F., Zoppi N., Colombi M.,
RA   Bittner R.E., Quijano-Roy S., Muntoni F., Cirak S., Schreiber G., Zou Y.,
RA   Hu Y., Romero N.B., Carlier R.Y., Amberger A., Deutschmann A., Straub V.,
RA   Rohrbach M., Steinmann B., Rostasy K., Karall D., Bonnemann C.G.,
RA   Zschocke J., Fauth C.;
RT   "Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with
RT   progressive kyphoscoliosis, myopathy, and hearing loss.";
RL   Am. J. Hum. Genet. 90:201-216(2012).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, CALCIUM
RP   BINDING, AND PRESENCE OF DISULFIDE BOND.
RX   PubMed=24821723; DOI=10.1074/jbc.m114.561944;
RA   Ishikawa Y., Baechinger H.P.;
RT   "A substrate preference for the rough endoplasmic reticulum resident
RT   protein FKBP22 during collagen biosynthesis.";
RL   J. Biol. Chem. 289:18189-18201(2014).
RN   [7] {ECO:0007744|PDB:4DIP}
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 19-138, AND DISULFIDE BOND.
RA   Krojer T., Kiyani W., Goubin S., Muniz J.R.C., Filippakopoulos P.,
RA   Arrowsmith C.H., Edwards A., Bountra C., von Delft F., Oppermann U.,
RA   Zschocke J., Yue W.W.;
RT   "Crystal structure of human peptidyl-prolyl cis-trans isomerase FKBP14.";
RL   Submitted (JAN-2012) to the PDB data bank.
RN   [8] {ECO:0007744|PDB:4MSP}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 21-211 IN COMPLEX WITH CALCIUM,
RP   SUBUNIT, AND DISULFIDE BOND.
RX   PubMed=24272907; DOI=10.1002/pro.2391;
RA   Boudko S.P., Ishikawa Y., Nix J., Chapman M.S., Bachinger H.P.;
RT   "Structure of human peptidyl-prolyl cis-trans isomerase FKBP22 containing
RT   two EF-hand motifs.";
RL   Protein Sci. 23:67-75(2014).
CC   -!- FUNCTION: PPIase which accelerates the folding of proteins during
CC       protein synthesis. Has a preference for substrates containing 4-
CC       hydroxylproline modifications, including type III collagen. May also
CC       target type VI and type X collagens. {ECO:0000269|PubMed:24821723}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-peptidylproline (omega=180) = [protein]-
CC         peptidylproline (omega=0); Xref=Rhea:RHEA:16237, Rhea:RHEA-
CC         COMP:10747, Rhea:RHEA-COMP:10748, ChEBI:CHEBI:83833,
CC         ChEBI:CHEBI:83834; EC=5.2.1.8;
CC         Evidence={ECO:0000269|PubMed:24821723};
CC   -!- ACTIVITY REGULATION: Inhibited by tacrolimus/FK506.
CC       {ECO:0000269|PubMed:24821723}.
CC   -!- SUBUNIT: Monomer (PubMed:24821723, PubMed:24272907). Homodimer
CC       (PubMed:24821723, PubMed:24272907). Interacts with type III, type IV
CC       and type X collagens (PubMed:24821723). {ECO:0000269|PubMed:24272907,
CC       ECO:0000269|PubMed:24821723}.
CC   -!- INTERACTION:
CC       Q9NWM8; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-2477093, EBI-10982110;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen {ECO:0000255|PROSITE-
CC       ProRule:PRU10138, ECO:0000269|PubMed:22265013}.
CC   -!- DISEASE: Ehlers-Danlos syndrome, kyphoscoliotic type, 2 (EDSKSCL2)
CC       [MIM:614557]: A form of Ehlers-Danlos syndrome, a group of connective
CC       tissue disorders characterized by skin hyperextensibility, articular
CC       hypermobility, and tissue fragility. EDSKSCL2 is an autosomal recessive
CC       form characterized by severe generalized hypotonia at birth, myopathy,
CC       early-onset progressive kyphoscoliosis, joint hypermobility without
CC       contractures, hyperelastic skin with follicular hyperkeratosis, easy
CC       bruising, and occasional abnormal scarring, sensorineural hearing
CC       impairment, and normal pyridinoline excretion in urine.
CC       {ECO:0000269|PubMed:22265013}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY358643; AAQ89006.1; -; mRNA.
DR   EMBL; AK000738; BAA91351.1; -; mRNA.
DR   EMBL; BC005206; AAH05206.1; -; mRNA.
DR   CCDS; CCDS5423.1; -.
DR   RefSeq; NP_060416.1; NM_017946.3.
DR   PDB; 4DIP; X-ray; 1.82 A; A/B/C/D/E/F/G/H/I/J=19-138.
DR   PDB; 4MSP; X-ray; 1.90 A; A/B=21-211.
DR   PDBsum; 4DIP; -.
DR   PDBsum; 4MSP; -.
DR   SMR; Q9NWM8; -.
DR   BioGRID; 120362; 80.
DR   IntAct; Q9NWM8; 25.
DR   MINT; Q9NWM8; -.
DR   STRING; 9606.ENSP00000222803; -.
DR   BindingDB; Q9NWM8; -.
DR   ChEMBL; CHEMBL2342; -.
DR   GlyGen; Q9NWM8; 1 site.
DR   iPTMnet; Q9NWM8; -.
DR   PhosphoSitePlus; Q9NWM8; -.
DR   BioMuta; FKBP14; -.
DR   DMDM; 23821568; -.
DR   EPD; Q9NWM8; -.
DR   jPOST; Q9NWM8; -.
DR   MassIVE; Q9NWM8; -.
DR   MaxQB; Q9NWM8; -.
DR   PaxDb; Q9NWM8; -.
DR   PeptideAtlas; Q9NWM8; -.
DR   PRIDE; Q9NWM8; -.
DR   ProteomicsDB; 82955; -.
DR   Antibodypedia; 2831; 217 antibodies from 26 providers.
DR   DNASU; 55033; -.
DR   Ensembl; ENST00000222803; ENSP00000222803; ENSG00000106080.
DR   GeneID; 55033; -.
DR   KEGG; hsa:55033; -.
DR   MANE-Select; ENST00000222803.10; ENSP00000222803.5; NM_017946.4; NP_060416.1.
DR   UCSC; uc003tal.3; human.
DR   CTD; 55033; -.
DR   DisGeNET; 55033; -.
DR   GeneCards; FKBP14; -.
DR   GeneReviews; FKBP14; -.
DR   HGNC; HGNC:18625; FKBP14.
DR   HPA; ENSG00000106080; Low tissue specificity.
DR   MalaCards; FKBP14; -.
DR   MIM; 614505; gene.
DR   MIM; 614557; phenotype.
DR   neXtProt; NX_Q9NWM8; -.
DR   OpenTargets; ENSG00000106080; -.
DR   Orphanet; 300179; Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency.
DR   PharmGKB; PA38608; -.
DR   VEuPathDB; HostDB:ENSG00000106080; -.
DR   eggNOG; KOG0549; Eukaryota.
DR   GeneTree; ENSGT00940000157858; -.
DR   HOGENOM; CLU_013615_5_0_1; -.
DR   InParanoid; Q9NWM8; -.
DR   OMA; CYRKSKY; -.
DR   OrthoDB; 1507309at2759; -.
DR   PhylomeDB; Q9NWM8; -.
DR   TreeFam; TF105296; -.
DR   BRENDA; 5.2.1.8; 2681.
DR   PathwayCommons; Q9NWM8; -.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   SignaLink; Q9NWM8; -.
DR   BioGRID-ORCS; 55033; 8 hits in 1047 CRISPR screens.
DR   ChiTaRS; FKBP14; human.
DR   GenomeRNAi; 55033; -.
DR   Pharos; Q9NWM8; Tbio.
DR   PRO; PR:Q9NWM8; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9NWM8; protein.
DR   Bgee; ENSG00000106080; Expressed in tibia and 219 other tissues.
DR   ExpressionAtlas; Q9NWM8; baseline and differential.
DR   Genevisible; Q9NWM8; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0003755; F:peptidyl-prolyl cis-trans isomerase activity; IEA:UniProtKB-KW.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR001179; PPIase_FKBP_dom.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   Pfam; PF00254; FKBP_C; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   PROSITE; PS00014; ER_TARGET; 1.
DR   PROSITE; PS50059; FKBP_PPIASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Deafness; Direct protein sequencing; Disulfide bond;
KW   Ehlers-Danlos syndrome; Endoplasmic reticulum; Glycoprotein; Isomerase;
KW   Metal-binding; Reference proteome; Repeat; Rotamase; Signal.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           20..211
FT                   /note="Peptidyl-prolyl cis-trans isomerase FKBP14"
FT                   /id="PRO_0000025521"
FT   DOMAIN          45..135
FT                   /note="PPIase FKBP-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00277"
FT   DOMAIN          135..170
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          179..211
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   CA_BIND         148..159
FT                   /note="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448,
FT                   ECO:0000269|PubMed:24272907, ECO:0000305|PubMed:24821723,
FT                   ECO:0007744|PDB:4MSP"
FT   CA_BIND         192..203
FT                   /note="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448,
FT                   ECO:0000269|PubMed:24272907, ECO:0000305|PubMed:24821723,
FT                   ECO:0007744|PDB:4MSP"
FT   MOTIF           208..211
FT                   /note="Prevents secretion from ER"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10138"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        38..96
FT                   /evidence="ECO:0000269|Ref.7, ECO:0000305|PubMed:24821723,
FT                   ECO:0007744|PDB:4DIP, ECO:0007744|PDB:4MSP"
FT   HELIX           19..21
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          28..33
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          47..56
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   TURN            57..59
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          62..65
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   HELIX           66..69
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   TURN            70..72
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          75..78
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   TURN            79..82
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   HELIX           86..91
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          100..105
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   TURN            110..114
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   STRAND          125..135
FT                   /evidence="ECO:0007829|PDB:4DIP"
FT   HELIX           141..147
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   HELIX           157..170
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   HELIX           177..191
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   STRAND          196..200
FT                   /evidence="ECO:0007829|PDB:4MSP"
FT   HELIX           201..205
FT                   /evidence="ECO:0007829|PDB:4MSP"
SQ   SEQUENCE   211 AA;  24172 MW;  858184954FE10029 CRC64;
     MRLFLWNAVL TLFVTSLIGA LIPEPEVKIE VLQKPFICHR KTKGGDLMLV HYEGYLEKDG
     SLFHSTHKHN NGQPIWFTLG ILEALKGWDQ GLKGMCVGEK RKLIIPPALG YGKEGKGKIP
     PESTLIFNID LLEIRNGPRS HESFQEMDLN DDWKLSKDEV KAYLKKEFEK HGAVVNESHH
     DALVEDIFDK EDEDKDGFIS AREFTYKHDE L
//
ID   FIGN_HUMAN              Reviewed;         759 AA.
AC   Q5HY92; B3KWM0; Q9H6M5; Q9NVZ9;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 2.
DT   23-FEB-2022, entry version 132.
DE   RecName: Full=Fidgetin;
GN   Name=FIGN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Salivary gland;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-532.
RX   PubMed=22672901; DOI=10.4161/cc.20849;
RA   Mukherjee S., Diaz Valencia J.D., Stewman S., Metz J., Monnier S., Rath U.,
RA   Asenjo A.B., Charafeddine R.A., Sosa H.J., Ross J.L., Ma A., Sharp D.J.;
RT   "Human Fidgetin is a microtubule severing the enzyme and minus-end
RT   depolymerase that regulates mitosis.";
RL   Cell Cycle 11:2359-2366(2012).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-400, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: ATP-dependent microtubule severing protein. Severs
CC       microtubules along their length and depolymerizes their ends, primarily
CC       the minus-end, that may lead to the suppression of microtubule growth
CC       from and attachment to centrosomes. Microtubule severing may promote
CC       rapid reorganization of cellular microtubule arrays and the release of
CC       microtubules from the centrosome following nucleation. Microtubule
CC       release from the mitotic spindle poles may allow depolymerization of
CC       the microtubule end proximal to the spindle pole, leading to poleward
CC       microtubule flux and poleward motion of chromosome.
CC       {ECO:0000269|PubMed:22672901}.
CC   -!- SUBUNIT: Interacts with AKAP8 (via C-terminus). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q5HY92; Q8IWX8: CHERP; NbExp=3; IntAct=EBI-12297985, EBI-2555370;
CC       Q5HY92; O14964: HGS; NbExp=3; IntAct=EBI-12297985, EBI-740220;
CC   -!- SUBCELLULAR LOCATION: Nucleus matrix {ECO:0000250}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:22672901}. Note=Localizes to centrosomes throughout
CC       mitosis and to the spindle midzone during telophase.
CC   -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX81992.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA91590.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA91590.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAB15231.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001267; BAA91590.1; ALT_SEQ; mRNA.
DR   EMBL; AK025747; BAB15231.1; ALT_INIT; mRNA.
DR   EMBL; AK125324; BAG54182.1; -; mRNA.
DR   EMBL; BX649105; CAI45980.1; -; mRNA.
DR   EMBL; AC093727; AAX81992.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS2221.2; -.
DR   RefSeq; NP_060556.2; NM_018086.3.
DR   SMR; Q5HY92; -.
DR   BioGRID; 120441; 8.
DR   IntAct; Q5HY92; 5.
DR   STRING; 9606.ENSP00000333836; -.
DR   iPTMnet; Q5HY92; -.
DR   PhosphoSitePlus; Q5HY92; -.
DR   BioMuta; FIGN; -.
DR   DMDM; 115502199; -.
DR   EPD; Q5HY92; -.
DR   jPOST; Q5HY92; -.
DR   MassIVE; Q5HY92; -.
DR   PaxDb; Q5HY92; -.
DR   PeptideAtlas; Q5HY92; -.
DR   PRIDE; Q5HY92; -.
DR   ProteomicsDB; 62925; -.
DR   Antibodypedia; 47964; 136 antibodies from 18 providers.
DR   DNASU; 55137; -.
DR   Ensembl; ENST00000333129; ENSP00000333836; ENSG00000182263.
DR   GeneID; 55137; -.
DR   KEGG; hsa:55137; -.
DR   MANE-Select; ENST00000333129.4; ENSP00000333836.3; NM_018086.4; NP_060556.2.
DR   UCSC; uc002uck.2; human.
DR   CTD; 55137; -.
DR   DisGeNET; 55137; -.
DR   GeneCards; FIGN; -.
DR   HGNC; HGNC:13285; FIGN.
DR   HPA; ENSG00000182263; Low tissue specificity.
DR   MIM; 605295; gene.
DR   neXtProt; NX_Q5HY92; -.
DR   OpenTargets; ENSG00000182263; -.
DR   PharmGKB; PA28147; -.
DR   VEuPathDB; HostDB:ENSG00000182263; -.
DR   eggNOG; KOG0740; Eukaryota.
DR   GeneTree; ENSGT00940000157526; -.
DR   HOGENOM; CLU_000688_21_10_1; -.
DR   InParanoid; Q5HY92; -.
DR   OMA; ESPVNHL; -.
DR   OrthoDB; 1176820at2759; -.
DR   PhylomeDB; Q5HY92; -.
DR   TreeFam; TF105015; -.
DR   PathwayCommons; Q5HY92; -.
DR   SignaLink; Q5HY92; -.
DR   BioGRID-ORCS; 55137; 5 hits in 1037 CRISPR screens.
DR   ChiTaRS; FIGN; human.
DR   GenomeRNAi; 55137; -.
DR   Pharos; Q5HY92; Tbio.
DR   PRO; PR:Q5HY92; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q5HY92; protein.
DR   Bgee; ENSG00000182263; Expressed in buccal mucosa cell and 204 other tissues.
DR   ExpressionAtlas; Q5HY92; baseline and differential.
DR   Genevisible; Q5HY92; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0016363; C:nuclear matrix; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0008568; F:microtubule-severing ATPase activity; IBA:GO_Central.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR003960; ATPase_AAA_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR015415; Vps4_C.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF09336; Vps4_C; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS00674; AAA; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell cycle; Cell division; Cytoplasm; Cytoskeleton;
KW   Microtubule; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..759
FT                   /note="Fidgetin"
FT                   /id="PRO_0000250748"
FT   NP_BIND         529..534
FT                   /note="ATP"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PIW4"
FT   REGION          89..111
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          196..237
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          258..290
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          339..457
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        204..234
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        264..289
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        339..423
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         489
FT                   /note="ATP; via amide nitrogen and carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PIW4"
FT   MOD_RES         400
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         96
FT                   /note="S -> L (in dbSNP:rs2231902)"
FT                   /id="VAR_027613"
FT   VARIANT         448
FT                   /note="R -> C (in dbSNP:rs2231904)"
FT                   /id="VAR_027614"
FT   VARIANT         565
FT                   /note="K -> R (in dbSNP:rs2231905)"
FT                   /id="VAR_027615"
FT   MUTAGEN         532
FT                   /note="K->A: Inhibits the ability to sever and depolymerize
FT                   microtubules."
FT                   /evidence="ECO:0000269|PubMed:22672901"
FT   CONFLICT        713
FT                   /note="L -> I (in Ref. 2; CAI45980)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   759 AA;  82146 MW;  68E1C4C8CA66AE2A CRC64;
     MISSTSVYGL KMQWTPEHAQ WPEQHFDITS TTRSPAHKVE AYRGHLQRTY QYAWANDDIS
     ALTASNLLKK YAEKYSGILE GPVDRPVLSN YSDTPSGLVN GRKNESEPWQ PSLNSEAVYP
     MNCVPDVITA SKAGVSSALP PADVSASIGS SPGVASNLTE PSYSSSTCGS HTVPSLHAGL
     PSQEYAPGYN GSYLHSTYSS QPAPALPSPH PSPLHSSGLL QPPPPPPPPP ALVPGYNGTS
     NLSSYSYPSA SYPPQTAVGS GYSPGGAPPP PSAYLPSGIP APTPLPPTTV PGYTYQGHGL
     TPIAPSALTN SSASSLKRKA FYMAGQGDMD SSYGNYSYGQ QRSTQSPMYR MPDNSISNTN
     RGNGFDRSAE TSSLAFKPTK QLMSSEQQRK FSSQSSRALT PPSYSTAKNS LGSRSSESFG
     KYTSPVMSEH GDEHRQLLSH PMQGPGLRAA TSSNHSVDEQ LKNTDTHLID LVTNEIITQG
     PPVDWNDIAG LDLVKAVIKE EVLWPVLRSD AFSGLTALPR SILLFGPRGT GKTLLGRCIA
     SQLGATFFKI AGSGLVAKWL GEAEKIIHAS FLVARCRQPS VIFVSDIDML LSSQVNEEHS
     PVSRMRTEFL MQLDTVLTSA EDQIVVICAT SKPEEIDESL RRYFMKRLLI PLPDSTARHQ
     IIVQLLSQHN YCLNDKEFAL LVQRTEGFSG LDVAHLCQEA VVGPLHAMPA TDLSAIMPSQ
     LRPVTYQDFE NAFCKIQPSI SQKELDMYVE WNKMFGCSQ
//
ID   ARMC1_HUMAN             Reviewed;         282 AA.
AC   Q9NVT9; B4E2W7; Q9H018; Q9H820;
DT   27-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   23-FEB-2022, entry version 153.
DE   RecName: Full=Armadillo repeat-containing protein 1;
GN   Name=ARMC1; Synonyms=ARCP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 78-282 (ISOFORM 1).
RC   TISSUE=Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-260, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-137; SER-189 AND SER-260, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   FUNCTION, INTERACTION WITH IMMT; MICOS10; SAMM50 AND MTX1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=31644573; DOI=10.1371/journal.pone.0218303;
RA   Wagner F., Kunz T.C., Chowdhury S.R., Thiede B., Fraunholz M., Eger D.,
RA   Kozjak-Pavlovic V.;
RT   "Armadillo repeat-containing protein 1 is a dual localization protein
RT   associated with mitochondrial intermembrane space bridging complex.";
RL   PLoS ONE 14:e0218303-e0218303(2019).
CC   -!- FUNCTION: In association with mitochondrial contact site and cristae
CC       organizing system (MICOS) complex components and mitochondrial outer
CC       membrane sorting assembly machinery (SAM) complex components may
CC       regulate mitochondrial dynamics playing a role in determining
CC       mitochondrial length, distribution and motility.
CC       {ECO:0000269|PubMed:31644573}.
CC   -!- SUBUNIT: Interacts with mitochondrial contact site and cristae
CC       organizing system (MICOS) complex components IMMT/MIC60 and
CC       MICOS10/MIC10 (PubMed:31644573). Interacts with mitochondrial outer
CC       membrane sorting assembly machinery (SAM) complex components SAMM50 and
CC       MTX1 (PubMed:31644573). {ECO:0000269|PubMed:31644573}.
CC   -!- INTERACTION:
CC       Q9NVT9; Q9H019: MTFR1L; NbExp=7; IntAct=EBI-3506974, EBI-2824497;
CC       Q9NVT9; Q9Y225-2: RNF24; NbExp=3; IntAct=EBI-3506974, EBI-13044680;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:31644573}.
CC       Mitochondrion {ECO:0000269|PubMed:31644573}. Mitochondrion outer
CC       membrane {ECO:0000269|PubMed:31644573}. Note=Associates with the outer
CC       mitochondrion membrane, most likely through its C-terminus
CC       (PubMed:31644573). Not integrated into the mitochondrial outer membrane
CC       (PubMed:31644573). {ECO:0000269|PubMed:31644573}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NVT9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NVT9-2; Sequence=VSP_054645, VSP_054646;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001373; BAA91656.1; -; mRNA.
DR   EMBL; AK024053; BAB14803.1; -; mRNA.
DR   EMBL; AK304463; BAG65279.1; -; mRNA.
DR   EMBL; AC055822; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC100814; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011607; AAH11607.1; -; mRNA.
DR   EMBL; AL512767; CAC21684.1; -; mRNA.
DR   CCDS; CCDS6181.1; -. [Q9NVT9-1]
DR   CCDS; CCDS69490.1; -. [Q9NVT9-2]
DR   RefSeq; NP_001273631.1; NM_001286702.1. [Q9NVT9-2]
DR   RefSeq; NP_060590.1; NM_018120.5. [Q9NVT9-1]
DR   RefSeq; XP_016869094.1; XM_017013605.1. [Q9NVT9-1]
DR   SMR; Q9NVT9; -.
DR   BioGRID; 120458; 53.
DR   IntAct; Q9NVT9; 30.
DR   MINT; Q9NVT9; -.
DR   STRING; 9606.ENSP00000276569; -.
DR   GlyGen; Q9NVT9; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9NVT9; -.
DR   PhosphoSitePlus; Q9NVT9; -.
DR   SwissPalm; Q9NVT9; -.
DR   BioMuta; ARMC1; -.
DR   DMDM; 74734555; -.
DR   EPD; Q9NVT9; -.
DR   jPOST; Q9NVT9; -.
DR   MassIVE; Q9NVT9; -.
DR   MaxQB; Q9NVT9; -.
DR   PaxDb; Q9NVT9; -.
DR   PeptideAtlas; Q9NVT9; -.
DR   PRIDE; Q9NVT9; -.
DR   ProteomicsDB; 5860; -.
DR   ProteomicsDB; 82856; -. [Q9NVT9-1]
DR   Antibodypedia; 11918; 204 antibodies from 19 providers.
DR   DNASU; 55156; -.
DR   Ensembl; ENST00000276569; ENSP00000276569; ENSG00000104442.
DR   Ensembl; ENST00000458464; ENSP00000388572; ENSG00000104442. [Q9NVT9-2]
DR   GeneID; 55156; -.
DR   KEGG; hsa:55156; -.
DR   MANE-Select; ENST00000276569.8; ENSP00000276569.3; NM_018120.6; NP_060590.1.
DR   UCSC; uc003xvl.4; human. [Q9NVT9-1]
DR   CTD; 55156; -.
DR   GeneCards; ARMC1; -.
DR   HGNC; HGNC:17684; ARMC1.
DR   HPA; ENSG00000104442; Low tissue specificity.
DR   neXtProt; NX_Q9NVT9; -.
DR   OpenTargets; ENSG00000104442; -.
DR   PharmGKB; PA134882659; -.
DR   VEuPathDB; HostDB:ENSG00000104442; -.
DR   eggNOG; ENOG502QU5Q; Eukaryota.
DR   GeneTree; ENSGT00390000014100; -.
DR   HOGENOM; CLU_077781_0_0_1; -.
DR   InParanoid; Q9NVT9; -.
DR   OMA; TMSAEMD; -.
DR   OrthoDB; 1490145at2759; -.
DR   PhylomeDB; Q9NVT9; -.
DR   TreeFam; TF316742; -.
DR   PathwayCommons; Q9NVT9; -.
DR   SignaLink; Q9NVT9; -.
DR   BioGRID-ORCS; 55156; 17 hits in 1045 CRISPR screens.
DR   ChiTaRS; ARMC1; human.
DR   GenomeRNAi; 55156; -.
DR   Pharos; Q9NVT9; Tbio.
DR   PRO; PR:Q9NVT9; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q9NVT9; protein.
DR   Bgee; ENSG00000104442; Expressed in secondary oocyte and 246 other tissues.
DR   ExpressionAtlas; Q9NVT9; baseline and differential.
DR   Genevisible; Q9NVT9; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:InterPro.
DR   GO; GO:0048312; P:intracellular distribution of mitochondria; IMP:UniProtKB.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000225; Armadillo.
DR   InterPro; IPR036163; HMA_dom_sf.
DR   InterPro; IPR016617; UCP013899_metal-bd.
DR   PANTHER; PTHR28592; PTHR28592; 1.
DR   Pfam; PF00514; Arm; 1.
DR   PIRSF; PIRSF013899; UCP013899; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF55008; SSF55008; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Cytoplasm; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Phosphoprotein; Reference proteome.
FT   CHAIN           1..282
FT                   /note="Armadillo repeat-containing protein 1"
FT                   /id="PRO_0000240882"
FT   REPEAT          39..81
FT                   /note="ARM"
FT   REGION          239..261
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        242..257
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         137
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         189
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9D7A8"
FT   MOD_RES         260
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         267
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9D7A8"
FT   VAR_SEQ         1..53
FT                   /note="MNSSTSTMSEEPDALSVVNQLRDLAADPLNRRAIVQDQGCLPGLILFMDHPN
FT                   P -> MSAWPYFIYGPSQPSSRPLRFACSSILGRMPCKQRKDERRTGYDVELTKCYTE
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054645"
FT   VAR_SEQ         54..155
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054646"
SQ   SEQUENCE   282 AA;  31281 MW;  9CDF2DCFEC6C3A08 CRC64;
     MNSSTSTMSE EPDALSVVNQ LRDLAADPLN RRAIVQDQGC LPGLILFMDH PNPPVVHSAL
     LALRYLAECR ANREKMKGEL GMMLSLQNVI QKTTTPGETK LLASEIYDIL QSSNMADGDS
     FNEMNSRRRK AQFFLGTTNK RAKTVVLHID GLDDTSRRNL CEEALLKIKG VISFTFQMAV
     QRCVVRIRSD LKAEALASAI ASTKVMKAQQ VVKSESGEEM LVPFQDTPVE VEQNTELPDY
     LPEDESPTKE QDKAVSRVGS HPEGGASWLS TAANFLSRSF YW
//
ID   S2536_HUMAN             Reviewed;         311 AA.
AC   Q96CQ1; A8MYF7; Q05CY1; Q9H0G8; Q9NVN5;
DT   26-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   23-FEB-2022, entry version 155.
DE   RecName: Full=Solute carrier family 25 member 36;
GN   Name=SLC25A36;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-129.
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   IDENTIFICATION, AND TISSUE SPECIFICITY.
RX   PubMed=17210862; DOI=10.1001/archopht.125.1.117;
RA   Rozsa F.W., Scott K.M., Pawar H., Samples J.R., Wirtz M.K., Richards J.E.;
RT   "Differential expression profile prioritization of positional candidate
RT   glaucoma genes: the GLC1C locus.";
RL   Arch. Ophthalmol. 125:117-127(2007).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=25320081; DOI=10.1074/jbc.m114.610808;
RA   Di Noia M.A., Todisco S., Cirigliano A., Rinaldi T., Agrimi G.,
RA   Iacobazzi V., Palmieri F.;
RT   "The human SLC25A33 and SLC25A36 genes of solute carrier family 25 encode
RT   two mitochondrial pyrimidine nucleotide transporters.";
RL   J. Biol. Chem. 289:33137-33148(2014).
CC   -!- FUNCTION: Mitochondrial transporter that imports/exports pyrimidine
CC       nucleotides into and from mitochondria. Transports preferentially
CC       cytosine and uracil (deoxy)nucleoside mono-, di-, and triphosphates by
CC       uniport and antiport mechanism. Also transports guanine but not adenine
CC       (deoxy)nucleotides. Is inhibited strongly by pyridoxal 5'-phosphate,
CC       4,7-diphenyl-1,10-phenanthroline, tannic acid, and mercurials (mercury
CC       dichloride, Mersalyl acid, p-hydroxymercuribenzoate). Participates in
CC       mitochondrial genome maintenance, regulation of mitochondrial membrane
CC       potential and mitochondrial respiration. {ECO:0000269|PubMed:25320081}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.19 mM for UTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         KM=0.21 mM for CTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         KM=2.5 mM for TTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         KM=0.23 mM for GTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         Vmax=30.7 umol/min/g enzyme toward UTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         Vmax=51.2 umol/min/g enzyme toward CTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         Vmax=8 umol/min/g enzyme toward TTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         Vmax=23.6 umol/min/g enzyme toward GTP (at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:25320081};
CC         Note=The inhibitory constants (Ki) of these compounds are 1.3 um
CC         (UTP), 224 um (CTP), 276 um (GTP), and 181 um (ITP). CTP is the best
CC         substrate. {ECO:0000269|PubMed:25320081};
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000305|PubMed:25320081}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q96CQ1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96CQ1-2; Sequence=VSP_026240, VSP_026241;
CC       Name=3;
CC         IsoId=Q96CQ1-3; Sequence=VSP_026242;
CC       Name=4;
CC         IsoId=Q96CQ1-4; Sequence=VSP_035517;
CC   -!- TISSUE SPECIFICITY: Expressed at moderate level.
CC       {ECO:0000269|PubMed:17210862}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier (TC 2.A.29) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001480; BAA91715.1; -; mRNA.
DR   EMBL; AC108727; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC132032; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79012.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79013.1; -; Genomic_DNA.
DR   EMBL; BC014064; AAH14064.1; -; mRNA.
DR   EMBL; BC019859; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL136803; CAB66737.2; -; mRNA.
DR   CCDS; CCDS3114.1; -. [Q96CQ1-3]
DR   CCDS; CCDS46927.1; -. [Q96CQ1-1]
DR   RefSeq; NP_001098117.1; NM_001104647.1. [Q96CQ1-1]
DR   RefSeq; NP_060625.2; NM_018155.2. [Q96CQ1-3]
DR   SMR; Q96CQ1; -.
DR   BioGRID; 120484; 5.
DR   IntAct; Q96CQ1; 3.
DR   STRING; 9606.ENSP00000320688; -.
DR   TCDB; 2.A.29.10.6; the mitochondrial carrier (mc) family.
DR   iPTMnet; Q96CQ1; -.
DR   PhosphoSitePlus; Q96CQ1; -.
DR   BioMuta; SLC25A36; -.
DR   DMDM; 74760768; -.
DR   EPD; Q96CQ1; -.
DR   jPOST; Q96CQ1; -.
DR   MassIVE; Q96CQ1; -.
DR   MaxQB; Q96CQ1; -.
DR   PaxDb; Q96CQ1; -.
DR   PeptideAtlas; Q96CQ1; -.
DR   PRIDE; Q96CQ1; -.
DR   ProteomicsDB; 76207; -. [Q96CQ1-1]
DR   ProteomicsDB; 76208; -. [Q96CQ1-2]
DR   ProteomicsDB; 76209; -. [Q96CQ1-3]
DR   ProteomicsDB; 76210; -. [Q96CQ1-4]
DR   Antibodypedia; 18006; 73 antibodies from 15 providers.
DR   DNASU; 55186; -.
DR   Ensembl; ENST00000324194; ENSP00000320688; ENSG00000114120.
DR   Ensembl; ENST00000446041; ENSP00000401938; ENSG00000114120. [Q96CQ1-3]
DR   Ensembl; ENST00000502594; ENSP00000423319; ENSG00000114120. [Q96CQ1-2]
DR   Ensembl; ENST00000631654; ENSP00000487839; ENSG00000114120. [Q96CQ1-2]
DR   GeneID; 55186; -.
DR   KEGG; hsa:55186; -.
DR   MANE-Select; ENST00000324194.12; ENSP00000320688.6; NM_001104647.3; NP_001098117.1.
DR   UCSC; uc003etr.3; human. [Q96CQ1-1]
DR   CTD; 55186; -.
DR   DisGeNET; 55186; -.
DR   GeneCards; SLC25A36; -.
DR   HGNC; HGNC:25554; SLC25A36.
DR   HPA; ENSG00000114120; Low tissue specificity.
DR   MIM; 616149; gene.
DR   neXtProt; NX_Q96CQ1; -.
DR   OpenTargets; ENSG00000114120; -.
DR   PharmGKB; PA142670908; -.
DR   VEuPathDB; HostDB:ENSG00000114120; -.
DR   eggNOG; KOG0757; Eukaryota.
DR   GeneTree; ENSGT00940000154369; -.
DR   HOGENOM; CLU_015166_6_0_1; -.
DR   InParanoid; Q96CQ1; -.
DR   OMA; NFYVYGN; -.
DR   OrthoDB; 1372287at2759; -.
DR   PhylomeDB; Q96CQ1; -.
DR   TreeFam; TF314220; -.
DR   PathwayCommons; Q96CQ1; -.
DR   SignaLink; Q96CQ1; -.
DR   BioGRID-ORCS; 55186; 12 hits in 1045 CRISPR screens.
DR   ChiTaRS; SLC25A36; human.
DR   GenomeRNAi; 55186; -.
DR   Pharos; Q96CQ1; Tbio.
DR   PRO; PR:Q96CQ1; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q96CQ1; protein.
DR   Bgee; ENSG00000114120; Expressed in caput epididymis and 251 other tissues.
DR   ExpressionAtlas; Q96CQ1; baseline and differential.
DR   Genevisible; Q96CQ1; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0015218; F:pyrimidine nucleotide transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; IDA:UniProtKB.
DR   GO; GO:0007005; P:mitochondrion organization; IDA:UniProtKB.
DR   GO; GO:1990519; P:pyrimidine nucleotide import into mitochondrion; IBA:GO_Central.
DR   GO; GO:0006864; P:pyrimidine nucleotide transport; IDA:UniProtKB.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:UniProtKB.
DR   Gene3D; 1.50.40.10; -; 1.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   InterPro; IPR023395; Mt_carrier_dom_sf.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; SSF103506; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Alternative splicing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Reference proteome; Repeat; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..311
FT                   /note="Solute carrier family 25 member 36"
FT                   /id="PRO_0000291797"
FT   TRANSMEM        7..27
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        41..57
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        111..131
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        180..200
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        226..246
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        291..311
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          4..108
FT                   /note="Solcar 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00282"
FT   REPEAT          116..203
FT                   /note="Solcar 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00282"
FT   REPEAT          224..308
FT                   /note="Solcar 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00282"
FT   VAR_SEQ         1..157
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_035517"
FT   VAR_SEQ         130..132
FT                   /note="FTA -> HFL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_026240"
FT   VAR_SEQ         133..311
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_026241"
FT   VAR_SEQ         248
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_026242"
FT   CONFLICT        216
FT                   /note="D -> G (in Ref. 1; BAA91715)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   311 AA;  34283 MW;  D87DFDF7BC992D83 CRC64;
     MSQRDTLVHL FAGGCGGTVG AILTCPLEVV KTRLQSSSVT LYISEVQLNT MAGASVNRVV
     SPGPLHCLKV ILEKEGPRSL FRGLGPNLVG VAPSRAIYFA AYSNCKEKLN DVFDPDSTQV
     HMISAAMAGF TAITATNPIW LIKTRLQLDA RNRGERRMGA FECVRKVYQT DGLKGFYRGM
     SASYAGISET VIHFVIYESI KQKLLEYKTA STMENDEESV KEASDFVGMM LAAATSKTCA
     TTIAYPHEVV RTRLREEGTK YRSFFQTLSL LVQEEGYGSL YRGLTTHLVR QIPNTAIMMA
     TYELVVYLLN G
//
ID   SBNO1_HUMAN             Reviewed;        1393 AA.
AC   A3KN83; Q05C06; Q3ZTS3; Q9H3T8; Q9NVB2;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 1.
DT   23-FEB-2022, entry version 116.
DE   RecName: Full=Protein strawberry notch homolog 1;
DE   AltName: Full=Monocyte protein 3;
DE            Short=MOP-3;
GN   Name=SBNO1; Synonyms=MOP3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Blood;
RA   Takayama K., Ukai Y., Fujii Y., Yoshimoto M.;
RT   "Molecular and biological characterization of a new nuclear protein, MOP-3
RT   which is highly expressed in human monocytes.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1-793 (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-783 (ISOFORM 2).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-1393 (ISOFORM 4).
RX   PubMed=16533400; DOI=10.1186/1471-2164-7-48;
RA   Kemmer D., Podowski R.M., Arenillas D., Lim J., Hodges E., Roth P.,
RA   Sonnhammer E.L.L., Hoeoeg C., Wasserman W.W.;
RT   "NovelFam3000 -- uncharacterized human protein domains conserved across
RT   model organisms.";
RL   BMC Genomics 7:48-48(2006).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-697, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214 AND SER-794, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-794 AND SER-815, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-149; LYS-413 AND LYS-1222, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-754; SER-755 AND SER-794, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-754 AND SER-755, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148; SER-162; SER-794 AND
RP   SER-1386, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-634; LYS-889 AND CYS-997.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=A3KN83-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=A3KN83-2; Sequence=VSP_030296;
CC       Name=3;
CC         IsoId=A3KN83-3; Sequence=VSP_030295;
CC       Name=4;
CC         IsoId=A3KN83-4; Sequence=VSP_030296, VSP_030297, VSP_030298;
CC   -!- SIMILARITY: Belongs to the SBNO family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ76814.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB014772; BAB19784.1; -; mRNA.
DR   EMBL; BC030544; AAH30544.1; -; mRNA.
DR   EMBL; BC133704; AAI33705.1; -; mRNA.
DR   EMBL; AK001695; BAA91842.1; -; mRNA.
DR   EMBL; AY364255; AAQ76814.1; ALT_INIT; mRNA.
DR   CCDS; CCDS53844.1; -. [A3KN83-1]
DR   CCDS; CCDS9246.1; -. [A3KN83-2]
DR   RefSeq; NP_001161328.1; NM_001167856.2. [A3KN83-1]
DR   RefSeq; NP_060653.3; NM_018183.4. [A3KN83-2]
DR   RefSeq; XP_005253630.1; XM_005253573.4.
DR   RefSeq; XP_005253633.1; XM_005253576.3.
DR   RefSeq; XP_006719536.1; XM_006719473.3.
DR   RefSeq; XP_006719537.1; XM_006719474.3.
DR   RefSeq; XP_011536835.1; XM_011538533.2.
DR   RefSeq; XP_016875045.1; XM_017019556.1.
DR   BioGRID; 120502; 54.
DR   IntAct; A3KN83; 7.
DR   STRING; 9606.ENSP00000387361; -.
DR   GlyConnect; 2874; 1 O-Linked glycan (1 site).
DR   GlyGen; A3KN83; 10 sites, 2 O-linked glycans (10 sites).
DR   iPTMnet; A3KN83; -.
DR   MetOSite; A3KN83; -.
DR   PhosphoSitePlus; A3KN83; -.
DR   BioMuta; SBNO1; -.
DR   EPD; A3KN83; -.
DR   jPOST; A3KN83; -.
DR   MassIVE; A3KN83; -.
DR   MaxQB; A3KN83; -.
DR   PaxDb; A3KN83; -.
DR   PeptideAtlas; A3KN83; -.
DR   PRIDE; A3KN83; -.
DR   ProteomicsDB; 582; -. [A3KN83-1]
DR   ProteomicsDB; 583; -. [A3KN83-2]
DR   ProteomicsDB; 584; -. [A3KN83-3]
DR   ProteomicsDB; 585; -. [A3KN83-4]
DR   Antibodypedia; 52514; 24 antibodies from 14 providers.
DR   DNASU; 55206; -.
DR   Ensembl; ENST00000267176; ENSP00000267176; ENSG00000139697. [A3KN83-2]
DR   Ensembl; ENST00000420886; ENSP00000387361; ENSG00000139697.
DR   Ensembl; ENST00000602398; ENSP00000473665; ENSG00000139697.
DR   GeneID; 55206; -.
DR   KEGG; hsa:55206; -.
DR   MANE-Select; ENST00000602398.3; ENSP00000473665.1; NM_001167856.3; NP_001161328.1.
DR   UCSC; uc010tao.3; human. [A3KN83-1]
DR   CTD; 55206; -.
DR   DisGeNET; 55206; -.
DR   GeneCards; SBNO1; -.
DR   HGNC; HGNC:22973; SBNO1.
DR   HPA; ENSG00000139697; Tissue enhanced (testis).
DR   neXtProt; NX_A3KN83; -.
DR   OpenTargets; ENSG00000139697; -.
DR   PharmGKB; PA134967986; -.
DR   VEuPathDB; HostDB:ENSG00000139697; -.
DR   eggNOG; KOG1513; Eukaryota.
DR   GeneTree; ENSGT00940000155449; -.
DR   HOGENOM; CLU_000212_2_2_1; -.
DR   InParanoid; A3KN83; -.
DR   OMA; WIKDDIK; -.
DR   OrthoDB; 141580at2759; -.
DR   PhylomeDB; A3KN83; -.
DR   TreeFam; TF313526; -.
DR   PathwayCommons; A3KN83; -.
DR   SignaLink; A3KN83; -.
DR   BioGRID-ORCS; 55206; 674 hits in 1051 CRISPR screens.
DR   ChiTaRS; SBNO1; human.
DR   GenomeRNAi; 55206; -.
DR   Pharos; A3KN83; Tdark.
DR   PRO; PR:A3KN83; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; A3KN83; protein.
DR   Bgee; ENSG00000139697; Expressed in testis and 234 other tissues.
DR   Genevisible; A3KN83; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0031490; F:chromatin DNA binding; IBA:GO_Central.
DR   GO; GO:0042393; F:histone binding; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR026937; SBNO_Helicase_C_dom.
DR   InterPro; IPR026741; SNO.
DR   InterPro; IPR039187; SNO_AAA.
DR   PANTHER; PTHR12706; PTHR12706; 1.
DR   Pfam; PF13872; AAA_34; 1.
DR   Pfam; PF13871; Helicase_C_4; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Coiled coil; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..1393
FT                   /note="Protein strawberry notch homolog 1"
FT                   /id="PRO_0000314555"
FT   REGION          129..148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          687..840
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          843..870
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        698..721
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        800..840
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         149
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         413
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q689Z5"
FT   MOD_RES         693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q689Z5"
FT   MOD_RES         697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         754
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         755
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         768
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q689Z5"
FT   MOD_RES         794
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         815
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1222
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1386
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         78..79
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_030295"
FT   VAR_SEQ         80..81
FT                   /note="QQ -> Q (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:16533400, ECO:0000303|Ref.1"
FT                   /id="VSP_030296"
FT   VAR_SEQ         722..733
FT                   /note="VGGLTGSSSDDS -> MSLMRMMKMIPG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16533400"
FT                   /id="VSP_030297"
FT   VAR_SEQ         734..1393
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16533400"
FT                   /id="VSP_030298"
FT   VARIANT         634
FT                   /note="T -> S (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_037910"
FT   VARIANT         728
FT                   /note="S -> N (in dbSNP:rs1060105)"
FT                   /id="VAR_037911"
FT   VARIANT         729
FT                   /note="S -> N (in dbSNP:rs1060105)"
FT                   /id="VAR_057794"
FT   VARIANT         889
FT                   /note="E -> K (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_037912"
FT   VARIANT         997
FT                   /note="S -> C (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_037913"
FT   CONFLICT        4
FT                   /note="P -> Q (in Ref. 4; AAQ76814)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        14
FT                   /note="S -> R (in Ref. 3; BAA91842)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        555
FT                   /note="V -> A (in Ref. 4; AAQ76814)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        774
FT                   /note="N -> S (in Ref. 1; BAB19784)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1393 AA;  154312 MW;  D2C42F29C7EEC20D CRC64;
     MVEPGQDLLL AALSESGISP NDLFDIDGGD AGLATPMPTP SVQQSVPLSA LELGLETEAA
     VPVKQEPETV PTPALLNVRQ QPPSTTTFVL NQINHLPPLG STIVMTKTPP VTTNRQTITL
     TKFIQTTAST RPSVSAPTVR NAMTSAPSKD QVQLKDLLKN NSLNELMKLK PPANIAQPVA
     TAATDVSNGT VKKESSNKEG ARMWINDMKM RSFSPTMKVP VVKEDDEPEE EDEEEMGHAE
     TYAEYMPIKL KIGLRHPDAV VETSSLSSVT PPDVWYKTSI SEETIDNGWL SALQLEAITY
     AAQQHETFLP NGDRAGFLIG DGAGVGKGRT IAGIIYENYL LSRKRALWFS VSNDLKYDAE
     RDLRDIGAKN ILVHSLNKFK YGKISSKHNG SVKKGVIFAT YSSLIGESQS GGKYKTRLKQ
     LLHWCGDDFD GVIVFDECHK AKNLCPVGSS KPTKTGLAVL ELQNKLPKAR VVYASATGAS
     EPRNMAYMNR LGIWGEGTPF REFSDFIQAV ERRGVGAMEI VAMDMKLRGM YIARQLSFTG
     VTFKIEEVLL SQSYVKMYNK AVKLWVIARE RFQQAADLID AEQRMKKSMW GQFWSAHQRF
     FKYLCIASKV KRVVQLAREE IKNGKCVVIG LQSTGEARTL EALEEGGGEL NDFVSTAKGV
     LQSLIEKHFP APDRKKLYSL LGIDLTAPSN NSSPRDSPCK ENKIKKRKGE EITREAKKAR
     KVGGLTGSSS DDSGSESDAS DNEESDYESS KNMSSGDDDD FNPFLDESNE DDENDPWLIR
     KDHKKNKEKK KKKSIDPDSI QSALLASGLG SKRPSFSSTP VISPAPNSTP ANSNTNSNSS
     LITSQDAVER AQQMKKDLLD KLEKLAEDLP PNTLDELIDE LGGPENVAEM TGRKGRVVSN
     DDGSISYESR SELDVPVEIL NITEKQRFMD GDKNIAIISE AASSGISLQA DRRAKNQRRR
     VHMTLELPWS ADRAIQQFGR THRSNQVTAP EYVFLISELA GEQRFASIVA KRLESLGALT
     HGDRRATESR DLSRFNFDNK YGRNALEIVM KSIVNLDSPM VSPPPDYPGE FFKDVRQGLI
     GVGLINVEDR SGILTLDKDY NNIGKFLNRI LGMEVHQQNA LFQYFADTLT AVVQNAKKNG
     RYDMGILDLG SGDEKVRKSD VKKFLTPGYS TSGHVELYTI SVERGMSWEE ATKIWAELTG
     PDDGFYLSLQ IRNNKKTAIL VKEVNPKKKL FLVYRPNTGK QLKLEIYADL KKKYKKVVSD
     DALMHWLDQY NSSADTCTHA YWRGNCKKAS LGLVCEIGLR CRTYYVLCGS VLSVWTKVEG
     VLASVSGTNV KMQIVRLRTE DGQRIVGLII PANCVSPLVN LLSTSDQSQQ LAVQQKQLWQ
     QHHPQSITNL SNA
//
ID   ACER3_HUMAN             Reviewed;         267 AA.
AC   Q9NUN7; B2RC99;
DT   14-AUG-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   23-FEB-2022, entry version 160.
DE   RecName: Full=Alkaline ceramidase 3;
DE            Short=AlkCDase 3;
DE            Short=Alkaline CDase 3;
DE            EC=3.5.1.- {ECO:0000269|PubMed:11356846, ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939};
DE            EC=3.5.1.23 {ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939, ECO:0000269|PubMed:26792856, ECO:0000269|PubMed:30575723};
DE   AltName: Full=Alkaline dihydroceramidase SB89;
DE   AltName: Full=Alkaline phytoceramidase;
DE            Short=aPHC;
GN   Name=ACER3; Synonyms=APHC, PHCA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=11356846; DOI=10.1074/jbc.m102818200;
RA   Mao C., Xu R., Szulc Z.M., Bielawska A., Galadari S.H., Obeid L.M.;
RT   "Cloning and characterization of a novel human alkaline ceramidase. A
RT   mammalian enzyme that hydrolyzes phytoceramide.";
RL   J. Biol. Chem. 276:26577-26588(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Li N., Zhang W., Wan T., Chen T., Cao X.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND TISSUE SPECIFICITY.
RX   PubMed=20207939; DOI=10.1096/fj.09-153635;
RA   Xu R., Sun W., Jin J., Obeid L.M., Mao C.;
RT   "Role of alkaline ceramidases in the generation of sphingosine and its
RT   phosphate in erythrocytes.";
RL   FASEB J. 24:2507-2515(2010).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND PATHWAY.
RX   PubMed=20068046; DOI=10.1074/jbc.m109.063586;
RA   Hu W., Xu R., Sun W., Szulc Z.M., Bielawski J., Obeid L.M., Mao C.;
RT   "Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides,
RT   and its down-regulation inhibits both cell proliferation and apoptosis.";
RL   J. Biol. Chem. 285:7964-7976(2010).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, INVOLVEMENT IN PLDECO, VARIANT PLDECO GLY-33,
RP   AND CHARACTERIZATION OF VARIANT PLDECO GLY-33.
RX   PubMed=26792856; DOI=10.1136/jmedgenet-2015-103457;
RA   Edvardson S., Yi J.K., Jalas C., Xu R., Webb B.D., Snider J., Fedick A.,
RA   Kleinman E., Treff N.R., Mao C., Elpeleg O.;
RT   "Deficiency of the alkaline ceramidase ACER3 manifests in early childhood
RT   by progressive leukodystrophy.";
RL   J. Med. Genet. 53:389-396(2016).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 2-244 IN COMPLEX WITH CALCIUM AND
RP   ZINC IONS, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, PATHWAY,
RP   CHARACTERIZATION OF VARIANT PLDECO GLY-33, SUBCELLULAR LOCATION, TOPOLOGY,
RP   AND MUTAGENESIS OF ASP-19; GLU-22; ASN-24; SER-99; TYR-149 AND SER-228.
RX   PubMed=30575723; DOI=10.1038/s41467-018-07864-w;
RA   Vasiliauskaite-Brooks I., Healey R.D., Rochaix P., Saint-Paul J.,
RA   Sounier R., Grison C., Waltrich-Augusto T., Fortier M., Hoh F., Saied E.M.,
RA   Arenz C., Basu S., Leyrat C., Granier S.;
RT   "Structure of a human intramembrane ceramidase explains enzymatic
RT   dysfunction found in leukodystrophy.";
RL   Nat. Commun. 9:5437-5437(2018).
CC   -!- FUNCTION: Endoplasmic reticulum and Golgi ceramidase that catalyzes the
CC       hydrolysis of unsaturated long-chain C18:1-, C20:1- and C20:4-
CC       ceramides, dihydroceramides and phytoceramides into sphingoid bases
CC       like sphingosine and free fatty acids at alkaline pH (PubMed:20068046,
CC       PubMed:26792856, PubMed:20207939, PubMed:11356846, PubMed:30575723).
CC       Ceramides, sphingosine, and its phosphorylated form sphingosine-1-
CC       phosphate are bioactive lipids that mediate cellular signaling pathways
CC       regulating several biological processes including cell proliferation,
CC       apoptosis and differentiation (PubMed:20068046). Controls the
CC       generation of sphingosine in erythrocytes, and thereby sphingosine-1-
CC       phosphate in plasma (PubMed:20207939). Through the regulation of
CC       ceramides and sphingosine-1-phosphate homeostasis in the brain may play
CC       a role in neurons survival and function (By similarity). By regulating
CC       the levels of proinflammatory ceramides in immune cells and tissues,
CC       may modulate the inflammatory response (By similarity).
CC       {ECO:0000250|UniProtKB:Q9D099, ECO:0000269|PubMed:11356846,
CC       ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939,
CC       ECO:0000269|PubMed:26792856, ECO:0000269|PubMed:30575723,
CC       ECO:0000303|PubMed:20068046}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acyl-(4R)-4-hydroxysphinganine + H2O = (4R)-
CC         hydroxysphinganine + a fatty acid; Xref=Rhea:RHEA:33555,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:28868, ChEBI:CHEBI:31998,
CC         ChEBI:CHEBI:64124; Evidence={ECO:0000269|PubMed:11356846,
CC         ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33556;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sphing-4-enine =
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoate + sphing-4-enine;
CC         Xref=Rhea:RHEA:45348, ChEBI:CHEBI:15377, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:57756, ChEBI:CHEBI:85198;
CC         Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45349;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sphinganine =
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoate + sphinganine;
CC         Xref=Rhea:RHEA:45376, ChEBI:CHEBI:15377, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:57817, ChEBI:CHEBI:85206;
CC         Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45377;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-(4R)-
CC         hydroxysphinganine = (4R)-hydroxysphinganine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoate; Xref=Rhea:RHEA:45380, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:64124, ChEBI:CHEBI:85207;
CC         Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45381;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(11Z-eicosenoyl)-sphing-4-enine = (11Z)-eicosenoate +
CC         sphing-4-enine; Xref=Rhea:RHEA:45356, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:32426, ChEBI:CHEBI:57756, ChEBI:CHEBI:85284;
CC         Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45357;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(11Z-eicosenoyl)-sphinganine = (11Z)-eicosenoate +
CC         sphinganine; Xref=Rhea:RHEA:45360, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:32426, ChEBI:CHEBI:57817, ChEBI:CHEBI:85285;
CC         Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45361;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(11Z-eicosenoyl)-(4R)-hydroxysphinganine = (11Z)-
CC         eicosenoate + (4R)-hydroxysphinganine; Xref=Rhea:RHEA:45364,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:32426, ChEBI:CHEBI:64124,
CC         ChEBI:CHEBI:85286; Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45365;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(9Z-octadecenoyl)-sphing-4-enine = (9Z)-octadecenoate
CC         + sphing-4-enine; Xref=Rhea:RHEA:41299, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:57756, ChEBI:CHEBI:77996;
CC         Evidence={ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:26792856};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41300;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(9Z-octadecenoyl)-sphinganine = (9Z)-octadecenoate +
CC         sphinganine; Xref=Rhea:RHEA:45372, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:57817, ChEBI:CHEBI:74100;
CC         Evidence={ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:30575723};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45373;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(9Z-octadecenoyl)-(4R)-hydroxysphinganine = (4R)-
CC         hydroxysphinganine + (9Z)-octadecenoate; Xref=Rhea:RHEA:45368,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:30823, ChEBI:CHEBI:64124,
CC         ChEBI:CHEBI:85204; Evidence={ECO:0000269|PubMed:20068046};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45369;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphing-4-enine + H2O = a fatty acid + sphing-4-enine;
CC         Xref=Rhea:RHEA:20856, ChEBI:CHEBI:15377, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:52639, ChEBI:CHEBI:57756; EC=3.5.1.23;
CC         Evidence={ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939,
CC         ECO:0000269|PubMed:26792856};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20857;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphinganine + H2O = a fatty acid + sphinganine;
CC         Xref=Rhea:RHEA:33551, ChEBI:CHEBI:15377, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:31488, ChEBI:CHEBI:57817;
CC         Evidence={ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33552;
CC         Evidence={ECO:0000305|PubMed:20068046};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:30575723};
CC   -!- ACTIVITY REGULATION: Activated by 5 mM Ca(2+) and inhibited by 5 mM
CC       Zn(2+). {ECO:0000269|PubMed:11356846}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 9.5. {ECO:0000269|PubMed:11356846};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000269|PubMed:20068046, ECO:0000269|PubMed:20207939,
CC       ECO:0000269|PubMed:30575723}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11356846}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11356846, ECO:0000269|PubMed:30575723}. Golgi
CC       apparatus membrane {ECO:0000269|PubMed:11356846}; Multi-pass membrane
CC       protein {ECO:0000269|PubMed:11356846, ECO:0000269|PubMed:30575723}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NUN7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NUN7-2; Sequence=VSP_039162, VSP_039163;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highly expressed in
CC       placenta (PubMed:11356846). Expressed in erythrocytes
CC       (PubMed:20207939). {ECO:0000269|PubMed:11356846,
CC       ECO:0000269|PubMed:20207939}.
CC   -!- DISEASE: Leukodystrophy, progressive, early childhood-onset (PLDECO)
CC       [MIM:617762]: A form of leukodystrophy, a disorder of myelin production
CC       or maintenance affecting the central nervous system. PELCO features
CC       include neurological regression between 6 and 13 months of age, truncal
CC       hypotonia, appendicular spasticity, dystonia, optic disk pallor,
CC       peripheral neuropathy and neurogenic bladder. Brain imaging shows
CC       progressive diffuse abnormal white matter signals, cerebral atrophy,
CC       and thin corpus callosum. Sural nerve biopsy shows decreased
CC       myelination. PLDECO inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:26792856, ECO:0000269|PubMed:30575723}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the alkaline ceramidase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF214454; AAK71923.1; -; mRNA.
DR   EMBL; AF327353; AAL56013.1; -; mRNA.
DR   EMBL; AK002100; BAA92085.1; -; mRNA.
DR   EMBL; AK315000; BAG37496.1; -; mRNA.
DR   EMBL; AP000752; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP002498; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003119; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW75010.1; -; Genomic_DNA.
DR   EMBL; BC073853; AAH73853.1; -; mRNA.
DR   CCDS; CCDS8247.1; -. [Q9NUN7-1]
DR   RefSeq; NP_060837.3; NM_018367.6. [Q9NUN7-1]
DR   PDB; 6G7O; X-ray; 2.70 A; A=2-244.
DR   PDB; 6YXH; X-ray; 2.60 A; A=2-244.
DR   PDBsum; 6G7O; -.
DR   PDBsum; 6YXH; -.
DR   SMR; Q9NUN7; -.
DR   BioGRID; 120612; 9.
DR   IntAct; Q9NUN7; 1.
DR   STRING; 9606.ENSP00000434480; -.
DR   SwissLipids; SLP:000000680; -.
DR   iPTMnet; Q9NUN7; -.
DR   PhosphoSitePlus; Q9NUN7; -.
DR   BioMuta; ACER3; -.
DR   DMDM; 296439452; -.
DR   MassIVE; Q9NUN7; -.
DR   PaxDb; Q9NUN7; -.
DR   PeptideAtlas; Q9NUN7; -.
DR   PRIDE; Q9NUN7; -.
DR   ProteomicsDB; 82700; -. [Q9NUN7-1]
DR   ProteomicsDB; 82701; -. [Q9NUN7-2]
DR   TopDownProteomics; Q9NUN7-1; -. [Q9NUN7-1]
DR   Antibodypedia; 53464; 126 antibodies from 25 providers.
DR   DNASU; 55331; -.
DR   Ensembl; ENST00000532485; ENSP00000434480; ENSG00000078124.
DR   GeneID; 55331; -.
DR   KEGG; hsa:55331; -.
DR   MANE-Select; ENST00000532485.6; ENSP00000434480.1; NM_018367.7; NP_060837.3.
DR   UCSC; uc009yum.2; human. [Q9NUN7-1]
DR   CTD; 55331; -.
DR   DisGeNET; 55331; -.
DR   GeneCards; ACER3; -.
DR   HGNC; HGNC:16066; ACER3.
DR   HPA; ENSG00000078124; Low tissue specificity.
DR   MalaCards; ACER3; -.
DR   MIM; 617036; gene.
DR   MIM; 617762; phenotype.
DR   neXtProt; NX_Q9NUN7; -.
DR   OpenTargets; ENSG00000078124; -.
DR   Orphanet; 502444; Alkaline ceramidase 3 deficiency.
DR   PharmGKB; PA33256; -.
DR   VEuPathDB; HostDB:ENSG00000078124; -.
DR   eggNOG; KOG2329; Eukaryota.
DR   GeneTree; ENSGT00730000110920; -.
DR   InParanoid; Q9NUN7; -.
DR   OMA; NFRKKMP; -.
DR   OrthoDB; 969354at2759; -.
DR   PhylomeDB; Q9NUN7; -.
DR   TreeFam; TF313019; -.
DR   BRENDA; 3.5.1.23; 2681.
DR   PathwayCommons; Q9NUN7; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; Q9NUN7; -.
DR   UniPathway; UPA00222; -.
DR   BioGRID-ORCS; 55331; 7 hits in 1046 CRISPR screens.
DR   ChiTaRS; ACER3; human.
DR   GeneWiki; ACER3; -.
DR   GenomeRNAi; 55331; -.
DR   Pharos; Q9NUN7; Tbio.
DR   PRO; PR:Q9NUN7; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9NUN7; protein.
DR   Bgee; ENSG00000078124; Expressed in placenta and 220 other tissues.
DR   ExpressionAtlas; Q9NUN7; baseline and differential.
DR   Genevisible; Q9NUN7; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0030173; C:integral component of Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0102121; F:ceramidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0071633; F:dihydroceramidase activity; IDA:UniProtKB.
DR   GO; GO:0017040; F:N-acylsphingosine amidohydrolase activity; IDA:UniProtKB.
DR   GO; GO:0070774; F:phytoceramidase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0046514; P:ceramide catabolic process; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IMP:UniProtKB.
DR   GO; GO:0071602; P:phytosphingosine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0043067; P:regulation of programmed cell death; IDA:UniProtKB.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR008901; ACER.
DR   PANTHER; PTHR46187; PTHR46187; 1.
DR   Pfam; PF05875; Ceramidase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Disease variant;
KW   Endoplasmic reticulum; Golgi apparatus; Hydrolase; Leukodystrophy;
KW   Lipid metabolism; Membrane; Metal-binding; Reference proteome;
KW   Sphingolipid metabolism; Transmembrane; Transmembrane helix; Zinc.
FT   CHAIN           1..267
FT                   /note="Alkaline ceramidase 3"
FT                   /id="PRO_0000212463"
FT   TOPO_DOM        1..33
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        34..55
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        56..61
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        62..82
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        83..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        88..108
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        109..118
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        119..139
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        140..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        142..162
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        163..173
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        174..194
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        195..215
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TRANSMEM        216..236
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   TOPO_DOM        237..267
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   METAL           19
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           20
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           22
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           24
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           33
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           81
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           217
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   METAL           221
FT                   /note="Zinc; catalytic"
FT                   /evidence="ECO:0000269|PubMed:30575723,
FT                   ECO:0007744|PDB:6G7O"
FT   VAR_SEQ         1..133
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_039162"
FT   VAR_SEQ         134..145
FT                   /note="TVYLKVKEPIFH -> MAQSRLIGTSTS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_039163"
FT   VARIANT         33
FT                   /note="E -> G (in PLDECO; impaired protein stability;
FT                   strongly decreased enzyme activity; decreased ceramide
FT                   catabolic process; in fibroblasts of patients homozygous
FT                   for the mutation; dbSNP:rs1554988032)"
FT                   /evidence="ECO:0000269|PubMed:26792856,
FT                   ECO:0000269|PubMed:30575723"
FT                   /id="VAR_081205"
FT   MUTAGEN         19
FT                   /note="D->G: Mildly decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   MUTAGEN         22
FT                   /note="E->G: Strongly decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   MUTAGEN         24
FT                   /note="N->G: Strongly decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   MUTAGEN         99
FT                   /note="S->A: No effect on enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   MUTAGEN         149
FT                   /note="Y->A: Decreased enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   MUTAGEN         228
FT                   /note="S->A: No effect on enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:30575723"
FT   CONFLICT        52
FT                   /note="V -> I (in Ref. 1; AAK71923, 2; AAL56013, 3;
FT                   BAG37496, 5; EAW75010 and 6; AAH73853)"
FT                   /evidence="ECO:0000305"
FT   STRAND          29..33
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           34..38
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           39..43
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           45..56
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           61..83
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           86..108
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           119..138
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           142..166
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           172..194
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           199..203
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           209..213
FT                   /evidence="ECO:0007829|PDB:6G7O"
FT   HELIX           216..243
FT                   /evidence="ECO:0007829|PDB:6G7O"
SQ   SEQUENCE   267 AA;  31552 MW;  CFD2A901F12A5918 CRC64;
     MAPAADREGY WGPTTSTLDW CEENYSVTWY IAEFWNTVSN LIMIIPPMFG AVQSVRDGLE
     KRYIASYLAL TVVGMGSWCF HMTLKYEMQL LDELPMIYSC CIFVYCMFEC FKIKNSVNYH
     LLFTLVLFSL IVTTVYLKVK EPIFHQVMYG MLVFTLVLRS IYIVTWVYPW LRGLGYTSLG
     IFLLGFLFWN IDNIFCESLR NFRKKVPPII GITTQFHAWW HILTGLGSYL HILFSLYTRT
     LYLRYRPKVK FLFGIWPVIL FEPLRKH
//
ID   MOT10_HUMAN             Reviewed;         515 AA.
AC   Q8TF71; B3KWY0; Q6ZMG0; Q8WVI5;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   23-FEB-2022, entry version 155.
DE   RecName: Full=Monocarboxylate transporter 10;
DE            Short=MCT 10;
DE   AltName: Full=Aromatic amino acid transporter 1;
DE   AltName: Full=Solute carrier family 16 member 10;
DE   AltName: Full=T-type amino acid transporter 1;
GN   Name=SLC16A10; Synonyms=MCT10, TAT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   FUNCTION.
RC   TISSUE=Thymus;
RX   PubMed=11827462; DOI=10.1006/geno.2001.6678;
RA   Kim D.K., Kanai Y., Matsuo H., Kim J.Y., Chairoungdua A., Kobayashi Y.,
RA   Enomoto A., Cha S.H., Goya T., Endou H.;
RT   "The human T-type amino acid transporter-1: characterization, gene
RT   organization, and chromosomal location.";
RL   Genomics 79:95-103(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta, Prostate, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-498, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-498 AND SER-501, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Sodium-independent transporter that mediates the uptake of
CC       aromatic acids. Can function as a net efflux pathway for aromatic amino
CC       acids in the basosolateral epithelial cells (By similarity).
CC       {ECO:0000250, ECO:0000269|PubMed:11827462}.
CC   -!- INTERACTION:
CC       Q8TF71; Q9BWH2: FUNDC2; NbExp=3; IntAct=EBI-17858931, EBI-714482;
CC       Q8TF71; Q9Y5U4: INSIG2; NbExp=3; IntAct=EBI-17858931, EBI-8503746;
CC       Q8TF71; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-17858931, EBI-8638294;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11827462};
CC       Multi-pass membrane protein {ECO:0000255}. Basolateral cell membrane
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Strongly expressed in kidney and skeletal muscle
CC       and at lower level in placenta and heart.
CC       {ECO:0000269|PubMed:11827462}.
CC   -!- PTM: Not N-glycosylated. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       Monocarboxylate porter (TC 2.A.1.13) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH17968.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB057445; BAB84670.1; -; mRNA.
DR   EMBL; AK126183; BAG54292.1; -; mRNA.
DR   EMBL; AK172789; BAD18768.1; -; mRNA.
DR   EMBL; AL360227; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48298.1; -; Genomic_DNA.
DR   EMBL; BC017968; AAH17968.1; ALT_INIT; mRNA.
DR   EMBL; BC066985; AAH66985.1; -; mRNA.
DR   CCDS; CCDS5089.1; -.
DR   RefSeq; NP_061063.2; NM_018593.4.
DR   SMR; Q8TF71; -.
DR   BioGRID; 125582; 33.
DR   IntAct; Q8TF71; 15.
DR   STRING; 9606.ENSP00000357844; -.
DR   DrugBank; DB02952; 2-aminoisobutyric acid.
DR   DrugBank; DB00160; Alanine.
DR   DrugBank; DB00125; Arginine.
DR   DrugBank; DB00174; Asparagine.
DR   DrugBank; DB00128; Aspartic acid.
DR   DrugBank; DB03107; beta-Alanine.
DR   DrugBank; DB00151; Cysteine.
DR   DrugBank; DB00138; Cystine.
DR   DrugBank; DB01786; D-Alanine.
DR   DrugBank; DB01746; D-Leucine.
DR   DrugBank; DB02556; D-Phenylalanine.
DR   DrugBank; DB03929; D-Serine.
DR   DrugBank; DB03225; D-Tryptophan.
DR   DrugBank; DB03839; D-Tyrosine.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugBank; DB00145; Glycine.
DR   DrugBank; DB00117; Histidine.
DR   DrugBank; DB00167; Isoleucine.
DR   DrugBank; DB00130; L-Glutamine.
DR   DrugBank; DB00123; L-Lysine.
DR   DrugBank; DB04398; Lactic acid.
DR   DrugBank; DB00149; Leucine.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00279; Liothyronine.
DR   DrugBank; DB01583; Liotrix.
DR   DrugBank; DB00134; Methionine.
DR   DrugBank; DB00120; Phenylalanine.
DR   DrugBank; DB00172; Proline.
DR   DrugBank; DB00119; Pyruvic acid.
DR   DrugBank; DB00133; Serine.
DR   DrugBank; DB00156; Threonine.
DR   DrugBank; DB00150; Tryptophan.
DR   DrugBank; DB00135; Tyrosine.
DR   DrugBank; DB00161; Valine.
DR   TCDB; 2.A.1.13.8; the major facilitator superfamily (mfs).
DR   iPTMnet; Q8TF71; -.
DR   PhosphoSitePlus; Q8TF71; -.
DR   BioMuta; SLC16A10; -.
DR   DMDM; 74751472; -.
DR   EPD; Q8TF71; -.
DR   jPOST; Q8TF71; -.
DR   MassIVE; Q8TF71; -.
DR   MaxQB; Q8TF71; -.
DR   PaxDb; Q8TF71; -.
DR   PeptideAtlas; Q8TF71; -.
DR   PRIDE; Q8TF71; -.
DR   ProteomicsDB; 74571; -.
DR   Antibodypedia; 19300; 123 antibodies from 21 providers.
DR   DNASU; 117247; -.
DR   Ensembl; ENST00000368851; ENSP00000357844; ENSG00000112394.
DR   GeneID; 117247; -.
DR   KEGG; hsa:117247; -.
DR   MANE-Select; ENST00000368851.10; ENSP00000357844.4; NM_018593.5; NP_061063.2.
DR   UCSC; uc003pus.4; human.
DR   CTD; 117247; -.
DR   DisGeNET; 117247; -.
DR   GeneCards; SLC16A10; -.
DR   HGNC; HGNC:17027; SLC16A10.
DR   HPA; ENSG00000112394; Tissue enhanced (choroid plexus, pancreas, skeletal muscle).
DR   MIM; 607550; gene.
DR   neXtProt; NX_Q8TF71; -.
DR   OpenTargets; ENSG00000112394; -.
DR   PharmGKB; PA38197; -.
DR   VEuPathDB; HostDB:ENSG00000112394; -.
DR   eggNOG; KOG2504; Eukaryota.
DR   GeneTree; ENSGT00940000157966; -.
DR   HOGENOM; CLU_001265_59_1_1; -.
DR   InParanoid; Q8TF71; -.
DR   OMA; FYSLWIM; -.
DR   OrthoDB; 916876at2759; -.
DR   PhylomeDB; Q8TF71; -.
DR   TreeFam; TF313792; -.
DR   PathwayCommons; Q8TF71; -.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   SignaLink; Q8TF71; -.
DR   BioGRID-ORCS; 117247; 5 hits in 1039 CRISPR screens.
DR   ChiTaRS; SLC16A10; human.
DR   GeneWiki; SLC16A10; -.
DR   GenomeRNAi; 117247; -.
DR   Pharos; Q8TF71; Tbio.
DR   PRO; PR:Q8TF71; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q8TF71; protein.
DR   Bgee; ENSG00000112394; Expressed in stomach and 165 other tissues.
DR   ExpressionAtlas; Q8TF71; baseline and differential.
DR   Genevisible; Q8TF71; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015171; F:amino acid transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0015173; F:aromatic amino acid transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0015349; F:thyroid hormone transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0006865; P:amino acid transport; TAS:Reactome.
DR   GO; GO:0015801; P:aromatic amino acid transport; TAS:HGNC-UCL.
DR   GO; GO:0006590; P:thyroid hormone generation; IEA:Ensembl.
DR   GO; GO:0070327; P:thyroid hormone transport; IDA:ARUK-UCL.
DR   GO; GO:0070460; P:thyroid-stimulating hormone secretion; IEA:Ensembl.
DR   Gene3D; 1.20.1250.20; -; 2.
DR   InterPro; IPR030762; MCT10.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   PANTHER; PTHR11360:SF119; PTHR11360:SF119; 1.
DR   Pfam; PF07690; MFS_1; 1.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Membrane; Phosphoprotein; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..515
FT                   /note="Monocarboxylate transporter 10"
FT                   /id="PRO_0000314253"
FT   TOPO_DOM        1..66
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        67..87
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        115..135
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        145..165
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        172..192
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..221
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        229..249
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        292..312
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        330..350
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        352..372
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        397..417
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        420..440
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        452..472
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        473..515
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        23..37
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91Y77"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         501
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         503
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U9N9"
FT   MOD_RES         504
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U9N9"
FT   VARIANT         508
FT                   /note="K -> Q (in dbSNP:rs17072442)"
FT                   /id="VAR_037874"
FT   CONFLICT        422
FT                   /note="F -> L (in Ref. 5; AAH17968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        431
FT                   /note="M -> T (in Ref. 2; BAD18768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        443
FT                   /note="D -> G (in Ref. 2; BAD18768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="K -> E (in Ref. 5; AAH17968)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   515 AA;  55493 MW;  A870E4DDC26B918E CRC64;
     MVLSQEEPDS ARGTSEAQPL GPAPTGAAPP PGPGPSDSPE AAVEKVEVEL AGPATAEPHE
     PPEPPEGGWG WLVMLAAMWC NGSVFGIQNA CGVLFVSMLE TFGSKDDDKM VFKTAWVGSL
     SMGMIFFCCP IVSVFTDLFG CRKTAVVGAA VGFVGLMSSS FVSSIEPLYL TYGIIFACGC
     SFAYQPSLVI LGHYFKKRLG LVNGIVTAGS SVFTILLPLL LRVLIDSVGL FYTLRVLCIF
     MFVLFLAGFT YRPLATSTKD KESGGSGSSL FSRKKFSPPK KIFNFAIFKV TAYAVWAVGI
     PLALFGYFVP YVHLMKHVNE RFQDEKNKEV VLMCIGVTSG VGRLLFGRIA DYVPGVKKVY
     LQVLSFFFIG LMSMMIPLCS IFGALIAVCL IMGLFDGCFI SIMAPIAFEL VGAQDVSQAI
     GFLLGFMSIP MTVGPPIAGL LRDKLGSYDV AFYLAGVPPL IGGAVLCFIP WIHSKKQREI
     SKTTGKEKME KMLENQNSLL SSSSGMFKKE SDSII
//
ID   KLHL7_HUMAN             Reviewed;         586 AA.
AC   Q8IXQ5; A4D144; B7Z5I9; G5E9G3; Q7Z765; Q96MV2; Q9BQF8; Q9UDQ9;
DT   21-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   23-FEB-2022, entry version 166.
DE   RecName: Full=Kelch-like protein 7;
GN   Name=KLHL7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Zhang W., He L., Wan T., Zhu X., Cao X.;
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16918702; DOI=10.1111/j.1365-3083.2006.01821.x;
RA   Bredholt G., Storstein A., Haugen M., Krossnes B.K., Husebye E.,
RA   Knappskog P., Vedeler C.A.;
RT   "Detection of autoantibodies to the BTB-kelch protein KLHL7 in cancer
RT   sera.";
RL   Scand. J. Immunol. 64:325-335(2006).
RN   [10]
RP   FUNCTION, IDENTIFICATION IN THE BCR(KLHL7) COMPLEX, HOMODIMERIZATION, AND
RP   CHARACTERIZATION OF VARIANTS RP42 THR-153 AND VAL-153.
RX   PubMed=21828050; DOI=10.1074/jbc.m111.245126;
RA   Kigoshi Y., Tsuruta F., Chiba T.;
RT   "Ubiquitin ligase activity of Cul3-KLHL7 protein is attenuated by autosomal
RT   dominant retinitis pigmentosa causative mutation.";
RL   J. Biol. Chem. 286:33613-33621(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS) OF 283-586.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the KELCH domain of human KLHL7.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [12]
RP   VARIANTS RP42 ASN-150; THR-153 AND VAL-153, VARIANTS ASN-255; TYR-423 AND
RP   GLN-472, AND VARIANT ARG-18 (ISOFORM 2).
RX   PubMed=19520207; DOI=10.1016/j.ajhg.2009.05.007;
RA   Friedman J.S., Ray J.W., Waseem N., Johnson K., Brooks M.J., Hugosson T.,
RA   Breuer D., Branham K.E., Krauth D.S., Bowne S.J., Sullivan L.S.,
RA   Ponjavic V., Graense L., Khanna R., Trager E.H., Gieser L.M.,
RA   Hughbanks-Wheaton D., Cojocaru R.I., Ghiasvand N.M., Chakarova C.F.,
RA   Abrahamson M., Goering H.H.H., Webster A.R., Birch D.G., Abecasis G.R.,
RA   Fann Y., Bhattacharya S.S., Daiger S.P., Heckenlively J.R., Andreasson S.,
RA   Swaroop A.;
RT   "Mutations in a BTB-Kelch protein, KLHL7, cause autosomal-dominant
RT   retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 84:792-800(2009).
RN   [13]
RP   VARIANT RP42 VAL-153.
RX   PubMed=20547956; DOI=10.1001/archophthalmol.2010.98;
RA   Hugosson T., Friedman J.S., Ponjavic V., Abrahamson M., Swaroop A.,
RA   Andreasson S.;
RT   "Phenotype associated with mutation in the recently identified autosomal
RT   dominant retinitis pigmentosa KLHL7 gene.";
RL   Arch. Ophthalmol. 128:772-778(2010).
RN   [14]
RP   VARIANTS RP42 ASN-150; THR-153 AND VAL-153.
RX   PubMed=22084217; DOI=10.1001/archophthalmol.2011.307;
RA   Wen Y., Locke K.G., Klein M., Bowne S.J., Sullivan L.S., Ray J.W.,
RA   Daiger S.P., Birch D.G., Hughbanks-Wheaton D.K.;
RT   "Phenotypic characterization of 3 families with autosomal dominant
RT   retinitis pigmentosa due to mutations in KLHL7.";
RL   Arch. Ophthalmol. 129:1475-1482(2011).
RN   [15]
RP   VARIANTS PERCHING GLN-372; CYS-420 AND SER-421, CHARACTERIZATION OF
RP   VARIANTS PERCHING GLN-372; CYS-420 AND SER-421, INVOLVEMENT IN PERCHING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=27392078; DOI=10.1016/j.ajhg.2016.05.026;
RA   Angius A., Uva P., Buers I., Oppo M., Puddu A., Onano S., Persico I.,
RA   Loi A., Marcia L., Hoehne W., Cuccuru G., Fotia G., Deiana M., Marongiu M.,
RA   Atalay H.T., Inan S., El Assy O., Smit L.M., Okur I., Boduroglu K.,
RA   Utine G.E., Kilic E., Zampino G., Crisponi G., Crisponi L., Rutsch F.;
RT   "Bi-allelic mutations in KLHL7 cause a Crisponi/CISS1-like phenotype
RT   associated with early-onset retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 99:236-245(2016).
CC   -!- FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3
CC       ubiquitin ligase complex. The BCR(KLHL7) complex acts by mediating
CC       ubiquitination and subsequent degradation of substrate proteins.
CC       Probably mediates 'Lys-48'-linked ubiquitination.
CC       {ECO:0000269|PubMed:21828050}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Component of the BCR(KLHL7) E3 ubiquitin ligase
CC       complex, at least composed of CUL3 and KLHL7 and RBX1.
CC       {ECO:0000269|PubMed:21828050}.
CC   -!- INTERACTION:
CC       Q8IXQ5; Q13618: CUL3; NbExp=9; IntAct=EBI-6153160, EBI-456129;
CC       Q8IXQ5; Q8IXQ5: KLHL7; NbExp=7; IntAct=EBI-6153160, EBI-6153160;
CC       Q8IXQ5-4; P40337-2: VHL; NbExp=3; IntAct=EBI-25895859, EBI-12157263;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16918702}. Cytoplasm
CC       {ECO:0000269|PubMed:27392078}. Note=Colocalizes with CUL3 in punctate
CC       structures at the perinuclear region of the cytoplasm.
CC       {ECO:0000269|PubMed:27392078}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8IXQ5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IXQ5-2; Sequence=VSP_038416;
CC       Name=3;
CC         IsoId=Q8IXQ5-3; Sequence=VSP_038417, VSP_038418;
CC       Name=4;
CC         IsoId=Q8IXQ5-4; Sequence=VSP_038416, VSP_038417, VSP_038418;
CC       Name=5;
CC         IsoId=Q8IXQ5-5; Sequence=VSP_046974;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in adult and
CC       fetal heart, CNS and adult testis. {ECO:0000269|PubMed:16918702}.
CC   -!- DISEASE: Perching syndrome (PERCHING) [MIM:617055]: An autosomal
CC       recessive multisystem disorder characterized by global developmental
CC       delay, dysmorphic facial features, feeding and respiratory difficulties
CC       with poor overall growth, axial hypotonia, and joint contractures. The
CC       features are variable, even within families, and may also include
CC       retinitis pigmentosa, cardiac or genitourinary anomalies, and abnormal
CC       sweating. {ECO:0000269|PubMed:27392078}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Retinitis pigmentosa 42 (RP42) [MIM:612943]: A retinal
CC       dystrophy belonging to the group of pigmentary retinopathies. Retinitis
CC       pigmentosa is characterized by retinal pigment deposits visible on
CC       fundus examination and primary loss of rod photoreceptor cells followed
CC       by secondary loss of cone photoreceptors. Patients typically have night
CC       vision blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field and
CC       eventually central vision as well. {ECO:0000269|PubMed:19520207,
CC       ECO:0000269|PubMed:20547956, ECO:0000269|PubMed:21828050,
CC       ECO:0000269|PubMed:22084217}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF111113; AAF27196.1; -; mRNA.
DR   EMBL; AL136597; CAB66532.1; -; mRNA.
DR   EMBL; AK056390; BAB71175.1; -; mRNA.
DR   EMBL; AK299006; BAH12925.1; -; mRNA.
DR   EMBL; EF560731; ABQ59041.1; -; mRNA.
DR   EMBL; AC005082; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006039; AAO21916.1; -; Genomic_DNA.
DR   EMBL; AC073992; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24261.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93770.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93773.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93774.1; -; Genomic_DNA.
DR   EMBL; BC009555; AAH09555.1; -; mRNA.
DR   EMBL; BC039585; AAH39585.1; -; mRNA.
DR   CCDS; CCDS34609.1; -. [Q8IXQ5-1]
DR   CCDS; CCDS5378.2; -. [Q8IXQ5-5]
DR   CCDS; CCDS55095.1; -. [Q8IXQ5-3]
DR   RefSeq; NP_001026880.2; NM_001031710.2. [Q8IXQ5-1]
DR   RefSeq; NP_001165899.1; NM_001172428.1. [Q8IXQ5-3]
DR   RefSeq; NP_061334.4; NM_018846.4. [Q8IXQ5-5]
DR   RefSeq; XP_016867928.1; XM_017012439.1. [Q8IXQ5-2]
DR   PDB; 3II7; X-ray; 1.63 A; A=283-586.
DR   PDBsum; 3II7; -.
DR   SMR; Q8IXQ5; -.
DR   BioGRID; 121021; 44.
DR   CORUM; Q8IXQ5; -.
DR   IntAct; Q8IXQ5; 28.
DR   STRING; 9606.ENSP00000343273; -.
DR   iPTMnet; Q8IXQ5; -.
DR   PhosphoSitePlus; Q8IXQ5; -.
DR   BioMuta; KLHL7; -.
DR   DMDM; 116242609; -.
DR   EPD; Q8IXQ5; -.
DR   jPOST; Q8IXQ5; -.
DR   MassIVE; Q8IXQ5; -.
DR   MaxQB; Q8IXQ5; -.
DR   PaxDb; Q8IXQ5; -.
DR   PeptideAtlas; Q8IXQ5; -.
DR   PRIDE; Q8IXQ5; -.
DR   ProteomicsDB; 33929; -.
DR   ProteomicsDB; 71041; -. [Q8IXQ5-1]
DR   ProteomicsDB; 71042; -. [Q8IXQ5-2]
DR   ProteomicsDB; 71043; -. [Q8IXQ5-3]
DR   ProteomicsDB; 71044; -. [Q8IXQ5-4]
DR   Antibodypedia; 25599; 103 antibodies from 19 providers.
DR   DNASU; 55975; -.
DR   Ensembl; ENST00000322275; ENSP00000323270; ENSG00000122550. [Q8IXQ5-3]
DR   Ensembl; ENST00000339077; ENSP00000343273; ENSG00000122550.
DR   Ensembl; ENST00000409689; ENSP00000386263; ENSG00000122550. [Q8IXQ5-5]
DR   Ensembl; ENST00000410047; ENSP00000386999; ENSG00000122550. [Q8IXQ5-4]
DR   GeneID; 55975; -.
DR   KEGG; hsa:55975; -.
DR   MANE-Select; ENST00000339077.10; ENSP00000343273.4; NM_001031710.3; NP_001026880.2.
DR   UCSC; uc003svq.4; human. [Q8IXQ5-1]
DR   CTD; 55975; -.
DR   DisGeNET; 55975; -.
DR   GeneCards; KLHL7; -.
DR   GeneReviews; KLHL7; -.
DR   HGNC; HGNC:15646; KLHL7.
DR   HPA; ENSG00000122550; Tissue enhanced (heart).
DR   MalaCards; KLHL7; -.
DR   MIM; 611119; gene.
DR   MIM; 612943; phenotype.
DR   MIM; 617055; phenotype.
DR   neXtProt; NX_Q8IXQ5; -.
DR   OpenTargets; ENSG00000122550; -.
DR   Orphanet; 157820; Cold-induced sweating syndrome.
DR   Orphanet; 603689; KLHL7-related Bohring-Opitz-like syndrome.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   PharmGKB; PA38392; -.
DR   VEuPathDB; HostDB:ENSG00000122550; -.
DR   eggNOG; KOG4441; Eukaryota.
DR   GeneTree; ENSGT00940000155602; -.
DR   HOGENOM; CLU_004253_14_2_1; -.
DR   InParanoid; Q8IXQ5; -.
DR   OMA; WRAASPM; -.
DR   OrthoDB; 293214at2759; -.
DR   PhylomeDB; Q8IXQ5; -.
DR   TreeFam; TF351653; -.
DR   PathwayCommons; Q8IXQ5; -.
DR   SignaLink; Q8IXQ5; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 55975; 19 hits in 1089 CRISPR screens.
DR   ChiTaRS; KLHL7; human.
DR   EvolutionaryTrace; Q8IXQ5; -.
DR   GeneWiki; KLHL7; -.
DR   GenomeRNAi; 55975; -.
DR   Pharos; Q8IXQ5; Tbio.
DR   PRO; PR:Q8IXQ5; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q8IXQ5; protein.
DR   Bgee; ENSG00000122550; Expressed in oocyte and 226 other tissues.
DR   ExpressionAtlas; Q8IXQ5; baseline and differential.
DR   Genevisible; Q8IXQ5; HS.
DR   GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:LIFEdb.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   Gene3D; 2.120.10.80; -; 1.
DR   Gene3D; 3.30.710.10; -; 1.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR017096; BTB-kelch_protein.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR015915; Kelch-typ_b-propeller.
DR   InterPro; IPR006652; Kelch_1.
DR   InterPro; IPR030599; KLHL7.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR24412:SF435; PTHR24412:SF435; 1.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF01344; Kelch_1; 3.
DR   PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00612; Kelch; 4.
DR   SUPFAM; SSF117281; SSF117281; 1.
DR   SUPFAM; SSF54695; SSF54695; 1.
DR   PROSITE; PS50097; BTB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Disease variant;
KW   Kelch repeat; Nucleus; Reference proteome; Repeat; Retinitis pigmentosa;
KW   Ubl conjugation pathway.
FT   CHAIN           1..586
FT                   /note="Kelch-like protein 7"
FT                   /id="PRO_0000228988"
FT   DOMAIN          44..111
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   DOMAIN          146..248
FT                   /note="BACK"
FT   REPEAT          294..336
FT                   /note="Kelch 1"
FT   REPEAT          337..382
FT                   /note="Kelch 2"
FT   REPEAT          383..430
FT                   /note="Kelch 3"
FT   REPEAT          431..481
FT                   /note="Kelch 4"
FT   REPEAT          483..528
FT                   /note="Kelch 5"
FT   REPEAT          530..575
FT                   /note="Kelch 6"
FT   VAR_SEQ         1..48
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046974"
FT   VAR_SEQ         1..40
FT                   /note="MAASGVEKSSKKKTEKKLAAREEAKLLAGFMGVMNNMRKQ -> MLGGTDCR
FT                   TFLTSHINLK (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005"
FT                   /id="VSP_038416"
FT   VAR_SEQ         149..166
FT                   /note="ISVLAECLDCPELKATAD -> EAEKVDQSLPECGMLFTV (in isoform
FT                   3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.1"
FT                   /id="VSP_038417"
FT   VAR_SEQ         167..586
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.1"
FT                   /id="VSP_038418"
FT   VARIANT         150
FT                   /note="S -> N (in RP42; dbSNP:rs137853112)"
FT                   /evidence="ECO:0000269|PubMed:19520207,
FT                   ECO:0000269|PubMed:22084217"
FT                   /id="VAR_060672"
FT   VARIANT         153
FT                   /note="A -> T (in RP42; impairs interaction with CUL3 and
FT                   ubiquitin ligase activity of the BCR(KLHL7) complex;
FT                   dbSNP:rs137853114)"
FT                   /evidence="ECO:0000269|PubMed:19520207,
FT                   ECO:0000269|PubMed:21828050, ECO:0000269|PubMed:22084217"
FT                   /id="VAR_060673"
FT   VARIANT         153
FT                   /note="A -> V (in RP42; impairs interaction with CUL3 and
FT                   ubiquitin ligase activity of the BCR(KLHL7) complex;
FT                   dbSNP:rs137853113)"
FT                   /evidence="ECO:0000269|PubMed:19520207,
FT                   ECO:0000269|PubMed:20547956, ECO:0000269|PubMed:21828050,
FT                   ECO:0000269|PubMed:22084217"
FT                   /id="VAR_060674"
FT   VARIANT         255
FT                   /note="D -> N (in a patient with retinitis pigmentosa;
FT                   uncertain pathological significance; dbSNP:rs1227070758)"
FT                   /evidence="ECO:0000269|PubMed:19520207"
FT                   /id="VAR_060675"
FT   VARIANT         372
FT                   /note="R -> Q (in PERCHING; subcellular localization in
FT                   punctate structures at the perinuclear region of cytoplasm
FT                   is similar to wild-type and colocalized with CUL3;
FT                   dbSNP:rs879255558)"
FT                   /evidence="ECO:0000269|PubMed:27392078"
FT                   /id="VAR_077161"
FT   VARIANT         420
FT                   /note="R -> C (in PERCHING; subcellular localization in
FT                   punctate structures at the perinuclear region of cytoplasm
FT                   is similar to wild-type and colocalized with CUL3;
FT                   dbSNP:rs780705654)"
FT                   /evidence="ECO:0000269|PubMed:27392078"
FT                   /id="VAR_077162"
FT   VARIANT         421
FT                   /note="C -> S (in PERCHING; subcellular localization in
FT                   punctate structures at the perinuclear region of cytoplasm
FT                   is similar to wild-type and colocalized with CUL3;
FT                   dbSNP:rs879255556)"
FT                   /evidence="ECO:0000269|PubMed:27392078"
FT                   /id="VAR_077163"
FT   VARIANT         423
FT                   /note="H -> Y"
FT                   /evidence="ECO:0000269|PubMed:19520207"
FT                   /id="VAR_060676"
FT   VARIANT         472
FT                   /note="K -> Q (in a patient with retinitis pigmentosa;
FT                   uncertain pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:19520207"
FT                   /id="VAR_060677"
FT   CONFLICT        85
FT                   /note="V -> L (in Ref. 8; AAH39585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        138
FT                   /note="K -> R (in Ref. 3; BAB71175)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        507
FT                   /note="E -> D (in Ref. 3; BAH12925)"
FT                   /evidence="ECO:0000305"
FT   STRAND          293..298
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          305..309
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            311..313
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          316..318
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          330..334
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          337..341
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          344..348
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          351..356
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            357..360
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          361..366
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          376..380
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          383..387
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          400..404
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            405..408
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          409..413
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          424..428
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          431..435
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          438..440
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            442..444
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          451..455
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            456..459
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          460..464
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          475..479
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          482..486
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          493..495
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          498..502
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            503..506
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          507..510
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          522..526
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          529..534
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          538..541
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          544..549
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   TURN            550..553
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          554..562
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   STRAND          570..575
FT                   /evidence="ECO:0007829|PDB:3II7"
FT   VARIANT         Q8IXQ5-2:18
FT                   /note="K -> R (in dbSNP:rs17147682)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082842"
SQ   SEQUENCE   586 AA;  65992 MW;  FA4ED8F1567AC7A8 CRC64;
     MAASGVEKSS KKKTEKKLAA REEAKLLAGF MGVMNNMRKQ KTLCDVILMV QERKIPAHRV
     VLAAASHFFN LMFTTNMLES KSFEVELKDA EPDIIEQLVE FAYTARISVN SNNVQSLLDA
     ANQYQIEPVK KMCVDFLKEQ VDASNCLGIS VLAECLDCPE LKATADDFIH QHFTEVYKTD
     EFLQLDVKRV THLLNQDTLT VRAEDQVYDA AVRWLKYDEP NRQPFMVDIL AKVRFPLISK
     NFLSKTVQAE PLIQDNPECL KMVISGMRYH LLSPEDREEL VDGTRPRRKK HDYRIALFGG
     SQPQSCRYFN PKDYSWTDIR CPFEKRRDAA CVFWDNVVYI LGGSQLFPIK RMDCYNVVKD
     SWYSKLGPPT PRDSLAACAA EGKIYTSGGS EVGNSALYLF ECYDTRTESW HTKPSMLTQR
     CSHGMVEANG LIYVCGGSLG NNVSGRVLNS CEVYDPATET WTELCPMIEA RKNHGLVFVK
     DKIFAVGGQN GLGGLDNVEY YDIKLNEWKM VSPMPWKGVT VKCAAVGSIV YVLAGFQGVG
     RLGHILEYNT ETDKWVANSK VRAFPVTSCL ICVVDTCGAN EETLET
//
ID   NCEH1_HUMAN             Reviewed;         408 AA.
AC   Q6PIU2; B7Z2K4; B7Z3A1; B7Z5U2; B7Z906; B7ZAW6; F5H7K4; Q86WZ1; Q9P2I4;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   12-DEC-2006, sequence version 3.
DT   23-FEB-2022, entry version 150.
DE   RecName: Full=Neutral cholesterol ester hydrolase 1;
DE            Short=NCEH;
DE            EC=3.1.1.-;
DE   AltName: Full=Arylacetamide deacetylase-like 1;
GN   Name=NCEH1; Synonyms=AADACL1, KIAA1363;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Brain, Hippocampus, Testis, Tongue, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT MET-343.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12149457; DOI=10.1073/pnas.162187599;
RA   Jessani N., Liu Y., Humphrey M., Cravatt B.F.;
RT   "Enzyme activity profiles of the secreted and membrane proteome that depict
RT   cancer cell invasiveness.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:10335-10340(2002).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=17052608; DOI=10.1016/j.chembiol.2006.08.008;
RA   Chiang K.P., Niessen S., Saghatelian A., Cravatt B.F.;
RT   "An enzyme that regulates ether lipid signaling pathways in cancer
RT   annotated by multidimensional profiling.";
RL   Chem. Biol. 13:1041-1050(2006).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=18782767; DOI=10.1074/jbc.m802686200;
RA   Okazaki H., Igarashi M., Nishi M., Sekiya M., Tajima M., Takase S.,
RA   Takanashi M., Ohta K., Tamura Y., Okazaki S., Yahagi N., Ohashi K.,
RA   Amemiya-Kudo M., Nakagawa Y., Nagai R., Kadowaki T., Osuga J.,
RA   Ishibashi S.;
RT   "Identification of neutral cholesterol ester hydrolase, a key enzyme
RT   removing cholesterol from macrophages.";
RL   J. Biol. Chem. 283:33357-33364(2008).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-287.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Hydrolyzes 2-acetyl monoalkylglycerol ether, the penultimate
CC       precursor of the pathway for de novo synthesis of platelet-activating
CC       factor (PubMed:17052608). May be responsible for cholesterol ester
CC       hydrolysis in macrophages (By similarity). Also involved in organ
CC       detoxification by hydrolyzing exogenous organophosphorus compounds (By
CC       similarity). May contribute to cancer pathogenesis by promoting tumor
CC       cell migration (PubMed:17052608). {ECO:0000250|UniProtKB:Q8BLF1,
CC       ECO:0000269|PubMed:17052608}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-2-acetyl-sn-glycerol + H2O = 1-O-hexadecyl-sn-
CC         glycerol + acetate + H(+); Xref=Rhea:RHEA:38563, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:34115,
CC         ChEBI:CHEBI:75936; Evidence={ECO:0000269|PubMed:17052608};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38564;
CC         Evidence={ECO:0000305|PubMed:17052608};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=cholesteryl (9Z-octadecenoate) + H2O = (9Z)-octadecenoate +
CC         cholesterol + H(+); Xref=Rhea:RHEA:33875, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16113, ChEBI:CHEBI:30823,
CC         ChEBI:CHEBI:46898; Evidence={ECO:0000250|UniProtKB:Q8BLF1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33876;
CC         Evidence={ECO:0000250|UniProtKB:Q8BLF1};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17052608,
CC       ECO:0000305|PubMed:12149457}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:12149457}. Microsome
CC       {ECO:0000250|UniProtKB:Q8BLF1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q6PIU2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6PIU2-2; Sequence=VSP_037519;
CC       Name=3;
CC         IsoId=Q6PIU2-3; Sequence=VSP_037518;
CC   -!- TISSUE SPECIFICITY: Expressed in monocyte-derived macrophages. Up-
CC       regulated in invasive melanoma and breast carcinoma cell lines.
CC       {ECO:0000269|PubMed:12149457, ECO:0000269|PubMed:18782767}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12149457,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- SIMILARITY: Belongs to the 'GDXG' lipolytic enzyme family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH28734.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH47588.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AC007919; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AC069237; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA92601.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAH13028.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAH14142.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAH14802.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB037784; BAA92601.1; ALT_INIT; mRNA.
DR   EMBL; AK294811; BAH11890.1; -; mRNA.
DR   EMBL; AK295641; BAH12137.1; -; mRNA.
DR   EMBL; AK299422; BAH13028.1; ALT_INIT; mRNA.
DR   EMBL; AK304253; BAH14142.1; ALT_INIT; mRNA.
DR   EMBL; AK316431; BAH14802.1; ALT_INIT; mRNA.
DR   EMBL; AC007919; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069237; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC028734; AAH28734.2; ALT_INIT; mRNA.
DR   EMBL; BC047588; AAH47588.2; ALT_INIT; mRNA.
DR   CCDS; CCDS33893.1; -. [Q6PIU2-1]
DR   CCDS; CCDS54681.1; -. [Q6PIU2-3]
DR   CCDS; CCDS54682.1; -. [Q6PIU2-2]
DR   RefSeq; NP_001139748.1; NM_001146276.1. [Q6PIU2-2]
DR   RefSeq; NP_001139749.1; NM_001146277.1. [Q6PIU2-3]
DR   RefSeq; NP_001139750.1; NM_001146278.1. [Q6PIU2-3]
DR   RefSeq; NP_065843.3; NM_020792.4. [Q6PIU2-1]
DR   SMR; Q6PIU2; -.
DR   BioGRID; 121608; 95.
DR   IntAct; Q6PIU2; 51.
DR   MINT; Q6PIU2; -.
DR   STRING; 9606.ENSP00000442464; -.
DR   BindingDB; Q6PIU2; -.
DR   ChEMBL; CHEMBL5048; -.
DR   SwissLipids; SLP:000000634; -.
DR   ESTHER; human-NCEH1; Arylacetamide_deacetylase.
DR   MEROPS; S09.992; -.
DR   GlyConnect; 1563; 3 N-Linked glycans (2 sites).
DR   GlyGen; Q6PIU2; 3 sites, 3 N-linked glycans (2 sites).
DR   iPTMnet; Q6PIU2; -.
DR   PhosphoSitePlus; Q6PIU2; -.
DR   SwissPalm; Q6PIU2; -.
DR   BioMuta; NCEH1; -.
DR   DMDM; 74737782; -.
DR   EPD; Q6PIU2; -.
DR   jPOST; Q6PIU2; -.
DR   MassIVE; Q6PIU2; -.
DR   MaxQB; Q6PIU2; -.
DR   PaxDb; Q6PIU2; -.
DR   PeptideAtlas; Q6PIU2; -.
DR   PRIDE; Q6PIU2; -.
DR   ProteomicsDB; 27511; -.
DR   ProteomicsDB; 67177; -. [Q6PIU2-1]
DR   ProteomicsDB; 67178; -. [Q6PIU2-2]
DR   ProteomicsDB; 67179; -. [Q6PIU2-3]
DR   Antibodypedia; 33731; 111 antibodies from 23 providers.
DR   DNASU; 57552; -.
DR   Ensembl; ENST00000475381; ENSP00000418571; ENSG00000144959.
DR   Ensembl; ENST00000543711; ENSP00000443227; ENSG00000144959. [Q6PIU2-3]
DR   GeneID; 57552; -.
DR   KEGG; hsa:57552; -.
DR   MANE-Select; ENST00000475381.7; ENSP00000418571.4; NM_020792.6; NP_065843.4.
DR   UCSC; uc003fig.4; human. [Q6PIU2-1]
DR   CTD; 57552; -.
DR   DisGeNET; 57552; -.
DR   GeneCards; NCEH1; -.
DR   HGNC; HGNC:29260; NCEH1.
DR   HPA; ENSG00000144959; Low tissue specificity.
DR   MIM; 613234; gene.
DR   neXtProt; NX_Q6PIU2; -.
DR   OpenTargets; ENSG00000144959; -.
DR   PharmGKB; PA165697847; -.
DR   VEuPathDB; HostDB:ENSG00000144959; -.
DR   eggNOG; KOG1515; Eukaryota.
DR   GeneTree; ENSGT00940000156699; -.
DR   HOGENOM; CLU_012494_12_0_1; -.
DR   InParanoid; Q6PIU2; -.
DR   OMA; ALGQQFS; -.
DR   OrthoDB; 1263520at2759; -.
DR   PhylomeDB; Q6PIU2; -.
DR   TreeFam; TF314978; -.
DR   BRENDA; 3.1.1.13; 2681.
DR   PathwayCommons; Q6PIU2; -.
DR   Reactome; R-HSA-8964038; LDL clearance.
DR   SignaLink; Q6PIU2; -.
DR   BioGRID-ORCS; 57552; 6 hits in 1049 CRISPR screens.
DR   ChiTaRS; NCEH1; human.
DR   GeneWiki; NCEH1; -.
DR   GenomeRNAi; 57552; -.
DR   Pharos; Q6PIU2; Tchem.
DR   PRO; PR:Q6PIU2; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q6PIU2; protein.
DR   Bgee; ENSG00000144959; Expressed in caudate nucleus and 208 other tissues.
DR   ExpressionAtlas; Q6PIU2; baseline and differential.
DR   Genevisible; Q6PIU2; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016787; F:hydrolase activity; IBA:GO_Central.
DR   GO; GO:0042301; F:phosphate ion binding; IEA:Ensembl.
DR   GO; GO:0017171; F:serine hydrolase activity; IEA:Ensembl.
DR   GO; GO:0004771; F:sterol esterase activity; TAS:Reactome.
DR   GO; GO:0046485; P:ether lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; TAS:Reactome.
DR   GO; GO:0006470; P:protein dephosphorylation; IEA:Ensembl.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IEA:Ensembl.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR013094; AB_hydrolase_3.
DR   InterPro; IPR017157; Arylacetamide_deacetylase.
DR   InterPro; IPR033140; Lipase_GDXG_put_SER_AS.
DR   Pfam; PF07859; Abhydrolase_3; 2.
DR   PIRSF; PIRSF037251; Arylacetamide_deacetylase; 1.
DR   SUPFAM; SSF53474; SSF53474; 1.
DR   PROSITE; PS01174; LIPASE_GDXG_SER; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Endoplasmic reticulum; Glycoprotein;
KW   Hydrolase; Lipid degradation; Lipid metabolism; Membrane; Microsome;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..408
FT                   /note="Neutral cholesterol ester hydrolase 1"
FT                   /id="PRO_0000265939"
FT   TOPO_DOM        1..4
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        5..25
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        26..408
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           113..115
FT                   /note="Involved in the stabilization of the negatively
FT                   charged intermediate by the formation of the oxyanion hole"
FT                   /evidence="ECO:0000250|UniProtKB:Q5NUF3"
FT   ACT_SITE        191
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10038"
FT   ACT_SITE        348
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10038"
FT   ACT_SITE        378
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10038"
FT   CARBOHYD        270
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        287
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        389
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..133
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037518"
FT   VAR_SEQ         123
FT                   /note="K -> SASWSPSDE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037519"
FT   VARIANT         19
FT                   /note="V -> F (in dbSNP:rs35316420)"
FT                   /id="VAR_047099"
FT   VARIANT         71
FT                   /note="K -> Q (in dbSNP:rs2302815)"
FT                   /id="VAR_047100"
FT   VARIANT         343
FT                   /note="L -> M (in dbSNP:rs17857335)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_047101"
FT   CONFLICT        16
FT                   /note="A -> T (in Ref. 1; BAA92601)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="H -> R (in Ref. 2; BAH13028)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        72
FT                   /note="K -> R (in Ref. 2; BAH14802)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        79
FT                   /note="Q -> K (in Ref. 4; AAH47588)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        254
FT                   /note="D -> G (in Ref. 2; BAH14142)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="A -> S (in Ref. 2; BAH14142)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   408 AA;  45808 MW;  E5754850BE9805B5 CRC64;
     MRSSCVLLTA LVALAAYYVY IPLPGSVSDP WKLMLLDATF RGAQQVSNLI HYLGLSHHLL
     ALNFIIVSFG KKSAWSSAQV KVTDTDFDGV EVRVFEGPPK PEEPLKRSVV YIHGGGWALA
     SAKIRYYDEL CTAMAEELNA VIVSIEYRLV PKVYFPEQIH DVVRATKYFL KPEVLQKYMV
     DPGRICISGD SAGGNLAAAL GQQFTQDASL KNKLKLQALI YPVLQALDFN TPSYQQNVNT
     PILPRYVMVK YWVDYFKGNY DFVQAMIVNN HTSLDVEEAA AVRARLNWTS LLPASFTKNY
     KPVVQTTGNA RIVQELPQLL DARSAPLIAD QAVLQLLPKT YILTCEHDVL RDDGIMYAKR
     LESAGVEVTL DHFEDGFHGC MIFTSWPTNF SVGIRTRNSY IKWLDQNL
//
ID   KLHL8_HUMAN             Reviewed;         620 AA.
AC   Q9P2G9; Q53XA3; Q6N018;
DT   12-FEB-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   23-FEB-2022, entry version 162.
DE   RecName: Full=Kelch-like protein 8;
GN   Name=KLHL8; Synonyms=KIAA1378;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [2]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cerebellum, and Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-520.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, IDENTIFICATION IN A BCR (BTB-CUL3-RBX1) E3 UBIQUITIN LIGASE
RP   COMPLEX, AND INTERACTION WITH RAPSN.
RX   PubMed=19158078; DOI=10.1074/jbc.m808230200;
RA   Nam S., Min K., Hwang H., Lee H.O., Lee J.H., Yoon J., Lee H., Park S.,
RA   Lee J.;
RT   "Control of rapsyn stability by the CUL-3-containing E3 ligase complex.";
RL   J. Biol. Chem. 284:8195-8206(2009).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3
CC       ubiquitin ligase complex required for The BCR(KLHL8) ubiquitin ligase
CC       complex mediates ubiquitination and degradation of RAPSN.
CC       {ECO:0000269|PubMed:19158078}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Component of the BCR(KLHL8) E3 ubiquitin ligase complex, at
CC       least composed of CUL3, KLHL8 and RBX1. Interacts with RAPSN.
CC       {ECO:0000269|PubMed:19158078}.
CC   -!- INTERACTION:
CC       Q9P2G9-2; Q7Z3E5-2: ARMC9; NbExp=3; IntAct=EBI-11959635, EBI-10256990;
CC       Q9P2G9-2; P35219: CA8; NbExp=3; IntAct=EBI-11959635, EBI-718700;
CC       Q9P2G9-2; Q9UER7: DAXX; NbExp=3; IntAct=EBI-11959635, EBI-77321;
CC       Q9P2G9-2; P45984: MAPK9; NbExp=3; IntAct=EBI-11959635, EBI-713568;
CC       Q9P2G9-2; P11086: PNMT; NbExp=3; IntAct=EBI-11959635, EBI-11305767;
CC       Q9P2G9-2; Q6IPC0: PPM1F; NbExp=3; IntAct=EBI-11959635, EBI-11993088;
CC       Q9P2G9-2; P12271: RLBP1; NbExp=3; IntAct=EBI-11959635, EBI-11959637;
CC       Q9P2G9-2; O00204: SULT2B1; NbExp=3; IntAct=EBI-11959635, EBI-749441;
CC       Q9P2G9-2; Q9BY14-2: TEX101; NbExp=3; IntAct=EBI-11959635, EBI-12306161;
CC       Q9P2G9-2; Q8NBR0: TP53I13; NbExp=3; IntAct=EBI-11959635, EBI-11992976;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9P2G9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9P2G9-2; Sequence=VSP_054443;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92616.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB037799; BAA92616.2; ALT_INIT; mRNA.
DR   EMBL; BX640727; CAE45843.1; -; mRNA.
DR   EMBL; BX640744; CAE45855.1; -; mRNA.
DR   EMBL; AC092658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108516; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX05982.1; -; Genomic_DNA.
DR   EMBL; BC041384; AAH41384.1; -; mRNA.
DR   CCDS; CCDS3617.1; -. [Q9P2G9-1]
DR   CCDS; CCDS77937.1; -. [Q9P2G9-2]
DR   RefSeq; NP_001278932.1; NM_001292003.1. [Q9P2G9-1]
DR   RefSeq; NP_001278935.1; NM_001292006.1. [Q9P2G9-2]
DR   RefSeq; NP_001278936.1; NM_001292007.1.
DR   RefSeq; NP_065854.3; NM_020803.4. [Q9P2G9-1]
DR   SMR; Q9P2G9; -.
DR   BioGRID; 121618; 80.
DR   CORUM; Q9P2G9; -.
DR   IntAct; Q9P2G9; 32.
DR   STRING; 9606.ENSP00000273963; -.
DR   GlyGen; Q9P2G9; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9P2G9; -.
DR   PhosphoSitePlus; Q9P2G9; -.
DR   BioMuta; KLHL8; -.
DR   DMDM; 124056473; -.
DR   EPD; Q9P2G9; -.
DR   jPOST; Q9P2G9; -.
DR   MassIVE; Q9P2G9; -.
DR   MaxQB; Q9P2G9; -.
DR   PaxDb; Q9P2G9; -.
DR   PeptideAtlas; Q9P2G9; -.
DR   PRIDE; Q9P2G9; -.
DR   ProteomicsDB; 66596; -.
DR   ProteomicsDB; 83814; -. [Q9P2G9-1]
DR   Antibodypedia; 2897; 100 antibodies from 20 providers.
DR   DNASU; 57563; -.
DR   Ensembl; ENST00000273963; ENSP00000273963; ENSG00000145332.
DR   Ensembl; ENST00000498875; ENSP00000426451; ENSG00000145332. [Q9P2G9-2]
DR   Ensembl; ENST00000512111; ENSP00000424131; ENSG00000145332.
DR   GeneID; 57563; -.
DR   KEGG; hsa:57563; -.
DR   MANE-Select; ENST00000273963.10; ENSP00000273963.5; NM_020803.5; NP_065854.3.
DR   UCSC; uc003hql.2; human. [Q9P2G9-1]
DR   CTD; 57563; -.
DR   DisGeNET; 57563; -.
DR   GeneCards; KLHL8; -.
DR   HGNC; HGNC:18644; KLHL8.
DR   HPA; ENSG00000145332; Tissue enhanced (epididymis).
DR   MIM; 611967; gene.
DR   neXtProt; NX_Q9P2G9; -.
DR   OpenTargets; ENSG00000145332; -.
DR   PharmGKB; PA38616; -.
DR   VEuPathDB; HostDB:ENSG00000145332; -.
DR   eggNOG; KOG4441; Eukaryota.
DR   GeneTree; ENSGT00940000157583; -.
DR   InParanoid; Q9P2G9; -.
DR   OMA; SVEAYDW; -.
DR   PhylomeDB; Q9P2G9; -.
DR   TreeFam; TF329218; -.
DR   PathwayCommons; Q9P2G9; -.
DR   SignaLink; Q9P2G9; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 57563; 7 hits in 1086 CRISPR screens.
DR   ChiTaRS; KLHL8; human.
DR   GeneWiki; KLHL8; -.
DR   GenomeRNAi; 57563; -.
DR   Pharos; Q9P2G9; Tdark.
DR   PRO; PR:Q9P2G9; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9P2G9; protein.
DR   Bgee; ENSG00000145332; Expressed in caput epididymis and 220 other tissues.
DR   ExpressionAtlas; Q9P2G9; baseline and differential.
DR   Genevisible; Q9P2G9; HS.
DR   GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   Gene3D; 2.120.10.80; -; 2.
DR   Gene3D; 3.30.710.10; -; 1.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR017096; BTB-kelch_protein.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011043; Gal_Oxase/kelch_b-propeller.
DR   InterPro; IPR015915; Kelch-typ_b-propeller.
DR   InterPro; IPR006652; Kelch_1.
DR   InterPro; IPR030605; KLHL8.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR24412:SF403; PTHR24412:SF403; 1.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF01344; Kelch_1; 6.
DR   PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00612; Kelch; 6.
DR   SUPFAM; SSF50965; SSF50965; 1.
DR   SUPFAM; SSF54695; SSF54695; 1.
DR   PROSITE; PS50097; BTB; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Kelch repeat; Reference proteome;
KW   Repeat; Ubl conjugation pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   CHAIN           2..620
FT                   /note="Kelch-like protein 8"
FT                   /id="PRO_0000119108"
FT   DOMAIN          67..134
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   DOMAIN          169..270
FT                   /note="BACK"
FT   REPEAT          319..366
FT                   /note="Kelch 1"
FT   REPEAT          367..413
FT                   /note="Kelch 2"
FT   REPEAT          415..460
FT                   /note="Kelch 3"
FT   REPEAT          462..507
FT                   /note="Kelch 4"
FT   REPEAT          508..554
FT                   /note="Kelch 5"
FT   REPEAT          556..601
FT                   /note="Kelch 6"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   VAR_SEQ         73..148
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_054443"
FT   VARIANT         520
FT                   /note="P -> R (in dbSNP:rs17854114)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030012"
SQ   SEQUENCE   620 AA;  68802 MW;  6C3C3C78CEC6FE84 CRC64;
     MASDSMSSKQ ARNHITKGKR QQQHQQIKNR SSISDGDGED SFIFEANEAW KDFHGSLLRF
     YENGELCDVT LKVGSKLISC HKLVLACVIP YFRAMFLSEM AEAKQTLIEI RDFDGDAIED
     LVKFVYSSRL TLTVDNVQPL LYAACILQVE LVARACCEYM KLHFHPSNCL AVRAFAESHN
     RIDLMDMADQ YACDHFTEVV ECEDFVSVSP QHLHKLLSSS DLNIENEKQV YNAAIKWLLA
     NPQHHSKWLD ETLAQVRLPL LPVDFLMGVV AKEQIVKQNL KCRDLLDEAR NYHLHLSSRA
     VPDFEYSIRT TPRKHTAGVL FCVGGRGGSG DPFRSIECYS INKNSWFFGP EMNSRRRHVG
     VISVEGKVYA VGGHDGNEHL GSMEMFDPLT NKWMMKASMN TKRRGIALAS LGGPIYAIGG
     LDDNTCFNDV ERYDIESDQW STVAPMNTPR GGVGSVALVN HVYAVGGNDG MASLSSVERY
     DPHLDKWIEV KEMGQRRAGN GVSKLHGCLY VVGGFDDNSP LSSVERYDPR SNKWDYVAAL
     TTPRGGVGIA TVMGKIFAVG GHNGNAYLNT VEAFDPVLNR WELVGSVSHC RAGAGVAVCS
     CLTSQIRDVG HGSNNVVDCM
//
ID   CAD26_HUMAN             Reviewed;         832 AA.
AC   Q8IXH8; A2A2M5; B3KNX3; Q6P5Y6; Q8TCH3; Q9BQN4; Q9NRU1;
DT   26-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 4.
DT   23-FEB-2022, entry version 161.
DE   RecName: Full=Cadherin-like protein 26;
DE   AltName: Full=Cadherin-like protein VR20;
DE   Flags: Precursor;
GN   Name=CDH26;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Lung, and Tonsillar carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 410-832 (ISOFORM 1).
RA   Kools P.F.J., van Roy F.;
RT   "Identification and characterization of a novel human cadherin with
RT   similarity to N-cadherin.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, GLYCOSYLATION, SUBUNIT,
RP   AND IDENTIFICATION IN A CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=28051089; DOI=10.1038/mi.2016.120;
RA   Caldwell J.M., Collins M.H., Kemme K.A., Sherrill J.D., Wen T., Rochman M.,
RA   Stucke E.M., Amin L., Tai H., Putnam P.E., Jimenez-Dalmaroni M.J.,
RA   Wormald M.R., Porollo A., Abonia J.P., Rothenberg M.E.;
RT   "Cadherin 26 is an alpha integrin-binding epithelial receptor regulated
RT   during allergic inflammation.";
RL   Mucosal Immunol. 10:1190-1201(2017).
CC   -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins. They
CC       preferentially interact with themselves in a homophilic manner in
CC       connecting cells; cadherins may thus contribute to the sorting of
CC       heterogeneous cell types. Ligand for integrins alpha-E/beta-7,
CC       ITGAE:ITGAB7, alpha-4/beta-7, ITGA4:ITGAB7 and alpha-4/beta-1,
CC       ITGA4:ITGAB1 through which modulates CD4(+) T cells activation
CC       (PubMed:28051089). {ECO:0000269|PubMed:28051089}.
CC   -!- SUBUNIT: Homodimer (PubMed:28051089). Component of a cadherin:catenin
CC       adhesion complex composed of at least of CDH26, beta-catenin/CTNNB1,
CC       alpha-catenin/CTNNA1 and p120 catenin/CTNND1 (PubMed:28051089).
CC       {ECO:0000269|PubMed:28051089}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28051089};
CC       Single-pass type I membrane protein {ECO:0000305|PubMed:28051089}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=3;
CC         IsoId=Q8IXH8-4; Sequence=Displayed;
CC       Name=1; Synonyms=a;
CC         IsoId=Q8IXH8-1; Sequence=VSP_059693;
CC       Name=2; Synonyms=b;
CC         IsoId=Q8IXH8-2; Sequence=VSP_008333, VSP_008334;
CC       Name=4;
CC         IsoId=Q8IXH8-5; Sequence=VSP_008333, VSP_008334, VSP_059694;
CC   -!- TISSUE SPECIFICITY: Expressed by epithelial cells of gastrointestinal
CC       tissue. {ECO:0000269|PubMed:28051089}.
CC   -!- DOMAIN: Three calcium ions are usually bound at the interface of each
CC       cadherin domain and rigidify the connections, imparting a strong
CC       curvature to the full-length ectodomain. {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:28051089}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK055202; BAG51485.1; -; mRNA.
DR   EMBL; AK074477; BAB85093.1; -; mRNA.
DR   EMBL; AL109928; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75420.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75421.1; -; Genomic_DNA.
DR   EMBL; BC062570; AAH62570.1; -; mRNA.
DR   EMBL; AF169690; AAF89687.1; -; mRNA.
DR   CCDS; CCDS13485.1; -. [Q8IXH8-4]
DR   CCDS; CCDS13486.1; -. [Q8IXH8-2]
DR   CCDS; CCDS86964.1; -. [Q8IXH8-5]
DR   RefSeq; NP_001335133.1; NM_001348204.1. [Q8IXH8-5]
DR   RefSeq; NP_068582.2; NM_021810.5. [Q8IXH8-2]
DR   RefSeq; NP_817089.1; NM_177980.3. [Q8IXH8-4]
DR   SMR; Q8IXH8; -.
DR   BioGRID; 121909; 2.
DR   STRING; 9606.ENSP00000339390; -.
DR   CarbonylDB; Q8IXH8; -.
DR   GlyGen; Q8IXH8; 5 sites.
DR   iPTMnet; Q8IXH8; -.
DR   PhosphoSitePlus; Q8IXH8; -.
DR   BioMuta; CDH26; -.
DR   DMDM; 152031568; -.
DR   MassIVE; Q8IXH8; -.
DR   PeptideAtlas; Q8IXH8; -.
DR   PRIDE; Q8IXH8; -.
DR   Antibodypedia; 2400; 154 antibodies from 24 providers.
DR   DNASU; 60437; -.
DR   Ensembl; ENST00000244049; ENSP00000244049; ENSG00000124215. [Q8IXH8-5]
DR   Ensembl; ENST00000348616; ENSP00000339390; ENSG00000124215.
DR   Ensembl; ENST00000350849; ENSP00000310845; ENSG00000124215. [Q8IXH8-2]
DR   GeneID; 60437; -.
DR   KEGG; hsa:60437; -.
DR   MANE-Select; ENST00000348616.9; ENSP00000339390.4; NM_177980.4; NP_817089.1.
DR   UCSC; uc002ybe.4; human. [Q8IXH8-4]
DR   CTD; 60437; -.
DR   GeneCards; CDH26; -.
DR   HGNC; HGNC:15902; CDH26.
DR   HPA; ENSG00000124215; Tissue enhanced (prostate).
DR   MIM; 617685; gene.
DR   neXtProt; NX_Q8IXH8; -.
DR   OpenTargets; ENSG00000124215; -.
DR   PharmGKB; PA26298; -.
DR   VEuPathDB; HostDB:ENSG00000124215; -.
DR   eggNOG; KOG3594; Eukaryota.
DR   GeneTree; ENSGT00940000161589; -.
DR   HOGENOM; CLU_005284_5_0_1; -.
DR   InParanoid; Q8IXH8; -.
DR   OMA; WRAKFNI; -.
DR   OrthoDB; 158870at2759; -.
DR   PhylomeDB; Q8IXH8; -.
DR   TreeFam; TF316817; -.
DR   PathwayCommons; Q8IXH8; -.
DR   BioGRID-ORCS; 60437; 9 hits in 1037 CRISPR screens.
DR   GenomeRNAi; 60437; -.
DR   Pharos; Q8IXH8; Tbio.
DR   PRO; PR:Q8IXH8; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q8IXH8; protein.
DR   Bgee; ENSG00000124215; Expressed in bronchial epithelial cell and 141 other tissues.
DR   ExpressionAtlas; Q8IXH8; baseline and differential.
DR   Genevisible; Q8IXH8; HS.
DR   GO; GO:0016342; C:catenin complex; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045294; F:alpha-catenin binding; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0070097; F:delta-catenin binding; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IDA:UniProtKB.
DR   GO; GO:0035710; P:CD4-positive, alpha-beta T cell activation; IDA:UniProtKB.
DR   GO; GO:0098742; P:cell-cell adhesion via plasma-membrane adhesion molecules; IBA:GO_Central.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   InterPro; IPR039808; Cadherin.
DR   InterPro; IPR002126; Cadherin-like_dom.
DR   InterPro; IPR015919; Cadherin-like_sf.
DR   InterPro; IPR020894; Cadherin_CS.
DR   PANTHER; PTHR24027; PTHR24027; 1.
DR   Pfam; PF00028; Cadherin; 3.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 4.
DR   SUPFAM; SSF49313; SSF49313; 5.
DR   PROSITE; PS00232; CADHERIN_1; 2.
DR   PROSITE; PS50268; CADHERIN_2; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cell adhesion; Cell membrane; Glycoprotein;
KW   Membrane; Metal-binding; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..832
FT                   /note="Cadherin-like protein 26"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000003829"
FT   TOPO_DOM        28..614
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        615..635
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        636..832
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          35..165
FT                   /note="Cadherin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          166..275
FT                   /note="Cadherin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          276..396
FT                   /note="Cadherin 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          397..500
FT                   /note="Cadherin 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   REGION          813..832
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        81
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        85
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        171
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        177
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        462
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..667
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008333"
FT   VAR_SEQ         668..673
FT                   /note="KGTSAQ -> MKPLIW (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008334"
FT   VAR_SEQ         700..832
FT                   /note="DLEEVPPSAASQSAQARCALGSWGYGKPFEPRSVKNIHSTPAYPDATMHRQL
FT                   LAPVEGRMAETLNQKLHVANVLEDDPGYLPHVYSEEGECGGAPSLSSLASLEQELQPDL
FT                   LDSLGSKATPFEEIYSESGVPS -> AYPDATMHRQLLAPVEGRMAETLNQSKERNRFS
FT                   LSRGCIIPQGRATAGRGLPQDIYKEMMPRRLTQTGKRKHGALARTPSFKKVVYDHKEDE
FT                   ENKAGRKQRSHLFKVMQLRNEQGGVRVQSAHSPSPLNKKACFPGDYRGESAGGHNCRAV
FT                   SG (in isoform 1)"
FT                   /id="VSP_059693"
FT   VAR_SEQ         700..740
FT                   /note="Missing (in isoform 4)"
FT                   /id="VSP_059694"
FT   VARIANT         144
FT                   /note="I -> T (in dbSNP:rs6015609)"
FT                   /id="VAR_055568"
FT   VARIANT         301
FT                   /note="R -> G (in dbSNP:rs11086690)"
FT                   /id="VAR_055569"
FT   VARIANT         448
FT                   /note="V -> A (in dbSNP:rs34866303)"
FT                   /id="VAR_055570"
FT   VARIANT         479
FT                   /note="P -> L (in dbSNP:rs6071067)"
FT                   /id="VAR_055571"
FT   VARIANT         615
FT                   /note="V -> L (in dbSNP:rs194998)"
FT                   /id="VAR_055572"
SQ   SEQUENCE   832 AA;  92416 MW;  0CEF6129FE255BBB CRC64;
     MAMRSGRHPS LLLLLVLLLW LLQVSIIDSV QQETDDLTKQ TKEKIYQPLR RSKRRWVITT
     LELEEEDPGP FPKLIGELFN NMSYNMSLMY LISGPGVDEY PEIGLFSLED HENGRIYVHR
     PVDREMTPSF TVYFDVVERS TGKIVDTSLI FNIRISDVND HAPQFPEKEF NITVQENQSA
     GQPIFQMLAV DLDEENTPNS QVLYFLISQT PLLKESGFRV DRLSGEIRLS GCLDYETAPQ
     FTLLIRARDC GEPSLSSTTT VHVDVQEGNN HRPAFTQENY KVQIPEGRAS QGVLRLLVQD
     RDSPFTSAWR AKFNILHGNE EGHFDISTDP ETNEGILNVI KPLDYETRPA QSLIIVVENE
     ERLVFCERGK LQPPRKAAAS ATVSVQVTDA NDPPAFHPQS FIVNKEEGAR PGTLLGTFNA
     MDPDSQIRYE LVHDPANWVS VDKNSGVVIT VEPIDRESPH VNNSFYVIII HAVDDGFPPQ
     TATGTLMLFL SDINDNVPTL RPRSRYMEVC ESAVHEPLHI EAEDPDLEPF SDPFTFELDN
     TWGNAEDTWK LGRNWGQSVE LLTLRSLPRG NYLVPLFIGD KQGLSQKQTV HVRICPCASG
     LTCVELADAE VGLHVGALFP VCAAFVALAV ALLFLLRCYF VLEPKRHGCS VSNDEGHQTL
     VMYNAESKGT SAQTWSDVEG QRPALLICTA AAGPTQGVKD LEEVPPSAAS QSAQARCALG
     SWGYGKPFEP RSVKNIHSTP AYPDATMHRQ LLAPVEGRMA ETLNQKLHVA NVLEDDPGYL
     PHVYSEEGEC GGAPSLSSLA SLEQELQPDL LDSLGSKATP FEEIYSESGV PS
//
ID   GBRB2_HUMAN             Reviewed;         512 AA.
AC   P47870; A8K115; A8K1A0; D1LYT0; D1LYT1; Q16323; Q4FZB2;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 2.
DT   23-FEB-2022, entry version 199.
DE   RecName: Full=Gamma-aminobutyric acid receptor subunit beta-2;
DE   AltName: Full=GABA(A) receptor subunit beta-2;
DE   Flags: Precursor;
GN   Name=GABRB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RC   TISSUE=Brain;
RX   PubMed=8264558;
RA   Hadingham K.L., Wingrove P.B., Wafford K.A., Bain C., Kemp J.A.,
RA   Palmer K.J., Wilson A.W., Wilcox A.S., Sikela J.M., Ragan C.I.;
RT   "Role of the beta subunit in determining the pharmacology of human gamma-
RT   aminobutyric acid type A receptors.";
RL   Mol. Pharmacol. 44:1211-1218(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=7707873; DOI=10.1016/0169-328x(94)00228-7;
RA   McKinley D.D., Lennon D.J., Carter D.B.;
RT   "Cloning, sequence analysis and expression of two forms of mRNA coding for
RT   the human beta 2 subunit of the GABAA receptor.";
RL   Brain Res. Mol. Brain Res. 28:175-179(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), TISSUE SPECIFICITY,
RP   MUTAGENESIS OF THR-389, FUNCTION, SUBCELLULAR LOCATION, AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Brain;
RX   PubMed=19763268; DOI=10.1371/journal.pone.0006977;
RA   Zhao C., Xu Z., Wang F., Chen J., Ng S.K., Wong P.W., Yu Z., Pun F.W.,
RA   Ren L., Lo W.S., Tsang S.Y., Xue H.;
RT   "Alternative-splicing in the exon-10 region of GABA(A) receptor beta(2)
RT   subunit gene: relationships between novel isoforms and psychotic
RT   disorders.";
RL   PLoS ONE 4:E6977-E6977(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=16983389; DOI=10.1038/sj.mp.4001899;
RA   Zhao C., Xu Z., Chen J., Yu Z., Tong K.L., Lo W.S., Pun F.W., Ng S.K.,
RA   Tsang S.Y., Xue H.;
RT   "Two isoforms of GABA(A) receptor beta2 subunit with different
RT   electrophysiological properties: Differential expression and genotypical
RT   correlations in schizophrenia.";
RL   Mol. Psychiatry 11:1092-1105(2006).
RN   [8]
RP   FUNCTION.
RX   PubMed=23909897; DOI=10.1111/ejn.12331;
RA   Fuchs C., Abitbol K., Burden J.J., Mercer A., Brown L., Iball J.,
RA   Anne Stephenson F., Thomson A.M., Jovanovic J.N.;
RT   "GABA(A) receptors can initiate the formation of functional inhibitory
RT   GABAergic synapses.";
RL   Eur. J. Neurosci. 38:3146-3158(2013).
RN   [9]
RP   FUNCTION.
RX   PubMed=25489750; DOI=10.3791/52115;
RA   Brown L.E., Fuchs C., Nicholson M.W., Stephenson F.A., Thomson A.M.,
RA   Jovanovic J.N.;
RT   "Inhibitory synapse formation in a co-culture model incorporating GABAergic
RT   medium spiny neurons and HEK293 cells stably expressing GABAA receptors.";
RL   J. Vis. Exp. 2014:E52115-E52115(2014).
RN   [10] {ECO:0007744|PDB:6D6T, ECO:0007744|PDB:6D6U}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.80 ANGSTROMS) OF 25-331 IN COMPLEX WITH
RP   GABA AND FLUMAZENIL, FUNCTION, ACTIVITY REGULATION, AND SUBUNIT.
RX   PubMed=29950725; DOI=10.1038/s41586-018-0255-3;
RA   Zhu S., Noviello C.M., Teng J., Walsh R.M. Jr., Kim J.J., Hibbs R.E.;
RT   "Structure of a human synaptic GABAA receptor.";
RL   Nature 559:67-72(2018).
RN   [11]
RP   VARIANT IECEE2 THR-79.
RX   PubMed=25124326; DOI=10.1002/ajmg.a.36714;
RA   Srivastava S., Cohen J., Pevsner J., Aradhya S., McKnight D., Butler E.,
RA   Johnston M., Fatemi A.;
RT   "A novel variant in GABRB2 associated with intellectual disability and
RT   epilepsy.";
RL   Am. J. Med. Genet. A 164A:2914-2921(2014).
RN   [12]
RP   INVOLVEMENT IN IECEE2, AND VARIANTS IECEE2 THR-79; HIS-244; SER-277;
RP   LYS-284; PRO-293; ARG-303; VAL-304 AND ILE-316.
RX   PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008;
RG   Deciphering Developmental Disorders Study;
RA   Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D.,
RA   Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M.,
RA   Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W.,
RA   Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C.,
RA   Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N.,
RA   Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A.,
RA   Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q.,
RA   Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N.,
RA   Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K.,
RA   Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C.,
RA   Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S.,
RA   Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G.,
RA   O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C.,
RA   Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R.,
RA   Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M.,
RA   Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G.,
RA   Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z.,
RA   Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C.,
RA   Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E.,
RA   Minassian B.A., Michaud J.L.;
RT   "High rate of recurrent de novo mutations in developmental and epileptic
RT   encephalopathies.";
RL   Am. J. Hum. Genet. 101:664-685(2017).
RN   [13]
RP   VARIANT IECEE2 PRO-287, CHARACTERIZATION OF VARIANT IECEE2 PRO-287, AND
RP   FUNCTION.
RX   PubMed=27789573; DOI=10.1136/jmedgenet-2016-104083;
RA   Ishii A., Kang J.Q., Schornak C.C., Hernandez C.C., Shen W., Watkins J.C.,
RA   Macdonald R.L., Hirose S.;
RT   "A de novo missense mutation of GABRB2 causes early myoclonic
RT   encephalopathy.";
RL   J. Med. Genet. 54:202-211(2017).
CC   -!- FUNCTION: Ligand-gated chloride channel which is a component of the
CC       heteropentameric receptor for GABA, the major inhibitory
CC       neurotransmitter in the brain (PubMed:8264558, PubMed:19763268,
CC       PubMed:27789573, PubMed:29950725). Plays an important role in the
CC       formation of functional inhibitory GABAergic synapses in addition to
CC       mediating synaptic inhibition as a GABA-gated ion channel
CC       (PubMed:23909897, PubMed:25489750). The gamma2 subunit is necessary but
CC       not sufficient for a rapid formation of active synaptic contacts and
CC       the synaptogenic effect of this subunit is influenced by the type of
CC       alpha and beta subunits present in the receptor pentamer (By
CC       similarity). The alpha1/beta2/gamma2 receptor and the
CC       alpha2/beta2/gamma2 receptor exhibit synaptogenic activity
CC       (PubMed:23909897, PubMed:25489750). Functions also as histamine
CC       receptor and mediates cellular responses to histamine (By similarity).
CC       {ECO:0000250|UniProtKB:P63137, ECO:0000250|UniProtKB:P63138,
CC       ECO:0000269|PubMed:19763268, ECO:0000269|PubMed:23909897,
CC       ECO:0000269|PubMed:25489750, ECO:0000269|PubMed:27789573,
CC       ECO:0000269|PubMed:29950725, ECO:0000269|PubMed:8264558}.
CC   -!- ACTIVITY REGULATION: Allosterically activated by benzodiazepines
CC       (PubMed:29950725). Allosterically activated by the anesthetic etomidate
CC       (By similarity). Inhibited by the antagonist bicuculline
CC       (PubMed:29950725). {ECO:0000250|UniProtKB:P0C2W5,
CC       ECO:0000269|PubMed:29950725}.
CC   -!- SUBUNIT: Heteropentamer, formed by a combination of alpha, beta, gamma,
CC       delta and rho chains (PubMed:8264558, PubMed:29950725). Interacts with
CC       UBQLN1 (By similarity). Interacts with KCTD8, KCTD12 and KCTD16; this
CC       interaction determines the pharmacology and kinetics of the receptor
CC       response, the KCTD proteins markedly accelerating the GABA-B response,
CC       although to different extents (By similarity). May interact with KIF21B
CC       (By similarity). Identified in a complex of 720 kDa composed of LHFPL4,
CC       NLGN2, GABRA1, GABRB2, GABRG2 and GABRB3 (By similarity).
CC       {ECO:0000250|UniProtKB:P63138, ECO:0000269|PubMed:29950725,
CC       ECO:0000269|PubMed:8264558}.
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane {ECO:0000250|UniProtKB:P63137}; Multi-pass membrane protein
CC       {ECO:0000255}. Cell membrane {ECO:0000269|PubMed:19763268,
CC       ECO:0000269|PubMed:8264558}; Multi-pass membrane protein {ECO:0000255}.
CC       Cytoplasmic vesicle membrane {ECO:0000250|UniProtKB:P63138}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long, Beta-2L;
CC         IsoId=P47870-2; Sequence=Displayed;
CC       Name=2; Synonyms=Short, Beta-2S;
CC         IsoId=P47870-1; Sequence=VSP_038825;
CC       Name=3; Synonyms=Beta-2S1;
CC         IsoId=P47870-3; Sequence=VSP_038823, VSP_038824, VSP_038828;
CC       Name=4; Synonyms=Beta-2S2;
CC         IsoId=P47870-4; Sequence=VSP_038825, VSP_038826, VSP_038827;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 show reduced expression in
CC       schizophrenic brain. Isoform 3 shows increased expression in
CC       schizophrenic and bipolar disorder brains while isoform 4 shows reduced
CC       expression. {ECO:0000269|PubMed:16983389, ECO:0000269|PubMed:19763268}.
CC   -!- DOMAIN: The extracellular domain contributes to synaptic contact
CC       formation. {ECO:0000250|UniProtKB:P63137}.
CC   -!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P63137}.
CC   -!- DISEASE: Epileptic encephalopathy, infantile or early childhood, 2
CC       (IECEE2) [MIM:617829]: A form of epileptic encephalopathy, a
CC       heterogeneous group of severe childhood onset epilepsies characterized
CC       by refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after which
CC       cognitive and motor delays become apparent. IECEE2 is an autosomal
CC       dominant condition with variable age at seizure onset, ranging from
CC       early infancy to 6 years. {ECO:0000269|PubMed:25124326,
CC       ECO:0000269|PubMed:27789573, ECO:0000269|PubMed:29100083}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRB2 sub-
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Forbidden fruit - Issue 56
CC       of March 2005;
CC       URL="https://web.expasy.org/spotlight/back_issues/056";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S67368; AAB29370.1; -; mRNA.
DR   EMBL; S77554; AAB33983.1; -; mRNA.
DR   EMBL; S77553; AAB33982.1; -; mRNA.
DR   EMBL; GU086163; ACY69094.1; -; mRNA.
DR   EMBL; GU086164; ACY69095.1; -; mRNA.
DR   EMBL; AK289730; BAF82419.1; -; mRNA.
DR   EMBL; AK289815; BAF82504.1; -; mRNA.
DR   EMBL; CH471062; EAW61543.1; -; Genomic_DNA.
DR   EMBL; BC099705; AAH99705.1; -; mRNA.
DR   EMBL; BC099719; AAH99719.1; -; mRNA.
DR   EMBL; BC105639; AAI05640.1; -; mRNA.
DR   CCDS; CCDS4354.1; -. [P47870-1]
DR   CCDS; CCDS4355.1; -. [P47870-2]
DR   PIR; I52656; I52656.
DR   RefSeq; NP_000804.1; NM_000813.2. [P47870-1]
DR   RefSeq; NP_068711.1; NM_021911.2. [P47870-2]
DR   PDB; 6D6T; EM; 3.80 A; A/C=25-331.
DR   PDB; 6D6U; EM; 3.80 A; A/C=25-331.
DR   PDB; 6X3S; EM; 3.12 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3T; EM; 2.55 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3U; EM; 3.49 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3V; EM; 3.50 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3W; EM; 3.30 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3X; EM; 2.92 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X3Z; EM; 3.23 A; A/C=25-331, A/C=487-512.
DR   PDB; 6X40; EM; 2.86 A; A/C=25-331, A/C=487-512.
DR   PDBsum; 6D6T; -.
DR   PDBsum; 6D6U; -.
DR   PDBsum; 6X3S; -.
DR   PDBsum; 6X3T; -.
DR   PDBsum; 6X3U; -.
DR   PDBsum; 6X3V; -.
DR   PDBsum; 6X3W; -.
DR   PDBsum; 6X3X; -.
DR   PDBsum; 6X3Z; -.
DR   PDBsum; 6X40; -.
DR   SMR; P47870; -.
DR   BioGRID; 108835; 6.
DR   ComplexPortal; CPX-2159; GABA-A receptor, alpha-1/beta-2/gamma-2.
DR   ComplexPortal; CPX-2952; GABA-A receptor, alpha-6/beta-2/delta.
DR   ComplexPortal; CPX-2953; GABA-A receptor, alpha-4/beta-2/delta.
DR   CORUM; P47870; -.
DR   IntAct; P47870; 4.
DR   MINT; P47870; -.
DR   STRING; 9606.ENSP00000274547; -.
DR   BindingDB; P47870; -.
DR   ChEMBL; CHEMBL1920; -.
DR   DrugBank; DB00659; Acamprosate.
DR   DrugBank; DB00546; Adinazolam.
DR   DrugBank; DB00404; Alprazolam.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB11901; Apalutamide.
DR   DrugBank; DB14719; Bentazepam.
DR   DrugBank; DB12537; Benzodiazepine.
DR   DrugBank; DB11859; Brexanolone.
DR   DrugBank; DB01558; Bromazepam.
DR   DrugBank; DB09017; Brotizolam.
DR   DrugBank; DB00237; Butabarbital.
DR   DrugBank; DB00241; Butalbital.
DR   DrugBank; DB01489; Camazepam.
DR   DrugBank; DB00395; Carisoprodol.
DR   DrugBank; DB00475; Chlordiazepoxide.
DR   DrugBank; DB14715; Cinazepam.
DR   DrugBank; DB01594; Cinolazepam.
DR   DrugBank; DB00349; Clobazam.
DR   DrugBank; DB01068; Clonazepam.
DR   DrugBank; DB00628; Clorazepic acid.
DR   DrugBank; DB01559; Clotiazepam.
DR   DrugBank; DB01553; Cloxazolam.
DR   DrugBank; DB01511; Delorazepam.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB00829; Diazepam.
DR   DrugBank; DB13837; Doxefazepam.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB01215; Estazolam.
DR   DrugBank; DB00402; Eszopiclone.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB00189; Ethchlorvynol.
DR   DrugBank; DB01545; Ethyl loflazepate.
DR   DrugBank; DB09166; Etizolam.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB01567; Fludiazepam.
DR   DrugBank; DB01205; Flumazenil.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00690; Flurazepam.
DR   DrugBank; DB06716; Fospropofol.
DR   DrugBank; DB01381; Ginkgo biloba.
DR   DrugBank; DB01437; Glutethimide.
DR   DrugBank; DB00801; Halazepam.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB01587; Ketazolam.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB13643; Loprazolam.
DR   DrugBank; DB00186; Lorazepam.
DR   DrugBank; DB13872; Lormetazepam.
DR   DrugBank; DB13437; Medazepam.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00371; Meprobamate.
DR   DrugBank; DB00463; Metharbital.
DR   DrugBank; DB01028; Methoxyflurane.
DR   DrugBank; DB01107; Methyprylon.
DR   DrugBank; DB15489; Mexazolam.
DR   DrugBank; DB00683; Midazolam.
DR   DrugBank; DB01595; Nitrazepam.
DR   DrugBank; DB14028; Nordazepam.
DR   DrugBank; DB00842; Oxazepam.
DR   DrugBank; DB14672; Oxazepam acetate.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB13335; Pinazepam.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB01588; Prazepam.
DR   DrugBank; DB00794; Primidone.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB01589; Quazepam.
DR   DrugBank; DB12404; Remimazolam.
DR   DrugBank; DB01236; Sevoflurane.
DR   DrugBank; DB09118; Stiripentol.
DR   DrugBank; DB00306; Talbutal.
DR   DrugBank; DB01956; Taurine.
DR   DrugBank; DB00231; Temazepam.
DR   DrugBank; DB11582; Thiocolchicoside.
DR   DrugBank; DB00897; Triazolam.
DR   DrugCentral; P47870; -.
DR   TCDB; 1.A.9.5.2; the neurotransmitter receptor, cys loop, ligand-gated ion channel (lic) family.
DR   GlyGen; P47870; 3 sites.
DR   iPTMnet; P47870; -.
DR   PhosphoSitePlus; P47870; -.
DR   BioMuta; GABRB2; -.
DR   DMDM; 292495010; -.
DR   MassIVE; P47870; -.
DR   PaxDb; P47870; -.
DR   PeptideAtlas; P47870; -.
DR   PRIDE; P47870; -.
DR   ProteomicsDB; 55801; -. [P47870-2]
DR   ProteomicsDB; 55802; -. [P47870-1]
DR   ProteomicsDB; 55803; -. [P47870-3]
DR   ProteomicsDB; 55804; -. [P47870-4]
DR   Antibodypedia; 4534; 334 antibodies from 34 providers.
DR   DNASU; 2561; -.
DR   Ensembl; ENST00000274547; ENSP00000274547; ENSG00000145864.
DR   Ensembl; ENST00000353437; ENSP00000274546; ENSG00000145864. [P47870-1]
DR   Ensembl; ENST00000393959; ENSP00000377531; ENSG00000145864.
DR   Ensembl; ENST00000520240; ENSP00000429320; ENSG00000145864. [P47870-1]
DR   Ensembl; ENST00000675303; ENSP00000502748; ENSG00000145864. [P47870-1]
DR   Ensembl; ENST00000675773; ENSP00000502701; ENSG00000145864. [P47870-1]
DR   GeneID; 2561; -.
DR   KEGG; hsa:2561; -.
DR   MANE-Select; ENST00000393959.6; ENSP00000377531.1; NM_001371727.1; NP_001358656.1.
DR   UCSC; uc003lyr.2; human. [P47870-2]
DR   CTD; 2561; -.
DR   DisGeNET; 2561; -.
DR   GeneCards; GABRB2; -.
DR   HGNC; HGNC:4082; GABRB2.
DR   HPA; ENSG00000145864; Tissue enriched (brain).
DR   MalaCards; GABRB2; -.
DR   MIM; 600232; gene.
DR   MIM; 617829; phenotype.
DR   neXtProt; NX_P47870; -.
DR   OpenTargets; ENSG00000145864; -.
DR   Orphanet; 442835; Non-specific early-onset epileptic encephalopathy.
DR   PharmGKB; PA28496; -.
DR   VEuPathDB; HostDB:ENSG00000145864; -.
DR   eggNOG; KOG3643; Eukaryota.
DR   GeneTree; ENSGT00940000154245; -.
DR   HOGENOM; CLU_010920_1_4_1; -.
DR   InParanoid; P47870; -.
DR   OMA; INKMDPH; -.
DR   OrthoDB; 480926at2759; -.
DR   PhylomeDB; P47870; -.
DR   TreeFam; TF315453; -.
DR   PathwayCommons; P47870; -.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-977443; GABA receptor activation.
DR   SignaLink; P47870; -.
DR   SIGNOR; P47870; -.
DR   BioGRID-ORCS; 2561; 3 hits in 1036 CRISPR screens.
DR   ChiTaRS; GABRB2; human.
DR   GeneWiki; GABRB2; -.
DR   GenomeRNAi; 2561; -.
DR   Pharos; P47870; Tclin.
DR   PRO; PR:P47870; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P47870; protein.
DR   Bgee; ENSG00000145864; Expressed in primary visual cortex and 155 other tissues.
DR   ExpressionAtlas; P47870; baseline and differential.
DR   Genevisible; P47870; HS.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:1902711; C:GABA-A receptor complex; IPI:ComplexPortal.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0099060; C:integral component of postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0005254; F:chloride channel activity; ISS:UniProtKB.
DR   GO; GO:0004890; F:GABA-A receptor activity; ISS:BHF-UCL.
DR   GO; GO:0022851; F:GABA-gated chloride ion channel activity; IEA:Ensembl.
DR   GO; GO:0005237; F:inhibitory extracellular ligand-gated ion channel activity; IEA:Ensembl.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:1904315; F:transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential; IEA:Ensembl.
DR   GO; GO:0071420; P:cellular response to histamine; ISS:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:ComplexPortal.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IDA:ComplexPortal.
DR   GO; GO:1904862; P:inhibitory synapse assembly; IDA:UniProtKB.
DR   GO; GO:0060119; P:inner ear receptor cell development; IEA:Ensembl.
DR   GO; GO:0060384; P:innervation; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050877; P:nervous system process; IBA:GO_Central.
DR   GO; GO:0042391; P:regulation of membrane potential; IBA:GO_Central.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0051932; P:synaptic transmission, GABAergic; ISS:BHF-UCL.
DR   Gene3D; 1.20.58.390; -; 1.
DR   Gene3D; 2.70.170.10; -; 1.
DR   InterPro; IPR006028; GABAA/Glycine_rcpt.
DR   InterPro; IPR002289; GABAAb_rcpt.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR038050; Neuro_actylchol_rec.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   PANTHER; PTHR18945; PTHR18945; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR01160; GABAARBETA.
DR   PRINTS; PR00253; GABAARECEPTR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF63712; SSF63712; 1.
DR   SUPFAM; SSF90112; SSF90112; 1.
DR   TIGRFAMs; TIGR00860; LIC; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane; Chloride;
KW   Chloride channel; Cytoplasmic vesicle; Disease variant; Disulfide bond;
KW   Epilepsy; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal; Synapse;
KW   Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000250"
FT   CHAIN           26..512
FT                   /note="Gamma-aminobutyric acid receptor subunit beta-2"
FT                   /id="PRO_0000000459"
FT   TOPO_DOM        26..244
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        245..266
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        270..292
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        304..326
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TOPO_DOM        327..489
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        490..511
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         441
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P63137"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        104
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        160..174
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..63
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:19763268"
FT                   /id="VSP_038823"
FT   VAR_SEQ         360..397
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:19763268,
FT                   ECO:0000303|PubMed:7707873, ECO:0000303|PubMed:8264558"
FT                   /id="VSP_038825"
FT   VAR_SEQ         360..376
FT                   /note="IFYKDIKQNGTQYRSLW -> VNSEGKPSLLLKLMEEC (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:19763268"
FT                   /id="VSP_038824"
FT   VAR_SEQ         377..512
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:19763268"
FT                   /id="VSP_038828"
FT   VAR_SEQ         410
FT                   /note="E -> D (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:19763268"
FT                   /id="VSP_038826"
FT   VAR_SEQ         411..512
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:19763268"
FT                   /id="VSP_038827"
FT   VARIANT         79
FT                   /note="M -> T (in IECEE2; unknown pathological
FT                   significance; dbSNP:rs606231468)"
FT                   /evidence="ECO:0000269|PubMed:25124326,
FT                   ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080712"
FT   VARIANT         244
FT                   /note="Y -> H (in IECEE2; unknown pathological
FT                   significance; dbSNP:rs1554094149)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080713"
FT   VARIANT         277
FT                   /note="L -> S (in IECEE2; unknown pathological
FT                   significance; dbSNP:rs1554094145)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080714"
FT   VARIANT         284
FT                   /note="T -> K (in IECEE2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080715"
FT   VARIANT         287
FT                   /note="T -> P (in IECEE2; loss of localization to the cell
FT                   membrane; retained intracellularly it affects the cell
FT                   surface expression of the GABA receptor; decreased GABA
FT                   receptor activity; dbSNP:rs1554093894)"
FT                   /evidence="ECO:0000269|PubMed:27789573"
FT                   /id="VAR_080716"
FT   VARIANT         293
FT                   /note="R -> P (in IECEE2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080717"
FT   VARIANT         303
FT                   /note="K -> R (in IECEE2; unknown pathological
FT                   significance; dbSNP:rs1554093885)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080718"
FT   VARIANT         304
FT                   /note="A -> V (in IECEE2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080719"
FT   VARIANT         316
FT                   /note="V -> I (in IECEE2; unknown pathological
FT                   significance; dbSNP:rs1554093884)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080720"
FT   MUTAGEN         389
FT                   /note="T->A: Displays reduced current rundown following
FT                   repeated receptor activation."
FT                   /evidence="ECO:0000269|PubMed:19763268"
FT   CONFLICT        336
FT                   /note="Q -> L (in Ref. 4; BAF82419)"
FT                   /evidence="ECO:0000305"
FT   HELIX           32..43
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            44..46
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          55..58
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          60..75
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            76..79
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          80..92
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           94..96
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           109..114
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          125..130
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          138..142
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          146..159
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            165..168
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          171..182
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            185..187
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          188..192
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            193..198
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          199..202
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          208..224
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          227..240
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           243..248
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           250..262
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           263..265
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           271..285
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            286..289
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           290..293
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           304..328
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            329..331
FT                   /evidence="ECO:0007829|PDB:6X40"
FT   HELIX           487..509
FT                   /evidence="ECO:0007829|PDB:6X3T"
SQ   SEQUENCE   512 AA;  59150 MW;  C390A0C92815DD89 CRC64;
     MWRVRKRGYF GIWSFPLIIA AVCAQSVNDP SNMSLVKETV DRLLKGYDIR LRPDFGGPPV
     AVGMNIDIAS IDMVSEVNMD YTLTMYFQQA WRDKRLSYNV IPLNLTLDNR VADQLWVPDT
     YFLNDKKSFV HGVTVKNRMI RLHPDGTVLY GLRITTTAAC MMDLRRYPLD EQNCTLEIES
     YGYTTDDIEF YWRGDDNAVT GVTKIELPQF SIVDYKLITK KVVFSTGSYP RLSLSFKLKR
     NIGYFILQTY MPSILITILS WVSFWINYDA SAARVALGIT TVLTMTTINT HLRETLPKIP
     YVKAIDMYLM GCFVFVFMAL LEYALVNYIF FGRGPQRQKK AAEKAASANN EKMRLDVNKI
     FYKDIKQNGT QYRSLWDPTG NLSPTRRTTN YDFSLYTMDP HENILLSTLE IKNEMATSEA
     VMGLGDPRST MLAYDASSIQ YRKAGLPRHS FGRNALERHV AQKKSRLRRR ASQLKITIPD
     LTDVNAIDRW SRIFFPVVFS FFNIVYWLYY VN
//
ID   TM168_HUMAN             Reviewed;         697 AA.
AC   Q9H0V1; A4D0T9; B4DDS0; Q8NEK4; Q9H8J2;
DT   17-APR-2007, integrated into UniProtKB/Swiss-Prot.
DT   17-APR-2007, sequence version 2.
DT   23-FEB-2022, entry version 138.
DE   RecName: Full=Transmembrane protein 168;
GN   Name=TMEM168;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 213-697 (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9H0V1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H0V1-2; Sequence=VSP_056846;
CC   -!- SIMILARITY: Belongs to the TMEM168 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ96836.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL136626; CAB66561.1; -; mRNA.
DR   EMBL; AK023638; BAB14624.1; ALT_INIT; mRNA.
DR   EMBL; AK293311; BAG56831.1; -; mRNA.
DR   EMBL; AK314460; BAG37068.1; -; mRNA.
DR   EMBL; AC079621; AAQ96836.1; ALT_INIT; Genomic_DNA.
DR   EMBL; CH236947; EAL24373.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83470.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83471.1; -; Genomic_DNA.
DR   EMBL; BC030804; AAH30804.2; -; mRNA.
DR   CCDS; CCDS5757.1; -. [Q9H0V1-1]
DR   RefSeq; NP_001274426.1; NM_001287497.1. [Q9H0V1-1]
DR   RefSeq; NP_071929.3; NM_022484.5. [Q9H0V1-1]
DR   RefSeq; XP_016868012.1; XM_017012523.1. [Q9H0V1-1]
DR   RefSeq; XP_016868014.1; XM_017012525.1.
DR   BioGRID; 122167; 12.
DR   IntAct; Q9H0V1; 6.
DR   STRING; 9606.ENSP00000323068; -.
DR   TCDB; 8.A.171.1.1; the transmembrane protein 168 (tmem168) family.
DR   GlyGen; Q9H0V1; 3 sites.
DR   iPTMnet; Q9H0V1; -.
DR   PhosphoSitePlus; Q9H0V1; -.
DR   SwissPalm; Q9H0V1; -.
DR   BioMuta; TMEM168; -.
DR   DMDM; 145566969; -.
DR   EPD; Q9H0V1; -.
DR   jPOST; Q9H0V1; -.
DR   MassIVE; Q9H0V1; -.
DR   MaxQB; Q9H0V1; -.
DR   PaxDb; Q9H0V1; -.
DR   PeptideAtlas; Q9H0V1; -.
DR   PRIDE; Q9H0V1; -.
DR   ProteomicsDB; 3886; -.
DR   ProteomicsDB; 80328; -. [Q9H0V1-1]
DR   Antibodypedia; 17378; 91 antibodies from 19 providers.
DR   DNASU; 64418; -.
DR   Ensembl; ENST00000312814; ENSP00000323068; ENSG00000146802.
DR   Ensembl; ENST00000447395; ENSP00000410307; ENSG00000146802. [Q9H0V1-2]
DR   Ensembl; ENST00000454074; ENSP00000390696; ENSG00000146802.
DR   GeneID; 64418; -.
DR   KEGG; hsa:64418; -.
DR   MANE-Select; ENST00000312814.11; ENSP00000323068.4; NM_022484.6; NP_071929.3.
DR   UCSC; uc003vgn.5; human. [Q9H0V1-1]
DR   CTD; 64418; -.
DR   DisGeNET; 64418; -.
DR   GeneCards; TMEM168; -.
DR   HGNC; HGNC:25826; TMEM168.
DR   HPA; ENSG00000146802; Low tissue specificity.
DR   neXtProt; NX_Q9H0V1; -.
DR   OpenTargets; ENSG00000146802; -.
DR   PharmGKB; PA147357253; -.
DR   VEuPathDB; HostDB:ENSG00000146802; -.
DR   eggNOG; ENOG502QRB6; Eukaryota.
DR   GeneTree; ENSGT00390000005941; -.
DR   HOGENOM; CLU_032315_0_0_1; -.
DR   InParanoid; Q9H0V1; -.
DR   OMA; HLANWFC; -.
DR   PhylomeDB; Q9H0V1; -.
DR   TreeFam; TF328518; -.
DR   PathwayCommons; Q9H0V1; -.
DR   SignaLink; Q9H0V1; -.
DR   BioGRID-ORCS; 64418; 12 hits in 1051 CRISPR screens.
DR   ChiTaRS; TMEM168; human.
DR   GenomeRNAi; 64418; -.
DR   Pharos; Q9H0V1; Tdark.
DR   PRO; PR:Q9H0V1; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9H0V1; protein.
DR   Bgee; ENSG00000146802; Expressed in placenta and 235 other tissues.
DR   ExpressionAtlas; Q9H0V1; baseline and differential.
DR   Genevisible; Q9H0V1; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030133; C:transport vesicle; IDA:LIFEdb.
DR   InterPro; IPR029713; TMEM168.
DR   PANTHER; PTHR14437; PTHR14437; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Glycoprotein; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..697
FT                   /note="Transmembrane protein 168"
FT                   /id="PRO_0000284630"
FT   TRANSMEM        36..56
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        63..83
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        89..109
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        172..192
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        199..219
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        223..243
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        265..285
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        293..313
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        352..372
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        380..400
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        646..666
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        111
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        533
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        598
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..384
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056846"
FT   CONFLICT        305
FT                   /note="W -> R (in Ref. 1; CAB66561)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        333
FT                   /note="H -> P (in Ref. 2; BAB14624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        574
FT                   /note="T -> A (in Ref. 2; BAB14624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="S -> C (in Ref. 1; CAB66561)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   697 AA;  79755 MW;  F23471DFF43D28E0 CRC64;
     MCKSLRYCFS HCLYLAMTRL EEVNREVNMH SSVRYLGYLA RINLLVAICL GLYVRWEKTA
     NSLILVIFIL GLFVLGIASI LYYYFSMEAA SLSLSNLWFG FLLGLLCFLD NSSFKNDVKE
     ESTKYLLLTS IVLRILCSLV ERISGYVRHR PTLLTTVEFL ELVGFAIAST TMLVEKSLSV
     ILLVVALAML IIDLRMKSFL AIPNLVIFAV LLFFSSLETP KNPIAFACFF ICLITDPFLD
     IYFSGLSVTE RWKPFLYRGR ICRRLSVVFA GMIELTFFIL SAFKLRDTHL WYFVIPGFSI
     FGIFWMICHI IFLLTLWGFH TKLNDCHKVY FTHRTDYNSL DRIMASKGMR HFCLISEQLV
     FFSLLATAIL GAVSWQPTNG IFLSMFLIVL PLESMAHGLF HELGNCLGGT SVGYAIVIPT
     NFCSPDGQPT LLPPEHVQEL NLRSTGMLNA IQRFFAYHMI ETYGCDYSTS GLSFDTLHSK
     LKAFLELRTV DGPRHDTYIL YYSGHTHGTG EWALAGGDTL RLDTLIEWWR EKNGSFCSRL
     IIVLDSENST PWVKEVRKIN DQYIAVQGAE LIKTVDIEEA DPPQLGDFTK DWVEYNCNSS
     NNICWTEKGR TVKAVYGVSK RWSDYTLHLP TGSDVAKHWM LHFPRITYPL VHLANWLCGL
     NLFWICKTCF RCLKRLKMSW FLPTVLDTGQ GFKLVKS
//
ID   NUP37_HUMAN             Reviewed;         326 AA.
AC   Q8NFH4; Q9H644;
DT   27-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   23-FEB-2022, entry version 168.
DE   RecName: Full=Nucleoporin Nup37;
DE            Short=p37;
DE   AltName: Full=Nup107-160 subcomplex subunit Nup37;
GN   Name=NUP37;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=12196509; DOI=10.1083/jcb.200206106;
RA   Cronshaw J.M., Krutchinsky A.N., Zhang W., Chait B.T., Matunis M.J.;
RT   "Proteomic analysis of the mammalian nuclear pore complex.";
RL   J. Cell Biol. 158:915-927(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 7-326.
RC   TISSUE=Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   IDENTIFICATION IN THE NUP107-160 COMPLEX, AND SUBCELLULAR LOCATION.
RX   PubMed=15146057; DOI=10.1091/mbc.e03-12-0878;
RA   Loieodice I., Alves A., Rabut G., Van Overbeek M., Ellenberg J.,
RA   Sibarita J.-B., Doye V.;
RT   "The entire Nup107-160 complex, including three new members, is targeted as
RT   one entity to kinetochores in mitosis.";
RL   Mol. Biol. Cell 15:3333-3344(2004).
RN   [5]
RP   FUNCTION OF THE NUP107-160 COMPLEX.
RX   PubMed=17363900; DOI=10.1038/sj.emboj.7601642;
RA   Zuccolo M., Alves A., Galy V., Bolhy S., Formstecher E., Racine V.,
RA   Sibarita J.-B., Fukagawa T., Shiekhattar R., Yen T., Doye V.;
RT   "The human Nup107-160 nuclear pore subcomplex contributes to proper
RT   kinetochore functions.";
RL   EMBO J. 26:1853-1864(2007).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE NUP107-160
RP   COMPLEX.
RX   PubMed=17360435; DOI=10.1073/pnas.0700058104;
RA   Glavy J.S., Krutchinsky A.N., Cristea I.M., Berke I.C., Boehmer T.,
RA   Blobel G., Chait B.T.;
RT   "Cell-cycle-dependent phosphorylation of the nuclear pore Nup107-160
RT   subcomplex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3811-3816(2007).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   FUNCTION, INVOLVEMENT IN MCPH24, VARIANT MCPH24 306-ARG--VAL-326 DEL, AND
RP   CHARACTERIZATION OF VARIANT MCPH24 306-ARG--VAL-326 DEL.
RX   PubMed=30179222; DOI=10.1172/jci98688;
RA   Braun D.A., Lovric S., Schapiro D., Schneider R., Marquez J., Asif M.,
RA   Hussain M.S., Daga A., Widmeier E., Rao J., Ashraf S., Tan W., Lusk C.P.,
RA   Kolb A., Jobst-Schwan T., Schmidt J.M., Hoogstraten C.A., Eddy K.,
RA   Kitzler T.M., Shril S., Moawia A., Schrage K., Khayyat A.I.A., Lawson J.A.,
RA   Gee H.Y., Warejko J.K., Hermle T., Majmundar A.J., Hugo H., Budde B.,
RA   Motameny S., Altmueller J., Noegel A.A., Fathy H.M., Gale D.P.,
RA   Waseem S.S., Khan A., Kerecuk L., Hashmi S., Mohebbi N., Ettenger R.,
RA   Serdaroglu E., Alhasan K.A., Hashem M., Goncalves S., Ariceta G.,
RA   Ubetagoyena M., Antonin W., Baig S.M., Alkuraya F.S., Shen Q., Xu H.,
RA   Antignac C., Lifton R.P., Mane S., Nuernberg P., Khokha M.K.,
RA   Hildebrandt F.;
RT   "Mutations in multiple components of the nuclear pore complex cause
RT   nephrotic syndrome.";
RL   J. Clin. Invest. 128:4313-4328(2018).
CC   -!- FUNCTION: Component of the Nup107-160 subcomplex of the nuclear pore
CC       complex (NPC). The Nup107-160 subcomplex is required for the assembly
CC       of a functional NPC. The Nup107-160 subcomplex is also required for
CC       normal kinetochore microtubule attachment, mitotic progression and
CC       chromosome segregation. {ECO:0000269|PubMed:17363900,
CC       ECO:0000269|PubMed:30179222}.
CC   -!- SUBUNIT: Component of the Nup107-160 subcomplex of the nuclear pore
CC       complex (NPC). The Nup107-160 subcomplex includes NUP160, NUP133,
CC       NUP107, NUP98, NUP85, NUP43, NUP37, SEH1 and SEC13.
CC       {ECO:0000269|PubMed:15146057, ECO:0000269|PubMed:17360435}.
CC   -!- INTERACTION:
CC       Q8NFH4; P55212: CASP6; NbExp=3; IntAct=EBI-2563158, EBI-718729;
CC       Q8NFH4; P13473-2: LAMP2; NbExp=3; IntAct=EBI-2563158, EBI-21591415;
CC       Q8NFH4; P55735: SEC13; NbExp=3; IntAct=EBI-2563158, EBI-1046596;
CC   -!- SUBCELLULAR LOCATION: Chromosome, centromere, kinetochore. Nucleus,
CC       nuclear pore complex.
CC   -!- DISEASE: Microcephaly 24, primary, autosomal recessive (MCPH24)
CC       [MIM:618179]: A form of microcephaly, a disease defined as a head
CC       circumference more than 3 standard deviations below the age, sex and
CC       ethnically matched mean. Brain weight is markedly reduced and the
CC       cerebral cortex is disproportionately small. MCPH24 patients
CC       additionally manifest mildly impaired intellectual development,
CC       cerebellar vermis hypoplasia, and fifth finger clinodactyly.
CC       {ECO:0000269|PubMed:30179222}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15422.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF514994; AAM76705.1; -; mRNA.
DR   EMBL; BC000861; AAH00861.2; -; mRNA.
DR   EMBL; AK026271; BAB15422.1; ALT_INIT; mRNA.
DR   CCDS; CCDS9089.1; -.
DR   RefSeq; NP_076962.2; NM_024057.3.
DR   PDB; 5A9Q; EM; 23.00 A; 2/K/T/b=1-326.
DR   PDB; 7PEQ; EM; 35.00 A; AK/BK/CK/DK=1-326.
DR   PDBsum; 5A9Q; -.
DR   PDBsum; 7PEQ; -.
DR   SMR; Q8NFH4; -.
DR   BioGRID; 122491; 55.
DR   ComplexPortal; CPX-873; Nuclear pore complex.
DR   CORUM; Q8NFH4; -.
DR   IntAct; Q8NFH4; 34.
DR   MINT; Q8NFH4; -.
DR   STRING; 9606.ENSP00000448054; -.
DR   TCDB; 1.I.1.1.3; the nuclear pore complex (npc) family.
DR   GlyGen; Q8NFH4; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8NFH4; -.
DR   PhosphoSitePlus; Q8NFH4; -.
DR   SwissPalm; Q8NFH4; -.
DR   BioMuta; NUP37; -.
DR   DMDM; 27923820; -.
DR   EPD; Q8NFH4; -.
DR   jPOST; Q8NFH4; -.
DR   MassIVE; Q8NFH4; -.
DR   MaxQB; Q8NFH4; -.
DR   PaxDb; Q8NFH4; -.
DR   PeptideAtlas; Q8NFH4; -.
DR   PRIDE; Q8NFH4; -.
DR   ProteomicsDB; 73306; -.
DR   Antibodypedia; 55085; 109 antibodies from 15 providers.
DR   DNASU; 79023; -.
DR   Ensembl; ENST00000251074; ENSP00000251074; ENSG00000075188.
DR   Ensembl; ENST00000552283; ENSP00000448054; ENSG00000075188.
DR   GeneID; 79023; -.
DR   KEGG; hsa:79023; -.
DR   MANE-Select; ENST00000552283.6; ENSP00000448054.1; NM_024057.4; NP_076962.2.
DR   UCSC; uc001tjc.4; human.
DR   CTD; 79023; -.
DR   DisGeNET; 79023; -.
DR   GeneCards; NUP37; -.
DR   HGNC; HGNC:29929; NUP37.
DR   HPA; ENSG00000075188; Low tissue specificity.
DR   MalaCards; NUP37; -.
DR   MIM; 609264; gene.
DR   MIM; 618179; phenotype.
DR   neXtProt; NX_Q8NFH4; -.
DR   OpenTargets; ENSG00000075188; -.
DR   Orphanet; 656; Genetic steroid-resistant nephrotic syndrome.
DR   PharmGKB; PA134948997; -.
DR   VEuPathDB; HostDB:ENSG00000075188; -.
DR   eggNOG; KOG0266; Eukaryota.
DR   GeneTree; ENSGT00390000010777; -.
DR   HOGENOM; CLU_074370_0_0_1; -.
DR   InParanoid; Q8NFH4; -.
DR   OMA; GGMAWHQ; -.
DR   OrthoDB; 921692at2759; -.
DR   PhylomeDB; Q8NFH4; -.
DR   TreeFam; TF325769; -.
DR   PathwayCommons; Q8NFH4; -.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-159227; Transport of the SLBP independent Mature mRNA.
DR   Reactome; R-HSA-159230; Transport of the SLBP Dependant Mature mRNA.
DR   Reactome; R-HSA-159231; Transport of Mature mRNA Derived from an Intronless Transcript.
DR   Reactome; R-HSA-159236; Transport of Mature mRNA derived from an Intron-Containing Transcript.
DR   Reactome; R-HSA-165054; Rev-mediated nuclear export of HIV RNA.
DR   Reactome; R-HSA-168271; Transport of Ribonucleoproteins into the Host Nucleus.
DR   Reactome; R-HSA-168276; NS1 Mediated Effects on Host Pathways.
DR   Reactome; R-HSA-168325; Viral Messenger RNA Synthesis.
DR   Reactome; R-HSA-168333; NEP/NS2 Interacts with the Cellular Export Machinery.
DR   Reactome; R-HSA-170822; Regulation of Glucokinase by Glucokinase Regulatory Protein.
DR   Reactome; R-HSA-180746; Nuclear import of Rev protein.
DR   Reactome; R-HSA-180910; Vpr-mediated nuclear import of PICs.
DR   Reactome; R-HSA-191859; snRNP Assembly.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-3232142; SUMOylation of ubiquitinylation proteins.
DR   Reactome; R-HSA-3301854; Nuclear Pore Complex (NPC) Disassembly.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-4085377; SUMOylation of SUMOylation proteins.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-4570464; SUMOylation of RNA binding proteins.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-5578749; Transcriptional regulation by small RNAs.
DR   Reactome; R-HSA-5619107; Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC).
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-6784531; tRNA processing in the nucleus.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   Reactome; R-HSA-9610379; HCMV Late Events.
DR   Reactome; R-HSA-9615933; Postmitotic nuclear pore complex (NPC) reformation.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; Q8NFH4; -.
DR   SIGNOR; Q8NFH4; -.
DR   BioGRID-ORCS; 79023; 62 hits in 1052 CRISPR screens.
DR   ChiTaRS; NUP37; human.
DR   GenomeRNAi; 79023; -.
DR   Pharos; Q8NFH4; Tbio.
DR   PRO; PR:Q8NFH4; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q8NFH4; protein.
DR   Bgee; ENSG00000075188; Expressed in oocyte and 218 other tissues.
DR   ExpressionAtlas; Q8NFH4; baseline and differential.
DR   Genevisible; Q8NFH4; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IEA:UniProtKB-KW.
DR   GO; GO:0005635; C:nuclear envelope; TAS:Reactome.
DR   GO; GO:0005637; C:nuclear inner membrane; IDA:ComplexPortal.
DR   GO; GO:0005640; C:nuclear outer membrane; IDA:ComplexPortal.
DR   GO; GO:0031080; C:nuclear pore outer ring; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007059; P:chromosome segregation; IEA:UniProtKB-KW.
DR   GO; GO:0051028; P:mRNA transport; IEA:UniProtKB-KW.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR037626; NUP37.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR22806; PTHR22806; 1.
DR   Pfam; PF00400; WD40; 1.
DR   SMART; SM00320; WD40; 3.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 1.
DR   PROSITE; PS50082; WD_REPEATS_2; 1.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell cycle; Cell division; Centromere; Chromosome;
KW   Chromosome partition; Disease variant; Kinetochore; Mitosis;
KW   mRNA transport; Nuclear pore complex; Nucleus; Primary microcephaly;
KW   Protein transport; Reference proteome; Repeat; Translocation; Transport;
KW   WD repeat.
FT   CHAIN           1..326
FT                   /note="Nucleoporin Nup37"
FT                   /id="PRO_0000051109"
FT   REPEAT          6..54
FT                   /note="WD 1"
FT   REPEAT          61..109
FT                   /note="WD 2"
FT   REPEAT          115..154
FT                   /note="WD 3"
FT   REPEAT          159..195
FT                   /note="WD 4"
FT   REPEAT          199..237
FT                   /note="WD 5"
FT   REPEAT          242..282
FT                   /note="WD 6"
FT   REPEAT          287..324
FT                   /note="WD 7"
FT   VARIANT         306..326
FT                   /note="Missing (in MCPH24; reduced mutant protein levels;
FT                   impairs assembly of nuclear pore complex as indicated by
FT                   lower number of nuclear pores in patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:30179222"
FT                   /id="VAR_081367"
SQ   SEQUENCE   326 AA;  36708 MW;  188E6D9D0CDF2DD7 CRC64;
     MKQDASRNAA YTVDCEDYVH VVEFNPFENG DSGNLIAYGG NNYVVIGTCT FQEEEADVEG
     IQYKTLRTFH HGVRVDGIAW SPETRLDSLP PVIKFCTSAA DMKIRLFTSD LQDKNEYKVL
     EGHTDFINGL VFDPKEGQEI ASVSDDHTCR IWNLEGVQTA HFVLHSPGMS VCWHPEETFK
     LMVAEKNGTI RFYDLLAQQA ILSLESEQVP LMSAHWCLKN TFKVGAVAGN DWLIWDITRS
     SYPQNKRPVH MDRACLFRWS TISENLFATT GYPGKMASQF QIHHLGHPQP ILMGSVAVGS
     GLSWHRTLPL CVIGGDHKLL FWVTEV
//
ID   DCA10_HUMAN             Reviewed;         559 AA.
AC   Q5QP82; A4VCJ5; Q32NE2; Q8N2Q5; Q96ET5; Q9BTQ5; Q9H5P6;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   04-JAN-2005, sequence version 1.
DT   23-FEB-2022, entry version 153.
DE   RecName: Full=DDB1- and CUL4-associated factor 10;
DE   AltName: Full=WD repeat-containing protein 32;
GN   Name=DCAF10; Synonyms=WDR32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 298-559 (ISOFORM 2).
RC   TISSUE=Ovary, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 145-559.
RC   TISSUE=Embryo, and Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   FUNCTION, INTERACTION WITH DDB1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16949367; DOI=10.1016/j.molcel.2006.08.010;
RA   Jin J., Arias E.E., Chen J., Harper J.W., Walter J.C.;
RT   "A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is
RT   required for S phase destruction of the replication factor Cdt1.";
RL   Mol. Cell 23:709-721(2006).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63; SER-92 AND SER-349, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63 AND SER-92, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-134, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- FUNCTION: May function as a substrate receptor for CUL4-DDB1 E3
CC       ubiquitin-protein ligase complex. {ECO:0000269|PubMed:16949367}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with DDB1. {ECO:0000269|PubMed:16949367}.
CC   -!- INTERACTION:
CC       Q5QP82; Q969G2: LHX4; NbExp=3; IntAct=EBI-723230, EBI-2865388;
CC       Q5QP82-2; O60260-5: PRKN; NbExp=3; IntAct=EBI-10983996, EBI-21251460;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q5QP82-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5QP82-2; Sequence=VSP_028513;
CC   -!- SIMILARITY: Belongs to the WD repeat DCAF10 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI08687.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB15574.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAC11043.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL138752; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58263.1; -; Genomic_DNA.
DR   EMBL; BC003520; AAH03520.2; -; mRNA.
DR   EMBL; BC011959; AAH11959.2; -; mRNA.
DR   EMBL; BC108686; AAI08687.1; ALT_INIT; mRNA.
DR   EMBL; BC139834; AAI39835.1; -; mRNA.
DR   EMBL; AK026854; BAB15574.1; ALT_INIT; mRNA.
DR   EMBL; AK074532; BAC11043.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6613.2; -. [Q5QP82-1]
DR   RefSeq; NP_001273739.1; NM_001286810.1.
DR   RefSeq; NP_077321.3; NM_024345.4. [Q5QP82-1]
DR   RefSeq; XP_005251634.1; XM_005251577.3. [Q5QP82-2]
DR   SMR; Q5QP82; -.
DR   BioGRID; 122612; 91.
DR   IntAct; Q5QP82; 40.
DR   MINT; Q5QP82; -.
DR   STRING; 9606.ENSP00000366953; -.
DR   iPTMnet; Q5QP82; -.
DR   PhosphoSitePlus; Q5QP82; -.
DR   BioMuta; DCAF10; -.
DR   DMDM; 74762212; -.
DR   EPD; Q5QP82; -.
DR   jPOST; Q5QP82; -.
DR   MassIVE; Q5QP82; -.
DR   MaxQB; Q5QP82; -.
DR   PaxDb; Q5QP82; -.
DR   PeptideAtlas; Q5QP82; -.
DR   PRIDE; Q5QP82; -.
DR   ProteomicsDB; 63640; -. [Q5QP82-1]
DR   ProteomicsDB; 63641; -. [Q5QP82-2]
DR   Antibodypedia; 12056; 96 antibodies from 20 providers.
DR   DNASU; 79269; -.
DR   Ensembl; ENST00000377724; ENSP00000366953; ENSG00000122741.
DR   GeneID; 79269; -.
DR   KEGG; hsa:79269; -.
DR   MANE-Select; ENST00000377724.8; ENSP00000366953.3; NM_024345.5; NP_077321.3.
DR   UCSC; uc004aao.5; human. [Q5QP82-1]
DR   CTD; 79269; -.
DR   GeneCards; DCAF10; -.
DR   HGNC; HGNC:23686; DCAF10.
DR   HPA; ENSG00000122741; Low tissue specificity.
DR   neXtProt; NX_Q5QP82; -.
DR   OpenTargets; ENSG00000122741; -.
DR   PharmGKB; PA165585713; -.
DR   VEuPathDB; HostDB:ENSG00000122741; -.
DR   eggNOG; KOG0264; Eukaryota.
DR   eggNOG; KOG4155; Eukaryota.
DR   GeneTree; ENSGT00390000012666; -.
DR   InParanoid; Q5QP82; -.
DR   OMA; ISSPHGF; -.
DR   OrthoDB; 1068414at2759; -.
DR   PhylomeDB; Q5QP82; -.
DR   TreeFam; TF323434; -.
DR   PathwayCommons; Q5QP82; -.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   SignaLink; Q5QP82; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 79269; 10 hits in 1086 CRISPR screens.
DR   ChiTaRS; DCAF10; human.
DR   GenomeRNAi; 79269; -.
DR   Pharos; Q5QP82; Tdark.
DR   PRO; PR:Q5QP82; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q5QP82; protein.
DR   Bgee; ENSG00000122741; Expressed in sperm and 228 other tissues.
DR   ExpressionAtlas; Q5QP82; baseline and differential.
DR   Genevisible; Q5QP82; HS.
DR   GO; GO:0080008; C:Cul4-RING E3 ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   Gene3D; 2.130.10.10; -; 2.
DR   InterPro; IPR039085; DCA10.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR14588; PTHR14588; 1.
DR   Pfam; PF00400; WD40; 2.
DR   SMART; SM00320; WD40; 5.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 1.
DR   PROSITE; PS50082; WD_REPEATS_2; 2.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Methylation; Phosphoprotein; Reference proteome;
KW   Repeat; Ubl conjugation pathway; WD repeat.
FT   CHAIN           1..559
FT                   /note="DDB1- and CUL4-associated factor 10"
FT                   /id="PRO_0000306833"
FT   REPEAT          166..205
FT                   /note="WD 1"
FT   REPEAT          209..247
FT                   /note="WD 2"
FT   REPEAT          251..290
FT                   /note="WD 3"
FT   REPEAT          296..335
FT                   /note="WD 4"
FT   REPEAT          408..448
FT                   /note="WD 5"
FT   REPEAT          470..508
FT                   /note="WD 6"
FT   REPEAT          526..559
FT                   /note="WD 7"
FT   REGION          1..119
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          350..396
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        40..61
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        84..98
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        350..372
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AKB9"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         89
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2AKB9"
FT   MOD_RES         92
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         134
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         349
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         352..388
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_028513"
FT   CONFLICT        309
FT                   /note="D -> G (in Ref. 4; BAC11043)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="K -> N (in Ref. 3; AAH03520)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        457
FT                   /note="C -> W (in Ref. 4; BAB15574)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   559 AA;  60582 MW;  583B5A781ADAED38 CRC64;
     MFPFGPHSPG GDGSAGAGAE EPTPHEGQAA ATGPPSPLHP GADATHPPPP ARSPRRPGAP
     SLSPAPRSGE LGLPGAPESS TASAPGEPSP PSPPCRRPGP DCRAKSRGRH GLGAGLGGPG
     ARLFGWLKER SLGRGLFVDP ARDNFRTMTS LYGSIHPADS VYLSTRTHGA VFNLEYSPDG
     SVLTVACEQT EVLLFDPISS KHIKTLSEAH EDCVNNIRFL DNRLFATCSD DTTIALWDLR
     KLNTKVCTLH GHTSWVKNIE YDTNTRLLVT SGFDGNVIIW DTNRYTEDGC PHKKFFHTRF
     LMRMRLTPDC SKMLISTSSG YLLILHDLDL TKSLEVGSYP ILRARRTTSS SDLTTSSSSS
     GPRVSGSPCH HSDSNSSEKH MSRASQREGV SPRNSLEVVT PEVLGESDHG NCITSLQLHP
     KGWATLLRCS SNSDDEECTC VYEFQEGAPV RPVSPRCSLR LTHYIEEANV GRGYIKELCF
     SPDGRMISSP HGYGIRLLGF DKQCSELVDC LPKEASPLRV IRSLYSHNDV VLTTKFSPTH
     CQIASGCLSG RVSLYQPKF
//
ID   ICE2_HUMAN              Reviewed;         982 AA.
AC   Q659A1; B2RU08; Q05CT1; Q3B7W6; Q63HP4; Q658Q0; Q68CN8; Q6IPW7; Q6UX23;
AC   Q71H65; Q96CY5; Q9HAA2;
DT   21-AUG-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 2.
DT   23-FEB-2022, entry version 125.
DE   RecName: Full=Little elongation complex subunit 2;
DE   AltName: Full=Interactor of little elongator complex ELL subunit 2;
DE   AltName: Full=NMDA receptor-regulated protein 2;
GN   Name=ICE2; Synonyms=BRCC1, NARG2; ORFNames=UNQ3101/PRO10100;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary cancer;
RA   Gokhale P.C., Dritschilo A., Rahman A., Ahmad I., Kasid U.N.;
RT   "Novel transcript in human breast cancer cells.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Embryo, and Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Adipose tissue, Bone marrow, Fetal kidney, and Heart;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone, Brain, Ovary, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=15606750; DOI=10.1111/j.1432-1033.2004.04414.x;
RA   Sugiura N., Dadashev V., Corriveau R.A.;
RT   "NARG2 encodes a novel nuclear protein with (S/T)PXX motifs that is
RT   expressed during development.";
RL   Eur. J. Biochem. 271:4629-4637(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   IDENTIFICATION IN THE LEC COMPLEX, AND INTERACTION WITH ELL.
RX   PubMed=22195968; DOI=10.1016/j.molcel.2011.12.008;
RA   Smith E.R., Lin C., Garrett A.S., Thornton J., Mohaghegh N., Hu D.,
RA   Jackson J., Saraf A., Swanson S.K., Seidel C., Florens L., Washburn M.P.,
RA   Eissenberg J.C., Shilatifard A.;
RT   "The little elongation complex regulates small nuclear RNA transcription.";
RL   Mol. Cell 44:954-965(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND SER-326, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE LEC COMPLEX, AND
RP   INTERACTION WITH ICE1.
RX   PubMed=23932780; DOI=10.1016/j.molcel.2013.07.003;
RA   Hu D., Smith E.R., Garruss A.S., Mohaghegh N., Varberg J.M., Lin C.,
RA   Jackson J., Gao X., Saraf A., Florens L., Washburn M.P., Eissenberg J.C.,
RA   Shilatifard A.;
RT   "The little elongation complex functions at initiation and elongation
RT   phases of snRNA gene transcription.";
RL   Mol. Cell 51:493-505(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the little elongation complex (LEC), a complex
CC       required to regulate small nuclear RNA (snRNA) gene transcription by
CC       RNA polymerase II and III. {ECO:0000269|PubMed:23932780}.
CC   -!- SUBUNIT: Component of the little elongation complex (LEC), at least
CC       composed of ELL (ELL, ELL2 or ELL3), ZC3H8, ICE1 and ICE2. Interacts
CC       with ICE1 (via C-terminus domain). Interacts with ELL.
CC       {ECO:0000269|PubMed:22195968, ECO:0000269|PubMed:23932780}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23932780}.
CC       Note=Colocalizes with COIL in subnuclear Cajal and histone locus
CC       bodies. Translocates in the LEC complex to Cajal and histone locus
CC       bodies at snRNA genes in a ICE1-dependent manner. Associates to
CC       transcriptionally active chromatin at snRNA genes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q659A1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q659A1-2; Sequence=VSP_041612, VSP_041613;
CC   -!- TISSUE SPECIFICITY: Expressed at low levels in lung and testis.
CC       {ECO:0000269|PubMed:15606750}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal brain, kidney, liver and lung.
CC       {ECO:0000269|PubMed:15606750}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the ICE2 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH13684.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH20918.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAI07428.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=AAQ88910.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305};
CC       Sequence=BAB13948.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAH18700.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF502591; AAQ07460.1; -; mRNA.
DR   EMBL; AY358546; AAQ88910.1; ALT_SEQ; mRNA.
DR   EMBL; CR749852; CAH18700.1; ALT_SEQ; mRNA.
DR   EMBL; BX647873; CAH56197.1; -; mRNA.
DR   EMBL; AK021958; BAB13948.1; ALT_INIT; mRNA.
DR   EMBL; AK055752; BAG51567.1; -; mRNA.
DR   EMBL; AL833122; CAH56202.1; -; mRNA.
DR   EMBL; AL832046; CAH56220.1; -; mRNA.
DR   EMBL; CH471082; EAW77589.1; -; Genomic_DNA.
DR   EMBL; BC013684; AAH13684.1; ALT_INIT; mRNA.
DR   EMBL; BC020918; AAH20918.1; ALT_SEQ; mRNA.
DR   EMBL; BC071685; AAH71685.1; -; mRNA.
DR   EMBL; BC107427; AAI07428.1; ALT_SEQ; mRNA.
DR   EMBL; BC140894; AAI40895.1; -; mRNA.
DR   CCDS; CCDS10176.1; -. [Q659A1-1]
DR   RefSeq; NP_001018099.1; NM_001018089.2.
DR   RefSeq; NP_078887.2; NM_024611.5. [Q659A1-1]
DR   RefSeq; XP_005254718.1; XM_005254661.1. [Q659A1-1]
DR   RefSeq; XP_011520311.1; XM_011522009.1. [Q659A1-1]
DR   RefSeq; XP_016878058.1; XM_017022569.1. [Q659A1-1]
DR   BioGRID; 122789; 66.
DR   IntAct; Q659A1; 35.
DR   STRING; 9606.ENSP00000261520; -.
DR   iPTMnet; Q659A1; -.
DR   PhosphoSitePlus; Q659A1; -.
DR   BioMuta; ICE2; -.
DR   DMDM; 156632596; -.
DR   EPD; Q659A1; -.
DR   jPOST; Q659A1; -.
DR   MassIVE; Q659A1; -.
DR   MaxQB; Q659A1; -.
DR   PaxDb; Q659A1; -.
DR   PeptideAtlas; Q659A1; -.
DR   PRIDE; Q659A1; -.
DR   ProteomicsDB; 65932; -. [Q659A1-1]
DR   ProteomicsDB; 65933; -. [Q659A1-2]
DR   Antibodypedia; 25471; 123 antibodies from 19 providers.
DR   DNASU; 79664; -.
DR   Ensembl; ENST00000261520; ENSP00000261520; ENSG00000128915.
DR   Ensembl; ENST00000558181; ENSP00000453593; ENSG00000128915. [Q659A1-2]
DR   Ensembl; ENST00000560668; ENSP00000453303; ENSG00000128915. [Q659A1-2]
DR   GeneID; 79664; -.
DR   KEGG; hsa:79664; -.
DR   MANE-Select; ENST00000261520.9; ENSP00000261520.4; NM_024611.6; NP_078887.2.
DR   UCSC; uc002agp.5; human. [Q659A1-1]
DR   CTD; 79664; -.
DR   DisGeNET; 79664; -.
DR   GeneCards; ICE2; -.
DR   HGNC; HGNC:29885; ICE2.
DR   HPA; ENSG00000128915; Tissue enhanced (parathyroid).
DR   MIM; 610835; gene.
DR   neXtProt; NX_Q659A1; -.
DR   OpenTargets; ENSG00000128915; -.
DR   PharmGKB; PA134960292; -.
DR   VEuPathDB; HostDB:ENSG00000128915; -.
DR   eggNOG; ENOG502QUWA; Eukaryota.
DR   GeneTree; ENSGT00390000006883; -.
DR   HOGENOM; CLU_327237_0_0_1; -.
DR   InParanoid; Q659A1; -.
DR   OMA; YSLAPNI; -.
DR   PhylomeDB; Q659A1; -.
DR   TreeFam; TF106272; -.
DR   PathwayCommons; Q659A1; -.
DR   Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes.
DR   SignaLink; Q659A1; -.
DR   SIGNOR; Q659A1; -.
DR   BioGRID-ORCS; 79664; 342 hits in 1048 CRISPR screens.
DR   ChiTaRS; ICE2; human.
DR   GenomeRNAi; 79664; -.
DR   Pharos; Q659A1; Tbio.
DR   PRO; PR:Q659A1; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q659A1; protein.
DR   Bgee; ENSG00000128915; Expressed in kidney and 228 other tissues.
DR   ExpressionAtlas; Q659A1; baseline and differential.
DR   Genevisible; Q659A1; HS.
DR   GO; GO:0015030; C:Cajal body; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0035363; C:histone locus body; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008023; C:transcription elongation factor complex; IDA:UniProtKB.
DR   GO; GO:0035327; C:transcriptionally active chromatin; IDA:UniProtKB.
DR   GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB.
DR   GO; GO:0042795; P:snRNA transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0042796; P:snRNA transcription by RNA polymerase III; IMP:UniProtKB.
DR   InterPro; IPR019535; ICE2_C.
DR   Pfam; PF10505; NARG2_C; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..982
FT                   /note="Little elongation complex subunit 2"
FT                   /id="PRO_0000297964"
FT   REGION          410..450
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          473..504
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          595..623
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          672..697
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          930..982
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        478..493
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        930..968
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         326
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UZ18"
FT   MOD_RES         573
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UZ18"
FT   VAR_SEQ         50..73
FT                   /note="RIGENLNASASSVENEPAVSSATQ -> ESRGVMWTCWLNTQRFLQIPKLLE
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_041612"
FT   VAR_SEQ         74..982
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_041613"
FT   CONFLICT        272
FT                   /note="L -> P (in Ref. 4; CAH18700)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        316
FT                   /note="S -> L (in Ref. 4; CAH18700)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        355
FT                   /note="T -> P (in Ref. 4; CAH56220)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        621
FT                   /note="T -> S (in Ref. 4; CAH56220)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        753
FT                   /note="T -> A (in Ref. 4; CAH18700)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        906
FT                   /note="W -> R (in Ref. 3; BAB13948)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        947
FT                   /note="P -> S (in Ref. 4; CAH56197)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   982 AA;  110011 MW;  09B36E742FC77597 CRC64;
     MSSKMVISEP GLNWDISPKN GLKTFFSREN YKDHSMAPSL KELRVLSNRR IGENLNASAS
     SVENEPAVSS ATQAKEKVKT TIGMVLLPKP RVPYPRFSRF SQREQRSYVD LLVKYAKIPA
     NSKAVGINKN DYLQYLDMKK HVNEEVTEFL KFLQNSAKKC AQDYNMLSDD ARLFTEKILR
     ACIEQVKKYS EFYTLHEVTS LMGFFPFRVE MGLKLEKTLL ALGSVKYVKT VFPSMPIKLQ
     LSKDDIATIE TSEQTAEAMH YDISKDPNAE KLVSRYHPQI ALTSQSLFTL LNNHGPTYKE
     QWEIPVCIQV IPVAGSKPVK VIYINSPLPQ KKMTMRERNQ IFHEVPLKFM MSKNTSVPVS
     AVFMDKPEEF ISEMDMSCEV NECRKIESLE NLYLDFDDDV TELETFGVTT TKVSKSPSPA
     STSTVPNMTD APTAPKAGTT TVAPSAPDIS ANSRSLSQIL MEQLQKEKQL VTGMDGGPEE
     CKNKDDQGFE SCEKVSNSDK PLIQDSDLKT SDALQLENSQ EIETSNKNDM TIDILHADGE
     RPNVLENLDN SKEKTVGSEA AKTEDTVLCS SDTDEECLII DTECKNNSDG KTAVVGSNLS
     SRPASPNSSS GQASVGNQTN TACSPEESCV LKKPIKRVYK KFDPVGEILK MQDELLKPIS
     RKVPELPLMN LENSKQPSVS EQLSGPSDSS SWPKSGWPSA FQKPKGRLPY ELQDYVEDTS
     EYLAPQEGNF VYKLFSLQDL LLLVRCSVQR IETRPRSKKR KKIRRQFPVY VLPKVEYQAC
     YGVEALTESE LCRLWTESLL HSNSSFYVGH IDAFTSKLFL LEEITSEELK EKLSALKISN
     LFNILQHILK KLSSLQEGSY LLSHAAEDSS LLIYKASDGK VTRTAYNLYK THCGLPGVPS
     SLSVPWVPLD PSLLLPYHIH HGRIPCTFPP KSLDTTTQQK IGGTRMPTRS HRNPVSMETK
     SSCLPAQQVE TEGVAPHKRK IT
//
ID   Z385D_HUMAN             Reviewed;         395 AA.
AC   Q9H6B1;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   23-FEB-2022, entry version 142.
DE   RecName: Full=Zinc finger protein 385D;
DE   AltName: Full=Zinc finger protein 659;
GN   Name=ZNF385D; Synonyms=ZNF659;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney epithelium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-386 AND GLN-387.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK026072; BAB15350.1; -; mRNA.
DR   EMBL; BC007212; AAH07212.1; -; mRNA.
DR   CCDS; CCDS2636.1; -.
DR   RefSeq; NP_078973.1; NM_024697.2.
DR   BioGRID; 122861; 1.
DR   IntAct; Q9H6B1; 1.
DR   STRING; 9606.ENSP00000281523; -.
DR   GlyGen; Q9H6B1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H6B1; -.
DR   PhosphoSitePlus; Q9H6B1; -.
DR   BioMuta; ZNF385D; -.
DR   DMDM; 74733598; -.
DR   EPD; Q9H6B1; -.
DR   MassIVE; Q9H6B1; -.
DR   PaxDb; Q9H6B1; -.
DR   PeptideAtlas; Q9H6B1; -.
DR   PRIDE; Q9H6B1; -.
DR   ProteomicsDB; 80972; -.
DR   Antibodypedia; 27129; 79 antibodies from 21 providers.
DR   DNASU; 79750; -.
DR   Ensembl; ENST00000281523; ENSP00000281523; ENSG00000151789.
DR   GeneID; 79750; -.
DR   KEGG; hsa:79750; -.
DR   MANE-Select; ENST00000281523.8; ENSP00000281523.2; NM_024697.3; NP_078973.1.
DR   UCSC; uc003cce.4; human.
DR   CTD; 79750; -.
DR   DisGeNET; 79750; -.
DR   GeneCards; ZNF385D; -.
DR   HGNC; HGNC:26191; ZNF385D.
DR   HPA; ENSG00000151789; Tissue enhanced (brain, testis).
DR   neXtProt; NX_Q9H6B1; -.
DR   OpenTargets; ENSG00000151789; -.
DR   PharmGKB; PA162410152; -.
DR   VEuPathDB; HostDB:ENSG00000151789; -.
DR   eggNOG; ENOG502QY40; Eukaryota.
DR   GeneTree; ENSGT00940000160242; -.
DR   HOGENOM; CLU_027876_1_0_1; -.
DR   InParanoid; Q9H6B1; -.
DR   OMA; ETQLKQX; -.
DR   OrthoDB; 899600at2759; -.
DR   PhylomeDB; Q9H6B1; -.
DR   TreeFam; TF326622; -.
DR   PathwayCommons; Q9H6B1; -.
DR   SignaLink; Q9H6B1; -.
DR   BioGRID-ORCS; 79750; 5 hits in 1041 CRISPR screens.
DR   ChiTaRS; ZNF385D; human.
DR   GenomeRNAi; 79750; -.
DR   Pharos; Q9H6B1; Tdark.
DR   PRO; PR:Q9H6B1; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9H6B1; protein.
DR   Bgee; ENSG00000151789; Expressed in tendon of biceps brachii and 174 other tissues.
DR   ExpressionAtlas; Q9H6B1; baseline and differential.
DR   Genevisible; Q9H6B1; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   InterPro; IPR003604; Matrin/U1-like-C_Znf_C2H2.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 3.
DR   SMART; SM00451; ZnF_U1; 3.
DR   SUPFAM; SSF57667; SSF57667; 3.
PE   2: Evidence at transcript level;
KW   Metal-binding; Nucleus; Reference proteome; Repeat; Zinc; Zinc-finger.
FT   CHAIN           1..395
FT                   /note="Zinc finger protein 385D"
FT                   /id="PRO_0000191819"
FT   ZN_FING         80..110
FT                   /note="Matrin-type 1"
FT   ZN_FING         204..234
FT                   /note="Matrin-type 2"
FT   ZN_FING         267..297
FT                   /note="Matrin-type 3"
FT   REGION          169..194
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          282..309
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        169..193
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VARIANT         386
FT                   /note="A -> T (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs757067821)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036058"
FT   VARIANT         387
FT                   /note="H -> Q (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036059"
SQ   SEQUENCE   395 AA;  42296 MW;  D16D251A935776AA CRC64;
     MRNIMYFGGT CQSPALPALV RPPAPPLQPS LDIKPFLPFP LDTAAAVNLF PNFNAMDPIQ
     KAVINHTFGV PLPHRRKQII SCNICQLRFN SDSQAAAHYK GTKHAKKLKA LEAMKNKQKS
     VTAKDSAKTT FTSITTNTIN TSSDKTDGTA GTPAISTTTT VEIRKSSVMT TEITSKVEKS
     PTTATGNSSC PSTETEEEKA KRLLYCSLCK VAVNSASQLE AHNSGTKHKT MLEARNGSGT
     IKAFPRAGVK GKGPVNKGNT GLQNKTFHCE ICDVHVNSET QLKQHISSRR HKDRAAGKPP
     KPKYSPYNKL QKTAHPLGVK LVFSKEPSKP LAPRILPNPL AAAAAAAAVA VSSPFSLRTA
     PAATLFQTSA LPPALLRPAP GPIRTAHTPV LFAPY
//
ID   DICER_HUMAN             Reviewed;        1922 AA.
AC   Q9UPY3; A7E2D3; B3KRG4; E0AD28; O95943; Q9UQ02;
DT   25-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 3.
DT   23-FEB-2022, entry version 200.
DE   RecName: Full=Endoribonuclease Dicer;
DE            EC=3.1.26.3;
DE   AltName: Full=Helicase with RNase motif;
DE            Short=Helicase MOI;
GN   Name=DICER1; Synonyms=DICER, HERNA, KIAA0928;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10786632; DOI=10.1016/s0167-4781(99)00221-3;
RA   Matsuda S., Ichigotani Y., Okuda T., Irimura T., Nakatsugawa S.,
RA   Hamaguchi M.;
RT   "Molecular cloning and characterization of a novel human gene (HERNA) which
RT   encodes a putative RNA-helicase.";
RL   Biochim. Biophys. Acta 1490:163-169(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Neuroblastoma;
RX   PubMed=20615407; DOI=10.1016/j.febslet.2010.06.045;
RA   Potenza N., Papa U., Scaruffi P., Mosca N., Tonini G.P., Russo A.;
RT   "A novel splice variant of the human dicer gene is expressed in
RT   neuroblastoma cells.";
RL   FEBS Lett. 584:3452-3457(2010).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RA   Provost P., Dishart D., Doucet D., Hermansson A., Frendewey D.,
RA   Samuelsson B., Radmark O.;
RT   "RNA binding and processing by recombinant human Dicer.";
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1248-1922 (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=10051563; DOI=10.1073/pnas.96.5.1881;
RA   Provost P., Samuelsson B., Radmark O.;
RT   "Interaction of 5-lipoxygenase with cellular proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1881-1885(1999).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF GLU-1313; ASP-1320;
RP   GLU-1340; GLU-1444; GLN-1702; ASP-1709; PRO-1729 AND GLU-1813.
RX   PubMed=15242644; DOI=10.1016/j.cell.2004.06.017;
RA   Zhang H., Kolb F.A., Jaskiewicz L., Westhof E., Filipowicz W.;
RT   "Single processing center models for human Dicer and bacterial RNase III.";
RL   Cell 118:57-68(2004).
RN   [12]
RP   INTERACTION WITH PIWIL1.
RX   PubMed=14749716; DOI=10.1038/sj.embor.7400070;
RA   Tahbaz N., Kolb F.A., Zhang H., Jaronczyk K., Filipowicz W., Hobman T.C.;
RT   "Characterization of the interactions between mammalian PAZ PIWI domain
RT   proteins and Dicer.";
RL   EMBO Rep. 5:189-194(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH AGO2 AND TARBP2.
RX   PubMed=16271387; DOI=10.1016/j.cell.2005.10.022;
RA   Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R.;
RT   "Human RISC couples microRNA biogenesis and posttranscriptional gene
RT   silencing.";
RL   Cell 123:631-640(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH AGO1
RP   AND AGO2.
RX   PubMed=16289642; DOI=10.1016/j.cub.2005.10.048;
RA   Meister G., Landthaler M., Peters L., Chen P.Y., Urlaub H., Luehrmann R.,
RA   Tuschl T.;
RT   "Identification of novel argonaute-associated proteins.";
RL   Curr. Biol. 15:2149-2155(2005).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH TARBP2.
RX   PubMed=16142218; DOI=10.1038/sj.embor.7400509;
RA   Haase A.D., Jaskiewicz L., Zhang H., Laine S., Sack R., Gatignol A.,
RA   Filipowicz W.;
RT   "TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts
RT   with Dicer and functions in RNA silencing.";
RL   EMBO Rep. 6:961-967(2005).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH AGO2.
RX   PubMed=16357216; DOI=10.1101/gad.1384005;
RA   Maniataki E., Mourelatos Z.;
RT   "A human, ATP-independent, RISC assembly machine fueled by pre-miRNA.";
RL   Genes Dev. 19:2979-2990(2005).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH AGO2
RP   AND TARBP2.
RX   PubMed=15973356; DOI=10.1038/nature03868;
RA   Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N.,
RA   Nishikura K., Shiekhattar R.;
RT   "TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene
RT   silencing.";
RL   Nature 436:740-744(2005).
RN   [18]
RP   FUNCTION, INTERACTION WITH PRKRA AND TARBP2, AND SUBCELLULAR LOCATION.
RX   PubMed=16424907; DOI=10.1038/sj.emboj.7600942;
RA   Lee Y., Hur I., Park S.-Y., Kim Y.-K., Suh M.R., Kim V.N.;
RT   "The role of PACT in the RNA silencing pathway.";
RL   EMBO J. 25:522-532(2006).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PRKRA AND TARBP2.
RX   PubMed=17452327; DOI=10.1074/jbc.m611768200;
RA   Kok K.H., Ng M.-H., Ching Y.-P., Jin D.-Y.;
RT   "Human TRBP and PACT directly interact with each other and associate with
RT   dicer to facilitate the production of small interfering RNA.";
RL   J. Biol. Chem. 282:17649-17657(2007).
RN   [20]
RP   INTERACTION WITH DHX9.
RX   PubMed=17531811; DOI=10.1016/j.molcel.2007.04.016;
RA   Robb G.B., Rana T.M.;
RT   "RNA helicase A interacts with RISC in human cells and functions in RISC
RT   loading.";
RL   Mol. Cell 26:523-537(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH AGO2; EIF6; MOV10;
RP   RPL7A AND TARBP2, AND ASSOCIATION WITH THE 60S RIBOSOME.
RX   PubMed=17507929; DOI=10.1038/nature05841;
RA   Chendrimada T.P., Finn K.J., Ji X., Baillat D., Gregory R.I.,
RA   Liebhaber S.A., Pasquinelli A.E., Shiekhattar R.;
RT   "MicroRNA silencing through RISC recruitment of eIF6.";
RL   Nature 447:823-828(2007).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH AGO2.
RX   PubMed=18690212; DOI=10.1038/nature07186;
RA   Qi H.H., Ongusaha P.P., Myllyharju J., Cheng D., Pakkanen O., Shi Y.,
RA   Lee S.W., Peng J., Shi Y.;
RT   "Prolyl 4-hydroxylation regulates Argonaute 2 stability.";
RL   Nature 455:421-424(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1016, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH AGO2
RP   AND TARBP2.
RX   PubMed=18178619; DOI=10.1073/pnas.0710869105;
RA   MacRae I.J., Ma E., Zhou M., Robinson C.V., Doudna J.A.;
RT   "In vitro reconstitution of the human RISC-loading complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:512-517(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   INTERACTION WITH ALOX5, AND SUBCELLULAR LOCATION.
RX   PubMed=19022417; DOI=10.1016/j.bbagrm.2008.10.002;
RA   Dincbas-Renqvist V., Pepin G., Rakonjac M., Plante I., Ouellet D.L.,
RA   Hermansson A., Goulet I., Doucet J., Samuelsson B., Raadmark O.,
RA   Provost P.;
RT   "Human Dicer C-terminus functions as a 5-lipoxygenase binding domain.";
RL   Biochim. Biophys. Acta 1789:99-108(2009).
RN   [27]
RP   RETRACTED PAPER.
RX   PubMed=19219043; DOI=10.1038/ng.317;
RA   Melo S.A., Ropero S., Moutinho C., Aaltonen L.A., Yamamoto H., Calin G.A.,
RA   Rossi S., Fernandez A.F., Carneiro F., Oliveira C., Ferreira B., Liu C.-G.,
RA   Villanueva A., Capella G., Schwartz S. Jr., Shiekhattar R., Esteller M.;
RT   "A TARBP2 mutation in human cancer impairs microRNA processing and DICER1
RT   function.";
RL   Nat. Genet. 41:365-370(2009).
RN   [28]
RP   RETRACTION NOTICE OF PUBMED:19219043 NOTICE FOR PUBMED:19219043.
RX   PubMed=26813765; DOI=10.1038/ng0216-221;
RA   Melo S.A., Ropero S., Moutinho C., Aaltonen L.A., Yamamoto H., Calin G.A.,
RA   Rossi S., Fernandez A.F., Carneiro F., Oliveira C., Ferreira B., Liu C.-G.,
RA   Villanueva A., Capella G., Schwartz S. Jr., Shiekhattar R., Esteller M.;
RT   "Retraction: A TARBP2 mutation in human cancer impairs microRNA processing
RT   and DICER1 function.";
RL   Nat. Genet. 48:221-221(2016).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   INVOLVEMENT IN RMSE2.
RX   PubMed=21882293; DOI=10.1002/humu.21600;
RA   Foulkes W.D., Bahubeshi A., Hamel N., Pasini B., Asioli S., Baynam G.,
RA   Choong C.S., Charles A., Frieder R.P., Dishop M.K., Graf N., Ekim M.,
RA   Bouron-Dal Soglio D., Arseneau J., Young R.H., Sabbaghian N.,
RA   Srivastava A., Tischkowitz M.D., Priest J.R.;
RT   "Extending the phenotypes associated with DICER1 mutations.";
RL   Hum. Mutat. 32:1381-1384(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-413 AND SER-415, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   INTERACTION WITH EBOLAVIRUS VP30 (MICROBIAL INFECTION), AND INTERACTION
RP   WITH EBOLAVIRUS VP35 (MICROBIAL INFECTION).
RX   PubMed=21228243; DOI=10.1128/jvi.01160-10;
RA   Fabozzi G., Nabel C.S., Dolan M.A., Sullivan N.J.;
RT   "Ebolavirus proteins suppress the effects of small interfering RNA by
RT   direct interaction with the mammalian RNA interference pathway.";
RL   J. Virol. 85:2512-2523(2011).
RN   [33]
RP   INTERACTION WITH BCDIN3D.
RX   PubMed=23063121; DOI=10.1016/j.cell.2012.08.041;
RA   Xhemalce B., Robson S.C., Kouzarides T.;
RT   "Human RNA methyltransferase BCDIN3D regulates microRNA processing.";
RL   Cell 151:278-288(2012).
RN   [34]
RP   INVOLVEMENT IN NON-EPITHELIAL OVARIAN TUMORS, VARIANTS LYS-1705; ASN-1709;
RP   GLU-1709; GLY-1709; HIS-1810; TYR-1810; ASN-1810; GLN-1813; GLY-1813 AND
RP   LYS-1813, AND CHARACTERIZATION OF VARIANTS LYS-1705; ASN-1709 AND GLU-1709.
RX   PubMed=22187960; DOI=10.1056/nejmoa1102903;
RA   Heravi-Moussavi A., Anglesio M.S., Cheng S.W., Senz J., Yang W.,
RA   Prentice L., Fejes A.P., Chow C., Tone A., Kalloger S.E., Hamel N.,
RA   Roth A., Ha G., Wan A.N., Maines-Bandiera S., Salamanca C., Pasini B.,
RA   Clarke B.A., Lee A.F., Lee C.H., Zhao C., Young R.H., Aparicio S.A.,
RA   Sorensen P.H., Woo M.M., Boyd N., Jones S.J., Hirst M., Marra M.A.,
RA   Gilks B., Shah S.P., Foulkes W.D., Morin G.B., Huntsman D.G.;
RT   "Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.";
RL   N. Engl. J. Med. 366:234-242(2012).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1160; SER-1460; SER-1470 AND
RP   SER-1868, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37] {ECO:0007744|PDB:2EB1}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1660-1852 IN COMPLEX WITH
RP   MAGNESIUM, CATALYTIC ACTIVITY, COFACTOR, AND SUBUNIT.
RX   PubMed=17920623; DOI=10.1016/j.jmb.2007.08.069;
RA   Takeshita D., Zenno S., Lee W.C., Nagata K., Saigo K., Tanokura M.;
RT   "Homodimeric structure and double-stranded RNA cleavage activity of the C-
RT   terminal RNase III domain of human dicer.";
RL   J. Mol. Biol. 374:106-120(2007).
RN   [38]
RP   VARIANT PPB ARG-1583.
RX   PubMed=19556464; DOI=10.1126/science.1174334;
RA   Hill D.A., Ivanovich J., Priest J.R., Gurnett C.A., Dehner L.P.,
RA   Desruisseau D., Jarzembowski J.A., Wikenheiser-Brokamp K.A., Suarez B.K.,
RA   Whelan A.J., Williams G., Bracamontes D., Messinger Y., Goodfellow P.J.;
RT   "DICER1 mutations in familial pleuropulmonary blastoma.";
RL   Science 325:965-965(2009).
RN   [39]
RP   VARIANT MNG1 PHE-839.
RX   PubMed=21205968; DOI=10.1001/jama.2010.1910;
RA   Rio Frio T., Bahubeshi A., Kanellopoulou C., Hamel N., Niedziela M.,
RA   Sabbaghian N., Pouchet C., Gilbert L., O'Brien P.K., Serfas K.,
RA   Broderick P., Houlston R.S., Lesueur F., Bonora E., Muljo S., Schimke R.N.,
RA   Bouron-Dal Soglio D., Arseneau J., Schultz K.A., Priest J.R., Nguyen V.H.,
RA   Harach H.R., Livingston D.M., Foulkes W.D., Tischkowitz M.;
RT   "DICER1 mutations in familial multinodular goiter with and without ovarian
RT   Sertoli-Leydig cell tumors.";
RL   JAMA 305:68-77(2011).
RN   [40]
RP   VARIANTS LEU-435 AND GLY-1898, VARIANTS GLOW TYR-1709 AND VAL-1713, AND
RP   INVOLVEMENT IN GLOW.
RX   PubMed=24676357; DOI=10.1136/jmedgenet-2013-101943;
RA   Klein S., Lee H., Ghahremani S., Kempert P., Ischander M., Teitell M.A.,
RA   Nelson S.F., Martinez-Agosto J.A.;
RT   "Expanding the phenotype of mutations in DICER1: mosaic missense mutations
RT   in the RNase IIIb domain of DICER1 cause GLOW syndrome.";
RL   J. Med. Genet. 51:294-302(2014).
CC   -!- FUNCTION: Double-stranded RNA (dsRNA) endoribonuclease playing a
CC       central role in short dsRNA-mediated post-transcriptional gene
CC       silencing. Cleaves naturally occurring long dsRNAs and short hairpin
CC       pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three
CC       nucleotides with 3' overhang of two nucleotides, producing respectively
CC       short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs
CC       serve as guide to direct the RNA-induced silencing complex (RISC) to
CC       complementary RNAs to degrade them or prevent their translation. Gene
CC       silencing mediated by siRNAs, also called RNA interference, controls
CC       the elimination of transcripts from mobile and repetitive DNA elements
CC       of the genome but also the degradation of exogenous RNA of viral origin
CC       for instance. The miRNA pathway on the other side is a mean to
CC       specifically regulate the expression of target genes.
CC       {ECO:0000269|PubMed:15242644, ECO:0000269|PubMed:15973356,
CC       ECO:0000269|PubMed:16142218, ECO:0000269|PubMed:16271387,
CC       ECO:0000269|PubMed:16289642, ECO:0000269|PubMed:16357216,
CC       ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:17452327,
CC       ECO:0000269|PubMed:18178619}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Endonucleolytic cleavage to 5'-phosphomonoester.; EC=3.1.26.3;
CC         Evidence={ECO:0000269|PubMed:15242644, ECO:0000269|PubMed:17920623};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:17920623};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000305|PubMed:17920623};
CC       Note=Binds 2 magnesium or manganese ions per subunit.
CC       {ECO:0000305|PubMed:17920623};
CC   -!- SUBUNIT: Component of the RISC loading complex (RLC), or micro-RNA
CC       (miRNA) loading complex (miRLC), which is composed of DICER1, AGO2 and
CC       TARBP2; DICER1 and TARBP2 are required to process precursor miRNAs
CC       (pre-miRNAs) to mature miRNAs and then load them onto AGO2. Note that
CC       the trimeric RLC/miRLC is also referred to as RISC. Interacts with
CC       DHX9, AGO1, PIWIL1 and PRKRA. Associates with the 60S ribosome.
CC       Interacts with BCDIN3D. Interacts with AGO2, TARBP2, EIF6, MOV10 and
CC       RPL7A (60S ribosome subunit); they form a large RNA-induced silencing
CC       complex (RISC) (PubMed:17507929). Interacts (via Dicer dsRNA-binding
CC       fold domain) with ALOX5 (via PLAT domain); this interaction enhances
CC       arachidonate 5-lipoxygenase activity and modifies the miRNA precursor
CC       processing activity of DICER1 (PubMed:19022417).
CC       {ECO:0000269|PubMed:14749716, ECO:0000269|PubMed:15973356,
CC       ECO:0000269|PubMed:16142218, ECO:0000269|PubMed:16271387,
CC       ECO:0000269|PubMed:16289642, ECO:0000269|PubMed:16357216,
CC       ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:17452327,
CC       ECO:0000269|PubMed:17507929, ECO:0000269|PubMed:17531811,
CC       ECO:0000269|PubMed:17920623, ECO:0000269|PubMed:18178619,
CC       ECO:0000269|PubMed:18690212, ECO:0000269|PubMed:19022417,
CC       ECO:0000269|PubMed:23063121}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus
CC       transcriptional activator VP30; this interaction prevents TARBP2/TRBP
CC       binding to DICER1 and thus allows the virus to counteract host RNA
CC       silencing. {ECO:0000269|PubMed:21228243}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus
CC       transcriptional activator VP35; this interaction prevents TARBP2/TRBP
CC       binding to DICER1 and thus allows the virus to counteract host RNA
CC       silencing. {ECO:0000269|PubMed:21228243}.
CC   -!- INTERACTION:
CC       Q9UPY3; P55265-1: ADAR; NbExp=4; IntAct=EBI-395506, EBI-6913056;
CC       Q9UPY3; P55265-5: ADAR; NbExp=8; IntAct=EBI-395506, EBI-6913210;
CC       Q9UPY3; Q9UL18: AGO1; NbExp=5; IntAct=EBI-395506, EBI-527363;
CC       Q9UPY3; Q9UKV8: AGO2; NbExp=20; IntAct=EBI-395506, EBI-528269;
CC       Q9UPY3; Q96C10: DHX58; NbExp=2; IntAct=EBI-395506, EBI-744193;
CC       Q9UPY3; P19525: EIF2AK2; NbExp=2; IntAct=EBI-395506, EBI-640775;
CC       Q9UPY3; Q96J94: PIWIL1; NbExp=2; IntAct=EBI-395506, EBI-527417;
CC       Q9UPY3; O75569: PRKRA; NbExp=8; IntAct=EBI-395506, EBI-713955;
CC       Q9UPY3; Q15633: TARBP2; NbExp=25; IntAct=EBI-395506, EBI-978581;
CC       Q9UPY3; O43508: TNFSF12; NbExp=3; IntAct=EBI-395506, EBI-6932080;
CC       Q9UPY3; Q8CJG0: Ago2; Xeno; NbExp=2; IntAct=EBI-395506, EBI-528299;
CC       Q9UPY3; Q9IK90: M; Xeno; NbExp=3; IntAct=EBI-395506, EBI-25747115;
CC       Q9UPY3; P0C205; Xeno; NbExp=7; IntAct=EBI-395506, EBI-8332963;
CC       Q9UPY3-1; Q9UKV8: AGO2; NbExp=14; IntAct=EBI-15569571, EBI-528269;
CC       Q9UPY3-1; Q92945: KHSRP; NbExp=3; IntAct=EBI-15569571, EBI-1049099;
CC       Q9UPY3-1; P24928: POLR2A; NbExp=3; IntAct=EBI-15569571, EBI-295301;
CC       Q9UPY3-1; Q15633: TARBP2; NbExp=5; IntAct=EBI-15569571, EBI-978581;
CC       Q9UPY3-1; Q61496: Ddx4; Xeno; NbExp=3; IntAct=EBI-15569571, EBI-15569589;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16424907}.
CC       Cytoplasm, perinuclear region {ECO:0000269|PubMed:19022417}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UPY3-1; Sequence=Displayed;
CC       Name=2; Synonyms=t-Dicer;
CC         IsoId=Q9UPY3-2; Sequence=VSP_042832;
CC       Name=3;
CC         IsoId=Q9UPY3-3; Sequence=VSP_055341, VSP_055342;
CC   -!- DISEASE: Pleuropulmonary blastoma (PPB) [MIM:601200]: A rare pediatric
CC       intrathoracic neoplasm. The tumor arises from the lung, pleura, or
CC       both, and appears to be purely mesenchymal in phenotype. It lacks
CC       malignant epithelial elements, a feature that distinguishes it from the
CC       classic adult-type pulmonary blastoma. It arises during fetal lung
CC       development and is often part of an inherited cancer syndrome. The
CC       tumor contain both epithelial and mesenchymal cells. Early in
CC       tumorigenesis, cysts form in lung airspaces, and these cysts are lined
CC       with benign-appearing epithelium. Mesenchymal cells susceptible to
CC       malignant transformation reside within the cyst walls and form a dense
CC       layer beneath the epithelial lining. In a subset of patients,
CC       overgrowth of the mesenchymal cells produces a sarcoma, a transition
CC       that is associated with a poorer prognosis. Some patients have
CC       multilocular cystic nephroma, a benign kidney tumor.
CC       {ECO:0000269|PubMed:19556464}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Goiter multinodular 1, with or without Sertoli-Leydig cell
CC       tumors (MNG1) [MIM:138800]: A common disorder characterized by nodular
CC       overgrowth of the thyroid gland. Some individuals may also develop
CC       Sertoli-Leydig cell tumors, usually of the ovary.
CC       {ECO:0000269|PubMed:21205968}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Rhabdomyosarcoma, embryonal, 2 (RMSE2) [MIM:180295]: A form of
CC       rhabdomyosarcoma, a highly malignant tumor of striated muscle derived
CC       from primitive mesenchymal cells and exhibiting differentiation along
CC       rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently
CC       occurring soft tissue sarcomas and the most common in children. It
CC       occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal
CC       rhabdomyosarcomas. {ECO:0000269|PubMed:21882293}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Global developmental delay, lung cysts, overgrowth, and Wilms
CC       tumor (GLOW) [MIM:618272]: A disease characterized by the association
CC       of congenital nephromegaly, bilateral Wilms tumor, somatic overgrowth,
CC       developmental delay, macrocephaly, and bilateral lung cysts.
CC       {ECO:0000269|PubMed:24676357}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=DICER1 mutations have been found in uterine cervix
CC       embryonal rhabdomyosarcoma, primitive neuroectodermal tumor, Wilms
CC       tumor, pulmonary sequestration and juvenile intestinal polyp
CC       (PubMed:21882293). Somatic missense mutations affecting the RNase IIIb
CC       domain of DICER1 are common in non-epithelial ovarian tumors. These
CC       mutations do not abolish DICER1 function but alter it in specific cell
CC       types, a novel mechanism through which perturbation of microRNA
CC       processing may be oncogenic (PubMed:22187960).
CC       {ECO:0000269|PubMed:21882293, ECO:0000269|PubMed:22187960}.
CC   -!- SIMILARITY: Belongs to the helicase family. Dicer subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00657}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-11 is the initiator.
CC       {ECO:0000305}.
CC   -!- CAUTION: A paper describing truncating mutations of TARBP2 in tumor
CC       cells and resultant effects on DICER1 stability and miRNA processing
CC       has been retracted, due to concerns of image duplication in some of the
CC       figures. {ECO:0000305|PubMed:19219043, ECO:0000305|PubMed:26813765}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB38857.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The dark side of RNA - Issue
CC       87 of October 2007;
CC       URL="https://web.expasy.org/spotlight/back_issues/087";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB028449; BAA78691.1; -; mRNA.
DR   EMBL; HM595745; ADK25182.1; -; mRNA.
DR   EMBL; AJ132261; CAB38857.2; ALT_INIT; mRNA.
DR   EMBL; AB023145; BAA76772.2; -; mRNA.
DR   EMBL; AK091513; BAG52376.1; -; mRNA.
DR   EMBL; AL356017; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL390254; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW81596.1; -; Genomic_DNA.
DR   EMBL; BC150287; AAI50288.1; -; mRNA.
DR   CCDS; CCDS55941.1; -. [Q9UPY3-2]
DR   CCDS; CCDS9931.1; -. [Q9UPY3-1]
DR   RefSeq; NP_001182502.1; NM_001195573.1. [Q9UPY3-2]
DR   RefSeq; NP_001258211.1; NM_001271282.2. [Q9UPY3-1]
DR   RefSeq; NP_001278557.1; NM_001291628.1. [Q9UPY3-1]
DR   RefSeq; NP_085124.2; NM_030621.4. [Q9UPY3-1]
DR   RefSeq; NP_803187.1; NM_177438.2. [Q9UPY3-1]
DR   RefSeq; XP_011534901.1; XM_011536599.1. [Q9UPY3-1]
DR   RefSeq; XP_011534902.1; XM_011536600.2. [Q9UPY3-1]
DR   RefSeq; XP_011534903.1; XM_011536601.2. [Q9UPY3-1]
DR   RefSeq; XP_011534904.1; XM_011536602.2. [Q9UPY3-1]
DR   RefSeq; XP_016876609.1; XM_017021120.1. [Q9UPY3-1]
DR   RefSeq; XP_016876610.1; XM_017021121.1. [Q9UPY3-1]
DR   PDB; 2EB1; X-ray; 2.00 A; A/B/C=1660-1852.
DR   PDB; 4NGB; X-ray; 2.25 A; A=765-1065.
DR   PDB; 4NGC; X-ray; 2.10 A; A=765-1065.
DR   PDB; 4NGD; X-ray; 1.96 A; A=765-1065.
DR   PDB; 4NGF; X-ray; 3.10 A; A/B/C/D=765-1065.
DR   PDB; 4NGG; X-ray; 2.60 A; A=765-1065.
DR   PDB; 4NH3; X-ray; 2.62 A; A=765-1065.
DR   PDB; 4NH5; X-ray; 2.55 A; A=765-1065.
DR   PDB; 4NH6; X-ray; 2.55 A; A=765-1065.
DR   PDB; 4NHA; X-ray; 3.40 A; A=765-1065.
DR   PDB; 4WYQ; X-ray; 3.20 A; A/D=267-389.
DR   PDB; 5ZAK; EM; 4.40 A; A=1-1922.
DR   PDB; 5ZAL; EM; 4.70 A; A=1-1922.
DR   PDB; 5ZAM; EM; 5.70 A; A=1-1922.
DR   PDBsum; 2EB1; -.
DR   PDBsum; 4NGB; -.
DR   PDBsum; 4NGC; -.
DR   PDBsum; 4NGD; -.
DR   PDBsum; 4NGF; -.
DR   PDBsum; 4NGG; -.
DR   PDBsum; 4NH3; -.
DR   PDBsum; 4NH5; -.
DR   PDBsum; 4NH6; -.
DR   PDBsum; 4NHA; -.
DR   PDBsum; 4WYQ; -.
DR   PDBsum; 5ZAK; -.
DR   PDBsum; 5ZAL; -.
DR   PDBsum; 5ZAM; -.
DR   SMR; Q9UPY3; -.
DR   BioGRID; 116978; 147.
DR   ComplexPortal; CPX-1072; RISC-loading complex, PRKRA variant.
DR   ComplexPortal; CPX-134; RISC-loading complex, TARBP2 variant.
DR   CORUM; Q9UPY3; -.
DR   DIP; DIP-29664N; -.
DR   IntAct; Q9UPY3; 138.
DR   MINT; Q9UPY3; -.
DR   STRING; 9606.ENSP00000437256; -.
DR   ChEMBL; CHEMBL2311232; -.
DR   GlyGen; Q9UPY3; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UPY3; -.
DR   MetOSite; Q9UPY3; -.
DR   PhosphoSitePlus; Q9UPY3; -.
DR   BioMuta; DICER1; -.
DR   DMDM; 257051056; -.
DR   EPD; Q9UPY3; -.
DR   jPOST; Q9UPY3; -.
DR   MassIVE; Q9UPY3; -.
DR   MaxQB; Q9UPY3; -.
DR   PaxDb; Q9UPY3; -.
DR   PeptideAtlas; Q9UPY3; -.
DR   PRIDE; Q9UPY3; -.
DR   ProteomicsDB; 3598; -.
DR   ProteomicsDB; 85471; -. [Q9UPY3-1]
DR   ProteomicsDB; 85472; -. [Q9UPY3-2]
DR   Antibodypedia; 19; 520 antibodies from 39 providers.
DR   DNASU; 23405; -.
DR   Ensembl; ENST00000343455; ENSP00000343745; ENSG00000100697.
DR   Ensembl; ENST00000393063; ENSP00000376783; ENSG00000100697.
DR   Ensembl; ENST00000526495; ENSP00000437256; ENSG00000100697.
DR   Ensembl; ENST00000527414; ENSP00000435681; ENSG00000100697.
DR   Ensembl; ENST00000541352; ENSP00000444719; ENSG00000100697. [Q9UPY3-2]
DR   GeneID; 23405; -.
DR   KEGG; hsa:23405; -.
DR   MANE-Select; ENST00000343455.8; ENSP00000343745.3; NM_177438.3; NP_803187.1.
DR   UCSC; uc001ydv.4; human. [Q9UPY3-1]
DR   CTD; 23405; -.
DR   DisGeNET; 23405; -.
DR   GeneCards; DICER1; -.
DR   GeneReviews; DICER1; -.
DR   HGNC; HGNC:17098; DICER1.
DR   HPA; ENSG00000100697; Low tissue specificity.
DR   MalaCards; DICER1; -.
DR   MIM; 138800; phenotype.
DR   MIM; 180295; phenotype.
DR   MIM; 601200; phenotype.
DR   MIM; 606241; gene.
DR   MIM; 618272; phenotype.
DR   neXtProt; NX_Q9UPY3; -.
DR   OpenTargets; ENSG00000100697; -.
DR   Orphanet; 276399; Familial multinodular goiter.
DR   Orphanet; 404476; Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome.
DR   Orphanet; 99914; Gynandroblastoma.
DR   Orphanet; 99915; Maligant granulosa cell tumor of the ovary.
DR   Orphanet; 99916; Malignant Sertoli-Leydig cell tumor of the ovary.
DR   Orphanet; 284343; Pleuropulmonary blastoma familial tumor susceptibility syndrome.
DR   PharmGKB; PA38437; -.
DR   VEuPathDB; HostDB:ENSG00000100697; -.
DR   eggNOG; KOG0701; Eukaryota.
DR   GeneTree; ENSGT00940000156287; -.
DR   HOGENOM; CLU_000907_4_4_1; -.
DR   InParanoid; Q9UPY3; -.
DR   OMA; YLMLFDP; -.
DR   OrthoDB; 1337630at2759; -.
DR   PhylomeDB; Q9UPY3; -.
DR   TreeFam; TF330258; -.
DR   BRENDA; 3.1.26.3; 2681.
DR   PathwayCommons; Q9UPY3; -.
DR   Reactome; R-HSA-203927; MicroRNA (miRNA) biogenesis.
DR   Reactome; R-HSA-426486; Small interfering RNA (siRNA) biogenesis.
DR   Reactome; R-HSA-9708296; tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis.
DR   SignaLink; Q9UPY3; -.
DR   SIGNOR; Q9UPY3; -.
DR   BioGRID-ORCS; 23405; 355 hits in 1061 CRISPR screens.
DR   ChiTaRS; DICER1; human.
DR   EvolutionaryTrace; Q9UPY3; -.
DR   GeneWiki; DICER1; -.
DR   GenomeRNAi; 23405; -.
DR   Pharos; Q9UPY3; Tbio.
DR   PRO; PR:Q9UPY3; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9UPY3; protein.
DR   Bgee; ENSG00000100697; Expressed in blood and 258 other tissues.
DR   ExpressionAtlas; Q9UPY3; baseline and differential.
DR   Genevisible; Q9UPY3; HS.
DR   GO; GO:0033167; C:ARC complex; IC:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016442; C:RISC complex; IDA:UniProtKB.
DR   GO; GO:0070578; C:RISC-loading complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004530; F:deoxyribonuclease I activity; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0004521; F:endoribonuclease activity; IDA:BHF-UCL.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0070883; F:pre-miRNA binding; IDA:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:BHF-UCL.
DR   GO; GO:0004525; F:ribonuclease III activity; IDA:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IBA:GO_Central.
DR   GO; GO:0035197; F:siRNA binding; IDA:BHF-UCL.
DR   GO; GO:0006309; P:apoptotic DNA fragmentation; IBA:GO_Central.
DR   GO; GO:0036404; P:conversion of ds siRNA to ss siRNA; IMP:AgBase.
DR   GO; GO:0033168; P:conversion of ds siRNA to ss siRNA involved in RNA interference; IMP:BHF-UCL.
DR   GO; GO:0035280; P:miRNA loading onto RISC involved in gene silencing by miRNA; IDA:BHF-UCL.
DR   GO; GO:0010586; P:miRNA metabolic process; TAS:Reactome.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0010626; P:negative regulation of Schwann cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:ARUK-UCL.
DR   GO; GO:0021675; P:nerve development; ISS:BHF-UCL.
DR   GO; GO:0048812; P:neuron projection morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IDA:ARUK-UCL.
DR   GO; GO:0032290; P:peripheral nervous system myelin formation; ISS:BHF-UCL.
DR   GO; GO:0031643; P:positive regulation of myelination; ISS:BHF-UCL.
DR   GO; GO:0014040; P:positive regulation of Schwann cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0031054; P:pre-miRNA processing; IDA:UniProtKB.
DR   GO; GO:0035196; P:production of miRNAs involved in gene silencing by miRNA; IDA:UniProtKB.
DR   GO; GO:0030422; P:production of siRNA involved in RNA interference; IDA:UniProtKB.
DR   GO; GO:0090501; P:RNA phosphodiester bond hydrolysis; IBA:GO_Central.
DR   GO; GO:0090502; P:RNA phosphodiester bond hydrolysis, endonucleolytic; IDA:BHF-UCL.
DR   GO; GO:0035087; P:siRNA loading onto RISC involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0030423; P:targeting of mRNA for destruction involved in RNA interference; IMP:UniProtKB.
DR   GO; GO:0016078; P:tRNA catabolic process; TAS:Reactome.
DR   CDD; cd10843; DSRM_DICER; 1.
DR   CDD; cd00593; RIBOc; 2.
DR   Gene3D; 1.10.1520.10; -; 2.
DR   Gene3D; 3.30.160.380; -; 1.
DR   Gene3D; 3.40.50.300; -; 2.
DR   InterPro; IPR038248; Dicer_dimer_sf.
DR   InterPro; IPR005034; Dicer_dimerisation_dom.
DR   InterPro; IPR044441; DICER_DSRM.
DR   InterPro; IPR014720; dsRBD_dom.
DR   InterPro; IPR006935; Helicase/UvrB_N.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR003100; PAZ_dom.
DR   InterPro; IPR036085; PAZ_dom_sf.
DR   InterPro; IPR000999; RNase_III_dom.
DR   InterPro; IPR036389; RNase_III_sf.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF02170; PAZ; 1.
DR   Pfam; PF04851; ResIII; 1.
DR   Pfam; PF00636; Ribonuclease_3; 2.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00358; DSRM; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00949; PAZ; 1.
DR   SMART; SM00535; RIBOc; 2.
DR   SUPFAM; SSF101690; SSF101690; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF69065; SSF69065; 2.
DR   PROSITE; PS51327; DICER_DSRBF; 1.
DR   PROSITE; PS50137; DS_RBD; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50821; PAZ; 1.
DR   PROSITE; PS00517; RNASE_3_1; 1.
DR   PROSITE; PS50142; RNASE_3_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm;
KW   Disease variant; Endonuclease; Helicase; Host-virus interaction; Hydrolase;
KW   Magnesium; Manganese; Metal-binding; Nuclease; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-binding;
KW   RNA-mediated gene silencing.
FT   CHAIN           1..1922
FT                   /note="Endoribonuclease Dicer"
FT                   /id="PRO_0000180470"
FT   DOMAIN          51..227
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          433..602
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   DOMAIN          630..722
FT                   /note="Dicer dsRNA-binding fold"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00657"
FT   DOMAIN          891..1042
FT                   /note="PAZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00142"
FT   DOMAIN          1276..1403
FT                   /note="RNase III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00177"
FT   DOMAIN          1666..1824
FT                   /note="RNase III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00177"
FT   DOMAIN          1849..1914
FT                   /note="DRBM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   NP_BIND         64..71
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   REGION          256..595
FT                   /note="Required for interaction with PRKRA and TARBP2"
FT   REGION          409..433
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           175..178
FT                   /note="DECH box"
FT   COMPBIAS        412..427
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   METAL           1316
FT                   /note="Magnesium 1"
FT                   /evidence="ECO:0000250"
FT   METAL           1395
FT                   /note="Magnesium 1"
FT                   /evidence="ECO:0000250"
FT   METAL           1398
FT                   /note="Magnesium 1"
FT                   /evidence="ECO:0000250"
FT   METAL           1705
FT                   /note="Magnesium 2"
FT                   /evidence="ECO:0000269|PubMed:17920623,
FT                   ECO:0007744|PDB:2EB1"
FT   METAL           1810
FT                   /note="Magnesium 2"
FT                   /evidence="ECO:0000269|PubMed:17920623,
FT                   ECO:0007744|PDB:2EB1"
FT   METAL           1813
FT                   /note="Magnesium 2"
FT                   /evidence="ECO:0000269|PubMed:17920623,
FT                   ECO:0007744|PDB:2EB1"
FT   SITE            1806
FT                   /note="Important for activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R418"
FT   MOD_RES         413
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         415
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1016
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1160
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1460
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1468
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R418"
FT   MOD_RES         1470
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1868
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..13
FT                   /note="MKSPALQPLSMAG -> MLAWESDHFLRIL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055341"
FT   VAR_SEQ         14..1115
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055342"
FT   VAR_SEQ         1789..1922
FT                   /note="LRRSEEDEEKEEDIEVPKAMGDIFESLAGAIYMDSGMSLETVWQVYYPMMRP
FT                   LIEKFSANVPRSPVRELLEMEPETAKFSPAERTYDGKVRVTVEVVGKGKFKGVGRSYRI
FT                   AKSAAARRALRSLKANQPQVPNS -> KSFLQMYPVPLCENCLKWNQKLPNLARLRELT
FT                   TGRSESLWK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:20615407"
FT                   /id="VSP_042832"
FT   VARIANT         435
FT                   /note="P -> L (found in Wilms tumor from a patient with
FT                   GLOW syndrome; somatic mutation; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:24676357"
FT                   /id="VAR_081917"
FT   VARIANT         839
FT                   /note="S -> F (in MNG1; dbSNP:rs387906934)"
FT                   /evidence="ECO:0000269|PubMed:21205968"
FT                   /id="VAR_065301"
FT   VARIANT         1583
FT                   /note="L -> R (in PPB; dbSNP:rs137852976)"
FT                   /evidence="ECO:0000269|PubMed:19556464"
FT                   /id="VAR_063150"
FT   VARIANT         1705
FT                   /note="E -> K (in non-epithelial ovarian tumor; somatic
FT                   mutation; results in reduced RNase IIIb activity but
FT                   retention of RNase IIIa activity)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067091"
FT   VARIANT         1709
FT                   /note="D -> E (in non-epithelial ovarian tumor; somatic
FT                   mutation; results in reduced RNase IIIb activity but
FT                   retention of RNase IIIa activity)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067092"
FT   VARIANT         1709
FT                   /note="D -> G (in non-epithelial ovarian tumor; somatic
FT                   mutation; dbSNP:rs1555366979)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067093"
FT   VARIANT         1709
FT                   /note="D -> N (in non-epithelial ovarian tumor; somatic
FT                   mutation; results in reduced RNase IIIb activity but
FT                   retention of RNase IIIa activity)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067094"
FT   VARIANT         1709
FT                   /note="D -> Y (in GLOW; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:24676357"
FT                   /id="VAR_081918"
FT   VARIANT         1713
FT                   /note="D -> V (in GLOW; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:24676357"
FT                   /id="VAR_081919"
FT   VARIANT         1810
FT                   /note="D -> H (in non-epithelial ovarian tumor; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067095"
FT   VARIANT         1810
FT                   /note="D -> N (in non-epithelial ovarian tumor; somatic
FT                   mutation; dbSNP:rs775912475)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067096"
FT   VARIANT         1810
FT                   /note="D -> Y (in non-epithelial ovarian tumor; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067097"
FT   VARIANT         1813
FT                   /note="E -> G (in non-epithelial ovarian tumor; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067098"
FT   VARIANT         1813
FT                   /note="E -> K (in non-epithelial ovarian tumor; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067099"
FT   VARIANT         1813
FT                   /note="E -> Q (in non-epithelial ovarian tumor; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:22187960"
FT                   /id="VAR_067100"
FT   VARIANT         1898
FT                   /note="R -> G (found in Wilms tumor from a patient with
FT                   GLOW syndrome; somatic mutation; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:24676357"
FT                   /id="VAR_081920"
FT   MUTAGEN         960
FT                   /note="F->A: 2-fold decrease in activity."
FT   MUTAGEN         971
FT                   /note="Y->A: 10-fold decrease in activity; when associated
FT                   with Y-972."
FT   MUTAGEN         972
FT                   /note="Y->A: 10-fold decrease in activity; when associated
FT                   with Y-971."
FT   MUTAGEN         1036
FT                   /note="E->A: 5-fold decrease in activity."
FT   MUTAGEN         1313
FT                   /note="E->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1320
FT                   /note="D->A: Decreased activity. Loss of activity; when
FT                   associated with D-1709."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1340
FT                   /note="E->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1444
FT                   /note="E->A: Decreased activity. Loss of activity; when
FT                   associated with E-1813."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1702
FT                   /note="Q->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1709
FT                   /note="D->A: Decreased activity. Loss of activity; when
FT                   associated with D-1320."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1729
FT                   /note="P->E: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   MUTAGEN         1813
FT                   /note="E->A: Decreased activity. Loss of activity; when
FT                   associated with E-1444."
FT                   /evidence="ECO:0000269|PubMed:15242644"
FT   CONFLICT        75..90
FT                   /note="VLLTKELSYQIRGDFS -> STTLLKSCLYLDLGETSA (in Ref. 1;
FT                   BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        189
FT                   /note="I -> F (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        195
FT                   /note="N -> I (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        214
FT                   /note="C -> W (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="E -> D (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        223
FT                   /note="I -> F (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        393..394
FT                   /note="QQ -> HS (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        492..493
FT                   /note="KQ -> NT (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        609
FT                   /note="D -> H (in Ref. 1; BAA78691)"
FT                   /evidence="ECO:0000305"
FT   HELIX           268..282
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   HELIX           297..313
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   HELIX           315..335
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   HELIX           339..361
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   STRAND          363..367
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   HELIX           375..385
FT                   /evidence="ECO:0007829|PDB:4WYQ"
FT   STRAND          768..780
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           783..785
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           795..797
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          801..808
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          816..820
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          823..836
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           840..855
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          877..883
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          890..892
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           894..902
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          906..908
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          916..918
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           924..927
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          931..937
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          939..941
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          945..951
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           968..976
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          987..992
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           1016..1030
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           1035..1037
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   STRAND          1038..1040
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           1045..1051
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   HELIX           1054..1061
FT                   /evidence="ECO:0007829|PDB:4NGD"
FT   TURN            1662..1665
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1666..1673
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1680..1687
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1702..1722
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1729..1739
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1742..1751
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1754..1756
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1763..1778
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1806..1822
FT                   /evidence="ECO:0007829|PDB:2EB1"
FT   HELIX           1827..1847
FT                   /evidence="ECO:0007829|PDB:2EB1"
SQ   SEQUENCE   1922 AA;  218682 MW;  9452B96A601D4551 CRC64;
     MKSPALQPLS MAGLQLMTPA SSPMGPFFGL PWQQEAIHDN IYTPRKYQVE LLEAALDHNT
     IVCLNTGSGK TFIAVLLTKE LSYQIRGDFS RNGKRTVFLV NSANQVAQQV SAVRTHSDLK
     VGEYSNLEVN ASWTKERWNQ EFTKHQVLIM TCYVALNVLK NGYLSLSDIN LLVFDECHLA
     ILDHPYREIM KLCENCPSCP RILGLTASIL NGKCDPEELE EKIQKLEKIL KSNAETATDL
     VVLDRYTSQP CEIVVDCGPF TDRSGLYERL LMELEEALNF INDCNISVHS KERDSTLISK
     QILSDCRAVL VVLGPWCADK VAGMMVRELQ KYIKHEQEEL HRKFLLFTDT FLRKIHALCE
     EHFSPASLDL KFVTPKVIKL LEILRKYKPY ERQQFESVEW YNNRNQDNYV SWSDSEDDDE
     DEEIEEKEKP ETNFPSPFTN ILCGIIFVER RYTAVVLNRL IKEAGKQDPE LAYISSNFIT
     GHGIGKNQPR NKQMEAEFRK QEEVLRKFRA HETNLLIATS IVEEGVDIPK CNLVVRFDLP
     TEYRSYVQSK GRARAPISNY IMLADTDKIK SFEEDLKTYK AIEKILRNKC SKSVDTGETD
     IDPVMDDDDV FPPYVLRPDD GGPRVTINTA IGHINRYCAR LPSDPFTHLA PKCRTRELPD
     GTFYSTLYLP INSPLRASIV GPPMSCVRLA ERVVALICCE KLHKIGELDD HLMPVGKETV
     KYEEELDLHD EEETSVPGRP GSTKRRQCYP KAIPECLRDS YPRPDQPCYL YVIGMVLTTP
     LPDELNFRRR KLYPPEDTTR CFGILTAKPI PQIPHFPVYT RSGEVTISIE LKKSGFMLSL
     QMLELITRLH QYIFSHILRL EKPALEFKPT DADSAYCVLP LNVVNDSSTL DIDFKFMEDI
     EKSEARIGIP STKYTKETPF VFKLEDYQDA VIIPRYRNFD QPHRFYVADV YTDLTPLSKF
     PSPEYETFAE YYKTKYNLDL TNLNQPLLDV DHTSSRLNLL TPRHLNQKGK ALPLSSAEKR
     KAKWESLQNK QILVPELCAI HPIPASLWRK AVCLPSILYR LHCLLTAEEL RAQTASDAGV
     GVRSLPADFR YPNLDFGWKK SIDSKSFISI SNSSSAENDN YCKHSTIVPE NAAHQGANRT
     SSLENHDQMS VNCRTLLSES PGKLHVEVSA DLTAINGLSY NQNLANGSYD LANRDFCQGN
     QLNYYKQEIP VQPTTSYSIQ NLYSYENQPQ PSDECTLLSN KYLDGNANKS TSDGSPVMAV
     MPGTTDTIQV LKGRMDSEQS PSIGYSSRTL GPNPGLILQA LTLSNASDGF NLERLEMLGD
     SFLKHAITTY LFCTYPDAHE GRLSYMRSKK VSNCNLYRLG KKKGLPSRMV VSIFDPPVNW
     LPPGYVVNQD KSNTDKWEKD EMTKDCMLAN GKLDEDYEEE DEEEESLMWR APKEEADYED
     DFLEYDQEHI RFIDNMLMGS GAFVKKISLS PFSTTDSAYE WKMPKKSSLG SMPFSSDFED
     FDYSSWDAMC YLDPSKAVEE DDFVVGFWNP SEENCGVDTG KQSISYDLHT EQCIADKSIA
     DCVEALLGCY LTSCGERAAQ LFLCSLGLKV LPVIKRTDRE KALCPTRENF NSQQKNLSVS
     CAAASVASSR SSVLKDSEYG CLKIPPRCMF DHPDADKTLN HLISGFENFE KKINYRFKNK
     AYLLQAFTHA SYHYNTITDC YQRLEFLGDA ILDYLITKHL YEDPRQHSPG VLTDLRSALV
     NNTIFASLAV KYDYHKYFKA VSPELFHVID DFVQFQLEKN EMQGMDSELR RSEEDEEKEE
     DIEVPKAMGD IFESLAGAIY MDSGMSLETV WQVYYPMMRP LIEKFSANVP RSPVRELLEM
     EPETAKFSPA ERTYDGKVRV TVEVVGKGKF KGVGRSYRIA KSAAARRALR SLKANQPQVP
     NS
//
ID   YIPF5_HUMAN             Reviewed;         257 AA.
AC   Q969M3; D3DQF5; Q4VSN6; Q53EX4; Q8NHE5; Q9H338; Q9H3U4;
DT   16-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   23-FEB-2022, entry version 149.
DE   RecName: Full=Protein YIPF5;
DE   AltName: Full=Five-pass transmembrane protein localizing in the Golgi apparatus and the endoplasmic reticulum 5;
DE   AltName: Full=Smooth muscle cell-associated protein 5;
DE            Short=SMAP-5;
DE   AltName: Full=YIP1 family member 5;
DE   AltName: Full=YPT-interacting protein 1 A;
GN   Name=YIPF5 {ECO:0000312|HGNC:HGNC:24877}; Synonyms=FINGER5, YIP1A;
GN   ORFNames=PP12723, SB140, UNQ3123/PRO10275;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH SEC23
RP   AND SEC24, AND SUBCELLULAR LOCATION.
RX   PubMed=11489904; DOI=10.1074/jbc.m106189200;
RA   Tang B.L., Ong Y.S., Huang B., Wei S., Wong E.T., Qi R., Horstmann H.,
RA   Hong W.;
RT   "A membrane protein enriched in endoplasmic reticulum exit sites interacts
RT   with COPII.";
RL   J. Biol. Chem. 276:40008-40017(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Coronary artery;
RX   PubMed=15922870; DOI=10.1016/j.gene.2005.03.012;
RA   Stolle K., Schnoor M., Fuellen G., Spitzer M., Engel T., Spener F.,
RA   Cullen P., Lorkowski S.;
RT   "Cloning, cellular localization, genomic organization, and tissue-specific
RT   expression of the TGFbeta1-inducible SMAP-5 gene.";
RL   Gene 351:119-130(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Zhang W., Li N., Zhang M., Wan T., Cao X.;
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Neuroblastoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney epithelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix, Eye, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 181-257 (ISOFORMS 1/2).
RC   TISSUE=Heart;
RA   Nishimoto S., Toyoda H., Tawara J., Aoki T., Komurasaki T.;
RT   "Molecular cloning and characterization of the human smooth muscle cell
RT   associated protein-5 (SMAP-5).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   FUNCTION, AND INTERACTION WITH RAB1A.
RX   PubMed=15611160; DOI=10.1534/genetics.104.032888;
RA   Chen C.Z., Calero M., DeRegis C.J., Heidtman M., Barlowe C., Collins R.N.;
RT   "Genetic analysis of yeast Yip1p function reveals a requirement for Golgi-
RT   localized rab proteins and rab-Guanine nucleotide dissociation inhibitor.";
RL   Genetics 168:1827-1841(2004).
RN   [13]
RP   INTERACTION WITH YIF1A, AND SUBCELLULAR LOCATION.
RX   PubMed=15990086; DOI=10.1016/j.bbrc.2005.06.051;
RA   Jin C., Zhang Y., Zhu H., Ahmed K., Fu C., Yao X.;
RT   "Human Yip1A specifies the localization of Yif1 to the Golgi apparatus.";
RL   Biochem. Biophys. Res. Commun. 334:16-22(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND INTERACTION WITH YIPF3 AND YIPF4.
RX   PubMed=27999994; DOI=10.1007/s00418-016-1527-3;
RA   Kranjc T., Dempsey E., Cagney G., Nakamura N., Shields D.C., Simpson J.C.;
RT   "Functional characterisation of the YIPF protein family in mammalian
RT   cells.";
RL   Histochem. Cell Biol. 147:439-451(2017).
RN   [18]
RP   VARIANTS MEDS2 VAL-97; SER-98; LYS-106 DEL; VAL-181 AND ARG-218,
RP   CHARACTERIZATION OF VARIANT MEDS2 SER-98, TISSUE SPECIFICITY, DEVELOPMENTAL
RP   STAGE, AND FUNCTION.
RX   PubMed=33164986; DOI=10.1172/jci141455;
RA   De Franco E., Lytrivi M., Ibrahim H., Montaser H., Wakeling M.N.,
RA   Fantuzzi F., Patel K., Demarez C., Cai Y., Igoillo-Esteve M., Cosentino C.,
RA   Lithovius V., Vihinen H., Jokitalo E., Laver T.W., Johnson M.B.,
RA   Sawatani T., Shakeri H., Pachera N., Haliloglu B., Ozbek M.N., Unal E.,
RA   Yildirim R., Godbole T., Yildiz M., Aydin B., Bilheu A., Suzuki I.,
RA   Flanagan S.E., Vanderhaeghen P., Senee V., Julier C., Marchetti P.,
RA   Eizirik D.L., Ellard S., Saarimaeki-Vire J., Otonkoski T., Cnop M.,
RA   Hattersley A.T.;
RT   "YIPF5 mutations cause neonatal diabetes and microcephaly through
RT   endoplasmic reticulum stress.";
RL   J. Clin. Invest. 130:6338-6353(2020).
CC   -!- FUNCTION: Plays a role in transport between endoplasmic reticulum and
CC       Golgi. In pancreatic beta cells, required to transport proinsulin from
CC       endoplasmic reticulum into the Golgi (PubMed:33164986).
CC       {ECO:0000269|PubMed:11489904, ECO:0000269|PubMed:15611160,
CC       ECO:0000269|PubMed:33164986}.
CC   -!- SUBUNIT: Interacts with the COPII coat components Sec23 (SEC23A and/or
CC       SEC23B) and Sec24 (SEC24A and/or SEC24B) (PubMed:11489904). Interacts
CC       with YIF1A (PubMed:15990086). May interact with RAB1A
CC       (PubMed:15611160). Interacts with YIPF3 and YIPF4 (PubMed:27999994).
CC       {ECO:0000269|PubMed:11489904, ECO:0000269|PubMed:15611160,
CC       ECO:0000269|PubMed:15990086, ECO:0000269|PubMed:27999994}.
CC   -!- INTERACTION:
CC       Q969M3; O75460: ERN1; NbExp=3; IntAct=EBI-2124787, EBI-371750;
CC       Q969M3; O95070: YIF1A; NbExp=8; IntAct=EBI-2124787, EBI-2799703;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:Q9EQQ2}; Multi-pass membrane protein. Golgi
CC       apparatus, cis-Golgi network membrane {ECO:0000269|PubMed:27999994};
CC       Multi-pass membrane protein. Cytoplasmic vesicle, COPII-coated vesicle
CC       {ECO:0000250|UniProtKB:Q5XID0}. Note=Enriched at the endoplasmic
CC       reticulum exit sites (By similarity). Incorporated into COPII-coated
CC       vesicles (By similarity). {ECO:0000250|UniProtKB:Q5XID0,
CC       ECO:0000250|UniProtKB:Q9EQQ2}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q969M3-1; Sequence=Displayed;
CC       Name=2; Synonyms=D;
CC         IsoId=Q969M3-2; Sequence=VSP_018253;
CC       Name=3; Synonyms=I;
CC         IsoId=Q969M3-3; Sequence=VSP_018254;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with abundant expression in
CC       pancreatic tissue, islets, beta cells, and brain. Highly expressed in
CC       coronary smooth muscles. {ECO:0000269|PubMed:15922870,
CC       ECO:0000269|PubMed:33164986}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in developing cortex at all stages
CC       examined but most strikingly at 12 gestational weeks. Expression is
CC       found in both progenitor (ventricular zone) and neuronal (intermediate
CC       zone and cortical plate) compartments. Also selectively expressed
CC       within the choroid plexus within the cerebral ventricles.
CC       {ECO:0000269|PubMed:33164986}.
CC   -!- INDUCTION: By TGFB1. {ECO:0000269|PubMed:15922870}.
CC   -!- DISEASE: Microcephaly, epilepsy, and diabetes syndrome 2 (MEDS2)
CC       [MIM:619278]: An autosomal recessive disorder characterized by neonatal
CC       or early-onset diabetes, severe microcephaly, and epilepsy.
CC       {ECO:0000269|PubMed:33164986}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the YIP1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF140225; AAG48521.1; -; mRNA.
DR   EMBL; AY640925; AAV51256.1; -; mRNA.
DR   EMBL; AY640926; AAV51257.1; -; mRNA.
DR   EMBL; AY640927; AAV51258.1; -; mRNA.
DR   EMBL; AY640928; AAV51259.1; -; mRNA.
DR   EMBL; AY640929; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AY640934; AAV51260.1; -; mRNA.
DR   EMBL; AY037152; AAK67644.1; -; mRNA.
DR   EMBL; AY358863; AAQ89222.1; -; mRNA.
DR   EMBL; AK054576; BAB70763.1; -; mRNA.
DR   EMBL; AF318329; AAL55836.1; -; mRNA.
DR   EMBL; AK223515; BAD97235.1; -; mRNA.
DR   EMBL; CR749463; CAH18295.1; -; mRNA.
DR   EMBL; CH471062; EAW61864.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61865.1; -; Genomic_DNA.
DR   EMBL; BC007829; AAH07829.1; -; mRNA.
DR   EMBL; BC014253; AAH14253.1; -; mRNA.
DR   EMBL; BC024737; AAH24737.1; -; mRNA.
DR   EMBL; AB014733; BAB20270.1; -; mRNA.
DR   CCDS; CCDS4279.1; -. [Q969M3-1]
DR   CCDS; CCDS64277.1; -. [Q969M3-2]
DR   RefSeq; NP_001020118.1; NM_001024947.3. [Q969M3-1]
DR   RefSeq; NP_001258661.1; NM_001271732.1. [Q969M3-2]
DR   RefSeq; NP_110426.4; NM_030799.8. [Q969M3-1]
DR   BioGRID; 123519; 97.
DR   IntAct; Q969M3; 62.
DR   MINT; Q969M3; -.
DR   STRING; 9606.ENSP00000274496; -.
DR   iPTMnet; Q969M3; -.
DR   PhosphoSitePlus; Q969M3; -.
DR   SwissPalm; Q969M3; -.
DR   BioMuta; YIPF5; -.
DR   DMDM; 74760683; -.
DR   EPD; Q969M3; -.
DR   jPOST; Q969M3; -.
DR   MassIVE; Q969M3; -.
DR   MaxQB; Q969M3; -.
DR   PaxDb; Q969M3; -.
DR   PeptideAtlas; Q969M3; -.
DR   PRIDE; Q969M3; -.
DR   ProteomicsDB; 75792; -. [Q969M3-1]
DR   ProteomicsDB; 75793; -. [Q969M3-2]
DR   ProteomicsDB; 75794; -. [Q969M3-3]
DR   Antibodypedia; 45624; 120 antibodies from 21 providers.
DR   DNASU; 81555; -.
DR   Ensembl; ENST00000274496; ENSP00000274496; ENSG00000145817.
DR   Ensembl; ENST00000448443; ENSP00000397704; ENSG00000145817.
DR   Ensembl; ENST00000513112; ENSP00000425422; ENSG00000145817. [Q969M3-2]
DR   GeneID; 81555; -.
DR   KEGG; hsa:81555; -.
DR   MANE-Select; ENST00000274496.10; ENSP00000274496.5; NM_030799.9; NP_110426.4.
DR   UCSC; uc003lnk.6; human. [Q969M3-1]
DR   CTD; 81555; -.
DR   DisGeNET; 81555; -.
DR   GeneCards; YIPF5; -.
DR   HGNC; HGNC:24877; YIPF5.
DR   HPA; ENSG00000145817; Low tissue specificity.
DR   MIM; 611483; gene.
DR   MIM; 619278; phenotype.
DR   neXtProt; NX_Q969M3; -.
DR   OpenTargets; ENSG00000145817; -.
DR   Orphanet; 306558; Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome.
DR   PharmGKB; PA142670548; -.
DR   VEuPathDB; HostDB:ENSG00000145817; -.
DR   eggNOG; KOG3103; Eukaryota.
DR   GeneTree; ENSGT00940000153168; -.
DR   HOGENOM; CLU_074741_2_0_1; -.
DR   InParanoid; Q969M3; -.
DR   OMA; IGINFDH; -.
DR   OrthoDB; 1457080at2759; -.
DR   PhylomeDB; Q969M3; -.
DR   TreeFam; TF313100; -.
DR   PathwayCommons; Q969M3; -.
DR   SignaLink; Q969M3; -.
DR   BioGRID-ORCS; 81555; 88 hits in 1047 CRISPR screens.
DR   ChiTaRS; YIPF5; human.
DR   GeneWiki; YIPF5; -.
DR   GenomeRNAi; 81555; -.
DR   Pharos; Q969M3; Tbio.
DR   PRO; PR:Q969M3; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q969M3; protein.
DR   Bgee; ENSG00000145817; Expressed in nasal cavity mucosa and 233 other tissues.
DR   ExpressionAtlas; Q969M3; baseline and differential.
DR   Genevisible; Q969M3; HS.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0070971; C:endoplasmic reticulum exit site; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005802; C:trans-Golgi network; IBA:GO_Central.
DR   GO; GO:0006888; P:endoplasmic reticulum to Golgi vesicle-mediated transport; IBA:GO_Central.
DR   GO; GO:0030070; P:insulin processing; IMP:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0060628; P:regulation of ER to Golgi vesicle-mediated transport; IMP:UniProtKB.
DR   GO; GO:0048280; P:vesicle fusion with Golgi apparatus; IBA:GO_Central.
DR   InterPro; IPR045231; Yip1/4-like.
DR   PANTHER; PTHR21236; PTHR21236; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasmic vesicle; Diabetes mellitus;
KW   Disease variant; Endoplasmic reticulum; Epilepsy; ER-Golgi transport;
KW   Golgi apparatus; Membrane; Protein transport; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..257
FT                   /note="Protein YIPF5"
FT                   /id="PRO_0000234328"
FT   TOPO_DOM        1..124
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:27999994"
FT   TRANSMEM        125..145
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        146
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        147..167
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        168..173
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        174..194
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        195..196
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        197..217
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        218..236
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        237..257
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          75..106
FT                   /note="Interaction with Sec23"
FT   VAR_SEQ         1..54
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15922870"
FT                   /id="VSP_018253"
FT   VAR_SEQ         242..257
FT                   /note="YPCALLYGVFALISVF -> LQPNITYGSNYFLFCCLPYPQQHF (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15922870"
FT                   /id="VSP_018254"
FT   VARIANT         97
FT                   /note="G -> V (in MEDS2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33164986"
FT                   /id="VAR_085533"
FT   VARIANT         98
FT                   /note="I -> S (in MEDS2; no effect on differentiation and
FT                   function of pancreatic beta cells; increased endoplasmic
FT                   reticulum stress-induced apoptosis; decreased in C-peptide
FT                   levels associated with increased proinsulin accumulation)"
FT                   /evidence="ECO:0000269|PubMed:33164986"
FT                   /id="VAR_085534"
FT   VARIANT         106
FT                   /note="Missing (in MEDS2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33164986"
FT                   /id="VAR_085535"
FT   VARIANT         181
FT                   /note="A -> V (in MEDS2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33164986"
FT                   /id="VAR_085536"
FT   VARIANT         218
FT                   /note="W -> R (in MEDS2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33164986"
FT                   /id="VAR_085537"
FT   CONFLICT        136..138
FT                   /note="AFG -> DLA (in Ref. 3; AAK67644)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        155
FT                   /note="I -> S (in Ref. 1; AAG48521)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="C -> W (in Ref. 3; AAK67644)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        192
FT                   /note="I -> Y (in Ref. 1; AAG48521)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        244
FT                   /note="C -> R (in Ref. 7; BAD97235)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   257 AA;  27989 MW;  B30EACB0E514DC67 CRC64;
     MSGFENLNTD FYQTSYSIDD QSQQSYDYGG SGGPYSKQYA GYDYSQQGRF VPPDMMQPQQ
     PYTGQIYQPT QAYTPASPQP FYGNNFEDEP PLLEELGINF DHIWQKTLTV LHPLKVADGS
     IMNETDLAGP MVFCLAFGAT LLLAGKIQFG YVYGISAIGC LGMFCLLNLM SMTGVSFGCV
     ASVLGYCLLP MILLSSFAVI FSLQGMVGII LTAGIIGWCS FSASKIFISA LAMEGQQLLV
     AYPCALLYGV FALISVF
//
ID   PG12A_HUMAN             Reviewed;         189 AA.
AC   Q9BZM1; Q9BZ89;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   23-FEB-2022, entry version 174.
DE   RecName: Full=Group XIIA secretory phospholipase A2;
DE            Short=GXII sPLA2;
DE            Short=sPLA2-XII;
DE            EC=3.1.1.4;
DE   AltName: Full=Phosphatidylcholine 2-acylhydrolase 12A;
DE   Flags: Precursor;
GN   Name=PLA2G12A; Synonyms=PLA2G12; ORFNames=FKSG38, UNQ2519/PRO6012;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND MASS SPECTROMETRY.
RX   PubMed=11031251; DOI=10.1074/jbc.c000671200;
RA   Gelb M.H., Valentin E., Ghomashchi F., Lazdunski M., Lambeau G.;
RT   "Cloning and recombinant expression of a structurally novel human secreted
RT   phospholipase A2.";
RL   J. Biol. Chem. 275:39823-39826(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Wang Y.-G., Gong L.;
RT   "Identification of FKSG38, a novel gene located on human chromosome 4q25.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12522102; DOI=10.1074/jbc.m211325200;
RA   Murakami M., Masuda S., Shimbara S., Bezzine S., Lazdunski M., Lambeau G.,
RA   Gelb M.H., Matsukura S., Kokubu F., Adachi M., Kudo I.;
RT   "Cellular arachidonate-releasing function of novel classes of secretory
RT   phospholipase A2s (groups III and XII).";
RL   J. Biol. Chem. 278:10657-10667(2003).
CC   -!- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl
CC       groups in 3-sn-phosphoglycerides. Does not exhibit detectable activity
CC       toward sn-2-arachidonoyl- or linoleoyl-phosphatidylcholine or
CC       -phosphatidylethanolamine. {ECO:0000269|PubMed:12522102}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10035};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 1 Ca(2+) ion per subunit. {ECO:0000250};
CC   -!- INTERACTION:
CC       Q9BZM1; P28799: GRN; NbExp=3; IntAct=EBI-3916751, EBI-747754;
CC       Q9BZM1; O76024: WFS1; NbExp=3; IntAct=EBI-3916751, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:12522102}. Cytoplasm
CC       {ECO:0000269|PubMed:12522102}.
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in heart, skeletal muscle,
CC       kidney, liver and pancreas.
CC   -!- MASS SPECTROMETRY: Mass=18702.6; Mass_error=0.5; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11031251};
CC   -!- SIMILARITY: Belongs to the phospholipase A2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF306567; AAG50243.1; -; mRNA.
DR   EMBL; AF332892; AAG50289.1; -; mRNA.
DR   EMBL; AY359024; AAQ89383.1; -; mRNA.
DR   EMBL; BC017218; AAH17218.1; -; mRNA.
DR   CCDS; CCDS3686.1; -.
DR   RefSeq; NP_110448.2; NM_030821.4.
DR   BioGRID; 123539; 14.
DR   IntAct; Q9BZM1; 13.
DR   STRING; 9606.ENSP00000243501; -.
DR   BindingDB; Q9BZM1; -.
DR   ChEMBL; CHEMBL6122; -.
DR   iPTMnet; Q9BZM1; -.
DR   PhosphoSitePlus; Q9BZM1; -.
DR   BioMuta; PLA2G12A; -.
DR   DMDM; 20143881; -.
DR   EPD; Q9BZM1; -.
DR   jPOST; Q9BZM1; -.
DR   MassIVE; Q9BZM1; -.
DR   MaxQB; Q9BZM1; -.
DR   PaxDb; Q9BZM1; -.
DR   PeptideAtlas; Q9BZM1; -.
DR   PRIDE; Q9BZM1; -.
DR   ProteomicsDB; 79873; -.
DR   Antibodypedia; 26354; 209 antibodies from 28 providers.
DR   DNASU; 81579; -.
DR   Ensembl; ENST00000243501; ENSP00000243501; ENSG00000123739.
DR   GeneID; 81579; -.
DR   KEGG; hsa:81579; -.
DR   MANE-Select; ENST00000243501.10; ENSP00000243501.5; NM_030821.5; NP_110448.2.
DR   UCSC; uc003hzp.4; human.
DR   CTD; 81579; -.
DR   DisGeNET; 81579; -.
DR   GeneCards; PLA2G12A; -.
DR   HGNC; HGNC:18554; PLA2G12A.
DR   HPA; ENSG00000123739; Low tissue specificity.
DR   MIM; 611652; gene.
DR   neXtProt; NX_Q9BZM1; -.
DR   OpenTargets; ENSG00000123739; -.
DR   PharmGKB; PA38347; -.
DR   VEuPathDB; HostDB:ENSG00000123739; -.
DR   eggNOG; ENOG502QU22; Eukaryota.
DR   GeneTree; ENSGT00390000008798; -.
DR   InParanoid; Q9BZM1; -.
DR   OMA; HDCDEEF; -.
DR   OrthoDB; 1299904at2759; -.
DR   PhylomeDB; Q9BZM1; -.
DR   TreeFam; TF323302; -.
DR   PathwayCommons; Q9BZM1; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   Reactome; R-HSA-1482925; Acyl chain remodelling of PG.
DR   Reactome; R-HSA-1483166; Synthesis of PA.
DR   SignaLink; Q9BZM1; -.
DR   BioGRID-ORCS; 81579; 24 hits in 1007 CRISPR screens.
DR   ChiTaRS; PLA2G12A; human.
DR   GeneWiki; PLA2G12A; -.
DR   GenomeRNAi; 81579; -.
DR   Pharos; Q9BZM1; Tbio.
DR   PRO; PR:Q9BZM1; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9BZM1; protein.
DR   Bgee; ENSG00000123739; Expressed in oviduct epithelium and 248 other tissues.
DR   ExpressionAtlas; Q9BZM1; baseline and differential.
DR   Genevisible; Q9BZM1; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0047498; F:calcium-dependent phospholipase A2 activity; NAS:UniProtKB.
DR   GO; GO:0004623; F:phospholipase A2 activity; IBA:GO_Central.
DR   GO; GO:0050482; P:arachidonic acid secretion; IEA:InterPro.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:InterPro.
DR   Gene3D; 1.20.90.10; -; 1.
DR   InterPro; IPR010711; PLA2G12.
DR   InterPro; IPR036444; PLipase_A2_dom_sf.
DR   InterPro; IPR033113; PLipase_A2_His_AS.
DR   PANTHER; PTHR12824; PTHR12824; 1.
DR   Pfam; PF06951; PLA2G12; 1.
DR   SUPFAM; SSF48619; SSF48619; 1.
DR   PROSITE; PS00118; PA2_HIS; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cytoplasm; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Metal-binding; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000305"
FT   CHAIN           23..189
FT                   /note="Group XIIA secretory phospholipase A2"
FT                   /id="PRO_0000022770"
FT   ACT_SITE        110
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10035"
FT   ACT_SITE        125
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10035"
FT   METAL           88
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   METAL           90
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   METAL           92
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   METAL           111
FT                   /note="Calcium"
FT                   /evidence="ECO:0000250"
FT   CONFLICT        94..95
FT                   /note="Missing (in Ref. 2; AAG50289)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   189 AA;  21067 MW;  7979881D6E9223A4 CRC64;
     MALLSRPALT LLLLLMAAVV RCQEQAQTTD WRATLKTIRN GVHKIDTYLN AALDLLGGED
     GLCQYKCSDG SKPFPRYGYK PSPPNGCGSP LFGVHLNIGI PSLTKCCNQH DRCYETCGKS
     KNDCDEEFQY CLSKICRDVQ KTLGLTQHVQ ACETTVELLF DSVIHLGCKP YLDSQRAACR
     CHYEEKTDL
//
ID   MAGT1_HUMAN             Reviewed;         335 AA.
AC   Q9H0U3; B2RAR4; D3DTE3; Q53G00; Q6P577; Q8NBN6;
DT   11-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   23-FEB-2022, entry version 190.
DE   RecName: Full=Magnesium transporter protein 1 {ECO:0000305};
DE            Short=MagT1;
DE   AltName: Full=Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit MAGT1;
DE            Short=Oligosaccharyl transferase subunit MAGT1;
DE   AltName: Full=Implantation-associated protein;
DE            Short=IAP;
DE   Flags: Precursor;
GN   Name=MAGT1 {ECO:0000312|HGNC:HGNC:28880}; Synonyms=IAG2;
GN   ORFNames=PSEC0084, UNQ628/PRO1244;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15804357; DOI=10.1186/1471-2164-6-48;
RA   Goytain A., Quamme G.A.;
RT   "Identification and characterization of a novel mammalian Mg2+ transporter
RT   with channel-like properties.";
RL   BMC Genomics 6:48-48(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-length
RT   human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA
RT   libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Adrenal cortex, Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   IDENTIFICATION IN THE OLIGOSACCHARYLTRANSFERASE (OST) COMPLEX, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12887896; DOI=10.1016/s1097-2765(03)00243-0;
RA   Kelleher D.J., Karaoglu D., Mandon E.C., Gilmore R.;
RT   "Oligosaccharyltransferase isoforms that contain different catalytic STT3
RT   subunits have distinct enzymatic properties.";
RL   Mol. Cell 12:101-111(2003).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INDUCTION, AND
RP   TOPOLOGY.
RX   PubMed=19717468; DOI=10.1073/pnas.0908332106;
RA   Zhou H., Clapham D.E.;
RT   "Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and
RT   vertebrate embryonic development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:15750-15755(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   FUNCTION, IDENTIFICATION IN THE OLIGOSACCHARYLTRANSFERASE COMPLEX,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-87 AND CYS-90.
RX   PubMed=25135935; DOI=10.1083/jcb.201404083;
RA   Cherepanova N.A., Shrimal S., Gilmore R.;
RT   "Oxidoreductase activity is necessary for N-glycosylation of cysteine-
RT   proximal acceptor sites in glycoproteins.";
RL   J. Cell Biol. 206:525-539(2014).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   FUNCTION.
RX   PubMed=26864433; DOI=10.1038/srep20946;
RA   Cherepanova N.A., Gilmore R.;
RT   "Mammalian cells lacking either the cotranslational or posttranslocational
RT   oligosaccharyltransferase complex display substrate-dependent defects in
RT   asparagine linked glycosylation.";
RL   Sci. Rep. 6:20946-20946(2016).
RN   [16] {ECO:0007744|PDB:6S7T}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.50 ANGSTROMS), IDENTIFICATION AS
RP   COMPONENT OF THE STT3B-CONTAINING OLIGOSACCHARYLTRANSFERASE (OST) COMPLEX,
RP   FUNCTION, AND PATHWAY.
RX   PubMed=31831667; DOI=10.1126/science.aaz3505;
RA   Ramirez A.S., Kowal J., Locher K.P.;
RT   "Cryo-electron microscopy structures of human oligosaccharyltransferase
RT   complexes OST-A and OST-B.";
RL   Science 366:1372-1375(2019).
RN   [17]
RP   VARIANT GLY-311, AND POSSIBLE ASSOCIATION WITH X-LINKED MENTAL RETARDATION.
RX   PubMed=18455129; DOI=10.1016/j.ajhg.2008.03.021;
RA   Molinari F., Foulquier F., Tarpey P.S., Morelle W., Boissel S., Teague J.,
RA   Edkins S., Futreal P.A., Stratton M.R., Turner G., Matthijs G., Gecz J.,
RA   Munnich A., Colleaux L.;
RT   "Oligosaccharyltransferase-subunit mutations in nonsyndromic mental
RT   retardation.";
RL   Am. J. Hum. Genet. 82:1150-1157(2008).
RN   [18]
RP   INVOLVEMENT IN XMEN, VARIANT XMEN 137-PRO--SER-335 DEL, AND
RP   CHARACTERIZATION OF VARIANT XMEN 137-PRO--SER-335 DEL.
RX   PubMed=21796205; DOI=10.1038/nature10246;
RA   Li F.Y., Chaigne-Delalande B., Kanellopoulou C., Davis J.C., Matthews H.F.,
RA   Douek D.C., Cohen J.I., Uzel G., Su H.C., Lenardo M.J.;
RT   "Second messenger role for Mg2+ revealed by human T-cell
RT   immunodeficiency.";
RL   Nature 475:471-476(2011).
RN   [19]
RP   LACK OF ASSOCIATION OF VARIANT GLY-311 WITH X-LINKED MENTAL RETARDATION.
RX   PubMed=23871722; DOI=10.1016/j.ajhg.2013.06.013;
RA   Piton A., Redin C., Mandel J.L.;
RT   "XLID-causing mutations and associated genes challenged in light of data
RT   from large-scale human exome sequencing.";
RL   Am. J. Hum. Genet. 93:368-383(2013).
RN   [20]
RP   INVOLVEMENT IN XMEN, VARIANT 137-PRO--SER-335 DEL, AND CHARACTERIZATION OF
RP   VARIANT 137-PRO--SER-335 DEL.
RX   PubMed=24550228; DOI=10.1182/blood-2013-11-538686;
RA   Li F.Y., Chaigne-Delalande B., Su H., Uzel G., Matthews H., Lenardo M.J.;
RT   "XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of
RT   immunity against Epstein-Barr virus.";
RL   Blood 123:2148-2152(2014).
RN   [21]
RP   VARIANT XMEN 238-HIS--SER-335 DEL, AND CHARACTERIZATION OF VARIANT XMEN
RP   238-HIS--SER-335 DEL.
RX   PubMed=25504528; DOI=10.1007/s10875-014-0116-2;
RA   Dhalla F., Murray S., Sadler R., Chaigne-Delalande B., Sadaoka T.,
RA   Soilleux E., Uzel G., Miller J., Collins G.P., Hatton C.S., Bhole M.,
RA   Ferry B., Chapel H.M., Cohen J.I., Patel S.Y.;
RT   "Identification of a novel mutation in MAGT1 and progressive multifocal
RT   leucoencephalopathy in a 58-year-old man with XMEN disease.";
RL   J. Clin. Immunol. 35:112-118(2015).
RN   [22]
RP   INVOLVEMENT IN CDG1CC, VARIANT XMEN 313-PHE--SER-335 DEL, VARIANTS CDG1CC
RP   ASN-324 AND 331-SER--SER-335 DEL, CHARACTERIZATION OF VARIANT XMEN
RP   313-PHE--SER-335 DEL, CHARACTERIZATION OF VARIANTS CDG1CC ASN-324 AND
RP   331-SER--SER-335 DEL, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=31036665; DOI=10.1073/pnas.1817815116;
RA   Blommaert E., Peanne R., Cherepanova N.A., Rymen D., Staels F., Jaeken J.,
RA   Race V., Keldermans L., Souche E., Corveleyn A., Sparkes R.,
RA   Bhattacharya K., Devalck C., Schrijvers R., Foulquier F., Gilmore R.,
RA   Matthijs G.;
RT   "Mutations in MAGT1 lead to a glycosylation disorder with a variable
RT   phenotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:9865-9870(2019).
CC   -!- FUNCTION: Accessory component of the STT3B-containing form of the N-
CC       oligosaccharyl transferase (OST) complex which catalyzes the transfer
CC       of a high mannose oligosaccharide from a lipid-linked oligosaccharide
CC       donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif
CC       in nascent polypeptide chains (PubMed:31831667). Involved in N-
CC       glycosylation of STT3B-dependent substrates (PubMed:31831667).
CC       Specifically required for the glycosylation of a subset of acceptor
CC       sites that are near cysteine residues; in this function seems to act
CC       redundantly with TUSC3. In its oxidized form proposed to form transient
CC       mixed disulfides with a glycoprotein substrate to facilitate access of
CC       STT3B to the unmodified acceptor site. Has also oxidoreductase-
CC       independent functions in the STT3B-containing OST complex possibly
CC       involving substrate recognition. {ECO:0000269|PubMed:25135935,
CC       ECO:0000269|PubMed:26864433, ECO:0000269|PubMed:31036665,
CC       ECO:0000269|PubMed:31831667, ECO:0000305}.
CC   -!- FUNCTION: May be involved in Mg(2+) transport in epithelial cells.
CC       {ECO:0000305|PubMed:15804357, ECO:0000305|PubMed:19717468}.
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC       {ECO:0000269|PubMed:31831667}.
CC   -!- SUBUNIT: Accessory component of the STT3B-containing form of the
CC       oligosaccharyltransferase (OST) complex (PubMed:31831667). OST exists
CC       in two different complex forms which contain common core subunits RPN1,
CC       RPN2, OST48, OST4, DAD1 and TMEM258, either STT3A or STT3B as catalytic
CC       subunits, and form-specific accessory subunits (PubMed:31831667). OST
CC       can form stable complexes with the Sec61 complex or with both the Sec61
CC       and TRAP complexes. The association of TUSC3 or MAGT1 with the STT3B-
CC       containing complex seems to be mutually exclusvice.
CC       {ECO:0000269|PubMed:25135935, ECO:0000269|PubMed:31831667,
CC       ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19717468};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:19717468}. Endoplasmic
CC       reticulum {ECO:0000269|PubMed:25135935}. Endoplasmic reticulum membrane
CC       {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9H0U3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H0U3-2; Sequence=VSP_056556, VSP_056557;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed at very low levels in brain,
CC       lung and kidney. {ECO:0000269|PubMed:12887896,
CC       ECO:0000269|PubMed:15804357, ECO:0000269|PubMed:19717468,
CC       ECO:0000269|PubMed:31036665}.
CC   -!- INDUCTION: Up-regulated by low extracellular Mg(2+).
CC       {ECO:0000269|PubMed:19717468}.
CC   -!- DISEASE: Immunodeficiency, X-linked, with magnesium defect, Epstein-
CC       Barr virus infection and neoplasia (XMEN) [MIM:300853]: A disease
CC       characterized by CD4 lymphopenia, severe chronic viral infections, and
CC       defective T-lymphocyte activation. {ECO:0000269|PubMed:21796205,
CC       ECO:0000269|PubMed:24550228, ECO:0000269|PubMed:25504528,
CC       ECO:0000269|PubMed:31036665}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Congenital disorder of glycosylation 1CC (CDG1CC)
CC       [MIM:301031]: A form of congenital disorder of glycosylation, a
CC       multisystem disorder caused by a defect in glycoprotein biosynthesis
CC       and characterized by under-glycosylated serum glycoproteins. Congenital
CC       disorders of glycosylation result in a wide variety of clinical
CC       features, such as defects in the nervous system development,
CC       psychomotor retardation, dysmorphic features, hypotonia, coagulation
CC       disorders, and immunodeficiency. The broad spectrum of features
CC       reflects the critical role of N-glycoproteins during embryonic
CC       development, differentiation, and maintenance of cell functions. CDG1CC
CC       is an X-linked recessive form mainly characterized by intellectual and
CC       developmental disability. {ECO:0000269|PubMed:31036665}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the OST3/OST6 family. {ECO:0000305}.
CC   -!- CAUTION: Although MAGT1 has been reported to be involved in mental
CC       retardation (PubMed:18455129), its pathological role is questionable
CC       (PubMed:23871722). {ECO:0000305|PubMed:18455129,
CC       ECO:0000305|PubMed:23871722}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ000004; AAY18811.1; -; mRNA.
DR   EMBL; AY358691; AAQ89054.1; -; mRNA.
DR   EMBL; AK075394; BAC11592.1; -; mRNA.
DR   EMBL; AL136636; CAB66571.1; -; mRNA.
DR   EMBL; AK223131; BAD96851.1; -; mRNA.
DR   EMBL; AK314309; BAG36961.1; -; mRNA.
DR   EMBL; AL138743; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356235; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471104; EAW98608.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98609.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98610.1; -; Genomic_DNA.
DR   EMBL; BC041014; AAH41014.1; -; mRNA.
DR   EMBL; BC060842; AAH60842.1; -; mRNA.
DR   EMBL; BC063037; AAH63037.1; -; mRNA.
DR   RefSeq; NP_115497.4; NM_032121.5.
DR   PDB; 6S7T; EM; 3.50 A; H=1-335.
DR   PDBsum; 6S7T; -.
DR   SMR; Q9H0U3; -.
DR   BioGRID; 123856; 149.
DR   ComplexPortal; CPX-5622; Oligosaccharyltransferase complex B.
DR   CORUM; Q9H0U3; -.
DR   IntAct; Q9H0U3; 39.
DR   MINT; Q9H0U3; -.
DR   STRING; 9606.ENSP00000354649; -.
DR   TCDB; 1.A.76.1.1; the magnesium transporter1 (magt1) family.
DR   TCDB; 9.B.142.3.17; the integral membrane glycosyltransferase family 39 (gt39) family.
DR   GlyGen; Q9H0U3; 1 site.
DR   iPTMnet; Q9H0U3; -.
DR   PhosphoSitePlus; Q9H0U3; -.
DR   SwissPalm; Q9H0U3; -.
DR   BioMuta; MAGT1; -.
DR   DMDM; 74761391; -.
DR   EPD; Q9H0U3; -.
DR   jPOST; Q9H0U3; -.
DR   MassIVE; Q9H0U3; -.
DR   MaxQB; Q9H0U3; -.
DR   PaxDb; Q9H0U3; -.
DR   PeptideAtlas; Q9H0U3; -.
DR   PRIDE; Q9H0U3; -.
DR   ProteomicsDB; 66990; -.
DR   ProteomicsDB; 80324; -. [Q9H0U3-1]
DR   Antibodypedia; 43998; 120 antibodies from 22 providers.
DR   DNASU; 84061; -.
DR   Ensembl; ENST00000358075; ENSP00000354649; ENSG00000102158.
DR   Ensembl; ENST00000373336; ENSP00000362433; ENSG00000102158. [Q9H0U3-2]
DR   Ensembl; ENST00000618282; ENSP00000480732; ENSG00000102158.
DR   GeneID; 84061; -.
DR   KEGG; hsa:84061; -.
DR   MANE-Select; ENST00000618282.5; ENSP00000480732.1; NM_001367916.1; NP_001354845.1.
DR   UCSC; uc065abq.1; human. [Q9H0U3-1]
DR   CTD; 84061; -.
DR   DisGeNET; 84061; -.
DR   GeneCards; MAGT1; -.
DR   GeneReviews; MAGT1; -.
DR   HGNC; HGNC:28880; MAGT1.
DR   HPA; ENSG00000102158; Low tissue specificity.
DR   MalaCards; MAGT1; -.
DR   MIM; 300715; gene.
DR   MIM; 300853; phenotype.
DR   MIM; 301031; phenotype.
DR   neXtProt; NX_Q9H0U3; -.
DR   OpenTargets; ENSG00000102158; -.
DR   Orphanet; 317476; X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia.
DR   PharmGKB; PA162394900; -.
DR   VEuPathDB; HostDB:ENSG00000102158; -.
DR   eggNOG; KOG2603; Eukaryota.
DR   GeneTree; ENSGT00390000012030; -.
DR   HOGENOM; CLU_052855_0_0_1; -.
DR   InParanoid; Q9H0U3; -.
DR   OrthoDB; 172471at2759; -.
DR   PhylomeDB; Q9H0U3; -.
DR   TreeFam; TF314850; -.
DR   PathwayCommons; Q9H0U3; -.
DR   Reactome; R-HSA-446203; Asparagine N-linked glycosylation.
DR   Reactome; R-HSA-5223345; Miscellaneous transport and binding events.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9694548; Maturation of spike protein.
DR   SignaLink; Q9H0U3; -.
DR   UniPathway; UPA00378; -.
DR   BioGRID-ORCS; 84061; 14 hits in 672 CRISPR screens.
DR   ChiTaRS; MAGT1; human.
DR   GeneWiki; RP11-217H1.1; -.
DR   GenomeRNAi; 84061; -.
DR   Pharos; Q9H0U3; Tbio.
DR   PRO; PR:Q9H0U3; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9H0U3; protein.
DR   Bgee; ENSG00000102158; Expressed in female gonad and 248 other tissues.
DR   ExpressionAtlas; Q9H0U3; baseline and differential.
DR   Genevisible; Q9H0U3; HS.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0008250; C:oligosaccharyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0050890; P:cognition; IMP:UniProtKB.
DR   GO; GO:0015693; P:magnesium ion transport; IMP:UniProtKB.
DR   GO; GO:0006487; P:protein N-linked glycosylation; IDA:ComplexPortal.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; IMP:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   InterPro; IPR006844; Mg_transporter-1.
DR   InterPro; IPR021149; OligosaccharylTrfase_OST3/OST6.
DR   InterPro; IPR036249; Thioredoxin-like_sf.
DR   PANTHER; PTHR12692; PTHR12692; 1.
DR   PANTHER; PTHR12692:SF2; PTHR12692:SF2; 1.
DR   Pfam; PF04756; OST3_OST6; 1.
DR   SUPFAM; SSF52833; SSF52833; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Congenital disorder of glycosylation; Disease variant; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Magnesium; Membrane;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000255"
FT   CHAIN           30..335
FT                   /note="Magnesium transporter protein 1"
FT                   /id="PRO_0000246057"
FT   TOPO_DOM        30..184
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        185..205
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        206..209
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        210..230
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        231..270
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        271..291
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        292..300
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        301..321
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        322..335
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          47..175
FT                   /note="Thioredoxin"
FT   CARBOHYD        71
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        87..90
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         131..134
FT                   /note="LNMN -> FQVF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056556"
FT   VAR_SEQ         135..335
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056557"
FT   VARIANT         137..335
FT                   /note="Missing (in XMEN; no protein expression)"
FT                   /evidence="ECO:0000269|PubMed:21796205,
FT                   ECO:0000269|PubMed:24550228"
FT                   /id="VAR_083418"
FT   VARIANT         238..335
FT                   /note="Missing (in XMEN; decreased protein expression)"
FT                   /evidence="ECO:0000269|PubMed:25504528"
FT                   /id="VAR_083419"
FT   VARIANT         311
FT                   /note="V -> G (rare variant found in patients with X-linked
FT                   mental retardation; unknown pathological significance;
FT                   dbSNP:rs145245774)"
FT                   /evidence="ECO:0000269|PubMed:18455129"
FT                   /id="VAR_045837"
FT   VARIANT         313..335
FT                   /note="Missing (in XMEN; no protein expression; decreased
FT                   protein N-linked glycosylation of STT3B-specific
FT                   substrates)"
FT                   /evidence="ECO:0000269|PubMed:31036665"
FT                   /id="VAR_083420"
FT   VARIANT         324
FT                   /note="K -> N (in CDG1CC; no effect on protein expression;
FT                   decreased protein N-linked glycosylation of STT3B-specific
FT                   substrates; dbSNP:rs373260156)"
FT                   /evidence="ECO:0000269|PubMed:31036665"
FT                   /id="VAR_083421"
FT   VARIANT         331..335
FT                   /note="Missing (in CDG1CC; no protein expression; decreased
FT                   protein N-linked glycosylation of STT3B-specific
FT                   substrates)"
FT                   /evidence="ECO:0000269|PubMed:31036665"
FT                   /id="VAR_083422"
FT   MUTAGEN         87
FT                   /note="C->S: Reduces N-glycosylation of cysteine-proximal
FT                   acceptor sites; when associated with S-90."
FT                   /evidence="ECO:0000269|PubMed:25135935"
FT   MUTAGEN         90
FT                   /note="C->S: Reduces N-glycosylation of cysteine-proximal
FT                   acceptor sites; when associated with S-87."
FT                   /evidence="ECO:0000269|PubMed:25135935"
FT   CONFLICT        30
FT                   /note="Q -> K (in Ref. 4; BAC11592)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290
FT                   /note="A -> V (in Ref. 6; BAD96851)"
FT                   /evidence="ECO:0000305"
FT   HELIX           216..230
FT                   /evidence="ECO:0007829|PDB:6S7T"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:6S7T"
FT   STRAND          259..262
FT                   /evidence="ECO:0007829|PDB:6S7T"
FT   HELIX           266..288
FT                   /evidence="ECO:0007829|PDB:6S7T"
FT   HELIX           296..324
FT                   /evidence="ECO:0007829|PDB:6S7T"
SQ   SEQUENCE   335 AA;  38037 MW;  29B8E9888FDE593E CRC64;
     MAARWRFWCV SVTMVVALLI VCDVPSASAQ RKKEMVLSEK VSQLMEWTNK RPVIRMNGDK
     FRRLVKAPPR NYSVIVMFTA LQLHRQCVVC KQADEEFQIL ANSWRYSSAF TNRIFFAMVD
     FDEGSDVFQM LNMNSAPTFI NFPAKGKPKR GDTYELQVRG FSAEQIARWI ADRTDVNIRV
     IRPPNYAGPL MLGLLLAVIG GLVYLRRSNM EFLFNKTGWA FAALCFVLAM TSGQMWNHIR
     GPPYAHKNPH TGHVNYIHGS SQAQFVAETH IVLLFNGGVT LGMVLLCEAA TSDMDIGKRK
     IMCVAGIGLV VLFFSWMLSI FRSKYHGYPY SFLMS
//
ID   KBTB7_HUMAN             Reviewed;         684 AA.
AC   Q8WVZ9; B5TZ86; Q5T6Y7; Q8NB99; Q9H0I6;
DT   15-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   23-FEB-2022, entry version 151.
DE   RecName: Full=Kelch repeat and BTB domain-containing protein 7 {ECO:0000305};
GN   Name=KBTBD7 {ECO:0000312|HGNC:HGNC:25266};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hu J., Peng X., Yang Z., Yuan W., Wang Y., Li Y., Wu X.;
RL   Submitted (AUG-2008) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-29, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   FUNCTION, PATHWAY, SUBUNIT, INTERACTION WITH GABARAP; GABARAPL1; GABARAPL2
RP   AND MAP1LC3B, SUBCELLULAR LOCATION, DOMAIN, MOTIF, AND MUTAGENESIS OF
RP   MET-99; 668-TRP--VAL-671 AND TRP-668.
RX   PubMed=25684205; DOI=10.1016/j.molcel.2014.12.040;
RA   Genau H.M., Huber J., Baschieri F., Akutsu M., Doetsch V., Farhan H.,
RA   Rogov V., Behrends C.;
RT   "CUL3-KBTBD6/KBTBD7 ubiquitin ligase cooperates with GABARAP proteins to
RT   spatially restrict TIAM1-RAC1 signaling.";
RL   Mol. Cell 57:995-1010(2015).
CC   -!- FUNCTION: As part of the CUL3(KBTBD6/7) E3 ubiquitin ligase complex
CC       functions as a substrate adapter for the RAC1 guanine exchange factor
CC       (GEF) TIAM1, mediating its 'Lys-48' ubiquitination and proteasomal
CC       degradation (PubMed:25684205). By controlling this ubiquitination,
CC       regulates RAC1 signal transduction and downstream biological processes
CC       including the organization of the cytoskeleton, cell migration and cell
CC       proliferation (PubMed:25684205). Ubiquitination of TIAM1 requires the
CC       membrane-associated protein GABARAP which may restrict locally the
CC       activity of the complex (PubMed:25684205).
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- SUBUNIT: Core component of a BCR3 (BTB-CUL3-RBX1) E3 ubiquitin ligase
CC       complex, also named Cul3-RING ubiquitin ligase complex CUL3(KBTBD6/7),
CC       composed of CUL3, RBX1, KBTBD6 and KBTBD7 (PubMed:25684205). Interacts
CC       with GABARAP; the interaction is direct and is required for the
CC       ubiquitination of TIAM1 (PubMed:25684205). Interacts with GABARAPL1,
CC       GABARAPL2 and MAP1LC3B; the interaction is direct (PubMed:25684205).
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- INTERACTION:
CC       Q8WVZ9; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-473695, EBI-711501;
CC       Q8WVZ9; O95166: GABARAP; NbExp=2; IntAct=EBI-473695, EBI-712001;
CC       Q8WVZ9; Q9H0R8: GABARAPL1; NbExp=6; IntAct=EBI-473695, EBI-746969;
CC       Q8WVZ9; P60520: GABARAPL2; NbExp=3; IntAct=EBI-473695, EBI-720116;
CC       Q8WVZ9; Q9UIH9: KLF15; NbExp=3; IntAct=EBI-473695, EBI-2796400;
CC       Q8WVZ9; Q9GZQ8: MAP1LC3B; NbExp=4; IntAct=EBI-473695, EBI-373144;
CC       Q8WVZ9; Q9BXW4: MAP1LC3C; NbExp=2; IntAct=EBI-473695, EBI-2603996;
CC       Q8WVZ9; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-473695, EBI-16439278;
CC       Q8WVZ9; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-473695, EBI-713786;
CC       Q8WVZ9; P61289: PSME3; NbExp=3; IntAct=EBI-473695, EBI-355546;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:25684205}. Nucleus
CC       {ECO:0000305|PubMed:25684205}.
CC   -!- DOMAIN: The ATG8 interaction motif (AIM) mediates interaction with
CC       proteins of the ATG8 family including GABARAP.
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- DOMAIN: The BTB domain is required for interaction with CUL3.
CC       {ECO:0000269|PubMed:25684205}.
CC   -!- DOMAIN: The Kelch repeats mediate interaction with TIAM1, a
CC       CUL3(KBTBD6/7) E3 ubiquitin ligase substrate.
CC       {ECO:0000269|PubMed:25684205}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL136782; CAB66716.1; -; mRNA.
DR   EMBL; FJ150424; ACH92650.1; -; mRNA.
DR   EMBL; AK091344; BAC03641.1; -; mRNA.
DR   EMBL; AL354696; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08647.1; -; Genomic_DNA.
DR   EMBL; BC022033; AAH22033.1; -; mRNA.
DR   CCDS; CCDS9377.1; -.
DR   RefSeq; NP_115514.2; NM_032138.5.
DR   SMR; Q8WVZ9; -.
DR   BioGRID; 123873; 208.
DR   IntAct; Q8WVZ9; 142.
DR   MINT; Q8WVZ9; -.
DR   STRING; 9606.ENSP00000368797; -.
DR   iPTMnet; Q8WVZ9; -.
DR   PhosphoSitePlus; Q8WVZ9; -.
DR   BioMuta; KBTBD7; -.
DR   DMDM; 45477155; -.
DR   EPD; Q8WVZ9; -.
DR   jPOST; Q8WVZ9; -.
DR   MassIVE; Q8WVZ9; -.
DR   MaxQB; Q8WVZ9; -.
DR   PaxDb; Q8WVZ9; -.
DR   PeptideAtlas; Q8WVZ9; -.
DR   PRIDE; Q8WVZ9; -.
DR   ProteomicsDB; 74839; -.
DR   Antibodypedia; 23391; 157 antibodies from 22 providers.
DR   DNASU; 84078; -.
DR   Ensembl; ENST00000379483; ENSP00000368797; ENSG00000120696.
DR   GeneID; 84078; -.
DR   KEGG; hsa:84078; -.
DR   MANE-Select; ENST00000379483.4; ENSP00000368797.3; NM_032138.7; NP_115514.2.
DR   UCSC; uc001uxw.2; human.
DR   CTD; 84078; -.
DR   DisGeNET; 84078; -.
DR   GeneCards; KBTBD7; -.
DR   HGNC; HGNC:25266; KBTBD7.
DR   HPA; ENSG00000120696; Low tissue specificity.
DR   MIM; 617739; gene.
DR   neXtProt; NX_Q8WVZ9; -.
DR   OpenTargets; ENSG00000120696; -.
DR   PharmGKB; PA134934036; -.
DR   VEuPathDB; HostDB:ENSG00000120696; -.
DR   eggNOG; ENOG502QWK2; Eukaryota.
DR   GeneTree; ENSGT00940000155175; -.
DR   HOGENOM; CLU_004253_15_1_1; -.
DR   InParanoid; Q8WVZ9; -.
DR   OMA; LPNDNIM; -.
DR   OrthoDB; 292881at2759; -.
DR   PhylomeDB; Q8WVZ9; -.
DR   TreeFam; TF332672; -.
DR   PathwayCommons; Q8WVZ9; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q8WVZ9; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 84078; 5 hits in 1089 CRISPR screens.
DR   ChiTaRS; KBTBD7; human.
DR   GeneWiki; KBTBD7; -.
DR   GenomeRNAi; 84078; -.
DR   Pharos; Q8WVZ9; Tdark.
DR   PRO; PR:Q8WVZ9; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q8WVZ9; protein.
DR   Bgee; ENSG00000120696; Expressed in neocortex and 215 other tissues.
DR   Genevisible; Q8WVZ9; HS.
DR   GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IEA:UniProtKB-KW.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0035020; P:regulation of Rac protein signal transduction; IMP:UniProtKB.
DR   Gene3D; 2.120.10.80; -; 1.
DR   Gene3D; 3.30.710.10; -; 1.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR017096; BTB-kelch_protein.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR015915; Kelch-typ_b-propeller.
DR   InterPro; IPR006652; Kelch_1.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF01344; Kelch_1; 1.
DR   PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00612; Kelch; 2.
DR   SUPFAM; SSF117281; SSF117281; 1.
DR   SUPFAM; SSF54695; SSF54695; 1.
DR   PROSITE; PS50097; BTB; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; Kelch repeat; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Signal transduction inhibitor; Ubl conjugation pathway.
FT   CHAIN           1..684
FT                   /note="Kelch repeat and BTB domain-containing protein 7"
FT                   /id="PRO_0000119085"
FT   DOMAIN          63..138
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   REPEAT          386..435
FT                   /note="Kelch 1"
FT   REPEAT          436..484
FT                   /note="Kelch 2"
FT   REPEAT          486..523
FT                   /note="Kelch 3"
FT   REPEAT          524..564
FT                   /note="Kelch 4"
FT   REPEAT          567..616
FT                   /note="Kelch 5"
FT   REGION          1..27
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          630..666
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           668..671
FT                   /note="ATG8 interaction motif (AIM)"
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   COMPBIAS        630..644
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        645..666
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         29
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MUTAGEN         99
FT                   /note="M->A: Loss of interaction with CUL3. Loss of
FT                   function in TIAM1 degradation."
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   MUTAGEN         668..671
FT                   /note="WVQV->AVQA: Decreased interaction with GABARAP and
FT                   GABARAPL2. Loss of function in TIAM1 ubiquitination and
FT                   degradation. No effect on assembly of the CUL3(KBTBD6/7) E3
FT                   ubiquitin ligase complex."
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   MUTAGEN         668
FT                   /note="W->A: Decreased interaction with GABARAP and
FT                   GABARAPL2."
FT                   /evidence="ECO:0000269|PubMed:25684205"
FT   CONFLICT        361
FT                   /note="P -> S (in Ref. 2; CAB66716)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        602
FT                   /note="L -> S (in Ref. 3; BAC03641)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        622
FT                   /note="C -> Y (in Ref. 3; BAC03641)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   684 AA;  77163 MW;  B2D8B6969A1AE5E9 CRC64;
     MQSREDVPRS RRLASPRGGR RPKRISKPSV SAFFTGPEEL KDTAHSAALL AQLKSFYDAR
     LLCDVTIEVV TPGSGPGTGR LFSCNRNVLA AACPYFKSMF TGGMYESQQA SVTMHDVDAE
     SFEVLVDYCY TGRVSLSEAN VQRLYAASDM LQLEYVREAC ASFLARRLDL TNCTAILKFA
     DAFDHHKLRS QAQSYIAHNF KQLSRMGSIR EETLADLTLA QLLAVLRLDS LDIESERTVC
     HVAVQWLEAA AKERGPSAAE VFKCVRWMHF TEEDQDYLEG LLTKPIVKKY CLDVIEGALQ
     MRYGDLLYKS LVPVPNSSSS SSSSNSLVSA AENPPQRLGM CAKEMVIFFG HPRDPFLCYD
     PYSGDIYTMP SPLTSFAHTK TVTSSAVCVS PDHDIYLAAQ PRKDLWVYKP AQNSWQQLAD
     RLLCREGMDV AYLNGYIYIL GGRDPITGVK LKEVECYSVQ RNQWALVAPV PHSFYSFELI
     VVQNYLYAVN SKRMLCYDPS HNMWLNCASL KRSDFQEACV FNDEIYCICD IPVMKVYNPA
     RGEWRRISNI PLDSETHNYQ IVNHDQKLLL ITSTTPQWKK NRVTVYEYDT REDQWINIGT
     MLGLLQFDSG FICLCARVYP SCLEPGQSFI TEEDDARSES STEWDLDGFS ELDSESGSSS
     SFSDDEVWVQ VAPQRNAQDQ QGSL
//
ID   LCOR_HUMAN              Reviewed;         433 AA.
AC   Q96JN0; D3DR47; Q5VW16; Q7Z723; Q86T32; Q86T33; Q8N3L6; Q8N655; Q9H945;
AC   Q9Y457;
DT   30-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   23-FEB-2022, entry version 152.
DE   RecName: Full=Ligand-dependent corepressor;
DE            Short=LCoR;
DE   AltName: Full=Mblk1-related protein 2;
GN   Name=LCOR {ECO:0000312|HGNC:HGNC:29503};
GN   Synonyms=C10orf12 {ECO:0000312|HGNC:HGNC:29503},
GN   KIAA1795 {ECO:0000312|EMBL:BAB47424.1}, MLR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND PARTIAL NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Bone marrow, Brain, and Skeletal muscle;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND PARTIAL NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   FUNCTION, INTERACTION WITH CTBP1; ESR1; ESR2; HDAC3 AND HDAC6, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF 56-LEU-LEU-57, AND TISSUE SPECIFICITY.
RX   PubMed=12535528; DOI=10.1016/s1097-2765(03)00014-5;
RA   Fernandes I., Bastien Y., Wai T., Nygard K., Lin R., Cormier O., Lee H.S.,
RA   Eng F., Bertos N.R., Pelletier N., Mader S., Han V.K.M., Yang X.-J.,
RA   White J.H.;
RT   "Ligand-dependent nuclear receptor corepressor LCoR functions by histone
RT   deacetylase-dependent and -independent mechanisms.";
RL   Mol. Cell 11:139-150(2003).
RN   [8]
RP   IDENTIFICATION IN A COREPRESSOR COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=12700765; DOI=10.1038/nature01550;
RA   Shi Y., Sawada J., Sui G., Affar E.B., Whetstine J.R., Lan F., Ogawa H.,
RA   Luke M.P.-S., Nakatani Y., Shi Y.;
RT   "Coordinated histone modifications mediated by a CtBP co-repressor
RT   complex.";
RL   Nature 422:735-738(2003).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-583 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1077 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63 AND SER-249,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-792; SER-1048 AND SER-1274
RP   (ISOFORM 3), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-583 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42 AND SER-249,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-583 AND SER-605 (ISOFORM 3),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-1214 AND LYS-1219 (ISOFORM 3),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-254 AND LYS-414, SUMOYLATION
RP   [LARGE SCALE ANALYSIS] AT LYS-345; LYS-391; LYS-543 AND LYS-976 (ISOFORM
RP   3), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [18]
RP   STRUCTURE BY NMR OF 343-405.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the HTH domain of human LCOR protein.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: May act as transcription activator that binds DNA elements
CC       with the sequence 5'-CCCTATCGATCGATCTCTACCT-3' (By similarity).
CC       Repressor of ligand-dependent transcription activation by target
CC       nuclear receptors. Repressor of ligand-dependent transcription
CC       activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR.
CC       {ECO:0000250, ECO:0000269|PubMed:12535528}.
CC   -!- SUBUNIT: Interacts with ESR1 and ESR2 in the presence of estradiol.
CC       Interacts with CTBP1, HDAC3 and HDAC6. Component of a large corepressor
CC       complex that contains about 20 proteins, including CTBP1, CTBP2, HDAC1
CC       and HDAC2. {ECO:0000269|PubMed:12535528, ECO:0000269|PubMed:12700765}.
CC   -!- INTERACTION:
CC       Q96JN0; Q13363: CTBP1; NbExp=7; IntAct=EBI-746045, EBI-908846;
CC       Q96JN0; P56545: CTBP2; NbExp=5; IntAct=EBI-746045, EBI-741533;
CC       Q96JN0; P56545-3: CTBP2; NbExp=3; IntAct=EBI-746045, EBI-10171902;
CC       Q96JN0; A2ABF9: EHMT2; NbExp=3; IntAct=EBI-746045, EBI-10174566;
CC       Q96JN0; Q08379: GOLGA2; NbExp=3; IntAct=EBI-746045, EBI-618309;
CC       Q96JN0; Q13077: TRAF1; NbExp=3; IntAct=EBI-746045, EBI-359224;
CC       Q96JN0-2; Q96CA5: BIRC7; NbExp=3; IntAct=EBI-10961483, EBI-517623;
CC       Q96JN0-2; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-10961483, EBI-739624;
CC       Q96JN0-2; Q92753-1: RORB; NbExp=3; IntAct=EBI-10961483, EBI-18560266;
CC       Q96JN0-2; Q13077: TRAF1; NbExp=3; IntAct=EBI-10961483, EBI-359224;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00320,
CC       ECO:0000269|PubMed:12535528}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96JN0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96JN0-2; Sequence=VSP_018585, VSP_018586;
CC       Name=3;
CC         IsoId=Q96JN0-3; Sequence=VSP_058760;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:12535528}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH24315.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14396.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB47424.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB058698; BAB47424.1; ALT_INIT; mRNA.
DR   EMBL; AL834245; CAD38921.2; -; mRNA.
DR   EMBL; AL832106; CAD91159.1; -; mRNA.
DR   EMBL; AL832044; CAD91160.1; -; mRNA.
DR   EMBL; AL049938; CAB43214.1; -; mRNA.
DR   EMBL; AL442123; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49963.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49965.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49966.1; -; Genomic_DNA.
DR   EMBL; BC024315; AAH24315.1; ALT_INIT; mRNA.
DR   EMBL; BC053359; AAH53359.1; -; mRNA.
DR   EMBL; AK023084; BAB14396.1; ALT_INIT; mRNA.
DR   CCDS; CCDS53561.1; -. [Q96JN0-2]
DR   CCDS; CCDS7451.1; -. [Q96JN0-1]
DR   CCDS; CCDS86132.1; -. [Q96JN0-3]
DR   PIR; T08672; T08672.
DR   RefSeq; NP_001164236.1; NM_001170765.1. [Q96JN0-1]
DR   RefSeq; NP_001164237.1; NM_001170766.1. [Q96JN0-2]
DR   RefSeq; NP_001333445.1; NM_001346516.1. [Q96JN0-3]
DR   RefSeq; NP_115816.2; NM_032440.3. [Q96JN0-1]
DR   RefSeq; XP_016872275.1; XM_017016786.1.
DR   RefSeq; XP_016872276.1; XM_017016787.1.
DR   RefSeq; XP_016872277.1; XM_017016788.1.
DR   PDB; 2COB; NMR; -; A=343-405.
DR   PDB; 6V3X; X-ray; 1.70 A; B=98-103.
DR   PDB; 6V3Y; X-ray; 1.63 A; B=5-9.
DR   PDBsum; 2COB; -.
DR   PDBsum; 6V3X; -.
DR   PDBsum; 6V3Y; -.
DR   SMR; Q96JN0; -.
DR   BioGRID; 117579; 53.
DR   BioGRID; 124093; 79.
DR   CORUM; Q96JN0; -.
DR   ELM; Q96JN0; -.
DR   IntAct; Q96JN0; 86.
DR   MINT; Q96JN0; -.
DR   STRING; 9606.ENSP00000360138; -.
DR   GlyGen; Q96JN0; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96JN0; -.
DR   PhosphoSitePlus; Q96JN0; -.
DR   BioMuta; LCOR; -.
DR   DMDM; 68565212; -.
DR   EPD; Q96JN0; -.
DR   jPOST; Q96JN0; -.
DR   MassIVE; Q96JN0; -.
DR   MaxQB; Q96JN0; -.
DR   PaxDb; Q96JN0; -.
DR   PeptideAtlas; Q96JN0; -.
DR   PRIDE; Q96JN0; -.
DR   ProteomicsDB; 72131; -.
DR   ProteomicsDB; 76989; -. [Q96JN0-1]
DR   ProteomicsDB; 76990; -. [Q96JN0-2]
DR   Antibodypedia; 30781; 223 antibodies from 25 providers.
DR   DNASU; 26148; -.
DR   DNASU; 84458; -.
DR   Ensembl; ENST00000356016; ENSP00000348298; ENSG00000196233.
DR   Ensembl; ENST00000371097; ENSP00000360138; ENSG00000196233.
DR   Ensembl; ENST00000371103; ENSP00000360144; ENSG00000196233.
DR   Ensembl; ENST00000421806; ENSP00000490116; ENSG00000196233. [Q96JN0-3]
DR   Ensembl; ENST00000540664; ENSP00000443431; ENSG00000196233. [Q96JN0-2]
DR   Ensembl; ENST00000675471; ENSP00000502633; ENSG00000196233.
DR   Ensembl; ENST00000675537; ENSP00000501560; ENSG00000196233.
DR   Ensembl; ENST00000675971; ENSP00000501639; ENSG00000196233.
DR   GeneID; 84458; -.
DR   KEGG; hsa:84458; -.
DR   MANE-Select; ENST00000421806.4; ENSP00000490116.2; NM_001346516.2; NP_001333445.1. [Q96JN0-3]
DR   UCSC; uc001kmr.4; human. [Q96JN0-1]
DR   CTD; 84458; -.
DR   DisGeNET; 84458; -.
DR   GeneCards; LCOR; -.
DR   HGNC; HGNC:29503; LCOR.
DR   HPA; ENSG00000196233; Low tissue specificity.
DR   MIM; 607698; gene.
DR   neXtProt; NX_Q96JN0; -.
DR   OpenTargets; ENSG00000196233; -.
DR   PharmGKB; PA145148487; -.
DR   VEuPathDB; HostDB:ENSG00000196233; -.
DR   eggNOG; KOG4565; Eukaryota.
DR   GeneTree; ENSGT00940000154965; -.
DR   HOGENOM; CLU_040042_0_0_1; -.
DR   InParanoid; Q96JN0; -.
DR   OMA; IYVQSKM; -.
DR   OrthoDB; 134164at2759; -.
DR   PhylomeDB; Q96JN0; -.
DR   TreeFam; TF319589; -.
DR   PathwayCommons; Q96JN0; -.
DR   SignaLink; Q96JN0; -.
DR   BioGRID-ORCS; 84458; 18 hits in 1073 CRISPR screens.
DR   EvolutionaryTrace; Q96JN0; -.
DR   GeneWiki; LCOR; -.
DR   GenomeRNAi; 84458; -.
DR   Pharos; Q96JN0; Tbio.
DR   PRO; PR:Q96JN0; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q96JN0; protein.
DR   Bgee; ENSG00000196233; Expressed in secondary oocyte and 227 other tissues.
DR   ExpressionAtlas; Q96JN0; baseline and differential.
DR   Genevisible; Q96JN0; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:ARUK-UCL.
DR   GO; GO:1990226; F:histone methyltransferase binding; IPI:ARUK-UCL.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:ARUK-UCL.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:ARUK-UCL.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:ARUK-UCL.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:ARUK-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR007889; HTH_Psq.
DR   Pfam; PF05225; HTH_psq; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS50960; HTH_PSQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; DNA-binding;
KW   Isopeptide bond; Methylation; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..433
FT                   /note="Ligand-dependent corepressor"
FT                   /id="PRO_0000236807"
FT   DOMAIN          340..392
FT                   /note="HTH psq-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00320"
FT   DNA_BIND        368..388
FT                   /note="H-T-H motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00320"
FT   REGION          1..51
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          64..147
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          299..348
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          393..412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           53..57
FT                   /note="Interaction with nuclear receptors"
FT   MOTIF           339..345
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        66..114
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        313..333
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        334..348
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        254
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        414
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         112..433
FT                   /note="RPGRPSQYRPDGLRSGDGVPPRSLQDGTREGFGHSTSLKVPLARSLQISEEL
FT                   LSRNQLSTAASLGPSGLQNHGQHLILSREASWAKPHYEFNLSRMKFRGNGALSNISDLP
FT                   FLAENSAFPKMALQAKQDGKKDVSHSSPVDLKIPQVRGMDLSWESRTGDQYSYSSLVMG
FT                   SQTESALSKKLRAILPKQSRKSMLDAGPDSWGSDAEQSTSGQPYPTSDQEGDPGSKQPR
FT                   KKRGRYRQYNSEILEEAISVVMSGKMSVSKAQSIYGIPHSTLEYKVKERLGTLKNPPKK
FT                   KMKLMRSEGPDVSVKIELDPQGEAAQSANESKNE -> ENSTEAKAVDSNNQSKSPLEK
FT                   FMVKLCTHHQKQFIRVLNDLYTESQPGTEDLQPSDSGAMDVSTCNAGCAQLSTKHKEKD
FT                   ALCLDMKSSASVDLFVDSSDSHSPLHLTEQTPKKPPPEINPVDGRENALTVVQKDSSEL
FT                   PTTKSNSINSSSVDSFTPGYLTASNCSSVNFHHIPKILEGQTTGQEQDTNVNICEDGKD
FT                   HMQSSALVESLITVKMAAENSEEGNTCIIPQRNLFKALSEEAWNSGFMGNSSRTADKEN
FT                   TLQCPKTPLRQDLEANEQDARPKQENHLHSLGRNKVGYHLHPSDKGQFDHSKDGWLGPG
FT                   PMPAVHKAANGHSRTKMISTSIKTARKSKRASGLRINDYDNQCDVVYISQPITECHFEN
FT                   QKSILSSRKTARKSTRGYFFNGDCCELPTVRTLARNLHSQEKASCSALASEAVFTPKQT
FT                   LTIPAPRHTVDVQLPREDNPEEPSKEITSHEEGGGDVSPRKEPQEPEVCPTKIKPNLSS
FT                   SPRSEETTASSLVWPLPAHLPEEDLPEGGSTVSAPTASGMSSPEHNQPPVALLDTEEMS
FT                   VPQDCHLLPSTESFSGGVSEDVISRPHSPPEIVSREESPQCSENQSSPMGLEPPMSLGK
FT                   AEDNQSISAEVESGDTQELNVDPLLKESSTFTDENPSETEESEAAGGIGKLEGEDGDVK
FT                   CLSEKDTYDTSIDSLEENLDKKKKGKKFPEASDRCLRSQLSDSSSADRCLRNQSSDSSS
FT                   ACLEIKVPKNPSAKRSKKEGHPGGTTPKGLLPDSFHTETLEDTEKPSVNERPSEKDAEQ
FT                   EGEGGGIITRQTLKNMLDKEVKELRGEIFPSRDPITTAGQPLPGERLEIYVQSKMDEKN
FT                   AHIPSESIACKRDPEQAKEEPGHIPTQHVEEAVNEVDNENTQQKDDESDAPCSSLGLSS
FT                   SGSGDAARAPKSVPRPKRLTSSTYNLRHAHSLGSLDASKVTSEKEAAQVNPIMPKENGA
FT                   SESGDPLDEDDVDTVVDEQPKFMEWCAEEENQELIANFNAQYMKVQKGWIQLEKEGQPT
FT                   PRARNKSDKLKEIWKSKKRSRKCRSSLESQKCSPVQMLFMTNFKLSNVCKWFLETTETR
FT                   SLVIVKKLNTRLPGDVPPVKHPLQKYAPSSLYPSSLQAERLKKHLKKFPGATPAKNNWK
FT                   MQKLWAKFRENPDQVEPEDGSDVSPGPNSEDSIEEVKEDRNSHPPANLPTPASTRILRK
FT                   YSNIRGKLRAQQRLIKNEKMECPDALAVESKPSRKSVCINPLMSPKLALQVDADGFPVK
FT                   PKSTEGMKGRKGKQVSEILPKAEVQSKRKRTEGSSPPDSKNKGPTVKASKEKHADGATK
FT                   TPAAKRPAARDRSSQPPKKTSLKENKVKIPKKSAGKSCPPSRKEKENTNKRPSQSIASE
FT                   TLTKPAKQKGAGESSSRPQKATNRKQSSGKTRARPSTKTPESSAAQRKRKLKAKLDCSH
FT                   SKRRRLDAK (in isoform 3)"
FT                   /id="VSP_058760"
FT   VAR_SEQ         405..406
FT                   /note="RS -> SG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018585"
FT   VAR_SEQ         407..433
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018586"
FT   MUTAGEN         56..57
FT                   /note="LL->AA: Loss of estradiol-dependent interaction with
FT                   ESR1 and ESR2."
FT                   /evidence="ECO:0000269|PubMed:12535528"
FT   CONFLICT        6
FT                   /note="Q -> P (in Ref. 2; CAD91159)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        321
FT                   /note="S -> P (in Ref. 2; CAD38921)"
FT                   /evidence="ECO:0000305"
FT   HELIX           351..362
FT                   /evidence="ECO:0007829|PDB:2COB"
FT   HELIX           368..375
FT                   /evidence="ECO:0007829|PDB:2COB"
FT   HELIX           379..389
FT                   /evidence="ECO:0007829|PDB:2COB"
FT   TURN            390..393
FT                   /evidence="ECO:0007829|PDB:2COB"
FT   MOD_RES         Q96JN0-3:583
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         Q96JN0-3:605
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         Q96JN0-3:792
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         Q96JN0-3:1048
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         Q96JN0-3:1077
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         Q96JN0-3:1214
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         Q96JN0-3:1219
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         Q96JN0-3:1274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   CROSSLNK        Q96JN0-3:345
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        Q96JN0-3:391
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        Q96JN0-3:543
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        Q96JN0-3:976
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CONFLICT        Q96JN0-3:922
FT                   /note="E -> G (in Ref. 6; BAB14396)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q96JN0-3:1209
FT                   /note="D -> G (in Ref. 6; BAB14396)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   433 AA;  47007 MW;  5F934FE687417740 CRC64;
     MQRMIQQFAA EYTSKNSSTQ DPSQPNSTKN QSLPKASPVT TSPTAATTQN PVLSKLLMAD
     QDSPLDLTVR KSQSEPSEQD GVLDLSTKKS PCAGSTSLSH SPGCSSTQGN GRPGRPSQYR
     PDGLRSGDGV PPRSLQDGTR EGFGHSTSLK VPLARSLQIS EELLSRNQLS TAASLGPSGL
     QNHGQHLILS REASWAKPHY EFNLSRMKFR GNGALSNISD LPFLAENSAF PKMALQAKQD
     GKKDVSHSSP VDLKIPQVRG MDLSWESRTG DQYSYSSLVM GSQTESALSK KLRAILPKQS
     RKSMLDAGPD SWGSDAEQST SGQPYPTSDQ EGDPGSKQPR KKRGRYRQYN SEILEEAISV
     VMSGKMSVSK AQSIYGIPHS TLEYKVKERL GTLKNPPKKK MKLMRSEGPD VSVKIELDPQ
     GEAAQSANES KNE
//
ID   UBP38_HUMAN             Reviewed;        1042 AA.
AC   Q8NB14; B3KX93; Q3ZCV1; Q8NDF5; Q96DK6; Q96PZ6; Q9BY55;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   10-OCT-2003, sequence version 2.
DT   23-FEB-2022, entry version 153.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 38;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 38;
DE   AltName: Full=HP43.8KD;
DE   AltName: Full=Ubiquitin thioesterase 38;
DE   AltName: Full=Ubiquitin-specific-processing protease 38;
GN   Name=USP38; Synonyms=KIAA1891;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Chondrocyte, and Gastric mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 263-1042 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=11572484; DOI=10.1093/dnares/8.4.179;
RA   Nagase T., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XXI. The
RT   complete sequences of 60 new cDNA clones from brain which code for large
RT   proteins.";
RL   DNA Res. 8:179-187(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 633-1042 (ISOFORM 1).
RC   TISSUE=Adrenal gland;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [8]
RP   TISSUE SPECIFICITY, AND ENZYME ACTIVITY.
RX   PubMed=14715245; DOI=10.1016/j.bbrc.2003.12.050;
RA   Quesada V., Diaz-Perales A., Gutierrez-Fernandez A., Garabaya C., Cal S.,
RA   Lopez-Otin C.;
RT   "Cloning and enzymatic analysis of 22 novel human ubiquitin-specific
RT   proteases.";
RL   Biochem. Biophys. Res. Commun. 314:54-62(2004).
RN   [9]
RP   FUNCTION, AND LINKAGE SPECIFICITY.
RX   PubMed=22689415; DOI=10.1002/cbic.201200261;
RA   Iphofer A., Kummer A., Nimtz M., Ritter A., Arnold T., Frank R.,
RA   van den Heuvel J., Kessler B.M., Jansch L., Franke R.;
RT   "Profiling ubiquitin linkage specificities of deubiquitinating enzymes with
RT   branched ubiquitin isopeptide probes.";
RL   ChemBioChem 13:1416-1420(2012).
CC   -!- FUNCTION: Deubiquitinating enzyme exhibiting a preference towards 'Lys-
CC       63'-linked ubiquitin chains. {ECO:0000269|PubMed:22689415}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:14715245};
CC   -!- INTERACTION:
CC       Q8NB14; Q92993: KAT5; NbExp=3; IntAct=EBI-2512509, EBI-399080;
CC       Q8NB14; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-2512509, EBI-11742507;
CC       Q8NB14; P17252: PRKCA; NbExp=3; IntAct=EBI-2512509, EBI-1383528;
CC       Q8NB14; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-2512509, EBI-9090795;
CC       Q8NB14; P61981: YWHAG; NbExp=3; IntAct=EBI-2512509, EBI-359832;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8NB14-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NB14-2; Sequence=VSP_054486;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle. Expressed in
CC       adrenal gland. {ECO:0000269|PubMed:11572484,
CC       ECO:0000269|PubMed:14715245}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK26248.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB71627.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAC03730.1; Type=Miscellaneous discrepancy; Note=The absence of the residues from Tyr-840 to Ser-871 is not the result of an alternative splicing.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK057992; BAB71627.1; ALT_INIT; mRNA.
DR   EMBL; AK091712; BAC03730.1; ALT_SEQ; mRNA.
DR   EMBL; AK126943; BAG54405.1; -; mRNA.
DR   EMBL; AL833976; CAD38820.1; -; mRNA.
DR   EMBL; AC099549; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116175; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471056; EAX05075.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX05076.1; -; Genomic_DNA.
DR   EMBL; BC039115; AAH39115.1; -; mRNA.
DR   EMBL; BC068975; AAH68975.1; -; mRNA.
DR   EMBL; AB067478; BAB67784.1; -; mRNA.
DR   EMBL; AF211481; AAK26248.1; ALT_INIT; mRNA.
DR   CCDS; CCDS3758.1; -. [Q8NB14-1]
DR   CCDS; CCDS77964.1; -. [Q8NB14-2]
DR   RefSeq; NP_001277254.1; NM_001290325.1. [Q8NB14-2]
DR   RefSeq; NP_001277255.1; NM_001290326.1.
DR   RefSeq; NP_115946.2; NM_032557.6. [Q8NB14-1]
DR   PDB; 4RXX; X-ray; 2.06 A; A=1-424.
DR   PDBsum; 4RXX; -.
DR   SMR; Q8NB14; -.
DR   BioGRID; 124165; 28.
DR   IntAct; Q8NB14; 15.
DR   MINT; Q8NB14; -.
DR   STRING; 9606.ENSP00000303434; -.
DR   MEROPS; C19.056; -.
DR   iPTMnet; Q8NB14; -.
DR   PhosphoSitePlus; Q8NB14; -.
DR   BioMuta; USP38; -.
DR   EPD; Q8NB14; -.
DR   jPOST; Q8NB14; -.
DR   MassIVE; Q8NB14; -.
DR   MaxQB; Q8NB14; -.
DR   PaxDb; Q8NB14; -.
DR   PeptideAtlas; Q8NB14; -.
DR   PRIDE; Q8NB14; -.
DR   ProteomicsDB; 61916; -.
DR   ProteomicsDB; 72715; -. [Q8NB14-1]
DR   Antibodypedia; 27336; 134 antibodies from 26 providers.
DR   DNASU; 84640; -.
DR   Ensembl; ENST00000307017; ENSP00000303434; ENSG00000170185.
DR   Ensembl; ENST00000510377; ENSP00000427647; ENSG00000170185. [Q8NB14-2]
DR   GeneID; 84640; -.
DR   KEGG; hsa:84640; -.
DR   MANE-Select; ENST00000307017.9; ENSP00000303434.4; NM_032557.6; NP_115946.2.
DR   UCSC; uc003ija.5; human. [Q8NB14-1]
DR   CTD; 84640; -.
DR   DisGeNET; 84640; -.
DR   GeneCards; USP38; -.
DR   HGNC; HGNC:20067; USP38.
DR   HPA; ENSG00000170185; Tissue enhanced (skeletal).
DR   MIM; 618322; gene.
DR   neXtProt; NX_Q8NB14; -.
DR   OpenTargets; ENSG00000170185; -.
DR   PharmGKB; PA134880611; -.
DR   VEuPathDB; HostDB:ENSG00000170185; -.
DR   eggNOG; KOG1864; Eukaryota.
DR   GeneTree; ENSGT00940000158403; -.
DR   HOGENOM; CLU_010910_0_0_1; -.
DR   InParanoid; Q8NB14; -.
DR   OMA; KQFKYDQ; -.
DR   OrthoDB; 802596at2759; -.
DR   PhylomeDB; Q8NB14; -.
DR   TreeFam; TF324529; -.
DR   PathwayCommons; Q8NB14; -.
DR   SignaLink; Q8NB14; -.
DR   BioGRID-ORCS; 84640; 9 hits in 1051 CRISPR screens.
DR   ChiTaRS; USP38; human.
DR   GenomeRNAi; 84640; -.
DR   Pharos; Q8NB14; Tbio.
DR   PRO; PR:Q8NB14; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q8NB14; protein.
DR   Bgee; ENSG00000170185; Expressed in amniotic fluid and 224 other tissues.
DR   ExpressionAtlas; Q8NB14; baseline and differential.
DR   Genevisible; Q8NB14; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0004843; F:thiol-dependent deubiquitinase; IDA:FlyBase.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:FlyBase.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   CDD; cd02664; Peptidase_C19H; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR033840; USP38.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00443; UCH; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Hydrolase; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..1042
FT                   /note="Ubiquitin carboxyl-terminal hydrolase 38"
FT                   /id="PRO_0000080668"
FT   DOMAIN          445..949
FT                   /note="USP"
FT   ACT_SITE        454
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   ACT_SITE        857
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   VAR_SEQ         990..1042
FT                   /note="EQELNARARALQAASASCSFRPNGFDDNDPPGSCGPTGGGGGGGFNTVGRLV
FT                   F -> VSWKYKLYLLKILNN (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054486"
FT   CONFLICT        646
FT                   /note="M -> V (in Ref. 1; BAC03730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        919
FT                   /note="S -> G (in Ref. 1; BAB71627)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2..9
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           15..28
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           35..51
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           55..71
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           73..79
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           82..91
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           101..114
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           120..136
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           141..153
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           155..157
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           162..175
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           185..208
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           210..212
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           213..224
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           235..240
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           246..258
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           264..276
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           286..299
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           303..319
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           327..340
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           346..351
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           355..362
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           368..387
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           392..402
FT                   /evidence="ECO:0007829|PDB:4RXX"
FT   HELIX           410..416
FT                   /evidence="ECO:0007829|PDB:4RXX"
SQ   SEQUENCE   1042 AA;  116546 MW;  D888D4F44C6E7251 CRC64;
     MDKILEGLVS SSHPLPLKRV IVRKVVESAE HWLDEAQCEA MFDLTTRLIL EGQDPFQRQV
     GHQVLEAYAR YHRPEFESFF NKTFVLGLLH QGYHSLDRKD VAILDYIHNG LKLIMSCPSV
     LDLFSLLQVE VLRMVCERPE PQLCARLSDL LTDFVQCIPK GKLSITFCQQ LVRTIGHFQC
     VSTQERELRE YVSQVTKVSN LLQNIWKAEP ATLLPSLQEV FASISSTDAS FEPSVALASL
     VQHIPLQMIT VLIRSLTTDP NVKDASMTQA LCRMIDWLSW PLAQHVDTWV IALLKGLAAV
     QKFTILIDVT LLKIELVFNR LWFPLVRPGA LAVLSHMLLS FQHSPEAFHL IVPHVVNLVH
     SFKNDGLPSS TAFLVQLTEL IHCMMYHYSG FPDLYEPILE AIKDFPKPSE EKIKLILNQS
     AWTSQSNSLA SCLSRLSGKS ETGKTGLINL GNTCYMNSVI QALFMATDFR RQVLSLNLNG
     CNSLMKKLQH LFAFLAHTQR EAYAPRIFFE ASRPPWFTPR SQQDCSEYLR FLLDRLHEEE
     KILKVQASHK PSEILECSET SLQEVASKAA VLTETPRTSD GEKTLIEKMF GGKLRTHIRC
     LNCRSTSQKV EAFTDLSLAF CPSSSLENMS VQDPASSPSI QDGGLMQASV PGPSEEPVVY
     NPTTAAFICD SLVNEKTIGS PPNEFYCSEN TSVPNESNKI LVNKDVPQKP GGETTPSVTD
     LLNYFLAPEI LTGDNQYYCE NCASLQNAEK TMQITEEPEY LILTLLRFSY DQKYHVRRKI
     LDNVSLPLVL ELPVKRITSF SSLSESWSVD VDFTDLSENL AKKLKPSGTD EASCTKLVPY
     LLSSVVVHSG ISSESGHYYS YARNITSTDS SYQMYHQSEA LALASSQSHL LGRDSPSAVF
     EQDLENKEMS KEWFLFNDSR VTFTSFQSVQ KITSRFPKDT AYVLLYKKQH STNGLSGNNP
     TSGLWINGDP PLQKELMDAI TKDNKLYLQE QELNARARAL QAASASCSFR PNGFDDNDPP
     GSCGPTGGGG GGGFNTVGRL VF
//
ID   PIGM_HUMAN              Reviewed;         423 AA.
AC   Q9H3S5;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   23-FEB-2022, entry version 150.
DE   RecName: Full=GPI mannosyltransferase 1;
DE            EC=2.4.1.-;
DE   AltName: Full=GPI mannosyltransferase I;
DE            Short=GPI-MT-I;
DE   AltName: Full=Phosphatidylinositol-glycan biosynthesis class M protein;
DE            Short=PIG-M;
GN   Name=PIGM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, AND
RP   MUTAGENESIS OF ASP-49 AND ASP-51.
RX   PubMed=11226175; DOI=10.1093/emboj/20.1.250;
RA   Maeda Y., Watanabe R., Harris C.L., Hong Y., Ohishi K., Kinoshita K.,
RA   Kinoshita T.;
RT   "PIG-M transfers the first mannose to glycosylphosphatidylinositol on the
RT   lumenal side of the ER.";
RL   EMBO J. 20:250-261(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-length
RT   human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA
RT   libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN GPIBD1.
RX   PubMed=16767100; DOI=10.1038/nm1410;
RA   Almeida A.M., Murakami Y., Layton D.M., Hillmen P., Sellick G.S., Maeda Y.,
RA   Richards S., Patterson S., Kotsianidis I., Mollica L., Crawford D.H.,
RA   Baker A., Ferguson M., Roberts I., Houlston R., Kinoshita T.,
RA   Karadimitris A.;
RT   "Hypomorphic promoter mutation in PIGM causes inherited
RT   glycosylphosphatidylinositol deficiency.";
RL   Nat. Med. 12:846-851(2006).
RN   [6]
RP   INVOLVEMENT IN GPIBD1.
RX   PubMed=31445883; DOI=10.1016/j.ymgme.2019.08.003;
RA   Pode-Shakked B., Heimer G., Vilboux T., Marek-Yagel D., Ben-Zeev B.,
RA   Davids M., Ferreira C.R., Philosoph A.M., Veber A., Pode-Shakked N.,
RA   Kenet G., Soudack M., Hoffmann C., Vernitsky H., Safaniev M., Lodzki M.,
RA   Lahad A., Shouval D.S., Levinkopf D., Weiss B., Barg A.A., Daka A.,
RA   Amariglio N., Malicdan M.C.V., Gahl W.A., Anikster Y.;
RT   "Cerebral and portal vein thrombosis, macrocephaly and atypical absence
RT   seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter
RT   mutation.";
RL   Mol. Genet. Metab. 128:151-161(2019).
CC   -!- FUNCTION: Mannosyltransferase involved in glycosylphosphatidylinositol-
CC       anchor biosynthesis. Transfers the first alpha-1,4-mannose to GlcN-
CC       acyl-PI during GPI precursor assembly. {ECO:0000269|PubMed:11226175}.
CC   -!- PATHWAY: Glycolipid biosynthesis; glycosylphosphatidylinositol-anchor
CC       biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11226175}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11226175}.
CC   -!- DISEASE: Glycosylphosphatidylinositol biosynthesis defect 1 (GPIBD1)
CC       [MIM:610293]: An autosomal recessive disorder characterized by portal
CC       vein thrombosis and portal hypertension, absence seizures,
CC       macrocephaly, splenomegaly, cytopenias and early-onset cerebral
CC       infarctions. {ECO:0000269|PubMed:16767100,
CC       ECO:0000269|PubMed:31445883}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PIGM family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB028127; BAB18567.1; -; mRNA.
DR   EMBL; AK074655; BAC11116.1; -; mRNA.
DR   EMBL; AL513302; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001803; AAH01803.1; -; mRNA.
DR   EMBL; BC019865; AAH19865.1; -; mRNA.
DR   CCDS; CCDS1192.1; -.
DR   RefSeq; NP_660150.1; NM_145167.2.
DR   BioGRID; 125010; 38.
DR   IntAct; Q9H3S5; 11.
DR   MINT; Q9H3S5; -.
DR   STRING; 9606.ENSP00000357069; -.
DR   CAZy; GT50; Glycosyltransferase Family 50.
DR   iPTMnet; Q9H3S5; -.
DR   PhosphoSitePlus; Q9H3S5; -.
DR   BioMuta; PIGM; -.
DR   DMDM; 74752622; -.
DR   EPD; Q9H3S5; -.
DR   jPOST; Q9H3S5; -.
DR   MassIVE; Q9H3S5; -.
DR   MaxQB; Q9H3S5; -.
DR   PaxDb; Q9H3S5; -.
DR   PeptideAtlas; Q9H3S5; -.
DR   PRIDE; Q9H3S5; -.
DR   ProteomicsDB; 80749; -.
DR   Antibodypedia; 34265; 75 antibodies from 17 providers.
DR   DNASU; 93183; -.
DR   Ensembl; ENST00000368090; ENSP00000357069; ENSG00000143315.
DR   GeneID; 93183; -.
DR   KEGG; hsa:93183; -.
DR   MANE-Select; ENST00000368090.5; ENSP00000357069.2; NM_145167.3; NP_660150.1.
DR   UCSC; uc001fuv.2; human.
DR   CTD; 93183; -.
DR   DisGeNET; 93183; -.
DR   GeneCards; PIGM; -.
DR   HGNC; HGNC:18858; PIGM.
DR   HPA; ENSG00000143315; Low tissue specificity.
DR   MalaCards; PIGM; -.
DR   MIM; 610273; gene.
DR   MIM; 610293; phenotype.
DR   neXtProt; NX_Q9H3S5; -.
DR   OpenTargets; ENSG00000143315; -.
DR   Orphanet; 83639; Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency.
DR   PharmGKB; PA38718; -.
DR   VEuPathDB; HostDB:ENSG00000143315; -.
DR   eggNOG; KOG3893; Eukaryota.
DR   GeneTree; ENSGT00390000017728; -.
DR   HOGENOM; CLU_024220_3_1_1; -.
DR   InParanoid; Q9H3S5; -.
DR   OMA; VTSQYFI; -.
DR   OrthoDB; 1003258at2759; -.
DR   PhylomeDB; Q9H3S5; -.
DR   TreeFam; TF314752; -.
DR   PathwayCommons; Q9H3S5; -.
DR   Reactome; R-HSA-162710; Synthesis of glycosylphosphatidylinositol (GPI).
DR   SignaLink; Q9H3S5; -.
DR   UniPathway; UPA00196; -.
DR   BioGRID-ORCS; 93183; 27 hits in 1046 CRISPR screens.
DR   ChiTaRS; PIGM; human.
DR   GenomeRNAi; 93183; -.
DR   Pharos; Q9H3S5; Tbio.
DR   PRO; PR:Q9H3S5; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9H3S5; protein.
DR   Bgee; ENSG00000143315; Expressed in nasal cavity epithelium and 215 other tissues.
DR   Genevisible; Q9H3S5; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:1990529; C:glycosylphosphatidylinositol-mannosyltransferase I complex; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0051751; F:alpha-1,4-mannosyltransferase activity; IEA:InterPro.
DR   GO; GO:0004376; F:glycolipid mannosyltransferase activity; IEA:InterPro.
DR   GO; GO:0000030; F:mannosyltransferase activity; IBA:GO_Central.
DR   GO; GO:0006506; P:GPI anchor biosynthetic process; IBA:GO_Central.
DR   InterPro; IPR007704; PIG-M.
DR   PANTHER; PTHR12886; PTHR12886; 1.
DR   Pfam; PF05007; Mannosyl_trans; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Glycosyltransferase; GPI-anchor biosynthesis;
KW   Membrane; Reference proteome; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..423
FT                   /note="GPI mannosyltransferase 1"
FT                   /id="PRO_0000246213"
FT   TOPO_DOM        1..17
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        18..38
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        39..79
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        80..100
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        101..138
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        139..161
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        162..169
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        170..190
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..225
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        226..246
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        247..287
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        288..308
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..314
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        315..337
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        338
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        339..350
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        351..357
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        358..378
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        379..384
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        385..405
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        406..423
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   VARIANT         365
FT                   /note="F -> L (in dbSNP:rs12409352)"
FT                   /id="VAR_027026"
FT   MUTAGEN         49
FT                   /note="D->A: Almost abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:11226175"
FT   MUTAGEN         51
FT                   /note="D->A: Abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:11226175"
SQ   SEQUENCE   423 AA;  49460 MW;  E17DCD8252E28EF0 CRC64;
     MGSTKHWGEW LLNLKVAPAG VFGVAFLARV ALVFYGVFQD RTLHVRYTDI DYQVFTDAAR
     FVTEGRSPYL RATYRYTPLL GWLLTPNIYL SELFGKFLFI SCDLLTAFLL YRLLLLKGLG
     RRQACGYCVF WLLNPLPMAV SSRGNADSIV ASLVLMVLYL IKKRLVACAA VFYGFAVHMK
     IYPVTYILPI TLHLLPDRDN DKSLRQFRYT FQACLYELLK RLCNRAVLLF VAVAGLTFFA
     LSFGFYYEYG WEFLEHTYFY HLTRRDIRHN FSPYFYMLYL TAESKWSFSL GIAAFLPQLI
     LLSAVSFAYY RDLVFCCFLH TSIFVTFNKV CTSQYFLWYL CLLPLVMPLV RMPWKRAVVL
     LMLWFIGQAM WLAPAYVLEF QGKNTFLFIW LAGLFFLLIN CSILIQIISH YKEEPLTERI
     KYD
//
ID   GTR12_HUMAN             Reviewed;         617 AA.
AC   Q8TD20; B3KV17; Q7Z6U3; Q96MR8;
DT   26-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   23-FEB-2022, entry version 163.
DE   RecName: Full=Solute carrier family 2, facilitated glucose transporter member 12 {ECO:0000305};
DE   AltName: Full=Glucose transporter type 12 {ECO:0000303|PubMed:11832379};
DE            Short=GLUT-12 {ECO:0000303|PubMed:11832379};
GN   Name=SLC2A12 {ECO:0000312|HGNC:HGNC:18067};
GN   Synonyms=GLUT12 {ECO:0000303|PubMed:11832379};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11832379; DOI=10.1152/ajpendo.2002.282.3.e733;
RA   Rogers S., Macheda M.L., Docherty S.E., Carty M.D., Henderson M.A.,
RA   Soeller W.C., Gibbs E.M., James D.E., Best J.D.;
RT   "Identification of a novel glucose transporter-like protein -- GLUT-12.";
RL   Am. J. Physiol. 282:E733-E738(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Meninges, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Insulin-independent facilitative glucose transporter.
CC       {ECO:0000250|UniProtKB:Q8BFW9}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-glucose(out) = D-glucose(in); Xref=Rhea:RHEA:60376,
CC         ChEBI:CHEBI:4167; Evidence={ECO:0000250|UniProtKB:Q8BFW9};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q8BFW9};
CC       Multi-pass membrane protein {ECO:0000255}. Endomembrane system
CC       {ECO:0000250|UniProtKB:Q5J316}; Multi-pass membrane protein
CC       {ECO:0000255}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:11832379}. Note=Localizes primarily perinuclear
CC       region in the absence of insulin. {ECO:0000269|PubMed:11832379}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in skeletal muscle, heart
CC       and prostate, with lower levels in brain, placenta and kidney.
CC       {ECO:0000269|PubMed:11832379}.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily. Sugar
CC       transporter (TC 2.A.1.1) family. Glucose transporter subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB71214.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY046419; AAL02327.1; -; mRNA.
DR   EMBL; AK056554; BAB71214.1; ALT_INIT; mRNA.
DR   EMBL; AK122628; BAG53629.1; -; mRNA.
DR   EMBL; AL035699; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL449363; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47994.1; -; Genomic_DNA.
DR   EMBL; BC070149; AAH70149.1; -; mRNA.
DR   CCDS; CCDS5169.1; -.
DR   RefSeq; NP_660159.1; NM_145176.2.
DR   SMR; Q8TD20; -.
DR   BioGRID; 127535; 71.
DR   IntAct; Q8TD20; 55.
DR   STRING; 9606.ENSP00000275230; -.
DR   DrugBank; DB01914; D-glucose.
DR   DrugBank; DB09341; Dextrose, unspecified form.
DR   DrugBank; DB09502; Fludeoxyglucose (18F).
DR   TCDB; 2.A.1.1.87; the major facilitator superfamily (mfs).
DR   GlyGen; Q8TD20; 4 sites.
DR   iPTMnet; Q8TD20; -.
DR   PhosphoSitePlus; Q8TD20; -.
DR   BioMuta; SLC2A12; -.
DR   DMDM; 74762615; -.
DR   EPD; Q8TD20; -.
DR   MassIVE; Q8TD20; -.
DR   PaxDb; Q8TD20; -.
DR   PeptideAtlas; Q8TD20; -.
DR   PRIDE; Q8TD20; -.
DR   ProteomicsDB; 74220; -.
DR   Antibodypedia; 32959; 118 antibodies from 24 providers.
DR   DNASU; 154091; -.
DR   Ensembl; ENST00000275230; ENSP00000275230; ENSG00000146411.
DR   GeneID; 154091; -.
DR   KEGG; hsa:154091; -.
DR   MANE-Select; ENST00000275230.6; ENSP00000275230.5; NM_145176.3; NP_660159.1.
DR   UCSC; uc003qem.2; human.
DR   CTD; 154091; -.
DR   DisGeNET; 154091; -.
DR   GeneCards; SLC2A12; -.
DR   HGNC; HGNC:18067; SLC2A12.
DR   HPA; ENSG00000146411; Tissue enhanced (choroid).
DR   MIM; 610372; gene.
DR   neXtProt; NX_Q8TD20; -.
DR   OpenTargets; ENSG00000146411; -.
DR   PharmGKB; PA38288; -.
DR   VEuPathDB; HostDB:ENSG00000146411; -.
DR   eggNOG; KOG0254; Eukaryota.
DR   GeneTree; ENSGT00940000159614; -.
DR   HOGENOM; CLU_001265_30_5_1; -.
DR   InParanoid; Q8TD20; -.
DR   OMA; SCHEQEM; -.
DR   OrthoDB; 430696at2759; -.
DR   PhylomeDB; Q8TD20; -.
DR   TreeFam; TF332408; -.
DR   PathwayCommons; Q8TD20; -.
DR   Reactome; R-HSA-189200; Cellular hexose transport.
DR   SignaLink; Q8TD20; -.
DR   BioGRID-ORCS; 154091; 4 hits in 1047 CRISPR screens.
DR   ChiTaRS; SLC2A12; human.
DR   GeneWiki; SLC2A12; -.
DR   GenomeRNAi; 154091; -.
DR   Pharos; Q8TD20; Tbio.
DR   PRO; PR:Q8TD20; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q8TD20; protein.
DR   Bgee; ENSG00000146411; Expressed in pigmented layer of retina and 182 other tissues.
DR   Genevisible; Q8TD20; HS.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0055056; F:D-glucose transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0008645; P:hexose transmembrane transport; TAS:Reactome.
DR   Gene3D; 1.20.1250.20; -; 2.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   InterPro; IPR003663; Sugar/inositol_transpt.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 2.
DR   PRINTS; PR00171; SUGRTRNSPORT.
DR   SUPFAM; SSF103473; SSF103473; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
PE   2: Evidence at transcript level;
KW   Cell membrane; Cytoplasm; Glycoprotein; Membrane; Reference proteome;
KW   Sugar transport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..617
FT                   /note="Solute carrier family 2, facilitated glucose
FT                   transporter member 12"
FT                   /id="PRO_0000292014"
FT   TOPO_DOM        1..44
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        45..65
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        66..80
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        81..101
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        102..115
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        116..136
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        137
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        138..158
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        159..172
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        173..193
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        194..197
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        198..218
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        219..278
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        279..299
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        300..317
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        318..338
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        339..345
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        346..366
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        367..466
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        467..487
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        488..498
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        499..519
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        520..528
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        529..549
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        550..617
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..29
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        8..22
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        371
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        383
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        396
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        401
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
SQ   SEQUENCE   617 AA;  66966 MW;  F176325CDED15249 CRC64;
     MVPVENTEGP SLLNQKGTAV ETEGSGSRHP PWARGCGMFT FLSSVTAAVS GLLVGYELGI
     ISGALLQIKT LLALSCHEQE MVVSSLVIGA LLASLTGGVL IDRYGRRTAI ILSSCLLGLG
     SLVLILSLSY TVLIVGRIAI GVSISLSSIA TCVYIAEIAP QHRRGLLVSL NELMIVIGIL
     SAYISNYAFA NVFHGWKYMF GLVIPLGVLQ AIAMYFLPPS PRFLVMKGQE GAASKVLGRL
     RALSDTTEEL TVIKSSLKDE YQYSFWDLFR SKDNMRTRIM IGLTLVFFVQ ITGQPNILFY
     ASTVLKSVGF QSNEAASLAS TGVGVVKVIS TIPATLLVDH VGSKTFLCIG SSVMAASLVT
     MGIVNLNIHM NFTHICRSHN SINQSLDESV IYGPGNLSTN NNTLRDHFKG ISSHSRSSLM
     PLRNDVDKRG ETTSASLLNA GLSHTEYQIV TDPGDVPAFL KWLSLASLLV YVAAFSIGLG
     PMPWLVLSEI FPGGIRGRAM ALTSSMNWGI NLLISLTFLT VTDLIGLPWV CFIYTIMSLA
     SLLFVVMFIP ETKGCSLEQI SMELAKVNYV KNNICFMSHH QEELVPKQPQ KRKPQEQLLE
     CNKLCGRGQS RQLSPET
//
ID   ASB3_HUMAN              Reviewed;         518 AA.
AC   Q9Y575; B3KPA3; D6W5B4; D6W5B5; G8JLA9; Q2TAI4; Q53TN0; Q53TN8; Q9NVZ2;
DT   10-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   23-FEB-2022, entry version 178.
DE   RecName: Full=Ankyrin repeat and SOCS box protein 3;
DE            Short=ASB-3;
GN   Name=ASB3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11111040; DOI=10.1016/s0378-1119(00)00402-9;
RA   Kile B.T., Viney E.M., Willson T.A., Brodnicki T.C., Cancilla M.R.,
RA   Herlihy A.S., Croker B.A., Baca M., Nicola N.A., Hilton D.J.,
RA   Alexander W.S.;
RT   "Cloning and characterization of the genes encoding the ankyrin repeat and
RT   SOCS box-containing proteins Asb-1, Asb-2, Asb-3 and Asb-4.";
RL   Gene 258:31-41(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Embryo, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain, Kidney, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH ELOB AND TNFRSF1B.
RX   PubMed=15899873; DOI=10.1128/mcb.25.11.4716-4726.2005;
RA   Chung A.S., Guan Y.J., Yuan Z.L., Albina J.E., Chin Y.E.;
RT   "Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and
RT   degradation of tumor necrosis factor receptor II.";
RL   Mol. Cell. Biol. 25:4716-4726(2005).
CC   -!- FUNCTION: Probable substrate-recognition component of a SCF-like ECS
CC       (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex
CC       which mediates the ubiquitination and subsequent proteasomal
CC       degradation of target proteins. Recognizes TNFRSF1B.
CC       {ECO:0000269|PubMed:15899873}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with ELOB and TNFRSF1B.
CC       {ECO:0000269|PubMed:15899873}.
CC   -!- INTERACTION:
CC       Q9Y575; Q9NP31: SH2D2A; NbExp=3; IntAct=EBI-2875625, EBI-490630;
CC       Q9Y575-3; P54253: ATXN1; NbExp=6; IntAct=EBI-14199987, EBI-930964;
CC       Q9Y575-3; P54252: ATXN3; NbExp=3; IntAct=EBI-14199987, EBI-946046;
CC       Q9Y575-3; P46379-2: BAG6; NbExp=3; IntAct=EBI-14199987, EBI-10988864;
CC       Q9Y575-3; Q9BSW2: CRACR2A; NbExp=3; IntAct=EBI-14199987, EBI-739773;
CC       Q9Y575-3; G5E9A7: DMWD; NbExp=3; IntAct=EBI-14199987, EBI-10976677;
CC       Q9Y575-3; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-14199987, EBI-744099;
CC       Q9Y575-3; P14136: GFAP; NbExp=3; IntAct=EBI-14199987, EBI-744302;
CC       Q9Y575-3; Q53GS7: GLE1; NbExp=3; IntAct=EBI-14199987, EBI-1955541;
CC       Q9Y575-3; P28799: GRN; NbExp=3; IntAct=EBI-14199987, EBI-747754;
CC       Q9Y575-3; P07686: HEXB; NbExp=3; IntAct=EBI-14199987, EBI-7133736;
CC       Q9Y575-3; P04792: HSPB1; NbExp=3; IntAct=EBI-14199987, EBI-352682;
CC       Q9Y575-3; O43464: HTRA2; NbExp=3; IntAct=EBI-14199987, EBI-517086;
CC       Q9Y575-3; P42858: HTT; NbExp=6; IntAct=EBI-14199987, EBI-466029;
CC       Q9Y575-3; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-14199987, EBI-1055254;
CC       Q9Y575-3; O60333-2: KIF1B; NbExp=3; IntAct=EBI-14199987, EBI-10975473;
CC       Q9Y575-3; O14901: KLF11; NbExp=3; IntAct=EBI-14199987, EBI-948266;
CC       Q9Y575-3; P51608: MECP2; NbExp=3; IntAct=EBI-14199987, EBI-1189067;
CC       Q9Y575-3; P19404: NDUFV2; NbExp=3; IntAct=EBI-14199987, EBI-713665;
CC       Q9Y575-3; P07196: NEFL; NbExp=3; IntAct=EBI-14199987, EBI-475646;
CC       Q9Y575-3; P29474: NOS3; NbExp=3; IntAct=EBI-14199987, EBI-1391623;
CC       Q9Y575-3; P50897: PPT1; NbExp=3; IntAct=EBI-14199987, EBI-1237011;
CC       Q9Y575-3; O60260-5: PRKN; NbExp=3; IntAct=EBI-14199987, EBI-21251460;
CC       Q9Y575-3; P60891: PRPS1; NbExp=3; IntAct=EBI-14199987, EBI-749195;
CC       Q9Y575-3; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-14199987, EBI-396669;
CC       Q9Y575-3; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-14199987, EBI-5235340;
CC       Q9Y575-3; Q13148: TARDBP; NbExp=3; IntAct=EBI-14199987, EBI-372899;
CC       Q9Y575-3; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-14199987, EBI-11139477;
CC       Q9Y575-3; Q08117-2: TLE5; NbExp=3; IntAct=EBI-14199987, EBI-11741437;
CC       Q9Y575-3; P02766: TTR; NbExp=3; IntAct=EBI-14199987, EBI-711909;
CC       Q9Y575-3; P40337-2: VHL; NbExp=3; IntAct=EBI-14199987, EBI-12157263;
CC       Q9Y575-3; O76024: WFS1; NbExp=3; IntAct=EBI-14199987, EBI-720609;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9Y575-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y575-2; Sequence=VSP_036392;
CC       Name=3;
CC         IsoId=Q9Y575-3; Sequence=VSP_044606;
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the Elongin
CC       BC complex, an adapter module in different E3 ubiquitin-protein ligase
CC       complexes. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the ankyrin SOCS box (ASB) family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI10916.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF156778; AAD41895.1; -; mRNA.
DR   EMBL; AK000985; BAA91455.1; -; mRNA.
DR   EMBL; AK001283; BAA91599.1; -; mRNA.
DR   EMBL; AK056069; BAG51615.1; -; mRNA.
DR   EMBL; AC007883; AAY24350.1; -; Genomic_DNA.
DR   EMBL; AC008064; AAX93180.1; -; Genomic_DNA.
DR   EMBL; AC008068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069157; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAX00167.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00168.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00169.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00170.1; -; Genomic_DNA.
DR   EMBL; BC006488; AAH06488.1; -; mRNA.
DR   EMBL; BC009569; AAH09569.1; -; mRNA.
DR   EMBL; BC110915; AAI10916.1; ALT_INIT; mRNA.
DR   CCDS; CCDS1846.1; -. [Q9Y575-1]
DR   CCDS; CCDS1847.1; -. [Q9Y575-2]
DR   RefSeq; NP_001157637.1; NM_001164165.1. [Q9Y575-3]
DR   RefSeq; NP_001188894.1; NM_001201965.1. [Q9Y575-2]
DR   RefSeq; NP_057199.1; NM_016115.4. [Q9Y575-1]
DR   RefSeq; NP_665862.1; NM_145863.2. [Q9Y575-2]
DR   SMR; Q9Y575; -.
DR   BioGRID; 119317; 79.
DR   BioGRID; 950460; 1.
DR   IntAct; Q9Y575; 68.
DR   MINT; Q9Y575; -.
DR   STRING; 9606.ENSP00000263634; -.
DR   iPTMnet; Q9Y575; -.
DR   PhosphoSitePlus; Q9Y575; -.
DR   SwissPalm; Q9Y575; -.
DR   BioMuta; ASB3; -.
DR   DMDM; 20532004; -.
DR   jPOST; Q9Y575; -.
DR   MassIVE; Q9Y575; -.
DR   MaxQB; Q9Y575; -.
DR   PaxDb; Q9Y575; -.
DR   PeptideAtlas; Q9Y575; -.
DR   PRIDE; Q9Y575; -.
DR   ProteomicsDB; 34171; -.
DR   ProteomicsDB; 86306; -. [Q9Y575-1]
DR   ProteomicsDB; 86307; -. [Q9Y575-2]
DR   Antibodypedia; 1141; 161 antibodies from 21 providers.
DR   DNASU; 51130; -.
DR   Ensembl; ENST00000263634; ENSP00000263634; ENSG00000115239.
DR   Ensembl; ENST00000394717; ENSP00000378206; ENSG00000115239. [Q9Y575-2]
DR   Ensembl; ENST00000406625; ENSP00000385085; ENSG00000115239.
DR   Ensembl; ENST00000406687; ENSP00000384728; ENSG00000115239. [Q9Y575-2]
DR   GeneID; 100302652; -.
DR   GeneID; 51130; -.
DR   KEGG; hsa:100302652; -.
DR   KEGG; hsa:51130; -.
DR   MANE-Select; ENST00000263634.8; ENSP00000263634.2; NM_016115.5; NP_057199.1.
DR   UCSC; uc002rxg.3; human. [Q9Y575-1]
DR   CTD; 100302652; -.
DR   CTD; 51130; -.
DR   DisGeNET; 100302652; -.
DR   DisGeNET; 51130; -.
DR   GeneCards; ASB3; -.
DR   HGNC; HGNC:16013; ASB3.
DR   HPA; ENSG00000115239; Low tissue specificity.
DR   MIM; 605760; gene.
DR   neXtProt; NX_Q9Y575; -.
DR   OpenTargets; ENSG00000115239; -.
DR   PharmGKB; PA25031; -.
DR   VEuPathDB; HostDB:ENSG00000115239; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   GeneTree; ENSGT00940000159080; -.
DR   HOGENOM; CLU_000134_3_0_1; -.
DR   InParanoid; Q9Y575; -.
DR   OMA; MCMVFQK; -.
DR   PhylomeDB; Q9Y575; -.
DR   TreeFam; TF315127; -.
DR   PathwayCommons; Q9Y575; -.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q9Y575; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 100302652; 7 hits in 944 CRISPR screens.
DR   BioGRID-ORCS; 51130; 24 hits in 1010 CRISPR screens.
DR   ChiTaRS; ASB3; human.
DR   GeneWiki; ASB3; -.
DR   Pharos; Q9Y575; Tbio.
DR   PRO; PR:Q9Y575; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9Y575; protein.
DR   Bgee; ENSG00000115239; Expressed in corpus callosum and 115 other tissues.
DR   ExpressionAtlas; Q9Y575; baseline and differential.
DR   Genevisible; Q9Y575; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030315; C:T-tubule; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0036371; P:protein localization to T-tubule; IBA:GO_Central.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; IBA:GO_Central.
DR   CDD; cd03722; SOCS_ASB3; 1.
DR   Gene3D; 1.25.40.20; -; 2.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR037329; ASB3_SOCS.
DR   InterPro; IPR001496; SOCS_box.
DR   InterPro; IPR036036; SOCS_box-like_dom_sf.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF13606; Ank_3; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 10.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF158235; SSF158235; 1.
DR   SUPFAM; SSF48403; SSF48403; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 6.
DR   PROSITE; PS50225; SOCS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ANK repeat; Reference proteome; Repeat;
KW   Ubl conjugation pathway.
FT   CHAIN           1..518
FT                   /note="Ankyrin repeat and SOCS box protein 3"
FT                   /id="PRO_0000066926"
FT   REPEAT          9..38
FT                   /note="ANK 1"
FT   REPEAT          42..71
FT                   /note="ANK 2"
FT   REPEAT          78..107
FT                   /note="ANK 3"
FT   REPEAT          111..140
FT                   /note="ANK 4"
FT   REPEAT          145..174
FT                   /note="ANK 5"
FT   REPEAT          178..207
FT                   /note="ANK 6"
FT   REPEAT          211..240
FT                   /note="ANK 7"
FT   REPEAT          246..275
FT                   /note="ANK 8"
FT   REPEAT          279..308
FT                   /note="ANK 9"
FT   REPEAT          315..346
FT                   /note="ANK 10"
FT   REPEAT          348..373
FT                   /note="ANK 11"
FT   DOMAIN          441..504
FT                   /note="SOCS box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00194"
FT   VAR_SEQ         1..73
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_036392"
FT   VAR_SEQ         1
FT                   /note="M -> MAMMPLVLHHPERQAELGSGLRDGGGAALRPPGRLVKQM (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044606"
FT   CONFLICT        118
FT                   /note="L -> S (in Ref. 2; BAA91599)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   518 AA;  57745 MW;  E6FC2EF76DD814DF CRC64;
     MDFTEAYADT CSTVGLAARE GNVKVLRKLL KKGRSVDVAD NRGWMPIHEA AYHNSVECLQ
     MLINADSSEN YIKMKTFEGF CALHLAASQG HWKIVQILLE AGADPNATTL EETTPLFLAV
     ENGQIDVLRL LLQHGANVNG SHSMCGWNSL HQASFQENAE IIKLLLRKGA NKECQDDFGI
     TPLFVAAQYG KLESLSILIS SGANVNCQAL DKATPLFIAA QEGHTKCVEL LLSSGADPDL
     YCNEDSWQLP IHAAAQMGHT KILDLLIPLT NRACDTGLNK VSPVYSAVFG GHEDCLEILL
     RNGYSPDAQA CLVFGFSSPV CMAFQKDCEF FGIVNILLKY GAQINELHLA YCLKYEKFSI
     FRYFLRKGCS LGPWNHIYEF VNHAIKAQAK YKEWLPHLLV AGFDPLILLC NSWIDSVSID
     TLIFTLEFTN WKTLAPAVER MLSARASNAW ILQQHIATVP SLTHLCRLEI RSSLKSERLR
     SDSYISQLPL PRSLHNYLLY EDVLRMYEVP ELAAIQDG
//
ID   GP155_HUMAN             Reviewed;         870 AA.
AC   Q7Z3F1; B2RCI2; D3DPE2; Q4G0Y6; Q53SJ3; Q53TA8; Q69YG8; Q86SP9; Q8N261;
AC   Q8N639; Q8N8K3; Q96MV6;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 2.
DT   23-FEB-2022, entry version 148.
DE   RecName: Full=Integral membrane protein GPR155;
DE   AltName: Full=G-protein coupled receptor PGR22;
GN   Name=GPR155; Synonyms=PGR22;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Amygdala, and Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 533-675.
RX   PubMed=12679517; DOI=10.1073/pnas.0230374100;
RA   Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E.,
RA   Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C.,
RA   Bergmann J.E., Gaitanaris G.A.;
RT   "The G protein-coupled receptor repertoires of human and mouse.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4903-4908(2003).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB71170.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK056381; BAB71170.1; ALT_INIT; mRNA.
DR   EMBL; AK091200; BAC03609.1; -; mRNA.
DR   EMBL; AK096665; BAC04835.1; -; mRNA.
DR   EMBL; AK315125; BAG37579.1; -; mRNA.
DR   EMBL; BX537947; CAD97915.1; -; mRNA.
DR   EMBL; AL834154; CAH10683.1; -; mRNA.
DR   EMBL; AC010894; AAY14707.1; -; Genomic_DNA.
DR   EMBL; AC018470; AAY24218.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11137.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11138.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11139.1; -; Genomic_DNA.
DR   EMBL; BC028730; AAH28730.1; -; mRNA.
DR   EMBL; BC035037; AAH35037.1; -; mRNA.
DR   EMBL; AY255528; AAO85040.1; -; mRNA.
DR   CCDS; CCDS2259.1; -.
DR   RefSeq; NP_001028217.1; NM_001033045.3.
DR   RefSeq; NP_001253979.1; NM_001267050.1.
DR   RefSeq; NP_001253980.1; NM_001267051.1.
DR   RefSeq; NP_689742.4; NM_152529.6.
DR   RefSeq; XP_016858974.1; XM_017003485.1.
DR   RefSeq; XP_016858975.1; XM_017003486.1.
DR   RefSeq; XP_016858976.1; XM_017003487.1.
DR   SMR; Q7Z3F1; -.
DR   BioGRID; 127389; 3.
DR   IntAct; Q7Z3F1; 1.
DR   STRING; 9606.ENSP00000376335; -.
DR   GlyGen; Q7Z3F1; 8 sites.
DR   iPTMnet; Q7Z3F1; -.
DR   PhosphoSitePlus; Q7Z3F1; -.
DR   BioMuta; GPR155; -.
DR   DMDM; 68052330; -.
DR   EPD; Q7Z3F1; -.
DR   jPOST; Q7Z3F1; -.
DR   MassIVE; Q7Z3F1; -.
DR   MaxQB; Q7Z3F1; -.
DR   PaxDb; Q7Z3F1; -.
DR   PeptideAtlas; Q7Z3F1; -.
DR   PRIDE; Q7Z3F1; -.
DR   ProteomicsDB; 69044; -.
DR   Antibodypedia; 50637; 153 antibodies from 12 providers.
DR   DNASU; 151556; -.
DR   Ensembl; ENST00000295500; ENSP00000295500; ENSG00000163328.
DR   Ensembl; ENST00000392551; ENSP00000376334; ENSG00000163328.
DR   Ensembl; ENST00000392552; ENSP00000376335; ENSG00000163328.
DR   GeneID; 151556; -.
DR   KEGG; hsa:151556; -.
DR   MANE-Select; ENST00000392552.7; ENSP00000376335.2; NM_152529.7; NP_689742.4.
DR   UCSC; uc002uit.5; human.
DR   CTD; 151556; -.
DR   DisGeNET; 151556; -.
DR   GeneCards; GPR155; -.
DR   HGNC; HGNC:22951; GPR155.
DR   HPA; ENSG00000163328; Tissue enhanced (choroid plexus, stomach).
DR   neXtProt; NX_Q7Z3F1; -.
DR   OpenTargets; ENSG00000163328; -.
DR   PharmGKB; PA134943679; -.
DR   VEuPathDB; HostDB:ENSG00000163328; -.
DR   eggNOG; ENOG502QQ69; Eukaryota.
DR   GeneTree; ENSGT00390000004153; -.
DR   HOGENOM; CLU_018490_0_0_1; -.
DR   InParanoid; Q7Z3F1; -.
DR   OMA; PHGLPEM; -.
DR   OrthoDB; 228997at2759; -.
DR   PhylomeDB; Q7Z3F1; -.
DR   TreeFam; TF324034; -.
DR   PathwayCommons; Q7Z3F1; -.
DR   SignaLink; Q7Z3F1; -.
DR   BioGRID-ORCS; 151556; 11 hits in 1036 CRISPR screens.
DR   ChiTaRS; GPR155; human.
DR   GeneWiki; GPR155; -.
DR   GenomeRNAi; 151556; -.
DR   Pharos; Q7Z3F1; Tbio.
DR   PRO; PR:Q7Z3F1; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q7Z3F1; protein.
DR   Bgee; ENSG00000163328; Expressed in dorsal root ganglion and 218 other tissues.
DR   ExpressionAtlas; Q7Z3F1; baseline and differential.
DR   Genevisible; Q7Z3F1; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0050890; P:cognition; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   CDD; cd04443; DEP_GPR155; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR000591; DEP_dom.
DR   InterPro; IPR037368; GPR155_DEP.
DR   InterPro; IPR004776; Mem_trans.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00610; DEP; 1.
DR   Pfam; PF03547; Mem_trans; 2.
DR   SMART; SM00049; DEP; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS50186; DEP; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..870
FT                   /note="Integral membrane protein GPR155"
FT                   /id="PRO_0000087551"
FT   TRANSMEM        39..59
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        80..100
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        105..125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        134..154
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        168..188
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        214..234
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        244..264
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        274..294
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        316..336
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        347..367
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        382..402
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        415..435
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        439..459
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        481..501
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        521..541
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        661..681
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        692..712
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          757..835
FT                   /note="DEP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00066"
FT   CARBOHYD        9
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        309
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        381
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        543
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        612
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CONFLICT        33
FT                   /note="D -> G (in Ref. 1; BAC03609)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        194
FT                   /note="K -> E (in Ref. 5; AAH28730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        260
FT                   /note="L -> H (in Ref. 1; BAB71170)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460
FT                   /note="W -> R (in Ref. 2; CAD97915)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        517
FT                   /note="G -> A (in Ref. 2; CAH10683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        550
FT                   /note="S -> G (in Ref. 5; AAH28730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        638
FT                   /note="C -> R (in Ref. 2; CAD97915)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        674
FT                   /note="S -> Y (in Ref. 5; AAH28730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        693
FT                   /note="Q -> R (in Ref. 2; CAH10683)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   870 AA;  96919 MW;  91A6CFC79B669ACB CRC64;
     MNSNLPAENL TIAVNMTKTL PTAVTHGFNS TNDPPSMSIT RLFPALLECF GIVLCGYIAG
     RANVITSTQA KGLGNFVSRF ALPALLFKNM VVLNFSNVDW SFLYSILIAK ASVFFIVCVL
     TLLVASPDSR FSKAGLFPIF ATQSNDFALG YPIVEALYQT TYPEYLQYIY LVAPISLMML
     NPIGFIFCEI QKWKDTQNAS QNKIKIVGLG LLRVLQNPIV FMVFIGIAFN FILDRKVPVY
     VENFLDGLGN SFSGSALFYL GLTMVGKIKR LKKSAFVVLI LLITAKLLVL PLLCREMVEL
     LDKGDSVVNH TSLSNYAFLY GVFPVAPGVA IFATQFNMEV EIITSGMVIS TFVSAPIMYV
     SAWLLTFPTM DPKPLAYAIQ NVSFDISIVS LISLIWSLAI LLLSKKYKQL PHMLTTNLLI
     AQSIVCAGMM IWNFVKEKNF VGQILVFVLL YSSLYSTYLW TGLLAISLFL LKKRERVQIP
     VGIIIISGWG IPALLVGVLL ITGKHNGDSI DSAFFYGKEQ MITTAVTLFC SILIAGISLM
     CMNQTAQAGS YEGFDQSQSH KVVEPGNTAF EESPAPVNEP ELFTSSIPET SCCSCSMGNG
     ELHCPSIEPI ANTSTSEPVI PSFEKNNHCV SRCNSQSCIL AQEEEQYLQS GDQQLTRHVL
     LCLLLIIGLF ANLSSCLWWL FNQEPGRLYV ELQFFCAVFN FGQGFISFGI FGLDKHLIIL
     PFKRRLEFLW NNKDTAENRD SPVSEEIKMT CQQFIHYHRD LCIRNIVKER RCGAKTSAGT
     FCGCDLVSWL IEVGLASDRG EAVIYGDRLV QGGVIQHITN EYEFRDEYLF YRFLQKSPEQ
     SPPAINANTL QQERYKEIEH SSPPSHSPKT
//
ID   CRERF_HUMAN             Reviewed;         639 AA.
AC   Q8IUR6; B3DFH2; B3KW49; D3DQM2; F5GXN3; Q5HYG4; Q5HYK0; Q86YR3; Q8IZG1;
DT   11-SEP-2007, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 2.
DT   23-FEB-2022, entry version 142.
DE   RecName: Full=CREB3 regulatory factor;
DE   AltName: Full=Luman recruitment factor;
DE            Short=LRF;
GN   Name=CREBRF; Synonyms=C5orf41;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, INTERACTION WITH
RP   CREB3, SUBCELLULAR LOCATION, AND INDUCTION.
RC   TISSUE=Cervix carcinoma, and Retina;
RX   PubMed=18391022; DOI=10.1128/mcb.01439-07;
RA   Audas T.E., Li Y., Liang G., Lu R.;
RT   "A novel protein, Luman/CREB3 recruitment factor, inhibits Luman activation
RT   of the unfolded protein response.";
RL   Mol. Cell. Biol. 28:3952-3966(2008).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-483.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-602 (ISOFORM 3).
RC   TISSUE=Adipose tissue, and Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
CC   -!- FUNCTION: Acts as a negative regulator of the endoplasmic reticulum
CC       stress response or unfolded protein response (UPR). Represses the
CC       transcriptional activity of CREB3 during the UPR. Recruits CREB3 into
CC       nuclear foci. {ECO:0000269|PubMed:18391022}.
CC   -!- SUBUNIT: Interacts (via leucine-zipper domain) with CREB3 (via leucine-
CC       zipper domain); the interaction promotes CREB3 degradation.
CC       {ECO:0000269|PubMed:18391022}.
CC   -!- INTERACTION:
CC       Q8IUR6; O43889-2: CREB3; NbExp=4; IntAct=EBI-1042699, EBI-625022;
CC       Q8IUR6; O60519: CREBL2; NbExp=5; IntAct=EBI-1042699, EBI-2872455;
CC       Q8IUR6; Q14451-3: GRB7; NbExp=3; IntAct=EBI-1042699, EBI-11991632;
CC       Q8IUR6; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-1042699, EBI-10172526;
CC       Q8IUR6; P41227: NAA10; NbExp=3; IntAct=EBI-1042699, EBI-747693;
CC       Q8IUR6; Q9BSU3: NAA11; NbExp=3; IntAct=EBI-1042699, EBI-2585120;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18391022}.
CC       Note=Colocalizes with CREB3 in nuclear foci.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8IUR6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IUR6-2; Sequence=VSP_027601, VSP_027602;
CC       Name=3;
CC         IsoId=Q8IUR6-3; Sequence=VSP_027603;
CC   -!- INDUCTION: Up-regulated by endoplasmic reticulum stress.
CC       {ECO:0000269|PubMed:18391022}.
CC   -!- PTM: Probably degraded by the proteasome.
CC   -!- SIMILARITY: Belongs to the bZIP family. CREBRF subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AC008378; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY139008; AAN28956.1; -; mRNA.
DR   EMBL; AY174896; AAO18732.1; -; mRNA.
DR   EMBL; AY635785; AAV34175.1; -; mRNA.
DR   EMBL; AK124117; BAG54011.1; -; mRNA.
DR   EMBL; AC008378; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61414.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61415.1; -; Genomic_DNA.
DR   EMBL; BC041709; AAH41709.1; -; mRNA.
DR   EMBL; BX647768; CAI46039.1; -; mRNA.
DR   EMBL; BX647573; CAI46104.1; -; mRNA.
DR   CCDS; CCDS34293.1; -. [Q8IUR6-1]
DR   CCDS; CCDS54948.1; -. [Q8IUR6-2]
DR   RefSeq; NP_001161865.1; NM_001168393.1. [Q8IUR6-2]
DR   RefSeq; NP_001161866.1; NM_001168394.1. [Q8IUR6-2]
DR   RefSeq; NP_705835.2; NM_153607.2. [Q8IUR6-1]
DR   RefSeq; XP_006714885.1; XM_006714822.3. [Q8IUR6-1]
DR   SMR; Q8IUR6; -.
DR   BioGRID; 127485; 10.
DR   IntAct; Q8IUR6; 8.
DR   STRING; 9606.ENSP00000296953; -.
DR   GlyGen; Q8IUR6; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q8IUR6; -.
DR   PhosphoSitePlus; Q8IUR6; -.
DR   BioMuta; CREBRF; -.
DR   DMDM; 158563850; -.
DR   MassIVE; Q8IUR6; -.
DR   MaxQB; Q8IUR6; -.
DR   PaxDb; Q8IUR6; -.
DR   PeptideAtlas; Q8IUR6; -.
DR   PRIDE; Q8IUR6; -.
DR   ProteomicsDB; 70604; -. [Q8IUR6-1]
DR   ProteomicsDB; 70605; -. [Q8IUR6-2]
DR   ProteomicsDB; 70606; -. [Q8IUR6-3]
DR   Antibodypedia; 28933; 28 antibodies from 12 providers.
DR   DNASU; 153222; -.
DR   Ensembl; ENST00000296953; ENSP00000296953; ENSG00000164463.
DR   Ensembl; ENST00000520420; ENSP00000428290; ENSG00000164463. [Q8IUR6-2]
DR   Ensembl; ENST00000522692; ENSP00000431107; ENSG00000164463. [Q8IUR6-2]
DR   GeneID; 153222; -.
DR   KEGG; hsa:153222; -.
DR   MANE-Select; ENST00000296953.6; ENSP00000296953.2; NM_153607.3; NP_705835.2.
DR   UCSC; uc003mcf.3; human. [Q8IUR6-1]
DR   CTD; 153222; -.
DR   DisGeNET; 153222; -.
DR   GeneCards; CREBRF; -.
DR   HGNC; HGNC:24050; CREBRF.
DR   HPA; ENSG00000164463; Tissue enhanced (bone).
DR   neXtProt; NX_Q8IUR6; -.
DR   OpenTargets; ENSG00000164463; -.
DR   PharmGKB; PA162380187; -.
DR   VEuPathDB; HostDB:ENSG00000164463; -.
DR   eggNOG; ENOG502QTAK; Eukaryota.
DR   GeneTree; ENSGT00390000007125; -.
DR   HOGENOM; CLU_791197_0_0_1; -.
DR   InParanoid; Q8IUR6; -.
DR   OMA; MYQKNGP; -.
DR   OrthoDB; 252839at2759; -.
DR   PhylomeDB; Q8IUR6; -.
DR   TreeFam; TF330810; -.
DR   PathwayCommons; Q8IUR6; -.
DR   Reactome; R-HSA-8874211; CREB3 factors activate genes.
DR   SignaLink; Q8IUR6; -.
DR   SIGNOR; Q8IUR6; -.
DR   BioGRID-ORCS; 153222; 6 hits in 1046 CRISPR screens.
DR   ChiTaRS; CREBRF; human.
DR   GenomeRNAi; 153222; -.
DR   Pharos; Q8IUR6; Tbio.
DR   PRO; PR:Q8IUR6; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q8IUR6; protein.
DR   Bgee; ENSG00000164463; Expressed in blood and 222 other tissues.
DR   ExpressionAtlas; Q8IUR6; baseline and differential.
DR   Genevisible; Q8IUR6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1900102; P:negative regulation of endoplasmic reticulum unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0032388; P:positive regulation of intracellular transport; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0051222; P:positive regulation of protein transport; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:UniProtKB.
DR   GO; GO:0006986; P:response to unfolded protein; IEA:UniProtKB-KW.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR039165; CREBRF.
DR   PANTHER; PTHR21552; PTHR21552; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Nucleus; Reference proteome; Repressor;
KW   Stress response; Transcription; Transcription regulation; Transport;
KW   Unfolded protein response.
FT   CHAIN           1..639
FT                   /note="CREB3 regulatory factor"
FT                   /id="PRO_0000299306"
FT   DOMAIN          521..584
FT                   /note="bZIP"
FT   REGION          302..422
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          523..532
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000250"
FT   REGION          533..540
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        311..327
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        353..405
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         409..417
FT                   /note="YENDSVEDL -> IIMLASLPD (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:18391022"
FT                   /id="VSP_027601"
FT   VAR_SEQ         418..639
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:18391022"
FT                   /id="VSP_027602"
FT   VAR_SEQ         472
FT                   /note="H -> HGK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_027603"
FT   VARIANT         483
FT                   /note="T -> A (in dbSNP:rs17854147)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_034795"
FT   CONFLICT        232
FT                   /note="K -> R (in Ref. 6; CAI46104)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        561
FT                   /note="D -> G (in Ref. 1; AAN28956)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        588
FT                   /note="N -> D (in Ref. 6; CAI46104)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   639 AA;  72149 MW;  878B8F6FFB9A67CA CRC64;
     MPQPSVSGMD PPFGDAFRSH TFSEQTLMST DLLANSSDPD FMYELDREMN YQQNPRDNFL
     SLEDCKDIEN LESFTDVLDN EGALTSNWEQ WDTYCEDLTK YTKLTSCDIW GTKEVDYLGL
     DDFSSPYQDE EVISKTPTLA QLNSEDSQSV SDSLYYPDSL FSVKQNPLPS SFPGKKITSR
     AAAPVCSSKT LQAEVPLSDC VQKASKPTSS TQIMVKTNMY HNEKVNFHVE CKDYVKKAKV
     KINPVQQSRP LLSQIHTDAA KENTCYCGAV AKRQEKKGME PLQGHATPAL PFKETQELLL
     SPLPQEGPGS LAAGESSSLS ASTSVSDSSQ KKEEHNYSLF VSDNLGEQPT KCSPEEDEED
     EEDVDDEDHD EGFGSEHELS ENEEEEEEEE DYEDDKDDDI SDTFSEPGYE NDSVEDLKEV
     TSISSRKRGK RRYFWEYSEQ LTPSQQERML RPSEWNRDTL PSNMYQKNGL HHGKYAVKKS
     RRTDVEDLTP NPKKLLQIGN ELRKLNKVIS DLTPVSELPL TARPRSRKEK NKLASRACRL
     KKKAQYEANK VKLWGLNTEY DNLLFVINSI KQEIVNRVQN PRDERGPNMG QKLEILIKDT
     LGLPVAGQTS EFVNQVLEKT AEGNPTGGLV GLRIPTSKV
//
ID   CACL1_HUMAN             Reviewed;         369 AA.
AC   Q86Y37; Q5XPL7; Q8IY11; Q8N7S4;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   23-FEB-2022, entry version 139.
DE   RecName: Full=CDK2-associated and cullin domain-containing protein 1;
DE   AltName: Full=Cdk-associated cullin 1;
GN   Name=CACUL1; Synonyms=C10orf46, CAC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Huang C., Wu S., Liu S.;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Rectum tumor;
RA   Kong Y., Chen Y., Xia Q.;
RT   "The expression of gene in human rectum carcinoma.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, AND INTERACTION WITH CDK2.
RX   PubMed=19829063; DOI=10.4161/cc.8.21.9955;
RA   Kong Y., Nan K., Yin Y.;
RT   "Identification and characterization of CAC1 as a novel CDK2-associated
RT   cullin.";
RL   Cell Cycle 8:3552-3561(2009).
CC   -!- FUNCTION: Cell cycle associated protein capable of promoting cell
CC       proliferation through the activation of CDK2 at the G1/S phase
CC       transition. {ECO:0000269|PubMed:19829063}.
CC   -!- SUBUNIT: Interacts with CDK2. {ECO:0000269|PubMed:19829063}.
CC   -!- INTERACTION:
CC       Q86Y37; P03372: ESR1; NbExp=5; IntAct=EBI-8168227, EBI-78473;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q86Y37-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86Y37-2; Sequence=VSP_013936, VSP_013937;
CC       Name=4;
CC         IsoId=Q86Y37-4; Sequence=VSP_013933;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with highest expression in
CC       the mammary gland and large intestine. Highly expressed in cancer
CC       tissues and cancer cell lines. During cell cycle progression expression
CC       is high in G1/S, low in the middle of S phase, and increases again in
CC       S/G2 phase. {ECO:0000269|PubMed:19829063}.
CC   -!- SIMILARITY: Belongs to the cullin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAU89709.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ544771; CAD67614.1; -; mRNA.
DR   EMBL; AY743663; AAU89709.1; ALT_FRAME; mRNA.
DR   EMBL; AK097728; BAC05153.1; -; mRNA.
DR   EMBL; AL139407; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC038294; AAH38294.1; -; mRNA.
DR   CCDS; CCDS41570.1; -. [Q86Y37-1]
DR   RefSeq; NP_722517.3; NM_153810.4. [Q86Y37-1]
DR   SMR; Q86Y37; -.
DR   BioGRID; 126801; 20.
DR   IntAct; Q86Y37; 3.
DR   MINT; Q86Y37; -.
DR   STRING; 9606.ENSP00000358147; -.
DR   GlyGen; Q86Y37; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q86Y37; -.
DR   PhosphoSitePlus; Q86Y37; -.
DR   BioMuta; CACUL1; -.
DR   DMDM; 67460542; -.
DR   EPD; Q86Y37; -.
DR   jPOST; Q86Y37; -.
DR   MassIVE; Q86Y37; -.
DR   MaxQB; Q86Y37; -.
DR   PaxDb; Q86Y37; -.
DR   PeptideAtlas; Q86Y37; -.
DR   PRIDE; Q86Y37; -.
DR   ProteomicsDB; 70367; -. [Q86Y37-1]
DR   ProteomicsDB; 70368; -. [Q86Y37-2]
DR   ProteomicsDB; 70369; -. [Q86Y37-4]
DR   Antibodypedia; 32069; 137 antibodies from 22 providers.
DR   DNASU; 143384; -.
DR   Ensembl; ENST00000369151; ENSP00000358147; ENSG00000151893.
DR   Ensembl; ENST00000493518; ENSP00000431329; ENSG00000151893. [Q86Y37-2]
DR   GeneID; 143384; -.
DR   KEGG; hsa:143384; -.
DR   MANE-Select; ENST00000369151.8; ENSP00000358147.2; NM_153810.5; NP_722517.3.
DR   UCSC; uc001lds.2; human. [Q86Y37-1]
DR   CTD; 143384; -.
DR   DisGeNET; 143384; -.
DR   GeneCards; CACUL1; -.
DR   HGNC; HGNC:23727; CACUL1.
DR   HPA; ENSG00000151893; Low tissue specificity.
DR   MIM; 618764; gene.
DR   neXtProt; NX_Q86Y37; -.
DR   OpenTargets; ENSG00000151893; -.
DR   PharmGKB; PA134869023; -.
DR   VEuPathDB; HostDB:ENSG00000151893; -.
DR   eggNOG; KOG2166; Eukaryota.
DR   GeneTree; ENSGT00390000000403; -.
DR   HOGENOM; CLU_062250_1_0_1; -.
DR   InParanoid; Q86Y37; -.
DR   OMA; IPNILPR; -.
DR   OrthoDB; 991620at2759; -.
DR   PhylomeDB; Q86Y37; -.
DR   TreeFam; TF329263; -.
DR   PathwayCommons; Q86Y37; -.
DR   SignaLink; Q86Y37; -.
DR   BioGRID-ORCS; 143384; 12 hits in 1053 CRISPR screens.
DR   ChiTaRS; CACUL1; human.
DR   GenomeRNAi; 143384; -.
DR   Pharos; Q86Y37; Tbio.
DR   PRO; PR:Q86Y37; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q86Y37; protein.
DR   Bgee; ENSG00000151893; Expressed in epithelium of mammary gland and 223 other tissues.
DR   Genevisible; Q86Y37; HS.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:InterPro.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   InterPro; IPR042652; CACUL1.
DR   InterPro; IPR001373; Cullin_N.
DR   InterPro; IPR016159; Cullin_repeat-like_dom_sf.
DR   PANTHER; PTHR46636; PTHR46636; 1.
DR   Pfam; PF00888; Cullin; 1.
DR   SUPFAM; SSF74788; SSF74788; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell cycle; Reference proteome.
FT   CHAIN           1..369
FT                   /note="CDK2-associated and cullin domain-containing protein
FT                   1"
FT                   /id="PRO_0000119817"
FT   REGION          1..56
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          342..369
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        33..49
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         1..123
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_013933"
FT   VAR_SEQ         296..303
FT                   /note="EWVQMAPT -> VSQNFTAV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013936"
FT   VAR_SEQ         304..369
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013937"
SQ   SEQUENCE   369 AA;  41064 MW;  7ABA2F6846C4F737 CRC64;
     MEESMEEEEG GSYEAMMDDQ NHNNWEAAVD GFRQPLPPPP PPSSIPAPAR EPPGGQLLAV
     PAVSVDRKGP KEGLPMGPQP PPEANGVIMM LKSCDAAAAV AKAAPAPTAS STININTSTS
     KFLMNVITIE DYKSTYWPKL DGAIDQLLTQ SPGDYIPISY EQIYSCVYKC VCQQHSEQMY
     SDLIKKITNH LERVSKELQA SPPDLYIERF NIALGQYMGA LQSIVPLFIY MNKFYIETKL
     NRDLKDDLIK LFTEHVAEKH IYSLMPLLLE AQSTPFQVTP STMANIVKGL YTLRPEWVQM
     APTLFSKFIP NILPPAVESE LSEYAAQDQK FQRELIQNGF TRGDQSRKRA GDELAYNSSS
     ACASSRGYR
//
ID   BDNF_HUMAN              Reviewed;         247 AA.
AC   P23560; A7LA85; A7LA92; D3DQZ2; Q598Q1; Q6DN19; Q6YNR2; Q6YNR3; Q9BYY7;
AC   Q9UC24;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   23-FEB-2022, entry version 214.
DE   RecName: Full=Brain-derived neurotrophic factor;
DE            Short=BDNF;
DE   AltName: Full=Abrineurin;
DE   Contains:
DE     RecName: Full=BDNF precursor form {ECO:0000305};
DE              Short=ProBDNF {ECO:0000305};
DE   Flags: Precursor;
GN   Name=BDNF {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:1033};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 1), AND
RP   TISSUE SPECIFICITY.
RX   PubMed=2236018; DOI=10.1073/pnas.87.20.8060;
RA   Jones K.R., Reichardt L.F.;
RT   "Molecular cloning of a human gene that is a member of the nerve growth
RT   factor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8060-8064(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=1889806; DOI=10.1016/0888-7543(91)90436-i;
RA   Maisonpierre P.C., le Beau M.M., Espinosa R. III, Ip N.Y., Belluscio L.,
RA   de la Monte S.M., Squinto S., Furth M.E., Yancopoulos G.D.;
RT   "Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene
RT   structures, distributions, and chromosomal localizations.";
RL   Genomics 10:558-568(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1339267; DOI=10.1016/s0006-291x(05)80148-2;
RA   Shintani A., Ono Y., Kaisho Y., Igarashi K.;
RT   "Characterization of the 5'-flanking region of the human brain-derived
RT   neurotrophic factor gene.";
RL   Biochem. Biophys. Res. Commun. 182:325-332(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=15666411; DOI=10.1002/ajmg.b.30109;
RA   Liu Q.-R., Walther D., Drgon T., Polesskaya O., Lesnick T.G., Strain K.J.,
RA   de Andrade M., Bower J.H., Maraganore D.M., Uhl G.R.;
RT   "Human brain derived neurotrophic factor (BDNF) genes, splicing patterns,
RT   and assessments of associations with substance abuse and Parkinson's
RT   Disease.";
RL   Am. J. Med. Genet. B Neuropsychiatr. Genet. 134:93-103(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5), ALTERNATIVE
RP   SPLICING, ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=17629449; DOI=10.1016/j.ygeno.2007.05.004;
RA   Pruunsild P., Kazantseva A., Aid T., Palm K., Timmusk T.;
RT   "Dissecting the human BDNF locus: bidirectional transcription, complex
RT   splicing, and multiple promoters.";
RL   Genomics 90:397-406(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Cheng Y., Gu J.;
RT   "A cDNA clone of human brain-derived neurotrophic factor (HUMBDNFD).";
RL   Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wu J., Zhang B., Zhou Y., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-66.
RA   Perez-Pinera P., Gonzalez-Martinez T., Garcia-Suarez O., Perez-Perez M.,
RA   Esteban I., Monjil D., Vega J.A.;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 185-227.
RC   TISSUE=Leukocyte;
RX   PubMed=2025430; DOI=10.1016/0896-6273(91)90180-8;
RA   Hallboeoek F., Ibanez C.F., Persson H.;
RT   "Evolutionary studies of the nerve growth factor family reveal a novel
RT   member abundantly expressed in Xenopus ovary.";
RL   Neuron 6:845-858(1991).
RN   [15]
RP   PROTEIN SEQUENCE OF 129-144, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   NTRK2.
RC   TISSUE=Serum;
RX   PubMed=8527932; DOI=10.1006/prep.1995.1062;
RA   Rosenfeld R.D., Zeni L., Haniu M., Talvenheimo J., Radka S.F., Bennett L.,
RA   Miller J.A., Welcher A.A.;
RT   "Purification and identification of brain-derived neurotrophic factor from
RT   human serum.";
RL   Protein Expr. Purif. 6:465-471(1995).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-197.
RX   PubMed=11214319; DOI=10.1038/35054550;
RA   Murphy W.J., Eizirik E., Johnson W.E., Zhang Y.-P., Ryder O.A.,
RA   O'Brien S.J.;
RT   "Molecular phylogenetics and the origins of placental mammals.";
RL   Nature 409:614-618(2001).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH NTRK2, PROTEOLYTIC
RP   CLEAVAGE, PARTIAL PROTEIN SEQUENCE, TISSUE SPECIFICITY, GLYCOSYLATION AT
RP   ASN-121, AND MUTAGENESIS OF ARG-54.
RX   PubMed=11152678; DOI=10.1074/jbc.m008104200;
RA   Mowla S.J., Farhadi H.F., Pareek S., Atwal J.K., Morris S.J., Seidah N.G.,
RA   Murphy R.A.;
RT   "Biosynthesis and post-translational processing of the precursor to brain-
RT   derived neurotrophic factor.";
RL   J. Biol. Chem. 276:12660-12666(2001).
RN   [18]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, VARIANT MET-66, GLYCOSYLATION
RP   AT ASN-121, AND TISSUE SPECIFICITY.
RX   PubMed=19467646; DOI=10.1016/j.archoralbio.2009.04.005;
RA   Mandel A.L., Ozdener H., Utermohlen V.;
RT   "Identification of pro- and mature brain-derived neurotrophic factor in
RT   human saliva.";
RL   Arch. Oral Biol. 54:689-695(2009).
RN   [19]
RP   INTERACTION WITH SORCS2 AND NGFR, AND FUNCTION.
RX   PubMed=24908487; DOI=10.1016/j.neuron.2014.04.022;
RA   Glerup S., Olsen D., Vaegter C.B., Gustafsen C., Sjoegaard S.S., Hermey G.,
RA   Kjolby M., Molgaard S., Ulrichsen M., Boggild S., Skeldal S.,
RA   Fjorback A.N., Nyengaard J.R., Jacobsen J., Bender D., Bjarkam C.R.,
RA   Soerensen E.S., Fuechtbauer E.M., Eichele G., Madsen P., Willnow T.E.,
RA   Petersen C.M., Nykjaer A.;
RT   "SorCS2 regulates dopaminergic wiring and is processed into an apoptotic
RT   two-chain receptor in peripheral glia.";
RL   Neuron 82:1074-1087(2014).
RN   [20] {ECO:0007744|PDB:1BND}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 129-247 IN COMPLEX WITH NTF3, AND
RP   DISULFIDE BONDS.
RX   PubMed=7703225; DOI=10.1021/bi00013a001;
RA   Robinson R.C., Radziejewski C., Stuart D.I., Jones E.Y.;
RT   "Structure of the brain-derived neurotrophic factor/neurotrophin 3
RT   heterodimer.";
RL   Biochemistry 34:4139-4146(1995).
RN   [21] {ECO:0007744|PDB:1B8M}
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 129-247 IN COMPLEX WITH NTF4, AND
RP   DISULFIDE BONDS.
RX   PubMed=10631974; DOI=10.1110/ps.8.12.2589;
RA   Robinson R.C., Radziejewski C., Spraggon G., Greenwald J., Kostura M.R.,
RA   Burtnick L.D., Stuart D.I., Choe S., Jones E.Y.;
RT   "The structures of the neurotrophin 4 homodimer and the brain-derived
RT   neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding
RT   site.";
RL   Protein Sci. 8:2589-2597(1999).
RN   [22]
RP   VARIANT MET-66.
RX   PubMed=15115760; DOI=10.1093/hmg/ddh137;
RA   Ribases M., Gratacos M., Fernandez-Aranda F., Bellodi L., Boni C.,
RA   Anderluh M., Cavallini M.C., Cellini E., Di Bella D., Erzegovesi S.,
RA   Foulon C., Gabrovsek M., Gorwood P., Hebebrand J., Hinney A., Holliday J.,
RA   Hu X., Karwautz A., Kipman A., Komel R., Nacmias B., Remschmidt H.,
RA   Ricca V., Sorbi S., Wagner G., Treasure J., Collier D.A., Estivill X.;
RT   "Association of BDNF with anorexia, bulimia and age of onset of weight loss
RT   in six European populations.";
RL   Hum. Mol. Genet. 13:1205-1212(2004).
RN   [23]
RP   INVOLVEMENT IN WAGRO SYNDROME.
RX   PubMed=18753648; DOI=10.1056/nejmoa0801119;
RA   Han J.C., Liu Q.-R., Jones M., Levinn R.L., Menzie C.M.,
RA   Jefferson-George K.S., Adler-Wailes D.C., Sanford E.L., Lacbawan F.L.,
RA   Uhl G.R., Rennert O.M., Yanovski J.A.;
RT   "Brain-derived neurotrophic factor and obesity in the WAGR syndrome.";
RL   N. Engl. J. Med. 359:918-927(2008).
RN   [24]
RP   ERRATUM OF PUBMED:18753648.
RA   Han J.C., Liu Q.-R., Jones M., Levinn R.L., Menzie C.M.,
RA   Jefferson-George K.S., Adler-Wailes D.C., Sanford E.L., Lacbawan F.L.,
RA   Uhl G.R., Rennert O.M., Yanovski J.A.;
RL   N. Engl. J. Med. 359:1414-1414(2008).
RN   [25]
RP   VARIANT MET-66.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [26]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [27]
RP   VARIANT CCHS ILE-2.
RX   PubMed=11840487; DOI=10.1002/ajmg.10133;
RA   Weese-Mayer D.E., Bolk S., Silvestri J.M., Chakravarti A.;
RT   "Idiopathic congenital central hypoventilation syndrome: evaluation of
RT   brain-derived neurotrophic factor genomic DNA sequence variation.";
RL   Am. J. Med. Genet. 107:306-310(2002).
RN   [28]
RP   VARIANT MET-66, AND ROLE OF VARIANT MET-66 IN OBSESSIVE-COMPULSIVE
RP   DISORDER.
RX   PubMed=12836135; DOI=10.1086/377003;
RA   Hall D., Dhilla A., Charalambous A., Gogos J.A., Karayiorgou M.;
RT   "Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are
RT   strongly associated with obsessive-compulsive disorder.";
RL   Am. J. Hum. Genet. 73:370-376(2003).
RN   [29]
RP   VARIANT MET-66, CHARACTERIZATION OF VARIANT MET-66, AND ROLE IN EPISODIC
RP   MEMORY.
RX   PubMed=12553913; DOI=10.1016/s0092-8674(03)00035-7;
RA   Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S.,
RA   Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B.,
RA   Weinberger D.R.;
RT   "The BDNF val66met polymorphism affects activity-dependent secretion of
RT   BDNF and human memory and hippocampal function.";
RL   Cell 112:257-269(2003).
RN   [30]
RP   VARIANT MET-66.
RX   PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [31]
RP   VARIANT MET-66, AND ASSOCIATION OF VARIANT MET-66 WITH ANR.
RX   PubMed=12888803; DOI=10.1038/sj.mp.4001281;
RA   Ribases M., Gratacos M., Armengol L., de Cid R., Badia A., Jimenez L.,
RA   Solano R., Vallejo J., Fernandez F., Estivill X.;
RT   "Met66 in the brain-derived neurotrophic factor (BDNF) precursor is
RT   associated with anorexia nervosa restrictive type.";
RL   Mol. Psychiatry 8:745-751(2003).
RN   [32]
RP   VARIANT THR-122.
RX   PubMed=28397838; DOI=10.1038/mp.2017.60;
RA   Harripaul R., Vasli N., Mikhailov A., Rafiq M.A., Mittal K.,
RA   Windpassinger C., Sheikh T.I., Noor A., Mahmood H., Downey S., Johnson M.,
RA   Vleuten K., Bell L., Ilyas M., Khan F.S., Khan V., Moradi M., Ayaz M.,
RA   Naeem F., Heidari A., Ahmed I., Ghadami S., Agha Z., Zeinali S., Qamar R.,
RA   Mozhdehipanah H., John P., Mir A., Ansar M., French L., Ayub M.,
RA   Vincent J.B.;
RT   "Mapping autosomal recessive intellectual disability: combined microarray
RT   and exome sequencing identifies 26 novel candidate genes in 192
RT   consanguineous families.";
RL   Mol. Psychiatry 23:973-984(2018).
RN   [33]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANT MET-66.
RX   PubMed=29909994; DOI=10.1016/j.neuron.2018.05.024;
RA   Giza J.I., Kim J., Meyer H.C., Anastasia A., Dincheva I., Zheng C.I.,
RA   Lopez K., Bains H., Yang J., Bracken C., Liston C., Jing D.,
RA   Hempstead B.L., Lee F.S.;
RT   "The BDNF Val66Met Prodomain Disassembles Dendritic Spines Altering Fear
RT   Extinction Circuitry and Behavior.";
RL   Neuron 99:163-178(2018).
CC   -!- FUNCTION: Important signaling molecule that activates signaling
CC       cascades downstream of NTRK2 (PubMed:11152678). During development,
CC       promotes the survival and differentiation of selected neuronal
CC       populations of the peripheral and central nervous systems. Participates
CC       in axonal growth, pathfinding and in the modulation of dendritic growth
CC       and morphology. Major regulator of synaptic transmission and plasticity
CC       at adult synapses in many regions of the CNS. The versatility of BDNF
CC       is emphasized by its contribution to a range of adaptive neuronal
CC       responses including long-term potentiation (LTP), long-term depression
CC       (LTD), certain forms of short-term synaptic plasticity, as well as
CC       homeostatic regulation of intrinsic neuronal excitability.
CC       {ECO:0000269|PubMed:11152678, ECO:0000269|PubMed:12553913,
CC       ECO:0000269|PubMed:29909994}.
CC   -!- FUNCTION: [BDNF precursor form]: Important signaling molecule that
CC       activates signaling cascades downstream of NTRK2. Activates signaling
CC       cascades via the heterodimeric receptor formed by NGFR and SORCS2
CC       (PubMed:24908487, PubMed:29909994). Signaling via NGFR and SORCS2 plays
CC       a role in synaptic plasticity and long-term depression (LTD). Binding
CC       to NGFR and SORCS2 promotes neuronal apoptosis. Promotes neuronal
CC       growth cone collapse (By similarity). {ECO:0000250|UniProtKB:P21237,
CC       ECO:0000269|PubMed:24908487, ECO:0000269|PubMed:29909994}.
CC   -!- SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB (PubMed:8527932,
CC       PubMed:11152678). Can form heterodimers with other neurotrophin family
CC       members, such as NTF3 and NTF4 (in vitro), but the physiological
CC       relevance of this is not clear (PubMed:7703225, PubMed:10631974). BDNF
CC       precursor form: interacts with the heterodimer formed by NGFR and
CC       SORCS2 (PubMed:24908487). {ECO:0000269|PubMed:10631974,
CC       ECO:0000269|PubMed:11152678, ECO:0000269|PubMed:24908487,
CC       ECO:0000269|PubMed:7703225, ECO:0000269|PubMed:8527932}.
CC   -!- INTERACTION:
CC       P23560; P34130: NTF4; NbExp=6; IntAct=EBI-1026003, EBI-3907456;
CC       P23560-2; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-12275524, EBI-10173507;
CC       P23560-2; Q15109: AGER; NbExp=3; IntAct=EBI-12275524, EBI-1646426;
CC       P23560-2; Q9UIJ7: AK3; NbExp=3; IntAct=EBI-12275524, EBI-3916527;
CC       P23560-2; Q8IWZ3-2: ANKHD1; NbExp=3; IntAct=EBI-12275524, EBI-9641396;
CC       P23560-2; Q8IWZ3-3: ANKHD1; NbExp=3; IntAct=EBI-12275524, EBI-25833200;
CC       P23560-2; Q6LES2: ANXA4; NbExp=3; IntAct=EBI-12275524, EBI-10250835;
CC       P23560-2; Q8WW43: APH1B; NbExp=3; IntAct=EBI-12275524, EBI-2606497;
CC       P23560-2; P05067: APP; NbExp=3; IntAct=EBI-12275524, EBI-77613;
CC       P23560-2; Q9H0C5: BTBD1; NbExp=3; IntAct=EBI-12275524, EBI-935503;
CC       P23560-2; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-12275524, EBI-1383687;
CC       P23560-2; Q8TAB7: CCDC26; NbExp=3; IntAct=EBI-12275524, EBI-10271580;
CC       P23560-2; Q9BV29: CCDC32; NbExp=3; IntAct=EBI-12275524, EBI-2874058;
CC       P23560-2; Q00535: CDK5; NbExp=3; IntAct=EBI-12275524, EBI-1041567;
CC       P23560-2; Q6QEF8-4: CORO6; NbExp=3; IntAct=EBI-12275524, EBI-10699285;
CC       P23560-2; Q14194: CRMP1; NbExp=3; IntAct=EBI-12275524, EBI-473101;
CC       P23560-2; P35222: CTNNB1; NbExp=3; IntAct=EBI-12275524, EBI-491549;
CC       P23560-2; Q15438: CYTH1; NbExp=3; IntAct=EBI-12275524, EBI-997830;
CC       P23560-2; Q9BPW9-4: DHRS9; NbExp=3; IntAct=EBI-12275524, EBI-19157435;
CC       P23560-2; P49184: DNASE1L1; NbExp=3; IntAct=EBI-12275524, EBI-20894690;
CC       P23560-2; P07099: EPHX1; NbExp=3; IntAct=EBI-12275524, EBI-6138796;
CC       P23560-2; O00471: EXOC5; NbExp=3; IntAct=EBI-12275524, EBI-949824;
CC       P23560-2; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-12275524, EBI-18304435;
CC       P23560-2; O75344: FKBP6; NbExp=3; IntAct=EBI-12275524, EBI-744771;
CC       P23560-2; Q10981: FUT2; NbExp=3; IntAct=EBI-12275524, EBI-9090702;
CC       P23560-2; P06241: FYN; NbExp=3; IntAct=EBI-12275524, EBI-515315;
CC       P23560-2; P22466: GAL; NbExp=3; IntAct=EBI-12275524, EBI-6624768;
CC       P23560-2; Q8NEA9: GMCL2; NbExp=3; IntAct=EBI-12275524, EBI-745707;
CC       P23560-2; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-12275524, EBI-13345167;
CC       P23560-2; Q9UBK5: HCST; NbExp=3; IntAct=EBI-12275524, EBI-2801937;
CC       P23560-2; O43365: HOXA3; NbExp=3; IntAct=EBI-12275524, EBI-8643838;
CC       P23560-2; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-12275524, EBI-25830912;
CC       P23560-2; Q92993-2: KAT5; NbExp=3; IntAct=EBI-12275524, EBI-20795332;
CC       P23560-2; P18428: LBP; NbExp=3; IntAct=EBI-12275524, EBI-3927059;
CC       P23560-2; Q96G30: MRAP2; NbExp=3; IntAct=EBI-12275524, EBI-9537218;
CC       P23560-2; Q13405: MRPL49; NbExp=3; IntAct=EBI-12275524, EBI-5325200;
CC       P23560-2; Q8TBJ4: PLPPR1; NbExp=3; IntAct=EBI-12275524, EBI-18063495;
CC       P23560-2; P17612: PRKACA; NbExp=3; IntAct=EBI-12275524, EBI-476586;
CC       P23560-2; P60891: PRPS1; NbExp=3; IntAct=EBI-12275524, EBI-749195;
CC       P23560-2; A0A0C4DFM3: PRUNE2; NbExp=3; IntAct=EBI-12275524, EBI-25830870;
CC       P23560-2; Q96GQ5: RUSF1; NbExp=3; IntAct=EBI-12275524, EBI-8636004;
CC       P23560-2; Q96GZ6: SLC41A3; NbExp=3; IntAct=EBI-12275524, EBI-7225508;
CC       P23560-2; Q8NCS7: SLC44A5; NbExp=3; IntAct=EBI-12275524, EBI-21504521;
CC       P23560-2; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-12275524, EBI-12336127;
CC       P23560-2; Q99523: SORT1; NbExp=3; IntAct=EBI-12275524, EBI-1057058;
CC       P23560-2; Q9H808: TLE6; NbExp=3; IntAct=EBI-12275524, EBI-3921684;
CC       P23560-2; P10599: TXN; NbExp=3; IntAct=EBI-12275524, EBI-594644;
CC       P23560-2; Q15386-3: UBE3C; NbExp=3; IntAct=EBI-12275524, EBI-25833079;
CC       P23560-2; Q9H6R7-2: WDCP; NbExp=3; IntAct=EBI-12275524, EBI-25833271;
CC       P23560-2; O60293-2: ZFC3H1; NbExp=3; IntAct=EBI-12275524, EBI-25833374;
CC       P23560-2; Q6P514: ZNF468; NbExp=3; IntAct=EBI-12275524, EBI-25833318;
CC       P23560-2; A0A087WZY1; NbExp=3; IntAct=EBI-12275524, EBI-13387614;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11152678,
CC       ECO:0000269|PubMed:19467646, ECO:0000269|PubMed:8527932}.
CC   -!- SUBCELLULAR LOCATION: [BDNF precursor form]: Secreted
CC       {ECO:0000269|PubMed:11152678, ECO:0000269|PubMed:19467646}. Note=A
CC       proportion of BDNF is secreted as immature precursor (proBDNF).
CC       {ECO:0000269|PubMed:11152678, ECO:0000269|PubMed:19467646}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;
CC         Comment=2 types of transcripts are produced: non-coding transcripts
CC         (antisense, opposite strand (OS), 8 exons) and coding transcripts (11
CC         exons). Brain BDNF and anti-BDNF transcripts form dsRNA duplexes.;
CC       Name=1;
CC         IsoId=P23560-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P23560-2; Sequence=VSP_037948;
CC       Name=3;
CC         IsoId=P23560-3; Sequence=VSP_038099;
CC       Name=4;
CC         IsoId=P23560-4; Sequence=VSP_038100;
CC       Name=5;
CC         IsoId=P23560-5; Sequence=VSP_038101;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma and in saliva (at protein
CC       level) (PubMed:11152678, PubMed:19467646). Brain. Highly expressed in
CC       hippocampus, amygdala, cerebral cortex and cerebellum. Also expressed
CC       in heart, lung, skeletal muscle, testis, prostate and placenta.
CC       {ECO:0000269|PubMed:11152678, ECO:0000269|PubMed:17629449,
CC       ECO:0000269|PubMed:19467646, ECO:0000269|PubMed:2236018}.
CC   -!- PTM: [BDNF precursor form]: N-glycosylated and glycosulfated, contrary
CC       to mature BDNF. {ECO:0000269|PubMed:11152678,
CC       ECO:0000269|PubMed:19467646}.
CC   -!- PTM: Mature BDNF is produced by proteolytic removal of the propeptide,
CC       catalyzed by a FURIN family member. In addition, the precursor form is
CC       proteolytically cleaved within the propeptide, but this is not an
CC       obligatory intermediate for the production of mature BDNF
CC       (PubMed:11152678). Can be converted into mature BDNF by plasmin (PLG)
CC       (PubMed:19467646). {ECO:0000269|PubMed:11152678,
CC       ECO:0000269|PubMed:19467646}.
CC   -!- DISEASE: Congenital central hypoventilation syndrome (CCHS)
CC       [MIM:209880]: Rare disorder characterized by abnormal control of
CC       respiration in the absence of neuromuscular or lung disease, or an
CC       identifiable brain stem lesion. A deficiency in autonomic control of
CC       respiration results in inadequate or negligible ventilatory and arousal
CC       responses to hypercapnia and hypoxemia. {ECO:0000269|PubMed:11840487}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the NGF-beta family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=BDNF entry;
CC       URL="https://en.wikipedia.org/wiki/Brain-derived_neurotrophic_factor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M37762; AAA51820.1; -; Genomic_DNA.
DR   EMBL; M61176; AAA69805.2; -; mRNA.
DR   EMBL; M61181; AAA96140.1; -; Genomic_DNA.
DR   EMBL; X60201; CAA42761.1; -; mRNA.
DR   EMBL; AY054392; AAL23557.2; -; mRNA.
DR   EMBL; AY054393; AAL23558.1; -; mRNA.
DR   EMBL; AY054394; AAL23559.1; -; mRNA.
DR   EMBL; AY054395; AAL23560.1; -; mRNA.
DR   EMBL; AY054396; AAL23561.1; -; mRNA.
DR   EMBL; AY054397; AAL23562.1; -; mRNA.
DR   EMBL; AY054398; AAL23563.1; -; mRNA.
DR   EMBL; AY054399; AAL23564.1; -; mRNA.
DR   EMBL; AY054400; AAL23565.2; -; mRNA.
DR   EMBL; AF411339; AAO15434.1; -; Genomic_DNA.
DR   EMBL; EF674517; ABS29021.1; -; mRNA.
DR   EMBL; EF674518; ABS29022.1; -; mRNA.
DR   EMBL; EF674519; ABS29023.1; -; mRNA.
DR   EMBL; EF674520; ABS29024.1; -; mRNA.
DR   EMBL; EF674521; ABS29025.1; -; mRNA.
DR   EMBL; EF689009; ABS32249.1; -; mRNA.
DR   EMBL; EF689010; ABS32250.1; -; mRNA.
DR   EMBL; EF689011; ABS32251.1; -; mRNA.
DR   EMBL; EF689012; ABS32252.1; -; mRNA.
DR   EMBL; EF689013; ABS32253.1; -; mRNA.
DR   EMBL; EF689014; ABS32254.1; -; mRNA.
DR   EMBL; EF689015; ABS32255.1; -; mRNA.
DR   EMBL; EF689016; ABS32256.1; -; mRNA.
DR   EMBL; EF689017; ABS32257.1; -; mRNA.
DR   EMBL; EF689018; ABS32258.1; -; mRNA.
DR   EMBL; EF689019; ABS32259.1; -; mRNA.
DR   EMBL; EF689020; ABS32260.1; -; mRNA.
DR   EMBL; EF689021; ABS32261.1; -; mRNA.
DR   EMBL; X91251; CAA62632.1; -; mRNA.
DR   EMBL; AF400438; AAK92487.1; -; mRNA.
DR   EMBL; AY656701; AAT74399.1; -; mRNA.
DR   EMBL; AK289853; BAF82542.1; -; mRNA.
DR   EMBL; AK289763; BAF82452.1; -; mRNA.
DR   EMBL; AC104563; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68274.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68278.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68279.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68275.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68276.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68277.1; -; Genomic_DNA.
DR   EMBL; BC029795; AAH29795.1; -; mRNA.
DR   EMBL; AY011481; AAG47514.1; -; Genomic_DNA.
DR   CCDS; CCDS41628.1; -. [P23560-3]
DR   CCDS; CCDS44558.1; -. [P23560-4]
DR   CCDS; CCDS7865.1; -. [P23560-2]
DR   CCDS; CCDS7866.1; -. [P23560-1]
DR   PIR; B36208; A40304.
DR   RefSeq; NP_001137277.1; NM_001143805.1. [P23560-1]
DR   RefSeq; NP_001137278.1; NM_001143806.1. [P23560-1]
DR   RefSeq; NP_001137279.1; NM_001143807.1. [P23560-1]
DR   RefSeq; NP_001137280.1; NM_001143808.1. [P23560-1]
DR   RefSeq; NP_001137281.1; NM_001143809.1. [P23560-5]
DR   RefSeq; NP_001137282.1; NM_001143810.1. [P23560-4]
DR   RefSeq; NP_001137283.1; NM_001143811.1. [P23560-1]
DR   RefSeq; NP_001137284.1; NM_001143812.1. [P23560-1]
DR   RefSeq; NP_001137285.1; NM_001143813.1. [P23560-1]
DR   RefSeq; NP_001137286.1; NM_001143814.1. [P23560-1]
DR   RefSeq; NP_001137288.1; NM_001143816.1. [P23560-1]
DR   RefSeq; NP_001700.2; NM_001709.4. [P23560-1]
DR   RefSeq; NP_733927.1; NM_170731.4. [P23560-2]
DR   RefSeq; NP_733928.1; NM_170732.4. [P23560-1]
DR   RefSeq; NP_733929.1; NM_170733.3. [P23560-1]
DR   RefSeq; NP_733930.1; NM_170734.3. [P23560-3]
DR   RefSeq; NP_733931.1; NM_170735.5. [P23560-1]
DR   RefSeq; XP_011518582.1; XM_011520280.2. [P23560-4]
DR   PDB; 1B8M; X-ray; 2.75 A; A=129-247.
DR   PDB; 1BND; X-ray; 2.30 A; A=129-247.
DR   PDBsum; 1B8M; -.
DR   PDBsum; 1BND; -.
DR   BMRB; P23560; -.
DR   SMR; P23560; -.
DR   BioGRID; 107096; 41.
DR   DIP; DIP-5719N; -.
DR   IntAct; P23560; 60.
DR   STRING; 9606.ENSP00000414303; -.
DR   BindingDB; P23560; -.
DR   ChEMBL; CHEMBL4523205; -.
DR   DrugBank; DB09301; Chondroitin sulfate.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB05047; CX-717.
DR   DrugBank; DB11823; Esketamine.
DR   GlyGen; P23560; 1 site.
DR   iPTMnet; P23560; -.
DR   PhosphoSitePlus; P23560; -.
DR   BioMuta; BDNF; -.
DR   DMDM; 114900; -.
DR   MassIVE; P23560; -.
DR   PaxDb; P23560; -.
DR   PeptideAtlas; P23560; -.
DR   PRIDE; P23560; -.
DR   ProteomicsDB; 54129; -. [P23560-1]
DR   ProteomicsDB; 54130; -. [P23560-2]
DR   ProteomicsDB; 54131; -. [P23560-3]
DR   ProteomicsDB; 54132; -. [P23560-4]
DR   ProteomicsDB; 54133; -. [P23560-5]
DR   TopDownProteomics; P23560-2; -. [P23560-2]
DR   ABCD; P23560; 4 sequenced antibodies.
DR   Antibodypedia; 4032; 1211 antibodies from 49 providers.
DR   DNASU; 627; -.
DR   Ensembl; ENST00000314915; ENSP00000320002; ENSG00000176697. [P23560-2]
DR   Ensembl; ENST00000356660; ENSP00000349084; ENSG00000176697.
DR   Ensembl; ENST00000395978; ENSP00000379302; ENSG00000176697.
DR   Ensembl; ENST00000395981; ENSP00000379305; ENSG00000176697.
DR   Ensembl; ENST00000395983; ENSP00000379307; ENSG00000176697.
DR   Ensembl; ENST00000395986; ENSP00000379309; ENSG00000176697. [P23560-3]
DR   Ensembl; ENST00000418212; ENSP00000400502; ENSG00000176697.
DR   Ensembl; ENST00000438929; ENSP00000414303; ENSG00000176697. [P23560-4]
DR   Ensembl; ENST00000439476; ENSP00000389345; ENSG00000176697.
DR   Ensembl; ENST00000525528; ENSP00000437138; ENSG00000176697.
DR   Ensembl; ENST00000525950; ENSP00000432035; ENSG00000176697.
DR   Ensembl; ENST00000530861; ENSP00000435564; ENSG00000176697.
DR   Ensembl; ENST00000532997; ENSP00000435805; ENSG00000176697.
DR   Ensembl; ENST00000533131; ENSP00000432727; ENSG00000176697.
DR   Ensembl; ENST00000533246; ENSP00000432376; ENSG00000176697.
DR   GeneID; 627; -.
DR   KEGG; hsa:627; -.
DR   MANE-Select; ENST00000356660.9; ENSP00000349084.4; NM_001709.5; NP_001700.2.
DR   UCSC; uc001mrt.4; human. [P23560-1]
DR   CTD; 627; -.
DR   DisGeNET; 627; -.
DR   GeneCards; BDNF; -.
DR   HGNC; HGNC:1033; BDNF.
DR   HPA; ENSG00000176697; Tissue enhanced (brain).
DR   MalaCards; BDNF; -.
DR   MIM; 113505; gene.
DR   MIM; 209880; phenotype.
DR   neXtProt; NX_P23560; -.
DR   OpenTargets; ENSG00000176697; -.
DR   Orphanet; 661; Ondine syndrome.
DR   Orphanet; 893; WAGR syndrome.
DR   PharmGKB; PA31891; -.
DR   VEuPathDB; HostDB:ENSG00000176697; -.
DR   eggNOG; ENOG502QRU8; Eukaryota.
DR   GeneTree; ENSGT00390000007725; -.
DR   HOGENOM; CLU_059942_0_0_1; -.
DR   InParanoid; P23560; -.
DR   OMA; YPGMRTH; -.
DR   OrthoDB; 1156054at2759; -.
DR   PhylomeDB; P23560; -.
DR   TreeFam; TF106463; -.
DR   PathwayCommons; P23560; -.
DR   Reactome; R-HSA-9022702; MECP2 regulates transcription of neuronal ligands.
DR   Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling.
DR   Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS.
DR   Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1.
DR   Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K.
DR   Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3.
DR   Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN.
DR   Reactome; R-HSA-9032759; NTRK2 activates RAC1.
DR   Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5.
DR   SignaLink; P23560; -.
DR   SIGNOR; P23560; -.
DR   BioGRID-ORCS; 627; 6 hits in 999 CRISPR screens.
DR   ChiTaRS; BDNF; human.
DR   EvolutionaryTrace; P23560; -.
DR   GeneWiki; Brain-derived_neurotrophic_factor; -.
DR   GenomeRNAi; 627; -.
DR   Pharos; P23560; Tbio.
DR   PRO; PR:P23560; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P23560; protein.
DR   Bgee; ENSG00000176697; Expressed in saphenous vein and 168 other tissues.
DR   ExpressionAtlas; P23560; baseline and differential.
DR   Genevisible; P23560; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0008021; C:synaptic vesicle; IBA:GO_Central.
DR   GO; GO:0008083; F:growth factor activity; IBA:GO_Central.
DR   GO; GO:0005163; F:nerve growth factor receptor binding; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; TAS:BHF-UCL.
DR   GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0048668; P:collateral sprouting; IDA:BHF-UCL.
DR   GO; GO:0007613; P:memory; IBA:GO_Central.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0021675; P:nerve development; IBA:GO_Central.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central.
DR   GO; GO:0007422; P:peripheral nervous system development; IBA:GO_Central.
DR   GO; GO:0031550; P:positive regulation of brain-derived neurotrophic factor receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0048672; P:positive regulation of collateral sprouting; IDA:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:1900122; P:positive regulation of receptor binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IDA:BHF-UCL.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IBA:GO_Central.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007416; P:synapse assembly; IDA:BHF-UCL.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR020430; Brain-der_neurotrophic_factor.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR020408; Nerve_growth_factor-like.
DR   InterPro; IPR002072; Nerve_growth_factor-rel.
DR   InterPro; IPR019846; Nerve_growth_factor_CS.
DR   PANTHER; PTHR11589; PTHR11589; 1.
DR   PANTHER; PTHR11589:SF3; PTHR11589:SF3; 1.
DR   Pfam; PF00243; NGF; 1.
DR   PIRSF; PIRSF001789; NGF; 1.
DR   PRINTS; PR01912; BDNFACTOR.
DR   PRINTS; PR00268; NGF.
DR   SMART; SM00140; NGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00248; NGF_1; 1.
DR   PROSITE; PS50270; NGF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Cleavage on pair of basic residues; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Glycoprotein; Growth factor;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..247
FT                   /note="BDNF precursor form"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000447533"
FT   PROPEP          19..128
FT                   /evidence="ECO:0000305|PubMed:8527932"
FT                   /id="PRO_0000019633"
FT   CHAIN           129..247
FT                   /note="Brain-derived neurotrophic factor"
FT                   /id="PRO_0000019634"
FT   SITE            57..58
FT                   /note="Cleavage; by MBTPS1"
FT                   /evidence="ECO:0000269|PubMed:11152678"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:11152678,
FT                   ECO:0000305|PubMed:19467646"
FT   DISULFID        141..208
FT                   /evidence="ECO:0000269|PubMed:10631974,
FT                   ECO:0000269|PubMed:7703225, ECO:0007744|PDB:1B8M,
FT                   ECO:0007744|PDB:1BND"
FT   DISULFID        186..237
FT                   /evidence="ECO:0000269|PubMed:10631974,
FT                   ECO:0000269|PubMed:7703225, ECO:0007744|PDB:1B8M,
FT                   ECO:0007744|PDB:1BND"
FT   DISULFID        196..239
FT                   /evidence="ECO:0000269|PubMed:10631974,
FT                   ECO:0000269|PubMed:7703225, ECO:0007744|PDB:1B8M,
FT                   ECO:0007744|PDB:1BND"
FT   VAR_SEQ         1
FT                   /note="M -> MFHQVRRVM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15666411, ECO:0000303|PubMed:17629449"
FT                   /id="VSP_037948"
FT   VAR_SEQ         1
FT                   /note="M -> MQSREEEWFHQVRRVM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15666411,
FT                   ECO:0000303|PubMed:17629449"
FT                   /id="VSP_038099"
FT   VAR_SEQ         1
FT                   /note="M -> MCGATSFLHECTRLILVTTQNAEFLQKGLQVHTCFGVYPHASVWHDC
FT                   ASQKKGCAVYLHVSVEFNKLIPENGFIKFHQVRRVM (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:17629449"
FT                   /id="VSP_038100"
FT   VAR_SEQ         1
FT                   /note="M -> MLCAISLCARVRKLRSAGRCGKFHQVRRVM (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17629449"
FT                   /id="VSP_038101"
FT   VARIANT         2
FT                   /note="T -> I (in CCHS; dbSNP:rs8192466)"
FT                   /evidence="ECO:0000269|PubMed:11840487"
FT                   /id="VAR_018260"
FT   VARIANT         66
FT                   /note="V -> M (strongly associated with susceptibility to
FT                   eating disorders such as anorexia nervosa and bulimia
FT                   nervosa; associated with poorer episodic memory; may have a
FT                   protective effect in obsessive-compulsive disorder; impairs
FT                   localization to secretory granules or synapses; decreases
FT                   density of dendritic mushroom spines and synapses;
FT                   dbSNP:rs6265)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:12553913, ECO:0000269|PubMed:12836135,
FT                   ECO:0000269|PubMed:12888803, ECO:0000269|PubMed:14566559,
FT                   ECO:0000269|PubMed:15115760, ECO:0000269|PubMed:29909994,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_004626"
FT   VARIANT         75
FT                   /note="Q -> H (in dbSNP:rs1048218)"
FT                   /id="VAR_011797"
FT   VARIANT         122
FT                   /note="M -> T (found in a small consanguineous family with
FT                   intellectual disability; unknown pathological significance;
FT                   dbSNP:rs765594245)"
FT                   /evidence="ECO:0000269|PubMed:28397838"
FT                   /id="VAR_080766"
FT   VARIANT         125
FT                   /note="R -> M (in dbSNP:rs1048220)"
FT                   /id="VAR_011798"
FT   VARIANT         127
FT                   /note="R -> L (in dbSNP:rs1048221)"
FT                   /id="VAR_011799"
FT   MUTAGEN         54
FT                   /note="R->A: Abolishes processing by MBTPS1."
FT                   /evidence="ECO:0000269|PubMed:11152678"
FT   STRAND          138..141
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          143..149
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   HELIX           150..153
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          163..166
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          168..171
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          173..178
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          180..186
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   HELIX           191..193
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   TURN            201..203
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          204..220
FT                   /evidence="ECO:0007829|PDB:1BND"
FT   STRAND          226..243
FT                   /evidence="ECO:0007829|PDB:1BND"
SQ   SEQUENCE   247 AA;  27818 MW;  0A60488254722A99 CRC64;
     MTILFLTMVI SYFGCMKAAP MKEANIRGQG GLAYPGVRTH GTLESVNGPK AGSRGLTSLA
     DTFEHVIEEL LDEDQKVRPN EENNKDADLY TSRVMLSSQV PLEPPLLFLL EEYKNYLDAA
     NMSMRVRRHS DPARRGELSV CDSISEWVTA ADKKTAVDMS GGTVTVLEKV PVSKGQLKQY
     FYETKCNPMG YTKEGCRGID KRHWNSQCRT TQSYVRALTM DSKKRIGWRF IRIDTSCVCT
     LTIKRGR
//
ID   PGM2L_HUMAN             Reviewed;         622 AA.
AC   Q6PCE3; Q96MQ7; Q9UIK3;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   23-FEB-2022, entry version 152.
DE   RecName: Full=Glucose 1,6-bisphosphate synthase {ECO:0000305};
DE            EC=2.7.1.106 {ECO:0000269|PubMed:17804405};
DE   AltName: Full=PMMLP;
DE   AltName: Full=Phosphoglucomutase-2-like 1;
GN   Name=PGM2L1 {ECO:0000312|HGNC:HGNC:20898}; Synonyms=BM32A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Mori K., Miyoshi Y., Nakamura Y.;
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-531.
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PRO-14 AND ILE-531.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17804405; DOI=10.1074/jbc.m706818200;
RA   Maliekal P., Sokolova T., Vertommen D., Veiga-da-Cunha M.,
RA   Van Schaftingen E.;
RT   "Molecular identification of mammalian phosphopentomutase and glucose-1,6-
RT   bisphosphate synthase, two members of the alpha-D-phosphohexomutase
RT   family.";
RL   J. Biol. Chem. 282:31844-31851(2007).
RN   [6]
RP   FUNCTION.
RX   PubMed=18927083; DOI=10.1074/jbc.m805224200;
RA   Veiga-da-Cunha M., Vleugels W., Maliekal P., Matthijs G.,
RA   Van Schaftingen E.;
RT   "Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-
RT   bisphosphatase.";
RL   J. Biol. Chem. 283:33988-33993(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Glucose 1,6-bisphosphate synthase using 1,3-
CC       bisphosphoglycerate as a phosphate donor and a series of 1-phosphate
CC       sugars as acceptors, including glucose 1-phosphate, mannose 1-
CC       phosphate, ribose 1-phosphate and deoxyribose 1-phosphate
CC       (PubMed:17804405). 5 or 6-phosphosugars are bad substrates, with the
CC       exception of glucose 6-phosphate (PubMed:17804405). Also synthesizes
CC       ribose 1,5-bisphosphate (PubMed:17804405). Has only low
CC       phosphopentomutase and phosphoglucomutase activities (PubMed:17804405).
CC       {ECO:0000269|PubMed:17804405, ECO:0000269|PubMed:18927083}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2R)-3-phospho-glyceroyl phosphate + alpha-D-glucose 1-
CC         phosphate = (2R)-3-phosphoglycerate + alpha-D-glucose 1,6-
CC         bisphosphate + H(+); Xref=Rhea:RHEA:16769, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:58272, ChEBI:CHEBI:58392,
CC         ChEBI:CHEBI:58601; EC=2.7.1.106;
CC         Evidence={ECO:0000269|PubMed:17804405};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16770;
CC         Evidence={ECO:0000305|PubMed:17804405};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.32 mM for alpha-D-glucose 1-phosphate (for glucose 1,6-
CC         bisphosphate synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.44 mM for alpha-D-ribose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.30 mM for 2-deoxyribose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.79 mM for alpha-D-mannose 1-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=0.36 mM for alpha-D-glucose 6-phosphate (for aldose-bisphosphate
CC         synthase activity) {ECO:0000269|PubMed:17804405};
CC         KM=5.2 uM for alpha-D-ribose 1-phosphate (for phosphomutase activity)
CC         {ECO:0000269|PubMed:17804405};
CC         KM=6.7 uM for 2-deoxyribose 1-phosphate (for phosphomutase activity)
CC         {ECO:0000269|PubMed:17804405};
CC         KM=20.7 uM for alpha-D-glucose 1-phosphate (for phosphomutase
CC         activity) {ECO:0000269|PubMed:17804405};
CC         Vmax=1.45 umol/min/mg enzyme for alpha-D-glucose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.93 umol/min/mg enzyme for alpha-D-ribose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.36 umol/min/mg enzyme for 2-deoxyribose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=1.38 umol/min/mg enzyme for alpha-D-mannose 1-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.77 umol/min/mg enzyme for alpha-D-glucose 6-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.14 umol/min/mg enzyme for alpha-D-Ribose 5-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.04 umol/min/mg enzyme for 2-deoxyribose 5-phosphate
CC         {ECO:0000269|PubMed:17804405};
CC         Vmax=0.71 umol/min/mg enzyme for alpha-D-ribose 1-phosphate (for
CC         phosphomutase activity) {ECO:0000269|PubMed:17804405};
CC         Vmax=0.09 umol/min/mg enzyme for 2-deoxyribose 1-phosphate (for
CC         phosphomutase activity) {ECO:0000269|PubMed:17804405};
CC         Vmax=0.87 umol/min/mg enzyme for alpha-D-glucose 1-phosphate (for
CC         phosphomutase activity) {ECO:0000269|PubMed:17804405};
CC   -!- SIMILARITY: Belongs to the phosphohexose mutase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB019210; BAA82756.1; -; mRNA.
DR   EMBL; AK056591; BAB71227.1; -; mRNA.
DR   EMBL; AP001085; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC059360; AAH59360.1; -; mRNA.
DR   CCDS; CCDS8231.1; -.
DR   RefSeq; NP_775853.2; NM_173582.4.
DR   SMR; Q6PCE3; -.
DR   BioGRID; 129496; 11.
DR   IntAct; Q6PCE3; 7.
DR   MINT; Q6PCE3; -.
DR   STRING; 9606.ENSP00000298198; -.
DR   iPTMnet; Q6PCE3; -.
DR   PhosphoSitePlus; Q6PCE3; -.
DR   BioMuta; PGM2L1; -.
DR   DMDM; 317373530; -.
DR   EPD; Q6PCE3; -.
DR   jPOST; Q6PCE3; -.
DR   MassIVE; Q6PCE3; -.
DR   MaxQB; Q6PCE3; -.
DR   PaxDb; Q6PCE3; -.
DR   PeptideAtlas; Q6PCE3; -.
DR   PRIDE; Q6PCE3; -.
DR   ProteomicsDB; 67064; -.
DR   Antibodypedia; 31067; 140 antibodies from 19 providers.
DR   DNASU; 283209; -.
DR   Ensembl; ENST00000298198; ENSP00000298198; ENSG00000165434.
DR   GeneID; 283209; -.
DR   KEGG; hsa:283209; -.
DR   MANE-Select; ENST00000298198.5; ENSP00000298198.4; NM_173582.6; NP_775853.2.
DR   UCSC; uc001ovb.2; human.
DR   CTD; 283209; -.
DR   GeneCards; PGM2L1; -.
DR   HGNC; HGNC:20898; PGM2L1.
DR   HPA; ENSG00000165434; Tissue enhanced (brain).
DR   MIM; 611610; gene.
DR   neXtProt; NX_Q6PCE3; -.
DR   OpenTargets; ENSG00000165434; -.
DR   PharmGKB; PA134938366; -.
DR   VEuPathDB; HostDB:ENSG00000165434; -.
DR   eggNOG; KOG1220; Eukaryota.
DR   GeneTree; ENSGT00940000158353; -.
DR   HOGENOM; CLU_016950_0_1_1; -.
DR   InParanoid; Q6PCE3; -.
DR   OMA; PQDNGYK; -.
DR   OrthoDB; 1041556at2759; -.
DR   PhylomeDB; Q6PCE3; -.
DR   TreeFam; TF300692; -.
DR   PathwayCommons; Q6PCE3; -.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70221; Glycogen breakdown (glycogenolysis).
DR   Reactome; R-HSA-70370; Galactose catabolism.
DR   SABIO-RK; Q6PCE3; -.
DR   SignaLink; Q6PCE3; -.
DR   BioGRID-ORCS; 283209; 11 hits in 1047 CRISPR screens.
DR   ChiTaRS; PGM2L1; human.
DR   GenomeRNAi; 283209; -.
DR   Pharos; Q6PCE3; Tbio.
DR   PRO; PR:Q6PCE3; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q6PCE3; protein.
DR   Bgee; ENSG00000165434; Expressed in dorsolateral prefrontal cortex and 211 other tissues.
DR   Genevisible; Q6PCE3; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0047933; F:glucose-1,6-bisphosphate synthase activity; IDA:UniProtKB.
DR   GO; GO:0016868; F:intramolecular transferase activity, phosphotransferases; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   InterPro; IPR005844; A-D-PHexomutase_a/b/a-I.
DR   InterPro; IPR016055; A-D-PHexomutase_a/b/a-I/II/III.
DR   InterPro; IPR005845; A-D-PHexomutase_a/b/a-II.
DR   InterPro; IPR005846; A-D-PHexomutase_a/b/a-III.
DR   InterPro; IPR005843; A-D-PHexomutase_C.
DR   InterPro; IPR036900; A-D-PHexomutase_C_sf.
DR   Pfam; PF02878; PGM_PMM_I; 1.
DR   Pfam; PF02879; PGM_PMM_II; 1.
DR   Pfam; PF02880; PGM_PMM_III; 1.
DR   Pfam; PF00408; PGM_PMM_IV; 1.
DR   SUPFAM; SSF53738; SSF53738; 3.
DR   SUPFAM; SSF55957; SSF55957; 1.
PE   1: Evidence at protein level;
KW   Carbohydrate metabolism; Glucose metabolism; Isomerase; Magnesium;
KW   Metal-binding; Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN           1..622
FT                   /note="Glucose 1,6-bisphosphate synthase"
FT                   /id="PRO_0000147784"
FT   REGION          175..176
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   REGION          336..337
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   REGION          434..436
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   ACT_SITE        175
FT                   /note="Phosphoserine intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   METAL           175
FT                   /note="Magnesium; via phosphate group"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   METAL           332
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   METAL           334
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   METAL           336
FT                   /note="Magnesium"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         69
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         73
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   BINDING         448
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P00949"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         14
FT                   /note="L -> P (in dbSNP:rs12049823)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028094"
FT   VARIANT         531
FT                   /note="V -> I (in dbSNP:rs592644)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028095"
FT   VARIANT         608
FT                   /note="N -> I (in dbSNP:rs36014178)"
FT                   /id="VAR_056665"
FT   CONFLICT        69
FT                   /note="T -> A (in Ref. 2; BAB71227)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   622 AA;  70442 MW;  8AE00403B5D973CA CRC64;
     MAENTEGDLN SNLLHAPYHT GDPQLDTAIG QWLRWDKNPK TKEQIENLLR NGMNKELRDR
     LCCRMTFGTA GLRSAMGAGF CYINDLTVIQ STQGMYKYLE RCFSDFKQRG FVVGYDTRGQ
     VTSSCSSQRL AKLTAAVLLA KDVPVYLFSR YVPTPFVPYA VQKLKAVAGV MITASHNRKE
     DNGYKVYWET GAQITSPHDK EILKCIEECV EPWNGSWNDN LVDTSPLKRD PLQDICRRYM
     EDLKKICFYR ELNSKTTLKF VHTSFHGVGH DYVQLAFKVF GFKPPIPVPE QKDPDPDFST
     VKCPNPEEGE SVLELSLRLA EKENARVVLA TDPDADRLAA AELQENGCWK VFTGNELAAL
     FGWWMFDCWK KNKSRNADVK NVYMLATTVS SKILKAIALK EGFHFEETLP GFKWIGSRII
     DLLENGKEVL FAFEESIGFL CGTSVLDKDG VSAAVVVAEM ASYLETMNIT LKQQLVKVYE
     KYGYHISKTS YFLCYEPPTI KSIFERLRNF DSPKEYPKFC GTFAILHVRD VTTGYDSSQP
     NKKSVLPVSK NSQMITFTFQ NGCVATLRTS GTEPKIKYYA EMCASPDQSD TALLEEELKK
     LIDALIENFL QPSKNGLIWR SV
//
ID   SIM14_HUMAN             Reviewed;          99 AA.
AC   Q96QK8;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   23-FEB-2022, entry version 136.
DE   RecName: Full=Small integral membrane protein 14;
GN   Name=SMIM14; Synonyms=C4orf34;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND MUTAGENESIS OF 26-LEU-ARG-27 AND
RP   76-ARG-GLY-77.
RX   PubMed=24499674; DOI=10.5483/bmbrep.2014.47.10.252;
RA   Jun M.H., Jun Y.W., Kim K.H., Lee J.A., Jang D.J.;
RT   "Characterization of the cellular localization of C4orf34 as a novel
RT   endoplasmic reticulum resident protein.";
RL   BMB Rep. 47:563-568(2014).
CC   -!- INTERACTION:
CC       Q96QK8; Q969F0: FATE1; NbExp=4; IntAct=EBI-373430, EBI-743099;
CC       Q96QK8; O43765: SGTA; NbExp=3; IntAct=EBI-373430, EBI-347996;
CC       Q96QK8; P03973: SLPI; NbExp=3; IntAct=EBI-373430, EBI-355293;
CC       Q96QK8; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-373430, EBI-5235340;
CC       Q96QK8; Q69YG0: TMEM42; NbExp=3; IntAct=EBI-373430, EBI-12038591;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:24499674}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:24499674}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BC008502; AAH08502.1; -; mRNA.
DR   CCDS; CCDS3456.1; -.
DR   RefSeq; NP_001304825.1; NM_001317896.1.
DR   RefSeq; NP_001304826.1; NM_001317897.1.
DR   RefSeq; NP_777581.1; NM_174921.2.
DR   RefSeq; XP_016863351.1; XM_017007862.1.
DR   RefSeq; XP_016863352.1; XM_017007863.1.
DR   BioGRID; 128406; 6.
DR   IntAct; Q96QK8; 6.
DR   MINT; Q96QK8; -.
DR   STRING; 9606.ENSP00000295958; -.
DR   iPTMnet; Q96QK8; -.
DR   PhosphoSitePlus; Q96QK8; -.
DR   BioMuta; SMIM14; -.
DR   DMDM; 74732680; -.
DR   jPOST; Q96QK8; -.
DR   MassIVE; Q96QK8; -.
DR   PaxDb; Q96QK8; -.
DR   PeptideAtlas; Q96QK8; -.
DR   PRIDE; Q96QK8; -.
DR   ProteomicsDB; 77885; -.
DR   Antibodypedia; 54789; 107 antibodies from 14 providers.
DR   DNASU; 201895; -.
DR   Ensembl; ENST00000295958; ENSP00000295958; ENSG00000163683.
DR   GeneID; 201895; -.
DR   KEGG; hsa:201895; -.
DR   MANE-Select; ENST00000295958.10; ENSP00000295958.4; NM_174921.3; NP_777581.1.
DR   UCSC; uc003guo.4; human.
DR   CTD; 201895; -.
DR   DisGeNET; 201895; -.
DR   GeneCards; SMIM14; -.
DR   HGNC; HGNC:27321; SMIM14.
DR   HPA; ENSG00000163683; Tissue enhanced (liver).
DR   neXtProt; NX_Q96QK8; -.
DR   OpenTargets; ENSG00000163683; -.
DR   PharmGKB; PA162379760; -.
DR   VEuPathDB; HostDB:ENSG00000163683; -.
DR   eggNOG; ENOG502S28C; Eukaryota.
DR   GeneTree; ENSGT00390000018294; -.
DR   HOGENOM; CLU_152284_0_0_1; -.
DR   InParanoid; Q96QK8; -.
DR   OMA; RQNQNAC; -.
DR   OrthoDB; 1588274at2759; -.
DR   PhylomeDB; Q96QK8; -.
DR   TreeFam; TF314023; -.
DR   PathwayCommons; Q96QK8; -.
DR   SignaLink; Q96QK8; -.
DR   BioGRID-ORCS; 201895; 4 hits in 1006 CRISPR screens.
DR   ChiTaRS; SMIM14; human.
DR   GenomeRNAi; 201895; -.
DR   Pharos; Q96QK8; Tdark.
DR   PRO; PR:Q96QK8; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q96QK8; protein.
DR   Bgee; ENSG00000163683; Expressed in layer of synovial tissue and 224 other tissues.
DR   ExpressionAtlas; Q96QK8; baseline and differential.
DR   Genevisible; Q96QK8; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0001835; P:blastocyst hatching; IEA:Ensembl.
DR   InterPro; IPR020309; Uncharacterised_CD034/YQF4.
DR   PANTHER; PTHR31019; PTHR31019; 1.
DR   Pfam; PF11027; DUF2615; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..99
FT                   /note="Small integral membrane protein 14"
FT                   /id="PRO_0000268816"
FT   TOPO_DOM        1..49
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        50..70
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        71..99
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          78..99
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MUTAGEN         26..27
FT                   /note="LR->TN: In N-gly,N; creates a N-glycosylation site."
FT                   /evidence="ECO:0000269|PubMed:24499674"
FT   MUTAGEN         76..77
FT                   /note="RG->TN: In N-gly,C; does not creates a N-
FT                   glycosylation site."
FT                   /evidence="ECO:0000269|PubMed:24499674"
SQ   SEQUENCE   99 AA;  10710 MW;  B0E90C424D2D34EB CRC64;
     MAEGGFDPCE CVCSHEHAMR RLINLLRQSQ SYCTDTECLQ ELPGPSGDNG ISVTMILVAW
     MVIALILFLL RPPNLRGSSL PGKPTSPHNG QDPPAPPVD
//
ID   GA2L3_HUMAN             Reviewed;         694 AA.
AC   Q86XJ1; B2RCN2;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   23-FEB-2022, entry version 139.
DE   RecName: Full=GAS2-like protein 3;
DE   AltName: Full=Growth arrest-specific protein 2-like 3;
GN   Name=GAS2L3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-441 AND SER-570, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [6]
RP   FUNCTION, INTERACTION WITH ACTIN AND MICROTUBULES, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=21561867; DOI=10.1074/jbc.m111.242263;
RA   Stroud M.J., Kammerer R.A., Ballestrem C.;
RT   "Characterization of G2L3 (GAS2-like 3), a new microtubule- and actin-
RT   binding protein related to spectraplakins.";
RL   J. Biol. Chem. 286:24987-24995(2011).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   INTERACTION WITH MAPRE1, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   373-ILE-PRO-374 AND 461-ILE-PRO-462.
RX   PubMed=24706950; DOI=10.1242/jcs.140558;
RA   Stroud M.J., Nazgiewicz A., McKenzie E.A., Wang Y., Kammerer R.A.,
RA   Ballestrem C.;
RT   "GAS2-like proteins mediate communication between microtubules and actin
RT   through interactions with end-binding proteins.";
RL   J. Cell Sci. 127:2672-2682(2014).
CC   -!- FUNCTION: Cytoskeletal linker protein. May promote and stabilize the
CC       formation of the actin and microtubule network.
CC       {ECO:0000269|PubMed:21561867}.
CC   -!- SUBUNIT: Interacts (via CH domain) with F-actin (PubMed:21561867).
CC       Interacts (via C terminus) with microtubules (PubMed:21561867).
CC       Interacts with MAPRE1 (PubMed:24706950). {ECO:0000269|PubMed:21561867,
CC       ECO:0000269|PubMed:24706950}.
CC   -!- INTERACTION:
CC       Q86XJ1; Q96GD4: AURKB; NbExp=4; IntAct=EBI-9248152, EBI-624291;
CC       Q86XJ1; O15392: BIRC5; NbExp=4; IntAct=EBI-9248152, EBI-518823;
CC       Q86XJ1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-9248152, EBI-979174;
CC       Q86XJ1; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-9248152, EBI-10242151;
CC       Q86XJ1; P60660: MYL6; NbExp=3; IntAct=EBI-9248152, EBI-300817;
CC       Q86XJ1; Q969E8: TSR2; NbExp=3; IntAct=EBI-9248152, EBI-746981;
CC       Q86XJ1; Q15915: ZIC1; NbExp=3; IntAct=EBI-9248152, EBI-11963196;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21561867}.
CC       Cytoplasm, cytoskeleton {ECO:0000269|PubMed:21561867,
CC       ECO:0000269|PubMed:24706950}. Note=Localizes to microtubule and actin
CC       cytoskeletons. {ECO:0000269|PubMed:21561867,
CC       ECO:0000269|PubMed:24706950}.
CC   -!- TISSUE SPECIFICITY: Expressed in the pancreas, heart, liver, placenta,
CC       brain, skeletal muscle, kidney and lung. {ECO:0000269|PubMed:21561867}.
CC   -!- DOMAIN: The GAR domain modulates the binding strength to each
CC       cytoskeletal network. {ECO:0000269|PubMed:21561867}.
CC   -!- SIMILARITY: Belongs to the GAS2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK315189; BAG37629.1; -; mRNA.
DR   EMBL; CH471054; EAW97641.1; -; Genomic_DNA.
DR   EMBL; BC043366; AAH43366.1; -; mRNA.
DR   CCDS; CCDS9079.1; -.
DR   RefSeq; NP_001290059.1; NM_001303130.1.
DR   RefSeq; NP_777602.1; NM_174942.2.
DR   RefSeq; XP_005268861.1; XM_005268804.3.
DR   RefSeq; XP_011536521.1; XM_011538219.2.
DR   RefSeq; XP_011536522.1; XM_011538220.2.
DR   RefSeq; XP_011536523.1; XM_011538221.2.
DR   RefSeq; XP_016874695.1; XM_017019206.1.
DR   SMR; Q86XJ1; -.
DR   BioGRID; 129559; 25.
DR   IntAct; Q86XJ1; 12.
DR   MINT; Q86XJ1; -.
DR   STRING; 9606.ENSP00000448955; -.
DR   GlyGen; Q86XJ1; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q86XJ1; -.
DR   PhosphoSitePlus; Q86XJ1; -.
DR   BioMuta; GAS2L3; -.
DR   DMDM; 73919616; -.
DR   EPD; Q86XJ1; -.
DR   jPOST; Q86XJ1; -.
DR   MassIVE; Q86XJ1; -.
DR   MaxQB; Q86XJ1; -.
DR   PaxDb; Q86XJ1; -.
DR   PeptideAtlas; Q86XJ1; -.
DR   PRIDE; Q86XJ1; -.
DR   ProteomicsDB; 70285; -.
DR   Antibodypedia; 30346; 97 antibodies from 16 providers.
DR   DNASU; 283431; -.
DR   Ensembl; ENST00000266754; ENSP00000266754; ENSG00000139354.
DR   Ensembl; ENST00000539410; ENSP00000439672; ENSG00000139354.
DR   Ensembl; ENST00000547754; ENSP00000448955; ENSG00000139354.
DR   GeneID; 283431; -.
DR   KEGG; hsa:283431; -.
DR   MANE-Select; ENST00000547754.6; ENSP00000448955.1; NM_174942.3; NP_777602.1.
DR   UCSC; uc001thu.4; human.
DR   CTD; 283431; -.
DR   GeneCards; GAS2L3; -.
DR   HGNC; HGNC:27475; GAS2L3.
DR   HPA; ENSG00000139354; Low tissue specificity.
DR   neXtProt; NX_Q86XJ1; -.
DR   OpenTargets; ENSG00000139354; -.
DR   PharmGKB; PA134979032; -.
DR   VEuPathDB; HostDB:ENSG00000139354; -.
DR   eggNOG; KOG0516; Eukaryota.
DR   GeneTree; ENSGT00940000159389; -.
DR   HOGENOM; CLU_025484_3_0_1; -.
DR   InParanoid; Q86XJ1; -.
DR   OMA; EPRNFPM; -.
DR   OrthoDB; 1343422at2759; -.
DR   PhylomeDB; Q86XJ1; -.
DR   TreeFam; TF323754; -.
DR   PathwayCommons; Q86XJ1; -.
DR   SignaLink; Q86XJ1; -.
DR   BioGRID-ORCS; 283431; 4 hits in 1052 CRISPR screens.
DR   ChiTaRS; GAS2L3; human.
DR   GenomeRNAi; 283431; -.
DR   Pharos; Q86XJ1; Tbio.
DR   PRO; PR:Q86XJ1; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q86XJ1; protein.
DR   Bgee; ENSG00000139354; Expressed in trigeminal ganglion and 179 other tissues.
DR   ExpressionAtlas; Q86XJ1; baseline and differential.
DR   Genevisible; Q86XJ1; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005884; C:actin filament; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0008093; F:cytoskeletal anchor activity; IBA:GO_Central.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0051764; P:actin crosslink formation; IBA:GO_Central.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IDA:UniProtKB.
DR   CDD; cd00014; CH; 1.
DR   Gene3D; 1.10.418.10; -; 1.
DR   Gene3D; 3.30.920.20; -; 1.
DR   InterPro; IPR001715; CH-domain.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR003108; GAR_dom.
DR   InterPro; IPR036534; GAR_dom_sf.
DR   InterPro; IPR029932; GAS2L3.
DR   PANTHER; PTHR46756:SF7; PTHR46756:SF7; 1.
DR   Pfam; PF00307; CH; 1.
DR   Pfam; PF02187; GAS2; 1.
DR   SMART; SM00033; CH; 1.
DR   SMART; SM00243; GAS2; 1.
DR   SUPFAM; SSF143575; SSF143575; 1.
DR   SUPFAM; SSF47576; SSF47576; 1.
DR   PROSITE; PS50021; CH; 1.
DR   PROSITE; PS51460; GAR; 1.
PE   1: Evidence at protein level;
KW   Actin-binding; Cytoplasm; Cytoskeleton; Microtubule; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..694
FT                   /note="GAS2-like protein 3"
FT                   /id="PRO_0000190446"
FT   DOMAIN          48..168
FT                   /note="Calponin-homology (CH)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          208..281
FT                   /note="GAR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00792"
FT   REGION          299..694
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        317..337
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        361..424
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        431..466
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        483..501
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        511..543
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        555..648
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        662..688
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         441
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         570
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         461
FT                   /note="L -> S (in dbSNP:rs11834625)"
FT                   /id="VAR_033944"
FT   VARIANT         500
FT                   /note="P -> T (in dbSNP:rs17030365)"
FT                   /id="VAR_033945"
FT   MUTAGEN         373..374
FT                   /note="LP->NN: No effect on microtubule localization and
FT                   MAPRE1 binding; when associated with 461-N-N-462."
FT                   /evidence="ECO:0000269|PubMed:24706950"
FT   MUTAGEN         461..462
FT                   /note="LP->NN: No effect on microtubule localization and
FT                   MAPRE1 binding; when associated with 373-N-N-374."
FT                   /evidence="ECO:0000269|PubMed:24706950"
SQ   SEQUENCE   694 AA;  75214 MW;  FF20533B5A0D4844 CRC64;
     MQPAIQVWFG EDLPLSPRSP LTPRHGPGLA NVCQYDEWIA VRHEATLLPM QEDLSIWLSG
     LLGIKVKAEK LLEELDNGVL LCQLIDVLQN MVKTCNSEES GNFPMRKVPC KKDAASGSFF
     ARDNTANFLH WCRDIGVDET YLFESEGLVL HKDPRQVYLC LLEIGRIVSR YGVEPPVLVK
     LEKEIELEET LLNTSGPEDS ISIPKSCCRH EELHEAVKHI AEDPPCSCSH RFSIEYLSEG
     RYRLGDKILF IRMLHGKHVM VRVGGGWDTL QGFLLKYDPC RILQFATLEQ KILAFQKGVS
     NESVPDSPAR TPQPPEMNPL SAVNMFQKQN SKPSVPVSIP KSKEKQGRPP GALVPASSLK
     GGNLGSMSVR SKLPNSPAAS SHPKLKSSKG ITKKPQAPSN NASSSLASLN PVGKNTSSPA
     LPRTAPCISE SPRKCISSPN TPKAKVIPAQ NSADLPESTL LPNKCSGKTQ PKYLKHNHIS
     SRDNAVSHLA AHSNSSSKCP KLPKANIPVR PKPSFQSSAK MTKTSSKTIA TGLGTQSQPS
     DGAPQAKPVP AQKLKSALNL NQPVSVSSVS PVKATQKSKD KNIVSATKKQ PQNKSAFQKT
     GPSSLKSPGR TPLSIVSLPQ SSTKTQTAPK SAQTVAKSQH STKGPPRSGK TPASIRKPPS
     SVKDADSGDK KPTAKKKEDD DHYFVMTGSK KPRK
//
ID   RAB3I_HUMAN             Reviewed;         476 AA.
AC   Q96QF0; B7WPJ6; Q6PCE4; Q96A24; Q96QE6; Q96QE7; Q96QE8; Q96QE9; Q96QF1;
AC   Q9H673;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   23-FEB-2022, entry version 168.
DE   RecName: Full=Rab-3A-interacting protein;
DE            Short=Rab3A-interacting protein;
DE   AltName: Full=Rabin-3;
DE   AltName: Full=SSX2-interacting protein;
GN   Name=RAB3IP {ECO:0000312|EMBL:CAC59836.1}; Synonyms=RABIN8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAC59836.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), INTERACTION WITH
RP   SSX2, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Testis {ECO:0000269|PubMed:12007189};
RX   PubMed=12007189; DOI=10.1002/gcc.10073;
RA   de Bruijn D.R.H., dos Santos N.R., Kater-Baats E., Thijssen J.,
RA   van den Berk L., Stap J., Balemans M., Schepens M., Merkx G.,
RA   van Kessel A.G.;
RT   "The cancer-related protein SSX2 interacts with the human homologue of a
RT   Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP.";
RL   Genes Chromosomes Cancer 34:285-298(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH RAB3A; RAB8A AND
RP   RAB8B, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=12221131; DOI=10.1091/mbc.e02-03-0143;
RA   Hattula K., Furuhjelm J., Arffman A., Peranen J.;
RT   "A Rab8-specific GDP/GTP exchange factor is involved in actin remodeling
RT   and polarized membrane transport.";
RL   Mol. Biol. Cell 13:3268-3280(2002).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAB15391.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 8).
RC   TISSUE=Small intestine {ECO:0000312|EMBL:BAB15391.1}, and
RC   Teratocarcinoma {ECO:0000312|EMBL:BAB55202.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAH59358.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 7 AND 8).
RC   TISSUE=Brain {ECO:0000312|EMBL:AAH59358.1}, and
RC   Colon {ECO:0000312|EMBL:AAH15548.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-163, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   FUNCTION AS GUANYL-NUCLEOTIDE EXCHANGE FACTOR.
RX   PubMed=20937701; DOI=10.1083/jcb.201008051;
RA   Yoshimura S., Gerondopoulos A., Linford A., Rigden D.J., Barr F.A.;
RT   "Family-wide characterization of the DENN domain Rab GDP-GTP exchange
RT   factors.";
RL   J. Cell Biol. 191:367-381(2010).
RN   [11]
RP   FUNCTION.
RX   PubMed=20890297; DOI=10.1038/ncb2106;
RA   Bryant D.M., Datta A., Rodriguez-Fraticelli A.E., Peraenen J.,
RA   Martin-Belmonte F., Mostov K.E.;
RT   "A molecular network for de novo generation of the apical surface and
RT   lumen.";
RL   Nat. Cell Biol. 12:1035-1045(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   INTERACTION WITH DCDC1.
RX   PubMed=22159412; DOI=10.1242/jcs.085407;
RA   Kaplan A., Reiner O.;
RT   "Linking cytoplasmic dynein and transport of Rab8 vesicles to the midbody
RT   during cytokinesis by the doublecortin domain-containing 5 protein.";
RL   J. Cell Sci. 124:3989-4000(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-163; SER-266 AND SER-288, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH RAB8A.
RX   PubMed=26824392; DOI=10.7554/elife.12813;
RA   Steger M., Tonelli F., Ito G., Davies P., Trost M., Vetter M., Wachter S.,
RA   Lorentzen E., Duddy G., Wilson S., Baptista M.A., Fiske B.K., Fell M.J.,
RA   Morrow J.A., Reith A.D., Alessi D.R., Mann M.;
RT   "Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates
RT   a subset of Rab GTPases.";
RL   Elife 5:0-0(2016).
RN   [17]
RP   INTERACTION WITH TRAPPC14, AND SUBCELLULAR LOCATION.
RX   PubMed=31467083; DOI=10.1074/jbc.ra119.008615;
RA   Cuenca A., Insinna C., Zhao H., John P., Weiss M.A., Lu Q., Walia V.,
RA   Specht S., Manivannan S., Stauffer J., Peden A.A., Westlake C.J.;
RT   "The C7orf43/TRAPPC14 component links the TRAPPII complex to Rabin8 for
RT   preciliary vesicle tethering at the mother centriole during ciliogenesis.";
RL   J. Biol. Chem. 294:15418-15434(2019).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) which may activate
CC       RAB8A and RAB8B (PubMed:12221131, PubMed:26824392). Promotes the
CC       exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into
CC       their active GTP-bound form (PubMed:12221131, PubMed:26824392).
CC       Mediates the release of GDP from RAB8A and RAB8B but not from RAB3A or
CC       RAB5 (PubMed:20937701, PubMed:26824392). Modulates actin organization
CC       and promotes polarized transport of RAB8A-specific vesicles to the cell
CC       surface (PubMed:12221131). Together with RAB11A, RAB8A, the exocyst
CC       complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of
CC       PODXL to the apical membrane initiation sites (AMIS), apical surface
CC       formation and lumenogenesis (PubMed:20890297).
CC       {ECO:0000269|PubMed:12221131, ECO:0000269|PubMed:20890297,
CC       ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:26824392}.
CC   -!- SUBUNIT: Interacts with the N-terminal region of SSX2
CC       (PubMed:12007189). Interacts with the GDP-bound forms of RAB8A and
CC       RAB8B (PubMed:26824392, PubMed:12221131). The interaction with RAB8A is
CC       prevented by phosphorylation of RAB8A at 'Thr-72' (PubMed:26824392).
CC       Interacts with the GDP-bound forms of RAB3A and RAB3D
CC       (PubMed:12221131). Interacts with DCDC1 (PubMed:22159412,
CC       PubMed:12007189, PubMed:12221131, PubMed:26824392). Interacts (via the
CC       N-terminal region) with TRAPPC14; this interaction mediates RAB3IP
CC       association with the TRAPP II complex (PubMed:31467083).
CC       {ECO:0000269|PubMed:12007189, ECO:0000269|PubMed:12221131,
CC       ECO:0000269|PubMed:22159412, ECO:0000269|PubMed:26824392,
CC       ECO:0000269|PubMed:31467083}.
CC   -!- INTERACTION:
CC       Q96QF0; Q8N9N5: BANP; NbExp=3; IntAct=EBI-747844, EBI-744695;
CC       Q96QF0; Q9NX63: CHCHD3; NbExp=3; IntAct=EBI-747844, EBI-743375;
CC       Q96QF0; Q86V42: FAM124A; NbExp=3; IntAct=EBI-747844, EBI-744506;
CC       Q96QF0; Q6A162: KRT40; NbExp=3; IntAct=EBI-747844, EBI-10171697;
CC       Q96QF0; P41227: NAA10; NbExp=3; IntAct=EBI-747844, EBI-747693;
CC       Q96QF0; O60568: PLOD3; NbExp=4; IntAct=EBI-747844, EBI-741582;
CC       Q96QF0; O60437: PPL; NbExp=3; IntAct=EBI-747844, EBI-368321;
CC       Q96QF0; P20336: RAB3A; NbExp=3; IntAct=EBI-747844, EBI-1045943;
CC       Q96QF0; Q8TBN0: RAB3IL1; NbExp=9; IntAct=EBI-747844, EBI-743796;
CC       Q96QF0; P61006: RAB8A; NbExp=5; IntAct=EBI-747844, EBI-722293;
CC       Q96QF0; Q96T51: RUFY1; NbExp=3; IntAct=EBI-747844, EBI-3941207;
CC       Q96QF0; P31947: SFN; NbExp=3; IntAct=EBI-747844, EBI-476295;
CC       Q96QF0; Q16385: SSX2B; NbExp=4; IntAct=EBI-747844, EBI-2210673;
CC       Q96QF0; P48553: TRAPPC10; NbExp=7; IntAct=EBI-747844, EBI-6160572;
CC       Q96QF0; O75865: TRAPPC6A; NbExp=4; IntAct=EBI-747844, EBI-743573;
CC       Q96QF0; Q86VK4: ZNF410; NbExp=3; IntAct=EBI-747844, EBI-720304;
CC       Q96QF0; PRO_0000449633 [P0DTD1]: rep; Xeno; NbExp=4; IntAct=EBI-747844, EBI-25492395;
CC       Q96QF0-1; Q8NFJ9: BBS1; NbExp=2; IntAct=EBI-747860, EBI-1805484;
CC       Q96QF0-2; O60568: PLOD3; NbExp=3; IntAct=EBI-747865, EBI-741582;
CC       Q96QF0-2; P62491: RAB11A; NbExp=8; IntAct=EBI-747865, EBI-745098;
CC       Q96QF0-2; O75154-1: RAB11FIP3; NbExp=6; IntAct=EBI-747865, EBI-15605207;
CC       Q96QF0-2; Q96QF0-2: RAB3IP; NbExp=2; IntAct=EBI-747865, EBI-747865;
CC       Q96QF0-2; P61006: RAB8A; NbExp=2; IntAct=EBI-747865, EBI-722293;
CC       Q96QF0-2; Q16385: SSX2B; NbExp=4; IntAct=EBI-747865, EBI-2210673;
CC       Q96QF0-7; P46379-2: BAG6; NbExp=3; IntAct=EBI-11984839, EBI-10988864;
CC       Q96QF0-7; Q8N9N5-2: BANP; NbExp=6; IntAct=EBI-11984839, EBI-11524452;
CC       Q96QF0-7; Q8N9N5-7: BANP; NbExp=3; IntAct=EBI-11984839, EBI-16429296;
CC       Q96QF0-7; A0A1B0GWI1: CCDC196; NbExp=3; IntAct=EBI-11984839, EBI-10181422;
CC       Q96QF0-7; G5E9A7: DMWD; NbExp=3; IntAct=EBI-11984839, EBI-10976677;
CC       Q96QF0-7; P59910: DNAJB13; NbExp=3; IntAct=EBI-11984839, EBI-11514233;
CC       Q96QF0-7; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-11984839, EBI-12593112;
CC       Q96QF0-7; P50570-2: DNM2; NbExp=3; IntAct=EBI-11984839, EBI-10968534;
CC       Q96QF0-7; P14136: GFAP; NbExp=3; IntAct=EBI-11984839, EBI-744302;
CC       Q96QF0-7; Q9UMF0: ICAM5; NbExp=3; IntAct=EBI-11984839, EBI-6398041;
CC       Q96QF0-7; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-11984839, EBI-1055254;
CC       Q96QF0-7; O14901: KLF11; NbExp=3; IntAct=EBI-11984839, EBI-948266;
CC       Q96QF0-7; Q8IYB1: MB21D2; NbExp=3; IntAct=EBI-11984839, EBI-11323212;
CC       Q96QF0-7; O95983-2: MBD3; NbExp=3; IntAct=EBI-11984839, EBI-11978579;
CC       Q96QF0-7; P41227: NAA10; NbExp=3; IntAct=EBI-11984839, EBI-747693;
CC       Q96QF0-7; P19404: NDUFV2; NbExp=3; IntAct=EBI-11984839, EBI-713665;
CC       Q96QF0-7; Q86TG7-2: PEG10; NbExp=3; IntAct=EBI-11984839, EBI-6259410;
CC       Q96QF0-7; Q16512: PKN1; NbExp=3; IntAct=EBI-11984839, EBI-602382;
CC       Q96QF0-7; D3DTS7: PMP22; NbExp=3; IntAct=EBI-11984839, EBI-25882629;
CC       Q96QF0-7; O60437: PPL; NbExp=3; IntAct=EBI-11984839, EBI-368321;
CC       Q96QF0-7; O43741: PRKAB2; NbExp=3; IntAct=EBI-11984839, EBI-1053424;
CC       Q96QF0-7; P20336: RAB3A; NbExp=3; IntAct=EBI-11984839, EBI-1045943;
CC       Q96QF0-7; O95716: RAB3D; NbExp=3; IntAct=EBI-11984839, EBI-3386067;
CC       Q96QF0-7; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-11984839, EBI-5235340;
CC       Q96QF0-7; Q8IYX1: TBC1D21; NbExp=3; IntAct=EBI-11984839, EBI-12018146;
CC       Q96QF0-7; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-11984839, EBI-11139477;
CC       Q96QF0-7; O14656-2: TOR1A; NbExp=3; IntAct=EBI-11984839, EBI-25847109;
CC       Q96QF0-7; O75865-2: TRAPPC6A; NbExp=3; IntAct=EBI-11984839, EBI-8451480;
CC       Q96QF0-7; Q05516: ZBTB16; NbExp=3; IntAct=EBI-11984839, EBI-711925;
CC       Q96QF0-7; Q86VK4-3: ZNF410; NbExp=3; IntAct=EBI-11984839, EBI-11741890;
CC       Q96QF0-7; P36508: ZNF76; NbExp=3; IntAct=EBI-11984839, EBI-7254550;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12007189,
CC       ECO:0000269|PubMed:31467083}. Nucleus {ECO:0000269|PubMed:12007189}.
CC       Cytoplasm, cytoskeleton {ECO:0000269|PubMed:12221131}. Cell projection,
CC       lamellipodium. Vesicle {ECO:0000269|PubMed:31467083}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:31467083}. Note=Predominantly cytoplasmic but a
CC       small proportion colocalizes with SSX2 in the nucleus. Activation of
CC       protein kinase C results in redistribution to the periphery of
CC       lamellipodia. {ECO:0000269|PubMed:12007189}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=2 {ECO:0000269|PubMed:12007189}; Synonyms=alpha2
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-1; Sequence=Displayed;
CC       Name=1 {ECO:0000269|PubMed:12007189}; Synonyms=alpha1
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-2; Sequence=VSP_051755;
CC       Name=3 {ECO:0000269|PubMed:12007189}; Synonyms=beta1
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-3; Sequence=VSP_051755, VSP_051761, VSP_051762;
CC       Name=4 {ECO:0000269|PubMed:12007189}; Synonyms=beta2
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-4; Sequence=VSP_051761, VSP_051762;
CC       Name=5 {ECO:0000269|PubMed:12007189}; Synonyms=gamma1
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-5; Sequence=VSP_051755, VSP_051757, VSP_051759;
CC       Name=6 {ECO:0000269|PubMed:12007189}; Synonyms=gamma2
CC       {ECO:0000303|PubMed:12007189};
CC         IsoId=Q96QF0-6; Sequence=VSP_051757, VSP_051759;
CC       Name=7 {ECO:0000305};
CC         IsoId=Q96QF0-7; Sequence=VSP_051755, VSP_051758, VSP_051760;
CC       Name=8 {ECO:0000305};
CC         IsoId=Q96QF0-8; Sequence=VSP_051756;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney, heart, pancreas and
CC       placenta. Not detected in skeletal muscle or liver.
CC       {ECO:0000269|PubMed:12007189, ECO:0000269|PubMed:12221131}.
CC   -!- SIMILARITY: Belongs to the SEC2 family. {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ312896; CAC59835.1; -; mRNA.
DR   EMBL; AJ312897; CAC59836.1; -; mRNA.
DR   EMBL; AJ312898; CAC59837.1; -; mRNA.
DR   EMBL; AJ312899; CAC59838.1; -; mRNA.
DR   EMBL; AJ312900; CAC59839.1; -; mRNA.
DR   EMBL; AJ312901; CAC59840.1; -; mRNA.
DR   EMBL; AK026201; BAB15391.1; -; mRNA.
DR   EMBL; AK027566; BAB55202.1; -; mRNA.
DR   EMBL; AK027671; BAB55283.1; -; mRNA.
DR   EMBL; AC025263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015548; AAH15548.1; -; mRNA.
DR   EMBL; BC059358; AAH59358.1; -; mRNA.
DR   CCDS; CCDS41811.1; -. [Q96QF0-4]
DR   CCDS; CCDS44942.1; -. [Q96QF0-8]
DR   CCDS; CCDS8993.1; -. [Q96QF0-1]
DR   CCDS; CCDS8995.1; -. [Q96QF0-2]
DR   CCDS; CCDS8996.1; -. [Q96QF0-3]
DR   RefSeq; NP_001019818.1; NM_001024647.3. [Q96QF0-8]
DR   RefSeq; NP_001265331.1; NM_001278402.1. [Q96QF0-8]
DR   RefSeq; NP_071901.2; NM_022456.4. [Q96QF0-2]
DR   RefSeq; NP_783322.1; NM_175623.3. [Q96QF0-1]
DR   RefSeq; NP_783323.1; NM_175624.3. [Q96QF0-3]
DR   RefSeq; NP_783324.1; NM_175625.3. [Q96QF0-4]
DR   RefSeq; XP_016874262.1; XM_017018773.1. [Q96QF0-2]
DR   RefSeq; XP_016874265.1; XM_017018776.1.
DR   RefSeq; XP_016874266.1; XM_017018777.1. [Q96QF0-8]
DR   PDB; 4LHX; X-ray; 3.05 A; C/D/E/F=173-248.
DR   PDB; 4LHY; X-ray; 3.10 A; C/D/E/F=173-248.
DR   PDB; 4LHZ; X-ray; 3.20 A; C/D/E/F=173-248.
DR   PDB; 4UJ3; X-ray; 3.00 A; B/E/H/K/N/Q/T/W=286-476.
DR   PDB; 4UJ4; X-ray; 4.20 A; B/E/H/K=286-476.
DR   PDB; 4UJ5; X-ray; 2.60 A; C/D=286-476.
DR   PDB; 6F6P; X-ray; 2.45 A; A/B/C/D=159-261.
DR   PDBsum; 4LHX; -.
DR   PDBsum; 4LHY; -.
DR   PDBsum; 4LHZ; -.
DR   PDBsum; 4UJ3; -.
DR   PDBsum; 4UJ4; -.
DR   PDBsum; 4UJ5; -.
DR   PDBsum; 6F6P; -.
DR   SMR; Q96QF0; -.
DR   BioGRID; 125566; 108.
DR   DIP; DIP-41703N; -.
DR   IntAct; Q96QF0; 90.
DR   MINT; Q96QF0; -.
DR   STRING; 9606.ENSP00000447300; -.
DR   GlyGen; Q96QF0; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96QF0; -.
DR   PhosphoSitePlus; Q96QF0; -.
DR   BioMuta; RAB3IP; -.
DR   DMDM; 71152025; -.
DR   EPD; Q96QF0; -.
DR   jPOST; Q96QF0; -.
DR   MassIVE; Q96QF0; -.
DR   MaxQB; Q96QF0; -.
DR   PaxDb; Q96QF0; -.
DR   PeptideAtlas; Q96QF0; -.
DR   PRIDE; Q96QF0; -.
DR   ProteomicsDB; 77867; -. [Q96QF0-1]
DR   ProteomicsDB; 77868; -. [Q96QF0-2]
DR   ProteomicsDB; 77869; -. [Q96QF0-3]
DR   ProteomicsDB; 77870; -. [Q96QF0-4]
DR   ProteomicsDB; 77871; -. [Q96QF0-5]
DR   ProteomicsDB; 77872; -. [Q96QF0-6]
DR   ProteomicsDB; 77873; -. [Q96QF0-7]
DR   ProteomicsDB; 77874; -. [Q96QF0-8]
DR   Antibodypedia; 29437; 219 antibodies from 24 providers.
DR   DNASU; 117177; -.
DR   Ensembl; ENST00000247833; ENSP00000247833; ENSG00000127328. [Q96QF0-2]
DR   Ensembl; ENST00000362025; ENSP00000355381; ENSG00000127328. [Q96QF0-4]
DR   Ensembl; ENST00000378815; ENSP00000368092; ENSG00000127328. [Q96QF0-7]
DR   Ensembl; ENST00000417413; ENSP00000436304; ENSG00000127328. [Q96QF0-5]
DR   Ensembl; ENST00000483530; ENSP00000419216; ENSG00000127328. [Q96QF0-3]
DR   Ensembl; ENST00000550536; ENSP00000447300; ENSG00000127328.
DR   Ensembl; ENST00000551641; ENSP00000448773; ENSG00000127328. [Q96QF0-8]
DR   Ensembl; ENST00000552199; ENSP00000448944; ENSG00000127328. [Q96QF0-6]
DR   Ensembl; ENST00000553099; ENSP00000448027; ENSG00000127328. [Q96QF0-8]
DR   GeneID; 117177; -.
DR   KEGG; hsa:117177; -.
DR   MANE-Select; ENST00000247833.12; ENSP00000247833.7; NM_022456.5; NP_071901.2. [Q96QF0-2]
DR   UCSC; uc001svm.5; human. [Q96QF0-1]
DR   CTD; 117177; -.
DR   DisGeNET; 117177; -.
DR   GeneCards; RAB3IP; -.
DR   HGNC; HGNC:16508; RAB3IP.
DR   HPA; ENSG00000127328; Low tissue specificity.
DR   MIM; 608686; gene.
DR   neXtProt; NX_Q96QF0; -.
DR   OpenTargets; ENSG00000127328; -.
DR   PharmGKB; PA34136; -.
DR   VEuPathDB; HostDB:ENSG00000127328; -.
DR   eggNOG; KOG4324; Eukaryota.
DR   GeneTree; ENSGT00940000157998; -.
DR   HOGENOM; CLU_038204_2_0_1; -.
DR   InParanoid; Q96QF0; -.
DR   OMA; AFTMAND; -.
DR   OrthoDB; 619794at2759; -.
DR   PhylomeDB; Q96QF0; -.
DR   TreeFam; TF313748; -.
DR   PathwayCommons; Q96QF0; -.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-5620916; VxPx cargo-targeting to cilium.
DR   Reactome; R-HSA-5620922; BBSome-mediated cargo-targeting to cilium.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   SignaLink; Q96QF0; -.
DR   SIGNOR; Q96QF0; -.
DR   BioGRID-ORCS; 117177; 6 hits in 1047 CRISPR screens.
DR   ChiTaRS; RAB3IP; human.
DR   GeneWiki; RAB3IP; -.
DR   GenomeRNAi; 117177; -.
DR   Pharos; Q96QF0; Tbio.
DR   PRO; PR:Q96QF0; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q96QF0; protein.
DR   Bgee; ENSG00000127328; Expressed in corpus callosum and 176 other tissues.
DR   ExpressionAtlas; Q96QF0; baseline and differential.
DR   Genevisible; Q96QF0; HS.
DR   GO; GO:0005813; C:centrosome; IDA:BHF-UCL.
DR   GO; GO:0036064; C:ciliary basal body; TAS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0070319; C:Golgi to plasma membrane transport vesicle; IBA:GO_Central.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:1990635; C:proximal dendrite; IEA:Ensembl.
DR   GO; GO:0051020; F:GTPase binding; IEA:Ensembl.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0097711; P:ciliary basal body-plasma membrane docking; TAS:Reactome.
DR   GO; GO:0060271; P:cilium assembly; IMP:BHF-UCL.
DR   GO; GO:0006887; P:exocytosis; IBA:GO_Central.
DR   GO; GO:0006893; P:Golgi to plasma membrane transport; TAS:BHF-UCL.
DR   GO; GO:0051490; P:negative regulation of filopodium assembly; IEA:Ensembl.
DR   GO; GO:0033365; P:protein localization to organelle; IMP:BHF-UCL.
DR   GO; GO:0006612; P:protein targeting to membrane; IDA:UniProtKB.
DR   InterPro; IPR040351; RAB3IL/RAB3IP/Sec2.
DR   InterPro; IPR009449; Sec2_N.
DR   PANTHER; PTHR14430; PTHR14430; 1.
DR   Pfam; PF06428; Sec2p; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection; Coiled coil;
KW   Cytoplasm; Cytoskeleton; Guanine-nucleotide releasing factor; Nucleus;
KW   Phosphoprotein; Protein transport; Reference proteome; Transport.
FT   CHAIN           1..476
FT                   /note="Rab-3A-interacting protein"
FT                   /id="PRO_0000097144"
FT   REGION          262..297
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          165..260
FT                   /evidence="ECO:0000255"
FT   MOD_RES         163
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68EF0"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         288
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68EF0"
FT   VAR_SEQ         1..222
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051756"
FT   VAR_SEQ         1..16
FT                   /note="Missing (in isoform 1, isoform 3, isoform 5 and
FT                   isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:12007189,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051755"
FT   VAR_SEQ         313..331
FT                   /note="ADLSLYNEFRLWKDEPTMD -> VTHQGLSPLTLLILVSSHH (in
FT                   isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051758"
FT   VAR_SEQ         313..320
FT                   /note="ADLSLYNE -> KMCSHWPE (in isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:12007189"
FT                   /id="VSP_051757"
FT   VAR_SEQ         321..476
FT                   /note="Missing (in isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:12007189"
FT                   /id="VSP_051759"
FT   VAR_SEQ         332..476
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051760"
FT   VAR_SEQ         394..411
FT                   /note="KCALTGQSKSCKHRIKLG -> SLLYVTFLHTFDTFSRDS (in isoform
FT                   3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12007189"
FT                   /id="VSP_051761"
FT   VAR_SEQ         412..476
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12007189"
FT                   /id="VSP_051762"
FT   CONFLICT        164
FT                   /note="P -> Q (in Ref. 5; AAH59358)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        286
FT                   /note="N -> D (in Ref. 3; BAB15391)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="Missing (in Ref. 3; BAB15391)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        464
FT                   /note="M -> V (in Ref. 3; BAB15391)"
FT                   /evidence="ECO:0000305"
FT   HELIX           165..260
FT                   /evidence="ECO:0007829|PDB:6F6P"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:4UJ3"
FT   HELIX           315..325
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   HELIX           335..343
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   HELIX           345..348
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   HELIX           354..365
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   STRAND          370..373
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   TURN            386..388
FT                   /evidence="ECO:0007829|PDB:4UJ3"
FT   TURN            396..398
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   STRAND          406..414
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   STRAND          416..419
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   HELIX           421..441
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   TURN            442..444
FT                   /evidence="ECO:0007829|PDB:4UJ5"
FT   HELIX           450..468
FT                   /evidence="ECO:0007829|PDB:4UJ5"
SQ   SEQUENCE   476 AA;  53021 MW;  DD77781823038F15 CRC64;
     MGLKKMKGLS YDEAFAMAND PLEGFHEVNL ASPTSPDLLG VYESGTQEQT TSPSVIYRPH
     PSALSSVPIQ ANALDVSELP TQPVYSSPRR LNCAEISSIS FHVTDPAPCS TSGVTAGLTK
     LTTRKDNYNA EREFLQGATI TEACDGSDDI FGLSTDSLSR LRSPSVLEVR EKGYERLKEE
     LAKAQRELKL KDEECERLSK VRDQLGQELE ELTASLFEEA HKMVREANIK QATAEKQLKE
     AQGKIDVLQA EVAALKTLVL SSSPTSPTQE PLPGGKTPFK KGHTRNKSTS SAMSGSHQDL
     SVIQPIVKDC KEADLSLYNE FRLWKDEPTM DRTCPFLDKI YQEDIFPCLT FSKSELASAV
     LEAVENNTLS IEPVGLQPIR FVKASAVECG GPKKCALTGQ SKSCKHRIKL GDSSNYYYIS
     PFCRYRITSV CNFFTYIRYI QQGLVKQQDV DQMFWEVMQL RKEMSLAKLG YFKEEL
//
ID   IL6RB_HUMAN             Reviewed;         918 AA.
AC   P40189; A0N0L4; Q5FC04; Q9UQ41;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   23-FEB-2022, entry version 234.
DE   RecName: Full=Interleukin-6 receptor subunit beta {ECO:0000305};
DE            Short=IL-6 receptor subunit beta;
DE            Short=IL-6R subunit beta;
DE            Short=IL-6R-beta;
DE            Short=IL-6RB;
DE   AltName: Full=CDw130;
DE   AltName: Full=Interleukin-6 signal transducer;
DE   AltName: Full=Membrane glycoprotein 130;
DE            Short=gp130 {ECO:0000303|PubMed:12829785};
DE   AltName: Full=Oncostatin-M receptor subunit alpha;
DE   AltName: CD_antigen=CD130;
DE   Flags: Precursor;
GN   Name=IL6ST {ECO:0000312|HGNC:HGNC:6021};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   VARIANT VAL-8, AND SUBUNIT.
RC   TISSUE=Myeloma, and Placenta;
RX   PubMed=2261637; DOI=10.1016/0092-8674(90)90411-7;
RA   Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T.;
RT   "Molecular cloning and expression of an IL-6 signal transducer, gp130.";
RL   Cell 63:1149-1157(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT VAL-8, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Synovium;
RX   PubMed=10880057; DOI=10.1172/jci7479;
RA   Tanaka M., Kishimura M., Ozaki S., Osakada F., Hashimoto H., Okubo M.,
RA   Murakami M., Nakao K.;
RT   "Cloning of novel soluble gp130 and detection of its neutralizing
RT   autoantibodies in rheumatoid arthritis.";
RL   J. Clin. Invest. 106:137-144(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Hayashi A., Sameshima E., Tabata Y., Iida K., Mitsuyama M., Kanai S.,
RA   Furuya T., Saito T.;
RT   "IL6ST mRNA, nirs splice variant 4.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-43;
RP   ASN-83; ASN-131; ASN-157; ASN-227; ASN-379; ASN-383; ASN-553 AND ASN-564.
RX   PubMed=11098061; DOI=10.1074/jbc.m009979200;
RA   Moritz R.L., Hall N.E., Connolly L.M., Simpson R.J.;
RT   "Determination of the disulfide structure and N-glycosylation sites of the
RT   extracellular domain of the human signal transducer gp130.";
RL   J. Biol. Chem. 276:8244-8253(2001).
RN   [8]
RP   SUBUNIT, AND INDUCTION.
RX   PubMed=8999038; DOI=10.1074/jbc.271.51.32635;
RA   Mosley B., De Imus C., Friend D., Boiani N., Thoma B., Park L.S.,
RA   Cosman D.;
RT   "Dual oncostatin M (OSM) receptors. Cloning and characterization of an
RT   alternative signaling subunit conferring OSM-specific receptor
RT   activation.";
RL   J. Biol. Chem. 271:32635-32643(1996).
RN   [9]
RP   INTERACTION WITH HCK.
RX   PubMed=9406996;
RA   Hallek M., Neumann C., Schaffer M., Danhauser-Riedl S., von Bubnoff N.,
RA   de Vos G., Druker B.J., Yasukawa K., Griffin J.D., Emmerich B.;
RT   "Signal transduction of interleukin-6 involves tyrosine phosphorylation of
RT   multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck,
RT   and Lyn in multiple myeloma cell lines.";
RL   Exp. Hematol. 25:1367-1377(1997).
RN   [10]
RP   PHOSPHORYLATION AT SER-782, MUTAGENESIS OF SER-782, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=10811661; DOI=10.1074/jbc.m907658199;
RA   Gibson R.M., Schiemann W.P., Prichard L.B., Reno J.M., Ericsson L.H.,
RA   Nathanson N.M.;
RT   "Phosphorylation of human gp130 at Ser-782 adjacent to the di-leucine
RT   internalization motif. Effects on expression and signaling.";
RL   J. Biol. Chem. 275:22574-22582(2000).
RN   [11]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=11121117; DOI=10.1046/j.1432-1327.2001.01867.x;
RA   Jostock T., Muellberg J., Ozbek S., Atreya R., Blinn G., Voltz N.,
RA   Fischer M., Neurath M.F., Rose-John S.;
RT   "Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor
RT   transsignaling responses.";
RL   Eur. J. Biochem. 268:160-167(2001).
RN   [12]
RP   INTERACTION WITH HERPES VIRUS-8/HHV-8 PROTEIN VIL6 (MICROBIAL INFECTION).
RX   PubMed=11238858; DOI=10.1128/jvi.75.7.3325-3334.2001;
RA   Li H., Wang H., Nicholas J.;
RT   "Detection of direct binding of human herpesvirus 8-encoded interleukin-6
RT   (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino
RT   acid residues of vIL-6 important for IL-6R-dependent and -independent
RT   signaling.";
RL   J. Virol. 75:3325-3334(2001).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-379 AND ASN-383.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-227 AND ASN-390.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   FUNCTION, AND IDENTIFICATION IN HUMANIN RECEPTOR COMPLEX.
RX   PubMed=19386761; DOI=10.1091/mbc.e09-02-0168;
RA   Hashimoto Y., Kurita M., Aiso S., Nishimoto I., Matsuoka M.;
RT   "Humanin inhibits neuronal cell death by interacting with a cytokine
RT   receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.";
RL   Mol. Biol. Cell 20:2864-2873(2009).
RN   [19]
RP   GLYCOSYLATION AT ASN-390.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=19915009; DOI=10.1074/jbc.m109.075952;
RA   Waetzig G.H., Chalaris A., Rosenstiel P., Suthaus J., Holland C., Karl N.,
RA   Valles Uriarte L., Till A., Scheller J., Grotzinger J., Schreiber S.,
RA   Rose-John S., Seegert D.;
RT   "N-linked glycosylation is essential for the stability but not the
RT   signaling function of the interleukin-6 signal transducer glycoprotein
RT   130.";
RL   J. Biol. Chem. 285:1781-1789(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=21990364; DOI=10.1074/jbc.m111.295758;
RA   Garbers C., Thaiss W., Jones G.W., Waetzig G.H., Lorenzen I., Guilhot F.,
RA   Lissilaa R., Ferlin W.G., Groetzinger J., Jones S.A., Rose-John S.,
RA   Scheller J.;
RT   "Inhibition of classic signaling is a novel function of soluble
RT   glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin
RT   6 and soluble interleukin 6 receptor.";
RL   J. Biol. Chem. 286:42959-42970(2011).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF CYS-172; 186-TYR--TYR-190; VAL-189; TYR-190;
RP   ASP-215 AND VAL-252.
RX   PubMed=23294003; DOI=10.1042/bj20121660;
RA   Schutt A., Zacharias M., Schneider N., Horn S., Grotzinger J.,
RA   Rose-John S., Schmidt-Arras D.;
RT   "gp130 activation is regulated by D2-D3 interdomain connectivity.";
RL   Biochem. J. 450:487-496(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667 AND SER-839, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-661 AND SER-667, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   FUNCTION, MUTAGENESIS OF TYR-759, AND INTERACTION WITH SRC AND YES.
RX   PubMed=25731159; DOI=10.1038/nature14228;
RA   Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X.,
RA   Wang K., Ho S.B., Boland B.S., Chang J.T., Sandborn W.J., Hardiman G.,
RA   Raz E., Maehara Y., Yoshimura A., Zucman-Rossi J., Guan K.L., Karin M.;
RT   "A gp130-Src-YAP module links inflammation to epithelial regeneration.";
RL   Nature 519:57-62(2015).
RN   [27]
RP   BIOTECHNOLOGY.
RX   PubMed=26876177; DOI=10.1016/j.celrep.2016.01.053;
RA   Lokau J., Nitz R., Agthe M., Monhasery N., Aparicio-Siegmund S.,
RA   Schumacher N., Wolf J., Moeller-Hackbarth K., Waetzig G.H., Groetzinger J.,
RA   Mueller-Newen G., Rose-John S., Scheller J., Garbers C.;
RT   "Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.";
RL   Cell Rep. 14:1761-1773(2016).
RN   [28]
RP   FUNCTION (ISOFORM 2), AND BIOTECHNOLOGY.
RX   PubMed=30279168; DOI=10.1126/scisignal.aar7388;
RA   Lamertz L., Rummel F., Polz R., Baran P., Hansen S., Waetzig G.H.,
RA   Moll J.M., Floss D.M., Scheller J.;
RT   "Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling
RT   but not intracellular autocrine responses.";
RL   Sci. Signal. 11:0-0(2018).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 122-325.
RX   PubMed=9501088; DOI=10.1093/emboj/17.6.1665;
RA   Bravo J., Staunton D., Heath J.K., Jones E.Y.;
RT   "Crystal structure of a cytokine-binding region of gp130.";
RL   EMBO J. 17:1665-1674(1998).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-325 IN COMPLEX WITH HERPES
RP   VIRUS-8/HHV-8 PROTEIN VIL6 (MICROBIAL INFECTION), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=11251120; DOI=10.1126/science.1058308;
RA   Chow D.-C., He X.-L., Snow A.L., Rose-John S., Garcia K.C.;
RT   "Structure of an extracellular gp130 cytokine receptor signaling complex.";
RL   Science 291:2150-2155(2001).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 123-323 IN COMPLEX WITH LIF.
RX   PubMed=14527405; DOI=10.1016/s1097-2765(03)00365-4;
RA   Boulanger M.J., Bankovich A.J., Kortemme T., Baker D., Garcia K.C.;
RT   "Convergent mechanisms for recognition of divergent cytokines by the shared
RT   signaling receptor gp130.";
RL   Mol. Cell 12:577-589(2003).
RN   [32] {ECO:0007744|PDB:1P9M}
RP   X-RAY CRYSTALLOGRAPHY (3.65 ANGSTROMS) OF 23-321 IN COMPLEX WITH IL6 AND
RP   IL6R, AND SUBUNIT.
RX   PubMed=12829785; DOI=10.1126/science.1083901;
RA   Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C.;
RT   "Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
RT   receptor/gp130 complex.";
RL   Science 300:2101-2104(2003).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 24-612, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-43; ASN-83; ASN-227; ASN-383 AND ASN-553.
RX   PubMed=20489211; DOI=10.1074/jbc.c110.129502;
RA   Xu Y., Kershaw N.J., Luo C.S., Soo P., Pocock M.J., Czabotar P.E.,
RA   Hilton D.J., Nicola N.A., Garrett T.P., Zhang J.G.;
RT   "Crystal structure of the entire ectodomain of gp130: insights into the
RT   molecular assembly of the tall cytokine receptor complexes.";
RL   J. Biol. Chem. 285:21214-21218(2010).
RN   [34]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-415.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [35]
RP   VARIANT GLY-200.
RX   PubMed=25242236; DOI=10.1016/j.cancergen.2014.07.003;
RA   Sun L., Sui L., Cong X., Ma K., Ma X., Huang Y., Fan C., Fu X., Ma K.;
RT   "Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a
RT   Chinese cohort.";
RL   Cancer Genet. 207:291-298(2014).
RN   [36]
RP   VARIANT ARG-148, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24629561; DOI=10.1016/j.metabol.2014.02.005;
RA   Wonnerth A., Katsaros K.M., Krychtiuk K.A., Speidl W.S., Kaun C.,
RA   Thaler K., Huber K., Wojta J., Maurer G., Seljeflot I., Arnesen H.,
RA   Weiss T.W.;
RT   "Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels.";
RL   Metabolism 63:647-653(2014).
RN   [37]
RP   VARIANT HIES4 TYR-404, INVOLVEMENT IN HIES4, FUNCTION, AND CHARACTERIZATION
RP   OF VARIANT HIES4 TYR-404.
RX   PubMed=28747427; DOI=10.1084/jem.20161810;
RA   Schwerd T., Twigg S.R.F., Aschenbrenner D., Manrique S., Miller K.A.,
RA   Taylor I.B., Capitani M., McGowan S.J., Sweeney E., Weber A., Chen L.,
RA   Bowness P., Riordan A., Cant A., Freeman A.F., Milner J.D., Holland S.M.,
RA   Frede N., Mueller M., Schmidt-Arras D., Grimbacher B., Wall S.A.,
RA   Jones E.Y., Wilkie A.O.M., Uhlig H.H.;
RT   "A biallelic mutation in IL6ST encoding the GP130 co-receptor causes
RT   immunodeficiency and craniosynostosis.";
RL   J. Exp. Med. 214:2547-2562(2017).
RN   [38]
RP   VARIANT HIES4 LEU-498, INVOLVEMENT IN HIES4, FUNCTION, AND CHARACTERIZATION
RP   OF VARIANT HIES4 LEU-498.
RX   PubMed=30309848; DOI=10.3324/haematol.2018.194233;
RA   Shahin T., Aschenbrenner D., Cagdas D., Bal S.K., Conde C.D., Garncarz W.,
RA   Medgyesi D., Schwerd T., Karaatmaca B., Cetinkaya P.G., Esenboga S.,
RA   Twigg S.R.F., Cant A., Wilkie A.O.M., Tezcan I., Uhlig H.H., Boztug K.;
RT   "Selective loss of function variants in IL6ST cause Hyper-IgE syndrome with
RT   distinct impairments of T-cell phenotype and function.";
RL   Haematologica 104:609-621(2019).
CC   -!- FUNCTION: Signal-transducing molecule (PubMed:2261637). The receptor
CC       systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST
CC       for initiating signal transmission. Binding of IL6 to IL6R induces
CC       IL6ST homodimerization and formation of a high-affinity receptor
CC       complex, which activates the intracellular JAK-MAPK and JAK-STAT3
CC       signaling pathways (PubMed:2261637, PubMed:19915009, PubMed:23294003).
CC       That causes phosphorylation of IL6ST tyrosine residues which in turn
CC       activates STAT3 (PubMed:19915009, PubMed:23294003, PubMed:25731159). In
CC       parallel, the IL6 signaling pathway induces the expression of two
CC       cytokine receptor signaling inhibitors, SOCS1 and SOCS3, which inhibit
CC       JAK and terminate the activity of the IL6 signaling pathway as a
CC       negative feedback loop (By similarity). Also activates the yes-
CC       associated protein 1 (YAP) and NOTCH pathways to control inflammation-
CC       induced epithelial regeneration, independently of STAT3 (By
CC       similarity). Acts as a receptor for the neuroprotective peptide humanin
CC       as part of a complex with IL27RA/WSX1 and CNTFR (PubMed:19386761).
CC       Mediates signals which regulate immune response, hematopoiesis, pain
CC       control and bone metabolism (By similarity). Has a role in embryonic
CC       development (By similarity). Essential for survival of motor and
CC       sensory neurons and for differentiation of astrocytes (By similarity).
CC       Required for expression of TRPA1 in nociceptive neurons (By
CC       similarity). Required for the maintenance of PTH1R expression in the
CC       osteoblast lineage and for the stimulation of PTH-induced osteoblast
CC       differentiation (By similarity). Required for normal trabecular bone
CC       mass and cortical bone composition (By similarity).
CC       {ECO:0000250|UniProtKB:Q00560, ECO:0000269|PubMed:19386761,
CC       ECO:0000269|PubMed:19915009, ECO:0000269|PubMed:2261637,
CC       ECO:0000269|PubMed:23294003, ECO:0000269|PubMed:25731159,
CC       ECO:0000269|PubMed:28747427, ECO:0000269|PubMed:30309848}.
CC   -!- FUNCTION: [Isoform 2]: Binds to the soluble IL6:sIL6R complex (hyper-
CC       IL6), thereby blocking IL6 trans-signaling. Inhibits sIL6R-dependent
CC       acute phase response (PubMed:11121117, PubMed:21990364,
CC       PubMed:30279168). Also blocks IL11 cluster signaling through IL11R
CC       (PubMed:30279168). {ECO:0000269|PubMed:11121117,
CC       ECO:0000269|PubMed:21990364, ECO:0000269|PubMed:30279168}.
CC   -!- SUBUNIT: Component of a hexamer of two molecules each of IL6, IL6R and
CC       IL6ST; associates with the complex IL6:IL6R but does not interact with
CC       IL6 (PubMed:12829785, PubMed:2261637). Forms heterodimers composed of
CC       LIFR and IL6ST (type I OSM receptor) which are activated by LIF and OSM
CC       (PubMed:8999038). Also forms heterodimers composed of OSMR and IL6ST
CC       (type II receptor) which are activated by OSM but not by LIF
CC       (PubMed:8999038). Component of a receptor complex composed of
CC       IL6ST/GP130, IL27RA/WSX1 and CNTFR which interacts with the
CC       neuroprotective peptide humanin (PubMed:19386761). Interacts with HCK
CC       (PubMed:9406996). Interacts with INPP5D/SHIP1 (By similarity).
CC       Interacts with SRC and YES (PubMed:25731159).
CC       {ECO:0000250|UniProtKB:Q00560, ECO:0000269|PubMed:12829785,
CC       ECO:0000269|PubMed:14527405, ECO:0000269|PubMed:19386761,
CC       ECO:0000269|PubMed:2261637, ECO:0000269|PubMed:25731159,
CC       ECO:0000269|PubMed:8999038, ECO:0000269|PubMed:9406996}.
CC   -!- SUBUNIT: (Microbial infection) The homodimer binds two molecules of
CC       herpes virus 8/HHV-8 protein vIL-6. {ECO:0000269|PubMed:11238858,
CC       ECO:0000269|PubMed:11251120}.
CC   -!- INTERACTION:
CC       P40189; P26441: CNTF; NbExp=10; IntAct=EBI-1030834, EBI-1050897;
CC       P40189; P40189: IL6ST; NbExp=2; IntAct=EBI-1030834, EBI-1030834;
CC       P40189; Q9NZI2-2: KCNIP1; NbExp=3; IntAct=EBI-1030834, EBI-22452746;
CC       P40189; Q9Y2W7: KCNIP3; NbExp=7; IntAct=EBI-1030834, EBI-751501;
CC       P40189; P15018: LIF; NbExp=2; IntAct=EBI-1030834, EBI-1037189;
CC       P40189; P43364: MAGEA11; NbExp=3; IntAct=EBI-1030834, EBI-739552;
CC       P40189; P13725: OSM; NbExp=2; IntAct=EBI-1030834, EBI-6595724;
CC       P40189; Q99650: OSMR; NbExp=2; IntAct=EBI-1030834, EBI-2804080;
CC       P40189; O43765: SGTA; NbExp=3; IntAct=EBI-1030834, EBI-347996;
CC       P40189; Q96EQ0: SGTB; NbExp=4; IntAct=EBI-1030834, EBI-744081;
CC       P40189; Q2HRC7: K2; Xeno; NbExp=2; IntAct=EBI-1030834, EBI-9007403;
CC       P40189; P42227: Stat3; Xeno; NbExp=4; IntAct=EBI-1030834, EBI-602878;
CC       P40189-1; P23458: JAK1; NbExp=3; IntAct=EBI-15742214, EBI-1383438;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:19915009}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:24629561}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P40189-1; Sequence=Displayed;
CC       Name=2; Synonyms=GP130-RAPS {ECO:0000303|PubMed:10880057};
CC         IsoId=P40189-2; Sequence=VSP_001684, VSP_001685;
CC       Name=3;
CC         IsoId=P40189-3; Sequence=VSP_043716;
CC   -!- TISSUE SPECIFICITY: Found in all the tissues and cell lines examined
CC       (PubMed:2261637). Expression not restricted to IL6 responsive cells
CC       (PubMed:2261637). {ECO:0000269|PubMed:2261637}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in blood serum (at protein
CC       level) (PubMed:24629561). {ECO:0000269|PubMed:24629561}.
CC   -!- INDUCTION: LIF and OSM activate the type I OSM receptor while only OSM
CC       can activate the type II OSM receptor. {ECO:0000269|PubMed:8999038}.
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-surface
CC       receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- PTM: Phosphorylation of Ser-782 down-regulates cell surface expression.
CC       {ECO:0000269|PubMed:10811661}.
CC   -!- PTM: Heavily N-glycosylated (PubMed:11098061, PubMed:16335952,
CC       PubMed:19159218, PubMed:19139490, PubMed:11251120). Glycosylation is
CC       required for protein stability and localization in plasma membrane but
CC       not for ligand binding (PubMed:19915009). {ECO:0000269|PubMed:11098061,
CC       ECO:0000269|PubMed:11251120, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19915009}.
CC   -!- DISEASE: Hyper-IgE recurrent infection syndrome 4, autosomal recessive
CC       (HIES4) [MIM:618523]: An immunologic disorder characterized by
CC       recurrent infections, mainly affecting the respiratory tract, skin and
CC       eye, and skeletal abnormalities including craniosynostosis and
CC       scoliosis. Immunologic workup shows increased serum IgE, intermittent
CC       eosinophilia, impaired development of certain B- and T-cell
CC       populations, as well as impaired acute-phase response. Disease onset is
CC       in early childhood. {ECO:0000269|PubMed:28747427,
CC       ECO:0000269|PubMed:30309848}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- BIOTECHNOLOGY: Two extracellular parts of IL6ST/gp130 linked to the Fc-
CC       portions of a human IgG1 antibody (sgp130Fc) inhibit IL6 trans-
CC       signaling by the IL6:IL6R complex and has no affinity of IL6 or IL6R
CC       alone (PubMed:11121117, PubMed:21990364, PubMed:30279168). Also blocks
CC       IL11 cluster signaling through IL11R (PubMed:30279168,
CC       PubMed:26876177). {ECO:0000269|PubMed:11121117,
CC       ECO:0000269|PubMed:21990364, ECO:0000269|PubMed:26876177,
CC       ECO:0000269|PubMed:30279168}.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M57230; AAA59155.1; -; mRNA.
DR   EMBL; AB015706; BAA78112.1; -; mRNA.
DR   EMBL; AB102802; BAD89393.1; -; mRNA.
DR   EMBL; EF064722; ABK41905.1; -; Genomic_DNA.
DR   EMBL; AC008914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016596; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471123; EAW54936.1; -; Genomic_DNA.
DR   CCDS; CCDS3971.1; -. [P40189-1]
DR   CCDS; CCDS47209.1; -. [P40189-2]
DR   CCDS; CCDS54856.1; -. [P40189-3]
DR   PIR; A36337; A36337.
DR   RefSeq; NP_001177910.1; NM_001190981.1. [P40189-3]
DR   RefSeq; NP_002175.2; NM_002184.3. [P40189-1]
DR   RefSeq; NP_786943.1; NM_175767.2. [P40189-2]
DR   PDB; 1BJ8; NMR; -; A=219-325.
DR   PDB; 1BQU; X-ray; 2.00 A; A/B=122-333.
DR   PDB; 1I1R; X-ray; 2.40 A; A=23-325.
DR   PDB; 1P9M; X-ray; 3.65 A; A=23-321.
DR   PDB; 1PVH; X-ray; 2.50 A; A/C=123-323.
DR   PDB; 3L5H; X-ray; 3.60 A; A=24-612.
DR   PDB; 3L5I; X-ray; 1.90 A; A=323-612.
DR   PDB; 3L5J; X-ray; 3.04 A; A/B=323-610.
DR   PDBsum; 1BJ8; -.
DR   PDBsum; 1BQU; -.
DR   PDBsum; 1I1R; -.
DR   PDBsum; 1P9M; -.
DR   PDBsum; 1PVH; -.
DR   PDBsum; 3L5H; -.
DR   PDBsum; 3L5I; -.
DR   PDBsum; 3L5J; -.
DR   BMRB; P40189; -.
DR   SMR; P40189; -.
DR   BioGRID; 109786; 55.
DR   CORUM; P40189; -.
DR   DIP; DIP-95N; -.
DR   IntAct; P40189; 31.
DR   MINT; P40189; -.
DR   STRING; 9606.ENSP00000370698; -.
DR   BindingDB; P40189; -.
DR   ChEMBL; CHEMBL3124734; -.
DR   DrugCentral; P40189; -.
DR   GuidetoPHARMACOLOGY; 2317; -.
DR   GlyConnect; 649; 16 N-Linked glycans (9 sites).
DR   GlyGen; P40189; 13 sites, 18 N-linked glycans (9 sites).
DR   iPTMnet; P40189; -.
DR   PhosphoSitePlus; P40189; -.
DR   SwissPalm; P40189; -.
DR   BioMuta; IL6ST; -.
DR   DMDM; 215273999; -.
DR   EPD; P40189; -.
DR   jPOST; P40189; -.
DR   MassIVE; P40189; -.
DR   MaxQB; P40189; -.
DR   PaxDb; P40189; -.
DR   PeptideAtlas; P40189; -.
DR   PRIDE; P40189; -.
DR   ProteomicsDB; 55338; -. [P40189-1]
DR   ProteomicsDB; 55339; -. [P40189-2]
DR   ProteomicsDB; 55340; -. [P40189-3]
DR   Antibodypedia; 2448; 818 antibodies from 39 providers.
DR   DNASU; 3572; -.
DR   Ensembl; ENST00000336909; ENSP00000338799; ENSG00000134352.
DR   Ensembl; ENST00000381287; ENSP00000370687; ENSG00000134352. [P40189-2]
DR   Ensembl; ENST00000381294; ENSP00000370694; ENSG00000134352. [P40189-3]
DR   Ensembl; ENST00000381298; ENSP00000370698; ENSG00000134352.
DR   Ensembl; ENST00000502326; ENSP00000462158; ENSG00000134352.
DR   Ensembl; ENST00000522633; ENSP00000435399; ENSG00000134352. [P40189-2]
DR   GeneID; 3572; -.
DR   KEGG; hsa:3572; -.
DR   MANE-Select; ENST00000381298.7; ENSP00000370698.2; NM_002184.4; NP_002175.2.
DR   UCSC; uc003jqq.4; human. [P40189-1]
DR   CTD; 3572; -.
DR   DisGeNET; 3572; -.
DR   GeneCards; IL6ST; -.
DR   HGNC; HGNC:6021; IL6ST.
DR   HPA; ENSG00000134352; Low tissue specificity.
DR   MalaCards; IL6ST; -.
DR   MIM; 600694; gene.
DR   MIM; 618523; phenotype.
DR   neXtProt; NX_P40189; -.
DR   OpenTargets; ENSG00000134352; -.
DR   PharmGKB; PA29837; -.
DR   VEuPathDB; HostDB:ENSG00000134352; -.
DR   eggNOG; ENOG502QXEG; Eukaryota.
DR   GeneTree; ENSGT00940000159608; -.
DR   HOGENOM; CLU_017990_0_0_1; -.
DR   InParanoid; P40189; -.
DR   OMA; YLITVYP; -.
DR   PhylomeDB; P40189; -.
DR   TreeFam; TF338122; -.
DR   PathwayCommons; P40189; -.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation. [P40189-1]
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation. [P40189-1]
DR   Reactome; R-HSA-6788467; IL-6-type cytokine receptor ligand interactions.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-9020956; Interleukin-27 signaling.
DR   SignaLink; P40189; -.
DR   SIGNOR; P40189; -.
DR   BioGRID-ORCS; 3572; 34 hits in 1058 CRISPR screens.
DR   ChiTaRS; IL6ST; human.
DR   EvolutionaryTrace; P40189; -.
DR   GeneWiki; Glycoprotein_130; -.
DR   GenomeRNAi; 3572; -.
DR   Pharos; P40189; Tclin.
DR   PRO; PR:P40189; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P40189; protein.
DR   Bgee; ENSG00000134352; Expressed in female gonad and 260 other tissues.
DR   ExpressionAtlas; P40189; baseline and differential.
DR   Genevisible; P40189; HS.
DR   GO; GO:0070110; C:ciliary neurotrophic factor receptor complex; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005896; C:interleukin-6 receptor complex; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:ARUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005900; C:oncostatin-M receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0004897; F:ciliary neurotrophic factor receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005127; F:ciliary neurotrophic factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0019955; F:cytokine binding; IBA:GO_Central.
DR   GO; GO:0004896; F:cytokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019970; F:interleukin-11 binding; IEA:Ensembl.
DR   GO; GO:0004921; F:interleukin-11 receptor activity; IEA:Ensembl.
DR   GO; GO:0045509; F:interleukin-27 receptor activity; IC:BHF-UCL.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:ARUK-UCL.
DR   GO; GO:0070120; P:ciliary neurotrophic factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0005977; P:glycogen metabolic process; IEA:Ensembl.
DR   GO; GO:0070106; P:interleukin-27-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060576; P:intestinal epithelial cell development; IDA:UniProtKB.
DR   GO; GO:0048861; P:leukemia inhibitory factor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:BHF-UCL.
DR   GO; GO:0070104; P:negative regulation of interleukin-6-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0038165; P:oncostatin-M-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002675; P:positive regulation of acute inflammatory response; IC:BHF-UCL.
DR   GO; GO:0002821; P:positive regulation of adaptive immune response; IC:BHF-UCL.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; TAS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:1901731; P:positive regulation of platelet aggregation; TAS:ARUK-UCL.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; TAS:BHF-UCL.
DR   GO; GO:0034097; P:response to cytokine; IDA:BHF-UCL.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR003529; Hematopoietin_rcpt_Gp130_CS.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR010457; IgC2-like_lig-bd.
DR   InterPro; IPR015321; TypeI_recpt_CBD.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF09240; IL6Ra-bind; 1.
DR   Pfam; PF06328; Lep_receptor_Ig; 1.
DR   SMART; SM00060; FN3; 5.
DR   SUPFAM; SSF49265; SSF49265; 5.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS01353; HEMATOPO_REC_L_F2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Membrane; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..22
FT   CHAIN           23..918
FT                   /note="Interleukin-6 receptor subunit beta"
FT                   /id="PRO_0000010899"
FT   TOPO_DOM        23..619
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        620..641
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        642..918
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..120
FT                   /note="Ig-like C2-type"
FT   DOMAIN          125..216
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          224..324
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          329..424
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          426..517
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          518..613
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   REGION          660..681
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          722..758
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           310..314
FT                   /note="WSXWS motif"
FT   MOTIF           651..659
FT                   /note="Box 1 motif"
FT   COMPBIAS        724..758
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         661
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         782
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10811661"
FT   MOD_RES         789
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q00560"
FT   MOD_RES         829
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         839
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        83
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        131
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   CARBOHYD        157
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   CARBOHYD        227
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:20489211"
FT   CARBOHYD        379
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:16335952"
FT   CARBOHYD        383
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:20489211"
FT   CARBOHYD        390
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        553
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   CARBOHYD        564
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11098061"
FT   DISULFID        28..54
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        48..103
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        134..144
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        172..182
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   DISULFID        458..466
FT                   /evidence="ECO:0000269|PubMed:11098061,
FT                   ECO:0000269|PubMed:20489211"
FT   VAR_SEQ         325..329
FT                   /note="RPSKA -> NIASF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10880057"
FT                   /id="VSP_001684"
FT   VAR_SEQ         330..918
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10880057"
FT                   /id="VSP_001685"
FT   VAR_SEQ         423..483
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_043716"
FT   VARIANT         8
FT                   /note="L -> V (in dbSNP:rs1063560)"
FT                   /evidence="ECO:0000269|PubMed:10880057,
FT                   ECO:0000269|PubMed:2261637"
FT                   /id="VAR_047782"
FT   VARIANT         148
FT                   /note="G -> R (associated with increased levels of soluble
FT                   IL6RB in blood serum; dbSNP:rs2228044)"
FT                   /evidence="ECO:0000269|PubMed:24629561"
FT                   /id="VAR_047783"
FT   VARIANT         200
FT                   /note="A -> G (found in patient with lung cancer; unknown
FT                   pathological significance; dbSNP:rs199905033)"
FT                   /evidence="ECO:0000269|PubMed:25242236"
FT                   /id="VAR_074654"
FT   VARIANT         397
FT                   /note="L -> V (in dbSNP:rs2228043)"
FT                   /id="VAR_047784"
FT   VARIANT         404
FT                   /note="N -> Y (in HIES4; results in defective cytokine-
FT                   mediated signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:28747427"
FT                   /id="VAR_083197"
FT   VARIANT         415
FT                   /note="T -> I (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036165"
FT   VARIANT         454
FT                   /note="I -> T (in dbSNP:rs2228046)"
FT                   /id="VAR_047785"
FT   VARIANT         498
FT                   /note="P -> L (in HIES4; results in defective cytokine-
FT                   mediated signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:30309848"
FT                   /id="VAR_083198"
FT   VARIANT         499
FT                   /note="V -> I (in dbSNP:rs34417936)"
FT                   /id="VAR_047786"
FT   MUTAGEN         172
FT                   /note="C->S: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         186..190
FT                   /note="Missing: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         189
FT                   /note="V->G: Does not induce ligand-independent
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         190
FT                   /note="Y->G: Does not induce ligand-independent
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         215
FT                   /note="D->G: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         252
FT                   /note="V->G: Induces ligand-independent activation."
FT                   /evidence="ECO:0000269|PubMed:23294003"
FT   MUTAGEN         759
FT                   /note="Y->F: Refractory to inhibition by SOCS3."
FT                   /evidence="ECO:0000269|PubMed:25731159"
FT   MUTAGEN         782
FT                   /note="S->A: Increases cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:10811661"
FT   STRAND          28..35
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          44..50
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   HELIX           52..58
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          65..69
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          80..83
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          86..91
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          97..107
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          111..123
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          130..137
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          143..147
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          157..164
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:1PVH"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          194..202
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          205..208
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   HELIX           216..218
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          226..231
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          234..238
FT                   /evidence="ECO:0007829|PDB:1I1R"
FT   STRAND          240..245
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   HELIX           248..251
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          255..263
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          282..286
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          291..303
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          317..321
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   HELIX           325..331
FT                   /evidence="ECO:0007829|PDB:1BQU"
FT   STRAND          332..338
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          345..351
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   HELIX           356..359
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          363..372
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          378..391
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          396..406
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          412..416
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          428..435
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          438..444
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          452..460
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          462..464
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          469..474
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          478..481
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          491..500
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          508..515
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          525..530
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          535..539
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   HELIX           544..547
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          553..560
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          566..571
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          575..579
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          587..596
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          599..602
FT                   /evidence="ECO:0007829|PDB:3L5I"
FT   STRAND          606..609
FT                   /evidence="ECO:0007829|PDB:3L5I"
SQ   SEQUENCE   918 AA;  103537 MW;  6510A4409FFCF08C CRC64;
     MLTLQTWLVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV
     NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI
     ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT
     SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL
     KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR
     CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN
     GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD
     FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT
     YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD
     QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG
     KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK
     SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN
     TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS
     ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV
     NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG
     MPKSYLPQTV RQGGYMPQ
//
ID   CREM_HUMAN              Reviewed;         345 AA.
AC   Q03060; A8K014; A8K3J7; A8K6A1; A8MPQ2; B4DXC1; C9J785; C9JZ10; E9PAR4;
AC   E9PHM1; O75519; Q14501; Q14503; Q14504; Q14505; Q14506; Q15731; Q16114;
AC   Q16116; Q5T9H7; Q5W1A6; Q5W1A7; Q5W1A8; Q5W1A9; Q5W1B0; Q5W1B2; Q7Z2Q6;
AC   Q8IVD4; Q96AG7; Q9NZ98; Q9NZ99; Q9NZB9;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 6.
DT   23-FEB-2022, entry version 206.
DE   RecName: Full=cAMP-responsive element modulator {ECO:0000305};
DE   AltName: Full=Inducible cAMP early repressor;
DE            Short=ICER;
GN   Name=CREM {ECO:0000312|HGNC:HGNC:2352};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3).
RX   PubMed=7916662;
RA   Masquilier D., Foulkes N.S., Mattei M.-G., Sassone-Corsi P.;
RT   "Human CREM gene: evolutionary conservation, chromosomal localization, and
RT   inducibility of the transcript.";
RL   Cell Growth Differ. 4:931-937(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 7; 8; 9 AND 23).
RX   PubMed=8206879; DOI=10.1093/oxfordjournals.jbchem.a124332;
RA   Fujimoto T., Fujisawa J., Yoshida M.;
RT   "Novel isoforms of human cyclic AMP-responsive element modulator (hCREM)
RT   mRNA.";
RL   J. Biochem. 115:298-303(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), ALTERNATIVE SPLICING (ISOFORMS 6; 7
RP   AND 9), AND VARIANT ARG-254.
RX   PubMed=8622971; DOI=10.1073/pnas.93.8.3536;
RA   Bodor J., Spetz A.L., Strominger J.L., Habener J.F.;
RT   "cAMP inducibility of transcriptional repressor ICER in developing and
RT   mature human T lymphocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3536-3541(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RA   Brodie C.R., Boland L.M., Orr H.T.;
RT   "Human ICER1, a predicted alternative splice form of CREM, is evident in
RT   JEG-3 cells.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Testis;
RA   Lu L., Huang X.Y., Xu M., Xu Z.Y., Li J.M., Zhou Z.M., Sha J.H.;
RT   "The function of an isoform of hCREM gene in testis development.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5; 7; 20 AND 21).
RC   TISSUE=Adrenal gland, Heart, Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 22).
RC   TISSUE=Brain, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-232.
RA   Vouk K., Lalli E., Scherer S.W., Sassone-Corsi P., Debeljak N., Komel R.,
RA   Rozman D.;
RT   "Searching for mutations in the human cAMP responsive element modulator
RT   (CREM) gene.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-10 (ISOFORM 10), AND ALTERNATIVE SPLICING
RP   (ISOFORMS 5; 10; 11 AND 12).
RX   PubMed=12397208; DOI=10.1093/molehr/8.11.965;
RA   Gellersen B., Kempf R., Sandhowe R., Weinbauer G.F., Behr R.;
RT   "Novel leader exons of the cyclic adenosine 3',5'-monophosphate response
RT   element modulator (CREM) gene, transcribed from promoters P3 and P4, are
RT   highly testis-specific in primates.";
RL   Mol. Hum. Reprod. 8:965-976(2002).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-344 (ISOFORM 4).
RC   TISSUE=Placenta;
RX   PubMed=1461747; DOI=10.1093/nar/20.22.6106;
RA   Meyer T.E., Habener J.F.;
RT   "Cyclic AMP response element binding protein CREB and modulator protein
RT   CREM are products of distinct genes.";
RL   Nucleic Acids Res. 20:6106-6106(1992).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 246-345, AND TISSUE SPECIFICITY.
RX   PubMed=16143638; DOI=10.1093/molehr/gah209;
RA   Vouk K., Hudler P., Strmsnik L., Fink M., Majdic G., Zorn B., Lalli E.,
RA   Sassone-Corsi P., Debeljak N., Komel R., Rozman D.;
RT   "Combinations of genetic changes in the human cAMP-responsive element
RT   modulator gene: a clue towards understanding some forms of male
RT   infertility?";
RL   Mol. Hum. Reprod. 11:567-574(2005).
RN   [13]
RP   FUNCTION, INTERACTION WITH CDC34, AND UBIQUITINATION.
RX   PubMed=10373550; DOI=10.1128/mcb.19.7.5001;
RA   Pati D., Meistrich M.L., Plon S.E.;
RT   "Human Cdc34 and Rad6B ubiquitin-conjugating enzymes target repressors of
RT   cyclic AMP-induced transcription for proteolysis.";
RL   Mol. Cell. Biol. 19:5001-5013(1999).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORMS 2; 4; 13; 15; 17 AND 18), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11044457; DOI=10.1093/molehr/6.11.967;
RA   Behr R., Weinbauer G.F.;
RT   "CREM activator and repressor isoforms in human testis: sequence variations
RT   and inaccurate splicing during impaired spermatogenesis.";
RL   Mol. Hum. Reprod. 6:967-972(2000).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS 5; 12; 14; 16 AND 19), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=14511788; DOI=10.1016/s0093-691x(03)00142-0;
RA   Bloecher S., Behr R., Weinbauer G.F., Bergmann M., Steger K.;
RT   "Different CREM-isoform gene expression between equine and human normal and
RT   impaired spermatogenesis.";
RL   Theriogenology 60:1357-1369(2003).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-271; SER-274 AND SER-277, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-271 AND SER-277, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Transcriptional regulator that binds the cAMP response
CC       element (CRE), a sequence present in many viral and cellular promoters.
CC       Isoforms are either transcriptional activators or repressors. Plays a
CC       role in spermatogenesis and is involved in spermatid maturation
CC       (PubMed:10373550). {ECO:0000269|PubMed:10373550}.
CC   -!- FUNCTION: [Isoform 6]: May play a role in the regulation of the
CC       circadian clock: acts as a transcriptional repressor of the core
CC       circadian component PER1 by directly binding to cAMP response elements
CC       in its promoter. {ECO:0000250}.
CC   -!- SUBUNIT: Binds DNA as a dimer. Interacts with FHL5 (By similarity).
CC       Interacts with CDC34 (PubMed:10373550). May interact with TSSK4 (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:P27699,
CC       ECO:0000269|PubMed:10373550}.
CC   -!- INTERACTION:
CC       Q03060; Q9Y6K1: DNMT3A; NbExp=2; IntAct=EBI-3907794, EBI-923653;
CC       Q03060-25; P46379-2: BAG6; NbExp=3; IntAct=EBI-12884642, EBI-10988864;
CC       Q03060-25; O14503: BHLHE40; NbExp=3; IntAct=EBI-12884642, EBI-711810;
CC       Q03060-25; P22607: FGFR3; NbExp=3; IntAct=EBI-12884642, EBI-348399;
CC       Q03060-25; Q9BZE0: GLIS2; NbExp=3; IntAct=EBI-12884642, EBI-7251368;
CC       Q03060-25; P84074: HPCA; NbExp=6; IntAct=EBI-12884642, EBI-12197079;
CC       Q03060-25; P37235: HPCAL1; NbExp=6; IntAct=EBI-12884642, EBI-749311;
CC       Q03060-25; Q9BUB5: MKNK1; NbExp=3; IntAct=EBI-12884642, EBI-73837;
CC       Q03060-25; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-12884642, EBI-5662487;
CC       Q03060-25; P61601: NCALD; NbExp=5; IntAct=EBI-12884642, EBI-749635;
CC       Q03060-25; P62166: NCS1; NbExp=3; IntAct=EBI-12884642, EBI-746987;
CC       Q03060-25; P14859-6: POU2F1; NbExp=3; IntAct=EBI-12884642, EBI-11526590;
CC       Q03060-25; Q9BQY4: RHOXF2; NbExp=3; IntAct=EBI-12884642, EBI-372094;
CC       Q03060-25; Q01974: ROR2; NbExp=3; IntAct=EBI-12884642, EBI-6422642;
CC       Q03060-25; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-12884642, EBI-6257312;
CC       Q03060-25; P14678-2: SNRPB; NbExp=3; IntAct=EBI-12884642, EBI-372475;
CC       Q03060-25; P09234: SNRPC; NbExp=3; IntAct=EBI-12884642, EBI-766589;
CC       Q03060-25; Q5T6F2: UBAP2; NbExp=3; IntAct=EBI-12884642, EBI-2514383;
CC       Q03060-25; O95231: VENTX; NbExp=3; IntAct=EBI-12884642, EBI-10191303;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=29;
CC       Name=1; Synonyms=CREM-BCEFGgammaHIbeta;
CC         IsoId=Q03060-5; Sequence=Displayed;
CC       Name=2; Synonyms=Beta, CREM-BCEFGHIbeta;
CC         IsoId=Q03060-1; Sequence=VSP_059705, VSP_059715;
CC       Name=3; Synonyms=CREM-BCEFGIalpha, Tau;
CC         IsoId=Q03060-6; Sequence=VSP_059705, VSP_059715, VSP_059717;
CC       Name=4; Synonyms=Alpha, CREM-BEFHIb, CREM-gamma;
CC         IsoId=Q03060-2; Sequence=VSP_059705, VSP_059708, VSP_059709;
CC       Name=5; Synonyms=CREM-theta2tau-gamma, CREM-theta2EFGHIb;
CC         IsoId=Q03060-7; Sequence=VSP_059704, VSP_059715;
CC       Name=6; Synonyms=CREM2alpha-a, IcergammaHIalpha, ICER1, ICERI;
CC         IsoId=Q03060-8; Sequence=VSP_059701, VSP_059717;
CC       Name=7; Synonyms=CREM2alpha-b, IcerHIalpha, ICERIgamma;
CC         IsoId=Q03060-9; Sequence=VSP_059698, VSP_059717;
CC       Name=8; Synonyms=CREM 2beta-a, IcergammaHIbeta, ICERII;
CC         IsoId=Q03060-10; Sequence=VSP_059701;
CC       Name=9; Synonyms=CREM 2beta-b, IcerHIbeta, ICERIIgamma;
CC         IsoId=Q03060-11; Sequence=VSP_059698;
CC       Name=10; Synonyms=CREMtheta1tau2beta, CREM-theta1EFGHIbeta;
CC         IsoId=Q03060-12; Sequence=VSP_059703, VSP_059715;
CC       Name=11; Synonyms=CREM-theta1beta, CREM-theta1EFHIbeta;
CC         IsoId=Q03060-13; Sequence=VSP_059703, VSP_059712, VSP_059716;
CC       Name=12; Synonyms=CREM-theta2beta, CREM-theta2EFHIb, CREM-theta2-gamma;
CC         IsoId=Q03060-14; Sequence=VSP_059704, VSP_059712, VSP_059716;
CC       Name=13; Synonyms=CREM-BEFGgammaHIbeta;
CC         IsoId=Q03060-15; Sequence=VSP_059705, VSP_059708;
CC       Name=14; Synonyms=CREM-tau2-gamma, CREM-BEFGHIbeta;
CC         IsoId=Q03060-16; Sequence=VSP_059705, VSP_059708, VSP_059715;
CC       Name=15; Synonyms=CREM-BGHIbeta;
CC         IsoId=Q03060-17; Sequence=VSP_059705, VSP_059707, VSP_059715;
CC       Name=16; Synonyms=CREM-deltaC-G, CREM-BgammaHIbeta;
CC         IsoId=Q03060-19; Sequence=VSP_059705, VSP_059706;
CC       Name=17; Synonyms=CREM-BHIbeta;
CC         IsoId=Q03060-20; Sequence=VSP_059705, VSP_059710;
CC       Name=18; Synonyms=CREM-BHIalpha;
CC         IsoId=Q03060-21; Sequence=VSP_059705, VSP_059710, VSP_059717;
CC       Name=19; Synonyms=CREM-theta1tau2gamma, CREM-theta1EFGgammaHIbeta;
CC         IsoId=Q03060-22; Sequence=VSP_059703;
CC       Name=20;
CC         IsoId=Q03060-23; Sequence=VSP_059699, VSP_059717;
CC       Name=21;
CC         IsoId=Q03060-24; Sequence=VSP_059697, VSP_059717;
CC       Name=22;
CC         IsoId=Q03060-25; Sequence=VSP_059708, VSP_059713, VSP_059714;
CC       Name=23;
CC         IsoId=Q03060-26; Sequence=VSP_059705, VSP_059708, VSP_059711,
CC                                   VSP_059717;
CC       Name=24;
CC         IsoId=Q03060-27; Sequence=VSP_059697;
CC       Name=25;
CC         IsoId=Q03060-28; Sequence=VSP_059702, VSP_059715;
CC       Name=26;
CC         IsoId=Q03060-29; Sequence=VSP_059700;
CC       Name=27;
CC         IsoId=Q03060-30; Sequence=VSP_059708, VSP_059709;
CC       Name=28;
CC         IsoId=Q03060-31; Sequence=VSP_059705, VSP_059708, VSP_059715,
CC                                   VSP_059717;
CC       Name=29;
CC         IsoId=Q03060-32; Sequence=VSP_059705, VSP_059708, VSP_059709,
CC                                   VSP_059717;
CC   -!- TISSUE SPECIFICITY: Expressed in testes (round spermatids) (at protein
CC       level). Isoform 14 is the major activator form in testes.
CC       {ECO:0000269|PubMed:11044457, ECO:0000269|PubMed:14511788,
CC       ECO:0000269|PubMed:16143638}.
CC   -!- PTM: Isoform 9 is ubiquitinated by CDC34 and RAD6B in order to be
CC       degraded by the proteasome. {ECO:0000269|PubMed:10373550}.
CC   -!- PTM: Stimulated by phosphorylation. Phosphorylated on Ser-116 by TSSK4
CC       in vitro. {ECO:0000250|UniProtKB:P27699, ECO:0000250|UniProtKB:Q01147}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing of isoform
CC       1. Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       1. Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative promoter usage.
CC       Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative promoter usage.
CC       Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing of isoform
CC       6. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       6. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       6. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Produced by alternative promoter usage.
CC       Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 11]: Produced by alternative splicing of
CC       isoform 10. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Produced by alternative splicing of
CC       isoform 5. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 13]: Produced by alternative splicing of
CC       isoform 1. Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 14]: Produced by alternative splicing of
CC       isoform 1. Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 15]: Produced by alternative splicing of
CC       isoform 1. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 16]: Produced by alternative splicing of
CC       isoform 1. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 17]: Produced by alternative splicing of
CC       isoform 1. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 18]: Produced by alternative splicing of
CC       isoform 1. Repressor. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 19]: Produced by alternative splicing of
CC       isoform 10. Activator. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 24]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 25]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 26]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 27]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 28]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 29]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the bZIP family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB03751.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF68266.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D14825; BAA03562.1; -; mRNA.
DR   EMBL; D14826; BAA03564.1; -; mRNA.
DR   EMBL; D14826; BAA03565.1; -; mRNA.
DR   EMBL; D14826; BAA03566.1; -; mRNA.
DR   EMBL; D14826; BAA03567.1; -; mRNA.
DR   EMBL; U44836; AAB03751.1; ALT_SEQ; mRNA.
DR   EMBL; AF069065; AAC19383.1; -; mRNA.
DR   EMBL; AY292864; AAP44115.1; -; mRNA.
DR   EMBL; AK289379; BAF82068.1; -; mRNA.
DR   EMBL; AK290612; BAF83301.1; -; mRNA.
DR   EMBL; AK291566; BAF84255.1; -; mRNA.
DR   EMBL; AK301906; BAG63333.1; -; mRNA.
DR   EMBL; AL117336; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL157783; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW85917.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW85918.1; -; Genomic_DNA.
DR   EMBL; BC017117; AAH17117.1; -; mRNA.
DR   EMBL; BC066342; AAH66342.1; -; mRNA.
DR   EMBL; BC090051; AAH90051.1; -; mRNA.
DR   EMBL; AF213899; AAF68266.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF212158; AAF68266.2; JOINED; Genomic_DNA.
DR   EMBL; AF213897; AAF68266.2; JOINED; Genomic_DNA.
DR   EMBL; AF213898; AAF68266.2; JOINED; Genomic_DNA.
DR   EMBL; AF417234; AAN32656.1; -; mRNA.
DR   EMBL; S68271; AAC60616.2; -; mRNA.
DR   EMBL; S68134; AAC60617.2; -; mRNA.
DR   EMBL; Z15159; CAA78858.1; -; mRNA.
DR   EMBL; AF217318; AAF66158.2; -; Genomic_DNA.
DR   EMBL; AF214665; AAF66158.2; JOINED; Genomic_DNA.
DR   EMBL; AF217318; AAF68682.1; -; Genomic_DNA.
DR   EMBL; AF214665; AAF68682.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS31181.1; -. [Q03060-32]
DR   CCDS; CCDS53517.1; -. [Q03060-10]
DR   CCDS; CCDS53518.1; -. [Q03060-9]
DR   CCDS; CCDS53519.1; -. [Q03060-11]
DR   CCDS; CCDS53520.1; -. [Q03060-27]
DR   CCDS; CCDS53521.1; -. [Q03060-23]
DR   CCDS; CCDS58074.1; -. [Q03060-22]
DR   CCDS; CCDS58075.1; -. [Q03060-28]
DR   CCDS; CCDS58076.1; -. [Q03060-29]
DR   CCDS; CCDS7180.1; -. [Q03060-16]
DR   CCDS; CCDS7181.1; -. [Q03060-31]
DR   CCDS; CCDS7182.1; -. [Q03060-26]
DR   CCDS; CCDS7183.1; -. [Q03060-30]
DR   CCDS; CCDS7184.1; -. [Q03060-25]
DR   CCDS; CCDS7185.1; -. [Q03060-12]
DR   CCDS; CCDS7186.1; -. [Q03060-7]
DR   CCDS; CCDS7187.1; -. [Q03060-8]
DR   CCDS; CCDS7188.1; -. [Q03060-24]
DR   PIR; JC2087; JC2087.
DR   PIR; JC6135; JC6135.
DR   PIR; JX0307; JX0307.
DR   PIR; S26685; S26685.
DR   RefSeq; NP_001254491.1; NM_001267562.1.
DR   RefSeq; NP_001254493.1; NM_001267564.1. [Q03060-22]
DR   RefSeq; NP_001254496.1; NM_001267567.1. [Q03060-28]
DR   RefSeq; NP_001254499.1; NM_001267570.1. [Q03060-29]
DR   RefSeq; NP_001872.3; NM_001881.3. [Q03060-25]
DR   RefSeq; NP_853549.1; NM_181571.2. [Q03060-16]
DR   RefSeq; NP_874386.1; NM_182717.1. [Q03060-8]
DR   RefSeq; NP_874387.1; NM_182718.1. [Q03060-11]
DR   RefSeq; NP_874388.1; NM_182719.1. [Q03060-10]
DR   RefSeq; NP_874389.1; NM_182720.1. [Q03060-9]
DR   RefSeq; NP_874390.1; NM_182721.1. [Q03060-24]
DR   RefSeq; NP_874392.1; NM_182723.1. [Q03060-23]
DR   RefSeq; NP_874393.1; NM_182724.1. [Q03060-27]
DR   RefSeq; NP_877570.1; NM_182769.2. [Q03060-7]
DR   RefSeq; NP_877571.1; NM_182770.2.
DR   RefSeq; NP_877572.1; NM_182771.1. [Q03060-12]
DR   RefSeq; NP_877573.1; NM_182772.1.
DR   RefSeq; NP_898829.1; NM_183011.1. [Q03060-31]
DR   RefSeq; NP_898830.1; NM_183012.1. [Q03060-32]
DR   RefSeq; NP_898831.1; NM_183013.2. [Q03060-26]
DR   RefSeq; NP_898883.1; NM_183060.2. [Q03060-30]
DR   RefSeq; XP_006717441.1; XM_006717378.3. [Q03060-16]
DR   RefSeq; XP_006717442.1; XM_006717379.3. [Q03060-31]
DR   RefSeq; XP_006717445.1; XM_006717382.3. [Q03060-2]
DR   RefSeq; XP_006717446.1; XM_006717383.3. [Q03060-32]
DR   RefSeq; XP_011517626.1; XM_011519324.2. [Q03060-15]
DR   RefSeq; XP_011517627.1; XM_011519325.2. [Q03060-15]
DR   RefSeq; XP_016871211.1; XM_017015722.1. [Q03060-30]
DR   SMR; Q03060; -.
DR   BioGRID; 107780; 44.
DR   IntAct; Q03060; 32.
DR   MINT; Q03060; -.
DR   GlyGen; Q03060; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q03060; -.
DR   PhosphoSitePlus; Q03060; -.
DR   BioMuta; CREM; -.
DR   DMDM; 259016392; -.
DR   jPOST; Q03060; -.
DR   MassIVE; Q03060; -.
DR   MaxQB; Q03060; -.
DR   PeptideAtlas; Q03060; -.
DR   PRIDE; Q03060; -.
DR   ProteomicsDB; 12335; -.
DR   ProteomicsDB; 19066; -.
DR   ProteomicsDB; 1908; -.
DR   ProteomicsDB; 20564; -.
DR   ProteomicsDB; 58163; -. [Q03060-5]
DR   ProteomicsDB; 58164; -. [Q03060-1]
DR   ProteomicsDB; 58165; -. [Q03060-10]
DR   ProteomicsDB; 58166; -. [Q03060-11]
DR   ProteomicsDB; 58167; -. [Q03060-12]
DR   ProteomicsDB; 58168; -. [Q03060-13]
DR   ProteomicsDB; 58169; -. [Q03060-14]
DR   ProteomicsDB; 58170; -. [Q03060-15]
DR   ProteomicsDB; 58171; -. [Q03060-16]
DR   ProteomicsDB; 58172; -. [Q03060-17]
DR   ProteomicsDB; 58173; -. [Q03060-19]
DR   ProteomicsDB; 58174; -. [Q03060-2]
DR   ProteomicsDB; 58175; -. [Q03060-20]
DR   ProteomicsDB; 58176; -. [Q03060-21]
DR   ProteomicsDB; 58177; -. [Q03060-22]
DR   ProteomicsDB; 58178; -. [Q03060-23]
DR   ProteomicsDB; 58179; -. [Q03060-24]
DR   ProteomicsDB; 58180; -. [Q03060-25]
DR   ProteomicsDB; 58181; -. [Q03060-6]
DR   ProteomicsDB; 58182; -. [Q03060-7]
DR   ProteomicsDB; 58183; -. [Q03060-8]
DR   ProteomicsDB; 58184; -. [Q03060-9]
DR   ProteomicsDB; 65804; -.
DR   ProteomicsDB; 65805; -.
DR   ProteomicsDB; 8870; -.
DR   Antibodypedia; 4333; 425 antibodies from 36 providers.
DR   DNASU; 1390; -.
DR   Ensembl; ENST00000337656; ENSP00000337138; ENSG00000095794. [Q03060-31]
DR   Ensembl; ENST00000342105; ENSP00000341875; ENSG00000095794. [Q03060-7]
DR   Ensembl; ENST00000345491; ENSP00000265372; ENSG00000095794. [Q03060-16]
DR   Ensembl; ENST00000348787; ENSP00000345384; ENSG00000095794. [Q03060-30]
DR   Ensembl; ENST00000354759; ENSP00000346804; ENSG00000095794. [Q03060-26]
DR   Ensembl; ENST00000356917; ENSP00000349387; ENSG00000095794. [Q03060-9]
DR   Ensembl; ENST00000361599; ENSP00000354593; ENSG00000095794. [Q03060-12]
DR   Ensembl; ENST00000374726; ENSP00000363858; ENSG00000095794. [Q03060-25]
DR   Ensembl; ENST00000374728; ENSP00000363860; ENSG00000095794. [Q03060-30]
DR   Ensembl; ENST00000374734; ENSP00000363866; ENSG00000095794. [Q03060-32]
DR   Ensembl; ENST00000395887; ENSP00000379225; ENSG00000095794. [Q03060-22]
DR   Ensembl; ENST00000429130; ENSP00000393538; ENSG00000095794.
DR   Ensembl; ENST00000439705; ENSP00000409220; ENSG00000095794. [Q03060-26]
DR   Ensembl; ENST00000463314; ENSP00000418336; ENSG00000095794. [Q03060-28]
DR   Ensembl; ENST00000468236; ENSP00000419810; ENSG00000095794. [Q03060-29]
DR   Ensembl; ENST00000473940; ENSP00000420681; ENSG00000095794. [Q03060-8]
DR   Ensembl; ENST00000474931; ENSP00000417562; ENSG00000095794. [Q03060-24]
DR   Ensembl; ENST00000479070; ENSP00000420511; ENSG00000095794. [Q03060-15]
DR   Ensembl; ENST00000487763; ENSP00000417807; ENSG00000095794. [Q03060-10]
DR   Ensembl; ENST00000488328; ENSP00000417460; ENSG00000095794. [Q03060-11]
DR   Ensembl; ENST00000488741; ENSP00000419075; ENSG00000095794. [Q03060-23]
DR   Ensembl; ENST00000489321; ENSP00000419924; ENSG00000095794. [Q03060-25]
DR   Ensembl; ENST00000490511; ENSP00000417327; ENSG00000095794. [Q03060-27]
DR   GeneID; 1390; -.
DR   KEGG; hsa:1390; -.
DR   UCSC; uc001ixx.4; human. [Q03060-5]
DR   CTD; 1390; -.
DR   DisGeNET; 1390; -.
DR   GeneCards; CREM; -.
DR   HGNC; HGNC:2352; CREM.
DR   HPA; ENSG00000095794; Tissue enhanced (testis).
DR   MIM; 123812; gene.
DR   neXtProt; NX_Q03060; -.
DR   OpenTargets; ENSG00000095794; -.
DR   PharmGKB; PA26871; -.
DR   VEuPathDB; HostDB:ENSG00000095794; -.
DR   GeneTree; ENSGT00940000156952; -.
DR   HOGENOM; CLU_142602_0_0_1; -.
DR   InParanoid; Q03060; -.
DR   OMA; MSKCSRK; -.
DR   OrthoDB; 957343at2759; -.
DR   PhylomeDB; Q03060; -.
DR   TreeFam; TF106464; -.
DR   PathwayCommons; Q03060; -.
DR   Reactome; R-HSA-400253; Circadian Clock. [Q03060-6]
DR   SignaLink; Q03060; -.
DR   SIGNOR; Q03060; -.
DR   BioGRID-ORCS; 1390; 5 hits in 1072 CRISPR screens.
DR   ChiTaRS; CREM; human.
DR   GeneWiki; CAMP_responsive_element_modulator; -.
DR   GenomeRNAi; 1390; -.
DR   Pharos; Q03060; Tbio.
DR   PRO; PR:Q03060; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q03060; protein.
DR   Bgee; ENSG00000095794; Expressed in right testis and 232 other tissues.
DR   ExpressionAtlas; Q03060; baseline and differential.
DR   Genevisible; Q03060; HS.
DR   GO; GO:1990589; C:ATF4-CREB1 transcription factor complex; IBA:GO_Central.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005667; C:transcription regulator complex; IBA:GO_Central.
DR   GO; GO:0008140; F:cAMP response element binding protein binding; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IMP:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:NTNU_SB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR003102; Coactivator_CBP_pKID.
DR   InterPro; IPR001630; Leuzip_CREB.
DR   PANTHER; PTHR45879; PTHR45879; 1.
DR   Pfam; PF00170; bZIP_1; 1.
DR   Pfam; PF02173; pKID; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   PROSITE; PS50217; BZIP; 1.
DR   PROSITE; PS00036; BZIP_BASIC; 1.
DR   PROSITE; PS50953; KID; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative promoter usage; Alternative splicing;
KW   Biological rhythms; Cytoplasm; Developmental protein; Differentiation;
KW   DNA-binding; Nucleus; Phosphoprotein; Reference proteome; Repressor;
KW   Spermatogenesis; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..345
FT                   /note="cAMP-responsive element modulator"
FT                   /id="PRO_0000076607"
FT   DOMAIN          88..147
FT                   /note="KID"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00312"
FT   DOMAIN          286..345
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          287..312
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          314..335
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   MOD_RES         102
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P27699"
FT   MOD_RES         129
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         271
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         1..244
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQVAAIAETDESAESEGVIDSHKR
FT                   REILSRRPSYRKILNELSSDVPGVPKIEEERSEEEGTPPSIATMAVPTSIYQTSTGQYI
FT                   AIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQFFVPGSQV
FT                   VVQDEETELAPSHMA -> MNRTQELSGQLS (in isoform 21 and isoform
FT                   24)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_059697"
FT   VAR_SEQ         1..244
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQVAAIAETDESAESEGVIDSHKR
FT                   REILSRRPSYRKILNELSSDVPGVPKIEEERSEEEGTPPSIATMAVPTSIYQTSTGQYI
FT                   AIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQFFVPGSQV
FT                   VVQDEETELAPSHMA -> MAVTGDDT (in isoform 7 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:8206879"
FT                   /id="VSP_059698"
FT   VAR_SEQ         1..242
FT                   /note="Missing (in isoform 20)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_059699"
FT   VAR_SEQ         1..232
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQVAAIAETDESAESEGVIDSHKR
FT                   REILSRRPSYRKILNELSSDVPGVPKIEEERSEEEGTPPSIATMAVPTSIYQTSTGQYI
FT                   AIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQFFVPGSQV
FT                   VVQ -> MNRTQELSGQLS (in isoform 26)"
FT                   /id="VSP_059700"
FT   VAR_SEQ         1..232
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQVAAIAETDESAESEGVIDSHKR
FT                   REILSRRPSYRKILNELSSDVPGVPKIEEERSEEEGTPPSIATMAVPTSIYQTSTGQYI
FT                   AIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQFFVPGSQV
FT                   VVQ -> MAVTGDDT (in isoform 6 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:8206879,
FT                   ECO:0000303|PubMed:8622971, ECO:0000303|Ref.4"
FT                   /id="VSP_059701"
FT   VAR_SEQ         1..195
FT                   /note="Missing (in isoform 25)"
FT                   /id="VSP_059702"
FT   VAR_SEQ         1..89
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQ -> MWWHQHNLCFRRPIEEDY
FT                   SSGDVEEK (in isoform 10, isoform 11 and isoform 19)"
FT                   /evidence="ECO:0000303|PubMed:12397208"
FT                   /id="VSP_059703"
FT   VAR_SEQ         1..89
FT                   /note="MTMETVESQHDGSITASLTESKSAHVQTQTGQNSIPALAQVSVAGSGTRRGS
FT                   PAVTLVQLPSGQTIHVQGVIQTPQPWVIQSSEIHTVQ -> M (in isoform 5
FT                   and isoform 12)"
FT                   /id="VSP_059704"
FT   VAR_SEQ         1
FT                   /note="M -> MSKCARKKYIKTNPRQM (in isoform 2, isoform 3,
FT                   isoform 4, isoform 13, isoform 14, isoform 15, isoform 16,
FT                   isoform 17, isoform 18, isoform 23, isoform 28 and isoform
FT                   29)"
FT                   /evidence="ECO:0000303|PubMed:1461747,
FT                   ECO:0000303|PubMed:7916662, ECO:0000303|PubMed:8206879"
FT                   /id="VSP_059705"
FT   VAR_SEQ         42..232
FT                   /note="Missing (in isoform 16)"
FT                   /id="VSP_059706"
FT   VAR_SEQ         42..169
FT                   /note="Missing (in isoform 15)"
FT                   /id="VSP_059707"
FT   VAR_SEQ         42..90
FT                   /note="Missing (in isoform 4, isoform 13, isoform 14,
FT                   isoform 22, isoform 23, isoform 27, isoform 28 and isoform
FT                   29)"
FT                   /evidence="ECO:0000303|PubMed:1461747,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8206879"
FT                   /id="VSP_059708"
FT   VAR_SEQ         170..245
FT                   /note="IAIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQ
FT                   FFVPGSQVVVQDEETELAPSHMAA -> T (in isoform 4, isoform 27 and
FT                   isoform 29)"
FT                   /id="VSP_059709"
FT   VAR_SEQ         170..244
FT                   /note="Missing (in isoform 17 and isoform 18)"
FT                   /id="VSP_059710"
FT   VAR_SEQ         170..233
FT                   /note="IAIAQGGTIQISNPGSDGVQGLQALTMTNSGAPPPGATIVQYAAQSADGTQQ
FT                   FFVPGSQVVVQD -> N (in isoform 23)"
FT                   /evidence="ECO:0000303|PubMed:8206879"
FT                   /id="VSP_059711"
FT   VAR_SEQ         170..232
FT                   /note="Missing (in isoform 11 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:12397208"
FT                   /id="VSP_059712"
FT   VAR_SEQ         170..186
FT                   /note="IAIAQGGTIQISNPGSD -> SMYAAIRYDTVLALSLL (in isoform
FT                   22)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_059713"
FT   VAR_SEQ         187..345
FT                   /note="Missing (in isoform 22)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_059714"
FT   VAR_SEQ         233..244
FT                   /note="Missing (in isoform 2, isoform 3, isoform 5, isoform
FT                   10, isoform 14, isoform 15, isoform 25 and isoform 28)"
FT                   /evidence="ECO:0000303|PubMed:12397208,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7916662, ECO:0000303|Ref.5"
FT                   /id="VSP_059715"
FT   VAR_SEQ         245
FT                   /note="A -> T (in isoform 12 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:1461747"
FT                   /id="VSP_059716"
FT   VAR_SEQ         301..345
FT                   /note="KECRRRKKEYVKCLESRVAVLEVQNKKLIEELETLKDICSPKTDY -> REC
FT                   RRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKVE (in isoform 3,
FT                   isoform 6, isoform 7, isoform 18, isoform 20, isoform 21,
FT                   isoform 23, isoform 28 and isoform 29)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:7916662, ECO:0000303|PubMed:8206879,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_059717"
FT   VARIANT         254
FT                   /note="Q -> R (in dbSNP:rs1804604)"
FT                   /evidence="ECO:0000269|PubMed:8622971"
FT                   /id="VAR_055561"
FT   CONFLICT        33
FT                   /note="N -> I (in Ref. 11; AAC60616/AAC60617)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        39
FT                   /note="A -> R (in Ref. 1; CAA78858)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        41..45
FT                   /note="VSVAG -> CSELR (in Ref. 11; AAC60616/AAC60617)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        276
FT                   /note="H -> R (in Ref. 2; BAA03562 and 4; BAA03564/
FT                   BAA03565/BAA03566/BAA03567)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q03060-8:7
FT                   /note="D -> E (in Ref. 4; AAC19383)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q03060-8:112
FT                   /note="K -> R (in Ref. 4; AAC19383)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q03060-10:7
FT                   /note="D -> E (in Ref. 3; AAB03751)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   345 AA;  37006 MW;  4DDEE62904CDD0E6 CRC64;
     MTMETVESQH DGSITASLTE SKSAHVQTQT GQNSIPALAQ VSVAGSGTRR GSPAVTLVQL
     PSGQTIHVQG VIQTPQPWVI QSSEIHTVQV AAIAETDESA ESEGVIDSHK RREILSRRPS
     YRKILNELSS DVPGVPKIEE ERSEEEGTPP SIATMAVPTS IYQTSTGQYI AIAQGGTIQI
     SNPGSDGVQG LQALTMTNSG APPPGATIVQ YAAQSADGTQ QFFVPGSQVV VQDEETELAP
     SHMAAATGDM PTYQIRAPTA ALPQGVVMAA SPGSLHSPQQ LAEEATRKRE LRLMKNREAA
     KECRRRKKEY VKCLESRVAV LEVQNKKLIE ELETLKDICS PKTDY
//
ID   CLD10_HUMAN             Reviewed;         228 AA.
AC   P78369; Q6IBF9; Q96N78;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 2.
DT   23-FEB-2022, entry version 174.
DE   RecName: Full=Claudin-10;
DE   AltName: Full=Oligodendrocyte-specific protein-like;
DE            Short=OSP-like;
GN   Name=CLDN10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION, SUBCELLULAR
RP   LOCATION, AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   PubMed=19383724; DOI=10.1242/jcs.040113;
RA   Gunzel D., Stuiver M., Kausalya P.J., Haisch L., Krug S.M., Rosenthal R.,
RA   Meij I.C., Hunziker W., Fromm M., Muller D.;
RT   "Claudin-10 exists in six alternatively spliced isoforms that exhibit
RT   distinct localization and function.";
RL   J. Cell Sci. 122:1507-1517(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Keen T.J.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INVOLVEMENT IN HELIX, FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   VARIANT HELIX LEU-131, AND CHARACTERIZATION OF VARIANT HELIX LEU-131.
RX   PubMed=28771254; DOI=10.1038/gim.2017.71;
RA   Hadj-Rabia S., Brideau G., Al-Sarraj Y., Maroun R.C., Figueres M.L.,
RA   Leclerc-Mercier S., Olinger E., Baron S., Chaussain C., Nochy D.,
RA   Taha R.Z., Knebelmann B., Joshi V., Curmi P.A., Kambouris M.,
RA   Vargas-Poussou R., Bodemer C., Devuyst O., Houillier P., El-Shanti H.;
RT   "Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX
RT   syndrome.";
RL   Genet. Med. 20:190-201(2018).
RN   [9]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, SUBUNIT, INVOLVEMENT IN
RP   HELIX, VARIANT HELIX LYS-48, AND CHARACTERIZATION OF VARIANT HELIX LYS-48.
RX   PubMed=28686597; DOI=10.1371/journal.pgen.1006897;
RA   Klar J., Piontek J., Milatz S., Tariq M., Jameel M., Breiderhoff T.,
RA   Schuster J., Fatima A., Asif M., Sher M., Maebert K., Fromm A., Baig S.M.,
RA   Guenzel D., Dahl N.;
RT   "Altered paracellular cation permeability due to a rare CLDN10B variant
RT   causes anhidrosis and kidney damage.";
RL   PLoS Genet. 13:E1006897-E1006897(2017).
CC   -!- FUNCTION: Plays a major role in tight junction-specific obliteration of
CC       the intercellular space, through calcium-independent cell-adhesion
CC       activity. Involved in the regulation of paracellular epithelia
CC       permeability to ions in multiple organs. It acts as a paracellular ion
CC       channel probably forming permselective pores; isoform 1 appears to
CC       create pores preferentially permeable to cations and isoform 2 for
CC       anions. In sweat glands and in the thick ascending limb (TAL) of
CC       Henle's loop in kidney, it controls paracellular sodium permeability
CC       which is essential for proper sweat production and renal function
CC       (PubMed:19383724, PubMed:28771254, PubMed:28686597).
CC       {ECO:0000269|PubMed:19383724, ECO:0000269|PubMed:28686597,
CC       ECO:0000269|PubMed:28771254}.
CC   -!- SUBUNIT: Can form homodimers both in trans (interaction between CLDN10
CC       molecules in opposing membranes) and in cis (interaction between CLDN10
CC       molecules within one membrane). {ECO:0000269|PubMed:28686597}.
CC   -!- INTERACTION:
CC       P78369; Q8NFU1: BEST2; NbExp=3; IntAct=EBI-13372810, EBI-19947314;
CC       P78369; Q8N5K1: CISD2; NbExp=3; IntAct=EBI-13372810, EBI-1045797;
CC       P78369; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-13372810, EBI-18053395;
CC       P78369; P35372-10: OPRM1; NbExp=3; IntAct=EBI-13372810, EBI-12807478;
CC       P78369; O00623: PEX12; NbExp=3; IntAct=EBI-13372810, EBI-594836;
CC       P78369; Q9H902: REEP1; NbExp=3; IntAct=EBI-13372810, EBI-1644241;
CC       P78369; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-13372810, EBI-8638294;
CC       P78369; Q9P0T7: TMEM9; NbExp=3; IntAct=EBI-13372810, EBI-723976;
CC   -!- SUBCELLULAR LOCATION: Cell junction, tight junction
CC       {ECO:0000269|PubMed:19383724}. Cell membrane
CC       {ECO:0000269|PubMed:19383724, ECO:0000269|PubMed:28686597,
CC       ECO:0000269|PubMed:28771254}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Cldn10b;
CC         IsoId=P78369-1; Sequence=Displayed;
CC       Name=2; Synonyms=Cldn10a;
CC         IsoId=P78369-2; Sequence=VSP_042898;
CC       Name=3; Synonyms=Cldn10a_i1;
CC         IsoId=P78369-3; Sequence=VSP_053550;
CC   -!- TISSUE SPECIFICITY: Expressed in the kidney, eccrine sweat glands and
CC       in all layers of the epidermis. In the kidney, it is detected in the
CC       thick ascending limb of Henle's loop (TAL) (PubMed:28771254,
CC       PubMed:28686597). In the sweat glands, it is expressed in cells from
CC       secretory portions, corresponding to the clear cells (PubMed:28686597).
CC       {ECO:0000269|PubMed:28686597, ECO:0000269|PubMed:28771254}.
CC   -!- DOMAIN: The fourth transmembrane region (161-181) is necessary for
CC       integration into tight junctions. {ECO:0000250}.
CC   -!- DISEASE: HELIX syndrome (HELIX) [MIM:617671]: An autosomal recessive
CC       disease characterized by congenital heat intolerance, generalized
CC       anhidrosis, inability to produce tears, dry mouth, electrolyte
CC       imbalance, and ichthyosis. {ECO:0000269|PubMed:28686597,
CC       ECO:0000269|PubMed:28771254}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the claudin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CLDN10ID45827ch13q32.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U89916; AAC79506.1; -; mRNA.
DR   EMBL; AK055855; BAB71030.1; -; mRNA.
DR   EMBL; AK315737; BAG38092.1; -; mRNA.
DR   EMBL; CR456845; CAG33126.1; -; mRNA.
DR   EMBL; AL139376; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL357061; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL627382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471085; EAX08955.1; -; Genomic_DNA.
DR   EMBL; BC010920; AAH10920.1; -; mRNA.
DR   CCDS; CCDS9475.1; -. [P78369-2]
DR   CCDS; CCDS9476.1; -. [P78369-1]
DR   RefSeq; NP_001153572.1; NM_001160100.1. [P78369-3]
DR   RefSeq; NP_008915.1; NM_006984.4. [P78369-1]
DR   RefSeq; NP_878268.1; NM_182848.3. [P78369-2]
DR   SMR; P78369; -.
DR   BioGRID; 114529; 24.
DR   IntAct; P78369; 12.
DR   MINT; P78369; -.
DR   STRING; 9606.ENSP00000299339; -.
DR   iPTMnet; P78369; -.
DR   PhosphoSitePlus; P78369; -.
DR   BioMuta; CLDN10; -.
DR   DMDM; 6685311; -.
DR   EPD; P78369; -.
DR   MassIVE; P78369; -.
DR   PaxDb; P78369; -.
DR   PeptideAtlas; P78369; -.
DR   PRIDE; P78369; -.
DR   ProteomicsDB; 57597; -. [P78369-1]
DR   ProteomicsDB; 57598; -. [P78369-2]
DR   Antibodypedia; 4562; 271 antibodies from 32 providers.
DR   DNASU; 9071; -.
DR   Ensembl; ENST00000299339; ENSP00000299339; ENSG00000134873.
DR   Ensembl; ENST00000376873; ENSP00000366069; ENSG00000134873. [P78369-2]
DR   GeneID; 9071; -.
DR   KEGG; hsa:9071; -.
DR   MANE-Select; ENST00000299339.3; ENSP00000299339.2; NM_006984.5; NP_008915.1.
DR   UCSC; uc001vmg.3; human. [P78369-1]
DR   CTD; 9071; -.
DR   DisGeNET; 9071; -.
DR   GeneCards; CLDN10; -.
DR   HGNC; HGNC:2033; CLDN10.
DR   HPA; ENSG00000134873; Tissue enhanced (kidney, pancreas, salivary gland).
DR   MalaCards; CLDN10; -.
DR   MIM; 617579; gene.
DR   MIM; 617671; phenotype.
DR   neXtProt; NX_P78369; -.
DR   OpenTargets; ENSG00000134873; -.
DR   Orphanet; 528105; Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome.
DR   PharmGKB; PA26558; -.
DR   VEuPathDB; HostDB:ENSG00000134873; -.
DR   eggNOG; ENOG502QPNP; Eukaryota.
DR   GeneTree; ENSGT00940000155232; -.
DR   HOGENOM; CLU_076370_0_0_1; -.
DR   InParanoid; P78369; -.
DR   OMA; CKEFISM; -.
DR   OrthoDB; 1164514at2759; -.
DR   PhylomeDB; P78369; -.
DR   TreeFam; TF331936; -.
DR   PathwayCommons; P78369; -.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   SignaLink; P78369; -.
DR   BioGRID-ORCS; 9071; 4 hits in 1032 CRISPR screens.
DR   ChiTaRS; CLDN10; human.
DR   GeneWiki; CLDN10; -.
DR   GenomeRNAi; 9071; -.
DR   Pharos; P78369; Tbio.
DR   PRO; PR:P78369; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P78369; protein.
DR   Bgee; ENSG00000134873; Expressed in pancreas and 174 other tissues.
DR   ExpressionAtlas; P78369; baseline and differential.
DR   Genevisible; P78369; HS.
DR   GO; GO:0005923; C:bicellular tight junction; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IBA:GO_Central.
DR   GO; GO:0016338; P:calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0043269; P:regulation of ion transport; IMP:UniProtKB.
DR   InterPro; IPR006187; Claudin.
DR   InterPro; IPR003554; Claudin10.
DR   InterPro; IPR017974; Claudin_CS.
DR   InterPro; IPR004031; PMP22/EMP/MP20/Claudin.
DR   PANTHER; PTHR12002; PTHR12002; 1.
DR   PANTHER; PTHR12002:SF13; PTHR12002:SF13; 1.
DR   Pfam; PF00822; PMP22_Claudin; 1.
DR   PRINTS; PR01383; CLAUDIN10.
DR   PROSITE; PS01346; CLAUDIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell junction; Cell membrane; Disease variant;
KW   Ichthyosis; Ion transport; Membrane; Reference proteome; Tight junction;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..228
FT                   /note="Claudin-10"
FT                   /id="PRO_0000144757"
FT   TRANSMEM        1..21
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        22..80
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        81..101
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        102..115
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        116..136
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        137..160
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        161..181
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        182..228
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..73
FT                   /note="MASTASEIIAFMVSISGWVLVSSTLPTDYWKVSTIDGTVITTATYWANLWKA
FT                   CVTDSTGVSNCKDFPSMLALD -> MSRAQIWALVSGVGGFGALVAATTSNEWKVTTRA
FT                   SSVITATWVYQGLWMNCAGNALGSFHCRPHFTIFKVA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:19383724"
FT                   /id="VSP_042898"
FT   VAR_SEQ         1..73
FT                   /note="MASTASEIIAFMVSISGWVLVSSTLPTDYWKVSTIDGTVITTATYWANLWKA
FT                   CVTDSTGVSNCKDFPSMLALD -> MSRAQIWALVSGVGGFGALVAATTSNEWKVTTRA
FT                   SSVITATWVYQGLWMNCA (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:19383724"
FT                   /id="VSP_053550"
FT   VARIANT         48
FT                   /note="N -> K (in HELIX; decreased function in regulation
FT                   of paracellular ion transport as shown by reduced sodium
FT                   permeability of cell layers expressing the mutant; affects
FT                   self-interaction by inhibiting homodimerization in trans
FT                   and promoting homodimerization in cis; no effect on
FT                   localization to plasma membrane; dbSNP:rs759408749)"
FT                   /evidence="ECO:0000269|PubMed:28686597"
FT                   /id="VAR_080053"
FT   VARIANT         131
FT                   /note="S -> L (in HELIX; strongly reduced localization at
FT                   the plasma membrane; dbSNP:rs1555299783)"
FT                   /evidence="ECO:0000269|PubMed:28771254"
FT                   /id="VAR_080054"
SQ   SEQUENCE   228 AA;  24488 MW;  11E66F9F10BCC87B CRC64;
     MASTASEIIA FMVSISGWVL VSSTLPTDYW KVSTIDGTVI TTATYWANLW KACVTDSTGV
     SNCKDFPSML ALDGYIQACR GLMIAAVSLG FFGSIFALFG MKCTKVGGSD KAKAKIACLA
     GIVFILSGLC SMTGCSLYAN KITTEFFDPL FVEQKYELGA ALFIGWAGAS LCIIGGVIFC
     FSISDNNKTP RYTYNGATSV MSSRTKYHGG EDFKTTNPSK QFDKNAYV
//
ID   RB27A_HUMAN             Reviewed;         221 AA.
AC   P51159; O00195; Q6FI40; Q9UIR9; Q9Y5U3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   23-FEB-2022, entry version 210.
DE   RecName: Full=Ras-related protein Rab-27A;
DE            Short=Rab-27;
DE            EC=3.6.5.2 {ECO:0000305|PubMed:12531900, ECO:0000305|PubMed:15548590};
DE   AltName: Full=GTP-binding protein Ram;
GN   Name=RAB27A; Synonyms=RAB27;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Retina;
RX   PubMed=7592656; DOI=10.1074/jbc.270.41.24420;
RA   Seabra M.C., Ho Y.K., Anant J.S.;
RT   "Deficient geranylgeranylation of Ram/Rab27 in choroideremia.";
RL   J. Biol. Chem. 270:24420-24427(1995).
RN   [2]
RP   SEQUENCE REVISION TO 99.
RA   Seabra M.C.;
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Melanocyte;
RX   PubMed=9066979; DOI=10.1006/bmme.1996.2559;
RA   Chen D., Guo J., Miki T., Tachibana M., Gahl W.A.;
RT   "Molecular cloning and characterization of rab27a and rab27b, novel human
RT   rab proteins shared by melanocytes and platelets.";
RL   Biochem. Mol. Med. 60:27-37(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM LONG).
RX   PubMed=10571040; DOI=10.1016/s0378-1119(99)00371-6;
RA   Tolmachova T., Ramalho J.S., Anant J.S., Schultz R.A., Huxley C.M.,
RA   Seabra M.C.;
RT   "Cloning, mapping and characterization of the human RAB27A gene.";
RL   Gene 239:109-116(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RC   TISSUE=Pituitary;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM LONG).
RA   Anderson P.D., Huizing M., Anikster Y., Gahl W.A.;
RT   "Genomic organization of the human RAB27A gene.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH MLPH.
RX   PubMed=12062444; DOI=10.1016/s0014-5793(02)02634-0;
RA   Nagashima K., Torii S., Yi Z., Igarashi M., Okamoto K., Takeuchi T.,
RA   Izumi T.;
RT   "Melanophilin directly links Rab27a and myosin Va through its distinct
RT   coiled-coil regions.";
RL   FEBS Lett. 517:233-238(2002).
RN   [11]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K., Valencia J.,
RA   Muller J., Vieira W.D., Watabe H., Shabanowitz J., Hearing V.J., Hunt D.F.,
RA   Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [12]
RP   SUBCELLULAR LOCATION, INTERACTION WITH UNC13D, TISSUE SPECIFICITY,
RP   MUTAGENESIS OF THR-23, AND CHARACTERIZATION OF VARIANT GS2 GLY-73.
RX   PubMed=15548590; DOI=10.1091/mbc.e04-10-0923;
RA   Neeft M., Wieffer M., de Jong A.S., Negroiu G., Metz C.H., van Loon A.,
RA   Griffith J., Krijgsveld J., Wulffraat N., Koch H., Heck A.J.R., Brose N.,
RA   Kleijmeer M., van der Sluijs P.;
RT   "Munc13-4 is an effector of rab27a and controls secretion of lysosomes in
RT   hematopoietic cells.";
RL   Mol. Biol. Cell 16:731-741(2005).
RN   [13]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [14]
RP   INTERACTION WITH UNC13D, AND SUBCELLULAR LOCATION.
RX   PubMed=17237785; DOI=10.1038/ni1431;
RA   Menager M.M., Menasche G., Romao M., Knapnougel P., Ho C.-H., Garfa M.,
RA   Raposo G., Feldmann J., Fischer A., de Saint Basile G.;
RT   "Secretory cytotoxic granule maturation and exocytosis require the effector
RT   protein hMunc13-4.";
RL   Nat. Immunol. 8:257-267(2007).
RN   [15]
RP   FUNCTION, INTERACTION WITH SYTL2, AND MUTAGENESIS OF LEU-70 AND ALA-76.
RX   PubMed=18812475; DOI=10.1182/blood-2008-02-141069;
RA   Menasche G., Menager M.M., Lefebvre J.M., Deutsch E., Athman R.,
RA   Lambert N., Mahlaoui N., Court M., Garin J., Fischer A.,
RA   de Saint Basile G.;
RT   "A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T
RT   cells and participates in cytotoxic granule secretion.";
RL   Blood 112:5052-5062(2008).
RN   [16]
RP   LACK OF INTERACTION WITH THE BLOC-3 COMPLEX.
RX   PubMed=20048159; DOI=10.1074/jbc.m109.069088;
RA   Kloer D.P., Rojas R., Ivan V., Moriyama K., van Vlijmen T., Murthy N.,
RA   Ghirlando R., van der Sluijs P., Hurley J.H., Bonifacino J.S.;
RT   "Assembly of the biogenesis of lysosome-related organelles complex-3 (BLOC-
RT   3) and its interaction with Rab9.";
RL   J. Biol. Chem. 285:7794-7804(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH DENND10, ACTIVITY
RP   REGULATION, AND MUTAGENESIS OF THR-23 AND GLN-78.
RX   PubMed=30771381; DOI=10.1016/j.bbamcr.2019.02.006;
RA   Zhang J., Zhang K., Qi L., Hu Q., Shen Z., Liu B., Deng J., Zhang C.,
RA   Zhang Y.;
RT   "DENN domain-containing protein FAM45A regulates the homeostasis of
RT   late/multivesicular endosomes.";
RL   Biochim. Biophys. Acta 1866:916-929(2019).
RN   [22]
RP   VARIANTS GS2 GLY-73; PRO-130 AND PRO-152.
RX   PubMed=10835631; DOI=10.1038/76024;
RA   Menasche G., Pastural E., Feldmann J., Certain S., Ersoy F., Dupuis S.,
RA   Wulffraat N., Bianchi D., Fischer A., Le Deist F., de Saint Basile G.;
RT   "Mutations in RAB27A cause Griscelli syndrome associated with
RT   haemophagocytic syndrome.";
RL   Nat. Genet. 25:173-176(2000).
RN   [23]
RP   INVOLVEMENT IN GRISCELLI SYNDROME.
RX   PubMed=12058346; DOI=10.1086/341606;
RA   Anikster Y., Huizing M., Anderson P.D., Fitzpatrick D.L., Klar A.,
RA   Gross-Kieselstein E., Berkun Y., Shazberg G., Gahl W.A., Hurvitz H.;
RT   "Evidence that Griscelli syndrome with neurological involvement is caused
RT   by mutations in RAB27A, not MYO5A.";
RL   Am. J. Hum. Genet. 71:407-414(2002).
RN   [24]
RP   ERRATUM OF PUBMED:12058346.
RA   Anikster Y., Huizing M., Anderson P.D., Fitzpatrick D.L., Klar A.,
RA   Gross-Kieselstein E., Berkun Y., Shazberg G., Gahl W.A., Hurvitz H.;
RL   Am. J. Hum. Genet. 71:1007-1007(2002).
RN   [25]
RP   CHARACTERIZATION OF VARIANTS GS2 GLY-73; PRO-130 AND PRO-152.
RX   PubMed=12446441; DOI=10.1182/blood-2002-09-2789;
RA   Menasche G., Feldmann J., Houdusse A., Desaymard C., Fischer A., Goud B.,
RA   de Saint Basile G.;
RT   "Biochemical and functional characterization of Rab27a mutations occurring
RT   in Griscelli syndrome patients.";
RL   Blood 101:2736-2742(2003).
RN   [26]
RP   CHARACTERIZATION OF VARIANTS GS2 GLY-73; PRO-130 AND PRO-152.
RX   PubMed=12531900; DOI=10.1074/jbc.m211996200;
RA   Bahadoran P., Busca R., Chiaverini C., Westbroek W., Lambert J., Bille K.,
RA   Valony G., Fukuda M., Naeyaert J.-M., Ortonne J.-P., Ballotti R.;
RT   "Characterization of the molecular defects in Rab27a, caused by RAB27A
RT   missense mutations found in patients with Griscelli syndrome.";
RL   J. Biol. Chem. 278:11386-11392(2003).
CC   -!- FUNCTION: Small GTPase which cycles between active GTP-bound and
CC       inactive GDP-bound states. In its active state, binds to a variety of
CC       effector proteins to regulate homeostasis of late endocytic pathway,
CC       including endosomal positioning, maturation and secretion
CC       (PubMed:30771381). Plays a role in cytotoxic granule exocytosis in
CC       lymphocytes. Required for both granule maturation and granule docking
CC       and priming at the immunologic synapse. {ECO:0000269|PubMed:18812475,
CC       ECO:0000269|PubMed:30771381}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = GDP + H(+) + phosphate; Xref=Rhea:RHEA:19669,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2;
CC         Evidence={ECO:0000305|PubMed:12531900, ECO:0000305|PubMed:15548590};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670;
CC         Evidence={ECO:0000305|PubMed:12531900, ECO:0000305|PubMed:15548590};
CC   -!- ACTIVITY REGULATION: Regulated by guanine nucleotide exchange factors
CC       (GEFs) which promote the exchange of bound GDP for free GTP, GTPase
CC       activating proteins (GAPs) which increase the GTP hydrolysis activity,
CC       and GDP dissociation inhibitors which inhibit the dissociation of the
CC       nucleotide from the GTPase. Activated by GEFs such as DENND10.
CC       {ECO:0000305|PubMed:30771381}.
CC   -!- SUBUNIT: Binds SYTL1, SLAC2B, MYRIP, SYTL3, SYTL4 and SYTL5. Interacts
CC       with RPH3A and RPH3A (By similarity). Binds MLPH and SYTL2. Interacts
CC       with UNC13D. Does not interact with the BLOC-3 complex (heterodimer of
CC       HPS1 and HPS4) (PubMed:20048159). Interacts (GDP-bound form
CC       preferentially) with DENND10 (PubMed:30771381).
CC       {ECO:0000250|UniProtKB:Q9ERI2, ECO:0000269|PubMed:12062444,
CC       ECO:0000269|PubMed:15548590, ECO:0000269|PubMed:17237785,
CC       ECO:0000269|PubMed:18812475, ECO:0000269|PubMed:20048159,
CC       ECO:0000269|PubMed:30771381}.
CC   -!- INTERACTION:
CC       P51159; Q9BV36: MLPH; NbExp=4; IntAct=EBI-716881, EBI-7042162;
CC       P51159; Q8NFW9: MYRIP; NbExp=3; IntAct=EBI-716881, EBI-1759414;
CC       P51159; Q8IYJ3: SYTL1; NbExp=3; IntAct=EBI-716881, EBI-2802861;
CC       P51159; Q4VX76: SYTL3; NbExp=3; IntAct=EBI-716881, EBI-2840607;
CC       P51159; Q96C24: SYTL4; NbExp=3; IntAct=EBI-716881, EBI-747142;
CC       P51159; Q8TDW5-2: SYTL5; NbExp=3; IntAct=EBI-716881, EBI-12243980;
CC       P51159; Q70J99: UNC13D; NbExp=3; IntAct=EBI-716881, EBI-11479429;
CC       P51159-1; Q9BV36: MLPH; NbExp=2; IntAct=EBI-15528760, EBI-7042162;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Lipid-anchor
CC       {ECO:0000305}. Melanosome {ECO:0000269|PubMed:12643545,
CC       ECO:0000269|PubMed:17081065}. Late endosome
CC       {ECO:0000269|PubMed:15548590, ECO:0000269|PubMed:30771381}. Lysosome
CC       {ECO:0000269|PubMed:15548590}. Note=Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV (PubMed:12643545,
CC       PubMed:17081065). Localizes to endosomal exocytic vesicles
CC       (PubMed:17237785). {ECO:0000269|PubMed:12643545,
CC       ECO:0000269|PubMed:17081065, ECO:0000269|PubMed:17237785}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P51159-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P51159-2; Sequence=VSP_005529;
CC   -!- TISSUE SPECIFICITY: Found in all the examined tissues except in brain.
CC       Low expression was found in thymus, kidney, muscle and placenta.
CC       Detected in melanocytes, and in most tumor cell lines examined.
CC       Expressed in cytotoxic T-lymphocytes (CTL) and mast cells.
CC       {ECO:0000269|PubMed:15548590}.
CC   -!- DISEASE: Griscelli syndrome 2 (GS2) [MIM:607624]: Rare autosomal
CC       recessive disorder that results in pigmentary dilution of the skin and
CC       hair, the presence of large clumps of pigment in hair shafts, and an
CC       accumulation of melanosomes in melanocytes. GS2 patients also develop
CC       an uncontrolled T-lymphocyte and macrophage activation syndrome, known
CC       as hemophagocytic syndrome, leading to death in the absence of bone
CC       marrow transplantation. Neurological impairment is present in some
CC       patients, likely as a result of hemophagocytic syndrome.
CC       {ECO:0000269|PubMed:10835631, ECO:0000269|PubMed:12446441,
CC       ECO:0000269|PubMed:12531900, ECO:0000269|PubMed:15548590}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Rab family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=RAB27Abase; Note=RAB27A mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/RAB27Abase/";
CC   -!- WEB RESOURCE: Name=Mutations of the RAB27A gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/rab27mut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U38654; AAC50271.2; -; mRNA.
DR   EMBL; U57094; AAC51195.1; -; mRNA.
DR   EMBL; AF154840; AAD47629.1; -; Genomic_DNA.
DR   EMBL; AF154836; AAD47629.1; JOINED; Genomic_DNA.
DR   EMBL; AF154837; AAD47629.1; JOINED; Genomic_DNA.
DR   EMBL; AF154838; AAD47629.1; JOINED; Genomic_DNA.
DR   EMBL; AF154839; AAD47629.1; JOINED; Genomic_DNA.
DR   EMBL; AF125393; AAD43049.1; -; mRNA.
DR   EMBL; AF443871; AAL39097.1; -; Genomic_DNA.
DR   EMBL; AF498953; AAM21101.1; -; mRNA.
DR   EMBL; CR536496; CAG38735.1; -; mRNA.
DR   EMBL; CR541693; CAG46494.1; -; mRNA.
DR   EMBL; BC107680; AAI07681.1; -; mRNA.
DR   CCDS; CCDS10153.1; -. [P51159-1]
DR   PIR; I39198; I39198.
DR   RefSeq; NP_004571.2; NM_004580.4. [P51159-1]
DR   RefSeq; NP_899057.1; NM_183234.2. [P51159-1]
DR   RefSeq; NP_899058.1; NM_183235.2. [P51159-1]
DR   RefSeq; NP_899059.1; NM_183236.2. [P51159-1]
DR   RefSeq; XP_005254633.1; XM_005254576.4. [P51159-1]
DR   RefSeq; XP_011520154.1; XM_011521852.1. [P51159-1]
DR   RefSeq; XP_011520156.1; XM_011521854.1. [P51159-1]
DR   RefSeq; XP_011520157.1; XM_011521855.2. [P51159-1]
DR   RefSeq; XP_011520158.1; XM_011521856.2. [P51159-1]
DR   PDB; 6HUF; X-ray; 2.82 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2-192.
DR   PDBsum; 6HUF; -.
DR   SMR; P51159; -.
DR   BioGRID; 111811; 83.
DR   CORUM; P51159; -.
DR   DIP; DIP-44244N; -.
DR   IntAct; P51159; 50.
DR   MINT; P51159; -.
DR   STRING; 9606.ENSP00000379601; -.
DR   ChEMBL; CHEMBL4105702; -.
DR   GuidetoPHARMACOLOGY; 2916; -.
DR   GlyGen; P51159; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P51159; -.
DR   PhosphoSitePlus; P51159; -.
DR   SwissPalm; P51159; -.
DR   BioMuta; RAB27A; -.
DR   DMDM; 116242744; -.
DR   EPD; P51159; -.
DR   jPOST; P51159; -.
DR   MassIVE; P51159; -.
DR   MaxQB; P51159; -.
DR   PaxDb; P51159; -.
DR   PeptideAtlas; P51159; -.
DR   PRIDE; P51159; -.
DR   ProteomicsDB; 56289; -. [P51159-1]
DR   ProteomicsDB; 56290; -. [P51159-2]
DR   Antibodypedia; 687; 463 antibodies from 38 providers.
DR   DNASU; 5873; -.
DR   Ensembl; ENST00000336787; ENSP00000337761; ENSG00000069974.
DR   Ensembl; ENST00000396307; ENSP00000379601; ENSG00000069974.
DR   Ensembl; ENST00000564609; ENSP00000455012; ENSG00000069974.
DR   Ensembl; ENST00000569493; ENSP00000456059; ENSG00000069974.
DR   GeneID; 5873; -.
DR   KEGG; hsa:5873; -.
DR   MANE-Select; ENST00000336787.6; ENSP00000337761.1; NM_183235.3; NP_899058.1.
DR   UCSC; uc002aco.4; human. [P51159-1]
DR   CTD; 5873; -.
DR   DisGeNET; 5873; -.
DR   GeneCards; RAB27A; -.
DR   HGNC; HGNC:9766; RAB27A.
DR   HPA; ENSG00000069974; Tissue enhanced (stomach).
DR   MalaCards; RAB27A; -.
DR   MIM; 603868; gene.
DR   MIM; 607624; phenotype.
DR   neXtProt; NX_P51159; -.
DR   OpenTargets; ENSG00000069974; -.
DR   Orphanet; 79477; Griscelli syndrome type 2.
DR   PharmGKB; PA34117; -.
DR   VEuPathDB; HostDB:ENSG00000069974; -.
DR   eggNOG; KOG0081; Eukaryota.
DR   GeneTree; ENSGT00940000156218; -.
DR   InParanoid; P51159; -.
DR   OMA; CTGANIQ; -.
DR   OrthoDB; 1190514at2759; -.
DR   PhylomeDB; P51159; -.
DR   TreeFam; TF312895; -.
DR   PathwayCommons; P51159; -.
DR   Reactome; R-HSA-264876; Insulin processing.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8873719; RAB geranylgeranylation.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   SignaLink; P51159; -.
DR   BioGRID-ORCS; 5873; 4 hits in 1046 CRISPR screens.
DR   ChiTaRS; RAB27A; human.
DR   GeneWiki; RAB27A; -.
DR   GenomeRNAi; 5873; -.
DR   Pharos; P51159; Tchem.
DR   PRO; PR:P51159; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P51159; protein.
DR   Bgee; ENSG00000069974; Expressed in bone marrow and 231 other tissues.
DR   ExpressionAtlas; P51159; baseline and differential.
DR   Genevisible; P51159; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0070382; C:exocytic vesicle; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IDA:UniProtKB.
DR   GO; GO:0033162; C:melanosome membrane; TAS:Reactome.
DR   GO; GO:0032585; C:multivesicular body membrane; IDA:UniProtKB.
DR   GO; GO:0001750; C:photoreceptor outer segment; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IBA:GO_Central.
DR   GO; GO:0030667; C:secretory granule membrane; IEA:Ensembl.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:0033093; C:Weibel-Palade body; IEA:Ensembl.
DR   GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC.
DR   GO; GO:0019003; F:GDP binding; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; ISS:UniProtKB.
DR   GO; GO:0031489; F:myosin V binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0019882; P:antigen processing and presentation; IMP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0097278; P:complement-dependent cytotoxicity; IMP:UniProtKB.
DR   GO; GO:0043316; P:cytotoxic T cell degranulation; IEA:Ensembl.
DR   GO; GO:0006887; P:exocytosis; IDA:UniProtKB.
DR   GO; GO:1990182; P:exosomal secretion; IMP:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; IEA:Ensembl.
DR   GO; GO:0032400; P:melanosome localization; IMP:UniProtKB.
DR   GO; GO:0032402; P:melanosome transport; IBA:GO_Central.
DR   GO; GO:0036257; P:multivesicular body organization; IMP:UniProtKB.
DR   GO; GO:0071985; P:multivesicular body sorting pathway; IMP:UniProtKB.
DR   GO; GO:0043320; P:natural killer cell degranulation; IEA:Ensembl.
DR   GO; GO:1903435; P:positive regulation of constitutive secretory pathway; IMP:UniProtKB.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IMP:UniProtKB.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; IMP:UniProtKB.
DR   GO; GO:1903307; P:positive regulation of regulated secretory pathway; IMP:UniProtKB.
DR   GO; GO:0009306; P:protein secretion; IEA:Ensembl.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0048489; P:synaptic vesicle transport; TAS:ParkinsonsUK-UCL.
DR   CDD; cd04127; Rab27A; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR041837; Rab27a/b.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   Pfam; PF00071; Ras; 1.
DR   SMART; SM00174; RHO; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51419; RAB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Endosome; Exocytosis; GTP-binding;
KW   Hydrolase; Lipoprotein; Lysosome; Membrane; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Prenylation; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           2..221
FT                   /note="Ras-related protein Rab-27A"
FT                   /id="PRO_0000121221"
FT   NP_BIND         16..24
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         74..78
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         133..136
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         163..165
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   MOTIF           38..46
FT                   /note="Effector region"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         221
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000250"
FT   LIPID           219
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           221
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        123..188
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         146..153
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:10931946"
FT                   /id="VSP_005529"
FT   VARIANT         62
FT                   /note="T -> S (in dbSNP:rs1050930)"
FT                   /id="VAR_028206"
FT   VARIANT         73
FT                   /note="W -> G (in GS2; does not affect GTP binding; cannot
FT                   interact with MLPH; significant reduction in interaction
FT                   with UNC13D; abolishes localization to lysosomes;
FT                   dbSNP:rs28938176)"
FT                   /evidence="ECO:0000269|PubMed:10835631,
FT                   ECO:0000269|PubMed:12446441, ECO:0000269|PubMed:12531900,
FT                   ECO:0000269|PubMed:15548590"
FT                   /id="VAR_010654"
FT   VARIANT         84
FT                   /note="L -> F (in dbSNP:rs4340274)"
FT                   /id="VAR_028207"
FT   VARIANT         85
FT                   /note="T -> P (in dbSNP:rs719705)"
FT                   /id="VAR_028208"
FT   VARIANT         130
FT                   /note="L -> P (in GS2; strongly affects GTP binding; cannot
FT                   interact with MLPH; dbSNP:rs104894498)"
FT                   /evidence="ECO:0000269|PubMed:10835631,
FT                   ECO:0000269|PubMed:12446441, ECO:0000269|PubMed:12531900"
FT                   /id="VAR_011334"
FT   VARIANT         152
FT                   /note="A -> P (in GS2; interferes with melanosome
FT                   transport; dbSNP:rs104894499)"
FT                   /evidence="ECO:0000269|PubMed:10835631,
FT                   ECO:0000269|PubMed:12446441, ECO:0000269|PubMed:12531900"
FT                   /id="VAR_011335"
FT   MUTAGEN         23
FT                   /note="T->N: GDP-locked. Abolishes interaction with UNC13D
FT                   and localization to lysosomes. Increases interaction with
FT                   DENND10. Disrupts late endocytic pathway homeostasis."
FT                   /evidence="ECO:0000269|PubMed:15548590,
FT                   ECO:0000269|PubMed:30771381"
FT   MUTAGEN         70
FT                   /note="L->P: Abolishes interaction with SYTL2."
FT                   /evidence="ECO:0000269|PubMed:18812475"
FT   MUTAGEN         76
FT                   /note="A->V: Abolishes interaction with SYTL2."
FT                   /evidence="ECO:0000269|PubMed:18812475"
FT   MUTAGEN         78
FT                   /note="Q->L: GTP-locked. decreases interaction with
FT                   DENND10."
FT                   /evidence="ECO:0000269|PubMed:30771381"
FT   CONFLICT        48
FT                   /note="E -> P (in Ref. 3; AAC51195 and 5; AAD43049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        61..62
FT                   /note="AT -> PV (in Ref. 3; AAC51195 and 5; AAD43049)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..15
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           22..31
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          46..49
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          64..66
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          68..73
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           88..91
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          93..100
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           104..120
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          121..125
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          127..133
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           145..155
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   TURN            164..166
FT                   /evidence="ECO:0007829|PDB:6HUF"
FT   HELIX           170..187
FT                   /evidence="ECO:0007829|PDB:6HUF"
SQ   SEQUENCE   221 AA;  24868 MW;  4A6A0C8C5CC41A20 CRC64;
     MSDGDYDYLI KFLALGDSGV GKTSVLYQYT DGKFNSKFIT TVGIDFREKR VVYRASGPDG
     ATGRGQRIHL QLWDTAGQER FRSLTTAFFR DAMGFLLLFD LTNEQSFLNV RNWISQLQMH
     AYCENPDIVL CGNKSDLEDQ RVVKEEEAIA LAEKYGIPYF ETSAANGTNI SQAIEMLLDL
     IMKRMERCVD KSWIPEGVVR SNGHASTDQL SEEKEKGACG C
//
ID   CLD8_HUMAN              Reviewed;         225 AA.
AC   P56748; D3DSE3; Q53EX7;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 1.
DT   23-FEB-2022, entry version 166.
DE   RecName: Full=Claudin-8;
GN   Name=CLDN8 {ECO:0000312|HGNC:HGNC:2050};
GN   ORFNames=UNQ779/PRO1573 {ECO:0000303|Ref.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Keen T.J., Inglehearn C.F.;
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PRO-151.
RC   TISSUE=Colon;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=17287494; DOI=10.1095/biolreprod.106.059246;
RA   Dube E., Chan P.T.K., Hermo L., Cyr D.G.;
RT   "Gene expression profiling and its relevance to the blood-epididymal
RT   barrier in the human epididymis.";
RL   Biol. Reprod. 76:1034-1044(2007).
RN   [8]
RP   MISCELLANEOUS.
RX   PubMed=22042635; DOI=10.1074/mcp.m111.013458;
RA   Uhlen M., Oksvold P., Algenas C., Hamsten C., Fagerberg L., Klevebring D.,
RA   Lundberg E., Odeberg J., Ponten F., Kondo T., Sivertsson A.;
RT   "Antibody-based protein profiling of the human chromosome 21.";
RL   Mol. Cell. Proteomics 11:M111.013458-M111.013458(2012).
CC   -!- FUNCTION: Tight-junction protein required for paracellular chloride
CC       transport in the kidney. Mediates recruitment of CLDN4 to tight
CC       junction in the kidney. Claudins play a major role in tight junction-
CC       specific obliteration of the intercellular space, through calcium-
CC       independent cell-adhesion activity. {ECO:0000250|UniProtKB:Q9Z260}.
CC   -!- SUBUNIT: Directly interacts with TJP1/ZO-1, TJP2/ZO-2 and TJP3/ZO-3.
CC       Interacts with CLDN4. Interacts with KLHL3.
CC       {ECO:0000250|UniProtKB:Q9Z260}.
CC   -!- INTERACTION:
CC       P56748; Q8TC27: ADAM32; NbExp=3; IntAct=EBI-10215641, EBI-18273040;
CC       P56748; Q3SXY8: ARL13B; NbExp=3; IntAct=EBI-10215641, EBI-11343438;
CC       P56748; Q6ZS10: CLEC17A; NbExp=3; IntAct=EBI-10215641, EBI-11977093;
CC       P56748; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-10215641, EBI-781551;
CC       P56748; Q8N6L0: KASH5; NbExp=3; IntAct=EBI-10215641, EBI-749265;
CC       P56748; P35372-10: OPRM1; NbExp=3; IntAct=EBI-10215641, EBI-12807478;
CC       P56748; Q99640-2: PKMYT1; NbExp=3; IntAct=EBI-10215641, EBI-12257782;
CC       P56748; Q9BZL3: SMIM3; NbExp=3; IntAct=EBI-10215641, EBI-741850;
CC       P56748; Q8N205: SYNE4; NbExp=3; IntAct=EBI-10215641, EBI-7131783;
CC       P56748; Q96HE8: TMEM80; NbExp=3; IntAct=EBI-10215641, EBI-11742770;
CC       P56748; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-10215641, EBI-11988865;
CC   -!- SUBCELLULAR LOCATION: Cell junction, tight junction
CC       {ECO:0000269|PubMed:17287494}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q9Z260}; Multi-pass membrane protein
CC       {ECO:0000255}. Note=Localizes to tight junctions in all 3 segments of
CC       the epididymis, in the caput found in the lateral margins of principal
CC       cells, and in the corpus at the interface between basal and principal
CC       cells. {ECO:0000269|PubMed:17287494}.
CC   -!- TISSUE SPECIFICITY: Expressed in the epididymis, mainly in the caput
CC       segment. {ECO:0000269|PubMed:17287494}.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL3) E3 ubiquitin ligase complex in the
CC       kidney, leading to its degradation. {ECO:0000250|UniProtKB:Q9Z260}.
CC   -!- MISCELLANEOUS: A protein of the expected size has been detected by
CC       antibody binding and Western blot in at least one of the analyzed
CC       tissues or cells. {ECO:0000305|PubMed:22042635}.
CC   -!- SIMILARITY: Belongs to the claudin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ250711; CAB60615.1; -; Genomic_DNA.
DR   EMBL; AY358707; AAQ89070.1; -; mRNA.
DR   EMBL; AK223512; BAD97232.1; -; mRNA.
DR   EMBL; AP001707; BAA95567.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09901.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09902.1; -; Genomic_DNA.
DR   EMBL; BC020866; AAH20866.1; -; mRNA.
DR   EMBL; BC058004; AAH58004.1; -; mRNA.
DR   CCDS; CCDS13587.1; -.
DR   RefSeq; NP_955360.1; NM_199328.2.
DR   SMR; P56748; -.
DR   BioGRID; 114530; 13.
DR   IntAct; P56748; 11.
DR   STRING; 9606.ENSP00000382783; -.
DR   TCDB; 1.H.1.1.7; the claudin tight junction (claudin1) family.
DR   iPTMnet; P56748; -.
DR   PhosphoSitePlus; P56748; -.
DR   BioMuta; CLDN8; -.
DR   DMDM; 6685307; -.
DR   MassIVE; P56748; -.
DR   PaxDb; P56748; -.
DR   PeptideAtlas; P56748; -.
DR   PRIDE; P56748; -.
DR   ProteomicsDB; 56944; -.
DR   Antibodypedia; 6589; 254 antibodies from 28 providers.
DR   DNASU; 9073; -.
DR   Ensembl; ENST00000399899; ENSP00000382783; ENSG00000156284.
DR   GeneID; 9073; -.
DR   KEGG; hsa:9073; -.
DR   MANE-Select; ENST00000399899.2; ENSP00000382783.1; NM_199328.3; NP_955360.1.
DR   UCSC; uc002ynu.3; human.
DR   CTD; 9073; -.
DR   DisGeNET; 9073; -.
DR   GeneCards; CLDN8; -.
DR   HGNC; HGNC:2050; CLDN8.
DR   HPA; ENSG00000156284; Tissue enhanced (breast, intestine, kidney, salivary gland).
DR   MIM; 611231; gene.
DR   neXtProt; NX_P56748; -.
DR   OpenTargets; ENSG00000156284; -.
DR   PharmGKB; PA26576; -.
DR   VEuPathDB; HostDB:ENSG00000156284; -.
DR   eggNOG; ENOG502RTNJ; Eukaryota.
DR   GeneTree; ENSGT00940000159077; -.
DR   HOGENOM; CLU_076370_1_2_1; -.
DR   InParanoid; P56748; -.
DR   OMA; MQCTSCI; -.
DR   OrthoDB; 1314055at2759; -.
DR   PhylomeDB; P56748; -.
DR   TreeFam; TF331936; -.
DR   PathwayCommons; P56748; -.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   SignaLink; P56748; -.
DR   BioGRID-ORCS; 9073; 3 hits in 1038 CRISPR screens.
DR   GeneWiki; CLDN8; -.
DR   GenomeRNAi; 9073; -.
DR   Pharos; P56748; Tbio.
DR   PRO; PR:P56748; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; P56748; protein.
DR   Bgee; ENSG00000156284; Expressed in epithelium of mammary gland and 102 other tissues.
DR   ExpressionAtlas; P56748; baseline and differential.
DR   Genevisible; P56748; HS.
DR   GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005923; C:bicellular tight junction; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; HDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IBA:GO_Central.
DR   GO; GO:0016338; P:calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   InterPro; IPR006187; Claudin.
DR   InterPro; IPR003926; Claudin8.
DR   InterPro; IPR017974; Claudin_CS.
DR   InterPro; IPR004031; PMP22/EMP/MP20/Claudin.
DR   PANTHER; PTHR12002; PTHR12002; 1.
DR   PANTHER; PTHR12002:SF24; PTHR12002:SF24; 1.
DR   Pfam; PF00822; PMP22_Claudin; 1.
DR   PROSITE; PS01346; CLAUDIN; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Membrane; Reference proteome; Tight junction;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..225
FT                   /note="Claudin-8"
FT                   /id="PRO_0000144753"
FT   TOPO_DOM        1..7
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        8..28
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        29..81
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        82..102
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        103..117
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        118..138
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        139..166
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        167..187
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        188..225
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          206..225
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          224..225
FT                   /note="Interactions with TJP1, TJP2 and TJP3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z260"
FT   VARIANT         25
FT                   /note="T -> A (in dbSNP:rs1557294)"
FT                   /id="VAR_048739"
FT   VARIANT         129
FT                   /note="T -> A (in dbSNP:rs685967)"
FT                   /id="VAR_024417"
FT   VARIANT         151
FT                   /note="S -> P (in dbSNP:rs686364)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_020387"
FT   CONFLICT        170
FT                   /note="T -> A (in Ref. 3; BAD97232)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   225 AA;  24845 MW;  F7920E8E71682473 CRC64;
     MATHALEIAG LFLGGVGMVG TVAVTVMPQW RVSAFIENNI VVFENFWEGL WMNCVRQANI
     RMQCKIYDSL LALSPDLQAA RGLMCAASVM SFLAFMMAIL GMKCTRCTGD NEKVKAHILL
     TAGIIFIITG MVVLIPVSWV ANAIIRDFYN SIVNVAQKRE LGEALYLGWT TALVLIVGGA
     LFCCVFCCNE KSSSYRYSIP SHRTTQKSYH TGKKSPSVYS RSQYV
//
ID   ACSL3_HUMAN             Reviewed;         720 AA.
AC   O95573; Q60I92; Q8IUM9;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   23-FEB-2022, entry version 191.
DE   RecName: Full=Fatty acid CoA ligase Acsl3 {ECO:0000305};
DE   AltName: Full=Arachidonate--CoA ligase {ECO:0000250|UniProtKB:Q63151};
DE            EC=6.2.1.15 {ECO:0000250|UniProtKB:Q63151};
DE   AltName: Full=Long-chain acyl-CoA synthetase 3;
DE            Short=LACS 3;
DE   AltName: Full=Long-chain-fatty-acid--CoA ligase 3 {ECO:0000305};
DE            EC=6.2.1.3 {ECO:0000269|PubMed:22633490};
DE   AltName: Full=Medium-chain acyl-CoA ligase Acsl3 {ECO:0000250|UniProtKB:Q63151};
DE            EC=6.2.1.2 {ECO:0000250|UniProtKB:Q63151};
GN   Name=ACSL3 {ECO:0000312|HGNC:HGNC:3570}; Synonyms=ACS3, FACL3, LACS3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-551.
RC   TISSUE=Placenta;
RX   PubMed=9177793; DOI=10.1006/geno.1997.4710;
RA   Minekura H., Fujino T., Kang M.-J., Fujita T., Endo Y., Yamamoto T.T.;
RT   "Human acyl-coenzyme A synthetase 3 cDNA and localization of its gene
RT   (ACS3) to chromosome band 2q34-q35.";
RL   Genomics 42:180-181(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT SER-551.
RX   PubMed=11707336; DOI=10.1016/s0378-1119(01)00714-4;
RA   Minekura H., Kang M.-J., Inagaki Y., Suzuki H., Sato H., Fujino T.,
RA   Yamamoto T.T.;
RT   "Genomic organization and transcription units of the human acyl-CoA
RT   synthetase 3 gene.";
RL   Gene 278:185-192(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION.
RX   PubMed=18003621; DOI=10.1074/jbc.m706160200;
RA   Yao H., Ye J.;
RT   "Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is
RT   required for assembly of very low density lipoproteins in human hepatoma
RT   Huh7 cells.";
RL   J. Biol. Chem. 283:849-854(2008).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-683, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=22633490; DOI=10.1016/j.molcel.2012.04.033;
RA   Nakahara K., Ohkuni A., Kitamura T., Abe K., Naganuma T., Ohno Y.,
RA   Zoeller R.A., Kihara A.;
RT   "The Sjogren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of
RT   the sphingosine 1-phosphate degradation pathway.";
RL   Mol. Cell 46:461-471(2012).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-683, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Acyl-CoA synthetases (ACSL) activates long-chain fatty acids
CC       for both synthesis of cellular lipids, and degradation via beta-
CC       oxidation (PubMed:22633490). Required for the incorporation of fatty
CC       acids into phosphatidylcholine, the major phospholipid located on the
CC       surface of VLDL (very low density lipoproteins) (PubMed:18003621). Has
CC       mainly an anabolic role in energy metabolism. Mediates hepatic
CC       lipogenesis. Preferentially uses myristate, laurate, arachidonate and
CC       eicosapentaenoate as substrates. Both isoforms exhibit the same level
CC       of activity (By similarity). {ECO:0000250|UniProtKB:Q63151,
CC       ECO:0000269|PubMed:18003621, ECO:0000269|PubMed:22633490}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-
CC         CoA + AMP + diphosphate; Xref=Rhea:RHEA:15421, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57560,
CC         ChEBI:CHEBI:83139, ChEBI:CHEBI:456215; EC=6.2.1.3;
CC         Evidence={ECO:0000269|PubMed:22633490};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15422;
CC         Evidence={ECO:0000305|PubMed:22633490};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA =
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:19713, ChEBI:CHEBI:30616, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:456215; EC=6.2.1.15;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19714;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-hexadec-2-enoate + ATP + CoA = (2E)-hexadecenoyl-CoA + AMP
CC         + diphosphate; Xref=Rhea:RHEA:36139, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:61526,
CC         ChEBI:CHEBI:72745, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000269|PubMed:22633490};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36140;
CC         Evidence={ECO:0000305|PubMed:22633490};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=15-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + ATP + CoA = 15-
CC         hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52116, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:78832, ChEBI:CHEBI:136409,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52117;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + ATP + CoA = 12-
CC         hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52112, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:90718, ChEBI:CHEBI:136408,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52113;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = 5-
CC         hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52108, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:65341, ChEBI:CHEBI:136407,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52109;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + ATP + CoA = 14,15-
CC         epoxy-(5Z,8Z,11Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52016, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:84024, ChEBI:CHEBI:136117,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52017;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + ATP + CoA = 11,12-
CC         epoxy-(5Z,8Z,14Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52012, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:76625, ChEBI:CHEBI:136115,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52013;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a medium chain fatty acid + ATP + CoA = a medium-chain fatty
CC         acyl-CoA + AMP + diphosphate; Xref=Rhea:RHEA:48340,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:59558, ChEBI:CHEBI:90546, ChEBI:CHEBI:456215; EC=6.2.1.2;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48341;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + hexadecanoate = AMP + diphosphate + hexadecanoyl-
CC         CoA; Xref=Rhea:RHEA:30751, ChEBI:CHEBI:7896, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:30752;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + tetradecanoate = AMP + diphosphate +
CC         tetradecanoyl-CoA; Xref=Rhea:RHEA:33619, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:30807, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57385, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33620;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + dodecanoate = AMP + diphosphate + dodecanoyl-CoA;
CC         Xref=Rhea:RHEA:33623, ChEBI:CHEBI:18262, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57375,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33624;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + octadecanoate = AMP + diphosphate + octadecanoyl-
CC         CoA; Xref=Rhea:RHEA:33615, ChEBI:CHEBI:25629, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57394,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33616;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + eicosanoate = AMP + diphosphate + eicosanoyl-CoA;
CC         Xref=Rhea:RHEA:46208, ChEBI:CHEBI:30616, ChEBI:CHEBI:32360,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57380,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46209;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-octadecenoate + ATP + CoA = (9Z)-octadecenoyl-CoA + AMP +
CC         diphosphate; Xref=Rhea:RHEA:33607, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33608;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z)-hexadecenoate + ATP + CoA = (9Z)-hexadecenoyl-CoA + AMP +
CC         diphosphate; Xref=Rhea:RHEA:33647, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:32372, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:61540, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33648;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + ATP + CoA = (9Z,12Z)-
CC         octadecadienoyl-CoA + AMP + diphosphate; Xref=Rhea:RHEA:33651,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z,15Z)-octadecatrienoate + ATP + CoA = (9Z,12Z,15Z)-
CC         octadecatrienoyl-CoA + AMP + diphosphate; Xref=Rhea:RHEA:44936,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:32387, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:74034, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44937;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + ATP + CoA =
CC         (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:44932, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:74298, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44933;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + ATP + CoA =
CC         (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:67848, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:58562, ChEBI:CHEBI:73862,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67849;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a fatty acid + ATP + CoA = a fatty acyl-CoA + AMP +
CC         diphosphate; Xref=Rhea:RHEA:38883, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:77636, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38884;
CC         Evidence={ECO:0000250|UniProtKB:Q63151};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- INTERACTION:
CC       O95573; P56962: STX17; NbExp=5; IntAct=EBI-1190822, EBI-2797775;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane {ECO:0000250};
CC       Single-pass type III membrane protein {ECO:0000250}. Peroxisome
CC       membrane {ECO:0000250}; Single-pass type III membrane protein
CC       {ECO:0000250}. Microsome membrane {ECO:0000250}; Single-pass type III
CC       membrane protein {ECO:0000250}. Endoplasmic reticulum membrane
CC       {ECO:0000250}; Single-pass type III membrane protein {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the ATP-dependent AMP-binding enzyme family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D89053; BAA37142.1; -; mRNA.
DR   EMBL; AB061712; BAB72074.1; -; mRNA.
DR   EMBL; AB061436; BAB72139.1; -; Genomic_DNA.
DR   EMBL; BC041692; AAH41692.1; -; mRNA.
DR   CCDS; CCDS2455.1; -.
DR   RefSeq; NP_004448.2; NM_004457.3.
DR   RefSeq; NP_976251.1; NM_203372.1.
DR   RefSeq; XP_016859073.1; XM_017003584.1.
DR   SMR; O95573; -.
DR   BioGRID; 108477; 194.
DR   IntAct; O95573; 66.
DR   MINT; O95573; -.
DR   STRING; 9606.ENSP00000350012; -.
DR   SwissLipids; SLP:000000200; -.
DR   GlyGen; O95573; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O95573; -.
DR   MetOSite; O95573; -.
DR   PhosphoSitePlus; O95573; -.
DR   SwissPalm; O95573; -.
DR   BioMuta; ACSL3; -.
DR   EPD; O95573; -.
DR   jPOST; O95573; -.
DR   MassIVE; O95573; -.
DR   MaxQB; O95573; -.
DR   PaxDb; O95573; -.
DR   PeptideAtlas; O95573; -.
DR   PRIDE; O95573; -.
DR   ProteomicsDB; 50946; -.
DR   Antibodypedia; 1945; 202 antibodies from 29 providers.
DR   DNASU; 2181; -.
DR   Ensembl; ENST00000357430; ENSP00000350012; ENSG00000123983.
DR   Ensembl; ENST00000392066; ENSP00000375918; ENSG00000123983.
DR   Ensembl; ENST00000679514; ENSP00000506361; ENSG00000123983.
DR   Ensembl; ENST00000679558; ENSP00000504907; ENSG00000123983.
DR   Ensembl; ENST00000680147; ENSP00000504861; ENSG00000123983.
DR   Ensembl; ENST00000680251; ENSP00000505400; ENSG00000123983.
DR   Ensembl; ENST00000680395; ENSP00000505793; ENSG00000123983.
DR   Ensembl; ENST00000680684; ENSP00000506468; ENSG00000123983.
DR   Ensembl; ENST00000680921; ENSP00000505940; ENSG00000123983.
DR   Ensembl; ENST00000681383; ENSP00000505654; ENSG00000123983.
DR   Ensembl; ENST00000681697; ENSP00000505856; ENSG00000123983.
DR   GeneID; 2181; -.
DR   KEGG; hsa:2181; -.
DR   MANE-Select; ENST00000357430.8; ENSP00000350012.3; NM_004457.5; NP_004448.2.
DR   UCSC; uc002vni.4; human.
DR   CTD; 2181; -.
DR   DisGeNET; 2181; -.
DR   GeneCards; ACSL3; -.
DR   HGNC; HGNC:3570; ACSL3.
DR   HPA; ENSG00000123983; Tissue enhanced (parathyroid).
DR   MIM; 602371; gene.
DR   neXtProt; NX_O95573; -.
DR   OpenTargets; ENSG00000123983; -.
DR   PharmGKB; PA27967; -.
DR   VEuPathDB; HostDB:ENSG00000123983; -.
DR   eggNOG; KOG1180; Eukaryota.
DR   GeneTree; ENSGT00940000155954; -.
DR   HOGENOM; CLU_000022_45_2_1; -.
DR   InParanoid; O95573; -.
DR   OMA; ENLCLFW; -.
DR   PhylomeDB; O95573; -.
DR   TreeFam; TF314012; -.
DR   BRENDA; 6.2.1.3; 2681.
DR   PathwayCommons; O95573; -.
DR   Reactome; R-HSA-434313; Intracellular metabolism of fatty acids regulates insulin secretion.
DR   Reactome; R-HSA-75876; Synthesis of very long-chain fatty acyl-CoAs.
DR   SignaLink; O95573; -.
DR   BioGRID-ORCS; 2181; 197 hits in 1058 CRISPR screens.
DR   ChiTaRS; ACSL3; human.
DR   GeneWiki; ACSL3; -.
DR   GenomeRNAi; 2181; -.
DR   Pharos; O95573; Tbio.
DR   PRO; PR:O95573; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O95573; protein.
DR   Bgee; ENSG00000123983; Expressed in endothelial cell and 245 other tissues.
DR   ExpressionAtlas; O95573; baseline and differential.
DR   Genevisible; O95573; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0047676; F:arachidonate-CoA ligase activity; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004467; F:long-chain fatty acid-CoA ligase activity; IMP:UniProtKB.
DR   GO; GO:0031956; F:medium-chain fatty acid-CoA ligase activity; IEA:RHEA.
DR   GO; GO:0090433; F:palmitoyl-CoA ligase activity; TAS:Reactome.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0006631; P:fatty acid metabolic process; TAS:Reactome.
DR   GO; GO:0044539; P:long-chain fatty acid import into cell; IDA:UniProtKB.
DR   GO; GO:0001676; P:long-chain fatty acid metabolic process; IMP:UniProtKB.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0035336; P:long-chain fatty-acyl-CoA metabolic process; IBA:GO_Central.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0042998; P:positive regulation of Golgi to plasma membrane protein transport; IMP:UniProtKB.
DR   GO; GO:2001247; P:positive regulation of phosphatidylcholine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0051047; P:positive regulation of secretion; IMP:UniProtKB.
DR   GO; GO:0034379; P:very-low-density lipoprotein particle assembly; IMP:UniProtKB.
DR   Gene3D; 3.40.50.12780; -; 1.
DR   InterPro; IPR020845; AMP-binding_CS.
DR   InterPro; IPR000873; AMP-dep_Synth/Lig.
DR   InterPro; IPR042099; ANL_N_sf.
DR   Pfam; PF00501; AMP-binding; 1.
DR   PROSITE; PS00455; AMP_BINDING; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Endoplasmic reticulum; Fatty acid metabolism; Ligase;
KW   Lipid metabolism; Magnesium; Membrane; Microsome; Mitochondrion;
KW   Mitochondrion outer membrane; Nucleotide-binding; Peroxisome;
KW   Phosphoprotein; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..720
FT                   /note="Fatty acid CoA ligase Acsl3"
FT                   /id="PRO_0000193107"
FT   TRANSMEM        21..41
FT                   /note="Helical; Signal-anchor for type III membrane
FT                   protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        42..720
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         683
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   VARIANT         551
FT                   /note="F -> S (in dbSNP:rs1046032)"
FT                   /evidence="ECO:0000269|PubMed:11707336,
FT                   ECO:0000269|PubMed:9177793"
FT                   /id="VAR_026716"
FT   CONFLICT        246
FT                   /note="E -> D (in Ref. 1; BAA37142 and 2; BAB72074/
FT                   BAB72139)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   720 AA;  80420 MW;  AAC4B0B4543EC8DD CRC64;
     MNNHVSSKPS TMKLKHTINP ILLYFIHFLI SLYTILTYIP FYFFSESRQE KSNRIKAKPV
     NSKPDSAYRS VNSLDGLASV LYPGCDTLDK VFTYAKNKFK NKRLLGTREV LNEEDEVQPN
     GKIFKKVILG QYNWLSYEDV FVRAFNFGNG LQMLGQKPKT NIAIFCETRA EWMIAAQACF
     MYNFQLVTLY ATLGGPAIVH ALNETEVTNI ITSKELLQTK LKDIVSLVPR LRHIITVDGK
     PPTWSEFPKG IIVHTMAAVE ALGAKASMEN QPHSKPLPSD IAVIMYTSGS TGLPKGVMIS
     HSNIIAGITG MAERIPELGE EDVYIGYLPL AHVLELSAEL VCLSHGCRIG YSSPQTLADQ
     SSKIKKGSKG DTSMLKPTLM AAVPEIMDRI YKNVMNKVSE MSSFQRNLFI LAYNYKMEQI
     SKGRNTPLCD SFVFRKVRSL LGGNIRLLLC GGAPLSATTQ RFMNICFCCP VGQGYGLTES
     AGAGTISEVW DYNTGRVGAP LVCCEIKLKN WEEGGYFNTD KPHPRGEILI GGQSVTMGYY
     KNEAKTKADF FEDENGQRWL CTGDIGEFEP DGCLKIIDRK KDLVKLQAGE YVSLGKVEAA
     LKNLPLVDNI CAYANSYHSY VIGFVVPNQK ELTELARKKG LKGTWEELCN SCEMENEVLK
     VLSEAAISAS LEKFEIPVKI RLSPEPWTPE TGLVTDAFKL KRKELKTHYQ ADIERMYGRK
//
ID   MS4A7_HUMAN             Reviewed;         240 AA.
AC   Q9GZW8; A6NP53; Q6IAG8;
DT   04-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   23-FEB-2022, entry version 154.
DE   RecName: Full=Membrane-spanning 4-domains subfamily A member 7;
DE   AltName: Full=CD20 antigen-like 4;
DE   AltName: Full=CD20/FC-epsilon-RI-beta family member 4;
DE   AltName: Full=Four-span transmembrane protein 2;
GN   Name=MS4A7; Synonyms=4SPAN2, CD20L4, CFFM4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11245982; DOI=10.1016/s0378-1119(00)00598-9;
RA   Ishibashi K., Suzuki M., Sasaki S., Imai M.;
RT   "Identification of a new multigene four-transmembrane family (MS4A) related
RT   to CD20, HTm4 and beta subunit of the high-affinity IgE receptor.";
RL   Gene 264:87-93(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Peripheral blood;
RX   PubMed=11685457; DOI=10.1007/s002510100345;
RA   Gingras M.-C., Lapillonne H., Margolin J.F.;
RT   "CFFM4: a new member of the CD20/Fc-epsilon-RI-beta-family.";
RL   Immunogenetics 53:468-476(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Parathyroid;
RX   PubMed=11401424; DOI=10.1006/geno.2000.6472;
RA   Liang Y., Tedder T.F.;
RT   "Identification of a CD20-, Fc-epsilon-RI-beta-, and HTm4-related gene
RT   family: sixteen new MS4A family members expressed in human and mouse.";
RL   Genomics 72:119-127(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hulett M.D., Pagler E., Hogarth P.M., Eyre H.J., Baker E., Crawford J.,
RA   Sutherland G.R., Parish C.R.;
RT   "Isolation of a family of hematopoietic-expressed four-transmembrane genes
RT   related to CD20 and Fc-epsilon-RI-beta.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Dendritic cell;
RA   Li Y., Gu J., Peng Y., Qian B., Xu S., Han Z., Fu G., Chen Z.;
RT   "Novel genes expressed in human dendritic cells.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: May be involved in signal transduction as a component of a
CC       multimeric receptor complex.
CC   -!- INTERACTION:
CC       Q9GZW8; P21854: CD72; NbExp=3; IntAct=EBI-721391, EBI-307924;
CC       Q9GZW8; Q8N682: DRAM1; NbExp=3; IntAct=EBI-721391, EBI-10305400;
CC       Q9GZW8; P54849: EMP1; NbExp=3; IntAct=EBI-721391, EBI-4319440;
CC       Q9GZW8; P24593: IGFBP5; NbExp=3; IntAct=EBI-721391, EBI-720480;
CC       Q9GZW8; P05107: ITGB2; NbExp=3; IntAct=EBI-721391, EBI-300173;
CC       Q9GZW8; O43561-2: LAT; NbExp=3; IntAct=EBI-721391, EBI-8070286;
CC       Q9GZW8; P26678: PLN; NbExp=3; IntAct=EBI-721391, EBI-692836;
CC       Q9GZW8; Q01453: PMP22; NbExp=3; IntAct=EBI-721391, EBI-2845982;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9GZW8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9GZW8-2; Sequence=VSP_042009;
CC   -!- TISSUE SPECIFICITY: Ubiquitous expression in normal tissues. Expression
CC       is more elevated in adult liver, lung, spleen, and heart than in their
CC       fetal counterparts, and is higher in normal tissues than in the
CC       cancerous tissue or cell lines. Low levels of expression were detected
CC       in the promonocytic stage, whereas high levels of expression were
CC       detected in mature monocytes.
CC   -!- SIMILARITY: Belongs to the MS4A family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB026043; BAB18755.1; -; mRNA.
DR   EMBL; AF309653; AAG30930.1; -; mRNA.
DR   EMBL; AF237916; AAK37599.1; -; mRNA.
DR   EMBL; AF350501; AAL56221.1; -; mRNA.
DR   EMBL; AF201951; AAF17243.1; -; mRNA.
DR   EMBL; AK075106; BAC11405.1; -; mRNA.
DR   EMBL; AK297027; BAG59556.1; -; mRNA.
DR   EMBL; CR457187; CAG33468.1; -; mRNA.
DR   EMBL; AP003127; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW73878.1; -; Genomic_DNA.
DR   EMBL; CH471076; EAW73879.1; -; Genomic_DNA.
DR   EMBL; BC020673; AAH20673.1; -; mRNA.
DR   CCDS; CCDS7985.1; -. [Q9GZW8-1]
DR   CCDS; CCDS7986.1; -. [Q9GZW8-2]
DR   RefSeq; NP_067024.1; NM_021201.4. [Q9GZW8-1]
DR   RefSeq; NP_996821.1; NM_206938.1. [Q9GZW8-2]
DR   RefSeq; NP_996822.1; NM_206939.1. [Q9GZW8-1]
DR   RefSeq; NP_996823.1; NM_206940.1. [Q9GZW8-2]
DR   SMR; Q9GZW8; -.
DR   BioGRID; 121808; 11.
DR   IntAct; Q9GZW8; 12.
DR   STRING; 9606.ENSP00000300184; -.
DR   iPTMnet; Q9GZW8; -.
DR   PhosphoSitePlus; Q9GZW8; -.
DR   BioMuta; MS4A7; -.
DR   DMDM; 29611829; -.
DR   jPOST; Q9GZW8; -.
DR   MassIVE; Q9GZW8; -.
DR   PaxDb; Q9GZW8; -.
DR   PeptideAtlas; Q9GZW8; -.
DR   PRIDE; Q9GZW8; -.
DR   Antibodypedia; 2586; 144 antibodies from 22 providers.
DR   DNASU; 58475; -.
DR   Ensembl; ENST00000300184; ENSP00000300184; ENSG00000166927.
DR   Ensembl; ENST00000358246; ENSP00000350983; ENSG00000166927. [Q9GZW8-2]
DR   Ensembl; ENST00000534016; ENSP00000434637; ENSG00000166927. [Q9GZW8-2]
DR   GeneID; 58475; -.
DR   KEGG; hsa:58475; -.
DR   MANE-Select; ENST00000300184.8; ENSP00000300184.3; NM_021201.5; NP_067024.1.
DR   UCSC; uc001npf.4; human. [Q9GZW8-1]
DR   CTD; 58475; -.
DR   DisGeNET; 58475; -.
DR   GeneCards; MS4A7; -.
DR   HGNC; HGNC:13378; MS4A7.
DR   HPA; ENSG00000166927; Tissue enhanced (lymphoid).
DR   MIM; 606502; gene.
DR   neXtProt; NX_Q9GZW8; -.
DR   NIAGADS; ENSG00000166927; -.
DR   OpenTargets; ENSG00000166927; -.
DR   PharmGKB; PA31124; -.
DR   VEuPathDB; HostDB:ENSG00000166927; -.
DR   eggNOG; ENOG502RP28; Eukaryota.
DR   GeneTree; ENSGT00940000162779; -.
DR   HOGENOM; CLU_089673_0_0_1; -.
DR   InParanoid; Q9GZW8; -.
DR   OMA; DHIQHVK; -.
DR   PhylomeDB; Q9GZW8; -.
DR   TreeFam; TF335157; -.
DR   PathwayCommons; Q9GZW8; -.
DR   SignaLink; Q9GZW8; -.
DR   BioGRID-ORCS; 58475; 17 hits in 1019 CRISPR screens.
DR   ChiTaRS; MS4A7; human.
DR   GeneWiki; MS4A7; -.
DR   GenomeRNAi; 58475; -.
DR   Pharos; Q9GZW8; Tdark.
DR   PRO; PR:Q9GZW8; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9GZW8; protein.
DR   Bgee; ENSG00000166927; Expressed in spleen and 170 other tissues.
DR   ExpressionAtlas; Q9GZW8; baseline and differential.
DR   Genevisible; Q9GZW8; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:ARUK-UCL.
DR   InterPro; IPR007237; CD20-like.
DR   InterPro; IPR030417; MS4A.
DR   InterPro; IPR030423; MS4A7.
DR   PANTHER; PTHR23320; PTHR23320; 1.
DR   PANTHER; PTHR23320:SF8; PTHR23320:SF8; 1.
DR   Pfam; PF04103; CD20; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Membrane; Receptor; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..240
FT                   /note="Membrane-spanning 4-domains subfamily A member 7"
FT                   /id="PRO_0000158643"
FT   TOPO_DOM        1..47
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        48..68
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        69..83
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        84..104
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        105..121
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        122..142
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        143..178
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        179..199
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        200..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          218..240
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         50..94
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042009"
FT   VARIANT         34
FT                   /note="E -> K (in dbSNP:rs2233241)"
FT                   /id="VAR_053520"
FT   VARIANT         112
FT                   /note="P -> H (in dbSNP:rs2233249)"
FT                   /id="VAR_053521"
FT   VARIANT         157
FT                   /note="S -> F (in dbSNP:rs2233251)"
FT                   /id="VAR_053522"
SQ   SEQUENCE   240 AA;  26131 MW;  512BC9C126C76DC0 CRC64;
     MLLQSQTMGV SHSFTPKGIT IPQREKPGHM YQNEDYLQNG LPTETTVLGT VQILCCLLIS
     SLGAILVFAP YPSHFNPAIS TTLMSGYPFL GALCFGITGS LSIISGKQST KPFDLSSLTS
     NAVSSVTAGA GLFLLADSMV ALRTASQHCG SEMDYLSSLP YSEYYYPIYE IKDCLLTSVS
     LTGVLVVMLI FTVLELLLAA YSSVFWWKQL YSNNPGSSFS STQSQDHIQQ VKKSSSRSWI
//
ID   MBNL1_HUMAN             Reviewed;         388 AA.
AC   Q9NR56; E9PBW7; O43311; O43797; Q86UV8; Q86UV9; Q96P92; Q96RE3;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2001, sequence version 2.
DT   23-FEB-2022, entry version 177.
DE   RecName: Full=Muscleblind-like protein 1;
DE   AltName: Full=Triplet-expansion RNA-binding protein;
GN   Name=MBNL1; Synonyms=EXP, KIAA0428, MBNL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Borsani G., Barbieri A.;
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=9455477; DOI=10.1093/dnares/4.5.307;
RA   Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VIII. 78
RT   new cDNA clones from brain which code for large proteins in vitro.";
RL   DNA Res. 4:307-313(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), FUNCTION, ALTERNATIVE
RP   SPLICING, SUBCELLULAR LOCATION, RNA-BINDING, TISSUE SPECIFICITY, ROLE IN
RP   MYOTONIC DYSTROPHY, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10970838; DOI=10.1093/emboj/19.17.4439;
RA   Miller J.W., Urbinati C.R., Teng-Umnuay P., Stenberg M.G., Byrne B.J.,
RA   Thornton C.A., Swanson M.S.;
RT   "Recruitment of human muscleblind proteins to (CUG)(n) expansions
RT   associated with myotonic dystrophy.";
RL   EMBO J. 19:4439-4448(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND SUBCELLULAR LOCATION.
RX   PubMed=11590133; DOI=10.1093/hmg/10.19.2165;
RA   Mankodi A., Urbinati C.R., Yuan Q.P., Moxley R.T., Sansone V., Krym M.,
RA   Henderson D., Schalling M., Swanson M.S., Thornton C.A.;
RT   "Muscleblind localizes to nuclear foci of aberrant RNA in myotonic
RT   dystrophy types 1 and 2.";
RL   Hum. Mol. Genet. 10:2165-2170(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Blood;
RA   Pascual M., Terol J., Perez-Alonso M.;
RT   "Study of the role of the MBNL gene in the origin myotonic dystrophies in
RT   humans.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6 AND 7).
RC   TISSUE=Muscle;
RA   Kino Y., Ishiura S.;
RT   "Direct evidence that EXP/muscleblind interacts with CCUG tetranucleotide
RT   repeats.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND POSSIBLE INVOLVEMENT IN DM1.
RX   PubMed=11929853; DOI=10.1093/hmg/11.7.805;
RA   Fardaei M., Rogers M.T., Thorpe H.M., Larkin K., Hamshere M.G.,
RA   Harper P.S., Brook J.D.;
RT   "Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci
RT   of expanded-repeat transcripts in DM1 and DM2 cells.";
RL   Hum. Mol. Genet. 11:805-814(2002).
RN   [11]
RP   FUNCTION, AND RNA-BINDING.
RX   PubMed=15257297; DOI=10.1038/sj.emboj.7600300;
RA   Ho T.H., Charlet-B N., Poulos M.G., Singh G., Swanson M.S., Cooper T.A.;
RT   "Muscleblind proteins regulate alternative splicing.";
RL   EMBO J. 23:3103-3112(2004).
RN   [12]
RP   FUNCTION, INTERACTION WITH HNRNPH1, AND RNA-BINDING.
RX   PubMed=16946708; DOI=10.1038/sj.emboj.7601296;
RA   Paul S., Dansithong W., Kim D., Rossi J., Webster N.J., Comai L., Reddy S.;
RT   "Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated
RT   aberrant IR splicing.";
RL   EMBO J. 25:4271-4283(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH DDX1 AND YBX1, SUBCELLULAR LOCATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18335541; DOI=10.1002/jnr.21655;
RA   Onishi H., Kino Y., Morita T., Futai E., Sasagawa N., Ishiura S.;
RT   "MBNL1 associates with YB-1 in cytoplasmic stress granules.";
RL   J. Neurosci. Res. 86:1994-2002(2008).
RN   [14]
RP   FUNCTION, AND RNA-BINDING.
RX   PubMed=19470458; DOI=10.1073/pnas.0900342106;
RA   Warf M.B., Diegel J.V., von Hippel P.H., Berglund J.A.;
RT   "The protein factors MBNL1 and U2AF65 bind alternative RNA structures to
RT   regulate splicing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:9203-9208(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-6, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   INVOLVEMENT IN FECD3.
RX   PubMed=25593321; DOI=10.1074/jbc.m114.621607;
RA   Du J., Aleff R.A., Soragni E., Kalari K., Nie J., Tang X., Davila J.,
RA   Kocher J.P., Patel S.V., Gottesfeld J.M., Baratz K.H., Wieben E.D.;
RT   "RNA toxicity and missplicing in the common eye disease fuchs endothelial
RT   corneal dystrophy.";
RL   J. Biol. Chem. 290:5979-5990(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 9-90 IN COMPLEX WITH ZINC IONS
RP   AND 178-246 IN COMPLEX WITH ZINC IONS AND RNA, AND RNA-BINDING.
RX   PubMed=19043415; DOI=10.1038/nsmb.1519;
RA   Teplova M., Patel D.J.;
RT   "Structural insights into RNA recognition by the alternative-splicing
RT   regulator muscleblind-like MBNL1.";
RL   Nat. Struct. Mol. Biol. 15:1343-1351(2008).
RN   [19]
RP   VARIANTS DM1 MET-32; 171-ALA--ALA-173 DEL AND SER-338.
RX   PubMed=27222292; DOI=10.1038/ejhg.2016.41;
RA   Larsen M., Kress W., Schoser B., Hehr U., Mueller C.R., Rost S.;
RT   "Identification of variants in MBNL1 in patients with a myotonic dystrophy-
RT   like phenotype.";
RL   Eur. J. Hum. Genet. 24:1467-1472(2016).
CC   -!- FUNCTION: Mediates pre-mRNA alternative splicing regulation. Acts
CC       either as activator or repressor of splicing on specific pre-mRNA
CC       targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion
CC       but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle.
CC       Antagonizes the alternative splicing activity pattern of CELF proteins.
CC       Regulates the TNNT2 exon 5 skipping through competition with U2AF2.
CC       Inhibits the formation of the spliceosome A complex on intron 4 of
CC       TNNT2 pre-mRNA. Binds to the stem-loop structure within the
CC       polypyrimidine tract of TNNT2 intron 4 during spliceosome assembly.
CC       Binds to the 5'-YGCU(U/G)Y-3'consensus sequence. Binds to the IR RNA.
CC       Binds to expanded CUG repeat RNA, which folds into a hairpin structure
CC       containing GC base pairs and bulged, unpaired U residues.
CC       {ECO:0000269|PubMed:10970838, ECO:0000269|PubMed:15257297,
CC       ECO:0000269|PubMed:16946708, ECO:0000269|PubMed:18335541,
CC       ECO:0000269|PubMed:19470458}.
CC   -!- SUBUNIT: Interacts with DDX1 and YBX1. Interacts with HNRNPH1; the
CC       interaction in RNA-independent. {ECO:0000269|PubMed:16946708,
CC       ECO:0000269|PubMed:18335541, ECO:0000269|PubMed:19043415}.
CC   -!- INTERACTION:
CC       Q9NR56; O75553: DAB1; NbExp=4; IntAct=EBI-2805004, EBI-7875264;
CC       Q9NR56; P31943: HNRNPH1; NbExp=2; IntAct=EBI-2805004, EBI-351590;
CC       Q9NR56-5; P54253: ATXN1; NbExp=6; IntAct=EBI-25978262, EBI-930964;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10970838,
CC       ECO:0000269|PubMed:11590133, ECO:0000269|PubMed:11929853}. Cytoplasm
CC       {ECO:0000269|PubMed:18335541}. Cytoplasmic granule
CC       {ECO:0000269|PubMed:18335541}. Note=Localized with DDX1, TIAL1 and YBX1
CC       in stress granules upon stress (PubMed:18335541). Localized in the
CC       cytoplasm of multinucleated myotubes (PubMed:18335541). Colocalizes
CC       with nuclear foci of retained expanded-repeat transcripts in myotubes
CC       from patients affected by myotonic dystrophy (PubMed:10970838,
CC       PubMed:11590133, PubMed:11929853).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=EXP42;
CC         IsoId=Q9NR56-1; Sequence=Displayed;
CC       Name=2; Synonyms=EXP40;
CC         IsoId=Q9NR56-2; Sequence=VSP_006430;
CC       Name=3; Synonyms=EXP35;
CC         IsoId=Q9NR56-3; Sequence=VSP_006429, VSP_006430;
CC       Name=4; Synonyms=EXP36;
CC         IsoId=Q9NR56-4; Sequence=VSP_006429, VSP_006430, VSP_043799;
CC       Name=5; Synonyms=EXP41;
CC         IsoId=Q9NR56-5; Sequence=VSP_006430, VSP_043799;
CC       Name=6; Synonyms=EXP41S;
CC         IsoId=Q9NR56-6; Sequence=VSP_006430, VSP_043799, VSP_043800;
CC       Name=7;
CC         IsoId=Q9NR56-7; Sequence=VSP_044903;
CC   -!- TISSUE SPECIFICITY: Highly expressed in cardiac, skeletal muscle and
CC       during myoblast differentiation. Weakly expressed in other tissues (at
CC       protein level). Expressed in heart, brain, placenta, lung, liver,
CC       skeletal muscle, kidney and pancreas. {ECO:0000269|PubMed:10970838,
CC       ECO:0000269|PubMed:11929853}.
CC   -!- DISEASE: Dystrophia myotonica 1 (DM1) [MIM:160900]: A muscular disorder
CC       characterized by myotonia, muscle wasting in the distal extremities,
CC       cataract, hypogonadism, defective endocrine functions, male baldness
CC       and cardiac arrhythmias. {ECO:0000269|PubMed:11929853,
CC       ECO:0000269|PubMed:27222292}. Note=The protein represented in this
CC       entry may be involved in disease pathogenesis. In muscle cells from
CC       patients, MBNL1 is sequestered by DMPK RNAs containing pathogenic CUG
CC       triplet repeat expansions. MBNL1 binding is proportional to repeat
CC       length consistent with the direct correlation between the length of
CC       repeat expansion and disease severity.
CC   -!- DISEASE: Corneal dystrophy, Fuchs endothelial, 3 (FECD3) [MIM:613267]:
CC       A late-onset form of Fuchs endothelial corneal dystrophy, a disease
CC       caused by loss of endothelium of the central cornea. It is
CC       characterized by focal wart-like guttata that arise from Descemet
CC       membrane and develop in the central cornea, epithelial blisters,
CC       reduced vision and pain. Descemet membrane is thickened by abnormal
CC       collagenous deposition. {ECO:0000269|PubMed:25593321}. Note=The protein
CC       represented in this entry is involved in disease pathogenesis. In
CC       corneal endothelial cells from patients, MBNL1 is sequestered by TCF4
CC       RNAs containing pathogenic CUG triplet repeat expansions. This results
CC       in missplicing of essential MBNL1-regulated mRNAs.
CC       {ECO:0000269|PubMed:25593321}.
CC   -!- SIMILARITY: Belongs to the muscleblind family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA24858.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y13829; CAA74155.1; -; mRNA.
DR   EMBL; AB007888; BAA24858.2; ALT_INIT; mRNA.
DR   EMBL; AF255334; AAF76138.1; -; mRNA.
DR   EMBL; AF395876; AAK82889.1; -; mRNA.
DR   EMBL; AF401998; AAK94915.1; -; mRNA.
DR   EMBL; AJ308400; CAC83727.1; -; mRNA.
DR   EMBL; AF497718; AAP30726.1; -; mRNA.
DR   EMBL; AF497719; AAP30727.1; -; mRNA.
DR   EMBL; AC026347; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC106722; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78775.1; -; Genomic_DNA.
DR   EMBL; BC043493; AAH43493.1; -; mRNA.
DR   CCDS; CCDS3163.1; -. [Q9NR56-5]
DR   CCDS; CCDS3164.1; -. [Q9NR56-2]
DR   CCDS; CCDS3165.1; -. [Q9NR56-1]
DR   CCDS; CCDS3166.1; -. [Q9NR56-4]
DR   CCDS; CCDS3167.1; -. [Q9NR56-7]
DR   CCDS; CCDS3168.1; -. [Q9NR56-6]
DR   CCDS; CCDS54656.1; -. [Q9NR56-3]
DR   RefSeq; NP_001300986.1; NM_001314057.1.
DR   RefSeq; NP_066368.2; NM_021038.4. [Q9NR56-5]
DR   RefSeq; NP_997175.1; NM_207292.2. [Q9NR56-2]
DR   RefSeq; NP_997176.1; NM_207293.1. [Q9NR56-1]
DR   RefSeq; NP_997177.1; NM_207294.1. [Q9NR56-3]
DR   RefSeq; NP_997178.1; NM_207295.1. [Q9NR56-4]
DR   RefSeq; NP_997179.1; NM_207296.1. [Q9NR56-7]
DR   RefSeq; NP_997180.1; NM_207297.1. [Q9NR56-6]
DR   RefSeq; XP_005247523.1; XM_005247466.4.
DR   RefSeq; XP_005247528.1; XM_005247471.4.
DR   RefSeq; XP_011511149.1; XM_011512847.2.
DR   RefSeq; XP_011511151.1; XM_011512849.2.
DR   RefSeq; XP_016861914.1; XM_017006425.1.
DR   RefSeq; XP_016861915.1; XM_017006426.1.
DR   RefSeq; XP_016861916.1; XM_017006427.1.
DR   RefSeq; XP_016861917.1; XM_017006428.1.
DR   RefSeq; XP_016861918.1; XM_017006429.1.
DR   RefSeq; XP_016861919.1; XM_017006430.1.
DR   RefSeq; XP_016861920.1; XM_017006431.1.
DR   RefSeq; XP_016861925.1; XM_017006436.1.
DR   PDB; 3D2N; X-ray; 2.70 A; A=9-90.
DR   PDB; 3D2Q; X-ray; 1.50 A; A/B/C/D=178-246.
DR   PDB; 3D2S; X-ray; 1.70 A; A/B/C/D=178-246.
DR   PDB; 5U6H; NMR; -; A=1-92.
DR   PDB; 5U6L; NMR; -; A=173-255.
DR   PDB; 5U9B; NMR; -; A=1-92.
DR   PDBsum; 3D2N; -.
DR   PDBsum; 3D2Q; -.
DR   PDBsum; 3D2S; -.
DR   PDBsum; 5U6H; -.
DR   PDBsum; 5U6L; -.
DR   PDBsum; 5U9B; -.
DR   SMR; Q9NR56; -.
DR   BioGRID; 110324; 219.
DR   IntAct; Q9NR56; 29.
DR   MINT; Q9NR56; -.
DR   STRING; 9606.ENSP00000282486; -.
DR   ChEMBL; CHEMBL1293317; -.
DR   GlyGen; Q9NR56; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9NR56; -.
DR   PhosphoSitePlus; Q9NR56; -.
DR   SwissPalm; Q9NR56; -.
DR   BioMuta; MBNL1; -.
DR   DMDM; 17369313; -.
DR   EPD; Q9NR56; -.
DR   jPOST; Q9NR56; -.
DR   MassIVE; Q9NR56; -.
DR   MaxQB; Q9NR56; -.
DR   PaxDb; Q9NR56; -.
DR   PeptideAtlas; Q9NR56; -.
DR   PRIDE; Q9NR56; -.
DR   ProteomicsDB; 19310; -.
DR   ProteomicsDB; 82279; -. [Q9NR56-1]
DR   ProteomicsDB; 82280; -. [Q9NR56-2]
DR   ProteomicsDB; 82281; -. [Q9NR56-3]
DR   ProteomicsDB; 82282; -. [Q9NR56-4]
DR   ProteomicsDB; 82283; -. [Q9NR56-5]
DR   ProteomicsDB; 82284; -. [Q9NR56-6]
DR   Antibodypedia; 4292; 351 antibodies from 34 providers.
DR   DNASU; 4154; -.
DR   Ensembl; ENST00000282486; ENSP00000282486; ENSG00000152601.
DR   Ensembl; ENST00000324196; ENSP00000319374; ENSG00000152601. [Q9NR56-7]
DR   Ensembl; ENST00000324210; ENSP00000319429; ENSG00000152601. [Q9NR56-5]
DR   Ensembl; ENST00000355460; ENSP00000347637; ENSG00000152601. [Q9NR56-2]
DR   Ensembl; ENST00000357472; ENSP00000350064; ENSG00000152601. [Q9NR56-6]
DR   Ensembl; ENST00000463374; ENSP00000418108; ENSG00000152601.
DR   Ensembl; ENST00000465907; ENSP00000417630; ENSG00000152601. [Q9NR56-4]
DR   Ensembl; ENST00000485509; ENSP00000418876; ENSG00000152601. [Q9NR56-7]
DR   Ensembl; ENST00000485910; ENSP00000418427; ENSG00000152601. [Q9NR56-3]
DR   Ensembl; ENST00000492948; ENSP00000420103; ENSG00000152601. [Q9NR56-6]
DR   Ensembl; ENST00000545754; ENSP00000437491; ENSG00000152601. [Q9NR56-4]
DR   GeneID; 4154; -.
DR   KEGG; hsa:4154; -.
DR   MANE-Select; ENST00000324210.10; ENSP00000319429.5; NM_021038.5; NP_066368.2. [Q9NR56-5]
DR   UCSC; uc003ezh.4; human. [Q9NR56-1]
DR   CTD; 4154; -.
DR   DisGeNET; 4154; -.
DR   GeneCards; MBNL1; -.
DR   HGNC; HGNC:6923; MBNL1.
DR   HPA; ENSG00000152601; Low tissue specificity.
DR   MIM; 160900; phenotype.
DR   MIM; 606516; gene.
DR   MIM; 613267; phenotype.
DR   neXtProt; NX_Q9NR56; -.
DR   OpenTargets; ENSG00000152601; -.
DR   PharmGKB; PA30666; -.
DR   VEuPathDB; HostDB:ENSG00000152601; -.
DR   eggNOG; KOG2494; Eukaryota.
DR   GeneTree; ENSGT00950000182897; -.
DR   HOGENOM; CLU_053536_0_0_1; -.
DR   InParanoid; Q9NR56; -.
DR   OMA; KVPMVHG; -.
DR   OrthoDB; 1543798at2759; -.
DR   PhylomeDB; Q9NR56; -.
DR   TreeFam; TF321931; -.
DR   PathwayCommons; Q9NR56; -.
DR   SignaLink; Q9NR56; -.
DR   BioGRID-ORCS; 4154; 80 hits in 1061 CRISPR screens.
DR   ChiTaRS; MBNL1; human.
DR   EvolutionaryTrace; Q9NR56; -.
DR   GeneWiki; MBNL1; -.
DR   GenomeRNAi; 4154; -.
DR   Pharos; Q9NR56; Tbio.
DR   PRO; PR:Q9NR56; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9NR56; protein.
DR   Bgee; ENSG00000152601; Expressed in calcaneal tendon and 260 other tissues.
DR   ExpressionAtlas; Q9NR56; baseline and differential.
DR   Genevisible; Q9NR56; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0001069; F:regulatory region RNA binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0045445; P:myoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; ISS:UniProtKB.
DR   GO; GO:0000381; P:regulation of alternative mRNA splicing, via spliceosome; IBA:GO_Central.
DR   GO; GO:0043484; P:regulation of RNA splicing; IDA:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IDA:UniProtKB.
DR   InterPro; IPR000571; Znf_CCCH.
DR   Pfam; PF00642; zf-CCCH; 1.
DR   SMART; SM00356; ZnF_C3H1; 4.
DR   PROSITE; PS50103; ZF_C3H1; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Corneal dystrophy; Cytoplasm;
KW   Disease variant; Metal-binding; mRNA processing; mRNA splicing; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; RNA-binding; Zinc; Zinc-finger.
FT   CHAIN           1..388
FT                   /note="Muscleblind-like protein 1"
FT                   /id="PRO_0000089178"
FT   ZN_FING         13..41
FT                   /note="C3H1-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         47..73
FT                   /note="C3H1-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         179..207
FT                   /note="C3H1-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         215..241
FT                   /note="C3H1-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   MOD_RES         6
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         116..183
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10970838"
FT                   /id="VSP_006429"
FT   VAR_SEQ         270..370
FT                   /note="TQSAVKSLKRPLEATFDLGIPQAVLPPLPKRPALEKTNGATAVFNTGIFQYQ
FT                   QALANMQLQQHTAFLPPVPMVHGATPATVSAATTSATSVPFAATATANQ -> FPWCTV
FT                   LRQPLCPQQQHLPQVFPSLQQPQPTSPILDASTLLGATSCPAAAGKM (in isoform
FT                   7)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_044903"
FT   VAR_SEQ         270..287
FT                   /note="Missing (in isoform 2, isoform 3, isoform 4, isoform
FT                   5 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10970838,
FT                   ECO:0000303|PubMed:11590133, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9455477, ECO:0000303|Ref.5,
FT                   ECO:0000303|Ref.6"
FT                   /id="VSP_006430"
FT   VAR_SEQ         338
FT                   /note="P -> PGSILCMTPATSV (in isoform 4, isoform 5 and
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10970838,
FT                   ECO:0000303|PubMed:11590133, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|Ref.5, ECO:0000303|Ref.6"
FT                   /id="VSP_043799"
FT   VAR_SEQ         339..388
FT                   /note="VPMVHGATPATVSAATTSATSVPFAATATANQIPIISAEHLTSHKYVTQM
FT                   -> DTHNICRTSD (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_043800"
FT   VARIANT         32
FT                   /note="T -> M (in DM1; unknown pathological significance;
FT                   dbSNP:rs185894411)"
FT                   /evidence="ECO:0000269|PubMed:27222292"
FT                   /id="VAR_076508"
FT   VARIANT         171..173
FT                   /note="Missing (in DM1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27222292"
FT                   /id="VAR_076509"
FT   VARIANT         338
FT                   /note="P -> S (in DM1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27222292"
FT                   /id="VAR_076510"
FT   TURN            2..5
FT                   /evidence="ECO:0007829|PDB:5U6H"
FT   HELIX           12..14
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   STRAND          15..18
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   HELIX           22..24
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   TURN            31..33
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   STRAND          35..37
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   STRAND          49..51
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   HELIX           54..57
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   STRAND          67..69
FT                   /evidence="ECO:0007829|PDB:5U6H"
FT   HELIX           73..82
FT                   /evidence="ECO:0007829|PDB:3D2N"
FT   TURN            89..91
FT                   /evidence="ECO:0007829|PDB:5U9B"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:5U6L"
FT   STRAND          181..184
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   HELIX           186..189
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   TURN            197..199
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:5U6L"
FT   TURN            213..216
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   STRAND          217..220
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   HELIX           222..225
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   STRAND          235..237
FT                   /evidence="ECO:0007829|PDB:3D2S"
FT   HELIX           241..244
FT                   /evidence="ECO:0007829|PDB:3D2Q"
FT   TURN            252..254
FT                   /evidence="ECO:0007829|PDB:5U6L"
FT   CONFLICT        Q9NR56-7:317
FT                   /note="A -> AA (in Ref. 6; AAP30726)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   388 AA;  41817 MW;  118D256A81A86695 CRC64;
     MAVSVTPIRD TKWLTLEVCR EFQRGTCSRP DTECKFAHPS KSCQVENGRV IACFDSLKGR
     CSRENCKYLH PPPHLKTQLE INGRNNLIQQ KNMAMLAQQM QLANAMMPGA PLQPVPMFSV
     APSLATNASA AAFNPYLGPV SPSLVPAEIL PTAPMLVTGN PGVPVPAAAA AAAQKLMRTD
     RLEVCREYQR GNCNRGENDC RFAHPADSTM IDTNDNTVTV CMDYIKGRCS REKCKYFHPP
     AHLQAKIKAA QYQVNQAAAA QAAATAAAMT QSAVKSLKRP LEATFDLGIP QAVLPPLPKR
     PALEKTNGAT AVFNTGIFQY QQALANMQLQ QHTAFLPPVP MVHGATPATV SAATTSATSV
     PFAATATANQ IPIISAEHLT SHKYVTQM
//
ID   NIPA3_HUMAN             Reviewed;         410 AA.
AC   Q6NVV3; B3KTB0; Q68DA9;
DT   27-JUN-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   23-FEB-2022, entry version 126.
DE   RecName: Full=Magnesium transporter NIPA3;
DE   AltName: Full=NIPA-like protein 1;
DE   AltName: Full=Non-imprinted in Prader-Willi/Angelman syndrome region protein 3;
GN   Name=NIPAL1; Synonyms=NIPA3, NPAL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Acts as a Mg(2+) transporter. Can also transport other
CC       divalent cations such as Fe(2+), Sr(2+), Ba(2+), Mn(2+), Cu(2+) and
CC       Co(2+) but to a much less extent than Mg(2+) (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the NIPA family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK095299; BAG53022.1; -; mRNA.
DR   EMBL; CR749484; CAH18311.1; -; mRNA.
DR   EMBL; BC067881; AAH67881.1; -; mRNA.
DR   CCDS; CCDS3479.1; -.
DR   RefSeq; NP_997213.1; NM_207330.2.
DR   BioGRID; 127450; 113.
DR   STRING; 9606.ENSP00000295461; -.
DR   GlyGen; Q6NVV3; 4 sites.
DR   iPTMnet; Q6NVV3; -.
DR   PhosphoSitePlus; Q6NVV3; -.
DR   BioMuta; NIPAL1; -.
DR   DMDM; 74736867; -.
DR   MassIVE; Q6NVV3; -.
DR   MaxQB; Q6NVV3; -.
DR   PaxDb; Q6NVV3; -.
DR   PeptideAtlas; Q6NVV3; -.
DR   PRIDE; Q6NVV3; -.
DR   ProteomicsDB; 66724; -.
DR   Antibodypedia; 52126; 66 antibodies from 13 providers.
DR   DNASU; 152519; -.
DR   Ensembl; ENST00000295461; ENSP00000295461; ENSG00000163293.
DR   GeneID; 152519; -.
DR   KEGG; hsa:152519; -.
DR   MANE-Select; ENST00000295461.10; ENSP00000295461.5; NM_207330.3; NP_997213.1.
DR   UCSC; uc003gxw.4; human.
DR   CTD; 152519; -.
DR   DisGeNET; 152519; -.
DR   GeneCards; NIPAL1; -.
DR   HGNC; HGNC:27194; NIPAL1.
DR   HPA; ENSG00000163293; Tissue enhanced (esophagus, liver, skin).
DR   neXtProt; NX_Q6NVV3; -.
DR   OpenTargets; ENSG00000163293; -.
DR   PharmGKB; PA164723925; -.
DR   VEuPathDB; HostDB:ENSG00000163293; -.
DR   eggNOG; KOG2922; Eukaryota.
DR   GeneTree; ENSGT00940000160022; -.
DR   HOGENOM; CLU_012349_1_3_1; -.
DR   InParanoid; Q6NVV3; -.
DR   OMA; MSCKGLG; -.
DR   OrthoDB; 754939at2759; -.
DR   PhylomeDB; Q6NVV3; -.
DR   TreeFam; TF313214; -.
DR   PathwayCommons; Q6NVV3; -.
DR   Reactome; R-HSA-5223345; Miscellaneous transport and binding events.
DR   BioGRID-ORCS; 152519; 2 hits in 1028 CRISPR screens.
DR   ChiTaRS; NIPAL1; human.
DR   GenomeRNAi; 152519; -.
DR   Pharos; Q6NVV3; Tdark.
DR   PRO; PR:Q6NVV3; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q6NVV3; protein.
DR   Bgee; ENSG00000163293; Expressed in buccal mucosa cell and 160 other tissues.
DR   ExpressionAtlas; Q6NVV3; baseline and differential.
DR   Genevisible; Q6NVV3; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0015693; P:magnesium ion transport; IBA:GO_Central.
DR   InterPro; IPR008521; Mg_trans_NIPA.
DR   PANTHER; PTHR12570; PTHR12570; 1.
DR   Pfam; PF05653; Mg_trans_NIPA; 1.
PE   2: Evidence at transcript level;
KW   Glycoprotein; Ion transport; Magnesium; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..410
FT                   /note="Magnesium transporter NIPA3"
FT                   /id="PRO_0000242146"
FT   TOPO_DOM        1..67
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        68..88
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        89..114
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        115..135
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        136
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        137..157
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        158..165
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        166..186
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        187..207
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        208..228
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        229..233
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        234..254
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        255..273
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        274..294
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        295..305
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        306..326
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        327..336
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        337..357
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        358..410
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        25
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        50
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        55
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         324
FT                   /note="I -> V (in dbSNP:rs13116684)"
FT                   /id="VAR_026843"
FT   CONFLICT        201
FT                   /note="E -> G (in Ref. 2; CAH18311)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   410 AA;  44638 MW;  4690E95C87D43EB8 CRC64;
     MGAQVRLPPG EPCREGYVLS LVCPNSSQAW CEITNVSQLL ASPVLYTDLN YSINNLSISA
     NVENKYSLYV GLVLAVSSSI FIGSSFILKK KGLLQLASKG FTRAGQGGHS YLKEWLWWVG
     LLSMGAGEAA NFAAYAFAPA TLVTPLGALS VLISAILSSY FLNEHLNIHG KIGCILSILG
     STVMVIHAPQ EEEVTSLHEM EMKLRDPGFI SFAVIITVIS LVLILIVAPK KGQTNILVYI
     SICSLIGAFS VSSVKGLGIA IKELIEWKPV YKHPLVFVLL AVLVLSVTTQ INYLNKALDT
     FNTSLVTPIY YVFFTSMVVT CSAILFQEWY GMTAGDIIGT LSGFFTIIIG IFLLHAFKNT
     DITWSELTST AKKEAVSLNV NENNYVLLEN LECSAPGYND DVTLFSRTDD
//
ID   SEP14_HUMAN             Reviewed;         432 AA.
AC   Q6ZU15; A6NCC2; B4DXD6;
DT   10-JUL-2007, integrated into UniProtKB/Swiss-Prot.
DT   10-JUL-2007, sequence version 2.
DT   23-FEB-2022, entry version 135.
DE   RecName: Full=Septin-14 {ECO:0000312|HGNC:HGNC:33280};
GN   Name=SEPTIN14 {ECO:0000312|HGNC:HGNC:33280};
GN   Synonyms=SEPT14 {ECO:0000312|HGNC:HGNC:33280};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [3]
RP   INTERACTION WITH SEPTIN9, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17922164; DOI=10.1007/s00335-007-9065-x;
RA   Peterson E.A., Kalikin L.M., Steels J.D., Estey M.P., Trimble W.S.,
RA   Petty E.M.;
RT   "Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-
RT   specific septin.";
RL   Mamm. Genome 18:796-807(2007).
RN   [4]
RP   SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=32249155; DOI=10.1016/j.repbio.2020.03.007;
RA   Vahabi Barzi N., Kakavand K., Sodeifi N., Ghezelayagh Z., Sabbaghian M.;
RT   "Expression and localization of Septin 14 gene and protein in infertile men
RT   testis.";
RL   Reprod. Biol. 20:164-168(2020).
RN   [5]
RP   VARIANTS THR-123 AND THR-333, CHARACTERIZATION OF VARIANTS THR-123 AND
RP   THR-333, AND SUBCELLULAR LOCATION.
RX   PubMed=31450874; DOI=10.3390/jcm8091297;
RA   Wang Y.Y., Lai T.H., Chen M.F., Lee H.L., Kuo P.L., Lin Y.H.;
RT   "SEPT14 Mutations and Teratozoospermia: Genetic Effects on Sperm Head
RT   Morphology and DNA Integrity.";
RL   J. Clin. Med. 8:0-0(2019).
RN   [6]
RP   CHARACTERIZATION OF VARIANTS THR-123 AND THR-333, FUNCTION, AND INTERACTION
RP   WITH ACTN4.
RX   PubMed=33228246; DOI=10.3390/biomedicines8110518;
RA   Lin Y.H., Huang C.Y., Ke C.C., Wang Y.Y., Lai T.H., Liu H.C., Ku W.C.,
RA   Chan C.C., Lin Y.H.;
RT   "ACTN4 Mediates SEPT14 Mutation-Induced Sperm Head Defects.";
RL   Biomedicines 8:0-0(2020).
CC   -!- FUNCTION: Filament-forming cytoskeletal GTPase (Probable). Involved in
CC       the migration of cortical neurons and the formation of neuron leading
CC       processes during embryonic development (By similarity). Plays a role in
CC       sperm head formation during spermiogenesis, potentially via
CC       facilitating localization of ACTN4 to cell filaments (PubMed:33228246).
CC       {ECO:0000250|UniProtKB:Q9DA97, ECO:0000269|PubMed:33228246,
CC       ECO:0000305}.
CC   -!- SUBUNIT: Septins polymerize into heterooligomeric protein complexes
CC       that form filaments, and can associate with cellular membranes, actin
CC       filaments and microtubules. GTPase activity is required for filament
CC       formation. Interacts with ACTN4 (PubMed:33228246). Interacts with
CC       SEPTIN9 (PubMed:17922164). Interacts (via C-terminus) with SEPTIN4 (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:Q9DA97,
CC       ECO:0000269|PubMed:17922164, ECO:0000269|PubMed:33228246}.
CC   -!- INTERACTION:
CC       Q6ZU15; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-2009297, EBI-742909;
CC       Q6ZU15; Q9H5Z6-2: FAM124B; NbExp=3; IntAct=EBI-2009297, EBI-11986315;
CC       Q6ZU15; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-2009297, EBI-739467;
CC       Q6ZU15; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-2009297, EBI-741158;
CC       Q6ZU15; Q9UHD8-1: SEPTIN9; NbExp=3; IntAct=EBI-2009297, EBI-851558;
CC       Q6ZU15; Q9UHD8-3: SEPTIN9; NbExp=3; IntAct=EBI-2009297, EBI-851569;
CC       Q6ZU15; Q9BRG1: VPS25; NbExp=3; IntAct=EBI-2009297, EBI-741945;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17922164}.
CC       Cytoplasm, cytoskeleton {ECO:0000269|PubMed:17922164,
CC       ECO:0000269|PubMed:31450874}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q9DA97}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q9DA97}. Perikaryon
CC       {ECO:0000250|UniProtKB:Q9DA97}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:Q9DA97}. Cytoplasmic vesicle, secretory vesicle,
CC       acrosome {ECO:0000269|PubMed:32249155}. Note=Colocalizes with actin
CC       stress fibers (PubMed:17922164). Expressed in the perinuclear rim and
CC       manchette structure in early elongating spermatids during
CC       spermiogenesis (By similarity). {ECO:0000250|UniProtKB:Q9DA97,
CC       ECO:0000269|PubMed:17922164}.
CC   -!- TISSUE SPECIFICITY: Testis-specific (at protein level).
CC       {ECO:0000269|PubMed:17922164, ECO:0000269|PubMed:32249155}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in all cell stages of spermatogenesis.
CC       {ECO:0000269|PubMed:32249155}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class TrmE-Era-EngA-EngB-Septin-like
CC       GTPase superfamily. Septin GTPase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01056}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC86412.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK126048; BAC86412.1; ALT_INIT; mRNA.
DR   EMBL; AK301928; BAG63348.1; -; mRNA.
DR   EMBL; AC092647; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS5519.2; -.
DR   RefSeq; NP_997249.2; NM_207366.2.
DR   RefSeq; XP_011513675.1; XM_011515373.2.
DR   SMR; Q6ZU15; -.
DR   BioGRID; 131376; 28.
DR   IntAct; Q6ZU15; 17.
DR   STRING; 9606.ENSP00000373627; -.
DR   iPTMnet; Q6ZU15; -.
DR   PhosphoSitePlus; Q6ZU15; -.
DR   BioMuta; SEPT14; -.
DR   DMDM; 152112291; -.
DR   jPOST; Q6ZU15; -.
DR   MassIVE; Q6ZU15; -.
DR   MaxQB; Q6ZU15; -.
DR   PaxDb; Q6ZU15; -.
DR   PeptideAtlas; Q6ZU15; -.
DR   PRIDE; Q6ZU15; -.
DR   ProteomicsDB; 68306; -.
DR   Antibodypedia; 56888; 94 antibodies from 20 providers.
DR   DNASU; 346288; -.
DR   Ensembl; ENST00000388975; ENSP00000373627; ENSG00000154997.
DR   GeneID; 346288; -.
DR   KEGG; hsa:346288; -.
DR   MANE-Select; ENST00000388975.4; ENSP00000373627.3; NM_207366.3; NP_997249.2.
DR   UCSC; uc003tqz.2; human.
DR   CTD; 346288; -.
DR   DisGeNET; 346288; -.
DR   GeneCards; SEPTIN14; -.
DR   HGNC; HGNC:33280; SEPTIN14.
DR   HPA; ENSG00000154997; Tissue enriched (testis).
DR   MalaCards; SEPTIN14; -.
DR   MIM; 612140; gene.
DR   neXtProt; NX_Q6ZU15; -.
DR   OpenTargets; ENSG00000154997; -.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   PharmGKB; PA162402917; -.
DR   VEuPathDB; HostDB:ENSG00000154997; -.
DR   eggNOG; KOG3859; Eukaryota.
DR   GeneTree; ENSGT00940000161752; -.
DR   HOGENOM; CLU_017718_8_1_1; -.
DR   InParanoid; Q6ZU15; -.
DR   OMA; SFFEYHD; -.
DR   OrthoDB; 845354at2759; -.
DR   PhylomeDB; Q6ZU15; -.
DR   TreeFam; TF101080; -.
DR   PathwayCommons; Q6ZU15; -.
DR   SignaLink; Q6ZU15; -.
DR   BioGRID-ORCS; 346288; 6 hits in 958 CRISPR screens.
DR   ChiTaRS; SEPT14; human.
DR   GenomeRNAi; 346288; -.
DR   Pharos; Q6ZU15; Tbio.
DR   PRO; PR:Q6ZU15; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q6ZU15; protein.
DR   Bgee; ENSG00000154997; Expressed in testis and 27 other tissues.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0032153; C:cell division site; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IBA:GO_Central.
DR   GO; GO:0043204; C:perikaryon; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031105; C:septin complex; IBA:GO_Central.
DR   GO; GO:0005940; C:septin ring; IBA:GO_Central.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IBA:GO_Central.
DR   GO; GO:0060090; F:molecular adaptor activity; IBA:GO_Central.
DR   GO; GO:0034613; P:cellular protein localization; IBA:GO_Central.
DR   GO; GO:0061640; P:cytoskeleton-dependent cytokinesis; IBA:GO_Central.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:1905719; P:protein localization to perinuclear region of cytoplasm; IMP:UniProtKB.
DR   GO; GO:0007286; P:spermatid development; IMP:UniProtKB.
DR   CDD; cd01850; CDC_Septin; 1.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR030379; G_SEPTIN_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR016491; Septin.
DR   Pfam; PF00735; Septin; 1.
DR   PIRSF; PIRSF006698; Septin; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS51719; G_SEPTIN; 1.
PE   1: Evidence at protein level;
KW   Cell cycle; Cell division; Cell projection; Coiled coil; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; GTP-binding; Nucleotide-binding;
KW   Reference proteome.
FT   CHAIN           1..432
FT                   /note="Septin-14"
FT                   /id="PRO_0000294425"
FT   DOMAIN          49..315
FT                   /note="Septin-type G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01056"
FT   NP_BIND         59..66
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   NP_BIND         195..203
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   REGION          59..66
FT                   /note="G1 motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01056"
FT   REGION          111..114
FT                   /note="G3 motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01056"
FT   REGION          194..197
FT                   /note="G4 motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01056"
FT   REGION          369..432
FT                   /note="Required for interaction with SEPTIN4. Required for
FT                   migration of cortical neurons during corticogenesis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9DA97"
FT   COILED          332..412
FT                   /evidence="ECO:0000255"
FT   BINDING         114
FT                   /note="GTP; via amide nitrogen"
FT                   /evidence="ECO:0000250"
FT   BINDING         249
FT                   /note="GTP; via amide nitrogen and carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   BINDING         264
FT                   /note="GTP"
FT                   /evidence="ECO:0000250"
FT   VARIANT         123
FT                   /note="A -> T (found in patients with teratozoospermia;
FT                   unknown pathological significance; sperm heads are
FT                   malformed and contain vacuoles; chromatin packaging and
FT                   structure is abnormal with an increase in fragmented DNA;
FT                   decreases sperm filamentous structure formation; loss of
FT                   SEPTIN14 and ACTN4 localization to cell filament
FT                   structures; no effect on interaction with ACTN4;
FT                   dbSNP:rs1417582759)"
FT                   /evidence="ECO:0000269|PubMed:31450874,
FT                   ECO:0000269|PubMed:33228246"
FT                   /id="VAR_085117"
FT   VARIANT         333
FT                   /note="I -> T (found in patients with teratozoospermia;
FT                   unknown pathological significance; sperm heads are
FT                   malformed and contain vacuoles; chromatin packaging and
FT                   structure is abnormal with an increase in fragmented DNA;
FT                   decreases sperm filamentous structure formation; loss of
FT                   SEPTIN14 and ACTN4 localization to cell filament
FT                   structures; no effect on interaction with ACTN4;
FT                   dbSNP:rs185254020)"
FT                   /evidence="ECO:0000269|PubMed:31450874,
FT                   ECO:0000269|PubMed:33228246"
FT                   /id="VAR_085118"
SQ   SEQUENCE   432 AA;  50025 MW;  AFFF9A953F1FC637 CRC64;
     MAERTMAMPT QIPADGDTQK ENNIRCLTTI GHFGFECLPN QLVSRSIRQG FTFNILCVGE
     TGIGKSTLID TLFNTNLKDN KSSHFYSNVG LQIQTYELQE SNVQLKLTVV ETVGYGDQID
     KEASYQPIVD YIDAQFEAYL QEELKIKRSL FEYHDSRVHV CLYFISPTGH SLKSLDLLTM
     KNLDSKVNII PLIAKADTIS KNDLQTFKNK IMSELISNGI QIYQLPTDEE TAAQANSSVS
     GLLPFAVVGS TDEVKVGKRM VRGRHYPWGV LQVENENHCD FVKLRDMLLC TNMENLKEKT
     HTQHYECYRY QKLQKMGFTD VGPNNQPVSF QEIFEAKRQE FYDQCQREEE ELKQRFMQRV
     KEKEATFKEA EKELQDKFEH LKMIQQEEIR KLEEEKKQLE GEIIDFYKMK AASEALQTQL
     STDTKKDKHR KK
//
ID   ZC3HE_HUMAN             Reviewed;         736 AA.
AC   Q6PJT7; A8MY46; B4DXU8; B4DZW7; B4E2H4; G3V5R4; Q6MZU4; Q6PJ32; Q6PUI6;
AC   Q6PUI8; Q86TQ5; Q86TW0; Q86TW1; Q8NCT6; Q8NCZ3; Q8TDE2; Q9HAC9; Q9Y5A0;
DT   29-APR-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   23-FEB-2022, entry version 164.
DE   RecName: Full=Zinc finger CCCH domain-containing protein 14;
DE   AltName: Full=Mammalian suppressor of tau pathology-2;
DE            Short=MSUT-2;
DE   AltName: Full=Renal carcinoma antigen NY-REN-37;
GN   Name=ZC3H14;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RA   Guo J.H.;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3 AND 4).
RA   Zhou G., Wang X., Yu L.;
RT   "Homo sapiens putative NY-REN-37 antigen alternatively spliced isoforms.";
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 9; 10 AND 11).
RC   TISSUE=Embryo, Testis, Thymus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Esophageal carcinoma, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 91-736 (ISOFORM 2).
RC   TISSUE=Muscle, Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 86-736 (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 368-736 (ISOFORM 5), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 630-736 (ISOFORM 1).
RC   TISSUE=Neuroblastoma, and Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 563-736 (ISOFORM 2), AND IDENTIFICATION AS A
RP   RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515 AND SER-620, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17630287; DOI=10.1073/pnas.0701244104;
RA   Kelly S.M., Pabit S.A., Kitchen C.M., Guo P., Marfatia K.A., Murphy T.J.,
RA   Corbett A.H., Berland K.M.;
RT   "Recognition of polyadenosine RNA by zinc finger proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:12306-12311(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS 1; 3; 4 AND 6), AND SUBCELLULAR LOCATION.
RX   PubMed=19303045; DOI=10.1016/j.gene.2009.02.022;
RA   Leung S.W., Apponi L.H., Cornejo O.E., Kitchen C.M., Valentini S.R.,
RA   Pavlath G.K., Dunham C.M., Corbett A.H.;
RT   "Splice variants of the human ZC3H14 gene generate multiple isoforms of a
RT   zinc finger polyadenosine RNA binding protein.";
RL   Gene 439:71-78(2009).
RN   [16]
RP   INTERACTION WITH HOOK2.
RX   PubMed=19273536; DOI=10.1093/hmg/ddp099;
RA   Guthrie C.R., Schellenberg G.D., Kraemer B.C.;
RT   "SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans.";
RL   Hum. Mol. Genet. 18:1825-1838(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-357, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   INVOLVEMENT IN MRT56, SUBCELLULAR LOCATION (ISOFORM 6), AND TISSUE
RP   SPECIFICITY (ISOFORMS 1 AND 6).
RX   PubMed=21734151; DOI=10.1073/pnas.1107103108;
RA   Pak C., Garshasbi M., Kahrizi K., Gross C., Apponi L.H., Noto J.J.,
RA   Kelly S.M., Leung S.W., Tzschach A., Behjati F., Abedini S.S., Mohseni M.,
RA   Jensen L.R., Hu H., Huang B., Stahley S.N., Liu G., Williams K.R.,
RA   Burdick S., Feng Y., Sanyal S., Bassell G.J., Ropers H.H., Najmabadi H.,
RA   Corbett A.H., Moberg K.H., Kuss A.W.;
RT   "Mutation of the conserved polyadenosine RNA binding protein, ZC3H14/dNab2,
RT   impairs neural function in Drosophila and humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12390-12395(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-515, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240; SER-281; SER-327;
RP   SER-343; SER-390; SER-409; SER-421; SER-498 AND SER-515, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343 AND SER-515, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-175 AND LYS-413, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [27]
RP   FUNCTION, MISCELLANEOUS, AND SUBCELLULAR LOCATION.
RX   PubMed=24671764; DOI=10.1261/rna.043984.113;
RA   Kelly S.M., Leung S.W., Pak C., Banerjee A., Moberg K.H., Corbett A.H.;
RT   "A conserved role for the zinc finger polyadenosine RNA binding protein,
RT   ZC3H14, in control of poly(A) tail length.";
RL   RNA 20:681-688(2014).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-175 AND LYS-413, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-413, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [30]
RP   INTERACTION WITH ZFC3H1.
RX   PubMed=27871484; DOI=10.1016/j.molcel.2016.09.025;
RA   Meola N., Domanski M., Karadoulama E., Chen Y., Gentil C., Pultz D.,
RA   Vitting-Seerup K., Lykke-Andersen S., Andersen J.S., Sandelin A.,
RA   Jensen T.H.;
RT   "Identification of a nuclear exosome decay pathway for processed
RT   transcripts.";
RL   Mol. Cell 64:520-533(2016).
RN   [31]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-99; LYS-139; LYS-175; LYS-198;
RP   LYS-245; LYS-283; LYS-295; LYS-357; LYS-378; LYS-413 AND LYS-489, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Involved in poly(A) tail length control in neuronal cells.
CC       Binds the polyadenosine RNA oligonucleotides.
CC       {ECO:0000269|PubMed:17630287, ECO:0000269|PubMed:24671764}.
CC   -!- SUBUNIT: Interacts with HOOK2 (PubMed:19273536). Interacts with ZFC3H1
CC       in a RNase-sensitive manner (PubMed:27871484).
CC       {ECO:0000269|PubMed:19273536, ECO:0000269|PubMed:27871484}.
CC   -!- INTERACTION:
CC       Q6PJT7; P35638-2: DDIT3; NbExp=3; IntAct=EBI-740660, EBI-10173632;
CC       Q6PJT7-6; P51808: DYNLT3; NbExp=3; IntAct=EBI-12147703, EBI-743027;
CC       Q6PJT7-6; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-12147703, EBI-3044087;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000269|PubMed:17630287,
CC       ECO:0000269|PubMed:19303045, ECO:0000269|PubMed:24671764}.
CC       Note=Colocalizes with poly(A) RNA in nuclear speckles.
CC       {ECO:0000250|UniProtKB:Q7TMD5}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus speckle.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus speckle.
CC   -!- SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm
CC       {ECO:0000269|PubMed:21734151}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=10;
CC       Name=1; Synonyms=Isoform 1;
CC         IsoId=Q6PJT7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6PJT7-2; Sequence=VSP_033171;
CC       Name=3; Synonyms=Isoform 2;
CC         IsoId=Q6PJT7-3; Sequence=VSP_033166, VSP_033171;
CC       Name=4; Synonyms=Isoform 3 short;
CC         IsoId=Q6PJT7-4; Sequence=VSP_033164, VSP_033168;
CC       Name=5;
CC         IsoId=Q6PJT7-5; Sequence=VSP_033167;
CC       Name=6; Synonyms=Isoform 4;
CC         IsoId=Q6PJT7-6; Sequence=VSP_033163, VSP_033165, VSP_033168,
CC                                  VSP_033171;
CC       Name=8;
CC         IsoId=Q6PJT7-8; Sequence=VSP_033162, VSP_033169;
CC       Name=9;
CC         IsoId=Q6PJT7-9; Sequence=VSP_044645, VSP_033171;
CC       Name=10;
CC         IsoId=Q6PJT7-10; Sequence=VSP_055097, VSP_033166;
CC       Name=11;
CC         IsoId=Q6PJT7-11; Sequence=VSP_055096, VSP_033168, VSP_033171;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 6 are expressed in fetal and
CC       adult brain. Isoform 1 and isoform 6 are expressed in fetal and adult
CC       temporal lobe. {ECO:0000269|PubMed:21734151}.
CC   -!- DISEASE: Mental retardation, autosomal recessive 56 (MRT56)
CC       [MIM:617125]: A form of mental retardation, a disorder characterized by
CC       significantly below average general intellectual functioning associated
CC       with impairments in adaptive behavior and manifested during the
CC       developmental period. {ECO:0000269|PubMed:21734151}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: ZC3H14 can functionally substitute for Nab2 in fly
CC       neurons and can rescue defects in development and locomotion that are
CC       present in dNab2 null flies.
CC   -!- SIMILARITY: Belongs to the ZC3H14 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL83289.1; Type=Miscellaneous discrepancy; Note=Several sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=AAS90302.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAS90302.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC       Sequence=AK021868; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAE45933.1; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF474376; AAL83289.1; ALT_SEQ; mRNA.
DR   EMBL; AY578060; AAS90299.1; -; mRNA.
DR   EMBL; AY578061; AAS90300.1; -; mRNA.
DR   EMBL; AY578062; AAS90301.1; -; mRNA.
DR   EMBL; AY578063; AAS90302.1; ALT_SEQ; mRNA.
DR   EMBL; AK021868; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK302136; BAG63510.1; -; mRNA.
DR   EMBL; AK303123; BAG64229.1; -; mRNA.
DR   EMBL; AK304275; BAG65136.1; -; mRNA.
DR   EMBL; AL834215; CAD38897.1; -; mRNA.
DR   EMBL; BX640716; CAE45835.1; -; mRNA.
DR   EMBL; BX640876; CAE45933.1; ALT_SEQ; mRNA.
DR   EMBL; AL162171; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW81385.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81388.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81389.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81390.1; -; Genomic_DNA.
DR   EMBL; BC011793; AAH11793.1; -; mRNA.
DR   EMBL; BC023641; AAH23641.1; -; mRNA.
DR   EMBL; BC027607; AAH27607.1; -; mRNA.
DR   EMBL; BX248265; CAD62593.1; -; mRNA.
DR   EMBL; BX248281; CAD62609.1; -; mRNA.
DR   EMBL; BX248769; CAD66576.1; -; mRNA.
DR   EMBL; AF155107; AAD42873.1; -; mRNA.
DR   CCDS; CCDS32133.1; -. [Q6PJT7-1]
DR   CCDS; CCDS32134.1; -. [Q6PJT7-3]
DR   CCDS; CCDS32135.1; -. [Q6PJT7-4]
DR   CCDS; CCDS32136.1; -. [Q6PJT7-6]
DR   CCDS; CCDS55938.1; -. [Q6PJT7-9]
DR   CCDS; CCDS86418.1; -. [Q6PJT7-5]
DR   RefSeq; NP_001153575.1; NM_001160103.1. [Q6PJT7-2]
DR   RefSeq; NP_001153576.1; NM_001160104.1. [Q6PJT7-9]
DR   RefSeq; NP_001313236.1; NM_001326307.1. [Q6PJT7-5]
DR   RefSeq; NP_079100.2; NM_024824.4. [Q6PJT7-1]
DR   RefSeq; NP_997543.1; NM_207660.3. [Q6PJT7-3]
DR   RefSeq; NP_997544.1; NM_207661.2. [Q6PJT7-4]
DR   RefSeq; NP_997545.2; NM_207662.3. [Q6PJT7-6]
DR   RefSeq; XP_005268125.1; XM_005268068.4.
DR   BioGRID; 122967; 129.
DR   IntAct; Q6PJT7; 53.
DR   STRING; 9606.ENSP00000251038; -.
DR   GlyConnect; 2848; 1 O-Linked glycan (1 site). [Q6PJT7-2]
DR   GlyGen; Q6PJT7; 13 sites, 2 O-linked glycans (13 sites).
DR   iPTMnet; Q6PJT7; -.
DR   MetOSite; Q6PJT7; -.
DR   PhosphoSitePlus; Q6PJT7; -.
DR   SwissPalm; Q6PJT7; -.
DR   BioMuta; ZC3H14; -.
DR   DMDM; 74737935; -.
DR   EPD; Q6PJT7; -.
DR   jPOST; Q6PJT7; -.
DR   MassIVE; Q6PJT7; -.
DR   MaxQB; Q6PJT7; -.
DR   PaxDb; Q6PJT7; -.
DR   PeptideAtlas; Q6PJT7; -.
DR   PRIDE; Q6PJT7; -.
DR   ProteomicsDB; 33599; -.
DR   ProteomicsDB; 67217; -. [Q6PJT7-1]
DR   ProteomicsDB; 67218; -. [Q6PJT7-2]
DR   ProteomicsDB; 67219; -. [Q6PJT7-3]
DR   ProteomicsDB; 67220; -. [Q6PJT7-4]
DR   ProteomicsDB; 67221; -. [Q6PJT7-5]
DR   ProteomicsDB; 67222; -. [Q6PJT7-6]
DR   ProteomicsDB; 67223; -. [Q6PJT7-8]
DR   Antibodypedia; 26309; 145 antibodies from 24 providers.
DR   DNASU; 79882; -.
DR   Ensembl; ENST00000251038; ENSP00000251038; ENSG00000100722.
DR   Ensembl; ENST00000302216; ENSP00000307025; ENSG00000100722. [Q6PJT7-3]
DR   Ensembl; ENST00000318308; ENSP00000327176; ENSG00000100722. [Q6PJT7-6]
DR   Ensembl; ENST00000336693; ENSP00000338002; ENSG00000100722. [Q6PJT7-4]
DR   Ensembl; ENST00000393514; ENSP00000377150; ENSG00000100722. [Q6PJT7-5]
DR   Ensembl; ENST00000406216; ENSP00000384682; ENSG00000100722. [Q6PJT7-8]
DR   Ensembl; ENST00000555755; ENSP00000452475; ENSG00000100722. [Q6PJT7-9]
DR   GeneID; 79882; -.
DR   KEGG; hsa:79882; -.
DR   MANE-Select; ENST00000251038.10; ENSP00000251038.5; NM_024824.5; NP_079100.2.
DR   UCSC; uc001xww.4; human. [Q6PJT7-1]
DR   CTD; 79882; -.
DR   DisGeNET; 79882; -.
DR   GeneCards; ZC3H14; -.
DR   HGNC; HGNC:20509; ZC3H14.
DR   HPA; ENSG00000100722; Tissue enriched (testis).
DR   MalaCards; ZC3H14; -.
DR   MIM; 613279; gene.
DR   MIM; 617125; phenotype.
DR   neXtProt; NX_Q6PJT7; -.
DR   OpenTargets; ENSG00000100722; -.
DR   Orphanet; 88616; Autosomal recessive non-syndromic intellectual disability.
DR   PharmGKB; PA145007270; -.
DR   VEuPathDB; HostDB:ENSG00000100722; -.
DR   eggNOG; KOG3702; Eukaryota.
DR   GeneTree; ENSGT00440000038430; -.
DR   HOGENOM; CLU_022605_0_0_1; -.
DR   InParanoid; Q6PJT7; -.
DR   OMA; TFYHPTV; -.
DR   OrthoDB; 893844at2759; -.
DR   PhylomeDB; Q6PJT7; -.
DR   TreeFam; TF329509; -.
DR   PathwayCommons; Q6PJT7; -.
DR   SignaLink; Q6PJT7; -.
DR   BioGRID-ORCS; 79882; 10 hits in 1055 CRISPR screens.
DR   ChiTaRS; ZC3H14; human.
DR   GenomeRNAi; 79882; -.
DR   Pharos; Q6PJT7; Tbio.
DR   PRO; PR:Q6PJT7; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q6PJT7; protein.
DR   Bgee; ENSG00000100722; Expressed in testis and 239 other tissues.
DR   ExpressionAtlas; Q6PJT7; baseline and differential.
DR   Genevisible; Q6PJT7; HS.
DR   GO; GO:1904115; C:axon cytoplasm; IDA:FlyBase.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0032839; C:dendrite cytoplasm; IDA:FlyBase.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:FlyBase.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008143; F:poly(A) binding; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:1900364; P:negative regulation of mRNA polyadenylation; IBA:GO_Central.
DR   GO; GO:0043488; P:regulation of mRNA stability; IBA:GO_Central.
DR   InterPro; IPR040366; Nab2/ZC3H14.
DR   InterPro; IPR000571; Znf_CCCH.
DR   PANTHER; PTHR14738; PTHR14738; 1.
DR   SMART; SM00356; ZnF_C3H1; 3.
DR   PROSITE; PS50103; ZF_C3H1; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Cytoplasm; Isopeptide bond;
KW   Mental retardation; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..736
FT                   /note="Zinc finger CCCH domain-containing protein 14"
FT                   /id="PRO_0000331311"
FT   ZN_FING         595..620
FT                   /note="C3H1-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         621..640
FT                   /note="C3H1-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         641..656
FT                   /note="C3H1-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         682..699
FT                   /note="C3H1-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   ZN_FING         701..719
FT                   /note="C3H1-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00723"
FT   REGION          77..145
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          310..350
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          398..430
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        77..101
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         85
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BJ05"
FT   MOD_RES         240
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         343
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         357
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         421
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         515
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BJ05"
FT   MOD_RES         620
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   CROSSLNK        99
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        139
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        175
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        198
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        245
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        283
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        295
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        357
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        378
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        413
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        489
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..454
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_033162"
FT   VAR_SEQ         1..298
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_033163"
FT   VAR_SEQ         1..34
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:17974005, ECO:0000303|Ref.2"
FT                   /id="VSP_033164"
FT   VAR_SEQ         95..113
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055096"
FT   VAR_SEQ         123..159
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055097"
FT   VAR_SEQ         299..426
FT                   /note="VSSVVKVKKFNHDGEEEEEDDDYGSRTGSISSSVSVPAKPERRPSLPPSKQA
FT                   NKNLILKAISEAQESVTKTTNYSTVPQKQTLPVAPRTRTSQEELLAEVVQGQSRTPRIS
FT                   PPIKEEETKGDSVEKNQ -> MRMSSKFPSPPLPIFLPPEPVDLGSITSSSCSLNELDN
FT                   ISHLLRKISADINEIKGMKAAILTVEANLFDLNVRVSKNEAKISSLEVKMNEYSTTYEC
FT                   NRQFEDQEEDTESQSRTTDVKIIGFLRNVEK (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_033165"
FT   VAR_SEQ         427..582
FT                   /note="Missing (in isoform 3 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2"
FT                   /id="VSP_033166"
FT   VAR_SEQ         427..451
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.8"
FT                   /id="VSP_033167"
FT   VAR_SEQ         452..582
FT                   /note="Missing (in isoform 4, isoform 6 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005,
FT                   ECO:0000303|Ref.2"
FT                   /id="VSP_033168"
FT   VAR_SEQ         455..582
FT                   /note="DMESMVHADTRSFILKKPKLSEEVVVAPNQESGMKTADSLRVLSGHLMQTRD
FT                   LVQPDKPASPKFIVTLDGVPSPPGYMSDQEEDMCFEGMKPVNQTAASNKGLRGLLHPQQ
FT                   LHLLSRQLEDPNGSFSN -> MRMSSKFPSPPLPIFLPPEPVDLGSITSSSCSLNELDN
FT                   ISHLLRKISADINEIKGMKAAILTVEANLFDLNVRVSKNEAKISSLEVKMNEYSTTYEC
FT                   NRQFEDQEEDTESQSRTTDVKIIGFLRNVEK (in isoform 8)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_033169"
FT   VAR_SEQ         577..581
FT                   /note="Missing (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044645"
FT   VAR_SEQ         669
FT                   /note="Missing (in isoform 2, isoform 3, isoform 6, isoform
FT                   9 and isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:10508479,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|Ref.2, ECO:0000303|Ref.8"
FT                   /id="VSP_033171"
FT   CONFLICT        113
FT                   /note="A -> V (in Ref. 3; BAG63510)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="S -> P (in Ref. 3; BAG64229)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        532
FT                   /note="M -> V (in Ref. 3; BAG65136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        674
FT                   /note="A -> V (in Ref. 7; AAH23641)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        712
FT                   /note="C -> F (in Ref. 2; AAS90302 and 4; CAE45933)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        718
FT                   /note="T -> P (in Ref. 3; BAG65136)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   736 AA;  82876 MW;  BCF3E36CBA66170A CRC64;
     MEIGTEISRK IRSAIKGKLQ ELGAYVDEEL PDYIMVMVAN KKSQDQMTED LSLFLGNNTI
     RFTVWLHGVL DKLRSVTTEP SSLKSSDTNI FDSNVPSNKS NFSRGDERRH EAAVPPLAIP
     SARPEKRDSR VSTSSQESKT TNVRQTYDDG AATRLMSTVK PLREPAPSED VIDIKPEPDD
     LIDEDLNFVQ ENPLSQKKPT VTLTYGSSRP SIEIYRPPAS RNADSGVHLN RLQFQQQQNS
     IHAAKQLDMQ SSWVYETGRL CEPEVLNSLE ETYSPFFRNN SEKMSMEDEN FRKRKLPVVS
     SVVKVKKFNH DGEEEEEDDD YGSRTGSISS SVSVPAKPER RPSLPPSKQA NKNLILKAIS
     EAQESVTKTT NYSTVPQKQT LPVAPRTRTS QEELLAEVVQ GQSRTPRISP PIKEEETKGD
     SVEKNQGTQQ RQLLSRLQID PVMAETLQMS QDYYDMESMV HADTRSFILK KPKLSEEVVV
     APNQESGMKT ADSLRVLSGH LMQTRDLVQP DKPASPKFIV TLDGVPSPPG YMSDQEEDMC
     FEGMKPVNQT AASNKGLRGL LHPQQLHLLS RQLEDPNGSF SNAEMSELSV AQKPEKLLER
     CKYWPACKNG DECAYHHPIS PCKAFPNCKF AEKCLFVHPN CKYDAKCTKP DCPFTHVSRR
     IPVLSPKPAV APPAPPSSSQ LCRYFPACKK MECPFYHPKH CRFNTQCTRP DCTFYHPTIN
     VPPRHALKWI RPQTSE
//
